PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Iwata, T; Sato, S; Jimenez, J; McGowan, M; Moroni, M; Dey, A; Ibaraki, N; Reddy, VN; Carper, D				Iwata, T; Sato, S; Jimenez, J; McGowan, M; Moroni, M; Dey, A; Ibaraki, N; Reddy, VN; Carper, D			Osmotic response element is required for the induction of aldose reductase by tumor necrosis factor-alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED INSULIN-RESISTANCE; TYROSINE PHOSPHORYLATION; PROTEASOME ACTIVITIES; RECEPTOR SUBSTRATE-1; KAPPA-B; GENE; EXPRESSION; INHIBITION; PROTEIN; CELLS	Induction of aldose reductase (AR) was observed in human cells treated with tumor necrosis factor-alpha (TNF-alpha). AR protein expression increased severalfold in human liver cells after 1 day of exposure to 100 units/ml TNF-a. An increase in AR transcripts was also observed in human liver cells after 3 h of TNF-alpha treatment, reaching a maximum level of 11-fold at 48 h, Among the three inflammatory cytokines: TNF-alpha, interleukin-1, and interferon-gamma, TNF-alpha (100 units/ml) gave the most induction of AR. Differences in the pattern of AR induction were observed in human liver, lens, and retinal pigment epithelial cells with increasing concentrations of TNF-alpha. A similar pattern of AR promoter response was observed between TNF-alpha and osmotically stressed human liver cells. The deletion of the osmotic response element (ORE) abolished the induction by TNF-alpha and osmotic stress. A point mutation that converts ORE to a nuclear factor-kappa B (NF-kappa B) sequence abolished the osmotic response but maintained the TNF-alpha response. Electrophoretic gel mobility shift assays showed two NF-kappa B proteins, p50 and p52, capable of binding ORE sequence, and gel shift Western assay detected NF-kappa B proteins p50 and p65 in the ORE complex. Inhibitors of NF-kappa B signaling, lactacystin, and MG132 abolished the AR promoter response to TNF-alpha.	NEI, NIH, Lab Mechanisms Ocular Dis, Bethesda, MD 20892 USA; NEI, Lab Ocular Therapeut, Bethesda, MD 20892 USA; NICHD, Lab Mol Growth Regulat, NIH, Bethesda, MD 20892 USA; Nippon Med Sch, Dept Ophthalmol, Bunkyo Ku, Tokyo 113, Japan; Univ Michigan, Sch Med, Kellogg Eye Ctr, Ann Arbor, MI 48105 USA	National Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI); National Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Nippon Medical School; University of Michigan System; University of Michigan	Carper, D (corresponding author), NEI, NIH, Lab Mechanisms Ocular Dis, 9000 Rockville Pike,Bldg 6,Rm232, Bethesda, MD 20892 USA.				NATIONAL EYE INSTITUTE [Z01EY000312] Funding Source: NIH RePORTER	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		BAEUERLE PA, 1991, BIOCHIM BIOPHYS ACTA, V1072, P63, DOI 10.1016/0304-419X(91)90007-8; Bush KT, 1997, J BIOL CHEM, V272, P9086; CARPENTER GA, 1990, NEURAL NETWORKS, V3, P129, DOI 10.1016/0893-6080(90)90085-Y; Daoudal S, 1997, J BIOL CHEM, V272, P2615, DOI 10.1074/jbc.272.5.2615; FEINSTEIN R, 1993, J BIOL CHEM, V268, P26055; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; Ferraris JD, 1996, J BIOL CHEM, V271, P18318, DOI 10.1074/jbc.271.31.18318; GABBAY KH, 1973, NEW ENGL J MED, V288, P831, DOI 10.1056/NEJM197304192881609; HOFMANN C, 1994, ENDOCRINOLOGY, V134, P264, DOI 10.1210/en.134.1.264; HOTAMISLIGIL GS, 1994, DIABETES, V43, P1271, DOI 10.2337/diabetes.43.11.1271; Hotamisligil GS, 1996, SCIENCE, V271, P665, DOI 10.1126/science.271.5249.665; HOTAMISLIGIL GS, 1993, SCIENCE, V259, P87, DOI 10.1126/science.7678183; Ibaraki N, 1998, EXP EYE RES, V67, P577, DOI 10.1006/exer.1998.0551; Iwata T, 1997, J BIOL CHEM, V272, P32500, DOI 10.1074/jbc.272.51.32500; IWATA T, 1995, ADV EXP MED BIOL, V372, P373; KADOR PF, 1981, ANAL BIOCHEM, V114, P53, DOI 10.1016/0003-2697(81)90450-4; KANEKO M, 1990, EXP CELL RES, V188, P135, DOI 10.1016/0014-4827(90)90288-L; KANETY H, 1995, J BIOL CHEM, V270, P23780, DOI 10.1074/jbc.270.40.23780; KAWANO K, 1992, DIABETES, V41, P1422, DOI 10.2337/diabetes.41.11.1422; KINOSHIT.JH, 1974, INVEST OPHTH VISUAL, V13, P713; KLETZIEN RF, 1994, DIABETES, V43, pA82; Ko BCB, 1997, J BIOL CHEM, V272, P16431, DOI 10.1074/jbc.272.26.16431; KRIEGLER M, 1988, CELL, V53, P45, DOI 10.1016/0092-8674(88)90486-2; Kultz D, 1997, J BIOL CHEM, V272, P13165, DOI 10.1074/jbc.272.20.13165; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MINUCCI S, 1994, MOL CELL BIOL, V14, P360, DOI 10.1128/MCB.14.1.360; Miyakawa H, 1998, AM J PHYSIOL-RENAL, V274, pF753, DOI 10.1152/ajprenal.1998.274.4.F753; MORIYAMA T, 1989, J BIOL CHEM, V264, P16810; Nakamura J, 1997, LIFE SCI, V60, P1847, DOI 10.1016/S0024-3205(97)00145-8; ROBISON WG, 1983, SCIENCE, V221, P1170; Rosette C, 1996, SCIENCE, V274, P1194, DOI 10.1126/science.274.5290.1194; Sambrook J., 2002, MOL CLONING LAB MANU; Stephens JM, 1997, J BIOL CHEM, V272, P971, DOI 10.1074/jbc.272.2.971; TANAKA M, 1994, J BIOL CHEM, V269, P29379; THOMAS D, 1995, CELL, V80, P529; Tsubuki S, 1996, J BIOCHEM-TOKYO, V119, P572, DOI 10.1093/oxfordjournals.jbchem.a021280; Uysal KT, 1997, NATURE, V389, P610, DOI 10.1038/39335; VASSALLI P, 1992, ANNU REV IMMUNOL, V10, P411, DOI 10.1146/annurev.iy.10.040192.002211; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; VONHEYNINGEN R, 1959, NATURE, V184, P194; Zhou C, 1997, EXP EYE RES, V65, P349, DOI 10.1006/exer.1997.0335	41	62	62	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 19	1999	274	12					7993	8001		10.1074/jbc.274.12.7993	http://dx.doi.org/10.1074/jbc.274.12.7993			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	178LU	10075698	hybrid			2022-12-25	WOS:000079268100057
J	Sheridan, SD; Benham, CJ; Hatfield, GW				Sheridan, SD; Benham, CJ; Hatfield, GW			Inhibition of DNA supercoiling-dependent transcriptional activation by a distant B-DNA to Z-DNA transition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTEGRATION HOST FACTOR; ESCHERICHIA-COLI; CONFORMATIONAL TRANSITIONS; DUPLEX DESTABILIZATION; SUPERHELICAL DNA; ILVGMEDA OPERON; PROTEIN; MOLECULES; SEQUENCES; MULTIPLE	Negative DNA superhelicity can destabilize the local B-form DNA structure and can drive transitions to other conformations at susceptible sites. In a molecule containing multiple susceptible sites, superhelicity can couple these alternatives together, causing them to compete. In principle, these superhelically driven local structural transitions can be either facilitated or inhibited by proteins that bind at or near potential transition sites, If a DNA region that is susceptible to forming a superhelically induced alternate structure is stabilized in the B-form by a DNA-binding protein, its propensity for transition will be transferred to other sites within the same domain, If one of these secondary sites is in a promoter region, this transfer could facilitate open complex formation and thereby activate gene expression. We previously proposed that a supercoiling-dependent, DNA structural transmission mechanism of this type is responsible for the integration host factor-mediated activation of transcription from the ilvP(G) promoter of Escherichia coli (Sheridan, S, D,, Benham, C. J, & Hatfield, G, W, (1998) J, Biol, Chem, 273, 21298-21308), In this report we confirm the validity of this mechanism by demonstrating the ability of a distant Z-DNA-forming site to compete with the superhelical destabilization that is required for integration host factor-mediated transcriptional activation, and thereby delay its occurrence.	Univ Calif Irvine, Coll Med, Dept Mol Genet & Microbiol, Irvine, CA 92697 USA; CUNY Mt Sinai Sch Med, Dept Biomath Sci, New York, NY 10029 USA	University of California System; University of California Irvine; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Hatfield, GW (corresponding author), Univ Calif Irvine, Coll Med, Dept Mol Genet & Microbiol, Irvine, CA 92697 USA.	gwhatfie@uci.edu	Benham, Craig J/G-1512-2013		NIGMS NIH HHS [GM07311, GM55073, GM47012] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047012] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABOULELA F, 1992, J BIOL CHEM, V267, P1776; BARTON JK, 1988, CHEM ENG NEWS, V66, P30, DOI 10.1021/cen-v066n039.p030; BENHAM CJ, 1992, J MOL BIOL, V225, P835, DOI 10.1016/0022-2836(92)90404-8; BENHAM CJ, 1981, J MOL BIOL, V150, P43, DOI 10.1016/0022-2836(81)90324-7; BENHAM CJ, 1993, P NATL ACAD SCI USA, V90, P2999, DOI 10.1073/pnas.90.7.2999; Benham CJ, 1996, J MOL BIOL, V255, P425, DOI 10.1006/jmbi.1996.0035; BENHAM CJ, 1980, J CHEM PHYS, V72, P3633, DOI 10.1063/1.439625; BOWATER R, 1992, METHOD ENZYMOL, V212, P105; BOWATER RP, 1994, NUCLEIC ACIDS RES, V22, P2042, DOI 10.1093/nar/22.11.2042; ELLISON MJ, 1987, EMBO J, V6, P1513, DOI 10.1002/j.1460-2075.1987.tb02394.x; FURLONG JC, 1989, BIOCHEMISTRY-US, V28, P2009, DOI 10.1021/bi00431a008; Herbert JM, 1996, J BIOL CHEM, V271, P25928; KELLEHER RJ, 1986, P NATL ACAD SCI USA, V83, P6342, DOI 10.1073/pnas.83.17.6342; KLUMP HH, 1990, BIOPHYSICS-USSR, V1, P241; KOWALSKI D, 1988, P NATL ACAD SCI USA, V85, P9464, DOI 10.1073/pnas.85.24.9464; LILLEY DMJ, 1980, P NATL ACAD SCI-BIOL, V77, P6468, DOI 10.1073/pnas.77.11.6468; LIU LF, 1987, P NATL ACAD SCI USA, V84, P7024, DOI 10.1073/pnas.84.20.7024; NASH HA, 1987, J BACTERIOL, V169, P4124, DOI 10.1128/jb.169.9.4124-4127.1987; PAGEL JM, 1991, J BIOL CHEM, V266, P1985; PAGEL JM, 1992, J MOL BIOL, V224, P919, DOI 10.1016/0022-2836(92)90460-2; Parekh BS, 1996, J BIOL CHEM, V271, P20258, DOI 10.1074/jbc.271.34.20258; Parekh BS, 1996, P NATL ACAD SCI USA, V93, P1173, DOI 10.1073/pnas.93.3.1173; RAHMOUNI AR, 1989, SCIENCE, V246, P358, DOI 10.1126/science.2678475; Rice PA, 1996, CELL, V87, P1295, DOI 10.1016/S0092-8674(00)81824-3; RICH A, 1984, ANNU REV BIOCHEM, V53, P791, DOI 10.1146/annurev.bi.53.070184.004043; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Sheridan SD, 1998, J BIOL CHEM, V273, P21298, DOI 10.1074/jbc.273.33.21298; SINGLETON CK, 1982, ANAL BIOCHEM, V122, P253, DOI 10.1016/0003-2697(82)90277-9; VANHOLDE K, 1994, BIOESSAYS, V16, P59, DOI 10.1002/bies.950160110; Wang ZY, 1997, J MOL BIOL, V271, P499, DOI 10.1006/jmbi.1997.1197	30	37	37	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	1999	274	12					8169	8174		10.1074/jbc.274.12.8169	http://dx.doi.org/10.1074/jbc.274.12.8169			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	178LU	10075720	hybrid			2022-12-25	WOS:000079268100079
J	Coletta, M; Angeletti, M; Ascenzi, P; Bertollini, A; Della Longa, S; De Sanctis, G; Priori, AM; Santucci, R; Amiconi, G				Coletta, M; Angeletti, M; Ascenzi, P; Bertollini, A; Della Longa, S; De Sanctis, G; Priori, AM; Santucci, R; Amiconi, G			Coupling of the oxygen-linked interaction energy for inositol hexakisphosphate and bezafibrate binding to human HbA(0)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FERROUS HUMAN HEMOGLOBIN; T-STATE HEMOGLOBIN; X-RAY; STRUCTURAL-CHANGE; GLOBIN STRUCTURE; DEOXYHEMOGLOBIN; OXYHEMOGLOBIN; COOPERATIVITY; SPECTROSCOPY; TETRAMERS	The energetics of signal propagation between different functional domains (i.e, the binding sites for O-2, inositol hexakisphospate (IHP), and bezafibrate (BZF)) of human HbA(0) was analyzed at different heme ligation states and through the use of a stable, partially heme ligated intermediate. Present data allow three main conclusions to be drawn, and namely: (i) IHP and BZF enhance each others binding as the oxygenation proceeds, the coupling free energy going from close to zero in the deoxy state to -3.4 kJ/mol in the oxygenated form; (ii) the simultaneous presence of IHP and BZF stabilizes the hemoglobin T quaternary structure at very low O-2 pressures, but as oxygenation proceeds it does not impair the transition toward the R structure, which indeed occurs also under these conditions; (iii) under room air pressure (i.e. pO(2) = 150 torr), IHP and BZF together induce the formation of an asymmetric dioxygenated hemoglobin tetramer, whose features appear reminiscent of those suggested for transition state species (i.e. T- and R-like tertiary conformation(s) within a quaternary R-like structure).	Univ Roma Tor Vergata, Dept Expt Med & Biochem Sci, I-00133 Rome, Italy; Univ Camerino, Dept Mol Cellular & Anim Biol, I-62032 Camerino, MC, Italy; Univ Roma 3, Dept Biol, I-00146 Rome, Italy; Univ Rome La Sapienza, Dept Biochem Sci, I-00185 Rome, Italy; Univ Rome La Sapienza, CNR, Ctr Mol Biol, I-00185 Rome, Italy; Univ Aquila, Dept Expt Med, Biophys Grp, I-67100 Laquila, Italy	University of Rome Tor Vergata; University of Camerino; Roma Tre University; Sapienza University Rome; Consiglio Nazionale delle Ricerche (CNR); Sapienza University Rome; University of L'Aquila	Coletta, M (corresponding author), Univ Roma Tor Vergata, Dept Expt Med & Biochem Sci, Via Tor Vergata 135, I-00133 Rome, Italy.	coletta@seneca.uniroma2.it	Coletta, Massimiliano/GSN-5927-2022; Priori, Alberto/K-9603-2016; Angeletti, Mauro/AAC-5597-2019; Coletta, Massimo/N-9049-2015	Priori, Alberto/0000-0002-1549-3851; Angeletti, Mauro/0000-0001-6719-5517; della longa, stefano/0000-0002-8157-9530; COLETTA, Massimiliano/0000-0002-5489-9467				ABRAHAM DJ, 1992, J MOL BIOL, V227, P480, DOI 10.1016/0022-2836(92)90902-V; ACKERS GK, 1992, SCIENCE, V255, P54, DOI 10.1126/science.1553532; Adair GS, 1925, J BIOL CHEM, V63, P529; AMICONI G, 1989, BIOCHEMISTRY-US, V28, P8547, DOI 10.1021/bi00447a042; AMICONI G, 1981, J MOL BIOL, V152, P111, DOI 10.1016/0022-2836(81)90097-8; ANTONINI E, 1982, EUR J BIOCHEM, V121, P325, DOI 10.1111/j.1432-1033.1982.tb05789.x; Antonini E., 1971, HEMOGLOBIN MYOGLOBIN; ASCENZI P, 1993, J INORG BIOCHEM, V50, P263, DOI 10.1016/0162-0134(93)80053-C; BENESCH RE, 1986, J MOL BIOL, V190, P481, DOI 10.1016/0022-2836(86)90016-1; BENESCH RE, 1983, P NATL ACAD SCI-BIOL, V80, P6202, DOI 10.1073/pnas.80.20.6202; BORGSTAHL GEO, 1994, J MOL BIOL, V236, P831, DOI 10.1006/jmbi.1994.1192; COLETTA M, 1993, BIOCHIM BIOPHYS ACTA, V1162, P309, DOI 10.1016/0167-4838(93)90295-3; COLETTA M, 1998, IN PRESS BIOPHYS J; De Sanctis G, 1998, J BIOL INORG CHEM, V3, P135; DOLMAN D, 1978, ANAL BIOCHEM, V87, P127, DOI 10.1016/0003-2697(78)90576-6; DOYLE ML, 1988, J MOL BIOL, V196, P927; EATON WA, 1991, P NATL ACAD SCI USA, V88, P4472, DOI 10.1073/pnas.88.10.4472; GELIN BR, 1983, J MOL BIOL, V171, P489, DOI 10.1016/0022-2836(83)90042-6; Giardina B, 1981, Methods Enzymol, V76, P417; GILL SJ, 1987, BIOCHEMISTRY-US, V26, P3995, DOI 10.1021/bi00387a038; GILL SJ, 1989, BIOCHEM BIOPH RES CO, V165, P226, DOI 10.1016/0006-291X(89)91058-9; GRAY RD, 1971, J BIOL CHEM, V245, P2914; HENRY ER, 1992, METHOD ENZYMOL, V210, P129; HOFRICHTER J, 1991, BIOCHEMISTRY-US, V30, P6583, DOI 10.1021/bi00240a031; HOLT JM, 1995, FASEB J, V9, P210, DOI 10.1096/fasebj.9.2.7781923; HOPFIELD JJ, 1973, J MOL BIOL, V77, P207, DOI 10.1016/0022-2836(73)90332-X; IMAI K, 1975, J BIOL CHEM, V250, P2227; JAYARAMAN V, 1995, SCIENCE, V269, P1843, DOI 10.1126/science.7569921; LIDDINGTON R, 1992, J MOL BIOL, V228, P551, DOI 10.1016/0022-2836(92)90842-8; LUMRY R, 1954, J PHYS CHEM-US, V58, P110, DOI 10.1021/j150512a005; MARDEN MC, 1988, BIOCHEMISTRY-US, V27, P1659, DOI 10.1021/bi00405a041; MARDEN MC, 1990, BIOPHYS J, V57, P397, DOI 10.1016/S0006-3495(90)82556-X; Messana I, 1998, J BIOL CHEM, V273, P15329, DOI 10.1074/jbc.273.25.15329; MONOD J, 1965, J MOL BIOL, V12, P88, DOI 10.1016/S0022-2836(65)80285-6; Mouawad L, 1996, J MOL BIOL, V258, P393, DOI 10.1006/jmbi.1996.0257; PERUTZ MF, 1986, J AM CHEM SOC, V108, P1064, DOI 10.1021/ja00265a036; PERUTZ MF, 1983, LANCET, V2, P881; PERUTZ MF, 1974, BIOCHEMISTRY-US, V13, P2174, DOI 10.1021/bi00707a027; PIN S, 1994, METHOD ENZYMOL, V232, P266; Riggs A., 1981, Methods in Enzymology, V76, P5; SAWICKI CA, 1977, J BIOL CHEM, V252, P7538; SCHONERT H, 1988, EUR J BIOCHEM, V176, P319, DOI 10.1111/j.1432-1033.1988.tb14284.x; SHARMA VS, 1976, J BIOL CHEM, V251, P4267; WILLIAMS RC, 1973, ANAL BIOCHEM, V54, P137, DOI 10.1016/0003-2697(73)90256-X; Wilson J, 1996, J MOL BIOL, V264, P743, DOI 10.1006/jmbi.1996.0674; WYMAN J, 1984, Q REV BIOPHYS, V17, P453, DOI 10.1017/S0033583500004881	46	19	19	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 12	1999	274	11					6865	6874		10.1074/jbc.274.11.6865	http://dx.doi.org/10.1074/jbc.274.11.6865			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	175DV	10066739	hybrid			2022-12-25	WOS:000079078400011
J	Anandatheerthavarada, HK; Vijayasarathy, C; Bhagwat, SV; Biswas, G; Mullick, J; Avadhani, NG				Anandatheerthavarada, HK; Vijayasarathy, C; Bhagwat, SV; Biswas, G; Mullick, J; Avadhani, NG			Physiological role of the N-terminal processed P4501A1 targeted to mitochondria in erythromycin metabolism and reversal of erythromycin-mediated inhibition of mitochondrial protein synthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER MITOCHONDRIA; C6 CELL-LINE; CYTOCHROME-P-450 SYSTEM; ESCHERICHIA-COLI; OXIDATIVE DAMAGE; PRECURSOR FORMS; MULTIPLE FORMS; P-450; REDUCTASE; DNA	Recently, we showed that the major species of beta-naphthoflavone-inducible rat liver mitochondrial P450MT2 consists of N-terminal truncated microsomal P4501A1 (+33/1A1) and that the truncated enzyme exhibits different substrate specificity as compared with intact P4501A1. The results of the present study show that P450MT2 targeted to COS cell mitochondria by transient transfection of P4501A1 cDNA is localized inside the mitochondrial inner membrane in a membrane-extrinsic orientation. Go-expression with wild type P4501A1 and adrenodoxin (Adx) cDNAs resulted in 5-7-fold higher erythromycin N-demethylation (ERND) in the mitochondrial fraction but minimal changes in the microsomal fraction of transfected cells. Erythromycin, a potent inhibitor of bacterial and mitochondrial protein synthesis, caused 8-12-fold higher accumulation of CYP1A1 mRNA, preferential accumulation of P450MT2, and 5-6-fold higher ERND activity in the mitochondrial compartment of rat C6 glioma cells. Consistent with the increased mitochondrial ERND activity, cc-expression with P4501A1 and Adx in COS cells rendered complete protection against erythromycin-mediated mitochondrial translation inhibition. Mutations that specifically affect the mitochondrial targeting of P4501A1 also abolished protection against mitochondrial translation inhibition. These results for the first time suggest a physiological function for the xenobiotic inducible cytochrome P4501A1 against drug-mediated mitochondrial toxicity.	Univ Penn, Sch Vet Med, Dept Anim Biol, Philadelphia, PA 19104 USA	University of Pennsylvania	Avadhani, NG (corresponding author), Univ Penn, Sch Vet Med, Dept Anim Biol, Philadelphia, PA 19104 USA.	narayan@vet.upenn.edu			NIGMS NIH HHS [GM34883] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034883] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADDYA S, 1994, ARCH BIOCHEM BIOPHYS, V310, P82, DOI 10.1006/abbi.1994.1143; ADDYA S, 1991, BIOCHEMISTRY-US, V30, P8323, DOI 10.1021/bi00098a007; Addya S, 1997, J CELL BIOL, V139, P589, DOI 10.1083/jcb.139.3.589; Anandatheerthavarada HK, 1998, BIOCHEMISTRY-US, V37, P1150, DOI 10.1021/bi972046j; Anandatheerthavarada HK, 1997, ARCH BIOCHEM BIOPHYS, V339, P136, DOI 10.1006/abbi.1996.9855; AVADHANI NG, 1971, EXP CELL RES, V69, P226, DOI 10.1016/0014-4827(71)90331-4; AVADHANI NG, 1975, SUB-CELL BIOCHEM, V4, P93; BACHMANN E, 1979, TOXICOL LETT, V3, P29, DOI 10.1016/0378-4274(79)90103-6; BHAGWAT SV, 1995, ARCH BIOCHEM BIOPHYS, V320, P73, DOI 10.1006/abbi.1995.1344; Bhagwat SV, 1998, INT J ONCOL, V13, P281; Bhagwat SV, 1998, BIOCHEM PHARMACOL, V56, P831, DOI 10.1016/S0006-2952(98)00228-7; BHAGWAT SV, 1999, IN PRESS BIOCH PHARM; BHAT NK, 1982, BIOCHEMISTRY-US, V21, P2452, DOI 10.1021/bi00539a026; BHAT NK, 1985, BIOCHEMISTRY-US, V24, P8107, DOI 10.1021/bi00348a041; BHAT NK, 1982, CANCER RES, V42, P2764; BLACK SD, 1982, J BIOL CHEM, V257, P5929; BOWLING AC, 1993, J NEUROCHEM, V61, P2322, DOI 10.1111/j.1471-4159.1993.tb07478.x; BRIAN WR, 1990, BIOCHEMISTRY-US, V29, P11280, DOI 10.1021/bi00503a018; CHOMYN A, 1991, MOL CELL BIOL, V11, P2236, DOI 10.1128/MCB.11.4.2236; CLARK BJ, 1991, J BIOL CHEM, V266, P5898; DEVRIES H, 1973, BIOCHIM BIOPHYS ACTA, V331, P264, DOI 10.1016/0005-2787(73)90439-5; Dong MS, 1996, ARCH BIOCHEM BIOPHYS, V327, P11, DOI 10.1006/abbi.1996.0086; Geng J, 1997, BRAIN RES, V774, P11, DOI 10.1016/S0006-8993(97)81681-2; GENG J, 1995, J NEUROCHEM, V65, P554; GONZALEZ FJ, 1990, PHARMACOL THERAPEUT, V45, P1, DOI 10.1016/0163-7258(90)90006-N; Greenawalt J W, 1974, Methods Enzymol, V31, P310; HARRIS JM, 1991, BIOCHEM J, V278, P137, DOI 10.1042/bj2780137; HOFHAUS G, 1993, EMBO J, V12, P3043, DOI 10.1002/j.1460-2075.1993.tb05973.x; HONIG PK, 1992, CLIN PHARMACOL THER, V52, P231, DOI 10.1038/clpt.1992.135; HONKAKOSKI P, 1988, ARCH BIOCHEM BIOPHYS, V267, P558, DOI 10.1016/0003-9861(88)90063-X; IMAI T, 1993, J BIOL CHEM, V268, P19681; ISCAN M, 1990, BIOCHEM BIOPH RES CO, V169, P858, DOI 10.1016/0006-291X(90)91972-U; JENKINS CM, 1994, J BIOL CHEM, V269, P27401; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARSON JR, 1991, J BIOL CHEM, V266, P7321; LUDDEN TM, 1985, CLIN PHARMACOKINET, V10, P63, DOI 10.2165/00003088-198510010-00003; MACCECCHINI ML, 1979, P NATL ACAD SCI USA, V76, P343, DOI 10.1073/pnas.76.1.343; MARTELL R, 1986, ANN INTERN MED, V104, P660, DOI 10.7326/0003-4819-104-5-660; MICHAEL NL, 1984, EMBO J, V3, P3165, DOI 10.1002/j.1460-2075.1984.tb02275.x; Mitsuyama T, 1998, MOL CELL BIOCHEM, V181, P157, DOI 10.1023/A:1006894301389; MIZUNO Y, 1988, J NEUROL SCI, V86, P97, DOI 10.1016/0022-510X(88)90010-X; MUKHOPADHYAY CK, 1994, J BIOL CHEM, V269, P13390; NIRANJAN BG, 1984, J BIOL CHEM, V259, P2495; NIRANJAN BG, 1980, J BIOL CHEM, V255, P6575; NIRANJAN BG, 1982, SCIENCE, V215, P73, DOI 10.1126/science.6797067; OKAMURA T, 1985, P NATL ACAD SCI USA, V82, P5705, DOI 10.1073/pnas.82.17.5705; OKEY AB, 1990, PHARMACOL THERAPEUT, V45, P241, DOI 10.1016/0163-7258(90)90030-6; RAZA H, 1988, J BIOL CHEM, V263, P9533; Sakaki T, 1996, J BIOL CHEM, V271, P26209, DOI 10.1074/jbc.271.42.26209; SHAYIQ RM, 1991, METHOD ENZYMOL, V206, P587; SINCLAIR JF, 1981, BIOCHEM PHARMACOL, V30, P2805, DOI 10.1016/0006-2952(81)90418-4; SINGAL PK, 1987, J MOL CELL CARDIOL, V19, P817, DOI 10.1016/S0022-2828(87)80392-9; SOR F, 1984, NUCLEIC ACIDS RES, V12, P8313, DOI 10.1093/nar/12.22.8313; STADTMAN ER, 1991, J BIOL CHEM, V266, P2005; Tan GT, 1996, J MOL BIOL, V261, P222, DOI 10.1006/jmbi.1996.0454; Vellai T, 1998, J MOL EVOL, V46, P499, DOI 10.1007/PL00006331; VIJAYASARATHY C, 1993, BIOCHIM BIOPHYS ACTA, V1143, P38, DOI 10.1016/0005-2728(93)90213-Y; WALLACE DC, 1992, ANNU REV BIOCHEM, V61, P1175, DOI 10.1146/annurev.bi.61.070192.005523; Wang M, 1997, P NATL ACAD SCI USA, V94, P8411, DOI 10.1073/pnas.94.16.8411; WATKINS PB, 1989, J CLIN INVEST, V83, P688, DOI 10.1172/JCI113933; WAXMAN DJ, 1988, BIOCHEM PHARMACOL, V37, P71, DOI 10.1016/0006-2952(88)90756-3; WHATLEY FR, 1981, ANN NY ACAD SCI, V361, P330, DOI 10.1111/j.1749-6632.1981.tb46529.x; WILKIE D, 1977, MOL CELL BIOCHEM, V14, P97, DOI 10.1007/BF01734171; WUNDERLICH V, 1971, CHEM-BIOL INTERACT, V4, P81, DOI 10.1016/0009-2797(72)90001-4; YANG HYL, 1988, MOL PHARMACOL, V34, P67; ZUBER MX, 1988, P NATL ACAD SCI USA, V85, P699, DOI 10.1073/pnas.85.3.699	66	45	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	1999	274	10					6617	6625		10.1074/jbc.274.10.6617	http://dx.doi.org/10.1074/jbc.274.10.6617			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172BQ	10037757	hybrid			2022-12-25	WOS:000078902800079
J	Fujinaga, J; Tang, XB; Casey, JR				Fujinaga, J; Tang, XB; Casey, JR			Topology of the membrane domain of human erythrocyte anion exchange protein, AE1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METAL-TETRACYCLINE/H+ ANTIPORTER; SITE-DIRECTED MUTAGENESIS; PRO-868 -> LEU; TRANSPORT PROTEIN; BAND-3 PROTEIN; MONOCLONAL-ANTIBODIES; INTRACELLULAR PH; CYTOPLASMIC SIDE; TERMINAL REGION; BINDING-SITE	Anion exchanger 1 (AE1) is the chloride/bicarbonate exchange protein of the erythrocyte membrane. By using a combination of introduced cysteine mutants and sulfhydryl-specific chemistry, we have mapped the topology of the human AE1 membrane domain. Twenty-seven single cysteines were introduced throughout the Leu(708)-Val(911) region of human AE1, and these mutants were expressed by transient transfection of human embryonic kidney cells. On the basis of cysteine accessibility to membrane-permeant biotin maleimide and to membrane-impermeant lucifer yellow iodoacetamide, we have proposed a model for the topology of AE1 membrane domain. In this model, AE1 is composed of 13 typical transmembrane segments, and the Asp(807)-His(834) region is membrane-embedded but does not have the usual alpha-helical conformation. To identify amino acids that are important for anion transport, we analyzed the anion exchange activity for all introduced cysteine mutants, using a whole cell fluorescence assay, We found that mutants G714C, S725C, and S731C have very low transport activity, implying that this region has a structurally and/or catalytically important role, We measured the residual anion transport activity after mutant treatment with the membrane-impermeant, cysteine-directed compound, sodium (2-sulfonatoethyl) methanethiosulfonate) (MTSES). Only two mutants, S852C and A858C, were inhibited by MTSES, indicating that these residues may be located in a pore-lining region.	Univ Alberta, Dept Physiol, Edmonton, AB T6G 2H7, Canada	University of Alberta	Casey, JR (corresponding author), Univ Alberta, Dept Physiol, Edmonton, AB T6G 2H7, Canada.	joe.casey@ualberta.ca	Casey, Joseph/A-8888-2013	Casey, Joseph/0000-0002-9890-5056				AKABAS MH, 1994, J BIOL CHEM, V269, P14865; BRUCE LJ, 1993, BIOCHEM J, V293, P317, DOI 10.1042/bj2930317; CASEY JR, 1995, J BIOL CHEM, V270, P8521, DOI 10.1074/jbc.270.15.8521; Chernova MN, 1997, BBA-BIOMEMBRANES, V1329, P111, DOI 10.1016/S0005-2736(97)00090-4; Erickson HK, 1997, BIOCHEMISTRY-US, V36, P9958, DOI 10.1021/bi970493t; GRINSTEIN S, 1978, BIOCHIM BIOPHYS ACTA, V507, P294, DOI 10.1016/0005-2736(78)90424-8; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; JENNINGS ML, 1986, J BIOL CHEM, V261, P9002; JENNINGS ML, 1992, KIDNEY PHYSL PATHOPH, P503; KANG D, 1992, J BIOL CHEM, V267, P19211; KAWANO Y, 1988, J BIOL CHEM, V263, P8232; Kimura T, 1997, J BIOL CHEM, V272, P580; Kimura T, 1996, BIOCHEMISTRY-US, V35, P15896, DOI 10.1021/bi961568g; KOPITO RR, 1989, CELL, V59, P927, DOI 10.1016/0092-8674(89)90615-6; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE BS, 1991, J BIOL CHEM, V266, P11448; LIEBERMAN DM, 1987, BIOCHIM BIOPHYS ACTA, V903, P37, DOI 10.1016/0005-2736(87)90153-2; LIEBERMAN DM, 1983, BIOCHEMISTRY-US, V22, P4028, DOI 10.1021/bi00286a006; LIEBERMAN DM, 1988, J BIOL CHEM, V263, P10022; LINDSEY AE, 1990, P NATL ACAD SCI USA, V87, P5278, DOI 10.1073/pnas.87.14.5278; LOO TW, 1995, J BIOL CHEM, V270, P843, DOI 10.1074/jbc.270.2.843; LUX SE, 1989, P NATL ACAD SCI USA, V86, P9089, DOI 10.1073/pnas.86.23.9089; MAKINO S, 1982, J BIOCHEM-TOKYO, V92, P1069, DOI 10.1093/oxfordjournals.jbchem.a134022; MORI A, 1995, J BIOCHEM-TOKYO, V118, P1192, DOI 10.1093/oxfordjournals.jbchem.a125006; NILSSON I, 1993, J BIOL CHEM, V268, P5798; OKUBO K, 1994, J BIOL CHEM, V269, P1918; Popov M, 1997, J BIOL CHEM, V272, P18325, DOI 10.1074/jbc.272.29.18325; REITHMEIER RAF, 1996, HDB BIOL PHYSICS, V2; RUETZ S, 1993, J CELL BIOL, V121, P37, DOI 10.1083/jcb.121.1.37; SALHANY JM, 1995, P NATL ACAD SCI USA, V92, P11844, DOI 10.1073/pnas.92.25.11844; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; Tang XB, 1998, J BIOL CHEM, V273, P22545, DOI 10.1074/jbc.273.35.22545; THOMAS JA, 1979, BIOCHEMISTRY-US, V18, P2210, DOI 10.1021/bi00578a012; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WAINWRIGHT SD, 1990, BIOCHEM J, V272, P265, DOI 10.1042/bj2720265; WAINWRIGHT SD, 1989, BIOCHEM J, V258, P211, DOI 10.1042/bj2580211; XU M, 1993, J BIOL CHEM, V268, P21505	37	90	91	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1999	274	10					6626	6633		10.1074/jbc.274.10.6626	http://dx.doi.org/10.1074/jbc.274.10.6626			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172BQ	10037758	hybrid			2022-12-25	WOS:000078902800080
J	Gibson, AD; Lamerdin, JA; Zhuang, P; Baburaj, K; Serpersu, EH; Peterson, CB				Gibson, AD; Lamerdin, JA; Zhuang, P; Baburaj, K; Serpersu, EH; Peterson, CB			Orientation of heparin-binding sites in native vitronectin - Analyses of ligand binding to the primary glycosaminoglycan-binding site indicate that putative secondary sites are not functional	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMINOGEN-ACTIVATOR INHIBITOR-1; SOMATOMEDIN-B DOMAIN; S-PROTEIN VITRONECTIN; ANTITHROMBIN-III; BLOOD-COAGULATION; STRUCTURAL REQUIREMENTS; MULTIMERIC VITRONECTIN; CONFORMATIONAL CHANGE; PLASMA VITRONECTIN; CRYSTAL-STRUCTURE	A primary heparin-binding site in vitronectin has been localized to a cluster of cationic residues near the C terminus of the protein. More recently, secondary binding sites have been proposed. In order to investigate whether the binding site originally identified on vitronectin functions as an exclusive and independent heparin-binding domain, solution binding methods have been used in combination with NMR and recombinant approaches to evaluate Ligand binding to the primary site. Evaluation of the ionic strength dependence of heparin binding to vitronectin according to classical linkage theory indicates that a single ionic bond is prominent. It had been previously shown that chemical modification of vitronectin using an arginine reactive probe results in a significant reduction in heparin binding (Gibson, A, Baburaj, K, Day, D. E., Verhamme, I., Shore, J, D,, and Peterson, C, B, (1997) J. Biol Chem, 272, 5112-5121), The label has now been localized to arginine residues within the cyanogen bromide fragment-(341-380) that contains the primary heparin-binding site on vitronectin. One- and two-dimensional NMR on model peptides based on this primary heparin-binding site indicate that an arginine residue participates in the ionic interaction and that other nonionic interactions may be involved in forming a complex with heparin, A recombinant polypeptide corresponding to the C-terminal 129 amino acids of vitronectin exhibits heparin-binding affinity that is comparable to that of full-length vitronectin and is equally effective at neutralizing heparin anticoagulant activity. Results from this broad experimental approach argue that the behavior of the primary site is sufficient to account for the heparin binding activity of vitronectin and support an exposed orientation for the site in the structure of the native protein.	Univ Tennessee, Dept Biochem & Cellular & Mol Biol, Knoxville, TN 37996 USA	University of Tennessee System; University of Tennessee Knoxville	Peterson, CB (corresponding author), Univ Tennessee, Dept Biochem & Cellular & Mol Biol, M407 Walters Life Sci Bldg, Knoxville, TN 37996 USA.			Serpersu, Engin H./0000-0003-1420-455X	NHLBI NIH HHS [HL50676] Funding Source: Medline; NIGMS NIH HHS [R29 GM42661] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL050676, R01HL050676] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM042661] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARNES DW, 1983, J BIOL CHEM, V258, P2548; BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; BITTORF SV, 1993, J BIOL CHEM, V268, P24838; BOCK PE, 1985, J BIOL CHEM, V260, P2434; BRAUNSCHWEILER L, 1983, J MAGN RESON, V53, P521, DOI 10.1016/0022-2364(83)90226-3; CARDIN AD, 1989, ARTERIOSCLEROSIS, V9, P21, DOI 10.1161/01.ATV.9.1.21; CHAIN D, 1991, BIOCHEM J, V274, P387, DOI 10.1042/bj2740387; DAHLBACK B, 1985, BIOCHEMISTRY-US, V24, P2368, DOI 10.1021/bi00330a036; DANIELSSON A, 1981, BIOCHEM J, V193, P427; DAVIS DG, 1985, J AM CHEM SOC, V107, P2820, DOI 10.1021/ja00295a052; Deng G, 1996, J BIOL CHEM, V271, P12716, DOI 10.1074/jbc.271.22.12716; FABER HR, 1995, STRUCTURE, V3, P551, DOI 10.1016/S0969-2126(01)00189-7; Gechtman Z, 1997, BIOCHEM J, V325, P339, DOI 10.1042/bj3250339; GECHTMAN Z, 1993, FEBS LETT, V315, P293, DOI 10.1016/0014-5793(93)81181-X; Gibson A, 1997, J BIOL CHEM, V272, P5112, DOI 10.1074/jbc.272.8.5112; GomisRuth FX, 1996, J MOL BIOL, V264, P556, DOI 10.1006/jmbi.1996.0661; Hileman RE, 1998, BIOESSAYS, V20, P156, DOI 10.1002/(SICI)1521-1878(199802)20:2<156::AID-BIES8>3.3.CO;2-#; HONIG B, 1995, SCIENCE, V268, P1144, DOI 10.1126/science.7761829; HORNER AA, 1988, BIOCHEM J, V251, P141, DOI 10.1042/bj2510141; Hunt L T, 1987, Protein Seq Data Anal, V1, P21; HUSTEN EJ, 1987, J BIOL CHEM, V262, P12953; Kost C, 1996, EUR J BIOCHEM, V236, P682, DOI 10.1111/j.1432-1033.1996.0682d.x; KOST C, 1992, J BIOL CHEM, V267, P12098; LANE DA, 1987, J BIOL CHEM, V262, P16343; Liang OD, 1997, FEBS LETT, V407, P169, DOI 10.1016/S0014-5793(97)00330-X; MARION D, 1983, BIOCHEM BIOPH RES CO, V113, P967, DOI 10.1016/0006-291X(83)91093-8; MCGUIRE EA, 1988, J BIOL CHEM, V263, P1942; NORDENMAN B, 1981, BIOCHIM BIOPHYS ACTA, V672, P227, DOI 10.1016/0304-4165(81)90289-0; OLSON ST, 1991, J BIOL CHEM, V266, P6342; PETERSON CB, 1987, J BIOL CHEM, V262, P7559; Peterson CB, 1998, TRENDS CARDIOVAS MED, V8, P124, DOI 10.1016/S1050-1738(97)00136-9; PETERSON CB, 1985, J BIOL CHEM, V260, P610; PETERSON CB, 1987, J BIOL CHEM, V262, P7567; PREISSNER KT, 1991, THROMB HAEMOSTASIS, V66, P123; PREISSNER KT, 1985, BIOCHEM J, V231, P349, DOI 10.1042/bj2310349; PREISSNER KT, 1991, ANNU REV CELL BIOL, V7, P275, DOI 10.1146/annurev.cellbio.7.1.275; PREISSNER KT, 1987, J BIOL CHEM, V262, P12247; PREISSNER KT, 1986, EUR J BIOCHEM, V156, P645, DOI 10.1111/j.1432-1033.1986.tb09626.x; RECORD MT, 1976, J MOL BIOL, V107, P145, DOI 10.1016/S0022-2836(76)80023-X; SANE DC, 1991, THROMB HAEMOSTASIS, V66, P310; SEIFFERT D, 1991, J BIOL CHEM, V266, P2824; SEIFFERT D, 1994, J BIOL CHEM, V269, P2659; Seiffert D, 1997, J BIOL CHEM, V272, P9971; SOBEL M, 1992, J BIOL CHEM, V267, P8857; STOCKMANN A, 1993, J BIOL CHEM, V268, P22874; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; SUZUKI S, 1985, EMBO J, V4, P2519, DOI 10.1002/j.1460-2075.1985.tb03965.x; SUZUKI S, 1984, J BIOL CHEM, V259, P5307; TOLLEFSEN DM, 1990, J BIOL CHEM, V265, P9778; Tomasini B R, 1991, Prog Hemost Thromb, V10, P269; TOMASINI BR, 1988, BLOOD, V72, P903; TSCHOPP J, 1988, BIOCHEMISTRY-US, V27, P4103, DOI 10.1021/bi00411a029; YE J, 1991, J BIOL CHEM, V266, P23016; Yoneda A, 1998, BIOCHEMISTRY-US, V37, P6351, DOI 10.1021/bi972247n; YONEDA A, 1993, EUR J BIOCHEM, V218, P797, DOI 10.1111/j.1432-1033.1993.tb18434.x; Zhuang P, 1997, J BIOL CHEM, V272, P6858, DOI 10.1074/jbc.272.11.6858; Zhuang P, 1996, J BIOL CHEM, V271, P14323, DOI 10.1074/jbc.271.24.14323	57	32	32	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1999	274	10					6432	6442		10.1074/jbc.274.10.6432	http://dx.doi.org/10.1074/jbc.274.10.6432			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172BQ	10037735	hybrid			2022-12-25	WOS:000078902800057
J	Leblais, V; Demolombe, S; Vallette, G; Langin, D; Baro, I; Escande, D; Gauthier, C				Leblais, V; Demolombe, S; Vallette, G; Langin, D; Baro, I; Escande, D; Gauthier, C			beta(3)-adrenoceptor control the cystic fibrosis transmembrane conductance regulator through a cAMP/protein kinase A-independent pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN BETA-3-ADRENERGIC RECEPTOR; FUNCTIONAL BETA(3)-ADRENOCEPTOR; BETA(2)-ADRENERGIC RECEPTOR; SIGNAL-TRANSDUCTION; TRACHEAL EPITHELIUM; CHLORIDE CHANNEL; TRANSGENIC MICE; CL CHANNELS; CELL-LINE; CFTR	In human cardiac myocytes, we have previously identified a functional beta(3)-adrenoceptor in which stimulation reduces action potential duration. Surprisingly, in cardiac biopsies obtained hom cystic fibrosis patients, beta(3)-adrenoceptor agonists produced no effects on action potential duration. This result suggests the involvement of cystic fibrosis transmembrane conductance regulator (CFTR) chloride current in the electrophysiological effects of beta(3)-adrenoceptor stimulation in non-cystic fibrosis tissues. We therefore investigated the control of CFTR activity by human beta(3)-adrenoceptors in a recombinant system: A549 human cells were intranuclearly injected with plasmids encoding CFTR and beta(3)-adrenoceptors. CFTR activity was functionally assayed using the 6-methoxy-N-(3-sulfopropyl) quinolinium fluorescent probe and the patch-clamp technique. injection of CFTR-cDNA alone led to the expression of a functional CFTR protein activated by cAMP or cGMP. Co-expression of CFTR (but not of mutated Delta F508-CFTR) with high levels of beta(3)-adrenoceptor produced an increased halide permeability under base-line conditions that was not further sensitive to cAMP or beta(3)-adrenoceptor stimulation. Patch-clamp experiments confirmed that CFTR channels were permanently activated in cells co-expressing CFTR and a high level of beta(3)-adrenoceptor. Permanent CFTR activation was not associated with elevated intracellular cAMP or cGMP levels. When the expression level of beta(3)-adrenoceptor was lowered, CFTR was not activated under base-line conditions but became sensitive to beta(3)-adrenoceptor stimulation (isoproterenol plus nadolol, SR 58611, or CGP 12177). This later effect was not prevented by protein kinase A inhibitors. Our results provide molecular evidence that CFTR but not mutated Delta F508-CFTR is regulated by beta(3)-adrenoceptors expression through a protein kinase A-independent pathway.	Hotel Dieu, Lab Physiopathol & Pharmacol Cellulaires & Mol, INSERM, CJF 96 01, F-44093 Nantes, France; Hotel Dieu, INSERM, CJF 94 04, F-44093 Nantes, France; CHU Rangueil, INSERM, U317, F-31056 Toulouse, France; Univ Nantes, Fac Sci & Tech, F-44322 Nantes, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Nantes Universite; CHU de Nantes; Institut National de la Sante et de la Recherche Medicale (Inserm); Nantes Universite; CHU de Nantes; CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm); Nantes Universite	Gauthier, C (corresponding author), Hotel Dieu, Lab Physiopathol & Pharmacol Cellulaires & Mol, INSERM, CJF 96 01, Bat HBN,BP 1005, F-44093 Nantes, France.		Baró, Isabelle/D-3604-2015; Baró, Isabelle/ABH-5667-2020; Gauthier, Chantal/D-6198-2015; LEBLAIS, Véronique/Q-3845-2018	Baró, Isabelle/0000-0003-4850-4171; Baró, Isabelle/0000-0003-4850-4171; LEBLAIS, Véronique/0000-0001-9934-8944; Langin, Dominique/0000-0002-2669-7825				BARO I, 1994, J PHYSIOL-LONDON, V478, P469, DOI 10.1113/jphysiol.1994.sp020266; BEAR CE, 1992, CELL, V68, P809, DOI 10.1016/0092-8674(92)90155-6; BLIN N, 1993, MOL PHARMACOL, V44, P1094; Bohm M, 1997, J MOL MED, V75, P842, DOI 10.1007/s001090050175; BOND RA, 1995, NATURE, V374, P272, DOI 10.1038/374272a0; CANTIELLO HF, 1994, J BIOL CHEM, V269, P11224; CHAUDHRY A, 1994, CELL SIGNAL, V6, P457, DOI 10.1016/0898-6568(94)90093-0; CHENG SH, 1991, CELL, V66, P1027, DOI 10.1016/0092-8674(91)90446-6; DONG YJ, 1995, EMBO J, V14, P2700, DOI 10.1002/j.1460-2075.1995.tb07270.x; FINKBEINER WE, 1993, AM J RESP CELL MOL, V9, P547, DOI 10.1165/ajrcmb/9.5.547; Gauthier C, 1996, J CLIN INVEST, V98, P556, DOI 10.1172/JCI118823; Gauthier C, 1998, J CLIN INVEST, V102, P1377, DOI 10.1172/JCI2191; GAUTHIER C, 1994, J MOL CELL CARDIOL, V26, P1267, DOI 10.1006/jmcc.1994.1146; GJERTSEN BT, 1995, J BIOL CHEM, V270, P20599, DOI 10.1074/jbc.270.35.20599; GUILLAUME JL, 1994, EUR J BIOCHEM, V224, P761, DOI 10.1111/j.1432-1033.1994.00761.x; HOLLENGA C, 1991, EUR J PHARMACOL, V200, P325, DOI 10.1016/0014-2999(91)90590-M; KARTNER N, 1991, CELL, V64, P681, DOI 10.1016/0092-8674(91)90498-N; LEE RJ, 1975, EUR J PHARMACOL, V33, P371, DOI 10.1016/0014-2999(75)90182-X; LELIAS JM, 1993, FEBS LETT, V324, P127, DOI 10.1016/0014-5793(93)81377-C; LEVASSEUR S, 1995, GASTROEN CLIN BIOL, V19, P668; LEVESQUE PC, 1992, CIRC RES, V71, P1002, DOI 10.1161/01.RES.71.4.1002; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MILANO CA, 1994, SCIENCE, V264, P582, DOI 10.1126/science.8160017; MILLIGAN G, 1994, BIOCHEM PHARMACOL, V48, P1059; Mohammad-Panah R, 1998, AM J PHYSIOL-CELL PH, V274, pC310, DOI 10.1152/ajpcell.1998.274.2.C310; Pollard H, 1998, J BIOL CHEM, V273, P7507, DOI 10.1074/jbc.273.13.7507; REN Q, 1993, J BIOL CHEM, V268, P16483; RIORDAN JR, 1989, SCIENCE, V245, P1066; SAMAMA P, 1993, J BIOL CHEM, V268, P4625; Scheer A, 1997, J RECEPT SIGNAL TR R, V17, P57, DOI 10.3109/10799899709036594; SCHWIEBERT EM, 1994, AM J PHYSIOL, V267, pC272, DOI 10.1152/ajpcell.1994.267.1.C272; Strosberg AD, 1997, ANNU REV PHARMACOL, V37, P421, DOI 10.1146/annurev.pharmtox.37.1.421; TABCHARANI JA, 1990, FEBS LETT, V270, P157, DOI 10.1016/0014-5793(90)81257-O; TAMAOKI J, 1993, LIFE SCI, V53, P1509, DOI 10.1016/0024-3205(93)90558-K; TIEN XY, 1994, J BIOL CHEM, V269, P51; VANSPRONSEN A, 1993, EUR J BIOCHEM, V213, P1117, DOI 10.1111/j.1432-1033.1993.tb17861.x; WEBBER SE, 1992, BRIT J PHARMACOL, V105, P857, DOI 10.1111/j.1476-5381.1992.tb09068.x; Wilson S, 1996, J PHARMACOL EXP THER, V279, P214; Wotta DR, 1997, MOL BRAIN RES, V44, P55, DOI 10.1016/S0169-328X(96)00189-1; Zilberfarb V, 1997, J CELL SCI, V110, P801	40	35	39	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1999	274	10					6107	6113		10.1074/jbc.274.10.6107	http://dx.doi.org/10.1074/jbc.274.10.6107			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172BQ	10037693	hybrid			2022-12-25	WOS:000078902800015
J	Lindblom, A; Quadt, N; Marsh, T; Aeschlimann, D; Morgelin, M; Mann, K; Maurer, P; Paulsson, M				Lindblom, A; Quadt, N; Marsh, T; Aeschlimann, D; Morgelin, M; Mann, K; Maurer, P; Paulsson, M			The intrinsic factor vitamin B-12 receptor, cubilin, is assembled into trimers via a coiled-coil alpha-helix	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE TRANSGLUTAMINASE; FACTOR-COBALAMIN; LAMININ; PROTEIN; DOMAIN; STABILIZATION; PURIFICATION; COMPLEX; MATRIX; KIDNEY	A large protein was purified from bovine kidney, using selective extraction with EDTA to solubilize proteins anchored by divalent cation-dependent interactions. An antiserum raised against the purified protein labeled the apical cell surface of the epithelial cells in proximal tubules and the luminal surface of small intestine. Ten peptide sequences, derived from the protein, all matched the recently published sequences for rat (Moestrup, S. K. Kozyraki, R., Kristiansen, M., Kaysen, J. H., Helm Rasmussen, H., Brault, D., Pontillon, F., Goda, F. O., Christensen, E. I., Hammond, T. G., and Verroust, P. J. (1998) J. Biol. Chem. 273, 5235-5242) and human cubilin, a receptor for intrinsic factor-vitamin B-12 complexes, identifying the protein as bovine cubilin. In electron microscopy, a three-armed structure was seen, indicating an oligomerization of three identical subunits. This model was supported by the M-r values of about 1,500,000 for the intact protein and 440,000 for its subunits obtained by analytical ultracentrifugation. In a search for a potential assembly domain, we identified a region of heptad repeats in the N-terminal part of the cubilin sequence. Computer-assisted analysis supported the presence of a coiled-coil alpha-helix between amino acids 103 and 132 of the human cubilin sequence and predicted the formation of a triple coiled-coil. We therefore conclude that cubilin forms a noncovalent trimer of identical subunits connected by an N-terminal coiled-coil alpha-helix.	Univ Cologne, Fac Med, Inst Biochem, D-50931 Cologne, Germany; Univ Lund, Malmo Gen Hosp, Dept Internal Med, S-21401 Malmo, Sweden; Univ Bern, ME Muller Inst Biomech, CH-3010 Bern, Switzerland; Univ Wisconsin, Div Orthoped Surg, Madison, WI 53792 USA; Univ Lund, Dept Mol & Cell Biol, S-22100 Lund, Sweden; Max Planck Inst Biochem, Dept Prot Chem, D-82152 Martinsried, Germany	University of Cologne; Lund University; University of Bern; University of Wisconsin System; University of Wisconsin Madison; Lund University; Max Planck Society	Paulsson, M (corresponding author), Univ Cologne, Fac Med, Inst Biochem, Joseph Stelzmann Str 52, D-50931 Cologne, Germany.		Mann, Karlheinz/C-4254-2008	Aeschlimann, Daniel/0000-0003-0930-7706				AESCHLIMANN D, 1991, J BIOL CHEM, V266, P15308; AESCHLIMANN D, 1993, J CELL BIOL, V120, P1461, DOI 10.1083/jcb.120.6.1461; Beck K, 1997, EMBO J, V16, P3767, DOI 10.1093/emboj/16.13.3767; BECK K, 1992, PATTERNS PROTEIN SEQ, P229; *BECKM INSTR INC, 1991, MOD XLA AN ULTR OPT; BERGER B, 1995, P NATL ACAD SCI USA, V92, P8259, DOI 10.1073/pnas.92.18.8259; Birn H, 1997, J BIOL CHEM, V272, P26497, DOI 10.1074/jbc.272.42.26497; BORK P, 1993, J MOL BIOL, V231, P539, DOI 10.1006/jmbi.1993.1305; CAMPBELL ID, 1993, CURR OPIN STRUC BIOL, V3, P385, DOI 10.1016/S0959-440X(05)80111-3; CHERNYAK VY, 1982, ANAL BIOCHEM, V123, P110, DOI 10.1016/0003-2697(82)90630-3; COHEN C, 1994, SCIENCE, V263, P488, DOI 10.1126/science.8290957; ENGEL J, 1981, J MOL BIOL, V150, P97, DOI 10.1016/0022-2836(81)90326-0; GROSS E, 1961, J AM CHEM SOC, V83, P1510, DOI 10.1021/ja01467a052; GUEANT JL, 1991, BIOCHIM BIOPHYS ACTA, V1073, P614, DOI 10.1016/0304-4165(91)90238-C; KAWAHARA K, 1966, J BIOL CHEM, V241, P3228; Kohn WD, 1997, J MOL BIOL, V267, P1039, DOI 10.1006/jmbi.1997.0930; Kozyraki R, 1998, BLOOD, V91, P3593; KRIEGER M, 1994, ANNU REV BIOCHEM, V63, P601, DOI 10.1146/annurev.bi.63.070194.003125; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINDBLOM A, 1994, EUR J BIOCHEM, V219, P383, DOI 10.1111/j.1432-1033.1994.tb19950.x; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; MARCOULLIS G, 1977, BIOCHIM BIOPHYS ACTA, V496, P36, DOI 10.1016/0304-4165(77)90113-1; MARCOULLIS G, 1977, BIOCHIM BIOPHYS ACTA, V496, P309; MARQUSEE S, 1987, P NATL ACAD SCI USA, V84, P8898, DOI 10.1073/pnas.84.24.8898; Moestrup SK, 1998, J BIOL CHEM, V273, P5235, DOI 10.1074/jbc.273.9.5235; PAULSSON M, 1989, J BIOL CHEM, V264, P18726; PAULSSON M, 1987, EUR J BIOCHEM, V166, P11, DOI 10.1111/j.1432-1033.1987.tb13476.x; RAMABO MJ, 1997, J MOL BIOL, V274, P650; SAKASHITA S, 1980, FEBS LETT, V116, P243, DOI 10.1016/0014-5793(80)80654-5; SEETHARAM B, 1981, J BIOL CHEM, V256, P3785; SEETHARAM B, 1988, J BIOL CHEM, V263, P4443; SEETHARAM B, 1994, ADV T ADDISONS DIS, V2, P393; SHOTTON DM, 1979, J MOL BIOL, V131, P303, DOI 10.1016/0022-2836(79)90078-0; Varela PF, 1997, J MOL BIOL, V274, P635, DOI 10.1006/jmbi.1997.1424; Wolf E, 1997, PROTEIN SCI, V6, P1179, DOI 10.1002/pro.5560060606	35	25	25	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1999	274	10					6374	6380		10.1074/jbc.274.10.6374	http://dx.doi.org/10.1074/jbc.274.10.6374			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172BQ	10037728	hybrid			2022-12-25	WOS:000078902800050
J	Pedrajas, JR; Kosmidou, E; Miranda-Vizuete, A; Gustafsson, JA; Wright, APH; Spyrou, G				Pedrajas, JR; Kosmidou, E; Miranda-Vizuete, A; Gustafsson, JA; Wright, APH; Spyrou, G			Identification and functional characterization of a novel mitochondrial thioredoxin system in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PEROXIDE REDUCTASE; PROTEIN DISULFIDE-ISOMERASE; OXIDATIVE STRESS-RESPONSE; GLUTATHIONE-PEROXIDASE; ESCHERICHIA-COLI; HYDROGEN-PEROXIDE; GENE-EXPRESSION; BUDDING YEAST; DNA-SYNTHESIS; GROWTH	The so-called thioredoxin system, thioredoxin (Trx), thioredoxin reductase (Trr), and NADPH, acts as a disulfide reductase system and can protect cells against oxidative stress. In Saccharomyces cerevisiae, two thioredoxins (Trx1 and Trx2) and one thioredoxin reductase (Trr1) have been characterized, all of them located in the cytoplasm, We have identified and characterized a novel thioredoxin system in S. cerevisiae. The TRX3 gene codes for a 14-kDa protein containing the characteristic thioredoxin active site (WCGPC). The TRR2 gene codes for a protein of 37 kDa with the active-site motif (CAVC) present in prokaryotic thioredoxin reductases and binding sites for NADPH and FAD, We cloned and expressed both proteins in Escherichia coli, and the recombinant Trx3 and Trr2 proteins were active in the insulin reduction assay, Trx3 and Trr2 proteins have N-terminal domain extensions with characteristics of signals for import into mitochondria, By immunoblotting analysis of Saccharomyces subcellular fractions, we provide evidence that these proteins are located in mitochondria, We have also constructed S. cerevisiae strains null in Trx3 and Trr2 proteins and tested them for sensitivity to hydrogen peroxide, The Delta trr2 mutant was more sensitive to H2O2, whereas the Delta trx3 mutant was as sensitive as the wild type. These results suggest an important role of the mitochondrial thioredoxin reductase in protection against oxidative stress in S. cerevisiae.	Karolinska Inst, Novum, Ctr Biotechnol, Dept Biosci, S-14157 Huddinge, Sweden	Karolinska Institutet	Spyrou, G (corresponding author), Karolinska Inst, Novum, Ctr Biotechnol, Dept Biosci, S-14157 Huddinge, Sweden.	giannis.spyrou@cbt.ki.se	Pedrajas, José Rafael/M-9758-2015; Miranda-Vizuete, Antonio/D-6927-2012; IBIS, REDOX/J-7473-2017; Wright, Anthony/J-8187-2015	Pedrajas, José Rafael/0000-0003-1998-0638; Miranda-Vizuete, Antonio/0000-0002-6856-5396; Wright, Anthony/0000-0003-1029-9969				BJORNSTEDT M, 1995, J BIOL CHEM, V270, P11761, DOI 10.1074/jbc.270.20.11761; BJORNSTEDT M, 1994, J BIOL CHEM, V269, P29382; CHAE HZ, 1994, P NATL ACAD SCI USA, V91, P7017, DOI 10.1073/pnas.91.15.7017; CHAE HZ, 1994, J BIOL CHEM, V269, P27670; CHAMBERLIN M, 1974, J VIROL, V14, P509, DOI 10.1128/JVI.14.3.509-516.1974; CHRISTIANSON TW, 1992, GENE, V110, P119, DOI 10.1016/0378-1119(92)90454-W; Constantini P., 1996, J BIOL CHEM, V271, P6746; EJIRI SI, 1979, J BACTERIOL, V139, P161, DOI 10.1128/JB.139.1.161-164.1979; Fortuniak A, 1996, BIOCHEM MOL BIOL INT, V38, P901; FRIDOVICH I, 1975, ANNU REV BIOCHEM, V44, P147, DOI 10.1146/annurev.bi.44.070175.001051; GAN ZR, 1991, J BIOL CHEM, V266, P1692; GASDASKA JR, 1995, CELL GROWTH DIFFER, V6, P1643; GASDASKA PY, 1995, FEBS LETT, V373, P5, DOI 10.1016/0014-5793(95)01003-W; Gladyshev VN, 1996, P NATL ACAD SCI USA, V93, P6146, DOI 10.1073/pnas.93.12.6146; Glick BS, 1995, METHOD ENZYMOL, V260, P213, DOI 10.1016/0076-6879(95)60139-2; HARSHMAN KD, 1988, CELL, V14, P211; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; HOLMGREN A, 1995, METHOD ENZYMOL, V252, P199; HOLMGREN A, 1989, PLASMA MEMBRANE OXID, P295; Inoue Y, 1995, BBA-GEN SUBJECTS, V1245, P325, DOI 10.1016/0304-4165(95)00117-4; JAMIESON DJ, 1992, J BACTERIOL, V174, P6678, DOI 10.1128/JB.174.20.6678-6681.1992; Kang SW, 1998, J BIOL CHEM, V273, P6303, DOI 10.1074/jbc.273.11.6303; Kang SW, 1998, J BIOL CHEM, V273, P6297, DOI 10.1074/jbc.273.11.6297; Kayanoki Y, 1996, J BIOCHEM-TOKYO, V119, P817; LAURENT TC, 1964, J BIOL CHEM, V239, P3436; LIM CJ, 1985, J BACTERIOL, V161, P799, DOI 10.1128/JB.161.2.799-802.1985; LUNDSTROM J, 1990, J BIOL CHEM, V265, P9114; LUNDSTROMLJUNG J, 1995, FEBS LETT, V357, P305, DOI 10.1016/0014-5793(94)01386-F; MATTHEWS JR, 1992, NUCLEIC ACIDS RES, V20, P3821, DOI 10.1093/nar/20.15.3821; Miranda-Vizuete A, 1997, J BIOL CHEM, V272, P30841, DOI 10.1074/jbc.272.49.30841; Morgan BA, 1997, EMBO J, V16, P1035, DOI 10.1093/emboj/16.5.1035; MULLER EGD, 1994, J BIOL CHEM, V269, P24466; MULLER EGD, 1995, ARCH BIOCHEM BIOPHYS, V318, P356, DOI 10.1006/abbi.1995.1240; MULLER EGD, 1991, J BIOL CHEM, V266, P9194; Muller EGD, 1996, MOL BIOL CELL, V7, P1805, DOI 10.1091/mbc.7.11.1805; NAKAMURA H, 1994, IMMUNOL LETT, V42, P75, DOI 10.1016/0165-2478(94)90038-8; Niedenthal RK, 1996, YEAST, V12, P773, DOI 10.1002/(SICI)1097-0061(19960630)12:8<773::AID-YEA972>3.3.CO;2-C; PETRONILLI V, 1994, J BIOL CHEM, V269, P16638; PON L, 1991, MOL BIOL YEAST SACCH, P334; Rigobello MP, 1998, FREE RADICAL BIO MED, V24, P370, DOI 10.1016/S0891-5849(97)00216-5; ROVERI A, 1994, BBA-PROTEIN STRUCT M, V1208, P211, DOI 10.1016/0167-4838(94)90106-6; RUSSEL M, 1985, P NATL ACAD SCI USA, V82, P29, DOI 10.1073/pnas.82.1.29; SCHALLREUTER KU, 1986, BIOCHEM BIOPH RES CO, V136, P630, DOI 10.1016/0006-291X(86)90487-0; Sherman F., 1986, METHODS YEAST GENETI; SIES H, 1986, ANGEW CHEM INT EDIT, V25, P1058, DOI 10.1002/anie.198610581; SPECTOR A, 1988, J BIOL CHEM, V263, P4984; Spyrou G, 1997, J BIOL CHEM, V272, P2936, DOI 10.1074/jbc.272.5.2936; Stadtman TC, 1996, ANNU REV BIOCHEM, V65, P83, DOI 10.1146/annurev.bi.65.070196.000503; STEPHEN DWS, 1995, MOL MICROBIOL, V16, P415, DOI 10.1111/j.1365-2958.1995.tb02407.x; TAGAYA Y, 1989, EMBO J, V8, P757, DOI 10.1002/j.1460-2075.1989.tb03436.x; Tamura T, 1996, P NATL ACAD SCI USA, V93, P1006, DOI 10.1073/pnas.93.3.1006; Treger JM, 1998, BIOCHEM BIOPH RES CO, V243, P13, DOI 10.1006/bbrc.1997.8061; TSANG MLS, 1976, J BACTERIOL, V125, P923, DOI 10.1128/JB.125.3.923-933.1976; VONHEIJNE G, 1986, EMBO J, V5, P1335, DOI 10.1002/j.1460-2075.1986.tb04364.x; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; WAKASUGI N, 1990, P NATL ACAD SCI USA, V87, P8282, DOI 10.1073/pnas.87.21.8282; Watabe S, 1997, EUR J BIOCHEM, V249, P52, DOI 10.1111/j.1432-1033.1997.t01-1-00052.x; Xu ZY, 1996, J CELL BIOL, V132, P787, DOI 10.1083/jcb.132.5.787; Zhon LW, 1998, J BIOL CHEM, V273, P8581, DOI 10.1074/jbc.273.15.8581	59	179	186	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	1999	274	10					6366	6373		10.1074/jbc.274.10.6366	http://dx.doi.org/10.1074/jbc.274.10.6366			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172BQ	10037727	hybrid			2022-12-25	WOS:000078902800049
J	Yamada, Y; Chochi, Y; Takamiya, K; Sobue, K; Inui, R				Yamada, Y; Chochi, Y; Takamiya, K; Sobue, K; Inui, R			Modulation of the channel activity of the epsilon 2/zeta 1-subtype N-methyl D-Aspartate receptor by PSD-95	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; TUMOR-SUPPRESSOR PROTEIN; POSTSYNAPTIC DENSITY; NMDA RECEPTORS; GLUTAMATE RECEPTORS; MOLECULAR DIVERSITY; GUANYLATE KINASES; HIPPOCAMPAL LTP; FAMILY; ACTIVATION	A channel-associated protein PSD-95 has been shown to induce clustering of N-methyl D-aspartate (NMDA) receptors, interacting with the COOH terminus of the epsilon subunit of the receptors. The effects of PSD-95 on the channel activity of the epsilon 2/zeta 1 heteromeric NMDA receptor were examined by injection of PSD-95 cRNA into Xenopus oocytes expressing the NMDA receptors. Expression of PSD-95 decreased the sensitivity of the NMDA receptor channels to L-glutamate. Mutational studies showed that the interaction between the COOH terminus of the epsilon 2 subunit of the NMDA receptor and the second PSD-95/Dlg/Z0-1 domain of PSD-95 is critical for the decrease in glutamate sensitivity. It is known that protein kinase C markedly potentiates the channel activity of the MMDA receptor expressed in oocytes. PSD-95 inhibited the protein kinase C-mediated potentiation of the channels. Thus, we demonstrated that PSD-95 functionally modulates the channel activity of the epsilon 2/zeta 1 NMDA receptor. PSD-95 makes signal transmission more efficient by clustering the channels at postsynaptic sites. In addition to this, our results suggest that PSD-95 plays a protective role against neuronal excitotoxicity by decreasing the glutamate sensitivity of the channels and by inhibiting the protein kinase C mediated potentiation of the channels.	Yamaguchi Univ, Sch Med, Dept Pharmacol, Ube, Yamaguchi 7558505, Japan; Osaka Univ, Sch Med, Dept Neurochem & Neuropharmacol, Osaka 5650871, Japan	Yamaguchi University; Osaka University	Inui, R (corresponding author), Yamaguchi Univ, Sch Med, Dept Pharmacol, 1144 Kogushi, Ube, Yamaguchi 7558505, Japan.							BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; Brenman JE, 1996, CELL, V84, P757, DOI 10.1016/S0092-8674(00)81053-3; CHEN L, 1991, NEURON, V7, P319, DOI 10.1016/0896-6273(91)90270-A; Chen SJ, 1996, J NEUROCHEM, V67, P194; CHO KO, 1992, NEURON, V9, P929, DOI 10.1016/0896-6273(92)90245-9; Cohen NA, 1996, NEURON, V17, P759, DOI 10.1016/S0896-6273(00)80207-X; COLLINGRIDGE GL, 1989, PHARMACOL REV, V41, P143; GERBER G, 1989, J NEUROSCI, V9, P3606; Gereau RW, 1998, NEURON, V20, P143, DOI 10.1016/S0896-6273(00)80442-0; HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335; Horio Y, 1997, J BIOL CHEM, V272, P12885, DOI 10.1074/jbc.272.20.12885; Hsueh YP, 1997, NEURON, V18, P803, DOI 10.1016/S0896-6273(00)80319-0; Irie M, 1997, SCIENCE, V277, P1511, DOI 10.1126/science.277.5331.1511; Kawashima N, 1997, FEBS LETT, V418, P301, DOI 10.1016/S0014-5793(97)01399-9; Kim E, 1997, J CELL BIOL, V136, P669, DOI 10.1083/jcb.136.3.669; Kim E, 1996, NEURON, V17, P103, DOI 10.1016/S0896-6273(00)80284-6; KIM E, 1995, NATURE, V378, P85, DOI 10.1038/378085a0; KISTNER U, 1993, J BIOL CHEM, V268, P4580; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; Kutsuwada T, 1996, NEURON, V16, P333, DOI 10.1016/S0896-6273(00)80051-3; KUTSUWADA T, 1992, NATURE, V358, P36, DOI 10.1038/358036a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARKMAN AU, 1995, CURR OPIN NEUROBIOL, V5, P324, DOI 10.1016/0959-4388(95)80045-X; LAUBE B, 1997, NEURON, V18, P439; LI YQ, 1994, CELL, V76, P427, DOI 10.1016/0092-8674(94)90108-2; LUE RA, 1994, P NATL ACAD SCI USA, V91, P9818, DOI 10.1073/pnas.91.21.9818; MARKRAM H, 1992, J PHYSIOL-LONDON, V457, P491, DOI 10.1113/jphysiol.1992.sp019389; MCBAIN CJ, 1994, PHYSIOL REV, V74, P723, DOI 10.1152/physrev.1994.74.3.723; MONYER H, 1992, SCIENCE, V256, P1217, DOI 10.1126/science.256.5060.1217; MORI H, 1993, NEUROREPORT, V4, P519, DOI 10.1097/00001756-199305000-00014; MULLER BM, 1995, J NEUROSCI, V15, P2354, DOI 10.1523/JNEUROSCI.15-03-02354.1995; Muller BM, 1996, NEURON, V17, P255, DOI 10.1016/S0896-6273(00)80157-9; NAKANISHI S, 1992, SCIENCE, V258, P597, DOI 10.1126/science.1329206; Niethammer M, 1998, NEURON, V20, P693, DOI 10.1016/S0896-6273(00)81009-0; Niethammer M, 1996, J NEUROSCI, V16, P2157; PATNEAU DK, 1990, J NEUROSCI, V10, P2385; SAKIMURA K, 1995, NATURE, V373, P151, DOI 10.1038/373151a0; SATHER W, 1992, J PHYSIOL-LONDON, V450, P643, DOI 10.1113/jphysiol.1992.sp019148; Sucher NJ, 1996, TRENDS PHARMACOL SCI, V17, P348, DOI 10.1016/S0165-6147(96)10046-8; Takeuchi M, 1997, J BIOL CHEM, V272, P11943, DOI 10.1074/jbc.272.18.11943; Topinka JR, 1998, NEURON, V20, P125, DOI 10.1016/S0896-6273(00)80440-7; Wagner DA, 1996, NEUROPHARMACOLOGY, V35, P29, DOI 10.1016/0028-3908(95)00177-8; WANG YT, 1994, NATURE, V369, P233, DOI 10.1038/369233a0; WATANABE M, 1992, NEUROREPORT, V3, P1138, DOI 10.1097/00001756-199212000-00027; WILLIAMS K, 1993, MOL PHARMACOL, V44, P851; YAMAZAKI M, 1992, FEBS LETT, V300, P39, DOI 10.1016/0014-5793(92)80160-I	46	70	72	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1999	274	10					6647	6652		10.1074/jbc.274.10.6647	http://dx.doi.org/10.1074/jbc.274.10.6647			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172BQ	10037761	hybrid			2022-12-25	WOS:000078902800083
J	Kim, DY; Kam, Y; Koo, SK; Joe, CO				Kim, DY; Kam, Y; Koo, SK; Joe, CO			Gating connexin 43 channels reconstituted in lipid vesicles by mitogen-activated protein kinase phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAP-JUNCTION PROTEIN; EPIDERMAL GROWTH-FACTOR; INTERCELLULAR COMMUNICATION; SUBSTRATE RECOGNITION; EPITHELIAL-CELLS; HORIZONTAL CELLS; MEMBRANE CHANNEL; PLASMA-MEMBRANE; GLIOMA-CELLS; RAT-LIVER	The regulation of gap junctional permeability by phosphorylation was examined in a model system in which connexin 43 (Cx43) gap junction hemichannels were reconstituted in lipid vesicles. Cx43 was immunoaffinity-purified from rat brain, and Cx43 channels were reconstituted into unilamellar phospholipid liposomes. The activities of the reconstituted channels were measured by monitoring liposome permeability. Liposomes containing the Cx43 protein were fractionated on the basis of permeability to sucrose using sedimentation in an iso-osmolar density gradient. The gradient allowed separation of the sucrose-permeable and -impermeable liposomes. Liposomes that were permeable to sucrose were also permeable to the communicating dye molecule lucifer yellow. Permeability, and therefore activity of the reconstituted Cx43 channels, were directly dependent on the state of Cx43 phosphorylation. The permeability of liposomes containing Cx43 channels was increased by treatment of liposomes with calf intestinal phosphatase. Moreover, liposomes formed with Cx43 that had been dephosphorylated by calf intestinal phosphatase treatment showed increased permeability to sucrose. The role of phosphorylation in the gating mechanism of Cx43 channels was supported further by the observation that phosphorylation of Cx43 by mitogen-activated protein kinase reversibly reduced the permeability of liposomes containing dephosphorylated Cx43. Our results show a direct correlation between gap junctional permeability and the phosphorylation state of Cx43.	Korea Adv Inst Sci & Technol, Dept Biol Sci, Taejon 305701, South Korea; NIH, Lab Genet Dis, Dept Biomed Sci, Seoul 122020, South Korea	Korea Advanced Institute of Science & Technology (KAIST); Korea Centers for Disease Control & Prevention (KCDC); Korea National Institute of Health (KNIH)	Joe, CO (corresponding author), Korea Adv Inst Sci & Technol, Dept Biol Sci, Taejon 305701, South Korea.	cojoe@sorak.kaist.ac.kr	Joe, Cheol O/C-1917-2011	Kam, Yoonseok/0000-0003-4712-9058				ALLEN F, 1990, DEVELOPMENT, V108, P623; ALVAREZ E, 1991, J BIOL CHEM, V266, P15277; ASMOTO M, 1991, MOL CARCINOG, V4, P322; BENNETT MVL, 1991, NEURON, V6, P305, DOI 10.1016/0896-6273(91)90241-Q; Bevans CG, 1998, J BIOL CHEM, V273, P2808, DOI 10.1074/jbc.273.5.2808; BEYER EC, 1989, J CELL BIOL, V108, P595, DOI 10.1083/jcb.108.2.595; BEYER EC, 1987, J CELL BIOL, V105, P2621, DOI 10.1083/jcb.105.6.2621; Bruzzone R, 1996, EUR J BIOCHEM, V238, P1, DOI 10.1111/j.1432-1033.1996.0001q.x; BUEHLER LK, 1995, BIOPHYS J, V68, P1767, DOI 10.1016/S0006-3495(95)80353-X; CASCIO M, 1995, J BIOL CHEM, V270, P18643, DOI 10.1074/jbc.270.31.18643; CHARLES AC, 1992, J CELL BIOL, V118, P195, DOI 10.1083/jcb.118.1.195; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P15180; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; CROW DS, 1990, MOL CELL BIOL, V10, P1754, DOI 10.1128/MCB.10.4.1754; deFeijter AW, 1996, MOL CARCINOGEN, V16, P203, DOI 10.1002/(SICI)1098-2744(199608)16:4<203::AID-MC4>3.3.CO;2-F; DEVRIES SH, 1992, J PHYSIOL-LONDON, V445, P201, DOI 10.1113/jphysiol.1992.sp018920; DONALDSON P, 1992, J MEMBRANE BIOL, V129, P155; DUPONT E, 1991, EUR J BIOCHEM, V200, P263, DOI 10.1111/j.1432-1033.1991.tb21075.x; EGHBALI B, 1991, P NATL ACAD SCI USA, V88, P10701, DOI 10.1073/pnas.88.23.10701; Falk MM, 1997, EMBO J, V16, P2703, DOI 10.1093/emboj/16.10.2703; GONZALEZ FA, 1991, J BIOL CHEM, V266, P22159; GUTHRIE S, 1988, DEVELOPMENT, V103, P769; HARRIS AL, 1992, MOL BRAIN RES, V15, P269, DOI 10.1016/0169-328X(92)90118-U; HEUSSEN GAH, 1992, CARCINOGENESIS, V13, P719, DOI 10.1093/carcin/13.4.719; Kanemitsu MY, 1998, CELL GROWTH DIFFER, V9, P13; KANEMITSU MY, 1993, MOL BIOL CELL, V4, P837, DOI 10.1091/mbc.4.8.837; Koo SK, 1997, MOL CELL BIOCHEM, V167, P41, DOI 10.1023/A:1006831114120; LAU AF, 1992, MOL BIOL CELL, V3, P865, DOI 10.1091/mbc.3.8.865; LAWRENCE TS, 1978, NATURE, V272, P501, DOI 10.1038/272501a0; Li HY, 1996, J CELL BIOL, V134, P1019, DOI 10.1083/jcb.134.4.1019; LOEWENSTEIN WR, 1981, PHYSIOL REV, V61, P829, DOI 10.1152/physrev.1981.61.4.829; LOO LWM, 1995, J BIOL CHEM, V270, P12751, DOI 10.1074/jbc.270.21.12751; MADHUKAR BV, 1989, CARCINOGENESIS, V10, P13, DOI 10.1093/carcin/10.1.13; MALCHOW RP, 1993, J NEUROSCI RES, V35, P237, DOI 10.1002/jnr.490350303; MIMMS LT, 1981, BIOCHEMISTRY-US, V20, P833, DOI 10.1021/bi00507a028; MUSIL LS, 1993, CELL, V74, P1065, DOI 10.1016/0092-8674(93)90728-9; NA MR, 1995, TOXICOLOGY, V98, P199, DOI 10.1016/0300-483X(94)02931-J; PAUL DL, 1991, J CELL BIOL, V115, P1077, DOI 10.1083/jcb.115.4.1077; Rhee SK, 1996, BIOCHEMISTRY-US, V35, P9212, DOI 10.1021/bi960295m; ROSE B, 1993, CARCINOGENESIS, V14, P1073, DOI 10.1093/carcin/14.5.1073; SAEZ JC, 1989, P NATL ACAD SCI USA, V86, P2708, DOI 10.1073/pnas.86.8.2708; SAEZ JC, 1993, ADV SEC MESS PHOSPH, V27, P163; Saez JC, 1997, J MOL CELL CARDIOL, V29, P2131, DOI 10.1006/jmcc.1997.0447; STAROS JV, 1989, METHOD ENZYMOL, V172, P609; Trexler EB, 1996, P NATL ACAD SCI USA, V93, P5836, DOI 10.1073/pnas.93.12.5836; TROSKO JE, 1990, PATHOBIOLOGY, V58, P265, DOI 10.1159/000163596; VanderMolen MA, 1996, J BIOL CHEM, V271, P12165, DOI 10.1074/jbc.271.21.12165; VANHAMME L, 1989, EXP CELL RES, V180, P297, DOI 10.1016/0014-4827(89)90234-6; Warn-Cramer BJ, 1998, J BIOL CHEM, V273, P9188, DOI 10.1074/jbc.273.15.9188; WarnCramer BJ, 1996, J BIOL CHEM, V271, P3779; Xie HQ, 1997, J CELL BIOL, V137, P203, DOI 10.1083/jcb.137.1.203; YOUNG JDE, 1987, CELL, V48, P733, DOI 10.1016/0092-8674(87)90071-7; ZHU D, 1991, P NATL ACAD SCI USA, V88, P1883, DOI 10.1073/pnas.88.5.1883	53	97	102	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 26	1999	274	9					5581	5587		10.1074/jbc.274.9.5581	http://dx.doi.org/10.1074/jbc.274.9.5581			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	170KG	10026174	hybrid			2022-12-25	WOS:000078804400045
J	Neuhierl, B; Thanbichler, M; Lottspeich, F; Bock, A				Neuhierl, B; Thanbichler, M; Lottspeich, F; Bock, A			A family of S-methylmethionine-dependent thiol/selenol methyltransferases - Role in selenium tolerance and evolutionary relation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENOSYL-L-METHIONINE; HIGH-LEVEL EXPRESSION; ESCHERICHIA-COLI; TRIMETHYLSELENONIUM ION; ADENOSYLMETHIONINE; SELENOCYSTEINE; METABOLISM; TOXICITY; PROTEINS; PLANTS	Several plant species can tolerate high concentrations of selenium in the environment, and they accumulate organoselenium compounds. One of these compounds is Se-methylselenocysteine, synthesized by a number of species from the genus Astragalus (Fabaceae), like A. bisulcatus, An enzyme has been previously isolated from this organism that catalyzes methyl transfer from S-adenosylmethionine to selenocysteine. To elucidate the role of the enzyme in selenium tolerance, the cDNA coding for selenocysteine methyltransferase from A. bisulcatus was cloned and sequenced. Data base searches revealed the existence of several apparent homologs of hitherto unassigned function, The gene for one of them, yagD from Escherichia coli, was cloned, and the protein was overproduced and purified. A functional analysis showed that the YagD protein catalyzes methylation of homocysteine, selenohomocysteine, and selenocysteine with S-adenosylmethionine and S-methylmethionine as methyl group donors. S-Methylmethionine was now shown to be also the physiological methyl group donor for the A. bisulcatus selenocysteine methyltransferase. A model system was set up in E, coli which demonstrated that expression of the plant and, although to a much lesser degree, of the bacterial methyltransferase gene increases selenium tolerance and strongly reduces unspecific selenium incorporation into proteins, provided that S-methylmethionine is present in the medium, It is postulated that the selenocysteine methyltransferase under selective pressure developed from an S-methylmethionine-dependent thiol/selenol methyltransferase.	Univ Munich, Lehrstuhl Mikrobiol, D-80638 Munich, Germany; Max Planck Inst Biochem, Prot Chem Abt, D-82152 Martinsried, Germany	University of Munich; Max Planck Society	Bock, A (corresponding author), Univ Munich, Lehrstuhl Mikrobiol, Maria Ward Str 1A, D-80638 Munich, Germany.		Thanbichler, Martin/E-6035-2010					ABRAHAMSON L, 1965, ARCH BIOCHEM BIOPHYS, V109, P376, DOI 10.1016/0003-9861(65)90376-0; AIBA H, 1981, J BIOL CHEM, V256, P1905; BALISH E, 1967, ARCH BIOCHEM BIOPHYS, V119, P62, DOI 10.1016/0003-9861(67)90429-8; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; BRINKMANN U, 1989, GENE, V85, P109, DOI 10.1016/0378-1119(89)90470-8; BROWN TA, 1982, BIOL REV, V57, P59, DOI 10.1111/j.1469-185X.1982.tb00364.x; BROWN TA, 1981, PLANT PHYSIOL, V67, P1051, DOI 10.1104/pp.67.5.1051; BURNELL JN, 1981, PLANT PHYSIOL, V67, P316, DOI 10.1104/pp.67.2.316; CARRITHERS SL, 1994, BIOCHEM PHARMACOL, V48, P1017, DOI 10.1016/0006-2952(94)90373-5; CHANG ACY, 1978, J BACTERIOL, V134, P1141, DOI 10.1128/JB.134.3.1141-1156.1978; Cournoyer B, 1998, BBA-GENE STRUCT EXPR, V1397, P161, DOI 10.1016/S0167-4781(98)00020-7; COX JC, 1981, J BACTERIOL, V145, P1317, DOI 10.1128/JB.145.3.1317-1324.1981; DEV IK, 1984, J BIOL CHEM, V259, P8402; GANTHER HE, 1966, BIOCHEMISTRY-US, V5, P1089, DOI 10.1021/bi00867a039; Goulding CW, 1997, BIOCHEMISTRY-US, V36, P8082, DOI 10.1021/bi9705164; GUBLER U, 1988, NUCLEIC ACIDS RES, V16, P2726, DOI 10.1093/nar/16.6.2726; HAMILTON CM, 1989, J BACTERIOL, V171, P4617, DOI 10.1128/jb.171.9.4617-4622.1989; HOFFMAN JL, 1987, ARCH BIOCHEM BIOPHYS, V254, P534, DOI 10.1016/0003-9861(87)90134-2; HOFFMAN JL, 1986, BIOCHEMISTRY-US, V25, P4444, DOI 10.1021/bi00363a041; HOLLOWAY CT, 1970, J BACTERIOL, V104, P734, DOI 10.1128/JB.104.2.734-747.1970; Huttenhofer A, 1998, COLD SPRING HARBOR M, P603; JAMES F, 1995, J BIOL CHEM, V270, P22344, DOI 10.1074/jbc.270.38.22344; KUHN I, 1986, GENE, V42, P253, DOI 10.1016/0378-1119(86)90229-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAUCHLI A, 1993, BOT ACTA, V106, P455; LOW B, 1968, P NATL ACAD SCI USA, V60, P160, DOI 10.1073/pnas.60.1.160; McConnell KP, 1942, J BIOL CHEM, V145, P55; Miller JH., 1992, SHORT COURSE BACTERI, P72; MOZIER NM, 1988, J BIOL CHEM, V263, P4527; MUDD SH, 1990, PLANT PHYSIOL, V93, P623, DOI 10.1104/pp.93.2.623; MULLER S, 1994, BIOCHEMISTRY-US, V33, P3404, DOI 10.1021/bi00177a034; Neuhierl B, 1996, EUR J BIOCHEM, V239, P235, DOI 10.1111/j.1432-1033.1996.0235u.x; PALMER IS, 1970, BIOCHIM BIOPHYS ACTA, V208, P260, DOI 10.1016/0304-4165(70)90244-8; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Schultz J, 1940, J BIOL CHEM, V133, P199; SHAPIRO SK, 1964, J BIOL CHEM, V239, P1551; SHAPIRO SK, 1965, J BIOL CHEM, V240, P2512; SHRIFT A, 1969, ANN REV PLANT PHYSIO, V20, P475, DOI 10.1146/annurev.pp.20.060169.002355; SHRIFT A, 1965, BIOCHIM BIOPHYS ACTA, V100, P65, DOI 10.1016/0304-4165(65)90428-9; SHRIFT A, 1963, BIOCHIM BIOPHYS ACTA, V71, P483, DOI 10.1016/0006-3002(63)91113-2; Spallholz JE, 1997, BIOMED ENVIRON SCI, V10, P260; Stadtman TC, 1996, ANNU REV BIOCHEM, V65, P83, DOI 10.1146/annurev.bi.65.070196.000503; STADTMAN TC, 1990, ANNU REV BIOCHEM, V59, P111, DOI 10.1146/annurev.bi.59.070190.000551; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; TANAKA H, 1987, METHOD ENZYMOL, V143, P240; TRELEASE SAM F., 1942, SCIENCE, V95, P656, DOI 10.1126/science.95.2478.656; TRELEASE SF, 1960, SCIENCE, V132, P618, DOI 10.1126/science.132.3427.618; Trossat C, 1998, PLANT PHYSIOL, V116, P165, DOI 10.1104/pp.116.1.165; VIRUPAKSHA TK, 1965, BIOCHIM BIOPHYS ACTA, V107, P69, DOI 10.1016/0304-4165(65)90389-2; WITTWER AJ, 1986, ARCH BIOCHEM BIOPHYS, V248, P540, DOI 10.1016/0003-9861(86)90507-2; WU SE, 1983, BIOCHEMISTRY-US, V22, P2828, DOI 10.1021/bi00281a009; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; YASUKAWA T, 1995, J BIOL CHEM, V270, P25328, DOI 10.1074/jbc.270.43.25328; ZAPPIA V, 1969, BIOCHIM BIOPHYS ACTA, V178, P185, DOI 10.1016/0005-2744(69)90147-8	55	148	163	2	18	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 26	1999	274	9					5407	5414		10.1074/jbc.274.9.5407	http://dx.doi.org/10.1074/jbc.274.9.5407			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	170KG	10026151	hybrid			2022-12-25	WOS:000078804400022
J	Saxena, A; Shriml, LM; Dean, M; Ali, IU				Saxena, A; Shriml, LM; Dean, M; Ali, IU			Comparative molecular genetic profiles of anaplastic astrocytomas glioblastomas multiforme and their subsequent recurrences	ONCOGENE			English	Article						malignant gliomas; recurrence; genetic profiles	TUMOR-SUPPRESSOR GENE; MALIGNANT BRAIN-TUMORS; GROWTH-FACTOR RECEPTOR; TISSUE INHIBITOR; GELATINASE-A; P53; GLIOMAS; PROGRESSION; EXPRESSION; MUTATION	Malignant glial tumors (anaplastic astrocytomas and glioblastomas multiforme) arise mostly either from the progression of low grade precursor lesions or rapidly in a de novo fashion and contain distinct genetic alterations. There is, however, a third subset of malignant gliomas in which genetic lesions remain to be identified, Following surgical resection, all gliomas appear to have an inherent tendency to recur, Comparative molecular analysis of ten primary malignant gliomas (three anaplastic astrocytomas and seven glioblastomas multiforme) with their recurrences identified two distinct subgroups of recurrent tumors. In one group, primary tumors harbored genetic aberrations frequently associated with linear progression or ne novo formation pathways of glial tumorigenesis and maintained their genetic profiles upon recurrence. In the other subset with no detectable known genetic mutations at first presentation, the recurrent tumors sustained specific abnormalities associated with pathways of linear progression or ne novo formation. These included loss of genes on chromosomes 17 and 10, mutations in the p53 gene, homozygous deletion of the DMBTA1 and p16 and/or p15 genes and amplification and/or overexpression of CDK4 and alpha form of the PDGF receptor. Recurrent tumors from both groups also displayed an abnormal expression profile of the metalloproteinase, gel A, and its inhibitor, TIMP-2, consistent with their highly invasive behavior, Delineation of the molecular differences between malignant glioblastomas and their subsequent recurrences may have important implications for the development of rational clinical approaches for this neoplasm that remains refractory to existing therapeutic modalities.	NCI, Chemoprevent Branch, NIH, Bethesda, MD 20892 USA; NINCDS, Surg Neurol Branch, NIH, Bethesda, MD 20892 USA; NCI, Lab Genom Divers, NIH, Frederick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Ali, IU (corresponding author), NCI, Chemoprevent Branch, NIH, Bethesda, MD 20892 USA.		Dean, Michael C/G-8172-2012; Dean, Michael/R-7501-2019	Dean, Michael C/0000-0003-2234-0631; 	NATIONAL CANCER INSTITUTE [ZIABC005652, Z01BC005652] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BERKMAN RA, 1992, J NEUROSURG, V77, P432, DOI 10.3171/jns.1992.77.3.0432; Berns EMJJ, 1998, BRIT J CANCER, V77, P1130, DOI 10.1038/bjc.1998.187; Brachmann RK, 1996, P NATL ACAD SCI USA, V93, P4091, DOI 10.1073/pnas.93.9.4091; CHO Y, 1994, SCIENCE, V265, P1994; Erber R, 1998, ONCOGENE, V16, P1671, DOI 10.1038/sj.onc.1201690; FLEMING TP, 1992, CANCER RES, V52, P4550; GUTIERREZ MI, 1994, HUM MOL GENET, V3, P2247, DOI 10.1093/hmg/3.12.2247; HAYASHI Y, 1991, BIOCHEM BIOPH RES CO, V180, P1145, DOI 10.1016/S0006-291X(05)81186-6; Hermanson M, 1996, CANCER RES, V56, P164; KERN SE, 1991, ONCOGENE, V6, P131; Kleihues P, 1993, HISTOLOGICAL TYPING; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Louis DN, 1997, BRAIN PATHOL, V7, P755, DOI 10.1111/j.1750-3639.1997.tb01062.x; LOUIS DN, 1995, TRENDS GENET, V11, P412, DOI 10.1016/S0168-9525(00)89125-8; MIKKELSEN T, 1995, J NEUROSURG, V83, P285, DOI 10.3171/jns.1995.83.2.0285; Mollenhauer J, 1997, NAT GENET, V17, P32, DOI 10.1038/ng0997-32; MORSE RP, 1994, J NEURO-ONCOL, V21, P151, DOI 10.1007/BF01052899; NAKAGAWA T, 1994, J NEUROSURG, V81, P69, DOI 10.3171/jns.1994.81.1.0069; NEMETH JA, 1993, EXP CELL RES, V207, P376, DOI 10.1006/excr.1993.1204; PRUCHON E, 1994, CANCER GENET CYTOGEN, V76, P85, DOI 10.1016/0165-4608(94)90454-5; RAJAN B, 1994, EUR J CANCER, V30A, P1809, DOI 10.1016/0959-8049(94)00248-4; Reifenberger J, 1996, J NEUROPATH EXP NEUR, V55, P822, DOI 10.1097/00005072-199607000-00007; RITTER AM, 1994, NEUROSURGERY, V35, P192, DOI 10.1227/00006123-199408000-00003; ROLLEY N, 1995, ONCOGENE, V11, P763; Rosenberg JE, 1996, ONCOGENE, V13, P2483; SAXENA A, 1995, INT J ONCOL, V7, P469; Saxena A, 1996, ONCOGENE, V13, P661; SAXENA A, 1992, CANCER RES, V52, P6716; SIDRANSKY D, 1992, NATURE, V355, P846, DOI 10.1038/355846a0; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; STETLERSTEVENSON WG, 1992, FEBS LETT, V296, P231, DOI 10.1016/0014-5793(92)80386-U; VONDEIMLING A, 1993, BRAIN PATHOL, V3, P19; Yamamoto M, 1996, CANCER RES, V56, P384; YAMAMOTO M, 1994, J NEURO-ONCOL, V22, P139, DOI 10.1007/BF01052889; YONG WH, 1995, J NEUROPATH EXP NEUR, V54, P622, DOI 10.1097/00005072-199509000-00002	35	31	33	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 11	1999	18	6					1385	1390		10.1038/sj.onc.1202440	http://dx.doi.org/10.1038/sj.onc.1202440			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	165FW	10022821				2022-12-25	WOS:000078510900015
J	Darnay, BG; Ni, J; Moore, PA; Aggarwal, BB				Darnay, BG; Ni, J; Moore, PA; Aggarwal, BB			Activation of NF-kappa B by RANK requires tumor necrosis factor receptor-associated factor (TRAF) 6 and NF-kappa B-inducing kinase - Identification of a novel TRAF6 interaction motif	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TNF RECEPTOR; TERMINAL KINASE; FAMILY MEMBER; INDUCTION; LIGAND; DOMAIN; CD30; IL-1	Various members of the tumor necrosis factor (TNF) receptor superfamily activate nuclear factor kappa B (NF-kappa B) and the c-Jun N-terminal kinase (JNK) pathways through their interaction with TNF receptor-associated factors (TRAFs) and NF-kappa B-inducing kinase (NIK). We have previously shown that the cytoplasmic domain of receptor activator of NF-kappa B (RANK) interacts with TRAF2, TRAF5, and TRAF6 and that its overexpression activates NF-kappa B and JNK pathways. Through a detailed mutational analysis of the cytoplasmic domain of RANK, we demonstrate that TRAF2 and TRAF5 bind to consensus TRAF binding motifs located in the C terminus at positions 565-568 and 606-611, respectively. In contrast, TRAF6 interacts with a novel motif located between residues 340 and 358 of RANK. Furthermore, transfection experiments with RANK and its deletion mutants in human embryonic 293 cells revealed that the TRAF6-binding region (340-358), but not the TRAF2 or TRAF5-binding region, is necessary and sufficient for RANK-induced NF-kappa B activation. Moreover, a kinase mutant of NIK (NIK-KM) inhibited RANK-induced NF-kappa B activation. However, RANK-mediated JNK activation required a distal portion (427-603) of RANK containing the TRAF2-binding domain. Thus, our results indicate that RANK interacts with various TRAFs through distinct motifs and activates NF-kappa B via a novel TRAF6 interaction motif, which then activates MK, thus leading to NF-kappa B activation, whereas RANK most likely activates JNK through a TRAF2-interacting region in RANK.	Univ Texas, MD Anderson Cancer Ctr, Dept Mol Oncol, Cytokine Res Lab, Houston, TX 77030 USA; Human Genome Sci Inc, Rockville, MD 20850 USA	University of Texas System; UTMD Anderson Cancer Center; GlaxoSmithKline; Human Genome Sciences Inc	Aggarwal, BB (corresponding author), Univ Texas, MD Anderson Cancer Ctr, Dept Mol Oncol, Cytokine Res Lab, 1515 Holcombe Blvd,Box 143, Houston, TX 77030 USA.		Aggarwal, Bharat B/G-3388-2013					Akiba H, 1998, J BIOL CHEM, V273, P13353, DOI 10.1074/jbc.273.21.13353; Anderson DM, 1997, NATURE, V390, P175, DOI 10.1038/36593; Arch RH, 1998, MOL CELL BIOL, V18, P558, DOI 10.1128/MCB.18.1.558; Arch RH, 1998, GENE DEV, V12, P2821, DOI 10.1101/gad.12.18.2821; Boucher LM, 1997, BIOCHEM BIOPH RES CO, V233, P592, DOI 10.1006/bbrc.1997.6509; Cao ZD, 1996, NATURE, V383, P443, DOI 10.1038/383443a0; Cohen L, 1998, NATURE, V395, P292, DOI 10.1038/26254; Darnay BG, 1998, J BIOL CHEM, V273, P20551, DOI 10.1074/jbc.273.32.20551; Duckett CS, 1997, MOL CELL BIOL, V17, P1535, DOI 10.1128/MCB.17.3.1535; Geleziunas R, 1998, MOL CELL BIOL, V18, P5157, DOI 10.1128/MCB.18.9.5157; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; Hsu HL, 1997, J BIOL CHEM, V272, P13471, DOI 10.1074/jbc.272.21.13471; Ishida T, 1996, J BIOL CHEM, V271, P28745, DOI 10.1074/jbc.271.46.28745; Karin M, 1998, P NATL ACAD SCI USA, V95, P9067, DOI 10.1073/pnas.95.16.9067; Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092-8674(00)81569-X; Ling L, 1998, P NATL ACAD SCI USA, V95, P3792, DOI 10.1073/pnas.95.7.3792; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; Marsters SA, 1997, J BIOL CHEM, V272, P14029, DOI 10.1074/jbc.272.22.14029; Miller WE, 1998, MOL CELL BIOL, V18, P2835, DOI 10.1128/MCB.18.5.2835; Muzio M, 1997, SCIENCE, V278, P1612, DOI 10.1126/science.278.5343.1612; Nakano H, 1996, J BIOL CHEM, V271, P14661, DOI 10.1074/jbc.271.25.14661; Nakano H, 1998, P NATL ACAD SCI USA, V95, P3537, DOI 10.1073/pnas.95.7.3537; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0; Song HY, 1997, P NATL ACAD SCI USA, V94, P9792, DOI 10.1073/pnas.94.18.9792; Sylla BS, 1998, P NATL ACAD SCI USA, V95, P10106, DOI 10.1073/pnas.95.17.10106; Uhlik M, 1998, J BIOL CHEM, V273, P21132, DOI 10.1074/jbc.273.33.21132; Wesche H, 1997, IMMUNITY, V7, P837, DOI 10.1016/S1074-7613(00)80402-1; Wong BR, 1997, J BIOL CHEM, V272, P25190, DOI 10.1074/jbc.272.40.25190; Wong BR, 1998, J BIOL CHEM, V273, P28355, DOI 10.1074/jbc.273.43.28355; Wong BR, 1997, J EXP MED, V186, P2075, DOI 10.1084/jem.186.12.2075; Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597; Yuasa T, 1998, J BIOL CHEM, V273, P22681, DOI 10.1074/jbc.273.35.22681	34	315	337	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 19	1999	274	12					7724	7731		10.1074/jbc.274.12.7724	http://dx.doi.org/10.1074/jbc.274.12.7724			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	178LU	10075662	hybrid			2022-12-25	WOS:000079268100021
J	Li, S; Moy, L; Pittman, N; Shue, G; Aufiero, B; Neufeld, EJ; LeLeiko, NS; Walsh, MJ				Li, S; Moy, L; Pittman, N; Shue, G; Aufiero, B; Neufeld, EJ; LeLeiko, NS; Walsh, MJ			Transcriptional repression of the cystic fibrosis transmembrane conductance regulator gene, mediated by CCAAT displacement protein cut homolog, is associated with histone deacetylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENSORY ORGAN IDENTITY; BINDING FACTOR CBF; HOMEODOMAIN PROTEIN; DNA-BINDING; DOWN-REGULATION; SACCHAROMYCES-CEREVISIAE; EPITHELIAL-CELLS; PROMOTER REGION; KINASE-C; EXPRESSION	Human cystic fibrosis transmembrane conductance regulator gene (CFTR) transcription is tightly regulated by nucleotide sequences upstream of the initiator sequences. Our studies of human CFTR transcription focus on identifying transcription factors bound to an inverted CCAAT consensus or "Y-box element." The human homeodomain CCAAT displacement protein/cut homolog (CDP/cut) can bind to the Y-box element through a cut repeat and homeobox, Analysis of stably transfected cell lines with wild-type and mutant human CFTR-directed reporter genes demonstrates that human histone acetyltransferase GCN5 and transcription factor ATF-1 can potentiate CFTR transcription through the Y-box element, We have found 1) that human CDP/cut acts as a repressor of CFTR transcription through the Y-box element by competing for the sites of transactivators hGCN5 and ATF-1;2) that the ability of CDP/cut to repress activities of hGCN5 and ATF-1 activity is contingent on the amount of CDP/cut expression; 3) that histone acetylation may have a role in the regulation of gene transcription by altering the accessibility of the CFTR Y-box for sequence-specific transcription factors; 4) that trichostatin A, an inhibitor of histone deacetylase activity, activates transcription of CFTR through the Y-box element; 5) that the inhibition of histone deacetylase activity leads to an alteration of local chromatin structure requiring an intact Y-box sequence in CFTR; 6) that immunocomplexes of CDP/cut possess an associated histone deacetylase activity; 7) that the carboxyl region of CDP/cut, responsible for the transcriptional repressor function, interacts with the histone deacetylase, HDAC1, We propose that CFTR transcription may be regulated through interactions with factors directing the modification of chromatin and requires the conservation of the inverted CCAAT CY-box) element of the CFTR promoter.	CUNY Mt Sinai Sch Med, Dept Pediat, Div Pediat Gastroenterol & Liver Dis, New York, NY 10029 USA; CUNY Mt Sinai Sch Med, Program Mol Cellular Biochem & Dev Sci, New York, NY 10029 USA; CUNY Mt Sinai Sch Med, Dept Med, Div Mol Med, New York, NY 10029 USA; Harvard Univ, Sch Med, Childrens Hosp, Med Div Hematol Oncol, Boston, MA 02115 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; Harvard University; Boston Children's Hospital; Harvard Medical School	Walsh, MJ (corresponding author), CUNY Mt Sinai Sch Med, Dept Pediat, Div Pediat Gastroenterol & Liver Dis, 1 Gustave L Levy Pl, New York, NY 10029 USA.	walsh@msvax.mssm.edu	Neufeld, Ellis J./F-9331-2011; LeLeiko, Neal/GRJ-6855-2022	Neufeld, Ellis J./0000-0001-8092-6281; leleiko, neal/0000-0001-7699-1400				ANDRES V, 1992, DEVELOPMENT, V116, P321; AUFIERO B, 1994, P NATL ACAD SCI USA, V91, P7757, DOI 10.1073/pnas.91.16.7757; Ausubel F.M., 1992, SHORT PROTOCOLS MOL; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; Banan M, 1997, J BIOL CHEM, V272, P18440, DOI 10.1074/jbc.272.29.18440; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; BARBERIS A, 1987, CELL, V50, P347, DOI 10.1016/0092-8674(87)90489-2; BARGON J, 1992, MOL CELL BIOL, V12, P1872, DOI 10.1128/MCB.12.4.1872; BARGON J, 1992, J BIOL CHEM, V267, P16056; Bi WM, 1997, J BIOL CHEM, V272, P26562, DOI 10.1074/jbc.272.42.26562; BLOCHLINGER K, 1993, DEVELOPMENT, V117, P441; BLOCHLINGER K, 1988, NATURE, V333, P629, DOI 10.1038/333629a0; BREUER W, 1993, J BIOL CHEM, V268, P13935; BREUER W, 1992, J BIOL CHEM, V267, P10465; Brownell JE, 1996, CELL, V84, P843, DOI 10.1016/S0092-8674(00)81063-6; Brownell JE, 1996, CURR OPIN GENET DEV, V6, P176, DOI 10.1016/S0959-437X(96)80048-7; Candau R, 1996, MOL CELL BIOL, V16, P593; CHOU JL, 1991, J BIOL CHEM, V266, P24471; Coustry F, 1996, J BIOL CHEM, V271, P14485, DOI 10.1074/jbc.271.24.14485; Currie RA, 1998, J BIOL CHEM, V273, P1430, DOI 10.1074/jbc.273.3.1430; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DUFORT D, 1994, MOL CELL BIOL, V14, P4251, DOI 10.1128/MCB.14.6.4251; ELHODIRI HM, 1995, MOL CELL BIOL, V15, P3587; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; Harlow E., 1988, ANTIBODIES LAB MANUA; Hassig CA, 1997, CELL, V89, P341, DOI 10.1016/S0092-8674(00)80214-7; Higgy NA, 1997, BBA-GENE STRUCT EXPR, V1351, P313, DOI 10.1016/S0167-4781(96)00221-7; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; JACK J, 1991, DEVELOPMENT, V113, P735; Jin SK, 1998, MOL CELL BIOL, V18, P4377, DOI 10.1128/MCB.18.7.4377; Kadosh D, 1998, MOL CELL BIOL, V18, P5121, DOI 10.1128/MCB.18.9.5121; KIJIMA M, 1993, J BIOL CHEM, V268, P22429; Kim EC, 1997, CELL GROWTH DIFFER, V8, P1329; KOH J, 1993, J BIOL CHEM, V268, P15912; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; Laherty CD, 1998, MOL CELL, V2, P33, DOI 10.1016/S1097-2765(00)80111-2; Linhoff MW, 1997, MOL CELL BIOL, V17, P4589, DOI 10.1128/MCB.17.8.4589; Luo W, 1996, J BIOL CHEM, V271, P18203, DOI 10.1074/jbc.271.30.18203; Mailly F, 1996, MOL CELL BIOL, V16, P5346; MAITY SN, 1988, SCIENCE, V241, P582, DOI 10.1126/science.3399893; MAITY SN, 1992, J BIOL CHEM, V267, P16574; Mantovani R, 1998, NUCLEIC ACIDS RES, V26, P1135, DOI 10.1093/nar/26.5.1135; Matthews RP, 1996, J BIOL CHEM, V271, P31869, DOI 10.1074/jbc.271.50.31869; Mink S, 1997, MOL CELL BIOL, V17, P6609, DOI 10.1128/MCB.17.11.6609; Minucci S, 1997, P NATL ACAD SCI USA, V94, P11295, DOI 10.1073/pnas.94.21.11295; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; NEUFELD EJ, 1992, NAT GENET, V1, P50, DOI 10.1038/ng0492-50; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; PITTMAN N, 1995, J BIOL CHEM, V270, P28848, DOI 10.1074/jbc.270.48.28848; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROMMENS JM, 1989, SCIENCE, V245, P1059, DOI 10.1126/science.2772657; Rundlett SE, 1996, P NATL ACAD SCI USA, V93, P14503, DOI 10.1073/pnas.93.25.14503; Sinha S, 1996, MOL CELL BIOL, V16, P328; SKALNIK DG, 1991, J BIOL CHEM, V266, P16736; Smith AN, 1996, J BIOL CHEM, V271, P9947, DOI 10.1074/jbc.271.17.9947; Taunton J, 1996, SCIENCE, V272, P408, DOI 10.1126/science.272.5260.408; TRAPNELL BC, 1991, J BIOL CHEM, V266, P10319; VALARCHE I, 1993, DEVELOPMENT, V119, P881; VetteseDadey M, 1996, EMBO J, V15, P2508, DOI 10.1002/j.1460-2075.1996.tb00608.x; Wade PA, 1997, TRENDS BIOCHEM SCI, V22, P128, DOI 10.1016/S0968-0004(97)01016-5; WADE PA, 1997, CURR BIOL, V7, P82; WANG HM, 1993, MOL CELL BIOL, V13, P1805, DOI 10.1128/MCB.13.3.1805; WANG HM, 1990, MOL CELL BIOL, V10, P5927, DOI 10.1128/MCB.10.11.5927; Wolffe AP, 1996, CELL, V84, P817, DOI 10.1016/S0092-8674(00)81059-4; Wolffe AP, 1996, SCIENCE, V272, P371, DOI 10.1126/science.272.5260.371; Xu L, 1998, NATURE, V395, P301, DOI 10.1038/26270; Yang WM, 1996, P NATL ACAD SCI USA, V93, P12845, DOI 10.1073/pnas.93.23.12845; YANG XJ, 1996, CELL, V87, P953; Yao TP, 1998, CELL, V93, P361, DOI 10.1016/S0092-8674(00)81165-4; YOSHIDA M, 1995, BIOESSAYS, V17, P423, DOI 10.1002/bies.950170510; YOSHIMURA K, 1991, J BIOL CHEM, V266, P9140	71	114	116	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 19	1999	274	12					7803	7815		10.1074/jbc.274.12.7803	http://dx.doi.org/10.1074/jbc.274.12.7803			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	178LU	10075672	hybrid			2022-12-25	WOS:000079268100031
J	Yuan, G; Bin, JC; McKay, DJ; Snyder, FF				Yuan, G; Bin, JC; McKay, DJ; Snyder, FF			Cloning and characterization of human guanine deaminase - Purification and partial amino acid sequence of the mouse protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BRAIN; DIHYDROOROTASE; METABOLISM; ENZYMES; MICE	Mouse erythrocyte guanine deaminase has been purified to homogeneity, The native enzyme was dimeric, being comprised of two identical subunits of approximately 50,000 Da, The protein sequence was obtained from five cyanogen bromide cleavage products giving sequences ranging from 12 to 25 amino acids in length and corresponding to 99 residues. Basic Local Alignment Search Tool (BLAST) analysis of expressed sequence databases enabled the retrieval of a human expressed sequence tag cDNA clone highly homologous to one of the mouse peptide sequences. The presumed coding region of this clone was used to screen a human kidney cDNA library and secondarily to polymerase chain reaction-amplify the full-length coding sequence of the human brain cDNA corresponding to an open reading frame of 1365 nucleotides and encoding a protein of 51,040 Da, Comparison of the mouse peptide sequences with the inferred human protein sequence revealed 88 of 99 residues to be identical. The human coding sequence of the putative enzyme was subcloned into the bacterial expression vector pMAL-c2, expressed, purified, and characterized as having guanine deaminase activity with a K-m for guanine of 9.5 +/- 1.7 mu M. The protein shares a 9-residue motif with other aminohydrolases and amidohydrolases (PGX[VI]DXH[TVI]H) that has been shown to be ligated with heavy metal ions, commonly zinc, The purified recombinant guanine deaminase was found to contain approximately 1 atom of zinc per 51-kDa monomer.	Univ Calgary, Fac Med, Dept Med Genet, Calgary, AB T2N 4N1, Canada; Univ Calgary, Dept Biochem & Mol Biol, Fac Med, Calgary, AB T2N 4N1, Canada	University of Calgary; University of Calgary	Snyder, FF (corresponding author), Univ Calgary, Fac Med, Dept Med Genet, 3330 Hosp Dr NW, Calgary, AB T2N 4N1, Canada.	snyder@ucalgary.ca						ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Bairoch A, 1997, NUCLEIC ACIDS RES, V25, P217, DOI 10.1093/nar/25.1.217; BERGER SJ, 1985, J NEUROCHEM, V44, P1736, DOI 10.1111/j.1471-4159.1985.tb07162.x; BERGSTROM JD, 1979, ARCH BIOCHEM BIOPHYS, V194, P107, DOI 10.1016/0003-9861(79)90600-3; BOULIEU R, 1984, CLIN CHIM ACTA, V142, P82; BROOKS SPJ, 1992, BIOTECHNIQUES, V13, P906; BROSH S, 1990, J NEUROCHEM, V54, P1776, DOI 10.1111/j.1471-4159.1990.tb01233.x; DAWSON DM, 1971, NEUROLOGY, V21, P621, DOI 10.1212/WNL.21.6.621; FARKAS WR, 1978, SCIENCE, V199, P786, DOI 10.1126/science.622568; GALILEA JM, 1981, INT J BIOCHEM, V13, P773, DOI 10.1016/0020-711X(81)90052-5; Gros E., 1967, METHOD ENZYMOL, V11, P238; GUPTA NK, 1985, ARCH BIOCHEM BIOPHYS, V236, P266, DOI 10.1016/0003-9861(85)90626-5; HENDERSO.JF, 1968, J BIOL CHEM, V243, P2514; ITO S, 1989, J HISTOCHEM CYTOCHEM, V37, P611, DOI 10.1177/37.5.2649557; KANTZ J, 1989, EUR J BIOCHEM, V181, P431; Karlin S, 1997, P NATL ACAD SCI USA, V94, P14231, DOI 10.1073/pnas.94.26.14231; Kim GJ, 1998, BIOCHEM J, V330, P295, DOI 10.1042/bj3300295; KRENITSKY TA, 1969, J BIOL CHEM, V244, P1263; KUMAR S, 1979, NEW ENGL J MED, V330, P1332; KUZMITS R, 1980, ENZYME, V25, P148, DOI 10.1159/000459240; LETISSIER PR, 1994, ANAL BIOCHEM, V222, P168, DOI 10.1006/abio.1994.1469; LEWIS AS, 1974, J BIOL CHEM, V249, P3862; MIYAMOTO S, 1982, J BIOCHEM, V91, P167, DOI 10.1093/oxfordjournals.jbchem.a133673; MOHAMEDALI KA, 1993, J BIOL CHEM, V268, P23728; NARDIELLO S, 1978, ENZYME, V23, P353, DOI 10.1159/000458600; Nygaard P, 1996, J BACTERIOL, V178, P846, DOI 10.1128/jb.178.3.846-853.1996; ROSSI CA, 1978, BIOCHIM BIOPHYS ACTA, V526, P235, DOI 10.1016/0005-2744(78)90308-X; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHOLAR EM, 1973, CANCER RES, V33, P94; SITARAMAYYA A, 1974, BIOCHEM J, V138, P143, DOI 10.1042/bj1380143; SNYDER FF, 1994, BBA-MOL BASIS DIS, V1227, P33, DOI 10.1016/0925-4439(94)90103-1; Snyder FF, 1997, P NATL ACAD SCI USA, V94, P2522, DOI 10.1073/pnas.94.6.2522; SOLAINI G, 1982, ITAL J BIOCHEM, V31, P253; TARR GE, 1986, MICROCHARACTERIZATIO, P155; VANWAEG G, 1986, PURINE PYRIMIDINE ME, P425; WILLIAMS NK, 1995, BIOCHEMISTRY-US, V34, P11344, DOI 10.1021/bi00036a007; ZIMMERMANN BH, 1995, BIOCHEMISTRY-US, V34, P7038, DOI 10.1021/bi00021a015	37	55	59	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 19	1999	274	12					8175	8180		10.1074/jbc.274.12.8175	http://dx.doi.org/10.1074/jbc.274.12.8175			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	178LU	10075721	hybrid			2022-12-25	WOS:000079268100080
J	Zerhusen, B; Zhao, JY; Xie, JX; Davis, PB; Ma, JJ				Zerhusen, B; Zhao, JY; Xie, JX; Davis, PB; Ma, JJ			A single conductance pore for chloride ions formed by two cystic fibrosis transmembrane conductance regulator molecules	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTIONAL RECONSTITUTION; CFTR; CHANNEL; GENE	The cystic fibrosis transmembrane conductance regulator (CFTR) is a cAMP-dependent protein kinase (PRA)- and ATP-regulated chloride channel, whose gating process involves intra- or intermolecular interactions among the cytosolic domains of the CFTR protein. Tandem linkage of two CFTR molecules produces a functional chloride channel with properties that are similar to those of the native CFTR channel, including trafficking to the plasma membrane, ATP- and PKA-dependent gating, and a unitary conductance of 8 picosiemens (pS), A heterodimer, consisting of a wild type and a mutant CFTR, also forms an 8-pS chloride channel with mixed gating properties of the wild type and mutant CFTR channels. The data suggest that two CFTR molecules interact together to form a single conductance pore for chloride ions.	Case Western Reserve Univ, Dept Physiol & Biophys, Sch Med, Cleveland, OH 44106 USA; Case Western Reserve Univ, Dept Pediat, Sch Med, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University	Ma, JJ (corresponding author), Case Western Reserve Univ, Dept Physiol & Biophys, Sch Med, Cleveland, OH 44106 USA.	jxm63@po.cwru.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK051770] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01-DK51770, R01-DK27556] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BEAR CE, 1992, CELL, V68, P809, DOI 10.1016/0092-8674(92)90155-6; Cheung M, 1997, J GEN PHYSIOL, V109, P289, DOI 10.1085/jgp.109.3.289; EGAN M, 1992, NATURE, V358, P581, DOI 10.1038/358581a0; Eskandari S, 1998, P NATL ACAD SCI USA, V95, P11235, DOI 10.1073/pnas.95.19.11235; GADSBY DC, 1994, TRENDS BIOCHEM SCI, V19, P513, DOI 10.1016/0968-0004(94)90141-4; GUNDERSON KL, 1994, J BIOL CHEM, V269, P19349; LOO MA, 1997, PEDIATR PULM, V14, P212; MA J, 1997, J BIOL CHEM, V273, P28133; MA J, 1995, J BIOL CHEM, V271, P7351; MARSHALL J, 1994, J BIOL CHEM, V269, P2987; NAREN AP, 1998, PEDIATR PULM, V17, P94; QUINTON PM, 1986, AM J PHYSIOL, V251, pC649, DOI 10.1152/ajpcell.1986.251.4.C649; RICH DP, 1991, SCIENCE, V253, P205, DOI 10.1126/science.1712985; RIORDAN JR, 1989, SCIENCE, V245, P1066; SMIT LS, 1993, P NATL ACAD SCI USA, V90, P9963, DOI 10.1073/pnas.90.21.9963; STUTTS MJ, 1995, SCIENCE, V269, P847, DOI 10.1126/science.7543698; TABCHARANI JA, 1993, NATURE, V366, P79, DOI 10.1038/366079a0; TSUI LC, 1995, AM J RESP CRIT CARE, V151, pS47, DOI 10.1164/ajrccm/151.3_Pt_2.S47; WELSH MJ, 1993, CELL, V73, P1251, DOI 10.1016/0092-8674(93)90353-R; Winter MC, 1997, NATURE, V389, P294, DOI 10.1038/38514; XIE JX, 1995, J BIOL CHEM, V270, P28084; Zielenski J, 1995, ANNU REV GENET, V29, P777, DOI 10.1146/annurev.ge.29.120195.004021	22	59	62	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	1999	274	12					7627	7630		10.1074/jbc.274.12.7627	http://dx.doi.org/10.1074/jbc.274.12.7627			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	178LU	10075649	hybrid			2022-12-25	WOS:000079268100008
J	Eliasson, R; Pontis, E; Jordan, A; Reichard, P				Eliasson, R; Pontis, E; Jordan, A; Reichard, P			Allosteric control of three B-12-dependent (class II) ribonucleotide reductases - Implications for the evolution of ribonucleotide reduction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; SUBSTRATE-SPECIFICITY; NRDEF ENZYME; PROTEIN; BACTERIOPHAGE-T4; CLONING; BINDING; R1	Three separate classes of ribonucleotide reductases are known, each with a distinct protein structure. One common feature of all enzymes is that a single protein generates each of the four deoxyribonucleotides. Class I and III enzymes contain an allosteric substrate specificity site capable of binding effecters (ATP or various deoxyribonucleoside triphosphates) that direct enzyme specificity, Some (but not all) enzymes contain a second allosteric site that binds only ATP or dATP. Binding of dATP to this site inhibits the activity of these enzymes, X-ray crystallography has localized the two sites within the structure of the Escherichia coli class I enzyme and identified effector-binding amino acids, Here, we have studied the regulation of three class II enzymes, one from the archaebacterium Thermoplasma acidophilum and two from eubacteria (Lactobacillus leichmannii and Thermotoga maritima). Each enzyme has an allosteric site that binds ATP or various deoxyribonucleoside triphosphates and that regulates its substrate specificity according to the same rules as for class I and III enzymes. dATP does not inhibit enzyme activity, suggesting the absence of a second active allosteric site. For the L, leichmannii and T, maritima enzymes, binding experiments also indicate the presence of only one allosteric site, Their primary sequences suggest that these enzymes lack the structural requirements for a second site. In contrast, the T, acidophilum enzyme binds dATP at two separate sites, and its sequence contains putative effector-binding amino acids for a second site. The presence of a second site without apparent physiological function leads to the hypothesis that a functional site was present early during the evolution of ribonucleotide reductases, but that its function was lost from the T, acidophilum enzyme, The other two B-12 enzymes lost not only the function, but also the structural basis for the site, Also a large subgroup (Ib) of class I enzymes, but none of the investigated class III enzymes, has lost this site. This is further indirect evidence that class II and I enzymes may have arisen by divergent evolution from class III enzymes.	Karolinska Inst, MBB, Med Nobel Inst, Dept Biochem 1, S-17177 Stockholm, Sweden; Autonomous Univ Barcelona, Fac Sci, Dept Genet & Microbiol, E-08193 Barcelona, Spain	Karolinska Institutet; Autonomous University of Barcelona	Reichard, P (corresponding author), Karolinska Inst, MBB, Med Nobel Inst, Dept Biochem 1, S-17177 Stockholm, Sweden.	peter.reichard@mbb.ki.se	jordan, albert/ABC-8229-2020; jordan, albert/K-4678-2014	jordan, albert/0000-0002-3970-8693; jordan, albert/0000-0002-3970-8693				BECK WS, 1967, J BIOL CHEM, V242, P3148; BERGLUND O, 1972, J BIOL CHEM, V247, P7276; BOOKER S, 1993, P NATL ACAD SCI USA, V90, P8352, DOI 10.1073/pnas.90.18.8352; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN NC, 1969, J MOL BIOL, V46, P25, DOI 10.1016/0022-2836(69)90055-2; BROWN NC, 1969, J MOL BIOL, V46, P39, DOI 10.1016/0022-2836(69)90056-4; BROWN NC, 1969, EUR J BIOCHEM, V9, P561, DOI 10.1111/j.1432-1033.1969.tb00646.x; CHEN AK, 1974, BIOCHEMISTRY-US, V13, P654, DOI 10.1021/bi00701a004; ELIASSON R, 1994, J BIOL CHEM, V269, P26052; Eliasson R, 1996, J BIOL CHEM, V271, P26582, DOI 10.1074/jbc.271.43.26582; Eriksson M, 1997, STRUCTURE, V5, P1077, DOI 10.1016/S0969-2126(97)00259-1; Fontecave M., 1992, ADV ENZYMOL RELAT AR, V65, P147; Hofer A, 1997, P NATL ACAD SCI USA, V94, P6959, DOI 10.1073/pnas.94.13.6959; Jordan A, 1997, P NATL ACAD SCI USA, V94, P13487, DOI 10.1073/pnas.94.25.13487; Jordan A, 1996, J BIOL CHEM, V271, P8779, DOI 10.1074/jbc.271.15.8779; Jordan A, 1998, ANNU REV BIOCHEM, V67, P71, DOI 10.1146/annurev.biochem.67.1.71; KIM JJ, 1977, ARCH BIOCHEM BIOPHYS, V182, P674, DOI 10.1016/0003-9861(77)90548-3; Licht S, 1996, SCIENCE, V271, P477, DOI 10.1126/science.271.5248.477; NIKAS I, 1986, Proteins Structure Function and Genetics, V1, P376, DOI 10.1002/prot.340010411; Ollagnier S, 1996, J BIOL CHEM, V271, P9410, DOI 10.1074/jbc.271.16.9410; ORMO M, 1990, ANAL BIOCHEM, V182, P674; PANAGOU D, 1972, BIOCHEMISTRY-US, V11, P2378, DOI 10.1021/bi00762a025; REICHARD P, 1993, J BIOL CHEM, V268, P8383; REICHARD P, 1993, SCIENCE, V260, P1773, DOI 10.1126/science.8511586; Sjoberg BM, 1997, STRUCT BOND, V88, P139; Stubbe JA, 1995, CHEM BIOL, V2, P793, DOI 10.1016/1074-5521(95)90084-5; Tauer A, 1997, P NATL ACAD SCI USA, V94, P53, DOI 10.1073/pnas.94.1.53; Thelander L, 1978, Methods Enzymol, V51, P227; YOUNG P, 1994, J BIOL CHEM, V269, P27815	29	36	37	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	1999	274	11					7182	7189		10.1074/jbc.274.11.7182	http://dx.doi.org/10.1074/jbc.274.11.7182			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	175DV	10066778	hybrid			2022-12-25	WOS:000079078400050
J	Satoh, D; Horii, A; Ochiai, M; Ashida, M				Satoh, D; Horii, A; Ochiai, M; Ashida, M			Prophenoloxidase-activating enzyme of the silkworm, Bombyx mori - Purification, characterization, and cDNA cloning	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DORSAL-VENTRAL PATTERN; HORSESHOE-CRAB HEMOCYTES; BLOOD-COAGULATION FACTOR; SERINE-PROTEASE ZYMOGEN; AMINO-ACID-SEQUENCE; PRO-PHENOL OXIDASE; 4 TANDEM REPEATS; PLASMA PREKALLIKREIN; RECOGNITION PROTEIN; PROCLOTTING ENZYME	Prophenoloxidase-activating enzyme (PPAE) was purified to homogeneity as judged by SDS-polyacrylamide gel electrophoresis from larval cuticles of the silkworm, Bombyx mori. The purified PPAE preparation was shown to be a mixture of the isozymes of PPAE (PPAE-I and PPAE-II), which were eluted at different retention times in reversed-phase high performance liquid chromatography, PPAE-I and PPAE-II seemed to be post translationally modified isozymes and/or allelic variants. Both PPAE isozymes were proteins composed of two polypeptides (heavy and light chains) that are linked by disulfide linkage(s) and glycosylated serine proteases, The results of cDNA cloning, peptide mapping, and amino acid sequencing of PPAE revealed that PPAE is synthesized as prepro-PPAE with 441 amino acid residues and is activated from pro-PPAE: by cleavage of a peptide bond between Lys(152) and Ile(153), The homology search showed 36.9% identity of PPAE to easter, which is a serine protease involved in dorsoventral pattern formation in the Drosophila embryo, and indicated the presence of two consecutive clip-like domains in the light chain. A single copy of the PPAE gene was suggested to be present in the silkworm genome. In the fifth instar larvae, PPAE transcripts were detected in the integument, hemocytes, and salivary glands but not in the fat body or mid gut. A polypeptide cross-reactive to mono-specific anti-PPAE/IgG was transiently detected in the extract of eggs between 1 and 3 h after they were laid.	Hokkaido Univ, Inst Low Temp Sci, Biochem Lab, Sapporo, Hokkaido 0600189, Japan	Hokkaido University	Ashida, M (corresponding author), Hokkaido Univ, Inst Low Temp Sci, Biochem Lab, Sapporo, Hokkaido 0600189, Japan.	ashida@pop.lowtem.hokudai.ac.jp	Ochiai, Masanori/A-4372-2012	Ochiai, Masanori/0000-0002-0022-347X				ANDERSSON K, 1989, INSECT BIOCHEM, V19, P629, DOI 10.1016/0020-1790(89)90097-8; ASHIDA M, 1980, INSECT BIOCHEM, V10, P37, DOI 10.1016/0020-1790(80)90036-0; ASHIDA M, 1971, ARCH BIOCHEM BIOPHYS, V144, P749, DOI 10.1016/0003-9861(71)90383-3; ASHIDA M, 1967, ARCH BIOCHEM BIOPHYS, V122, P411, DOI 10.1016/0003-9861(67)90213-5; ASHIDA M, 1983, BIOCHEM BIOPH RES CO, V113, P562, DOI 10.1016/0006-291X(83)91762-X; Ashida M., 1990, P239; ASHIDA M, 1995, P NATL ACAD SCI USA, V92, P10698, DOI 10.1073/pnas.92.23.10698; ASHIDA M, 1974, BIOCHEM BIOPH RES CO, V57, P1089, DOI 10.1016/0006-291X(74)90808-0; ASHIDA M, 1988, INSECT BIOCHEM, V18, P11, DOI 10.1016/0020-1790(88)90031-5; Ashida Masaaki, 1998, P135; BREY PT, 1993, P NATL ACAD SCI USA, V90, P6275, DOI 10.1073/pnas.90.13.6275; CHASAN R, 1989, CELL, V56, P391, DOI 10.1016/0092-8674(89)90242-0; CHEN CL, 1995, BIOCHEM J, V310, P23, DOI 10.1042/bj3100023; Chosa N, 1997, INSECT BIOCHEM MOLEC, V27, P61, DOI 10.1016/S0965-1748(96)00070-7; CHUNG DW, 1986, BIOCHEMISTRY-US, V25, P2410, DOI 10.1021/bi00357a017; DAVIS BJ, 1964, ANN NY ACAD SCI, V121, P404, DOI 10.1111/j.1749-6632.1964.tb14213.x; DEGEN SJF, 1987, BIOCHEMISTRY-US, V26, P6165, DOI 10.1021/bi00393a033; DELOTTO R, 1986, NATURE, V323, P688, DOI 10.1038/323688a0; Dimopoulos G, 1997, P NATL ACAD SCI USA, V94, P11508, DOI 10.1073/pnas.94.21.11508; DOHKE K, 1973, ARCH BIOCHEM BIOPHYS, V157, P210, DOI 10.1016/0003-9861(73)90407-4; EDMAN P, 1967, EUR J BIOCHEM, V1, P80, DOI 10.1111/j.1432-1033.1967.tb00047.x; FENIMORE JA, 1998, 3 INT S MOL INS SCI; FUJIKAWA K, 1986, BIOCHEMISTRY-US, V25, P2417, DOI 10.1021/bi00357a018; FURIE B, 1982, J BIOL CHEM, V257, P3875; Horii A., 1995, Zoological Science (Tokyo), V12, P44; HULTMARK D, 1994, NATURE, V367, P116, DOI 10.1038/367116a0; Jiang HB, 1998, P NATL ACAD SCI USA, V95, P12220, DOI 10.1073/pnas.95.21.12220; Johansson M.W., 1996, Progress in Molecular and Subcellular Biology, V15, P46; KATSUMI Y, 1995, EUR J BIOCHEM, V228, P870, DOI 10.1111/j.1432-1033.1995.tb20334.x; KAWABATA T, 1995, P NATL ACAD SCI USA, V92, P7774, DOI 10.1073/pnas.92.17.7774; KOSHLAND DEJ, 1970, ENZYMES, V1, P348; KURACHI K, 1982, P NATL ACAD SCI-BIOL, V79, P6461, DOI 10.1073/pnas.79.21.6461; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEBONNIEC BF, 1992, J BIOL CHEM, V267, P6970; Lee SY, 1998, EUR J BIOCHEM, V254, P50, DOI 10.1046/j.1432-1327.1998.2540050.x; Lee SY, 1998, EUR J BIOCHEM, V257, P615, DOI 10.1046/j.1432-1327.1998.2570615.x; Lemaitre B, 1996, CELL, V86, P973, DOI 10.1016/S0092-8674(00)80172-5; LIPMAN DJ, 1985, SCIENCE, V227, P1435, DOI 10.1126/science.2983426; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MASON HS, 1965, ANNU REV BIOCHEM, V34, P595, DOI 10.1146/annurev.bi.34.070165.003115; Morisato D, 1995, ANNU REV GENET, V29, P371, DOI 10.1146/annurev.genet.29.1.371; MURUGASUOEI B, 1995, GENE DEV, V9, P139, DOI 10.1101/gad.9.2.139; MUTA T, 1993, J BIOL CHEM, V268, P21384; MUTA T, 1990, J BIOL CHEM, V265, P22426; NAKAMURA T, 1985, J BIOCHEM, V97, P1561, DOI 10.1093/oxfordjournals.jbchem.a135213; NAPPI AJ, 1993, PIGM CELL RES, V6, P117, DOI 10.1111/j.1600-0749.1993.tb00590.x; OCHIAI M, 1988, J BIOL CHEM, V263, P12056; Peter J, 1998, BBA-GEN SUBJECTS, V1380, P93, DOI 10.1016/S0304-4165(97)00135-9; SAITO T, 1995, J BIOCHEM-TOKYO, V117, P1131, DOI 10.1093/oxfordjournals.jbchem.a124818; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHWERT GW, 1955, BIOCHIM BIOPHYS ACTA, V16, P570, DOI 10.1016/0006-3002(55)90280-8; SKOOG B, 1986, TRAC-TREND ANAL CHEM, V5, P82, DOI 10.1016/0165-9936(86)80045-0; SMITH C, 1994, GENETICS, V136, P1355; TANG YQ, 1993, J BIOL CHEM, V268, P6649; TISELIUS A, 1956, ARCH BIOCHEM BIOPHYS, V65, P132, DOI 10.1016/0003-9861(56)90183-7; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Wrigley C.W., 1971, METHOD ENZYMOL, V22, P559; YASUHARA Y, 1995, ARCH BIOCHEM BIOPHYS, V320, P14, DOI 10.1006/abbi.1995.1337; YOSHIDA H, 1986, INSECT BIOCHEM, V16, P539, DOI 10.1016/0020-1790(86)90031-4; Yoshida H, 1996, J BIOL CHEM, V271, P13854, DOI 10.1074/jbc.271.23.13854	60	205	219	2	25	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	1999	274	11					7441	7453		10.1074/jbc.274.11.7441	http://dx.doi.org/10.1074/jbc.274.11.7441			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	175DV	10066809	hybrid			2022-12-25	WOS:000079078400081
J	Annunen, P; Koivunen, P; Kivirikko, KI				Annunen, P; Koivunen, P; Kivirikko, KI			Cloning of the alpha subunit of prolyl 4-hydroxylase from Drosophila and expression and characterization of the corresponding enzyme tetramer with some unique properties	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ISOMERASE BETA-SUBUNIT; BACULOVIRUS EXPRESSION; CAENORHABDITIS-ELEGANS; HISTIDINE-RESIDUES; MOLECULAR-CLONING; LYSYL HYDROXYLASE; SEQUENCE; IDENTIFICATION; COLLAGEN; ISOFORM	Prolyl 4-hydroxylase catalyzes the formation of 4-hydroxyproline in collagens. The vertebrate enzymes are alpha(2)beta(2) tetramers, whereas the Caenorhabditis elegans enzyme is an alpha beta dimer, the beta subunit being identical to protein-disulfide isomerase (PDI), We report here that the processed Drosophila melanogaster a subunit is 516 amino acid residues in length and shows 34 and 35% sequence identities to the two types of human alpha subunit and 31% identity to the C, elegans alpha subunit. Its coexpression in insect cells with the Drosophila PDI polypeptide produced an active enzyme tetramer, and small amounts of a hybrid tetramer were also obtained upon coexpression with human PDI, Four of the five recently identified critical residues at the catalytic site were conserved, but a histidine that probably helps the binding of 2-oxoglutarate to the Fe2+ and its decarboxylation was replaced by arginine 490, The enzyme had a higher K-m for 2-oxoglutarate, a lower reaction velocity, and a higher percentage of uncoupled decarboxylation than the human enzymes. The mutation R490H reduced the percentage of uncoupled decarboxylation, whereas R490S increased the K-m for 2-oxoglutarate, reduced the reaction velocity, and increased the percentage of uncoupled decarboxylation. The recently identified peptide-binding domain showed a relatively low identity to those from other species, and the K-m of the Drosophila enzyme for (Pro-Pro-Gly)(10) was higher than that of any other animal prolyl 4-hydroxylase studied. A 1.9-kilobase mRNA coding for this alpha subunit was present in Drosophila larvae.	Univ Oulu, Dept Med Biochem, FIN-90220 Oulu, Finland; Univ Oulu, Bioctr, Collagen Res Unit, FIN-90220 Oulu, Finland	University of Oulu; University of Oulu	Kivirikko, KI (corresponding author), Univ Oulu, Dept Med Biochem, Kajaanintie 52 A, FIN-90220 Oulu, Finland.							Annunen P, 1997, J BIOL CHEM, V272, P17342, DOI 10.1074/jbc.272.28.17342; Annunen P, 1998, J BIOL CHEM, V273, P5989, DOI 10.1074/jbc.273.11.5989; BLUMBERG B, 1988, J BIOL CHEM, V263, P18328; FESSLER JH, 1989, ANNU REV CELL BIOL, V5, P309, DOI 10.1146/annurev.cb.05.110189.001521; GRUENWALD S, 1994, BACULOVIRUS EXPRESSI; HELAAKOSKI T, 1989, P NATL ACAD SCI USA, V86, P4392, DOI 10.1073/pnas.86.12.4392; HELAAKOSKI T, 1995, P NATL ACAD SCI USA, V92, P4427, DOI 10.1073/pnas.92.10.4427; Kivirikko KI, 1998, MATRIX BIOL, V16, P357, DOI 10.1016/S0945-053X(98)90009-9; KIVIRIKKO KI, 1982, METHOD ENZYMOL, V82, P245; Kivirikko KI, 1998, ADV ENZYMOL RAMB, V72, P325; LAMBERG A, 1995, J BIOL CHEM, V270, P9926, DOI 10.1074/jbc.270.17.9926; LUCKOW VA, 1989, VIROLOGY, V170, P31, DOI 10.1016/0042-6822(89)90348-6; MCKAY RR, 1995, INSECT BIOCHEM MOLEC, V25, P647, DOI 10.1016/0965-1748(95)00001-C; Myllyharju J, 1999, EMBO J, V18, P306, DOI 10.1093/emboj/18.2.306; Myllyharju J, 1997, EMBO J, V16, P1173, DOI 10.1093/emboj/16.6.1173; MYLLYLA R, 1992, BIOCHEM J, V286, P923, DOI 10.1042/bj2860923; MYLLYLA R, 1977, EUR J BIOCHEM, V80, P349, DOI 10.1111/j.1432-1033.1977.tb11889.x; MYLLYLA R, 1991, J BIOL CHEM, V266, P2805; Passoja K, 1998, P NATL ACAD SCI USA, V95, P10482, DOI 10.1073/pnas.95.18.10482; Passoja K, 1998, FEBS LETT, V434, P145, DOI 10.1016/S0014-5793(98)00966-1; PROCKOP DJ, 1995, ANNU REV BIOCHEM, V64, P403, DOI 10.1146/annurev.biochem.64.1.403; ROACH PL, 1995, NATURE, V375, P700, DOI 10.1038/375700a0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Valtavaara M, 1998, J BIOL CHEM, V273, P12881, DOI 10.1074/jbc.273.21.12881; Veijola J, 1996, BIOCHEM J, V317, P721, DOI 10.1042/bj3170721; VEIJOLA J, 1994, J BIOL CHEM, V269, P26746; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; VUORI K, 1992, P NATL ACAD SCI USA, V89, P7467, DOI 10.1073/pnas.89.16.7467; Yasothornsrikul S, 1997, GENE, V198, P17, DOI 10.1016/S0378-1119(97)00274-6	29	34	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1999	274	10					6790	6796		10.1074/jbc.274.10.6790	http://dx.doi.org/10.1074/jbc.274.10.6790			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172BQ	10037780	hybrid			2022-12-25	WOS:000078902800102
J	Hamid, J; Nelson, D; Spaetgens, R; Dubel, SJ; Snutch, TP; Zamponi, GW				Hamid, J; Nelson, D; Spaetgens, R; Dubel, SJ; Snutch, TP; Zamponi, GW			Identification of an integration center for cross-talk between protein kinase C and G protein modulation of N-type calcium channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTIONAL EXPRESSION; CA2+ CHANNELS; SUBCELLULAR-DISTRIBUTION; RECEPTOR INHIBITION; INTRACELLULAR LOOP; DOMAIN-II; SUBUNIT; NEURONS; BRAIN; DETERMINANTS	The modulation of presynaptic calcium channel activity by second messengers provides a fine tuning mechanism for neurotransmitter release. In neurons, the activation of certain G protein-coupled receptors reduces N-type channel activity by similar to 60%. In contrast, activation of protein kinase C (PKC) results in an approximately 50% increase in N-type channel activity, and subsequent G protein inhibition is antagonized. Here, we describe the molecular determinants that control the dual effects of PKC-dependent phosphorylation. The double substitution of two adjacent PKC consensus sites in the calcium channel domain I-II linker (Thr(422), Ser(425)) to alanines abolished both PKC-dependent up-regulation and the PKC-G protein cross-talk. The single substitution of Ser(425) to glutamic acid abolished PRC up-regulation but had no effect on G protein modulation. Replacement of Thr(422) With glutamic acid eliminated PKC-dependent up-regulation and mimicked the effects of PKC phosphorylation on G protein inhibition. Our data suggest that Thr(422) mediates the antagonistic effect of PKC on G protein modulation, while phosphorylation of either Thr(422) or Ser(425) are sufficient to increase N-type channel activity. Thus, Thr(422) serves as a molecular switch by which PKC is able to simultaneously trigger the upregulation of channel activity and antagonize G protein inhibition.	Univ Calgary, Dept Pharmacol & Therapeut, Neurosci Res Grp, Calgary, AB T2N 4N1, Canada; Univ British Columbia, Biotechnol Lab, Vancouver, BC V6T 1Z3, Canada	University of Calgary; University of British Columbia	Zamponi, GW (corresponding author), Univ Calgary, Dept Pharmacol & Therapeut, Neurosci Res Grp, 3330 Hosp Dr NW, Calgary, AB T2N 4N1, Canada.	Zamponi@acs.ucalgary.ca	Snutch, Terrance P/L-3464-2019	Snutch, Terrance P/0000-0001-5182-1296; Zamponi, Gerald W./0000-0002-0644-9066				BEAN BP, 1989, NATURE, V340, P153, DOI 10.1038/340153a0; BOLAND LM, 1993, J NEUROSCI, V13, P515; Bourinet E, 1996, P NATL ACAD SCI USA, V93, P1486, DOI 10.1073/pnas.93.4.1486; DeWaard M, 1997, NATURE, V385, P446, DOI 10.1038/385446a0; DUBEL SJ, 1992, P NATL ACAD SCI USA, V89, P5058, DOI 10.1073/pnas.89.11.5058; DUNLAP K, 1981, J PHYSIOL-LONDON, V317, P519, DOI 10.1113/jphysiol.1981.sp013841; Fisher SE, 1997, GENOMICS, V45, P340, DOI 10.1006/geno.1997.4941; FUJITA Y, 1993, NEURON, V10, P585, DOI 10.1016/0896-6273(93)90162-K; Herlitze S, 1996, NATURE, V380, P258, DOI 10.1038/380258a0; Herlitze S, 1997, P NATL ACAD SCI USA, V94, P1512, DOI 10.1073/pnas.94.4.1512; HILLE B, 1994, TRENDS NEUROSCI, V17, P531, DOI 10.1016/0166-2236(94)90157-0; IKEDA SR, 1989, J PHYSIOL-LONDON, V409, P221, DOI 10.1113/jphysiol.1989.sp017494; Ikeda SR, 1996, NATURE, V380, P255, DOI 10.1038/380255a0; MINTZ IM, 1993, NEURON, V10, P889, DOI 10.1016/0896-6273(93)90204-5; MORI Y, 1991, NATURE, V350, P398, DOI 10.1038/350398a0; Page KM, 1998, J NEUROSCI, V18, P4815; Page KM, 1997, J NEUROSCI, V17, P1330; Patil PG, 1996, BIOPHYS J, V71, P2509, DOI 10.1016/S0006-3495(96)79444-4; Perez-Reyes E, 1998, NATURE, V391, P896, DOI 10.1038/36110; QUIN N, 1997, P NATL ACAD SCI USA, V95, P8866; SATHER WA, 1993, NEURON, V11, P291, DOI 10.1016/0896-6273(93)90185-T; SHENG ZH, 1994, NEURON, V13, P1303, DOI 10.1016/0896-6273(94)90417-0; Shistik E, 1998, J BIOL CHEM, V273, P17901, DOI 10.1074/jbc.273.28.17901; SOONG TW, 1993, SCIENCE, V260, P1133, DOI 10.1126/science.8388125; STEA A, 1995, NEURON, V15, P929, DOI 10.1016/0896-6273(95)90183-3; STEA A, 1994, P NATL ACAD SCI USA, V91, P10567; Stephens GJ, 1998, J PHYSIOL-LONDON, V509, P163, DOI 10.1111/j.1469-7793.1998.163bo.x; SWARTZ KJ, 1993, NATURE, V361, P165, DOI 10.1038/361165a0; SWARTZ KJ, 1993, NEURON, V11, P305, DOI 10.1016/0896-6273(93)90186-U; TOMLINSON WJ, 1993, NEUROPHARMACOLOGY, V32, P1117, DOI 10.1016/0028-3908(93)90006-O; WESTENBROEK RE, 1995, J NEUROSCI, V15, P6403; WESTENBROEK RE, 1992, NEURON, V9, P1099, DOI 10.1016/0896-6273(92)90069-P; WILLIAMS ME, 1992, SCIENCE, V257, P389, DOI 10.1126/science.1321501; WILLIAMS ME, 1994, J BIOL CHEM, V269, P22347; WILLIAMS ME, 1992, NEURON, V8, P71, DOI 10.1016/0896-6273(92)90109-Q; Yokoyama CT, 1997, J NEUROSCI, V17, P6929; Zamponi GW, 1997, NATURE, V385, P442, DOI 10.1038/385442a0; Zamponi GW, 1998, P NATL ACAD SCI USA, V95, P4035, DOI 10.1073/pnas.95.7.4035; Zamponi GW, 1996, J MEMBRANE BIOL, V151, P77, DOI 10.1007/s002329900059; Zhang JF, 1996, NEURON, V17, P991, DOI 10.1016/S0896-6273(00)80229-9	40	102	107	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1999	274	10					6195	6202		10.1074/jbc.274.10.6195	http://dx.doi.org/10.1074/jbc.274.10.6195			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172BQ	10037705				2022-12-25	WOS:000078902800027
J	Li, C; Kraemer, FB; Ahlborn, TE; Liu, JW				Li, C; Kraemer, FB; Ahlborn, TE; Liu, JW			Induction of low density lipoprotein receptor (LDLR) transcription by oncostatin M is mediated by the extracellular signal-regulated kinase signaling pathway and the repeat 3 element of the LDLR promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; LEUKEMIA INHIBITORY FACTOR; GENE-EXPRESSION; HEPG2 CELLS; NUCLEAR-PROTEIN; FACTOR SP1; IDENTIFICATION; SEQUENCE; BINDS; REPRESSION	Oncostatin M (OM) activates the transcription of the human low density lipoprotein receptor (LDLR) in HepG2 cells through a sterol-independent mechanism. Our previous studies showed that mutations within the repeat 3 sequence of the LDLR promoter significantly decreased OM activity on LDLR promoter luciferase reporter constructs that contain the sterol responsive element-1 (repeat 2) and Sp1 binding sites (repeats 1 and 3), In this study, we investigated the signal transduction pathways that are involved in OM-induced LDLR transcription, In HepG2 cells, OM induced a rapid increase in LDLR mRNA expression, with increases detected at 30 min and maximal induction at 1 h, This OM effect was not blocked by protein synthesis inhibitors, inhibitors of p38 kinase, phosphatidylinositol 3-kinase, or c-Jun N-terminal kinase, but OM activity was completely abolished by pretreating cells with inhibitors of the extracellular signal-regulated kinase (ERK) kinase (mitogen/ ERK kinase (MEK)), To investigate whether the repeat 3 sequence of the LDLR promoter is the OM-responsive element that converts ERK activation at the promoter level, three luciferase reporters, pLDLR-TATA containing only the TATA-like elements of the promoter, pLDLR-R3 containing repeat 3 and the TATA-like elements, and pLDLR-234 containing repeats 1, 2, 3 and the TATA-like elements were constructed and transiently transfected into HepG2 cells. OM had no effect on the basal promoter construct pLDLR-TATA; however, including a single copy of repeat 3 sequence in the TATA vector (pLDLR-R3) resulted in a full OM response. The activity of OM on pLDLR-R3 was identical to that of pLDLR-234, Importantly, the ability of OM to increase luciferase activities in both pLDLR-R3- and pLDLR-234-transfected cells was blocked in a dose-dependent manner by inhibition of MEK, These results demonstrate that the mitogen-activated protein kinase MEK/ERK cascade is the essential signaling pathway by which OM activates LDLR gene transcription and provide the first evidence that the repeat 3 element is a new downstream target of ERK activation.	Dept Vet Affairs Palo Alto Hlth Care Syst, Palo Alto, CA 94304 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System	Liu, JW (corresponding author), Dept Vet Affairs Palo Alto Hlth Care Syst, 3801 Miranda Ave, Palo Alto, CA 94304 USA.	liu@icon.palo-alto.med.va.gov	Kraemer, Fredric/AAC-3633-2019	Kraemer, Fredric/0000-0003-2468-7807				Akira S, 1997, INT J BIOCHEM CELL B, V29, P1401, DOI 10.1016/S1357-2725(97)00063-0; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; AUWERX JH, 1989, MOL CELL BIOL, V9, P2298, DOI 10.1128/MCB.9.6.2298; Bellido T, 1998, J BIOL CHEM, V273, P21137, DOI 10.1074/jbc.273.33.21137; BLOCK LH, 1993, P NATL ACAD SCI USA, V90, P4097, DOI 10.1073/pnas.90.9.4097; BRIGGS MR, 1993, J BIOL CHEM, V268, P14490; Chen YR, 1998, ONCOGENE, V17, P173, DOI 10.1038/sj.onc.1201941; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DAWSON PA, 1988, J BIOL CHEM, V263, P3372; Faris M, 1998, AIDS, V12, P19, DOI 10.1097/00002030-199801000-00003; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Fukunaga R, 1997, EMBO J, V16, P1921, DOI 10.1093/emboj/16.8.1921; GILLE H, 1995, EMBO J, V14, P951, DOI 10.1002/j.1460-2075.1995.tb07076.x; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; GROVE RI, 1991, J BIOL CHEM, V266, P18194; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; JACKSON S, 1993, ADV SEC MESS PHOSPH, V28, P279; Korzus E, 1997, J BIOL CHEM, V272, P1188, DOI 10.1074/jbc.272.2.1188; Kumar A, 1997, J LIPID RES, V38, P2240; Kumar A, 1998, J BIOL CHEM, V273, P15742, DOI 10.1074/jbc.273.25.15742; Liu JW, 1997, ARTERIOSCL THROM VAS, V17, P2948, DOI 10.1161/01.ATV.17.11.2948; Liu JW, 1997, J LIPID RES, V38, P2035; LIU JW, 1994, CELL GROWTH DIFFER, V5, P1333; Mehta KD, 1996, J BIOL CHEM, V271, P33616, DOI 10.1074/jbc.271.52.33616; Oh H, 1998, J BIOL CHEM, V273, P9703, DOI 10.1074/jbc.273.16.9703; Pak YK, 1996, J LIPID RES, V37, P985; ROBBINS DJ, 1993, J BIOL CHEM, V268, P5097; Rohlff C, 1997, J BIOL CHEM, V272, P21137, DOI 10.1074/jbc.272.34.21137; RUDLING M, 1993, P NATL ACAD SCI USA, V90, P8851, DOI 10.1073/pnas.90.19.8851; RUDLING M, 1992, P NATL ACAD SCI USA, V89, P6983, DOI 10.1073/pnas.89.15.6983; SANCHEZ HB, 1995, J BIOL CHEM, V270, P1161, DOI 10.1074/jbc.270.3.1161; SCHWARZSCHILD MA, 1994, J NEUROCHEM, V63, P1246; SMITH JR, 1990, J BIOL CHEM, V265, P2306; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; Stancato LF, 1998, J BIOL CHEM, V273, P18701, DOI 10.1074/jbc.273.30.18701; Stancato LF, 1997, MOL CELL BIOL, V17, P3833, DOI 10.1128/MCB.17.7.3833; STOPECK AT, 1993, J BIOL CHEM, V268, P17489; SUDHOF TC, 1987, CELL, V48, P1061, DOI 10.1016/0092-8674(87)90713-6; SUDHOF TC, 1987, J BIOL CHEM, V262, P10773; THOMA B, 1994, J BIOL CHEM, V269, P6215; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; WANG XD, 1993, J BIOL CHEM, V268, P14497; WANG XD, 1994, CELL, V77, P53, DOI 10.1016/0092-8674(94)90234-8; WEGENKA UM, 1994, MOL CELL BIOL, V14, P3186, DOI 10.1128/MCB.14.5.3186; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; YIN TG, 1994, J BIOL CHEM, V269, P3731; YOKOYAMA C, 1993, CELL, V75, P187, DOI 10.1016/S0092-8674(05)80095-9; ZHANG ZX, 1995, J BIOL CHEM, V270, P24287, DOI 10.1074/jbc.270.41.24287; ZHAO Y, 1995, J BIOL CHEM, V270, P16449, DOI 10.1074/jbc.270.27.16449	52	48	50	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1999	274	10					6747	6753		10.1074/jbc.274.10.6747	http://dx.doi.org/10.1074/jbc.274.10.6747			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172BQ	10037774	hybrid			2022-12-25	WOS:000078902800096
J	Turpin, P; Hay, RT; Dargemont, C				Turpin, P; Hay, RT; Dargemont, C			Characterization of I kappa B alpha nuclear import pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN IMPORT; DNA-BINDING; LOCALIZATION SEQUENCES; NUCLEOCYTOPLASMIC TRANSPORT; CYTOPLASMIC RETENTION; TERMINAL DOMAIN; EXPORT PATHWAY; PORE COMPLEX; HNRNP A1; SIGNAL	I kappa B alpha controls the transcriptional activity of nuclear factor (NF)-kappa B by retaining it in the cytoplasm; but, when expressed in the nucleus, it can also inhibit the interaction of NF-kappa B with DNA and promote the export of NF-kappa B from the nucleus to the cytoplasm, Here, we report that I kappa B alpha, when not bound to NF-kappa B, is constitutively transported to the nucleus, and we confirm that the interaction of NF-kappa B with NF-kappa B retains I kappa B alpha in the cytoplasm, Nuclear import of I kappa B alpha does not result from passive diffusion but from a specific energy-dependent transport process that requires the ankyrin repeats of I kappa B alpha. Nuclear accumulation of I kappa B alpha is dependent on importins alpha and beta as well as the small GTPase Ran, which are also responsible for the nuclear import mediated by basic nuclear localization sequences (NLS). However, these proteins are not sufficient to promote I kappa B alpha nuclear translocation. Factor(s) can be removed selectively from cell extracts with ankyrin repeats of I kappa B alpha which strongly reduce import of I kappa B alpha but not of proteins containing basic NLS. These findings indicate that I kappa B alpha is imported in the nucleus by a piggy-back mechanism that involves additional protein(s) containing a basic NLS and able to interact with ankyrin repeats of I kappa B alpha.	Inst Curie, CNRS, Unite Mixte Rech 144, Lab Transport Nucleocytoplasm, F-75248 Paris 05, France; Univ St Andrews, Sch Biomed Sci, Inst Biomol Sci, St Andrews, Fife, Scotland	UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Centre National de la Recherche Scientifique (CNRS); Sorbonne Universite; University of St Andrews	Dargemont, C (corresponding author), Inst Curie, CNRS, Unite Mixte Rech 144, Lab Transport Nucleocytoplasm, 26 Rue Ulm, F-75248 Paris 05, France.		Hay, Ronald/S-3233-2019; Hay, Ronald T/F-9338-2011	Hay, Ronald/0000-0001-7113-9024; Hay, Ronald T/0000-0001-7113-9024				ADAM SA, 1990, J CELL BIOL, V111, P807, DOI 10.1083/jcb.111.3.807; Aitchison JD, 1996, SCIENCE, V274, P624, DOI 10.1126/science.274.5287.624; ARENZANASEISDEDOS F, 1995, MOL CELL BIOL, V15, P2689; ArenzanaSeisdedos F, 1997, J CELL SCI, V110, P369; Aster JC, 1997, J BIOL CHEM, V272, P11336; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; BEG AA, 1992, GENE DEV, V6, P1899, DOI 10.1101/gad.6.10.1899; BLANK V, 1991, EMBO J, V10, P4159, DOI 10.1002/j.1460-2075.1991.tb04994.x; Chi NC, 1996, J CELL BIOL, V135, P559, DOI 10.1083/jcb.135.3.559; CHIAO PJ, 1994, P NATL ACAD SCI USA, V91, P28, DOI 10.1073/pnas.91.1.28; CRESSMAN DE, 1993, ONCOGENE, V8, P2567; DASSO M, 1994, EMBO J, V13, P5732, DOI 10.1002/j.1460-2075.1994.tb06911.x; Deane R, 1997, MOL CELL BIOL, V17, P5087, DOI 10.1128/MCB.17.9.5087; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; FISCHER U, 1995, CELL, V82, P475, DOI 10.1016/0092-8674(95)90436-0; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Fritz CC, 1996, CURR BIOL, V6, P848, DOI 10.1016/S0960-9822(02)00608-5; Fukuda M, 1997, NATURE, V390, P308, DOI 10.1038/36894; Galli T, 1998, MOL BIOL CELL, V9, P1437, DOI 10.1091/mbc.9.6.1437; GANCHI PA, 1992, MOL BIOL CELL, V3, P1339, DOI 10.1091/mbc.3.12.1339; GORLICH D, 1995, NATURE, V377, P246, DOI 10.1038/377246a0; GORLICH D, 1994, CELL, V79, P767, DOI 10.1016/0092-8674(94)90067-1; GORLICH D, 1995, CURR BIOL, V5, P383, DOI 10.1016/S0960-9822(95)00079-0; Gorlich D, 1996, EMBO J, V15, P1810, DOI 10.1002/j.1460-2075.1996.tb00530.x; Gorlich D, 1997, J CELL BIOL, V138, P65, DOI 10.1083/jcb.138.1.65; Gorlich D, 1996, EMBO J, V15, P5584, DOI 10.1002/j.1460-2075.1996.tb00943.x; Goto K, 1996, P NATL ACAD SCI USA, V93, P11196, DOI 10.1073/pnas.93.20.11196; HANKE T, 1992, J GEN VIROL, V73, P653, DOI 10.1099/0022-1317-73-3-653; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; HATADA EN, 1993, EMBO J, V12, P2781, DOI 10.1002/j.1460-2075.1993.tb05939.x; HAY RT, 1993, BIOCHEM SOC T, V21, P926, DOI 10.1042/bst0210926; HENKEL T, 1993, NATURE, V365, P182, DOI 10.1038/365182a0; HENKEL T, 1992, CELL, V68, P1121, DOI 10.1016/0092-8674(92)90083-O; IMAMOTO N, 1995, EMBO J, V14, P3617, DOI 10.1002/j.1460-2075.1995.tb00031.x; Imbert V, 1996, CELL, V86, P787, DOI 10.1016/S0092-8674(00)80153-1; INOUE J, 1992, CELL, V68, P1109, DOI 10.1016/0092-8674(92)90082-N; Iovine MK, 1995, J CELL BIOL, V131, P1699, DOI 10.1083/jcb.131.6.1699; Izaurralde E, 1997, EMBO J, V16, P6535, DOI 10.1093/emboj/16.21.6535; Izaurralde E, 1997, J CELL BIOL, V137, P27, DOI 10.1083/jcb.137.1.27; JAFFRAY E, 1995, MOL CELL BIOL, V15, P2166; KLEBE C, 1993, BIOCHEMISTRY-US, V32, P11923, DOI 10.1021/bi00095a023; Kopan R, 1996, P NATL ACAD SCI USA, V93, P1683, DOI 10.1073/pnas.93.4.1683; Kroll M, 1997, ONCOGENE, V15, P1841, DOI 10.1038/sj.onc.1201560; LEBAIL O, 1993, EMBO J, V12, P5043, DOI 10.1002/j.1460-2075.1993.tb06197.x; Liou HC, 1993, CURR OPIN CELL BIOL, V5, P477, DOI 10.1016/0955-0674(93)90014-H; MATTHEWS JR, 1995, NUCLEIC ACIDS RES, V23, P3393, DOI 10.1093/nar/23.17.3393; MELCHIOR F, 1995, J CELL BIOL, V131, P571, DOI 10.1083/jcb.131.3.571; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Mizuno T, 1996, J CELL SCI, V109, P2627; MOORE MS, 1993, NATURE, V365, P661, DOI 10.1038/365661a0; MOORE MS, 1994, P NATL ACAD SCI USA, V91, P10212, DOI 10.1073/pnas.91.21.10212; MOROIANU J, 1995, P NATL ACAD SCI USA, V92, P2008, DOI 10.1073/pnas.92.6.2008; MOROIANU J, 1995, P NATL ACAD SCI USA, V92, P6532, DOI 10.1073/pnas.92.14.6532; Nehrbass U, 1996, SCIENCE, V272, P120, DOI 10.1126/science.272.5258.120; Nigg EA, 1997, NATURE, V386, P779, DOI 10.1038/386779a0; Ohno M, 1998, CELL, V92, P327, DOI 10.1016/S0092-8674(00)80926-5; OssarehNazari B, 1997, SCIENCE, V278, P141, DOI 10.1126/science.278.5335.141; Palacios I, 1996, J CELL BIOL, V133, P485, DOI 10.1083/jcb.133.3.485; PASCHAL BM, 1995, J CELL BIOL, V129, P925, DOI 10.1083/jcb.129.4.925; Pollard VW, 1996, CELL, V86, P985, DOI 10.1016/S0092-8674(00)80173-7; RADU A, 1995, P NATL ACAD SCI USA, V92, P1769, DOI 10.1073/pnas.92.5.1769; REXACH M, 1995, CELL, V83, P683, DOI 10.1016/0092-8674(95)90181-7; Richards SA, 1997, SCIENCE, V276, P1842, DOI 10.1126/science.276.5320.1842; RODRIGUEZ MS, 1995, MOL CELL BIOL, V15, P2413; Rout MP, 1997, CELL, V89, P715, DOI 10.1016/S0092-8674(00)80254-8; Schlenstedt G, 1997, EMBO J, V16, P6237, DOI 10.1093/emboj/16.20.6237; SIOMI H, 1995, J CELL BIOL, V129, P551, DOI 10.1083/jcb.129.3.551; Spiecker M, 1997, J BIOL CHEM, V272, P30969, DOI 10.1074/jbc.272.49.30969; Stade K, 1997, CELL, V90, P1041, DOI 10.1016/S0092-8674(00)80370-0; Stancovski I, 1997, CELL, V91, P299, DOI 10.1016/S0092-8674(00)80413-4; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; Suyang H, 1996, MOL CELL BIOL, V16, P5444; Tran K, 1997, MOL CELL BIOL, V17, P5386, DOI 10.1128/MCB.17.9.5386; Verma IM, 1997, P NATL ACAD SCI USA, V94, P11758, DOI 10.1073/pnas.94.22.11758; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; WEIS K, 1995, SCIENCE, V268, P1049, DOI 10.1126/science.7754385; Weis K, 1996, EMBO J, V15, P1818, DOI 10.1002/j.1460-2075.1996.tb00531.x; WEN W, 1995, CELL, V82, P463, DOI 10.1016/0092-8674(95)90435-2; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Yaseen NR, 1997, P NATL ACAD SCI USA, V94, P4451, DOI 10.1073/pnas.94.9.4451; ZABEL U, 1993, EMBO J, V12, P201, DOI 10.1002/j.1460-2075.1993.tb05646.x; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; ZHANG Q, 1994, MOL CELL BIOL, V14, P3915, DOI 10.1128/MCB.14.6.3915	83	97	100	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1999	274	10					6804	6812		10.1074/jbc.274.10.6804	http://dx.doi.org/10.1074/jbc.274.10.6804			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172BQ	10037782	hybrid			2022-12-25	WOS:000078902800104
J	Bonaventura, C; Godette, G; Tesh, S; Holm, DE; Bonaventura, J; Crumbliss, AL; Pearce, LL; Peterson, J				Bonaventura, C; Godette, G; Tesh, S; Holm, DE; Bonaventura, J; Crumbliss, AL; Pearce, LL; Peterson, J			Internal electron transfer between hemes and Cu(II) bound at cysteine beta 93 promotes methemoglobin reduction by carbon monoxide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C-OXIDASE; INOSITOL HEXAPHOSPHATE; HUMAN-HEMOGLOBIN; OXIDATION; SPECTROSCOPY; BINDING; COPPER; HORSE; ION	Previous studies showed that CO/H2O oxidation provides electrons to drive the reduction of oxidized hemoglobin (metHb), We report here that Cu(II) addition accelerates the rate of metHb beta chain reduction by CO by a factor of about 1000, A mechanism whereby electron transfer occurs via an internal pathway coupling CO/H2O oxidation to Fe(III) and Cu(II) reduction is suggested by the observation that the copper-induced rate enhancement is inhibited by blocking Cys-beta 93 with N-ethylmaleimide. Furthermore, this internal electron-transfer pathway is more readily established at low Cu(II) concentrations in Hb Deer Lodge (beta 2His --> Arg) and other species lacking His-beta 2 than in Hb A(0). This difference is consistent with preferential binding of Cu(II) in Hb A(0) to a high affinity site involving His-beta 2, which is ineffective in promoting electron exchange between Cu(II) and the beta heme iron, Effective electron transfer is thus affected by Hb type but is not governed by the R <-> T conformational equilibrium. The beta hemes in Cu(II)-metHb are reduced under CO at rates close to those observed for cytochrome c oxidase, where heme and copper are present together in the oxygen-binding site and where internal electron transfer also occurs.	Duke Univ, Marine Lab, Marine Freshwater Biomed Ctr, Beaufort, NC 28516 USA; Univ Alabama, Dept Chem, Tuscaloosa, AL 35487 USA; Duke Univ, Dept Chem, Durham, NC 27708 USA; Univ Pittsburgh, Sch Med, Dept Pharmacol, Pittsburgh, PA 15261 USA; Carnegie Mellon Univ, Dept Chem, Pittsburgh, PA 15213 USA	Duke University; University of Alabama System; University of Alabama Tuscaloosa; Duke University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Carnegie Mellon University	Bonaventura, C (corresponding author), Duke Univ, Marine Lab, Marine Freshwater Biomed Ctr, Beaufort, NC 28516 USA.			Pearce, Linda/0000-0002-0940-965X; Peterson, James/0000-0002-7300-5887	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058248] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES001908, P50ES001908] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL58248] Funding Source: Medline; NIEHS NIH HHS [ESO1908] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ALAYASH AI, 1993, ARCH BIOCHEM BIOPHYS, V303, P332, DOI 10.1006/abbi.1993.1292; ANTHOLINE WE, 1984, J INORG BIOCHEM, V21, P125, DOI 10.1016/0162-0134(84)85045-X; ANTHOLINE WE, 1985, J INORG BIOCHEM, V25, P95, DOI 10.1016/0162-0134(85)80018-0; Antonini E., 1971, HEMOGLOBIN MYOGLOBIN; ARNONE A, 1974, NATURE, V249, P34, DOI 10.1038/249034a0; BEMSKI G, 1969, BIOCHEM BIOPH RES CO, V35, P599, DOI 10.1016/0006-291X(69)90446-X; BICKAR D, 1984, J BIOL CHEM, V259, P777; Bonaventura C, 1998, BIOCHEMISTRY-US, V37, P496, DOI 10.1021/bi971574s; BONAVENTURA J, 1975, J BIOL CHEM, V250, P9250; BONOMO RP, 1995, J INORG BIOCHEM, V59, P773, DOI 10.1016/0162-0134(94)00063-G; BRITTAIN T, 1976, BIOCHEM J, V155, P453, DOI 10.1042/bj1550453; CHIANCONE E, 1974, J BIOL CHEM, V249, P5689; CRUMBLISS AL, 1975, INORG CHEM, V14, P1529, DOI 10.1021/ic50149a017; DAY EP, 1993, BIOCHEMISTRY-US, V32, P7855, DOI 10.1021/bi00082a003; EVERSE J, 1994, METHOD ENZYMOL, V231, P547; GADSBY PMA, 1990, J AM CHEM SOC, V112, P5003, DOI 10.1021/ja00169a002; GERACI G, 1969, J BIOL CHEM, V244, P4664; GREENWOOD C, 1974, BIOCHEM J, V137, P205, DOI 10.1042/bj1370205; HARTZELL CR, 1974, BIOCHIM BIOPHYS ACTA, V368, P318, DOI 10.1016/0005-2728(74)90178-9; Hyde J. S., 1986, ADV MAGN RESON, P363; Jia L, 1996, NATURE, V380, P221, DOI 10.1038/380221a0; KILMARTIN JV, 1973, BIOCHEM J, V133, P725, DOI 10.1042/bj1330725; LOURO SRW, 1986, STUD BIOPHYS, V113, P75; LOURO SRW, 1977, J MAGN RESON, V28, P427; MANSOURI A, 1979, BIOCHEM BIOPH RES CO, V89, P441, DOI 10.1016/0006-291X(79)90649-1; NAGEL RL, 1970, ARCH BIOCHEM BIOPHYS, V137, P428, DOI 10.1016/0003-9861(70)90459-5; NICHOLLS P, 1981, BIOCHIM BIOPHYS ACTA, V634, P256, DOI 10.1016/0005-2728(81)90144-4; PERUTZ MF, 1974, BIOCHEMISTRY-US, V13, P2187, DOI 10.1021/bi00707a028; RIFKIND JM, 1976, BIOCHEMISTRY-US, V15, P5337, DOI 10.1021/bi00669a021; RIFKIND JM, 1981, MET IONS BIOL SYST, P191; WHARTON DC, 1968, J BIOL CHEM, V243, P702; WINTERBOURN C C, 1977, INSERM (Institut National de la Sante et de la Recherche Medicale) Colloque, V70, P97; WINTERBOURN CC, 1977, BIOCHEM J, V165, P141, DOI 10.1042/bj1650141; YOUNG LJ, 1987, J BIOL CHEM, V262, P15019; YOUNG LJE, 1980, FED PROC, V39, P2090; YUBISUI T, 1977, BIOCHEM BIOPH RES CO, V76, P174, DOI 10.1016/0006-291X(77)91683-7	36	27	27	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 26	1999	274	9					5499	5507		10.1074/jbc.274.9.5499	http://dx.doi.org/10.1074/jbc.274.9.5499			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	170KG	10026163	hybrid			2022-12-25	WOS:000078804400034
J	Cotten, JF; Welsh, MJ				Cotten, JF; Welsh, MJ			Cystic fibrosis-associated mutations at arginine 347 alter the pore architecture of CFTR - Evidence for disruption of a salt bridge	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSMEMBRANE CONDUCTANCE REGULATOR; CHLORIDE CHANNEL; CL CHANNELS; POTASSIUM CHANNEL; ESCHERICHIA-COLI; LINING RESIDUES; ION-CHANNEL; GENE; IDENTIFICATION; MEMBRANE	Arginine 347 in the sixth transmembrane domain of cystic fibrosis transmembrane conductance regulator (CFTR) is a site of four cystic fibrosis-associated mutations. To better understand the function of Arg-347 and to learn how mutations at this site disrupt channel activity, we mutated Arg-347 to Asp, Cys, Glu, His, Leu, or Lys and examined single-channel function. Every Arg-347 mutation examined, except R347K, had a destabilizing effect on the pore, causing the channel to flutter between two conductance states. Chloride flow through the larger conductance state was similar to that of wildtype CFTR, suggesting that the residue at position 347 does not interact directly with permeating anions, We hypothesized that Arg-347 stabilizes the channel through an electrostatic interaction with an anionic residue in another transmembrane domain. To test this, we mutated anionic residues (Asp-924, Asp-993, and Glu-1104) to Arg in the context of either R347E or R347D mutations. Interestingly, the D924R mutation complemented R347D, yielding a channel that behaved Like wild-type CFTR, These data suggest that Arg-347 plays an important structural role in CFTR, at least in part by forming a salt bridge with Asp-924; cystic fibrosis-associated mutations disrupt this interaction.	Univ Iowa, Coll Med, Howard Hughes Med Inst, Iowa City, IA 52242 USA; Univ Iowa, Coll Med, Dept Internal Med, Iowa City, IA 52242 USA; Univ Iowa, Coll Med, Dept Physiol & Biophys, Iowa City, IA 52242 USA	Howard Hughes Medical Institute; University of Iowa; University of Iowa; University of Iowa	Welsh, MJ (corresponding author), Univ Iowa, Coll Med, Howard Hughes Med Inst, 500 EMRB, Iowa City, IA 52242 USA.	mjwelsh@blue.weeg.uiowa.edu		Welsh, Michael/0000-0002-1646-6206	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL029851, R37HL029851, P50HL042385] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL29851, HL42385] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AKABAS MH, 1994, J BIOL CHEM, V269, P14865; ANDERSON MP, 1992, SCIENCE, V257, P1701, DOI 10.1126/science.1382316; ANDERSON MP, 1991, SCIENCE, V253, P202, DOI 10.1126/science.1712984; Antosiewicz J, 1996, BIOCHEMISTRY-US, V35, P7819, DOI 10.1021/bi9601565; AUDREZET MP, 1993, HUM MOL GENET, V2, P51, DOI 10.1093/hmg/2.1.51; BEAR CE, 1991, J BIOL CHEM, V266, P19142; BERGER HA, 1991, J CLIN INVEST, V88, P1422, DOI 10.1172/JCI115450; CARSON MR, 1993, AM J PHYSIOL, V265, pL27, DOI 10.1152/ajplung.1993.265.1.L27; Cheung M, 1996, BIOPHYS J, V70, P2688, DOI 10.1016/S0006-3495(96)79838-7; Cremonesi Laura, 1992, Human Mutation, V1, P314, DOI 10.1002/humu.1380010409; DEAN M, 1990, CELL, V61, P863, DOI 10.1016/0092-8674(90)90196-L; EIGEN M, 1960, J AM CHEM SOC, V82, P3482; GADSBY DC, 1993, SCIENCE, V260, P100, DOI 10.1126/science.7682009; GUNDERSON KL, 1994, J BIOL CHEM, V269, P19349; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HANRAHAN JW, 1995, SOC GEN PHY, V50, P125; Hille B., 1992, IONIC CHANNELS EXCIT; Ishihara H, 1997, AM J PHYSIOL-CELL PH, V273, pC1278, DOI 10.1152/ajpcell.1997.273.4.C1278; KARTNER N, 1991, CELL, V64, P681, DOI 10.1016/0092-8674(91)90498-N; KING SC, 1991, BIOCHIM BIOPHYS ACTA, V1062, P177, DOI 10.1016/0005-2736(91)90390-T; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAUGER P, 1991, ELECTOGENIC ION PUMP; Li CH, 1996, J BIOL CHEM, V271, P28463, DOI 10.1074/jbc.271.45.28463; Linsdell P, 1996, J PHYSIOL-LONDON, V496, P687, DOI 10.1113/jphysiol.1996.sp021719; LU Z, 1995, BIOCHEMISTRY-US, V34, P13133, DOI 10.1021/bi00040a026; Mansoura MK, 1998, BIOPHYS J, V74, P1320, DOI 10.1016/S0006-3495(98)77845-2; MCDONOUGH S, 1994, NEURON, V13, P623, DOI 10.1016/0896-6273(94)90030-2; PERUTZ MF, 1978, SCIENCE, V201, P1187, DOI 10.1126/science.694508; RIORDAN JR, 1993, ANNU REV PHYSIOL, V55, P609, DOI 10.1146/annurev.ph.55.030193.003141; ROOT MJ, 1994, SCIENCE, V265, P1852, DOI 10.1126/science.7522344; SAHINTOTH M, 1992, P NATL ACAD SCI USA, V89, P10547, DOI 10.1073/pnas.89.21.10547; SHEPPARD DN, 1995, EMBO J, V14, P876, DOI 10.1002/j.1460-2075.1995.tb07069.x; SHEPPARD DN, 1993, NATURE, V362, P160, DOI 10.1038/362160a0; TABCHARANI JA, 1993, NATURE, V366, P79, DOI 10.1038/366079a0; Tabcharani JA, 1997, J GEN PHYSIOL, V110, P341, DOI 10.1085/jgp.110.4.341; WINTER MC, 1994, BIOPHYS J, V66, P1398, DOI 10.1016/S0006-3495(94)80930-0; Yang J, 1997, P NATL ACAD SCI USA, V94, P1568, DOI 10.1073/pnas.94.4.1568	37	92	92	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 26	1999	274	9					5429	5435		10.1074/jbc.274.9.5429	http://dx.doi.org/10.1074/jbc.274.9.5429			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	170KG	10026154	hybrid			2022-12-25	WOS:000078804400025
J	Manna, PR; Tena-Sempere, M; Huhtaniemi, IT				Manna, PR; Tena-Sempere, M; Huhtaniemi, IT			Molecular mechanisms of thyroid hormone-stimulated steroidogenesis in mouse Leydig tumor cells - Involvement of the steroidogenic acute regulatory (StAR) protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR TRIIODOTHYRONINE RECEPTORS; ADRENAL HYPOPLASIA CONGENITA; MESSENGER-RIBONUCLEIC-ACID; RAT TESTIS; MITOCHONDRIAL PROTEINS; GRANULOSA-CELLS; CONTACT SITES; TESTOSTERONE PRODUCTION; ENDOCRINE DEVELOPMENT; REPRODUCTIVE AXIS	Using a mouse Leydig tumor cell line, we explored the mechanisms involved in thyroid hormone-induced steroidogenic acute regulatory (StAR) protein gene expression, and steroidogenesis. Triiodothyronine (T-3) induced a similar to 3.6-fold increase in the steady-state level of StAR mRNA which paralleled with those of the acute steroid response (similar to 4.0-fold), as monitored by quantitative reverse transcriptase-polymerase chain reaction assay and progesterone production, respectively. The T-3-stimulated progesterone production was effectively inhibited by actinomycin-D or cycloheximide, indicating the requirement of on-going mRNA and protein synthesis. T-3 displayed the highest affinity of [I-125]iodo-T-3 binding and was most potent in stimulating StAR mRNA expression. In accordance, T-3 significantly increased testosterone production in primary cultures of adult mouse Leydig cells. The T-3 and human chorionic gonadotropin (hCG) effects on StAR expression were similar in magnitude and additive. Cells expressing steroidogenic factor 1 (SF-l) showed marginal elevation of StAR expression, but coordinately increased T-3-induced StAR mRNA expression and progesterone levels. In contrast, overexpression of DAX-1 markedly diminished the SF-1 mRNA expression, and concomitantly abolished T-3-mediated responses. Noteworthy, T-3 augmented the SF-1 mRNA expression while inhibition of the latter by DAX-1 strongly impaired T-3 action. Northern hybridization analysis revealed four StAR transcripts which increased 3-6-fold following T-3 stimulation. These observations clearly identified a regulatory cascade of thyroid hormone-stimulated StAR expression and steroidogenesis that provides novel insight into the importance of a thyroid-gonadal connection in the hormonal control of Leydig cell steroidogenesis.	Univ Turku, Dept Physiol, Inst Biomed, FIN-20520 Turku, Finland	University of Turku	Huhtaniemi, IT (corresponding author), Univ Turku, Dept Physiol, Inst Biomed, Kiinamyllynkatu 10, FIN-20520 Turku, Finland.	ilpo.huhtaniemi@utu.fi	Tena-Sempere, Manuel/AAX-3602-2021	Tena-Sempere, Manuel/0000-0002-4741-5567				Arakane F, 1997, J BIOL CHEM, V272, P32656, DOI 10.1074/jbc.272.51.32656; ARDAIL D, 1991, J BIOL CHEM, V266, P7978; Bandyopadhyay A, 1996, J ENDOCRINOL, V150, P309, DOI 10.1677/joe.0.1500309; BHATTACHARYA S, 1988, EXPERIENTIA, V44, P1005, DOI 10.1007/BF01939903; Caron KM, 1997, MOL ENDOCRINOL, V11, P138, DOI 10.1210/me.11.2.138; Caron KM, 1997, STEROIDS, V62, P53, DOI 10.1016/S0039-128X(96)00159-6; Caron KM, 1997, P NATL ACAD SCI USA, V94, P11540, DOI 10.1073/pnas.94.21.11540; CHAN WK, 1986, ENDOCRINOLOGY, V119, P2353, DOI 10.1210/endo-119-5-2353; Cherradi N, 1997, J BIOL CHEM, V272, P7899, DOI 10.1074/jbc.272.12.7899; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLARK BJ, 1995, MOL ENDOCRINOL, V9, P1346, DOI 10.1210/me.9.10.1346; CLARK BJ, 1994, J BIOL CHEM, V269, P28314; COOKE BA, 1975, BIOCHEM J, V150, P413, DOI 10.1042/bj1500413; DING YQ, 1989, ACTA ENDOCRINOL-COP, V121, P46, DOI 10.1530/acta.0.1210046; El-Gehani F, 1998, ENDOCRINOLOGY, V139, P1474, DOI 10.1210/en.139.4.1474; EPSTEIN LF, 1991, J BIOL CHEM, V266, P19739; GERHARD I, 1991, HUM REPROD, V6, P338, DOI 10.1093/oxfordjournals.humrep.a137335; GOLDMAN S, 1993, MOL CELL ENDOCRINOL, V96, P125, DOI 10.1016/0303-7207(93)90102-P; HARTUNG S, 1995, BIOCHEM BIOPH RES CO, V215, P646, DOI 10.1006/bbrc.1995.2513; HUHTANIEMI I, 1985, J CLIN ENDOCR METAB, V61, P698, DOI 10.1210/jcem-61-4-698; IIDA S, 1989, ENDOCRINOLOGY, V124, P2619, DOI 10.1210/endo-124-5-2619; Ikeda Y, 1996, MOL ENDOCRINOL, V10, P1261, DOI 10.1210/me.10.10.1261; INGRAHAM HA, 1994, GENE DEV, V8, P2302, DOI 10.1101/gad.8.19.2302; Ito M, 1997, MOL CELL BIOL, V17, P1476, DOI 10.1128/MCB.17.3.1476; JANA NR, 1994, J ENDOCRINOL, V143, P549, DOI 10.1677/joe.0.1430549; JANNINI EA, 1995, ENDOCR REV, V16, P443, DOI 10.1210/er.16.4.443; JANS NR, 1996, BIOCHIM BIOPHYS ACTA, V1292, P209; JEFCOATE CR, 1987, J STEROID BIOCHEM, V27, P721, DOI 10.1016/0022-4731(87)90142-7; LALA DS, 1992, MOL ENDOCRINOL, V6, P1249, DOI 10.1210/me.6.8.1249; Lalli E, 1997, MOL ENDOCRINOL, V11, P1950, DOI 10.1210/me.11.13.1950; LAWSON GM, 1987, LAB METHODS MANUAL H; LIN D, 1995, SCIENCE, V267, P1828, DOI 10.1126/science.7892608; MENDELSON C, 1975, J BIOL CHEM, V250, P8818; MENDELSON C, 1975, BIOCHIM BIOPHYS ACTA, V411, P222, DOI 10.1016/0304-4165(75)90302-5; MILLER WL, 1988, ENDOCR REV, V9, P295, DOI 10.1210/edrv-9-3-295; Miller WL, 1995, J STEROID BIOCHEM, V55, P607, DOI 10.1016/0960-0760(95)00212-X; Nishikawa T, 1996, BIOCHEM BIOPH RES CO, V223, P12, DOI 10.1006/bbrc.1996.0838; Oppenheimer J., 1983, MOL BASS THYROID HOR, P1; OPPENHEIMER JH, 1979, SCIENCE, V203, P971, DOI 10.1126/science.218285; OPPENHEIMER JH, 1974, ENDOCRINOLOGY, V95, P897, DOI 10.1210/endo-95-3-897; PALMERO S, 1993, J ENDOCRINOL, V136, P277, DOI 10.1677/joe.0.1360277; PALMERO S, 1992, J MOL ENDOCRINOL, V9, P55, DOI 10.1677/jme.0.0090055; Parker KL, 1997, ENDOCR REV, V18, P361, DOI 10.1210/er.18.3.361; PRIVALLE CT, 1983, P NATL ACAD SCI-BIOL, V80, P702, DOI 10.1073/pnas.80.3.702; REBOIS RV, 1982, J CELL BIOL, V94, P70, DOI 10.1083/jcb.94.1.70; SADOVSKY Y, 1995, P NATL ACAD SCI USA, V92, P10939, DOI 10.1073/pnas.92.24.10939; Sandhoff TW, 1996, ENDOCRINE, V4, P259, DOI 10.1007/BF02738692; SCHLEYER M, 1985, CELL, V43, P339, DOI 10.1016/0092-8674(85)90039-X; SIMBENI R, 1991, J BIOL CHEM, V266, P10047; SIMPSON ER, 1979, J BIOL CHEM, V253, P3135; STOCCO DM, 1991, ENDOCRINOLOGY, V128, P1918, DOI 10.1210/endo-128-4-1918; Stocco DM, 1996, ENDOCR REV, V17, P221, DOI 10.1210/er.17.3.221; STOCCO DM, 1988, BIOCHEM J, V249, P95, DOI 10.1042/bj2490095; STOCCO DM, 1991, J BIOL CHEM, V266, P19731; Sugawara T, 1996, BIOCHEMISTRY-US, V35, P9052, DOI 10.1021/bi960057r; SUGAWARA T, 1995, P NATL ACAD SCI USA, V92, P4778, DOI 10.1073/pnas.92.11.4778; TAGAMI T, 1990, ENDOCRINOLOGY, V127, P1727, DOI 10.1210/endo-127-4-1727; TENASEMPERE M, 1994, ENDOCRINOLOGY, V135, P1018, DOI 10.1210/en.135.3.1018; VUORENTO T, 1989, SCAND J CLIN LAB INV, V49, P395, DOI 10.3109/00365518909089113; WAKIM AN, 1993, FERTIL STERIL, V59, P1187; WATERMAN MR, 1994, J BIOL CHEM, V269, P27783; Zazopoulos E, 1997, NATURE, V390, P311, DOI 10.1038/36899; Zhang FP, 1997, ENDOCRINOLOGY, V138, P2481, DOI 10.1210/en.138.6.2481	63	88	92	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 26	1999	274	9					5909	5918		10.1074/jbc.274.9.5909	http://dx.doi.org/10.1074/jbc.274.9.5909			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	170KG	10026215	hybrid			2022-12-25	WOS:000078804400086
J	Ozaki, I; Tani, E; Ikemoto, H; Kitagawa, H; Fujikawa, H				Ozaki, I; Tani, E; Ikemoto, H; Kitagawa, H; Fujikawa, H			Activation of stress-activated protein kinase/c-Jun NH2-terminal kinase and p38 kinase in calphostin C-induced apoptosis requires caspase-3-like proteases but is dispensable for cell death	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL PERMEABILITY TRANSITION; LYMPHOBLASTIC-LEUKEMIA CELLS; ICE/CED-3 FAMILY PROTEASES; FAS-MEDIATED APOPTOSIS; POLY(ADP-RIBOSE) POLYMERASE; SIGNAL-TRANSDUCTION; HEMATOPOIETIC-CELLS; SERINE PHOSPHORYLATION; JNK ACTIVATION; MAP KINASES	Apoptosis was induced in human glioma cell lines by exposure to 100 nM calphostin C, a specific inhibitor of protein kinase C, Calphostin C-induced apoptosis was associated with synchronous down-regulation of Bcl-2 and Bcl-x(L), as well as activation of caspase-3 but not caspase-1, The exposure to calphostin C led to activation of stress-activated protein kinase/c-Jun NH2-terminal kinase (SAPK/JNK) and p38 kinase and concurrent inhibition of extracellular signal-regulated kinase (ERK). Upstream of ERK, Shc was shown to be activated, but its downstream Raf1 and ERR were inhibited. The pretreatment with acetyl-Tyr-Val-Ala-Asp-aldehyde, a relatively selective inhibitor of caspase-3, or benzyloxycarbonyl-Val-Ala-Asp-fluoromethylketone (z-VAD.fmk), a broad spectrum caspase inhibitor, similarly inhibited calphostin C-induced activation of SAPK/JNK and p38 kinase as well as apoptotic nuclear damages (chromatin condensation and DNA fragmentation) and cell shrinkage, suggesting that caspase-3 functions upstream of SAPK/JNR and p38 kinase, but did not block calphostin C-induced surface blebbing and cell death. On the other hand, the inhibition of SAPK/JNK by transfection of dominant negative SAPK/JNK: and that of p38 kinase by SB203580 induced similar effects on the calphostin C-induced apoptotic phenotypes and cell death as did z-VAD.fmk and acetyl-Tyr-Val-Ala-Asp-aldehyde, but the calphostin C-induced PARP cleavage was not changed, suggesting that SAPK/JNK and p38 kinase are involved in the DNA fragmentation pathway downstream of caspase-3. The present findings suggest, therefore, that the activation of SAPK/JNK and p38 kinase is dispensable for calphostin C-mediated and z-VAD.fmk-resistant cell death.	Hyogo Med Univ, Dept Neurosurg, Mol Biol Res Lab, Nishinomiya, Hyogo 6638501, Japan	Hyogo College of Medicine; University of Hyogo	Tani, E (corresponding author), Hyogo Med Univ, Dept Neurosurg, Mol Biol Res Lab, 1-1 Mukogawa Cho, Nishinomiya, Hyogo 6638501, Japan.							Amarante-Mendes GP, 1998, CELL DEATH DIFFER, V5, P298, DOI 10.1038/sj.cdd.4400354; Berra E, 1997, MOL CELL BIOL, V17, P4346, DOI 10.1128/MCB.17.8.4346; Berra E, 1998, J BIOL CHEM, V273, P10792, DOI 10.1074/jbc.273.17.10792; BLUMER KJ, 1994, TRENDS BIOCHEM SCI, V19, P236, DOI 10.1016/0968-0004(94)90147-3; Brunet CL, 1998, CELL DEATH DIFFER, V5, P107, DOI 10.1038/sj.cdd.4400334; Canman CE, 1996, NATURE, V384, P213, DOI 10.1038/384213a0; Cardone MH, 1997, CELL, V90, P315, DOI 10.1016/S0092-8674(00)80339-6; CARROLL MP, 1994, J BIOL CHEM, V269, P1249; CHEN CY, 1995, ONCOGENE, V11, P1487; Chen CY, 1996, J BIOL CHEM, V271, P2376, DOI 10.1074/jbc.271.5.2376; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; DOWNWARD J, 1992, BIOESSAYS, V14, P177, DOI 10.1002/bies.950140308; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; Gardner AM, 1996, J BIOL CHEM, V271, P14560, DOI 10.1074/jbc.271.24.14560; Geley S, 1997, FEBS LETT, V402, P36, DOI 10.1016/S0014-5793(96)01496-2; Geley S, 1997, FEBS LETT, V400, P15, DOI 10.1016/S0014-5793(96)01284-7; Hengartner MO, 1998, NATURE, V391, P441, DOI 10.1038/35036; Hirsch T, 1997, ONCOGENE, V15, P1573, DOI 10.1038/sj.onc.1201324; Hortelano S, 1997, FEBS LETT, V410, P373, DOI 10.1016/S0014-5793(97)00623-6; HOSHI M, 1988, J BIOL CHEM, V263, P5396; HU QJ, 1995, SCIENCE, V268, P100, DOI 10.1126/science.7701328; HUANG JT, 1995, J BIOL CHEM, V270, P5065, DOI 10.1074/jbc.270.10.5065; IKEMOTO H, 1995, J NEUROSURG, V83, P1008, DOI 10.3171/jns.1995.83.6.1008; JOHNSON GL, 1994, CURR OPIN CELL BIOL, V6, P230, DOI 10.1016/0955-0674(94)90141-4; Johnson NL, 1996, J BIOL CHEM, V271, P3229, DOI 10.1074/jbc.271.6.3229; Juo P, 1997, MOL CELL BIOL, V17, P24, DOI 10.1128/MCB.17.1.24; KAUFMANN SH, 1993, CANCER RES, V53, P3976; Khwaja A, 1997, J CELL BIOL, V139, P1017, DOI 10.1083/jcb.139.4.1017; KINOSHITA T, 1995, EMBO J, V14, P266, DOI 10.1002/j.1460-2075.1995.tb07000.x; KINOSHITA T, 1995, ONCOGENE, V10, P2207; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; Lau QC, 1998, ONCOGENE, V16, P1899, DOI 10.1038/sj.onc.1201709; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; Liu ZG, 1996, NATURE, V384, P273, DOI 10.1038/384273a0; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; McCarthy NJ, 1997, J CELL BIOL, V136, P215, DOI 10.1083/jcb.136.1.215; MOORE MW, 1988, CELL, V54, P777, DOI 10.1016/S0092-8674(88)91043-4; Morrison DK, 1997, CURR OPIN CELL BIOL, V9, P174, DOI 10.1016/S0955-0674(97)80060-9; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Nishina H, 1997, NATURE, V385, P350, DOI 10.1038/385350a0; Park DS, 1996, J BIOL CHEM, V271, P21898, DOI 10.1074/jbc.271.36.21898; RAPP UR, 1991, ONCOGENE, V6, P495; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; ROSSOMANDO AJ, 1989, P NATL ACAD SCI USA, V86, P6940, DOI 10.1073/pnas.86.18.6940; Sakahira H, 1998, NATURE, V391, P96, DOI 10.1038/34214; Sarin A, 1997, IMMUNITY, V6, P209, DOI 10.1016/S1074-7613(00)80427-6; Schlegel J, 1996, J BIOL CHEM, V271, P1841, DOI 10.1074/jbc.271.4.1841; Smith A, 1997, CURR BIOL, V7, P893, DOI 10.1016/S0960-9822(06)00380-0; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; Ueda Y, 1996, J BIOL CHEM, V271, P23512, DOI 10.1074/jbc.271.38.23512; vanBiesen T, 1996, J BIOL CHEM, V271, P1266, DOI 10.1074/jbc.271.3.1266; VANBIESEN T, 1995, NATURE, V376, P781, DOI 10.1038/376781a0; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; Wang HG, 1996, CELL, V87, P629, DOI 10.1016/S0092-8674(00)81383-5; Widmann C, 1998, MOL CELL BIOL, V18, P2416, DOI 10.1128/MCB.18.4.2416; Wilson DJ, 1996, EUR J IMMUNOL, V26, P989, DOI 10.1002/eji.1830260505; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Xiang JL, 1996, P NATL ACAD SCI USA, V93, P14559, DOI 10.1073/pnas.93.25.14559; Yang XL, 1997, CELL, V89, P1067, DOI 10.1016/S0092-8674(00)80294-9; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3	65	73	75	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 26	1999	274	9					5310	5317		10.1074/jbc.274.9.5310	http://dx.doi.org/10.1074/jbc.274.9.5310			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	170KG	10026138	hybrid			2022-12-25	WOS:000078804400009
J	Shen, AL; Sem, DS; Kasper, CB				Shen, AL; Sem, DS; Kasper, CB			Mechanistic studies on the reductive half-reaction of NADPH-cytochrome P450 oxidoreductase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; PHTHALATE DIOXYGENASE REDUCTASE; ADENINE-DINUCLEOTIDE PHOSPHATE; ALTERNATE SUBSTRATE INHIBITOR; ENZYME-CATALYZED REACTIONS; FUNCTION OXIDASE SYSTEM; P-450 REDUCTASE; NADPH-CYTOCHROME-P-450 OXIDOREDUCTASE; SPECTRAL CHARACTERIZATION; FERREDOXIN REDUCTASE	Site-directed mutagenesis has been employed to study the mechanism of hydride transfer from NADPH to NADPH-cytochrome P450 oxidoreductase. Specifically, Ser(457), Asp(675), and Cys(630) have been selected because of their proximity to the isoalloxazine ring of FAD, Substitution of Asp(675) with asparagine or valine decreased cytochrome c reductase activities 17- and 677-fold, respectively, while the C630A substitution decreased enzymatic activity 49-fold. Earlier studies had shown that the S457A mutation decreased cytochrome c reductase activity 90-fold and also lowered the redox potential of the FAD semiquinone (Shen, A, and Kasper, C, B, (1996) Biochemistry 35, 9451-9459). The S457A/D675N and S457A/D675N/C630A mutants produced roughly multiplicative decreases in cytochrome c reductase activity (774- and 22000-fold, respectively) with corresponding decreases in the rates of flavin reduction. For each mutation, increases were observed in the magnitudes of the primary deuterium isotope effects with NADPD, consistent with decreased rates of hydride transfer from NADPH to FAD and an increase in the relative rate limitation of hydride transfer. Asp(675) substitutions lowered the redox potential of the FAD semiquinone. In addition, the C630A substitution shifted the pK(a) of an ionizable group previously identified as necessary for catalysis (Sem, D. S,, and Kasper, C, B. (1993) Biochemistry 32, 11539-11547) from 6.9 to 7.8, These results are consistent with a model in which Ser(457), Asp(675), and Cys(630) stabilize the transition state for hydride transfer. Ser(457) and Asp(675) interact to stabilize both the transition state and the FAD semiquinone, while Cys(630) interacts with the nicotinamide ring and the fully reduced FAD, functioning as a proton donor/acceptor to FAD.	Mcardle Lab Canc Res, Madison, WI 53706 USA		Kasper, CB (corresponding author), Mcardle Lab Canc Res, Madison, WI 53706 USA.			Sem, Daniel/0000-0002-2108-6646	NCI NIH HHS [CA0920, CA22484] Funding Source: Medline; NCRR NIH HHS [RR02301] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA022484, K04CA000920] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR002301] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ALIVERTI A, 1995, BIOCHEMISTRY-US, V34, P8371, DOI 10.1021/bi00026a019; ALIVERTI A, 1993, BIOCHEMISTRY-US, V32, P6374, DOI 10.1021/bi00076a010; BATIE CJ, 1984, J BIOL CHEM, V259, P1976; BRUNS CM, 1995, J MOL BIOL, V247, P125, DOI 10.1006/jmbi.1994.0127; Cleland W W, 1977, Adv Enzymol Relat Areas Mol Biol, V45, P273; CLELAND WW, 1982, METHOD ENZYMOL, V87, P390; CORRELL CC, 1993, PROTEIN SCI, V2, P2112, DOI 10.1002/pro.5560021212; FAEDER EJ, 1973, ANAL BIOCHEM, V53, P332, DOI 10.1016/0003-2697(73)90442-9; GASSNER G, 1994, BIOCHEMISTRY-US, V33, P12184, DOI 10.1021/bi00206a022; Higuchi R., 1989, PCR TECHNOLOGY, P61; Hodgson AV, 1996, ARCH BIOCHEM BIOPHYS, V325, P99, DOI 10.1006/abbi.1996.0012; IYANAGI T, 1981, BIOCHEMISTRY-US, V20, P1722, DOI 10.1021/bi00510a004; IYANAGI T, 1973, BIOCHEMISTRY-US, V12, P2297, DOI 10.1021/bi00736a018; IYANAGI T, 1978, BIOCHEMISTRY-US, V17, P2224, DOI 10.1021/bi00604a032; IYANAGI T, 1974, BIOCHEMISTRY-US, V13, P1701, DOI 10.1021/bi00705a023; KAMIN H, 1966, FLAVINS FLAVOPROTEIN, P306; KARPLUS PA, 1991, SCIENCE, V251, P60, DOI 10.1126/science.1986412; KIM JJP, 1997, FLAVINS FLAVOPROTEIN, P455; KUNKEL TA, 1989, SHORT PROTOCOLS MOL, P235; KURZBAN GP, 1986, J BIOL CHEM, V261, P7824; KURZBAN GP, 1990, J BIOL CHEM, V265, P12272; KYTE J, 1995, MECH PROTEIN CHEM, P73; MASTERS BSS, 1965, J BIOL CHEM, V240, P921; MASTERS BSS, 1980, ENZYMATIC BASIS DETO, P183; MATTHEWS RG, 1991, FLAVINS AND FLAVOPROTEINS 1990, P593; Medina M, 1998, BIOCHEMISTRY-US, V37, P2715, DOI 10.1021/bi971795y; NARAYANASAMI R, 1995, ARCH BIOCHEM BIOPHYS, V316, P267, DOI 10.1006/abbi.1995.1037; OPRIAN DD, 1979, J BIOL CHEM, V254, P8895; PORTER TD, 1986, BIOCHEMISTRY-US, V25, P1682, DOI 10.1021/bi00355a036; PORTER TD, 1991, TRENDS BIOCHEM SCI, V16, P154, DOI 10.1016/0968-0004(91)90059-5; SEM DS, 1992, BIOCHEMISTRY-US, V31, P3391, DOI 10.1021/bi00128a013; SEM DS, 1993, BIOCHEMISTRY-US, V32, P11548, DOI 10.1021/bi00094a011; SEM DS, 1994, BIOCHEMISTRY-US, V33, P12012, DOI 10.1021/bi00206a002; SEM DS, 1993, BIOCHEMISTRY-US, V32, P11539, DOI 10.1021/bi00094a010; SEM DS, 1995, BIOCHEMISTRY-US, V34, P12768, DOI 10.1021/bi00039a037; Sevrioukova I, 1996, BIOCHEMISTRY-US, V35, P7058, DOI 10.1021/bi960060a; SHEN AL, 1991, J BIOL CHEM, V266, P19976; SHEN AL, 1989, J BIOL CHEM, V264, P7584; Shen AL, 1996, BIOCHEMISTRY-US, V35, P9451, DOI 10.1021/bi960587n; SHEN AL, 1993, HDB EXPT PHARM, V105, P35; SMITH GCM, 1994, P NATL ACAD SCI USA, V91, P8710, DOI 10.1073/pnas.91.18.8710; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SWEET WL, 1991, BIOCHEMISTRY-US, V30, P8702, DOI 10.1021/bi00099a031; VERMILION JL, 1978, J BIOL CHEM, V253, P2694; VERMILION JL, 1981, J BIOL CHEM, V256, P266; Wang M, 1997, P NATL ACAD SCI USA, V94, P8411, DOI 10.1073/pnas.94.16.8411; YASUKOCHI Y, 1979, J BIOL CHEM, V254, P7097	47	52	55	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 26	1999	274	9					5391	5398		10.1074/jbc.274.9.5391	http://dx.doi.org/10.1074/jbc.274.9.5391			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	170KG	10026149	hybrid			2022-12-25	WOS:000078804400020
J	von Germar, F; Galan, A; Llorca, O; Carrascosa, JL; Valpuesta, JM; Mantele, W; Muga, A				von Germar, F; Galan, A; Llorca, O; Carrascosa, JL; Valpuesta, JM; Mantele, W; Muga, A			Conformational changes generated in GroEL during ATP hydrolysis as seen by time-resolved infrared spectroscopy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHAPERONIN GROEL; CATALYTIC CYCLE; DIFFERENCE SPECTROSCOPY; SECONDARY STRUCTURE; PROTEIN-STRUCTURE; BINDING; CA2+-ATPASE; POLYPEPTIDE; ABSORPTION; MECHANISM	Changes in the vibrational spectrum of the chaperonin GroEL in the presence of ADP and ATP have been followed as a function of time using rapid scan Fourier transform infrared spectroscopy. The interaction of nucleotides with GroEL was triggered by the photochemical release of the ligands hom their corresponding biologically inactive precursors (caged nucleotides; P-3-1-(2-nitro)phenylethyl nucleotide). Binding of either ADP or ATP induced the appearance of small differential signals in the amide I band of the protein, sensitive to protein secondary structure, suggesting a subtle and localized change in protein conformation. Moreover, conformational changes associated with ATP hydrolysis were detected that differed markedly from those observed upon nucleotide binding. Both, high-amplitude absorbance changes and difference bands attributable to modifications in the interaction between oppositely charged residues were observed during ATP hydrolysis. Once this process had occurred, the protein relaxed to an ADP-like conformation. Our results suggest that the secondary structure as well as salt bridges of GroEL are modified during ATP hydrolysis, as compared with the ATP and ADP bound protein states.	Univ Basque Country, Consejo Super Invest Cient, Unidad Asociada, Dept Bioquim & Biol Mol, E-48080 Bilbao, Spain; Univ Erlangen Nurnberg, Inst Phys & Theoret Chem, D-91058 Erlangen, Germany; Univ Autonoma Madrid, Ctr Nacl Biotecnol, Consejo Super Invest Cient, Madrid 28049, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); University of Basque Country; University of Erlangen Nuremberg; Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB)	Muga, A (corresponding author), Univ Basque Country, Consejo Super Invest Cient, Unidad Asociada, Dept Bioquim & Biol Mol, Aptdo 644, E-48080 Bilbao, Spain.	gbpmuvia@lg.ehu.es	Llorca, Oscar/P-2784-2019; Valpuesta, José M/T-1977-2017; Llorca, Oscar/K-1144-2014; Muga, Arturo/N-1174-2014; Valpuesta, Jose M/AAA-6002-2019	Llorca, Oscar/0000-0001-5705-0699; Valpuesta, José M/0000-0001-7468-8053; Llorca, Oscar/0000-0001-5705-0699; Muga, Arturo/0000-0003-0345-6882; 				Aharoni A, 1997, P NATL ACAD SCI USA, V94, P1698, DOI 10.1073/pnas.94.5.1698; ARRONDO JLR, 1993, PROG BIOPHYS MOL BIO, V59, P23, DOI 10.1016/0079-6107(93)90006-6; BARTH A, 1994, BBA-BIOMEMBRANES, V1194, P75, DOI 10.1016/0005-2736(94)90205-4; Barth A, 1996, J BIOL CHEM, V271, P30637, DOI 10.1074/jbc.271.48.30637; BARTH A, 1991, BIOCHIM BIOPHYS ACTA, V1057, P115, DOI 10.1016/S0005-2728(05)80091-X; BAYKOV AA, 1988, ANAL BIOCHEM, V171, P266, DOI 10.1016/0003-2697(88)90484-8; BRAIG K, 1994, NATURE, V371, P578, DOI 10.1038/371578a0; BURSTON SG, 1995, J MOL BIOL, V249, P138, DOI 10.1006/jmbi.1995.0285; BYLER DM, 1986, BIOPOLYMERS, V25, P469, DOI 10.1002/bip.360250307; CHIRGADZE YN, 1975, BIOPOLYMERS, V14, P679, DOI 10.1002/bip.1975.360140402; Fenton WA, 1997, PROTEIN SCI, V6, P743; Gibbons DL, 1996, J BIOL CHEM, V271, P238, DOI 10.1074/jbc.271.1.238; Gorovits BM, 1997, J BIOL CHEM, V272, P6842, DOI 10.1074/jbc.272.11.6842; Horovitz A, 1998, CURR OPIN STRUC BIOL, V8, P93, DOI 10.1016/S0959-440X(98)80015-8; JACKSON GS, 1993, BIOCHEMISTRY-US, V32, P2554, DOI 10.1021/bi00061a013; JACKSON M, 1995, CRIT REV BIOCHEM MOL, V30, P95, DOI 10.3109/10409239509085140; Kad NM, 1998, J MOL BIOL, V278, P267, DOI 10.1006/jmbi.1998.1704; LLORCA O, 1994, FEBS LETT, V345, P181, DOI 10.1016/0014-5793(94)00432-3; Llorca O, 1997, J STRUCT BIOL, V118, P31, DOI 10.1006/jsbi.1996.3832; MANTELE W, 1993, TRENDS BIOCHEM SCI, V18, P197, DOI 10.1016/0968-0004(93)90186-Q; MCCRAY JA, 1980, P NATL ACAD SCI-BIOL, V77, P7237, DOI 10.1073/pnas.77.12.7237; Mendoza JA, 1996, J BIOL CHEM, V271, P16344, DOI 10.1074/jbc.271.27.16344; MUGA A, 1991, BIOCHEMISTRY-US, V30, P2629, DOI 10.1021/bi00224a010; Murai N, 1996, J BIOL CHEM, V271, P28229, DOI 10.1074/jbc.271.45.28229; Richardson A, 1998, TRENDS BIOCHEM SCI, V23, P138, DOI 10.1016/S0968-0004(98)01193-1; Roseman AM, 1996, CELL, V87, P241, DOI 10.1016/S0092-8674(00)81342-2; Rye HS, 1997, NATURE, V388, P792, DOI 10.1038/42047; SUREWICZ WK, 1993, BIOCHEMISTRY-US, V32, P389, DOI 10.1021/bi00053a001; VENYAMINOV SY, 1990, BIOPOLYMERS, V30, P1259, DOI 10.1002/bip.360301310; White HE, 1997, NAT STRUCT BIOL, V4, P690, DOI 10.1038/nsb0997-690; Xu ZH, 1997, NATURE, V388, P741, DOI 10.1038/41944; Yifrach O, 1996, J MOL BIOL, V255, P356, DOI 10.1006/jmbi.1996.0028	32	25	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 26	1999	274	9					5508	5513		10.1074/jbc.274.9.5508	http://dx.doi.org/10.1074/jbc.274.9.5508			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	170KG	10026164	hybrid			2022-12-25	WOS:000078804400035
J	Xue, HW; Pical, C; Brearley, C; Elge, S; Muller-Rober, B				Xue, HW; Pical, C; Brearley, C; Elge, S; Muller-Rober, B			A plant 126-kDa phosphatidylinositol 4-kinase with a novel repeat structure - Cloning and functional expression in baculovirus-infected insect cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPASE-C; PLASMA-MEMBRANE; PHOSPHOINOSITIDE 3-KINASE; INOSITOL TRISPHOSPHATE; ARABIDOPSIS-THALIANA; WORTMANNIN; PROTEIN; POLYPHOSPHOINOSITIDES; SEQUENCE; KINASE	Phosphatidylinositol metabolism plays a central role in signaling pathways in animals and is also believed to be of importance in signal transduction in higher plants, We report here the molecular cloning of a cDNA encoding a previously unidentified 126-kDa phosphatidylinositol (PI) 4-kinase (AtPI4K beta) from the higher plant Arabidopsis thaliana. The novel protein possesses the conserved domains present in animal and yeast PI 4-kinases, namely a lipid kinase unique domain and a catalytic domain. An additional domain, approximately 300 amino acids long, containing a high percentage (46%) of charged amino acids is specific to this plant enzyme. Recombinant AtPI4K beta expressed in baculovirus-infected insect (Spodoptera frugiperda) cells phosphorylated phosphatidylinositol exclusively at the D4 position of the inositol ring. Recombinant protein was maximally activated by 0.6% Triton X-100 but was inhibited by adenosine with an IC50 of similar to 200 mu M. Wortmannin at a concentration of 10 mu M inhibited AtPI4K beta activity by similar to 90%. AtPI4K beta transcript levels were similar in all tissues analyzed. Light or treatment with hormones or salts did not change AtPI4K beta transcript levels to a great extent, indicating constitutive expression of the AtPI4K beta gene.	Max Planck Inst Mol Plant Physiol, D-14476 Golm, Germany; Lund Univ, SE-22100 Lund, Sweden; Univ Cambridge, Dept Plant Sci, Cambridge CB2 3EA, England	Max Planck Society; Lund University; University of Cambridge	Muller-Rober, B (corresponding author), Max Planck Inst Mol Plant Physiol, Karl Liebknecht Str 25,Haus 20, D-14476 Golm, Germany.	mueller@mpimp-golm.mpg.de	Xue, Hao/GXV-4717-2022	Brearley, Charles/0000-0001-6179-9109				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Bae YS, 1998, J BIOL CHEM, V273, P4465, DOI 10.1074/jbc.273.8.4465; Balla T, 1997, J BIOL CHEM, V272, P18358, DOI 10.1074/jbc.272.29.18358; BERRIDGE MJ, 1984, BIOCHEM J, V220, P345, DOI 10.1042/bj2200345; BERRIDGE MJ, 1984, NATURE, V312, P315, DOI 10.1038/312315a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brearley CA, 1997, BIOCHEM J, V324, P123, DOI 10.1042/bj3240123; BRENDEL V, 1992, P NATL ACAD SCI USA, V89, P2002, DOI 10.1073/pnas.89.6.2002; C elegans Sequencing Consortium, 1998, SCIENCE, V282, P2012, DOI 10.1126/science.282.5396.2012; CHEN QY, 1990, PLANT PHYSIOL, V94, P1820, DOI 10.1104/pp.94.4.1820; CHEN QY, 1991, PLANT PHYSIOL, V96, P340, DOI 10.1104/pp.96.1.340; Cutler NS, 1997, J BIOL CHEM, V272, P27671, DOI 10.1074/jbc.272.44.27671; DeCamilli P, 1996, SCIENCE, V271, P1533, DOI 10.1126/science.271.5255.1533; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; ENDEMANN G, 1987, BIOCHEMISTRY-US, V26, P6845, DOI 10.1021/bi00395a039; Falasca M, 1998, EMBO J, V17, P414, DOI 10.1093/emboj/17.2.414; FIEUW S, 1995, PLANT PHYSIOL, V107, P905, DOI 10.1104/pp.107.3.905; Gehrmann T, 1998, EUR J BIOCHEM, V253, P357, DOI 10.1046/j.1432-1327.1998.2530357.x; Hanenberg A, 1995, PLANT SCI, V112, P53, DOI 10.1016/0168-9452(95)04258-V; HENDRIX KW, 1989, PROTOPLASMA, V151, P62, DOI 10.1007/BF01403302; Hirayama T, 1997, PLANT MOL BIOL, V34, P175, DOI 10.1023/A:1005885230896; HIRAYAMA T, 1995, P NATL ACAD SCI USA, V92, P3903, DOI 10.1073/pnas.92.9.3903; JANMEY PA, 1987, NATURE, V325, P362, DOI 10.1038/325362a0; Jones SM, 1998, J BIOL CHEM, V273, P10349, DOI 10.1074/jbc.273.17.10349; Kopka J, 1998, PLANT PHYSIOL, V116, P239, DOI 10.1104/pp.116.1.239; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANSCHUTZE V, 1995, EMBO J, V14, P660; LASSING I, 1985, NATURE, V314, P472, DOI 10.1038/314472a0; LOGEMANN J, 1987, ANAL BIOCHEM, V163, P16, DOI 10.1016/0003-2697(87)90086-8; LUCKOW VA, 1988, BIO-TECHNOL, V6, P47, DOI 10.1038/nbt0188-47; MATSUOKA K, 1995, J CELL BIOL, V130, P1307, DOI 10.1083/jcb.130.6.1307; MEMON AR, 1990, J BIOL CHEM, V265, P14817; Meyers R, 1997, J BIOL CHEM, V272, P4384, DOI 10.1074/jbc.272.7.4384; Mikami K, 1998, PLANT J, V15, P563, DOI 10.1046/j.1365-313X.1998.00227.x; Munnik T, 1998, BBA-LIPID LIPID MET, V1389, P222, DOI 10.1016/S0005-2760(97)00158-6; MURASHIGE T, 1962, PHYSIOL PLANTARUM, V15, P473, DOI 10.1111/j.1399-3054.1962.tb08052.x; Nakagawa T, 1996, BIOCHEM J, V320, P643, DOI 10.1042/bj3200643; NAKANISHI S, 1995, P NATL ACAD SCI USA, V92, P5317, DOI 10.1073/pnas.92.12.5317; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; Oh ES, 1998, J BIOL CHEM, V273, P10624, DOI 10.1074/jbc.273.17.10624; OKPODU C M, 1990, Plant Physiology (Rockville), V93, P63; OKPODU CM, 1995, PLANT PHYSIOL, V107, P491, DOI 10.1104/pp.107.2.491; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PIKE LJ, 1992, ENDOCR REV, V13, P692, DOI 10.1210/er.13.4.692; Qin WS, 1997, J BIOL CHEM, V272, P28267, DOI 10.1074/jbc.272.45.28267; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SATTERLEE JS, 1997, PLANT PHYSIOL, V115, P864; SHI JR, 1995, PLANT J, V8, P381, DOI 10.1046/j.1365-313X.1995.08030381.x; SOMMARIN M, 1988, BIOCHIM BIOPHYS ACTA, V958, P268, DOI 10.1016/0005-2760(88)90185-3; Staiger CJ, 1997, TRENDS PLANT SCI, V2, P275, DOI 10.1016/S1360-1385(97)86350-9; Stevenson JM, 1998, J BIOL CHEM, V273, P22761, DOI 10.1074/jbc.273.35.22761; UI M, 1995, TRENDS BIOCHEM SCI, V20, P303, DOI 10.1016/S0968-0004(00)89056-8; WELTERS P, 1994, P NATL ACAD SCI USA, V91, P11398, DOI 10.1073/pnas.91.24.11398; WONG K, 1994, J BIOL CHEM, V269, P28878; Wymann MP, 1996, MOL CELL BIOL, V16, P1722; XU P, 1992, PLANT CELL, V4, P941, DOI 10.1105/tpc.4.8.941; YAMAMOTO YT, 1995, PLANT PHYSIOL, V107, P1029, DOI 10.1104/pp.107.3.1029; YANG W, 1994, J BIOL CHEM, V269, P3852; YANG WN, 1993, J BIOL CHEM, V268, P392; ZHOU KM, 1995, MOL CELL BIOL, V15, P5645	60	56	58	0	7	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 26	1999	274	9					5738	5745		10.1074/jbc.274.9.5738	http://dx.doi.org/10.1074/jbc.274.9.5738			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	170KG	10026194	hybrid			2022-12-25	WOS:000078804400065
J	Yegneswaran, S; Smirnov, MD; Safa, O; Esmon, NL; Esmon, CT; Johnson, AE				Yegneswaran, S; Smirnov, MD; Safa, O; Esmon, NL; Esmon, CT; Johnson, AE			Relocating the active site of activated protein C eliminates the need for its protein S cofactor - A fluorescence resonance energy transfer study	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-CARBOXYGLUTAMIC ACID; COAGULATION FACTOR VIIA; PEPTIDE-BOND CLEAVAGES; CLOTTING FACTOR-X; HUMAN FACTOR VA; BLOOD-COAGULATION; MEMBRANE-SURFACE; TISSUE FACTOR; CONFORMATIONAL SENSITIVITY; PHOSPHOLIPID SURFACE	The effect of replacing the gamma-carboxyglutamic acid domain of activated protein C (APC) with that of prothrombin on the topography of the membrane-bound enzyme was examined using fluorescence resonance energy transfer. The average distance of closest approach (assuming kappa(2) = 2/3) between a fluorescein in the active site of the chimera and octadecylrhodamine at the membrane surface was 89 Angstrom, compared with 94 Angstrom for wildtype APC, The gamma-carboxyglutamic acid domain substitution therefore lowered and/or reoriented the active site, repositioning it close to the 84 Angstrom observed for the APC protein S complex. Protein S enhances wild-type APC cleavage of factor Va at Arg(306), but the inactivation rate of factor Va Leiden by the chimera alone is essentially equal to that by wild-type APC plus protein S. These data suggest that the activities of the chimera and of the APC protein S complex are equivalent because the active site of the chimeric protein is already positioned near the optimal location above the membrane surface to cleave Arg(306). Thus, one mechanism by which protein S regulates APC activity is by relocating its active site to the proper position above the membrane surface to optimize factor Va cleavage.	Texas A&M Univ, Hlth Sci Ctr, Coll Med, Dept Med Biochem & Genet, College Stn, TX 77843 USA; Oklahoma Med Res Fdn, Cardiovasc Biol Res Program, Oklahoma City, OK 73104 USA; Univ Oklahoma, Hlth Sci Ctr, Dept Pathol, Oklahoma City, OK 73190 USA; Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma City, OK 73190 USA; Howard Hughes Med Inst, Oklahoma City, OK 73104 USA; Texas A&M Univ, Dept Chem, College Stn, TX 77843 USA; Texas A&M Univ, Dept Biochem & Biophys, College Stn, TX 77843 USA	Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; Oklahoma Medical Research Foundation; University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center; Howard Hughes Medical Institute; Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station	Johnson, AE (corresponding author), Texas A&M Univ, Hlth Sci Ctr, Coll Med, Dept Med Biochem & Genet, Rm 116,Reynolds Med Bldg, College Stn, TX 77843 USA.	aejohnson@tamu.edu	Johnson, Arthur E/G-3457-2012		NHLBI NIH HHS [R37 HL 30340, R01 HL 32934, R01 HL 29807] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL030340, R01HL029807, R01HL032934] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AHMAD SS, 1994, BIOCHEMISTRY-US, V33, P12048, DOI 10.1021/bi00206a006; ARMSTRONG SA, 1990, J BIOL CHEM, V265, P6210; Banner DW, 1996, NATURE, V380, P41, DOI 10.1038/380041a0; BOCK PE, 1988, BIOCHEMISTRY-US, V27, P6633, DOI 10.1021/bi00417a063; Cheung WF, 1996, P NATL ACAD SCI USA, V93, P11068, DOI 10.1073/pnas.93.20.11068; DAHLBACK B, 1986, J BIOL CHEM, V261, P2022; DEWEY TG, 1980, BIOPHYS J, V32, P1023, DOI 10.1016/S0006-3495(80)85033-8; DISCIPIO RG, 1979, BIOCHEMISTRY-US, V18, P899, DOI 10.1021/bi00572a026; Egan JO, 1997, PROTEIN SCI, V6, P2016, DOI 10.1002/pro.5560060922; ESMON CT, 1993, METHOD ENZYMOL, V222, P359; ESMON CT, 1989, J BIOL CHEM, V264, P4743; ESMON CT, 1977, CHEM BIOL THROMBIN, P403; ESMON CT, 1995, HEMATOLOGY BASIC PRI, V2, P1597; Geng JP, 1997, THROMB HAEMOSTASIS, V77, P926; HEEB MJ, 1995, BLOOD, V85, P3405, DOI 10.1182/blood.V85.12.3405.bloodjournal85123405; HOCHBERG Y, 1987, MULTIPLE COMP PROCED, P80; HOLOWKA D, 1983, BIOCHEMISTRY-US, V22, P3466, DOI 10.1021/bi00283a025; HUSTEN EJ, 1987, J BIOL CHEM, V262, P12953; KALAFATIS M, 1995, J BIOL CHEM, V270, P4053, DOI 10.1074/jbc.270.8.4053; KALAFATIS M, 1994, J BIOL CHEM, V269, P31869; KURACHI K, 1976, BIOCHEMISTRY-US, V15, P368, DOI 10.1021/bi00647a020; LIM TK, 1977, BIOCHEMISTRY-US, V16, P4177, DOI 10.1021/bi00638a007; LU RL, 1989, J BIOL CHEM, V264, P12956; LUCKOW EA, 1989, BIOCHEMISTRY-US, V28, P2348, DOI 10.1021/bi00431a055; MANN KG, 1988, ANNU REV BIOCHEM, V57, P915, DOI 10.1146/annurev.bi.57.070188.004411; McCallum CD, 1996, J BIOL CHEM, V271, P28168, DOI 10.1074/jbc.271.45.28168; McCallum CD, 1997, J BIOL CHEM, V272, P30160, DOI 10.1074/jbc.272.48.30160; MUTUCUMARANA VP, 1992, J BIOL CHEM, V267, P17012; NELSESTUEN GL, 1978, BIOCHEMISTRY-US, V17, P2134, DOI 10.1021/bi00604a017; NELSESTUEN GL, 1977, BIOCHEMISTRY-US, V16, P4172, DOI 10.1021/bi00638a006; NICOLAES GAF, 1995, J BIOL CHEM, V270, P21158, DOI 10.1074/jbc.270.36.21158; OWEN WG, 1974, J BIOL CHEM, V249, P594; Regan LM, 1997, J BIOL CHEM, V272, P26279, DOI 10.1074/jbc.272.42.26279; ROSING J, 1995, J BIOL CHEM, V270, P27852, DOI 10.1074/jbc.270.46.27852; Smirnov MD, 1998, J BIOL CHEM, V273, P9031, DOI 10.1074/jbc.273.15.9031; SORIANOGARCIA M, 1992, BIOCHEMISTRY-US, V31, P2554, DOI 10.1021/bi00124a016; TAYLOR F, 1991, BLOOD, V78, P357, DOI 10.1182/blood.V78.2.357.357; THOMPSON AR, 1977, ARCH BIOCHEM BIOPHYS, V178, P356, DOI 10.1016/0003-9861(77)90204-1; WALKER FJ, 1981, J BIOL CHEM, V256, P1128; WALKER FJ, 1981, THROMB RES, V22, P321, DOI 10.1016/0049-3848(81)90125-0; WALKER FJ, 1992, FASEB J, V6, P2561, DOI 10.1096/fasebj.6.8.1317308; WALKER FJ, 1980, J BIOL CHEM, V255, P5521; Yegneswaran S, 1997, J BIOL CHEM, V272, P25013, DOI 10.1074/jbc.272.40.25013	43	41	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 26	1999	274	9					5462	5468		10.1074/jbc.274.9.5462	http://dx.doi.org/10.1074/jbc.274.9.5462			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	170KG	10026158	hybrid			2022-12-25	WOS:000078804400029
J	Zizioli, D; Meyer, C; Guhde, G; Saftig, P; von Figura, K; Schu, P				Zizioli, D; Meyer, C; Guhde, G; Saftig, P; von Figura, K; Schu, P			Early embryonic death of mice deficient in gamma-adaptin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE-II PHOSPHORYLATION; CLATHRIN-COATED VESICLES; PREIMPLANTATION DEVELOPMENT; TARGETING SIGNAL; GOLGI MEMBRANES; PROTEIN; EXPRESSION; BINDING; COMPLEX; CELLS	Intracellular protein transport and sorting by vesicles in the secretory and endocytic pathways requires the formation of a protein coat on the membrane. The heterotetrameric adaptor protein complex 1 (AP-1) promotes the formation of clathrin-coated vesicles at the trans-Golgi network. AP-1 interacts with various sorting signals in the cytoplasmic tails of cargo molecules, thus indicating a function in protein sorting. We generated mutants of the gamma-adaptin subunit of AP-1 in mice to investigate its role in post-Golgi vesicle transport and sorting processes. gamma-Adaptin-deficient embryos develop until day 3.5 post coitus and die during the prenidation period, revealing that AP-1 is essential for viability. In heterozygous mice the amount of AP-1 complexes is reduced to half of controls. Free beta 1- or mu 1 chains were not detectable, indicating that they are unstable unless they are part of AP-1 complexes. Heterozygous mice weigh less then their wild-type littermates and show impaired T cell development.	Univ Gottingen, Dept Biochem 2, Zentrum Biochem & Mol Zellbiol, D-37073 Gottingen, Germany	University of Gottingen	Schu, P (corresponding author), Univ Gottingen, Dept Biochem 2, Zentrum Biochem & Mol Zellbiol, Gosslerstr 12D, D-37073 Gottingen, Germany.		Saftig, Paul/A-7966-2010	Zizioli, Daniela/0000-0003-0451-8029				Alconada A, 1996, EMBO J, V15, P6096, DOI 10.1002/j.1460-2075.1996.tb00998.x; Dell'Angelica EC, 1998, SCIENCE, V280, P431, DOI 10.1126/science.280.5362.431; Dietrich J, 1997, J CELL BIOL, V138, P271, DOI 10.1083/jcb.138.2.271; Dittie AS, 1997, EMBO J, V16, P4859, DOI 10.1093/emboj/16.16.4859; DITTMER F, 1999, IN PRESS TRANSGENIC; Faundez V, 1998, CELL, V93, P423, DOI 10.1016/S0092-8674(00)81170-8; FELDMAN B, 1995, SCIENCE, V267, P246, DOI 10.1126/science.7809630; Futter CE, 1998, J CELL BIOL, V141, P611, DOI 10.1083/jcb.141.3.611; GLICKMAN JN, 1989, EMBO J, V8, P1041, DOI 10.1002/j.1460-2075.1989.tb03471.x; HILLEREHFELD A, 1995, BBA-REV BIOMEMBRANES, V1241, P177, DOI 10.1016/0304-4157(95)00004-B; Hogan B, 1994, MANIPULATING MOUSE E; HONING S, 1995, J CELL BIOL, V128, P321, DOI 10.1083/jcb.128.3.321; Honing S, 1998, EMBO J, V17, P1304, DOI 10.1093/emboj/17.5.1304; Honing S, 1996, EMBO J, V15, P5230, DOI 10.1002/j.1460-2075.1996.tb00908.x; Honing S, 1997, J BIOL CHEM, V272, P19884, DOI 10.1074/jbc.272.32.19884; Kantheti P, 1998, NEURON, V21, P111, DOI 10.1016/S0896-6273(00)80519-X; KIDDER GM, 1992, DEV GENET, V13, P319, DOI 10.1002/dvg.1020130502; KORNFELD S, 1995, METABOLIC MOL BASES, P2495; LABORGNE R, 1997, J CELL BIOL, V137, P335; Ludwig T, 1996, DEV BIOL, V177, P517, DOI 10.1006/dbio.1996.0182; MATHEWS PM, 1992, J CELL BIOL, V118, P1027, DOI 10.1083/jcb.118.5.1027; Ohno H, 1996, J BIOL CHEM, V271, P29009, DOI 10.1074/jbc.271.46.29009; Ooi CE, 1997, EMBO J, V16, P4508; PAGE LJ, 1995, J CELL BIOL, V131, P619, DOI 10.1083/jcb.131.3.619; PERONA RM, 1986, DEV BIOL, V114, P42, DOI 10.1016/0012-1606(86)90382-9; PHAN HL, 1994, EMBO J, V13, P1706, DOI 10.1002/j.1460-2075.1994.tb06435.x; RAD MR, 1995, J CELL SCI, V108, P1605; Rapoport I, 1998, EMBO J, V17, P2148, DOI 10.1093/emboj/17.8.2148; ROBINSON MS, 1990, J CELL BIOL, V111, P2319, DOI 10.1083/jcb.111.6.2319; Rodionov DG, 1998, J BIOL CHEM, V273, P6005, DOI 10.1074/jbc.273.11.6005; Rohrer J, 1996, J CELL BIOL, V132, P565, DOI 10.1083/jcb.132.4.565; Rothman JE, 1996, SCIENCE, V272, P227, DOI 10.1126/science.272.5259.227; Salamero J, 1996, J BIOL CHEM, V271, P30318, DOI 10.1074/jbc.271.48.30318; Schekman R, 1996, SCIENCE, V271, P1526, DOI 10.1126/science.271.5255.1526; Schmid SL, 1997, ANNU REV BIOCHEM, V66, P511, DOI 10.1146/annurev.biochem.66.1.511; Simpson F, 1997, J CELL BIOL, V137, P835, DOI 10.1083/jcb.137.4.835; STAMNES MA, 1993, CELL, V73, P999, DOI 10.1016/0092-8674(93)90277-W; STEPP JD, 1995, MOL BIOL CELL, V6, P41, DOI 10.1091/mbc.6.1.41; Stewart CL, 1997, DEV GENET, V21, P91, DOI 10.1002/(SICI)1520-6408(1997)21:1&lt;91::AID-DVG11&gt;3.0.CO;2-D; STEWART CL, 1992, NATURE, V359, P76, DOI 10.1038/359076a0; Swank RT, 1998, PIGM CELL RES, V11, P60, DOI 10.1111/j.1600-0749.1998.tb00713.x; Vowels JJ, 1998, EMBO J, V17, P2482, DOI 10.1093/emboj/17.9.2482	42	108	109	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 26	1999	274	9					5385	5390		10.1074/jbc.274.9.5385	http://dx.doi.org/10.1074/jbc.274.9.5385			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	170KG	10026148	hybrid			2022-12-25	WOS:000078804400019
J	Eymin, B; Haugg, M; Droin, N; Sordet, O; Dimanche-Boitrel, MT; Solary, E				Eymin, B; Haugg, M; Droin, N; Sordet, O; Dimanche-Boitrel, MT; Solary, E			p27(Kip1) induces drug resistance by preventing apoptosis upstream of cytochrome c release and procaspase-3 activation in leukemic cells	ONCOGENE			English	Article						p27(Kip1); drug resistance; apoptosis; caspases; cytochrome c	ANTICANCER AGENTS; TOPOISOMERASE-II; CYCLE ARREST; MITOCHONDRIA; PROTEASE; CASPASES; DEATH; BCL-2; INHIBITORS; ETOPOSIDE	The cyclin-dependent kinase inhibitor p27(Kip1) has been implicated as a drug resistance factor in tumor cells grown as spheroids or confluent monolayers. Here, we show that p27(Kip1) overexpression also induces resistance to drug-induced apoptosis and cytotoxicity in human leukemic cells growing in suspension, The anti-apoptotic effect of p27(Kip1) is not restricted to DNA-damaging agents but extends to the tubulin poison vinblastin, agonistic anti-Fas antibodies and macromolecule synthesis inhibitors. To further identify at which level this protein interferes with the cell death pathway, we investigated its influence on caspase activation and mitochondrial changes. Exposure df mock-transfected U937 cells to 50 mu M etoposide activates procaspase-3 and the long isoform of procaspase-2 and induces mitochondrial potential decrease and cytochrome c release from mitochondria to the cytosol, All these events are prevented by p27(KiP1) overexpression. p27(Kip1) does not modulate BcL-2, BcL-X-L, Mel-1 and Bar protein level in leukemic cells but suppresses Mel-1 expression decrease observed in mock-transfected U937 cells undergoing etoposide-induced cell death. We conclude that p27(Kip1) prevents cell death upstream of the final pathway common to many apoptotic stimuli that involves cytochrome c release from mitochondria and activation of downstream caspases.	Fac Med & Pharm, CJF,Lab Oncohematol & Pharmacol, INSERM 94-08, Grp Biol & Therapie Canc JE515, F-21033 Dijon, France; CHU Le Bocoge, F-21033 Dijon, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Bourgogne	Solary, E (corresponding author), Fac Med & Pharm, CJF,Lab Oncohematol & Pharmacol, INSERM 9408, Grp Biol & Therapie Canc JE515, 7 Blvd Jeanne Arc, F-21033 Dijon, France.		Sordet, Olivier/M-3271-2014; Droin, Nathalie M/Y-5506-2018; eymin, beatrice/U-4670-2019; Dimanche-Boitrel, Marie-Therese M/I-4642-2015; Eymin, Beatrice/M-1962-2013	Sordet, Olivier/0000-0001-6027-4925; Droin, Nathalie M/0000-0002-6099-5324; eymin, beatrice/0000-0002-7311-3810; Eymin, Beatrice/0000-0002-7311-3810; Dimanche-Boitrel, Marie-Therese/0000-0002-8038-7780; Solary, Eric/0000-0002-8629-1341				BERTRAND R, 1995, DRUG DEVELOP RES, V34, P138, DOI 10.1002/ddr.430340206; BOUDREAU N, 1995, SCIENCE, V267, P891, DOI 10.1126/science.7531366; Cardone MH, 1997, CELL, V90, P315, DOI 10.1016/S0092-8674(00)80339-6; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Craig C, 1997, ONCOGENE, V14, P2283, DOI 10.1038/sj.onc.1201064; DIMANCHEBOITREL MT, 1998, IN PRESS INT J CANC; DROIN N, 1998, IN PRESS ONCOGENE; Duan H, 1997, NATURE, V385, P86, DOI 10.1038/385086a0; Dubrez L, 1996, EMBO J, V15, P5504, DOI 10.1002/j.1460-2075.1996.tb00935.x; Duttaroy A, 1997, J CELL BIOCHEM, V64, P434; EVAN GI, 1995, CURR OPIN CELL BIOL, V7, P825, DOI 10.1016/0955-0674(95)80066-2; Eymin B, 1997, CANCER RES, V57, P686; EYMIN B, 1995, INT J CANCER, V63, P268, DOI 10.1002/ijc.2910630221; Gorospe M, 1996, MOL CELL BIOL, V16, P6654; Han ZY, 1997, J BIOL CHEM, V272, P13432, DOI 10.1074/jbc.272.20.13432; Hirata H, 1998, J EXP MED, V187, P587, DOI 10.1084/jem.187.4.587; Katayose Y, 1997, CANCER RES, V57, P5441; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Levkau B, 1998, MOL CELL, V1, P553, DOI 10.1016/S1097-2765(00)80055-6; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Lu YJ, 1998, ONCOGENE, V16, P705, DOI 10.1038/sj.onc.1201585; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; PAN ZQ, 1995, J BIOL CHEM, V270, P22008, DOI 10.1074/jbc.270.37.22008; Reed JC, 1997, CELL, V91, P559, DOI 10.1016/S0092-8674(00)80442-0; Rosse T, 1998, NATURE, V391, P496, DOI 10.1038/35160; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SHI L, 1994, SCIENCE, V263, P1143, DOI 10.1126/science.8108732; SOLARY E, 1993, BLOOD, V81, P1359; Solary E, 1998, CELL BIOL TOXICOL, V14, P121, DOI 10.1023/A:1007481921502; StCroix B, 1996, NAT MED, V2, P1204; Susin SA, 1997, J EXP MED, V186, P25, DOI 10.1084/jem.186.1.25; Susin SA, 1996, J EXP MED, V184, P1331, DOI 10.1084/jem.184.4.1331; VanderHeiden MG, 1997, CELL, V91, P627, DOI 10.1016/S0092-8674(00)80450-X; Waldman T, 1997, NAT MED, V3, P1034, DOI 10.1038/nm0997-1034; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; Wang XT, 1997, ONCOGENE, V15, P2991, DOI 10.1038/sj.onc.1201450; Yan Y, 1997, GENE DEV, V11, P973, DOI 10.1101/gad.11.8.973; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Zhang W, 1995, CLIN CANCER RES, V1, P1051	41	84	87	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 18	1999	18	7					1411	1418		10.1038/sj.onc.1202437	http://dx.doi.org/10.1038/sj.onc.1202437			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	167UK	10050878				2022-12-25	WOS:000078651600003
J	Rickert, P; Corden, JL; Lees, E				Rickert, P; Corden, JL; Lees, E			Cyclin C CDK8 and cyclin H CDK7 p36 are biochemically distinct CTD kinases	ONCOGENE			English	Article						cyclin C; CDK8; CTD; RNA polymerase II	RNA-POLYMERASE-II; CARBOXYL-TERMINAL DOMAIN; TRANSCRIPTION FACTOR TFIIH; PRE-MESSENGER-RNA; LARGEST SUBUNIT; PROTEIN-KINASE; SACCHAROMYCES-CEREVISIAE; ACTIVATING KINASE; REPEAT DOMAIN; DEPENDENT KINASES	Phosphorylation of the carboxyl-terminal domain (CTD) of RNA polymerase IT is important for basal transcriptional processes in vivo and for cell viability. Several kinases, including certain cyclin-dependent kinases, can phosphorylate this substrate in vitro. It has been proposed that differential CTD phosphorylation by different kinases may regulate distinct transcriptional processes. We have found that two of these kinases, cyclin C/CDK8 and cyclin H/CDK7/p36, can specifically phosphorylate distinct residues in recombinant CTD substrates, This difference in specificity may be largely due to their varying ability to phosphorylate lysine-substituted heptapeptide repeats within the CTD, since they phosphorylate the same residue in CTD consensus heptapeptide repeats. Furthermore, this substrate specificity is reflected in vivo where cyclin C/CDK8 and cyclin H/CDK7/p36 can differentially phosphorylate an endogenous RNA polymerase II substrate, Several small-molecule kinase inhibitors have different specificities for these related kinases, indicating that these enzymes have diverse active-site conformations. These results suggest that cyclin C/CDK8 and cyclin H/CDK7/p36 are physically distinct enzymes that may have unique roles in transcriptional regulation mediated by their phosphorylation of specific sites on RNA polymerase II.	DNAX Res Inst Mol & Cellular Biol Inc, Dept Cell Signaling, Palo Alto, CA 94304 USA; Stanford Univ, Dept Chem, Stanford, CA 94305 USA; Johns Hopkins Univ, Sch Med, Dept Mol Biol & Genet, Baltimore, MD 21209 USA	Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.; Stanford University; Johns Hopkins University	Lees, E (corresponding author), DNAX Res Inst Mol & Cellular Biol Inc, Dept Cell Signaling, 901 Calif Ave, Palo Alto, CA 94304 USA.							ABRAHAM RT, 1995, BIOL CELL, V83, P105, DOI 10.1016/0248-4900(96)81298-6; AKOULITCHEV S, 1995, NATURE, V377, P557, DOI 10.1038/377557a0; ALLISON LA, 1988, MOL CELL BIOL, V8, P321, DOI 10.1128/MCB.8.1.321; ALLISON LA, 1985, CELL, V42, P599, DOI 10.1016/0092-8674(85)90117-5; ARIAS JA, 1991, J BIOL CHEM, V266, P8055; BARTOLOMEI MS, 1988, MOL CELL BIOL, V8, P330, DOI 10.1128/MCB.8.1.330; Baskaran R, 1997, J BIOL CHEM, V272, P18905, DOI 10.1074/jbc.272.30.18905; BASKARAN R, 1993, P NATL ACAD SCI USA, V90, P11167, DOI 10.1073/pnas.90.23.11167; Bellier S, 1997, MOL CELL BIOL, V17, P1434, DOI 10.1128/MCB.17.3.1434; BREGMAN DB, 1995, J CELL BIOL, V129, P287, DOI 10.1083/jcb.129.2.287; CADENA DL, 1987, J BIOL CHEM, V262, P12468; CAGAS PM, 1995, PROTEINS, V21, P149, DOI 10.1002/prot.340210209; CHAMBERS RS, 1994, J BIOL CHEM, V269, P26243; CHAPMAN AB, 1994, J BIOL CHEM, V269, P4754; CISEK LJ, 1989, NATURE, V339, P679, DOI 10.1038/339679a0; CISEK LJ, 1991, METHOD ENZYMOL, V200, P301; CISMOWSKI MJ, 1995, MOL CELL BIOL, V15, P2983; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; CORDEN JL, 1993, CURR OPIN GENET DEV, V3, P213, DOI 10.1016/0959-437X(93)90025-K; CORDEN JL, 1985, P NATL ACAD SCI USA, V82, P7934, DOI 10.1073/pnas.82.23.7934; DAHMUS ME, 1981, J BIOL CHEM, V256, P3332; Dahmus ME, 1996, J BIOL CHEM, V271, P19009, DOI 10.1074/jbc.271.32.19009; Du L, 1997, J CELL BIOL, V136, P5, DOI 10.1083/jcb.136.1.5; Dubois MF, 1997, NUCLEIC ACIDS RES, V25, P694, DOI 10.1093/nar/25.4.694; DUBOIS MF, 1994, J BIOL CHEM, V269, P13331; DUBOIS MF, 1994, EMBO J, V13, P4787, DOI 10.1002/j.1460-2075.1994.tb06804.x; Edwards MC, 1998, MOL CELL BIOL, V18, P4291, DOI 10.1128/MCB.18.7.4291; FEAVER WJ, 1991, CELL, V67, P1223, DOI 10.1016/0092-8674(91)90298-D; FEAVER WJ, 1994, CELL, V79, P1103, DOI 10.1016/0092-8674(94)90040-X; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; Gebara MM, 1997, J CELL BIOCHEM, V64, P390; GIESECKE H, 1991, BIOCHEM BIOPH RES CO, V180, P1350, DOI 10.1016/S0006-291X(05)81344-0; GLAB N, 1994, FEBS LETT, V353, P207, DOI 10.1016/0014-5793(94)01035-8; GRUENWALD S, 1993, BACULOVIRUS EXPRESSI; GRUSSENMEYER T, 1985, P NATL ACAD SCI USA, V82, P7952, DOI 10.1073/pnas.82.23.7952; JIANG Y, 1994, NUCLEIC ACIDS RES, V22, P4958, DOI 10.1093/nar/22.23.4958; Kim E, 1997, J CELL BIOL, V136, P19, DOI 10.1083/jcb.136.1.19; KUCHIN S, 1995, P NATL ACAD SCI USA, V92, P4006, DOI 10.1073/pnas.92.9.4006; LEE JM, 1991, GENE EXPRESSION, V1, P149; LEE JM, 1989, P NATL ACAD SCI USA, V86, P3624, DOI 10.1073/pnas.86.10.3624; Lee JM, 1997, J BIOL CHEM, V272, P10990; LIAO SM, 1995, NATURE, V374, P193, DOI 10.1038/374193a0; LOSIEWICZ MD, 1994, BIOCHEM BIOPH RES CO, V201, P589, DOI 10.1006/bbrc.1994.1742; LU H, 1992, NATURE, V358, P641, DOI 10.1038/358641a0; MAKELA TP, 1995, P NATL ACAD SCI USA, V92, P5174, DOI 10.1073/pnas.92.11.5174; Maldonado E, 1996, NATURE, V381, P86, DOI 10.1038/381086a0; MARSHALL NF, 1995, J BIOL CHEM, V270, P12335, DOI 10.1074/jbc.270.21.12335; Marshall NF, 1996, J BIOL CHEM, V271, P27176, DOI 10.1074/jbc.271.43.27176; McCracken S, 1997, NATURE, V385, P357, DOI 10.1038/385357a0; Meijer L, 1996, TRENDS CELL BIOL, V6, P393, DOI 10.1016/0962-8924(96)10034-9; MISTELI T, 1995, J CELL SCI, V108, P2715; Mortillaro MJ, 1996, P NATL ACAD SCI USA, V93, P8253, DOI 10.1073/pnas.93.16.8253; NONET M, 1987, CELL, V50, P909, DOI 10.1016/0092-8674(87)90517-4; PAYNE JM, 1993, J BIOL CHEM, V268, P80; Peng JM, 1998, GENE DEV, V12, P755, DOI 10.1101/gad.12.5.755; RICE SA, 1994, J VIROL, V68, P988, DOI 10.1128/JVI.68.2.988-1001.1994; Rickert P, 1996, ONCOGENE, V12, P2631; RICKERT P, 1997, THESIS STANFORD U; ROY R, 1994, CELL, V79, P1093, DOI 10.1016/0092-8674(94)90039-6; SAMBROOK J, CLONIONG LAB MANUAL; SCHULZEGAHMEN U, 1995, PROTEINS, V22, P378, DOI 10.1002/prot.340220408; SEHGAL PB, 1976, CELL, V9, P473, DOI 10.1016/0092-8674(76)90092-1; SERIZAWA H, 1993, J BIOL CHEM, V268, P17300; SERIZAWA H, 1993, NATURE, V363, P371, DOI 10.1038/363371a0; SERIZAWA H, 1995, NATURE, V374, P280, DOI 10.1038/374280a0; SHIEKHATTAR R, 1995, NATURE, V374, P283, DOI 10.1038/374283a0; Shilatifard A, 1997, CURR OPIN GENET DEV, V7, P199, DOI 10.1016/S0959-437X(97)80129-3; SIMON M, 1986, EMBO J, V5, P2697, DOI 10.1002/j.1460-2075.1986.tb04553.x; Song CZ, 1996, BIOCHEM BIOPH RES CO, V229, P810, DOI 10.1006/bbrc.1996.1885; Steinmetz EJ, 1997, CELL, V89, P491, DOI 10.1016/S0092-8674(00)80230-5; STEVENS A, 1989, BIOCHEM BIOPH RES CO, V159, P508, DOI 10.1016/0006-291X(89)90022-3; VALAY JG, 1993, J MOL BIOL, V234, P307, DOI 10.1006/jmbi.1993.1587; VENETIANER A, 1995, EUR J BIOCHEM, V233, P83, DOI 10.1111/j.1432-1033.1995.083_1.x; VESELY J, 1994, EUR J BIOCHEM, V224, P771, DOI 10.1111/j.1432-1033.1994.00771.x; Wei P, 1998, CELL, V92, P451, DOI 10.1016/S0092-8674(00)80939-3; WEST ML, 1995, GENETICS, V140, P1223; YANKULOV K, 1995, J BIOL CHEM, V270, P23922, DOI 10.1074/jbc.270.41.23922; Yuryev A, 1996, GENETICS, V143, P661; Yuryev A, 1996, P NATL ACAD SCI USA, V93, P6975, DOI 10.1073/pnas.93.14.6975; ZEHRING WA, 1988, P NATL ACAD SCI USA, V85, P3698, DOI 10.1073/pnas.85.11.3698; ZHOU SY, 1994, CURR BIOL, V4, P973, DOI 10.1016/S0960-9822(00)00221-9; Zhu YR, 1997, GENE DEV, V11, P2622, DOI 10.1101/gad.11.20.2622	82	96	99	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 28	1999	18	4					1093	1102		10.1038/sj.onc.1202399	http://dx.doi.org/10.1038/sj.onc.1202399			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	165FT	10023686				2022-12-25	WOS:000078510600027
J	Calsou, P; Frit, P; Humbert, O; Muller, C; Chen, DJ; Salles, B				Calsou, P; Frit, P; Humbert, O; Muller, C; Chen, DJ; Salles, B			The DNA-dependent protein kinase catalytic activity regulates DNA end processing by means of Ku entry into DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRAND BREAK REPAIR; NUCLEOTIDE EXCISION-REPAIR; ATOMIC-FORCE MICROSCOPY; V(D)J RECOMBINATION; HELICASE-II; BINDING-PROTEIN; CELL-EXTRACTS; DAMAGED DNA; IN-VITRO; AUTOANTIGEN	The DNA-dependent protein kinase (DNA-PK) is required for double-strand break repair in mammalian cells. DNA-PK contains the heterodimer Ku and a 460-kDa serine/threonine kinase catalytic subunit (p460), Ku binds in vitro to DNA termini or other discontinuities in the DNA helix and is able to enter the DNA molecule by an ATP-independent process. It is clear from in vitro experiments that Ku stimulates the recruitment to DNA of p460 and activates the kinase activity toward DNA-binding protein substrates in the vicinity. Here, we have examined in human nuclear cell extracts the influence of the kinase catalytic activity on Ku binding to DNA, We demonstrate that, although Ku can enter DNA from free ends in the absence of p460 subunit, the kinase activity is required for Ku translocation along the DNA helix when the whole Ku/p460 assembles on DNA termini, When the kinase activity is impaired, DNA-PK including Ku and p460 is blocked at DNA ends and prevents their processing by either DNA polymerization, degradation, or ligation. The control of Ku entry into DNA by DNA-PK catalytic activity potentially represents an important regulation of DNA transactions at DNA termini.	Inst Pharmacol & Biol Struct, CNRS UPR 9062, F-31077 Toulouse, France; Univ Calif Los Alamos Natl Lab, DNA Damage & Repair Grp, Div Life Sci, Los Alamos, NM 87545 USA	Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); United States Department of Energy (DOE); Los Alamos National Laboratory	Calsou, P (corresponding author), Inst Pharmacol & Biol Struct, CNRS UPR 9062, 205 Route Narbonne, F-31077 Toulouse, France.		salles, bernard/B-8531-2008; MULLER, Catherine/E-2060-2011; calsou, patrick/AAB-5123-2020; MULLER, Catherine/M-2185-2018	Calsou, Patrick/0000-0001-7951-9806				Anderson CW, 1995, METHODS IN PROTEIN STRUCTURE ANALYSIS, P395; Badie C, 1997, CANCER RES, V57, P4600; BIGGERSTAFF M, 1991, MUTAT RES, V254, P217, DOI 10.1016/0921-8777(91)90059-X; BLIER PR, 1993, J BIOL CHEM, V268, P7594; Bliss TM, 1997, J BIOL CHEM, V272, P5765, DOI 10.1074/jbc.272.9.5765; BOUBNOV NV, 1995, MOL CELL BIOL, V15, P5700; Boulton SJ, 1998, EMBO J, V17, P1819, DOI 10.1093/emboj/17.6.1819; Calsou P, 1996, J BIOL CHEM, V271, P27601, DOI 10.1074/jbc.271.44.27601; CAO QP, 1994, BIOCHEMISTRY-US, V33, P8548, DOI 10.1021/bi00194a021; CARTER T, 1990, MOL CELL BIOL, V10, P6460, DOI 10.1128/MCB.10.12.6460; Cary RB, 1997, P NATL ACAD SCI USA, V94, P4267, DOI 10.1073/pnas.94.9.4267; Chan DW, 1996, J BIOL CHEM, V271, P8936, DOI 10.1074/jbc.271.15.8936; Chu G, 1997, J BIOL CHEM, V272, P24097, DOI 10.1074/jbc.272.39.24097; DEVRIES E, 1989, J MOL BIOL, V208, P65, DOI 10.1016/0022-2836(89)90088-0; DVIR A, 1992, P NATL ACAD SCI USA, V89, P11920, DOI 10.1073/pnas.89.24.11920; Dynan WS, 1998, NUCLEIC ACIDS RES, V26, P1551, DOI 10.1093/nar/26.7.1551; FALZON M, 1993, J BIOL CHEM, V268, P10546; Finnie NJ, 1996, PHILOS T ROY SOC B, V351, P173, DOI 10.1098/rstb.1996.0014; FRANCOEUR AM, 1985, J IMMUNOL, V135, P2378; Frit P, 1998, J MOL BIOL, V284, P963, DOI 10.1006/jmbi.1998.2257; GOTTLIEB TM, 1993, CELL, V72, P131, DOI 10.1016/0092-8674(93)90057-W; Gravel S, 1998, SCIENCE, V280, P741, DOI 10.1126/science.280.5364.741; GRIFFITH AJ, 1992, J BIOL CHEM, V267, P331; Gu XY, 1996, J BIOL CHEM, V271, P19660, DOI 10.1074/jbc.271.33.19660; Han ZY, 1996, J BIOL CHEM, V271, P14098, DOI 10.1074/jbc.271.24.14098; HARTLEY KO, 1995, CELL, V82, P849, DOI 10.1016/0092-8674(95)90482-4; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; Jeggo PA, 1997, MUTAT RES-DNA REPAIR, V384, P1, DOI 10.1016/S0921-8777(97)00009-8; Jeggo PA, 1998, ADV GENET, V38, P185, DOI 10.1016/S0065-2660(08)60144-3; Jin SF, 1997, CANCER SURV, V29, P221; Jin SF, 1997, EMBO J, V16, P6874, DOI 10.1093/emboj/16.22.6874; Labhart P, 1996, FEBS LETT, V386, P110, DOI 10.1016/0014-5793(96)00420-6; LEESMILLER SP, 1992, MOL CELL BIOL, V12, P5041, DOI 10.1128/MCB.12.11.5041; LEESMILLER SP, 1990, MOL CELL BIOL, V10, P6472, DOI 10.1128/MCB.10.12.6472; LeRomancer M, 1996, J CELL SCI, V109, P3121; LIEBER MR, 1988, CELL, V55, P7, DOI 10.1016/0092-8674(88)90004-9; LINDAHL T, 1995, TRENDS BIOCHEM SCI, V20, P405, DOI 10.1016/S0968-0004(00)89089-1; Lu H, 1998, CANCER RES, V58, P84; MIMORI T, 1986, J BIOL CHEM, V261, P375; MOLINETE M, 1993, EMBO J, V12, P2109, DOI 10.1002/j.1460-2075.1993.tb05859.x; Muller C, 1998, NUCLEIC ACIDS RES, V26, P1382, DOI 10.1093/nar/26.6.1382; Ochem AE, 1997, J BIOL CHEM, V272, P29919, DOI 10.1074/jbc.272.47.29919; Ono M, 1996, MOL IMMUNOL, V33, P787, DOI 10.1016/0161-5890(96)00030-2; ONO M, 1994, NUCLEIC ACIDS RES, V22, P3918, DOI 10.1093/nar/22.19.3918; PAILLARD S, 1991, NUCLEIC ACIDS RES, V19, P5619, DOI 10.1093/nar/19.20.5619; Pang DL, 1997, CANCER RES, V57, P1412; POWIS G, 1994, CANCER RES, V54, P2419; Ramsden DA, 1998, EMBO J, V17, P609, DOI 10.1093/emboj/17.2.609; RATHMELL WK, 1994, MOL CELL BIOL, V14, P4741, DOI 10.1128/MCB.14.7.4741; ROTH DB, 1992, CELL, V70, P983, DOI 10.1016/0092-8674(92)90248-B; Satoh MS, 1996, NUCLEIC ACIDS RES, V24, P3576, DOI 10.1093/nar/24.18.3576; SATOH MS, 1993, J BIOL CHEM, V268, P5480; SHAPIRO DJ, 1988, DNA-J MOLEC CELL BIO, V7, P47, DOI 10.1089/dna.1988.7.47; Smider V, 1998, MOL CELL BIOL, V18, P6853, DOI 10.1128/MCB.18.11.6853; SUWA A, 1994, P NATL ACAD SCI USA, V91, P6904, DOI 10.1073/pnas.91.15.6904; Tsukamoto Y, 1997, NATURE, V388, P900, DOI 10.1038/42288; Turchi JJ, 1997, BIOCHEMISTRY-US, V36, P7586, DOI 10.1021/bi963124q; Turchi JJ, 1996, J BIOL CHEM, V271, P13861, DOI 10.1074/jbc.271.23.13861; Tuteja N, 1997, BIOCHEM BIOPH RES CO, V236, P636, DOI 10.1006/bbrc.1997.7021; TUTEJA N, 1994, EMBO J, V13, P4991, DOI 10.1002/j.1460-2075.1994.tb06826.x; WALKER AI, 1985, EMBO J, V4, P139, DOI 10.1002/j.1460-2075.1985.tb02328.x; WEAVER DT, 1995, ADV IMMUNOL, V58, P29, DOI 10.1016/S0065-2776(08)60619-7; West RB, 1998, MOL CELL BIOL, V18, P5908, DOI 10.1128/MCB.18.10.5908; Wu XT, 1996, MOL CELL BIOL, V16, P5186; Yaneva M, 1997, EMBO J, V16, P5098, DOI 10.1093/emboj/16.16.5098; ZHANG WW, 1992, BIOCHEM BIOPH RES CO, V186, P574, DOI 10.1016/S0006-291X(05)80847-2; Zhu C, 1996, CANCER SURV, V28, P295	67	89	91	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 19	1999	274	12					7848	7856		10.1074/jbc.274.12.7848	http://dx.doi.org/10.1074/jbc.274.12.7848			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	178LU	10075677	hybrid			2022-12-25	WOS:000079268100036
J	Jiang, HL; Okamura, CS; Lucy, MC				Jiang, HL; Okamura, CS; Lucy, MC			Isolation and characterization of a novel promoter for the bovine growth hormone receptor gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIVER-SPECIFIC PROMOTER; GH BINDING-PROTEIN; ALDOLASE-A GENE; MESSENGER-RNA; PLACENTAL-LACTOGEN; GENOMIC STRUCTURE; FACTOR-I; EXPRESSION; MOUSE; CLONING	The use of alternative promoters represents an important mechanism for the regulation of growth hormone receptor (GHR) gene expression. Two promoters have been isolated previously for the GHR gene: the pi promoter that drives liver-specific expression, and the P2 promoter that drives ubiquitous expression. In the present study, we isolated a third GHR promoter termed P3, The P3 promoter was GC-rich and TATA-less, The P3 promoter was able to drive the expression of a luciferase reporter gene in cell lines Hep G2, PLC/PRF/5, and BHK-21. In vivo, the P3 promoter initiated transcription from two major sites in exon 1C of the GHR gene in many tissues. In the adult bovine liver, the P3-transcribed GHR mRNA represented only 10% of the total GHR mRNA pool. In non-hepatic tissues such as kidney, skeletal muscle, mammary gland, and uterus, PB-transcribed GHR mRNA represented 30-40% of the total GHR mRNA pool, Within the bovine GHR gene, the P3 promoter was located immediately downstream from the P2 promoter. In transfected cells, the P2 promoter served as an enhancer for the P3 promoter. Existence and co-regulation of two ubiquitous promoters may be a mechanism for achieving a high level of expression of the GHR gene in multiple tissues.	Univ Missouri, Dept Anim Sci, ASRC 164, Columbia, MO 65211 USA	University of Missouri System; University of Missouri Columbia	Lucy, MC (corresponding author), Univ Missouri, Dept Anim Sci, ASRC 164, Columbia, MO 65211 USA.	lucym@missouri.edu		, Honglin/0000-0001-9540-5788				ADAMS TE, 1995, MOL CELL ENDOCRINOL, V108, P23, DOI 10.1016/0303-7207(95)92575-9; ADAMS TE, 1990, MOL CELL ENDOCRINOL, V73, P135, DOI 10.1016/0303-7207(90)90126-S; Argetsinger LS, 1996, PHYSIOL REV, V76, P1089, DOI 10.1152/physrev.1996.76.4.1089; Barnes KV, 1997, J BIOL CHEM, V272, P11510, DOI 10.1074/jbc.272.17.11550; BARTON DE, 1989, CYTOGENET CELL GENET, V50, P137, DOI 10.1159/000132743; BAUMBACH WR, 1989, GENE DEV, V3, P1199, DOI 10.1101/gad.3.8.1199; Bennett PA, 1996, ENDOCRINOLOGY, V137, P3891, DOI 10.1210/en.137.9.3891; BILLESTRUP N, 1991, ENDOCRINOLOGY, V129, P883, DOI 10.1210/endo-129-2-883; Brakebusch C, 1997, J BIOL CHEM, V272, P3674, DOI 10.1074/jbc.272.6.3674; BYATT JC, 1995, P SOC EXP BIOL MED, V210, P20, DOI 10.3181/00379727-210-43919; Chen NY, 1997, ENDOCRINOLOGY, V138, P1988, DOI 10.1210/en.138.5.1988; CIOFFI JA, 1990, NUCLEIC ACIDS RES, V18, P6451, DOI 10.1093/nar/18.21.6451; Clegg CH, 1996, J BIOL CHEM, V271, P1638, DOI 10.1074/jbc.271.3.1638; CONCORDET JP, 1991, NUCLEIC ACIDS RES, V19, P4173, DOI 10.1093/nar/19.15.4173; DOMENE HM, 1995, DNA CELL BIOL, V14, P195, DOI 10.1089/dna.1995.14.195; DYNAN WS, 1986, TRENDS GENET, V2, P196, DOI 10.1016/0168-9525(86)90226-X; Edens A, 1998, ENDOCR REV, V19, P559, DOI 10.1210/er.19.5.559; Florini JR, 1996, ENDOCR REV, V17, P481, DOI 10.1210/edrv-17-5-481; GODOWSKI PJ, 1989, P NATL ACAD SCI USA, V86, P8083, DOI 10.1073/pnas.86.20.8083; Greenberg D, 1995, P NATL ACAD SCI USA, V92, P12347, DOI 10.1073/pnas.92.26.12347; HAUSER SD, 1990, MOL CELL ENDOCRINOL, V72, P187, DOI 10.1016/0303-7207(90)90143-V; HEAP D, 1995, J ANIM SCI, V73, P1529; Heap D, 1996, DOMEST ANIM ENDOCRIN, V13, P421, DOI 10.1016/0739-7240(96)00072-0; Heinemeyer T, 1998, NUCLEIC ACIDS RES, V26, P362, DOI 10.1093/nar/26.1.362; JONES NC, 1988, GENE DEV, V2, P267, DOI 10.1101/gad.2.3.267; Jux C, 1998, ENDOCRINOLOGY, V139, P3296, DOI 10.1210/en.139.7.3296; KELLY PA, 1991, ENDOCR REV, V12, P235, DOI 10.1210/edrv-12-3-235; LANS MS, 1994, J BIOL CHEM, V269, P14170; LEUNG DW, 1987, NATURE, V330, P537, DOI 10.1038/330537a0; Li DZ, 1998, J BIOL CHEM, V273, P6812, DOI 10.1074/jbc.273.12.6812; Li J, 1996, ENDOCRINOLOGY, V137, P1650, DOI 10.1210/en.137.5.1650; Lucy MC, 1998, J DAIRY SCI, V81, P1889, DOI 10.3168/jds.S0022-0302(98)75760-1; MAIRE P, 1987, J MOL BIOL, V197, P425, DOI 10.1016/0022-2836(87)90556-0; Martini JF, 1997, J BIOL CHEM, V272, P18951, DOI 10.1074/jbc.272.30.18951; MATHEWS LS, 1989, J BIOL CHEM, V264, P9905; MENON RK, 1995, J BIOL CHEM, V270, P8851, DOI 10.1074/jbc.270.15.8851; Nguyen AP, 1996, ENDOCRINOLOGY, V137, P3659, DOI 10.1210/en.137.9.3659; OMAHONEY JV, 1994, MOL CELL ENDOCRINOL, V101, P129, DOI 10.1016/0303-7207(94)90227-5; Pantaleon M, 1997, P NATL ACAD SCI USA, V94, P5125, DOI 10.1073/pnas.94.10.5125; PEKHLETSKY RI, 1992, MOL CELL ENDOCRINOL, V90, P103, DOI 10.1016/0303-7207(92)90107-H; SEPULVEDA AR, 1994, J BIOL CHEM, V269, P10699; Silos SA, 1996, J BIOL CHEM, V271, P17504, DOI 10.1074/jbc.271.29.17504; SMITH WC, 1989, MOL ENDOCRINOL, V3, P984, DOI 10.1210/mend-3-6-984; VANDIJK MA, 1991, MOL CELL ENDOCRINOL, V81, P81, DOI 10.1016/0303-7207(91)90207-9; Wang ZY, 1997, J BIOL CHEM, V272, P27957, DOI 10.1074/jbc.272.44.27957; Yoshida Y, 1996, J BIOL CHEM, V271, P30167, DOI 10.1074/jbc.271.47.30167; ZENNARO MC, 1995, J BIOL CHEM, V270, P21016, DOI 10.1074/jbc.270.36.21016; Zhou YH, 1997, P NATL ACAD SCI USA, V94, P13215, DOI 10.1073/pnas.94.24.13215; Zou LL, 1997, ENDOCRINOLOGY, V138, P1771, DOI 10.1210/en.138.4.1771	49	51	56	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	1999	274	12					7893	7900		10.1074/jbc.274.12.7893	http://dx.doi.org/10.1074/jbc.274.12.7893			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	178LU	10075683	hybrid			2022-12-25	WOS:000079268100042
J	Li, XF; Lytton, J				Li, XF; Lytton, J			A circularized sodium-calcium exchanger exon 2 transcript	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SARCOLEMMAL NA+-CA2+ EXCHANGER; NA-CA EXCHANGER; NA+/CA2+ EXCHANGER; MOLECULAR-CLONING; TRANSMEMBRANE SEGMENTS; SARCOPLASMIC-RETICULUM; BINDING-PROTEIN; MOUSE TESTIS; GENE; EXPRESSION	Previous reports of Na/Ca exchanger gene 1 (NCX1) expression have revealed a major RNA transcript of 7 kilobase pairs (kb), minor transcripts of similar to 13 and similar to 4 kb, and a relatively abundant 1.8-kb RNA band. In the present report we demonstrate that the 1.8-kb message, which has a tissue and subcellular distribution matching that of full-length NCX1 but is not polyadenylated, corresponds to a perfectly circularized exon 2 species. The circular transcript contained the normal NCX1 start codon, a new stop codon introduced as a consequence of circularization, and encoded a protein corresponding to the NH2-terminal portion of NCX1, terminating just after amino acid 600 in the cytoplasmic loop, A linear version of the circular transcript was prepared and transfected into HEK-293 cells. A protein, matching the predicted size of similar to 70 kDa, was expressed, and the transfected cells possessed Na/Ca exchange activity. Although in native tissue we could not detect a protein corresponding exactly to that predicted from the circular transcript, a prominent band of slightly shorter size, possibly representing further proteolytic processing of circular transcript protein, was observed in membranes from LLC-MK2 cells and rat kidney.	Univ Calgary, Hlth Sci Ctr, Dept Biochem & Mol Biol, Calgary, AB T2N 4N1, Canada	University of Calgary; University of Manitoba; Children's Hospital Research Institute of Manitoba	Lytton, J (corresponding author), Univ Calgary, Hlth Sci Ctr, Dept Biochem & Mol Biol, 3330 Hosp Dr NW, Calgary, AB T2N 4N1, Canada.			Lytton, Jonathan/0000-0003-4770-2512				Ausubel FM, 1998, CURRENT PROTOCOLS MO; Barnes KV, 1997, J BIOL CHEM, V272, P11510, DOI 10.1074/jbc.272.17.11550; CAPEL B, 1993, CELL, V73, P1019, DOI 10.1016/0092-8674(93)90279-Y; CHEN CY, 1995, SCIENCE, V268, P415, DOI 10.1126/science.7536344; COCQUERELLE C, 1993, FASEB J, V7, P155, DOI 10.1096/fasebj.7.1.7678559; Dolci S, 1997, BIOL REPROD, V57, P1128, DOI 10.1095/biolreprod57.5.1128; Dubin RA, 1995, GENE, V167, P245, DOI 10.1016/0378-1119(95)00639-7; GABELLINI N, 1995, J BIOL CHEM, V270, P6917, DOI 10.1074/jbc.270.12.6917; Gabellini N, 1996, EUR J BIOCHEM, V239, P897, DOI 10.1111/j.1432-1033.1996.0897u.x; KOFUJI P, 1994, J BIOL CHEM, V269, P5145; KOFUJI P, 1992, AM J PHYSIOL, V263, pC1241, DOI 10.1152/ajpcell.1992.263.6.C1241; KOMURO I, 1992, P NATL ACAD SCI USA, V89, P4769, DOI 10.1073/pnas.89.10.4769; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; Kraev A, 1996, GENOMICS, V37, P105, DOI 10.1006/geno.1996.0526; Lederer WJ, 1996, ANN NY ACAD SCI, V779, P7, DOI 10.1111/j.1749-6632.1996.tb44764.x; LEE SL, 1994, J BIOL CHEM, V269, P14849; LI ZP, 1992, J BIOL CHEM, V267, P7828; LYTTON J, 1992, J BIOL CHEM, V267, P14483; LYTTON J, 1988, J BIOL CHEM, V263, P15024; Lytton J, 1996, ANN NY ACAD SCI, V779, P58, DOI 10.1111/j.1749-6632.1996.tb44770.x; MATSUOKA S, 1993, P NATL ACAD SCI USA, V90, P3870, DOI 10.1073/pnas.90.9.3870; Nicholas SB, 1998, AM J PHYSIOL-HEART C, V274, pH217, DOI 10.1152/ajpheart.1998.274.1.H217; Nicoll DA, 1996, J BIOL CHEM, V271, P13385, DOI 10.1074/jbc.271.23.13385; Philipson KD, 1996, ANN NY ACAD SCI, V779, P20, DOI 10.1111/j.1749-6632.1996.tb44766.x; PHILIPSON KD, 1988, BIOCHIM BIOPHYS ACTA, V945, P298, DOI 10.1016/0005-2736(88)90492-0; PORZIG H, 1993, AM J PHYSIOL, V265, pC748, DOI 10.1152/ajpcell.1993.265.3.C748; Quednau BD, 1997, AM J PHYSIOL-CELL PH, V272, pC1250, DOI 10.1152/ajpcell.1997.272.4.C1250; REILLY RF, 1992, AM J PHYSIOL, V262, pF1105, DOI 10.1152/ajprenal.1992.262.6.F1105; RUKNUDIN A, 1998, BIOPHYS J, V74, P193; SACHS AB, 1989, CELL, V58, P857, DOI 10.1016/0092-8674(89)90938-0; Sambrook J., 2002, MOL CLONING LAB MANU; Scheller T, 1998, J BIOL CHEM, V273, P7643, DOI 10.1074/jbc.273.13.7643; Schwarz EM, 1997, P NATL ACAD SCI USA, V94, P10249, DOI 10.1073/pnas.94.19.10249; STUDER R, 1994, CIRC RES, V75, P443, DOI 10.1161/01.RES.75.3.443; TOYOFUKU T, 1994, J BIOL CHEM, V269, P3088; Tsoi M, 1998, J BIOL CHEM, V273, P4155, DOI 10.1074/jbc.273.7.4155; WU KD, 1993, AM J PHYSIOL, V264, pC333, DOI 10.1152/ajpcell.1993.264.2.C333; YU ASL, 1992, AM J PHYSIOL, V263, pF680, DOI 10.1152/ajprenal.1992.263.4.F680; Zaphiropoulos PG, 1997, MOL CELL BIOL, V17, P2985, DOI 10.1128/MCB.17.6.2985; Zaphiropoulos PG, 1996, P NATL ACAD SCI USA, V93, P6536, DOI 10.1073/pnas.93.13.6536	40	82	90	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 19	1999	274	12					8153	8160		10.1074/jbc.274.12.8153	http://dx.doi.org/10.1074/jbc.274.12.8153			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	178LU	10075718	hybrid			2022-12-25	WOS:000079268100077
J	Cannon, KS; Helenius, A				Cannon, KS; Helenius, A			Trimming and readdition of glucose to N-linked oligosaccharides determines calnexin association of a substrate glycoprotein in living cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VESICULAR STOMATITIS-VIRUS; ATP-COUPLED TRANSPORT; G-PROTEIN; ENDOPLASMIC-RETICULUM; MOLECULAR CHAPERONE; QUALITY-CONTROL; BREFELDIN-A; INTERMEDIATE COMPARTMENT; INTRACELLULAR-TRANSPORT; INFLUENZA HEMAGGLUTININ	To analyze the role of glucose trimming and reglucosylation in the binding of substrate proteins to calnexin in the endoplasmic reticulum (ER) of living cells, we made use of the thermosensitive vesicular stomatitis virus tsO45 glycoprotein (Gr protein). At nonpermissive temperature the G protein failed to fold completely and remained bound to calnexin, When the cells were shifted to permissive temperature, complete folding occurred accompanied by glucosidase-mediated elimination of calnexin-G protein complexes. If release from calnexin was blocked during the temperature shift by inhibiting the glucosidases, folding occurred, albeit at a reduced rate. In contrast, when unfolded by a shift from permissive to nonpermissive temperature, the G protein was reglucosylated rapidly and became capable of rebinding to calnexin. The rate at which calnexin binding occurred showed a 20-min delay that was explained by accumulation of the G protein in calnexin-free exit sites of the ER. These contained the glucosyltransferase responsible for reglucosylation of misfolded glycoproteins but had little or no calnexin, After unfolding and reglucosylation, the G proteins moved slowly from these structures back to the ER where they reassociated with the chaperone. Taken together, these results in live cells fully supported the lectin-only model of calnexin function. The ER exit sites emerged as a potentially important location for components of the quality control system.	Swiss Fed Inst Technol, Biochem Lab, CH-8092 Zurich, Switzerland; Yale Univ, Sch Med, Dept Cell Biol, New Haven, CT 06520 USA	Swiss Federal Institutes of Technology Domain; ETH Zurich; Yale University	Helenius, A (corresponding author), Swiss Fed Inst Technol, Biochem Lab, Univ Str 16, CH-8092 Zurich, Switzerland.				NIGMS NIH HHS [GM 52972] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052972] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BALCH WE, 1986, J BIOL CHEM, V261, P4690; BALCH WE, 1994, CELL, V76, P841, DOI 10.1016/0092-8674(94)90359-X; BALCH WE, 1986, J BIOL CHEM, V261, P4681; Cannon KS, 1996, J BIOL CHEM, V271, P14280, DOI 10.1074/jbc.271.24.14280; DESILVA A, 1993, J CELL BIOL, V120, P647, DOI 10.1083/jcb.120.3.647; DESILVA AM, 1990, J CELL BIOL, V111, P857, DOI 10.1083/jcb.111.3.857; DOMS RW, 1987, J CELL BIOL, V105, P1957, DOI 10.1083/jcb.105.5.1957; DOMS RW, 1989, J CELL BIOL, V109, P61, DOI 10.1083/jcb.109.1.61; DOMS RW, 1988, J CELL BIOL, V107, P89, DOI 10.1083/jcb.107.1.89; GALLIONE CJ, 1985, J VIROL, V54, P374, DOI 10.1128/JVI.54.2.374-382.1985; GANAN S, 1991, BIOCHEMISTRY-US, V30, P3098, DOI 10.1021/bi00226a017; Gilbert A, 1998, EXP CELL RES, V242, P144, DOI 10.1006/excr.1998.4101; HAMMOND C, 1994, P NATL ACAD SCI USA, V91, P913, DOI 10.1073/pnas.91.3.913; HAMMOND C, 1994, SCIENCE, V266, P456, DOI 10.1126/science.7939687; HAMMOND C, 1994, J CELL BIOL, V126, P41, DOI 10.1083/jcb.126.1.41; HEBERT DN, 1995, CELL, V81, P425, DOI 10.1016/0092-8674(95)90395-X; Hebert DN, 1996, EMBO J, V15, P2961, DOI 10.1002/j.1460-2075.1996.tb00659.x; Helenius A, 1997, TRENDS CELL BIOL, V7, P193; HOBMAN TC, 1992, J CELL BIOL, V118, P795, DOI 10.1083/jcb.118.4.795; LEFRANCOIS L, 1982, VIROLOGY, V121, P157, DOI 10.1016/0042-6822(82)90125-8; LODISH HF, 1983, VIROLOGY, V125, P335, DOI 10.1016/0042-6822(83)90206-4; MACHAMER CE, 1990, J BIOL CHEM, V265, P6879; MELLMAN I, 1992, CELL, V68, P829, DOI 10.1016/0092-8674(92)90027-A; METSIKKO K, 1986, EMBO J, V5, P1913, DOI 10.1002/j.1460-2075.1986.tb04444.x; PARODI AJ, 1982, J BIOL CHEM, V257, P7641; Presley JF, 1998, MOL BIOL CELL, V9, P1617, DOI 10.1091/mbc.9.7.1617; Rodan AR, 1996, EMBO J, V15, P6921, DOI 10.1002/j.1460-2075.1996.tb01084.x; ROSE JK, 1981, J VIROL, V39, P519, DOI 10.1128/JVI.39.2.519-528.1981; ROTHMAN JE, 1977, NATURE, V269, P775, DOI 10.1038/269775a0; SARASTE J, 1984, CELL, V38, P535, DOI 10.1016/0092-8674(84)90508-7; Scheel J, 1997, J CELL BIOL, V137, P319, DOI 10.1083/jcb.137.2.319; SOUSA MC, 1992, BIOCHEMISTRY-US, V31, P97, DOI 10.1021/bi00116a015; Spiro RG, 1996, J BIOL CHEM, V271, P11588, DOI 10.1074/jbc.271.19.11588; SUH KS, 1989, J CELL BIOL, V108, P811, DOI 10.1083/jcb.108.3.811; TAKATSUKI A, 1985, AGR BIOL CHEM TOKYO, V49, P899, DOI 10.1080/00021369.1985.10866826; TATU U, 1995, EMBO J, V14, P1340, DOI 10.1002/j.1460-2075.1995.tb07120.x; Trombetta ES, 1998, CURR OPIN STRUC BIOL, V8, P587, DOI 10.1016/S0959-440X(98)80148-6; VanLeeuwen JEM, 1997, J BIOL CHEM, V272, P4179, DOI 10.1074/jbc.272.7.4179; Vassilakos A, 1998, BIOCHEMISTRY-US, V37, P3480, DOI 10.1021/bi972465g; Vassilakos A, 1996, EMBO J, V15, P1495, DOI 10.1002/j.1460-2075.1996.tb00493.x; Wada I, 1997, EMBO J, V16, P5420, DOI 10.1093/emboj/16.17.5420; WARE FE, 1995, J BIOL CHEM, V270, P4697, DOI 10.1074/jbc.270.9.4697; WILLIAMS DB, 1995, BIOCHEM CELL BIOL, V73, P123, DOI 10.1139/o95-015; ZAPUN A, 1992, PROTEINS, V14, P10, DOI 10.1002/prot.340140104	44	66	66	3	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	1999	274	11					7537	7544		10.1074/jbc.274.11.7537	http://dx.doi.org/10.1074/jbc.274.11.7537			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	175DV	10066821	hybrid			2022-12-25	WOS:000079078400093
J	Gang, DR; Kasahara, H; Xia, ZQ; Vander Mijnsbrugge, K; Bauw, G; Boerjan, W; Van Montagu, M; Davin, LB; Lewis, NG				Gang, DR; Kasahara, H; Xia, ZQ; Vander Mijnsbrugge, K; Bauw, G; Boerjan, W; Van Montagu, M; Davin, LB; Lewis, NG			Evolution of plant defense mechanisms - Relationships of phenylcoumaran benzylic ether reductases to pinoresinol-lariciresinol and isoflavone reductases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEDICAGO-SATIVA L; PHYTOALEXIN BIOSYNTHESIS; FORSYTHIA-INTERMEDIA; DILIGNOL GLYCOSIDES; PHENOLIC-COMPOUNDS; MOLECULAR-CLONING; STRESS RESPONSES; CONIFER NEEDLES; CELL-DIVISION; PIPER WIGHTII	Pinoresinol-lariciresinol and isoflavone reductase classes are phylogenetically related, as is a third, the so-called "isoflavone reductase homologs," This study establishes the first known catalytic function for the latter, as being able to engender the NADPH-dependent reduction of phenylcoumaran benzylic ethers, Accordingly, all three reductase classes are involved in the biosynthesis of important and related phenylpropanoid-derived plant defense compounds. In this investigation, the phenylcoumaran benzylic ether reductase from the gymnosperm, Pinus taeda, was cloned, with the recombinant protein heterologously expressed in Escherichia coli, The purified enzyme reduces the benzylic ether functionalities of both dehydrodiconiferyl alcohol and dihydrodehydrodiconiferyl alcohol, with a higher affinity for the former, as measured by apparent K-m and V-max values and observed kinetic H-3-isotope effects. It abstracts the 4R-hydride of the required NADPH cofactor in a manner analogous to that of the pinoresinol-lariciresinol reductases and isoflavone reductases. A similar catalytic function was observed for the corresponding recombinant reductase whose gene was cloned from the angiosperm, Populus trichocarpa. Interestingly, both pinoresinol-lariciresinol reductases and isoflavone reductases catalyze enantiospecific conversions, whereas the phenylcoumaran benzylic ether reductase only shows regiospecific discrimination. A possible evolutionary relationship among the three reductase classes is proposed, based on the supposition that phenylcoumaran benzylic ether reductases represent the progenitors of pinoresinol-lariciresinol and isoflavone reductases.	Washington State Univ, Inst Biol Chem, Pullman, WA 99164 USA; State Univ Ghent VIB, Genet Lab, B-9000 Ghent, Belgium	Washington State University; Flanders Institute for Biotechnology (VIB); Ghent University	Lewis, NG (corresponding author), Washington State Univ, Inst Biol Chem, Pullman, WA 99164 USA.	lewisn@wsu.edu	Boerjan, Wout/Y-4158-2019; Gang, David/B-1001-2013; Kasahara, Hiroyuki/F-6445-2012	Boerjan, Wout/0000-0003-1495-510X; Kasahara, Hiroyuki/0000-0002-4858-0978; Lewis, Norman/0000-0001-5742-032X; Davin, Laurence/0000-0002-3248-6485				APPEL RD, 1994, TRENDS BIOCHEM SCI, V19, P258, DOI 10.1016/0968-0004(94)90153-8; ASAKAW AY, 1997, HETROCYCLES, V46, P795; Attucci S., 1996, PLANT PHYSIOL, V110, P1435; Ausubel FM., 2006, ENZYMATIC MANIPULATI; BABIYCHUK E, 1995, J BIOL CHEM, V270, P26224, DOI 10.1074/jbc.270.44.26224; BANKS SW, 1982, J CHEM SOC CHEM COMM, P157, DOI 10.1039/c39820000157; BINNS AN, 1987, P NATL ACAD SCI USA, V84, P980, DOI 10.1073/pnas.84.4.980; CHU A, 1993, J BIOL CHEM, V268, P27026; DEWICK PM, 1977, J CHEM SOC CHEM COMM, P338, DOI 10.1039/c39770000338; DEYAMA T, 1987, CHEM PHARM BULL, V35, P1803; DinkovaKostova AT, 1996, J BIOL CHEM, V271, P29473, DOI 10.1074/jbc.271.46.29473; DIXON RA, 1995, PHYSIOL PLANTARUM, V93, P385, DOI 10.1111/j.1399-3054.1995.tb02243.x; Dong JZ, 1996, PLANT CELL REP, V15, P516, DOI 10.1007/BF00232985; DUMAS B, 1992, PLANT PHYSIOL, V98, P796, DOI 10.1104/pp.98.2.796; FREUDENBERG K, 1959, NATURE, V183, P1152, DOI 10.1038/1831152a0; Freudenberg K, 1968, CONSTITUTION BIOSYNT, P47; Fujita M, 1999, J BIOL CHEM, V274, P618, DOI 10.1074/jbc.274.2.618; Gang DR, 1997, ACS SYM SER, V658, P58; Gang DR, 1998, ACS SYM SER, V697, P389, DOI DOI 10.1021/BK-1998-0697.CH025; GARDNER JAF, 1960, CAN J CHEM, V38, P2387, DOI 10.1139/v60-324; GARDNER JAF, 1966, CAN J CHEMISTRY, V44, P52, DOI 10.1139/v66-009; GARDNER JAF, 1959, CAN J CHEM, V37, P1703, DOI 10.1139/v59-246; *GEN COMP GROUP, 1994, GCG SEQ AN SOFTW PAC; HIBI N, 1994, PLANT CELL, V6, P723, DOI 10.1105/tpc.6.5.723; Ikeda Tomoko, 1994, Natural Medicines, V48, P32; KATAYAMA T, 1993, PHYTOCHEMISTRY, V33, P581, DOI 10.1016/0031-9422(93)85452-W; KESSMANN H, 1990, PLANT PHYSIOL, V94, P227, DOI 10.1104/pp.94.1.227; Kraus C, 1997, PHYTOCHEMISTRY, V44, P59, DOI 10.1016/S0031-9422(96)00388-3; KRAUS R, 1990, PHYTOCHEMISTRY, V29, P1653, DOI 10.1016/0031-9422(90)80140-C; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lers A, 1998, PLANT MOL BIOL, V36, P847, DOI 10.1023/A:1005996515602; LEWIS NG, 1998, ACS SYM SER, V697, P1; LUNDGREN LN, 1985, ACTA CHEM SCAND B, V39, P241, DOI 10.3891/acta.chem.scand.39b-0241; LUNDGREN LN, 1981, PHYTOCHEMISTRY, V20, P1967, DOI 10.1016/0031-9422(81)84046-0; LYNN DG, 1987, P NATL ACAD SCI USA, V84, P615, DOI 10.1073/pnas.84.3.615; MACLEAN H, 1967, CAN J CHEMISTRY, V45, P305, DOI 10.1139/v67-054; MACLEAN H, 1967, CAN J CHEMISTRY, V45, P739, DOI 10.1139/v67-120; MACLEAN H, 1966, CAN J CHEMISTRY, V44, P1541, DOI 10.1139/v66-229; MACLEAN H., 1956, Forest Products Journal, V6, P510; MACLEAN H, 1966, CAN J CHEMISTRY, V44, P1827, DOI 10.1139/v66-274; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; NOSE M, 1995, PHYTOCHEMISTRY, V39, P71, DOI 10.1016/0031-9422(95)95268-Y; ORR JD, 1992, PLANT PHYSIOL, V98, P343, DOI 10.1104/pp.98.1.343; Otsuka H, 1996, PHYTOCHEMISTRY, V42, P1435, DOI 10.1016/0031-9422(96)00143-4; PAIVA NL, 1994, ARCH BIOCHEM BIOPHYS, V312, P501, DOI 10.1006/abbi.1994.1338; PAIVA NL, 1991, PLANT MOL BIOL, V17, P653, DOI 10.1007/BF00037051; Petrucco S, 1996, PLANT CELL, V8, P69, DOI 10.1105/tpc.8.1.69; PRASAD AK, 1994, TETRAHEDRON, V50, P2231, DOI 10.1016/S0040-4020(01)85081-X; Ralph J, 1997, SCIENCE, V277, P235, DOI 10.1126/science.277.5323.235; RICE P, 1996, PROGRAM MANUAL EGCG; Sambrook J, 1994, MOL CLONING LAB MANU; SATAKE T, 1978, CHEM PHARM BULL, V26, P1619; SCHENK PM, 1995, BIOTECHNIQUES, V19, P196; SCHLIEPER D, 1990, PHYTOCHEMISTRY, V29, P1519, DOI 10.1016/0031-9422(90)80112-T; Segel IH, 1975, ENZYME KINETICS BEHA; SHAIN L, 1971, PHYTOPATHOLOGY, V61, P841, DOI 10.1094/Phyto-61-841; SMITE E, 1995, PHYTOCHEMISTRY, V40, P341, DOI 10.1016/0031-9422(95)00057-E; STRACK D, 1989, PHYTOCHEMISTRY, V28, P2071, DOI 10.1016/S0031-9422(00)97922-6; SU WC, 1995, PHYTOCHEMISTRY, V40, P563, DOI 10.1016/0031-9422(95)00269-D; SWAN EP, 1969, PHYTOCHEMISTRY, V8, P345, DOI 10.1016/S0031-9422(00)85430-8; TAN RX, 1990, PLANTA MED, V56, P475, DOI 10.1055/s-2006-961015; TIEMANN K, 1991, EUR J BIOCHEM, V200, P751, DOI 10.1111/j.1432-1033.1991.tb16241.x; TYAGI OD, 1994, ACTA CHEM SCAND, V48, P1007, DOI 10.3891/acta.chem.scand.48-1007; vanHeerden PS, 1996, J BIOL CHEM, V271, P12350, DOI 10.1074/jbc.271.21.12350	64	153	161	2	34	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 12	1999	274	11					7516	7527		10.1074/jbc.274.11.7516	http://dx.doi.org/10.1074/jbc.274.11.7516			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	175DV	10066819	hybrid			2022-12-25	WOS:000079078400091
J	Launay, P; Patry, C; Lehuen, A; Pasquier, B; Blank, U; Monteiro, RC				Launay, P; Patry, C; Lehuen, A; Pasquier, B; Blank, U; Monteiro, RC			Alternative endocytic pathway for immunoglobulin A Fc receptors (CD89) depends on the lack of FcR gamma association and protects against degradation of bound ligand	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; HUMAN POLYMORPHONUCLEAR LEUKOCYTES; CYTOPLASMIC DOMAIN HETEROGENEITY; HUMAN SERUM IGA; HUMAN MONOCYTES; EPSILON-RI; MEDIATED PHAGOCYTOSIS; PHYSICAL ASSOCIATION; EXPRESSION; BINDING	IgA is the most abundant immunoglobulin in mucosal areas but is only the second most common antibody isotype in serum because it is catabolized faster than IgG, IgA exists in monomeric and polymeric forms that function through receptors expressed on effector cells. Here, we show that IgA Fc receptor(s) (Fc alpha R) are expressed with or without the gamma chain on monocytes and neutrophils, gamma-less Fc alpha R represent a significant fraction of surface Fc alpha R molecules even on cells overexpressing the gamma chain. The Fc alpha R-gamma 2 association is up-regulated by phorbol esters and interferon-gamma. To characterize gamma-less Fc alpha R functionally, we generated mast cell transfectants expressing wild-type human Fc alpha R or a receptor with a point mutation (Arg --> Leu at position 209) which was unable to associate with the gamma chain. Mutant gamma-less Fc alpha R bound monomeric and polymeric human IgA1 or IgA2 but failed to induce exocytosis after receptor clustering. The two types of transfectant showed similar kinetics of Fc alpha R-mediated endocytosis; however, the endocytosis pathways of the two types of receptor differed. Whereas mutant Fc alpha R were localized mainly in early endosomes, those containing Fc alpha R-gamma 2 were found in endo-lysosomal compartments. Mutant gamma-less Fc alpha R recycled the internalized IgA toward the cell surface and protected against IgA degradation. Cells expressing the two forms of Fc alpha R, associated or unassociated with gamma chains, may thus have differential functions either by degrading IgA antibody complexes or by recycling serum IgA.	Hop Necker Enfants Malad, INSERM, U25, F-75743 Paris 15, France; Inst Curie, CNRS, Unite Mixte Rech, F-75005 Paris, France; Inst Pasteur, Unite Immunoallergie, F-75015 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Monteiro, RC (corresponding author), Hop Necker Enfants Malad, INSERM, U25, 161 Rue Sevres, F-75743 Paris 15, France.	monteiro@necker.fr	Monteiro, Renato C/U-8633-2017; Launay, Pierre/AAH-7076-2019	Monteiro, Renato C/0000-0001-5202-5646; Blank, Ulrich/0000-0002-2661-2983; Lehuen, Agnes/0000-0002-0450-3321				ABUGHAZALEH RI, 1989, J IMMUNOL, V142, P2393; ALBRECHTSEN M, 1988, IMMUNOLOGY, V64, P201; Amigorena S, 1998, J EXP MED, V187, P505, DOI 10.1084/jem.187.4.505; AMIGORENA S, 1992, SCIENCE, V256, P1808, DOI 10.1126/science.1535455; BARSUMIAN EL, 1981, EUR J IMMUNOL, V11, P317, DOI 10.1002/eji.1830110410; BROWN TA, 1982, J IMMUNOL, V128, P2183; Carayannopoulos L, 1996, J EXP MED, V183, P1579, DOI 10.1084/jem.183.4.1579; CHEVAILLER A, 1989, J IMMUNOL, V142, P2244; CONLEY ME, 1987, ANN INTERN MED, V106, P892, DOI 10.7326/0003-4819-106-6-892; Daeron M, 1997, ANNU REV IMMUNOL, V15, P203, DOI 10.1146/annurev.immunol.15.1.203; DAVIS W, 1995, EMBO J, V14, P432, DOI 10.1002/j.1460-2075.1995.tb07019.x; DEWIT TPM, 1995, J IMMUNOL, V155, P1203; GODING JW, 1980, J IMMUNOL, V124, P2082; Gulle H, 1998, BLOOD, V91, P383, DOI 10.1182/blood.V91.2.383.383_383_391; HARRISON PT, 1994, J BIOL CHEM, V269, P24396; KINET JP, 1985, BIOCHEMISTRY-US, V24, P4117, DOI 10.1021/bi00336a046; KUSTER H, 1990, J BIOL CHEM, V265, P6448; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Launay P, 1998, J LEUKOCYTE BIOL, V63, P636, DOI 10.1002/jlb.63.5.636; LETOURNEUR O, 1991, J IMMUNOL, V147, P2652; MALISZEWSKI CR, 1990, J EXP MED, V172, P1665, DOI 10.1084/jem.172.6.1665; Mestecky J, 1997, BIOCHEM SOC T, V25, P457, DOI 10.1042/bst0250457; MIETTINEN HM, 1989, CELL, V58, P317, DOI 10.1016/0092-8674(89)90846-5; Miller KL, 1996, J EXP MED, V183, P2227, DOI 10.1084/jem.183.5.2227; MILLER L, 1989, SCIENCE, V244, P334, DOI 10.1126/science.2523561; MONTEIRO RC, 1993, J CLIN INVEST, V92, P1681, DOI 10.1172/JCI116754; MONTEIRO RC, 1992, J IMMUNOL, V148, P1764; MONTEIRO RC, 1990, J EXP MED, V171, P597, DOI 10.1084/jem.171.3.597; Morton HC, 1996, CRIT REV IMMUNOL, V16, P423; Morton HC, 1996, IMMUNOGENETICS, V43, P246, DOI 10.1007/s002510050057; MORTON HC, 1995, J BIOL CHEM, V270, P29781; NIKOLOVA EB, 1995, J LEUKOCYTE BIOL, V57, P875, DOI 10.1002/jlb.57.6.875; PATRY C, 1995, IMMUNOLOGY, V86, P1; Patry C, 1996, J IMMUNOL, V156, P4442; PFEFFERKORN LC, 1994, J IMMUNOL, V153, P3228; Pleass RJ, 1996, BIOCHEM J, V318, P771, DOI 10.1042/bj3180771; POLAT GL, 1993, IMMUNOLOGY, V80, P287; Reterink TJF, 1996, GENE, V175, P279, DOI 10.1016/0378-1119(96)00152-7; Reterink TJF, 1997, EUR J IMMUNOL, V27, P2219, DOI 10.1002/eji.1830270915; RIFAI A, 1989, LAB INVEST, V61, P381; Roa M, 1997, J IMMUNOL, V159, P2815; Russell MW, 1997, BIOCHEM SOC T, V25, P466, DOI 10.1042/bst0250466; Saito K, 1995, J ALLERGY CLIN IMMUN, V96, P1152, DOI 10.1016/S0091-6749(95)70200-8; SALISBURY JG, 1981, BIOCHEM J, V194, P351, DOI 10.1042/bj1940351; Saudrais C, 1998, J IMMUNOL, V160, P2597; SCHOLL PR, 1993, P NATL ACAD SCI USA, V90, P8847, DOI 10.1073/pnas.90.19.8847; Sela, 1974, ANTIGENS, VII, P365; SHEN L, 1994, J IMMUNOL, V152, P4080; SHEN L, 1989, J IMMUNOL, V143, P4117; SILVAIN C, 1995, J IMMUNOL, V155, P1606; Solomon A, 1980, CANCER MARKERS, P57, DOI 10.1007/978-1-4612-6117-9_3; STOCKERT RJ, 1982, P NATL ACAD SCI-BIOL, V79, P6229, DOI 10.1073/pnas.79.20.6229; TADOU G, 1993, INT ARCH ALLERGY IMM, V100, P344; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; vanDijk TB, 1996, BLOOD, V88, P4229; VANEPPS DE, 1976, J EXP MED, V144, P1227, DOI 10.1084/jem.144.5.1227; WEISBART RH, 1988, NATURE, V332, P647, DOI 10.1038/332647a0; White S, 1998, J BIOL CHEM, V273, P14355, DOI 10.1074/jbc.273.23.14355; WILTON JMA, 1978, CLIN EXP IMMUNOL, V34, P423; Wolf HM, 1996, CLIN EXP IMMUNOL, V105, P537, DOI 10.1046/j.1365-2249.1996.d01-793.x; WOLF HM, 1994, BLOOD, V83, P1278	62	70	75	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 12	1999	274	11					7216	7225		10.1074/jbc.274.11.7216	http://dx.doi.org/10.1074/jbc.274.11.7216			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	175DV	10066783	hybrid			2022-12-25	WOS:000079078400055
J	Becker, DL; Fredenburgh, JC; Stafford, AR; Weitz, JI				Becker, DL; Fredenburgh, JC; Stafford, AR; Weitz, JI			Exosites 1 and 2 are essential for protection of fibrin-bound thrombin from heparin-catalyzed inhibition by antithrombin and heparin cofactor II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-WEIGHT HEPARIN; TERNARY COMPLEX; DERMATAN SULFATE; ALPHA-THROMBIN; FACTOR-XA; MECHANISM; KINETICS; BINDING; GLYCOSAMINOGLYCANS; IDENTIFICATION	Assembly of ternary thrombin-heparin-fibrin complexes, formed when fibrin binds to exosite 1 on thrombin and fibrin-bound heparin binds to exosite 2, produces a 58- and 247-fold reduction in the heparin-catalyzed rate of thrombin inhibition by antithrombin and heparin cofactor II, respectively. The greater reduction for heparin cofactor II reflects its requirement for access to exosite 1 during the inhibitory process. Protection from inhibition by antithrombin and heparin cofactor II requires ligation of both exosites 1. and 2 because minimal protection is seen when exosite 1 variants (gamma-thrombin and thrombin Quick 1) or an exosite 2 variant (Arg(93) --> Ala, Arg(97) --> Ala, and Arg(101) --> Ala thrombin) is substituted for thrombin, Likewise, the rate of thrombin inhibition by the heparin-independent inhibitor, alpha(1)-antitrypsin Met(358) --> Arg, is decreased less than 2-fold in the presence of soluble fibrin and heparin, In contrast, thrombin is protected from inhibition by a covalent antithrombin-heparin complex, suggesting that access of heparin to exosite 2 of thrombin is hampered when ternary complex formation occurs. These results reveal the importance of exosites 1 and 2 of thrombin in assembly of the ternary complex and the subsequent protection of thrombin from inhibition by heparin-catalyzed inhibitors.	Hamilton Civ Hosp, Res Ctr, Hamilton, ON L8V 1C3, Canada; McMaster Univ, Dept Med, Hamilton, ON L8V 1C3, Canada	McMaster University; McMaster University	Weitz, JI (corresponding author), Hamilton Civ Hosp, Res Ctr, 711 Concess St, Hamilton, ON L8V 1C3, Canada.	jweitz@thrombosis.hhscr.org	Weitz, Jeffrey/AAD-1929-2019	Weitz, Jeffrey/0000-0002-1092-7550				Becker DL, 1997, ADV EXP MED BIOL, V425, P55; BENDAYAN P, 1994, THROMB HAEMOSTASIS, V71, P576; Berry L, 1998, J BIOL CHEM, V273, P34730, DOI 10.1074/jbc.273.52.34730; BJORK I, 1982, MOL CELL BIOCHEM, V48, P161, DOI 10.1007/BF00421226; BLOOM JW, 1979, BIOCHEMISTRY-US, V18, P4419, DOI 10.1021/bi00587a023; BRIGINSHAW GF, 1974, ARCH BIOCHEM BIOPHYS, V161, P683, DOI 10.1016/0003-9861(74)90354-3; Chan A, 1997, J BIOL CHEM, V272, P22111, DOI 10.1074/jbc.272.35.22111; Cosmi B, 1997, CIRCULATION, V95, P118, DOI 10.1161/01.CIR.95.1.118; DANIELSSON A, 1986, J BIOL CHEM, V261, P5467; DiCera E, 1997, CELL MOL LIFE SCI, V53, P701, DOI 10.1007/s000180050091; ELION J, 1986, ANN NY ACAD SCI, V485, P16, DOI 10.1111/j.1749-6632.1986.tb34564.x; ESMON CT, 1995, FASEB J, V9, P946, DOI 10.1096/fasebj.9.10.7615164; FENTON JW, 1988, SEMIN THROMB HEMOST, V14, P234, DOI 10.1055/s-2007-1002783; Fredenburgh JC, 1997, J BIOL CHEM, V272, P25493, DOI 10.1074/jbc.272.41.25493; Granger CB, 1998, J AM COLL CARDIOL, V31, P497, DOI 10.1016/S0735-1097(97)00539-1; GRIFFITH MJ, 1982, J BIOL CHEM, V257, P7360; HATTON MWC, 1978, THROMB RES, V13, P655, DOI 10.1016/0049-3848(78)90155-X; HEENE D L, 1973, Thrombosis Research, V2, P137, DOI 10.1016/0049-3848(73)90025-X; HENRIKSEN RA, 1988, BIOCHEMISTRY-US, V27, P9160, DOI 10.1021/bi00426a013; Hermann JPR, 1997, THROMB HAEMOSTASIS, V78, P367; HOGG PJ, 1990, J BIOL CHEM, V265, P248; HOGG PJ, 1989, P NATL ACAD SCI USA, V86, P3619, DOI 10.1073/pnas.86.10.3619; Hogg PJ, 1996, J BIOL CHEM, V271, P26088, DOI 10.1074/jbc.271.42.26088; HOGG PJ, 1990, J BIOL CHEM, V265, P241; Hogg PJ, 1997, THROMB HAEMOSTASIS, V77, P424; HOPKINS PCR, 1995, J BIOL CHEM, V270, P11866, DOI 10.1074/jbc.270.20.11866; HORTIN G, 1986, J BIOL CHEM, V261, P5827; JACKMAN MP, 1992, J BIOL CHEM, V267, P15375; JAKUBOWSKI HV, 1986, J BIOL CHEM, V261, P3876; JORDAN RE, 1980, J BIOL CHEM, V255, P81; KAWASAKI K, 1992, CHEM PHARM BULL, V40, P3253, DOI 10.1248/cpb.40.3253; LEFKOVITS J, 1994, CIRCULATION, V90, P1522, DOI 10.1161/01.CIR.90.3.1522; LEWIS SD, 1985, BIOCHEMISTRY-US, V24, P6772, DOI 10.1021/bi00345a007; McKenzie CR, 1996, ARTERIOSCL THROM VAS, V16, P1285, DOI 10.1161/01.ATV.16.10.1285; OLSON ST, 1988, J BIOL CHEM, V263, P1698; OLSON ST, 1993, METHOD ENZYMOL, V222, P525; OWEN MC, 1983, NEW ENGL J MED, V309, P694, DOI 10.1056/NEJM198309223091203; RAGG H, 1990, J BIOL CHEM, V265, P5211; Rezaie AR, 1998, J BIOL CHEM, V273, P16824, DOI 10.1074/jbc.273.27.16824; ROSENBERG RD, 1973, J BIOL CHEM, V248, P6490; SCHOEN P, 1987, J BIOL CHEM, V262, P11268; STONE SR, 1994, BIOCHEMISTRY-US, V33, P7731, DOI 10.1021/bi00190a028; STUBBS MT, 1993, THROMB RES, V69, P1, DOI 10.1016/0049-3848(93)90002-6; TOLLEFSEN DM, 1995, THROMB HAEMOSTASIS, V74, P1209; VANDEERLIN VMD, 1991, J BIOL CHEM, V266, P20223; WEITZ J, 1993, J LAB CLIN MED, V122, P364; WEITZ JI, 1990, J CLIN INVEST, V86, P385, DOI 10.1172/JCI114723; WHINNA HC, 1993, J PROTEIN CHEM, V12, P677, DOI 10.1007/BF01024926; YE J, 1994, J BIOL CHEM, V269, P17965; YOUNG E, 1990, THROMB HAEMOSTASIS, V64, P559	50	71	73	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	1999	274	10					6226	6233		10.1074/jbc.274.10.6226	http://dx.doi.org/10.1074/jbc.274.10.6226			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172BQ	10037709	hybrid			2022-12-25	WOS:000078902800031
J	Berger, J; Leibowitz, MD; Doebber, TW; Elbrecht, A; Zhang, B; Zhou, GC; Biswas, C; Cullinan, CA; Hayes, NS; Li, Y; Tanen, M; Ventre, J; Wu, MS; Berger, GD; Mosley, R; Marquis, R; Santini, C; Sahoo, SP; Tolman, RL; Smith, RG; Moller, DE				Berger, J; Leibowitz, MD; Doebber, TW; Elbrecht, A; Zhang, B; Zhou, GC; Biswas, C; Cullinan, CA; Hayes, NS; Li, Y; Tanen, M; Ventre, J; Wu, MS; Berger, GD; Mosley, R; Marquis, R; Santini, C; Sahoo, SP; Tolman, RL; Smith, RG; Moller, DE			Novel peroxisome proliferator-activated receptor (PPAR) gamma and PPAR delta ligands produce distinct biological effects	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; GENE-EXPRESSION; FATTY-ACIDS; GLUCOSE-TOLERANCE; DIFFERENTIAL ACTIVATION; CONFORMATIONAL CHANGE; NUCLEAR RECEPTORS; 3T3-L1 CELLS; INSULIN; THIAZOLIDINEDIONES	The peroxisome proliferator-activated receptors (PPARs) include three receptor subtypes encoded by separate genes: PPAR alpha; PPAR delta, and PPAR gamma, PPAR gamma has been implicated as a mediator of adipocyte differentiation and the mechanism by which thiazolidinedione drugs exert in vivo insulin sensitization. Here we characterized novel, non-thiazolidinedione agonists for PPAR gamma and PPAR delta that were identified by radioligand binding assays. In transient transactivation assays these ligands were agonists of the receptors to which they bind. Protease protection studies showed that ligand binding produced specific alterations in receptor conformation. Both PPAR gamma and PPAR delta directly interacted with a nuclear receptor co-activator (CREB-binding protein) in an agonist-dependent manner. Only the PPAR gamma agonists were able to promote differentiation of 3T3-L1 preadipocytes, In diabetic db/db mice all PPAR gamma agonists were orally active insulin-sensitizing agents producing reductions of elevated plasma glucose and triglyceride concentrations. In contrast, selective in vivo activation of PPAR delta did not significantly affect these parameters. In vivo PPAR alpha activation with WY-14653 resulted in reductions in elevated triglyceride levels with minimal effect on hyperglycemia, We conclude that: 1) synthetic non-thiazolidinediones can serve as ligands of PPAR gamma and PPAR delta; 2) ligand-dependent activation of PPAR delta involves an apparent conformational change and association of the receptor ligand binding domain with CREB-binding protein; 3) PPAR gamma activation (but not PPAR delta or PPAR alpha activation) is sufficient to potentiate preadipocyte differentiation; 4) non-thiazolidinedione PPAR gamma agonists improve hyperglycemia and hypertriglyceridemia in vivo; 5) although PPAR alpha activation is sufficient to affect triglyceride metabolism, PPAR delta activation does not appear to modulate glucose or triglyceride levels.	Merck Res Labs, Dept Mol Endocrinol, Rahway, NJ 07065 USA; Merck Res Labs, Dept Med Chem, Rahway, NJ 07065 USA	Merck & Company; Merck & Company	Berger, J (corresponding author), Merck Res Labs, Dept Mol Endocrinol, RY80N-C31,126 E Lincoln Ave, Rahway, NJ 07065 USA.	joel_berger@merck.com	Santini, Conrad/N-2615-2018					ALLAN GF, 1992, J BIOL CHEM, V267, P19513; AMRI EZ, 1995, J BIOL CHEM, V270, P2367, DOI 10.1074/jbc.270.5.2367; Berger J, 1996, ENDOCRINOLOGY, V137, P4189, DOI 10.1210/en.137.10.4189; Brandes R, 1995, BIOCHEM PHARMACOL, V50, P1949, DOI 10.1016/0006-2952(95)02082-9; Brown PJ, 1997, CHEM BIOL, V4, P909, DOI 10.1016/S1074-5521(97)90299-4; Brun RP, 1996, GENE DEV, V10, P974, DOI 10.1101/gad.10.8.974; DiRenzo J, 1997, MOL CELL BIOL, V17, P2166, DOI 10.1128/MCB.17.4.2166; Dowell P, 1997, J BIOL CHEM, V272, P2013, DOI 10.1074/jbc.272.3.2013; Dowell P, 1997, J BIOL CHEM, V272, P33435, DOI 10.1074/jbc.272.52.33435; Forman BM, 1997, P NATL ACAD SCI USA, V94, P4312, DOI 10.1073/pnas.94.9.4312; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; Gimble JM, 1996, MOL PHARMACOL, V50, P1087; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HOLLON T, 1989, ANAL BIOCHEM, V182, P411, DOI 10.1016/0003-2697(89)90616-7; Houseknecht KL, 1998, BIOCHEM BIOPH RES CO, V244, P678, DOI 10.1006/bbrc.1998.8303; HU ED, 1995, P NATL ACAD SCI USA, V92, P9856, DOI 10.1073/pnas.92.21.9856; INOUE I, 1994, DIABETES RES CLIN PR, V25, P199, DOI 10.1016/0168-8227(94)90009-4; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; KLETZIEN RF, 1992, MOL PHARMACOL, V41, P393; Kliewer SA, 1997, P NATL ACAD SCI USA, V94, P4318, DOI 10.1073/pnas.94.9.4318; KOBAYASHI M, 1988, DIABETES CARE, V11, P495, DOI 10.2337/diacare.11.6.495; KOHANSKI RA, 1986, J BIOL CHEM, V261, P2272; Krey G, 1997, MOL ENDOCRINOL, V11, P779, DOI 10.1210/me.11.6.779; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; LITHELL H, 1977, EUR J CLIN PHARMACOL, V12, P51, DOI 10.1007/BF00561405; Matsui HR, 1997, DIABETES, V46, P348, DOI 10.2337/diabetes.46.3.348; MCDONNELL DP, 1995, MOL ENDOCRINOL, V9, P659, DOI 10.1210/me.9.6.659; Mukherjee R, 1998, ARTERIOSCL THROM VAS, V18, P272, DOI 10.1161/01.ATV.18.2.272; Mukherjee R, 1997, NATURE, V386, P407, DOI 10.1038/386407a0; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; SCHMIDT A, 1992, MOL ENDOCRINOL, V6, P1634, DOI 10.1210/me.6.10.1634; Schoonjans K, 1996, BBA-LIPID LIPID MET, V1302, P93, DOI 10.1016/0005-2760(96)00066-5; Schoonjans K, 1996, EMBO J, V15, P5336, DOI 10.1002/j.1460-2075.1996.tb00918.x; Schoonjans K, 1997, CURR OPIN LIPIDOL, V8, P159, DOI 10.1097/00041433-199706000-00006; Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304; Spiegelman BM, 1998, DIABETES, V47, P507, DOI 10.2337/diabetes.47.4.507; SZALKOWSKI D, 1995, ENDOCRINOLOGY, V136, P1474, DOI 10.1210/en.136.4.1474; TONTONOZ P, 1995, MOL CELL BIOL, V15, P351, DOI 10.1128/MCB.15.1.351; TONTONOZ P, 1994, GENE DEV, V8, P1224, DOI 10.1101/gad.8.10.1224; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; VidalPuig A, 1996, J CLIN INVEST, V97, P2553, DOI 10.1172/JCI118703; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; WAHLI W, 1995, CHEM BIOL, V2, P261, DOI 10.1016/1074-5521(95)90045-4; Willson TM, 1996, J MED CHEM, V39, P665, DOI 10.1021/jm950395a; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; YU K, 1995, J BIOL CHEM, V270, P23975, DOI 10.1074/jbc.270.41.23975; Zhang B, 1996, MOL ENDOCRINOL, V10, P1457, DOI 10.1210/me.10.11.1457; ZHU YJ, 1995, P NATL ACAD SCI USA, V92, P7921, DOI 10.1073/pnas.92.17.7921; Zhu YJ, 1996, GENE EXPRESSION, V6, P185	49	352	383	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1999	274	10					6718	6725		10.1074/jbc.274.10.6718	http://dx.doi.org/10.1074/jbc.274.10.6718			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172BQ	10037770	hybrid			2022-12-25	WOS:000078902800092
J	Guerrette, S; Acharya, S; Fishel, R				Guerrette, S; Acharya, S; Fishel, R			The interaction of the human MutL homologues in hereditary nonpolyposis colon cancer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA MISMATCH REPAIR; COLORECTAL-CANCER; ESCHERICHIA-COLI; GENE-PRODUCT; MUTATIONS; YEAST; MSH2; CELLS; MLH1; PMS1	Germline mutations in two human mismatch repair (MMR) genes, hMSH2 and hMLH1, appear to account for approximately 70% of the common cancer susceptibility syndrome hereditary nonpolyposis colorectal cancer (HNPCC). Although the hMLH1 protein has been found to copurify with another MMR protein hPMS2 as a heterodimer, their function in MMR is unknown. In this study, we have identified the physical interaction regions of both hMLH1 with hPMS2. We then examined the effects of hMLH1 missense alterations found in HNPCC kindreds for their interaction with hPMS2. Four of these missense alterations (L574P, K616 Delta, R659P, and A681T) displayed >95% reduction in binding to hPMS2. Two additional missense alterations (K618A and K618T) displayed a >85% reduction in binding to hPMS2, whereas three missense alterations (S44F, V506A, and E578G) displayed 25-65% reduction in binding to hPMS2. Interestingly, two HNPCC missense alterations (Q542L and L582V) contained within the consensus interaction region displayed no effect on interaction with hPMS2, suggesting that they may affect other functions of hMLH1. These data confirm that functional deficiencies in the interaction of hMLH1 with hPMS2 are associated with HNPCC as well as suggest that other unknown functional alteration of the human MutL homologues may lead to tumorigenesis in HNPCC kindreds.	Thomas Jefferson Univ, Kimmel Canc Ctr BLSB933, Dept Microbiol & Immunol, Genet & Mol Biol Program, Philadelphia, PA 19107 USA	Jefferson University	Fishel, R (corresponding author), Thomas Jefferson Univ, Kimmel Canc Ctr BLSB933, Dept Microbiol & Immunol, Genet & Mol Biol Program, 233 S 10th St, Philadelphia, PA 19107 USA.	rfishel@hendrix.jci.tju.edu			NCI NIH HHS [CA67007, R01 CA067007, CA56542] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA056542, R01CA067007] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akiyama Y, 1997, CANCER RES, V57, P3920; BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0; DEMEREC M, 1957, CARNEGIE I WASH YB, V370, P390; FISHEL R, 1994, CANCER RES, V54, P5539; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; Fishel R, 1997, CURR OPIN GENET DEV, V7, P105, DOI 10.1016/S0959-437X(97)80117-7; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; GLICKMAN BW, 1980, P NATL ACAD SCI-BIOL, V77, P1063, DOI 10.1073/pnas.77.2.1063; GRILLEY M, 1989, J BIOL CHEM, V264, P1000; Guerrette S, 1998, MOL CELL BIOL, V18, P6616, DOI 10.1128/MCB.18.11.6616; Kallal L, 1997, MOL CELL BIOL, V17, P2897, DOI 10.1128/MCB.17.5.2897; Kolodner R, 1996, GENE DEV, V10, P1433, DOI 10.1101/gad.10.12.1433; LAHUE RS, 1989, SCIENCE, V245, P160, DOI 10.1126/science.2665076; LI GM, 1995, P NATL ACAD SCI USA, V92, P1950, DOI 10.1073/pnas.92.6.1950; MIYAKE T, 1960, GENETICS, V45, P755; Miyaki M, 1997, NAT GENET, V17, P271, DOI 10.1038/ng1197-271; MODRICH P, 1991, ANNU REV GENET, V25, P229, DOI 10.1146/annurev.ge.25.120191.001305; NAN HJ, 1995, HUM MOL GENET, V4, P237, DOI 10.1093/hmg/4.2.237; NICOLAIDES NC, 1994, NATURE, V371, P75, DOI 10.1038/371075a0; Pang QS, 1997, MOL CELL BIOL, V17, P4465, DOI 10.1128/MCB.17.8.4465; Peltomaki P, 1997, GASTROENTEROLOGY, V113, P1146, DOI 10.1053/gast.1997.v113.pm9322509; PROLLA TA, 1994, SCIENCE, V265, P1091, DOI 10.1126/science.8066446; PROLLA TA, 1994, MOL CELL BIOL, V14, P407, DOI 10.1128/MCB.14.1.407; RYDBERG B, 1978, MUTAT RES, V52, P11, DOI 10.1016/0027-5107(78)90091-X; Shimodaira H, 1998, NAT GENET, V19, P384, DOI 10.1038/1277; VASEN HFA, 1991, DIS COLON RECTUM, V34, P424, DOI 10.1007/BF02053699; WELSH KM, 1987, J BIOL CHEM, V262, P15624	27	141	148	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	1999	274	10					6336	6341		10.1074/jbc.274.10.6336	http://dx.doi.org/10.1074/jbc.274.10.6336			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172BQ	10037723	hybrid			2022-12-25	WOS:000078902800045
J	McMurry, JL; Kendall, DA				McMurry, JL; Kendall, DA			An artificial transmembrane segment directs SecA, SecB, and electrochemical potential-dependent translocation of a long amino-terminal tail	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-PROTEIN; SECRETION MACHINERY; SIGNAL SEQUENCE; INSERTION; PEPTIDE; HYDROPHOBICITY; CONSTRUCTION; ORIENTATION; RESIDUES; MUTANTS	Many integral membrane proteins contain an aminoterminal segment, often referred to as an N-tail, that is translocated across a membrane. In many cases, translocation of the N-tail is initiated by a cleavable, aminoterminal signal peptide. For N-tail proteins lacking a signal peptide, translocation is initiated by a transmembrane segment that is carboxyl to the translocated segment. The mechanism of membrane translocation of these segments, although poorly understood, has been reported to be independent of the protein secretion machinery. In contrast, here we describe alkaline phosphatase mutants containing artificial transmembrane segments that demonstrate that translocation of a long N-tail across the membrane is dependent upon SecA, SecB, and the electrochemical potential in the absence of a signal peptide. The corresponding mutants containing signal peptides also use the secretion machinery but are less sensitive to inhibition of its components. We present evidence that inhibition of SecA by sodium azide is incomplete even at high concentrations of inhibitor, which suggests why SecA-dependent translocation may not have been detected in other systems. Furthermore, by varying the charge around the transmembrane segment, we find that in the absence of a signal peptide, the orientation of the membrane-bound alkaline phosphatase is dictated by the positive inside rule, However, the presence of a signal peptide is an overriding factor in membrane orientation and renders all mutants in an N-out-C-in orientation.	Univ Connecticut, Dept Mol & Cell Biol, Storrs, CT 06269 USA	University of Connecticut	Kendall, DA (corresponding author), Univ Connecticut, Dept Mol & Cell Biol, Box U-44, Storrs, CT 06269 USA.	kendall@uconnvm.uconn.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037639] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM37639] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BLANC JP, 1984, J BIOL CHEM, V259, P9549; CAO GQ, 1994, EMBO J, V13, P4662, DOI 10.1002/j.1460-2075.1994.tb06789.x; CAO GQ, 1995, EMBO J, V14, P866, DOI 10.1002/j.1460-2075.1995.tb07068.x; CHEN HF, 1995, J BIOL CHEM, V270, P14115, DOI 10.1074/jbc.270.23.14115; DALBEY RE, 1995, TRENDS CELL BIOL, V5, P380, DOI 10.1016/S0962-8924(00)89079-0; Denzer AJ, 1995, EMBO J, V14, P6311, DOI 10.1002/j.1460-2075.1995.tb00321.x; ENGELMAN DM, 1981, CELL, V23, P411, DOI 10.1016/0092-8674(81)90136-7; Francetic O, 1996, J BACTERIOL, V178, P5954, DOI 10.1128/jb.178.20.5954-5959.1996; Izard JW, 1996, J BIOL CHEM, V271, P21579, DOI 10.1074/jbc.271.35.21579; KENDALL DA, 1988, J BIOL CHEM, V263, P7261; KENDALL DA, 1986, NATURE, V321, P706, DOI 10.1038/321706a0; KIM EE, 1991, J MOL BIOL, V218, P449, DOI 10.1016/0022-2836(91)90724-K; KIM EE, 1989, CLIN CHIM ACTA, V186, P175; Kim J, 1998, J BACTERIOL, V180, P1396, DOI 10.1128/JB.180.6.1396-1401.1998; KUHN A, 1985, J BIOL CHEM, V260, P5914; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MCGOVERN K, 1991, J BIOL CHEM, V266, P20870; Miller J. H., 1972, EXPT MOL GENETICS, P431; OLIVER DB, 1990, P NATL ACAD SCI USA, V87, P8227, DOI 10.1073/pnas.87.21.8227; RUSCH SL, 1994, J CELL BIOCHEM, V55, P209, DOI 10.1002/jcb.240550208; RUSSEL M, 1982, CELL, V28, P177, DOI 10.1016/0092-8674(82)90387-7; Sambrook J., 1989, MOL CLONING, pA1; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Traxler B, 1996, J BIOL CHEM, V271, P12394, DOI 10.1074/jbc.271.21.12394; VONHEIJNE G, 1988, EUR J BIOCHEM, V174, P671; VONHEIJNE G, 1994, ANNU REV BIOPH BIOM, V23, P167; WALLIN E, 1995, PROTEIN ENG, V8, P693, DOI 10.1093/protein/8.7.693; WHITLEY P, 1995, J BIOL CHEM, V270, P29831	28	10	10	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1999	274	10					6776	6782		10.1074/jbc.274.10.6776	http://dx.doi.org/10.1074/jbc.274.10.6776			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172BQ	10037778	hybrid			2022-12-25	WOS:000078902800100
J	Moche, M; Schneider, G; Edwards, P; Dehesh, K; Lindqvist, Y				Moche, M; Schneider, G; Edwards, P; Dehesh, K; Lindqvist, Y			Structure of the complex between the antibiotic cerulenin and its target, beta-ketoacyl-acyl carrier protein synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACID SYNTHASE; MACROMOLECULAR STRUCTURES; ESCHERICHIA-COLI; INHIBITION; SYNTHETASE; MUTANTS; PROGRAM; CELLS; GENE	In the biosynthesis of fatty acids, the beta-ketoacyl-acyl carrier protein (ACP) synthases catalyze chain elongation by the addition of two-carbon units derived from malonyl-ACP to an acyl group bound to either ACP or CoA. The enzyme is a possible drug target for treatment of certain cancers and for tuberculosis. The crystal structure of the complex of the enzyme from Escherichia coli, and the fungal mycotoxin cerulenin reveals that the inhibitor is bound in a hydrophobic pocket formed at the dimer interface. Cerulenin is covalently attached to the active site cysteine through its C2 carbon atom. The fit of the inhibitor to the active site is not optimal, and there is thus room for improvement through structure based design.	Karolinska Inst, Dept Med Biochem & Biophys, S-17177 Stockholm, Sweden; Calgene Inc, Oils Div, Davis, CA 95616 USA	Karolinska Institutet	Lindqvist, Y (corresponding author), Karolinska Inst, Dept Med Biochem & Biophys, Doktorsringen 9A1, S-17177 Stockholm, Sweden.	ylva@alfa.mbb.ki.se	Lindqvist, Ylva/F-9009-2010	Lindqvist, Ylva/0000-0003-3162-8661; Schneider, Gunter/0000-0003-0622-5713; Moche, Martin/0000-0002-4834-7076				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Child CJ, 1998, BIOCHEM J, V330, P933; DAGNOLO G, 1973, BIOCHIM BIOPHYS ACTA, V326, P155, DOI 10.1016/0005-2760(73)90241-5; Dehesh K, 1998, PLANT J, V15, P383, DOI 10.1046/j.1365-313X.1998.00218.x; Edwards P, 1997, FEBS LETT, V402, P62, DOI 10.1016/S0014-5793(96)01437-8; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; Evans P. R., 1993, P CCP4 STUD WEEK DAT, P114; FUNABASHI H, 1989, J BIOCHEM-TOKYO, V105, P751, DOI 10.1093/oxfordjournals.jbchem.a122739; GARWIN JL, 1980, J BIOL CHEM, V255, P3263; HOPWOOD DA, 1990, ANNU REV GENET, V24, P37, DOI 10.1146/annurev.ge.24.120190.000345; Huang WJ, 1998, EMBO J, V17, P1183, DOI 10.1093/emboj/17.5.1183; INOKOSHI J, 1994, MOL GEN GENET, V244, P90, DOI 10.1007/BF00280191; JAWORSKI JG, 1989, PLANT PHYSIOL, V90, P41, DOI 10.1104/pp.90.1.41; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KATZ L, 1993, ANNU REV MICROBIOL, V47, P875, DOI 10.1146/annurev.mi.47.100193.004303; KAUPPINEN S, 1988, CARLSBERG RES COMMUN, V53, P357, DOI 10.1007/BF02983311; KAWAGUCHI A, 1979, ARCH BIOCHEM BIOPHYS, V197, P30, DOI 10.1016/0003-9861(79)90214-5; KLEYWEGT GJ, 1994, ACTA CRYSTALLOGR D, V50, P178, DOI 10.1107/S0907444993011333; Kleywegt GJ, 1996, ACTA CRYSTALLOGR D, V52, P829, DOI 10.1107/S0907444996001783; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; MAGNUSON K, 1993, MICROBIOL REV, V57, P522, DOI 10.1128/MMBR.57.3.522-542.1993; Mdluli K, 1998, SCIENCE, V280, P1607, DOI 10.1126/science.280.5369.1607; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MORISAKI N, 1993, EUR J BIOCHEM, V211, P111, DOI 10.1111/j.1432-1033.1993.tb19876.x; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Otwinowski Z., 1993, P CCP4 STUD WEEK DAT, P56; Pizer ES, 1996, CANCER RES, V56, P745; Pizer ES, 1996, CANCER RES, V56, P2745; Rastogi N, 1998, FEMS IMMUNOL MED MIC, V21, P149, DOI 10.1111/j.1574-695X.1998.tb01161.x; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; SOMERVILLE C, 1991, SCIENCE, V252, P80, DOI 10.1126/science.252.5002.80; TOMODA H, 1984, J BIOCHEM-TOKYO, V995, P1712; VANCE D, 1972, BIOCHEM BIOPH RES CO, V48, P649, DOI 10.1016/0006-291X(72)90397-X; WAKIL SJ, 1989, BIOCHEMISTRY-US, V28, P4523, DOI 10.1021/bi00437a001	35	177	185	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	1999	274	10					6031	6034		10.1074/jbc.274.10.6031	http://dx.doi.org/10.1074/jbc.274.10.6031			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172BQ	10037680	hybrid			2022-12-25	WOS:000078902800002
J	Meilhac, O; Escargueil-Blanc, I; Thiers, JC; Salvayre, R; Negre-Salvayre, A				Meilhac, O; Escargueil-Blanc, I; Thiers, JC; Salvayre, R; Negre-Salvayre, A			Bcl-2 alters the balance between apoptosis and necrosis, but does not prevent cell death induced by oxidized low density lipoproteins	FASEB JOURNAL			English	Article						oxidized LDL; atherosclerosis; DNA ladder; cytosolic calcium concentration; antisense oligonucleotides	HUMAN-ENDOTHELIAL-CELLS; ACTIVATED PROTEIN-KINASE; VASCULAR SMOOTH-MUSCLE; ATHEROSCLEROTIC PLAQUES; DNA FRAGMENTATION; LIPID PEROXIDES; CYTOCHROME-C; CALCIUM; PATHWAY; LDL	Oxidized low density lipoproteins (oxLDL) participate in atherosclerosis plaque formation, rupture, and subsequent thrombosis. Because oxLDL are toxic to cultured cells and Bcl-2 protein prevents apoptosis, the present work aimed to study whether Bcl-2 may counterbalance the toxicity of oxLDL, Two experimental model systems were used in which Bcl-2 levels were modulated: 1) lymphocytes in which the (high) basal level of Bcl-2 was reduced by antisense oligonucleotides; 2) HL60 and HL60/B (transduced by Bcl-2) expressing low and high Bcl-2 levels, respectively. In cells expressing relatively high Bcl-2 levels (lymphocytes and HL60/B), oxLDL induced mainly primary necrosis, In cells expressing low Bcl-2 levels (antisense-treated lymphocytes, HL60 and ECV-304 endothelial cells), the rate of oxLDL-induced apoptosis was higher than that of primary necrosis. OxLDL evoked a sustained calcium rise, which is a common trigger to necrosis and apoptosis since both types of cell death were blocked by the calcium chelator EGTA, Conversely, a sustained calcium influx elicited by the calcium ionophore A23187 induced necrosis in cells expressing high Bcl-2 levels and apoptosis in cells expressing low Bcl-2 levels. This suggests that Bcl-2 acts downstream from the calcium peak and inhibits only the apoptotic pathway, not the necrosis pathway, thus explaining the apparent shift from oxLDL-induced apoptosis toward necrosis when Bcl-2 is overexpressed.	CHU Rangueil, Biochim Lab, INSERM, U466, F-31403 Toulouse 4, France; CHU Rangueil, Dept Biochem & Mol Biol, F-31403 Toulouse, France	CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm); CHU de Toulouse	Negre-Salvayre, A (corresponding author), CHU Rangueil, Biochim Lab, INSERM, U466, 1 Ave Jean Poulhes,IFR-31, F-31403 Toulouse 4, France.		Meilhac, Olivier/N-4385-2017	Meilhac, Olivier/0000-0002-3740-7539; Negre-Salvayre, Anne/0000-0003-2136-5706				ARENDS MJ, 1990, AM J PATHOL, V136, P593; Auge N, 1998, J BIOL CHEM, V273, P12893, DOI 10.1074/jbc.273.21.12893; BENNETT MR, 1995, J CLIN INVEST, V95, P2266, DOI 10.1172/JCI117917; Bjorkerud S, 1996, AM J PATHOL, V149, P367; BOOBIS AR, 1989, TRENDS PHARMACOL SCI, V10, P275, DOI 10.1016/0165-6147(89)90027-8; Caspar-Bauguil S, 1998, BIOCHEM J, V330, P659, DOI 10.1042/bj3300659; CATHCART MK, 1989, J IMMUNOL, V142, P1963; Chatterjee S, 1997, GLYCOBIOLOGY, V7, P703, DOI 10.1093/glycob/7.5.703; CORY S, 1995, ANNU REV IMMUNOL, V13, P513, DOI 10.1146/annurev.iy.13.040195.002501; Crisby M, 1997, ATHEROSCLEROSIS, V130, P17, DOI 10.1016/S0021-9150(96)06037-6; Deigner HP, 1996, FEBS LETT, V385, P149, DOI 10.1016/0014-5793(96)00371-7; Dimmeler S, 1997, CIRCULATION, V95, P1760; Dong Z, 1997, AM J PATHOL, V151, P1205; EscargueilBlanc I, 1997, ARTERIOSCL THROM VAS, V17, P331, DOI 10.1161/01.ATV.17.2.331; ESCARGUEILBLANC I, 1994, FASEB J, V8, P1075, DOI 10.1096/fasebj.8.13.7926374; ESTERBAUER H, 1990, CHEM RES TOXICOL, V3, P77, DOI 10.1021/tx00014a001; FARBER JL, 1990, CHEM RES TOXICOL, V3, P503, DOI 10.1021/tx00018a003; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GOLDSTEIN JL, 1977, ANNU REV BIOCHEM, V46, P897, DOI 10.1146/annurev.bi.46.070177.004341; Harada K, 1997, FEBS LETT, V411, P63, DOI 10.1016/S0014-5793(97)00662-5; HENRIKSEN T, 1979, SCAND J CLIN LAB INV, V39, P361, DOI 10.3109/00365517909106120; HESSLER JR, 1979, ATHEROSCLEROSIS, V32, P213, DOI 10.1016/0021-9150(79)90166-7; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; KAISER AM, 1995, AM J PHYSIOL-CELL PH, V269, pC1295, DOI 10.1152/ajpcell.1995.269.5.C1295; KAPUSCINSKI J, 1977, ANAL BIOCHEM, V83, P252, DOI 10.1016/0003-2697(77)90533-4; Karsan A, 1996, BLOOD, V87, P3089, DOI 10.1182/blood.V87.8.3089.bloodjournal8783089; Kinscherf R, 1998, FASEB J, V12, P461, DOI 10.1096/fasebj.12.6.461; KITADA S, 1994, ANTISENSE RES DEV, V4, P71, DOI 10.1089/ard.1994.4.71; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; LAM M, 1994, P NATL ACAD SCI USA, V91, P6569, DOI 10.1073/pnas.91.14.6569; Lizard G, 1997, FEBS LETT, V419, P276, DOI 10.1016/S0014-5793(97)01473-7; McConkey DJ, 1997, BIOCHEM BIOPH RES CO, V239, P357, DOI 10.1006/bbrc.1997.7409; MCCONKEY DJ, 1989, FASEB J, V3, P1843, DOI 10.1096/fasebj.3.7.2497041; Nagy L, 1998, CELL, V93, P229, DOI 10.1016/S0092-8674(00)81574-3; NAUMOVSKI L, 1994, BLOOD, V83, P2261; NEGRESALVAYRE A, 1990, BIOCHIM BIOPHYS ACTA, V1045, P224, DOI 10.1016/0005-2760(90)90124-G; NEGRESALVAYRE A, 1992, FEBS LETT, V299, P60, DOI 10.1016/0014-5793(92)80101-L; ORRENIUS S, 1989, TRENDS PHARMACOL SCI, V10, P281, DOI 10.1016/0165-6147(89)90029-1; Pollman MJ, 1998, NAT MED, V4, P222, DOI 10.1038/nm0298-222; Reed JC, 1997, NATURE, V387, P773, DOI 10.1038/42867; REID VC, 1993, ATHEROSCLEROSIS, V98, P17, DOI 10.1016/0021-9150(93)90219-K; ROSL F, 1992, NUCLEIC ACIDS RES, V20, P52; ROSS RC, 1993, NATURE, V302, P801; Sambrook J., 1989, MOL CLONING LAB MANU; STARY HC, 1990, EUR HEART J, V11, P3, DOI 10.1093/eurheartj/11.suppl_E.3; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; Suc I, 1998, FASEB J, V12, P665, DOI 10.1096/fasebj.12.9.665; Thomas A.P., 1991, CELLULAR CALCIUM PRA, P1; Via D P, 1986, Methods Enzymol, V129, P848; WITZTUM JL, 1991, J CLIN INVEST, V88, P1785, DOI 10.1172/JCI115499; WOLFF SP, 1994, METHOD ENZYMOL, V233, P182; WYLLIE AH, 1991, CELL DEATH BIOL PATH, P9; YAGI K, 1987, CHEM PHYS LIPIDS, V45, P337, DOI 10.1016/0009-3084(87)90071-5; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129	54	77	77	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	1999	13	3					485	494		10.1096/fasebj.13.3.485	http://dx.doi.org/10.1096/fasebj.13.3.485			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	174CF	10064615				2022-12-25	WOS:000079016000008
J	Furstenau, U; Schwaninger, M; Blume, R; Jendrusch, EM; Knepel, W				Furstenau, U; Schwaninger, M; Blume, R; Jendrusch, EM; Knepel, W			Characterization of a novel calcium response element in the glucagon gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED T-CELLS; PIG PANCREATIC-ALPHA-2 CELLS; TRANSCRIPTION FACTOR NFATP; NUCLEAR FACTOR; NF-AT; CYCLOSPORINE-A; BETA-CELL; IMMUNOSUPPRESSIVE DRUGS; PHOSPHATASE CALCINEURIN; MEMBRANE DEPOLARIZATION	To maintain blood glucose levels within narrow limits, the synthesis and secretion of pancreatic islet hormones is controlled by a variety of extracellular signals. Depolarization-induced calcium influx into islet cells has been shown to stimulate glucagon gene transcription through the transcription factor cAMP response element-binding protein that binds to the glucagon cAMP response element. By transient transfection of glucagon-reporter fusion genes into islet cell lines, this study identified a second calcium response element in the glucagon gene (G2 element, from -165 to -200), Membrane depolarization was found to induce the binding of a nuclear complex with NFATp-like immunoreactivity to the G2 element, Consistent with nuclear translocation, a comigrating complex was found in cytosolic extracts of unstimulated cells, and the induction of nuclear protein binding was blocked by inhibition of calcineurin phosphatase activity by FK506, A mutational analysis of G2 function and nuclear protein binding as well as the effect of FK506 indicate that calcium responsiveness is conferred to the G2 element by NFATp, functionally interacting with HNF-3 beta binding to a closely associated site. Transcription factors of the NFAT family are known to cooperate with AP-1 proteins in T cells for calcium-dependent activation of cytokine genes. This study shows a novel pairing of NFATp with the cell lineage-specific transcription factor HNF-3 beta in islet cells to form a novel calcium response element in the glucagon gene.	Univ Gottingen, Dept Mol Pharmacol, D-37070 Gottingen, Germany	University of Gottingen	Knepel, W (corresponding author), Univ Gottingen, Dept Mol Pharmacol, Robert Koch Str 40, D-37070 Gottingen, Germany.	wknepel@med.uni-goettingen.de		Schwaninger, Markus/0000-0002-4510-9718				ANG SL, 1994, CELL, V78, P561, DOI 10.1016/0092-8674(94)90522-3; BADING H, 1993, SCIENCE, V260, P181, DOI 10.1126/science.8097060; Beals CR, 1997, SCIENCE, V275, P1930, DOI 10.1126/science.275.5308.1930; Beals CR, 1997, GENE DEV, V11, P824, DOI 10.1101/gad.11.7.824; CLEVIDENCE DE, 1994, DEV BIOL, V166, P195, DOI 10.1006/dbio.1994.1307; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; COCKELL M, 1995, MOL CELL BIOL, V15, P1933; DEROBERTIS EM, 1995, NATURE, V374, P407, DOI 10.1038/374407a0; Diedrich T, 1997, BIOL CHEM, V378, P89, DOI 10.1515/bchm.1997.378.2.89; DIEM P, 1990, ENDOCRINOLOGY, V127, P1609, DOI 10.1210/endo-127-4-1609; Dolmetsch RE, 1997, NATURE, V386, P855, DOI 10.1038/386855a0; Furstenau U, 1997, MOL CELL BIOL, V17, P1805; Garcia-Rodriguez C, 1998, J EXP MED, V187, P2031, DOI 10.1084/jem.187.12.2031; Genot E, 1996, EMBO J, V15, P3923, DOI 10.1002/j.1460-2075.1996.tb00766.x; GHOSH A, 1995, SCIENCE, V268, P239, DOI 10.1126/science.7716515; HAMAGUCHI K, 1990, DIABETES, V39, P415, DOI 10.2337/diabetes.39.4.415; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; HO AM, 1994, J BIOL CHEM, V269, P28181; HOCHHUTH C, 1994, ENDOCRINE, V2, P833; HOLZ GG, 1992, TRENDS BIOCHEM SCI, V17, P388, DOI 10.1016/0968-0004(92)90006-U; JAIN J, 1992, NATURE, V356, P801, DOI 10.1038/356801a0; JOHANSSON H, 1989, CELL CALCIUM, V10, P205, DOI 10.1016/0143-4160(89)90003-1; KEAHEY HH, 1989, DIABETES, V38, P188, DOI 10.2337/diabetes.38.2.188; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; KNEPEL W, 1990, J BIOL CHEM, V265, P8725; KNEPEL W, 1991, MOL ENDOCRINOL, V5, P1457, DOI 10.1210/mend-5-10-1457; KNEPEL W, 1990, MOL CELL BIOL, V10, P6799, DOI 10.1128/MCB.10.12.6799; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LAI E, 1993, P NATL ACAD SCI USA, V90, P10421, DOI 10.1073/pnas.90.22.10421; LAI E, 1991, GENE DEV, V5, P416, DOI 10.1101/gad.5.3.416; Luo C, 1996, J EXP MED, V184, P141, DOI 10.1084/jem.184.1.141; Luo C, 1996, MOL CELL BIOL, V16, P3955; MASUDA ES, 1995, MOL CELL BIOL, V15, P2697; MCCAFFREY PG, 1993, J BIOL CHEM, V268, P3747; MCCAFFREY PG, 1993, SCIENCE, V262, P750, DOI 10.1126/science.8235597; MCCAFFREY PG, 1992, J BIOL CHEM, V267, P1864; MISRA RP, 1994, J BIOL CHEM, V269, P25483; Nirula A, 1997, J BIOL CHEM, V272, P7736, DOI 10.1074/jbc.272.12.7736; NITSCH D, 1993, P NATL ACAD SCI USA, V90, P5479, DOI 10.1073/pnas.90.12.5479; NOLAN GP, 1994, CELL, V77, P795, DOI 10.1016/0092-8674(94)90126-0; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; NORTHROP JP, 1994, NATURE, V369, P497, DOI 10.1038/369497a0; NORTHROP JP, 1993, J BIOL CHEM, V268, P2917; OETJEN E, 1994, J BIOL CHEM, V269, P27036; OKEEFE SJ, 1992, NATURE, V357, P692, DOI 10.1038/357692a0; OVERDIER DG, 1994, MOL CELL BIOL, V14, P2755, DOI 10.1128/MCB.14.4.2755; Peterson BR, 1996, P NATL ACAD SCI USA, V93, P13671, DOI 10.1073/pnas.93.24.13671; PHILIPPE J, 1988, MOL CELL BIOL, V8, P4877, DOI 10.1128/MCB.8.11.4877; PHILIPPE J, 1995, MOL ENDOCRINOL, V9, P368, DOI 10.1210/me.9.3.368; PHILIPPE J, 1994, MOL CELL BIOL, V14, P3514, DOI 10.1128/MCB.14.5.3514; POWERS AC, 1990, DIABETES, V39, P406, DOI 10.2337/diabetes.39.4.406; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; RORSMAN P, 1988, J GEN PHYSIOL, V91, P223, DOI 10.1085/jgp.91.2.223; RORSMAN P, 1988, J GEN PHYSIOL, V91, P243, DOI 10.1085/jgp.91.2.243; Sander M, 1997, GENE DEV, V11, P1662, DOI 10.1101/gad.11.13.1662; SANTERRE RF, 1981, P NATL ACAD SCI-BIOL, V78, P4339, DOI 10.1073/pnas.78.7.4339; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SCHREIBER SL, 1992, IMMUNOL TODAY, V13, P136, DOI 10.1016/0167-5699(92)90111-J; SCHWANINGER M, 1993, J BIOL CHEM, V268, P23111; SCHWANINGER M, 1995, J BIOL CHEM, V270, P8860, DOI 10.1074/jbc.270.15.8860; SCHWANINGER M, 1993, J BIOL CHEM, V268, P5168; SCHWANINGER M, 1993, N-S ARCH PHARMACOL, V348, P541; SHENG M, 1988, MOL CELL BIOL, V8, P2787, DOI 10.1128/MCB.8.7.2787; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; Shibasaki F, 1996, NATURE, V382, P370, DOI 10.1038/382370a0; SUN P, 1996, J BIOL CHEM, V271, P30066; Timmerman LA, 1996, NATURE, V383, P837, DOI 10.1038/383837a0; UNGER RH, 1981, NEW ENGL J MED, V304, P1518, DOI 10.1056/NEJM198106183042504; WEGNER M, 1992, SCIENCE, V256, P370, DOI 10.1126/science.256.5055.370; WEINSTEIN DC, 1994, CELL, V78, P575, DOI 10.1016/0092-8674(94)90523-1; Wolfe SA, 1997, NATURE, V385, P172, DOI 10.1038/385172a0; Wrege Antje, 1995, Gene Expression, V4, P205; YANEY GC, 1992, MOL ENDOCRINOL, V6, P2143, DOI 10.1210/me.6.12.2143	73	41	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 26	1999	274	9					5851	5860		10.1074/jbc.274.9.5851	http://dx.doi.org/10.1074/jbc.274.9.5851			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	170KG	10026208	hybrid			2022-12-25	WOS:000078804400079
J	Shi, YG; An, J; Liang, JD; Hayes, SE; Sandusky, GE; Stramm, LE; Yang, NN				Shi, YG; An, J; Liang, JD; Hayes, SE; Sandusky, GE; Stramm, LE; Yang, NN			Characterization of a mutant pancreatic eIF-2 alpha kinase, PEK, and co-localization with somatostatin in islet delta cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; STRANDED-RNA-BINDING; INSULIN GENE-EXPRESSION; INITIATION FACTOR-II; SACCHAROMYCES-CEREVISIAE; TRANSLATIONAL CONTROL; MOLECULAR-CLONING; INTERFERON ACTION; PKR; CDNA	Phosphorylation of eukaryotic translation initiation factor-2 alpha (eIF-2 alpha) is one of the key steps where protein synthesis is regulated in response to changes in environmental conditions. The phosphorylation is carried out in part by three distinct eIF-2 alpha kinases including mammalian double-stranded RNA-dependent eIF-2 alpha: kinase (PKR) and heme-regulated inhibitor kinase (HRI), and yeast GCN2. We report the identification and characterization of a related kinase, PEK, which shares common features with other eIF-2 alpha kinases including phosphorylation of eIF-2 alpha in vitro, We show that human PEK is regulated by different mechanisms than PKR or HRI, In contrast to PKR or HRI, which are dependent on autophosphorylation for their kinase activity, a point mutation that replaced the conserved Lys-614 with an alanine completely abolished the eIF-2 alpha: kinase activity, whereas the mutant PEK was still autophosphorylated when expressed in Sf-9 cells. Northern blot analysis indicates that PEK mRNA was predominantly expressed in pancreas, though low expression was also present in several tissues. Consistent with the high levels of mRNA in pancreas, the PEK protein was only detected in human pancreatic islets, and the kinase co-localized with somatostatin, a pancreatic delta cell-specific hormone. Thus PEK is believed to play an important role in regulating protein synthesis in the pancreatic islet, especially in islet delta cells.	Eli Lilly & Co, Diabet Res, Lilly Res Labs, Div Endocrine, Indianapolis, IN 46285 USA	Eli Lilly	Shi, YG (corresponding author), Eli Lilly & Co, Diabet Res, Lilly Res Labs, Div Endocrine, DC 0545, Indianapolis, IN 46285 USA.							BARBER GN, 1992, VIROLOGY, V191, P670, DOI 10.1016/0042-6822(92)90242-H; BONNERWEIR S, 1994, JOSLINS DIABETES MEL; Cai RR, 1998, J BIOL CHEM, V273, P11274, DOI 10.1074/jbc.273.18.11274; CHEFALO PJ, 1994, J BIOL CHEM, V269, P25788; CHEN JJ, 1995, TRENDS BIOCHEM SCI, V20, P105, DOI 10.1016/S0968-0004(00)88975-6; CHEN JJ, 1991, P NATL ACAD SCI USA, V88, P7729, DOI 10.1073/pnas.88.17.7729; CLEMENS MJ, 1987, J BIOL CHEM, V262, P767; Clemens MJ, 1996, TRANSLATIONAL CONTRO, P139; CROSBY JS, 1994, MOL CELL BIOL, V14, P3906, DOI 10.1128/MCB.14.6.3906; deHaro C, 1996, FASEB J, V10, P1378, DOI 10.1096/fasebj.10.12.8903508; Dever TE, 1998, P NATL ACAD SCI USA, V95, P4164, DOI 10.1073/pnas.95.8.4164; DEVER TE, 1993, P NATL ACAD SCI USA, V90, P4616, DOI 10.1073/pnas.90.10.4616; FELDHOFF RC, 1993, PREP BIOCHEM, V23, P363, DOI 10.1080/10826069308544562; FENG GS, 1992, P NATL ACAD SCI USA, V89, P5447, DOI 10.1073/pnas.89.12.5447; GEBALLE AP, 1996, TRANSLATIONAL CONTRO, P173; Gilligan M, 1996, J BIOL CHEM, V271, P2121, DOI 10.1074/jbc.271.4.2121; GOODISON S, 1992, BIOCHEM J, V285, P563, DOI 10.1042/bj2850563; GRIMALDI KA, 1987, BIOCHEM J, V245, P567, DOI 10.1042/bj2450567; GUEST PC, 1989, BIOCHEM J, V257, P431, DOI 10.1042/bj2570431; GUEST PC, 1991, BIOCHEM J, V274, P73, DOI 10.1042/bj2740073; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; HIDDINGA HJ, 1988, SCIENCE, V241, P451, DOI 10.1126/science.3393910; Hinnebusch AG, 1997, J BIOL CHEM, V272, P21661, DOI 10.1074/jbc.272.35.21661; Hinnebusch Alan G., 1994, Seminars in Cell Biology, V5, P417, DOI 10.1006/scel.1994.1049; ICELY PL, 1991, J BIOL CHEM, V266, P16073; JEFFREY IW, 1995, EXP CELL RES, V218, P17, DOI 10.1006/excr.1995.1126; KATZE MG, 1991, MOL CELL BIOL, V11, P5497, DOI 10.1128/MCB.11.11.5497; KOZAK M, 1991, J BIOL CHEM, V266, P19867; Mathews M. B., 1996, TRANSLATIONAL CONTRO, P1; MELLOR H, 1994, J BIOL CHEM, V269, P10201; MELLOR H, 1994, BBA-GENE STRUCT EXPR, V1219, P693, DOI 10.1016/0167-4781(94)90229-1; Merrick WC., 1996, TRANSLATION CONTROL, P31; MEURS E, 1990, CELL, V62, P379, DOI 10.1016/0092-8674(90)90374-N; MEURS EF, 1993, P NATL ACAD SCI USA, V90, P232, DOI 10.1073/pnas.90.1.232; Mohrle JJ, 1997, BIOCHEM J, V328, P677; NIELSEN DA, 1985, J BIOL CHEM, V260, P3585; OLMSTED EA, 1993, J BIOL CHEM, V268, P12552; Olsen DS, 1998, GENETICS, V149, P1495; PROUD CG, 1995, TRENDS BIOCHEM SCI, V20, P241, DOI 10.1016/S0968-0004(00)89025-8; ROMANO PR, 1995, MOL CELL BIOL, V15, P365, DOI 10.1128/MCB.15.1.365; Romano PR, 1998, MOL CELL BIOL, V18, P2282, DOI 10.1128/MCB.18.4.2282; ROUSSOU I, 1988, MOL CELL BIOL, V8, P2132, DOI 10.1128/MCB.8.5.2132; Sambrook J., 2002, MOL CLONING LAB MANU; SAMUEL CE, 1993, J BIOL CHEM, V268, P7603; Samuel CE, 1997, INT J HEMATOL, V65, P227; Santoyo J, 1997, J BIOL CHEM, V272, P12544, DOI 10.1074/jbc.272.19.12544; SARRE TF, 1989, BIOCHEM J, V262, P569, DOI 10.1042/bj2620569; Shi YG, 1998, MOL CELL BIOL, V18, P7499, DOI 10.1128/MCB.18.12.7499; Taylor DR, 1996, MOL CELL BIOL, V16, P6295; THOMIS DC, 1992, VIROLOGY, V188, P33, DOI 10.1016/0042-6822(92)90732-5; THOMIS DC, 1993, J VIROL, V67, P7695, DOI 10.1128/JVI.67.12.7695-7700.1993; WEK RC, 1994, TRENDS BIOCHEM SCI, V19, P491, DOI 10.1016/0968-0004(94)90136-8; WEK RC, 1989, P NATL ACAD SCI USA, V86, P4579, DOI 10.1073/pnas.86.12.4579; Williams BRG, 1997, BIOCHEM SOC T, V25, P509, DOI 10.1042/bst0250509; Yang YL, 1995, EMBO J, V14, P6095, DOI 10.1002/j.1460-2075.1995.tb00300.x; Zhu SH, 1997, J BIOL CHEM, V272, P14434, DOI 10.1074/jbc.272.22.14434; Zhu SH, 1998, J BIOL CHEM, V273, P1808, DOI 10.1074/jbc.273.3.1808	57	55	61	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 26	1999	274	9					5723	5730		10.1074/jbc.274.9.5723	http://dx.doi.org/10.1074/jbc.274.9.5723			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	170KG	10026192	hybrid			2022-12-25	WOS:000078804400063
J	Takeo, J; Yamashita, S				Takeo, J; Yamashita, S			Two distinct isoforms of cDNA encoding rainbow trout androgen receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR-TFIIB; GLUCOCORTICOID RECEPTOR; ESTROGEN-RECEPTOR; SEX CONTROL; FISH; GENE; BINDING; CLONING; SUPERFAMILY; COACTIVATOR	Androgens play an important role in male sexual differentiation and development, The activity of androgens is mediated by an androgen receptor (AR), which binds to specific DNA recognition sites and regulates transcription. We describe here the isolation of two distinct rainbow trout cDNA clones, designated rtAR-alpha: and rtAR-beta, which contain the entire androgen receptor coding region. Comparison of the predicted amino acid sequence of rtAR-alpha to that of rtAR-beta revealed 85% identity. interestingly, despite this high homology, rtAR-alpha activated transcription of an androgen-responsive reporter gene in co-transfection assays, but rtAR-beta did not. These results suggest that rainbow trout contains two distinct isoforms of androgen receptors whose functions differ. The region of rtAR-beta responsible for its inactivity was mapped to its ligand binding domain by analyzing chimeras of the rtAR-alpha, rtAR-beta, and rtGR-I (glucocorticoid) receptors. Alteration of any one of three out of four segments within this domain restored activity. Extracts made from COS-I cells transfected with an rtAR-alpha expression plasmid produced a high level of [H-3]mibolerone binding, whereas no binding was observed by extracts of cells transfected with an rtAR-beta expression plasmid. These data demonstrate that the lack of transactivation activity of rtAR-beta is due to its inability to bind hormone.	Nippon Suisan Kaisha Ltd, Cent Res Lab, Hachioji, Tokyo 1920906, Japan	Nippon Suisan Kaisha, Ltd.	Yamashita, S (corresponding author), Nippon Suisan Kaisha Ltd, Cent Res Lab, 559-6 Kitanomachi, Hachioji, Tokyo 1920906, Japan.	KYE00332@nifty.ne.jp						BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; CHANG CS, 1988, P NATL ACAD SCI USA, V85, P7211, DOI 10.1073/pnas.85.19.7211; CHANG CS, 1995, CRIT REV EUKAR GENE, V5, P97, DOI 10.1615/CritRevEukarGeneExpr.v5.i2.10; DONALDSON EM, 1982, CAN J FISH AQUAT SCI, V39, P99, DOI 10.1139/f82-012; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FABER PW, 1991, BIOCHEM J, V278, P269, DOI 10.1042/bj2780269; FIJAN N, 1983, ANN INST PASTEUR VIR, V134, P207, DOI 10.1016/S0769-2617(83)80060-4; HAM J, 1988, NUCLEIC ACIDS RES, V16, P5263, DOI 10.1093/nar/16.12.5263; Hata J, 1997, J BIOL CHEM, V272, P7285, DOI 10.1074/jbc.272.11.7285; Hata J, 1997, FISHERIES SCI, V63, P1050, DOI 10.2331/fishsci.63.1050; Hong H, 1996, P NATL ACAD SCI USA, V93, P4948, DOI 10.1073/pnas.93.10.4948; HUNTER GA, 1983, FISH PHYSIOL, V9, P223; HUNTER GA, 1982, T AM FISH SOC, V111, P367, DOI 10.1577/1548-8659(1982)111&lt;367:POAASC&gt;2.0.CO;2; JOHNSTONE R, 1979, AQUACULTURE, V18, P13, DOI 10.1016/0044-8486(79)90096-6; Kuiper GGJM, 1996, P NATL ACAD SCI USA, V93, P5925, DOI 10.1073/pnas.93.12.5925; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Mosselman S, 1996, FEBS LETT, V392, P49, DOI 10.1016/0014-5793(96)00782-X; RIEGMAN PHJ, 1991, MOL ENDOCRINOL, V5, P1921, DOI 10.1210/mend-5-12-1921; SCHEIDEREIT C, 1986, DNA-J MOLEC CELL BIO, V5, P383, DOI 10.1089/dna.1986.5.383; STRAHLE U, 1987, P NATL ACAD SCI USA, V84, P7871, DOI 10.1073/pnas.84.22.7871; Takeo J, 1996, FEBS LETT, V389, P244, DOI 10.1016/0014-5793(96)00596-0; TILLEY WD, 1989, P NATL ACAD SCI USA, V86, P327, DOI 10.1073/pnas.86.1.327; YAMADA S, 1993, J BIOL CHEM, V268, P24361; Yamamoto T. O., 1969, P117; YAMASHITA S, 1993, SCIENCE, V261, P463, DOI 10.1126/science.8332911; YAMASHITA S, 1992, P NATL ACAD SCI USA, V89, P2839, DOI 10.1073/pnas.89.7.2839; Yeh SY, 1996, P NATL ACAD SCI USA, V93, P5517, DOI 10.1073/pnas.93.11.5517	28	98	106	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 26	1999	274	9					5674	5680		10.1074/jbc.274.9.5674	http://dx.doi.org/10.1074/jbc.274.9.5674			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	170KG	10026186	hybrid			2022-12-25	WOS:000078804400057
J	Urban, S; Kruse, C; Multhaup, G				Urban, S; Kruse, C; Multhaup, G			A soluble form of the avian hepatitis B virus receptor - Biochemical characterization and functional analysis of the receptor ligand complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBOXYPEPTIDASE-D; INFECTION; PROTEIN; SEQUENCE; GLYCOPROTEIN; HEPATOCYTES; REPLICATION; PARTICLES; BINDING; MEMBER	Avian hepatitis B virus infection is initiated by the specific interaction of the extracellular preS part of the large viral envelope protein with carboxypeptidase D (gp180), the primary cellular receptor. To functionally and biochemically characterize this interaction, we purified a soluble form of duck carboxypeptidase D from a baculovirus expression system, confirmed its receptor function, and investigated the contribution of different preS sequence elements to receptor binding by surface plasmon resonance analysis. We found that preS binds duck carboxypeptidase D with a 1:1 stoichiometry, thereby inducing conformational changes but not oligomerization, The association constant of the complex was determined to be 2.2 x 10(7) M-1 at 37 degrees C, pH 7.4, with an association rate of 4.0 x 10(4) M-1 s(-1) and a dissociation rate of 1.9 x 10(-3) s(-1), substantiating high affinity interaction of avihepadnaviruses with their receptor carboxypeptidase D, The separately expressed receptor-binding domain, comprising about 50% of preS as defined by mutational analysis, exhibits similar constants. The domain consists of an essential element, probably responsible for the initial receptor contact and a part that contributes to complex stabilization in a conformation sensitive manner. Together with previous results from cell biological studies these data provide new insights into the initial step of hepadnaviral infection.	Univ Heidelberg, Zentrum Mol Biol, ZMBH, D-69120 Heidelberg, Germany	Ruprecht Karls University Heidelberg	Urban, S (corresponding author), Univ Heidelberg, Zentrum Mol Biol, ZMBH, Neuenheimer Feld 282, D-69120 Heidelberg, Germany.							Breiner KM, 1998, J VIROL, V72, P8098, DOI 10.1128/JVI.72.10.8098-8104.1998; Bruns M, 1998, J VIROL, V72, P1462, DOI 10.1128/JVI.72.2.1462-1468.1998; DeMeyer S, 1997, J VIRAL HEPATITIS, V4, P145, DOI 10.1046/j.1365-2893.1997.00126.x; Eng FJ, 1998, J BIOL CHEM, V273, P8382, DOI 10.1074/jbc.273.14.8382; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; HEUKESHOVEN J, 1988, ELECTROPHORESIS, V9, P28, DOI 10.1002/elps.1150090106; Hildt E, 1996, SEMIN VIROL, V7, P333, DOI 10.1006/smvy.1996.0041; HITCHCOCK M, 1964, BIOCHEM J, V93, P392, DOI 10.1042/bj0930392; ISHIKAWA T, 1994, VIROLOGY, V202, P1061, DOI 10.1006/viro.1994.1440; Jilbert AR, 1996, VIROLOGY, V226, P338, DOI 10.1006/viro.1996.0661; KLINGMULLER U, 1993, J VIROL, V67, P7414; KUROKI K, 1995, J BIOL CHEM, V270, P15022, DOI 10.1074/jbc.270.25.15022; KUROKI K, 1994, J VIROL, V68, P2091, DOI 10.1128/JVI.68.4.2091-2096.1994; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MASON WS, 1991, CURRENT TOP MICROBIO, V168; McGwire GB, 1997, LIFE SCI, V60, P715, DOI 10.1016/S0024-3205(96)00642-X; Nassal M, 1996, J VIRAL HEPATITIS, V3, P217, DOI 10.1111/j.1365-2893.1996.tb00047.x; Nassal M, 1993, Trends Microbiol, V1, P221, DOI 10.1016/0966-842X(93)90136-F; OReilly D.R., 1992, BACULOVIRUS EXPRESSI; PLUMMER TH, 1978, J BIOL CHEM, V253, P3907; RIGG RJ, 1992, J VIROL, V66, P2829, DOI 10.1128/JVI.66.5.2829-2836.1992; SONG LX, 1995, J BIOL CHEM, V270, P25007, DOI 10.1074/jbc.270.42.25007; Song LX, 1996, J BIOL CHEM, V271, P28884, DOI 10.1074/jbc.271.46.28884; Swameye I, 1997, J VIROL, V71, P9434, DOI 10.1128/JVI.71.12.9434-9441.1997; Tan FL, 1997, BIOCHEM J, V327, P81, DOI 10.1042/bj3270081; TONG SP, 1995, J VIROL, V69, P7106, DOI 10.1128/JVI.69.11.7106-7112.1995; TUTTLEMAN JS, 1986, J VIROL, V58, P17, DOI 10.1128/JVI.58.1.17-25.1986; Urban S, 1998, J VIROL, V72, P8089, DOI 10.1128/JVI.72.10.8089-8097.1998; Varlamov O, 1998, J CELL SCI, V111, P877; Xin XN, 1997, DNA CELL BIOL, V16, P897, DOI 10.1089/dna.1997.16.897	30	14	15	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 26	1999	274	9					5707	5715		10.1074/jbc.274.9.5707	http://dx.doi.org/10.1074/jbc.274.9.5707			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	170KG	10026190	hybrid			2022-12-25	WOS:000078804400061
J	Uchida, H; Downing, JR; Miyazaki, Y; Frank, R; Zhang, J; Nimer, SD				Uchida, H; Downing, JR; Miyazaki, Y; Frank, R; Zhang, J; Nimer, SD			Three distinct domains in TEL-AML1 are required for transcriptional repression of the IL-3 promoter	ONCOGENE			English	Article						transcription; repression; TEL-AML1	ACUTE LYMPHOBLASTIC-LEUKEMIA; COLONY-STIMULATING FACTOR; ACUTE LYMPHOCYTIC-LEUKEMIA; FETAL LIVER HEMATOPOIESIS; T(8-21) FUSION PROTEIN; ACUTE MYELOID-LEUKEMIA; HUMAN RECOMBINANT IL-3; CORE BINDING-FACTOR; MYELOPROLIFERATIVE DISORDERS; CHROMOSOMAL TRANSLOCATION	A cytogenetically cryptic (12;21) translocation is the most common molecular abnormality identified in childhood acute lymphoblastic leukemia (ALL), and it generates a chimeric TEL-AML1 protein. Fusion of the Helix-Loop-Helix (HLH) (also called the pointed) domain of TEL to AML1 has been suggested to convert AML1 from a transcriptional activator to a repressor. To define the structural features of this chimeric protein required for repression, we analysed the transcriptional activity of a series of TEL-AML1 mutants on the AML1-responsive interleukin-3 (IL-3) promoter, potentially relevant gene target. Our results demonstrate that TEL-AML1 represses basal IL-3 promoter activity in lymphoid cells, and deletion mutant analysis identified three distinct domains of TEL-AML1 that are required for repression; the HLH (pointed) motif contained in the TEL portion of TEL-AML1, and both the runt homology domain (Rhd) and the 74 amino acids downstream of the Rhd that are present in the AML1 portion of the fusion protein. Although AML1B (and a shorter AML1 isoform, AML1A) have transcriptional activating activity on the IL-3 promoter, fusion of the AML1 gene to the TEL gene generates a repressor of IL-3 expression. Consistent with this activity, freshly isolated human ALL cells that contain TEL-AML1 do not express IL-3.	Mem Sloan Kettering Canc Ctr, Lab Mol Aspects Hematopoiesis, New York, NY 10021 USA; St Jude Childrens Res Hosp, Dept Pathol, Memphis, TN 38109 USA	Memorial Sloan Kettering Cancer Center; St Jude Children's Research Hospital	Nimer, SD (corresponding author), Mem Sloan Kettering Canc Ctr, Lab Mol Aspects Hematopoiesis, 1275 York Ave, New York, NY 10021 USA.		Downing, James R./N-8102-2018		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK052208, R01DK052208, R01DK043025] Funding Source: NIH RePORTER; NCI NIH HHS [CA 70388] Funding Source: Medline; NIDDK NIH HHS [DK 52208, DK43025] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aguiar RCT, 1996, BRIT J HAEMATOL, V95, P673, DOI 10.1046/j.1365-2141.1996.d01-1946.x; Bruhn L, 1997, GENE DEV, V11, P640, DOI 10.1101/gad.11.5.640; BUIJS A, 1995, ONCOGENE, V10, P1511; CANN AJ, 1988, ONCOGENE, V3, P123; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; ERICKSON P, 1992, BLOOD, V80, P1825; Fears S, 1997, P NATL ACAD SCI USA, V94, P1949, DOI 10.1073/pnas.94.5.1949; Frank R, 1995, ONCOGENE, V11, P2667; GOLUB TR, 1994, CELL, V77, P307, DOI 10.1016/0092-8674(94)90322-0; GOLUB TR, 1995, P NATL ACAD SCI USA, V92, P4917, DOI 10.1073/pnas.92.11.4917; GRIMALDI JC, 1989, BLOOD, V73, P2081; He LZ, 1998, NAT GENET, V18, P126, DOI 10.1038/ng0298-126; Hiebert SW, 1996, MOL CELL BIOL, V16, P1349; KINASHI T, 1988, P NATL ACAD SCI USA, V85, P4473, DOI 10.1073/pnas.85.12.4473; Kitabayashi I, 1998, EMBO J, V17, P2994, DOI 10.1093/emboj/17.11.2994; Klampfer L, 1996, P NATL ACAD SCI USA, V93, P14059, DOI 10.1073/pnas.93.24.14059; LENNY N, 1995, ONCOGENE, V11, P1761; LIU P, 1993, SCIENCE, V261, P1041, DOI 10.1126/science.8351518; McLean TW, 1996, BLOOD, V88, P4252; MEEKER TC, 1990, BLOOD, V76, P285; MEYERS S, 1995, MOL CELL BIOL, V15, P1974; MEYERS S, 1993, MOL CELL BIOL, V13, P6336, DOI 10.1128/MCB.13.10.6336; MITANI K, 1994, EMBO J, V13, P504, DOI 10.1002/j.1460-2075.1994.tb06288.x; MIYATAKE S, 1985, EMBO J, V4, P2561, DOI 10.1002/j.1460-2075.1985.tb03971.x; Miyazaki Y, 1996, ONCOGENE, V13, P1721; MIYOSHI H, 1991, P NATL ACAD SCI USA, V88, P10431, DOI 10.1073/pnas.88.23.10431; NIMER SD, 1995, STEM CELLS, V13, P324, DOI 10.1002/stem.5530130402; NUCIFORA G, 1995, BLOOD, V86, P1; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; PAPADOPOULOS P, 1995, CANCER RES, V55, P34; Peeters P, 1997, CANCER RES, V57, P564; Peeters P, 1997, BLOOD, V90, P2535, DOI 10.1182/blood.V90.7.2535.2535_2535_2540; Raynaud S, 1996, LEUKEMIA, V10, P1529; Rhoades KL, 1996, P NATL ACAD SCI USA, V93, P11895, DOI 10.1073/pnas.93.21.11895; ROGERS SY, 1994, EXP HEMATOL, V22, P593; ROMANA SP, 1995, BLOOD, V85, P3662, DOI 10.1182/blood.V85.12.3662.bloodjournal85123662; ROMANA SP, 1995, BLOOD, V86, P4263, DOI 10.1182/blood.V86.11.4263.bloodjournal86114263; Sasaki K, 1996, P NATL ACAD SCI USA, V93, P12359, DOI 10.1073/pnas.93.22.12359; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; Shih LY, 1996, LEUKEMIA, V10, P1456; Shurtleff SA, 1995, LEUKEMIA, V9, P1985; TADMORI W, 1989, J IMMUNOL, V142, P1950; Uchida H, 1997, J IMMUNOL, V158, P2251; Wang Q, 1996, CELL, V87, P697, DOI 10.1016/S0092-8674(00)81389-6; Wang Q, 1996, P NATL ACAD SCI USA, V93, P3444, DOI 10.1073/pnas.93.8.3444; WOLIN M, 1993, ONCOGENE, V8, P1905; WOTTON D, 1994, MOL CELL BIOL, V14, P840, DOI 10.1128/MCB.14.1.840; XIA X, 1992, J IMMUNOL, V148, P491; Yamagata T, 1996, MOL CELL BIOL, V16, P1283; YANG YC, 1986, CELL, V47, P3, DOI 10.1016/0092-8674(86)90360-0; Yonemura Y, 1996, P NATL ACAD SCI USA, V93, P4040, DOI 10.1073/pnas.93.9.4040; Zeng CM, 1997, P NATL ACAD SCI USA, V94, P6746, DOI 10.1073/pnas.94.13.6746; Zent CS, 1996, P NATL ACAD SCI USA, V93, P1044, DOI 10.1073/pnas.93.3.1044; Zhang DE, 1996, MOL CELL BIOL, V16, P1231	54	49	49	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 28	1999	18	4					1015	1022		10.1038/sj.onc.1202383	http://dx.doi.org/10.1038/sj.onc.1202383			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	165FT	10023677				2022-12-25	WOS:000078510600018
J	Huang, HB; Horiuchi, A; Watanabe, T; Shih, SR; Tsay, HJ; Li, HC; Greengard, P; Nairn, AC				Huang, HB; Horiuchi, A; Watanabe, T; Shih, SR; Tsay, HJ; Li, HC; Greengard, P; Nairn, AC			Characterization of the inhibition of protein phosphatase-1 by DARPP-32 and inhibitor-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAMP-REGULATED PHOSPHOPROTEIN; SITE-DIRECTED MUTAGENESIS; RABBIT SKELETAL-MUSCLE; CATALYTIC SUBUNIT; PHOSPHORYLATION; EXPRESSION; MECHANISM; BINDING; CLONING; TYPE-1	Phospho-DARPP-32 (where DARPP-32 is dopamine-and cAMP-regulated phosphoprotein, M-r 32,000), its homolog, phospho-inhibitor-l, and inhibitor-a are potent inhibitors (IC50 similar to 1 nM) of the catalytic subunit of protein phosphatase-l (PP1), Our previous studies have indicated that a region encompassing residues 6-11 (RKKIQF) and phospho-Thr-34, of phospho-DARPP-32, interacts with PP1, However, little is known about specific regions of inhibitor-a that interact with PP1, We have now characterized in detail the interaction of phospho-DARPP-32 and inhibitor-a with PP1, Mutagenesis studies indicate that within DARPP-32 Phe-11 and Ile-9 play critical roles, with Lys-7 playing a lesser role in inhibition of PP1, Pro-33 and Pro-35 are also important, as is the number of amino acids between residues 7 and 11 and phospho-Thr-34, For inhibitor-a, deletion of amino acids 1-8 (I2-(9-204)) or 100-204 (12-(1-99)) had little effect on the ability of the mutant proteins to inhibit PP1, Further deletion of residues 9-13 (12-(14-204)) resulted in a large decrease in inhibitory potency (IC50 similar to 800 nm), whereas further COOH-terminal deletion (12(1-84)) caused a moderate decrease in inhibitory potency (IC50 similar to 10 nM), Within residues 9-13 (PIKGI), mutagenesis indicated that Ile-10, Lys-11, and Ile-13 play critical roles. The peptide I2-(6-20) antagonized the inhibition of PP-1 by inhibitor-2 but had no effect on inhibition by phospho-DARPP-32, In contrast, the peptide D32-(6-38) antagonized the inhibition of PP1 by phospho-DARPP-32, inhibitor-2, and I2-(1-120) but not I2-(85204), These results indicate that distinct amino acid motifs contained within the NH, termini of phospho-DARPP-32 (KKIQF, where italics indicate important residues) and inhibitor-2 (IKGI) are critical for inhibition of PP1. Moreover, residues 14-84 of inhibitor-a and residues 6-38 of phospho-DARPP-32 share elements that are important for interaction with PP1.	Rockefeller Univ, Mol & Cellular Neurosci Lab, New York, NY 10021 USA; Chi Coll Med & Humanities, Inst Biochem, Hualien 970, Taiwan; Natl Yang Ming Univ, Inst Neurosci, Taipei 112, Taiwan; CUNY Mt Sinai Sch Med, Dept Biochem, New York, NY 10029 USA	Rockefeller University; Tzu Chi University; National Yang Ming Chiao Tung University; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Nairn, AC (corresponding author), Rockefeller Univ, Mol & Cellular Neurosci Lab, 1230 York Ave, New York, NY 10021 USA.	nairn@rockvax.rockefeller.edu		Nairn, Angus/0000-0002-7075-0195	NATIONAL INSTITUTE OF MENTAL HEALTH [P01MH040899] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [P01DA010044] Funding Source: NIH RePORTER; NIDA NIH HHS [P01 DA010044] Funding Source: Medline; NIMH NIH HHS [MH 40899] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Allen PB, 1997, P NATL ACAD SCI USA, V94, P9956, DOI 10.1073/pnas.94.18.9956; Allen PB, 1998, J BIOL CHEM, V273, P4089, DOI 10.1074/jbc.273.7.4089; BRAUTIGAN DL, 1990, NATURE, V344, P74, DOI 10.1038/344074a0; Campos M, 1996, J BIOL CHEM, V271, P28478, DOI 10.1074/jbc.271.45.28478; COHEN P, 1988, METHOD ENZYMOL, V159, P390; DESDOUITS F, 1995, BIOCHEM BIOPH RES CO, V206, P652, DOI 10.1006/bbrc.1995.1092; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; Egloff MP, 1997, EMBO J, V16, P1876, DOI 10.1093/emboj/16.8.1876; Endo S, 1996, BIOCHEMISTRY-US, V35, P5220, DOI 10.1021/bi952940f; Endo S, 1997, BIOCHEMISTRY-US, V36, P6986, DOI 10.1021/bi970418i; Faux MC, 1996, TRENDS BIOCHEM SCI, V21, P312, DOI 10.1016/0968-0004(96)10040-2; FOULKES JG, 1983, EUR J BIOCHEM, V132, P309, DOI 10.1111/j.1432-1033.1983.tb07363.x; GIRAULT JA, 1989, J BIOL CHEM, V264, P21748; GOLDBERG J, 1995, NATURE, V376, P745, DOI 10.1038/376745a0; He B, 1997, P NATL ACAD SCI USA, V94, P843, DOI 10.1073/pnas.94.3.843; Helps NR, 1995, FEBS LETT, V377, P295, DOI 10.1016/0014-5793(95)01347-4; HELPS NR, 1994, FEBS LETT, V340, P93, DOI 10.1016/0014-5793(94)80179-7; HEMMINGS HC, 1990, J BIOL CHEM, V265, P20369; Hirano K, 1996, FEBS LETT, V389, P191, DOI 10.1016/0014-5793(96)00577-7; Hirano K, 1997, J BIOL CHEM, V272, P3683, DOI 10.1074/jbc.272.6.3683; HOLMES CFB, 1986, EUR J BIOCHEM, V155, P173, DOI 10.1111/j.1432-1033.1986.tb09473.x; Huang HB, 1997, P NATL ACAD SCI USA, V94, P3530, DOI 10.1073/pnas.94.8.3530; HUBBARD MJ, 1993, TRENDS BIOCHEM SCI, V18, P172, DOI 10.1016/0968-0004(93)90109-Z; Johnson DF, 1996, EUR J BIOCHEM, V239, P317, DOI 10.1111/j.1432-1033.1996.0317u.x; KACZMAREK LK, 1980, P NATL ACAD SCI-BIOL, V77, P7487, DOI 10.1073/pnas.77.12.7487; Kakinoki Y, 1997, J BIOL CHEM, V272, P32308, DOI 10.1074/jbc.272.51.32308; KISSINGER CR, 1995, NATURE, V378, P641, DOI 10.1038/378641a0; Kreivi JP, 1997, FEBS LETT, V420, P57, DOI 10.1016/S0014-5793(97)01485-3; Kwon YG, 1997, P NATL ACAD SCI USA, V94, P3536, DOI 10.1073/pnas.94.8.3536; MACKINTOSH C, 1990, FEBS LETT, V264, P187, DOI 10.1016/0014-5793(90)80245-E; OHKURA H, 1991, CELL, V64, P149, DOI 10.1016/0092-8674(91)90216-L; PARK IK, 1994, J BIOL CHEM, V269, P28919; PARK IK, 1994, J BIOL CHEM, V269, P944; PICKING WD, 1991, BIOCHEMISTRY-US, V30, P10280, DOI 10.1021/bi00106a028; SHENOLIKAR S, 1991, ADV SEC MESS PHOSPH, V23, P1; SHENOLIKAR S, 1994, ANNU REV CELL BIOL, V10, P55, DOI 10.1146/annurev.cellbio.10.1.55; SILVA EFDE, 1995, J NEUROSCI, V15, P3375; TUNG HYL, 1995, MOL CELL BIOL, V15, P6064; Van Eynde A, 1995, J BIOL CHEM, V270, P28068, DOI 10.1074/jbc.270.47.28068; WERA S, 1995, BIOCHEM J, V311, P17, DOI 10.1042/bj3110017; Yang J, 1998, FASEB J, V12, pA1407; Zhao SM, 1997, J BIOL CHEM, V272, P28368, DOI 10.1074/jbc.272.45.28368	42	119	120	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	1999	274	12					7870	7878		10.1074/jbc.274.12.7870	http://dx.doi.org/10.1074/jbc.274.12.7870			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	178LU	10075680	hybrid			2022-12-25	WOS:000079268100039
J	Kraner, SD; Rich, MM; Sholl, MA; Zhou, HY; Zorc, CS; Kallen, RG; Barchi, RL				Kraner, SD; Rich, MM; Sholl, MA; Zhou, HY; Zorc, CS; Kallen, RG; Barchi, RL			Interaction between the skeletal muscle type 1 Na+ channel promoter E-box and an upstream repressor element - Release of repression by myogenin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR EPSILON-SUBUNIT; MONOCLONAL-ANTIBODIES; SODIUM-CHANNELS; GENE; TRANSCRIPTION; EXPRESSION; LOCALIZATION; ADENOVIRUS; ACTIVATION; ENHANCER	We have defined how four elements that regulate expression of the rat skeletal muscle type 1 sodium channel (SkM1) gene cooperate to yield specific expression in differentiated muscle. A basal promoter region containing within it a promoter E-box (-31/-26) is broadly expressed in many cells, including myoblasts and myotubes; mutations within the promoter E-box that disrupt binding of the myogenic basic helix-loop-helix (bHLH) factors reduce expression in all cell types only slightly. Sequential addition of upstream elements to the wildtype promoter confer increasing specificity of expression in differentiated cells, even though all three upstream elements, including a positive element (-85/-57), a repressor E-box (-90/-85), and upstream repressor sequences (-135/-95), bind ubiquitously expressed transcription factors. Mutations in the promoter E-box that disrupt the binding of the bHLH factors counteract the specificity conferred by addition of the upstream elements, with the greatest interaction observed between the upstream repressor sequences and the promoter E-box, Forced expression of myogenin in myoblasts releases repression exerted by the upstream repressor sequences in conjunction with the wild-type, but not mutant, promoter E-box, and also initiates expression of the endogenous SkM1 protein. Our data suggest that particular myogenic bHLH proteins bound at the promoter E-box control expression of SkM1 by releasing repression exerted by upstream repressor sequences in differentiated muscle cells.	Univ Penn, Sch Med, Dept Neurosci, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Neurol, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Biochem & Biophys, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania	Kraner, SD (corresponding author), Univ Penn, Sch Med, Dept Neurosci, 223 Stemmler Hall,36th & Hamilton Walk, Philadelphia, PA 19104 USA.	kraner@mail.med.upenn.edu			NINDS NIH HHS [NS-01852, NS-34954] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [K08NS001852, R01NS034954] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BANERJEEBASU S, 1993, MOL CELL BIOL, V13, P7019, DOI 10.1128/MCB.13.11.7019; BARR E, 1994, GENE THER, V1, P51; BERBERICH C, 1993, EUR J BIOCHEM, V216, P395, DOI 10.1111/j.1432-1033.1993.tb18157.x; CASADEI JM, 1984, P NATL ACAD SCI-BIOL, V81, P6227, DOI 10.1073/pnas.81.19.6227; CHAHINE KG, 1992, DEVELOPMENT, V115, P213; CHIARAMELLO A, 1995, MOL CELL BIOL, V15, P6036; COHEN SA, 1992, J MEMBRANE BIOL, V128, P219; DiRocco G, 1997, MOL CELL BIOL, V17, P1244, DOI 10.1128/MCB.17.3.1244; DURR I, 1994, EUR J BIOCHEM, V224, P353, DOI 10.1111/j.1432-1033.1994.00353.x; FLUCHER BE, 1989, NEURON, V3, P163, DOI 10.1016/0896-6273(89)90029-9; HAIMOVICH B, 1987, J NEUROSCI, V7, P2957; Kraner SD, 1998, J NEUROCHEM, V70, P1628; Kraner SD, 1998, J BIOL CHEM, V273, P11327, DOI 10.1074/jbc.273.18.11327; LI H, 1994, EMBO J, V13, P3580, DOI 10.1002/j.1460-2075.1994.tb06665.x; LILLIEN L, 1995, NATURE, V377, P158, DOI 10.1038/377158a0; LUPA MT, 1993, J NEUROSCI, V13, P1326; MANDEL G, 1988, P NATL ACAD SCI USA, V85, P924, DOI 10.1073/pnas.85.3.924; MAUE RA, 1990, NEURON, V4, P223, DOI 10.1016/0896-6273(90)90097-Y; PRODY CA, 1991, J BIOL CHEM, V266, P22588; Rossner MJ, 1997, MOL CELL NEUROSCI, V9, P460, DOI 10.1006/mcne.1997.0640; SIMON AM, 1993, MOL CELL BIOL, V13, P5133, DOI 10.1128/MCB.13.9.5133; SUNYER T, 1993, J NEUROSCI RES, V36, P224, DOI 10.1002/jnr.490360213; THIMMAPPAYA B, 1982, CELL, V31, P543, DOI 10.1016/0092-8674(82)90310-5; YANG JS, 1993, NEURON, V11, P915, DOI 10.1016/0896-6273(93)90121-7; YANG JS, 1991, NEURON, V7, P412	25	20	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 19	1999	274	12					8129	8136		10.1074/jbc.274.12.8129	http://dx.doi.org/10.1074/jbc.274.12.8129			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	178LU	10075715	hybrid			2022-12-25	WOS:000079268100074
J	Ng, GYK; Clark, J; Coulombe, N; Ethier, N; Hebert, TE; Sullivan, R; Kargman, S; Chateauneuf, A; Tsukamoto, N; McDonald, T; Whiting, P; Mezey, E; Johnson, MP; Liu, QY; Kolakowski, LF; Evans, JF; Bonner, TI; O'Neill, GP				Ng, GYK; Clark, J; Coulombe, N; Ethier, N; Hebert, TE; Sullivan, R; Kargman, S; Chateauneuf, A; Tsukamoto, N; McDonald, T; Whiting, P; Mezey, E; Johnson, MP; Liu, QY; Kolakowski, LF; Evans, JF; Bonner, TI; O'Neill, GP			Identification of a GABA(B) receptor subunit, gb2, required for functional GABA(B) receptor activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXPRESSION CLONING; NERVOUS-SYSTEM; RAT-BRAIN; PEPTIDES	G protein-coupled receptors are commonly thought to bind their cognate ligands and elicit functional responses primarily as monomeric receptors. In studying the recombinant gamma-aminobutyric acid, type B (GABA,) receptor (gb1a) and a GABA(B)-like orphan receptor (gb2), we observed that both receptors are functionally inactive when expressed individually in multiple heterologous systems. Characterization of the tissue distribution of each of the receptors by in situ hybridization histochemistry in rat brain revealed co-localization of gb1 and gb2 transcripts in many brain regions, suggesting the hypothesis that gb1 and gb2 may interact in vivo. In three established functional systems (inwardly rectifying K+ channel currents in Xenopus oocytes, melanophore pigment aggregation, and direct cAMP measurements in HEK-293 cells), GABA mediated a functional response in cells coexpressing gb1a and gb2 brit not in cells expressing either receptor individually. This GABA activity could be blocked with the GABA(B) receptor antagonist CGP71872, In COS-7 cells coexpressing gb1a and gb2 receptors, co-immunoprecipitation of gb1a and gb2 receptors was demonstrated, indicating that gb1a and gb2 act as subunits in the formation of a functional GABA(B) receptor.	Merck Frosst Ctr Therapeut Res, Kirkland, PQ H9H 3L1, Canada; Merck Sharp & Dohme Ltd, Res Labs, Harlow CM20 2QR, Essex, England; Banyu Pharmaceut Co Ltd, Tsukuba, Ibaraki 3002611, Japan; Montreal Heart Inst, Montreal, PQ H1T 1C8, Canada; NINDS, NIH, Bethesda, MD 20892 USA; NIMH, Genet Sect, Bethesda, MD 20892 USA; Univ Texas, Hlth Sci Ctr, Dept Pharmacol, San Antonio, TX 78284 USA; Univ Texas, Hlth Sci Ctr, Dept Biochem, San Antonio, TX 78284 USA	Merck & Company; Merck & Company; Merck & Company; Universite de Montreal; National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH); University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio	Ng, GYK (corresponding author), Merck Frosst Ctr Therapeut Res, Kirkland, PQ H9H 3L1, Canada.	gordon_ng@merck.com	Clark, Janet/P-4896-2018; Mezey, Eva/A-8105-2008	Mezey, Eva/0000-0002-5907-4691; Whiting, Paul/0000-0002-4121-1379				Bai M, 1998, J BIOL CHEM, V273, P23605, DOI 10.1074/jbc.273.36.23605; BLAKELY RD, 1991, ANAL BIOCHEM, V194, P302, DOI 10.1016/0003-2697(91)90233-J; BRADLEY DJ, 1992, J NEUROSCI, V12, P2288; Brooker G, 1979, Adv Cyclic Nucleotide Res, V10, P1; Clark JA, 1998, MOL ENDOCRINOL, V12, P193, DOI 10.1210/me.12.2.193; Couve A, 1998, J BIOL CHEM, V273, P26361, DOI 10.1074/jbc.273.41.26361; HEBERT TE, 1994, P ROY SOC B-BIOL SCI, V256, P253, DOI 10.1098/rspb.1994.0078; HEBERT TE, 1996, J BIOL CHEM, V272, P29229; HILL DR, 1981, NATURE, V290, P149, DOI 10.1038/290149a0; Jones KA, 1998, NATURE, V396, P674, DOI 10.1038/25348; JONES KA, 1998, SOC NEUR ABSTR LOS A; Kaupmann K, 1998, NATURE, V396, P683, DOI 10.1038/25360; Kaupmann K, 1997, NATURE, V386, P239, DOI 10.1038/386239a0; Kolakowski LF, 1998, J NEUROCHEM, V71, P2239; Kuner R, 1999, SCIENCE, V283, P74, DOI 10.1126/science.283.5398.74; MAGGIO R, 1993, P NATL ACAD SCI USA, V90, P3103, DOI 10.1073/pnas.90.7.3103; MAIDMENT NT, 1989, NEUROSCIENCE, V33, P549, DOI 10.1016/0306-4522(89)90407-7; MISGELD U, 1995, PROG NEUROBIOL, V46, P423, DOI 10.1016/0301-0082(95)00012-K; Ng GYK, 1999, GENOMICS, V56, P288, DOI 10.1006/geno.1998.5706; Ng GYK, 1996, BIOCHEM BIOPH RES CO, V227, P200, DOI 10.1006/bbrc.1996.1489; Romano C, 1996, J BIOL CHEM, V271, P28612, DOI 10.1074/jbc.271.45.28612; White JH, 1998, NATURE, V396, P679, DOI 10.1038/25354	22	181	188	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	1999	274	12					7607	7610		10.1074/jbc.274.12.7607	http://dx.doi.org/10.1074/jbc.274.12.7607			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	178LU	10075644	hybrid			2022-12-25	WOS:000079268100003
J	Stempien-Otero, A; Karsan, A; Cornejo, CJ; Xiang, H; Eunson, T; Morrison, RS; Kay, M; Winn, R; Harlan, J				Stempien-Otero, A; Karsan, A; Cornejo, CJ; Xiang, H; Eunson, T; Morrison, RS; Kay, M; Winn, R; Harlan, J			Mechanisms of hypoxia-induced endothelial cell death - Role of p53 in apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; TUMOR-NECROSIS-FACTOR; DNA-DAMAGE; PROTEIN; DEGRADATION; ACTIVATION; GROWTH; PHOSPHORYLATION; UBIQUITINATION; FIBROBLASTS	Endothelial cell death may contribute to tissue injury from ischemia, Little is known, however, about the characteristics of endothelial cell death in response to hypoxia. Using an in vitro model, we found that human umbilical vein endothelial cells were resistant to hypoxia-induced cell death with only a 2% reduction in viability at 24 h and 45% reduction in viability at 48 h. Overexpression of a mutant, I kappa B alpha, via adenoviral vector did not potentiate cell death in hypoxia, indicating that nuclear factor-kappa B activation was not involved in cytoprotection. Cell death in hypoxia was determined to be apoptotic by 3' labeling of DNA using terminal deoxynucleotidyl transferase staining and reversibility of cell death with a caspase inhibitor. Exposure of endothelial cells to hypoxia did not alter levels of proapoptotic and antiapoptotic Bcl-2 family members Bar and Bcl-X-L by immunoblot analysis. In contrast, changes in p53 protein levels correlated with the induction of apoptosis in hypoxic endothelial cells. Inhibition of the proteasome increased p53 protein levels and accelerated cell death in hypoxia. Overexpression of p53 by adenoviral transduction was sufficient to initiate apoptosis of normoxic endothelial cells. These data provide a framework for the study of factors regulating endothelial cell survival and death in hypoxia.	Univ Washington, Med Ctr, Dept Med, Seattle, WA 98195 USA; Univ Washington, Dept Neurol Surg, Seattle, WA 98195 USA; Univ Washington, Dept Surg, Seattle, WA 98195 USA; Univ British Columbia, Dept Pathol, Vancouver, BC V6T 2B5, Canada; Stanford Univ, Dept Genet, Palo Alto, CA 94305 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of British Columbia; Stanford University	Stempien-Otero, A (corresponding author), Univ Washington, Med Ctr, Dept Med, Box 357710, Seattle, WA 98195 USA.		Karsan, Aly/K-2067-2015	Kay, Mark/0000-0002-2799-2615				ADES EW, 1992, J INVEST DERMATOL, V99, P683, DOI 10.1111/1523-1747.ep12613748; Amellem O, 1997, EXP CELL RES, V232, P361, DOI 10.1006/excr.1997.3497; An WG, 1998, NATURE, V392, P405, DOI 10.1038/32925; ANTWERP DJV, 1996, SCIENCE, V274, P787; ARNOULD T, 1994, BLOOD, V83, P3705; Arora AS, 1996, J CELL PHYSIOL, V167, P434, DOI 10.1002/(SICI)1097-4652(199606)167:3<434::AID-JCP7>3.0.CO;2-Q; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; DiDonato J, 1996, MOL CELL BIOL, V16, P1295; Dietrich C, 1996, P NATL ACAD SCI USA, V93, P10815, DOI 10.1073/pnas.93.20.10815; Ferran C, 1998, BLOOD, V91, P2249, DOI 10.1182/blood.V91.7.2249.2249_2249_2258; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; GRAEBER TG, 1994, MOL CELL BIOL, V14, P6264, DOI 10.1128/MCB.14.9.6264; Hagar H, 1996, KIDNEY INT, V49, P355, DOI 10.1038/ki.1996.52; Hochachka PW, 1996, P NATL ACAD SCI USA, V93, P9493, DOI 10.1073/pnas.93.18.9493; Hochstrasser M, 1996, CELL, V84, P813, DOI 10.1016/S0092-8674(00)81058-2; Hu XL, 1998, BLOOD, V92, P2759, DOI 10.1182/blood.V92.8.2759.420k29_2759_2765; Jacobson MD, 1996, J CELL BIOL, V133, P1041, DOI 10.1083/jcb.133.5.1041; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; KARAKURUM M, 1994, J CLIN INVEST, V93, P1564, DOI 10.1172/JCI117135; Karsan A, 1996, J BIOL CHEM, V271, P27201, DOI 10.1074/jbc.271.44.27201; Karsan A, 1997, AM J PATHOL, V151, P1775; Kirshenbaum LA, 1997, CIRCULATION, V96, P1580, DOI 10.1161/01.CIR.96.5.1580; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Long XL, 1997, J CLIN INVEST, V99, P2635, DOI 10.1172/JCI119452; Maki CG, 1996, CANCER RES, V56, P2649; Messmer UK, 1996, J BIOL CHEM, V271, P20192, DOI 10.1074/jbc.271.33.20192; OLTVAI ZN, 1994, CELL, V79, P189, DOI 10.1016/0092-8674(94)90188-0; Patel T, 1996, FASEB J, V10, P587, DOI 10.1096/fasebj.10.5.8621058; POHLMAN TH, 1989, CELL IMMUNOL, V119, P41, DOI 10.1016/0008-8749(89)90222-0; POLYAK K, 1997, NATURE, V389, P2307; READ MA, 1995, IMMUNITY, V2, P493, DOI 10.1016/1074-7613(95)90030-6; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; ROSENBAUM DM, 1994, ANN NEUROL, V36, P864, DOI 10.1002/ana.410360610; Schmedtje JF, 1997, J BIOL CHEM, V272, P601; SCHOTT AF, 1995, ONCOGENE, V11, P1389; STRATFORDPERRICAUDET LD, 1992, J CLIN INVEST, V90, P626, DOI 10.1172/JCI115902; Thiagarajan RR, 1997, THROMB HAEMOSTASIS, V78, P310; TRETYAKOV AV, 1995, J CLIN INVEST, V95, P738, DOI 10.1172/JCI117721; Vaziri H, 1997, EMBO J, V16, P6018, DOI 10.1093/emboj/16.19.6018; Vercammen D, 1998, J EXP MED, V188, P919, DOI 10.1084/jem.188.5.919; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wu M, 1996, EMBO J, V15, P4682, DOI 10.1002/j.1460-2075.1996.tb00845.x; Xiang H, 1996, J NEUROSCI, V16, P6753; Yang E, 1996, BLOOD, V88, P386, DOI 10.1182/blood.V88.2.386.bloodjournal882386; YAO KS, 1995, J NATL CANCER I, V87, P117, DOI 10.1093/jnci/87.2.117; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zhu WJ, 1996, EMBO J, V15, P4130, DOI 10.1002/j.1460-2075.1996.tb00788.x; Zund G, 1996, P NATL ACAD SCI USA, V93, P7075, DOI 10.1073/pnas.93.14.7075	48	123	129	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 19	1999	274	12					8039	8045		10.1074/jbc.274.12.8039	http://dx.doi.org/10.1074/jbc.274.12.8039			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	178LU	10075703	hybrid			2022-12-25	WOS:000079268100062
J	Candi, E; Tarcsa, E; Idler, WW; Kartasova, T; Marekov, LN; Steinert, PM				Candi, E; Tarcsa, E; Idler, WW; Kartasova, T; Marekov, LN; Steinert, PM			Transglutaminase cross-linking properties of the small proline-rich 1 family of cornified cell envelope proteins - Integration with loricrin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN EPIDERMAL-KERATINOCYTES; DIFFERENTIATION-SPECIFIC GENES; MALIGNANT KERATINOCYTES; SUBSTRATE-SPECIFICITY; PROTRANSGLUTAMINASE-E; EPITHELIAL-CELLS; BOND FORMATION; RETINOIC ACID; SPR1 GENE; EXPRESSION	Small proline-rich 1 (SPR1) proteins are important for barrier function in stratified squamous epithelia, To explore their properties, we expressed in bacteria a recombinant human SPR1 protein and isolated native SPR1 proteins from cultured mouse keratinocytes. By circular dichroism, they possess no alpha or beta structure but have some organized structure associated with their central peptide repeat domain. The transglutaminase (TGase) 1 and 3 enzymes use the SPR1 proteins as complete substrates in vitro but in different ways: head domain A sequences at the amino terminus were used preferentially for cross-linking by TGase 3, whereas those in head domain B sequences were used for cross-linking by TGase 1. The TGase 2 enzyme cross-linked SPR1 proteins poorly. Together with our data base of 141 examples of in vivo cross-links between SPRs and loricrin, this means that both TGase 1 and 3 are required for cross-linking SPR1 proteins in epithelia in vivo. Double in vitro cross-linking experiments suggest that oligomerization of SPR1 into large polymers can occur only by further TGase 1 cross-linking of an initial TGase 3 reaction. Accordingly, we propose that TGase 3 first cross-links loricrin and SPRs together to form small interchain oligomers, which are then permanently affixed to the developing CE by further cross-linking by the TGase 1 enzyme. This is consistent with the known consequences of diminished barrier function in TGase 1 deficiency models.	NIAMS, Skin Biol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)	Steinert, PM (corresponding author), NIAMS, Skin Biol Lab, NIH, Bldg 6,Rm 425,9000 Rockville Pike, Bethesda, MD 20892 USA.	pemast@helix.nih.gov			NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [Z01AR041086, Z01AR041087] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Aeschlimann D, 1998, J BIOL CHEM, V273, P3452, DOI 10.1074/jbc.273.6.3452; AESCHLIMANN D, 1991, J BIOL CHEM, V266, P15308; AN G, 1993, J CELL PHYSIOL, V157, P562, DOI 10.1002/jcp.1041570316; AN G, 1993, J BIOL CHEM, V268, P10977; Austin SJ, 1996, J BIOL CHEM, V271, P3737, DOI 10.1074/jbc.271.7.3737; BACKENDORF C, 1992, NAT GENET, V2, P91, DOI 10.1038/ng1092-91; BARRY ELR, 1990, J BIOL CHEM, V265, P9302; BIRCKBICHLER PJ, 1977, BIOCHEM BIOPH RES CO, V78, P1, DOI 10.1016/0006-291X(77)91213-X; Candi E, 1998, J BIOL CHEM, V273, P13693, DOI 10.1074/jbc.273.22.13693; CANDI E, 1995, J BIOL CHEM, V270, P26382, DOI 10.1074/jbc.270.44.26382; FOLK JE, 1985, METHOD ENZYMOL, V113, P358; FOLK JE, 1983, ADV ENZYMOL RAMB, V54, P1; Fujimoto W, 1997, J INVEST DERMATOL, V108, P200, DOI 10.1111/1523-1747.ep12334240; GANG A, 1992, AM J RESP CELL MOL, V7, P104, DOI 10.1165/ajrcmb/7.1.104; GIBBS S, 1990, NUCLEIC ACIDS RES, V18, P4401, DOI 10.1093/nar/18.15.4401; GIBBS S, 1993, GENOMICS, V16, P630, DOI 10.1006/geno.1993.1240; GILCHREST BA, 1994, ARCH DERMATOL, V130, P82, DOI 10.1001/archderm.130.1.82; GRECO MA, 1995, J INVEST DERMATOL, V104, P204, DOI 10.1111/1523-1747.ep12612759; HOHL D, 1990, DERMATOLOGICA, V180, P201, DOI 10.1159/000248031; HOHL D, 1995, J INVEST DERMATOL, V104, P902, DOI 10.1111/1523-1747.ep12606176; HOHL D, 1991, J BIOL CHEM, V266, P6626; IshidaYamamoto A, 1997, J INVEST DERMATOL, V108, P12, DOI 10.1111/1523-1747.ep12285611; Jarnik M, 1996, J CELL SCI, V109, P1381; Kartasova T, 1996, J INVEST DERMATOL, V106, P294, DOI 10.1111/1523-1747.ep12340741; KARTASOVA T, 1988, MOL CELL BIOL, V8, P2195, DOI 10.1128/MCB.8.5.2195; KARTASOVA T, 1988, MOL CELL BIOL, V8, P2204, DOI 10.1128/MCB.8.5.2204; KILLACKEY JJF, 1989, MOL PHARMACOL, V35, P701; KIM HC, 1990, J BIOL CHEM, V265, P21971; KIM IG, 1993, J BIOL CHEM, V268, P12682; KIM SY, 1995, J BIOL CHEM, V270, P18026, DOI 10.1074/jbc.270.30.18026; KIM SY, 1994, J BIOL CHEM, V269, P27979; Koizumi H, 1996, BRIT J DERMATOL, V134, P686, DOI 10.1111/j.1365-2133.1996.tb06971.x; LORAND L, 1984, MOL CELL BIOCHEM, V58, P9, DOI 10.1007/BF00240602; MARTINET N, 1988, BIOCHEM J, V271, P305; MARVIN KW, 1992, P NATL ACAD SCI USA, V89, P11026, DOI 10.1073/pnas.89.22.11026; Matsuki M, 1998, P NATL ACAD SCI USA, V95, P1044, DOI 10.1073/pnas.95.3.1044; MEHREL T, 1990, CELL, V61, P1103, DOI 10.1016/0092-8674(90)90073-N; OWENS DM, 1926, J INVEST DERMATOL, V647, P96; PHILLIPS SB, 1990, COMP BIOCHEM PHYS B, V95, P781, DOI 10.1016/0305-0491(90)90317-M; Reichert Uwe, 1993, P107; RICE RH, 1977, CELL, V11, P417, DOI 10.1016/0092-8674(77)90059-9; Robinson NA, 1997, J BIOL CHEM, V272, P12035, DOI 10.1074/jbc.272.18.12035; SAUNDERS NA, 1994, J BIOL CHEM, V269, P2016; SAUNDERS NA, 1993, BIOCHEM BIOPH RES CO, V197, P46, DOI 10.1006/bbrc.1993.2439; SIMON M, 1988, J BIOL CHEM, V263, P18093; SIMON M, 1994, KERATINOCYTE HDB, P275; Stanwell C, 1996, J INVEST DERMATOL, V106, P482, DOI 10.1111/1523-1747.ep12343690; Steinert PM, 1996, J BIOL CHEM, V271, P26242, DOI 10.1074/jbc.271.42.26242; Steinert PM, 1998, J STRUCT BIOL, V122, P76, DOI 10.1006/jsbi.1998.3957; Steinert PM, 1998, J BIOL CHEM, V273, P11758, DOI 10.1074/jbc.273.19.11758; STEINERT PM, 1995, J BIOL CHEM, V270, P17702, DOI 10.1074/jbc.270.30.17702; Steinert PM, 1996, BIOCHEM BIOPH RES CO, V221, P101, DOI 10.1006/bbrc.1996.0552; Steinert PM, 1997, J BIOL CHEM, V272, P2021, DOI 10.1074/jbc.272.3.2021; Tarcsa E, 1998, J BIOL CHEM, V273, P23297, DOI 10.1074/jbc.273.36.23297; Tarcsa E, 1997, J BIOL CHEM, V272, P27893, DOI 10.1074/jbc.272.44.27893; Tarcsa E, 1996, J BIOL CHEM, V271, P30709, DOI 10.1074/jbc.271.48.30709; TESFAIGZI J, 1993, AM J RESP CELL MOL, V9, P434, DOI 10.1165/ajrcmb/9.4.434; YAAR M, 1995, EXP CELL RES, V217, P217, DOI 10.1006/excr.1995.1081	58	74	78	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	1999	274	11					7226	7237		10.1074/jbc.274.11.7226	http://dx.doi.org/10.1074/jbc.274.11.7226			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	175DV	10066784	hybrid			2022-12-25	WOS:000079078400056
J	Nuber, U; Scheffner, M				Nuber, U; Scheffner, M			Identification of determinants in E2 ubiquitin-conjugating enzymes required for hect E3 ubiquitin protein ligase interaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-END RULE; CELL-CYCLE; DEGRADATION; E6-AP; COMPLEX; ENCODES; SYSTEM; GENE; P53; PROTEOLYSIS	Members of the hect domain protein family are characterized by sequence similarity of their C-terminal regions to the C terminus of EG-AP, an E3 ubiquitin-protein ligase, An essential intermediate step in E6-AP-dependent ubiquitination is the formation of a thioester complex between EG-AP and ubiquitin in the presence of distinct E2 ubiquitin-conjugating enzymes including human UbcH5, a member of the UBC4/UBC5 subfamily of E2s. Similarly, several hect domain proteins, including Saccharomyces cerevisiae RSPB, form ubiquitin thioester complexes, indicating that hect domain proteins in general have E3 activity. We show here, by the use of chimeric E2s generated between UbcH5 and other E2s, that a region of UbcH5 encompassing the catalytic site cysteine residue is critical for its ability to interact with E6-AP and RSP5. Of particular importance is a phenylalanine residue at position 62 of UbcH5 that is con served among the members of the UBC4/UBC5 subfamily but is not present in any of the other known E2s, whereas the N-terminal 60 amino acids do not contribute significantly to the specificity of these interactions. The conservation of this phenylalanine residue throughout evolution underlines the importance of the ability to interact with hect domain proteins for the cellular function of UBC4/UBC5 subfamily members.	Deutsch Krebsforschungszentrum, D-69120 Heidelberg, Germany	Helmholtz Association; German Cancer Research Center (DKFZ)	Scheffner, M (corresponding author), Deutsch Krebsforschungszentrum, Neuenheimer Feld 242, D-69120 Heidelberg, Germany.		Scheffner, Martin/K-2940-2012	Scheffner, Martin/0000-0003-2229-0128				BARTEL B, 1990, EMBO J, V9, P3179, DOI 10.1002/j.1460-2075.1990.tb07516.x; Byrd C, 1998, EMBO J, V17, P269, DOI 10.1093/emboj/17.1.269; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; COOK WJ, 1992, J BIOL CHEM, V267, P15116; COOK WJ, 1993, BIOCHEMISTRY-US, V32, P13809, DOI 10.1021/bi00213a009; DOHMEN RJ, 1991, P NATL ACAD SCI USA, V88, P7351, DOI 10.1073/pnas.88.16.7351; Feldman RMR, 1997, CELL, V91, P221, DOI 10.1016/S0092-8674(00)80404-3; Galan JM, 1997, EMBO J, V16, P5847, DOI 10.1093/emboj/16.19.5847; GOEBL MG, 1988, SCIENCE, V241, P1331, DOI 10.1126/science.2842867; Hershko A, 1996, ADV EXP MED BIOL, V389, P221; Hicke L, 1996, CELL, V84, P277, DOI 10.1016/S0092-8674(00)80982-4; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; HUIBREGTSE JM, 1993, MOL CELL BIOL, V13, P4918, DOI 10.1128/MCB.13.8.4918; HUIBREGTSE JM, 1995, P NATL ACAD SCI USA, V92, P2563, DOI 10.1073/pnas.92.7.2563; JENTSCH S, 1995, CELL, V82, P881, DOI 10.1016/0092-8674(95)90021-7; JENTSCH S, 1992, ANNU REV GENET, V26, P179, DOI 10.1146/annurev.ge.26.120192.001143; JUNGMANN J, 1993, NATURE, V361, P369, DOI 10.1038/361369a0; King RW, 1996, SCIENCE, V274, P1652, DOI 10.1126/science.274.5293.1652; Kumar S, 1997, J BIOL CHEM, V272, P13548, DOI 10.1074/jbc.272.21.13548; Lisztwan J, 1998, EMBO J, V17, P368, DOI 10.1093/emboj/17.2.368; Lyapina SA, 1998, P NATL ACAD SCI USA, V95, P7451, DOI 10.1073/pnas.95.13.7451; Mathias N, 1998, J BIOL CHEM, V273, P4040, DOI 10.1074/jbc.273.7.4040; Matuschewski K, 1996, J BIOL CHEM, V271, P2789, DOI 10.1074/jbc.271.5.2789; Nefsky B, 1996, EMBO J, V15, P1301, DOI 10.1002/j.1460-2075.1996.tb00472.x; Nuber U, 1996, J BIOL CHEM, V271, P2795, DOI 10.1074/jbc.271.5.2795; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; SCHEFFNER M, 1995, NATURE, V373, P81, DOI 10.1038/373081a0; SCHEFFNER M, 1994, P NATL ACAD SCI USA, V91, P8797, DOI 10.1073/pnas.91.19.8797; SCHNEIDER R, 1990, EMBO J, V9, P1431, DOI 10.1002/j.1460-2075.1990.tb08259.x; Schwarz SE, 1998, J BIOL CHEM, V273, P12148, DOI 10.1074/jbc.273.20.12148; SEUFERT W, 1990, EMBO J, V9, P543, DOI 10.1002/j.1460-2075.1990.tb08141.x; Skowyra D, 1997, CELL, V91, P209, DOI 10.1016/S0092-8674(00)80403-1; Smith SE, 1996, BIOL CHEM, V377, P437; SUNG P, 1991, EMBO J, V10, P2187, DOI 10.1002/j.1460-2075.1991.tb07754.x; TREIER M, 1992, EMBO J, V11, P367, DOI 10.1002/j.1460-2075.1992.tb05059.x; Varshavsky A, 1997, TRENDS BIOCHEM SCI, V22, P383, DOI 10.1016/S0968-0004(97)01122-5; ZHEN M, 1993, MOL CELL BIOL, V13, P1371, DOI 10.1128/MCB.13.3.1371	37	49	50	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 12	1999	274	11					7576	7582		10.1074/jbc.274.11.7576	http://dx.doi.org/10.1074/jbc.274.11.7576			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	175DV	10066826	hybrid			2022-12-25	WOS:000079078400098
J	Chang, BHJ; Liao, W; Li, L; Nakamuta, M; Mack, D; Chan, L				Chang, BHJ; Liao, W; Li, L; Nakamuta, M; Mack, D; Chan, L			Liver-specific inactivation of the abetalipoproteinemia gene completely abrogates very low density lipoprotein low density lipoprotein production in a viable conditional knockout mouse	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRIGLYCERIDE-TRANSFER-PROTEIN; B-CONTAINING LIPOPROTEINS; APOLIPOPROTEIN-B; INTRACELLULAR DEGRADATION; EXPRESSION; CELLS; SECRETION; SUBUNIT; CLONING; DEFECTS	Conventional knockout of the microsomal triglyceride transfer protein large subunit (lMTP) gene is embryonic lethal in the homozygous state in mice. We have produced a conditional lMTP knockout mouse by inserting loxP sequences flanking exons 5 and 6 by gene targeting. Homozygous flexed mice were born live with normal plasma lipids. Intravenous injection of an adenovirus harboring Cre recombinase (AdCre1) produced deletion of exons 5 and 6 and disappearance of lMTP mRNA and immunoreactive protein in a liver-specific manner. There was also disappearance of plasma apolipoprotein (apo) B-100 and marked reduction in apoB-48 levels. Wild-type mice showed no response, and heterozygous mice, an intermediate response, to AdCre1. Wild-type mice doubled their plasma cholesterol level following a high cholesterol diet. This hypercholesterolemia was abolished in AdCre1-treated lMTP(-/-) mice, the result of a complete absence of very low/intermediate/low density lipoproteins and a slight reduction in high density lipoprotein. Heterozygous mice showed an intermediate lipoprotein phenotype. The rate of accumulation of plasma triglyceride following Triton WR1339 treatment in lMTP(-/-) mice was <10% that in wild-type animals, indicating a failure of triglyceride-rich lipoprotein production. Pulse-chase experiments using hepatocytes isolated from wild-type and lMTP(-/-) mice revealed a failure of apoB secretion in lMTP(-/-) animals. Therefore, the liver-specific inactivation of the lMTP gene completely abrogates apoB 100 and very low/intermediate/low density lipoprotein production. These conditional knockout mice are a useful in vivo model for studying the role of MTP in apoB biosynthesis and the biogenesis of apoB-containing lipoproteins.	Baylor Coll Med, Dept Cell Biol, Houston, TX 77030 USA; Baylor Coll Med, Dept Med, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine	Chan, L (corresponding author), Baylor Coll Med, Dept Cell Biol, MS112A,1 Baylor Plaza, Houston, TX 77030 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL016512, R37HL016512] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-16512] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANTON M, 1995, J VIROL, V69, P4600, DOI 10.1128/JVI.69.8.4600-4606.1995; CHAN L, 1995, CURR OPIN LIPIDOL, V6, P335, DOI 10.1097/00041433-199510000-00014; COLE TG, 1988, BIOCOMMUNIQUE, V4, P4; GORDON DA, 1994, P NATL ACAD SCI USA, V91, P7628, DOI 10.1073/pnas.91.16.7628; Gordon DA, 1997, CURR OPIN LIPIDOL, V8, P131, DOI 10.1097/00041433-199706000-00002; Gordon DA, 1996, J BIOL CHEM, V271, P33047, DOI 10.1074/jbc.271.51.33047; JAMIL H, 1995, J BIOL CHEM, V270, P6549, DOI 10.1074/jbc.270.12.6549; KANE JP, 1995, METABOLIC MOL BASES, P1853; KOBAYASHI K, 1996, J BIOL CHEM, V271, P6851; LEIPER JM, 1994, J BIOL CHEM, V269, P21951; LIN MCM, 1995, J LIPID RES, V36, P1073; Nakamuta M, 1996, J BIOL CHEM, V271, P25981, DOI 10.1074/jbc.271.42.25981; Nakamuta M, 1996, GENOMICS, V33, P313, DOI 10.1006/geno.1996.0200; NARCISI TME, 1995, AM J HUM GENET, V57, P1298; Raabe M, 1998, P NATL ACAD SCI USA, V95, P8686, DOI 10.1073/pnas.95.15.8686; Rustaeus S, 1998, J BIOL CHEM, V273, P5196, DOI 10.1074/jbc.273.9.5196; SHARP D, 1993, NATURE, V365, P65, DOI 10.1038/365065a0; SHOULDERS CC, 1993, HUM MOL GENET, V2, P2109, DOI 10.1093/hmg/2.12.2109; WETTERAU JR, 1992, SCIENCE, V258, P999; WETTERAU JR, 1990, J BIOL CHEM, V265, P9800; Wetterau JR, 1997, BBA-LIPID LIPID MET, V1345, P136, DOI 10.1016/S0005-2760(96)00168-3; WETTERAU JR, 1984, J BIOL CHEM, V259, P863; White AL, 1997, CLIN GENET, V52, P326; Yao ZM, 1997, J LIPID RES, V38, P1937; Yeung SJ, 1996, BIOCHEMISTRY-US, V35, P13843, DOI 10.1021/bi9618777	25	107	110	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1999	274	10					6051	6055		10.1074/jbc.274.10.6051	http://dx.doi.org/10.1074/jbc.274.10.6051			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172BQ	10037685	hybrid			2022-12-25	WOS:000078902800007
J	Cheng, M; Wang, D; Roussel, MF				Cheng, M; Wang, D; Roussel, MF			Expression of c-Myc in response to colony-stimulating factor-1 requires mitogen-activated protein kinase kinase-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NIH 3T3 CELLS; FACTOR-I RECEPTOR; D-TYPE CYCLINS; GROWTH-FACTOR; SIGNAL-TRANSDUCTION; TYROSINE KINASES; SRC FAMILY; INHIBITOR P27(KIP1); MAMMALIAN-CELLS; GENE-EXPRESSION	The mitogen-inducible gene c-myc is a key regulator of cell proliferation and transformation. Yet, the signaling pathway(s) that regulate its expression have remained largely unresolved. Using the mitogen-activated protein kinase kinase (MEK1/2) inhibitor PD98059 and dominant negative forms of Ras (N17) and ERK1 (K71R), we found that activation of Ras and extracellular signal-regulated kinase (ERK) is necessary for colony-stimulating factor-1 (CSF-1)-mediated c-Myc expression and DNA synthetic (S) phase entry. Quiescent NIH-3T3 cells expressing a partially defective CSF-1 receptor, CSF-1R (Y809F), exhibited impaired ERK1 activation and c-Myc expression and failed to enter the S phase of the cell division cycle in response to CSF-1 stimulation. Ectopic expression of a constitutively active form of MEK1 in cells expressing CSF-1R (Y809F) rescued c-Myc expression and S phase entry, but only in the presence of CSF-1-induced cooperating signals. Therefore, MEK1 participates in an obligate signaling pathway linking CSF-1R to c-Myc expression, but other signals from CSF-1R must cooperate with the MEK/ERK pathway to induce c-Myc expression and S phase entry in response to CSF-1 stimulation.	St Jude Childrens Res Hosp, Dept Tumor Cell Biol, Memphis, TN 38105 USA; St Jude Childrens Res Hosp, Dept Biochem, Memphis, TN 38105 USA	St Jude Children's Research Hospital; St Jude Children's Research Hospital	Roussel, MF (corresponding author), St Jude Childrens Res Hosp, Dept Tumor Cell Biol, 332 N Lauderdale St, Memphis, TN 38105 USA.		Wang, Demin/AAX-4449-2020; Roussel, Martine F/F-1469-2016	Wang, Demin/0000-0001-5549-3795; Roussel, Martine F/0000-0002-1740-8139	NCI NIH HHS [T32-CA70089, CA-56819, CA-21705] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA070089, R01CA056819] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aktas H, 1997, MOL CELL BIOL, V17, P3850, DOI 10.1128/MCB.17.7.3850; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; BARONE MV, 1995, NATURE, V378, P509, DOI 10.1038/378509a0; BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; BORTNER DM, 1992, INT J ONCOL, V1, P221; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; BRUNNER D, 1994, NATURE, V370, P386, DOI 10.1038/370386a0; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Cheng MG, 1998, P NATL ACAD SCI USA, V95, P1091, DOI 10.1073/pnas.95.3.1091; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; Davis JN, 1997, MOL CELL BIOL, V17, P7398, DOI 10.1128/MCB.17.12.7398; DENHARDT DT, 1966, BIOCHEM BIOPH RES CO, V23, P641, DOI 10.1016/0006-291X(66)90447-5; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; ERPEL T, 1995, CURR OPIN CELL BIOL, V7, P176, DOI 10.1016/0955-0674(95)80025-5; Fowles LF, 1998, MOL CELL BIOL, V18, P5148, DOI 10.1128/MCB.18.9.5148; Galaktionov K, 1996, NATURE, V382, P511, DOI 10.1038/382511a0; GALAKTIONOV K, 1995, GENE DEV, V9, P1046, DOI 10.1101/gad.9.9.1046; Grandori C, 1996, EMBO J, V15, P4344, DOI 10.1002/j.1460-2075.1996.tb00808.x; Grandori C, 1997, TRENDS BIOCHEM SCI, V22, P177, DOI 10.1016/S0968-0004(97)01025-6; Greulich H, 1998, J BIOL CHEM, V273, P13280, DOI 10.1074/jbc.273.21.13280; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; JANSENDURR P, 1993, P NATL ACAD SCI USA, V90, P3685, DOI 10.1073/pnas.90.8.3685; KATO JY, 1990, BLOOD, V75, P1780; Kerkhoff E, 1997, MOL CELL BIOL, V17, P2576, DOI 10.1128/MCB.17.5.2576; Kerkhoff E, 1998, ONCOGENE, V16, P211, DOI 10.1038/sj.onc.1201520; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; LEMAITRE JM, 1996, ADV CANCER RES, V70, P96; MAI S, 1994, NUCLEIC ACIDS RES, V22, P2264, DOI 10.1093/nar/22.12.2264; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; McCarthy SA, 1997, MOL CELL BIOL, V17, P2401, DOI 10.1128/MCB.17.5.2401; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P1068, DOI 10.1093/nar/18.4.1068; Muller D, 1997, ONCOGENE, V15, P2561, DOI 10.1038/sj.onc.1201440; NORI M, 1991, MOL CELL BIOL, V11, P2812, DOI 10.1128/MCB.11.5.2812; PerezRoger I, 1997, ONCOGENE, V14, P2373, DOI 10.1038/sj.onc.1201197; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; QURESHI SA, 1991, J BIOL CHEM, V266, P20594; REUTER CWM, 1995, METHOD ENZYMOL, V255, P245; ROUSSEL MF, 1990, P NATL ACAD SCI USA, V87, P6738, DOI 10.1073/pnas.87.17.6738; ROUSSEL MF, 1989, P NATL ACAD SCI USA, V86, P7924, DOI 10.1073/pnas.86.20.7924; ROUSSEL MF, 1995, P NATL ACAD SCI USA, V92, P6837, DOI 10.1073/pnas.92.15.6837; ROUSSEL MF, 1991, NATURE, V353, P361, DOI 10.1038/353361a0; ROUSSEL MF, 1994, ONCOGENE, V9, P405; Roussel MF, 1996, MOL CELL BIOL, V16, P2796; SHERR CJ, 1985, CELL, V41, P665, DOI 10.1016/S0092-8674(85)80047-7; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; STANLEY ER, 1983, J CELL BIOCHEM, V21, P151, DOI 10.1002/jcb.240210206; TWAMLEYSTEIN GM, 1993, P NATL ACAD SCI USA, V90, P7696, DOI 10.1073/pnas.90.16.7696; VALLANCE SJ, 1994, HYBRIDOMA, V13, P37, DOI 10.1089/hyb.1994.13.37; Vlach J, 1996, EMBO J, V15, P6595, DOI 10.1002/j.1460-2075.1996.tb01050.x; Wang DM, 1996, MOL CELL BIOL, V16, P6141; Weber JD, 1997, BIOCHEM J, V326, P61, DOI 10.1042/bj3260061; Winston JT, 1996, ONCOGENE, V12, P127; XU SC, 1995, P NATL ACAD SCI USA, V92, P6808, DOI 10.1073/pnas.92.15.6808; Yang BS, 1996, MOL CELL BIOL, V16, P538; Zou XM, 1997, GENE DEV, V11, P654, DOI 10.1101/gad.11.5.654	59	39	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1999	274	10					6553	6558		10.1074/jbc.274.10.6553	http://dx.doi.org/10.1074/jbc.274.10.6553			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172BQ	10037749	hybrid			2022-12-25	WOS:000078902800071
J	Froesch, BA; Aime-Sempe, C; Leber, B; Andrews, D; Reed, JC				Froesch, BA; Aime-Sempe, C; Leber, B; Andrews, D; Reed, JC			Inhibition of p53 transcriptional activity by Bcl-2 requires its membrane-anchoring domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR PROTEIN; WILD-TYPE P53; HUMAN FOLLICULAR LYMPHOMA; PROGRAMMED CELL-DEATH; IN-VIVO; BREAST-CANCER; MITOCHONDRIAL-MEMBRANES; P53-DEPENDENT APOPTOSIS; P53-TRIGGERED APOPTOSIS; ENDOPLASMIC-RETICULUM	We show here that the anti-apoptosis protein Bcl-2 potently inhibits p53-dependent transcriptional activation of various p53-responsive promoters in reporter gene co-transfection assays in human embryonic kidney 295 and MCF7 cells, without affecting nuclear accumulation of p53 protein. In contrast, Bcl-2(Delta transmembrane (TM)), which lacks a hydrophobic membrane-anchoring domain, had no effect on p53 activity. Similarly, in MCF7 cells stably expressing either Bcl-2 or Bcl-2(Delta TM), nuclear levels of p53 protein were up-regulated upon treatment with the DNA-damaging agents doxorubicin and UV radiation, whereas p53 responsive promoter activity and expression of p21(CIP1/WAF1) were strongly reduced in MCF7-Bcl-2 cells but not in MCF7-Bcl-2(Delta TM) or control MCF7 cells. The issue of membrane anchoring was further explored by testing the effects of Bcl-2 chimeric proteins that contained heterologous transmembrane domains from the mitochondrial protein ActA or the endoplasmic reticulum protein cytochrome b5, Both Bcl-2(ActA) and Bcl-2(Cytob5) suppressed p53-mediated transactivation of reporter gene plasmids with efficiencies comparable to wild-type Bcl-2. These results suggest that (a) Bcl-2 not only suppresses p53-mediated apoptosis but also interferes with the transcriptional activation of p53 target genes at least in some cell lines, and (b) membrane anchoring is required for this function of Bcl-2. We speculate that membrane-anchored Bcl-2 may sequester an unknown factor necessary for p53 transcriptional activity.	Burnham Inst, La Jolla, CA 92037 USA; McMaster Univ, Dept Med, Hamilton, ON, Canada; McMaster Univ, Dept Biochem, Hamilton, ON, Canada	Sanford Burnham Prebys Medical Discovery Institute; McMaster University; McMaster University	Reed, JC (corresponding author), Burnham Inst, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.	jreed@burnham-inst.org		Sempe, Christine/0000-0001-6903-1575; Leber, Brian/0000-0001-5502-1480; Andrews, David/0000-0002-9266-7157	NCI NIH HHS [CA55164-07] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA055164] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKAO Y, 1994, CANCER RES, V54, P2468; BAFFY G, 1993, J BIOL CHEM, V268, P6511; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BAUDIER J, 1992, P NATL ACAD SCI USA, V89, P11627, DOI 10.1073/pnas.89.23.11627; Beham A, 1997, ONCOGENE, V15, P2767, DOI 10.1038/sj.onc.1201464; BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766; BORNER C, 1994, J CELL BIOL, V126, P1059, DOI 10.1083/jcb.126.4.1059; Chawla S, 1998, SCIENCE, V281, P1505, DOI 10.1126/science.281.5382.1505; CHENLEVY Z, 1989, MOL CELL BIOL, V9, P701, DOI 10.1128/MCB.9.2.701; CHIOU SK, 1994, MOL CELL BIOL, V14, P2556, DOI 10.1128/MCB.14.4.2556; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; EWEN ME, 1995, GENE DEV, V9, P204, DOI 10.1101/gad.9.2.204; FERNANDEZSARABIA MJ, 1993, NATURE, V366, P274, DOI 10.1038/366274a0; FISHER DE, 1994, CELL, V78, P539, DOI 10.1016/0092-8674(94)90518-5; FONTANINI G, 1995, BRIT J CANCER, V71, P1003, DOI 10.1038/bjc.1995.193; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Grimm S, 1996, J CELL BIOL, V134, P13, DOI 10.1083/jcb.134.1.13; Guillot C, 1997, ONCOGENE, V14, P45, DOI 10.1038/sj.onc.1200803; HALDAR S, 1994, CANCER RES, V54, P2095; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; IWABUCHI K, 1994, P NATL ACAD SCI USA, V91, P6098, DOI 10.1073/pnas.91.13.6098; Iwahashi H, 1997, NATURE, V390, P413, DOI 10.1038/37144; JAMAL S, 1995, ONCOGENE, V10, P2095; JUVEN T, 1993, ONCOGENE, V8, P3411; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; KRAJEWSKI S, 1993, CANCER RES, V53, P4701; Kroemer G, 1997, NAT MED, V3, P614, DOI 10.1038/nm0697-614; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LEESMILLER SP, 1992, MOL CELL BIOL, V12, P5041, DOI 10.1128/MCB.12.11.5041; Li F, 1997, J BIOL CHEM, V272, P30299, DOI 10.1074/jbc.272.48.30299; Lill NL, 1997, NATURE, V387, P823, DOI 10.1038/42981; Lohrum M, 1996, ONCOGENE, V13, P2527; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MARIN MC, 1994, ONCOGENE, V9, P3107; Marin MC, 1996, ONCOGENE, V12, P2259; MATTHIAS P, 1989, NUCLEIC ACIDS RES, V17, P6418, DOI 10.1093/nar/17.15.6418; McDonnell TJ, 1997, J UROLOGY, V157, P569, DOI 10.1016/S0022-5347(01)65204-2; MEEK DW, 1990, EMBO J, V9, P3253, DOI 10.1002/j.1460-2075.1990.tb07524.x; MILNE DM, 1995, J BIOL CHEM, V270, P5511, DOI 10.1074/jbc.270.10.5511; MILNE DM, 1992, ONCOGENE, V7, P1361; MILNE DM, 1994, J BIOL CHEM, V269, P9253; MILNER J, 1990, EMBO J, V9, P2885, DOI 10.1002/j.1460-2075.1990.tb07478.x; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, ONCOGENE, V9, P1799; MOLL UM, 1992, P NATL ACAD SCI USA, V89, P7262, DOI 10.1073/pnas.89.15.7262; MOSNER J, 1995, EMBO J, V14, P4442, DOI 10.1002/j.1460-2075.1995.tb00123.x; Naumovski L, 1996, MOL CELL BIOL, V16, P3884; OKAMOTO K, 1994, EMBO J, V13, P4816, DOI 10.1002/j.1460-2075.1994.tb06807.x; OLTVAI ZN, 1994, CELL, V79, P189, DOI 10.1016/0092-8674(94)90188-0; Reed JC, 1996, J CELL BIOCHEM, V60, P23, DOI 10.1002/(SICI)1097-4644(19960101)60:1<23::AID-JCB5>3.3.CO;2-3; Reed JC, 1997, NATURE, V387, P773, DOI 10.1038/42867; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; RENZING J, 1995, ONCOGENE, V10, P1865; RYAN JJ, 1994, P NATL ACAD SCI USA, V91, P5878, DOI 10.1073/pnas.91.13.5878; SABBATINI P, 1995, MOL CELL BIOL, V15, P1060; SALVAKUMARAN M, 1994, ONCOGENE, V9, P1791; SATO T, 1994, P NATL ACAD SCI USA, V91, P9238, DOI 10.1073/pnas.91.20.9238; Scotto C, 1998, MOL CELL BIOL, V18, P4272, DOI 10.1128/MCB.18.7.4272; SEBAG M, 1994, J INVEST DERMATOL, V103, P323, DOI 10.1111/1523-1747.ep12394802; SHEN YQ, 1994, P NATL ACAD SCI USA, V91, P8940, DOI 10.1073/pnas.91.19.8940; Shibasaki F, 1997, NATURE, V386, P728, DOI 10.1038/386728a0; SILVESTRINI R, 1994, J NATL CANCER I, V86, P499, DOI 10.1093/jnci/86.7.499; Takayama S, 1998, CANCER RES, V58, P3116; TAKAYAMA S, 1995, CELL, V80, P279, DOI 10.1016/0092-8674(95)90410-7; TANAKA S, 1993, J BIOL CHEM, V268, P10920; TSUJIMOTO Y, 1987, ONCOGENE, V2, P3; TSUJIMOTO Y, 1985, SCIENCE, V228, P1440, DOI 10.1126/science.3874430; UNGER T, 1993, MOL CELL BIOL, V13, P5186, DOI 10.1128/MCB.13.9.5186; UPADHYAY S, 1995, CANCER RES, V55, P4520; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; Wang HG, 1996, CELL, V87, P629, DOI 10.1016/S0092-8674(00)81383-5; WANG YS, 1993, ONCOGENE, V8, P3427; WANG YS, 1995, CELL GROWTH DIFFER, V6, P1071; Wu GS, 1997, NAT GENET, V17, P141, DOI 10.1038/ng1097-141; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0; ZAUBERMAN A, 1995, ONCOGENE, V10, P2361; Zhu WJ, 1996, EMBO J, V15, P4130, DOI 10.1002/j.1460-2075.1996.tb00788.x	81	50	52	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1999	274	10					6469	6475		10.1074/jbc.274.10.6469	http://dx.doi.org/10.1074/jbc.274.10.6469			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172BQ	10037739	hybrid			2022-12-25	WOS:000078902800061
J	Kobayashi, A; Ito, E; Toki, T; Kogame, K; Takahashi, S; Igarashi, K; Hayashi, N; Yamamoto, M				Kobayashi, A; Ito, E; Toki, T; Kogame, K; Takahashi, S; Igarashi, K; Hayashi, N; Yamamoto, M			Molecular cloning and functional characterization of a new Cap'n' collar family transcription factor Nrf3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMALL MAF PROTEINS; GENE-EXPRESSION; FACTOR NF-E2; REGION; FOS; HETERODIMERS; ACTIVATOR; ONCOGENE; LCR-F1; CELLS	The NF-E2-binding sites or Maf recognition elements (MARE) are essential cis-acting elements in the regulatory regions of erythroid-specific genes recognized by the erythroid transcription factor NF-E2, composed of p45 and MafK. Recently, two p45-related factors Nrf1 and Nrf2 were isolated, and they are now collectively grouped as the Cap'n' collar (CNC) family. CNC factors bind to MARE through heterodimer formation with small Maf proteins. We report here the identification and characterization of a novel CNC factor, Nrf3, encoding a predicted 73-kDa protein with a basic region-leucine zipper domain highly homologous to those of other CNC proteins. In vitro and in vivo analyses showed that Nrf3 can heterodimerize with MafK and that this complex binds to the MARE in the chicken beta-globin enhancer and can activate transcription. Nrf3 mRNA is highly expressed in human placenta and B cell and monocyte lineage. Chromosomal localization of human Nrf3 is 7p14-15, which lies near the hoxA gene locus. As the genetic loci of p45, nrf1, and nrf2 have been mapped close to those of hoxC, hoxB, and hoxD, respectively, the present study strongly argues for the idea that a single ancestral gene for the CNC family members may have been localized near the ancestral Hox cluster and have diverged to give rise to four closely related CNC factors through chromosome duplication.	Tohoku Univ, Sch Med, Dept Biochem, Aoba Ku, Sendai, Miyagi 9808575, Japan; Hirosaki Univ, Sch Med, Dept Pediat, Hirosaki, Aomori 036, Japan; Hirosaki Univ, Sch Med, Clin Lab, Hirosaki, Aomori 036, Japan; Univ Tsukuba, Ctr Tsukuba Adv Res Alliance, Tsukuba, Ibaraki 3058577, Japan; Univ Tsukuba, Inst Basic Med Sci, Tsukuba, Ibaraki 3058577, Japan	Tohoku University; Hirosaki University; Hirosaki University; University of Tsukuba; University of Tsukuba	Kobayashi, A (corresponding author), Tohoku Univ, Sch Med, Dept Biochem, Aoba Ku, 2-1 Seiryomachi, Sendai, Miyagi 9808575, Japan.	akira-k@mail.cc.tohoku.ac.jp	Yamamoto, Masayuki/A-4873-2010; Takahashi, Shinichiro/AAX-7125-2020; Kobayashi, Akira/AAN-8003-2020	Yamamoto, Masayuki/0000-0002-9073-9436; Igarashi, Kazuhiko/0000-0002-2470-2475; Ito, Etsuro/0000-0002-0168-2475; Kobayashi, Akira/0000-0001-9727-1218; Takahashi, Shinichiro/0000-0003-0011-6065				ANDREWS NC, 1993, P NATL ACAD SCI USA, V90, P11488, DOI 10.1073/pnas.90.24.11488; Blank V, 1997, BLOOD, V89, P3925, DOI 10.1182/blood.V89.11.3925; CATERINA JJ, 1994, NUCLEIC ACIDS RES, V22, P2383, DOI 10.1093/nar/22.12.2383; CHAN JY, 1995, HUM GENET, V95, P265; Chan JY, 1998, EMBO J, V17, P1779, DOI 10.1093/emboj/17.6.1779; CHAN JY, 1993, P NATL ACAD SCI USA, V90, P11366, DOI 10.1073/pnas.90.23.11366; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Farmer SC, 1997, GENE DEV, V11, P786, DOI 10.1101/gad.11.6.786; FUJIWARA KT, 1993, ONCOGENE, V8, P2371; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; IGARASHI K, 1995, J BIOL CHEM, V270, P7615, DOI 10.1074/jbc.270.13.7615; IGARASHI K, 1994, NATURE, V367, P568, DOI 10.1038/367568a0; INAZAWA J, 1991, GENOMICS, V10, P1075, DOI 10.1016/0888-7543(91)90202-P; Itoh K, 1997, BIOCHEM BIOPH RES CO, V236, P313, DOI 10.1006/bbrc.1997.6943; ITOH K, 1995, MOL CELL BIOL, V15, P4184, DOI 10.1128/mcb.15.8.4184; Johnsen O, 1998, NUCLEIC ACIDS RES, V26, P512, DOI 10.1093/nar/26.2.512; JORDAN SA, 1998, GENE DEV, V12, P2164; KATAOKA K, 1994, MOL CELL BIOL, V14, P700, DOI 10.1128/MCB.14.1.700; KATAOKA K, 1994, MOL CELL BIOL, V14, P7581, DOI 10.1128/MCB.14.11.7581; KATAOKA K, 1995, MOL CELL BIOL, V15, P2180; Kobayashi A, 1997, J BIOCHEM, V122, P703; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; Kuroha T, 1998, J BIOCHEM-TOKYO, V123, P376; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUNA L, 1994, GENOMICS, V22, P553, DOI 10.1006/geno.1994.1428; Ma GT, 1997, DEVELOPMENT, V124, P907; Martin F, 1998, BLOOD, V91, P3459, DOI 10.1182/blood.V91.9.3459.3459_3459_3466; MIGNOTTE V, 1990, J BIOL CHEM, V265, P22090; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; MOHLER J, 1991, MECH DEVELOP, V34, P3, DOI 10.1016/0925-4773(91)90086-L; MOI P, 1994, P NATL ACAD SCI USA, V91, P9926, DOI 10.1073/pnas.91.21.9926; MOSCOVICI C, 1977, CELL, V11, P95, DOI 10.1016/0092-8674(77)90320-8; Nagai T, 1998, J BIOL CHEM, V273, P5358, DOI 10.1074/jbc.273.9.5358; Oyake T, 1996, MOL CELL BIOL, V16, P6083; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHIVDASANI RA, 1995, CELL, V81, P695, DOI 10.1016/0092-8674(95)90531-6; Toki T, 1997, ONCOGENE, V14, P1901, DOI 10.1038/sj.onc.1201024	38	233	245	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	1999	274	10					6443	6452		10.1074/jbc.274.10.6443	http://dx.doi.org/10.1074/jbc.274.10.6443			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172BQ	10037736	hybrid			2022-12-25	WOS:000078902800058
J	Perrin, L; Romby, P; Laurenti, P; Berenger, H; Kallenbach, S; Bourbon, HM; Pradel, J				Perrin, L; Romby, P; Laurenti, P; Berenger, H; Kallenbach, S; Bourbon, HM; Pradel, J			The Drosophila modifier of variegation modulo gene product binds specific RNA sequences at the nucleolus and interacts with DNA and chromatin in a phosphorylation-dependent manner	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; PROTEIN; RIBOSOME; MOLECULE; DOMAIN	modulo belongs to the modifier of Position Effect Variegation class of Drosophila genes, suggesting a role for its product in regulating chromatin structure. Genetics assigned a second function to the gene, in protein synthesis capacity. Bifunctionality is consistent with protein localization in two distinct subnuclear compartments, chromatin and nucleolus, and with its organization in modules potentially involved in DNA and RNA binding. In this study, we examine nucleic acid interactions established by Module at nucleolus and chromatin and the mechanism that controls the distribution and balances the function of the protein in the two compartments. Structure/function analysis and oligomer selection/amplification experiments indicate that, in vitro, two basic terminal domains independently contact DNA without sequence specificity, whereas a central RNA Recognition Motif (RRM)-containing domain allows recognition of a novel sequence-/motif-specific RNA class. Phosphorylation moreover is shown to down-regulate DNA binding, Evidence is provided that in vivo nucleolar Module is highly phosphorylated and belongs to a ribonucleoprotein particle, whereas chromatin-associated protein is not modified. A functional scheme is finally proposed in which modification by phosphorylation modulates Mod subnuclear distribution and balances its function at the nucleolus and chromatin.	CNRS, Inst Biol Dev Marseille, Biol & Genet Dev Lab, F-13288 Marseille 9, France; CNRS, Inst Biol Mol & Cellulaire, UPR 9002, F-67084 Strasbourg, France; Ctr Dev Biol, F-31062 Toulouse, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Pradel, J (corresponding author), CNRS, Inst Biol Dev Marseille, Biol & Genet Dev Lab, Parc Sci Luminy,Case 907, F-13288 Marseille 9, France.		Perrin, Laurent/L-8301-2016; Laurenti, Patrick/I-8785-2012; ROMBY, Pascale/AGP-3328-2022	Perrin, Laurent/0000-0002-4139-8743; Laurenti, Patrick/0000-0002-2903-1148; 				Bellaiche Y, 1996, DEVELOPMENT, V122, P3499; BIRNEY E, 1993, NUCLEIC ACIDS RES, V21, P5803, DOI 10.1093/nar/21.25.5803; CLARK RF, 1991, METHOD CELL BIOL, V35, P203; EHRESMANN C, 1987, NUCLEIC ACIDS RES, V15, P9109, DOI 10.1093/nar/15.22.9109; Elgin SCR, 1996, CURR OPIN GENET DEV, V6, P193, DOI 10.1016/S0959-437X(96)80050-5; GARZINO V, 1992, EMBO J, V11, P4471, DOI 10.1002/j.1460-2075.1992.tb05548.x; GARZINO V, 1987, BIOL CELL, V61, P5, DOI 10.1111/j.1768-322X.1987.tb00563.x; GhisolfiNieto L, 1996, J MOL BIOL, V260, P34, DOI 10.1006/jmbi.1996.0380; Henikoff S, 1996, BIOESSAYS, V18, P401, DOI 10.1002/bies.950180510; KAY MA, 1987, TRENDS GENET, V3, P347, DOI 10.1016/0168-9525(87)90295-2; KREJCI E, 1989, NUCLEIC ACIDS RES, V17, P8101, DOI 10.1093/nar/17.20.8101; LATHAM JA, 1989, SCIENCE, V245, P276, DOI 10.1126/science.2501870; Lentzen G, 1996, RNA, V2, P244; LINDSLEY DL, 1992, GENOME DROSOPHILA ME, P433; MAXWELL ES, 1995, ANNU REV BIOCHEM, V35, P897; MELESE T, 1995, CURR OPIN CELL BIOL, V7, P319, DOI 10.1016/0955-0674(95)80085-9; NAGAI K, 1990, NATURE, V348, P515, DOI 10.1038/348515a0; Naora H, 1998, J CELL BIOL, V141, P741, DOI 10.1083/jcb.141.3.741; NOMURA M, 1984, SCI AM, V250, P102, DOI 10.1038/scientificamerican0184-102; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; OLIPHANT AR, 1989, MOL CELL BIOL, V9, P2944, DOI 10.1128/MCB.9.7.2944; Perrin L, 1998, J CELL SCI, V111, P2753; Richter L, 1996, GENES CELLS, V1, P325, DOI 10.1046/j.1365-2443.1996.26027.x; Saeboe-Larssen S, 1998, GENETICS, V148, P1215; Shaw PJ, 1995, ANNU REV CELL DEV BI, V11, P93, DOI 10.1146/annurev.cb.11.110195.000521; Smith CM, 1997, CELL, V89, P669, DOI 10.1016/S0092-8674(00)80247-0; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Tollervey D, 1997, CURR OPIN CELL BIOL, V9, P337, DOI 10.1016/S0955-0674(97)80005-1; TSAI DE, 1991, NUCLEIC ACIDS RES, V19, P4931, DOI 10.1093/nar/19.18.4931; TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121; Wakimoto BT, 1998, CELL, V93, P321, DOI 10.1016/S0092-8674(00)81159-9; WATSON KL, 1992, P NATL ACAD SCI USA, V89, P11302, DOI 10.1073/pnas.89.23.11302; Wool IG, 1996, TRENDS BIOCHEM SCI, V21, P164, DOI 10.1016/S0968-0004(96)20011-8; WYATT JR, 1993, RNA WORLD, P465; Xue Zhixiong, 1994, Trends in Cell Biology, V4, P414, DOI 10.1016/0962-8924(94)90095-7; Zhimulev IF, 1998, ADV GENET, V37, P1; ZUKER M, 1989, SCIENCE, V244, P48, DOI 10.1126/science.2468181	37	26	26	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1999	274	10					6315	6323		10.1074/jbc.274.10.6315	http://dx.doi.org/10.1074/jbc.274.10.6315			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172BQ	10037720	hybrid			2022-12-25	WOS:000078902800042
J	Abraham, N; Stojdl, DF; Duncan, PI; Methot, N; Ishii, T; Dube, M; Vanderhyden, BC; Atkins, HL; Gray, DA; McBurney, MW; Koromilas, AE; Brown, EG; Sonenberg, N; Bell, JC				Abraham, N; Stojdl, DF; Duncan, PI; Methot, N; Ishii, T; Dube, M; Vanderhyden, BC; Atkins, HL; Gray, DA; McBurney, MW; Koromilas, AE; Brown, EG; Sonenberg, N; Bell, JC			Characterization of transgenic mice with targeted disruption of the catalytic domain of the double-stranded RNA-dependent protein kinase, PKR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENOVIRUS VAI RNA; NF-KAPPA-B; 58,000-DALTON CELLULAR INHIBITOR; IMMUNODEFICIENCY-VIRUS TYPE-1; REGULATED EIF-2-ALPHA KINASE; INITIATION-FACTOR 2-ALPHA; TUMOR NECROSIS FACTOR; MALIGNANT TRANSFORMATION; TRANSLATIONAL CONTROL; VACCINIA VIRUS	The interferon-inducible, double-stranded RNA dependent protein kinase PKR has been implicated in anti-viral, anti-tumor, and apoptotic responses, Others have attempted to examine the requirement of PKR in these roles by targeted disruption at the amino terminal-encoding region of the Phr gene. By using a strategy that aims at disruption of the catalytic domain of PHR, we have generated mice that are genetically ablated for functional PKR Similar to the other mouse model of Pkr disruption, we have observed no consequences of loss of PKR on tumor suppression. Anti-viral response to influenza and vaccinia also appeared to be normal in mice and in cells lacking PKR Cytokine signaling in the type I interferon pathway is normal but may be compromised in the erythropoietin pathway in erythroid bone marrow precursors. Contrary to the aminoterminal targeted Phr mouse, tumor necrosis factor alpha-induced apoptosis and the anti-viral apoptosis response to influenza is not impaired in catalytic domain-targeted Pkr-null cells. The observation of intact eukaryotic initiation factor-2 alpha phosphorylation in these Pkr-null cells provides proof of rescue by another eukaryotic initiation factor-2 alpha kinase(s).	Ottawa Reg Canc Ctr, Res Labs, Ottawa, ON K1H 8L6, Canada; Univ Ottawa, Dept Biochem, Ottawa, ON K1H 8M5, Canada; Univ Geneva, Dept Mol Biol, CH-1211 Geneva, Switzerland; Ottawa Gen Hosp, Div Hematol, Ottawa, ON K1H 8L6, Canada; Lady Davis Inst Med Res, Dept Oncol & Med, Montreal, PQ H3T 1E2, Canada; Univ Ottawa, Dept Microbiol & Immunol, Ottawa, ON K1H 8M5, Canada; McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada	University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa; University of Geneva; University of Ottawa; Ottawa Hospital Research Institute; Lady Davis Institute; McGill University; University of Ottawa; McGill University	Bell, JC (corresponding author), Ottawa Reg Canc Ctr, Res Labs, Ottawa, ON K1H 8L6, Canada.		Abraham, Ninan/K-5572-2012; /U-3554-2018	Abraham, Ninan/0000-0002-2747-1246; /0000-0002-8634-4984				BARBER GN, 1995, MOL CELL BIOL, V15, P3138; BARBER GN, 1995, J BIOL CHEM, V270, P17423, DOI 10.1074/jbc.270.29.17423; BARBER GN, 1994, P NATL ACAD SCI USA, V91, P4278, DOI 10.1073/pnas.91.10.4278; Benkirane M, 1997, EMBO J, V16, P611, DOI 10.1093/emboj/16.3.611; Brostrom CO, 1996, J BIOL CHEM, V271, P24995, DOI 10.1074/jbc.271.40.24995; BROWN EG, 1990, J VIROL, V64, P4523, DOI 10.1128/JVI.64.9.4523-4533.1990; CHEN JJ, 1995, TRENDS BIOCHEM SCI, V20, P105, DOI 10.1016/S0968-0004(00)88975-6; CHONG KL, 1992, EMBO J, V11, P1553, DOI 10.1002/j.1460-2075.1992.tb05200.x; CLEM RJ, 1993, J VIROL, V67, P3730, DOI 10.1128/JVI.67.7.3730-3738.1993; CLEMENS MJ, 1994, BIOCHIMIE, V76, P770, DOI 10.1016/0300-9084(94)90081-7; COLBY C, 1969, NATURE, V222, P940, DOI 10.1038/222940a0; CROSBY JS, 1994, MOL CELL BIOL, V14, P3906, DOI 10.1128/MCB.14.6.3906; DAVIES MV, 1992, J VIROL, V66, P1943, DOI 10.1128/JVI.66.4.1943-1950.1992; DAVIES MV, 1993, J VIROL, V67, P1688, DOI 10.1128/JVI.67.3.1688-1692.1993; DeGracia DJ, 1997, J CEREBR BLOOD F MET, V17, P1291, DOI 10.1097/00004647-199712000-00004; Der SD, 1997, P NATL ACAD SCI USA, V94, P3279, DOI 10.1073/pnas.94.7.3279; DEVER TE, 1993, P NATL ACAD SCI USA, V90, P4616, DOI 10.1073/pnas.90.10.4616; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DONZE O, 1995, EMBO J, V14, P3828, DOI 10.1002/j.1460-2075.1995.tb00052.x; DUBOIS MF, 1991, J BIOL CHEM, V266, P9707; Durbin JE, 1996, CELL, V84, P443, DOI 10.1016/S0092-8674(00)81289-1; FARRELL PJ, 1977, CELL, V11, P187, DOI 10.1016/0092-8674(77)90330-0; GALABRU J, 1989, EUR J BIOCHEM, V178, P581, DOI 10.1111/j.1432-1033.1989.tb14485.x; GALABRU J, 1987, J BIOL CHEM, V262, P15538; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; HINNEBUSCH AG, 1994, TRENDS BIOCHEM SCI, V19, P409, DOI 10.1016/0968-0004(94)90089-2; ICELY PL, 1991, J BIOL CHEM, V266, P16073; ITO T, 1994, P NATL ACAD SCI USA, V91, P7455, DOI 10.1073/pnas.91.16.7455; JAGUS R, 1994, BIOCHIMIE, V76, P779, DOI 10.1016/0300-9084(94)90082-5; JAKOBOVITS A, 1993, P NATL ACAD SCI USA, V90, P2551, DOI 10.1073/pnas.90.6.2551; JUDWARE R, 1992, J BIOL CHEM, V267, P21685; KATZE MG, 1987, EMBO J, V6, P689, DOI 10.1002/j.1460-2075.1987.tb04809.x; Kibler KV, 1997, J VIROL, V71, P1992, DOI 10.1128/JVI.71.3.1992-2003.1997; KITAJEWSKI J, 1986, CELL, V45, P195, DOI 10.1016/0092-8674(86)90383-1; KOROMILAS AE, 1995, J BIOL CHEM, V270, P25426, DOI 10.1074/jbc.270.43.25426; KOROMILAS AE, 1992, SCIENCE, V257, P1685, DOI 10.1126/science.1382315; KOSTURA M, 1989, MOL CELL BIOL, V9, P1576, DOI 10.1128/MCB.9.4.1576; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; Kuhen KL, 1996, GENOMICS, V36, P197, DOI 10.1006/geno.1996.0446; KUMAR A, 1994, P NATL ACAD SCI USA, V91, P6288, DOI 10.1073/pnas.91.14.6288; Kumar A, 1997, EMBO J, V16, P406, DOI 10.1093/emboj/16.2.406; LAZARISKARATZAS A, 1990, NATURE, V345, P544, DOI 10.1038/345544a0; Lee SB, 1997, VIROLOGY, V231, P81, DOI 10.1006/viro.1997.8494; LEE SB, 1993, VIROLOGY, V193, P1037, DOI 10.1006/viro.1993.1223; LEE SB, 1994, VIROLOGY, V199, P491, DOI 10.1006/viro.1994.1151; LEE TG, 1994, MOL CELL BIOL, V14, P2331, DOI 10.1128/MCB.14.4.2331; LEE TG, 1992, J BIOL CHEM, V267, P14238; LEE TG, 1990, P NATL ACAD SCI USA, V87, P6208, DOI 10.1073/pnas.87.16.6208; LEIST M, 1994, J IMMUNOL, V153, P1778; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; MARAN A, 1994, SCIENCE, V265, P789, DOI 10.1126/science.7914032; Martin SJ, 1996, J BIOL CHEM, V271, P28753, DOI 10.1074/jbc.271.46.28753; Megeney LA, 1996, GENE DEV, V10, P1173, DOI 10.1101/gad.10.10.1173; MELLOR H, 1994, BBA-GENE STRUCT EXPR, V1219, P693, DOI 10.1016/0167-4781(94)90229-1; Meraz MA, 1996, CELL, V84, P431, DOI 10.1016/S0092-8674(00)81288-X; MEURS EF, 1993, P NATL ACAD SCI USA, V90, P232, DOI 10.1073/pnas.90.1.232; POHLMAN TH, 1989, CELL IMMUNOL, V119, P41, DOI 10.1016/0008-8749(89)90222-0; Polyak SJ, 1996, J BIOL CHEM, V271, P1702, DOI 10.1074/jbc.271.3.1702; RAY CA, 1992, CELL, V69, P597, DOI 10.1016/0092-8674(92)90223-Y; RHOADS RE, 1993, J BIOL CHEM, V268, P3017; ROY S, 1991, J VIROL, V65, P632, DOI 10.1128/JVI.65.2.632-640.1991; SAH VP, 1995, NAT GENET, V10, P175, DOI 10.1038/ng0695-175; SCHIFF LA, 1988, MOL CELL BIOL, V8, P273, DOI 10.1128/MCB.8.1.273; SEN GC, 1992, J BIOL CHEM, V267, P5017; SENGUPTA DN, 1990, P NATL ACAD SCI USA, V87, P7492, DOI 10.1073/pnas.87.19.7492; SMEENK CA, 1994, J VIROL, V68, P530, DOI 10.1128/JVI.68.1.530-534.1994; SONENBERG N, 1990, New Biologist, V2, P402; Takizawa T, 1996, J VIROL, V70, P8128, DOI 10.1128/JVI.70.11.8128-8132.1996; TANAKA H, 1995, GENE, V153, P283, DOI 10.1016/0378-1119(94)00821-9; TANAKA H, 1994, P NATL ACAD SCI USA, V91, P7995, DOI 10.1073/pnas.91.17.7995; Tanaka N, 1998, GENES CELLS, V3, P29, DOI 10.1046/j.1365-2443.1998.00164.x; Taylor DR, 1996, MOL CELL BIOL, V16, P6295; THOMIS DC, 1992, VIROLOGY, V188, P33, DOI 10.1016/0042-6822(92)90732-5; Wong AHT, 1997, EMBO J, V16, P1291, DOI 10.1093/emboj/16.6.1291; Yang YL, 1995, EMBO J, V14, P6095, DOI 10.1002/j.1460-2075.1995.tb00300.x; Yeung MC, 1996, P NATL ACAD SCI USA, V93, P12451, DOI 10.1073/pnas.93.22.12451; Zhu SH, 1998, J BIOL CHEM, V273, P1808, DOI 10.1074/jbc.273.3.1808	77	193	199	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 26	1999	274	9					5953	5962		10.1074/jbc.274.9.5953	http://dx.doi.org/10.1074/jbc.274.9.5953			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	170KG	10026221	hybrid			2022-12-25	WOS:000078804400092
J	Gao, ZH; Chen, TS; Weber, MJ; Linden, J				Gao, ZH; Chen, TS; Weber, MJ; Linden, J			A(2B) adenosine and P2Y(2) receptors stimulate mitogen-activated protein kinase in human embryonic kidney-293 cells - Cross-talk between cyclic AMP and protein kinase C pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; MAP KINASE; MAST-CELLS; COUPLED RECEPTORS; TYROSINE KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; CALCIUM MOBILIZATION; DISTINCT PATHWAYS; PHOSPHOLIPASE-C; NEURONAL CELLS	Mitogen-activated protein kinase (MAPK) cascades underlie long-term mitogenic, morphogenic, and secretory activities of purinergic receptors. In HEK-293 cells, N-ethylcarboxamidoadenosine (NECA) activates endogenous A(2B)ARs that signal through G(s) and G(q)/11. UTP activates P2Y(2) receptors and signals only through G(q)/11. The MAPK isoforms, extracellular-signal regulated kinase 1/2 (ERK), are activated by NECA and UTP. H-89 blocks ERR activation by forskolin, but weakly affects the response to NECA or UTP. ERR activation by NECA or UTP is unaffected by a tyrosine kinase inhibitor (genistein), attenuated by a phospholipase C inhibitor (U73122), and is abolished by a MEK inhibitor (PD098059) or dominant negative Ras. Inhibition of protein kinase C (PRC) by GF 109203X failed to block ERK activation by NECA or UTP, however, another PRC inhibitor, Ro 31-8220, which unlike GF 109203X, can block the zeta-isoform, and prevents UTP- but not NECA-induced ERK activation. In the presence of forskolin, Ro 31-8220 loses its ability to block UTP-stimulated ERR activation. PRA has opposing effects on B-Raf and c-Raf-1, both of which are found in HEK-293 cells. The data are explained by a model in which ERK activity is modulated by differential effects of PRC zeta and PRA on Raf isoforms.	Univ Virginia, Hlth Sci Ctr 6012, Dept Mol Physiol & Biol Phys, Charlottesville, VA 22908 USA; Univ Virginia, Dept Microbiol, Charlottesville, VA 22908 USA; Univ Virginia, Dept Internal Med, Charlottesville, VA 22908 USA	University of Virginia; University of Virginia; University of Virginia	Linden, J (corresponding author), Univ Virginia, Hlth Sci Ctr 6012, Dept Mol Physiol & Biol Phys, Box MR4, Charlottesville, VA 22908 USA.		Chen, Taosheng/I-6351-2013	Chen, Taosheng/0000-0001-6420-3809	NHLBI NIH HHS [R01-HL37942] Funding Source: Medline; NIGMS NIH HHS [GM 47332] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL037942] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047332] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abbracchio MP, 1996, DRUG DEVELOP RES, V39, P393, DOI 10.1002/(SICI)1098-2299(199611/12)39:3/4<393::AID-DDR21>3.0.CO;2-1; ABBRACCHIO MP, 1995, BIOCHEM BIOPH RES CO, V213, P908, DOI 10.1006/bbrc.1995.2215; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; ALI H, 1990, J BIOL CHEM, V265, P745; ANTONYSAMY MA, 1995, J IMMUNOL, V155, P2813; Auchampach JA, 1997, MOL PHARMACOL, V52, P846, DOI 10.1124/mol.52.5.846; BROOKER G, 1979, SCIENCE, V184, P270; BUDWORTH J, 1995, FEBS LETT, V362, P139, DOI 10.1016/0014-5793(95)00227-Z; Cowen DS, 1996, J BIOL CHEM, V271, P22297, DOI 10.1074/jbc.271.37.22297; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; Daaka Y, 1997, NATURE, V390, P88, DOI 10.1038/36362; Daaka Y, 1998, J BIOL CHEM, V273, P685, DOI 10.1074/jbc.273.2.685; Das M, 1997, AM J PHYSIOL-LUNG C, V273, pL1276, DOI 10.1152/ajplung.1997.273.6.L1276; DAVIS PD, 1992, J MED CHEM, V35, P994, DOI 10.1021/jm00084a004; DellaRocca GJ, 1997, J BIOL CHEM, V272, P19125, DOI 10.1074/jbc.272.31.19125; DER CJ, 1986, MOL CELL BIOL, V6, P3291, DOI 10.1128/MCB.6.9.3291; DIAZMECO MT, 1994, J BIOL CHEM, V269, P31706; FEOKTISTOV I, 1995, J CLIN INVEST, V96, P1979, DOI 10.1172/JCI118245; Feoktistov I, 1997, PHARMACOL REV, V49, P381; Gutkind JS, 1998, J BIOL CHEM, V273, P1839, DOI 10.1074/jbc.273.4.1839; HAWES BE, 1995, J BIOL CHEM, V270, P17148, DOI 10.1074/jbc.270.29.17148; HIRASAWA N, 1995, J IMMUNOL, V154, P5391; HIRASAWA N, 1995, J BIOL CHEM, V270, P10960, DOI 10.1074/jbc.270.18.10960; Hoffman HM, 1997, INFLAMMATION, V21, P55, DOI 10.1023/A:1027390825353; Hooks SB, 1998, MOL PHARMACOL, V53, P188, DOI 10.1124/mol.53.2.188; HOWE LR, 1993, J BIOL CHEM, V268, P20717; HUGHES PJ, 1986, AGENTS ACTIONS, V18, P81, DOI 10.1007/BF01987989; HUGHES PJ, 1984, BIOCHEM PHARMACOL, V33, P3847, DOI 10.1016/0006-2952(84)90050-9; ISN AJ, 1993, BIOCHEM SOC T, V21, pS386; JIN WZ, 1994, BRAIN RES, V642, P237, DOI 10.1016/0006-8993(94)90927-X; Jones T, 1997, BIOCHEM PHARMACOL, V53, P1413, DOI 10.1016/S0006-2952(96)00863-5; Jordan NJ, 1996, BRIT J PHARMACOL, V117, P1245, DOI 10.1111/j.1476-5381.1996.tb16722.x; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; Liao DF, 1997, J BIOL CHEM, V272, P6146, DOI 10.1074/jbc.272.10.6146; LIMATOLA C, 1994, BIOCHEM J, V304, P1001, DOI 10.1042/bj3041001; Luttrell LM, 1997, J BIOL CHEM, V272, P31648, DOI 10.1074/jbc.272.50.31648; LUTTRELL LM, 1995, J BIOL CHEM, V270, P16495, DOI 10.1074/jbc.270.28.16495; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MARTINYBARON G, 1993, J BIOL CHEM, V268, P9194; Mitchell R, 1998, NATURE, V392, P411, DOI 10.1038/32937; MORINELLI TA, 1994, J BIOL CHEM, V269, P5693; Neary JT, 1996, DRUG DEVELOP RES, V39, P407, DOI 10.1002/(SICI)1098-2299(199611/12)39:3/4<407::AID-DDR22>3.0.CO;2-X; Neary JT, 1996, TRENDS NEUROSCI, V19, P13, DOI 10.1016/0166-2236(96)81861-3; OZAWA K, 1993, J BIOL CHEM, V268, P1749; PANG L, 1993, BIOCHEM J, V289, P283, DOI 10.1042/bj2890283; RAMKUMAR V, 1993, J BIOL CHEM, V268, P16887; Robeva AS, 1996, DRUG DEVELOP RES, V39, P243, DOI 10.1002/(SICI)1098-2299(199611/12)39:3/4<243::AID-DDR3>3.0.CO;2-R; Rumenapp U, 1997, EUR J BIOCHEM, V248, P407, DOI 10.1111/j.1432-1033.1997.00407.x; SADOSHIMA J, 1995, CIRC RES, V76, P1; Schachter JB, 1997, NEUROPHARMACOLOGY, V36, P1181, DOI 10.1016/S0028-3908(97)00138-X; SEXL V, 1995, BRIT J PHARMACOL, V114, P1577, DOI 10.1111/j.1476-5381.1995.tb14942.x; TANAKA Y, 1994, EXP CELL RES, V213, P242, DOI 10.1006/excr.1994.1196; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; TOWNSENDNICHOLS.A, 1997, RRECEPTOR SIGNAL TRA, P45; TUCKER AL, 1993, CARDIOVASC RES, V27, P62, DOI 10.1093/cvr/27.1.62; VANCORVEN EJ, 1993, P NATL ACAD SCI USA, V90, P1257, DOI 10.1073/pnas.90.4.1257; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; WANG YZ, 1993, J CARDIOVASC PHARM, V22, pS164, DOI 10.1097/00005344-199322008-00044; WILKINSON SE, 1993, BIOCHEM J, V294, P335, DOI 10.1042/bj2940335; WINITZ S, 1993, J BIOL CHEM, V268, P19196	61	126	138	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 26	1999	274	9					5972	5980		10.1074/jbc.274.9.5972	http://dx.doi.org/10.1074/jbc.274.9.5972			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	170KG	10026223	hybrid			2022-12-25	WOS:000078804400094
J	Grigoryev, SA; Bednar, J; Woodcock, CL				Grigoryev, SA; Bednar, J; Woodcock, CL			MENT, a heterochromatin protein that mediates higher order chromatin folding, is a new serpin family member	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POSITION EFFECT VARIEGATION; CRYSTAL-STRUCTURE; CONFORMATIONAL CHANGE; ELECTRON-MICROSCOPY; GENE-EXPRESSION; NUCLEAR MATRIX; DNA; NUCLEOSOME; BINDING; CELLS	Terminal cell differentiation is correlated with the extensive sequestering of previously active genes into compact transcriptionally inert heterochromatin. In vertebrate blood cells, these changes can be traced to the accumulation of a developmentally regulated heterochromatin protein, MENT. Cryoelectron microscopy of chicken granulocyte chromatin, which is highly enriched with MENT, reveals exceptionally compact polynucleosomes, which maintain a level of higher order folding above that imposed by linker histones. The amino acid sequence of MENT reveals a close structural relationship with serpins, a large family of proteins known for their ability to undergo dramatic conformational transitions. Conservation of the "hinge region" consensus in MENT indicates that this ability is retained by the protein. MENT is distinguished from the other serpins by being a basic protein, containing several positively charged surface clusters, which are likely to be involved in ionic interactions with DNA. One of the positively charged domains bears a significant similarity to the chromatin binding region of nuclear lamina proteins and with the A T-rich DNA-binding motif, which may account for the targeting of MENT to peripheral heterochromatin. MENT ectopically expressed in a mammalian cell Line is transported into nuclei and is associated with intranuclear foci of condensed chromatin.	Univ Massachusetts, Dept Biol, Amherst, MA 01003 USA	University of Massachusetts System; University of Massachusetts Amherst	Grigoryev, SA (corresponding author), Univ Massachusetts, Dept Biol, Amherst, MA 01003 USA.	sergei@bio.umass.edu	Bednar, Jan/K-2162-2012; Bednar, Jan/H-3648-2017	Bednar, Jan/0000-0003-0879-6405	NIGMS NIH HHS [GM-43786, GM-51352] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043786, R55GM051352] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alkema MJ, 1997, GENE DEV, V11, P226, DOI 10.1101/gad.11.2.226; ALLAN J, 1980, NATURE, V288, P675, DOI 10.1038/288675a0; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Aravind L, 1998, NUCLEIC ACIDS RES, V26, P4413, DOI 10.1093/nar/26.19.4413; AULAK KS, 1993, J BIOL CHEM, V268, P18088; BAUMANN U, 1992, J MOL BIOL, V226, P1207, DOI 10.1016/0022-2836(92)91062-T; BEAULIEU AD, 1992, J BIOL CHEM, V267, P426; Bednar J, 1998, P NATL ACAD SCI USA, V95, P14173, DOI 10.1073/pnas.95.24.14173; BEDNAR J, 1995, J CELL BIOL, V131, P1365, DOI 10.1083/jcb.131.6.1365; BJELLQVIST B, 1994, ELECTROPHORESIS, V15, P529, DOI 10.1002/elps.1150150171; BURLEY SK, 1993, COLD SPRING HARB SYM, V58, P123, DOI 10.1101/SQB.1993.058.01.016; Bustin M, 1996, PROG NUCLEIC ACID RE, V54, P35, DOI 10.1016/S0079-6603(08)60360-8; CLARK DJ, 1990, J MOL BIOL, V211, P883, DOI 10.1016/0022-2836(90)90081-V; COCKELL M, 1995, J CELL BIOL, V129, P909, DOI 10.1083/jcb.129.4.909; DUBOCHET J, 1988, Q REV BIOPHYS, V21, P129, DOI 10.1017/S0033583500004297; Elgin SCR, 1996, CURR OPIN GENET DEV, V6, P193, DOI 10.1016/S0959-437X(96)80050-5; Falciola L, 1997, J CELL BIOL, V137, P19, DOI 10.1083/jcb.137.1.19; FRENSTER JH, 1974, CELL NUCLEUS, P565; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; Garnier J, 1996, METHOD ENZYMOL, V266, P540; Girard F, 1998, EMBO J, V17, P2079, DOI 10.1093/emboj/17.7.2079; GRIGORYEV SA, 1992, EXP CELL RES, V198, P268, DOI 10.1016/0014-4827(92)90379-M; Grigoryev SA, 1998, J BIOL CHEM, V273, P3082, DOI 10.1074/jbc.273.5.3082; GRIGORYEV SA, 1993, EXP CELL RES, V206, P335, DOI 10.1006/excr.1993.1154; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Hamiche A, 1996, J MOL BIOL, V257, P30, DOI 10.1006/jmbi.1996.0144; HECHT A, 1995, CELL, V80, P583, DOI 10.1016/0092-8674(95)90512-X; Heitz E, 1928, JAHRB WISS BOT, V69, P762; Henikoff S, 1997, CURR OPIN CELL BIOL, V9, P388, DOI 10.1016/S0955-0674(97)80012-9; HILWIG I, 1971, CHROMOSOMA, V34, P243; HOGER TH, 1990, CHROMOSOMA, V99, P379, DOI 10.1007/BF01726689; HOLMQUIST GP, 1987, AM J HUM GENET, V40, P151; HOROWITZ RA, 1994, J CELL BIOL, V125, P1, DOI 10.1083/jcb.125.1.1; HUBER R, 1989, BIOCHEMISTRY-US, V28, P8952; John B, 1988, HETEROCHROMATIN MOL, P1; JORCANO JL, 1980, P NATL ACAD SCI-BIOL, V77, P6443, DOI 10.1073/pnas.77.11.6443; Kennedy BK, 1997, CELL, V89, P381, DOI 10.1016/S0092-8674(00)80219-6; Kingston RE, 1996, GENE DEV, V10, P905, DOI 10.1101/gad.10.8.905; KOMAIKO W, 1985, BIOCHEMISTRY-US, V24, P1186, DOI 10.1021/bi00326a020; LAFOND RE, 1983, EXP CELL RES, V147, P31, DOI 10.1016/0014-4827(83)90268-9; Lauber AH, 1997, J BIOL CHEM, V272, P24657, DOI 10.1074/jbc.272.39.24657; LEUBA SH, 1994, P NATL ACAD SCI USA, V91, P11621, DOI 10.1073/pnas.91.24.11621; Lohe A., 1988, HETEROCHROMATIN MOL, P148; LOHE AR, 1995, CURR OPIN GENET DEV, V5, P746, DOI 10.1016/0959-437X(95)80007-R; LOMAS DA, 1992, NATURE, V357, P605, DOI 10.1038/357605a0; LOMAS DA, 1993, J BIOL CHEM, V268, P15333; LUDERUS MEE, 1992, CELL, V70, P949, DOI 10.1016/0092-8674(92)90245-8; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; Madireddi MT, 1996, CELL, V87, P75, DOI 10.1016/S0092-8674(00)81324-0; METCALF D, 1989, NATURE, V339, P27, DOI 10.1038/339027a0; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Peitsch MC, 1996, BIOCHEM SOC T, V24, P274, DOI 10.1042/bst0240274; PEMBERTON PA, 1988, NATURE, V336, P257, DOI 10.1038/336257a0; Pirrotta V, 1998, CELL, V93, P333, DOI 10.1016/S0092-8674(00)81162-9; Pollard KM, 1997, J IMMUNOL, V158, P3521; POTEMPA J, 1994, J BIOL CHEM, V269, P15957; REUTER G, 1992, BIOESSAYS, V14, P605, DOI 10.1002/bies.950140907; ROWLEY AF, 1988, VERTEBRATE BLOOD CEL; RUIZCARRILLO A, 1980, BIOCHEMISTRY-US, V19, P2544, DOI 10.1021/bi00553a002; Sachs L, 1996, P NATL ACAD SCI USA, V93, P4742, DOI 10.1073/pnas.93.10.4742; Schwarz PM, 1996, BIOCHEMISTRY-US, V35, P4009, DOI 10.1021/bi9525684; Singh PB, 1998, DEV GENET, V22, P85, DOI 10.1002/(SICI)1520-6408(1998)22:1<85::AID-DVG9>3.0.CO;2-3; STEIN PE, 1991, J MOL BIOL, V221, P941, DOI 10.1016/0022-2836(91)80185-W; STEIN PE, 1989, BIOCHEM J, V262, P103, DOI 10.1042/bj2620103; STRAUSS F, 1984, CELL, V37, P889, DOI 10.1016/0092-8674(84)90424-0; Tan S, 1998, NATURE, V391, P660, DOI 10.1038/35563; TANIURA H, 1995, J CELL BIOL, V131, P33, DOI 10.1083/jcb.131.1.33; THOMA F, 1979, J CELL BIOL, V83, P403, DOI 10.1083/jcb.83.2.403; TOBIN AJ, 1978, DEV BIOL, V67, P11, DOI 10.1016/0012-1606(78)90296-8; Torriglia A, 1998, MOL CELL BIOL, V18, P3612, DOI 10.1128/MCB.18.6.3612; van Holde K.E., 1988, CHROMATIN; vanHolde K, 1996, P NATL ACAD SCI USA, V93, P10548, DOI 10.1073/pnas.93.20.10548; WALLRATH LL, 1995, GENE DEV, V9, P1263, DOI 10.1101/gad.9.10.1263; WEINTRAUB H, 1985, CELL, V42, P705, DOI 10.1016/0092-8674(85)90267-3; WEINTRAUB H, 1984, CELL, V38, P17, DOI 10.1016/0092-8674(84)90522-1; WEITH A, 1985, CHROMOSOMA, V91, P287, DOI 10.1007/BF00328224; Whisstock J, 1998, TRENDS BIOCHEM SCI, V23, P63, DOI 10.1016/S0968-0004(97)01172-9; WIDOM J, 1986, J MOL BIOL, V190, P411, DOI 10.1016/0022-2836(86)90012-4; WILKIE TM, 1994, METHOD ENZYMOL, V237, P327; Wolffe A., 1995, CHROMATIN STRUCTURE; WOLFFE AP, 1993, COLD SPRING HARB SYM, V58, P225, DOI 10.1101/SQB.1993.058.01.027; WOODCOCK CL, 1993, P NATL ACAD SCI USA, V90, P9021, DOI 10.1073/pnas.90.19.9021; WOODCOCK CL, 1995, TRENDS CELL BIOL, V5, P272, DOI 10.1016/S0962-8924(00)89038-8; Woodcock CL, 1997, METHODS, V12, P84, DOI 10.1006/meth.1997.0450; WORCEL A, 1981, P NATL ACAD SCI-BIOL, V78, P1461, DOI 10.1073/pnas.78.3.1461; WREGGETT KA, 1994, CYTOGENET CELL GENET, V66, P99, DOI 10.1159/000133676; Zou S, 1997, P NATL ACAD SCI USA, V94, P7412, DOI 10.1073/pnas.94.14.7412; [No title captured]	88	93	100	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 26	1999	274	9					5626	5636		10.1074/jbc.274.9.5626	http://dx.doi.org/10.1074/jbc.274.9.5626			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	170KG	10026180	hybrid			2022-12-25	WOS:000078804400051
J	Sei, Y; Gallagher, KL; Basile, AS				Sei, Y; Gallagher, KL; Basile, AS			Skeletal muscle type ryanodine receptor is involved in calcium signaling in human B lymphocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL ANTIGEN RECEPTOR; SARCOPLASMIC-RETICULUM; RELEASE CHANNEL; CA-2+ RELEASE; CA2+ RELEASE; SURFACE-IMMUNOGLOBULIN; MALIGNANT HYPERTHERMIA; MOLECULAR-CLONING; BRAIN; ACTIVATION	The regulation of intracellular free Ca2+ concentration ([Ca2+](i)) in B cells remains poorly understood and is presently explained almost solely by inositol 1,4,5-triphosphate (IP3)-mediated Ca2+ release, followed by activation of a store-operated channel mechanism. In fact, there are reports indicating that IP3 production does not always correlate with the magnitude of Ca2+ release. We demonstrate here that human B cells ex press a ryanodine receptor (RYR) that functions as a Ca2+ release channel during the B cell antigen receptor (BCR)-stimulated Ca2+ signaling process. Immunoblotting studies showed that both human primary CD19(+) B and DAHIKI cells express a 565-kDa immunoreactive protein that is indistinguishable in molecular size and immunoreactivity from the RYR. Selective reverse transcription-polymerase chain reaction, restriction fragment length polymorphism, and sequencing of cloned cDNA indicated that the major isoform of the RYR expressed in primary CD19(+) B and DAKIKI cells is identical to the skeletal muscle type (RYR1). Saturation analysis of [H-3]ryanodine binding yielded B-max = 150 fmol/mg of protein and K-d = 110 nM in DAKIKI cells. In fluo-3-loaded CD19(+) B and DAKIKI cells, 4-chloro-m-cresol, a potent activator of Ca2+ release mediated by the ryanodine-sensitive Ca2+ release channel, induced Ca2+ release in a dose-dependent and ryanodine-sensitive fashion. Furthermore, BCR-mediated Ca2+ release in CD19(+) B cells was significantly altered by 4-chloro-m-cresol and ryanodine. These results indicate that RYR1 functions as a Ca2+ release channel during BCR-stimulated Ca2+ signaling and suggest that complex Ca2+ signals that control the cellular activities of B cells may be generated by cooperation of the IP3 receptor and RYR1.	Uniformed Serv Univ Hlth Sci, Dept Anesthesiol, Bethesda, MD 20814 USA; NIDDK, NIH, Bioorgan Chem Lab, Bethesda, MD 20814 USA	Uniformed Services University of the Health Sciences - USA; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Sei, Y (corresponding author), Uniformed Serv Univ Hlth Sci, Dept Anesthesiol, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA.	ysei@mx3.usuhs.mil						Akha AAS, 1996, J BIOL CHEM, V271, P7297, DOI 10.1074/jbc.271.13.7297; Berridge MJ, 1997, J PHYSIOL-LONDON, V499, P291, DOI 10.1113/jphysiol.1997.sp021927; BIJSTERBOSCH MK, 1986, BIOCHEM BIOPH RES CO, V137, P500, DOI 10.1016/0006-291X(86)91238-6; BOURGUIGNON LYW, 1995, J BIOL CHEM, V270, P17917, DOI 10.1074/jbc.270.30.17917; BROOKS SPJ, 1992, ANAL BIOCHEM, V201, P119, DOI 10.1016/0003-2697(92)90183-8; BUIXERAS E, 1993, IMMUNOL REV, V132, P5; CAMBIER JC, 1994, ANNU REV IMMUNOL, V12, P457, DOI 10.1146/annurev.immunol.12.1.457; CAMPBELL KP, 1981, J BIOL CHEM, V256, P4626; CHEN SRW, 1993, BIOCHEMISTRY-US, V32, P3743, DOI 10.1021/bi00065a029; CORONADO R, 1994, AM J PHYSIOL, V266, pC1485, DOI 10.1152/ajpcell.1994.266.6.C1485; DELMETSCH RE, 1997, NATUIRE, V386, P855; GIANNINI G, 1995, J CELL BIOL, V128, P893, DOI 10.1083/jcb.128.5.893; GILLARD EF, 1992, GENOMICS, V13, P1247, DOI 10.1016/0888-7543(92)90042-Q; HAKAMATA Y, 1994, FEBS LETT, V352, P206, DOI 10.1016/0014-5793(94)00955-4; HAKAMATA Y, 1992, FEBS LETT, V312, P229, DOI 10.1016/0014-5793(92)80941-9; HerrmannFrank A, 1996, BIOCHEM PHARMACOL, V52, P149, DOI 10.1016/0006-2952(96)00175-X; HerrmannFrank A, 1996, BBA-GEN SUBJECTS, V1289, P31, DOI 10.1016/0304-4165(95)00131-X; HOTH M, 1992, NATURE, V355, P353, DOI 10.1038/355353a0; IMAGAWA T, 1987, J BIOL CHEM, V262, P16636; INUI M, 1987, J BIOL CHEM, V262, P1740; MACDONALD RJ, 1987, METHOD ENZYMOL, V152, P219; MILLET I, 1988, EUR J IMMUNOL, V18, P545, DOI 10.1002/eji.1830180409; Ono Atsuko, 1995, Bulletin of Tokyo Medical and Dental University, V42, P9; OTSU K, 1990, J BIOL CHEM, V265, P13472; PADEH S, 1991, J CLIN INVEST, V87, P1114, DOI 10.1172/JCI115074; PEAKER CJG, 1994, CURR OPIN IMMUNOL, V6, P359, DOI 10.1016/0952-7915(94)90113-9; PUTNEY JW, 1990, CELL CALCIUM, V11, P611, DOI 10.1016/0143-4160(90)90016-N; ROIFMAN CM, 1987, EUR J IMMUNOL, V17, P1737, DOI 10.1002/eji.1830171209; SEI Y, 1991, J IMMUNOL METHODS, V137, P237; SEI Y, 1995, EXP CELL RES, V216, P222, DOI 10.1006/excr.1995.1028; TAKEMURA H, 1989, J BIOL CHEM, V264, P12266; TAKESHIMA H, 1989, NATURE, V339, P439, DOI 10.1038/339439a0; TAKESHIMA H, 1993, FEBS LETT, V322, P105, DOI 10.1016/0014-5793(93)81547-D; TEDDER TE, 1994, IMMUNOL TODAY, V15, P437, DOI 10.1016/0167-5699(94)90274-7; YAMADA H, 1993, J EXP MED, V177, P1613, DOI 10.1084/jem.177.6.1613; ZORZATO F, 1990, J BIOL CHEM, V265, P2244; ZORZATO F, 1993, MOL PHARMACOL, V44, P1192; Zucchi R, 1997, PHARMACOL REV, V49, P1; ZWEIFACH A, 1993, P NATL ACAD SCI USA, V90, P6295, DOI 10.1073/pnas.90.13.6295	39	92	95	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 26	1999	274	9					5995	6002		10.1074/jbc.274.9.5995	http://dx.doi.org/10.1074/jbc.274.9.5995			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	170KG	10026226	hybrid			2022-12-25	WOS:000078804400097
J	Thankavel, K; Shah, AH; Cohen, MS; Ikeda, T; Lorenz, RG; Curtiss, R; Abraham, SN				Thankavel, K; Shah, AH; Cohen, MS; Ikeda, T; Lorenz, RG; Curtiss, R; Abraham, SN			Molecular basis for the enterocyte tropism exhibited by Salmonella typhimurium type 1 fimbriae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; KLEBSIELLA-PNEUMONIAE; FAMILY ENTEROBACTERIACEAE; ADHESION PROTEIN; URINARY-TRACT; CELLS; EXPRESSION; ADHERENCE; SURFACE; BINDING	Salmonella typhimurium exhibits a distinct tropism for mouse enterocytes that is linked to their expression of type 1 fimbriae, The distinct binding traits of Salmonella type 1 fimbriae is also reflected in their binding to selected mannosylated proteins and in their ability to promote secondary bacterial aggregation on enterocyte surfaces. The determinant of binding in Salmonella type I fimbriae is a 35-kDa structurally distinct fimbrial subunit, FimHs, because inactivation of fimHs abolished binding activity in the resulting mutant without any apparent effect on fimbrial expression. Surprisingly, when expressed in the absence of other fimbrial components and as a translational fusion protein with MalE, FimHs failed to demonstrate any specific binding tropism and bound equally to all cells and mannosylated proteins tested. To determine if the binding specificity of Salmonella type 1 fimbriae was determined by the fimbrial shaft that is intimately associated with FimHs, we replaced the amino-terminal half of FimHs with the corresponding sequence from Escherichia coli FimH (FimHE) that contains the receptor binding domain of FimHE, The resulting hybrid fimbriae bearing FimHES on a Salmonella fimbrial shaft exhibited binding traits that resembled that of Salmonella rather than E, coli fimbriae, Apparently, the quaternary constraints imposed by the fimbrial shaft on the adhesin determine the distinct binding traits of S. typhimurium type 1 fimbriae.	Duke Univ, Med Ctr, Dept Pathol & Microbiol, Durham, NC 27710 USA; Washington Univ, Dept Biol, St Louis, MO 63130 USA; Azabu Univ, Sch Vet Med, Dept Vet Med, Kanagawa 229, Japan; Washington Univ, Sch Med, Dept Pathol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA	Duke University; Washington University (WUSTL); Azabu University; Washington University (WUSTL); Washington University (WUSTL)	Thankavel, K (corresponding author), Duke Univ, Med Ctr, Dept Pathol & Microbiol, Campus Box 3020, Durham, NC 27710 USA.	krishnan@acpub.duke.edu	Lorenz, Robin G/AAJ-1499-2021	Lorenz, Robin G/0000-0002-2514-9819	NIAID NIH HHS [AI 35678] Funding Source: Medline; NIDDK NIH HHS [DK 508141] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI035678] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABRAHAM SN, 1988, NATURE, V336, P682, DOI 10.1038/336682a0; BlancPotard AB, 1997, EMBO J, V16, P5376, DOI 10.1093/emboj/16.17.5376; CLEGG S, 1985, INFECT IMMUN, V48, P275, DOI 10.1128/IAI.48.2.275-279.1985; Clegg S., 1994, FIMBRIAE ADHESION GE, P105; Connell H, 1996, P NATL ACAD SCI USA, V93, P9827, DOI 10.1073/pnas.93.18.9827; DODD DC, 1982, INFECT IMMUN, V38, P764, DOI 10.1128/IAI.38.2.764-773.1982; DUGUID JP, 1976, J MED MICROBIOL, V9, P459, DOI 10.1099/00222615-9-4-459; DUGUID JP, 1966, J PATHOL BACTERIOL, V92, P107, DOI 10.1002/path.1700920113; DUGUID JP, 1980, BACTERIAL ADHERENC B, V6, P185; Ewen SWB, 1997, FEMS IMMUNOL MED MIC, V18, P185, DOI 10.1016/S0928-8244(97)00038-2; FAVREBONTE S, 1995, INFECT IMMUN, V63, P1318, DOI 10.1128/IAI.63.4.1318-1328.1995; FINLAY BB, 1989, MOL MICROBIOL, V3, P1833, DOI 10.1111/j.1365-2958.1989.tb00170.x; FIRON N, 1983, CARBOHYD RES, V120, P235, DOI 10.1016/0008-6215(83)88019-7; Galan JE, 1996, MOL MICROBIOL, V20, P263, DOI 10.1111/j.1365-2958.1996.tb02615.x; Groisman EA, 1996, CELL, V87, P791, DOI 10.1016/S0092-8674(00)81985-6; Hancox LS, 1997, FEMS IMMUNOL MED MIC, V19, P289, DOI 10.1016/S0928-8244(97)00095-3; HANSON MS, 1988, NATURE, V332, P265, DOI 10.1038/332265a0; JONSSON AB, 1994, MOL MICROBIOL, V13, P403, DOI 10.1111/j.1365-2958.1994.tb00435.x; KLEMM P, 1987, MOL GEN GENET, V208, P439, DOI 10.1007/BF00328136; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee CA, 1997, TRENDS MICROBIOL, V5, P148, DOI 10.1016/S0966-842X(97)01029-9; LOCKMAN HA, 1992, MOL MICROBIOL, V6, P933, DOI 10.1111/j.1365-2958.1992.tb01543.x; MADISON B, 1994, INFECT IMMUN, V62, P843, DOI 10.1128/IAI.62.3.843-848.1994; Malaviya R, 1996, NATURE, V381, P77, DOI 10.1038/381077a0; MILLS DM, 1995, MOL MICROBIOL, V15, P749, DOI 10.1111/j.1365-2958.1995.tb02382.x; ORNDORFF PE, 1984, J BACTERIOL, V159, P736, DOI 10.1128/JB.159.2.736-744.1984; PECK R, 1985, J IMMUNOL METHODS, V82, P131, DOI 10.1016/0022-1759(85)90232-7; PONNIAH S, 1991, J BACTERIOL, V173, P4195, DOI 10.1128/jb.173.13.4195-4202.1991; Sambrook J., 1989, MOL CLONING, pA1; SANDERSON KE, 1995, MICROBIOL REV, V59, P241, DOI 10.1128/MMBR.59.2.241-303.1995; Sokurenko EV, 1997, J BIOL CHEM, V272, P17880, DOI 10.1074/jbc.272.28.17880; Sokurenko EV, 1998, P NATL ACAD SCI USA, V95, P8922, DOI 10.1073/pnas.95.15.8922; STROMBERG N, 1991, P NATL ACAD SCI USA, V88, P9340, DOI 10.1073/pnas.88.20.9340; Sukupolvi S, 1997, INFECT IMMUN, V65, P5320, DOI 10.1128/IAI.65.12.5320-5325.1997; Svanborg C, 1996, ANN NY ACAD SCI, V797, P177, DOI 10.1111/j.1749-6632.1996.tb52959.x; SWENSON DL, 1994, MOL GEN GENET, V244, P216, DOI 10.1007/BF00283525; Thankavel K, 1997, J CLIN INVEST, V100, P1123, DOI 10.1172/JCI119623; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; van der Velden AWM, 1998, INFECT IMMUN, V66, P2803, DOI 10.1128/IAI.66.6.2803-2808.1998; YEH KS, 1995, J BACTERIOL, V177, P6861, DOI 10.1128/jb.177.23.6861-6865.1995; Zhang JP, 1996, SCIENCE, V273, P1234, DOI 10.1126/science.273.5279.1234	41	52	54	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 26	1999	274	9					5797	5809		10.1074/jbc.274.9.5797	http://dx.doi.org/10.1074/jbc.274.9.5797			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	170KG	10026202	hybrid			2022-12-25	WOS:000078804400073
J	Falchetti, ML; Falcone, G; D'Ambrosio, E; Verna, R; Alema, S; Levi, A				Falchetti, ML; Falcone, G; D'Ambrosio, E; Verna, R; Alema, S; Levi, A			Induction of telomerase activity in v-myc-transformed avian cells	ONCOGENE			English	Article						telomerase; v-Myc; v-Src; transformation; TRAP	DIFFERENTIATION PROGRAM; MYOGENIC CELLS; IMMORTAL CELLS; STEM-CELLS; ONCOGENES; CANCER; TRANSCRIPTION; PROTEIN; LINES; GENE	Telomerase activity is detectable in the majority of tumors or immortalized cell lines, but is repressed in most normal human somatic cells. It is generally assumed that reactivation of telomerase prevents the erosion of chromosome ends which occurs in cycling cells and, hence, hinders cellular replicative senescence. Here, we show that the expression of v-Myc oncoprotein by retroviral infection of telomerase-negative embryonal quail myoblasts and chicken neuroretina cells is sufficient for reactivating telomerase activity, earlier than telomere shortening could occur. Furthermore, the use of a conditional v-Myc-estrogen receptor protein (v-MycER) causes estrogen-dependent expression of detectable levels of telomerase activity in recently infected chick embryo fibroblasts and neuroretina cells. We conclude that the high levels of telomerase activity in v-Myc-expressing avian cells are not the mere consequence of transformation or of a differentiative block, since v-Src tyrosine kinase, which prevents terminal differentiation and promotes cell transformation, fails to induce telomerase activity.	Univ Roma La Sapienza, Ist Neurobiol, Rome, Italy; Univ Roma La Sapienza, Ist Biol Cellulare, Rome, Italy; Univ Roma La Sapienza, CNR, Ist Med Sperimentale, Rome, Italy; Univ Roma La Sapienza, Dipartimento Med Sperimentale, Rome, Italy	Sapienza University Rome; Sapienza University Rome; Consiglio Nazionale delle Ricerche (CNR); Sapienza University Rome; Sapienza University Rome	Levi, A (corresponding author), Univ Roma La Sapienza, Ist Neurobiol, Rome, Italy.		falchetti, maria laura/AAA-5586-2019; Falcone, Germana/A-3735-2016	Alema, Stefano/0000-0002-9869-6354; VERNA, Roberto/0000-0002-1869-3912; Falcone, Germana/0000-0002-3508-7623				ALEMA S, 1987, ADV CANCER RES, V49, P1, DOI 10.1016/S0065-230X(08)60792-7; ALEMA S, 1994, SEMIN CANCER BIOL, V5, P147; AMATI B, 1994, CURR OPIN GENET DEV, V4, P102, DOI 10.1016/0959-437X(94)90098-1; Belair CD, 1997, P NATL ACAD SCI USA, V94, P13677, DOI 10.1073/pnas.94.25.13677; Bilaud T, 1997, NAT GENET, V17, P236, DOI 10.1038/ng1097-236; BISTER K, 1987, ONCOGENE, V1, P97; Blasco MA, 1996, NAT GENET, V12, P200, DOI 10.1038/ng0296-200; Blasco MA, 1997, CELL, V91, P25, DOI 10.1016/S0092-8674(01)80006-4; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; BOETTIGER D, 1989, CURR TOP MICROBIOL, V147, P31; Broccoli D, 1996, MOL CELL BIOL, V16, P3765; Broccoli D, 1997, NAT GENET, V17, P231, DOI 10.1038/ng1097-231; BRYAN TM, 1995, EMBO J, V14, P4240, DOI 10.1002/j.1460-2075.1995.tb00098.x; CASALBORE P, 1987, NATURE, V326, P188, DOI 10.1038/326188a0; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; DELANGE T, 1995, TELOMERES, P265; Falchetti ML, 1998, NUCLEIC ACIDS RES, V26, P862, DOI 10.1093/nar/26.3.862; FALCONE G, 1985, P NATL ACAD SCI USA, V82, P426, DOI 10.1073/pnas.82.2.426; FALCONE G, 1991, MOL CELL BIOL, V11, P3331, DOI 10.1128/MCB.11.6.3331; FRANZA BR, 1986, CELL, V44, P409, DOI 10.1016/0092-8674(86)90462-9; Fujimoto K, 1997, BIOCHEM BIOPH RES CO, V241, P775, DOI 10.1006/bbrc.1997.7806; Grandori C, 1997, TRENDS BIOCHEM SCI, V22, P177, DOI 10.1016/S0968-0004(97)01025-6; Greaves M, 1996, TRENDS GENET, V12, P127, DOI 10.1016/0168-9525(96)30016-4; HARLEY CB, 1991, MUTAT RES, V256, P271, DOI 10.1016/0921-8734(91)90018-7; HARLEY CB, 1995, TELOMERES, P247; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; HIYAMA E, 1995, NAT MED, V1, P249, DOI 10.1038/nm0395-249; Holt SE, 1996, MOL CELL BIOL, V16, P2932; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Klingelhutz AJ, 1996, NATURE, V380, P79, DOI 10.1038/380079a0; LEJNINE S, 1995, P NATL ACAD SCI USA, V92, P2393, DOI 10.1073/pnas.92.6.2393; Li H, 1997, J BIOL CHEM, V272, P16729, DOI 10.1074/jbc.272.27.16729; LI LH, 1994, EMBO J, V13, P4070, DOI 10.1002/j.1460-2075.1994.tb06724.x; Lustig AJ, 1997, TRENDS CELL BIOL, V7, P299, DOI 10.1016/S0962-8924(97)01110-0; Makarov VL, 1997, CELL, V88, P657, DOI 10.1016/S0092-8674(00)81908-X; Meyerson M, 1997, CELL, V90, P785, DOI 10.1016/S0092-8674(00)80538-3; Pain B, 1996, DEVELOPMENT, V122, P2339; POLLERBERG GE, 1995, J NEUROSCI RES, V41, P427, DOI 10.1002/jnr.490410402; RAMSAY G, 1980, NATURE, V288, P170, DOI 10.1038/288170a0; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Shay JW, 1997, EUR J CANCER, V33, P787, DOI 10.1016/S0959-8049(97)00062-2; Stoppler H, 1997, J BIOL CHEM, V272, P13332, DOI 10.1074/jbc.272.20.13332; Strahl C, 1996, MOL CELL BIOL, V16, P53; Tahara H, 1995, CLIN CANCER RES, V1, P1245; Vaziri H, 1998, CURR BIOL, V8, P279, DOI 10.1016/S0960-9822(98)70109-5; VOJTA PJ, 1995, BBA-REV CANCER, V1242, P29, DOI 10.1016/0304-419X(95)00002-W; WEINBERG RA, 1989, CANCER RES, V49, P3713; WHITAKER NJ, 1995, ONCOGENE, V11, P971	49	23	23	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 18	1999	18	7					1515	1519		10.1038/sj.onc.1202438	http://dx.doi.org/10.1038/sj.onc.1202438			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	167UK	10050888				2022-12-25	WOS:000078651600013
J	Harhaj, EW; Good, LF; Xiao, GT; Sun, SC				Harhaj, EW; Good, LF; Xiao, GT; Sun, SC			Gene expression profiles in HTLV-I-immortalized T cells: deregulated expression of genes involved in apoptosis regulation	ONCOGENE			English	Article						HTLV-I; adult T-cell leukemia; T-cell immortalization; gene array; gene expression profile	VIRUS TYPE-I; TRANSCRIPTION FACTOR YB-1; NF-KAPPA-B; LEUKEMIA-VIRUS; TAX-PROTEIN; MOLECULAR-CLONING; SIGNALING COMPLEX; BINDING PROTEIN; INFECTED-CELLS; FAS-LIGAND	Human T-cell leukemia virus type I (HTLV-I) is the etiologic agent of adult T-cell leukemia, an acute and often fatal T-cell malignancy. A key step in HTLV-I-induced leukemigenesis is induction of abnormal T-cell growth and survival. Unlike antigen-stimulated T cells, which cease proliferation after a finite number of cell division, HTLV-I-infected T cells proliferate indefinitely (immortalized), thus facilitating occurrence of secondary genetic changes leading to malignant transformation. To explore the molecular basis of HTLV-I-induced abnormal T-cell survival, we compared the gene expression profiles of normal and HTLV-I-immortalized T cells using 'gene array'. These studies revealed a strikingly altered expression pattern of a large number of genes along with HTLV-I-mediated T-cell immortalization. Interestingly, many of these deregulated genes are involved in the control of programmed cell death or apoptosis. These findings indicate that disruption of the cellular apoptosis-regulatory network may play a role in the HTLV-I-mediated oncogenesis.	Penn State Univ, Coll Med, Dept Microbiol & Immunol, Hershey, PA 17033 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Sun, SC (corresponding author), Penn State Univ, Coll Med, Dept Microbiol & Immunol, 500 Univ Dr, Hershey, PA 17033 USA.				NCI NIH HHS [R01 CA68471-03] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA068471] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akagi Tsuyoshi, 1997, Leukemia (Basingstoke), V11, P25; ALEXANDRE C, 1991, ONCOGENE, V6, P543; Arai M, 1998, AIDS RES HUM RETROV, V14, P261, DOI 10.1089/aid.1998.14.261; Bargou RC, 1997, NAT MED, V3, P447, DOI 10.1038/nm0497-447; BAUM PR, 1994, EMBO J, V13, P3992, DOI 10.1002/j.1460-2075.1994.tb06715.x; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Brauweiler A, 1997, VIROLOGY, V231, P135, DOI 10.1006/viro.1997.8509; BROWNING JL, 1995, J IMMUNOL, V154, P33; Butscher WG, 1998, J BIOL CHEM, V273, P552, DOI 10.1074/jbc.273.1.552; Chenchik A, 1998, CLONTECHNIQUES, V13, P16; COPELAND KFT, 1994, AIDS RES HUM RETROV, V10, P1259, DOI 10.1089/aid.1994.10.1259; Crepieux P, 1997, MOL CELL BIOL, V17, P7375, DOI 10.1128/MCB.17.12.7375; CROSS SL, 1987, CELL, V49, P47, DOI 10.1016/0092-8674(87)90754-9; Deveraux QL, 1997, NATURE, V388, P300, DOI 10.1038/40901; Dick T, 1996, MOL CELL BIOL, V16, P1966; DORMAN DM, 1992, J BIOL CHEM, V267, P1279; Eischen CM, 1997, J IMMUNOL, V159, P1135; FEUER G, 1992, BIOCHIM BIOPHYS ACTA, V1114, P223, DOI 10.1016/0304-419X(92)90017-S; Foletta VC, 1998, J LEUKOCYTE BIOL, V63, P139, DOI 10.1002/jlb.63.2.139; Fujii J, 1996, NEPHROL DIAL TRANSPL, V11, P34; FUJII M, 1988, P NATL ACAD SCI USA, V85, P8526, DOI 10.1073/pnas.85.22.8526; Gajewski TF, 1996, CELL, V87, P589, DOI 10.1016/S0092-8674(00)81377-X; GonzalezGarcia A, 1997, J IMMUNOL, V158, P4104; GREEN PL, 1990, FASEB J, V4, P169, DOI 10.1096/fasebj.4.2.2404818; GRUSS HJ, 1995, BLOOD, V85, P3378, DOI 10.1182/blood.V85.12.3378.bloodjournal85123378; Guenal I, 1997, ONCOGENE, V15, P347, DOI 10.1038/sj.onc.1201182; Hetts SW, 1998, JAMA-J AM MED ASSOC, V279, P300, DOI 10.1001/jama.279.4.300; HINTZEN RQ, 1994, IMMUNOL TODAY, V15, P307, DOI 10.1016/0167-5699(94)90077-9; Imura A, 1996, J EXP MED, V183, P2185, DOI 10.1084/jem.183.5.2185; INOUE J, 1986, EMBO J, V5, P2883, DOI 10.1002/j.1460-2075.1986.tb04583.x; Janicke RU, 1996, MOL CELL BIOL, V16, P5245; JEANG KT, 1990, SCIENCE, V247, P1082, DOI 10.1126/science.2309119; KASHANCHI F, 1994, J VIROL, V68, P561, DOI 10.1128/JVI.68.1.561-565.1994; Kawai T, 1998, MOL CELL BIOL, V18, P1642, DOI 10.1128/MCB.18.3.1642; Kishi S, 1997, J EXP MED, V186, P57, DOI 10.1084/jem.186.1.57; KOEFFLER HP, 1984, BLOOD, V64, P482; Koni PA, 1997, IMMUNITY, V6, P491, DOI 10.1016/S1074-7613(00)80292-7; Lemasson I, 1997, J VIROL, V71, P1975, DOI 10.1128/JVI.71.3.1975-1983.1997; LI CCH, 1993, J VIROL, V67, P4205, DOI 10.1128/JVI.67.7.4205-4213.1993; LYNCH DH, 1995, IMMUNOL TODAY, V16, P569, DOI 10.1016/0167-5699(95)80079-4; MALEFYT RD, 1990, J IMMUNOL, V145, P2297; MARUYAMA M, 1987, CELL, V48, P343, DOI 10.1016/0092-8674(87)90437-5; Mehlen P, 1996, J BIOL CHEM, V271, P16510, DOI 10.1074/jbc.271.28.16510; Mehlen P, 1997, J BIOL CHEM, V272, P31657, DOI 10.1074/jbc.272.50.31657; Mena MA, 1997, J NEUROCHEM, V69, P21; MERL S, 1984, BLOOD, V64, P967; MIGITA K, 1995, IMMUNOLOGY, V85, P550; MIURA K, 1992, BIOCHEM BIOPH RES CO, V187, P375, DOI 10.1016/S0006-291X(05)81503-7; MIURA S, 1991, MOL CELL BIOL, V11, P1313, DOI 10.1128/MCB.11.3.1313; MIYOSHI I, 1981, GANN, V72, P978; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; NAGATA K, 1989, J VIROL, V63, P3220, DOI 10.1128/JVI.63.8.3220-3226.1989; Ohga T, 1996, CANCER RES, V56, P4224; Ohtani K, 1998, J BIOL CHEM, V273, P14119, DOI 10.1074/jbc.273.23.14119; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; PERSAUD D, 1995, J VIROL, V69, P6297, DOI 10.1128/JVI.69.10.6297-6303.1995; Petricoin EF, 1997, NATURE, V390, P629, DOI 10.1038/37648; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; PROSPERI MT, 1993, J BIOL CHEM, V268, P11050; Rothe M, 1995, CELL, V83, P1243, DOI 10.1016/0092-8674(95)90149-3; Roy N, 1997, EMBO J, V16, P6914, DOI 10.1093/emboj/16.23.6914; SAGGIORO D, 1991, AIDS RES HUM RETROV, V7, P571, DOI 10.1089/aid.1991.7.571; SAURI H, 1995, BIOCHEM BIOPH RES CO, V208, P964, DOI 10.1006/bbrc.1995.1428; SIEKEVITZ M, 1987, P NATL ACAD SCI USA, V84, P5389, DOI 10.1073/pnas.84.15.5389; SMITH MR, 1991, J CLIN INVEST, V87, P761, DOI 10.1172/JCI115078; SODROSKI J, 1992, BIOCHIM BIOPHYS ACTA, V1114, P19, DOI 10.1016/0304-419X(92)90003-H; SUGIMOTO A, 1995, EMBO J, V14, P4434, DOI 10.1002/j.1460-2075.1995.tb00122.x; TSUJIMOTO A, 1991, J VIROL, V65, P1420, DOI 10.1128/JVI.65.3.1420-1426.1991; Tsushima H, 1997, CELL GROWTH DIFFER, V8, P1317; Uchiyama T, 1997, ANNU REV IMMUNOL, V15, P15, DOI 10.1146/annurev.immunol.15.1.15; UITTENBOGAARD MN, 1995, J BIOL CHEM, V270, P28503, DOI 10.1074/jbc.270.48.28503; Uren AG, 1996, P NATL ACAD SCI USA, V93, P4974, DOI 10.1073/pnas.93.10.4974; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; VanSnick J, 1996, J IMMUNOL, V157, P2570; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Ware CF, 1996, J CELL BIOCHEM, V60, P47, DOI 10.1002/(SICI)1097-4644(19960101)60:1<47::AID-JCB8>3.3.CO;2-H; Weiss Arthur, 1993, P467; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; YAMAMOTO M, 1990, GENE DEV, V4, P1650, DOI 10.1101/gad.4.10.1650; Yin CY, 1997, NATURE, V385, P637, DOI 10.1038/385637a0; YOSHIDA M, 1995, J CANCER RES CLIN, V121, P521, DOI 10.1007/BF01197764; YOSHIDA M, 1982, P NATL ACAD SCI-BIOL, V79, P2031, DOI 10.1073/pnas.79.6.2031	84	75	76	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 11	1999	18	6					1341	1349		10.1038/sj.onc.1202405	http://dx.doi.org/10.1038/sj.onc.1202405			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	165FW	10022816				2022-12-25	WOS:000078510900010
J	Kroll, M; Margottin, F; Kohl, A; Renard, P; Durand, H; Concordet, JP; Bachelerie, F; Arenzana-Seisdedos, F; Benarous, R				Kroll, M; Margottin, F; Kohl, A; Renard, P; Durand, H; Concordet, JP; Bachelerie, F; Arenzana-Seisdedos, F; Benarous, R			Inducible degradation of I kappa B alpha by the proteasome requires interaction with the F-box protein h-beta TrCP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN PROTEOLYSIS MACHINERY; VIRUS EXPRESSION SYSTEM; PRECURSOR P105; VPU PROTEIN; CELL-CYCLE; ACTIVATION; PHOSPHORYLATION; PATHWAY; COMPLEX; KINASE	Activation of NF-kappa B transcription factors requires phosphorylation and ubiquitin-proteasome-dependent degradation of I kappa B proteins. We provide evidence that a human F-box protein, h-beta TrCP, a component of Skp1-Cullin-F-box protein (SCF) complexes, a new class of E3 ubiquitin ligases, is essential for inducible degradation of I kappa B alpha. beta TrCP associates with Ser(32)-Ser(36) phosphorylated, but not with unmodified I kappa B alpha or Ser(32)-Ser(36) phosphorylation-deficient mutants. Expression of a F-box-deleted beta TrCP inhibits I kappa B alpha degradation, promotes accumulation of phosphorylated Ser(32)-Ser(36) I kappa B alpha, and prevents NF-kappa B-dependent transcription. Our findings indicate that beta TrCP is the adaptor protein required for I kappa B alpha recognition by the SCFbeta TrCP E3 complex that ubiquitinates I kappa B alpha and makes it a substrate for the proteasome.	Inst Cochin Genet Mol, INSERM CJF9703, F-75014 Paris, France; Univ Paris 05, ICGM, U129 INSERM, F-75014 Paris, France; Inst Pasteur, Unite Immunol Virale, F-75724 Paris, France; Inst Pasteur, Grp Bunyavirides, Unite Arbovirus & Virus Fievres Hemorrag, F-75724 Paris 15, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Universite de Montpellier; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Benarous, R (corresponding author), Inst Cochin Genet Mol, INSERM CJF9703, F-75014 Paris, France.		Arenzana-Seisdedos, Fernando/E-5835-2016; concordet, jean-paul/C-3417-2015; BACHELERIE, FRANCOISE/F-8823-2013; Margottin-Goguet, Florence/F-9272-2013	BACHELERIE, FRANCOISE/0000-0002-0399-3277; Margottin-Goguet, Florence/0000-0002-3124-6690; Durand, Herve/0000-0002-8167-4693; Concordet, Jean-Paul/0000-0001-8924-4316				ALKALAY I, 1995, P NATL ACAD SCI USA, V92, P10599, DOI 10.1073/pnas.92.23.10599; ARENZANASEISDEDOS F, 1993, J VIROL, V67, P6596, DOI 10.1128/JVI.67.11.6596-6604.1993; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Bai C, 1996, CELL, V86, P263, DOI 10.1016/S0092-8674(00)80098-7; Baldi L, 1996, J BIOL CHEM, V271, P376, DOI 10.1074/jbc.271.1.376; BEG AA, 1993, GENE DEV, V7, P2064, DOI 10.1101/gad.7.11.2064; BERGLUND P, 1993, BIO-TECHNOL, V11, P916, DOI 10.1038/nbt0893-916; Blasey HD, 1997, CYTOTECHNOLOGY, V24, P65, DOI 10.1023/A:1007974121182; Chen ZJ, 1996, CELL, V84, P853, DOI 10.1016/S0092-8674(00)81064-8; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Feldman RMR, 1997, CELL, V91, P221, DOI 10.1016/S0092-8674(00)80404-3; FRIBORG J, 1995, J ACQ IMMUN DEF SYND, V8, P10; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Haas AL, 1997, FASEB J, V11, P1257; HENKEL T, 1993, NATURE, V365, P182, DOI 10.1038/365182a0; HERSHKO A, 1983, CELL, V34, P11, DOI 10.1016/0092-8674(83)90131-9; Hiscott J, 1997, J LEUKOCYTE BIOL, V62, P82, DOI 10.1002/jlb.62.1.82; HOCHSTRASSER M, 1995, CURR OPIN CELL BIOL, V7, P215, DOI 10.1016/0955-0674(95)80031-X; JAFFRAY E, 1995, MOL CELL BIOL, V15, P2166; JENTSCH S, 1995, CELL, V82, P881, DOI 10.1016/0092-8674(95)90021-7; Jiang J, 1998, NATURE, V391, P493, DOI 10.1038/35154; Li FN, 1997, EMBO J, V16, P5629, DOI 10.1093/emboj/16.18.5629; LILJESTROM P, 1991, BIO-TECHNOL, V9, P1356, DOI 10.1038/nbt1291-1356; LILJESTROM P, 1995, CURRENT PROTOCOLS MO, V2; Ling L, 1998, P NATL ACAD SCI USA, V95, P3792, DOI 10.1073/pnas.95.7.3792; Lisztwan J, 1998, EMBO J, V17, P368, DOI 10.1093/emboj/17.2.368; Lyapina SA, 1998, P NATL ACAD SCI USA, V95, P7451, DOI 10.1073/pnas.95.13.7451; Margottin F, 1998, MOL CELL, V1, P565, DOI 10.1016/S1097-2765(00)80056-8; MELLITS KH, 1993, NUCLEIC ACIDS RES, V21, P5059, DOI 10.1093/nar/21.22.5059; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Michel JJ, 1998, CELL GROWTH DIFFER, V9, P435; NAUMANN M, 1993, EMBO J, V12, P213, DOI 10.1002/j.1460-2075.1993.tb05647.x; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; Patton EE, 1998, TRENDS GENET, V14, P236, DOI 10.1016/S0168-9525(98)01473-5; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; Rodriguez MS, 1996, ONCOGENE, V12, P2425; Sachdev S, 1998, MOL CELL BIOL, V18, P5445, DOI 10.1128/MCB.18.9.5445; SCHERER DC, 1995, P NATL ACAD SCI USA, V92, P11259, DOI 10.1073/pnas.92.24.11259; SCHUBERT U, 1994, J VIROL, V68, P2260, DOI 10.1128/JVI.68.4.2260-2271.1994; Skowyra D, 1997, CELL, V91, P209, DOI 10.1016/S0092-8674(00)80403-1; Willems AR, 1996, CELL, V86, P453, DOI 10.1016/S0092-8674(00)80118-X; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; Yaron A, 1997, EMBO J, V16, P6486, DOI 10.1093/emboj/16.21.6486; Yaron A, 1998, NATURE, V396, P590, DOI 10.1038/25159; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7	48	112	118	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 19	1999	274	12					7941	7945		10.1074/jbc.274.12.7941	http://dx.doi.org/10.1074/jbc.274.12.7941			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	178LU	10075690	hybrid			2022-12-25	WOS:000079268100049
J	Musch, MW; Hubert, EM; Goldstein, L				Musch, MW; Hubert, EM; Goldstein, L			Volume expansion stimulates p72(syk) and p56(lyn) in skate erythrocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL ANTIGEN RECEPTOR; PROTEIN TYROSINE PHOSPHORYLATION; AMINO-ACID-SEQUENCE; BAND-3 PROTEIN; TAURINE EFFLUX; CROSS-LINKING; SYK; KINASE; TRANSPORT; ACTIVATION	Hypotonic volume expansion of skate erythrocytes rapidly stimulates the tyrosine phosphorylation of band 3, the membrane protein thought to mediate the osmotically sensitive taurine efflux, Skate erythrocytes possess numerous tyrosine kinases including p59fyn, p56lyn, pp60(src), and p72(syk), demonstrated by immune complex assays measuring autocatalytic kinase activity. Inclusion of the cytoplasmic domain of band 3 in this assay showed that only Syk and Lyn can directly phosphorylate the cytoplasmic domain of band 3, Upon cell volume expansion, Syk activity was increased as assessed by three different assays (immune complex assay measuring autophosphorylation, assay of the level of phosphotyrosine of the immunoprecipitated kinase, and assay of level of P-32 in the kinase immunoprecipitated from cells prelabeled with (PO4)-P-32 and then volume-expanded). The tyrosine kinase Lyn was also stimulated by volume expansion, most notably when analyzed by the latter two methods. Volume expansion stimulated a large increase in the ability of Syk to phosphorylate band 3 at times that coincide with the stimulation of taurine flux. The stilbene piceatannol inhibited Syk preferentially over Lyn and other tyrosine kinases and inhibited volume-stimulated taurine efflux in a concentration-dependent manner similar to that for the inhibition of Syk, Two major phosphorylation peaks were detected in tryptic digests of cdb3 separated by reverse phase HPLC, Edman degradation demonstrated a phosphotyrosine in a YXXL motif. In conclusion, p72(syk) appears to be a strong candidate as a pivotal signal-transducing step in the volume-activated taurine efflux in skate red cells. The level of band-3 phosphorylation may be regulated, in addition, by a protein-tyrosine phosphatase of the 1B variety.	Brown Univ, Div Biol & Med, Providence, RI 02912 USA; Mt Desert Isl Biol Lab, Salsbury Cove, ME 04672 USA; Univ Chicago, Inflammatory Bowel Dis Res Ctr, Chicago, IL 60637 USA	Brown University; Mount Desert Island Biological Laboratory; University of Chicago	Goldstein, L (corresponding author), Brown Univ, Div Biol & Med, Box GB-311, Providence, RI 02912 USA.	Leon_Goldstein@brown.edu			NIDDK NIH HHS [DK-47722, DK-42086, DK-38510] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK042086, R37DK047722, R01DK038510, R01DK047722] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		CLARI G, 1987, BIOCHEM BIOPH RES CO, V142, P587, DOI 10.1016/0006-291X(87)90314-7; FIEVET B, 1995, EMBO J, V14, P5158, DOI 10.1002/j.1460-2075.1995.tb00200.x; Fievet B, 1998, P NATL ACAD SCI USA, V95, P10996, DOI 10.1073/pnas.95.18.10996; GOLDSTEIN L, 1991, AM J PHYSIOL, V260, pR1014, DOI 10.1152/ajpregu.1991.260.5.R1014; Goldstein L, 1996, KIDNEY INT, V49, P1690, DOI 10.1038/ki.1996.249; Gotoh A, 1997, CELL GROWTH DIFFER, V8, P721; HARRISON ML, 1994, J BIOL CHEM, V269, P955; HEFFETZ D, 1990, J BIOL CHEM, V265, P2896; HUBNER S, 1992, BIOCHEM J, V285, P17; HUNKAPILLER MW, 1983, METHOD ENZYMOL, V91, P227; JENNINGS ML, 1984, J MEMBRANE BIOL, V80, P105, DOI 10.1007/BF01868768; Latour S, 1996, J BIOL CHEM, V271, P22782, DOI 10.1074/jbc.271.37.22782; Minetti G, 1998, BIOCHEM J, V335, P305, DOI 10.1042/bj3350305; MUSCH MW, 1994, AM J PHYSIOL, V266, pR65, DOI 10.1152/ajpregu.1994.266.1.R65; Musch MW, 1996, J BIOL CHEM, V271, P21221, DOI 10.1074/jbc.271.35.21221; MUSCH MW, 1994, J BIOL CHEM, V269, P19683; Musch MW, 1998, AM J PHYSIOL-REG I, V274, pR1677, DOI 10.1152/ajpregu.1998.274.6.R1677; Peters JD, 1996, J BIOL CHEM, V271, P4755; Qin SF, 1997, J BIOL CHEM, V272, P17994, DOI 10.1074/jbc.272.29.17994; Richards JD, 1996, J BIOL CHEM, V271, P6458, DOI 10.1074/jbc.271.11.6458; TUY FPD, 1983, NATURE, V305, P435; Wan Y, 1997, J BIOL CHEM, V272, P17209, DOI 10.1074/jbc.272.27.17209; Wang XY, 1997, J BIOCHEM-TOKYO, V121, P325; WEISS A, 1993, CELL, V73, P209, DOI 10.1016/0092-8674(93)90221-B; Yan SR, 1997, J IMMUNOL, V158, P1902; YANNOUKAKOS D, 1991, BIOCHIM BIOPHYS ACTA, V1066, P70, DOI 10.1016/0005-2736(91)90252-4; ZICK Y, 1990, BIOCHEMISTRY-US, V29, P10240, DOI 10.1021/bi00496a013; Zipser Y, 1996, BIOCHEM J, V314, P881, DOI 10.1042/bj3140881	28	43	44	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 19	1999	274	12					7923	7928		10.1074/jbc.274.12.7923	http://dx.doi.org/10.1074/jbc.274.12.7923			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	178LU	10075687	hybrid			2022-12-25	WOS:000079268100046
J	Prichard, L; Deloulme, JC; Storm, DR				Prichard, L; Deloulme, JC; Storm, DR			Interactions between neurogranin and calmodulin in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; LONG-TERM POTENTIATION; BINDING-PROTEIN; NEUROMODULIN GAP-43; 2-HYBRID SYSTEM; SYNAPTIC TRANSMISSION; PHOSPHORYLATION SITE; SELECTIVE INCREASE; DEPENDENT TARGET; ADENYLYL-CYCLASE	Neurogranin is a neural-specific, calmodulin (CaM)binding protein that is phosphorylated by protein kinase C (PKC) within its IQ domain at serine 36. Since CaM binds to neurogranin through the IQ domain, PKC phosphorylation and CaM binding are mutually exclusive. Consequently, we hypothesize that neurogranin may function to concentrate CaM at specific sites in neurons and release free CaM in response to increased Ca2+ and PKC activation. However, it has not been established that neurogranin interacts with CaM in vivo, In this study, we examined this question using yeast two-hybrid methodology. We also searched for additional proteins that might interact with neurogranin by screening brain cDNA libraries. Our data illustrate that CaM binds to neurogranin in vivo and that CaM is the only neurogranin-interacting protein isolated from brain cDNA libraries. Single amino acid mutagenesis indicated that residues within the IQ domain are important for CaM binding to neurogranin in vivo. The Ile-33 --> Gin point mutant completely inhibited and Arg-38 --> Gin and Ser-36 --> Asp point mutants reduced neurogranin/CaM interactions. These data demonstrate that CaM is the major protein that interacts with neurogranin in uiuo and support the hypothesis that phosphorylation of neurogranin at Ser-36 regulates its binding to CaM.	Univ Washington, Dept Pharmacol, Seattle, WA 98195 USA; CENG, BRCE, DBMS, INSERM U244, F-38054 Grenoble 9, France	University of Washington; University of Washington Seattle; Institut National de la Sante et de la Recherche Medicale (Inserm)	Storm, DR (corresponding author), Univ Washington, Dept Pharmacol, Box 357280, Seattle, WA 98195 USA.		Deloulme, Jean Christophe/P-6858-2017	Deloulme, Jean Christophe/0000-0002-2234-5865				ALEXANDER KA, 1987, J BIOL CHEM, V262, P6108; ALEXANDER KA, 1988, J BIOL CHEM, V263, P7544; ANDREASEN TJ, 1983, BIOCHEMISTRY-US, V22, P4615, DOI 10.1021/bi00289a001; Apel E D, 1992, Perspect Dev Neurobiol, V1, P3; APEL ED, 1990, BIOCHEMISTRY-US, V29, P2330, DOI 10.1021/bi00461a017; BARTEL P, 1993, BIOTECHNIQUES, V14, P920; Bartel P. L., 1993, CELLULAR INTERACTION, P153; BAUDIER J, 1989, J BIOL CHEM, V264, P1824; BAUDIER J, 1991, J BIOL CHEM, V266, P229; Benowitz LI, 1997, TRENDS NEUROSCI, V20, P84, DOI 10.1016/S0166-2236(96)10072-2; BIEGALKE BJ, 1990, VIROLOGY, V177, P657, DOI 10.1016/0042-6822(90)90531-U; Brill S, 1996, MOL CELL BIOL, V16, P4869; Chao S, 1996, MOL BRAIN RES, V40, P195, DOI 10.1016/0169-328X(96)00049-6; CHAPMAN ER, 1991, J BIOL CHEM, V266, P207; CHAPMAN ER, 1992, J BIOL CHEM, V267, P25233; CHAPMAN ER, 1991, PROG BRAIN RES, V89, P37; CHENEY R E, 1992, Current Opinion in Cell Biology, V4, P27, DOI 10.1016/0955-0674(92)90055-H; DELOULME JC, 1991, FEBS LETT, V282, P183, DOI 10.1016/0014-5793(91)80473-G; FEDOROV NB, 1995, EUR J NEUROSCI, V7, P819, DOI 10.1111/j.1460-9568.1995.tb00685.x; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; Gamby C, 1996, J BIOL CHEM, V271, P26698, DOI 10.1074/jbc.271.43.26698; GEBALLE AP, 1988, J VIROL, V62, P3334, DOI 10.1128/JVI.62.9.3334-3340.1988; GERENDASY DD, 1994, J BIOL CHEM, V269, P22420; GERENDASY DD, 1995, J BIOL CHEM, V270, P6741, DOI 10.1074/jbc.270.12.6741; Gerendasy DD, 1997, MOL NEUROBIOL, V15, P131, DOI 10.1007/BF02740632; GERENDASY DD, 1994, J MOL NEUROSCI, V5, P133, DOI 10.1007/BF02736729; GIANOTTI C, 1992, NEURON, V8, P843, DOI 10.1016/0896-6273(92)90198-M; HOUBRE D, 1991, J BIOL CHEM, V266, P7121; JANOUEIXLEROSEY I, 1995, J BIOL CHEM, V270, P14801, DOI 10.1074/jbc.270.24.14801; KAUER JA, 1988, NATURE, V334, P250, DOI 10.1038/334250a0; KLANN E, 1992, J NEUROCHEM, V58, P1576, DOI 10.1111/j.1471-4159.1992.tb11382.x; LIU YC, 1990, TRENDS PHARMACOL SCI, V11, P107; LOVINGER DM, 1985, BRAIN RES, V343, P137, DOI 10.1016/0006-8993(85)91167-9; Lu PJ, 1997, J BIOL CHEM, V272, P466; MALENKA RC, 1988, SCIENCE, V242, P81, DOI 10.1126/science.2845577; MARTZEN MR, 1995, J NEUROCHEM, V64, P92; NEEL VA, 1994, DEVELOPMENT, V120, P2235; NeunerJehle M, 1996, BRAIN RES, V733, P149, DOI 10.1016/0006-8993(96)00786-X; NICOLL RA, 1988, NEURON, V1, P97, DOI 10.1016/0896-6273(88)90193-6; NICOLL RA, 1995, NATURE, V377, P115, DOI 10.1038/377115a0; PAUDEL HK, 1993, J BIOL CHEM, V268, P6207; PERSECHINI A, 1989, J BIOL CHEM, V264, P8052; Petrova TV, 1996, J BIOL CHEM, V271, P26646, DOI 10.1074/jbc.271.43.26646; RAMAKERS GMJ, 1995, J BIOL CHEM, V270, P13892, DOI 10.1074/jbc.270.23.13892; REPRESA A, 1990, J NEUROSCI, V10, P3782, DOI 10.1523/JNEUROSCI.10-12-03782.1990; ROBERSON ED, 1995, BEHAV BRAIN SCI, V18, P485, DOI 10.1017/S0140525X0003942X; ROUTTENBERG A, 1985, BEHAV NEURAL BIOL, V43, P3, DOI 10.1016/S0163-1047(85)91426-8; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; Sheu FS, 1996, J BIOL CHEM, V271, P22407, DOI 10.1074/jbc.271.37.22407; SLEMMON JR, 1994, BIOCHEMISTRY-US, V33, P5653, DOI 10.1021/bi00184a039; Son H, 1996, CELL, V87, P1015, DOI 10.1016/S0092-8674(00)81796-1; Storm DR, 1998, NEURON, V20, P1199, DOI 10.1016/S0896-6273(00)80500-0; Villacres EC, 1998, J NEUROSCI, V18, P3186; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; VOJTEK AB, 1997, YEAST 2 HYBRID SYSTE, P29; WATSON JB, 1992, P NATL ACAD SCI USA, V89, P8581, DOI 10.1073/pnas.89.18.8581; WATSON JB, 1994, MOL BRAIN RES, V27, P323, DOI 10.1016/0169-328X(94)90017-5; WATSON JB, 1990, J NEUROSCI RES, V26, P397, DOI 10.1002/jnr.490260402; WONG YH, 1991, NATURE, V351, P63, DOI 10.1038/351063a0; XIA ZG, 1993, J NEUROCHEM, V60, P305, DOI 10.1111/j.1471-4159.1993.tb05852.x	60	80	82	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	1999	274	12					7689	7694		10.1074/jbc.274.12.7689	http://dx.doi.org/10.1074/jbc.274.12.7689			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	178LU	10075657	hybrid			2022-12-25	WOS:000079268100016
J	Asano, S; Matsuda, S; Hoshina, S; Sakamoto, S; Takeguchi, N				Asano, S; Matsuda, S; Hoshina, S; Sakamoto, S; Takeguchi, N			A chimeric gastric H+,K+-ATPase inhibitable with both ouabain and SCH 28080	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NA,K-ATPASE ALPHA-SUBUNIT; SITE-DIRECTED MUTAGENESIS; CATALYTIC SUBUNIT; BINDING; ATPASE; IDENTIFICATION; SCH-28080; SENSITIVITY; RESISTANCE; MECHANISM	2-Methyl-8-(phenylmethoxy) imidazo( 1,2-a) pyridine-3-acetonitrile (SCH 28080) is a K+ site inhibitor specific for gastric H+,K+-ATPase and seems to be a counterpart of ouabain for Na+,K+-ATPase from the viewpoint of reaction pattern (i.e. reversible binding, K+ antagonism, and binding on the extracellular side). In this study, we constructed several chimeric molecules between H+,K+-ATPase and Na+,K+-ATPase alpha-subunits by using rabbit H+,K+-ATPase as a parental molecule. We found that the entire extracellular loop 1 segment between the first and second transmembrane segments (M1 and M2) and the luminal half of the M1 transmembrane segment of H+,K+-ATPase alpha-subunit were exchangeable with those of Na+,K+-ATPase, respectively, preserving H+,K+-ATPase activity, and that these segments are not essential for SCH 28080 binding. We found that several amino acid residues, including Glu-822, Thr-825, and Pro-829 in the M6 segment of H+,K+-ATPase alpha-subunit are involved in determining the affinity for this inhibitor. Furthermore, we found that a chimeric H+,K+-ATPase acquired ouabain sensitivity and maintained SCH 28080 sensitivity when the loop I segment and Cys-815 in the loop 3 segment of the H+,K+-ATPase cu-subunit were simultaneously replaced by the corresponding segment and amino acid residue (Thr) of Na+,K+-ATPase, respectively, indicating that the binding sites of ouabain and SCH 28080 are separate. In this H+,K+-ATPase chimera, 12 amino acid residues in M1, M4, and loop 1-4 that have been suggested to be involved in ouabain binding of Na+,K+-ATPase alpha-subunit are present; however, the low ouabain sensitivity indicates the possibility that the sensitivity may be increased by additional amino acid substitutions, which shift the overall structural integrity of this chimeric H+,K+-ATPase toward that of Na+,K+-ATPase.	Toyama Med & Pharmaceut Univ, Mol Genet Res Ctr, Toyama 9300194, Japan; Toyama Med & Pharmaceut Univ, Fac Pharmaceut Sci, Toyama 9300194, Japan	University of Toyama; University of Toyama	Asano, S (corresponding author), Toyama Med & Pharmaceut Univ, Mol Genet Res Ctr, 2630 Sugitani, Toyama 9300194, Japan.	shinji@ms.toyama-mpu.ac.jp		Asano, Shinji/0000-0003-1443-8970				ASANO S, 1994, BIOCHEM J, V299, P59, DOI 10.1042/bj2990059; Asano S, 1997, J BIOL CHEM, V272, P17668, DOI 10.1074/jbc.272.28.17668; Asano S, 1996, J BIOL CHEM, V271, P2740, DOI 10.1074/jbc.271.5.2740; ASKEW GR, 1994, J BIOL CHEM, V269, P24120; BAMBERG K, 1992, BIOCHIM BIOPHYS ACTA, V1131, P69, DOI 10.1016/0167-4781(92)90100-E; BEIL W, 1986, BRIT J PHARMACOL, V88, P19, DOI 10.1111/j.1476-5381.1986.tb09466.x; BLOSTEIN R, 1993, J BIOL CHEM, V268, P10654; Burns EL, 1996, J BIOL CHEM, V271, P15879, DOI 10.1074/jbc.271.27.15879; CANESSA CM, 1993, J BIOL CHEM, V268, P17722; CANESSA CM, 1992, EMBO J, V11, P1681, DOI 10.1002/j.1460-2075.1992.tb05218.x; Canfield VA, 1998, BIOCHEMISTRY-US, V37, P7509, DOI 10.1021/bi980174h; Cougnon M, 1996, J BIOL CHEM, V271, P7277, DOI 10.1074/jbc.271.13.7277; Croyle ML, 1997, EUR J BIOCHEM, V248, P488, DOI 10.1111/j.1432-1033.1997.00488.x; FENG JN, 1994, BIOCHEMISTRY-US, V33, P4218, DOI 10.1021/bi00180a015; ISHII T, 1993, P NATL ACAD SCI USA, V90, P8881, DOI 10.1073/pnas.90.19.8881; KOELING DJ, 1989, J BIOL CHEM, V264, P5545; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lyu RM, 1997, AM J PHYSIOL-CELL PH, V272, pC1717, DOI 10.1152/ajpcell.1997.272.5.C1717; MORII M, 1989, GASTROENTEROLOGY, V96, P1453, DOI 10.1016/0016-5085(89)90512-X; MORII M, 1995, BIOCHEM PHARMACOL, V49, P1729, DOI 10.1016/0006-2952(95)00090-M; MUNSON KB, 1991, J BIOL CHEM, V266, P18976; Palasis M, 1996, J BIOL CHEM, V271, P14176, DOI 10.1074/jbc.271.24.14176; PRICE EM, 1988, BIOCHEMISTRY-US, V27, P8400, DOI 10.1021/bi00422a016; SCHULTHEIS PJ, 1993, J BIOL CHEM, V268, P22686; SCOTT CK, 1985, EUR J PHARMACOL, V112, P268, DOI 10.1016/0014-2999(85)90508-4; SHULL GE, 1985, NATURE, V316, P691, DOI 10.1038/316691a0; SHULL GE, 1986, BIOCHEMISTRY-US, V25, P8125, DOI 10.1021/bi00373a001; Swarts HGP, 1996, J BIOL CHEM, V271, P29764, DOI 10.1074/jbc.271.47.29764; TAKEGUCHI M, 1990, GASTROENTEROLOGY, V99, P1339, DOI 10.1016/0016-5085(90)91159-4; WALLMARK B, 1985, J BIOL CHEM, V260, P3681; Yamamoto S, 1996, AM J PHYSIOL-CELL PH, V270, pC457, DOI 10.1152/ajpcell.1996.270.2.C457; YODA A, 1970, BIOCHEM BIOPH RES CO, V40, P880, DOI 10.1016/0006-291X(70)90985-X	32	30	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	1999	274	11					6848	6854		10.1074/jbc.274.11.6848	http://dx.doi.org/10.1074/jbc.274.11.6848			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	175DV	10066737	hybrid			2022-12-25	WOS:000079078400009
J	Barak, LS; Warabi, K; Feng, X; Caron, MG; Kwatra, MM				Barak, LS; Warabi, K; Feng, X; Caron, MG; Kwatra, MM			Real-time visualization of the cellular redistribution of G protein-coupled receptor kinase 2 and beta-arrestin 2 during homologous desensitization of the substance P receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PAROTID ACINAR-CELLS; ACTIVATION; AGONIST; INTERNALIZATION; PHOSPHOLIPIDS; FIBROBLASTS; HYDROLYSIS; MIGRATION	The substance P receptor (SPR) is a G protein-coupled receptor (GPCR) that plays a key role in pain regulation. The SPR desensitizes in the continued presence of agonist, presumably via mechanisms that implicate G protein coupled receptor kinases (GRKs) and beta-arrestins, The temporal relationship of these proposed biochemical events has never been established for any GPCR other than rhodopsin beyond the resolution provided by biochemical assays. We investigate the real-time activation and desensitization of the human SPR in live HEK293 cells using green fluorescent protein conjugates of protein kinase C, GRK2, and beta-arrestin 2. The translocation of protein kinase C beta II-green fluorescent protein to and from the plasma membrane in response to substance P indicates that the human SPR becomes activated within seconds of agonist exposure, and the response desensitizes within 30 s, This desensitization process coincides with a redistribution of GRK2 from the cytosol to the plasma membrane, followed by a robust redistribution of beta-arrestin 2 and a profound change in cell morphology that occurs after I min of SPR stimulation. These data establish a role for GrRKs and beta-arrestins in homologous desensitization of the SPR and provide the first visual and temporal resolution of the sequence of events underlying homologous desensitization of a GPCR in living cells.	Duke Univ, Med Ctr, Dept Anesthesiol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Cell Biol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Pharmacol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Canc Biol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Howard Hughes Med Inst, Durham, NC 27710 USA	Duke University; Duke University; Duke University; Duke University; Duke University; Duke University; Howard Hughes Medical Institute	Kwatra, MM (corresponding author), Duke Univ, Med Ctr, Dept Anesthesiol, Box 3094, Durham, NC 27710 USA.	kwatr001@mc.duke.edu	Kwatra, Madan/ABD-2008-2020		NHLBI NIH HHS [HL03422] Funding Source: Medline; NINDS NIH HHS [NS19576, NS 33405] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL003422] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS033405, R01NS019576] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Barak LS, 1997, J BIOL CHEM, V272, P27497, DOI 10.1074/jbc.272.44.27497; Cao YQ, 1998, NATURE, V392, P390, DOI 10.1038/32897; CASTAGNA M, 1982, J BIOL CHEM, V257, P7847; De Felipe C, 1998, NATURE, V392, P394, DOI 10.1038/32904; EXTON JH, 1994, ANNU REV PHYSIOL, V56, P349; Feng X, 1998, J BIOL CHEM, V273, P10755, DOI 10.1074/jbc.273.17.10755; Ferguson SSG, 1996, SCIENCE, V271, P363, DOI 10.1126/science.271.5247.363; Ferguson SSG, 1996, CAN J PHYSIOL PHARM, V74, P1095, DOI 10.1139/y96-124; Freedman NJ, 1996, RECENT PROG HORM RES, V51, P319; Garland AM, 1996, MOL PHARMACOL, V49, P438; GUREVICH VV, 1995, J BIOL CHEM, V270, P720, DOI 10.1074/jbc.270.2.720; HERSHEY AD, 1991, ANN NY ACAD SCI, V632, P63, DOI 10.1111/j.1749-6632.1991.tb33095.x; HUNTER JC, 1985, BIOCHEM BIOPH RES CO, V127, P616, DOI 10.1016/S0006-291X(85)80205-9; KAHLER CM, 1993, EUR J PHARMACOL, V249, P281, DOI 10.1016/0014-2999(93)90523-K; KIM CM, 1993, J BIOL CHEM, V268, P15412; Krupnick JG, 1998, ANNU REV PHARMACOL, V38, P289, DOI 10.1146/annurev.pharmtox.38.1.289; KWATRA MM, 1993, J BIOL CHEM, V268, P9161; MACCIONI RB, 1986, EUR J BIOCHEM, V154, P427, DOI 10.1111/j.1432-1033.1986.tb09415.x; McConalogue K, 1998, MOL BIOL CELL, V9, P2305, DOI 10.1091/mbc.9.8.2305; MCMILLIAN MK, 1987, BIOCHEM BIOPH RES CO, V148, P1017, DOI 10.1016/S0006-291X(87)80233-4; MENNITI FS, 1991, MOL PHARMACOL, V40, P727; Nishimura K, 1998, BIOCHEMISTRY-US, V37, P1192, DOI 10.1021/bi972302s; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; OTSUKA M, 1993, PHYSIOL REV, V73, P229, DOI 10.1152/physrev.1993.73.2.229; Parenti A, 1996, N-S ARCH PHARMACOL, V353, P475; Pitcher JA, 1998, J BIOL CHEM, V273, P12316, DOI 10.1074/jbc.273.20.12316; PITCHER JA, 1992, SCIENCE, V257, P1264, DOI 10.1126/science.1325672; RuizGomez A, 1997, J BIOL CHEM, V272, P9601; STRASSER RH, 1986, P NATL ACAD SCI USA, V83, P6362, DOI 10.1073/pnas.83.17.6362; SUGIYA H, 1987, BIOCHEM J, V244, P647, DOI 10.1042/bj2440647; WEISS SJ, 1982, BIOCHEM J, V206, P555, DOI 10.1042/bj2060555	31	72	78	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	1999	274	11					7565	7569		10.1074/jbc.274.11.7565	http://dx.doi.org/10.1074/jbc.274.11.7565			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	175DV	10066824	hybrid			2022-12-25	WOS:000079078400096
J	Couture, M; Das, TK; Lee, HC; Peisach, J; Rousseau, DL; Wittenberg, BA; Wittenberg, JB; Guertin, M				Couture, M; Das, TK; Lee, HC; Peisach, J; Rousseau, DL; Wittenberg, BA; Wittenberg, JB; Guertin, M			Chlamydomonas chloroplast ferrous hemoglobin - Heme pocket structure and reactions with ligands	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-PARAMAGNETIC RESONANCE; PECTINATA BACTERIA SYMBIOSIS; CYTOCHROME-C PEROXIDASE; AMINO-ACID-SEQUENCE; ASCARIS HEMOGLOBIN; RAMAN-SCATTERING; DISTAL HISTIDINE; LUCINA-PECTINATA; NITRIC-OXIDE; TYROSINE B10	We report the optical and resonance Raman spectral characterization of ferrous recombinant Chlamydomonas LI637 hemoglobin. We show that it is present in three pH dependent equilibrium forms including a 4-coordinate species at acid pH, a 6-coordinate high spin species at neutral pH, and a 6-coordinate low spin species at alkaline pH, The proximal ligand to the heme is the imidazole group of a histidine, Kinetics of the reactions with ligands were determined by stopped-flow spectroscopy. At alkaline pH, combination with oxygen, nitric oxide, and carbon monoxide displays a kinetic behavior that is interpreted as being rate-limited by conversion of the 6-coordinate form to a reactive 5-coordinate form. At neutral pH, combination rates of the 5-coordinate form with oxygen and carbon monoxide were much faster (>10(7) mu M-1 s(-1)). The dissociation rate constant measured for oxygen is among the slowest known, 0.014 s(-1), and is independent of pH, Replacement of the tyrosine 63 (B10) by leucine or of the putative distal glutamine by glycine increases the dissociation rate constant 70- and 30-fold and increases the rate of autoxidation 20- and 90-fold, respectively. These results are consistent with at least two hydrogen bonds stabilizing the bound oxygen molecule, one from tyrosine B10 and the other from the distal glutamine, In addition, the high frequency (232 cm(-1)) of the iron-histidine bond suggests a structure that lacks any proximal strain thus contributing to high ligand affinity.	Univ Laval, Fac Sci & Engn, Dept Biochem, Quebec City, PQ G1K 7P4, Canada; Albert Einstein Coll Med, Dept Physiol & Biophys, Bronx, NY 10461 USA	Laval University; Yeshiva University; Albert Einstein College of Medicine	Guertin, M (corresponding author), Univ Laval, Fac Sci & Engn, Dept Biochem, Quebec City, PQ G1K 7P4, Canada.	mguertin@bcm.ulaval.ca	Couture, Manon/F-8326-2015	Couture, Manon/0000-0001-8296-8055; Das, Tapan/0000-0002-3641-3988	NIGMS NIH HHS [GM54806, GM40168, GM54812] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054812, R01GM040168, R37GM040168, R01GM054806] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Andersson CR, 1996, P NATL ACAD SCI USA, V93, P5682, DOI 10.1073/pnas.93.12.5682; ANDERSSON LA, 1989, J BIOL CHEM, V264, P19099; ANTONINI E, 1971, HEMOGLOBIN MYOGLOBIN, P1; APPLEBY CA, 1973, J BIOL CHEM, V248, P3183; ARGADE PV, 1984, J AM CHEM SOC, V106, P6593, DOI 10.1021/ja00334a024; ArredondoPeter R, 1997, PLANT PHYSIOL, V115, P1259, DOI 10.1104/pp.115.3.1259; BARRICK D, 1994, BIOCHEMISTRY-US, V33, P6546, DOI 10.1021/bi00187a023; BISIG DA, 1995, J BIOL CHEM, V270, P20754, DOI 10.1074/jbc.270.35.20754; Blumberg WE, 1971, PROBES STRUCTURE FUN, V2, P215; Bolognesi M, 1997, PROG BIOPHYS MOL BIO, V68, P29, DOI 10.1016/S0079-6107(97)00017-5; CHEVION M, 1977, BIOCHIM BIOPHYS ACTA, V490, P272, DOI 10.1016/0005-2795(77)90002-2; Coletta M, 1996, EUR J BIOCHEM, V235, P49, DOI 10.1111/j.1432-1033.1996.00049.x; COUTURE M, 1994, MOL GEN GENET, V243, P185, DOI 10.1007/BF00280316; DASGUPTA S, 1989, J BIOL CHEM, V264, P654; DEBAERE I, 1994, P NATL ACAD SCI USA, V91, P1594, DOI 10.1073/pnas.91.4.1594; DEROPP JS, 1985, J AM CHEM SOC, V107, P8268, DOI 10.1021/ja00312a080; Duff SMG, 1997, J BIOL CHEM, V272, P16746, DOI 10.1074/jbc.272.27.16746; FRIEDMAN JM, 1982, ANNU REV PHYS CHEM, V33, P471, DOI 10.1146/annurev.pc.33.100182.002351; GAGNE G, 1992, PLANT MOL BIOL, V18, P429, DOI 10.1007/BF00040659; GIBSON QH, 1989, J BIOL CHEM, V264, P100; GIBSON QH, 1965, PROC R SOC SER B-BIO, V163, P206, DOI 10.1098/rspb.1965.0067; Hargrove MS, 1997, J MOL BIOL, V266, P1032, DOI 10.1006/jmbi.1996.0833; HAYASHI A, 1973, BIOCHIM BIOPHYS ACTA, V310, P309, DOI 10.1016/0005-2795(73)90110-4; HENRY Y, 1976, J BIOL CHEM, V251, P1578; HORI H, 1971, BIOCHIM BIOPHYS ACTA, V251, P227, DOI 10.1016/0005-2795(71)90106-1; Hu SZ, 1996, J AM CHEM SOC, V118, P12638, DOI 10.1021/ja962239e; Huang SC, 1996, J BIOL CHEM, V271, P958, DOI 10.1074/jbc.271.2.958; IRIE T, 1980, COMP BIOCHEM PHYS B, V67, P549, DOI 10.1016/0305-0491(80)90413-7; IWAASA H, 1990, J BIOL CHEM, V265, P8603; IWAASA H, 1989, J MOL BIOL, V208, P355, DOI 10.1016/0022-2836(89)90395-1; Kaneko T, 1996, DNA Res, V3, P109; KEILIN J, 1966, HEMES HEMOPROTEINS, P173; Kiger L, 1998, BIOPHYS J, V75, P990, DOI 10.1016/S0006-3495(98)77587-3; Kloek AP, 1996, J MOL EVOL, V43, P101, DOI 10.1007/BF02337354; KRAUS DW, 1990, J BIOL CHEM, V265, P16043; KRAUS DW, 1990, J BIOL CHEM, V265, P16054; Lamb DC, 1998, J AM CHEM SOC, V120, P2981, DOI 10.1021/ja973781l; MANSELL JB, 1993, BIOCHEM MOL BIOL INT, V30, P643; MCREE DE, 1994, P NATL ACAD SCI USA, V91, P12847, DOI 10.1073/pnas.91.26.12847; MORIKIS D, 1989, BIOCHEMISTRY-US, V28, P4791, DOI 10.1021/bi00437a041; NAGAI K, 1980, J MOL BIOL, V136, P271, DOI 10.1016/0022-2836(80)90374-5; Olson JS, 1997, J BIOL INORG CHEM, V2, P544, DOI 10.1007/s007750050169; PEISACH J, 1968, J BIOL CHEM, V243, P1871; Peterson ES, 1997, BIOCHEMISTRY-US, V36, P13110, DOI 10.1021/bi971156n; POTTS M, 1992, SCIENCE, V256, P1690, DOI 10.1126/science.256.5064.1690; PRONIEWICZ LM, 1988, J AM CHEM SOC, V110, P4541, DOI 10.1021/ja00222a009; Rashid AK, 1997, J BIOL CHEM, V272, P2992, DOI 10.1074/jbc.272.5.3000; ROUSSEAU DL, 1983, ANNU REV BIOPHYS BIO, V12, P357, DOI 10.1146/annurev.bb.12.060183.002041; SMULEVICH G, 1991, BIOCHEMISTRY-US, V30, P9546, DOI 10.1021/bi00103a023; SPIRO TG, 1976, J AM CHEM SOC, V98, P5482, DOI 10.1021/ja00434a013; SPRINGER BA, 1994, CHEM REV, V94, P699, DOI 10.1021/cr00027a007; SPRINGER BA, 1989, J BIOL CHEM, V264, P3057; Tang Q, 1998, BIOCHEMISTRY-US, V37, P7047, DOI 10.1021/bi9729413; Thorsteinsson MV, 1996, BBA-PROTEIN STRUCT M, V1292, P133, DOI 10.1016/0167-4838(95)00178-6; Trevaskis B, 1997, P NATL ACAD SCI USA, V94, P12230, DOI 10.1073/pnas.94.22.12230; VANFLETEREN JR, 1994, MOL PHYLOGENET EVOL, V3, P92, DOI 10.1006/mpev.1994.1012; Wang J., 1996, METHODS NITRIC OXIDE, P427; WANG JL, 1995, BIOCHEMISTRY-US, V34, P9819, DOI 10.1021/bi00031a001; WERDAN K, 1975, BIOCHIM BIOPHYS ACTA, V396, P276, DOI 10.1016/0005-2728(75)90041-9; YANG J, 1995, P NATL ACAD SCI USA, V92, P4224, DOI 10.1073/pnas.92.10.4224; YONETANI T, 1972, J BIOL CHEM, V247, P2447; Yu N.-T., 1988, BIOL APPLICATIONS RA, V3, P39	62	112	114	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	1999	274	11					6898	6910		10.1074/jbc.274.11.6898	http://dx.doi.org/10.1074/jbc.274.11.6898			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	175DV	10066743	hybrid			2022-12-25	WOS:000079078400015
J	Jaquemar, D; Schenker, T; Trueb, B				Jaquemar, D; Schenker, T; Trueb, B			An ankyrin-like protein with transmembrane domains is specifically lost after oncogenic transformation of human fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ERYTHROCYTE ANION-EXCHANGER; MEMBRANE-PROTEINS; SERINE-PROTEASE; MESSENGER-RNA; CELLS; DNA; HYBRIDIZATION; INSITU; ENTRY; CA2+	We have identified a novel transformation-sensitive mRNA, which is present in cultured fibroblasts but is lacking in SV40 transformed cells as well as in many mesenchymal tumor cell lines. The corresponding gene is located on human chromosome 8 in band 8q13, The open reading frame of the mRNA encodes a protein of 1119 amino acids forming two distinct domains. The N-terminal domain consists of 18 repeats that are related to the cytoskeletal protein ankyrin, The C-terminal domain contains six putative transmembrane segments that resemble many ion channels. This overall structure is reminiscent of TRP-like proteins that function as store-operated calcium channels. The novel protein with an M-r of 130 kDa is expressed at a very low level in human fibroblasts and at a moderate level in liposarcoma cells. Overexpression in eukaryotic cells appears to interfere with normal growth, suggesting that it might play a direct or indirect role in signal transduction and growth control.	Univ Bern, ME Muller Inst, CH-3010 Bern, Switzerland	University of Bern	Jaquemar, D (corresponding author), Univ Bern, ME Muller Inst, CH-3010 Bern, Switzerland.		Trueb, Beat/AAL-9621-2020	Trueb, Beat/0000-0001-8684-6856				Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; Baltensperger H, 1997, J BIOL CHEM, V272, P10151; BENNETT V, 1992, J BIOL CHEM, V267, P8703; BENTON WD, 1977, SCIENCE, V196, P180, DOI 10.1126/science.322279; BERRIDGE MJ, 1995, BIOCHEM J, V312, P1, DOI 10.1042/bj3120001; DUBBELMAN TMAR, 1982, BIOCHIM BIOPHYS ACTA, V693, P177, DOI 10.1016/0005-2736(82)90485-0; ENGELMAN DM, 1986, ANNU REV BIOPHYS BIO, V15, P321, DOI 10.1146/annurev.bb.15.060186.001541; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GILLILAND G, 1990, P NATL ACAD SCI USA, V87, P2725, DOI 10.1073/pnas.87.7.2725; Harlow E., 1988, ANTIBODIES LAB MANUA; HENG HHQ, 1992, P NATL ACAD SCI USA, V89, P9509, DOI 10.1073/pnas.89.20.9509; Hynes RO, 1990, FIBRONECTINS; JAN LY, 1992, CELL, V69, P715, DOI 10.1016/0092-8674(92)90280-P; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MACKINNON R, 1995, NEURON, V14, P889, DOI 10.1016/0896-6273(95)90327-5; Michaely P, 1992, Trends Cell Biol, V2, P127, DOI 10.1016/0962-8924(92)90084-Z; Montell C, 1997, MOL PHARMACOL, V52, P755, DOI 10.1124/mol.52.5.755; PASTAN I, 1978, NATURE, V274, P645, DOI 10.1038/274645a0; PETERS LL, 1993, SEMIN HEMATOL, V30, P85; ROWE DW, 1978, BIOCHEMISTRY-US, V17, P1581, DOI 10.1021/bi00602a001; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Schenker T, 1998, EXP CELL RES, V239, P161, DOI 10.1006/excr.1997.3896; SCHENKER T, 1994, J BIOL CHEM, V269, P25447; SIPOS L, 1993, EUR J BIOCHEM, V213, P1333, DOI 10.1111/j.1432-1033.1993.tb17885.x; TAM LY, 1994, J BIOL CHEM, V269, P32542; TANNER MJA, 1993, SEMIN HEMATOL, V30, P34; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRUEB B, 1986, EMBO J, V5, P2815, DOI 10.1002/j.1460-2075.1986.tb04573.x; Zhu X, 1996, CELL, V85, P661, DOI 10.1016/S0092-8674(00)81233-7; Zumbrunn J, 1997, GENOMICS, V45, P461, DOI 10.1006/geno.1997.4953; Zumbrunn J, 1996, EUR J BIOCHEM, V241, P657, DOI 10.1111/j.1432-1033.1996.00657.x; Zumbrunn J, 1996, FEBS LETT, V398, P187, DOI 10.1016/S0014-5793(96)01229-X	33	222	252	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 12	1999	274	11					7325	7333		10.1074/jbc.274.11.7325	http://dx.doi.org/10.1074/jbc.274.11.7325			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	175DV	10066796	hybrid			2022-12-25	WOS:000079078400068
J	Kuroda, K; Tani, S; Tamura, K; Minoguchi, S; Kurooka, H; Honjo, T				Kuroda, K; Tani, S; Tamura, K; Minoguchi, S; Kurooka, H; Honjo, T			Delta-induced notch signaling mediated by RBP-J inhibits MyoD expression and myogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOOP-HELIX FACTORS; BARR-VIRUS EBNA2; J-KAPPA; TRANSCRIPTION FACTOR; DROSOPHILA HOMOLOG; NERVOUS-SYSTEM; BINDING-SITE; MOUSE NOTCH; CELL FATE; GENE	Signaling induced by interaction between the receptor Notch and its ligand Delta plays an important role in cell fate determination in vertebrates as well as invertebrates. Vertebrate Notch signaling has been investigated using its constitutively active form, i.e. the truncated intracellular region which is believed to mimic Notch-Delta signaling by interaction with a DNA-binding protein RBP-J. However, the molecular mechanism for Notch signaling triggered by ligand binding, which leads to inhibition of differentiation, is not clear. We have established a myeloma cell line expressing mouse Deltal on its cell surface which can block muscle differentiation by co-culture with C2C12 muscle progenitor cells. We showed that Delta-induced Notch signaling stimulated transcriptional activation of RBP-J binding motif, containing promoters including the HES1 promoter. Furthermore, ligand-induced Notch signaling up-regulated HES1 mRNA expression within 1 h and subsequently reduced expression of MyoD mRNA, Since cycloheximide treatment did not inhibit induction of HES1 mRNA, the HES1 promoter appears to be a primary target of activated Notch. In addition, a transcriptionally active form of RBP-J, i.e. VP16-RBP-J, inhibited muscle differentiation of C2C12 cells by blocking the expression of MyoD protein. These results suggest that HES1 induction by the Deltal/Notch signaling is mediated by RBP-J and blocks myogenic differentiation of C2C12 cells by subsequent inhibition of MyoD expression.	Kyoto Univ, Fac Med, Dept Med Chem, Sakyo Ku, Kyoto 6068501, Japan; Univ Calif San Diego, Sch Med, Dept Pharmacol, La Jolla, CA 92093 USA	Kyoto University; University of California System; University of California San Diego	Honjo, T (corresponding author), Kyoto Univ, Fac Med, Dept Med Chem, Sakyo Ku, Kyoto 6068501, Japan.	honjo@mfour.med.kyoto-u.ac.jp	Honjo, Tasuku/N-4470-2016					ARUFFO A, 1990, CELL, V61, P1303, DOI 10.1016/0092-8674(90)90694-A; ASAKURA A, 1993, MOL CELL BIOL, V13, P7153, DOI 10.1128/MCB.13.11.7153; Aster JC, 1997, J BIOL CHEM, V272, P11336; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BETTENHAUSEN B, 1995, DEVELOPMENT, V121, P2407; BLAU HM, 1983, CELL, V32, P1171, DOI 10.1016/0092-8674(83)90300-8; BRAUN T, 1989, EMBO J, V8, P3617, DOI 10.1002/j.1460-2075.1989.tb08535.x; BRAUN T, 1989, EMBO J, V8, P701, DOI 10.1002/j.1460-2075.1989.tb03429.x; CONLON RA, 1995, DEVELOPMENT, V121, P1533; Couso JP, 1995, CURR BIOL, V5, P1437, DOI 10.1016/S0960-9822(95)00281-8; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; deAngelis MH, 1997, NATURE, V386, P717, DOI 10.1038/386717a0; DECELIS JF, 1993, P NATL ACAD SCI USA, V90, P4037, DOI 10.1073/pnas.90.9.4037; DELAMO FF, 1993, GENOMICS, V15, P259, DOI 10.1006/geno.1993.1055; delaPompa J, 1997, DEVELOPMENT, V124, P1139; EDMONDSON DG, 1989, GENE DEV, V3, P628, DOI 10.1101/gad.3.5.628; FORTINI ME, 1994, CELL, V79, P273, DOI 10.1016/0092-8674(94)90196-1; FUJISAWASEHARA A, 1990, J BIOL CHEM, V265, P15219; FURUKAWA T, 1995, JPN J GENET, V70, P505, DOI 10.1266/jjg.70.505; FURUKAWA T, 1992, CELL, V69, P1191, DOI 10.1016/0092-8674(92)90640-X; GREENWALD I, 1992, CELL, V68, P271, DOI 10.1016/0092-8674(92)90470-W; GU Y, 1995, DEVELOPMENT, V121, P855; GUNNING P, 1987, P NATL ACAD SCI USA, V84, P4831, DOI 10.1073/pnas.84.14.4831; HAMAGUCHI Y, 1992, J BIOCHEM-TOKYO, V112, P314, DOI 10.1093/oxfordjournals.jbchem.a123898; HEITZLER P, 1991, CELL, V64, P1083, DOI 10.1016/0092-8674(91)90263-X; Honjo T, 1996, GENES CELLS, V1, P1, DOI 10.1046/j.1365-2443.1996.10010.x; HSIEH JJD, 1995, SCIENCE, V268, P560, DOI 10.1126/science.7725102; Hsieh JJD, 1997, J VIROL, V71, P1938, DOI 10.1128/JVI.71.3.1938-1945.1997; Hsieh JJD, 1996, MOL CELL BIOL, V16, P952; Ishibashi M, 1995, GENE DEV, V9, P3136, DOI 10.1101/gad.9.24.3136; JARRIAULT S, 1995, NATURE, V377, P355, DOI 10.1038/377355a0; Kageyama R, 1997, CURR OPIN GENET DEV, V7, P659, DOI 10.1016/S0959-437X(97)80014-7; Kato H, 1996, FEBS LETT, V395, P221, DOI 10.1016/0014-5793(96)01046-0; Kato H, 1997, DEVELOPMENT, V124, P4133; KIM J, 1995, CELL, V82, P795, DOI 10.1016/0092-8674(95)90476-X; KOPAN R, 1994, DEVELOPMENT, V120, P2385; Kopan R, 1996, P NATL ACAD SCI USA, V93, P1683, DOI 10.1073/pnas.93.4.1683; Luo B, 1997, MOL CELL BIOL, V17, P6057, DOI 10.1128/MCB.17.10.6057; MATSUDA F, 1993, NAT GENET, V3, P88, DOI 10.1038/ng0193-88; MATSUNAMI N, 1989, NATURE, V342, P934, DOI 10.1038/342934a0; Matsuno K, 1997, DEVELOPMENT, V124, P4265; Minoguchi S, 1997, MOL CELL BIOL, V17, P2679, DOI 10.1128/MCB.17.5.2679; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; MUSKAVITCH MAT, 1994, DEV BIOL, V166, P415, DOI 10.1006/dbio.1994.1326; NYE JS, 1994, DEVELOPMENT, V120, P2421; OKA C, 1995, DEVELOPMENT, V121, P3291; PERLMANN T, 1993, GENE DEV, V7, P1411, DOI 10.1101/gad.7.7b.1411; REBAY I, 1991, CELL, V67, P687, DOI 10.1016/0092-8674(91)90064-6; Robey E, 1996, CELL, V87, P483, DOI 10.1016/S0092-8674(00)81368-9; Sakai T, 1998, J VIROL, V72, P6034, DOI 10.1128/JVI.72.7.6034-6039.1998; SAKAI T, 1995, J BIOCHEM-TOKYO, V118, P921; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SASAI Y, 1992, GENE DEV, V6, P2620, DOI 10.1101/gad.6.12b.2620; Schroeter EH, 1998, NATURE, V393, P382, DOI 10.1038/30756; SCHWEISGUTH F, 1992, CELL, V69, P1199, DOI 10.1016/0092-8674(92)90641-O; Shawber C, 1996, DEVELOPMENT, V122, P3765; SPEICHER SA, 1994, DEVELOPMENT, V120, P535; SWIATEK PJ, 1994, GENE DEV, V8, P707, DOI 10.1101/gad.8.6.707; TAKEBAYASHI K, 1994, J BIOL CHEM, V269, P5150; Tamura K, 1995, CURR BIOL, V5, P1416, DOI 10.1016/S0960-9822(95)00279-X; THAYER MJ, 1989, CELL, V58, P241, DOI 10.1016/0092-8674(89)90838-6; Tsakonas SA, 1995, SCIENCE, V268, P225; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; Waltzer L, 1995, NUCLEIC ACIDS RES, V23, P4939, DOI 10.1093/nar/23.24.4939; Weinmaster G, 1997, MOL CELL NEUROSCI, V9, P91, DOI 10.1006/mcne.1997.0612; WEINTRAUB H, 1993, CELL, V75, P1241, DOI 10.1016/0092-8674(93)90610-3; WRIGHT WE, 1991, MOL CELL BIOL, V11, P4104, DOI 10.1128/MCB.11.8.4104; YAFFE D, 1977, NATURE, V270, P725, DOI 10.1038/270725a0; Yoshida N, 1998, J CELL SCI, V111, P769	69	215	225	3	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	1999	274	11					7238	7244		10.1074/jbc.274.11.7238	http://dx.doi.org/10.1074/jbc.274.11.7238			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	175DV	10066785	hybrid			2022-12-25	WOS:000079078400057
J	Rubio, F; Schwarz, M; Gassmann, W; Schroeder, JI				Rubio, F; Schwarz, M; Gassmann, W; Schroeder, JI			Genetic selection of mutations in the high affinity K+ transporter HKT1 that define functions of a loop site for reduced Na+ permeability and increased Na+ tolerance	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; SALT TOLERANCE; POTASSIUM-TRANSPORT; PLASMA-MEMBRANE; HIGHER-PLANTS; ARABIDOPSIS-THALIANA; CORN ROOTS; YEAST; ATPASE; CHANNELS	Potassium is an important macronutrient required for plant growth, whereas sodium (Na+) can be toxic at high concentrations. The wheat K+ uptake transporter HKT1 has been shown to function in yeast and oocytes as a high affinity K+-Na+ cotransporter, and as a low affinity Na+ transporter at high external Naf, A previous study showed that point mutations in HKT1, which confer enhancement of Na+ tolerance to yeast, can be isolated by genetic selection. Here we report on the isolation of mutations in new domains of HKT1 showing further large increases in Na+ tolerance. By selection in a Na+ ATPase deletion mutant of yeast that shows a high Na+ sensitivity, new HKT1 mutants at positions Gln-270 and Asn-365 were isolated. Several independent mutations were isolated at the Asn-365 site. N365S dramatically increased Naf tolerance in yeast compared with all other HKT1 mutants. Cation uptake experiments in yeast and biophysical characterization in Xenopus oocytes showed that the mechanisms underlying the Na+ tolerance conferred by the N365S mutant were: reduced inhibition of high affinity Rb+ (K+) uptake at high Na+ concentrations, reduced low affinity Na+ uptake, and reduced Na+ to K+ content ratios in yeast. In addition, the N365S mutant could be clearly distinguished from less Na+-tolerant HKT1 mutants by a markedly decreased relative permeability for Na+ at high Na+ concentrations, The new mutations contribute to the identification of new functional domains and an amino acid in a loop domain that is involved in cation specificity of a plant high affinity K+ transporter and will be valuable for molecular analyses of Na+ transport mechanisms and stress in plants.	Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA; Univ Calif San Diego, Ctr Mol Genet, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego	Schroeder, JI (corresponding author), Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA.	Julian@biomail.ucsd.edu	Rubio, Francisco/ABF-8662-2020; Rubio, Francisco/K-2854-2014	Rubio, Francisco/0000-0001-7640-9548; Rubio, Francisco/0000-0001-7640-9548; Schroeder, Julian/0000-0002-3283-5972; Gassmann, Walter/0000-0002-7527-0385				ANDERSON JA, 1992, P NATL ACAD SCI USA, V89, P3736, DOI 10.1073/pnas.89.9.3736; BARISH ME, 1983, J PHYSIOL-LONDON, V342, P309, DOI 10.1113/jphysiol.1983.sp014852; BUURMAN ET, 1995, J BIOL CHEM, V270, P6678, DOI 10.1074/jbc.270.12.6678; Cadwell R C, 1992, PCR Methods Appl, V2, P28, DOI 10.1101/gr.2.1.28; CHEESEMAN JM, 1980, PLANT PHYSIOL, V65, P1139, DOI 10.1104/pp.65.6.1139; Diatloff E, 1998, FEBS LETT, V432, P31, DOI 10.1016/S0014-5793(98)00833-3; Ding L, 1997, PLANT PHYSIOL, V113, P795, DOI 10.1104/pp.113.3.795; DOHMEN RJ, 1991, YEAST, V7, P691, DOI 10.1002/yea.320070704; EPSTEIN E, 1963, P NATL ACAD SCI USA, V49, P684, DOI 10.1073/pnas.49.5.684; EPSTEIN E, 1965, P NATL ACAD SCI USA, V53, P1320, DOI 10.1073/pnas.53.6.1320; EPSTEIN E, 1976, TRANSPORT PLANTS B, V2, P70; FERNANDO M, 1992, PLANT PHYSIOL, V100, P1269, DOI 10.1104/pp.100.3.1269; Fersht A., 1985, ENZYME STRUCTURE MEC; Fu HH, 1998, PLANT CELL, V10, P63, DOI 10.1105/tpc.10.1.63; GARCIADEBLAS B, 1993, MOL GEN GENET, V236, P363, DOI 10.1007/BF00277134; Gassmann W, 1996, PLANT J, V10, P869, DOI 10.1046/j.1365-313X.1996.10050869.x; GLASS ADM, 1978, CAN J BOT, V56, P1759, DOI 10.1139/b78-209; GREENWAY H, 1980, ANNU REV PLANT PHYS, V31, P149, DOI 10.1146/annurev.pp.31.060180.001053; HARO R, 1991, FEBS LETT, V291, P189, DOI 10.1016/0014-5793(91)81280-L; HARTMANN HA, 1991, SCIENCE, V251, P942, DOI 10.1126/science.2000495; HEGINBOTHAM L, 1992, SCIENCE, V258, P1152, DOI 10.1126/science.1279807; HEGINBOTHAM L, 1993, BIOPHYS J, V64, pA16; Hille B., 1992, IONIC CHANNELS EXCIT; Kim EJ, 1998, PLANT CELL, V10, P51, DOI 10.1105/tpc.10.1.51; KO CH, 1991, MOL CELL BIOL, V11, P4266, DOI 10.1128/MCB.11.8.4266; KOCHIAN LV, 1982, PLANT PHYSIOL, V70, P1723, DOI 10.1104/pp.70.6.1723; Maathuis FJM, 1996, PLANT PHYSIOL, V112, P1609, DOI 10.1104/pp.112.4.1609; MUHLRAD D, 1992, YEAST, V8, P79, DOI 10.1002/yea.320080202; MUNNS R, 1993, PLANT CELL ENVIRON, V16, P15, DOI 10.1111/j.1365-3040.1993.tb00840.x; MURGUIA JR, 1995, SCIENCE, V267, P232; Murguia JR, 1996, J BIOL CHEM, V271, P29029, DOI 10.1074/jbc.271.46.29029; OMIELAN JA, 1991, GENOME, V34, P961, DOI 10.1139/g91-149; Quintero FJ, 1997, FEBS LETT, V415, P206, DOI 10.1016/S0014-5793(97)01125-3; RAINS DW, 1967, PLANT PHYSIOL, V42, P314, DOI 10.1104/pp.42.3.314; RAINS DW, 1965, SCIENCE, V148, P1611, DOI 10.1126/science.148.3677.1611; RAMOS J, 1986, EUR J BIOCHEM, V154, P307, DOI 10.1111/j.1432-1033.1986.tb09398.x; RODRIGUEZNAVARRO A, 1984, J BACTERIOL, V159, P940; RUBIO F, 1995, SCIENCE, V270, P1660, DOI 10.1126/science.270.5242.1660; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Santa-Maria GE, 1997, PLANT CELL, V9, P2281, DOI 10.1105/tpc.9.12.2281; Schachtman DP, 1997, P NATL ACAD SCI USA, V94, P11079, DOI 10.1073/pnas.94.20.11079; SCHACHTMAN DP, 1994, NATURE, V370, P655, DOI 10.1038/370655a0; SCHROEDER JI, 1994, ANNU REV BIOPH BIOM, V23, P441, DOI 10.1146/annurev.bb.23.060194.002301; SERRANO R, 1986, NATURE, V319, P689, DOI 10.1038/319689a0; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; SUSSMAN MR, 1994, ANNU REV PLANT PHYS, V45, P211, DOI 10.1146/annurev.pp.45.060194.001235; TARCZYNSKI MC, 1993, SCIENCE, V259, P508, DOI 10.1126/science.259.5094.508; Wu SJ, 1996, PLANT CELL, V8, P617, DOI 10.1105/tpc.8.4.617; YOOL AJ, 1991, NATURE, V349, P700, DOI 10.1038/349700a0	49	99	110	1	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	1999	274	11					6839	6847		10.1074/jbc.274.11.6839	http://dx.doi.org/10.1074/jbc.274.11.6839			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	175DV	10066736	hybrid			2022-12-25	WOS:000079078400008
J	Stafforini, DM; Tjoelker, LW; McCormick, SPA; Vaitkus, D; McIntyre, TM; Gray, PW; Young, SG; Prescott, SM				Stafforini, DM; Tjoelker, LW; McCormick, SPA; Vaitkus, D; McIntyre, TM; Gray, PW; Young, SG; Prescott, SM			Molecular basis of the interaction between plasma platelet-activating factor acetylhydrolase and low density lipoprotein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN APOLIPOPROTEIN B100; NECROTIZING ENTEROCOLITIS; TRANSGENIC MICE; ANTAGONIST; EXPRESSION; PAF; ASSOCIATION; MODEL	The platelet-activating factor acetylhydrolases are enzymes that were initially characterized by their ability to hydrolyze platelet-activating factor (PAF). In human plasma, PAF acetylhydrolase (EC 3.1.1.47) circulates in a complex with low density lipoproteins (LDL) and high density lipoproteins (HDL). This association defines the physical state of PAF acetylhydrolase, confers a long half-life, and is a major determinant of its catalytic efficiency in vivo. The lipoprotein-associated enzyme accounts for all of the PAF hydrolysis in plasma but only two-thirds of the protein mass. To characterize the enzyme-lipoprotein interaction, we employed site-directed mutagenesis techniques. Two domains within the primary sequence of human PAF acetylhydrolase, tyrosine 205 and residues 115 and 116, were important for its binding to LDL. Mutation or deletion of those sequences prevented the association of the enzyme with lipoproteins. When residues 115 and 116 from human PAF acetylhydrolase were introduced into mouse PAF acetylhydrolase (which normally does not associate with LDL), the mutant mouse PAF acetylhydrolase associated with lipoproteins, To analyze the role of apolipoprotein (apo) B100 in the formation of the PAF acetylhydrolase-LDL complex, we tested the ability of PAF acetylhydrolase to bind to lipoproteins containing truncated forms of apoB, These studies indicated that the carboxyl terminus of apoB plays a key role in the association of PAF acetylhydrolase with LDL. These data on the molecular basis of the PAF acetylhydrolase-LDL association provide a new level of understanding regarding the pathway for the catabolism of PAF in human blood.	Univ Utah, Eccles Inst Human Genet, Program Human Mol Biol & Genet, Huntsman Canc Inst, Salt Lake City, UT 84112 USA; Univ Utah, Cardiovasc Res & Training Inst, Salt Lake City, UT 84112 USA; ICOS Corp, Bothell, WA 98021 USA; Univ Calif San Francisco, Gladstone Inst Cardiovasc Dis, Cardiovasc Res Inst, San Francisco, CA 94141 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94141 USA	Huntsman Cancer Institute; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Icos Corporation; University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco	Stafforini, DM (corresponding author), Univ Utah, Eccles Inst Human Genet, Program Human Mol Biol & Genet, Huntsman Canc Inst, 15 N 2030 East,Rm 2100, Salt Lake City, UT 84112 USA.	diana.stafforini@hci.utah.edu		McCormick, Sally/0000-0001-9857-0703; Young, Stephen/0000-0001-7270-3176	NCI NIH HHS [CA42014] Funding Source: Medline; NHLBI NIH HHS [HL41633, HL35828] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA042014] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL041633, R01HL035828] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Blencowe C, 1995, J BIOL CHEM, V270, P31151, DOI 10.1074/jbc.270.52.31151; Boren J, 1998, J CLIN INVEST, V101, P1084, DOI 10.1172/JCI1847; Caplan MS, 1997, PEDIATR RES, V42, P779, DOI 10.1203/00006450-199712000-00010; Caplan MS, 1997, J PEDIATR GASTR NUTR, V24, P296, DOI 10.1097/00005176-199703000-00012; CHIESA GL, 1993, J BIOL CHEM, V268, P23747; Debek W, 1998, EXP TOXICOL PATHOL, V50, P19; Derewenda ZS, 1998, CELL MOL LIFE SCI, V54, P446, DOI 10.1007/s000180050172; FLESS GM, 1986, J BIOL CHEM, V261, P8712; Galloway SW, 1996, PANCREAS, V13, P140, DOI 10.1097/00006676-199608000-00004; Giral M, 1996, BRIT J PHARMACOL, V118, P1223, DOI 10.1111/j.1476-5381.1996.tb15527.x; HORTIN GL, 1989, P NATL ACAD SCI USA, V86, P1338, DOI 10.1073/pnas.86.4.1338; Kim E, 1998, J LIPID RES, V39, P703; LINTON MF, 1993, J CLIN INVEST, V92, P3029, DOI 10.1172/JCI116927; Mathiak G, 1997, SHOCK, V7, P391, DOI 10.1097/00024382-199706000-00001; MCCORMICK SPA, 1994, J BIOL CHEM, V269, P24284; Miotla JM, 1998, AM J RESP CELL MOL, V18, P197, DOI 10.1165/ajrcmb.18.2.2846; Muguruma K, 1997, ADV EXP MED BIOL, V407, P379; Oh SO, 1997, J LAB CLIN MED, V130, P191, DOI 10.1016/S0022-2143(97)90095-0; PRESCOTT SM, 1990, J BIOL CHEM, V265, P17381; SOMMER A, 1991, BIOCHEMISTRY-US, V30, P11245, DOI 10.1021/bi00111a008; STAFFORINI DM, 1989, P NATL ACAD SCI USA, V86, P2393, DOI 10.1073/pnas.86.7.2393; STAFFORINI DM, 1990, METHOD ENZYMOL, V187, P344; Stafforini DM, 1997, J BIOL CHEM, V272, P17895, DOI 10.1074/jbc.272.29.17895; STAFFORINI DM, 1987, J BIOL CHEM, V262, P4223; Stafforini DM, 1996, BBA-LIPID LIPID MET, V1301, P161, DOI 10.1016/0005-2760(96)00040-9; STAFFORINI DM, 1987, J BIOL CHEM, V262, P4215; TJOELKER LW, 1995, NATURE, V374, P549, DOI 10.1038/374549a0; TJOELKER LW, 1995, J BIOL CHEM, V270, P25481, DOI 10.1074/jbc.270.43.25481; TSAOUSSIS V, 1994, J LIPID MEDIAT CELL, V9, P301; UTERMANN G, 1989, SCIENCE, V246, P904, DOI 10.1126/science.2530631; Wei YY, 1998, STRUCTURE, V6, P511, DOI 10.1016/S0969-2126(98)00052-5; YAMADA Y, 1994, P NATL ACAD SCI USA, V91, P10320, DOI 10.1073/pnas.91.22.10320	32	132	141	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	1999	274	11					7018	7024		10.1074/jbc.274.11.7018	http://dx.doi.org/10.1074/jbc.274.11.7018			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	175DV	10066756	hybrid			2022-12-25	WOS:000079078400028
J	Ueda, Y; Royer, L; Gong, E; Zhang, JL; Cooper, PN; Francone, O; Rubin, EM				Ueda, Y; Royer, L; Gong, E; Zhang, JL; Cooper, PN; Francone, O; Rubin, EM			Lower plasma levels and accelerated clearance of high density lipoprotein (HDL) and non-HDL cholesterol in scavenger receptor class B type I transgenic mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CORONARY HEART-DISEASE; SELECTIVE LIPID UPTAKE; APOLIPOPROTEIN-A-I; SR-BI; ADRENAL-GLAND; EXPRESSION; CELLS; GENE; OVEREXPRESSION; DELIVERY	Recent studies have indicated that the scavenger receptor class B type I (SR-BI) may play an important role in the uptake of high density lipoprotein (HDL) cholesteryl ester in liver and steroidogenic tissues. To investigate the in vivo effects of liver-specific SR-BI overexpression on lipid metabolism, we created several lines of SR-BI transgenic mice with an SR-BI genomic construct where the SR-BI promoter region had been replaced by the apolipoprotein (apo)A-I promoter. The effect of constitutively increased SR-BI expression on plasma HDL and non-HDL lipoproteins and apolipoproteins was characterized. There was an inverse correlation between SR-BI expression and apoA-I and HDL cholesterol levels in transgenic mice fed either mouse chow or a diet high in fat and cholesterol. An unexpected finding in the SR-BI transgenic mice was the dramatic impact of the SR-BI transgene on non-HDL cholesterol and apoB whose levels were also inversely correlated with SR-BI expression. Consistent with the decrease in plasma HDL and non-HDL cholesterol was an accelerated clearance of HDL, non-HDL, and their major associated apolipoproteins in the transgenics compared with control animals. These in vivo studies of the effect of SR-BI overexpression on plasma lipoproteins support the previously proposed hypothesis that SR-BI accelerates the metabolism of HDL and also highlight the capacity of this receptor to participate in the metabolism of non-HDL lipoproteins.	Univ Calif Berkeley, Lawrence Berkeley Lab, Berkeley, CA 94720 USA; Pfizer Inc, Dept Cardiovasc & Metab Dis, Groton, CT 06340 USA	United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; Pfizer	Rubin, EM (corresponding author), Univ Calif Berkeley, Lawrence Berkeley Lab, 1 Cyclotron Rd,MS-84-171, Berkeley, CA 94720 USA.		Eckhardt, Erik/G-1567-2010		NHLBI NIH HHS [HL-50590, HL-18574] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL018574, R01HL050590] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Acton S, 1996, SCIENCE, V271, P518, DOI 10.1126/science.271.5248.518; ACTON SL, 1994, J BIOL CHEM, V269, P21003; Babitt J, 1997, J BIOL CHEM, V272, P13242, DOI 10.1074/jbc.272.20.13242; Boren J, 1996, GENOME RES, V6, P1123, DOI 10.1101/gr.6.11.1123; Cao GP, 1997, J BIOL CHEM, V272, P33068, DOI 10.1074/jbc.272.52.33068; CASTELLI WP, 1977, CIRCULATION, V55, P767, DOI 10.1161/01.CIR.55.5.767; CHAJEKSHAUL T, 1991, P NATL ACAD SCI USA, V88, P6731, DOI 10.1073/pnas.88.15.6731; GLASS CK, 1983, J BIOL CHEM, V258, P7161; HOGAN B, 1994, MANIPULATING MOUSE E, P217; KEYS A, 1980, LANCET, V2, P603; Kozarsky KF, 1997, NATURE, V387, P414, DOI 10.1038/387414a0; Landschulz KT, 1996, J CLIN INVEST, V98, P984, DOI 10.1172/JCI118883; NAVAB M, 1991, J CLIN INVEST, V88, P2039, DOI 10.1172/JCI115532; Ng DS, 1997, J BIOL CHEM, V272, P15777, DOI 10.1074/jbc.272.25.15777; NICHOLS AV, 1986, METHOD ENZYMOL, V128, P417; NISHINA PM, 1990, J LIPID RES, V31, P859; PARTHASARATHY S, 1990, BIOCHIM BIOPHYS ACTA, V1044, P275, DOI 10.1016/0005-2760(90)90314-N; Rigotti A, 1997, P NATL ACAD SCI USA, V94, P12610, DOI 10.1073/pnas.94.23.12610; Rigotti A, 1996, J BIOL CHEM, V271, P33545, DOI 10.1074/jbc.271.52.33545; RIGOTTI A, 1995, J BIOL CHEM, V270, P16221, DOI 10.1074/jbc.270.27.16221; SCHULTZ JR, 1992, J BIOL CHEM, V267, P21630; Temel RE, 1997, P NATL ACAD SCI USA, V94, P13600, DOI 10.1073/pnas.94.25.13600; Varban ML, 1998, P NATL ACAD SCI USA, V95, P4619, DOI 10.1073/pnas.95.8.4619; Wang N, 1996, J BIOL CHEM, V271, P21001, DOI 10.1074/jbc.271.35.21001; Xu SZ, 1997, J LIPID RES, V38, P1289; YOKODE M, 1990, SCIENCE, V250, P1273, DOI 10.1126/science.2244210	26	207	214	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 12	1999	274	11					7165	7171		10.1074/jbc.274.11.7165	http://dx.doi.org/10.1074/jbc.274.11.7165			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	175DV	10066776	hybrid			2022-12-25	WOS:000079078400048
J	Agarwal, C; Efimova, T; Welter, JF; Crish, JF; Eckert, RL				Agarwal, C; Efimova, T; Welter, JF; Crish, JF; Eckert, RL			CCAAT/enhancer-binding proteins - A role in regulation of human involucrin promoter response to phorbol ester	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KERATIN INTERMEDIATE FILAMENTS; TRANSCRIPTION FACTORS C/EBP; ADIPOCYTE DIFFERENTIATION; TRANSGENIC MICE; EXPRESSION; GENE; ENVELOPE; FAMILY; ALPHA; CELLS	The phorbol ester 12-O-tetradecanoylphorbol-13-acetate (TPA) is a potent inducer of keratinocyte differentiation and of involucrin gene expression. In the present study we show that a CCAAT/enhancer-binding protein (C/EBP) site in the proximal regulatory region is required for the phorbol ester response. Mutation of the C/EBP site results in the loss of basal and TPA-responsive activity. Gel mobility supershift analysis shows that C/EBP alpha binding to this site is increased by TPA treatment. Moreover, cotransfection of the human involucrin reporter plasmid with C/EBP alpha increases promoter activity to an extent comparable with TPA treatment. Mutation of the C/EBP-binding site eliminates these responses. Transfection experiments using GADD153 to create C/EBP-null conditions confirm that C/EBP factors are absolutely required for promoter activity and TPA responsiveness. C/EBP alpha and C/EBP delta inhibit both TPA- and C/EBP alpha-dependent promoter activation, indicating functional differences among C/EBP family members. These results suggest that C/EBP transcription factor activity is necessary for basal promoter activity and TPA response of the involucrin gene.	Case Western Reserve Univ, Sch Med, Dept Physiol & Biophys, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Dermatol, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Reprod Biol, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Biochem, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Oncol, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University; Case Western Reserve University; Case Western Reserve University; Case Western Reserve University	Eckert, RL (corresponding author), Case Western Reserve Univ, Sch Med, Dept Physiol & Biophys, Rm 532,2109 Adelbert Rd, Cleveland, OH 44106 USA.	rle2@po.cwru.edu		Efimova, Tatiana/0000-0002-9869-1545	NIAMS NIH HHS [AR41456, AR39750] Funding Source: Medline; NIGMS NIH HHS [GM43751] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041456, R55AR041456, P30AR039750] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043751] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Banks EB, 1999, BIOCHEM J, V337, P507, DOI 10.1042/0264-6021:3370507; Banks EB, 1998, BIOCHEM J, V331, P61, DOI 10.1042/bj3310061; BANKSSCHLEGEL S, 1981, J CELL BIOL, V90, P732, DOI 10.1083/jcb.90.3.732; BARTLETT JD, 1992, J BIOL CHEM, V267, P20465; CARROLL JM, 1993, P NATL ACAD SCI USA, V90, P10270, DOI 10.1073/pnas.90.21.10270; Chowdhury S, 1996, EUR J BIOCHEM, V236, P500, DOI 10.1111/j.1432-1033.1996.00500.x; Crish JF, 1998, J BIOL CHEM, V273, P30460, DOI 10.1074/jbc.273.46.30460; CRISH JF, 1993, DIFFERENTIATION, V53, P191, DOI 10.1111/j.1432-0436.1993.tb00708.x; ECKERT RL, 1993, J INVEST DERMATOL, V100, P613, DOI 10.1111/1523-1747.ep12472288; Eckert RL, 1997, J INVEST DERMATOL, V109, P501, DOI 10.1111/1523-1747.ep12336477; Eckert RL, 1997, PHYSIOL REV, V77, P397, DOI 10.1152/physrev.1997.77.2.397; Efimova T, 1998, J BIOL CHEM, V273, P24387, DOI 10.1074/jbc.273.38.24387; Fawcett TW, 1996, J BIOL CHEM, V271, P14285, DOI 10.1074/jbc.271.24.14285; HENDRICKSTAYLOR LR, 1995, NUCLEIC ACIDS RES, V23, P4726, DOI 10.1093/nar/23.22.4726; HUBER M, 1995, SCIENCE, V267, P525, DOI 10.1126/science.7824952; JUHLIN L, 1992, ACTA DERM-VENEREOL, V72, P407; Lane MD, 1996, INT J OBESITY, V20, pS91; LaPres JJ, 1996, J BIOL CHEM, V271, P23154, DOI 10.1074/jbc.271.38.23154; LopezBayghen E, 1996, J BIOL CHEM, V271, P512, DOI 10.1074/jbc.271.1.512; MACDOUGALD OA, 1995, ANNU REV BIOCHEM, V64, P345, DOI 10.1146/annurev.bi.64.070195.002021; MAHONEY CW, 1992, J BIOL CHEM, V267, P19396; Maytin EV, 1998, J INVEST DERMATOL, V110, P238, DOI 10.1046/j.1523-1747.1998.00123.x; Maytin EV, 1998, J INVEST DERMATOL, V110, P493; MURPHY GF, 1984, J INVEST DERMATOL, V82, P453, DOI 10.1111/1523-1747.ep12260945; NOLTEN LA, 1994, MOL ENDOCRINOL, V8, P1636, DOI 10.1210/me.8.12.1636; PIONTKEWITZ Y, 1993, ENDOCRINOLOGY, V133, P2327, DOI 10.1210/en.133.5.2327; RICE RH, 1979, CELL, V18, P681, DOI 10.1016/0092-8674(79)90123-5; RON D, 1992, GENE DEV, V6, P439, DOI 10.1101/gad.6.3.439; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SCOTT LM, 1992, BLOOD, V80, P1725; Steinert P M, 1995, Cell Death Differ, V2, P33; STEINERT PM, 1994, J INVEST DERMATOL, V103, pS19, DOI 10.1111/1523-1747.ep12398900; STEINERT PM, 1993, TRENDS GENET, V9, P280, DOI 10.1016/0168-9525(93)90014-9; Sun TT, 1984, CANCER CELLS, V1, P169; Swart GWM, 1997, BIOL CHEM, V378, P373, DOI 10.1515/bchm.1997.378.5.373; TAKAHASHI H, 1993, J INVEST DERMATOL, V100, P10, DOI 10.1111/1523-1747.ep12349867; UMEK RM, 1991, SCIENCE, V251, P288, DOI 10.1126/science.1987644; Wang H, 1996, J VIROL, V70, P4839, DOI 10.1128/JVI.70.7.4839-4844.1996; WATT FM, 1981, J CELL BIOL, V90, P738, DOI 10.1083/jcb.90.3.738; Welter JF, 1996, J BIOL CHEM, V271, P14727, DOI 10.1074/jbc.271.25.14727; WELTER JF, 1995, J BIOL CHEM, V270, P12614, DOI 10.1074/jbc.270.21.12614; WILLIAMS SC, 1991, GENE DEV, V5, P1553, DOI 10.1101/gad.5.9.1553; YEH WC, 1995, GENE DEV, V9, P168, DOI 10.1101/gad.9.2.168	43	44	44	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	1999	274	10					6190	6194		10.1074/jbc.274.10.6190	http://dx.doi.org/10.1074/jbc.274.10.6190			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172BQ	10037704	hybrid			2022-12-25	WOS:000078902800026
J	Brown, LM; Burbach, BJ; McKenzie, BA; Connell, GJ				Brown, LM; Burbach, BJ; McKenzie, BA; Connell, GJ			A cis-acting A-U sequence element induces kinetoplastid U-insertions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA LIGASE ACTIVITIES; MITOCHONDRIAL RIBONUCLEOPROTEIN COMPLEXES; LEISHMANIA-TARENTOLAE MITOCHONDRIA; TRYPANOSOMA-BRUCEI MITOCHONDRIA; CYTOCHROME-B TRANSCRIPTS; MESSENGER-RNA; IN-VITRO; GUIDE RNAS; SECONDARY STRUCTURE; URIDINE INSERTION	A 34-nucleotide A-U sequence located immediately upstream of the editing sites of the Leishmania tarentolae cytochrome b mRNA induces a mitochondrial extract to insert U nucleotides independent of guide RNA. Insertions are localized to positions immediately 5' and 3' of the A-U sequence. When placed within an unedited mammalian transcript, the A-Il sequence is sufficient to induce U-insertions. The sequence has a high degree of similarity with the templating nucleotides of a cytochrome b guide RNA and with a sequence adjacent to the editing sites in ND7 mRNA, the other characterized kinetoplastid mRNA supporting guide RNA-independent U-insertions. At least one protein specifically interacts with the A-U sequence. The reaction is consistent with a mechanism proposed for guide RNA-directed editing.	Univ Minnesota, Dept Pharmacol, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities	Connell, GJ (corresponding author), Univ Minnesota, Dept Pharmacol, 3-249 Millard Hall, Minneapolis, MN 55455 USA.	gconnell@lenti.med.umn.edu		Burbach, Brandon/0000-0003-0922-7722	NIAID NIH HHS [R29-AI41138] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI041138] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ATTARDI G, 1988, ANNU REV CELL BIOL, V4, P289, DOI 10.1146/annurev.cellbio.4.1.289; BAKALARA N, 1989, J BIOL CHEM, V264, P18679; BLUM B, 1990, CELL, V60, P189, DOI 10.1016/0092-8674(90)90735-W; BLUM B, 1990, CELL, V62, P391, DOI 10.1016/0092-8674(90)90375-O; Bohjanen PR, 1996, NUCLEIC ACIDS RES, V24, P3733, DOI 10.1093/nar/24.19.3733; BRALY P, 1974, J PROTOZOOL, V21, P782, DOI 10.1111/j.1550-7408.1974.tb03752.x; Byrne EM, 1996, EMBO J, V15, P6758, DOI 10.1002/j.1460-2075.1996.tb01065.x; Connell GJ, 1997, J BIOL CHEM, V272, P4212, DOI 10.1074/jbc.272.7.4212; CruzReyes J, 1996, P NATL ACAD SCI USA, V93, P8901, DOI 10.1073/pnas.93.17.8901; ELLINGTON AD, 1990, NATURE, V346, P818, DOI 10.1038/346818a0; FEAGIN JE, 1987, CELL, V49, P337, DOI 10.1016/0092-8674(87)90286-8; FEAGIN JE, 1988, P NATL ACAD SCI USA, V85, P539, DOI 10.1073/pnas.85.2.539; FRECH GC, 1995, EMBO J, V14, P178, DOI 10.1002/j.1460-2075.1995.tb06988.x; GORINGER HU, 1994, P NATL ACAD SCI USA, V91, P1776, DOI 10.1073/pnas.91.5.1776; GREER CL, 1983, CELL, V32, P537, DOI 10.1016/0092-8674(83)90473-7; HUANG J, 1988, NUCLEIC ACIDS RES, V16, P9737, DOI 10.1093/nar/16.20.9737; Kable ML, 1996, SCIENCE, V273, P1189, DOI 10.1126/science.273.5279.1189; KONARSKA MM, 1986, CELL, V46, P845, DOI 10.1016/0092-8674(86)90066-8; KOSLOWSKY DJ, 1992, MOL CELL BIOL, V12, P2043, DOI 10.1128/MCB.12.5.2043; MILLIGAN JF, 1989, METHOD ENZYMOL, V180, P51; MITTELMEIER TM, 1995, MOL CELL BIOL, V15, P780; OJALA D, 1981, NATURE, V290, P470, DOI 10.1038/290470a0; PAN T, 1993, GENE, V125, P111, DOI 10.1016/0378-1119(93)90317-V; PERIS M, 1994, EMBO J, V13, P1664, DOI 10.1002/j.1460-2075.1994.tb06430.x; POLLARD VW, 1992, EMBO J, V11, P4429, DOI 10.1002/j.1460-2075.1992.tb05543.x; Preiss T, 1998, NATURE, V392, P516, DOI 10.1038/33192; Puttaraju M, 1995, Nucleic Acids Symp Ser, P49; READ LK, 1994, MOL CELL BIOL, V14, P2629, DOI 10.1128/MCB.14.4.2629; RILEY GR, 1995, NUCLEIC ACIDS RES, V23, P708, DOI 10.1093/nar/23.4.708; Rusche LN, 1997, EMBO J, V16, P4069, DOI 10.1093/emboj/16.13.4069; SCHINDEWOLF CA, 1995, NUCLEIC ACIDS RES, V23, P1133, DOI 10.1093/nar/23.7.1133; SCHMID B, 1995, NUCLEIC ACIDS RES, V23, P3093, DOI 10.1093/nar/23.16.3093; Seiwert SD, 1996, CELL, V84, P831, DOI 10.1016/S0092-8674(00)81062-4; SIMPSON L, 1989, CELL, V57, P355, DOI 10.1016/0092-8674(89)90911-2; Sloof P, 1997, TRENDS MICROBIOL, V5, P189, DOI 10.1016/S0966-842X(97)01034-2; Stuart K, 1997, MICROBIOL MOL BIOL R, V61, P105, DOI 10.1128/.61.1.105-120.1997; STURM NR, 1990, CELL, V61, P871, DOI 10.1016/0092-8674(90)90197-M; SUGISAKI H, 1993, J BIOL CHEM, V268, P887; Tarun SZ, 1996, EMBO J, V15, P7168, DOI 10.1002/j.1460-2075.1996.tb01108.x; TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121; WHITE TC, 1987, NUCLEIC ACIDS RES, V15, P3275, DOI 10.1093/nar/15.8.3275; ZUKER M, 1989, SCIENCE, V244, P48, DOI 10.1126/science.2468181	42	11	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	1999	274	10					6295	6304		10.1074/jbc.274.10.6295	http://dx.doi.org/10.1074/jbc.274.10.6295			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172BQ	10037718	hybrid			2022-12-25	WOS:000078902800040
J	Franchimont, N; Durant, D; Rydziel, S; Canalis, E				Franchimont, N; Durant, D; Rydziel, S; Canalis, E			Platelet-derived growth factor induces interleukin-6 transcription in osteoblasts through the activator protein-1 complex and activating transcription factor-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BONE CELL-CULTURES; RAT PARIETAL BONE; PARATHYROID-HORMONE; C-FOS; DEOXYRIBONUCLEIC-ACID; ENRICHED CULTURES; GENE-EXPRESSION; BINDING; ISOFORMS; RECEPTOR	Platelet-derived growth factor (PDGF) BE, a mitogen that stimulates bone resorption, increases the expression of interleukin-6 (IL-6), a cytokine that induces osteoclast recruitment. The mechanisms involved in IL-6 induction by PDGF BE are poorly understood. We examined the effect of PDGF BE on IL-6 expression in cultures of osteoblasts from fetal rat calvariae (Ob cells). PDGF BE increased IL-6 mRNA and heterogeneous nuclear RNA levels, the rate of transcription, and the activity of base pairs (bp) -2906 to +20 IL-6 promoter fragments transiently transfected into Ob cells. Deletion analysis revealed two responsive regions, one containing an activator protein-1 (AP-1) site located between bp -276 and -257, and a second, less well defined, downstream of -257. Targeted mutations of a cyclic AMP-responsive element (CRE), and nuclear factor-IL-6 and nuclear factor-kappa B binding sites in a bp -257 to +20 IL-6 construct that was transfected into Ob cells, revealed that the CRE also contributed to IL-6 promoter induction by PDGF BE. Electrophoretic mobility shift assay revealed AP-1 and CRE nuclear protein complexes that were enhanced by PDGF BE. Supershift assays revealed binding of Jun and Fos to AP-1 and CRE sequences and binding of activating transcription factor-a to CRE. In conclusion, PDGF BE induces IL-6 transcription in osteoblasts by regulating nuclear proteins of the AP-1 complex and activating transcription factor-2.	St Francis Hosp & Med Ctr, Res Dept, Worcester, MA 01605 USA; St Francis Hosp & Med Ctr, Dept Med, Worcester, MA 01605 USA; Univ Connecticut, Sch Med, Farmington, CT 06030 USA	University of Connecticut	Canalis, E (corresponding author), St Francis Hosp & Med Ctr, Res Dept, 114 Woodland St, Worcester, MA 01605 USA.	ecanalis@stfranciscare.org			NIAMS NIH HHS [AR21707] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR021707, R37AR021707] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AKIRA S, 1992, CHEM IMMUNOL, V51, P299; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; BAFFET G, 1991, MOL BIOL MED, V8, P141; CANALIS E, 1989, J CELL PHYSIOL, V140, P530, DOI 10.1002/jcp.1041400319; CENTRELLA M, 1989, ENDOCRINOLOGY, V125, P13, DOI 10.1210/endo-125-1-13; CENTRELLA M, 1991, J CELL PHYSIOL, V147, P420, DOI 10.1002/jcp.1041470306; CHASE LR, 1970, J BIOL CHEM, V245, P1520; CLAESSONWELSH L, 1994, J BIOL CHEM, V269, P32023; CLAESSONWELSH L, 1989, ACTA ONCOL, V28, P331, DOI 10.3109/02841868909111202; COCHRAN DL, 1993, BONE, V14, P53, DOI 10.1016/8756-3282(93)90256-A; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FEYEN JHM, 1989, J BONE MINER RES, V4, P633, DOI 10.1002/jbmr.5650040422; Franchimont N, 1997, J CLIN INVEST, V100, P1797, DOI 10.1172/JCI119707; FRANCHIMONT N, 1995, ENDOCRINOLOGY, V136, P5469, DOI 10.1210/en.136.12.5469; FRANCHIMONT N, 1993, P 1993 4 INT S OST C, P249; FRIELING JTM, 1994, CYTOKINE, V6, P376, DOI 10.1016/1043-4666(94)90061-2; GIRASOLE G, 1995, J BONE MINER RES, V10, pS160; GRAVES DT, 1984, SCIENCE, V226, P972, DOI 10.1126/science.6209798; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; GREENFIELD EM, 1993, J BONE MINER RES, V8, P1163; GRIGORIADIS AE, 1994, SCIENCE, V266, P443, DOI 10.1126/science.7939685; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HART CE, 1990, BIOCHEMISTRY-US, V29, P166, DOI 10.1021/bi00453a022; HELDIN CH, 1987, J CELL PHYSIOL, P31; HELLE M, 1988, EUR J IMMUNOL, V18, P957, DOI 10.1002/eji.1830180619; HOCK JM, 1994, ENDOCRINOLOGY, V134, P1423, DOI 10.1210/en.134.3.1423; Horton R M, 1993, Methods Mol Biol, V15, P251, DOI 10.1385/0-89603-244-2:251; JILKA RL, 1992, SCIENCE, V257, P88, DOI 10.1126/science.1621100; LITTLEWOOD AJ, 1991, ENDOCRINOLOGY, V129, P1513, DOI 10.1210/endo-129-3-1513; Lorenzo JA, 1998, ENDOCRINOLOGY, V139, P3022, DOI 10.1210/en.139.6.3022; McCabe LR, 1996, ENDOCRINOLOGY, V137, P4398, DOI 10.1210/en.137.10.4398; MCCARTHY TL, 1988, J BONE MINER RES, V3, P401; MEYER TE, 1993, ENDOCR REV, V14, P269, DOI 10.1210/er.14.3.269; Moore DD, 1995, GLOB MOB SURV; MOROOKA H, 1995, J BIOL CHEM, V270, P30084; NORTHEMANN W, 1989, J BIOL CHEM, V264, P16072; Pacifici R, 1998, ENDOCRINOLOGY, V139, P2659, DOI 10.1210/en.139.6.2659; PARTRIDGE NC, 1994, J CELL BIOCHEM, V55, P321, DOI 10.1002/jcb.240550308; Pearman AT, 1996, J BIOL CHEM, V271, P25715, DOI 10.1074/jbc.271.41.25715; Reimold AM, 1996, NATURE, V379, P262, DOI 10.1038/379262a0; ROODMAN GD, 1992, J BONE MINER RES, V7, P475, DOI 10.1002/jbmr.5650070502; ROTHMAN A, 1994, J BIOL CHEM, V269, P6399; RYDZIEL S, 1992, ENDOCRINOLOGY, V130, P1916, DOI 10.1210/en.130.4.1916; Rydziel S, 1996, ENDOCRINOLOGY, V137, P4115, DOI 10.1210/en.137.10.4115; Scott V, 1994, Methods Mol Biol, V31, P339; SEHGAL PB, 1992, RES IMMUNOL, V143, P724, DOI 10.1016/0923-2494(92)80011-9; Wall F.J., 1986, STAT DATA ANAL HDB; WANG ZQ, 1992, NATURE, V360, P471	48	58	61	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	1999	274	10					6783	6789		10.1074/jbc.274.10.6783	http://dx.doi.org/10.1074/jbc.274.10.6783			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172BQ	10037779	hybrid			2022-12-25	WOS:000078902800101
J	Gasic, S; Tian, B; Green, A				Gasic, S; Tian, B; Green, A			Tumor necrosis factor alpha stimulates lipolysis in adipocytes by decreasing G(i) protein concentrations	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT DIABETES-MELLITUS; LIPOPROTEIN-LIPASE ACTIVITY; INDUCED INSULIN-RESISTANCE; ADENYLATE-CYCLASE; DOWN-REGULATION; NICOTINIC-ACID; RAT ADIPOCYTES; FAT-CELLS; HETEROLOGOUS DESENSITIZATION; SIGNAL-TRANSDUCTION	Prolonged treatment (12-24 h) of adipocytes with tumor necrosis factor alpha (TNF alpha) stimulates Lipolysis, We have investigated the hypothesis that TNF alpha stimulates lipolysis by blocking the action of endogenous adenosine, Adipocytes were incubated for 48 h with TNF alpha, and lipolysis was measured in the absence or presence of adenosine deaminase, Without adenosine deaminase, the rate of glycerol release was 2-3-fold higher in the TNF alpha-treated cells, but with adenosine deaminase lipolysis increased in the controls to approximately that in the TNF alpha-treated cells. This suggests that TNF alpha blocks adenosine release or prevents its antilipolytic effect. Both N-6-phenylisopropyl adenosine and nicotinic acid were less potent and efficacious inhibitors of lipolysis in treated cells. A decrease in the concentration of alpha-subunits of all three G(i) subtypes was detected by Western blotting without a change in G(s)proteins or beta-subunits. G(i2)alpha was about 50% of control, whereas G(i1)alpha and G(i3)alpha were about 20 and 40% of control values, respectively. The time course of G(i) down-regulation correlated with the stimulation of Lipolysis, Furthermore, dawn-regulation of Gi by an alternative approach (prolonged incubation with N-6-phenylisopropyladenosine) stimulated lipolysis. These findings indicate that TNF alpha stimulates lipolysis by blunting endogenous inhibition of lipolysis. The mechanism appears to be a G(i) protein down-regulation.	Mary Imogene Bassett Hosp, Bassett Res Inst, Cooperstown, NY 13326 USA; Univ Texas, Med Branch, Dept Pharmacol, Galveston, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston	Green, A (corresponding author), Mary Imogene Bassett Hosp, Bassett Res Inst, 1 Atwell Rd, Cooperstown, NY 13326 USA.	allan.green@bassett.org						AKTORIES K, 1980, N-S ARCH PHARMACOL, V312, P167, DOI 10.1007/BF00569726; AKTORIES K, 1983, FEBS LETT, V156, P88, DOI 10.1016/0014-5793(83)80254-3; DOERRLER W, 1994, CYTOKINE, V6, P478, DOI 10.1016/1043-4666(94)90074-4; DORIS R, 1994, BIOCHEM J, V297, P41, DOI 10.1042/bj2970041; DRESSLER KA, 1992, SCIENCE, V255, P1715, DOI 10.1126/science.1313189; FEINGOLD KR, 1992, ENDOCRINOLOGY, V130, P10, DOI 10.1210/en.130.1.10; FRAZE E, 1985, J CLIN ENDOCR METAB, V61, P807, DOI 10.1210/jcem-61-5-807; GARCIASAINZ JA, 1985, BIOCHEM J, V232, P439, DOI 10.1042/bj2320439; GASIC S, 1995, BIOCHEM PHARMACOL, V49, P785, DOI 10.1016/0006-2952(94)00537-V; Green A, 1996, AM J PHYSIOL-ENDOC M, V271, pE271, DOI 10.1152/ajpendo.1996.271.2.E271; GREEN A, 1994, ENDOCRINOLOGY, V134, P2581, DOI 10.1210/en.134.6.2581; GREEN A, 1992, J BIOL CHEM, V267, P3223; GREEN A, 1990, J BIOL CHEM, V265, P5206; GROOP LC, 1989, J CLIN INVEST, V84, P205, DOI 10.1172/JCI114142; HANNUN YA, 1995, TRENDS BIOCHEM SCI, V20, P73, DOI 10.1016/S0968-0004(00)88961-6; HONNOR RC, 1985, J BIOL CHEM, V260, P5130; HOTAMISLIGIL GS, 1994, DIABETES, V43, P1271, DOI 10.2337/diabetes.43.11.1271; Hotamisligil GS, 1996, SCIENCE, V271, P665, DOI 10.1126/science.271.5249.665; HOTAMISLIGIL GS, 1993, SCIENCE, V259, P87, DOI 10.1126/science.7678183; HOTAMISLIGIL GS, 1995, J CLIN INVEST, V95, P2409, DOI 10.1172/JCI117936; Jensen MD, 1998, AM J CLIN NUTR, V67, p531S, DOI 10.1093/ajcn/67.3.531S; KAWAKAMI M, 1981, J EXP MED, V154, P631, DOI 10.1084/jem.154.3.631; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARCUS C, 1989, PEDIATR RES, V26, P255, DOI 10.1203/00006450-198909000-00020; MARSHALL S, 1984, J BIOL CHEM, V259, P6376; MCGOWAN MW, 1983, CLIN CHEM, V29, P538; MILLIGAN G, 1991, TRENDS PHARMACOL SCI, V12, P207, DOI 10.1016/0165-6147(91)90551-3; Mittelman SD, 1997, J CLIN INVEST, V100, P3121, DOI 10.1172/JCI119867; OGAWA H, 1989, BIOCHIM BIOPHYS ACTA, V1003, P131, DOI 10.1016/0005-2760(89)90246-4; Perseghin G, 1996, NEW ENGL J MED, V335, P1357, DOI 10.1056/NEJM199610313351804; RANDLE PJ, 1963, LANCET, V1, P785; REITHMANN C, 1991, EUR J PHARM-MOLEC PH, V206, P53, DOI 10.1016/0922-4106(91)90146-9; RODBELL M, 1964, J BIOL CHEM, V239, P375; Schwabe U, 1975, Adv Cyclic Nucleotide Res, V5, P569; SCHWABE U, 1973, N-S ARCH PHARMACOL, V276, P133, DOI 10.1007/BF00501186; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; Souza SC, 1998, DIABETES, V47, P691, DOI 10.2337/diabetes.47.4.691; SPRANG SR, 1990, TRENDS BIOCHEM SCI, V15, P366, DOI 10.1016/0968-0004(90)90228-4; Stephens JM, 1997, J BIOL CHEM, V272, P971, DOI 10.1074/jbc.272.2.971; TRACEY KJ, 1994, ANNU REV MED, V45, P491, DOI 10.1146/annurev.med.45.1.491; Vassault A, 1984, METHODS ENZYM ANAL, V3, P118; WIESER PB, 1975, ENDOCRINOLOGY, V96, P1221, DOI 10.1210/endo-96-5-1221; WILLIAMSON JR, 1966, P NATL ACAD SCI USA, V56, P247, DOI 10.1073/pnas.56.1.247	43	109	111	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	1999	274	10					6770	6775		10.1074/jbc.274.10.6770	http://dx.doi.org/10.1074/jbc.274.10.6770			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172BQ	10037777	hybrid			2022-12-25	WOS:000078902800099
J	Mukherjee, PK; DeCoster, MA; Campbell, FZ; Davis, RJ; Bazan, NG				Mukherjee, PK; DeCoster, MA; Campbell, FZ; Davis, RJ; Bazan, NG			Glutamate receptor signaling interplay modulates stress-sensitive mitogen-activated protein kinases and neuronal cell death	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG-TERM POTENTIATION; CYTOSOLIC PHOSPHOLIPASE A(2); FREE FATTY-ACIDS; STRIATAL NEURONS; BRAIN INJURY; INHIBITORY AVOIDANCE; ANTAGONIST BN-52021; AGONIST 1S,3R-ACPD; CORTICAL CULTURES; MAP KINASE	Glutamate receptors modulate multiple signaling pathways, several of which involve mitogen-activated protein (MAP) kinases, with subsequent physiological or pathological consequences. Here we report that stimulation of the N-methyl-D-aspartate (NMDA) receptor, using platelet-activating factor (PAF) as a messenger, activates MAP kinases, including c-Jun NH2-terminal kinase, p38, and extracellular signal-regulated kinase, in primary cultures of hippocampal neurons. Activation of the metabotropic glutamate receptor (mGluR) blocks this NMDA-signaling through PAF and MAP kinases, and the resultant cell death. Recombinant PAF-acetylhydrolase degrades PAF generated by NMDA receptor activation; the hetrazepine BN50730 (an intracellular PAF receptor antagonist) also inhibits both NMDA-stimulated MAP kinases and neuronal cell death. The finding that the NMDA receptor-PAF-MAP kinase signaling pathway is attenuated by mGluR activation highlights the exquisite interplay between glutamate receptors in the decision making process between neuronal survival and death.	Louisiana State Univ, Med Ctr, Sch Med, Ctr Neurosci, New Orleans, LA 70112 USA; Univ Massachusetts, Med Ctr, Howard Hughes Med Inst, Worcester, MA 01605 USA	Louisiana State University System; Howard Hughes Medical Institute; University of Massachusetts System; University of Massachusetts Worcester	Bazan, NG (corresponding author), Louisiana State Univ, Med Ctr, Sch Med, Neurosci Ctr Excellence, 2020 Gravier St,Suite D, New Orleans, LA 70112 USA.	nbazan@lsumc.edu	DeCoster, Mark/AAF-5224-2020; Bazan, Nicolas/AAN-4121-2020	Bazan, Nicolas/0000-0002-9243-5444	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS023002] Funding Source: NIH RePORTER; NINDS NIH HHS [NS23002] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AVELDANO MI, 1975, BRAIN RES, V100, P99, DOI 10.1016/0006-8993(75)90244-9; BADING H, 1991, SCIENCE, V253, P912, DOI 10.1126/science.1715095; BAZAN NG, 1995, NATURE, V374, P501, DOI 10.1038/374501a0; BAZAN NG, 1970, BIOCHIM BIOPHYS ACTA, V218, P1, DOI 10.1016/0005-2760(70)90086-X; BAZAN NG, 1994, P NATL ACAD SCI USA, V91, P5252, DOI 10.1073/pnas.91.12.5252; Bonaccorsi L, 1997, BBA-MOL CELL RES, V1355, P155, DOI 10.1016/S0167-4889(96)00125-5; Bonventre JV, 1997, NATURE, V390, P622, DOI 10.1038/37635; BRUNO V, 1994, EUR J PHARMACOL, V256, P109, DOI 10.1016/0014-2999(94)90624-6; BURKE JP, 1994, J NEUROSCI, V14, P5120; CLAPP LE, 1995, BRAIN RES, V693, P101, DOI 10.1016/0006-8993(95)00720-B; CLARK GD, 1992, NEURON, V9, P1211, DOI 10.1016/0896-6273(92)90078-R; DECOSTER MA, 1995, BRAIN RES, V671, P45, DOI 10.1016/0006-8993(94)01294-R; DECOSTER MA, 1994, INT J DEV NEUROSCI, V12, P227, DOI 10.1016/0736-5748(94)90044-2; DUMUIS A, 1988, NATURE, V336, P68, DOI 10.1038/336068a0; DUMUIS A, 1990, NATURE, V347, P182, DOI 10.1038/347182a0; English JD, 1996, J BIOL CHEM, V271, P24329, DOI 10.1074/jbc.271.40.24329; FIORE RS, 1993, J NEUROCHEM, V61, P1626, DOI 10.1111/j.1471-4159.1993.tb09796.x; FOUDA SI, 1995, BIOCHEM J, V308, P815, DOI 10.1042/bj3080815; GILBOE DD, 1991, J NEUROCHEM, V56, P311, DOI 10.1111/j.1471-4159.1991.tb02597.x; GONG QZ, 1995, BRAIN RES, V700, P299, DOI 10.1016/0006-8993(95)01081-6; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HONDA Z, 1994, J BIOL CHEM, V269, P2307; IZQUIERDO I, 1995, P NATL ACAD SCI USA, V92, P5047, DOI 10.1073/pnas.92.11.5047; JERUSALINSKY D, 1994, BEHAV NEURAL BIOL, V62, P1, DOI 10.1016/S0163-1047(05)80052-4; KATO K, 1994, NATURE, V367, P175, DOI 10.1038/367175a0; KOH JY, 1991, P NATL ACAD SCI USA, V88, P9431, DOI 10.1073/pnas.88.21.9431; Kolko M, 1996, J BIOL CHEM, V271, P32722, DOI 10.1074/jbc.271.51.32722; KORNECKI E, 1988, SCIENCE, V240, P1792, DOI 10.1126/science.3381103; KURINO M, 1995, J NEUROCHEM, V65, P1282; MARCHESELLI VL, 1990, J BIOL CHEM, V265, P9140; Marcheselli VL, 1996, J BIOL CHEM, V271, P24794, DOI 10.1074/jbc.271.40.24794; MCDONALD JW, 1993, J NEUROSCI, V13, P4445; MOHIT AA, 1995, NEURON, V14, P67, DOI 10.1016/0896-6273(95)90241-4; Mukhin A, 1996, J NEUROSCI, V16, P6012; Nicoletti F, 1996, TRENDS NEUROSCI, V19, P267, DOI 10.1016/S0166-2236(96)20019-0; Nishida K, 1996, STROKE, V27, P514, DOI 10.1161/01.STR.27.3.514; Nishida K, 1996, J NEUROCHEM, V66, P433; Orlando LR, 1995, NEUROSCI LETT, V202, P109, DOI 10.1016/0304-3940(95)12219-2; Packard MG, 1996, NEUROBIOL LEARN MEM, V66, P176, DOI 10.1006/nlme.1996.0058; PANETTA T, 1987, BIOCHEM BIOPH RES CO, V149, P580, DOI 10.1016/0006-291X(87)90407-4; PREHN JHM, 1993, J NEUROSCI RES, V34, P179, DOI 10.1002/jnr.490340205; PRESCOTT SM, 1990, J BIOL CHEM, V265, P17381; SCHOEPP DD, 1995, NEURODEGENERATION, V4, P71, DOI 10.1006/neur.1995.0008; Stafforini DM, 1997, J BIOL CHEM, V272, P17895, DOI 10.1074/jbc.272.29.17895; TJOELKER LW, 1995, NATURE, V374, P549, DOI 10.1038/374549a0; Wang YM, 1997, BRAIN RES, V772, P45, DOI 10.1016/S0006-8993(97)00837-8; WIERASZKO A, 1993, NEURON, V10, P553, DOI 10.1016/0896-6273(93)90342-O; WILLIAMS RJ, 1995, J NEUROCHEM, V65, P241; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yang DD, 1997, NATURE, V389, P865, DOI 10.1038/39899; YUE TL, 1990, J NEUROCHEM, V54, P1809, DOI 10.1111/j.1471-4159.1990.tb01239.x	51	76	85	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1999	274	10					6493	6498		10.1074/jbc.274.10.6493	http://dx.doi.org/10.1074/jbc.274.10.6493			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172BQ	10037742	hybrid			2022-12-25	WOS:000078902800064
J	Suzuki, M; Sato, J; Kutsuwada, K; Ooki, G; Imai, M				Suzuki, M; Sato, J; Kutsuwada, K; Ooki, G; Imai, M			Cloning of a stretch-inhibitable nonselective cation channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INACTIVATED ION CHANNELS; PARATHYROID-HORMONE; MDX-MYOTUBES; GADOLINIUM; RECEPTOR; PRESSURE; TUBULE; BLOCK; CELLS	A homologue of the capsaicin receptor-nonselective cation channel was cloned from the rat kidney to investigate a mechanosensitive channel. We found this channel to be inactivated by membrane stretch and have designated it stretch-inactivated channel (SIC), SIC encodes a 563-amino acid protein with putative six transmembrane segments. The cDNA was expressed in mammalian cells, and electophysiological studies were performed. SIG-induced large cation currents were found to be regulated by cell volume, with currents being stimulated by cell shrinkage and inhibited by cell swelling. Single channel analysis showed a conductance of 250 pS with cation permeability (PC1/PNa < 0.1), and the channel possessed some of the characteristics of a stretch-inactivated channel in that it was permeable to calcium, sensitive to membrane stretch, and blocked by Gd3+. Therefore, we cloned one of the mechanosensitive cation channels of mammals, which is considered to regulate Ca2+ influx in response to mechanical stress on the cell membrane.	Jichi Med Sch, Dept Pharmacol, Minamimaki, Tochigi 32904, Japan	Jichi Medical University	Suzuki, M (corresponding author), Jichi Med Sch, Dept Pharmacol, 3311-1 Yakushiji, Minamimaki, Tochigi 32904, Japan.	macsuz@jichi.ac.jp						Bourque CW, 1997, ANNU REV PHYSIOL, V59, P601, DOI 10.1146/annurev.physiol.59.1.601; Caterina MJ, 1997, NATURE, V389, P816, DOI 10.1038/39807; FRANCO A, 1990, NATURE, V344, P670, DOI 10.1038/344670a0; FRANCO A, 1991, BIOPHYS J, V59, P1164, DOI 10.1016/S0006-3495(91)82332-3; HILLE B, 1994, ION CHANNELS EXCITAB, P337; HISADA T, 1993, PFLUG ARCH EUR J PHY, V422, P393, DOI 10.1007/BF00374296; HOLSTEINRATHLOU NH, 1986, ACTA PHYSIOL SCAND, V126, P333, DOI 10.1111/j.1748-1716.1986.tb07824.x; Maniatis T., 1982, MOL CLONING LAB MANU; MORRIS CE, 1989, SCIENCE, V243, P807, DOI 10.1126/science.2536958; MORRIS CE, 1991, SCIENCE, V251, P1246, DOI 10.1126/science.1706535; Navarro B, 1996, SCIENCE, V272, P1950, DOI 10.1126/science.272.5270.1950; SACKIN H, 1995, ANNU REV PHYSIOL, V57, P333, DOI 10.1146/annurev.ph.57.030195.002001; SAKMANN B, 1985, NATURE, V318, P538, DOI 10.1038/318538a0; SAKMANN B, 1995, SINGLE CHANNEL RECOR, P3; SUZUKI M, 1991, J CLIN INVEST, V88, P735, DOI 10.1172/JCI115370; TANIGUCHI J, 1994, J MEMBRANE BIOL, V140, P123; TSENGCRANK J, 1994, NEURON, V13, P1315, DOI 10.1016/0896-6273(94)90418-9; Xie JY, 1998, SCIENCE, V280, P443, DOI 10.1126/science.280.5362.443; YANG XC, 1989, SCIENCE, V243, P1068, DOI 10.1126/science.2466333; YANG XC, 1993, NONSELECTIVE CATION	20	99	109	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	1999	274	10					6330	6335		10.1074/jbc.274.10.6330	http://dx.doi.org/10.1074/jbc.274.10.6330			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172BQ	10037722	hybrid			2022-12-25	WOS:000078902800044
J	Spittler, A; Reissner, CM; Oehler, R; Gornikiewicz, A; Gruenberger, T; Manhart, N; Brodowicz, T; Mittlboeck, M; Boltz-Nitulescu, G; Roth, E				Spittler, A; Reissner, CM; Oehler, R; Gornikiewicz, A; Gruenberger, T; Manhart, N; Brodowicz, T; Mittlboeck, M; Boltz-Nitulescu, G; Roth, E			Immunomodulatory effects of glycine on LPS-treated monocytes: reduced TNF-alpha production and accelerated IL-10 expression	FASEB JOURNAL			English	Article						sepsis; cytokines; antigen expression; tumor necrosis factor; whole blood cell	TUMOR-NECROSIS-FACTOR; T-CELL PROLIFERATION; INTERLEUKIN-1 RECEPTOR ANTAGONIST; INHIBITS CYTOKINE PRODUCTION; MULTICENTER CLINICAL-TRIAL; HUMAN BLOOD MONOCYTES; MONOCLONAL-ANTIBODY; SEPTIC SHOCK; DOUBLE-BLIND; SEPSIS SYNDROME	Cytokines play a pivotal role in the pathogenesis of septic shock. Proinflammatory cytokines such as tumor necrosis factora-alpha (TNF-alpha) and interleukin-1 eta (IL-1 beta) stimulate the progression of septic shock whereas the anti-inflammatory cytokine ILIO has counterregulative potency. The amino acid glycine (GLY) has been shown to protect against endotoxin shock in the rat by inhibiting TNF-alpha production. In the current study we investigated the role of GLY on lipopolysaccharide (LPS) -induced cell surface marker expression, phagocytosis, and cytokine production on purified monocytes from healthy donors. GLY did not modulate the expression of HLA-DR and CD64 on monocytes, whereas CD11b/CD18 expression (P < 0.05) and E. coli phagocytosis (P < 0.05) decreased significantly. GLY decreased LPS-induced TNF-alpha production (P < 0.01) and increased ILIO expression of purified monocytes, Similarly, in a whole blood assay, GLY reduced TNF-alpha (P < 0.0001) and IL-1 beta (P < 0.0001) synthesis and increased IL-10 expression (P < 0.05) in a dose-dependent manner. The inhibitory effects of GLY were neutralized by strychnine, and the production of IL-10 and TNF-alpha was augmented by anti-IL-10 antibodies. Furthermore, GLY decreased the amount of IL-1 beta and TNF-alpha-specific mRNA. Our data indicate that GLY has a potential to be used as an additional immunomodulatory tool in the early phase of sepsis and in different pathophysiological situations related to hypoxia and reperfusion.	Univ Vienna, Dept Surg, Res Labs, AKH, A-1090 Vienna, Austria; Univ Vienna, Inst Gen & Expt Pathol, A-1090 Vienna, Austria; Univ Vienna, Dept Med Comp Sci, A-1090 Vienna, Austria	University of Vienna; University of Vienna; University of Vienna	Spittler, A (corresponding author), Univ Vienna, Dept Surg, Res Labs, AKH, Waehringer Guertel 18-20, A-1090 Vienna, Austria.	a.spittler@akh-wien.ac.at	Gruenberger, Thomas/ABA-1661-2020	Gruenberger, Thomas/0000-0002-2671-0540; Mittlboeck, Martina/0000-0003-1097-4047; Oehler, Rudolf/0000-0003-2891-7155; Spittler, Andreas/0000-0003-2657-6836				ABRAHAM E, 1995, JAMA-J AM MED ASSOC, V273, P934, DOI 10.1001/jama.273.12.934; BARRON RL, 1993, CLIN PHARMACY, V12, P829; BEUTLER B, 1985, SCIENCE, V229, P869, DOI 10.1126/science.3895437; Beutler B, 1993, New Horiz, V1, P3; BONE RC, 1995, CRIT CARE MED, V23, P994, DOI 10.1097/00003246-199506000-00003; DHAINAUT JFA, 1994, CRIT CARE MED, V22, P1720, DOI 10.1097/00003246-199422110-00005; DING L, 1992, J IMMUNOL, V148, P3133; DOHERTY GM, 1992, J IMMUNOL, V149, P1666; ERTEL W, 1995, BLOOD, V85, P1341, DOI 10.1182/blood.V85.5.1341.bloodjournal8551341; FIORENTINO DF, 1989, J EXP MED, V170, P2081, DOI 10.1084/jem.170.6.2081; FIORENTINO DF, 1991, J IMMUNOL, V147, P3815; Fisher CJ, 1996, NEW ENGL J MED, V334, P1697, DOI 10.1056/NEJM199606273342603; FISHER CJ, 1994, JAMA-J AM MED ASSOC, V271, P1836, DOI 10.1001/jama.271.23.1836; FISHER CJ, 1993, CRIT CARE MED, V21, P318, DOI 10.1097/00003246-199303000-00006; GREENMAN RL, 1991, JAMA-J AM MED ASSOC, V266, P1097, DOI 10.1001/jama.266.8.1097; Griffiths RD, 1997, NUTRITION, V13, P295; HOUDIJK APJ, 1998, JPEN, V22, pS2; HOWARD M, 1993, J EXP MED, V177, P1205, DOI 10.1084/jem.177.4.1205; Ikejima K, 1997, AM J PHYSIOL-GASTR L, V272, pG1581, DOI 10.1152/ajpgi.1997.272.6.G1581; Ikejima K, 1996, AM J PHYSIOL-GASTR L, V271, pG97, DOI 10.1152/ajpgi.1996.271.1.G97; JUNG T, 1993, J IMMUNOL METHODS, V159, P197, DOI 10.1016/0022-1759(93)90158-4; MALEFYT RD, 1991, J EXP MED, V174, P1209; MALEFYT RD, 1991, J EXP MED, V174, P915; MARSH DC, 1993, HEPATOLOGY, V17, P91, DOI 10.1016/0270-9139(93)90197-U; MOORE KW, 1993, ANNU REV IMMUNOL, V11, P165, DOI 10.1146/annurev.immunol.11.1.165; OHLSSON K, 1990, NATURE, V348, P550, DOI 10.1038/348550a0; PARRILLO JE, 1993, NEW ENGL J MED, V328, P1471, DOI 10.1056/nejm199305203282008; Spittler A, 1997, IMMUNOLOGY, V90, P286, DOI 10.1046/j.1365-2567.1997.00148.x; SPITTLER A, 1995, BLOOD, V86, P1564, DOI 10.1182/blood.V86.4.1564.bloodjournal8641564; SPITTLER A, 1995, IMMUNOLOGY, V85, P311; STANDIFORD TJ, 1995, J IMMUNOL, V155, P2222; TAGA K, 1992, J IMMUNOL, V148, P1143; Thurman RG, 1997, TRANSPLANTATION, V63, P1661, DOI 10.1097/00007890-199706150-00021; TRACEY KJ, 1987, NATURE, V330, P662, DOI 10.1038/330662a0; Wang RX, 1997, J IMMUNOL, V158, P2856; WEINBERG JM, 1987, J CLIN INVEST, V80, P1446, DOI 10.1172/JCI113224; WEINBERG JM, 1991, J CLIN INVEST, V87, P581, DOI 10.1172/JCI115033; Zhong Z, 1996, AM J PHYSIOL-GASTR L, V270, pG332, DOI 10.1152/ajpgi.1996.270.2.G332	38	85	95	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	1999	13	3					563	571		10.1096/fasebj.13.3.563	http://dx.doi.org/10.1096/fasebj.13.3.563			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	174CF	10064624				2022-12-25	WOS:000079016000017
J	Al-Shami, A; Naccache, PH				Al-Shami, A; Naccache, PH			Granulocyte-macrophage colony-stimulating factor-activated signaling pathways in human neutrophils - Involvement of Jak2 in the stimulation of phosphatidylinositol 3-kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR GM-CSF; PROTEIN-TYROSINE KINASE; PHOSPHOINOSITIDE 3-KINASE; BETA-SUBUNIT; CELL-LINE; CYTOPLASMIC DOMAINS; PHOSPHATIDIC-ACID; PHOSPHOLIPASE-D; FAMILY MEMBERS; JANUS KINASES	Granulocyte-macrophage colony-stimulating factor (GM-CSF) regulates many of the biological activities of human neutrophils. The signaling pathways via which these effects are mediated are not fully understood. We have shown previously that GM-CSF treatment of human neutrophils activates the Janus kinase/signal transducers and activators of transcription (Jak/STAT) pathway and, more specifically, Jak2, STAT3, and STAT5B in neutrophils. GM-CSF also stimulates the activity of the phosphatidylinositol 3-kinase (PI3-kinase) in a tyrosine kinase-dependent manner. Here we report that pretreating the cells with a Jak2 inhibitor (AG-490) abolishes tyrosine phosphorylation of the p85 subunit of PI3-kinase induced by GM CSF. Furthermore, p85 was found to associate with Jak2, but not with Lyn, in stimulated cells in situ and with its autophosphorylated form in vitro; however, Jak2 did not bind to either of the two Src homology 2 (SH2) domains of the p85 subunit of PI3-kinase. Although STAT5B bound to the carboxyl-terminal SH2 domain of p85, it was absent from the complex containing PI3-kinase and Jak2. These results suggest that stimulation of the activity of PI3-kinase induced by GM-CSF is mediated by Jak2 and that the association between Jak2 and p85 depends on an adaptor protein yet to be identified.	CHUL, Ctr Rech, Ctr Rech Rhumatol & Immunol, St Foy, PQ G1V 4G2, Canada; Univ Laval, Dept Med, Fac Med, St Foy, PQ G1V 4G2, Canada	Laval University; Laval University	Naccache, PH (corresponding author), CHUL, Ctr Rech, Ctr Rech Rhumatol & Immunol, 2705 Blvd Laurier, St Foy, PQ G1V 4G2, Canada.		Al-Shami, Amin/D-3889-2009					Al-Shami A, 1998, J BIOL CHEM, V273, P1058, DOI 10.1074/jbc.273.2.1058; AlShami A, 1997, BLOOD, V89, P1035, DOI 10.1182/blood.V89.3.1035; AlShami A, 1997, J IMMUNOL METHODS, V202, P183, DOI 10.1016/S0022-1759(97)00004-5; ATKINSON YH, 1988, IMMUNOLOGY, V64, P519; Belova LA, 1997, BIOCHEMISTRY-MOSCOW+, V62, P563; BOURGOIN S, 1990, J EXP MED, V172, P767, DOI 10.1084/jem.172.3.767; Brizzi MF, 1996, J BIOL CHEM, V271, P3562; Burfoot MS, 1997, J BIOL CHEM, V272, P24183, DOI 10.1074/jbc.272.39.24183; Carpenter CL, 1996, CURR OPIN CELL BIOL, V8, P153, DOI 10.1016/S0955-0674(96)80060-3; CASSATELLA MA, 1995, IMMUNOL TODAY, V16, P21, DOI 10.1016/0167-5699(95)80066-2; CLARK SC, 1988, INT J CELL CLONING, V6, P365, DOI 10.1002/stem.5530060602; COREY S, 1993, EMBO J, V12, P2681, DOI 10.1002/j.1460-2075.1993.tb05929.x; DANDREA R, 1994, BLOOD, V83, P2802, DOI 10.1182/blood.V83.10.2802.2802; Domin J, 1997, FEBS LETT, V410, P91, DOI 10.1016/S0014-5793(97)00617-0; DORSCH M, 1994, BIOCHEM BIOPH RES CO, V200, P562, DOI 10.1006/bbrc.1994.1485; DURSTIN M, 1994, P NATL ACAD SCI USA, V91, P3142, DOI 10.1073/pnas.91.8.3142; GASSON JC, 1984, SCIENCE, V226, P1339, DOI 10.1126/science.6390681; GOLD MR, 1994, J BIOL CHEM, V269, P5403; GOMEZCAMBRONERO J, 1989, P NATL ACAD SCI USA, V86, P3569, DOI 10.1073/pnas.86.10.3569; GOMEZCAMBRONERO J, 1993, BIOCHEM J, V291, P211, DOI 10.1042/bj2910211; Hallett MB, 1997, BIOESSAYS, V19, P615, DOI 10.1002/bies.950190712; HANAZONO Y, 1993, EMBO J, V12, P1641, DOI 10.1002/j.1460-2075.1993.tb05809.x; HAYASHIDA K, 1990, P NATL ACAD SCI USA, V87, P9655, DOI 10.1073/pnas.87.24.9655; HERBST JJ, 1994, BIOCHEMISTRY-US, V33, P9376, DOI 10.1021/bi00198a002; HILES ID, 1992, CELL, V70, P419, DOI 10.1016/0092-8674(92)90166-A; Horvath CM, 1997, CURR OPIN CELL BIOL, V9, P233, DOI 10.1016/S0955-0674(97)80067-1; Ihle JN, 1996, PHILOS T R SOC B, V351, P159, DOI 10.1098/rstb.1996.0012; IHLE JN, 1995, TRENDS GENET, V11, P69, DOI 10.1016/S0168-9525(00)89000-9; KANAKURA Y, 1991, BLOOD, V77, P243; KANAKURA Y, 1991, J BIOL CHEM, V266, P490; Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701; LI Y, 1995, J IMMUNOL, V155, P2165; LINNEKIN D, 1995, J BIOL CHEM, V270, P4950, DOI 10.1074/jbc.270.9.4950; LISCOVITCH M, 1994, CELL, V77, P329, DOI 10.1016/0092-8674(94)90148-1; LOPEZ AF, 1986, J CLIN INVEST, V78, P1220, DOI 10.1172/JCI112705; Marte BM, 1997, TRENDS BIOCHEM SCI, V22, P355, DOI 10.1016/S0968-0004(97)01097-9; Matsuguchi T, 1997, J BIOL CHEM, V272, P17450, DOI 10.1074/jbc.272.28.17450; MCCOLL SR, 1991, BLOOD, V78, P1842; Meydan N, 1996, NATURE, V379, P645, DOI 10.1038/379645a0; Milani D, 1996, J BIOL CHEM, V271, P22961, DOI 10.1074/jbc.271.38.22961; MUI ALF, 1995, EMBO J, V14, P1166, DOI 10.1002/j.1460-2075.1995.tb07100.x; Muto A, 1995, J ALLERGY CLIN IMMUN, V96, P1100, DOI 10.1016/S0091-6749(95)70195-8; Naccache PH, 1997, J LEUKOCYTE BIOL, V62, P901, DOI 10.1002/jlb.62.6.901; NACCACHE PH, 1991, CELL SIGNAL, V3, P635, DOI 10.1016/0898-6568(91)90040-2; NACCACHE PH, 1988, J IMMUNOL, V140, P3541; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; NATHAN CF, 1989, BLOOD, V73, P301; PARKER PJ, 1992, CELL GROWTH DIFFER, V3, P747; Pellegrini S, 1997, EUR J BIOCHEM, V248, P615, DOI 10.1111/j.1432-1033.1997.00615.x; Pfeffer LM, 1997, SCIENCE, V276, P1418, DOI 10.1126/science.276.5317.1418; POLOTSKAYA A, 1993, CELL GROWTH DIFFER, V4, P523; POWIS G, 1994, CANCER METAST REV, V13, P91, DOI 10.1007/BF00690420; QUELLE FW, 1994, MOL CELL BIOL, V14, P4335, DOI 10.1128/MCB.14.7.4335; RAPOPORT AP, 1992, BLOOD REV, V6, P43, DOI 10.1016/0268-960X(92)90007-D; ROBERTS PJ, 1994, BLOOD, V84, P1064; Rosen RL, 1996, BLOOD, V88, P1206, DOI 10.1182/blood.V88.4.1206.bloodjournal8841206; SAKAMAKI K, 1992, EMBO J, V11, P3541, DOI 10.1002/j.1460-2075.1992.tb05437.x; SHAAFI RI, 1988, PROG ALLERGY, V42, P1; SHARFE N, 1995, BLOOD, V86, P2077, DOI 10.1182/blood.V86.6.2077.bloodjournal8662077; Silvennoinen O, 1997, APMIS, V105, P497, DOI 10.1111/j.1699-0463.1997.tb05047.x; SMITH JA, 1994, J LEUKOCYTE BIOL, V56, P672, DOI 10.1002/jlb.56.6.672; Stephens LR, 1997, CELL, V89, P105, DOI 10.1016/S0092-8674(00)80187-7; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; TANAKA N, 1994, P NATL ACAD SCI USA, V91, P7271, DOI 10.1073/pnas.91.15.7271; THOMPSON NT, 1995, BIOCHEM SOC T, V23, pS196, DOI 10.1042/bst023196s; TOKER A, 1994, J BIOL CHEM, V269, P32358; Vanhaesebroeck B, 1997, P NATL ACAD SCI USA, V94, P4330, DOI 10.1073/pnas.94.9.4330; Vanhaesebroeck B, 1997, TRENDS BIOCHEM SCI, V22, P267, DOI 10.1016/S0968-0004(97)01061-X; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; WENNSTROM S, 1994, CURR BIOL, V4, P385, DOI 10.1016/S0960-9822(00)00087-7; WIESBART RH, 1985, NATURE, V314, P361; WITTHUHN BA, 1994, NATURE, V370, P153, DOI 10.1038/370153a0; WOJCHOWSKI DM, 1993, STEM CELLS, V11, P381, DOI 10.1002/stem.5530110505; YANO H, 1993, J BIOL CHEM, V268, P25846; YUO A, 1993, BIOCHIM BIOPHYS ACTA, V1156, P197, DOI 10.1016/0304-4165(93)90136-V; Zhang XL, 1998, SEMIN CELL DEV BIOL, V9, P153, DOI 10.1006/scdb.1997.0220	76	74	75	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 26	1999	274	9					5333	5338		10.1074/jbc.274.9.5333	http://dx.doi.org/10.1074/jbc.274.9.5333			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	170KG	10026141	hybrid			2022-12-25	WOS:000078804400012
J	Armah, DA; Mensa-Wilmot, K				Armah, DA; Mensa-Wilmot, K			S-myristoylation of a glycosylphosphatidylinositol-specific phospholipase C in Trypanosoma brucei	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VARIANT SURFACE GLYCOPROTEIN; ADENYLATE-CYCLASE; MEMBRANE-FORM; PROTEINS; PALMITOYLATION; PURIFICATION; ANCHOR; ACTIVATION; ACYLATION; MYRISTATE	Covalent modification with lipid can target cytosolic proteins to biological membranes. With intrinsic membrane proteins, the role of acylation can be elusive. Herein, we describe covalent lipid modification of an integral membrane glycosylphosphatidylinositol-specific phospholipase C (GPI-PLC) from the kinetoplastid Trypanosoma brucei. Myristic acid was detected on cysteine residue(s) (i.e. thiomyristoylation). Thiomyristoylation occurred both co- and post-translationally Acylated GPI-PLC was active against variant surface glycoprotein (VSG). The half-life of fatty acid on GPI-PLC was 45 min, signifying the dynamic nature of the modification. Deacylation in vitro decreased activity of GPI-PLC 18-30-fold. Thioacylation, from kinetic analysis, activated GPI-PLC by accelerating the conversion of a GPI-PLC VSG complex to product. Reversible thioacylation is a novel mechanism for regulating the activity of a phospholipase C.	Univ Georgia, Dept Cellular Biol, Athens, GA 30602 USA	University System of Georgia; University of Georgia	Armah, DA (corresponding author), Univ Georgia, Dept Cellular Biol, 724 Biol Sci, Athens, GA 30602 USA.				NIAID NIH HHS [AI33383] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI033383, R29AI033383] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BANGS JD, 1986, J CELL BIOL, V103, P255, DOI 10.1083/jcb.103.1.255; BERTHIAUME L, 1994, J BIOL CHEM, V269, P6498; BIZZOZERO OA, 1995, METHOD ENZYMOL, V250, P361; BULOW R, 1989, J CELL SCI, V93, P233; BULOW R, 1986, J BIOL CHEM, V261, P1918; Buxbaum LU, 1996, P NATL ACAD SCI USA, V93, P1178, DOI 10.1073/pnas.93.3.1178; CASEY PJ, 1995, SCIENCE, V268, P221, DOI 10.1126/science.7716512; CROSS GAM, 1975, PARASITOLOGY, V71, P393, DOI 10.1017/S003118200004717X; DOERING TL, 1993, J BIOL CHEM, V268, P9215; FERGUSON MAJ, 1985, J BIOL CHEM, V260, P4547; FERGUSON MAJ, 1984, J BIOL CHEM, V259, P3011; FOX JA, 1986, J BIOL CHEM, V261, P5767; Garg N, 1997, J BIOL CHEM, V272, P12482, DOI 10.1074/jbc.272.19.12482; HACKETT M, 1994, SCIENCE, V266, P433, DOI 10.1126/science.7939682; HEISE N, 1995, MOL BIOCHEM PARASIT, V70, P71, DOI 10.1016/0166-6851(95)00009-P; HERELD D, 1986, J BIOL CHEM, V261, P3813; Hurley JH, 1997, CURR OPIN STRUC BIOL, V7, P557, DOI 10.1016/S0959-440X(97)80122-4; KNOLL LJ, 1995, METHOD ENZYMOL, V250, P405; MENSAWILMOT K, 1994, J CELL BIOL, V124, P935, DOI 10.1083/jcb.124.6.935; MENSAWILMOT K, 1995, METHOD ENZYMOL, V250, P641; MENSAWILMOT K, 1992, MOL BIOCHEM PARASIT, V56, P311, DOI 10.1016/0166-6851(92)90180-R; Morris JC, 1997, J BIOL CHEM, V272, P29554, DOI 10.1074/jbc.272.47.29554; Mumby SM, 1997, CURR OPIN CELL BIOL, V9, P148, DOI 10.1016/S0955-0674(97)80056-7; PATNAIK PK, 1993, MOL BIOCHEM PARASIT, V58, P97, DOI 10.1016/0166-6851(93)90094-E; Rolin S, 1996, J BIOL CHEM, V271, P10844, DOI 10.1074/jbc.271.18.10844; ROSS EM, 1995, CURR BIOL, V5, P107, DOI 10.1016/S0960-9822(95)00026-1; Tu YP, 1997, SCIENCE, V278, P1132, DOI 10.1126/science.278.5340.1132; VIDUGIRIENE J, 1994, J CELL BIOL, V127, P333, DOI 10.1083/jcb.127.2.333	28	29	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 26	1999	274	9					5931	5938		10.1074/jbc.274.9.5931	http://dx.doi.org/10.1074/jbc.274.9.5931			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	170KG	10026218	hybrid			2022-12-25	WOS:000078804400089
J	Che, SL; El-Hodiri, HM; Wu, CF; Nelman-Gonzalez, M; Weil, MM; Etkin, LD; Clark, RB; Kuang, J				Che, SL; El-Hodiri, HM; Wu, CF; Nelman-Gonzalez, M; Weil, MM; Etkin, LD; Clark, RB; Kuang, J			Identification and cloning of Xp95, a putative signal transduction protein in Xenopus oocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MATURATION-PROMOTING FACTOR; CELL-CYCLE; MAP KINASE; MEIOTIC MATURATION; PHOSPHORYLATION; CDC25; ACTIVATION; MPM-2; GENE; MOS	A 95-kDa protein in Xenopus oocytes, Xp95, was shown to be phosphorylated from the first through the second meiotic divisions during progesterone-induced oocyte maturation. Xp95 was purified and cloned. The Xp95 protein sequence exhibited homology to mouse Rhophilin, budding yeast Bro1, and Aspergillus PalA, all of which are implicated in signal transduction. It also contained three conserved features including seven conserved tyrosines, a phosphorylation consensus sequence for the Src family of tyrosine kinases, and a proline-rich domain near the C terminus that contains multiple SH3 domain-binding motifs. me showed the following: 1) that both Xp95 isolated from Xenopus oocytes and a synthetic peptide containing the Src phosphorylation consensus sequence of Xp95 were phosphorylated in vitro by Src kinase and to a lesser extent by Fyn kinase; 2) Xp95 from Xenopus oocytes or eggs was recognized by an anti-phosphotyrosine antibody, and the relative abundance of tyrosine-phosphorylated Xp95 increased during oocyte maturation; and 3) microinjection of deregulated Src mRNA into Xenopus oocytes increased the abundance of tyrosine-phosphorylated Xp95, These results suggest that Xp95 is an element in a tyrosine kinase signaling pathway that may be involved in progesterone-induced Xenopus oocyte maturation.	Univ Texas, MD Anderson Cancer Ctr, Dept Clin Invest, Houston, TX 77030 USA; Univ Texas, MD Anderson Cancer Ctr, Dept Mol Genet, Houston, TX 77030 USA; Univ Texas, MD Anderson Cancer Ctr, Dept Expt Radiat Oncol, Houston, TX 77030 USA; Univ Texas, Sch Med, Dept Pharmacol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System	Kuang, J (corresponding author), Univ Texas, MD Anderson Cancer Ctr, Dept Clin Invest, Box 019,1515 Holcombe Blvd, Houston, TX 77030 USA.		El-hodiri, Heithem/E-3019-2011		NATIONAL CANCER INSTITUTE [T32CA009299] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM048457] Funding Source: NIH RePORTER; NCI NIH HHS [CA09299] Funding Source: Medline; NIGMS NIH HHS [R-29 GM48457-02] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Che SL, 1997, BBA-GENE STRUCT EXPR, V1354, P231, DOI 10.1016/S0167-4781(97)00112-7; COOK R, 1994, PROTEIN BLOTTING PRA, V1, P207; Cork R. John, 1994, Zygote, V2, P289; DUNPHY WG, 1988, CELL, V54, P423, DOI 10.1016/0092-8674(88)90205-X; FABIAN JR, 1993, J CELL BIOL, V122, P645, DOI 10.1083/jcb.122.3.645; FERRELL JE, 1991, MOL CELL BIOL, V11, P1965, DOI 10.1128/MCB.11.4.1965; GAUTIER J, 1991, CELL, V67, P197, DOI 10.1016/0092-8674(91)90583-K; GAUTIER J, 1988, CELL, V54, P433, DOI 10.1016/0092-8674(88)90206-1; GEAHLEN RL, 1990, PEPT PROT PHOSPH, P239; GOTOH Y, 1991, EMBO J, V10, P2661, DOI 10.1002/j.1460-2075.1991.tb07809.x; GRATECOS D, 1974, BIOCHEM BIOPH RES CO, V58, P960, DOI 10.1016/S0006-291X(74)80237-8; GURDON JB, 1976, J EMBRYOL EXP MORPH, V36, P523; Hock B, 1998, P NATL ACAD SCI USA, V95, P9779, DOI 10.1073/pnas.95.17.9779; HSIAO KM, 1994, P NATL ACAD SCI USA, V91, P5480, DOI 10.1073/pnas.91.12.5480; IZUMI T, 1992, MOL BIOL CELL, V3, P927, DOI 10.1091/mbc.3.8.927; KOSAKO H, 1994, EMBO J, V13, P2131, DOI 10.1002/j.1460-2075.1994.tb06489.x; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; Kozak M, 1996, MAMM GENOME, V7, P563, DOI 10.1007/s003359900171; KUANG J, 1994, MOL BIOL CELL, V5, P135, DOI 10.1091/mbc.5.2.135; KUANG J, 1993, J CELL BIOL, V123, P859, DOI 10.1083/jcb.123.4.859; KUANG J, 1991, DEV BIOL, V144, P54, DOI 10.1016/0012-1606(91)90478-L; KUMAGAI A, 1992, CELL, V70, P139, DOI 10.1016/0092-8674(92)90540-S; Kumagai A, 1996, SCIENCE, V273, P1377, DOI 10.1126/science.273.5280.1377; Lin PN, 1998, P NATL ACAD SCI USA, V95, P8829, DOI 10.1073/pnas.95.15.8829; Machesky LM, 1996, TRENDS CELL BIOL, V6, P304, DOI 10.1016/0962-8924(96)10026-X; Maller J L, 1985, Dev Biol (N Y 1985), V1, P289; MILLER M, 1991, DEVELOPMENT, V113, P569; MOSES RM, 1989, EXP CELL RES, V185, P271, DOI 10.1016/0014-4827(89)90055-4; MURRAY AW, 1989, NATURE, V339, P275, DOI 10.1038/339275a0; MUSLIN AJ, 1993, MOL CELL BIOL, V13, P4197, DOI 10.1128/MCB.13.7.4197; NegreteUrtasun S, 1997, J BACTERIOL, V179, P1832, DOI 10.1128/jb.179.5.1832-1835.1997; Nickas ME, 1996, MOL CELL BIOL, V16, P2585; Nigg E A, 1991, Semin Cell Biol, V2, P261; PASADA J, 1993, MOL CELL BIOL, V13, P2546; PENG HB, 1991, METHOD CELL BIOL, V36, P657; RUPP RAW, 1994, GENE DEV, V8, P1311, DOI 10.1101/gad.8.11.1311; SAGATA N, 1989, SCIENCE, V245, P643, DOI 10.1126/science.2474853; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SHIBUYA EK, 1992, EMBO J, V11, P3963, DOI 10.1002/j.1460-2075.1992.tb05490.x; SMITH LD, 1989, DEVELOPMENT, V107, P685; SPIVACK JG, 1984, MOL CELL BIOL, V4, P1631, DOI 10.1128/MCB.4.8.1631; TURNER DL, 1994, GENE DEV, V8, P1434, DOI 10.1101/gad.8.12.1434; UNGER TF, 1992, MOL CELL BIOL, V12, P5485, DOI 10.1128/MCB.12.12.5485; Watanabe G, 1996, SCIENCE, V271, P645, DOI 10.1126/science.271.5249.645; YEW N, 1992, NATURE, V355, P649, DOI 10.1038/355649a0; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0	46	43	45	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 26	1999	274	9					5522	5531		10.1074/jbc.274.9.5522	http://dx.doi.org/10.1074/jbc.274.9.5522			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	170KG	10026166	hybrid			2022-12-25	WOS:000078804400037
J	Endrich, MM; Gehrig, P; Gehring, H				Endrich, MM; Gehrig, P; Gehring, H			Maturation-induced conformational changes of HIV-1 capsid protein and identification of two high affinity sites for cyclophilins in the C-terminal domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; CRYSTAL-STRUCTURE; GAG PROTEINS; VIRIONS; CORE; RP24	Viral incorporation of cyclophilin A (CS PA) during the assembly of human immunodeficiency virus type-1 (HIV-1) is crucial for efficient viral replication, CyPA binds to the previously identified Gly-Pro(90) site of the capsid protein p24, but its role remained unclear. Here we report two new interaction sites between cyclophilins and p24, Both are located in the C-terminal domain of p24 around Gly-Pro(157) and Gly-Pro(224). Peptides corresponding to these regions showed higher affinities (K-d similar to 0.3 mu M) for both CyPA and cyclophilin B than the best peptide derived from the Gly-Pro(90) site (similar to 8 mu M) and thus revealed new sequence motifs flanking Gly-Pro that are important for tight interaction of peptide ligands with cyclophilins. Between CS PA and an immature (unprocessed) form of p24, a K-d of similar to 8 mu M was measured, which corresponded with the K-d of the best of the Gly-Pro(90) peptides, indicating an association via this site, Processing of immature p24 by the viral protease, yielding mature p24, elicited a conformational change in its C-terminal domain that was signaled by the covalently attached fluorescence label acrylodan. Consequently, CyPA and cyclophilin B bound with much higher affinities (similar to 0.6 and 0.25 mu M) to the new, i.e. maturation-generated sites. Since this domain is essential for p24 oligomerization and capsid cone formation, CyPA bound to the new sites might impair the regularity of the capsid cone and thus facilitate in vivo core disassembly after host infection.	Univ Zurich, Inst Biochem, CH-8057 Zurich, Switzerland	University of Zurich	Gehring, H (corresponding author), Univ Zurich, Inst Biochem, Winterthurerstr 190, CH-8057 Zurich, Switzerland.	gehring@bioc.unizh.ch						Accola MA, 1998, J VIROL, V72, P2072, DOI 10.1128/JVI.72.3.2072-2078.1998; Ackerson B, 1998, J VIROL, V72, P303, DOI 10.1128/JVI.72.1.303-308.1998; Agresta BE, 1997, J VIROL, V71, P6921, DOI 10.1128/JVI.71.9.6921-6927.1997; BILLICH A, 1995, J VIROL, V69, P2451, DOI 10.1128/JVI.69.4.2451-2461.1995; Braaten D, 1996, J VIROL, V70, P3551, DOI 10.1128/JVI.70.6.3551-3560.1996; Braaten D, 1996, J VIROL, V70, P5170, DOI 10.1128/JVI.70.8.5170-5176.1996; Braaten D, 1996, J VIROL, V70, P4220, DOI 10.1128/JVI.70.7.4220-4227.1996; EHRLICH LS, 1992, J VIROL, V66, P4874, DOI 10.1128/JVI.66.8.4874-4883.1992; Endrich MM, 1998, EUR J BIOCHEM, V252, P441, DOI 10.1046/j.1432-1327.1998.2520441.x; Endrich MM, 1996, BIOL CELL, V88, P15, DOI 10.1016/S0248-4900(97)86826-8; FRANKE EK, 1994, NATURE, V372, P359, DOI 10.1038/372359a0; GALAT A, 1995, PROG BIOPHYS MOL BIO, V63, P67, DOI 10.1016/0079-6107(94)00009-X; Gamble TR, 1996, CELL, V87, P1285, DOI 10.1016/S0092-8674(00)81823-1; Gamble TR, 1997, SCIENCE, V278, P849, DOI 10.1126/science.278.5339.849; Gay B, 1998, VIROLOGY, V247, P160, DOI 10.1006/viro.1998.9237; Gitti RK, 1996, SCIENCE, V273, P231, DOI 10.1126/science.273.5272.231; Gross I, 1998, J VIROL, V72, P4798, DOI 10.1128/JVI.72.6.4798-4810.1998; HARRISON RK, 1990, BIOCHEMISTRY-US, V29, P3813, DOI 10.1021/bi00468a001; HAUSDORF G, 1994, J VIROL METHODS, V50, P1, DOI 10.1016/0166-0934(94)90158-9; HENDERSON LE, 1992, J VIROL, V66, P1856, DOI 10.1128/JVI.66.4.1856-1865.1992; Jones I, 1996, NAT STRUCT BIOL, V3, P818, DOI 10.1038/nsb1096-818; LUBAN J, 1993, CELL, V73, P1067, DOI 10.1016/0092-8674(93)90637-6; Luhan J, 1996, CELL, V87, P1157; McDermott J, 1996, J VIROL, V70, P5106, DOI 10.1128/JVI.70.8.5106-5114.1996; MISSELWITZ R, 1995, BBA-PROTEIN STRUCT M, V1250, P9, DOI 10.1016/0167-4838(95)00041-R; Momany C, 1996, NAT STRUCT BIOL, V3, P763, DOI 10.1038/nsb0996-763; NERMUT MV, 1993, AIDS RES HUM RETROV, V9, P929, DOI 10.1089/aid.1993.9.929; SCHMID D, 1994, SCIENCE, V263, P971, DOI 10.1126/science.8310296; THALI M, 1994, NATURE, V372, P363, DOI 10.1038/372363a0; Vajdos FE, 1997, PROTEIN SCI, V6, P2297; von Schwedler UK, 1998, EMBO J, V17, P1555, DOI 10.1093/emboj/17.6.1555; WILLS JW, 1991, AIDS, V5, P639, DOI 10.1097/00002030-199106000-00002; Yoo SH, 1997, J MOL BIOL, V269, P780, DOI 10.1006/jmbi.1997.1051; Zhao YD, 1997, STRUCTURE, V5, P139, DOI 10.1016/S0969-2126(97)00172-X	34	33	33	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 26	1999	274	9					5326	5332		10.1074/jbc.274.9.5326	http://dx.doi.org/10.1074/jbc.274.9.5326			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	170KG	10026140	hybrid			2022-12-25	WOS:000078804400011
J	Kaminski, MJ; MacKenzie, CR; Mooibroek, MJ; Dahms, TES; Hirama, T; Houghton, AN; Chapman, PB; Evans, SV				Kaminski, MJ; MacKenzie, CR; Mooibroek, MJ; Dahms, TES; Hirama, T; Houghton, AN; Chapman, PB; Evans, SV			The role of homophilic binding in anti-tumor antibody R24 recognition of molecular surfaces - Demonstration of an intermolecular beta-sheet interaction between V(H) domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE MONOCLONAL-ANTIBODY; CRYSTAL-STRUCTURE; ANGSTROM RESOLUTION; MALIGNANT-MELANOMA; PLASMON RESONANCE; HUMAN MELANOCYTES; GD3 GANGLIOSIDE; FAB; AFFINITY; IMMUNOTHERAPY	The murine antibody R24 and mouse-human Fv-IgG1(kappa) chimeric antibody chR24 are specific for the cell-surface tumor antigen disialoganglioside GD3. X-ray diffraction and surface plasmon resonance experiments have been employed to study the mechanism of "homophilic binding," in which molecules of R24 recognize and bind to other molecules of R24 though their heavy chain variable domains. R24 exhibits strong binding to liposomes containing disialoganglioside GD3; however, the kinetics are unusual in that saturation of binding is not observed. The binding of chR24 to GD3-bearing liposomes is significantly weaker, suggesting that cooperative interactions involving antibody constant regions contribute to R24 binding of membrane-bound GD3. The crystal structures of the Fabs from R24 and chR24 reveal the mechanism for homophilic binding and confirm that the homophilic and antigen-binding idiotopes are distinct. The homophilic binding idiotope is formed largely by an anti-parallel beta-sheet dimerization between the H2 complementarity determining region (CDR) loops of two Fabs, while the antigen-binding idiotope is a pocket formed by the three CDR loops on the heavy chain. The formation of homophilic dimers requires the presence of a canonical conformation for the H2 CDR in conjunction with participation of side chains. The relative positions of the homophilic and antigen-binding sites allows for a lattice of GD3-specific antibodies to be constructed, which is stabilized by the presence of the cell membrane. This model provides for the selective recognition by R24 of cells that overexpress GD3 on the cell surface.	Univ Ottawa, Dept Biochem, Ottawa, ON K1H 8M5, Canada; Natl Res Council Canada, Inst Biol Sci, Ottawa, ON K1A 0R6, Canada; Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA	University of Ottawa; National Research Council Canada; Memorial Sloan Kettering Cancer Center	Evans, SV (corresponding author), Univ Ottawa, Dept Biochem, 451 Smyth, Ottawa, ON K1H 8M5, Canada.	evans@uottawa.ca		Evans, Stephen/0000-0002-0366-4027				ALBINO AP, 1986, J EXP MED, V164, P1710, DOI 10.1084/jem.164.5.1710; AREVALO JH, 1993, NATURE, V365, P859, DOI 10.1038/365859a0; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BOON T, 1993, INT J CANCER, V54, P177, DOI 10.1002/ijc.2910540202; BRADY RL, 1992, J MOL BIOL, V227, P253, DOI 10.1016/0022-2836(92)90695-G; BRUNGER AT, 1992, XPLOR MANUAL VERSION; CARUBIA JM, 1984, BIOCHEM BIOPH RES CO, V120, P500, DOI 10.1016/0006-291X(84)91282-8; CAULFIELD MJ, 1990, J BIOL RESP MODIF, V9, P319; CHAPMAN PB, 1990, CANCER RES, V50, P1503; CHAPMAN PB, 1990, J IMMUNOL, V145, P891; CHOTHIA C, 1989, NATURE, V342, P877, DOI 10.1038/342877a0; COOPER LJN, 1994, MOL IMMUNOL, V31, P577, DOI 10.1016/0161-5890(94)90165-1; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; EVANS SV, 1994, J MOL BIOL, V241, P691, DOI 10.1006/jmbi.1994.1544; FITZGERALD PMD, 1988, J APPL CRYSTALLOGR, V21, P273, DOI 10.1107/S0021889887012299; GREENSPAN NS, 1987, J IMMUNOL, V138, P285; GUDDAT LW, 1994, J MOL BIOL, V236, P247, DOI 10.1006/jmbi.1994.1133; HAKAMORI S, 1981, ANNU REV BIOCHEM, V50, P733; HAMILTON WB, 1993, INT J CANCER, V53, P566, DOI 10.1002/ijc.2910530407; HIRABAYASHI Y, 1987, JPN J CANCER RES, V78, P614; IRIE RF, 1990, THERAPEUTIC MONOCLON, P75; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; Kievit E, 1996, BRIT J CANCER, V73, P457, DOI 10.1038/bjc.1996.81; LLOYD KO, 1993, ANN NY ACAD SCI, V690, P50; MacKenzie CR, 1997, J BIOL CHEM, V272, P5533, DOI 10.1074/jbc.272.9.5533; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PUKEL CS, 1982, J EXP MED, V155, P1133, DOI 10.1084/jem.155.4.1133; RAYMOND J, 1991, P AN M AM SOC CLIN, V10, P298; ROSE DR, 1993, PROTEIN SCI, V2, P1106, DOI 10.1002/pro.5560020705; SAUL FA, 1992, PROTEINS, V14, P363, DOI 10.1002/prot.340140305; Sheriff S, 1996, J MOL BIOL, V259, P938, DOI 10.1006/jmbi.1996.0371; STANFIELD RL, 1993, STRUCTURE, V1, P83, DOI 10.1016/0969-2126(93)90024-B; THURIN J, 1985, J BIOL CHEM, V260, P4556; VADHANRAJ S, 1988, J CLIN ONCOL, V6, P1636, DOI 10.1200/JCO.1988.6.10.1636; VELDERS MP, 1995, CANCER RES, V55, P4398; YAMAGUCHI Y, 1995, J IMMUNOL METHODS, V181, P259, DOI 10.1016/0022-1759(95)00010-8; Yan XY, 1996, J IMMUNOL, V157, P1582	37	32	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 26	1999	274	9					5597	5604		10.1074/jbc.274.9.5597	http://dx.doi.org/10.1074/jbc.274.9.5597			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	170KG	10026176	hybrid			2022-12-25	WOS:000078804400047
J	Liu, Y; Choudhury, P; Cabral, CM; Sifers, RN				Liu, Y; Choudhury, P; Cabral, CM; Sifers, RN			Oligosaccharide modification in the early secretory pathway directs the selection of a misfolded glycoprotein for degradation by the proteasome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESISTANT ALPHA-MANNOSIDASE; ENDOPLASMIC-RETICULUM; QUALITY-CONTROL; LINKED OLIGOSACCHARIDES; PROTEIN-DEGRADATION; INTRACELLULAR DEGRADATION; MEMBRANE-PROTEIN; HUMAN-DISEASE; CALNEXIN; ASSOCIATION	The role of conformation-based quality control in the early secretory pathway is to eliminate misfolded polypeptides and unassembled multimeric protein complexes from the endoplasmic reticulum, ensuring the deployment of only functional molecules to distal sites. The intracellular fate of terminally misfolded human alpha(1)-antitrypsin was examined in hepatoma cells to identify the functional role of asparagine-linked oligosaccharide modification in the selection of glycoproteins for degradation by the cytosolic proteasome. Proteasomal degradation required physical interaction with the molecular chaperone calnexin. Altered sedimentation of intracellular complexes following treatment with the specific proteasome inhibitor lactacystin, and in combination with mannosidase inhibition, revealed that the removal of mannose from attached oligosaccharides abrogates the release of misfolded alpha(1)-antitrypsin from calnexin prior to proteasomal degradation. Intracellular turnover was arrested with kifunensine, implicating the participation of endoplasmic reticulum mannosidase I in the disposal process. Accelerated degradation occurred in a mannosidase-independent manner and was arrested by lactacystin, in response to the posttranslational inhibition of glucosidase II, demonstrating that the attenuated removal of glucose from attached oligosaccharides functions as the underlying rate-limiting step in the proteasome-mediated pathway. A model is proposed in which the removal of mannose from multiple attached oligosaccharides directs calnexin in the selection of misfolded alpha(1)-antitrypsin for degradation by the proteasome.	Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA; Baylor Coll Med, Dept Cell Biol, Houston, TX 77030 USA; Baylor Coll Med, Cell & Mol Biol Program, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine	Sifers, RN (corresponding author), Baylor Coll Med, Dept Pathol, One Baylor Plaza, Houston, TX 77030 USA.	rsifers@bcm.tmc.edu	Sifers, Richard Norman/AGQ-7262-2022					ANFINSEN CB, 1973, SCIENCE, V181, P223, DOI 10.1126/science.181.4096.223; Choudhury P, 1997, J BIOL CHEM, V272, P13446, DOI 10.1074/jbc.272.20.13446; Choudhury P, 1997, NEWS PHYSIOL SCI, V12, P162; de Virgilio M, 1998, J BIOL CHEM, V273, P9734, DOI 10.1074/jbc.273.16.9734; ELBEIN AD, 1991, FASEB J, V5, P3055, DOI 10.1096/fasebj.5.15.1743438; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; Galan JM, 1998, FASEB J, V12, P315, DOI 10.1096/fasebj.12.3.315; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GODELAINE D, 1981, J BIOL CHEM, V256, P161; GRINNA LS, 1980, J BIOL CHEM, V255, P2255; HAMMOND C, 1994, P NATL ACAD SCI USA, V91, P913, DOI 10.1073/pnas.91.3.913; HAMMOND C, 1995, CURR OPIN CELL BIOL, V7, P523, DOI 10.1016/0955-0674(95)80009-3; HEBERT DN, 1995, CELL, V81, P425, DOI 10.1016/0092-8674(95)90395-X; HELENIUS A, 1994, MOL BIOL CELL, V5, P253, DOI 10.1091/mbc.5.3.253; Hiller MM, 1996, SCIENCE, V273, P1725, DOI 10.1126/science.273.5282.1725; Jakob CA, 1998, J CELL BIOL, V142, P1223, DOI 10.1083/jcb.142.5.1223; JENSEN TJ, 1995, CELL, V83, P129, DOI 10.1016/0092-8674(95)90241-4; KEARSE KP, 1994, EMBO J, V13, P3678, DOI 10.1002/j.1460-2075.1994.tb06677.x; KLAUSNER RD, 1990, CELL, V62, P611, DOI 10.1016/0092-8674(90)90104-M; Kopito RR, 1997, CELL, V88, P427, DOI 10.1016/S0092-8674(00)81881-4; LE A, 1990, J BIOL CHEM, V265, P14001; LE AQ, 1992, J BIOL CHEM, V267, P1072; LE AQ, 1994, J BIOL CHEM, V269, P7514; Liu Y, 1997, J BIOL CHEM, V272, P7946, DOI 10.1074/jbc.272.12.7946; McCracken AA, 1996, J CELL BIOL, V132, P291, DOI 10.1083/jcb.132.3.291; MOREMEN KW, 1994, GLYCOBIOLOGY, V4, P113, DOI 10.1093/glycob/4.2.113; OU WJ, 1993, NATURE, V364, P771, DOI 10.1038/364771a0; PARODI AJ, 1983, J BIOL CHEM, V258, P8260; Qu DF, 1996, J BIOL CHEM, V271, P22791, DOI 10.1074/jbc.271.37.22791; RIVETT AJ, 1993, BIOCHEM J, V291, P1; SIFERS RN, 1989, MOL BIOL MED, V6, P127; SIFERS RN, 1988, J BIOL CHEM, V263, P7330; SOUSA M, 1995, EMBO J, V14, P4196, DOI 10.1002/j.1460-2075.1995.tb00093.x; STEIN PE, 1995, NAT STRUCT BIOL, V2, P96, DOI 10.1038/nsb0295-96; SU K, 1993, J BIOL CHEM, V268, P14301; Teckman JH, 1996, J BIOL CHEM, V271, P13215, DOI 10.1074/jbc.271.22.13215; THOMAS PJ, 1995, TRENDS BIOCHEM SCI, V20, P456, DOI 10.1016/S0968-0004(00)89100-8; WADA I, 1991, J BIOL CHEM, V266, P19599; WALTER P, 1984, CELL, V38, P5, DOI 10.1016/0092-8674(84)90520-8; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6; WARE FE, 1995, J BIOL CHEM, V270, P4697, DOI 10.1074/jbc.270.9.4697; Weng SA, 1996, ARCH BIOCHEM BIOPHYS, V325, P113, DOI 10.1006/abbi.1996.0014; WENG SA, 1993, J BIOL CHEM, V268, P25656; Werner ED, 1996, P NATL ACAD SCI USA, V93, P13797, DOI 10.1073/pnas.93.24.13797; Wiertz EJHJ, 1996, CELL, V84, P769, DOI 10.1016/S0092-8674(00)81054-5; Wiertz EJHJ, 1996, NATURE, V384, P432, DOI 10.1038/384432a0; WU Y, 1994, P NATL ACAD SCI USA, V91, P9014, DOI 10.1073/pnas.91.19.9014; Yang M, 1998, J EXP MED, V187, P835, DOI 10.1084/jem.187.6.835; Zapun A, 1997, CELL, V88, P29, DOI 10.1016/S0092-8674(00)81855-3	49	207	211	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 26	1999	274	9					5861	5867		10.1074/jbc.274.9.5861	http://dx.doi.org/10.1074/jbc.274.9.5861			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	170KG	10026209	hybrid			2022-12-25	WOS:000078804400080
J	Wiegmann, K; Schwandner, R; Krut, O; Yeh, WC; Mak, TW; Kronke, M				Wiegmann, K; Schwandner, R; Krut, O; Yeh, WC; Mak, TW; Kronke, M			Requirement of FADD for tumor necrosis factor-induced activation of acid sphingomyelinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; NIEMANN-PICK DISEASE; SIGNALS CELL-DEATH; FACTOR RECEPTOR; TNF-RECEPTOR; NEUTRAL SPHINGOMYELINASE; CYTOPLASMIC DOMAIN; DEFICIENT MICE; PROTEIN; APOPTOSIS	The generation of mice strains deficient for select members of the signaling complex of the 55-kDa tumor necrosis factor receptor (TNF-R55) has allowed the assignment of specific cellular responses to distinct TNF-R55-associated proteins. In particular, the TNF-R55-associated protein FADD seems to be responsible for recruitment and subsequent activation of caspase 8. In this report we demonstrate the requirement of FADD for TNF-induced activation of endosomal acid sphingomyelinase (A-SMase), In primary embryonic fibroblasts from FADD-deficient mice the activation of A-SMase by TNF-R55 ligation was almost completely impaired. This effect is specific in that other TNF responses like activation of NF-kappa B or neutral (N-)SMase remained unaffected. In addition, interleukin-l-induced activation of A-SMase in FADD-deficient cells was unaltered. In FADD(-/-) embryonic fibroblasts reconstituted by transfection with a FADD cDNA expression construct, the TNF responsiveness of A-SMase was restored. The results of this study suggest that FADD, in addition to its role in triggering a proapoptotic caspase cascade, is required for TNF-induced activation of A-SMase.	Univ Kiel, Inst Immunol, D-24105 Kiel, Germany; Univ Toronto, Amgen Inst, Toronto, ON M5G 2M9, Canada; Ontario Canc Inst, Toronto, ON M5G 2M9, Canada	University of Kiel; University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto	Kronke, M (corresponding author), Univ Kiel, Inst Immunol, Brunswiker Str 4, D-24105 Kiel, Germany.							ADACHI M, 1995, NAT GENET, V11, P294, DOI 10.1038/ng1195-294; Adam D, 1996, J BIOL CHEM, V271, P14617, DOI 10.1074/jbc.271.24.14617; ADAM D, 1995, J BIOL CHEM, V270, P17482; AdamKlages S, 1996, CELL, V86, P937, DOI 10.1016/S0092-8674(00)80169-5; Ausubel FM, 1994, CURRENT PROTOCOLS MO; Hofmeister R, 1997, J BIOL CHEM, V272, P27730, DOI 10.1074/jbc.272.44.27730; HORINOUCHI K, 1995, NAT GENET, V10, P288, DOI 10.1038/ng0795-288; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Kelliher MA, 1998, IMMUNITY, V8, P297, DOI 10.1016/S1074-7613(00)80535-X; Kolesnick RN, 1998, ANNU REV PHYSIOL, V60, P643, DOI 10.1146/annurev.physiol.60.1.643; LIU PS, 1995, J BIOL CHEM, V270, P27179, DOI 10.1074/jbc.270.45.27179; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; OTTERBACH B, 1995, CELL, V81, P1053, DOI 10.1016/S0092-8674(05)80010-8; PFEFFER K, 1993, CELL, V73, P457, DOI 10.1016/0092-8674(93)90134-C; PUSHKAREVA M, 1995, IMMUNOL TODAY, V16, P294, DOI 10.1016/0167-5699(95)80184-7; Rothe M, 1995, CELL, V83, P1243, DOI 10.1016/0092-8674(95)90149-3; ROTHE M, 1995, SCIENCE, V269, P1424, DOI 10.1126/science.7544915; SCHUTZE S, 1999, IN PRESS J BIOL CHEM, V274; Schwandner R, 1998, J BIOL CHEM, V273, P5916, DOI 10.1074/jbc.273.10.5916; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; Wallach D, 1997, TRENDS BIOCHEM SCI, V22, P107, DOI 10.1016/S0968-0004(97)01015-3; WIEGMANN K, 1994, CELL, V78, P1005, DOI 10.1016/0092-8674(94)90275-5; Yeh WC, 1998, SCIENCE, V279, P1954, DOI 10.1126/science.279.5358.1954; Yeh WC, 1997, IMMUNITY, V7, P715, DOI 10.1016/S1074-7613(00)80391-X	24	49	51	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 26	1999	274	9					5267	5270		10.1074/jbc.274.9.5267	http://dx.doi.org/10.1074/jbc.274.9.5267			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	170KG	10026132	hybrid			2022-12-25	WOS:000078804400003
J	Buess, M; Engler, O; Hirsch, HH; Moroni, C				Buess, M; Engler, O; Hirsch, HH; Moroni, C			Search for oncogenic regulators in an autocrine tumor model using differential display PCR: Identification of novel candidate genes including the calcium channel mtrp6	ONCOGENE			English	Article						mast cells; serine protease; ras; mRNA fingerprinting; differential cloning	INTERLEUKIN-3 MESSENGER-RNA; 3' UNTRANSLATED REGION; MAST-CELLS; MOLECULAR-CLONING; GM-CSF; EXPRESSION; ENTRY; TRP; TRANSFORMATION; ACTIVATION	A hemopoietic multistep tumor model, in which IL-3 dependent PB-3c mast cells, following expression of v-H-ras progress in vivo to IL-3 producing autocrine tumors has previously been established. Central for this oncogenic progression is a recessive step, which is reversible by cell fusion and leads to stabilization of IL-3 mRNA with concomitant activation of the autocrine loop. Comparing the IL-3 dependent PB-3c and the IL-3 autocrine V2D1 tumor cells with differential display PCR revealed 12 differentially expressed genes of which eight were upregulated and four downregulated in the tumor. They included four proteases (mouse mast cell protease 2, granzyme B, pepsinogen F and serine protease 1) and two metabolic enzymes (adenine phosphoribosyltransferase and fructose1,6-bisphosphatase). For validation, expression of the identified genes was tested in independent PB-3c precursor clones and their tumor derivatives. Expression of an endogenous retroviral IAP element and three unknown transcripts were consistently upregulated in all tumor lines. In somatic cell hybrids, two of these unknown cDNAs showed a dominant and one a recessive expression pattern. One transcript, expressed in the precursor but downregulated in the tumor cells, was cloned and identified as the murine calcium channel mtrp6.	Univ Basel, Inst Med Microbiol, CH-4003 Basel, Switzerland	University of Basel	Moroni, C (corresponding author), Univ Basel, Inst Med Microbiol, Peterspl 10, CH-4003 Basel, Switzerland.			Hirsch, Hans H./0000-0003-0883-0423				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; BALL PE, 1983, DIFFERENTIATION, V24, P74, DOI 10.1111/j.1432-0436.1983.tb01305.x; Banholzer R, 1997, MOL CELL BIOL, V17, P3254, DOI 10.1128/MCB.17.6.3254; BAUER D, 1993, NUCLEIC ACIDS RES, V21, P4272, DOI 10.1093/nar/21.18.4272; BERTIOLI DJ, 1995, NUCLEIC ACIDS RES, V23, P4520, DOI 10.1093/nar/23.21.4520; Boulay G, 1997, J BIOL CHEM, V272, P29672, DOI 10.1074/jbc.272.47.29672; BRUNET JF, 1986, NATURE, V322, P268, DOI 10.1038/322268a0; BRUNET JF, 1987, J IMMUNOL, V138, P4102; Buess M, 1997, NUCLEIC ACIDS RES, V25, P2233, DOI 10.1093/nar/25.11.2233; BURNAY MM, 1994, ENDOCRINOLOGY, V135, P751, DOI 10.1210/en.135.2.751; Chenchik A, 1996, BIOTECHNIQUES, V21, P526; Darmon AJ, 1996, J BIOL CHEM, V271, P21709, DOI 10.1074/jbc.271.36.21709; DIAMANTIS ID, 1989, P NATL ACAD SCI USA, V86, P9299, DOI 10.1073/pnas.86.23.9299; FANGER CM, 1995, J CELL BIOL, V131, P655, DOI 10.1083/jcb.131.3.655; GOUGH NM, 1988, ANAL BIOCHEM, V173, P93, DOI 10.1016/0003-2697(88)90164-9; HARDIE RC, 1992, NEURON, V8, P643, DOI 10.1016/0896-6273(92)90086-S; HAWLEY RG, 1984, MOL CELL BIOL, V4, P2565, DOI 10.1128/MCB.4.12.2565; HIRSCH HH, 1993, J EXP MED, V178, P403, DOI 10.1084/jem.178.2.403; HIRSCH HH, 1995, J BIOL CHEM, V270, P20629, DOI 10.1074/jbc.270.35.20629; KARASUYAMA H, 1988, EUR J IMMUNOL, V18, P97, DOI 10.1002/eji.1830180115; KUFF EL, 1988, ADV CANCER RES, V51, P183, DOI 10.1016/S0065-230X(08)60223-7; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; LIANG P, 1995, CURR OPIN IMMUNOL, V7, P274, DOI 10.1016/0952-7915(95)80015-8; LIANG P, 1992, CANCER RES, V52, P6966; LIANG P, 1993, NUCLEIC ACIDS RES, V21, P3269, DOI 10.1093/nar/21.14.3269; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; MCNEIL HP, 1991, J BIOL CHEM, V266, P20316; Mirza H, 1997, BLOOD, V90, P3914, DOI 10.1182/blood.V90.10.3914; NAIR APK, 1992, ONCOGENE, V7, P1963; NAIR APK, 1989, MOL CELL BIOL, V9, P1183, DOI 10.1128/MCB.9.3.1183; NAIR APK, 1994, NATURE, V369, P239, DOI 10.1038/369239a0; NOMURA M, 1994, FEBS LETT, V348, P201, DOI 10.1016/0014-5793(94)00608-3; Philipp S, 1996, EMBO J, V15, P6166, DOI 10.1002/j.1460-2075.1996.tb01004.x; SAGER R, 1993, FASEB J, V7, P964, DOI 10.1096/fasebj.7.10.8344495; SERAFIN WE, 1990, J BIOL CHEM, V265, P423; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; STEVENS RL, 1989, IMMUNOL TODAY, V10, P381, DOI 10.1016/0167-5699(89)90272-7; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; TURKER MS, 1993, J MOL EVOL, V36, P31, DOI 10.1007/BF02407304; WODNARFILIPOWICZ A, 1989, NATURE, V339, P150, DOI 10.1038/339150a0; WODNARFILIPOWICZ A, 1990, P NATL ACAD SCI USA, V87, P777, DOI 10.1073/pnas.87.2.777; Zhu X, 1996, CELL, V85, P661, DOI 10.1016/S0092-8674(00)81233-7; ZWEIFACH A, 1993, P NATL ACAD SCI USA, V90, P6295, DOI 10.1073/pnas.90.13.6295	43	19	24	1	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 18	1999	18	7					1487	1494		10.1038/sj.onc.1202445	http://dx.doi.org/10.1038/sj.onc.1202445			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	167UK	10050885	Bronze			2022-12-25	WOS:000078651600010
J	Sala, A; Saitta, B; De Luca, P; Cervellera, MN; Casella, I; Lewis, RE; Watson, R; Peschle, C				Sala, A; Saitta, B; De Luca, P; Cervellera, MN; Casella, I; Lewis, RE; Watson, R; Peschle, C			B-MYB transactivates its own promoter through SP1-binding sites	ONCOGENE			English	Article						B-MYB; cell-cycle; promoter; SP1; transcription	V-MYB; A-MYB; CONSTITUTIVE EXPRESSION; TRANSCRIPTION FACTOR; ACTIVATION; CELLS; SP1; FAMILY; GENE; DIFFERENTIATION	B-MYB is an ubiquitous protein required for mammalian cell growth. In this report we show that B-MYB transactivates its own promoter through a 120 bp segment proximal to the transcription start site. The B-MYB-responsive element does not contain myb-binding sites and gel-shift analysis shows that SP1, but not B-MYB, protein contained in SAOS2 cell extracts binds to the 120 bp B-myb promoter fragment. B-MYB-dependent transactivation is cooperatively increased in the presence of SP1, but not SP3 overexpression, When the SP1 elements of the B-myb promoter are transferred in front of a heterologous promoter, an increased response to B-MYB results. In contrast, c-MYB, the prototype member of the Myb family, is not able to activate the luciferase construct containing the SP1 elements. With the use of an SP1-GAL4 fusion protein, we have determined that the cooperative activation occurs through the domain A of SP1, These observations suggest that B-MYB functions as a coactivator of SP1, and that diverse combinations of myb and SP1 sites may dictate the responsiveness of myb-target genes to the various members of the myb family.	Ist Ric Farmacol Mario Negri, Consorzio Mario Negri Sud, Dept Mol Pharmacol & Pathol, I-66030 Santa Maria Imbaro, CH, Italy; Thomas Jefferson Univ, Kimmel Canc Inst, Dept Immunol Microbiol, Philadelphia, PA 19107 USA; Dept Reumatol, Philadelphia, PA 19107 USA; Univ Naples Federico II, Dept Genet Mol & Gen Biol, I-80134 Naples, Italy; Univ Nebraska, Med Ctr, Eppley Canc Inst, Omaha, NE 68198 USA; St Marys Hosp, Sch Med, Ludwig Inst Canc Res, London W2 1PG, England; Ist Super Sanita, Lab Ematol Oncol, I-00161 Rome, Italy	Consorzio Mario Negri Sud; Istituto di Ricerche Farmacologiche Mario Negri IRCCS; Jefferson University; University of Naples Federico II; University of Nebraska System; University of Nebraska Medical Center; Imperial College London; Ludwig Institute for Cancer Research; Istituto Superiore di Sanita (ISS)	Sala, A (corresponding author), Ist Ric Farmacol Mario Negri, Consorzio Mario Negri Sud, Dept Mol Pharmacol & Pathol, Via Nazl, I-66030 Santa Maria Imbaro, CH, Italy.		De Luca, Pasquale/AAL-5673-2021; Lewis, Robert E./H-3404-2019; sala, arturo/C-4959-2008	De Luca, Pasquale/0000-0003-4289-6784; Sala, Arturo/0000-0002-2841-7866; Casella, Ida/0000-0002-3358-4976				ARSURA M, 1992, BLOOD, V79, P2708; Azizkhan Jane C., 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P229; BERG JM, 1992, P NATL ACAD SCI USA, V89, P11109, DOI 10.1073/pnas.89.23.11109; BIES J, 1995, CANCER RES, V55, P501; Bies J, 1996, ONCOGENE, V12, P355; BLAKE MC, 1990, MOL CELL BIOL, V10, P6632, DOI 10.1128/MCB.10.12.6632; CLARKE MF, 1988, MOL CELL BIOL, V8, P884, DOI 10.1128/MCB.8.2.884; DeLuca P, 1996, J BIOL CHEM, V271, P8533, DOI 10.1074/jbc.271.15.8533; Dennig J, 1996, EMBO J, V15, P5659, DOI 10.1002/j.1460-2075.1996.tb00950.x; ENGELKE U, 1995, VIROLOGY, V208, P467, DOI 10.1006/viro.1995.1177; FOOS G, 1992, EMBO J, V11, P4619, DOI 10.1002/j.1460-2075.1992.tb05564.x; GOLAY J, 1994, ONCOGENE, V9, P2469; IBANEZ CE, 1990, MOL CELL BIOL, V10, P2285, DOI 10.1128/MCB.10.5.2285; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; Kamano H, 1997, ONCOGENE, V14, P1223, DOI 10.1038/sj.onc.1200945; LAM EWF, 1995, GENE, V160, P277, DOI 10.1016/0378-1119(95)00184-8; LAM EWF, 1992, ONCOGENE, V7, P1885; Lane S, 1997, ONCOGENE, V14, P2445, DOI 10.1038/sj.onc.1201086; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; LIN D, 1994, P NATL ACAD SCI USA, V91, P10079, DOI 10.1073/pnas.91.21.10079; Lin SY, 1996, MOL CELL BIOL, V16, P1668; LYON J, 1994, CRIT REV ONCOGENESIS, V5, P373, DOI 10.1615/CritRevOncog.v5.i4.30; MAJELLO B, 1994, NUCLEIC ACIDS RES, V22, P4914, DOI 10.1093/nar/22.23.4914; Marhamati DJ, 1996, J BIOL CHEM, V271, P3359; MERIKA M, 1995, MOL CELL BIOL, V15, P2437; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; NOMURA N, 1988, NUCLEIC ACIDS RES, V16, P11075, DOI 10.1093/nar/16.23.11075; Prowse DM, 1997, J BIOL CHEM, V272, P1308, DOI 10.1074/jbc.272.2.1308; RASCHELLA G, 1995, J BIOL CHEM, V270, P8540, DOI 10.1074/jbc.270.15.8540; SADOWSKI I, 1989, NUCLEIC ACIDS RES, V17, P7539, DOI 10.1093/nar/17.18.7539; SALA A, 1992, P NATL ACAD SCI USA, V89, P10415, DOI 10.1073/pnas.89.21.10415; Sala A, 1996, J BIOL CHEM, V271, P9363, DOI 10.1074/jbc.271.16.9363; Sala A, 1997, P NATL ACAD SCI USA, V94, P532, DOI 10.1073/pnas.94.2.532; Sala A, 1996, J BIOL CHEM, V271, P28738, DOI 10.1074/jbc.271.46.28738; SETO E, 1993, NATURE, V365, P462, DOI 10.1038/365462a0; TASHIRO S, 1995, ONCOGENE, V10, P1699; TRAUTH K, 1994, EMBO J, V13, P5994, DOI 10.1002/j.1460-2075.1994.tb06945.x; Ziebold U, 1997, CURR BIOL, V7, P253, DOI 10.1016/S0960-9822(06)00121-7	38	40	40	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 11	1999	18	6					1333	1339		10.1038/sj.onc.1202421	http://dx.doi.org/10.1038/sj.onc.1202421			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	165FW	10022815				2022-12-25	WOS:000078510900009
J	Yeyati, PL; Shaknovich, R; Boterashvili, S; Li, J; Ball, HJ; Waxman, S; Nason-Burchenal, K; Dmitrovsky, E; Zelent, A; Licht, JD				Yeyati, PL; Shaknovich, R; Boterashvili, S; Li, J; Ball, HJ; Waxman, S; Nason-Burchenal, K; Dmitrovsky, E; Zelent, A; Licht, JD			Leukemia translocation protein PLZF inhibits cell growth and expression of cyclin A	ONCOGENE			English	Article						PLZF; acute promyelocytic leukemia; cell cycle; cyclin A	ACUTE PROMYELOCYTIC LEUKEMIA; ACID RECEPTOR-ALPHA; EMBRYONAL CARCINOMA-CELLS; ZINC-FINGER GENE; RETINOIC ACID; RAR-ALPHA; DNA-BINDING; S-PHASE; TRANSCRIPTIONAL PROPERTIES; MAMMALIAN FIBROBLASTS	The PLZF gene was identified by its fusion with the RAR alpha locus in a therapy resistant form of acute promyelocytic leukemia (APL) associated with the t(11;17)(q23;q21) translocation, Here we describe PLZF as a negative regulator of cell cycle progression ultimately leading to growth suppression, PLZF can bind and repress the cyclin A2 promoter while expression of cyclin A2 reverts the growth suppressed phenotype of myeloid cells expressing PLZF, In contrast RAR alpha-PLZF, a fusion protein generated in t(11;17)(q23;q21)APL activates cyclin A2 transcription and allows expression of cyclin A in anchorage-deprived NIH3T3 cells. Therefore, cyclin A2 is a candidate target gene for PLZF and inhibition of cyclin A expression may contribute to the growth suppressive properties of PLZF, Deregulation of cyclin A2 by RAR alpha-PLZF may represent an oncogenic mechanism of this chimeric protein and contribute to the aggressive clinical phenotype of t(11;17)(q23;q21)-associated APL.	CUNY Mt Sinai Sch Med, Derald H Ruttenberg Canc Ctr, New York, NY 10029 USA; CUNY Mt Sinai Sch Med, Brookdale Ctr Dev & Mol Biol, New York, NY 10029 USA; CUNY Mt Sinai Sch Med, Dept Med, New York, NY 10029 USA; Inst Canc Res, Leukaemia Res Fund Ctr, London SW3 6JB, England; Mem Sloan Kettering Canc Ctr, Mol Med Lab, New York, NY 10021 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; Memorial Sloan Kettering Cancer Center	Licht, JD (corresponding author), CUNY Mt Sinai Sch Med, Derald H Ruttenberg Canc Ctr, Box 1130,1 Gustave L Levy Pl, New York, NY 10029 USA.		Ball, Helen J/A-4242-2010; Zelent, Arthur/B-3532-2009; Licht, Jonathan/L-4239-2019	Ball, Helen J/0000-0003-3733-9748; Zelent, Arthur/0000-0002-7968-9888; Licht, Jonathan/0000-0002-3942-1369	NATIONAL CANCER INSTITUTE [R01CA062275, R01CA059936] Funding Source: NIH RePORTER; NCI NIH HHS [CA62275, CA59936] Funding Source: Medline; NIGMS NIH HHS [GM0707280-17] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ausubel F. M., 1988, CURRENT PROTOCOLS MO; AVANTAGGIATO V, 1995, J NEUROSCI, V15, P4927; CHEN Z, 1994, P NATL ACAD SCI USA, V91, P1178, DOI 10.1073/pnas.91.3.1178; CHEN Z, 1993, EMBO J, V12, P1161, DOI 10.1002/j.1460-2075.1993.tb05757.x; COOK M, 1995, P NATL ACAD SCI USA, V92, P2249, DOI 10.1073/pnas.92.6.2249; David G, 1998, ONCOGENE, V16, P2549, DOI 10.1038/sj.onc.1202043; Desdouets C, 1996, FEBS LETT, V385, P34, DOI 10.1016/0014-5793(96)00330-4; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; Dong S, 1996, P NATL ACAD SCI USA, V93, P3624, DOI 10.1073/pnas.93.8.3624; EAVES CJ, 1991, BLOOD, V78, P110; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; GRIGNANI F, 1994, BLOOD, V83, P10; Grignani F, 1998, NATURE, V391, P815, DOI 10.1038/35901; Grimwade D, 1997, BLOOD, V90, P4876; GUADAGNO TM, 1993, SCIENCE, V262, P1572, DOI 10.1126/science.8248807; GUIDEZ F, 1994, LEUKEMIA, V8, P312; Guidez F, 1998, BLOOD, V91, P2634, DOI 10.1182/blood.V91.8.2634.2634_2634_2642; He LZ, 1998, NAT GENET, V18, P126, DOI 10.1038/ng0298-126; HENGLEIN B, 1994, P NATL ACAD SCI USA, V91, P5490, DOI 10.1073/pnas.91.12.5490; Hong SH, 1997, P NATL ACAD SCI USA, V94, P9028, DOI 10.1073/pnas.94.17.9028; Huet X, 1996, MOL CELL BIOL, V16, P3789; HUNTER T, 1991, CELL, V66, P1071, DOI 10.1016/0092-8674(91)90028-W; JANSENDURR P, 1993, P NATL ACAD SCI USA, V90, P3685, DOI 10.1073/pnas.90.8.3685; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; KASTNER P, 1992, EMBO J, V11, P629, DOI 10.1002/j.1460-2075.1992.tb05095.x; KREIDER BL, 1990, MOL CELL BIOL, V10, P4846, DOI 10.1128/MCB.10.9.4846; Krek W, 1995, CELL, V83, P1149, DOI 10.1016/0092-8674(95)90141-8; LANOTTE M, 1991, BLOOD, V77, P1080; LEROY P, 1991, EMBO J, V10, P59, DOI 10.1002/j.1460-2075.1991.tb07921.x; Li JY, 1997, J BIOL CHEM, V272, P22447, DOI 10.1074/jbc.272.36.22447; Licht JD, 1996, ONCOGENE, V12, P323; LICHT JD, 1995, BLOOD, V85, P1083, DOI 10.1182/blood.V85.4.1083.bloodjournal8541083; Lin RJ, 1998, NATURE, V391, P811, DOI 10.1038/35895; Liu NS, 1998, ONCOGENE, V16, P2957, DOI 10.1038/sj.onc.1201838; Meyyappan M, 1998, MOL CELL BIOL, V18, P3163, DOI 10.1128/MCB.18.6.3163; MOASSER MM, 1995, ONCOGENE, V10, P1537; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; NAKAMURA T, 1995, EXP CELL RES, V216, P422, DOI 10.1006/excr.1995.1053; Ogryzko VV, 1997, MOL CELL BIOL, V17, P4877, DOI 10.1128/MCB.17.8.4877; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; OTSUKA H, 1976, J CELL PHYSIOL, V87, P213, DOI 10.1002/jcp.1040870209; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; Pandolfi PP, 1996, HAEMATOLOGICA, V81, P472; PANDOLFI PP, 1991, ONCOGENE, V6, P1285; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; Redner RL, 1996, BLOOD, V87, P882, DOI 10.1182/blood.V87.3.882.bloodjournal873882; REID A, 1995, BLOOD, V86, P4544, DOI 10.1182/blood.V86.12.4544.bloodjournal86124544; SCHMID I, 1991, CYTOMETRY, V12, P279, DOI 10.1002/cyto.990120312; SCHUSTERSEWC H, 1992, LETOPIS, V1, P9; Shaknovich R, 1998, MOL CELL BIOL, V18, P5533, DOI 10.1128/MCB.18.9.5533; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Sitterlin D, 1997, ONCOGENE, V14, P1067, DOI 10.1038/sj.onc.1200916; Wells RA, 1997, NAT GENET, V17, P109, DOI 10.1038/ng0997-109; YOSHIZUMI M, 1995, MOL CELL BIOL, V15, P3266; Zhu XY, 1996, J CELL BIOL, V133, P391, DOI 10.1083/jcb.133.2.391; ZINDY F, 1992, BIOCHEM BIOPH RES CO, V182, P1144, DOI 10.1016/0006-291X(92)91851-G; ZWICKER J, 1995, EMBO J, V14, P4514, DOI 10.1002/j.1460-2075.1995.tb00130.x	57	154	156	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 28	1999	18	4					925	934		10.1038/sj.onc.1202375	http://dx.doi.org/10.1038/sj.onc.1202375			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	165FT	10023668				2022-12-25	WOS:000078510600009
J	Timmermann, S; Hinds, PW; Munger, K				Timmermann, S; Hinds, PW; Munger, K			Re-expression of endogenous p16(ink4a) in oral squamous cell carcinoma lines by 5-aza-2 '-deoxycytidine treatment induces a senescence-like state	ONCOGENE			English	Article						cdk inhibitor; retinoblastoma protein; promoter methylation	CYCLIN-DEPENDENT KINASE-6; TUMOR-SUPPRESSOR GENE; RETINOBLASTOMA PROTEIN; CDKN2 GENE; DNA METHYLTRANSFERASE; HUMAN FIBROBLASTS; MAMMALIAN-CELLS; HEAD; NECK; AMPLIFICATION	We have previously reported that a set of oral squamous cell carcinoma lines express specifically elevated cdk6 activity. One of the cell lines, SCC4, contains a cdk6 amplification and expresses functional p16(ink4a), the other cell lines express undetectable levels of p16(ink4a), despite a lack of coding-region mutations. Two of the cell lines, SCC15 and SCC40 have a hypermethylated p16(ink4A) promoter and a third cell line, SCC9, has a mutation in the p16(ink4a) promoter. Using the demethylation agent 5-aza-2'-deoxycytidine, we showed that the p16(ink4a) protein was re-expressed after a 5-day treatment with this chemical, One cell line, SCC15 espressed high levels of p16(ink4a). In this line, cdk6 activity was decreased after 5-aza-2'deoxycytidine treatment, and the hypophosphorylated, growth suppressive form of the retinoblastoma tumor suppressor protein PRE was detected. Expression of p16(ink4a) persisted, even after the drug was removed and the cells espressed senescence-associated beta-galactosidase activity. Ectopic expression of p16(ink4a) with a recombinant retrovirus in this cell line also induced a similar senescence-like phenotype, Hence, it was possible to restore a functional pRB pathway in an oral squamous cell carcinoma line by inducing re-expression of endogenous p16(ink4a) in response to treatment with a demethylating agent.	Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Ctr Canc Biol, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	Munger, K (corresponding author), Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA.			Munger, Karl/0000-0003-3288-9935	NIDCR NIH HHS [1 PO1 DE12467-01] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P01DE012467] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ABELE R, 1987, EUR J CANCER CLIN ON, V23, P1921, DOI 10.1016/0277-5379(87)90060-5; Alcorta DA, 1996, P NATL ACAD SCI USA, V93, P13742, DOI 10.1073/pnas.93.24.13742; Ausubel F.M., 1992, SHORT PROTOCOLS MOL; Bartek J, 1996, CURR OPIN CELL BIOL, V8, P805, DOI 10.1016/S0955-0674(96)80081-0; Baylin SB, 1998, ADV CANCER RES, V72, P141; Bender CM, 1998, CANCER RES, V58, P95; BUCKLEY MF, 1993, ONCOGENE, V8, P2127; BURNS JE, 1993, BRIT J CANCER, V67, P1274, DOI 10.1038/bjc.1993.238; Costello JF, 1997, CANCER RES, V57, P1250; CREUSOT F, 1982, J BIOL CHEM, V257, P2041; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Fernandez-Martinez J A, 1995, Bull Group Int Rech Sci Stomatol Odontol, V38, P11; Foster SA, 1998, MOL CELL BIOL, V18, P1793, DOI 10.1128/MCB.18.4.1793; Gonzalez MV, 1997, J CLIN PATHOL, V50, P509, DOI 10.1136/jcp.50.6.509; Gonzalgo ML, 1998, CANCER RES, V58, P1245; Hall M, 1996, ADV CANCER RES, V68, P67, DOI 10.1016/S0065-230X(08)60352-8; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HE J, 1995, CANCER RES, V55, P4833; HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; JUTTERMANN R, 1994, P NATL ACAD SCI USA, V91, P11797, DOI 10.1073/pnas.91.25.11797; KAMB A, 1994, NAT GENET, V8, P22, DOI 10.1038/ng0994-22; KATO J, 1993, GENE DEV, V7, P331; KOH J, 1995, NATURE, V375, P506, DOI 10.1038/375506a0; Liggett WH, 1998, J CLIN ONCOL, V16, P1197, DOI 10.1200/JCO.1998.16.3.1197; Loughran D, 1996, J MANAGE ENG, V12, P13; LYDIATT WM, 1995, GENE CHROMOSOME CANC, V13, P94, DOI 10.1002/gcc.2870130204; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MEDEMA RH, 1995, P NATL ACAD SCI USA, V92, P6289, DOI 10.1073/pnas.92.14.6289; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; MICHALOWSKY LA, 1987, MOL CELL BIOL, V7, P3076, DOI 10.1128/MCB.7.9.3076; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; MIN BM, 1994, ORAL ONCOL, V30B, P338, DOI 10.1016/0964-1955(94)90036-1; Ory DS, 1996, P NATL ACAD SCI USA, V93, P11400, DOI 10.1073/pnas.93.21.11400; OTTERSON GA, 1995, ONCOGENE, V11, P1211; PARKIN DM, 1988, INT J CANCER, V41, P184, DOI 10.1002/ijc.2910410205; Pollock PM, 1996, GENE CHROMOSOME CANC, V15, P77, DOI 10.1002/(SICI)1098-2264(199602)15:2<77::AID-GCC1>3.0.CO;2-0; Reed AL, 1996, CANCER RES, V56, P3630; RHEINWALD JG, 1980, CELL, V22, P629, DOI 10.1016/0092-8674(80)90373-6; RHEINWALD JG, 1981, CANCER RES, V41, P1657; Schwoebel A, 1997, J PERINAT NEONAT NUR, V11, P78, DOI 10.1097/00005237-199712000-00009; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SONODA Y, 1995, ONCOGENE, V11, P2145; STEIN GH, 1995, BIOESSAYS, V17, P537, DOI 10.1002/bies.950170610; Timmermann S, 1997, CELL GROWTH DIFFER, V8, P361; Uhrbom L, 1997, ONCOGENE, V15, P505, DOI 10.1038/sj.onc.1201227; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Willemze R, 1997, LEUKEMIA S1, V11, P24; ZHANG SY, 1994, CANCER RES, V54, P5050	55	66	69	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 31	1998	17	26					3445	3453		10.1038/sj.onc.1202244	http://dx.doi.org/10.1038/sj.onc.1202244			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	157XD	10030668				2022-12-25	WOS:000078086200005
J	Lawinger, P; Rastelli, L; Zhao, ZY; Majumder, S				Lawinger, P; Rastelli, L; Zhao, ZY; Majumder, S			Lack of enhancer function in mammals is unique to oocytes and fertilized eggs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							RNA-POLYMERASE-II; PREIMPLANTATION MOUSE EMBRYO; ZYGOTIC GENE ACTIVATION; STAGE-SPECIFIC EXPRESSION; XENOPUS-LAEVIS OOCYTES; TERMINAL DOMAIN CTD; HUMAN CELL-LINE; CHROMATIN STRUCTURE; DNA-REPLICATION; BINDING PROTEIN	Previous studies have shown that the lack of novel coactivator activity in mouse oocytes and one-cell embryos (fertilized eggs) renders them incapable of utilizing Gal4:VP16-dependent enhancers (distal elements) but not promoters (proximal elements) in regulating transcription. This coactivator activity first appears in two- to four-cell embryos coincident with the major activation of zygotic gene expression. Here we show that whereas oocytes and fertilized eggs could utilize Spl-dependent promoters, they could not utilize Spl-dependent enhancers, although they showed promoter repression, which is a requirement for delineating enhancer function. In contrast, both Spl-dependent promoters and enhancers were functional in two- to four-cell embryos. Furthermore, the same embryonic stem cell mRNA that provided the coactivator activity for Gal4: VP16-dependent enhancer function also provided Sp1-dependent enhancer function in oocytes, Therefore, the coactivator activity appears to be a requirement for general enhancer function. To determine whether the absence of enhancer function is a unique property of oocytes or a general property of other terminally differentiated cells, transcription was examined in terminally differentiated hNT neurons and their precursors, undifferentiated NT2 stem cells. The results showed that both cell types could utilize enhancers and promoters. Thus, in mammals, the lack of enhancer function appears to be unique to oocytes and fertilized eggs, suggesting that it provides a safeguard against premature activation of genes prior to zygotic gene expression during development.	Univ Texas, MD Anderson Cancer Ctr, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Majumder, S (corresponding author), Univ Texas, MD Anderson Cancer Ctr, 1515 Holcombe Blvd,Box 100, Houston, TX 77030 USA.	majumder@audumla.mdacc.tmc.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053454] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM53454] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABBONDANZO SJ, 1993, METHOD ENZYMOL, V225, P803; Adenot PG, 1997, DEVELOPMENT, V124, P4615; ALMOUZNI G, 1993, GENE DEV, V7, P2033, DOI 10.1101/gad.7.10.2033; Aoki F, 1997, DEV BIOL, V181, P296, DOI 10.1006/dbio.1996.8466; Armstrong JA, 1998, CURR OPIN GENET DEV, V8, P165, DOI 10.1016/S0959-437X(98)80137-8; BACHVAROVA RF, 1992, CELL, V69, P895, DOI 10.1016/0092-8674(92)90606-D; Bagga R, 1997, GENE DEV, V11, P629, DOI 10.1101/gad.11.5.629; BARTON MC, 1994, GENE DEV, V8, P2453, DOI 10.1101/gad.8.20.2453; Blackwood EM, 1998, SCIENCE, V281, P60, DOI 10.1126/science.281.5373.60; BONI J, 1989, J VIROL, V63, P4088; CHALIFOUR LE, 1987, GENE DEV, V1, P1096, DOI 10.1101/gad.1.10.1096; CHALIFOUR LE, 1986, J VIROL, V59, P619, DOI 10.1128/JVI.59.3.619-627.1986; CHRISTIANS E, 1995, DEVELOPMENT, V121, P113; CONOVER JC, 1991, DEV BIOL, V144, P392, DOI 10.1016/0012-1606(91)90431-2; Davidson E. H., 1986, GENE ACTIVITY EARLY; DEMPAMPHILIS ML, 1993, ANNU REV BIOCHEM, V62, P29; DePamphilis ML, 1997, METHODS, V13, P211, DOI 10.1006/meth.1997.0521; DEPAMPHILIS ML, 1993, J BIOL CHEM, V268, P1; DEPAMPHILIS ML, 1988, CELL, V52, P635, DOI 10.1016/0092-8674(88)90398-4; DOOLEY TP, 1989, DEVELOPMENT, V107, P945; Felsenfeld G, 1996, CELL, V86, P13, DOI 10.1016/S0092-8674(00)80073-2; GE H, 1994, CELL, V78, P513, DOI 10.1016/0092-8674(94)90428-6; GERBER HP, 1995, NATURE, V374, P660, DOI 10.1038/374660a0; GREEN J, 1987, VIROLOGY, V159, P339, DOI 10.1016/0042-6822(87)90472-7; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; Hagmann M, 1997, J VIROL, V71, P5952, DOI 10.1128/JVI.71.8.5952-5962.1997; HENERY CC, 1995, DEV BIOL, V169, P448, DOI 10.1006/dbio.1995.1160; HOGAN B, 1986, MANIPULATING MOUSE E; Imhof A, 1998, CURR BIOL, V8, pR422, DOI 10.1016/S0960-9822(98)70268-4; Kadonaga JT, 1998, CELL, V92, P307, DOI 10.1016/S0092-8674(00)80924-1; Kaneko KJ, 1997, DEVELOPMENT, V124, P1963; Kaneko KJ, 1998, DEV GENET, V22, P43, DOI 10.1002/(SICI)1520-6408(1998)22:1&lt;43::AID-DVG5&gt;3.0.CO;2-7; Keohane AM, 1998, DEV GENET, V22, P65, DOI 10.1002/(SICI)1520-6408(1998)22:1&lt;65::AID-DVG7&gt;3.0.CO;2-5; Kim TK, 1997, P NATL ACAD SCI USA, V94, P12268, DOI 10.1073/pnas.94.23.12268; KIMELMAN D, 1987, CELL, V48, P399, DOI 10.1016/0092-8674(87)90191-7; Kingston RE, 1996, GENE DEV, V10, P905, DOI 10.1101/gad.10.8.905; Kobayashi T, 1998, MOL CELL BIOL, V18, P3266, DOI 10.1128/MCB.18.6.3266; KRETZSCHMAR M, 1994, CELL, V78, P525, DOI 10.1016/0092-8674(94)90429-4; LATHAM KE, 1992, DEV BIOL, V149, P457, DOI 10.1016/0012-1606(92)90300-6; LeGouy E, 1998, DEV DYNAM, V212, P38, DOI 10.1002/(SICI)1097-0177(199805)212:1<38::AID-AJA4>3.0.CO;2-3; MAJUMDER S, 1995, BIOESSAYS, V17, P879, DOI 10.1002/bies.950171010; Majumder S, 1997, EMBO J, V16, P1721, DOI 10.1093/emboj/16.7.1721; MAJUMDER S, 1993, EMBO J, V12, P1131, DOI 10.1002/j.1460-2075.1993.tb05754.x; MAJUMDER S, 1994, MOL CELL BIOL, V14, P4258, DOI 10.1128/MCB.14.6.4258; MAJUMDER S, 1997, MICROINJECTION TRANS, P323; MANLEY JL, 1994, GENE DEV, V8, P259, DOI 10.1101/gad.8.3.259; MARTINEZSALAS E, 1989, GENE DEV, V3, P1493, DOI 10.1101/gad.3.10.1493; MARTINEZSALAS E, 1988, GENE DEV, V2, P1115, DOI 10.1101/gad.2.9.1115; Matsumoto K, 1998, EMBO J, V17, P2107, DOI 10.1093/emboj/17.7.2107; MELIN F, 1993, EMBO J, V12, P4657, DOI 10.1002/j.1460-2075.1993.tb06154.x; MICHAELI T, 1987, NUCLEIC ACIDS RES, V15, P1579, DOI 10.1093/nar/15.4.1579; MIRANDA M, 1993, METHOD ENZYMOL, V225, P412; Moosmann P, 1996, NUCLEIC ACIDS RES, V24, P4859, DOI 10.1093/nar/24.24.4859; Moosmann P, 1997, BIOL CHEM, V378, P669, DOI 10.1515/bchm.1997.378.7.669; Naar AM, 1998, GENE DEV, V12, P3020, DOI 10.1101/gad.12.19.3020; NONCHEV S, 1990, MOL REPROD DEV, V25, P72, DOI 10.1002/mrd.1080250113; Nothias JY, 1996, EMBO J, V15, P5715, DOI 10.1002/j.1460-2075.1996.tb00955.x; Oh B, 1997, DEVELOPMENT, V124, P493; Pazin MJ, 1997, CELL, V89, P325, DOI 10.1016/S0092-8674(00)80211-1; PLEASURE SJ, 1992, J NEUROSCI, V12, P1802; PLEASURE SJ, 1993, J NEUROSCI RES, V35, P585, DOI 10.1002/jnr.490350603; RASTELLI L, 1993, EMBO J, V12, P1513, DOI 10.1002/j.1460-2075.1993.tb05795.x; RASTELLI L, 1998, GENE THERAPY MOL BIO; RICHTER JD, 1991, BIOESSAYS, V13, P179, DOI 10.1002/bies.950130406; RODMAN TC, 1981, J CELL BIOL, V90, P351, DOI 10.1083/jcb.90.2.351; Roth SY, 1996, CELL, V87, P5, DOI 10.1016/S0092-8674(00)81316-1; SADOWSKI I, 1988, NATURE, V335, P563, DOI 10.1038/335563a0; SAMBROOK J, 1989, MOL CLONING LAB MANA; SCHULTZ GA, 1992, MUTAT RES, V296, P17, DOI 10.1016/0165-1110(92)90029-9; SCHULTZ RM, 1993, BIOESSAYS, V15, P531, DOI 10.1002/bies.950150806; SEIPEL K, 1992, EMBO J, V11, P4961, DOI 10.1002/j.1460-2075.1992.tb05603.x; SEIPEL K, 1993, NUCLEIC ACIDS RES, V21, P5609, DOI 10.1093/nar/21.24.5609; SEIPEL K, 1994, MOL REPROD DEV, V39, P215, DOI 10.1002/mrd.1080390215; SESHAGIRI PB, 1992, MOL REPROD DEV, V32, P229, DOI 10.1002/mrd.1080320307; SHIOKAWA K, 1990, ROUX ARCH DEV BIOL, V198, P322, DOI 10.1007/BF00383770; SHIOKAWA K, 1989, CELL DIFFER DEV, V28, P17, DOI 10.1016/0922-3371(89)90019-1; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; Steger David J., 1996, Bioessays, V18, P875, DOI 10.1002/bies.950181106; Stein P, 1997, MOL REPROD DEV, V47, P421, DOI 10.1002/(SICI)1098-2795(199708)47:4&lt;421::AID-MRD8&gt;3.0.CO;2-M; STEINBEISSER H, 1988, NUCLEIC ACIDS RES, V16, P3223, DOI 10.1093/nar/16.8.3223; STOW ND, 1986, J GEN VIROL, V67, P2571, DOI 10.1099/0022-1317-67-12-2571; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; TELFORD NA, 1990, MOL REPROD DEV, V26, P90, DOI 10.1002/mrd.1080260113; Temeles GL, 1997, J REPROD FERTIL, V109, P223, DOI 10.1530/jrf.0.1090223; THOMPSON EM, 1995, DEVELOPMENT, V121, P3425; Thompson EM, 1998, DEV GENET, V22, P31, DOI 10.1002/(SICI)1520-6408(1998)22:1&lt;31::AID-DVG4&gt;3.0.CO;2-8; TURNER CM, 1995, MOL BIOL CELL, V6, P22; Vermaak D, 1998, DEV GENET, V22, P1, DOI 10.1002/(SICI)1520-6408(1998)22:1&lt;1::AID-DVG1&gt;3.0.CO;2-A; Vermaak D, 1998, CURR BIOL, V8, P533, DOI 10.1016/S0960-9822(98)70206-4; Wang QX, 1997, MOL REPROD DEV, V47, P265, DOI 10.1002/(SICI)1098-2795(199707)47:3&lt;265::AID-MRD5&gt;3.0.CO;2-J; WIEKOWSKI M, 1991, DEV BIOL, V147, P403, DOI 10.1016/0012-1606(91)90298-H; WIEKOWSKI M, 1993, DEV BIOL, V159, P366, DOI 10.1006/dbio.1993.1248; WIEKOWSKI M, 1999, IN PRESS J CELL SCI; WIRAK DO, 1985, MOL CELL BIOL, V5, P2924, DOI 10.1128/MCB.5.11.2924; Wolffe AP, 1997, BIOCHEM SOC T, V25, P354, DOI 10.1042/bst0250354; Wolffe AP, 1996, CELL, V84, P817, DOI 10.1016/S0092-8674(00)81059-4; WONG JM, 1995, GENE DEV, V9, P2696, DOI 10.1101/gad.9.21.2696; Wong JM, 1998, EMBO J, V17, P520, DOI 10.1093/emboj/17.2.520; Wong JM, 1997, EMBO J, V16, P3158, DOI 10.1093/emboj/16.11.3158; WORRAD DM, 1995, DEVELOPMENT, V121, P2949; WORRAD DM, 1994, DEVELOPMENT, V120, P2347; Worrad DM, 1997, MOL REPROD DEV, V46, P268, DOI 10.1002/(SICI)1098-2795(199703)46:3&lt;268::AID-MRD5&gt;3.0.CO;2-N; Xu WT, 1998, MOL CELL BIOL, V18, P5659, DOI 10.1128/MCB.18.10.5659; YOUNKIN DP, 1993, P NATL ACAD SCI USA, V90, P2174, DOI 10.1073/pnas.90.6.2174; Zirkin B. R., 1989, The molecular biology of fertilization., P91	105	14	16	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	1999	274	12					8002	8011		10.1074/jbc.274.12.8002	http://dx.doi.org/10.1074/jbc.274.12.8002			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	178LU	10075699	hybrid			2022-12-25	WOS:000079268100058
J	Meredith, JE; Kiosses, WB; Takada, Y; Schwartz, MA				Meredith, JE; Kiosses, WB; Takada, Y; Schwartz, MA			Mutational analysis of cell cycle inhibition by integrin beta(1C)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-1 CYTOPLASMIC DOMAIN; SIGNAL-TRANSDUCTION; FIBRONECTIN RECEPTOR; MESSENGER-RNA; ALPHA-ACTININ; SUBUNIT; EXPRESSION; ISOFORM; PROLIFERATION; LOCALIZATION	Integrin beta(1C) is an alternatively spliced cytoplasmic variant of the beta 1 subunit that potently inhibits cell cycle progression. In this study, we analyzed the requirements for growth suppression by beta(1C) A chimera containing the extracellular/transmembrane domain of the Tac subunit of the human interleukin 2 receptor (gp55) fused to the cytoplasmic domain of beta(1C) (residues 732-805) strongly inhibited growth in mouse 10T1/2 cells even at low expression levels, whereas chimeras containing the beta(1A), beta(1B), beta(1D), beta(3), and beta(5) cytoplasmic domains had weak and variable effects. The beta(1C) cytoplasmic domain is composed of a membrane proximal region (732-757) common to all beta(1) variants and a COOH-terminal 48-amino acid domain (758-805) unique to beta(1C). The beta(1C)-specific domain (758-805) was sufficient to block cell growth even when expressed as a soluble cytoplasmic green fluorescent protein fusion protein. These results indicate that growth inhibition by beta(1C) does not require the intact receptor and can function in the absence of membrane targeting. Analysis of deletions within the beta(1C)-specific domain showed that the 18-amino acid sequence 775-792 is both necessary and sufficient for maximal growth inhibition, although the 13 COOH-terminal residues (793-805) also had weak activity. Finally, beta(1C) is known to be induced in endothelial cells in response to tumor necrosis factor and is down-regulated in prostate epithelial cells after transformation, The green fluorescent protein/beta(1C) (758-805) chimera blocked growth in the human endothelial cell line EV304 and in the transformed prostate epithelial cell line DU145, consistent with a role for beta(1C) as a growth inhibitor in vivo.	Scripps Res Inst, Dept Vasc Biol, La Jolla, CA 92037 USA	Scripps Research Institute	Schwartz, MA (corresponding author), Scripps Res Inst, Dept Vasc Biol, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.			schwartz, martin/0000-0002-2071-1243; takada, yoshikazu/0000-0001-5481-9589	NHLBI NIH HHS [P01 HL48728] Funding Source: Medline; NIGMS NIH HHS [R01 GM47214, GM47157] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL048728] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047157, R01GM047214] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKIYAMA SK, 1994, J BIOL CHEM, V269, P15961; ALTRUDA F, 1990, GENE, V95, P261, DOI 10.1016/0378-1119(90)90369-3; BALZAC F, 1993, J CELL BIOL, V121, P171, DOI 10.1083/jcb.121.1.171; BALZAC F, 1994, J CELL BIOL, V127, P557, DOI 10.1083/jcb.127.2.557; Baudoin C, 1996, CELL ADHES COMMUN, V4, P1, DOI 10.3109/15419069609010759; Belkin AM, 1998, J BIOL CHEM, V273, P15234, DOI 10.1074/jbc.273.24.15234; Belkin AM, 1996, J CELL BIOL, V132, P211, DOI 10.1083/jcb.132.1.211; CHEN YP, 1994, J BIOL CHEM, V269, P18307; Fornaro M, 1996, AM J PATHOL, V149, P765; FORNARO M, 1995, J BIOL CHEM, V270, P24666, DOI 10.1074/jbc.270.42.24666; Fornaro M, 1997, MATRIX BIOL, V16, P185, DOI 10.1016/S0945-053X(97)90007-X; HAYASHI Y, 1990, J CELL BIOL, V110, P175, DOI 10.1083/jcb.110.1.175; HORWITZ A, 1986, NATURE, V320, P531, DOI 10.1038/320531a0; Hungerford JE, 1996, J CELL BIOL, V135, P1383, DOI 10.1083/jcb.135.5.1383; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; LAFLAMME SE, 1994, J CELL BIOL, V126, P1287, DOI 10.1083/jcb.126.5.1287; LAFLAMME SE, 1992, J CELL BIOL, V117, P437, DOI 10.1083/jcb.117.2.437; LANGUINO LR, 1992, J BIOL CHEM, V267, P7116; MAKALOWSKI W, 1994, TRENDS GENET, V10, P188, DOI 10.1016/0168-9525(94)90254-2; MARCANTONIO EE, 1990, CELL REGUL, V1, P597, DOI 10.1091/mbc.1.8.597; MEREDITH J, 1995, SCIENCE, V269, P1570, DOI 10.1126/science.7545312; OTEY CA, 1993, J BIOL CHEM, V268, P21193; OTEY CA, 1990, J CELL BIOL, V111, P721, DOI 10.1083/jcb.111.2.721; Pfaff M, 1998, J BIOL CHEM, V273, P6104, DOI 10.1074/jbc.273.11.6104; RESZKA AA, 1992, J CELL BIOL, V117, P1321, DOI 10.1083/jcb.117.6.1321; Schmid CW, 1996, PROG NUCLEIC ACID RE, V53, P283, DOI 10.1016/S0079-6603(08)60148-8; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; SMILENOV L, 1994, MOL BIOL CELL, V5, P1215, DOI 10.1091/mbc.5.11.1215; TAPLEY P, 1989, ONCOGENE, V4, P325; ZHIDKOVA NI, 1995, BIOCHEM BIOPH RES CO, V214, P279, DOI 10.1006/bbrc.1995.2285	30	21	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 19	1999	274	12					8111	8116		10.1074/jbc.274.12.8111	http://dx.doi.org/10.1074/jbc.274.12.8111			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	178LU	10075712	hybrid			2022-12-25	WOS:000079268100071
J	Park, EI; Garrow, TA				Park, EI; Garrow, TA			Interaction between dietary methionine and methyl donor intake on rat liver betaine-homocysteine methyltransferase gene expression and organization of the human gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACIDS; CHOLINE; METABOLISM; MITOCHONDRIA; TRANSPORTER; OXIDATION; BALANCES; KINETICS; MAMMALS; CLONING	We previously showed that rat liver betaine-homocysteine methyltransferase (BHMT) mRNA content and activity increased l-fold when rats were fed a methionine-deficient diet containing adequate choline, compared with rats fed the same diet with control levels of methionine (Park, E, I., Renduchintala, M, S,, and Garrow, T, A. (1997) J, Nutr, Biochem. 8, 541-545), A further a-fold increase was observed in rats fed the methionine-deficient diet with supplemental betaine, The nutrition studies reported here were designed to determine whether other methyl donors would induce rat liver BHMT gene expression when added to a methionine-deficient diet and to define the relationship between the degree of methionine restriction and level of methyl donor intake on BHMT expression. Therefore, rats were fed amino acid-defined diets varying in methionine and methyl donor composition. The effect of diet on BHMT expression was evaluated using Northern, Western, and enzyme activity analyses. Similar to when betaine was added to a methionine-deficient diet, choline or sulfonium analogs of betaine induced BHMT expression. The diet-induced induction of hepatic BHMT activity was mediated by increases in the steady-state level of its mRNA and immunodetectable protein. Using methyl donor-free diets, we found that methionine restriction was required but alone not sufficient for the high induction of BHMT expression. Concomitant with methionine restriction, dietary methyl groups were required for high levels of BHMT induction, and a dose-dependent relationship was observed between methyl donor intake and BHMT induction. Furthermore, the severity of methionine restriction influenced the magnitude of BHMT induction, To study the molecular mechanisms that regulate the expression of BHMT, we have cloned the human BHMT gene. This gene spans about 20 kilobases of DNA and contains 8 exons and 7 introns, Using RNA isolated from human liver and hepatoma cells, a major transcriptional start site has been mapped using the 5' rapid amplification of cDNA ends technique, and this start site is 26 nucleotides downstream from a putative TATA box.	Univ Illinois, Dept Food Sci & Human Nutr, Urbana, IL 61801 USA; Univ Illinois, Div Nutr Sci, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign	Garrow, TA (corresponding author), Univ Illinois, Dept Food Sci & Human Nutr, 463 Bevier Hall,905 S Goodwin Ave, Urbana, IL 61801 USA.	t-garro@uiuc.edu			PHS HHS [52501] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Emmert JL, 1998, J ANIM SCI, V76, P606; Emmert JL, 1996, J NUTR, V126, P2050; FENTON WA, 1995, METABOLIC MOL BASIS, P3029; FINKELSTEIN JD, 1986, J NUTR, V116, P985, DOI 10.1093/jn/116.6.985; FINKELSTEIN JD, 1971, ARCH BIOCHEM BIOPHYS, V146, P84, DOI 10.1016/S0003-9861(71)80044-9; FINKELSTEIN JD, 1983, J NUTR, V113, P519, DOI 10.1093/jn/113.3.519; FINKELSTEIN JD, 1984, J BIOL CHEM, V259, P9508; FINKELSTEIN JD, 1982, ARCH BIOCHEM BIOPHYS, V218, P169, DOI 10.1016/0003-9861(82)90332-0; FINKELSTEIN JD, 1982, BIOCHEM BIOPH RES CO, V108, P344, DOI 10.1016/0006-291X(82)91872-1; FUNK MA, 1990, NUTR RES, V10, P1029, DOI 10.1016/S0271-5317(05)80044-2; GARCIAMARTINEZ LF, 1993, BIOCHEMISTRY-US, V32, P4671, DOI 10.1021/bi00068a027; Garrow TA, 1996, J BIOL CHEM, V271, P22831, DOI 10.1074/jbc.271.37.22831; Garrow TA, 1997, CHEMISTRY AND BIOLOGY OF PTERIDINES AND FOLATES 1997, P303; GRZELAKOWSKASZTABERT B, 1980, BIOCHIM BIOPHYS ACTA, V632, P164, DOI 10.1016/0304-4165(80)90074-4; HARPER AE, 1970, PHYSIOL REV, V50, P428, DOI 10.1152/physrev.1970.50.3.428; HAUBRICH DR, 1976, J NEUROCHEM, V27, P1305, DOI 10.1111/j.1471-4159.1976.tb02608.x; IIDA H, 1985, B JPN SOC SCI FISH, V51, P1145; KAPLAN CP, 1993, FEBS LETT, V321, P24, DOI 10.1016/0014-5793(93)80613-Y; Millian NS, 1998, ARCH BIOCHEM BIOPHYS, V356, P93, DOI 10.1006/abbi.1998.0757; Mudd S.H., 1995, METABOLIC MOL BASES, V1, P1279; MUDD SH, 1980, METABOLISM, V29, P707, DOI 10.1016/0026-0495(80)90192-4; MUDD SH, 1975, METABOLISM, V24, P721, DOI 10.1016/0026-0495(75)90040-2; Mudd SH, 1997, DEV CARDIOVASC MED, P77; Paquet L, 1995, CAN J BOT, V73, P1889, DOI 10.1139/b95-201; Park EI, 1997, J NUTR BIOCHEM, V8, P541, DOI 10.1016/S0955-2863(97)00101-0; PORTER RK, 1992, J BIOL CHEM, V267, P14637; Rao PV, 1998, J BIOL CHEM, V273, P30669, DOI 10.1074/jbc.273.46.30669; REVES PG, 1993, J NUTR, V123, P1939; ROSENBLATT DS, 1995, METABOLIC MOL BASIS, P3011; STORCH KJ, 1991, AM J CLIN NUTR, V54, P386, DOI 10.1093/ajcn/54.2.386; Sunden SLF, 1997, ARCH BIOCHEM BIOPHYS, V345, P171, DOI 10.1006/abbi.1997.0246; UCHIDA T, 1992, J BIOL CHEM, V267, P10156; WEINHOLD PA, 1973, LIFE SCI, V13, P621, DOI 10.1016/0024-3205(73)90055-6; ZAPPAVIGNA V, 1991, EMBO J, V10, P4177, DOI 10.1002/j.1460-2075.1991.tb04996.x	34	129	135	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	1999	274	12					7816	7824		10.1074/jbc.274.12.7816	http://dx.doi.org/10.1074/jbc.274.12.7816			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	178LU	10075673	hybrid			2022-12-25	WOS:000079268100032
J	Chin, KT; Ohki, S; Tang, DM; Cheng, HC; Wang, JH; Zhang, MJ				Chin, KT; Ohki, S; Tang, DM; Cheng, HC; Wang, JH; Zhang, MJ			Identification and structure characterization of a Cdk inhibitory peptide derived from neuronal-specific Cdk5 activator	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIN-DEPENDENT KINASE-5; DIRECTED PROTEIN-KINASE; CALMODULIN-BINDING DOMAIN; PAIRED HELICAL FILAMENTS; BRAIN-SPECIFIC ACTIVATOR; LIGHT-CHAIN KINASE; REGULATORY SUBUNIT; CDC2-LIKE KINASE; NMR-SPECTROSCOPY; DIFFERENTIATION	The activation of cyclin-dependent kinase 5 (Cdk5) depends on the binding of its neuronal specific activator Nck5a, The minimal activation domain of Nck5a is located in the region of amino acid residues 150 to 291 (Tang, D,, Chun, A. C. S., Zhang, M., and Wang, J. H, (1997) J, Biol. Chem. 272, 12318-12327), In this work we show that a 29-residue peptide, denoted as the alpha(N) peptide, encompassing amino acid residues Gln(145) to Asp(173) of Nck5a is capable of binding Cdk5 to result in kinase inhibition. This peptide also inhibits an active phospho-Cdk2-cyclin A complex, with a similar potency. Direct competition experiments have shown that this inhibitory peptide does not compete with Nck5a or cyclin A for Cdk5 or Cdk2, respectively. Steady state kinetic analysis has indicated that the cu, peptide acts as a non-competitive inhibitor of Cdg5 . Nck5a complex with respect to the peptide substrate. To understand the molecular basis of kinase inhibition by the peptide, we determined the structure of the peptide in solution by circular dichroism and two-dimensional H-1 MMR spectroscopy. The peptide adopts an amphipathic alpha-helical structure from residues Ser(149) to Arg(162) which can be further stabilized by the helix-stabilizing solvent trifluoroethanol, The hydrophobic face of the helix is likely to be the kinase binding surface.	Hong Kong Univ Sci & Technol, Dept Biochem, Hong Kong, Peoples R China; Univ Melbourne, Dept Biochem & Mol Biol, Parkville, Vic 3052, Australia	Hong Kong University of Science & Technology; University of Melbourne	Zhang, MJ (corresponding author), Hong Kong Univ Sci & Technol, Dept Biochem, Hong Kong, Peoples R China.	mzhang@uxmail.ust.hk	Tang, Damu/AAQ-1786-2021	Tang, Damu/0000-0002-3282-9521; Cheng, Heung-Chin/0000-0002-4965-7148				Andersen G, 1997, EMBO J, V16, P958, DOI 10.1093/emboj/16.5.958; BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; Bazan JF, 1996, PROTEINS, V24, P1; BLUMENTHAL DK, 1985, P NATL ACAD SCI USA, V82, P3187, DOI 10.1073/pnas.82.10.3187; BROWN NR, 1995, STRUCTURE, V3, P1235, DOI 10.1016/S0969-2126(01)00259-3; Cheng HC, 1996, BIOCHEMISTRY-US, V35, P11874, DOI 10.1021/bi9603940; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; DYSON HJ, 1991, ANNU REV BIOPHYS BIO, V20, P519; FAN JS, 1999, IN PRESS BIOCH BIOPH; HAYES TE, 1991, NEW BIOL, V3, P259; IKURA M, 1992, SCIENCE, V256, P632, DOI 10.1126/science.1585175; ISHIGURO K, 1992, J BIOL CHEM, V267, P10897; JASANOFF A, 1994, BIOCHEMISTRY-US, V33, P2129, DOI 10.1021/bi00174a020; JEFFREY PD, 1995, NATURE, V376, P313, DOI 10.1038/376313a0; Kim KK, 1996, NAT STRUCT BIOL, V3, P849, DOI 10.1038/nsb1096-849; LEE EM, 1993, MOL CELL BIOL, V13, P1194; LEW J, 1992, J BIOL CHEM, V267, P25922; LEW J, 1992, J BIOL CHEM, V267, P13383; LEW J, 1995, TRENDS BIOCHEM SCI, V20, P33, DOI 10.1016/S0968-0004(00)88948-3; LEW J, 1994, NATURE, V371, P423, DOI 10.1038/371423a0; MEADOR WE, 1992, SCIENCE, V257, P1251, DOI 10.1126/science.1519061; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Nikolic M, 1996, GENE DEV, V10, P816, DOI 10.1101/gad.10.7.816; Nikolic M, 1998, NATURE, V395, P194, DOI 10.1038/26034; NUGENT JA, 1991, J CELL SCI, V99, P674; OSHIMA T, 1996, P NATL ACAD SCI USA, V93, P11173; PAUDEL HK, 1993, J BIOL CHEM, V268, P23512; Philpott A, 1997, GENE DEV, V11, P1409, DOI 10.1101/gad.11.11.1409; Poon RYC, 1997, J BIOL CHEM, V272, P5703, DOI 10.1074/jbc.272.9.5703; QI Z, 1995, J BIOL CHEM, V270, P10847, DOI 10.1074/jbc.270.18.10847; Reymond MT, 1997, BIOCHEMISTRY-US, V36, P5234, DOI 10.1021/bi970038x; Segel IH, 1975, ENZYME KINETICS BEHA, P101; Smallcombe SH, 1995, J MAGN RESON SER A, V117, P295, DOI 10.1006/jmra.1995.0759; TANG DM, 1995, J BIOL CHEM, V270, P26897, DOI 10.1074/jbc.270.45.26897; Tang DM, 1997, J BIOL CHEM, V272, P12318, DOI 10.1074/jbc.272.19.12318; TSAI LH, 1994, NATURE, V371, P419, DOI 10.1038/371419a0; WISHART DS, 1992, BIOCHEMISTRY-US, V31, P1647, DOI 10.1021/bi00121a010; Wuthrich K, 1986, NMR PROTEINS NUCL AC; ZHANG MJ, 1993, PROTEIN SCI, V2, P1931, DOI 10.1002/pro.5560021114	39	13	14	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 12	1999	274	11					7120	7127		10.1074/jbc.274.11.7120	http://dx.doi.org/10.1074/jbc.274.11.7120			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	175DV	10066770	hybrid			2022-12-25	WOS:000079078400042
J	Houssa, B; de Widt, J; Kranenburg, O; Moolenaar, WH; van Blitterswijk, WJ				Houssa, B; de Widt, J; Kranenburg, O; Moolenaar, WH; van Blitterswijk, WJ			Diacylglycerol kinase theta binds to and is negatively regulated by active RhoA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN; CYTOSKELETON; FIBROBLASTS; ACTIVATION; GTPASES	Diacylglycerol kinase (DGK) phosphorylates the second messenger diacylglycerol to yield phosphatidic acid. To date, very little is known about the regulation of DGK activity. We have previously identified the DGK theta isotype, which is predominantly expressed in brain (Houssa, B,, Schaap, D., van der Wal, J., Goto, K., Kondo, H., Yamakawa, A., Shibata, M., Takenawa, T., and Van Blitterswijk, W. J. (1997) J. Biol, Chem. 272, 10422-10428), We now report that DGK theta binds specifically to activated RhoA in transfected COS cells as well as in nontransfected neuronal N1E-115 cells. Binding is abolished by a point mutation (Y34N) in the effector loop of RhoA DGK theta does not bind to inactive RhoA, nor to the other Rho-family GTPases, Rac or Cdc42, Like active RhoA, DGK theta localizes to the plasma membrane. Strikingly, the binding of activated RhoA to DGK theta completely inhibits DGK catalytic activity. Our results suggest that DGK theta is a downstream effector of RhoA and that its activity is negatively regulated by RhoA, Through accumulation of newly produced diacylglycerol, RhoA-mediated inhibition of DGK theta may lead to enhanced PKC activity in response to external stimuli.	Netherlands Canc Inst, Div Cellular Biochem, NL-1066 CX Amsterdam, Netherlands	Netherlands Cancer Institute	van Blitterswijk, WJ (corresponding author), Netherlands Canc Inst, Div Cellular Biochem, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.		Kranenburg, Onno/K-4115-2015	Kranenburg, Onno/0000-0002-2112-4390				ADAMSON P, 1992, J CELL BIOL, V119, P617, DOI 10.1083/jcb.119.3.617; Bae CD, 1998, J BIOL CHEM, V273, P11596, DOI 10.1074/jbc.273.19.11596; Chang JH, 1998, MOL CELL BIOL, V18, P4986, DOI 10.1128/MCB.18.9.4986; Gebbink MFBG, 1997, J CELL BIOL, V137, P1603, DOI 10.1083/jcb.137.7.1603; Hippenstiel S, 1998, BIOCHEM BIOPH RES CO, V245, P830, DOI 10.1006/bbrc.1998.8525; Hodgkin MN, 1998, TRENDS BIOCHEM SCI, V23, P200, DOI 10.1016/S0968-0004(98)01200-6; Houssa B, 1997, J BIOL CHEM, V272, P10422; Houssa B, 1998, BIOCHEM J, V331, P677; Kamada Y, 1996, J BIOL CHEM, V271, P9193, DOI 10.1074/jbc.271.16.9193; KANOH H, 1990, TRENDS BIOCHEM SCI, V15, P47, DOI 10.1016/0968-0004(90)90172-8; Malcolm KC, 1996, J BIOL CHEM, V271, P13135, DOI 10.1074/jbc.271.22.13135; NONAKA H, 1995, EMBO J, V14, P5931, DOI 10.1002/j.1460-2075.1995.tb00281.x; Ren XD, 1998, CURR OPIN GENET DEV, V8, P63, DOI 10.1016/S0959-437X(98)80063-4; Sahai E, 1998, EMBO J, V17, P1350, DOI 10.1093/emboj/17.5.1350; Symons M, 1996, TRENDS BIOCHEM SCI, V21, P178, DOI 10.1016/S0968-0004(96)10022-0; Tapon N, 1997, CURR OPIN CELL BIOL, V9, P86, DOI 10.1016/S0955-0674(97)80156-1; Tolias KF, 1998, MOL CELL BIOL, V18, P762, DOI 10.1128/MCB.18.2.762; Topham MK, 1998, NATURE, V394, P697, DOI 10.1038/29337; van Dijk MCM, 1998, BBA-LIPID LIPID MET, V1391, P273, DOI 10.1016/S0005-2760(98)00016-2; VANBLITTERSWIJK WJ, 1991, J BIOL CHEM, V266, P10337; VANBLITTERSWIJK WJ, 1999, IN PRESS CHEM PHYS L; VANDERBEND RL, 1994, J BIOL CHEM, V269, P4098; Wittinghofer A, 1996, TRENDS BIOCHEM SCI, V21, P488, DOI 10.1016/S0968-0004(96)10064-5	23	75	84	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 12	1999	274	11					6820	6822		10.1074/jbc.274.11.6820	http://dx.doi.org/10.1074/jbc.274.11.6820			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	175DV	10066731	hybrid			2022-12-25	WOS:000079078400003
J	Ammini, CV; Hauswirth, WW				Ammini, CV; Hauswirth, WW			Mitochondrial gene expression is regulated at the level of transcription during early embryogenesis of Xenopus laevis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENERGY-METABOLISM; EMBRYOS; EGGS; FROG; CA2+; FERTILIZATION; ACTIVATION; OOCYTES; MOUSE; WAVE	Mitochondrial transcription in the early Xenopus laevis embryo resumes several hours before active mtDNA replication, effectively decoupling mtDNA transcription and replication. This developmental feature makes Xenopus embryogenesis an appealing model system to investigate the regulation of mitochondrial transcription. Studies reported here refine our understanding of the timing, magnitude, and mechanism of this transcriptional induction event. Northern analyses of six mitochondrial mRNAs (normalized to mtDNA) reveal that transcript levels remain basal between fertilization and gastrulation and then undergo a coordinate induction, culminating in a 20-28-fold increase over egg levels by 48 h of development. Measurement of mitochondrial run-on transcription rates demonstrates a good correlation between transcription rates and transcript levels, showing that transcription itself is the primary determinant of transcript abundance. Experimental increases in mitochondrial ATP and energy charge also correlate with patterns of transcript levels and transcription rates, suggesting that developmental changes in the biochemical composition of the mitochondrial matrix could be regulating transcriptional activity. Consistent with this idea, transcriptional run-on rates in mitochondria of early embryos can be stimulated by the addition of tricarboxylic acid cycle intermediates to the run on reaction. However, mitochondria of later stages do not show this response to the addition of metabolite. In combination, these data suggest that mitochondrial transcription is under metabolic regulation during early Xenopus embryogenesis.	Univ Florida, Dept Mol Genet & Microbiol, Gainesville, FL 32610 USA; Univ Florida, Dept Ophthalmol, Gainesville, FL 32610 USA	State University System of Florida; University of Florida; State University System of Florida; University of Florida	Hauswirth, WW (corresponding author), Univ Florida, J Hillis Miller Hlth Ctr, Dept Mol Genet & Microbiol, Box 100266, Gainesville, FL 32610 USA.							Ammini C V, 1996, Methods Enzymol, V264, P23, DOI 10.1016/S0076-6879(96)64005-1; BUSA WB, 1985, J CELL BIOL, V100, P1325, DOI 10.1083/jcb.100.4.1325; BUSA WB, 1985, J CELL BIOL, V101, P677, DOI 10.1083/jcb.101.2.677; CHASE JW, 1972, DEV BIOL, V27, P504, DOI 10.1016/0012-1606(72)90189-3; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; DAWID IB, 1985, J EMBRYOL EXP MORPH, V89, P113; DWORKIN MB, 1991, TRENDS BIOCHEM SCI, V16, P229, DOI 10.1016/0968-0004(91)90091-9; DWORKIN MB, 1989, DEV BIOL, V132, P512, DOI 10.1016/0012-1606(89)90246-7; DWORKIN MB, 1990, DEV BIOL, V138, P177, DOI 10.1016/0012-1606(90)90187-N; GAINES G, 1987, J BIOL CHEM, V262, P1907; Gaines G L 3rd, 1996, Methods Enzymol, V264, P43, DOI 10.1016/S0076-6879(96)64007-5; GINSBERG L, 1973, J EMBRYOL EXP MORPH, V30, P267; HAJNOCZKY G, 1995, CELL, V82, P415, DOI 10.1016/0092-8674(95)90430-1; HOLLINGER TG, 1980, GAMETE RES, V3, P45, DOI 10.1002/mrd.1120030106; KUBOTA HY, 1987, DEV BIOL, V119, P129, DOI 10.1016/0012-1606(87)90214-4; LOVTRUPREIN H, 1982, EXP CELL BIOL, V50, P162; LOVTRUPREIN H, 1982, CELL DIFFER DEV, V11, P125, DOI 10.1016/0045-6039(82)90002-1; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCCORMACK JG, 1993, DEV NEUROSCI-BASEL, V15, P165, DOI 10.1159/000111332; MCKEE EE, 1990, AM J PHYSIOL, V258, pE492, DOI 10.1152/ajpendo.1990.258.3.E492; MEZIANE AE, 1989, EMBO J, V8, P1649; MILLS RM, 1967, EXP CELL RES, V47, P337, DOI 10.1016/0014-4827(67)90236-4; NEWPORT J, 1982, CELL, V30, P687, DOI 10.1016/0092-8674(82)90273-2; Nieuwkoop PD, 1967, NORMAL TABLES XENOPU; PIKO L, 1987, DEV BIOL, V123, P364, DOI 10.1016/0012-1606(87)90395-2; PIKO L, 1973, J CELL BIOL, V58, P357, DOI 10.1083/jcb.58.2.357; PRALONG WF, 1994, J BIOL CHEM, V269, P27310; RIZZUTO R, 1994, J CELL BIOL, V126, P1183, DOI 10.1083/jcb.126.5.1183; ROE BA, 1985, J BIOL CHEM, V260, P9759; STERN S, 1971, J EXP ZOOL, V176, P179, DOI 10.1002/jez.1401760206; THOMAN M, 1979, DEV BIOL, V68, P191, DOI 10.1016/0012-1606(79)90253-7; WEBB AC, 1977, DEV BIOL, V56, P219, DOI 10.1016/0012-1606(77)90166-X; WEBB AC, 1975, DEV BIOL, V45, P44, DOI 10.1016/0012-1606(75)90239-0; WEINBERG JM, 1989, J LAB CLIN MED, V113, P612; YOUNG PG, 1973, DEV BIOL, V33, P196, DOI 10.1016/0012-1606(73)90174-7	35	16	16	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1999	274	10					6265	6271		10.1074/jbc.274.10.6265	http://dx.doi.org/10.1074/jbc.274.10.6265			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172BQ	10037714	hybrid			2022-12-25	WOS:000078902800036
J	Cranmer, SL; Ulsemer, P; Cooke, BM; Salem, HH; de la Salle, C; Lanza, F; Jackson, SP				Cranmer, SL; Ulsemer, P; Cooke, BM; Salem, HH; de la Salle, C; Lanza, F; Jackson, SP			Glycoprotein (GP) Ib-IX-transfected cells roll on a von Willebrand factor matrix under flow - Importance of the GPIb/actin-binding protein (ABP-280) interaction in maintaining adhesion under high shear	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTEGRIN ALPHA(IIB)BETA(3); VONWILLEBRAND-FACTOR; CYTOPLASMIC DOMAIN; PLATELETS; COMPLEX; ALPHA; IDENTIFICATION; ATTACHMENT; EXPRESSION; FIBRINOGEN	Adhesion of platelets to sites of vascular injury is critical for hemostasis and thrombosis and is dependent on the binding of the vascular adhesive protein von Willebrand factor (vWf) to the glycoprotein (GP) Ib-V-M complex on the platelet surface. A unique but poorly defined characteristic of this receptor/ligand interaction is its ability to support platelet adhesion under conditions of high shear stress. To examine the structural domains of the GPIb-V-IX complex involved in mediating cell adhesion under flow, we have expressed partial (GPIb-IX), complete (GPIb-V-IX), and mutant (GPIb alpha cytoplasmic tail mutants) receptor complexes on the surface of Chinese hamster ovary (CHO) cells and examined their ability to adhere to a vWf matrix in flow-based adhesion assays. Our studies demonstrate that the partial receptor complex (GPIb-IX) supports CHO cell tethering and rolling on a bovine or human vWf matrix under flow. The adhesion was specifically inhibited by an antiGPI alpha blocking antibody (AK2) and was not observed with CHO cells expressing GPIb beta and GPIX alone. The velocity of rolling was dependent on the level of shear stress, receptor density, and matrix concentration and was not altered by the presence of GPV. In contrast to selectins, which mediate cell rolling under conditions of low shear (20-200 s(-1)), GPIb-IX was able to support cell rolling at both venous (150 s(-1)) and arterial (1500-10,500 s(-1)) shear rates. Studies with a mutant GPIba receptor subunit lacking the binding domain for actin-binding protein demonstrated that the association of the receptor complex with the membrane skeleton is not essential for cell tethering or rolling under low shear conditions, but is critical for maintaining adhesion at high shear rates (3000-6000 s(-1)). These studies demonstrate that the GPIb-IX complex is sufficient to mediate cell rolling on a vWf matrix at both venous and arterial levels of shear independent of other platelet adhesion receptors. Furthermore, our results suggest that the association between GPIb alpha and actin-binding protein plays an important role in enabling cells to remain tethered to a vWf matrix under conditions of high shear stress.	Monash Med Sch, Dept Med, Australian Ctr Blood Dis, Box Hill, Vic 3128, Australia; Monash Univ, Dept Microbiol, Box Hill, Vic 3128, Australia; Box Hill Hosp, Dept Pathol, Box Hill, Vic 3128, Australia; Etablissement Transfus Sanguine, INSERM, U311, F-67065 Strasbourg, France	Monash University; Monash University; Box Hill Hospital; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Jackson, SP (corresponding author), Box Hill Hosp, Monash Med Sch, Australian Ctr Blood Dis, Dept Med, Arnold St, Box Hill, Vic 3128, Australia.		Lanza, Francois/H-9252-2016	Lanza, Francois/0000-0002-5802-4748; Jackson, Shaun/0000-0002-4750-1991				ANDREWS RK, 1992, J BIOL CHEM, V267, P18605; COOKE BM, 1993, MICROVASC RES, V45, P33, DOI 10.1006/mvre.1993.1004; Cunningham JG, 1996, J BIOL CHEM, V271, P11581, DOI 10.1074/jbc.271.19.11581; Dong JF, 1997, BIOCHEMISTRY-US, V36, P12421, DOI 10.1021/bi970636b; FOX JEB, 1985, J CLIN INVEST, V76, P1673, DOI 10.1172/JCI112153; Fredrickson BJ, 1998, BLOOD, V92, P3684, DOI 10.1182/blood.V92.10.3684.422k39_3684_3693; HUBBE MA, 1981, PROG SURF SCI, V11, P65, DOI 10.1016/0079-6816(81)90009-5; JAKOBSEN E, 1973, Thrombosis Research, V3, P145, DOI 10.1016/0049-3848(73)90065-0; Kroll MH, 1996, BLOOD, V88, P1525; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAWRENCE MB, 1991, CELL, V65, P859, DOI 10.1016/0092-8674(91)90393-D; LI CQ, 1995, J BIOL CHEM, V270, P16302, DOI 10.1074/jbc.270.27.16302; LOPEZ JA, 1992, J BIOL CHEM, V267, P12851; MOAKE JL, 1980, THROMB RES, V19, P21, DOI 10.1016/0049-3848(80)90400-4; MONTGOMERY RR, 1978, J CLIN INVEST, V61, P1498, DOI 10.1172/JCI109070; PUSZKIN EG, 1990, BLOOD, V76, P1572; Ruggeri ZM, 1997, J CLIN INVEST, V99, P559, DOI 10.1172/JCI119195; Savage B, 1996, CELL, V84, P289, DOI 10.1016/S0092-8674(00)80983-6; SAVAGE B, 1992, J BIOL CHEM, V267, P11300; SCHOENWAELDER SM, 1994, J BIOL CHEM, V269, P32479; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; TURRITO VT, 1980, SCIENCE, V207, P541; WENGER RH, 1988, BIOCHEM BIOPH RES CO, V156, P389, DOI 10.1016/S0006-291X(88)80853-2; Yuan YP, 1997, J BIOL CHEM, V272, P21847, DOI 10.1074/jbc.272.35.21847	24	72	72	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1999	274	10					6097	6106		10.1074/jbc.274.10.6097	http://dx.doi.org/10.1074/jbc.274.10.6097			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172BQ	10037692	hybrid			2022-12-25	WOS:000078902800014
J	Di Bartolo, V; Mege, D; Germain, V; Pelosi, M; Dufour, E; Michel, F; Magistrelli, G; Isacchi, A; Acuto, O				Di Bartolo, V; Mege, D; Germain, V; Pelosi, M; Dufour, E; Michel, F; Magistrelli, G; Isacchi, A; Acuto, O			Tyrosine 319, a newly identified phosphorylation site of ZAP-70, plays a critical role in T cell antigen receptor signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEVERE COMBINED IMMUNODEFICIENCY; PHOSPHOTYROSINE-BINDING DOMAIN; FOCAL ADHESION KINASE; SH2 DOMAIN; SYK; ACTIVATION; INTERACTS; PROTEINS; SLP-76; TCR	Following T cell antigen receptor (TCR) engagement, the protein tyrosine kinase (PTK) ZAP-70 is rapidly phosphorylated on several tyrosine residues, presumably by two mechanisms: an autophosphorylation and a trans-phosphorylation by the Src-family PTK Lck, These events have been implicated in both positive and negative regulation of ZAP-70 activity and in coupling this PTK to downstream signaling pathways in T cells. We show here that Tyr(315) and Tyr(319) in the interdomain B of ZAP-70 are autophosphorylated in vitro and become phosphorylated in vivo upon TCR triggering. Moreover, by mutational analysis, we demonstrate that phosphorylation of Tyr(319) is required for the positive regulation of ZAP-70 function. Indeed, overexpression in Jurkat cells and in a murine T cell hybridoma of a ZAP-70 mutant in which Tyr(319) was replaced by phenylalanine (ZAP-70-Y319F) dramatically impaired anti-TCR-induced activation of the nuclear factor of activated T cells and interleukin-2 production, respectively. Surprisingly, an analogous mutation of Tyr(315) had little or no effect. The inhibitory effect of ZAP-70-Y319F correlated with a substantial loss of its activation-induced tyrosine phosphorylation and up-regulation of catalytic activity, as well as with a decreased in vivo capacity to phosphorylate known ZAP-70 substrates, such as SLP-76 and LAT, Collectively, our data reveal the pivotal role of Tyr(319) phosphorylation in the positive regulation of ZAP-70 and in TCR-mediated signaling.	Inst Pasteur, Dept Immunol, Mol Immunol Unit, F-75724 Paris 15, France; Pharmacia & Upjohn Inc, Dept Biol, I-20014 Nerviano, Italy	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Pfizer	Acuto, O (corresponding author), Inst Pasteur, Dept Immunol, Mol Immunol Unit, 25 Rue Docteur Roux, F-75724 Paris 15, France.	oacuto@pasteur.fr	Di Bartolo, Vincenzo/AAL-6834-2020	Di Bartolo, Vincenzo/0000-0002-5453-947X; Michel, Frederique/0000-0002-3524-2232				ARPAIA E, 1994, CELL, V76, P947, DOI 10.1016/0092-8674(94)90368-9; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BURKHARDT AL, 1994, J BIOL CHEM, V269, P23642; CALALB MB, 1995, MOL CELL BIOL, V15, P954; CHAN AC, 1994, SCIENCE, V264, P1599, DOI 10.1126/science.8202713; CHAN AC, 1995, EMBO J, V14, P2499, DOI 10.1002/j.1460-2075.1995.tb07247.x; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; CHENG AM, 1995, NATURE, V378, P303, DOI 10.1038/378303a0; CRABTREE GR, 1994, ANNU REV BIOCHEM, V63, P1045, DOI 10.1146/annurev.biochem.63.1.1045; DUPLAY P, 1994, J EXP MED, V179, P1163, DOI 10.1084/jem.179.4.1163; ELDER ME, 1994, SCIENCE, V264, P1596, DOI 10.1126/science.8202712; FURLONG MT, 1997, BIOCHIM BIOPHYS ACTA, P177; HATADA MH, 1995, NATURE, V377, P32, DOI 10.1038/377032a0; Huby RDJ, 1995, J BIOL CHEM, V270, P30241, DOI 10.1074/jbc.270.51.30241; Isakov N, 1996, J BIOL CHEM, V271, P15753, DOI 10.1074/jbc.271.26.15753; IWASHIMA M, 1994, SCIENCE, V263, P1136, DOI 10.1126/science.7509083; JACKMAN JK, 1995, J BIOL CHEM, V270, P7029, DOI 10.1074/jbc.270.13.7029; KATZAV S, 1994, J BIOL CHEM, V269, P32579; KLOHE EP, 1988, J IMMUNOL, V141, P2158; Kong GH, 1996, MOL CELL BIOL, V16, P5026; KREIS TE, 1986, EMBO J, V5, P931, DOI 10.1002/j.1460-2075.1986.tb04306.x; Latour S, 1998, EMBO J, V17, P2584, DOI 10.1093/emboj/17.9.2584; Law CL, 1996, MOL CELL BIOL, V16, P1305; LUO K, 1990, ONCOGENE, V5, P921; Lupher ML, 1996, J BIOL CHEM, V271, P24063, DOI 10.1074/jbc.271.39.24063; Lupher ML, 1997, J BIOL CHEM, V272, P33140, DOI 10.1074/jbc.272.52.33140; Mege D, 1996, J BIOL CHEM, V271, P32644, DOI 10.1074/jbc.271.51.32644; Michel F, 1998, J BIOL CHEM, V273, P31932, DOI 10.1074/jbc.273.48.31932; Milia E, 1996, ONCOGENE, V13, P767; MOLL H, 1993, EUR J IMMUNOL, V23, P1595, DOI 10.1002/eji.1830230730; NEGISHI I, 1995, NATURE, V376, P435, DOI 10.1038/376435a0; NEUMEISTER EN, 1995, MOL CELL BIOL, V15, P3171; Ota Y, 1997, SCIENCE, V276, P418, DOI 10.1126/science.276.5311.418; Pacini S, 1998, J BIOL CHEM, V273, P20487, DOI 10.1074/jbc.273.32.20487; Plas DR, 1996, SCIENCE, V272, P1173, DOI 10.1126/science.272.5265.1173; Qian DP, 1997, CURR OPIN CELL BIOL, V9, P205, DOI 10.1016/S0955-0674(97)80064-6; Raab M, 1997, IMMUNITY, V6, P155, DOI 10.1016/S1074-7613(00)80422-7; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; Tuosto L, 1996, J EXP MED, V184, P1161, DOI 10.1084/jem.184.3.1161; TURNER M, 1995, NATURE, V378, P298, DOI 10.1038/378298a0; vanOers NSC, 1996, J EXP MED, V183, P1053, DOI 10.1084/jem.183.3.1053; WANGE RL, 1995, J BIOL CHEM, V270, P18730, DOI 10.1074/jbc.270.32.18730; Wardenburg JB, 1996, J BIOL CHEM, V271, P19641, DOI 10.1074/jbc.271.33.19641; WATTS JD, 1994, J BIOL CHEM, V269, P29520; Weber JR, 1998, J EXP MED, V187, P1157, DOI 10.1084/jem.187.7.1157; Wu J, 1997, J EXP MED, V185, P1877, DOI 10.1084/jem.185.10.1877; Zeitlmann L, 1998, J BIOL CHEM, V273, P15445, DOI 10.1074/jbc.273.25.15445; Zhang WG, 1998, CELL, V92, P83, DOI 10.1016/S0092-8674(00)80901-0; Zhao QH, 1996, MOL CELL BIOL, V16, P6765; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	51	105	107	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	1999	274	10					6285	6294		10.1074/jbc.274.10.6285	http://dx.doi.org/10.1074/jbc.274.10.6285			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172BQ	10037717	hybrid			2022-12-25	WOS:000078902800039
J	Rogers, JT; Leiter, LM; McPhee, J; Cahill, CM; Zhan, SS; Potter, H; Nilsson, LNG				Rogers, JT; Leiter, LM; McPhee, J; Cahill, CM; Zhan, SS; Potter, H; Nilsson, LNG			Translation of the Alzheimer amyloid precursor protein mRNA is up-regulated by interleukin-1 through 5 '-untranslated region sequences	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NONSTEROIDAL ANTIINFLAMMATORY DRUGS; IRON-RESPONSIVE ELEMENT; FERRITIN MESSENGER-RNA; BETA-PROTEIN; APOLIPOPROTEIN-E; GENE-EXPRESSION; TRANSGENIC MICE; RAT-BRAIN; IN-VITRO; DISEASE	The amyloid precursor protein (APP) has been associated with Alzheimer's disease (AD) because APP is processed into the beta-peptide that accumulates in amyloid plaques, and APP gene mutations can cause early onset AD. Inflammation is also associated with AD as exemplified by increased expression of interleukin-l (IL-1) in microglia in affected areas of the AD brain. Here we demonstrate that IL-1 alpha and IL-beta increase APP synthesis by up to 6-fold in primary human astrocytes and by 15-fold in human astrocytoma cells without changing the steady-state levels of APP mRNA. A 90-nucleotide sequence in the APP gene 5'-untranslated region (5'-UTR) conferred translational regulation by IL-l alpha and IL-1 beta to a chloramphenicol acetyltransferase (CAT) reporter gene. Steady-state levels of transfected APP(5'-UTR)/CAT mRNAs were unchanged, whereas both baseline and IL-l-dependent CAT protein synthesis were increased. This APP mRNA translational enhancer maps from +55 to +144 nucleotides from the 5'-cap site and is homologous to related translational control elements in the 5'-UTR of the light and and heavy ferritin genes. Enhanced translation of APP mRNA provides a mechanism by which IL-1 influences the pathogenesis of AD.	Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Med,Div Hematol, Boston, MA 02115 USA; Massachusetts Gen Hosp, Dept Med, Diabet Unit, Boston, MA 02114 USA; Univ S Florida, Dept Biochem & Mol Biol, Tampa, FL 33612 USA; Univ S Florida, Suncoast Gerontol Ctr, Tampa, FL 33612 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Massachusetts General Hospital; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida	Rogers, JT (corresponding author), 604 LMRC,221 Longwood Ave, Boston, MA 02115 USA.	Rogers@calvin.bwh.harvard.edu		nilsson, lars/0000-0002-8362-1042; Rogers, Jack/0000-0003-1262-8578; McPhee, James/0000-0001-9329-3479	NIAMS NIH HHS [AR29I32717] Funding Source: Medline; PHS HHS [6872302] Funding Source: Medline; ADAMHA HHS [AD09665] Funding Source: Medline	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); ADAMHA HHS		ABRAHAM CR, 1988, CELL, V52, P487, DOI 10.1016/0092-8674(88)90462-X; ANDERSEN K, 1995, NEUROLOGY, V45, P1441, DOI 10.1212/WNL.45.8.1441; AURON PE, 1994, EUR CYTOKINE NETW, V5, P573; Bales KR, 1997, NAT GENET, V17, P263, DOI 10.1038/ng1197-263; Blom MAA, 1997, BRAIN RES, V777, P210, DOI 10.1016/S0006-8993(97)01204-3; BODOVITZ S, 1995, J NEUROCHEM, V64, P307; BUSCIGLIO J, 1993, P NATL ACAD SCI USA, V90, P2092, DOI 10.1073/pnas.90.5.2092; BUXBAUM JD, 1992, P NATL ACAD SCI USA, V89, P10075, DOI 10.1073/pnas.89.21.10075; CHANDRA T, 1983, BIOCHEMISTRY-US, V22, P5055, DOI 10.1021/bi00291a001; CITRON M, 1992, NATURE, V360, P672, DOI 10.1038/360672a0; COHEN ML, 1988, P NATL ACAD SCI USA, V85, P1227, DOI 10.1073/pnas.85.4.1227; DAS S, 1995, NEURON, V14, P447, DOI 10.1016/0896-6273(95)90300-3; DESAUVAGE F, 1992, EMBO J, V11, P3099, DOI 10.1002/j.1460-2075.1992.tb05382.x; Dinarello CA, 1996, BLOOD, V87, P2095, DOI 10.1182/blood.V87.6.2095.bloodjournal8762095; ElKhoury J, 1996, NATURE, V382, P716; EVANS KC, 1995, P NATL ACAD SCI USA, V92, P763, DOI 10.1073/pnas.92.3.763; FORLONI G, 1992, MOL BRAIN RES, V16, P128, DOI 10.1016/0169-328X(92)90202-M; Frautschy SA, 1998, AM J PATHOL, V152, P307; GAMES D, 1995, NATURE, V373, P523, DOI 10.1038/373523a0; Gingras AC, 1998, GENE DEV, V12, P502, DOI 10.1101/gad.12.4.502; GIULIAN D, 1987, J NEUROSCI RES, V18, P155, DOI 10.1002/jnr.490180123; GIULIAN D, 1985, SCIENCE, V228, P497, DOI 10.1126/science.3872478; GOATE A, 1991, NATURE, V349, P704, DOI 10.1038/349704a0; GOLDGABER D, 1989, P NATL ACAD SCI USA, V86, P7606, DOI 10.1073/pnas.86.19.7606; GRAY CW, 1993, MOL BRAIN RES, V19, P251, DOI 10.1016/0169-328X(93)90037-P; GRIFFIN WST, 1989, P NATL ACAD SCI USA, V86, P7611; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; HOLZMAN DM, 1992, EMBO J, V11, P619; Janciauskiene S, 1996, NAT STRUCT BIOL, V3, P668, DOI 10.1038/nsb0896-668; JohnsonWood K, 1997, P NATL ACAD SCI USA, V94, P1550, DOI 10.1073/pnas.94.4.1550; Johnston JA, 1996, MOL BRAIN RES, V43, P85, DOI 10.1016/S0169-328X(96)00161-1; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KONIJN AM, 1977, BRIT J HAEMATOL, V37, P7, DOI 10.1111/j.1365-2141.1977.tb08806.x; LEBLANC AC, 1991, FEBS LETT, V292, P171, DOI 10.1016/0014-5793(91)80861-V; Leedman PJ, 1996, J BIOL CHEM, V271, P12017, DOI 10.1074/jbc.271.20.12017; MA JY, 1994, NATURE, V372, P92, DOI 10.1038/372092a0; Machein U, 1995, NEUROREPORT, V6, P2283, DOI 10.1097/00001756-199511270-00004; Moir RD, 1998, J BIOL CHEM, V273, P5013, DOI 10.1074/jbc.273.9.5013; Multhaup G, 1996, SCIENCE, V271, P1406, DOI 10.1126/science.271.5254.1406; Neve RL, 1996, MOL BRAIN RES, V39, P185, DOI 10.1016/0169-328X(96)00007-1; NIETOSAMPEDRO M, 1987, J NEUROSCI RES, V17, P214, DOI 10.1002/jnr.490170303; NILSSON L, 1998, FRONT BIOSCI, V3, P436; Pantopoulos K, 1997, J BIOL CHEM, V272, P9802; QUON D, 1991, NATURE, V352, P239, DOI 10.1038/352239a0; RICH JB, 1995, NEUROLOGY, V45, P51, DOI 10.1212/WNL.45.1.51; ROBERTS GW, 1991, LANCET, V338, P1422, DOI 10.1016/0140-6736(91)92724-G; ROGERS J, 1992, P NATL ACAD SCI USA, V89, P10016, DOI 10.1073/pnas.89.21.10016; ROGERS JT, 1990, J BIOL CHEM, V265, P14572; ROGERS JT, 1994, NUCLEIC ACIDS RES, V22, P2678, DOI 10.1093/nar/22.13.2678; Rogers JT, 1996, BLOOD, V87, P2525, DOI 10.1182/blood.V87.6.2525.bloodjournal8762525; ROUAULT TA, 1991, CELL, V64, P881, DOI 10.1016/0092-8674(91)90312-M; SANAN DA, 1994, J CLIN INVEST, V94, P860, DOI 10.1172/JCI117407; Schalinske KL, 1996, J BIOL CHEM, V271, P7168, DOI 10.1074/jbc.271.12.7168; Scheuner D, 1996, NAT MED, V2, P864, DOI 10.1038/nm0896-864; SELKOE DJ, 1988, P NATL ACAD SCI USA, V85, P7341, DOI 10.1073/pnas.85.19.7341; Sheng JG, 1996, NEUROBIOL AGING, V17, P761; SIMAN R, 1989, NEURON, V3, P275, DOI 10.1016/0896-6273(89)90252-3; TANZI RE, 1987, SCIENCE, V235, P880, DOI 10.1126/science.2949367; Thomas T, 1996, NATURE, V380, P168, DOI 10.1038/380168a0; TOKUNAGA K, 1987, CANCER RES, V47, P5616; VANNOSTRAND WE, 1991, P NATL ACAD SCI USA, V88, P10302, DOI 10.1073/pnas.88.22.10302; WISNIEWSKI KE, 1985, ANN NEUROL, V17, P278, DOI 10.1002/ana.410170310; WISNIEWSKI T, 1994, AM J PATHOL, V145, P1030; Wisniewski T, 1996, NEUROREPORT, V7, P667, DOI 10.1097/00001756-199601310-00068; Yan SD, 1996, NATURE, V382, P685, DOI 10.1038/382685a0; ZAIDI SHE, 1995, J BIOL CHEM, V270, P17292, DOI 10.1074/jbc.270.29.17292; ZUKER M, 1989, SCIENCE, V244, P48, DOI 10.1126/science.2468181	67	246	268	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	1999	274	10					6421	6431		10.1074/jbc.274.10.6421	http://dx.doi.org/10.1074/jbc.274.10.6421			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172BQ	10037734	hybrid			2022-12-25	WOS:000078902800056
J	Chavin, KD; Yang, SQ; Lin, HZ; Chatham, J; Chacko, VP; Hoek, JB; Walajtys-Rode, E; Rashid, A; Chen, CH; Huang, CC; Wu, TC; Lane, MD; Diehl, AM				Chavin, KD; Yang, SQ; Lin, HZ; Chatham, J; Chacko, VP; Hoek, JB; Walajtys-Rode, E; Rashid, A; Chen, CH; Huang, CC; Wu, TC; Lane, MD; Diehl, AM			Obesity induces expression of uncoupling protein-2 in hepatocytes and promotes liver ATP depletion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; ADIPOSE-TISSUE; FACTOR-ALPHA; MITOCHONDRIAL; METABOLISM; INTERLEUKIN-6; TRANSPORT; HOMOLOG; INJURY; MICE	Uncoupling protein 2 (UCP2) uncouples respiration from oxidative phosphorylation and may contribute to obesity through effects on energy metabolism. Because basal metabolic rate is decreased in obesity, UCP2 expression is predicted to be reduced. Paradoxically, hepatic expression of UCP2 mRNA is increased in genetically obese (ob/ob) mice, In situ hybridization and immunohistochemical analysis of ob/ob livers demonstrate that UCP2 mRNA and protein expression are increased in hepatocytes, which do not express UCP2 in lean mice. Mitochondria isolated from ob/ob livers exhibit an increased rate of H+ leak which partially dissipates the mitochondrial membrane potential when the rate of electron transport is suppressed. In addition, hepatic ATP stores are reduced and these livers are more vulnerable to necrosis after transient hepatic ischemia. Hence, hepatocytes adapt to obesity by up-regulating UCP2. However, because this decreases the efficiency of energy trapping, the cells become vulnerable to ATP depletion when energy needs increase acutely.	Johns Hopkins Univ, Dept Med, Baltimore, MD 21205 USA; Johns Hopkins Univ, Dept Surg, Baltimore, MD 21205 USA; Johns Hopkins Univ, Dept Radiol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Dept Pathol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Dept Biol Chem, Baltimore, MD 21205 USA; Thomas Jefferson Univ, Dept Pathol Anat & Cell Biol, Philadelphia, PA 19107 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Jefferson University	Diehl, AM (corresponding author), Johns Hopkins Univ, Dept Med, 912 Ross Bldg,720 Rutland St, Baltimore, MD 21205 USA.	amdiehl@welchlink.welch.jhu.edu			NIAAA NIH HHS [AA09347, AA00173, AA08714] Funding Source: Medline; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA008714, R01AA009347] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		BANKFALVI A, 1994, J PATHOL, V174, P223, DOI 10.1002/path.1711740312; BLIN N, 1976, NUCLEIC ACIDS RES, V3, P2303, DOI 10.1093/nar/3.9.2303; Boss O, 1998, LANCET, V351, P1933, DOI 10.1016/S0140-6736(05)78617-7; Boss O, 1997, FEBS LETT, V412, P111, DOI 10.1016/S0014-5793(97)00755-2; BRADY LJ, 1985, BIOCHEM J, V231, P439, DOI 10.1042/bj2310439; BROWN GC, 1988, BIOCHEM J, V252, P473, DOI 10.1042/bj2520473; Camargo CA, 1997, HEPATOLOGY, V26, P1513, DOI 10.1002/hep.510260619; Campfield LA, 1996, HORM METAB RES, V28, P619, DOI 10.1055/s-2007-979867; CHANCE B, 1979, PHYSIOL REV, V59, P527, DOI 10.1152/physrev.1979.59.3.527; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Cortez-Pinto H, 1998, BIOCHEM BIOPH RES CO, V251, P313, DOI 10.1006/bbrc.1998.9473; Faggioni R, 1998, BIOCHEM BIOPH RES CO, V244, P75, DOI 10.1006/bbrc.1998.8219; Fleury C, 1997, NAT GENET, V15, P269, DOI 10.1038/ng0397-269; FRASER DR, 1983, BIOCHEM J, V214, P163, DOI 10.1042/bj2140163; Garlid KD, 1996, J BIOL CHEM, V271, P2615, DOI 10.1074/jbc.271.5.2615; Gimeno RE, 1997, DIABETES, V46, P900, DOI 10.2337/diabetes.46.5.900; Hatano E, 1996, HEPATOLOGY, V24, P663, DOI 10.1002/hep.510240332; KATYARE SS, 1978, ARCH BIOCHEM BIOPHYS, V188, P15, DOI 10.1016/0003-9861(78)90349-1; Keller JN, 1998, J NEUROSCI, V18, P687; KERN PA, 1995, J CLIN INVEST, V95, P2111, DOI 10.1172/JCI117899; Larrouy D, 1997, BIOCHEM BIOPH RES CO, V235, P760, DOI 10.1006/bbrc.1997.6852; LEE FYJ, 1999, IN PRESS HEPATOLOGY; MCCULLOUGH AJ, 1991, SEMIN LIVER DIS, V11, P265, DOI 10.1055/s-2008-1040445; Millet L, 1997, J CLIN INVEST, V100, P2665, DOI 10.1172/JCI119811; Nedergaard J., 1992, MOL MECH BIOENERGETI, P385; NegreSalvayre A, 1997, FASEB J, V11, P809, DOI 10.1096/fasebj.11.10.9271366; NICHOLLS DG, 1984, PHYSIOL REV, V64, P1, DOI 10.1152/physrev.1984.64.1.1; Nicholls DG, 1997, BIOSCIENCE REP, V17, P251, DOI 10.1023/A:1027376426860; NICHOLLS DG, 1992, BIOENERGETICS INTRO; Nordfors L, 1998, DIABETOLOGIA, V41, P935, DOI 10.1007/s001250051010; PORTER RK, 1993, NATURE, V362, P628, DOI 10.1038/362628a0; PORTER RK, 1995, AM J PHYSIOL-REG I, V269, pR1213, DOI 10.1152/ajpregu.1995.269.5.R1213; Ricquier D, 1998, BIOCHEM SOC T, V26, P120, DOI 10.1042/bst0260120; RICQUIER D, 1991, FASEB J, V5, P2237, DOI 10.1096/fasebj.5.9.1860614; Rosenbaum M, 1997, NEW ENGL J MED, V337, P396, DOI 10.1056/NEJM199708073370606; SAAD B, 1995, EUR J BIOCHEM, V229, P349, DOI 10.1111/j.1432-1033.1995.0349k.x; Samec S, 1998, FASEB J, V12, P715, DOI 10.1096/fasebj.12.9.715; SCHULZEOSTHOFF K, 1993, EMBO J, V12, P3095, DOI 10.1002/j.1460-2075.1993.tb05978.x; Skulachev VP, 1998, BBA-BIOENERGETICS, V1363, P100, DOI 10.1016/S0005-2728(97)00091-1; Skulachev VP, 1996, Q REV BIOPHYS, V29, P169, DOI 10.1017/S0033583500005795; Surwit RS, 1998, P NATL ACAD SCI USA, V95, P4061, DOI 10.1073/pnas.95.7.4061; VANDENBERGHE G, 1991, J INHERIT METAB DIS, V14, P407, DOI 10.1007/BF01797914; VidalPuig A, 1997, BIOCHEM BIOPH RES CO, V235, P79, DOI 10.1006/bbrc.1997.6740; WALAJTYSRHODE E, 1992, J BIOL CHEM, V267, P370; Walder K, 1998, HUM MOL GENET, V7, P1431, DOI 10.1093/hmg/7.9.1431; WASSERMAN DH, 1991, AM J PHYSIOL, V260, pE811, DOI 10.1152/ajpendo.1991.260.6.E811; YAMAKAWA T, 1995, CLIN IMMUNOL IMMUNOP, V75, P51, DOI 10.1006/clin.1995.1052; Yang SQ, 1997, P NATL ACAD SCI USA, V94, P2557, DOI 10.1073/pnas.94.6.2557	48	366	391	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 26	1999	274	9					5692	5700		10.1074/jbc.274.9.5692	http://dx.doi.org/10.1074/jbc.274.9.5692			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	170KG	10026188	hybrid			2022-12-25	WOS:000078804400059
J	Galbiati, F; Volonte, D; Meani, D; Milligan, G; Lublin, DM; Lisanti, MP; Parenti, M				Galbiati, F; Volonte, D; Meani, D; Milligan, G; Lublin, DM; Lisanti, MP; Parenti, M			The dually acylated NH2-terminal domain of G(i1 alpha) is sufficient to target a green fluorescent protein reporter to caveolin-enriched plasma membrane domains - Palmitoylation of caveolin-1 is required for the recognition of dually acylated G-protein alpha subunits in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-TERMINAL MOTIF; TYROSINE KINASES; FATTY ACYLATION; CARDIAC MYOCYTES; RECEPTOR; ACTIVATION; LOCALIZATION; CELLS; MYRISTOYLATION; PALMITYLATION	Here we investigate the molecular mechanisms that govern the targeting of G-protein cr subunits to the plasma membrane. For this purpose, we used G(i1 alpha), as a model dually acylated G-protein, We fused full-length G(i1 alpha) or its extreme NH2-terminal domain (residues 1-32 or 1-122) to green fluorescent protein (GFP) and analyzed the subcellular localization of these fusion proteins. We show that the first 32 amino acids of G(i1 alpha) are sufficient to target GFP to caveolin-enriched domains of the plasma membrane in vivo, as demonstrated by cofractionation and co-immunoprecipitation with caveolin-1, Interestingly, when dual acylation of this 32-amino acid domain was blocked by specific point mutations (G2A or C3S), the resulting GFP fusion proteins were localized to the cytoplasm and excluded from caveolin-rich regions. The myristoylated but nonpalmitoylated (C3S) chimera only partially partitioned into caveolin-containing fractions. However, both nonacylated GFP fusions (G2A and C3S) no longer co-immunoprecipitated with caveolin-1, Taken together, these results indicate that lipid modification of the NH2-terminal of G(i1 alpha) is essential for targeting to its correct destination and interaction with caveolin-1, Also, a caveolin-1 mutant lacking all three palmitoylation sites (C133S, C143S, and C156S) was unable to co-immunoprecipitate these dually acylated GFP-G-protein fusions, Thus, dual acylation of the NH2-terminal domain of G(i1 alpha) and palmitoylation of caveolin-1 are both required to stabilize and perhaps regulate this reciprocal interaction at the plasma membrane in vivo. Our results provide the first demonstration of a functional role for caveolin-1 palmitoylation in its interaction with signaling molecules.	Univ Milan, Sch Med, Dept Pharmacol, I-20129 Milan, Italy; Yeshiva Univ Albert Einstein Coll Med, Dept Mol Pharmacol, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Albert Einstein Canc Ctr, Bronx, NY 10461 USA; Univ Glasgow, Inst Biomed & Life Sci, Div Mol Biol & Biochem, Mol Pharmacol Grp, Glasgow G12 8QQ, Lanark, Scotland; Washington Univ, Sch Med, Dept Pathol, St Louis, MO 63110 USA	University of Milan; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; University of Glasgow; Washington University (WUSTL)	Parenti, M (corresponding author), Univ Milan, Sch Med, Dept Pharmacol, Via Vanvitelli 32, I-20129 Milan, Italy.	marco.parenti@unimi.it	Lisanti, Michael/B-6131-2018; Lisanti, Michael P/C-6866-2013; Milligan, Graeme/F-9426-2011; Galbiati, Ferruccio/AAF-3527-2020	Lisanti, Michael/0000-0003-2034-1382; Milligan, Graeme/0000-0002-6946-3519; 				ALLAND L, 1994, J BIOL CHEM, V269, P16701; Bijlmakers MJJE, 1997, J CELL BIOL, V137, P1029, DOI 10.1083/jcb.137.5.1029; BONNER WM, 1974, EUR J BIOCHEM, V46, P83, DOI 10.1111/j.1432-1033.1974.tb03599.x; Brown RE, 1998, J CELL SCI, V111, P1; CHANG WJ, 1994, J CELL BIOL, V126, P127, DOI 10.1083/jcb.126.1.127; Couet J, 1997, J BIOL CHEM, V272, P6525, DOI 10.1074/jbc.272.10.6525; DEALMEIDA JB, 1994, J CELL SCI, V107, P507; DEGTYAREV MY, 1993, J BIOL CHEM, V268, P23769; deWeerd WFC, 1997, J BIOL CHEM, V272, P17858, DOI 10.1074/jbc.272.28.17858; DIETZEN DJ, 1995, J BIOL CHEM, V270, P6838, DOI 10.1074/jbc.270.12.6838; Feron O, 1997, J BIOL CHEM, V272, P17744, DOI 10.1074/jbc.272.28.17744; Feron O, 1996, J BIOL CHEM, V271, P22810, DOI 10.1074/jbc.271.37.22810; GALBIATI F, 1994, BIOCHEM J, V303, P697, DOI 10.1042/bj3030697; GRASSIE MA, 1994, BIOCHEM J, V302, P913, DOI 10.1042/bj3020913; Huang CF, 1997, MOL BIOL CELL, V8, P2365, DOI 10.1091/mbc.8.12.2365; KOEGL M, 1994, BIOCHEM J, V303, P749, DOI 10.1042/bj3030749; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; LI SW, 1995, J BIOL CHEM, V270, P15693, DOI 10.1074/jbc.270.26.15693; Li SW, 1996, J BIOL CHEM, V271, P29182, DOI 10.1074/jbc.271.46.29182; MAGEE AI, 1995, METHOD ENZYMOL, V250, P330; Monier S, 1996, FEBS LETT, V388, P143, DOI 10.1016/0014-5793(96)00519-4; Morales J, 1998, MOL BIOL CELL, V9, P1, DOI 10.1091/mbc.9.1.1; MUMBY SM, 1994, P NATL ACAD SCI USA, V91, P2800, DOI 10.1073/pnas.91.7.2800; Okamoto T, 1998, J BIOL CHEM, V273, P5419, DOI 10.1074/jbc.273.10.5419; PARENTI M, 1993, BIOCHEM J, V291, P349, DOI 10.1042/bj2910349; Parolini I, 1996, BLOOD, V87, P3783, DOI 10.1182/blood.V87.9.3783.bloodjournal8793783; RODGERS W, 1994, MOL CELL BIOL, V14, P5384, DOI 10.1128/MCB.14.8.5384; ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z; SARGIACOMO M, 1995, P NATL ACAD SCI USA, V92, P9407, DOI 10.1073/pnas.92.20.9407; SARGIACOMO M, 1993, J CELL BIOL, V122, P789, DOI 10.1083/jcb.122.4.789; SHENOYSCARIA AM, 1993, MOL CELL BIOL, V13, P6385, DOI 10.1128/MCB.13.10.6385; SHENOYSCARIA AM, 1994, J CELL BIOL, V126, P353, DOI 10.1083/jcb.126.2.353; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Song KS, 1996, J BIOL CHEM, V271, P9690, DOI 10.1074/jbc.271.16.9690; Song KS, 1997, CELL MOL BIOL, V43, P293; Stanislaus D, 1997, MOL ENDOCRINOL, V11, P738, DOI 10.1210/me.11.6.738; Tu YP, 1997, SCIENCE, V278, P1132, DOI 10.1126/science.278.5340.1132; WEDEGAERTNER PB, 1994, CELL, V77, P1063, DOI 10.1016/0092-8674(94)90445-6; WILSON PT, 1995, J BIOL CHEM, V270, P9667, DOI 10.1074/jbc.270.16.9667; Wise A, 1997, BIOCHEMISTRY-US, V36, P10620, DOI 10.1021/bi9702997; Wolven A, 1997, MOL BIOL CELL, V8, P1159, DOI 10.1091/mbc.8.6.1159; Zlatkine P, 1997, J CELL SCI, V110, P673	43	95	96	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 26	1999	274	9					5843	5850		10.1074/jbc.274.9.5843	http://dx.doi.org/10.1074/jbc.274.9.5843			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	170KG	10026207	hybrid			2022-12-25	WOS:000078804400078
J	Garcia-Guzman, M; Dolfi, F; Russello, M; Vuori, K				Garcia-Guzman, M; Dolfi, F; Russello, M; Vuori, K			Cell adhesion regulates the interaction between the docking protein p130(Cas) and the 14-3-3 proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE-PHOSPHORYLATION; SERINE PHOSPHORYLATION; SIGNAL-TRANSDUCTION; FOCAL ADHESIONS; SH3 DOMAINS; T-CELLS; V-CRK; SUBSTRATE P130(CAS); DIRECT BINDING; SRC KINASE	Integrin Ligand binding induces a signaling complex formation via the direct association of the docking protein p130(Cas) (Cas) with diverse molecules. We report here that the 14-3-3 zeta protein interacts with Cas in the yeast two-hybrid assay, we also found that the two proteins associate in mammalian cells and that this interaction takes place in a phosphoserine-dependent manner, because treatment of Cas with a serine phosphatase greatly reduced its ability to bind 14-3-3 zeta. Furthermore, the Cas-14-3-3 zeta interaction was found to be regulated by integrin-mediated cell adhesion. Thus, when cells are detached from the extracellular matrix, the binding of Cas to 14-3-3 zeta is greatly diminished, whereas replating the cells onto fibronectin rapidly induces the association. Consistent with these results, we found that the subcellular localization of Cas and 14-3-3 is also regulated by integrin ligand binding and that the two proteins display a significant co-localization during cell attachment to the extracellular matrix. In conclusion, our results demonstrate that 14-3-3 proteins participate in integrin-activated signaling pathways through their interaction with Gas, which, in turn, may contribute to important biological responses regulated by cell adhesion to the extracellular matrix.	Burnham Inst, La Jolla Canc Res Ctr, La Jolla, CA 92037 USA	Sanford Burnham Prebys Medical Discovery Institute	Vuori, K (corresponding author), Burnham Inst, La Jolla Canc Res Ctr, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.	kvuori@ljcrf.edu			NATIONAL CANCER INSTITUTE [R01CA071560] Funding Source: NIH RePORTER; NCI NIH HHS [CA71560] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aitken A, 1996, TRENDS CELL BIOL, V6, P341, DOI 10.1016/0962-8924(96)10029-5; Alexandropoulos K, 1996, GENE DEV, V10, P1341, DOI 10.1101/gad.10.11.1341; Altun-Gultekin ZF, 1998, MOL CELL BIOL, V18, P3044, DOI 10.1128/MCB.18.5.3044; Astier A, 1997, J BIOL CHEM, V272, P19719, DOI 10.1074/jbc.272.32.19719; AUVINEN M, 1995, MOL CELL BIOL, V15, P6513; BELLIS SL, 1995, J BIOL CHEM, V270, P17437, DOI 10.1074/jbc.270.29.17437; BONNEFOYBERARD N, 1995, P NATL ACAD SCI USA, V92, P10142, DOI 10.1073/pnas.92.22.10142; BURBELO PD, 1995, CURR BIOL, V5, P95, DOI 10.1016/S0960-9822(95)00022-4; Burnham MR, 1996, ONCOGENE, V12, P2467; Cary LA, 1998, J CELL BIOL, V140, P211, DOI 10.1083/jcb.140.1.211; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; CONKLIN DS, 1995, P NATL ACAD SCI USA, V92, P7892, DOI 10.1073/pnas.92.17.7892; DeNichilo MO, 1996, J BIOL CHEM, V271, P11016, DOI 10.1074/jbc.271.18.11016; Dolfi F, 1998, P NATL ACAD SCI USA, V95, P15394, DOI 10.1073/pnas.95.26.15394; ESTOJAK J, 1995, MOL CELL BIOL, V15, P5820; FANTL WJ, 1994, NATURE, V371, P612, DOI 10.1038/371612a0; Felsenfeld DP, 1996, NATURE, V383, P438, DOI 10.1038/383438a0; FREED E, 1994, SCIENCE, V265, P1713, DOI 10.1126/science.8085158; FU H, 1994, SCIENCE, V266, P126, DOI 10.1126/science.7939632; Garton AJ, 1997, ONCOGENE, V15, P877, DOI 10.1038/sj.onc.1201279; Golemis EA, 1997, YEAST 2 HYBRID SYSTE, P43; Hamasaki K, 1996, BIOCHEM BIOPH RES CO, V222, P338, DOI 10.1006/bbrc.1996.0745; Harte MT, 1996, J BIOL CHEM, V271, P13649, DOI 10.1074/jbc.271.23.13649; HOLLENBERG SM, 1995, MOL CELL BIOL, V15, P3813; Honda H, 1998, NAT GENET, V19, P361, DOI 10.1038/1246; IRIE K, 1994, SCIENCE, V265, P1716, DOI 10.1126/science.8085159; Ishino M, 1995, ONCOGENE, V11, P2331; Jockusch BM, 1995, ANNU REV CELL DEV BI, V11, P379, DOI 10.1146/annurev.cellbio.11.1.379; KANNER SB, 1991, EMBO J, V10, P1689, DOI 10.1002/j.1460-2075.1991.tb07693.x; Klemke RL, 1998, J CELL BIOL, V140, P961, DOI 10.1083/jcb.140.4.961; Ku NO, 1998, EMBO J, V17, P1892, DOI 10.1093/emboj/17.7.1892; Law SF, 1996, MOL CELL BIOL, V16, P3327; LIU D, 1995, NATURE, V376, P191, DOI 10.1038/376191a0; Liu F, 1996, J BIOL CHEM, V271, P31290, DOI 10.1074/jbc.271.49.31290; Liu YC, 1996, J BIOL CHEM, V271, P14591, DOI 10.1074/jbc.271.24.14591; Liu YC, 1997, J BIOL CHEM, V272, P9979, DOI 10.1074/jbc.272.15.9979; MATSUDA M, 1990, SCIENCE, V248, P1537, DOI 10.1126/science.1694307; MAYER BJ, 1995, CURR BIOL, V5, P296, DOI 10.1016/S0960-9822(95)00060-1; MAYER BJ, 1990, J VIROL, V64, P3581, DOI 10.1128/JVI.64.8.3581-3589.1990; Minegishi M, 1996, J EXP MED, V184, P1365, DOI 10.1084/jem.184.4.1365; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; Nakamoto T, 1997, MOL CELL BIOL, V17, P3884, DOI 10.1128/MCB.17.7.3884; Nakamoto T, 1996, J BIOL CHEM, V271, P8959, DOI 10.1074/jbc.271.15.8959; Nojima Y, 1996, Hum Cell, V9, P169; NOJIMA Y, 1995, J BIOL CHEM, V270, P15398, DOI 10.1074/jbc.270.25.15398; OGAWA S, 1994, ONCOGENE, V9, P1669; PATCH LA, 1995, J CELL SCI, V108, P1371; POLTE TR, 1995, P NATL ACAD SCI USA, V92, P10678, DOI 10.1073/pnas.92.23.10678; Richardson A, 1997, BIOCHEM J, V324, P141, DOI 10.1042/bj3240141; Sakai R, 1997, ONCOGENE, V14, P1419, DOI 10.1038/sj.onc.1200954; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; Schlaepfer DD, 1997, MOL CELL BIOL, V17, P1702, DOI 10.1128/MCB.17.3.1702; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; SINGER II, 1982, J CELL BIOL, V92, P398, DOI 10.1083/jcb.92.2.398; THERIOT JA, 1991, NATURE, V352, P126, DOI 10.1038/352126a0; VOJTEK AB, 1997, YEAST 2 HYBRID SYSTE, P29; Vuori K, 1996, MOL CELL BIOL, V16, P2606; VUORI K, 1995, J BIOL CHEM, V270, P22259, DOI 10.1074/jbc.270.38.22259; Wang HN, 1998, J BIOL CHEM, V273, P16297, DOI 10.1074/jbc.273.26.16297; Waterman MJF, 1998, NAT GENET, V19, P175, DOI 10.1038/542; Yaffe MB, 1997, CELL, V91, P961, DOI 10.1016/S0092-8674(00)80487-0; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zhang LX, 1997, J BIOL CHEM, V272, P13717, DOI 10.1074/jbc.272.21.13717	63	63	64	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 26	1999	274	9					5762	5768		10.1074/jbc.274.9.5762	http://dx.doi.org/10.1074/jbc.274.9.5762			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	170KG	10026197	hybrid			2022-12-25	WOS:000078804400068
J	Grant, PA; Eberharter, A; John, S; Cook, RG; Turner, BM; Workman, JL				Grant, PA; Eberharter, A; John, S; Cook, RG; Turner, BM; Workman, JL			Expanded lysine acetylation specificity of Gcn5 in native complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INACTIVE X-CHROMOSOME; HISTONE ACETYLATION; CHROMATIN STRUCTURE; YEAST; TRANSCRIPTION; H4; H3; REPRESSION; IDENTIFICATION; PROTEINS	The coactivator/adaptor protein Gcn5 is a conserved histone acetyltransferase, which functions as the catalytic subunit in multiple yeast transcriptional regulatory complexes. The ability of Gcn5 to acetylate nucleosomal histones is significantly reduced relative to its activity on free histones, where it predominantly modifies histone H3 at lysine 14. However, the association of Gcn5 in multisubunit complexes potentiates its nucleosomal histone acetyltransferase activity. Here, we show that the association of Gcn5 with other proteins in two native yeast complexes, Ada and SAGA (Spt-Ada-Gcn5-acetyltransferase), directly confers upon Gcn5 the ability to acetylate an expanded set of lysines on H3. Furthermore Ada and SAGA have overlapping, yet distinct, patterns of acetylation, suggesting that the association of specific subunits determines site specificity.	Penn State Univ, Howard Hughes Med Inst, Dept Biochem & Mol Biol, University Pk, PA 16802 USA; Baylor Coll Med, Dept Microbiol & Immunol, Houston, TX 77030 USA; Univ Birmingham, Sch Med, Dept Anat, Chromatin & Gene Express Grp, Birmingham B15 2TT, W Midlands, England	Howard Hughes Medical Institute; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Baylor College of Medicine; University of Birmingham	Workman, JL (corresponding author), Penn State Univ, Howard Hughes Med Inst, Dept Biochem & Mol Biol, University Pk, PA 16802 USA.	jlw10@psu.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM047867, R01GM047867] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM47867] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Belyaev ND, 1996, HUM GENET, V97, P573; BRADBURY EM, 1992, BIOESSAYS, V14, P9; Brandl CJ, 1996, J BIOL CHEM, V271, P9298, DOI 10.1074/jbc.271.16.9298; BRAUNSTEIN M, 1993, GENE DEV, V7, P592, DOI 10.1101/gad.7.4.592; Candau R, 1996, MOL CELL BIOL, V16, P593; Edmondson DG, 1996, GENE DEV, V10, P1247, DOI 10.1101/gad.10.10.1247; Fletcher TM, 1996, CRIT REV EUKAR GENE, V6, P149, DOI 10.1615/CritRevEukarGeneExpr.v6.i2-3.40; GEORGAKOPOULOS T, 1992, EMBO J, V11, P4145, DOI 10.1002/j.1460-2075.1992.tb05507.x; Grant PA, 1997, GENE DEV, V11, P1640, DOI 10.1101/gad.11.13.1640; Grant PA, 1998, TRENDS CELL BIOL, V8, P193, DOI 10.1016/S0962-8924(98)01263-X; Grant PA, 1998, CELL, V94, P45, DOI 10.1016/S0092-8674(00)81220-9; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; HEBBES TR, 1994, EMBO J, V13, P1823, DOI 10.1002/j.1460-2075.1994.tb06451.x; HECHT A, 1995, CELL, V80, P583, DOI 10.1016/0092-8674(95)90512-X; Hendzel MJ, 1998, MOL BIOL CELL, V9, P2491, DOI 10.1091/mbc.9.9.2491; JEPPESEN P, 1993, CELL, V74, P281, DOI 10.1016/0092-8674(93)90419-Q; Johnson CA, 1998, NUCLEIC ACIDS RES, V26, P994, DOI 10.1093/nar/26.4.994; Kuo MH, 1998, GENE DEV, V12, P627, DOI 10.1101/gad.12.5.627; Kuo MH, 1996, NATURE, V383, P269, DOI 10.1038/383269a0; Martens JA, 1996, J BIOL CHEM, V271, P15884, DOI 10.1074/jbc.271.27.15884; MULLEN JR, 1989, EMBO J, V8, P2067, DOI 10.1002/j.1460-2075.1989.tb03615.x; ONEILL LP, 1995, EMBO J, V14, P3946, DOI 10.1002/j.1460-2075.1995.tb00066.x; Orphanides G, 1998, CELL, V92, P105, DOI 10.1016/S0092-8674(00)80903-4; Owen-Hughes Thomas, 1994, Critical Reviews in Eukaryotic Gene Expression, V4, P403; PARANJAPE SM, 1994, ANNU REV BIOCHEM, V63, P265, DOI 10.1146/annurev.biochem.63.1.265; PETERSON CL, 1994, P NATL ACAD SCI USA, V91, P2905, DOI 10.1073/pnas.91.8.2905; Pollard KJ, 1997, MOL CELL BIOL, V17, P6212, DOI 10.1128/MCB.17.11.6212; Roth SY, 1996, CELL, V87, P5, DOI 10.1016/S0092-8674(00)81316-1; RuizGarcia AB, 1997, FEBS LETT, V403, P186, DOI 10.1016/S0014-5793(97)00049-5; Rundlett SE, 1998, NATURE, V392, P831, DOI 10.1038/33952; Saleh A, 1997, J BIOL CHEM, V272, P5571, DOI 10.1074/jbc.272.9.5571; SOBEL RE, 1994, J BIOL CHEM, V269, P18576; Steger DJ, 1998, P NATL ACAD SCI USA, V95, P12924, DOI 10.1073/pnas.95.22.12924; Stein P, 1997, MOL REPROD DEV, V47, P421, DOI 10.1002/(SICI)1098-2795(199708)47:4&lt;421::AID-MRD8&gt;3.0.CO;2-M; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; Syntichaki P, 1998, J BIOL CHEM, V273, P24414, DOI 10.1074/jbc.273.38.24414; THOMPSON JS, 1994, NATURE, V369, P245, DOI 10.1038/369245a0; Tse C, 1998, J BIOL CHEM, V273, P32388, DOI 10.1074/jbc.273.49.32388; TURNER BM, 1992, CELL, V69, P375, DOI 10.1016/0092-8674(92)90417-B; Turner BM, 1998, CELL MOL LIFE SCI, V54, P21, DOI 10.1007/s000180050122; TURNER BM, 1995, SEMIN CELL BIOL, V6, P229, DOI 10.1006/scel.1995.0031; Utley RT, 1998, NATURE, V394, P498, DOI 10.1038/28886; VetteseDadey M, 1996, EMBO J, V15, P2508, DOI 10.1002/j.1460-2075.1996.tb00608.x; Wade PA, 1997, TRENDS BIOCHEM SCI, V22, P128, DOI 10.1016/S0968-0004(97)01016-5; Wang L, 1998, GENE DEV, V12, P640, DOI 10.1101/gad.12.5.640; Welihinda AA, 1997, P NATL ACAD SCI USA, V94, P4289, DOI 10.1073/pnas.94.9.4289; Workman JL, 1998, ANNU REV BIOCHEM, V67, P545, DOI 10.1146/annurev.biochem.67.1.545; Zhang WZ, 1998, EMBO J, V17, P3155, DOI 10.1093/emboj/17.11.3155	48	285	304	4	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 26	1999	274	9					5895	5900		10.1074/jbc.274.9.5895	http://dx.doi.org/10.1074/jbc.274.9.5895			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	170KG	10026213	hybrid			2022-12-25	WOS:000078804400084
J	Kuzuguchi, T; Morita, Y; Sagami, I; Sagami, H; Ogura, K				Kuzuguchi, T; Morita, Y; Sagami, I; Sagami, H; Ogura, K			Human geranylgeranyl diphosphate synthase - cDNA cloning and expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FARNESYL PYROPHOSPHATE SYNTHETASE; NUCLEAR RECEPTOR; ALPHA-SUBUNIT; PROTEINS; PURIFICATION; CELLS; CHROMATOGRAPHY; IDENTIFICATION; TRANSFERASE; STIMULATION	Geranylgeranyl diphosphate (GGPP) synthase (GGPPSase) catalyzes the synthesis of GGPP, which is an important molecule responsible for the C-20-prenylated protein biosynthesis and for the regulation of a nuclear hormone receptor (LXR.RXR). The human GGPPSase cDNA encodes a protein of 300 amino acids which shows 16%, sequence identity with the known human farnesyl diphosphate (FPP) synthase (FPPSase). The GGPPSase expressed in Escherichia coli catalyzes the GGPP formation (240 nmol/min/mg) from FPP and isopentenyl diphosphate. The human GGPPSase behaves as an oligomeric molecule with 280 kDa on a gel filtration column and cross-reacts with an antibody directed against bovine brain GGPPSase, which differs immunochemically from bovine brain FPPSase. Northern blot analysis indicates the presence of two forms of the mRNA.	Tohoku Univ, Inst Chem React Sci, Aoba Ku, Sendai, Miyagi 9808577, Japan	Tohoku University	Sagami, H (corresponding author), Tohoku Univ, Inst Chem React Sci, Aoba Ku, 2-1-1 Katahira, Sendai, Miyagi 9808577, Japan.	yasagami@icrs.tohoku.ac.jp	fujimura, yuiko/M-7393-2013; Morita-fujimura, Yuiko/N-4804-2014					ANDRES DA, 1993, CELL, V73, P1091, DOI 10.1016/0092-8674(93)90639-8; ARMSTRONG SA, 1993, J BIOL CHEM, V268, P12221; BARTLETT DL, 1985, METHOD ENZYMOL, V110, P171; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; CHEN AJ, 1994, PROTEIN SCI, V3, P600; CHEN WJ, 1991, P NATL ACAD SCI USA, V88, P11368, DOI 10.1073/pnas.88.24.11368; CLARKE CF, 1987, MOL CELL BIOL, V7, P3138, DOI 10.1128/MCB.7.9.3138; CLARKE S, 1992, ANNU REV BIOCHEM, V61, P355, DOI 10.1146/annurev.bi.61.070192.002035; DAVISSON VJ, 1985, METHOD ENZYMOL, V110, P130; DING VDH, 1991, BIOCHEM J, V275, P61, DOI 10.1042/bj2750061; EPSTEIN WW, 1991, P NATL ACAD SCI USA, V88, P9668, DOI 10.1073/pnas.88.21.9668; FARNSWORTH CC, 1990, SCIENCE, V247, P320, DOI 10.1126/science.2296721; Forman BM, 1997, P NATL ACAD SCI USA, V94, P10588, DOI 10.1073/pnas.94.20.10588; FORMAN BM, 1995, CELL, V81, P687, DOI 10.1016/0092-8674(95)90530-8; FUJII H, 1982, BIOCHIM BIOPHYS ACTA, V712, P716; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; Guan GM, 1998, J BIOL CHEM, V273, P12526, DOI 10.1074/jbc.273.20.12526; HORIUCHI H, 1992, MOL CELL BIOL, V12, P4515, DOI 10.1128/MCB.12.10.4515; ITOH T, 1993, J BIOL CHEM, V268, P3025; KURODA Y, 1993, SCIENCE, V259, P683, DOI 10.1126/science.8430318; LUTZ RJ, 1992, J BIOL CHEM, V267, P7983; MALTESE WA, 1990, FASEB J, V4, P3319, DOI 10.1096/fasebj.4.15.2123808; REED BC, 1975, BIOCHEMISTRY-US, V14, P50, DOI 10.1021/bi00672a009; RILLING HC, 1990, SCIENCE, V247, P318, DOI 10.1126/science.2296720; RINE J, 1990, New Biologist, V2, P219; SAGAMI H, 1993, J BIOCHEM-TOKYO, V114, P118, DOI 10.1093/oxfordjournals.jbchem.a124125; SAGAMI H, 1992, ARCH BIOCHEM BIOPHYS, V297, P314, DOI 10.1016/0003-9861(92)90678-P; SAGAMI H, 1994, J BIOL CHEM, V269, P20561; SAGAMI H, 1992, J LIPID RES, V33, P1857; SAGAMI H, 1981, BIOCHEM INT, V3, P669; SCHMIDT RA, 1984, J BIOL CHEM, V259, P175; SEPPLORENZINO L, 1991, EUR J BIOCHEM, V200, P579, DOI 10.1111/j.1432-1033.1991.tb16221.x; SHEARES BT, 1989, BIOCHEMISTRY-US, V28, P8129, DOI 10.1021/bi00446a025; STIMMEL JB, 1990, BIOCHEMISTRY-US, V29, P9651, DOI 10.1021/bi00493a021; TAKAI Y, 1992, INT REV CYTOL, V133, P187, DOI 10.1016/S0074-7696(08)61861-6; WILKIN DJ, 1990, J BIOL CHEM, V265, P4607	36	46	49	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 26	1999	274	9					5888	5894		10.1074/jbc.274.9.5888	http://dx.doi.org/10.1074/jbc.274.9.5888			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	170KG	10026212	hybrid			2022-12-25	WOS:000078804400083
J	Munaut, C; Salonurmi, T; Kontusaari, S; Reponen, P; Morita, T; Foidart, JM; Tryggvason, K				Munaut, C; Salonurmi, T; Kontusaari, S; Reponen, P; Morita, T; Foidart, JM; Tryggvason, K			Murine matrix metalloproteinase 9 gene - 5 '-upstream region contains cis-acting elements for expression in osteoclasts and migrating keratinocytes in transgenic mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IV COLLAGENASE GENE; BASEMENT-MEMBRANE COLLAGEN; HUMAN COLON-CANCER; MESSENGER-RNA; MOUSE DEVELOPMENT; GELATINASE-B; TUMOR-CELLS; ALVEOLAR MACROPHAGES; MOLECULAR-CLONING; EPITHELIAL-CELLS	Knowledge about the regulation of cell lineage-specific expression of extracellular matrix metalloproteinases is limited. In the present work, the murine matrix metalloproteinase 9 (MMP-9) gene was shown to contain 13 exons, and the 2.8-kilobase pair upstream region was found to contain several common promoter elements including a TATA boxlike motif, three GC boxes, four AP-1-like binding sites, an AP-2 site, and three PEA3 consensus sequences that may be important for basic activity of the gene. In order to identify cell-specific regulatory elements, constructs containing varying lengths of the upstream region in front of a LacZ reporter gene were made and studied for expression in transgenic mice generated by microinjection into fertilized oocytes. Analyses of the mice revealed that the presence of sequences between -2722 and -7745 allowed for expression in osteoclasts and migrating keratinocytes, ie. cells that have been shown to normally express the enzyme in vivo. The results represent the first in vivo demonstration of the location of cell-specific control elements in a matrix metalloproteinase gene and show that element(s) regulating most cell-specific activities of 92-kDa type collagenase are located in the -2722 to -7745 base pair region.	Karolinska Inst, Dept Med Biochem & Biophys, Div Matrix Biol, S-17177 Stockholm, Sweden; Univ Liege, Dept Biol, B-4000 Liege, Belgium; Univ Oulu, Bioctr, FIN-90570 Oulu, Finland; Univ Oulu, Dept Biochem, FIN-90570 Oulu, Finland	Karolinska Institutet; University of Liege; University of Oulu; Finland National Institute for Health & Welfare; University of Oulu	Tryggvason, K (corresponding author), Karolinska Inst, Dept Med Biochem & Biophys, Div Matrix Biol, S-17177 Stockholm, Sweden.	karl.tryggvason@mbh.ki.se	Salonurmi, Tuire/L-3637-2018; Munaut, Carine/K-8138-2019	Salonurmi, Tuire/0000-0001-5104-5792; 				BANCROFT JD, 1990, THEORY PRATICE HISTO; BASSET P, 1990, NATURE, V348, P699, DOI 10.1038/348699a0; BEHRENDTSEN O, 1992, DEVELOPMENT, V114, P447; BEHRINGER RR, 1993, DEVELOPMENT, V117, P823; BIRKEDALHANSEN H, 1993, CRIT REV ORAL BIOL M, V4, P197, DOI 10.1177/10454411930040020401; BREATHNACH R, 1987, NUCLEIC ACIDS RES, V15, P1139, DOI 10.1093/nar/15.3.1139; CHARMICHAEL DF, 1986, P NATL ACAD SCI USA, V83, P2407; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLLIER IE, 1988, J BIOL CHEM, V263, P6579; DREWS R, 1994, BIOTECHNIQUES, V17, P866; FINI ME, 1994, J BIOL CHEM, V269, P28620; GOLDBERG GI, 1986, J BIOL CHEM, V261, P6600; GOLDBERG GI, 1989, P NATL ACAD SCI USA, V86, P8207, DOI 10.1073/pnas.86.21.8207; Gum R, 1996, J BIOL CHEM, V271, P10672, DOI 10.1074/jbc.271.18.10672; Gum R, 1997, ONCOGENE, V14, P1481, DOI 10.1038/sj.onc.1200973; GUTMAN A, 1990, EMBO J, V9, P2241, DOI 10.1002/j.1460-2075.1990.tb07394.x; HANLEY T, 1991, BIOTECHNIQUES, V10, P56; HASTY KA, 1990, J BIOL CHEM, V265, P11421; HIBBS MS, 1985, J BIOL CHEM, V260, P2493; Himelstein BP, 1997, ONCOGENE, V14, P1995, DOI 10.1038/sj.onc.1201012; Hogan B, 1986, MANIPULATING MOUSE E, P1; HUHTALA P, 1990, GENOMICS, V6, P554, DOI 10.1016/0888-7543(90)90486-E; HUHTALA P, 1991, J BIOL CHEM, V266, P16485; Iivanainen A, 1997, J BIOL CHEM, V272, P27862, DOI 10.1074/jbc.272.44.27862; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; MAINARDI CL, 1984, COLLAGEN REL RES, V4, P479; MASURE S, 1993, EUR J BIOCHEM, V218, P129, DOI 10.1111/j.1432-1033.1993.tb18359.x; MATRISIAN LM, 1985, EMBO J, V4, P1435, DOI 10.1002/j.1460-2075.1985.tb03799.x; METSARANTA M, 1995, DEV DYNAM, V204, P202, DOI 10.1002/aja.1002040211; MUNAUT C, 1994, ANN NY ACAD SCI, V732, P369, DOI 10.1111/j.1749-6632.1994.tb24756.x; Nielsen BS, 1996, INT J CANCER, V65, P57, DOI 10.1002/(SICI)1097-0215(19960103)65:1<57::AID-IJC10>3.0.CO;2-F; POULSOM R, 1992, AM J PATHOL, V141, P389; PYKE C, 1993, AM J PATHOL, V142, P359; PYKE C, 1992, CANCER RES, V52, P1336; REPONEN P, 1994, J CELL BIOL, V124, P1091, DOI 10.1083/jcb.124.6.1091; REPONEN P, 1992, J BIOL CHEM, V267, P7856; REPONEN P, 1995, DEV DYNAM, V202, P388, DOI 10.1002/aja.1002020408; ROSSI P, 1987, P NATL ACAD SCI USA, V84, P5590, DOI 10.1073/pnas.84.16.5590; SALO T, 1994, LAB INVEST, V70, P176; SALO T, 1983, J BIOL CHEM, V258, P3058; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SATO H, 1993, J BIOL CHEM, V268, P23460; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; SATO H, 1993, ONCOGENE, V8, P395; SHAPIRO SD, 1992, J BIOL CHEM, V267, P4664; SHAPIRO SD, 1993, J BIOL CHEM, V268, P23824; STASKUS PW, 1991, J BIOL CHEM, V266, P449; STETLERSTEVENSON WG, 1989, J BIOL CHEM, V264, P17374; TAKINO T, 1995, J BIOL CHEM, V270, P23013, DOI 10.1074/jbc.270.39.23013; TRYGGVASON K, 1993, BREAST CANCER RES TR, V24, P209, DOI 10.1007/BF01833261; WHITHAM SE, 1986, BIOCHEM J, V240, P913, DOI 10.1042/bj2400913; WILHELM SM, 1989, J BIOL CHEM, V264, P17213; Wilkinson D. G., 1990, POSTIMPLANTATION MAM, P155; WILL H, 1995, EUR J BIOCHEM, V231, P602, DOI 10.1111/j.1432-1033.1995.0602d.x; WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705; YOKOO T, 1996, J PHYSL, V270, pF123	56	52	53	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 26	1999	274	9					5588	5596		10.1074/jbc.274.9.5588	http://dx.doi.org/10.1074/jbc.274.9.5588			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	170KG	10026175	Green Published, hybrid			2022-12-25	WOS:000078804400046
J	Nishitani, J; Nishinaka, T; Cheng, CH; Rong, W; Yokoyama, KK; Chiu, R				Nishitani, J; Nishinaka, T; Cheng, CH; Rong, W; Yokoyama, KK; Chiu, R			Recruitment of the retinoblastoma protein to c-jun enhances transcription activity mediated through the AP-1 binding site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENOVIRUS E1A PROTEINS; GENE-PRODUCT; SUSCEPTIBILITY GENE; SP1-MEDIATED TRANSCRIPTION; NEGATIVE REGULATOR; CELLULAR PROTEINS; FOS; EXPRESSION; CELLS; DIFFERENTIATION	The retinoblastoma susceptibility gene product (RB) is a transcriptional modulator. One of the targets for this modulator effect is the AP-1 binding site within the c-jun and collagenase promoters. The physical interactions between RE and c-Jun were demonstrated by coimmunoprecipitation of these two proteins using anti-c-Jun or anti-RE antisera, glutathione S-transferase affinity matrix binding assays in vitro, and electrophoretic mobility shift assays. The C-terminal site of the leucine zipper of c-Jun mediated the interaction with RB. Although the B-pocket domain of RE alone bound to c-Jun, a second c-Jun binding site in the RE was also suggested. Mammalian two-hybrid-based assay provided corroborative evidence that transactivation of gene expression by RE required the C-terminal region of c-Jun. me conclude that RE enhances transcription activity mediated through the AP-1 binding site. Adenovirus E1A or human papillomavirus E7 inhibits RE-mediated transcription activity. These data reveal that the interactions between these two distinct classes of oncoproteins RE and c-Jun may be involved in controlling cell growth and differentiation mediated by transcriptional regulation.	Univ Calif Los Angeles, Sch Dent, Dent Res Inst, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90095 USA; RIKEN, Tsukuba Life Sci Ctr, Ibaraki, Osaka 305, Japan	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; RIKEN	Chiu, R (corresponding author), Univ Calif Los Angeles, Sch Dent, Dent Res Inst, Box 951668, Los Angeles, CA 90095 USA.				NCI NIH HHS [CA 66746] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA066746] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; ARANY Z, 1994, CELL, V77, P799, DOI 10.1016/0092-8674(94)90127-9; BAGCHI S, 1990, CELL, V62, P659, DOI 10.1016/0092-8674(90)90112-R; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHEN LI, 1994, MOL CELL BIOL, V14, P4380, DOI 10.1128/MCB.14.7.4380; Chen PL, 1996, P NATL ACAD SCI USA, V93, P465, DOI 10.1073/pnas.93.1.465; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; Chen PL, 1996, GENE DEV, V10, P2794, DOI 10.1101/gad.10.21.2794; CHESTERS PM, 1990, J GEN VIROL, V71, P449, DOI 10.1099/0022-1317-71-2-449; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; Chow KNB, 1996, MOL CELL BIOL, V16, P4862; COHEN DR, 1989, GENE DEV, V3, P173, DOI 10.1101/gad.3.2.173; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DYSON N, 1992, J VIROL, V66, P6893, DOI 10.1128/JVI.66.12.6893-6902.1992; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; EDMONDS C, 1989, J VIROL, V63, P2650, DOI 10.1128/JVI.63.6.2650-2656.1989; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; HENSEL CH, 1990, CANCER RES, V50, P3067; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; KIM SJ, 1992, MOL CELL BIOL, V12, P2455, DOI 10.1128/MCB.12.6.2455; KIM SJ, 1992, NATURE, V358, P331, DOI 10.1038/358331a0; KITABAYASHI I, 1995, EMBO J, V14, P3496, DOI 10.1002/j.1460-2075.1995.tb07356.x; Lee JS, 1996, MOL CELL BIOL, V16, P4312; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; MAKI Y, 1987, P NATL ACAD SCI USA, V84, P2847; Nead MA, 1998, EMBO J, V17, P2342, DOI 10.1093/emboj/17.8.2342; Nishinaka T, 1997, BBA-GENE STRUCT EXPR, V1351, P274, DOI 10.1016/S0167-4781(96)00210-2; OFFRINGA R, 1990, CELL, V62, P527, DOI 10.1016/0092-8674(90)90017-9; PHELPS WC, 1988, CELL, V53, P539, DOI 10.1016/0092-8674(88)90570-3; PIETENPOL JA, 1991, P NATL ACAD SCI USA, V88, P10227, DOI 10.1073/pnas.88.22.10227; RAUSCHER FJ, 1988, GENE DEV, V2, P1687, DOI 10.1101/gad.2.12b.1687; ROBBINS PD, 1990, NATURE, V346, P668, DOI 10.1038/346668a0; SCHUTTE J, 1989, P NATL ACAD SCI USA, V86, P2257, DOI 10.1073/pnas.86.7.2257; Sellers WR, 1996, BBA-REV CANCER, V1288, pM1, DOI 10.1016/0304-419X(96)00014-5; SMEAL T, 1989, GENE DEV, V3, P2091, DOI 10.1101/gad.3.12b.2091; WANG CY, 1993, SCIENCE, V260, P1330, DOI 10.1126/science.8493578; Welter JF, 1995, ONCOGENE, V11, P2681; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; YANG-YEN H-F, 1990, New Biologist, V2, P351; YASUMOTO S, 1986, J VIROL, V57, P572, DOI 10.1128/JVI.57.2.572-577.1986; ZERIAL M, 1989, EMBO J, V8, P805, DOI 10.1002/j.1460-2075.1989.tb03441.x	46	37	37	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 26	1999	274	9					5454	5461		10.1074/jbc.274.9.5454	http://dx.doi.org/10.1074/jbc.274.9.5454			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	170KG	10026157	hybrid			2022-12-25	WOS:000078804400028
J	Trinh, KY; Jin, TR; Drucker, DJ				Trinh, KY; Jin, TR; Drucker, DJ			Identification of domains mediating transcriptional activation and cytoplasmic export in the caudal homeobox protein Cdx-3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGLUCAGON GENE-TRANSCRIPTION; HOMEODOMAIN PROTEIN; EPITHELIAL-CELLS; ISLET CELLS; EXPRESSION; INTESTINE; PROMOTER; EXTRADENTICLE; TRANSLOCATION; DOPAMINE	The caudal genes have important functions in embryonic development and cell differentiation. The caudal-related protein Cdx-2/3 (the protein designated Cdx-2 in the mouse and Cdx-3 in the hamster) is expressed in the gastrointestinal epithelium and in islet and enteroendocrine cells, where it activates proglucagon gene transcription. We show here that Cdx-3 sequences aminoterminal to the homeodomain (amino acids 1-180) function as a heterologous transcriptional activation domain when fused to the LexA. DNA binding domain, A Cdx-3-Pit-1 fusion protein containing only the first 83 amino acids of Cdx-3 linked to the POU domain of Pit-1 markedly stimulated the transcriptional activity of a Pit-1-responsive promoter. Analysis of the transcriptional properties of Cdx-3 mutants in fibroblasts and islet cells revealed distinct amino-terminal subdomains that function in a cell-specific manner. Point mutations within the amino-terminal A domain were associated with reduced transcriptional activity. Furthermore, internal deletions and selected point mutations within domain A, but not the B or C domains, resulted in accumulation of mutant Cdx-3 in the cytoplasm, Unexpectedly, mutation of an Asp-Lys-Asp motif within domain A identified a putative cytoplasmic membrane-associated export signal that mediates Cdx-3 compartmentalization, These experiments delineate unique activities for specific amino-terminal sequences that are functionally important for Cdx-3 biological activity.	Univ Toronto, Toronto Hosp, Dept Med, Banting & Best Diabet Ctr, Toronto, ON M5G 2C4, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto	Drucker, DJ (corresponding author), Univ Toronto, Toronto Hosp, Dept Med, Banting & Best Diabet Ctr, 200 Elizabeth St,CCRW3-838, Toronto, ON M5G 2C4, Canada.		Drucker, Daniel J/A-4092-2010					BONNER CA, 1995, GENOMICS, V28, P206, DOI 10.1006/geno.1995.1132; Chawengsaksophak K, 1997, NATURE, V386, P84, DOI 10.1038/386084a0; Chen XN, 1997, NUCLEIC ACIDS RES, V25, P682, DOI 10.1093/nar/25.3.682; Doll U, 1996, EUR J CELL BIOL, V70, P260; DRUCKER DJ, 1988, ENDOCRINOLOGY, V123, P1861, DOI 10.1210/endo-123-4-1861; Drummond F, 1996, EUR J BIOCHEM, V236, P670, DOI 10.1111/j.1432-1033.1996.t01-1-00670.x; DUPREY P, 1988, GENE DEV, V2, P1647, DOI 10.1101/gad.2.12a.1647; ELSHOLTZ HP, 1991, J BIOL CHEM, V266, P22919; GAMER LW, 1993, MECH DEVELOP, V43, P71, DOI 10.1016/0925-4773(93)90024-R; GERMAN MS, 1992, GENE DEV, V6, P2165, DOI 10.1101/gad.6.11.2165; Gorlich D, 1996, SCIENCE, V271, P1513, DOI 10.1126/science.271.5255.1513; HORN JM, 1995, HUM MOL GENET, V4, P1041, DOI 10.1093/hmg/4.6.1041; HU YL, 1993, J BIOL CHEM, V268, P27214; Jin TR, 1996, MOL CELL BIOL, V16, P19; Jin TR, 1997, MOL ENDOCRINOL, V11, P203, DOI 10.1210/me.11.2.203; Joliot A, 1997, DEVELOPMENT, V124, P1865; JOLY JS, 1992, DIFFERENTIATION, V50, P75, DOI 10.1111/j.1432-0436.1992.tb00488.x; KAUFMANN SH, 1983, J BIOL CHEM, V258, P2710; Kim PS, 1998, ENDOCR REV, V19, P173, DOI 10.1210/er.19.2.173; Lambert M, 1996, EUR J BIOCHEM, V236, P778, DOI 10.1111/j.1432-1033.1996.00778.x; Laser B, 1996, J BIOL CHEM, V271, P28984, DOI 10.1074/jbc.271.46.28984; Lee SY, 1996, J BIOL CHEM, V271, P707, DOI 10.1074/jbc.271.2.707; LEW AM, 1995, J BIOL CHEM, V270, P7156, DOI 10.1074/jbc.270.13.7156; Lorentz O, 1997, J CELL BIOL, V139, P1553, DOI 10.1083/jcb.139.6.1553; MACDONALD PM, 1986, NATURE, V324, P537, DOI 10.1038/324537a0; Mann RS, 1996, NATURE, V383, P630, DOI 10.1038/383630a0; MARMIROLI S, 1994, J BIOL CHEM, V269, P13; MLODZIK M, 1990, DEVELOPMENT, V109, P271; MLODZIK M, 1985, EMBO J, V4, P2961, DOI 10.1002/j.1460-2075.1985.tb04030.x; Nishimura N, 1997, SCIENCE, V277, P556, DOI 10.1126/science.277.5325.556; Rieckhof GE, 1997, CELL, V91, P171, DOI 10.1016/S0092-8674(00)80400-6; Schatz G, 1996, SCIENCE, V271, P1519, DOI 10.1126/science.271.5255.1519; STARK MR, 1994, NATURE, V371, P429, DOI 10.1038/371429a0; SUBRAMANIAN V, 1995, CELL, V83, P641, DOI 10.1016/0092-8674(95)90104-3; Suh E, 1996, MOL CELL BIOL, V16, P619; SUH E, 1994, MOL CELL BIOL, V14, P7340, DOI 10.1128/MCB.14.11.7340; Taylor JK, 1997, NUCLEIC ACIDS RES, V25, P2293, DOI 10.1093/nar/25.12.2293; Taylor JK, 1997, DNA CELL BIOL, V16, P1419, DOI 10.1089/dna.1997.16.1419; Troelsen JT, 1997, BIOCHEM J, V322, P833, DOI 10.1042/bj3220833; WANG M, 1995, J BIOL CHEM, V270, P12646, DOI 10.1074/jbc.270.21.12584; WANG XD, 1994, CELL, V77, P53, DOI 10.1016/0092-8674(94)90234-8	41	26	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 26	1999	274	9					6011	6019		10.1074/jbc.274.9.6011	http://dx.doi.org/10.1074/jbc.274.9.6011			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	170KG	10026228	hybrid			2022-12-25	WOS:000078804400099
J	Koken, MHM; Daniel, MT; Gianni, M; Zelent, A; Licht, J; Buzyn, A; Minard, P; Degos, L; Varet, B; de The, H				Koken, MHM; Daniel, MT; Gianni, M; Zelent, A; Licht, J; Buzyn, A; Minard, P; Degos, L; Varet, B; de The, H			Retinoic acid, but not arsenic trioxide, degrades the PLZF/RAR alpha fusion protein, without inducing terminal differentiation or apoptosis, in a RA-therapy resistant t(11;17)(q23;q21) APL patient	ONCOGENE			English	Article						nuclear dot; leukaemia; degradation; PML; t(15;17); translocation	ACUTE PROMYELOCYTIC LEUKEMIA; PML GROWTH-SUPPRESSOR; RECEPTOR-ALPHA; T(15-17) TRANSLOCATION; NUCLEAR-BODIES; DNA-BINDING; CELLS; ONCOPROTEIN; GENE; EXPRESSION	Primary blasts of a t(11;17)(q23;q21) acute promyelocytic leukaemia (APL) patient were analysed with respect to retinoic acid (RA) and arsenic trioxide (As2O3) sensitivity as well as PLZF/RAR alpha status. Although RA induced partial monocytic differentiation ex vivo, but not in vivo, As203 failed to induce apoptosis in culture, contrasting with t(15;17) APL and arguing against the clinical use of As203 in t(11;17)(q23;q21) APL. Prior to cell culture, PLZF/RAR alpha was found to exactly co-localize with PML onto PML nuclear bodies. However upon cell culture, it quickly shifted towards microspeckles, its localization found in transfection experiments. Arsenic trioxide, known to induce aggregation of PML nuclear bodies, left the microspeckled PLZF/RAR alpha localization completely unaffected. RA treatment led to PLZF/RARa degradation. However, this complete PLZF/RAR alpha degradation was not accompanied by differentiation or apoptosis, which could suggest a contribution of the reciprocal RAR alpha/PLZF fusion product in leukaemogenesis or the existence of irreversible changes induced by the chimera.	Hop St Louis, Lab Associe Comite Paris Ligue Contre Canc, CNRS, UPR 90 51, F-75010 Paris, France; Hop St Louis, Serv Clin Malad Sang, Paris, France; Hop Necker Enfants Malad, Hematol Serv, Paris, France; Hop Moulins, Serv Med Interne, Moulins, France; Hop St Louis, Hematol Serv, Paris, France; Inst Canc Res, Chester Beatty Labs, London SW3 6JB, England; CUNY, Mt Sinai Med Ctr, New York, NY USA	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Koken, MHM (corresponding author), Hop St Louis, Lab Associe Comite Paris Ligue Contre Canc, CNRS, UPR 90 51, 1 Av Claude Vellefaux, F-75010 Paris, France.		koken, marcel/N-1349-2019; Licht, Jonathan/L-4239-2019; Zelent, Arthur/B-3532-2009; Gianni, Maurizio/ABG-6322-2020; koken, marcel/J-8154-2012; Minard, Philippe/GRS-4797-2022	Gianni, Maurizio/0000-0002-6945-708X; koken, marcel/0000-0002-0839-0125; Minard, Philippe/0000-0002-3256-528X; Licht, Jonathan/0000-0002-3942-1369; Zelent, Arthur/0000-0002-7968-9888				BORROW J, 1990, SCIENCE, V249, P1577, DOI 10.1126/science.2218500; CAMPBELL IG, 1994, HUM MOL GENET, V3, P589, DOI 10.1093/hmg/3.4.589; ChelbiAlix MK, 1995, LEUKEMIA, V9, P2027; Chen GQ, 1997, BLOOD, V89, P3345; Chen GQ, 1996, BLOOD, V88, P1052; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; CHEN Z, 1993, EMBO J, V12, P1161, DOI 10.1002/j.1460-2075.1993.tb05757.x; DANIEL MT, 1993, BLOOD, V82, P1858; DEGOS L, 1993, LEUKEMIA, V7, P766; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; DETHE H, 1990, NATURE, V347, P558, DOI 10.1038/347558a0; Dhordain P, 1997, P NATL ACAD SCI USA, V94, P10762, DOI 10.1073/pnas.94.20.10762; Dong S, 1996, P NATL ACAD SCI USA, V93, P3624, DOI 10.1073/pnas.93.8.3624; DYCK JA, 1994, CELL, V76, P333, DOI 10.1016/0092-8674(94)90340-9; Grignani F, 1998, NATURE, V391, P815, DOI 10.1038/35901; Guidez F, 1998, BLOOD, V91, P2634, DOI 10.1182/blood.V91.8.2634.2634_2634_2642; He L. Z., 1997, Blood, V90, p320A; Hong SH, 1997, P NATL ACAD SCI USA, V94, P9028, DOI 10.1073/pnas.94.17.9028; HUANG ME, 1988, BLOOD, V72, P567, DOI 10.1182/blood.V72.2.567.567; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; KASTNER P, 1992, EMBO J, V11, P629, DOI 10.1002/j.1460-2075.1992.tb05095.x; KOKEN MHM, 1995, ONCOGENE, V10, P1315; KOKEN MHM, 1994, EMBO J, V13, P1073, DOI 10.1002/j.1460-2075.1994.tb06356.x; Koken MHM, 1997, P NATL ACAD SCI USA, V94, P10255, DOI 10.1073/pnas.94.19.10255; Li JY, 1997, J BIOL CHEM, V272, P22447, DOI 10.1074/jbc.272.36.22447; LICHT JD, 1995, BLOOD, V85, P1083, DOI 10.1182/blood.V85.4.1083.bloodjournal8541083; Lin RJ, 1998, NATURE, V391, P811, DOI 10.1038/35895; MU ZM, 1994, MOL CELL BIOL, V14, P6858, DOI 10.1128/MCB.14.10.6858; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; PANDOLFI PP, 1991, ONCOGENE, V6, P1285; Quignon F, 1997, BBA-REV CANCER, V1333, pM53, DOI 10.1016/S0304-419X(97)00025-5; Raelson JV, 1996, BLOOD, V88, P2826, DOI 10.1182/blood.V88.8.2826.bloodjournal8882826; Redner RL, 1996, BLOOD, V87, P882, DOI 10.1182/blood.V87.3.882.bloodjournal873882; Sitterlin D, 1997, ONCOGENE, V14, P1067, DOI 10.1038/sj.onc.1200916; Stadler M, 1995, ONCOGENE, V11, P2565; WEIS K, 1994, CELL, V76, P345, DOI 10.1016/0092-8674(94)90341-7; Wells RA, 1997, NAT GENET, V17, P109, DOI 10.1038/ng0997-109; Yeyati P. L., 1997, Blood, V90, p245A; Yoshida H, 1996, CANCER RES, V56, P2945; Zhu J, 1997, P NATL ACAD SCI USA, V94, P3978, DOI 10.1073/pnas.94.8.3978	40	82	84	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 28	1999	18	4					1113	1118		10.1038/sj.onc.1202414	http://dx.doi.org/10.1038/sj.onc.1202414			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	165FT	10023688				2022-12-25	WOS:000078510600029
J	Armes, NA; Neal, KA; Smith, JC				Armes, NA; Neal, KA; Smith, JC			A short loop on the ALK-2 and ALK-4 activin receptors regulates signaling specificity but cannot account for all their effects on early Xenopus development	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BONE MORPHOGENETIC PROTEIN-4; TGF-BETA RECEPTOR; GROWTH-FACTOR-BETA; I RECEPTOR; KINASE; GENE; IDENTIFICATION; DROSOPHILA; DOMAIN; FAMILY	Activin, a member of the transforming growth factor beta (TGF-beta) superfamily, signals through a heteromeric complex of type I and type II serine-threonine kinase receptors, The two activin type I receptors previously identified, ALK-2 (ActR-I) and ALK-4 (ActR-IB), have distinct effects on gene expression, differentiation and morphogenesis in the Xenopus animal cap assay. ALK-4 reproduces the effects of activin treatment including the dose-dependent induction of progressively more dorso-anterior mesodermal and endodermal markers, whereas ALK-2 induces only ventral mesodermal markers and counteracts the effects of ALK-4, To identify regions of the receptors that determine signaling specificity we have generated chimeras of the constitutively active ALK-2 and ALK-4 receptors (termed ALK-2* and ALK-4*), The effects of these chimeric receptors on gene expression and morphogenetic movements implicate the loop between kinase subdomains TV and V in mediating the strong dorsal gene-inducing properties of ALK-4*; when the seven amino acids comprising this loop are transferred from ALK-4* to ALK-2*, the resulting chimeric receptor is capable of inducing the expression of dorsal-specific genes. In contrast, when the equivalent region of ALK-2* is transferred to the ALK-4* backbone it cannot effectively counteract the dorsalizing effects of ALK-4*, suggesting that other regions of type I receptors are also involved in determining signal specificity.	Natl Inst Med Res, Div Dev Biol, London NW7 1AA, England	MRC National Institute for Medical Research	Smith, JC (corresponding author), Natl Inst Med Res, Div Dev Biol, The Ridgeway,Mill Hill, London NW7 1AA, England.			Smith, Jim/0000-0003-2413-9392				ALTABA AR, 1989, CELL, V57, P317, DOI 10.1016/0092-8674(89)90969-0; ALTABA ARI, 1992, DEVELOPMENT, V116, P81; Armes NA, 1997, DEVELOPMENT, V124, P3797; Baker JC, 1996, GENE DEV, V10, P1880, DOI 10.1101/gad.10.15.1880; BRUMMEL TJ, 1994, CELL, V78, P251, DOI 10.1016/0092-8674(94)90295-X; Candia AF, 1997, DEVELOPMENT, V124, P4467; CHO KWY, 1991, CELL, V67, P1111, DOI 10.1016/0092-8674(91)90288-A; COOKE J, 1987, DEVELOPMENT, V101, P893; DALE L, 1992, DEVELOPMENT, V115, P573; DIRKSEN ML, 1992, GENE DEV, V6, P599, DOI 10.1101/gad.6.4.599; Dyson S, 1997, CURR BIOL, V7, P81, DOI 10.1016/S0960-9822(06)00030-3; Feng XH, 1997, EMBO J, V16, P3912, DOI 10.1093/emboj/16.13.3912; GEORGI LL, 1990, CELL, V61, P635, DOI 10.1016/0092-8674(90)90475-T; Graff JM, 1996, CELL, V85, P479, DOI 10.1016/S0092-8674(00)81249-0; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; Hoodless PA, 1996, CELL, V85, P489, DOI 10.1016/S0092-8674(00)81250-7; Jones CM, 1996, DEVELOPMENT, V122, P1545; Jones CM, 1996, CURR BIOL, V6, P1468, DOI 10.1016/S0960-9822(96)00751-8; Kim J, 1997, NATURE, V388, P304, DOI 10.1038/40906; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; Kretzschmar M, 1997, GENE DEV, V11, P984, DOI 10.1101/gad.11.8.984; Liu F, 1996, NATURE, V381, P620, DOI 10.1038/381620a0; Lo RS, 1998, EMBO J, V17, P996, DOI 10.1093/emboj/17.4.996; MaciasSilva M, 1996, CELL, V87, P1215, DOI 10.1016/S0092-8674(00)81817-6; Massague Joan, 1994, Trends in Cell Biology, V4, P172, DOI 10.1016/0962-8924(94)90202-X; MOHUN TJ, 1984, NATURE, V311, P716, DOI 10.1038/311716a0; Moriguchi T, 1996, J BIOL CHEM, V271, P13675, DOI 10.1074/jbc.271.23.13675; Nieuwkoop P. D., 1975, NORMAL TABLE XENOPUS; Saitoh M, 1996, J BIOL CHEM, V271, P2769, DOI 10.1074/jbc.271.5.2769; SARGENT MG, 1990, DEVELOPMENT, V109, P967; Shibuya H, 1998, EMBO J, V17, P1019, DOI 10.1093/emboj/17.4.1019; Shibuya H, 1996, SCIENCE, V272, P1179, DOI 10.1126/science.272.5265.1179; SLACK JMW, 1994, CURR BIOL, V4, P116, DOI 10.1016/S0960-9822(94)00027-8; SMITH JC, 1991, CELL, V67, P79, DOI 10.1016/0092-8674(91)90573-H; SMITH JC, 1993, CELLULAR INTERACTION, P181; Suzuki A, 1997, DEV BIOL, V184, P402, DOI 10.1006/dbio.1997.8548; TENDIJKE P, 1994, J BIOL CHEM, V269, P16985; TENDIJKE P, 1993, ONCOGENE, V8, P2879; Thomsen GH, 1996, DEVELOPMENT, V122, P2359; WIESER R, 1995, EMBO J, V14, P2199, DOI 10.1002/j.1460-2075.1995.tb07214.x; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; WRANA JL, 1994, MOL CELL BIOL, V14, P944, DOI 10.1128/MCB.14.2.944; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008; Zhang Y, 1997, CURR BIOL, V7, P270, DOI 10.1016/S0960-9822(06)00123-0	44	11	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	1999	274	12					7929	7935		10.1074/jbc.274.12.7929	http://dx.doi.org/10.1074/jbc.274.12.7929			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	178LU	10075688	hybrid			2022-12-25	WOS:000079268100047
J	Gu, C; Cooper, DMF				Gu, C; Cooper, DMF			Calmodulin-binding sites on adenylyl cyclase type VIII	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; CYTOSOLIC DOMAINS; AUTOINHIBITORY DOMAIN; DISCRETE REGIONS; IN-VITRO; CA2+; IDENTIFICATION; CALCIUM; KINASE; FORSKOLIN	Ca2+ stimulation of adenylyl cyclase type VIII (ACVIII) occurs through loosely bound calmodulin. However, where calmodulin binds in ACVIII and how the binding activates this cyclase have not yet been investigated. We have located two putative calmodulin-binding sites in ACVIII, One site is located at the N terminus as revealed by overlay assays; the other is located at the C terminus, as indicated by mutagenesis studies. Both of these calmodulin-binding sites were confirmed by synthetic peptide studies. The N-terminal site has the typical motif of a Ca2+-dependent calmodulin-binding domain, which is defined by a characteristic pattern of hydrophobic amino acids, basic and aromatic amino acids, and a tendency to form amphipathic cu-helix structures. Functional, mutagenesis studies suggest that this binding makes a minor contribution to the Ca2+ stimulation of ACVIII activity, although it might be involved in calmodulin trapping by ACVIII. The primary structure of the C-terminal site resembles another calmodulin-binding motif, the so-called IQ motif, which is commonly Ca2+-independent. Mutagenesis and functional assays indicate that this latter site is a calcium-dependent calmodulin-binding site, which is largely responsible for the Ca2+ stimulation of ACVIII, Removal of this latter calmodulin-binding region from ACVIII results in a hyperactivated enzyme state and a loss of Ca2+ sensitivity. Thus, Ca2+/calmodulin regulation of ACVIII may be through a disinhibitory mechanism, as is the case for a number of other targets of Ca2+/calmodulin.	Univ Colorado, Hlth Sci Ctr, Dept Pharmacol, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Neurosci Program, Denver, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Cooper, DMF (corresponding author), Univ Colorado, Hlth Sci Ctr, Dept Pharmacol, Box C-236,4200 E 9th Ave, Denver, CO 80262 USA.	cooperd@essex.uchsc.edu	Gu, Chen/E-3163-2011		NIGMS NIH HHS [GM 32483] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032483] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BLUMENTHAL DK, 1985, P NATL ACAD SCI USA, V82, P3187, DOI 10.1073/pnas.82.10.3187; BOYAJIAN CL, 1991, J BIOL CHEM, V266, P4995; CALDWELL KK, 1988, ANAL BIOCHEM, V175, P177, DOI 10.1016/0003-2697(88)90376-4; CALDWELL KK, 1992, CELL CALCIUM, V13, P107, DOI 10.1016/0143-4160(92)90004-C; Cali JJ, 1996, J BIOL CHEM, V271, P1089, DOI 10.1074/jbc.271.2.1089; CALI JJ, 1994, J BIOL CHEM, V269, P12190; CECH SY, 1980, MOL CELL BIOCHEM, V33, P67; CHIONO M, 1995, J BIOL CHEM, V270, P1149, DOI 10.1074/jbc.270.3.1149; Cooper Dermot M.F., 1998, Advances in Second Messenger and Phosphoprotein Research, V32, P23; COOPER DMF, 1994, BIOCHEM J, V297, P437, DOI 10.1042/bj2970437; COOPER DMF, 1994, METHOD ENZYMOL, V238, P71; COOPER DMF, 1994, CELL SIGNAL, V6, P823, DOI 10.1016/0898-6568(94)90016-7; COOPER DMF, 1995, NATURE, V374, P421, DOI 10.1038/374421a0; DEISS LP, 1995, GENE DEV, V9, P15, DOI 10.1101/gad.9.1.15; Dessauer CW, 1997, J BIOL CHEM, V272, P22272, DOI 10.1074/jbc.272.35.22272; ENYEDI A, 1989, J BIOL CHEM, V264, P12313; EVANS T, 1984, MOL PHARMACOL, V26, P395; Fagan KA, 1998, J BIOL CHEM, V273, P9297, DOI 10.1074/jbc.273.15.9297; Fagan KA, 1996, J BIOL CHEM, V271, P12438, DOI 10.1074/jbc.271.21.12438; GOLDHAMMER A, 1982, ANAL BIOCHEM, V124, P45, DOI 10.1016/0003-2697(82)90217-2; HASHIMOTO Y, 1990, J BIOL CHEM, V265, P1924; HUGHES MJ, 1996, BIOTECHNIQUES, V20, P192; KRUPINSKI J, 1989, SCIENCE, V244, P1558, DOI 10.1126/science.2472670; Krupinski John, 1998, Advances in Second Messenger and Phosphoprotein Research, V32, P53; LEVIN LR, 1995, J BIOL CHEM, V270, P7573, DOI 10.1074/jbc.270.13.7573; Munshi HG, 1996, BIOCHEMISTRY-US, V35, P15883, DOI 10.1021/bi962107y; Nakahashi Y, 1997, J BIOL CHEM, V272, P18093, DOI 10.1074/jbc.272.29.18093; PHILLIPS DR, 1972, BIOCHEMISTRY-US, V11, P4582, DOI 10.1021/bi00774a025; Putney James W. Jr, 1992, Advances in Second Messenger and Phosphoprotein Research, V26, P143; Salerno JC, 1997, J BIOL CHEM, V272, P29769, DOI 10.1074/jbc.272.47.29769; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; Sunahara RK, 1997, J BIOL CHEM, V272, P22265, DOI 10.1074/jbc.272.35.22265; Sunahara RK, 1996, ANNU REV PHARMACOL, V36, P461, DOI 10.1146/annurev.pa.36.040196.002333; TANG WJ, 1995, BIOCHEMISTRY-US, V34, P14563, DOI 10.1021/bi00044a035; TANG WJ, 1995, SCIENCE, V268, P1769, DOI 10.1126/science.7792604; Tesmer JJG, 1997, SCIENCE, V278, P1907, DOI 10.1126/science.278.5345.1907; Tokumitsu H, 1997, BIOCHEMISTRY-US, V36, P12823, DOI 10.1021/bi971348i; VORHERR T, 1993, BIOCHEMISTRY-US, V32, P6081, DOI 10.1021/bi00074a020; Wakabayashi S, 1997, BIOCHEMISTRY-US, V36, P12854, DOI 10.1021/bi9715472; Weitz D, 1998, EMBO J, V17, P2273, DOI 10.1093/emboj/17.8.2273; Whisnant RE, 1996, P NATL ACAD SCI USA, V93, P6621, DOI 10.1073/pnas.93.13.6621; WU ZL, 1993, J BIOL CHEM, V268, P23766; Yan SZ, 1996, J BIOL CHEM, V271, P10941, DOI 10.1074/jbc.271.18.10941; Yan SZ, 1997, J BIOL CHEM, V272, P12342, DOI 10.1074/jbc.272.19.12342; Yan SZ, 1997, J BIOL CHEM, V272, P18849, DOI 10.1074/jbc.272.30.18849; YOKOKURA H, 1995, J BIOL CHEM, V270, P23851, DOI 10.1074/jbc.270.40.23851; Zhang GY, 1997, NATURE, V386, P247, DOI 10.1038/386247a0; Zhi G, 1998, J BIOL CHEM, V273, P8951, DOI 10.1074/jbc.273.15.8951	48	63	65	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 19	1999	274	12					8012	8021		10.1074/jbc.274.12.8012	http://dx.doi.org/10.1074/jbc.274.12.8012			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	178LU	10075700	hybrid			2022-12-25	WOS:000079268100059
J	Lee, RJ; Albanese, C; Stenger, RJ; Watanabe, G; Inghirami, G; Haines, GK; Webster, M; Muller, WJ; Brugge, JS; Davis, RJ; Pestell, RG				Lee, RJ; Albanese, C; Stenger, RJ; Watanabe, G; Inghirami, G; Haines, GK; Webster, M; Muller, WJ; Brugge, JS; Davis, RJ; Pestell, RG			pp60(v-src) induction of cyclin D1 requires collaborative interactions between the extracellular signal-regulated kinase, p38, and Jun kinase pathways - A role for cAMP response element-binding protein and activating transcription factor-2 in pp60(v-src) signaling in breast cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOMINANT-NEGATIVE MUTANTS; NIH 3T3 CELLS; V-SRC; GENE-EXPRESSION; RETINOBLASTOMA-PROTEIN; TRANSDUCTION PATHWAY; GROWTH-FACTOR; CELLULAR STRESSES; COLLAGENASE GENE; TYROSINE KINASES	The cyclin D1 gene is overexpressed in breast tumors and encodes a regulatory subunit of cyclin-dependent kinases that phosphorylate the retinoblastoma protein. pp60(c-src) activity is frequently increased in breast tumors; however, the mechanisms governing pp60(c-src) regulation of the cell cycle in breast epithelium are poorly understood. In these studies, pp60(v-src) induced cyclin D1 protein levels and promoter activity (48-fold) in MCF7 cells. Cyclin D1-associated kinase activity and protein levels were increased in mammary tumors from murine mammary tumor virus-pp60(c-src527F) transgenic mice. Optimal induction of cyclin D1 by pp60(v-src) involved the extracellular signal-regulated kinase, p38, and c-Jun N-terminal kinase members of the mitogen-activated protein kinase family. Cyclin D1 promoter activation by pps60(v-src) involved a cAMP response element-binding protein (CREB)/activating transcription factor 2 (ATF-2) binding site. Dominant negative mutants of CREB and ATF-2 but not c-Jun inhibited pp60(v-src) induction of cyclin D1, pp60(v-src) induction of CREB was blocked by the p38 inhibitor SB203580 or by mutation of CREB at Ser(133), pp60(v-src) induction of ATF-2 was abolished by the a-Jun N-terminal kinase inhibitor JNK-interacting protein-1 or by mutation of ATF-2 at Thr(69) and Thr(71). CREB and ATF-2, which bind to a common pp60(v-src) response element, are transcriptionally activated by distinct mitogen-activated protein kinases. Induction of cyclin D1 activity by pp60(v-src) may contribute to breast tumorigenesis through phosphorylation and inactivation of the retinoblastoma protein.	Albert Einstein Coll Med, Albert Einstein Canc Ctr, Dept Med, Bronx, NY 10461 USA; Albert Einstein Coll Med, Albert Einstein Canc Ctr, Dept Dev & Mol Biol, Bronx, NY 10461 USA; NYU, Med Ctr, Dept Pathol, New York, NY 10016 USA; Northwestern Univ, Sch Med, Dept Pathol, Chicago, IL 60611 USA; McMaster Univ, Dept Pathol, Hamilton, ON L8S 4K1, Canada; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; Univ Massachusetts, Sch Med, Dept Biochem & Mol Biol, Program Mol Med, Worcester, MA 01605 USA; Univ Massachusetts, Sch Med, Howard Hughes Med Inst, Worcester, MA 01605 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; New York University; Northwestern University; McMaster University; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; University of Massachusetts System; University of Massachusetts Worcester; Howard Hughes Medical Institute; University of Massachusetts System; University of Massachusetts Worcester	Pestell, RG (corresponding author), Albert Einstein Coll Med, Albert Einstein Canc Ctr, Dept Med, Chanin 302,1300 Morris Pk Ave, Bronx, NY 10461 USA.	pestell@aecom.yu.edu			NCI NIH HHS [R29CA70897, RI1 CA75503] Funding Source: Medline; NHLBI NIH HHS [P50-HL56399] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R55CA075503, R01CA075503, R01CA070897] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL056399] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABDELHAFIZ HA, 1992, MOL ENDOCRINOL, V6, P2079, DOI 10.1210/me.6.12.2079; AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Amundadottir LT, 1998, ONCOGENE, V16, P737, DOI 10.1038/sj.onc.1201829; APEL I, 1992, MOL CELL BIOL, V12, P3356, DOI 10.1128/MCB.12.8.3356; BARTKOVA J, 1994, INT J CANCER, V57, P353, DOI 10.1002/ijc.2910570311; BIRCHENALLROBERTS MC, 1990, MOL CELL BIOL, V10, P4978, DOI 10.1128/MCB.10.9.4978; BODRUG SE, 1994, EMBO J, V13, P2124, DOI 10.1002/j.1460-2075.1994.tb06488.x; Bromberg JF, 1998, MOL CELL BIOL, V18, P2553, DOI 10.1128/MCB.18.5.2553; Brown JR, 1998, MOL CELL BIOL, V18, P5609, DOI 10.1128/MCB.18.9.5609; Brown PH, 1996, CELL GROWTH DIFFER, V7, P1013; BUCKLEY MF, 1993, ONCOGENE, V8, P2127; Chen TK, 1996, MOL CARCINOGEN, V15, P215, DOI 10.1002/(SICI)1098-2744(199603)15:3<215::AID-MC7>3.0.CO;2-G; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; Cohen P, 1997, TRENDS CELL BIOL, V7, P353, DOI 10.1016/S0962-8924(97)01105-7; COLLETT MS, 1980, NATURE, V285, P167, DOI 10.1038/285167a0; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; Cuenda A, 1997, EMBO J, V16, P295, DOI 10.1093/emboj/16.2.295; Deak M, 1998, EMBO J, V17, P4426, DOI 10.1093/emboj/17.15.4426; DEHBI M, 1992, MOL CELL BIOL, V12, P1490, DOI 10.1128/MCB.12.4.1490; Dickens M, 1997, SCIENCE, V277, P693, DOI 10.1126/science.277.5326.693; Diehl JA, 1997, GENE DEV, V11, P957, DOI 10.1101/gad.11.8.957; Fuchs SY, 1997, J BIOL CHEM, V272, P32163, DOI 10.1074/jbc.272.51.32163; GHOSH A, 1995, SCIENCE, V268, P239, DOI 10.1126/science.7716515; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; GUTMAN A, 1990, EMBO J, V9, P2241, DOI 10.1002/j.1460-2075.1990.tb07394.x; HAEFNER B, 1995, J BIOL CHEM, V270, P7937, DOI 10.1074/jbc.270.14.7937; HANAFUSA H, 1977, COMPREHENSIVE VIROLO, V10, P401; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; Iordanov M, 1997, EMBO J, V16, P1009, DOI 10.1093/emboj/16.5.1009; IVASHKIV LB, 1992, NEW BIOL, V4, P360; Johnson D, 1998, ONCOGENE, V16, P2017, DOI 10.1038/sj.onc.1201727; JOHNSON PJ, 1985, MOL CELL BIOL, V5, P1073, DOI 10.1128/MCB.5.5.1073; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; LIU JJ, 1995, MOL CELL BIOL, V15, P3654; LIVINGSTONE C, 1995, EMBO J, V14, P1785, DOI 10.1002/j.1460-2075.1995.tb07167.x; Lukas J, 1996, MOL CELL BIOL, V16, P6917; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MUKHOPADHYAY D, 1995, NATURE, V375, P577, DOI 10.1038/375577a0; MUSGROVE EA, 1993, MOL CELL BIOL, V13, P3577, DOI 10.1128/MCB.13.6.3577; ODELL TJ, 1991, NATURE, V353, P558, DOI 10.1038/353558a0; OTTENHOFFKALFF AE, 1992, CANCER RES, V52, P4773; Peeper DS, 1997, NATURE, V386, P177, DOI 10.1038/386177a0; Pende M, 1997, J NEUROSCI, V17, P1291; PESTELL RG, 1994, J BIOL CHEM, V269, P31090; PlanasSilva MD, 1997, MOL CELL BIOL, V17, P4059, DOI 10.1128/MCB.17.7.4059; QURESHI SA, 1991, J BIOL CHEM, V266, P10802; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; Ramakrishnan M, 1998, AM J RESP CELL MOL, V18, P736, DOI 10.1165/ajrcmb.18.6.3152; Reynisdottir I, 1997, GENE DEV, V11, P492, DOI 10.1101/gad.11.4.492; Robles AI, 1998, GENE DEV, V12, P2469, DOI 10.1101/gad.12.16.2469; SATO H, 1993, J BIOL CHEM, V268, P23460; SCHUURING E, 1992, ONCOGENE, V7, P355; Shambaugh GE, 1996, J NEUROPATH EXP NEUR, V55, P1009, DOI 10.1097/00005072-199609000-00008; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; Tan Y, 1996, EMBO J, V15, P4629, DOI 10.1002/j.1460-2075.1996.tb00840.x; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; UEHARA Y, 1991, METHOD ENZYMOL, V201, P370; VANRENTERGHEM B, 1994, J BIOL CHEM, V269, P24666; WAEBER G, 1991, MOL ENDOCRINOL, V5, P1418, DOI 10.1210/mend-5-10-1418; WALTON KM, 1992, MOL ENDOCRINOL, V6, P647, DOI 10.1210/me.6.4.647; Wang EH, 1997, GENE DEV, V11, P2658, DOI 10.1101/gad.11.20.2658; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; Watanabe G, 1996, J BIOL CHEM, V271, P22570, DOI 10.1074/jbc.271.37.22570; Watanabe G, 1998, DEV BRAIN RES, V108, P77, DOI 10.1016/S0165-3806(98)00032-7; Watanabe G, 1996, P NATL ACAD SCI USA, V93, P12861, DOI 10.1073/pnas.93.23.12861; WEBSTER MA, 1995, P NATL ACAD SCI USA, V92, P7849, DOI 10.1073/pnas.92.17.7849; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WEINSTATSASLOW D, 1995, NAT MED, V1, P1257, DOI 10.1038/nm1295-1257; Westwick JK, 1998, J BIOL CHEM, V273, P16739, DOI 10.1074/jbc.273.27.16739; Westwick JK, 1997, MOL CELL BIOL, V17, P1324, DOI 10.1128/MCB.17.3.1324; Whitmarsh AJ, 1996, J MOL MED-JMM, V74, P589, DOI 10.1007/s001090050063; Whitmarsh AJ, 1998, SCIENCE, V281, P1671, DOI 10.1126/science.281.5383.1671; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; XIE WL, 1994, MOL CELL BIOL, V14, P6531, DOI 10.1128/MCB.14.10.6531; XIE WL, 1995, J BIOL CHEM, V270, P27622, DOI 10.1074/jbc.270.46.27622; Yang DD, 1997, NATURE, V389, P865, DOI 10.1038/39899; Zwijsen RML, 1996, MOL CELL BIOL, V16, P2554	85	202	208	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	1999	274	11					7341	7350		10.1074/jbc.274.11.7341	http://dx.doi.org/10.1074/jbc.274.11.7341			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	175DV	10066798	hybrid			2022-12-25	WOS:000079078400070
J	Ping, YH; Rana, TM				Ping, YH; Rana, TM			Tat-associated kinase (P-TEFb): a component of transcription preinitiation and elongation complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; IMMUNODEFICIENCY-VIRUS TYPE-1; CARBOXYL-TERMINAL DOMAIN; PROTEINS SPECIFICALLY ASSOCIATE; IN-VITRO; ACTIVATED TRANSCRIPTION; TRANSACTIVATOR TAT; HIV-1 PROMOTER; INITIATION; PHOSPHORYLATION	Human immunodeficiency virus, type 1 (HIV-1) Tat protein activates transcription from the HIV-1 long terminal repeat. Tat interacts with TFIIH and Tat-associated kinase (a transcription elongation factor P-TEFb) and requires the carboxyl-terminal domain of the largest subunit of RNA polymerase II (pol II) for transactivation. We developed a stepwise RNA pol II walking approach and used Western blotting to determine the role of TFIIH and P-TEFb in HIV-1 transcription elongation. Our results demonstrate the new findings that P-TEFb is a component of the preinitiation complex and travels with the elongating RNA pol II, whereas TFIIH is released from the elongation complexes before the trans-activation responsive region RNA is synthesized. Our results suggest that TFIIH and P-TEFb are involved in the clearance of promoter-proximal pausing of RNA pol II on the HIV-1 long terminal repeat at different stages.	Rutgers State Univ, Robert Wood Johnson Med Sch, Dept Pharmacol, Piscataway, NJ 08854 USA; Rutgers State Univ, Mol Biosci Grad Program, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick	Rana, TM (corresponding author), Rutgers State Univ, Robert Wood Johnson Med Sch, Dept Pharmacol, 675 Hoes Ln, Piscataway, NJ 08854 USA.			Ping, Yueh-Hsin/0000-0003-2604-9913	FIC NIH HHS [TW 00702] Funding Source: Medline; NIAID NIH HHS [AI 41404, AI 43198] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI043198, R01AI041404, R56AI041404] Funding Source: NIH RePORTER	FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BENTLEY DL, 1995, CURR OPIN GENET DEV, V5, P210, DOI 10.1016/0959-437X(95)80010-7; Blair WS, 1996, EMBO J, V15, P1658, DOI 10.1002/j.1460-2075.1996.tb00511.x; CAI H, 1987, J BIOL CHEM, V262, P298; CHIANG CM, 1995, SCIENCE, V267, P531, DOI 10.1126/science.7824954; Chun RF, 1996, J BIOL CHEM, V271, P27888, DOI 10.1074/jbc.271.44.27888; Cujec TP, 1997, GENE DEV, V11, P2645, DOI 10.1101/gad.11.20.2645; CULLEN BR, 1993, CELL, V73, P417, DOI 10.1016/0092-8674(93)90126-B; Cullen BR, 1998, CELL, V93, P685, DOI 10.1016/S0092-8674(00)81431-2; DAHMUS ME, 1995, BBA-GENE STRUCT EXPR, V1261, P171, DOI 10.1016/0167-4781(94)00233-S; Dahmus ME, 1996, J BIOL CHEM, V271, P19009, DOI 10.1074/jbc.271.32.19009; Deissler H, 1996, J BIOL CHEM, V271, P4327; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Dvir A, 1997, P NATL ACAD SCI USA, V94, P9006, DOI 10.1073/pnas.94.17.9006; Emerman M, 1998, SCIENCE, V280, P1880, DOI 10.1126/science.280.5371.1880; GarciaMartinez LF, 1997, J BIOL CHEM, V272, P6951, DOI 10.1074/jbc.272.11.6951; GarciaMartinez LF, 1997, EMBO J, V16, P2836, DOI 10.1093/emboj/16.10.2836; GREENBLATT J, 1993, NATURE, V364, P401, DOI 10.1038/364401a0; HERRMANN CH, 1993, VIROLOGY, V197, P601, DOI 10.1006/viro.1993.1634; HERRMANN CH, 1995, J VIROL, V69, P1612, DOI 10.1128/JVI.69.3.1612-1620.1995; JEANG KT, 1993, J VIROL, V67, P6224, DOI 10.1128/JVI.67.10.6224-6233.1993; JONES KA, 1994, ANNU REV BIOCHEM, V63, P717, DOI 10.1146/annurev.bi.63.070194.003441; Jones KA, 1997, GENE DEV, V11, P2593, DOI 10.1101/gad.11.20.2593; KASHANCHI F, 1994, NATURE, V367, P295, DOI 10.1038/367295a0; Keen NJ, 1997, EMBO J, V16, P5260, DOI 10.1093/emboj/16.17.5260; Keen NJ, 1996, P NATL ACAD SCI USA, V93, P2505, DOI 10.1073/pnas.93.6.2505; Kumar KP, 1998, P NATL ACAD SCI USA, V95, P9767, DOI 10.1073/pnas.95.17.9767; LU H, 1991, P NATL ACAD SCI USA, V88, P10004, DOI 10.1073/pnas.88.22.10004; Mancebo HSY, 1997, GENE DEV, V11, P2633, DOI 10.1101/gad.11.20.2633; MARSHALL NF, 1992, MOL CELL BIOL, V12, P2078, DOI 10.1128/MCB.12.5.2078; MARSHALL NF, 1995, J BIOL CHEM, V270, P12335, DOI 10.1074/jbc.270.21.12335; Marshall NF, 1996, J BIOL CHEM, V271, P27176, DOI 10.1074/jbc.271.43.27176; Mavankal G, 1996, P NATL ACAD SCI USA, V93, P2089, DOI 10.1073/pnas.93.5.2089; Okamoto H, 1996, P NATL ACAD SCI USA, V93, P11575, DOI 10.1073/pnas.93.21.11575; Parada CA, 1996, NATURE, V384, P375, DOI 10.1038/384375a0; Peng JM, 1998, GENE DEV, V12, P755, DOI 10.1101/gad.12.5.755; SPENCER CA, 1990, ONCOGENE, V5, P777; Svejstrup JQ, 1997, P NATL ACAD SCI USA, V94, P6075, DOI 10.1073/pnas.94.12.6075; Uptain SM, 1997, ANNU REV BIOCHEM, V66, P117, DOI 10.1146/annurev.biochem.66.1.117; von Hippel PH, 1998, SCIENCE, V281, P660, DOI 10.1126/science.281.5377.660; Wang ZY, 1997, P NATL ACAD SCI USA, V94, P6688, DOI 10.1073/pnas.94.13.6688; Wei P, 1998, CELL, V92, P451, DOI 10.1016/S0092-8674(00)80939-3; WRIGHT S, 1993, MOL BIOL CELL, V4, P661, DOI 10.1091/mbc.4.7.661; Yang XZ, 1997, P NATL ACAD SCI USA, V94, P12331, DOI 10.1073/pnas.94.23.12331; Yang XZ, 1996, J VIROL, V70, P4576, DOI 10.1128/JVI.70.7.4576-4584.1996; ZAWEL L, 1995, GENE DEV, V9, P1479, DOI 10.1101/gad.9.12.1479; Zhu YR, 1997, GENE DEV, V11, P2622, DOI 10.1101/gad.11.20.2622	46	81	82	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 12	1999	274	11					7399	7404		10.1074/jbc.274.11.7399	http://dx.doi.org/10.1074/jbc.274.11.7399			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	175DV	10066804	hybrid			2022-12-25	WOS:000079078400076
J	Shariat-Madar, Z; Mahdi, F; Schmaier, AH				Shariat-Madar, Z; Mahdi, F; Schmaier, AH			Mapping binding domains of kininogens on endothelial cell cytokeratin 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-WEIGHT KININOGEN; RECEPTOR; PROTEIN; SITE; IDENTIFICATION; ACTIVATION; EXPRESSION; IDENTITY; KERATINS	Human cytokeratin 1 (CK1) in human umbilical vein endothelial cells (HUVEC) is expressed on their membranes and is able to bind high molecular weight kininogen (HK) (Hasan, A. A. K,, Zisman, T., and Schmaier, A.H. (1998) Proc. Natl, Acad, Sci, U. S. A. 95, 3615-3620), New investigations have been performed to demonstrate the HK binding domain on CK1, Four overlapping recombinant (r) CK1 proteins were produced in Escherichia coli by a glutathione S-transferase gene fusion system. Biotin-HK specifically bound to rCK1(28) and rCK1(31) in the presence of Zn2+ but not to (Deleted1-6)rCK1(31). Recombinant CK1(28) and rCK1(31) also inhibited biotin-HK binding to HUVEC with IC50 of 0.4 and 0.5 mu M, respectively. Alternatively, rCK1(14) and (Deleted1-6)rCK1(31) did not inhibit binding at concentrations greater than or equal to 1 mu M. Seven sequential 20 amino acid peptides of CK1 were prepared to cover the protein coded by exons 1-3. Only the first peptide (GYG20) coded by exon 1 significantly inhibited HK binding to HUVEC with an IC50 of 35 mu M. Fine mapping studies isolated two overlapping peptides also coded by exon 1 (GPV15 and PGG15) that inhibited binding to HUVEC with IC50 of 18 and 9 mu M, respectively. A sequence scrambled peptide of PGG15 did not block binding to HUVEC and biotin-GPV20 specifically bound to HK. Peptides GPV15 and PGG15 also blocked prekallikrein activation on endothelial cells. However, inhibition of PK activation by peptide PGG15 occurred at 10-fold lower concentration (IC50 = 1 mu M) than inhibition of biotin-HK binding to HUVEC (IC50 = 10 mu M). These studies indicate that HK binds to a region of 20 amino acids coded by exon 1 on CK1 which is carboxyl-terminal to its glycine-rich amino-terminal globular domain. Furthermore, HK binding to Chi modulates PK activation on HUVEC.	Univ Michigan, Dept Internal Med, Div Hematol & Oncol, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Pathol, Div Hematol & Oncol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Schmaier, AH (corresponding author), Univ Michigan, Dept Internal Med, Div Hematol & Oncol, 5301 MSRB 3,1150 W Med Ctr Dr, Ann Arbor, MI 48109 USA.		Schmaier, Alvin/AAM-1063-2020	Schmaier, Alvin/0000-0002-3884-6234	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL056416, R43HL055907, R01HL052779, R44HL055907] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL52779, HL55907, HL56416] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BARNATHAN ES, 1990, J BIOL CHEM, V265, P2865; Colman RW, 1997, J CLIN INVEST, V100, P1481, DOI 10.1172/JCI119669; Colman RW, 1997, BLOOD, V90, P3819, DOI 10.1182/blood.V90.10.3819; Dedio J, 1996, FEBS LETT, V399, P255, DOI 10.1016/S0014-5793(96)01339-7; GARSON JA, 1990, LANCET, V335, P419; GINSBURG D, 1985, SCIENCE, V228, P1401, DOI 10.1126/science.3874428; HASAN AAK, 1995, J BIOL CHEM, V270, P19256, DOI 10.1074/jbc.270.33.19256; Hasan AAK, 1998, P NATL ACAD SCI USA, V95, P3615, DOI 10.1073/pnas.95.7.3615; HASAN AAK, 1995, BLOOD, V85, P3134, DOI 10.1182/blood.V85.11.3134.bloodjournal85113134; HERWALD H, 1995, J BIOL CHEM, V270, P14634; Herwald H, 1996, J BIOL CHEM, V271, P13040, DOI 10.1074/jbc.271.22.13040; JOHNSON LD, 1985, P NATL ACAD SCI USA, V82, P1896, DOI 10.1073/pnas.82.7.1896; Joseph K, 1996, P NATL ACAD SCI USA, V93, P8552, DOI 10.1073/pnas.93.16.8552; JOSEPH K, 1997, J INVEST MED, V45, P265; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; Liao J, 1996, J CELL BIOL, V133, P345, DOI 10.1083/jcb.133.2.345; Lin YZ, 1997, BLOOD, V90, P690, DOI 10.1182/blood.V90.2.690.690_690_697; Motta G, 1998, BLOOD, V91, P516, DOI 10.1182/blood.V91.2.516.516_516_528; Rojkjaer R, 1998, THROMB HAEMOSTASIS, V80, P74, DOI 10.1055/s-0037-1615142; SCHMAIER AH, 1988, J LAB CLIN MED, V112, P182; SCHMAIER AH, 1988, J BIOL CHEM, V263, P16327; STEINERT PM, 1985, J BIOL CHEM, V260, P7142; ZINI JM, 1993, BLOOD, V81, P2936	23	50	52	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 12	1999	274	11					7137	7145		10.1074/jbc.274.11.7137	http://dx.doi.org/10.1074/jbc.274.11.7137			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	175DV	10066772	hybrid			2022-12-25	WOS:000079078400044
J	Liu, CB; Itoh, T; Arai, K; Watanabe, S				Liu, CB; Itoh, T; Arai, K; Watanabe, S			Constitutive activation of JAK2 confers murine interleukin-3-independent survival and proliferation of BA/F3 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; CYTOKINE RECEPTOR SUPERFAMILY; NIH 3T3 CELLS; C-FOS; TYROSINE PHOSPHORYLATION; SIGNAL-TRANSDUCTION; GROWTH SIGNAL; BETA-SUBUNIT; INTERLEUKIN-5; DOMAIN	The Janus tyrosine kinase 2 (JAK2) plays an essential role of cytokine receptor signaling, including that of the human granulocyte-macrophage colony-stimulating factor (GM-CSF) receptor. We reported earlier that the activation of JAK2 is essential for all the examined signals induced by human GM-CSF through the box1 region of pc, such as promotion of cell survival and proliferation. To elucidate the role of JAK2 in cell survival and proliferation, we generated an artificial activation system by constructing a chimeric molecule (beta/JAK2) consisting of pc extracellular and transmembrane regions fused with JAK2, and we analyzed various signaling events in interleukin-3-dependent mouse pro-B cell, BA/F3. The beta/JAK2 was constitutively phosphorylated in the absence of human GM-CSF and murine interleukin-3, and this led to proliferation and cell survival. Western blot analysis showed that STAT5, Shc, and SHP-2 were not phosphorylated in the cells, and the consistent activation of beta-casein and c-fos promoters was not enhanced. In contrast, c-myc transcription was constitutively activated. We propose that the activation of beta/JAK2 suffices for survival and proliferation and that the activation of STAT5 and mitogen-activated protein kinase cascade is not required for these activities in BA/F3 cells.	Univ Tokyo, Inst Med Sci, Dept Mol & Dev Biol, Minato Ku, Tokyo 1088639, Japan; Japan Sci & Technol Corp, CREST, Minato Ku, Tokyo 1088639, Japan	University of Tokyo; Japan Science & Technology Agency (JST)	Watanabe, S (corresponding author), Univ Tokyo, Inst Med Sci, Dept Mol & Dev Biol, Minato Ku, 4-6-1 Shirokanedai, Tokyo 1088639, Japan.	sumiko@ims.u-tokyo.ac.jp	Itoh, Tohru/GYQ-8698-2022	Itoh, Tohru/0000-0002-6579-1638				Farrar MA, 1996, NATURE, V383, P178, DOI 10.1038/383178a0; IHLE JN, 1995, TRENDS GENET, V11, P69, DOI 10.1016/S0168-9525(00)89000-9; IHLE JN, 1994, TRENDS BIOCHEM SCI, V19, P222, DOI 10.1016/0968-0004(94)90026-4; Itoh T, 1996, J BIOL CHEM, V271, P7587, DOI 10.1074/jbc.271.13.7587; Itoh T, 1998, MOL CELL BIOL, V18, P742, DOI 10.1128/MCB.18.2.742; Joneja B, 1997, J BIOL CHEM, V272, P11176, DOI 10.1074/jbc.272.17.11176; Lacronique V, 1997, SCIENCE, V278, P1309, DOI 10.1126/science.278.5341.1309; LOPEZ AF, 1991, J BIOL CHEM, V266, P24741; MIYAJIMA A, 1993, BLOOD, V82, P1960; Mohi MG, 1998, MOL BIOL CELL, V9, P3299, DOI 10.1091/mbc.9.12.3299; MUI ALF, 1995, EMBO J, V14, P1166, DOI 10.1002/j.1460-2075.1995.tb07100.x; Muto A, 1996, J EXP MED, V183, P1911, DOI 10.1084/jem.183.4.1911; Nakamura N, 1996, J BIOL CHEM, V271, P19483, DOI 10.1074/jbc.271.32.19483; Neubauer H, 1998, CELL, V93, P397, DOI 10.1016/S0092-8674(00)81168-X; Okuda K, 1997, BLOOD, V90, P4759, DOI 10.1182/blood.V90.12.4759.4759_4759_4766; Parganas E, 1998, CELL, V93, P385, DOI 10.1016/S0092-8674(00)81167-8; Peeters P, 1997, BLOOD, V90, P2535, DOI 10.1182/blood.V90.7.2535.2535_2535_2540; QUELLE FW, 1994, MOL CELL BIOL, V14, P4335, DOI 10.1128/MCB.14.7.4335; RAO P, 1995, J BIOL CHEM, V270, P6886, DOI 10.1074/jbc.270.12.6886; SAKAMAKI K, 1992, EMBO J, V11, P3541, DOI 10.1002/j.1460-2075.1992.tb05437.x; Taglialatela G, 1996, NEUROREPORT, V7, P977, DOI 10.1097/00001756-199604100-00004; ULLICH A, 1990, CELL, V61, P203; WAKAO H, 1994, EMBO J, V13, P2182, DOI 10.1002/j.1460-2075.1994.tb06495.x; WATANABE S, 1993, MOL CELL BIOL, V13, P1440, DOI 10.1128/MCB.13.3.1440; Watanabe S, 1996, CURR OPIN GENET DEV, V6, P587, DOI 10.1016/S0959-437X(96)80088-8; Watanabe S, 1996, J BIOL CHEM, V271, P12681, DOI 10.1074/jbc.271.21.12681; WATANABE S, 1993, MOL BIOL CELL, V4, P983, DOI 10.1091/mbc.4.10.983	27	28	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	1999	274	10					6342	6349		10.1074/jbc.274.10.6342	http://dx.doi.org/10.1074/jbc.274.10.6342			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172BQ	10037724	hybrid			2022-12-25	WOS:000078902800046
J	McCloskey, DE; Coleman, CS; Pegg, AE				McCloskey, DE; Coleman, CS; Pegg, AE			Properties and regulation of human spermidine/spermine N-1-acetyltransferase stably expressed in Chinese hamster ovary cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BREAST-CANCER CELLS; SPERMINE N1-ACETYLTRANSFERASE; POLYAMINE ANALOG; GROWTH-INHIBITION; LUNG-CANCER; INDUCTION; METABOLISM; INCREASES	Spermidine/spermine N-1-acetyltransferase (SSAT) appears to be the rate-limiting enzyme of polyamine catabolism, yet studies of its regulation have been limited by the low amounts of SSAT in uninduced cells. A system for studying SSAT was established by stably transfecting Chinese hamster ovary cells with a construct where SSAT cDNA was under control of the cytomegalovirus promoter. Thirteen of 44 clones expressed significantly increased SSAT activity (650-1900 compared with 24 pmol/min/mg protein in control cells). SSAT activity was directly proportional to SSAT protein, which turned over very rapidly (t(1/2) of 29 min) and was degraded through the ubiquitin/proteasomal pathway. The increased SSAT activity caused perturbations in polyamine homeostasis and led to a reduction in the rate of growth under clonal conditions. N-1-N-12-bis(ethyl)spermine greatly increased SSAT activity in controls and SSAT transfected clones (to about 10 and 60 nmol/min/mg protein, respectively). N-1,N-12-Bis(ethyl) spermine caused an increase in the SSAT half-life and a slight increase in SSAT mRNA, but these changes were insufficient to account for the increase in SSAT protein suggesting that translational regulation of SSAT must also occur.	Penn State Univ, Milton S Hershey Med Ctr, Coll Med, Dept Cellular & Mol Physiol, Hershey, PA 17033 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Pegg, AE (corresponding author), Penn State Univ, Milton S Hershey Med Ctr, Coll Med, Dept Cellular & Mol Physiol, POB 850, Hershey, PA 17033 USA.	aep1@psu.edu			NIGMS NIH HHS [GM-26290] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026290] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alhonen L, 1998, J BIOL CHEM, V273, P1964, DOI 10.1074/jbc.273.4.1964; CASERO RA, 1992, CANCER RES, V52, P5359; CASERO RA, 1989, CANCER RES, V49, P3829; CASERO RA, 1991, J BIOL CHEM, V266, P810; CASERO RA, 1994, CANCER RES, V54, P3955; CASERO RA, 1993, FASEB J, V7, P653, DOI 10.1096/fasebj.7.8.8500690; Coleman CS, 1997, J BIOL CHEM, V272, P12164, DOI 10.1074/jbc.272.18.12164; DAVIDSON NE, 1993, CANCER RES, V53, P2071; DELLARAGIONE F, 1983, BIOCHEM J, V213, P701, DOI 10.1042/bj2130701; ERWIN BG, 1986, BIOCHEM J, V238, P581, DOI 10.1042/bj2380581; FogelPetrovic M, 1996, BIOCHEMISTRY-US, V35, P14436, DOI 10.1021/bi9612273; FOGELPETROVIC M, 1993, J BIOL CHEM, V268, P19118; LIBBY PR, 1989, BIOCHEM PHARMACOL, V38, P1435, DOI 10.1016/0006-2952(89)90182-2; LIBBY PR, 1989, CANCER RES, V49, P6226; MAKI C, 1996, CANCER RES, V56, P2469; MATSUI I, 1981, BIOCHIM BIOPHYS ACTA, V675, P373; MATSUI I, 1981, J BIOL CHEM, V256, P2454; MCCLOSKEY DE, 1995, CANCER RES, V55, P3233; PARRY L, 1995, BIOCHEMISTRY-US, V34, P2701, DOI 10.1021/bi00008a038; PARRY L, 1995, BIOCHEM J, V305, P451, DOI 10.1042/bj3050451; PEGG AE, 1986, BIOCHEM J, V234, P249, DOI 10.1042/bj2340249; PEGG AE, 1989, BIOCHEMISTRY-US, V28, P8446, DOI 10.1021/bi00447a026; PEGG AE, 1985, BIOCHEM J, V231, P285, DOI 10.1042/bj2310285; PORTER CW, 1991, CANCER RES, V51, P3716; SEILER N, 1987, CAN J PHYSIOL PHARM, V65, P2024, DOI 10.1139/y87-317; Shantz LM, 1999, INT J BIOCHEM CELL B, V31, P107, DOI 10.1016/S1357-2725(98)00135-6	26	40	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1999	274	10					6175	6182		10.1074/jbc.274.10.6175	http://dx.doi.org/10.1074/jbc.274.10.6175			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172BQ	10037702	hybrid			2022-12-25	WOS:000078902800024
J	Xu, J; Esmon, NL; Esmon, CT				Xu, J; Esmon, NL; Esmon, CT			Reconstitution of the human endothelial cell protein C receptor with thrombomodulin in phosphatidylcholine vesicles enhances protein C activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPID-VESICLES; RABBIT THROMBOMODULIN; HUMAN THROMBIN; HUMAN-PLASMA; EXPRESSION; COMPLEX; ANTICOAGULATION; IDENTIFICATION; COFACTOR; PATHWAY	Blocking protein C binding to the endothelial cell protein C receptor (EPCR) on the endothelium is known to reduce protein C activation rates. Now we isolate human EPCR and thrombomodulin (TM) and reconstitute them into phosphatidylcholine vesicles. The EPCR increases protein C activation rates in a concentration-dependent fashion that does not saturate at 14 EPCR molecules/TM. Without EPCR, the protein C concentration dependence fits a single class of sites (K-m = 2.17 +/- 0.13 mu M). With EPCR, two classes of sites are apparent K-m = 20 +/- 15 nM and K-m = 3.2 +/- 1.7 mu M). Increasing the EPCR concentration at a constant TM concentration increases the percentage of high affinity sites. Holding the TRI: EPCR ratio constant while decreasing the density of these proteins results in a decrease in the EPCR enhancement of protein C activation, suggesting that there is little affinity of the EPCR for TM. Negatively charged phospholipids also enhance protein C activation. EPCR acceleration of protein C activation is blocked by anti-EPCR antibodies, but not by annexin V, whereas the reverse is true with negatively charged phospholipids, Human umbilical cord endothelium expresses approximately 7 times more EPCR than TM, Anti-EPCR antibody reduces protein C activation rates 7-fold over these cells, whereas annexin V is ineffective, indicating that EPCR rather than negatively charged phospholipid provide the surface for protein C activation. EPCR expression Varies dramatically among vascular beds. The present results indicate that the EPCR concentration will determine the effectiveness of the protein C activation complex.	Oklahoma Med Res Fdn, Howard Hughes Med Inst, Cardiovasc Biol Res Program, Oklahoma City, OK 73104 USA; Univ Oklahoma, Hlth Sci Ctr, Dept Pathol, Oklahoma City, OK 73104 USA; Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma City, OK 73104 USA	Howard Hughes Medical Institute; Oklahoma Medical Research Foundation; University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center	Esmon, CT (corresponding author), Oklahoma Med Res Fdn, Howard Hughes Med Inst, Cardiovasc Biol Res Program, 825 NE 13th St, Oklahoma City, OK 73104 USA.	Charles-Esmon@omrf.ouhsc.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL054804] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01 HL54804] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BARENHOLZ Y, 1977, BIOCHEMISTRY-US, V16, P2806, DOI 10.1021/bi00631a035; BAUER KA, 1984, J CLIN INVEST, V74, P2033, DOI 10.1172/JCI111626; BOURIN MC, 1988, J BIOL CHEM, V263, P8044; BUSCH C, 1982, LAB INVEST, V47, P498; CASTELLINO FJ, 1995, TRENDS CARDIOVAS MED, V5, P55, DOI 10.1016/1050-1738(94)00031-X; DAHLBACK B, 1994, J CLIN INVEST, V94, P923, DOI 10.1172/JCI117458; Ding W, 1996, CIRCULATION, V94, P4056; ESMON CT, 1995, TRENDS CARDIOVAS MED, V5, P141, DOI 10.1016/1050-1738(95)00054-D; ESMON CT, 1993, METHOD ENZYMOL, V222, P359; ESMON CT, 1989, J BIOL CHEM, V264, P4743; ESMON NL, 1983, J BIOL CHEM, V258, P5548; FREYSSINET JM, 1986, BIOCHEM J, V238, P151, DOI 10.1042/bj2380151; Fukudome K, 1998, J EXP MED, V187, P1029, DOI 10.1084/jem.187.7.1029; Fukudome K, 1996, J BIOL CHEM, V271, P17491, DOI 10.1074/jbc.271.29.17491; FUKUDOME K, 1995, J BIOL CHEM, V270, P5571, DOI 10.1074/jbc.270.10.5571; FUKUDOME K, 1994, J BIOL CHEM, V269, P26486; GALVIN JB, 1987, J BIOL CHEM, V262, P2199; Houston DS, 1997, J BIOL CHEM, V272, P11778, DOI 10.1074/jbc.272.18.11778; JACKMAN RW, 1987, P NATL ACAD SCI USA, V84, P6425, DOI 10.1073/pnas.84.18.6425; KISIEL W, 1979, J CLIN INVEST, V64, P761, DOI 10.1172/JCI109521; Kurosawa S, 1997, J CLIN INVEST, V100, P411, DOI 10.1172/JCI119548; Kurosawa S, 1998, BLOOD, V91, P725, DOI 10.1182/blood.V91.2.725; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lane DA, 1996, THROMB HAEMOSTASIS, V76, P651; Laszik Z, 1997, CIRCULATION, V96, P3633; LIN JH, 1994, J BIOL CHEM, V269, P25021; MANN KG, 1988, ANNU REV BIOCHEM, V57, P915, DOI 10.1146/annurev.bi.57.070188.004411; MARUYAMA I, 1985, J BIOL CHEM, V260, P5432; MILETICH JP, 1978, J BIOL CHEM, V253, P6908; MIMMS LT, 1981, BIOCHEMISTRY-US, V20, P833, DOI 10.1021/bi00507a028; OWEN WG, 1974, J BIOL CHEM, V249, P594; Regan LM, 1997, J BIOL CHEM, V272, P26279, DOI 10.1074/jbc.272.42.26279; REZAIE AR, 1992, J BIOL CHEM, V267, P26104; SALEM HH, 1984, J BIOL CHEM, V259, P2246; SEEGERS WH, 1981, SEMIN THROMB HEMOST, V7, P177; StearnsKurosawa DJ, 1996, P NATL ACAD SCI USA, V93, P10212, DOI 10.1073/pnas.93.19.10212; SUZUKI K, 1987, EMBO J, V6, P1891, DOI 10.1002/j.1460-2075.1987.tb02448.x; THOMPSON AR, 1977, ARCH BIOCHEM BIOPHYS, V178, P356, DOI 10.1016/0003-9861(77)90204-1; WEN DZ, 1987, BIOCHEMISTRY-US, V26, P4350, DOI 10.1021/bi00388a025; XU J, 1998, VASC BIOL M APR 15 1	40	75	81	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	1999	274	10					6704	6710		10.1074/jbc.274.10.6704	http://dx.doi.org/10.1074/jbc.274.10.6704			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172BQ	10037768	hybrid			2022-12-25	WOS:000078902800090
J	Zhang, Y; Lee, YC				Zhang, Y; Lee, YC			Acid-catalyzed lactonization of alpha 2,8-linked oligo/polysialic acids studied by high performance anion-exchange chromatography	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ADHESION MOLECULE; POLYSIALIC ACID; NEISSERIA-MENINGITIDIS; GANGLIOSIDE LACTONES; SIALIC ACIDS; POLYSACCHARIDE; GD1B; POLYSIALYLTRANSFERASE; POLYSIALYLATION; IDENTIFICATION	Recent studies from many laboratories revealed remarkable structural, distributional, and functional diversities of oligo/polysialic acids (OSA/PSA) that exist in organisms ranging from bacteria to man. These diversities are further complicated by the fact that OSA/PSA spontaneously form lactones under even mildly acidic conditions. By using high performance anion-exchange chromatography (HPAEC) with nitrate eluents, we found that lactonization of alpha 2,8-linked OSA/PSA (oligo/poly-Neu5Ac, oligo/poly-Neu5Gc and oligo/poly-KDN) proceeds readily, and the lactonization process displays three discrete stages. The initial stage is characterized by limited lactonization occurring between two internal sialic acid residues, reflected by a regular pattern of lactone peaks interdigitated with non-lactonized peaks on HPAEC. In the middle stage, multiple lactonized species are formed from a molecule with a given degree of polymerization (DP), in which the maximum number of lactone rings formed equals DP minus 2. At the final stage, completely lactonized species become the major components, resulting in drastic changes in the physicochemical properties of the sample. Interestingly, the smallest lactonizable OSA are tetramer, trimer, and dimer at the initial, middle, and final stages, respectively. At any of the stages, OSA/PSA of higher DP lactonize more rapidly, but all the lactone rings rapidly open up when exposed 60 mild alkali. Lactonized OSA/PSA are resistant to both enzyme- and acid-catalyzed glycosidic bond cleavage. The latter fact was utilized to obtain more high DP oligo/poly(alpha 2,8-Neu5Gc) chains from a polysialoglycoprotein. Our results should be useful in preparation, storage, and analysis of OSA/PSA. Possible biological significance and bioengineering potentials of lactonization are discussed.	Johns Hopkins Univ, Dept Biol, Baltimore, MD 21218 USA	Johns Hopkins University	Lee, YC (corresponding author), Johns Hopkins Univ, Dept Biol, Baltimore, MD 21218 USA.							ACQUOTTI D, 1991, CHEM PHYS LIPIDS, V59, P107, DOI 10.1016/0009-3084(91)90001-R; ANDO S, 1989, J BIOL CHEM, V264, P3478; Angata K, 1997, J BIOL CHEM, V272, P7182, DOI 10.1074/jbc.272.11.7182; BASSI R, 1989, CARBOHYD RES, V193, P141, DOI 10.1016/0008-6215(89)85113-4; BAUMANN H, 1993, BIOCHEMISTRY-US, V32, P4007, DOI 10.1021/bi00066a022; Cheng MC, 1998, ANAL BIOCHEM, V260, P154, DOI 10.1006/abio.1998.2701; Fernandes AI, 1997, BBA-PROTEIN STRUCT M, V1341, P26, DOI 10.1016/S0167-4838(97)00056-3; Fernandes AI, 1996, BBA-PROTEIN STRUCT M, V1293, P90, DOI 10.1016/0167-4838(95)00227-8; GROSS SK, 1975, CARBOHYD RES, V41, P344, DOI 10.1016/S0008-6215(00)87038-X; GROSS SK, 1980, J NEUROCHEM, V34, P1351, DOI 10.1111/j.1471-4159.1980.tb11215.x; Ijuin T, 1996, GLYCOCONJUGATE J, V13, P401, DOI 10.1007/BF00731473; KAWAKAMI H, 1994, BIOSCI BIOTECH BIOCH, V58, P1314, DOI 10.1271/bbb.58.1314; KAWASHIMA I, 1994, INT J CANCER, V58, P263, DOI 10.1002/ijc.2910580220; KIELCZYNSKI W, 1994, GLYCOBIOLOGY, V4, P791, DOI 10.1093/glycob/4.6.791; KITAZUME S, 1992, ANAL BIOCHEM, V202, P25, DOI 10.1016/0003-2697(92)90200-Q; Kitazume S, 1996, J BIOL CHEM, V271, P6694, DOI 10.1074/jbc.271.12.6694; LEE YC, 1966, J BIOL CHEM, V241, P1899; LIFELY MR, 1984, CARBOHYD RES, V134, P229, DOI 10.1016/0008-6215(84)85040-5; LIFELY MR, 1981, CARBOHYD RES, V94, P193, DOI 10.1016/S0008-6215(00)80717-X; MANZI AE, 1994, J BIOL CHEM, V269, P23617; MCGUIRE EJ, 1964, BIOCHEMISTRY-US, V3, P247, DOI 10.1021/bi00890a017; MICHON F, 1987, BIOCHEMISTRY-US, V26, P8399, DOI 10.1021/bi00399a055; MYERS RW, 1980, ANAL BIOCHEM, V101, P166, DOI 10.1016/0003-2697(80)90056-1; OConnell AW, 1997, J NEUROCHEM, V68, P2538; Ogawa T, 1996, J CHROMATOGR A, V741, P295, DOI 10.1016/0021-9673(96)00217-8; Ong E, 1998, GLYCOBIOLOGY, V8, P415, DOI 10.1093/glycob/8.4.415; Qu BX, 1996, P NATL ACAD SCI USA, V93, P8995, DOI 10.1073/pnas.93.17.8995; RIBONI L, 1986, J BIOL CHEM, V261, P8514; ROTH J, 1992, SCIENCE, V256, P673, DOI 10.1126/science.1585182; Rutishauser U, 1996, TRENDS NEUROSCI, V19, P422; Saito M, 1995, BIOL SIALIC ACIDS, P261, DOI [10.1007/978-1-4757-9504-2_8, DOI 10.1007/978-1-4757-9504-2_8]; SATO C, 1993, J BIOL CHEM, V268, P23675; Shen HM, 1997, J NEUROSCI, V17, P5221; Shi WX, 1996, J BIOL CHEM, V271, P31517, DOI 10.1074/jbc.271.49.31517; Terabayashi T, 1996, CARBOHYD POLYM, V29, P35, DOI 10.1016/0144-8617(95)00153-0; TROY FA, 1992, GLYCOBIOLOGY, V2, P5, DOI 10.1093/glycob/2.1.5; TSUDA M, 1994, CHEM PHYS LIPIDS, V70, P95, DOI 10.1016/0009-3084(94)90051-5; VARKI A, 1992, GLYCOBIOLOGY, V2, P25, DOI 10.1093/glycob/2.1.25; WEI XS, 1998, GLYCOBIOLOGY, V8, P199; YANG PF, 1994, J BIOL CHEM, V269, P23039; Zhang Y, 1997, ANAL BIOCHEM, V250, P245, DOI 10.1006/abio.1997.2225; ZHANG Y, 1997, GLYCOBIOLOGY, V7, P1027	42	44	44	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1999	274	10					6183	6189		10.1074/jbc.274.10.6183	http://dx.doi.org/10.1074/jbc.274.10.6183			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172BQ	10037703	hybrid			2022-12-25	WOS:000078902800025
J	Kloeker, S; Wadzinski, BE				Kloeker, S; Wadzinski, BE			Purification and identification of a novel subunit of protein serine/threonine phosphatase 4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERINE THREONINE PHOSPHATASES; AFFINITY-CHROMATOGRAPHY; CATALYTIC SUBUNIT; 2A; PHOSPHORYLATION; EXPRESSION; FAMILY	The catalytic subunit of protein serine/threonine phosphatase 4 (PP4(C)) has greater than 65% amino acid identity to the catalytic subunit of protein phosphatase 2A (PP2A(C)). Despite this high homology, PP4 does not appear to associate with known PP2A regulatory subunits. As a first step toward characterization of PP4 holoenzymes and identification of putative PP4 regulatory subunits, PP4 was purified from bovine testis soluble extracts, PP4 existed in two complexes of approximately 270-300 and 400-450 kDa as determined by gel filtration chromatography. The smaller PP4 complex was purified by sequential phenyl-Sepharose, Source 15Q, DEAE2, and Superdex 200 gel filtration chromatographies, The final product contained two major proteins: the PP4 catalytic subunit plus a protein that migrated as a doublet of 120-125 kDa on SDS-polyacrylamide gel electrophoresis. The associated protein, termed PP4(R1), and PP4(C) also bound to microcystin-Sepharose, Mass spectrometry analysis of the purified complex revealed two major peaks, at 35 (PP4(C)) and 105 kDa (PP4(R1)). Amino acid sequence information of several peptides derived from the 105 kDa protein was utilized to isolate a human cDNA clone. Analysis of the predicted amino acid sequence revealed 13 nonidentical repeats similar to repeats found in the A subunit of PP2A (PP2A(A)). The PP4(R1) cDNA clone engineered with an N-terminal Myc tag was expressed in COS M6 cells and PP4(C) co-immunoprecipitated with Myc-tagged PP4,,. These data indicate that one form of PP4 is similar to the core complex of PP2A in that it consists of a catalytic subunit and a "PP2A(A)-like" structural subunit.	Vanderbilt Univ, Med Ctr, Dept Pharmacol, Nashville, TN 37232 USA	Vanderbilt University	Wadzinski, BE (corresponding author), Vanderbilt Univ, Med Ctr, Dept Pharmacol, Rm 421 MRBI, Nashville, TN 37232 USA.				NCI NIH HHS [CA68485] Funding Source: Medline; NIDDK NIH HHS [DK20593] Funding Source: Medline; NIGMS NIH HHS [GM51366] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA068485] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P60DK020593, P30DK020593] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051366, R56GM051366] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOSCH M, 1995, EUR J BIOCHEM, V230, P1037, DOI 10.1111/j.1432-1033.1995.tb20653.x; BRAUTIGAN DL, 1994, RECENT PROG HORM RES, V49, P197; BREWIS ND, 1992, BIOCHIM BIOPHYS ACTA, V1171, P231, DOI 10.1016/0167-4781(92)90129-N; BREWIS ND, 1993, EMBO J, V12, P987, DOI 10.1002/j.1460-2075.1993.tb05739.x; Campos M, 1996, J BIOL CHEM, V271, P28478, DOI 10.1074/jbc.271.45.28478; CHEN MX, 1992, FEBS LETT, V306, P54, DOI 10.1016/0014-5793(92)80836-6; CHEN SC, 1989, J BIOL CHEM, V264, P7267; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; COHEN PTW, 1990, FEBS LETT, V268, P355, DOI 10.1016/0014-5793(90)81285-V; DEPAOLIROACH AA, 1994, ADV ENZYME REGUL, V34, P199, DOI 10.1016/0065-2571(94)90017-5; DING JB, 1992, BIOCHIM BIOPHYS ACTA, V1133, P235, DOI 10.1016/0167-4889(92)90074-L; Farmer TB, 1998, J MASS SPECTROM, V33, P697, DOI 10.1002/(SICI)1096-9888(199808)33:8<697::AID-JMS711>3.0.CO;2-H; FAVRE B, 1994, J BIOL CHEM, V269, P16311; GUO H, 1993, P NATL ACAD SCI USA, V90, P2500, DOI 10.1073/pnas.90.6.2500; Harlow E., 1988, ANTIBODIES LAB MANUA; Helps NR, 1998, J CELL SCI, V111, P1331; HEMMINGS BA, 1990, BIOCHEMISTRY-US, V29, P3166, DOI 10.1021/bi00465a002; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; IMAOKA T, 1983, J BIOL CHEM, V258, P1526; KAMIBAYASHI C, 1994, J BIOL CHEM, V269, P20139; KAMIBAYASHI C, 1991, J BIOL CHEM, V266, P13251; Kloeker S, 1997, BIOCHEM J, V327, P481, DOI 10.1042/bj3270481; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Mayer-Jaekel Regina E., 1994, Trends in Cell Biology, V4, P287, DOI 10.1016/0962-8924(94)90219-4; MOORHEAD G, 1994, FEBS LETT, V356, P46, DOI 10.1016/0014-5793(94)01232-6; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; MUMBY MC, 1993, PHYSIOL REV, V73, P673, DOI 10.1152/physrev.1993.73.4.673; NISHIWAKI S, 1991, FEBS LETT, V279, P115, DOI 10.1016/0014-5793(91)80264-4; RUEDIGER R, 1992, MOL CELL BIOL, V12, P4872, DOI 10.1128/MCB.12.11.4872; SELDEN RF, 1995, CURRENT PROTOCOLS MO, V1; SHENOLIKAR S, 1994, ANNU REV CELL BIOL, V10, P55, DOI 10.1146/annurev.cellbio.10.1.55; Sontag E, 1996, NEURON, V17, P1201, DOI 10.1016/S0896-6273(00)80250-0; Strack S, 1997, MOL BRAIN RES, V49, P15, DOI 10.1016/S0169-328X(97)00117-4; Strack S, 1997, J NEUROCHEM, V68, P2119; WADZINSKI BE, 1993, MOL CELL BIOL, V13, P2822, DOI 10.1128/MCB.13.5.2822; WADZINSKI BE, 1992, J BIOL CHEM, V267, P16883; WERA S, 1995, BIOCHEM J, V311, P17, DOI 10.1042/bj3110017; Westphal RS, 1998, SCIENCE, V280, P1258, DOI 10.1126/science.280.5367.1258	39	63	69	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 26	1999	274	9					5339	5347		10.1074/jbc.274.9.5339	http://dx.doi.org/10.1074/jbc.274.9.5339			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	170KG	10026142	hybrid			2022-12-25	WOS:000078804400013
J	Manabe, R; Oh-e, N; Sekiguchi, K				Manabe, R; Oh-e, N; Sekiguchi, K			Alternatively spliced EDA segment regulates fibronectin-dependent cell cycle progression and mitogenic signal transduction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; TYROSINE PHOSPHORYLATION; RETINOBLASTOMA PROTEIN; MAP KINASE; INTEGRINS; ACTIVATION; P130(CAS); ISOFORM; DOMAIN; ALPHA-5-BETA-1	Fibronectin (FN) is comprised of multiple isoforms arising from alternative splicing of a single gene transcript. One of the alternatively spliced segments, EDA, is expressed prominently in embryonic development, malignant transformation, and wound healing. We showed previously that EDA(+) FN was more potent than EDA(-) FN in promoting cell spreading and cell migration because of its enhanced binding affinity to integrin alpha 5 beta 1 (Manabe, R., Oh-e, N., Maeda, T., Fukuda, T., and Sekiguchi, K. (1997) J. Cell Biol. 139, 295-307). In this study, we compared the cell cycle progression and its associated signal transduction events induced by FN isoforms with or without the EDA segment to examine whether the EDA segment modulates the cell proliferative potential of FN. We found that EDA(+) FN was more potent than EDA- FN in inducing G(1)-S phase transition. Inclusion of the EDA segment potentiated the ability of FN to induce expression of cyclin D1, hyperphosphorylation of pRb, and activation of mitogen-activated protein kinase extracellular signal regulated kinase 2 (ERK2). EDA(+) FN was also more potent than EDA(-) FN in promoting FN-mediated tyrosine phosphorylation of p130(Cas), but not focal adhesion kinase, which occurred in parallel with the activation of ERK2, suggesting that p130(Cas) may be involved in activation of ERK2, These results indicated that alternative splicing at the EDA region is a novel mechanism that promotes FN-induced cell cycle progression through up-regulation of integrin-mediated mitogenic signal transduction.	Osaka Med Ctr Maternal & Child Hlth, Inst Res, Osaka 5941101, Japan		Sekiguchi, K (corresponding author), Osaka Univ, Inst Prot Res, 3-2 Yamadaoka, Osaka 5650871, Japan.	sekiguch@protein.osaka-u.ac.jp						Arai H, 1997, AM J PATHOL, V151, P403; BOETTIGER D, 1995, DEV BIOL, V169, P261, DOI 10.1006/dbio.1995.1142; BROWN LF, 1993, AM J PATHOL, V142, P793; CARNEMOLLA B, 1989, J CELL BIOL, V108, P1139, DOI 10.1083/jcb.108.3.1139; CASTELLANI P, 1994, INT J CANCER, V59, P612, DOI 10.1002/ijc.2910590507; Chen J, 1996, CELL ADHES COMMUN, V4, P237, DOI 10.3109/15419069609010769; CHEN QM, 1994, J BIOL CHEM, V269, P26602; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; FFRENCHCONSTANT C, 1995, EXP CELL RES, V221, P261, DOI 10.1006/excr.1995.1374; FFRENCHCONSTANT C, 1989, J CELL BIOL, V109, P903, DOI 10.1083/jcb.109.2.903; FFRENCHCONSTANT C, 1989, DEVELOPMENT, V106, P375; Giancotti FG, 1997, CURR OPIN CELL BIOL, V9, P691, DOI 10.1016/S0955-0674(97)80123-8; GUAN JL, 1991, CELL REGUL, V2, P951, DOI 10.1091/mbc.2.11.951; GUAN JL, 1990, CELL, V60, P53, DOI 10.1016/0092-8674(90)90715-Q; HANKS SK, 1992, P NATL ACAD SCI USA, V89, P8487, DOI 10.1073/pnas.89.18.8487; HEMLER ME, 1987, J BIOL CHEM, V262, P11478; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Hynes RO, 1990, FIBRONECTINS; KIEFFER N, 1991, J CELL BIOL, V113, P451, DOI 10.1083/jcb.113.2.451; Kolanus W, 1997, CURR OPIN CELL BIOL, V9, P725, DOI 10.1016/S0955-0674(97)80127-5; KORNBLIHTT AR, 1984, NUCLEIC ACIDS RES, V12, P5853, DOI 10.1093/nar/12.14.5853; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; Leahy DJ, 1996, CELL, V84, P155, DOI 10.1016/S0092-8674(00)81002-8; Lin TH, 1997, J CELL BIOL, V136, P1385, DOI 10.1083/jcb.136.6.1385; Liu F, 1998, CURR BIOL, V8, P173, DOI 10.1016/S0960-9822(98)70066-1; Lundell BI, 1996, BLOOD, V87, P2450, DOI 10.1182/blood.V87.6.2450.bloodjournal8762450; MAEDA T, 1989, J BIOL CHEM, V264, P15165; Manabe R, 1997, J CELL BIOL, V139, P295, DOI 10.1083/jcb.139.1.295; MORINO N, 1995, J BIOL CHEM, V270, P269, DOI 10.1074/jbc.270.1.269; MOULD AP, 1990, J BIOL CHEM, V265, P4020; MULLER U, 1995, MOL BIOL CELL, V6, P433; NOJIMA Y, 1990, J EXP MED, V172, P1185, DOI 10.1084/jem.172.4.1185; NOJIMA Y, 1995, J BIOL CHEM, V270, P15398, DOI 10.1074/jbc.270.25.15398; ORREN DK, 1995, MOL CELL BIOL, V15, P3722; OYAMA F, 1993, CANCER RES, V53, P2005; OYAMA F, 1989, BIOCHEMISTRY-US, V28, P3293; PATCH LA, 1995, J CELL SCI, V108, P1371; RUOSLAHTI E, 1994, CELL, V77, P477, DOI 10.1016/0092-8674(94)90209-7; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; Schlaepfer DD, 1997, MOL CELL BIOL, V17, P1702, DOI 10.1128/MCB.17.3.1702; SCHLAEPFER DD, 1994, NATURE, V372, P786; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; SCHWARZBAUER JE, 1987, EMBO J, V6, P2573, DOI 10.1002/j.1460-2075.1987.tb02547.x; SCHWARZBAUER JE, 1983, CELL, V35, P421, DOI 10.1016/0092-8674(83)90175-7; VARTIO T, 1987, J CELL SCI, V88, P419; Vuori K, 1996, MOL CELL BIOL, V16, P2606; VUORI K, 1995, J BIOL CHEM, V270, P22259, DOI 10.1074/jbc.270.38.22259; Wary KK, 1996, CELL, V87, P733, DOI 10.1016/S0092-8674(00)81392-6; WAYNER EA, 1989, J CELL BIOL, V109, P1321, DOI 10.1083/jcb.109.3.1321; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; YAMADA KM, 1991, J BIOL CHEM, V266, P12809; ZARDI L, 1987, EMBO J, V6, P2337, DOI 10.1002/j.1460-2075.1987.tb02509.x; Zhu XY, 1996, J CELL BIOL, V133, P391, DOI 10.1083/jcb.133.2.391; ZHU XY, 1995, MOL BIOL CELL, V6, P273, DOI 10.1091/mbc.6.3.273	55	93	94	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 26	1999	274	9					5919	5924		10.1074/jbc.274.9.5919	http://dx.doi.org/10.1074/jbc.274.9.5919			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	170KG	10026216	hybrid, Green Published			2022-12-25	WOS:000078804400087
J	Kubota, S; Copeland, TD; Pomerantz, RJ				Kubota, S; Copeland, TD; Pomerantz, RJ			Nuclear and nucleolar targeting of human ribosomal protein S25: Common features shared with HIV-1 regulatory proteins	ONCOGENE			English	Article						ribosome; protein; nuclear targeting; rev; HIV-1	IMMUNODEFICIENCY-VIRUS TYPE-1; REV TRANS-ACTIVATOR; GENE-EXPRESSION; MESSENGER-RNA; POSTTRANSCRIPTIONAL REGULATION; FUNCTIONAL-ANALYSIS; VISNA VIRUS; I REX; LOCALIZATION; SEQUENCE	The nuclear and nucleolar targeting properties of human ribosomal protein S25 (RPS25) were analysed by the expression of epitope-tagged RPS25 cDNAs in Cos-l cells. The tagged RPS25 was localized to the cell nucleus, with a strong predominance in the nucleolus. At the amino terminus of RPS25, two stretches of highly basic residues juxtapose. This configuration shares common features with the nucleolar targeting signals (NOS) of lentiviral RNA-binding transactivators, including human immunodeficiency viruses' (HIV) Rev proteins. Deletion and site-directed mutational analyses demonstrated that the first NOS-like stretch is dispensable for both nuclear and nucleolar localization of RPS25, and that the nuclear targeting signal is located within the second NOS-like stretch. It has also been suggested that a set of continuous basic residues and the total number of basic residues should be required for nucleolar targeting. Signal-mediated nuclear/nucleolar targeting was further characterized by the construction and expression of a variety of chimeric constructs, utilizing three different backbones with RPS25 cDNA fragments. Immunofluorescence analyses demonstrated a 17 residue peptide of RPS25 as a potential nuclear/nucleolar targeting signal. The identified peptide signal may belong to a putative subclass of NOS, characterized by compact structure, together with lentiviral RNA binding transactivators.	Thomas Jefferson Univ, Jefferson Med Coll, Dept Med,Dorrance H Hamilton Labs, Div Infect Dis,Ctr Human Virol, Philadelphia, PA 19107 USA; NCI, Frederick Canc Res & Dev Ctr, ABL Basic Res Program, Ft Detrick, MD 21702 USA	Jefferson University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	Pomerantz, RJ (corresponding author), Thomas Jefferson Univ, Jefferson Med Coll, Dept Med,Dorrance H Hamilton Labs, Div Infect Dis,Ctr Human Virol, Philadelphia, PA 19107 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI036552] Funding Source: NIH RePORTER; NIAID NIH HHS [AI36552] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADACHI Y, 1992, J BIOL CHEM, V267, P21977; AGRAWAL MG, 1987, J BIOL CHEM, V262, P4868; AKEY CW, 1989, J CELL BIOL, V109, P971, DOI 10.1083/jcb.109.3.971; ALONI R, 1992, MOL CELL BIOL, V12, P2203, DOI 10.1128/MCB.12.5.2203; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; DANG CV, 1989, J BIOL CHEM, V264, P18019; ENG FJ, 1991, CELL, V65, P797, DOI 10.1016/0092-8674(91)90387-E; FISCHER U, 1994, EMBO J, V13, P4105, DOI 10.1002/j.1460-2075.1994.tb06728.x; GOLDFARB DS, 1997, CURR BIOL, V7, P1213; Gorlich D, 1996, SCIENCE, V271, P1513, DOI 10.1126/science.271.5255.1513; GRITZ L, 1985, MOL CELL BIOL, V5, P3436, DOI 10.1128/MCB.5.12.3436; HEAPHY S, 1990, CELL, V60, P685, DOI 10.1016/0092-8674(90)90671-Z; IMAI T, 1994, GENOMICS, V20, P142, DOI 10.1006/geno.1994.1145; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; KALLAND KH, 1994, MOL CELL BIOL, V14, P7436, DOI 10.1128/MCB.14.11.7436; KUBOTA S, 1991, J VIROL, V65, P2452, DOI 10.1128/JVI.65.5.2452-2456.1991; KUBOTA S, 1989, BIOCHEM BIOPH RES CO, V162, P963, DOI 10.1016/0006-291X(89)90767-5; Kubota S, 1996, J VIROL, V70, P1282, DOI 10.1128/JVI.70.2.1282-1287.1996; LI H, 1995, J MOL BIOL, V250, P447, DOI 10.1006/jmbi.1995.0389; LI ML, 1991, GENE, V107, P329, DOI 10.1016/0378-1119(91)90335-9; MAGER WH, 1988, BIOCHIM BIOPHYS ACTA, V949, P1, DOI 10.1016/0167-4781(88)90048-6; MALIM MH, 1991, CELL, V65, P241, DOI 10.1016/0092-8674(91)90158-U; MALIM MH, 1989, NATURE, V338, P254, DOI 10.1038/338254a0; MALIM MH, 1989, CELL, V58, P205, DOI 10.1016/0092-8674(89)90416-9; MartinNieto J, 1997, J CELL SCI, V110, P955; MELCHIOR F, 1995, CURR OPIN CELL BIOL, V7, P310, DOI 10.1016/0955-0674(95)80084-0; MEYER BE, 1994, GENE DEV, V8, P1538, DOI 10.1101/gad.8.13.1538; Michael WM, 1996, J BIOL CHEM, V271, P11571, DOI 10.1074/jbc.271.19.11571; MORELAND RB, 1985, P NATL ACAD SCI USA, V82, P6561, DOI 10.1073/pnas.82.19.6561; NOSAKA T, 1993, EXP CELL RES, V209, P89, DOI 10.1006/excr.1993.1289; PECULIS BA, 1992, J CELL BIOL, V116, P1, DOI 10.1083/jcb.116.1.1; RICHARD N, 1994, VIROLOGY, V204, P123, DOI 10.1006/viro.1994.1516; Rout MP, 1997, CELL, V89, P715, DOI 10.1016/S0092-8674(00)80254-8; Russo G, 1997, J BIOL CHEM, V272, P5229, DOI 10.1074/jbc.272.8.5229; SCHMIDT C, 1995, MOL BIOL CELL, V6, P1875, DOI 10.1091/mbc.6.12.1875; SCHMIDTZACHMANN MS, 1993, J CELL SCI, V105, P799; SCHOBORG RV, 1994, VIROLOGY, V202, P485, DOI 10.1006/viro.1994.1367; SEIKI M, 1988, P NATL ACAD SCI USA, V85, P7124, DOI 10.1073/pnas.85.19.7124; SIOMI H, 1988, CELL, V55, P197, DOI 10.1016/0092-8674(88)90043-8; SIOMI H, 1990, J VIROL, V64, P1803, DOI 10.1128/JVI.64.4.1803-1807.1990; SIOMI H, 1995, J CELL BIOL, V129, P551, DOI 10.1083/jcb.129.3.551; SODROSKI J, 1985, SCIENCE, V227, P171, DOI 10.1126/science.2981427; SOLLNERWEBB B, 1991, TRENDS BIOCHEM SCI, V16, P58, DOI 10.1016/0968-0004(91)90025-Q; SOMMERVILLE J, 1986, TRENDS BIOCHEM SCI, V11, P438, DOI 10.1016/0968-0004(86)90242-2; TAN RY, 1993, CELL, V73, P1031, DOI 10.1016/0092-8674(93)90280-4; TANG CK, 1990, BIOCHEMISTRY-US, V29, P4434, DOI 10.1021/bi00470a025; TASHEVA ES, 1995, GENE DEV, V9, P304, DOI 10.1101/gad.9.3.304; TILEY LS, 1991, J VIROL, V65, P3877, DOI 10.1128/JVI.65.7.3877-3881.1991; Warner JR, 1990, CURR OPIN CELL BIOL, V2, P521, DOI 10.1016/0955-0674(90)90137-4; YAN C, 1993, J CELL BIOL, V123, P1081, DOI 10.1083/jcb.123.5.1081; ZAPP ML, 1989, NATURE, V342, P714, DOI 10.1038/342714a0	51	36	40	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 18	1999	18	7					1503	1514		10.1038/sj.onc.1202429	http://dx.doi.org/10.1038/sj.onc.1202429			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	167UK	10050887				2022-12-25	WOS:000078651600012
J	Ess, KC; Witte, DP; Bascomb, CP; Aronow, BJ				Ess, KC; Witte, DP; Bascomb, CP; Aronow, BJ			Diverse developing mouse lineages exhibit high-level c-Myb expression in immature cells and loss of expression upon differentiation	ONCOGENE			English	Article						in situ hybridization; transcription factor; repression; anti-differentiation; development; stem cell; embryogenesis	ADENOSINE-DEAMINASE GENE; LOCUS-CONTROL REGION; B-MYB; A-MYB; TRANSGENIC MICE; HAIR FOLLICLE; TERMINAL DIFFERENTIATION; TRANSCRIPTION FACTORS; LUNG MORPHOGENESIS; GUT EPITHELIUM	The c-myb gene encodes a sequence specific transactivator that is required for fetal hematopoiesis, but its potential role in other tissues is less clear because of the early fetal demise of mice with targeted deletions of the c-myb gene and incomplete of knowledge about c-myb's expression pattern. In the hematopoietic system, c-Myb protein acts on target genes whose expression is restricted to individual lineages, despite Myb's presence and role in multiple immature lineages. This suggests that c-Myb actions within different cell type-specific contexts are strongly affected by combinatorial interactions, To consider the possibility of similar c-Myb actions could extend into non-hematopoietic systems in other cell and tissue compartments, we characterized c-myb expression in developing and adult mice using in situ hybridization and correlated this with stage-specific differentiation and mitotic activity, Diverse tissues exhibited strong c-myb expression during development, notably tooth buds, the thyroid primordium, developing trachea and proximal branching airway epithelium, hair follicles, hematopoietic cells, and gastrointestinal crypt epithelial cells, The latter three of these all maintained high expression into adulthood, but with characteristic restriction to immature cell lineages prior to their terminal differentiation. In all sites, during fetal and adult stages, loss of c-Myb expression correlated strikingly with the initiation of terminal differentiation, but not the loss of mitotic activity. Based on these data, we hypothesize that c-Myb's function during cellular differentiation is both an activator of immature gene expression and a suppressor of terminal differentiation in diverse lineages.	Univ Cincinnati, Childrens Hosp Res Fdn, Div Med & Mol Genet, Cincinnati, OH 45229 USA; Univ Cincinnati, Childrens Hosp Res Fdn, Dept Pathol, Cincinnati, OH 45229 USA; Miami Valley Lab, Div Corp Res, Cincinnati, OH 45061 USA	Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation; University System of Ohio; University of Cincinnati; Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation; University System of Ohio; University of Cincinnati	Aronow, BJ (corresponding author), Univ Cincinnati, Childrens Hosp Res Fdn, Div Med & Mol Genet, Cincinnati, OH 45229 USA.		Aronow, Bruce J/F-8438-2012		NHLBI NIH HHS [HL07527] Funding Source: Medline; NIDDK NIH HHS [DK47022] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047022] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARONOW B, 1989, GENE DEV, V3, P1384, DOI 10.1101/gad.3.9.1384; ARONOW BJ, 1995, MOL CELL BIOL, V15, P1123; ARONOW BJ, 1992, MOL CELL BIOL, V12, P4170, DOI 10.1128/MCB.12.9.4170; BADIANI P, 1994, GENE DEV, V8, P770, DOI 10.1101/gad.8.7.770; BARLETTA C, 1992, European Journal of Gynaecological Oncology, V13, P53; Bellon T, 1997, BLOOD, V90, P1828, DOI 10.1182/blood.V90.5.1828; Bellusci S, 1996, DEVELOPMENT, V122, P1693; Bellusci S, 1997, DEVELOPMENT, V124, P53; BEPLER G, 1989, ONCOGENE, V4, P45; BOHINSKI RJ, 1994, MOL CELL BIOL, V14, P5671, DOI 10.1128/MCB.14.9.5671; BritosBray M, 1997, MOL CELL BIOL, V17, P5127, DOI 10.1128/MCB.17.9.5127; CHANDRASENA G, 1992, CELL MOL BIOL, V38, P243; COHN SM, 1992, J CELL BIOL, V119, P27, DOI 10.1083/jcb.119.1.27; CUDDIHY AE, 1993, MOL CELL BIOL, V13, P3505, DOI 10.1128/MCB.13.6.3505; Dai P, 1996, GENE DEV, V10, P528, DOI 10.1101/gad.10.5.528; DESBIENS X, 1991, DEVELOPMENT, V111, P699; ESS KC, 1995, MOL CELL BIOL, V15, P5707; GEWIRTZ AM, 1989, SCIENCE, V245, P180, DOI 10.1126/science.2665077; GOODLAD RA, 1992, VIRCHOWS ARCH B, V61, P415, DOI 10.1007/BF02890445; GORDON JI, 1994, CURR OPIN CELL BIOL, V6, P795, DOI 10.1016/0955-0674(94)90047-7; HERNANDEZMUNAIN C, 1994, MOL CELL BIOL, V14, P473, DOI 10.1128/MCB.14.1.473; HIJIYA N, 1994, P NATL ACAD SCI USA, V91, P4499, DOI 10.1073/pnas.91.10.4499; HOFFMANLIEBERMANN B, 1991, MOL CELL BIOL, V11, P2375, DOI 10.1128/MCB.11.5.2375; HSIANG YHH, 1995, J IMMUNOL, V154, P5195; INTRONA M, 1994, SEMIN CANCER BIOL, V5, P113; KaneiIshii C, 1997, SCIENCE, V277, P246, DOI 10.1126/science.277.5323.246; KIEFER PE, 1987, CANCER RES, V47, P6236; KLEMPNAUER KH, 1982, CELL, V31, P453, DOI 10.1016/0092-8674(82)90138-6; Kollar EJ, 1983, EPITHELIAL MESENCHYM, P27; KowenzLeutz E, 1997, CELL, V91, P185, DOI 10.1016/S0092-8674(00)80401-8; LAM EWF, 1992, ONCOGENE, V7, P1885; Latham KE, 1996, ONCOGENE, V13, P1161; LAZZARO D, 1991, DEVELOPMENT, V113, P1093; LYON J, 1994, CRIT REV ONCOGENESIS, V5, P373, DOI 10.1615/CritRevOncog.v5.i4.30; MACKENZIE A, 1992, DEVELOPMENT, V115, P403; MCCRACKEN S, 1994, ONCOGENE, V9, P3609; MCDERMOTT FT, 1976, VIRCHOWS ARCH B, V22, P353; MIZUGUCHI G, 1995, J BIOL CHEM, V270, P9384, DOI 10.1074/jbc.270.16.9384; MIZUGUCHI G, 1990, J BIOL CHEM, V265, P9280; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; MUKHOPADHYAYA R, 1992, J VIROL, V66, P6035, DOI 10.1128/JVI.66.10.6035-6044.1992; NAKAGOSHI H, 1993, J BIOL CHEM, V268, P14161; NASONBURCHENAL K, 1993, P NATL ACAD SCI USA, V90, P1619, DOI 10.1073/pnas.90.4.1619; NESS SA, 1993, GENE DEV, V7, P749, DOI 10.1101/gad.7.5.749; Oh IH, 1997, J BIOL CHEM, V272, P21432, DOI 10.1074/jbc.272.34.21432; Postigo AA, 1997, EMBO J, V16, P3924, DOI 10.1093/emboj/16.13.3924; QUEVA C, 1992, DEVELOPMENT, V114, P125; Rosenthal MA, 1996, CELL GROWTH DIFFER, V7, P961; ROTTMAN JN, 1993, J BIOL CHEM, V268, P11994; SEIBERG M, 1995, J INVEST DERMATOL, V104, P78, DOI 10.1111/1523-1747.ep12613555; SELVAKUMARAN M, 1992, MOL CELL BIOL, V12, P2493, DOI 10.1128/MCB.12.6.2493; SHAPIRO LH, 1995, J BIOL CHEM, V270, P8763, DOI 10.1074/jbc.270.15.8763; SHEINESS D, 1984, MOL CELL BIOL, V4, P1206, DOI 10.1128/MCB.4.7.1206; Sitzmann J, 1996, ONCOGENE, V12, P1889; STENN KS, 1994, J INVEST DERMATOL, V103, P107, DOI 10.1111/1523-1747.ep12391844; TASHIRO S, 1995, ONCOGENE, V10, P1699; THOMPSON CB, 1986, NATURE, V319, P374, DOI 10.1038/319374a0; THOMPSON MA, 1995, BIOESSAYS, V17, P341, DOI 10.1002/bies.950170410; Thompson MA, 1997, ONCOGENE, V14, P1715, DOI 10.1038/sj.onc.1201007; TORELLI G, 1987, CANCER RES, V47, P5266; Toscani A, 1997, NATURE, V386, P713, DOI 10.1038/386713a0; TRAUTH K, 1994, EMBO J, V13, P5994, DOI 10.1002/j.1460-2075.1994.tb06945.x; Tung J, 1997, AM J PHYSIOL-GASTR L, V273, pG83, DOI 10.1152/ajpgi.1997.273.1.G83; VANGENDEREN C, 1994, GENE DEV, V8, P2691, DOI 10.1101/gad.8.22.2691; Wallrapp C, 1997, CANCER RES, V57, P3135; WERT SE, 1993, DEV BIOL, V156, P426, DOI 10.1006/dbio.1993.1090; WILSON C, 1994, DIFFERENTIATION, V55, P127, DOI 10.1046/j.1432-0436.1994.5520127.x; WITTE DP, 1991, J CELL BIOL, V115, P179, DOI 10.1083/jcb.115.1.179; WOLFF L, 1991, J VIROL, V65, P3607, DOI 10.1128/JVI.65.7.3607-3616.1991; Zannini M, 1997, EMBO J, V16, P3185, DOI 10.1093/emboj/16.11.3185; ZHOU PB, 1995, GENE DEV, V9, P700, DOI 10.1101/gad.9.6.700	71	43	45	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 28	1999	18	4					1103	1111		10.1038/sj.onc.1202387	http://dx.doi.org/10.1038/sj.onc.1202387			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	165FT	10023687				2022-12-25	WOS:000078510600028
J	Watts, RG; Huang, CS; Young, MR; Li, JJ; Dong, ZG; Pennie, WD; Colburn, NH				Watts, RG; Huang, CS; Young, MR; Li, JJ; Dong, ZG; Pennie, WD; Colburn, NH			Expression of dominant negative Erk2 inhibits AP-1 transactivation and neoplastic transformation	ONCOGENE			English	Article						MAP kinases; transcription factors; tumor promotion; neoplastic transformation	ACTIVATED PROTEIN-KINASE; SERUM RESPONSE ELEMENT; PROMOTER-INDUCED TRANSFORMATION; SIGNAL-REGULATED KINASES; GROWTH-FACTOR RECEPTOR; C-FOS EXPRESSION; TERNARY COMPLEX; MAP KINASE; JB6 CELLS; S6 KINASE	The mitogen activated protein (MAP) kinases or extracellular signal-regulated kinases (Erks) are activated in response to Ras expression or exposure to tumor promoters or to growth factors, and have been implicated in AP-I transactivation in some models. We have shown that tumor promoter induced activation of the transcription factor AP-1 is required for induced neoplastic transformation in the Balb/C JB6 cell model. Jun and Fos family protein levels have been found not to be limiting for AP-l response. The present study asks whether activation of Erks1 and 2 is required for AP-1 transactivation and transformation of JB6 cells and whether Erks might be targeted for cancer prevention. Expression of either of two different dominant negative kinase inactive Erk2 mutants in transformation sensitive (P+) JB6 cells substantially inhibited the tumor promoter induced activation of Erks1 and 2 and of AP-I measured by a collagenase-luciferase reporter. Multiple mutant Erk2 expressing clonal lines were also rendered non-responsive to induced neoplastic transformation. These observations, together with our recent finding attributing AP-1 non-responsiveness to Erk deficiency in a clonal line of transformation resistant (P-) cells, argue for a requirement for Erks1 and/or 2 activation in AP-1 transactivation in the mouse JB6 neoplastic progression model, and suggest the utility of Erks as a prevention target.	NCI, Frederick Canc Res & Dev Ctr, Lab Biochem Pathol, Frederick, MD 21702 USA; Univ Minnesota, Hormel Inst, Austin, MN 55912 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; University of Minnesota System	Colburn, NH (corresponding author), NCI, Frederick Canc Res & Dev Ctr, Lab Biochem Pathol, Bldg 560, Frederick, MD 21702 USA.			Li, Jian Jian/0000-0003-3694-9675; Huang, Chuanshu/0000-0003-4133-5096				AHN NG, 1990, J BIOL CHEM, V265, P11495; ALVAREZ E, 1991, J BIOL CHEM, V266, P15277; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ANGEL P, 1988, CELL, V5, P62; BENARI ET, 1992, MOL CARCINOGEN, V5, P62, DOI 10.1002/mc.2940050111; BERNSTEIN LR, 1994, J BIOL CHEM, V269, P9401; BERNSTEIN LR, 1989, SCIENCE, V244, P566, DOI 10.1126/science.2541502; BERNSTEIN LR, 1991, ENVIRON HEALTH PERSP, V93, P111, DOI 10.2307/3431178; Buttice G, 1996, ONCOGENE, V13, P2297; CAVIGELLI M, 1995, EMBO J, V14, P5957, DOI 10.1002/j.1460-2075.1995.tb00284.x; COBB MH, 1991, CELL REGUL, V2, P965, DOI 10.1091/mbc.2.12.965; COLBURN NH, 1981, P NATL ACAD SCI-BIOL, V78, P6912, DOI 10.1073/pnas.78.11.6912; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; DONG ZG, 1994, P NATL ACAD SCI USA, V91, P609, DOI 10.1073/pnas.91.2.609; FROST JA, 1994, P NATL ACAD SCI USA, V91, P3844, DOI 10.1073/pnas.91.9.3844; GILLE H, 1995, CURR BIOL, V5, P1191, DOI 10.1016/S0960-9822(95)00235-1; GILLE H, 1995, EMBO J, V14, P951, DOI 10.1002/j.1460-2075.1995.tb07076.x; GREGORY JS, 1989, J BIOL CHEM, V264, P18397; GRUDA MC, 1994, ONCOGENE, V9, P2537; Huang CS, 1998, P NATL ACAD SCI USA, V95, P156, DOI 10.1073/pnas.95.1.156; KORTENJANN M, 1994, MOL CELL BIOL, V14, P4815, DOI 10.1128/MCB.14.7.4815; LEE RM, 1992, J BIOL CHEM, V267, P1088; Li JJ, 1996, CANCER RES, V56, P483; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MINDEN A, 1994, MOL CELL BIOL, V14, P6683, DOI 10.1128/MCB.14.10.6683; MIRANTI CK, 1995, MOL CELL BIOL, V15, P3672; NORTHWOOD IC, 1991, J BIOL CHEM, V266, P15266; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; ROBBINS DJ, 1993, J BIOL CHEM, V268, P5097; Robinson MJ, 1996, BIOCHEMISTRY-US, V35, P5641, DOI 10.1021/bi952723e; SHAW PE, 1989, CELL, V56, P563, DOI 10.1016/0092-8674(89)90579-5; Strahl T, 1996, P NATL ACAD SCI USA, V93, P11563, DOI 10.1073/pnas.93.21.11563; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; TAKASHIMA K, 1991, P NATL ACAD SCI USA, V88, P2520; THOMAS G, 1992, CELL, V68, P3, DOI 10.1016/0092-8674(92)90199-M; TRIESMAN R, 1992, TRENDS BIOCHEM SCI, V17, P423; Vogt P K, 1990, Adv Cancer Res, V55, P1, DOI 10.1016/S0065-230X(08)60466-2; Waskiewicz AJ, 1997, EMBO J, V16, P1909, DOI 10.1093/emboj/16.8.1909; WATTS RG, 1995, MOL CARCINOGEN, V13, P27, DOI 10.1002/mc.2940130106; WESTWICK JK, 1994, P NATL ACAD SCI USA, V91, P6030, DOI 10.1073/pnas.91.13.6030; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; Winston LA, 1995, J BIOL CHEM, V270, P30837, DOI 10.1074/jbc.270.52.30837; ZINCK R, 1995, MOL CELL BIOL, V15, P4930	45	103	105	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 31	1998	17	26					3493	3498		10.1038/sj.onc.1202259	http://dx.doi.org/10.1038/sj.onc.1202259			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	157XD	10030673				2022-12-25	WOS:000078086200010
J	Elbrecht, A; Chen, YL; Adams, A; Berger, J; Griffin, P; Klatt, T; Zhang, B; Menke, J; Zhou, GC; Smith, RG; Moller, DE				Elbrecht, A; Chen, YL; Adams, A; Berger, J; Griffin, P; Klatt, T; Zhang, B; Menke, J; Zhou, GC; Smith, RG; Moller, DE			L-764406 is a partial agonist of human peroxisome proliferator-activated receptor gamma - The role of Cys(313) in ligand binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACIDS; ESTROGEN-RECEPTOR; GENE-EXPRESSION; EICOSANOIDS; SUPERFAMILY; HORMONE; MEMBER; AGENTS; ALPHA; J(2)	Insulin-sensitizing thiazolidinedione (TZD) compounds are high affinity ligands for a member of the nuclear receptor family, peroxisome proliferator-activated receptor (PPAR) gamma, A scintillation proximity assay for measurement of H-3-radiolabeled TZD binding to human PPAR gamma under homogeneous conditions was developed. Using this approach, a novel non-TZD compound (L-764406) was shown to be a potent (apparent binding IC50 of 70 nM) PPAR gamma ligand, Preincubation of PPAR gamma with L-764406 prevented binding of the [H-3]TZD, suggesting a covalent interaction with the receptor; in addition, structurally related analogues of L-764406, which would be predicted not to interact with PPAR gamma in a covalent fashion, did not displace [H-3]TZD binding to PPAR gamma, Covalent binding of L-764406 was proven by an observed molecular weight shift of a tryptic PPAR gamma ligand binding domain (LBD) peptide by mass spectrometric analysis. A specific cysteine residue (Cys(313) in, helix 3 of hPPAR gamma 2) was identified as the attachment site for this compound. In protease protection experiments, the liganded receptor adopted a typical agonist conformation. L-764406 exhibited partial agonist activity in cells expressing a chimeric receptor containing the PPAR gamma LED and a cognate reporter gene and also induced the expression of the adipocyte-specific gene aP2 in 3T3-L1 cells. In contrast, L-764406 did not exhibit activity in cells transfected with chimeric receptors containing PPAR alpha or PPAR delta LBDs. The partial agonist properties of L-764406 were also evident in a co-activator association assay, indicating that the increased transcription in cells was co-activator mediated. Thus, L-764406 is a novel non-TZD ligand for PPAR gamma and is also the first known partial agonist for this receptor. The results suggest a critical functional role for Cys(313) and helix 3, in contributing to ligand binding and subsequent agonist-induced conformational changes.	Merck Res Labs, Dept Mol Endocrinol, Rahway, NJ 07065 USA; Merck Res Labs, Dept Basic Chem, Rahway, NJ 07065 USA	Merck & Company; Merck & Company	Elbrecht, A (corresponding author), Merck Res Labs, Dept Mol Endocrinol, Bldg R80N-C31,126 E Lincoln Ave, Rahway, NJ 07065 USA.	alex_elbrecht@merck.com						ALLAN GF, 1992, J BIOL CHEM, V267, P19513; Berger J, 1996, ENDOCRINOLOGY, V137, P4189, DOI 10.1210/en.137.10.4189; Bisgaier CL, 1998, J LIPID RES, V39, P17; Brown PJ, 1997, CHEM BIOL, V4, P909, DOI 10.1016/S1074-5521(97)90299-4; Brzozowski AM, 1997, NATURE, V389, P753, DOI 10.1038/39645; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; Ekena K, 1998, J BIOL CHEM, V273, P693, DOI 10.1074/jbc.273.2.693; Elbrecht A, 1996, BIOCHEM BIOPH RES CO, V224, P431, DOI 10.1006/bbrc.1996.1044; Forman BM, 1997, P NATL ACAD SCI USA, V94, P4312, DOI 10.1073/pnas.94.9.4312; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; HOLLON T, 1989, ANAL BIOCHEM, V182, P411, DOI 10.1016/0003-2697(89)90616-7; ISSEMANN I, 1990, NATURE, V347, P645, DOI 10.1038/347645a0; Kliewer SA, 1997, P NATL ACAD SCI USA, V94, P4318, DOI 10.1073/pnas.94.9.4318; KLIEWER SA, 1995, CELL, V83, P813, DOI 10.1016/0092-8674(95)90194-9; Krey G, 1997, MOL ENDOCRINOL, V11, P779, DOI 10.1210/me.11.6.779; LARSEN ML, 1993, CURR OPIN LIPIDOL, V4, P34, DOI 10.1097/00041433-199302000-00007; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Marburg S, 1996, BIOCONJUGATE CHEM, V7, P612, DOI 10.1021/bc960053z; MCDONNELL DP, 1995, MOL ENDOCRINOL, V9, P659, DOI 10.1210/me.9.6.659; NOLAN JJ, 1994, NEW ENGL J MED, V331, P1188, DOI 10.1056/NEJM199411033311803; Nolte RT, 1998, NATURE, V395, P137, DOI 10.1038/25931; RENAUD JP, 1995, NATURE, V378, P681, DOI 10.1038/378681a0; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCHMIDT A, 1992, MOL ENDOCRINOL, V6, P1634, DOI 10.1210/me.6.10.1634; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; Zhou GC, 1998, MOL ENDOCRINOL, V12, P1594, DOI 10.1210/me.12.10.1594; ZHU YJ, 1995, P NATL ACAD SCI USA, V92, P7921, DOI 10.1073/pnas.92.17.7921	29	97	102	2	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 19	1999	274	12					7913	7922		10.1074/jbc.274.12.7913	http://dx.doi.org/10.1074/jbc.274.12.7913			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	178LU	10075686	hybrid			2022-12-25	WOS:000079268100045
J	Ichimori, K; Fukahori, M; Nakazawa, H; Okamoto, K; Nishino, T				Ichimori, K; Fukahori, M; Nakazawa, H; Okamoto, K; Nishino, T			Inhibition of xanthine oxidase and xanthine dehydrogenase by nitric oxide - Nitric oxide converts reduced xanthine-oxidizing enzymes into the desulfo-type inactive form	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPR CHARACTERIZATION; REPERFUSION INJURY; MECHANISM; OXYGEN; CELLS; MACROPHAGES; REDUCTASE; RADICALS; SYSTEM; LIVER	Xanthine oxidase (XO) and xanthine dehydrogenase (XDH) were inactivated by incubation with nitric oxide under anaerobic conditions in the presence of xanthine or allopurinol, The inactivation was not pronounced in the absence of an electron donor, indicating that only the reduced enzyme form was inactivated by nitric oxide. The second-order rate constant of the reaction between reduced XO and nitric oxide was determined to be 14.8 +/- 1.4 M-1 s(-1) at 25 degrees C, The inactivated enzymes lacked xanthine-dichlorophenolindophenol activity, and the oxypurinol-bound form of XO was partly protected from the inactivation. The absorption spectrum of the inactivated enzyme was not markedly different from that of the normal enzyme. The flavin and iron-sulfur centers of inactivated XO were reduced by dithionite and reoxidized readily with oxygen, and inactivated XDH retained electron transfer activities from NADH to electron accepters, consistent with the conclusion that the flavin and iron-sulfur centers of the inactivated enzyme both remained intact. Inactivated XO reduced with 6-methylpurine showed no "very rapid" spectra, indicating that the molybdopterin moiety was damaged. Furthermore, inactivated XO reduced by dithionite showed the same slow Mo(V) spectrum as that derived from the desulfo-type enzyme. On the other hand, inactivated XO reduced by dithionite exhibited the same signals for iron-sulfur centers as the normal enzyme. Inactivated XO recovered its activity in the presence of a sulfide-generating system. It is concluded that nitric oxide reacts with an essential sulfur of the reduced molybdenum center of XO and XDH to produce desulfo-type inactive enzymes.	Nippon Med Sch, Dept Biochem & Mol Biol, Tokyo 1138602, Japan; Tokai Univ, Sch Med, Dept Physiol 2, Isehara, Kanagawa 25911, Japan	Nippon Medical School; Tokai University	Nishino, T (corresponding author), Nippon Med Sch, Dept Biochem & Mol Biol, 1-1-5 Sendagi, Tokyo 1138602, Japan.	nishino@nms.ac.jp						ASAHI M, 1995, J BIOL CHEM, V270, P21035, DOI 10.1074/jbc.270.36.21035; BENNETT B, 1994, BIOCHEM SOC T, V22, pS285, DOI 10.1042/bst022285s; CLANCY RM, 1992, J CLIN INVEST, V90, P1116, DOI 10.1172/JCI115929; CLEETER MWJ, 1994, FEBS LETT, V345, P50, DOI 10.1016/0014-5793(94)00424-2; Cote CG, 1996, AM J PHYSIOL-LUNG C, V271, pL869, DOI 10.1152/ajplung.1996.271.5.L869; Della Corte E, 1968, Biochem J, V108, P349; DELLACOR.E, 1972, BIOCHEM J, V126, P739, DOI 10.1042/bj1260739; DRAPIER JC, 1991, J BIOL CHEM, V266, P10162; Fujii H, 1997, J BIOL CHEM, V272, P32773, DOI 10.1074/jbc.272.52.32773; FUKAHORI M, 1994, FREE RADICAL RES, V21, P203, DOI 10.3109/10715769409056572; Gardner PR, 1997, J BIOL CHEM, V272, P25071, DOI 10.1074/jbc.272.40.25071; GARTHWAITE J, 1995, ANNU REV PHYSIOL, V57, P683, DOI 10.1146/annurev.ph.57.030195.003343; GRANGER DN, 1981, GASTROENTEROLOGY, V81, P22; GROSS SS, 1995, ANNU REV PHYSIOL, V57, P737, DOI 10.1146/annurev.ph.57.030195.003513; Harrison R, 1997, BIOCHEM SOC T, V25, P786, DOI 10.1042/bst0250786; HASSOUN PM, 1994, AM J PHYSIOL, V266, pL163, DOI 10.1152/ajplung.1994.266.2.L163; HASSOUN PM, 1995, AM J PHYSIOL-LUNG C, V268, pL809, DOI 10.1152/ajplung.1995.268.5.L809; HENRY Y, 1993, FASEB J, V7, P1124, DOI 10.1096/fasebj.7.12.8397130; HILLE R, 1995, FASEB J, V9, P995, DOI 10.1096/fasebj.9.11.7649415; IKEGAMI T, 1986, ARCH BIOCHEM BIOPHYS, V247, P254, DOI 10.1016/0003-9861(86)90582-5; LEPOIVRE M, 1992, J BIOL CHEM, V267, P22994; MALTHOUSE JPG, 1981, BIOCHEM J, V199, P629, DOI 10.1042/bj1990629; MASSEY V, 1970, J BIOL CHEM, V245, P6595; MASSEY V, 1970, J BIOL CHEM, V245, P2837; MASSEY V, 1969, J BIOL CHEM, V244, P1682; MCCORD JM, 1985, NEW ENGL J MED, V312, P159; MURPHY ME, 1994, METHOD ENZYMOL, V233, P240; NAKAMURA M, 1982, J BIOCHEM-TOKYO, V92, P1279, DOI 10.1093/oxfordjournals.jbchem.a134046; NISHINO T, 1981, FEBS LETT, V131, P369, DOI 10.1016/0014-5793(81)80406-1; NISHINO T, 1989, J BIOL CHEM, V264, P2518; NISHINO T, 1983, P NATL ACAD SCI-BIOL, V80, P1826, DOI 10.1073/pnas.80.7.1826; NISHINO T, 1994, J BIOCHEM, V116, P1; NISHINO T, 1991, ADV EXP MED BIOL, V309, P327; Nishino T, 1997, BIOCHEM SOC T, V25, P783, DOI 10.1042/bst0250783; OLSON JS, 1974, J BIOL CHEM, V249, P4363; PALMER G, 1969, J BIOL CHEM, V244, P2614; Riggs A., 1981, Methods in Enzymology, V76, P5; RINALDO JE, 1994, AM J RESP CELL MOL, V11, P625, DOI 10.1165/ajrcmb.11.5.7524568; Rothgeb T M, 1978, Methods Enzymol, V52, P473; SAUGSTAD OD, 1988, PEDIATR RES, V23, P143, DOI 10.1203/00006450-198802000-00001; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P7674, DOI 10.1073/pnas.89.16.7674; STAUB NC, 1998, PHYSIOLOGY, P561; Wittenberg J.B., 1981, Methods in Enzymology, V76, P29	43	69	71	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	1999	274	12					7763	7768		10.1074/jbc.274.12.7763	http://dx.doi.org/10.1074/jbc.274.12.7763			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	178LU	10075667	hybrid			2022-12-25	WOS:000079268100026
J	Imaizumi, K; Morihara, T; Mori, Y; Katayama, T; Tsuda, M; Furuyama, T; Wanaka, A; Takeda, M; Tohyama, M				Imaizumi, K; Morihara, T; Mori, Y; Katayama, T; Tsuda, M; Furuyama, T; Wanaka, A; Takeda, M; Tohyama, M			The cell death-promoting gene DP5, which interacts with the BCL2 family, is induced during neuronal apoptosis following exposure to amyloid beta protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR DEPENDENCE; CALCIUM HOMEOSTASIS; CORTICAL-NEURONS; ENDOPLASMIC-RETICULUM; LIPID-PEROXIDATION; PEPTIDE; CA2+; TOXICITY; POLYPEPTIDE; HIPPOCAMPAL	DP5, which contains a BH3 domain, was cloned as a neuronal apoptosis-inducing gene. To confirm that DP5 interacts with members of the Bcl-2 family, 293T cells were transiently co-transfected with DP5 and Bcl-xl cDNA constructs, and immunoprecipitation was carried out. The 30-kDa Bcl-xl was co-immunoprecipitated with Myc-tagged DP5, suggesting that DP5 physically interacts with Bcl-xl in mammalian cells. Previously, we reported that DP5 is induced during neuronal apoptosis in cultured sympathetic neurons. Here, we analyzed DP5 gene expression and the specific interaction of DP5 with Bcl-xl during neuronal death induced by amyloid-beta protein (A beta), DP5 mRNA was induced 6 h after treatment with A beta in cultured rat cortical neurons, The protein encoded by DP5 mRNA showed a specific interaction with Bcl-xl, Induction of DP5 gene expression was blocked by nifedipine, an inhibitor of L-type voltage-dependent calcium channels, and dantrolene, an inhibitor of calcium release from the endoplasmic reticulum, These results suggested that the induction of DP5 mRNA occurs downstream of the increase in cytosolic calcium concentration caused by A beta, Moreover, DP5 specifically interacts with Bcl-xl during neuronal apoptosis following exposure to A beta, and its binding could impair the survival-promoting activities of Bcl-xl, Thus, the induction of DP5 mRNA and the interaction of DP5 and Bcl-xl could play significant roles in neuronal degeneration following exposure to A beta.	Osaka Univ, Sch Med, Dept Anat & Neurosci, Suita, Osaka 5650871, Japan; Osaka Univ, Sch Med, Dept Neuropsychiat, Suita, Osaka 5650871, Japan; Tanabe Seiyaku Co Ltd, Yodogawa Ku, Osaka 5320031, Japan; Fukushima Med Coll, Inst Biomed Sci, Fukushima 9601247, Japan; CREST, Kawaguchi 3320012, Japan	Osaka University; Osaka University; Mitsubishi Tanabe Pharma Corporation; Fukushima Medical University; Japan Science & Technology Agency (JST)	Imaizumi, K (corresponding author), Osaka Univ, Sch Med, Dept Anat & Neurosci, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.	imaizumi@anat2.med.osaka-u.ac.jp	Wanaka, Akio/ABE-4671-2020; Morihara, Takashi/AAK-2709-2021; Wanaka, Akio/GPW-8926-2022; Wanaka, Akio/AAC-9754-2019	Wanaka, Akio/0000-0001-9951-9862				Antonsson B, 1997, SCIENCE, V277, P370, DOI 10.1126/science.277.5324.370; BEHL C, 1994, CELL, V77, P817, DOI 10.1016/0092-8674(94)90131-7; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; BOYD JM, 1995, ONCOGENE, V11, P1921; COPANI A, 1995, MOL PHARMACOL, V47, P890; ESTUS S, 1994, J CELL BIOL, V127, P1717, DOI 10.1083/jcb.127.6.1717; Estus S, 1997, J NEUROSCI, V17, P7736; FORLONI G, 1993, NEUROREPORT, V4, P523, DOI 10.1097/00001756-199305000-00015; FUKUYAMA R, 1994, BRAIN RES, V667, P269, DOI 10.1016/0006-8993(94)91505-9; GOODMAN Y, 1994, EXP NEUROL, V128, P1, DOI 10.1006/exnr.1994.1107; Guo Q, 1997, J NEUROSCI, V17, P4212; Han J, 1996, MOL CELL BIOL, V16, P5857; He HL, 1997, J CELL BIOL, V138, P1219, DOI 10.1083/jcb.138.6.1219; Imaizumi K, 1997, J BIOL CHEM, V272, P18842, DOI 10.1074/jbc.272.30.18842; Inohara N, 1997, EMBO J, V16, P1686, DOI 10.1093/emboj/16.7.1686; Kanazawa K, 1998, MOL BRAIN RES, V54, P316, DOI 10.1016/S0169-328X(97)00360-4; Khan AA, 1996, SCIENCE, V273, P503, DOI 10.1126/science.273.5274.503; KILLER RJ, 1987, SCIENCE, V235, P46; KOIKE T, 1989, P NATL ACAD SCI USA, V86, P6421, DOI 10.1073/pnas.86.16.6421; KOIKE T, 1991, P NATL ACAD SCI USA, V88, P3892, DOI 10.1073/pnas.88.9.3892; LAM M, 1993, MOL ENDOCRINOL, V7, P686, DOI 10.1210/me.7.5.686; LAM M, 1994, P NATL ACAD SCI USA, V91, P6569, DOI 10.1073/pnas.91.14.6569; LOO DT, 1993, P NATL ACAD SCI USA, V90, P7951, DOI 10.1073/pnas.90.17.7951; Mark RJ, 1997, J NEUROSCI, V17, P1046; Mark RJ, 1997, J NEUROCHEM, V68, P255; MATTSON MP, 1992, J NEUROSCI, V12, P376, DOI 10.1523/jneurosci.12-02-00376.1992; MATTSON MP, 1993, BRAIN RES, V621, P35, DOI 10.1016/0006-8993(93)90295-X; No D, 1996, P NATL ACAD SCI USA, V93, P3346, DOI 10.1073/pnas.93.8.3346; SONG SK, 1993, P NATL ACAD SCI USA, V90, P3933, DOI 10.1073/pnas.90.9.3933; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Wang K, 1996, GENE DEV, V10, P2859, DOI 10.1101/gad.10.22.2859; WEISS JH, 1994, J NEUROCHEM, V62, P372	32	86	90	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	1999	274	12					7975	7981		10.1074/jbc.274.12.7975	http://dx.doi.org/10.1074/jbc.274.12.7975			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	178LU	10075695	hybrid			2022-12-25	WOS:000079268100054
J	Paudel, HK; Li, W				Paudel, HK; Li, W			Heparin-induced conformational change in microtubule-associated protein tau as detected by chemical cross-linking and phosphopeptide mapping	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PAIRED HELICAL FILAMENTS; ALZHEIMER-LIKE STATE; KINASE PHOSPHORYLATES TAU; IN-VITRO; DISEASE; BRAIN; SITES; IDENTIFICATION; BINDING; SULFATE	In Alzheimer's disease, microtubule-associated protein tau becomes abnormally phosphorylated and aggregates into paired helical filaments. Sulfated glycosaminoglycans such as heparin and heparan sulfate were shown to accumulate in pretangle neurons, stimulate in vitro tau phosphorylation, and cause tan aggregation into paired helical filament-like filaments. The sulfated glycosaminoglycan-tau interaction was suggested to be the central event in the development of neuropathology in Alzheimer's disease brain (Goedert, M,, Jakes, R., Spillantini, M. G., Hasegawa, M., Smith, M. J., and Crowther, R, A. (1996) Nature 383, 550-553), The biochemical mechanism by which sulfated glycosaminoglycans stimulate tau phosphorylation and cause tan aggregation remains unclear. In this study, disuccinimidyl suberate (DSS), a bifunctional chemical cross-linker, cross-linked tau dimers, tetramers, high molecular size aggregates, and two tau species of sizes 72 and 83 kDa in the presence of heparin, In the absence of heparin only dimeric tau was cross-linked by DSS, Fast protein liquid chromatography gel filtration revealed that 72- and 83-kDa species were formed by intramolecular cross-linking of tau by DSS, These observations indicate that heparin, in addition to causing aggregation, also induces a conformational change in tau in which reactive groups are unmasked or move closer leading to the DSS crosslinking of 72- and 83-kDa species. Heparin-induced structural changes in tau molecule depended on time of heparin exposure. Dimerization and tetramerization peaked at 48 h, whereas conformational change was completed within 30 min of heparin exposure. Heparin exposure beyond 48 h caused an abrupt aggregation of tau into high molecular size species. Heparin stimulated tau phosphorylation by neuronal cdc2-like kinase (NCLK) and cAMP-dependent protein kinase, Phosphopeptide mapping and phosphopeptide sequencing revealed that tau is phosphorylated by NCLK on Thr(212) and Thr(231) and by cAMP-dependent protein kinase on Ser(262) only in the presence of heparin, Heparin stimulation of tau phosphorylation by NCLK showed dependence on time of heparin exposure and correlated with the heparin-induced conformational change of tau, Our data suggest that heparin-induced conformational change exposes new sites for phosphorylation within tau molecule.	Bloomfield Ctr Res Aging, Lady Davis Inst Med Res, Montreal, PQ H3T 1E2, Canada; McGill Univ, Dept Neurol & Neurosurg, Montreal, PQ H3T 1E2, Canada; Sir Mortimer B Davis Jewish Hosp, Montreal, PQ H3T 1E2, Canada	Lady Davis Institute; McGill University; McGill University; McGill University	Paudel, HK (corresponding author), Bloomfield Ctr Res Aging, Lady Davis Inst Med Res, 3755 Cote Ste Catherine, Montreal, PQ H3T 1E2, Canada.	MDHP@MUSICA.McGILL.CA						ALONSO AD, 1994, P NATL ACAD SCI USA, V91, P5562, DOI 10.1073/pnas.91.12.5562; Beyreuther K, 1996, NATURE, V383, P476, DOI 10.1038/383476a0; BRANDT R, 1994, J BIOL CHEM, V269, P11776; CLEVELAND DW, 1977, J MOL BIOL, V116, P227, DOI 10.1016/0022-2836(77)90214-5; CORREAS I, 1992, J BIOL CHEM, V267, P15721; CROWTHER RA, 1992, FEBS LETT, V309, P199, DOI 10.1016/0014-5793(92)81094-3; DEWITT DA, 1993, EXP NEUROL, V121, P149, DOI 10.1006/exnr.1993.1081; DILL KA, 1995, ADV PROTEIN CHEM, V46, P59, DOI 10.1016/S0065-3233(08)60332-0; DREWES G, 1995, J BIOL CHEM, V270, P7679, DOI 10.1074/jbc.270.13.7679; DREWES G, 1992, EMBO J, V11, P2131, DOI 10.1002/j.1460-2075.1992.tb05272.x; GOEDERT M, 1993, TRENDS NEUROSCI, V16, P460, DOI 10.1016/0166-2236(93)90078-Z; GOEDERT M, 1992, NEURON, V8, P159, DOI 10.1016/0896-6273(92)90117-V; Goedert M, 1996, NATURE, V383, P550, DOI 10.1038/383550a0; GREENWOOD JA, 1994, J BIOL CHEM, V269, P4373; Hasegawa M, 1997, J BIOL CHEM, V272, P33118, DOI 10.1074/jbc.272.52.33118; Hasegawa M, 1996, FEBS LETT, V384, P25, DOI 10.1016/0014-5793(96)00271-2; HERZOG W, 1978, EUR J BIOCHEM, V92, P1, DOI 10.1111/j.1432-1033.1978.tb12716.x; ISHIGURO K, 1992, J BIOL CHEM, V267, P10897; Jaenicke R, 1997, ADV PROTEIN CHEM, V50, P1, DOI 10.1016/S0065-3233(08)60318-6; LEE VMY, 1991, SCIENCE, V251, P675, DOI 10.1126/science.1899488; LEW J, 1992, J BIOL CHEM, V267, P13383; Litersky JM, 1996, BIOCHEM J, V316, P655, DOI 10.1042/bj3160655; MANDELKOW EM, 1992, FEBS LETT, V314, P315, DOI 10.1016/0014-5793(92)81496-9; MAWALDEWAN M, 1992, J BIOL CHEM, V267, P19705; MORISHIMAKAWASHIMA M, 1995, J BIOL CHEM, V270, P823, DOI 10.1074/jbc.270.2.823; Paudel HK, 1997, J BIOL CHEM, V272, P28328, DOI 10.1074/jbc.272.45.28328; Paudel HK, 1997, J BIOL CHEM, V272, P1777; PAUDEL HK, 1993, J BIOL CHEM, V268, P23512; PERRY G, 1991, J NEUROSCI, V11, P3679; Reynolds CH, 1997, J NEUROCHEM, V69, P191; Reynolds CH, 1997, J NEUROCHEM, V68, P1736; Roden L., 1980, BIOCH GLYCOPROTEINS, P267; Roder HM, 1997, J BIOL CHEM, V272, P4509, DOI 10.1074/jbc.272.7.4509; SCHWEERS O, 1995, P NATL ACAD SCI USA, V92, P8463, DOI 10.1073/pnas.92.18.8463; SCHWEERS O, 1994, J BIOL CHEM, V269, P24290; SCOTT CW, 1993, J BIOL CHEM, V268, P1166; SEUBERT P, 1995, J BIOL CHEM, V270, P18917, DOI 10.1074/jbc.270.32.18917; SINGH TJ, 1995, J NEUROCHEM, V64, P1420; Singh TJ, 1996, FEBS LETT, V387, P145, DOI 10.1016/0014-5793(96)00485-1; Snow AD, 1996, EXP NEUROL, V138, P305, DOI 10.1006/exnr.1996.0069; STEINER B, 1990, EMBO J, V9, P3539, DOI 10.1002/j.1460-2075.1990.tb07563.x; SU JH, 1992, NEUROSCIENCE, V51, P801, DOI 10.1016/0306-4522(92)90521-3; WANG JZ, 1995, J BIOL CHEM, V270, P4854, DOI 10.1074/jbc.270.9.4854; WATANABE A, 1993, J BIOL CHEM, V268, P25712; YANG SD, 1994, J NEUROCHEM, V63, P1416	45	68	73	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	1999	274	12					8029	8038		10.1074/jbc.274.12.8029	http://dx.doi.org/10.1074/jbc.274.12.8029			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	178LU	10075702	hybrid			2022-12-25	WOS:000079268100061
J	Wei, G; Bai, XM; Sarkar, AK; Esko, JD				Wei, G; Bai, XM; Sarkar, AK; Esko, JD			Formation of HNK-1 determinants and the glycosaminoglycan tetrasaccharide linkage region by UDP-GlcUA : galactose beta 1,3-glucuronosyltransferases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARAN-SULFATE; CARBOHYDRATE EPITOPE; BIOSYNTHESIS; GLUCURONOSYLTRANSFERASE; LOCALIZATION; ANTIBODY; PROTEIN; OLIGOSACCHARIDE; GLYCOSYLATION; PROTEOGLYCANS	While expression-cloning enzymes involved in heparan sulfate biosynthesis, we isolated a cDNA that encodes a protein 65% identical to the UDP-GlcUA:glycoprotein beta 1,3-glucuronosyltransferase (GlcUAT-P) involved in forming HNK-1 carbohydrate epitopes (3OSO(3)GlcUA beta 1, 3Gal-) on glycoproteins. The cDNA contains an open reading frame coding for a protein of 335 amino acids with a predicted type II transmembrane protein orientation. Cotransfection of the cDNA with HNK-1 3-O-sulfotransferase produced HNK-1 carbohydrate epitopes in Chinese hamster ovary (CHO) cells and COS-7 cells. In vitro, a soluble recombinant form of the enzyme transferred GlcUA in beta-linkage to Gal beta 1,3/4GlcNAc beta-O-naphthalenemethanol, which resembles the core oligosaccharide on which the HNK-1 epitope is assembled. However, the enzyme greatly preferred Gal beta 1,3Gal beta-O-naphthalenemethanol, a disaccharide component found in the linkage region tetrasaccharide in chondroitin sulfate and heparan sulfate. During the course of this study, a human cDNA clone was described that was thought to encode UDP-GlcUA:Gal beta 1,3Gal-R glucuronosyltransferase (GlcUAT-I), involved in the formation of the linkage region of glycosaminoglycans (Kitagawa, H,, Tone, Y,, Tamura, J,, Neumann, K. W,, Ogawa, T,, Oka, S,, Kawasaki, T,, and Sugahara, K, (1998) J. Biol. Chem. 273, 6615-6618), The deduced amino acid sequences of the CHO and human cDNAs are 95% identical, suggesting that they are in fact homologues of the same gene. Transfection of a CHO cell mutant defective in GlcUAT-I with the hamster cDNA restored glycosaminoglycan assembly in vivo, confirming its identity. Interestingly, transfection of the mutant with GlcUAT-P also restored glycosaminoglycan synthesis. Thus, both GlcUAT-P and GlcUAT-I have overlapping substrate specificities. However, the expression of the two genes was entirely different, with GlcUAT-I expressed in all tissues tested and GlcUAT-P expressed only in brain. These findings suggest that, in neural tissues, GlcUAT-P may participate in both HNK-1 and glycosaminoglycan production.	Univ Calif San Diego, Div Cellular & Mol Med, Glycobiol Res & Training Program, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Esko, JD (corresponding author), Univ Calif San Diego, Div Cellular & Mol Med, Glycobiol Res & Training Program, 9500 Gilman Dr,CMM E 1055, La Jolla, CA 92093 USA.	jesko@ucsd.edu			NCI NIH HHS [CA46462] Funding Source: Medline; NIGMS NIH HHS [GM33063] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA046462] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM033063, R01GM033063] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABO T, 1981, J IMMUNOL, V127, P1024; BAME KJ, 1989, J BIOL CHEM, V264, P8059; BARANSKI TJ, 1991, J BIOL CHEM, V266, P23365; BARANSKI TJ, 1990, CELL, V63, P281, DOI 10.1016/0092-8674(90)90161-7; BERGER EG, 1991, J HISTOCHEM CYTOCHEM, V39, P1439, DOI 10.1177/39.10.1940315; BRANDT AE, 1969, P NATL ACAD SCI USA, V64, P374, DOI 10.1073/pnas.64.1.374; CHOU DKH, 1987, J NEUROCHEM, V49, P865, DOI 10.1111/j.1471-4159.1987.tb00974.x; CHOU DKH, 1986, J BIOL CHEM, V261, P1717; CURENTON T, 1991, BIOCHEM BIOPH RES CO, V179, P416, DOI 10.1016/0006-291X(91)91386-Q; DAS KK, 1991, J BIOL CHEM, V266, P5238; DEUTSCHER SL, 1984, CELL, V39, P295, DOI 10.1016/0092-8674(84)90007-2; DULBECCO R, 1954, J EXP MED, V99, P167, DOI 10.1084/jem.99.2.167; FRITZ TA, 1994, J BIOL CHEM, V269, P28809; HAM RG, 1965, P NATL ACAD SCI USA, V53, P288, DOI 10.1073/pnas.53.2.288; HELTING T, 1969, J BIOL CHEM, V244, P2799; HELTING T, 1972, J BIOL CHEM, V247, P4327; JACOBSSON I, 1979, J BIOL CHEM, V254, P2975; KAWASHIMA C, 1992, GLYCOCONJUGATE J, V9, P307, DOI 10.1007/BF00731091; Kitagawa H, 1998, J BIOL CHEM, V273, P6615, DOI 10.1074/jbc.273.12.6615; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LIDHOLT K, 1992, P NATL ACAD SCI USA, V89, P2267, DOI 10.1073/pnas.89.6.2267; LIND T, 1993, J BIOL CHEM, V268, P20705; Lind T, 1998, J BIOL CHEM, V273, P26265, DOI 10.1074/jbc.273.41.26265; MARGOLIS RK, 1993, EXPERIENTIA, V49, P429, DOI 10.1007/BF01923587; OKA S, 1992, J BIOL CHEM, V267, P22711; Ong E, 1998, J BIOL CHEM, V273, P5190, DOI 10.1074/jbc.273.9.5190; PAULSON JC, 1989, J BIOL CHEM, V264, P17615; Roden L., 1980, BIOCH GLYCOPROTEINS, P267; SCHACHNER M, 1995, TRENDS NEUROSCI, V18, P183, DOI 10.1016/0166-2236(95)93899-9; SHIBATA S, 1995, J BIOL CHEM, V270, P13794, DOI 10.1074/jbc.270.23.13794; Spicer AP, 1998, J BIOL CHEM, V273, P1923, DOI 10.1074/jbc.273.4.1923; SPIRO MJ, 1977, J BIOL CHEM, V252, P5424; SUGUMARAN G, 1991, J BIOL CHEM, V266, P9565; Sugumaran G, 1998, BIOCHEM J, V329, P203, DOI 10.1042/bj3290203; TARENTINO AL, 1994, METHOD ENZYMOL, V230, P44; Terayama K, 1997, P NATL ACAD SCI USA, V94, P6093, DOI 10.1073/pnas.94.12.6093; WEI Z, 1993, P NATL ACAD SCI USA, V90, P3885, DOI 10.1073/pnas.90.9.3885	38	47	50	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 19	1999	274	12					7857	7864		10.1074/jbc.274.12.7857	http://dx.doi.org/10.1074/jbc.274.12.7857			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	178LU	10075678	hybrid			2022-12-25	WOS:000079268100037
J	Lawrence, CC; Gerfen, GJ; Samano, V; Nitsche, R; Robins, MJ; Retey, J; Stubbe, J				Lawrence, CC; Gerfen, GJ; Samano, V; Nitsche, R; Robins, MJ; Retey, J; Stubbe, J			Binding of Cob(II)alamin to the adenosylcobalamin-dependent ribonucleotide reductase from Lactobacillus leichmannii - Identification of dimethylbenzimidazole as the axial ligand	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-PARAMAGNETIC-RESONANCE; COENZYME-A MUTASE; C BOND-CLEAVAGE; HISTIDINE RESIDUE; CRYSTAL-STRUCTURE; GLUTAMATE MUTASE; COMPONENT-S; B-12 MODELS; COBALT; VITAMIN-B12	The ribonucleoside triphosphate reductase (RTPR) from Lactobacillus leichmannii catalyzes the reduction of nucleoside 5'-triphosphates to 2'-deoxynucleoside 5'-triphosphates and uses coenzyme B-12, adenosylcobalamin (AdoCbl), as a cofactor. Use of a mechanism-based inhibitor, 2'-deoxy-2'-methylenecytidine 5'-triphosphate, and isotopically labeled RTPR and AdoCbl in conjunction with EPR spectroscopy has allowed identification of the lower axial ligand of cob(II)alamin when bound to RTPR. In common with the AdoCbl-dependent enzymes catalyzing irreversible heteroatom migrations and in contrast to the enzymes catalyzing reversible carbon skeleton rearrangements, the dimethylbenzimidazole moiety of the cofactor is not displaced by a protein histidine upon binding to RTPR.	MIT, Dept Chem, Cambridge, MA 02139 USA; MIT, Dept Biol, Cambridge, MA 02139 USA; Albert Einstein Coll Med, Dept Physiol & Biophys, Bronx, NY 10461 USA; Univ Karlsruhe, Inst Organ Chem, Lehrstuhl Biochem, D-76128 Karlsruhe, Germany; Brigham Young Univ, Dept Chem & Biochem, Provo, UT 84602 USA	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Yeshiva University; Albert Einstein College of Medicine; Helmholtz Association; Karlsruhe Institute of Technology; Brigham Young University	Stubbe, J (corresponding author), MIT, Dept Chem, Cambridge, MA 02139 USA.	stubbe@it.edu			NIGMS NIH HHS [GM 29595] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029595, R37GM029595] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abend A, 1998, ANGEW CHEM INT EDIT, V37, P625, DOI 10.1002/(SICI)1521-3773(19980316)37:5<625::AID-ANIE625>3.0.CO;2-4; BAYSTON JH, 1970, BIOCHEMISTRY-US, V9, P2164, DOI 10.1021/bi00812a020; BOOKER S, 1994, BIOCHEMISTRY-US, V33, P12676, DOI 10.1021/bi00208a019; BOOKER S, 1993, P NATL ACAD SCI USA, V90, P8352, DOI 10.1073/pnas.90.18.8352; BOOKER S, 1994, THESIS MIT; Brown KL, 1998, J AM CHEM SOC, V120, P9466, DOI 10.1021/ja981729z; Buckel W, 1996, CHEM SOC REV, V25, P329, DOI 10.1039/cs9962500329; CHEMALY SM, 1980, J CHEM SOC DALTON, P2274, DOI 10.1039/dt9800002274; DeRidder DJA, 1996, J MOL STRUCT, V374, P63, DOI 10.1016/0022-2860(95)09034-7; Dong SL, 1998, J AM CHEM SOC, V120, P9947, DOI 10.1021/ja981584w; DRENNAN CL, 1994, SCIENCE, V266, P1669, DOI 10.1126/science.7992050; FINKE RG, 1998, VITAMIN B12 B12 PROT, P383; GENO MK, 1987, J AM CHEM SOC, V109, P1238, DOI 10.1021/ja00238a039; Gerfen GJ, 1996, J AM CHEM SOC, V118, P8192, DOI 10.1021/ja960363s; GRATE JH, 1979, J AM CHEM SOC, V101, P4601, DOI 10.1021/ja00510a027; HAMILTON JA, 1971, BIOCHEMISTRY-US, V10, P347, DOI 10.1021/bi00778a023; KRAUTLER B, 1994, INORG CHEM, V33, P4128; KRAUTLER B, 1998, VITAMIN B12 B12 PROT, P3; Lawrence CC, 1998, CURR OPIN CHEM BIOL, V2, P650, DOI 10.1016/S1367-5931(98)80097-5; Licht S, 1996, SCIENCE, V271, P477, DOI 10.1126/science.271.5248.477; Licht SS, 1999, BIOCHEMISTRY-US, V38, P1221, DOI 10.1021/bi981885i; Licht SS, 1999, BIOCHEMISTRY-US, V38, P1234, DOI 10.1021/bi981886a; LUNN CA, 1984, J BIOL CHEM, V259, P469; MALMSTRO.BG, 1970, BIOCHIM BIOPHYS ACTA, V205, P48, DOI 10.1016/0005-2728(70)90060-5; Mancia F, 1998, STRUCTURE, V6, P711, DOI 10.1016/S0969-2126(98)00073-2; Mancia F, 1996, STRUCTURE, V4, P339, DOI 10.1016/S0969-2126(96)00037-8; MARSH ENG, 1992, FEBS LETT, V310, P167, DOI 10.1016/0014-5793(92)81321-C; MARZILLI LG, 1985, J AM CHEM SOC, V107, P6880, DOI 10.1021/ja00310a023; NG FTT, 1982, J AM CHEM SOC, V104, P621, DOI 10.1021/ja00366a045; ORMEJOHNSON WH, 1974, J BIOL CHEM, V249, P2338; PADMAKUMAR R, 1995, J BIOL CHEM, V270, P9295, DOI 10.1074/jbc.270.16.9295; RANDACCIO L, 1981, J AM CHEM SOC, V103, P6347, DOI 10.1021/ja00411a014; RUSSEL M, 1985, J BACTERIOL, V163, P238, DOI 10.1128/JB.163.1.238-242.1985; SAMANO V, 1991, SYNTHESIS-STUTTGART, P283; Sauer K, 1998, EUR J BIOCHEM, V253, P698, DOI 10.1046/j.1432-1327.1998.2530698.x; Sauer K, 1998, FEBS LETT, V436, P401, DOI 10.1016/S0014-5793(98)01180-6; Scheuring E, 1997, J AM CHEM SOC, V119, P12192, DOI 10.1021/ja9635239; STEEPER JR, 1970, ANAL BIOCHEM, V34, P123, DOI 10.1016/0003-2697(70)90092-8; Stubbe J., 1998, VITAMIN B12 B12 PROT, P321; STUPPERICH E, 1990, EUR J BIOCHEM, V193, P105, DOI 10.1111/j.1432-1033.1990.tb19310.x; TAMAO Y, 1973, BIOCHEMISTRY-US, V12, P24, DOI 10.1021/bi00725a005; Yamanishi M, 1998, BIOCHEMISTRY-US, V37, P4799, DOI 10.1021/bi972572a; ZELDER O, 1995, FEBS LETT, V369, P252, DOI 10.1016/0014-5793(95)00762-X	43	59	61	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 12	1999	274	11					7039	7042		10.1074/jbc.274.11.7039	http://dx.doi.org/10.1074/jbc.274.11.7039			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	175DV	10066759	hybrid, Green Submitted			2022-12-25	WOS:000079078400031
J	Nordin, BE; Schimmel, P				Nordin, BE; Schimmel, P			RNA determinants for translational editing - Mischarging a minihelix substrate by a tRNA synthetase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHENYLALANINE TRANSFER-RNA; PROTEIN-SYNTHESIS; ESCHERICHIA-COLI; ACCEPTOR STEM; SINGLE NUCLEOTIDE; GENETIC-CODE; DNA APTAMER; AMINO-ACIDS; AMINOACYLATION; RECOGNITION	The fidelity of protein synthesis requires efficient discrimination of amino acid substrates by aminoacyl-tRNA synthetases, Accurate discrimination of the structurally similar amino acids, valine and isoleucine, by isoleucyl-tRNA synthetase (IleRS) results, in part, from a hydrolytic editing reaction, which prevents misactivated valine from being stably joined to tRNA(Ile). The editing reaction is dependent on the presence of tRNA(Ile), which contains discrete D-loop nucleotides that are necessary to promote editing of misactivated valine, RNA minihelices comprised of just the acceptor-T Psi C helix of tRNA(Ile) are substrates for specific aminoacylation by IleRS, These substrates lack the aforementioned D-loop nucleotides. Because minihelices contain determinants for aminoacylation, we thought that they might also play a role in editing that has not previously been recognized, Here we show that, in contrast to tRNA(Ile) minihelix(Ile) is unable to trigger the hydrolysis of misactivated valine and, in fact, is mischarged with valine, In addition, mutations in minihelix(Ile) that enhance or suppress charging with isoleucine do the same with valine, Thus, minihelix(Ile) contains signals for charging (by Il-eRS) that are independent of the amino acid and, by itself, minihelix(Ile) provides no determinants for editing. An RNA hairpin that mimics the D-stem/loop of tRNA(Ile) is also unable to induce the hydrolysis of misactivated valine, both by itself and in combination with minihelix(Ile). Thus, the native tertiary fold of tRNA(Ile) is required to promote efficient editing. Considering that the minihelix is thought to be the more ancestral part of the tRNA structure, these results are consistent with the idea that, during the development of the genetic code, RNA determinants for editing were added after the establishment of an aminoacylation system.	Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Chem, La Jolla, CA 92037 USA; Skaggs Inst Chem Biol, La Jolla, CA USA	Scripps Research Institute; Scripps Research Institute; Scripps Research Institute	Schimmel, P (corresponding author), Scripps Res Inst, Dept Mol Biol, 10550 N Torrey Pines Rd,Mail Code BCC-379, La Jolla, CA 92037 USA.	schimmel@scripps.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM015539, R01GM015539] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM15539] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alexander RW, 1998, P NATL ACAD SCI USA, V95, P12214, DOI 10.1073/pnas.95.21.12214; BALDWIN AN, 1966, J BIOL CHEM, V241, P839; BIOU V, 1994, SCIENCE, V263, P1404, DOI 10.1126/science.8128220; CARTER CW, 1993, ANNU REV BIOCHEM, V62, P715, DOI 10.1146/annurev.bi.62.070193.003435; CRAMER F, 1991, BIOCHIMIE, V73, P1027, DOI 10.1016/0300-9084(91)90144-P; ELDRED EW, 1972, J BIOL CHEM, V247, P2961; FERSHT AR, 1979, BIOCHEMISTRY-US, V18, P2627, DOI 10.1021/bi00579a030; FERSHT AR, 1985, ENZYME STRUCTURE MEC, P355; FRUGIER M, 1994, EMBO J, V13, P2218, DOI 10.1002/j.1460-2075.1994.tb06499.x; GIEGE R, 1993, PROG NUCLEIC ACID RE, V45, P129, DOI 10.1016/S0079-6603(08)60869-7; Glasfeld E, 1996, BIOCHEMISTRY-US, V35, P4139, DOI 10.1021/bi9527810; Hale SP, 1997, SCIENCE, V276, P1250, DOI 10.1126/science.276.5316.1250; Hale SP, 1997, TETRAHEDRON, V53, P11985, DOI 10.1016/S0040-4020(97)00711-4; Hale SP, 1996, P NATL ACAD SCI USA, V93, P2755, DOI 10.1073/pnas.93.7.2755; HAMANN CS, 1995, BIOCHEMISTRY-US, V34, P6527, DOI 10.1021/bi00019a034; JAKUBOWSKI H, 1981, NUCLEIC ACIDS RES, V9, P3105, DOI 10.1093/nar/9.13.3105; KIM SH, 1974, SCIENCE, V185, P435, DOI 10.1126/science.185.4149.435; LAPOINTE J, 1991, TRANSLATION EUKARYOT, P35; Lin L, 1996, NATURE, V384, P33, DOI 10.1038/384033b0; MAIZELS N, 1994, P NATL ACAD SCI USA, V91, P6729, DOI 10.1073/pnas.91.15.6729; Martinis Susan A., 1995, P349; Noller H.F., 1993, RNA WORLD, P137; NUREKI O, 1994, J MOL BIOL, V236, P710, DOI 10.1006/jmbi.1994.1184; Nureki O, 1998, SCIENCE, V280, P578, DOI 10.1126/science.280.5363.578; NUREKI O, 1993, TRANSLATIONAL APPARATUS, P59; PARK SJ, 1988, J BIOL CHEM, V263, P16527; RICH A, 1976, ANNU REV BIOCHEM, V45, P805, DOI 10.1146/annurev.bi.45.070176.004105; ROBERTUS JD, 1974, NATURE, V250, P546, DOI 10.1038/250546a0; Rodin S, 1996, P NATL ACAD SCI USA, V93, P4537, DOI 10.1073/pnas.93.10.4537; ROULD MA, 1989, SCIENCE, V246, P1135, DOI 10.1126/science.2479982; Saks ME, 1996, EMBO J, V15, P2843, DOI 10.1002/j.1460-2075.1996.tb00645.x; SCHIMMEL P, 1993, P NATL ACAD SCI USA, V90, P8763, DOI 10.1073/pnas.90.19.8763; SCHIMMEL P, 1995, CELL, V81, P983, DOI 10.1016/S0092-8674(05)80002-9; SCHMIDT E, 1995, BIOCHEMISTRY-US, V34, P11204, DOI 10.1021/bi00035a028; SCHMIDT E, 1994, SCIENCE, V264, P265, DOI 10.1126/science.8146659; SCHMIDT E, 1996, THESIS MIT CAMBRIDGE, P160; SHEPARD A, 1992, P NATL ACAD SCI USA, V89, P9964, DOI 10.1073/pnas.89.20.9964; SHIBA K, 1992, P NATL ACAD SCI USA, V89, P1880, DOI 10.1073/pnas.89.5.1880; STARZYK RM, 1987, SCIENCE, V237, P1614, DOI 10.1126/science.3306924; Stoll A., 1958, FESTSCHRIFT A STOLL, P597; WEINER AM, 1987, P NATL ACAD SCI USA, V84, P7383, DOI 10.1073/pnas.84.21.7383; WINCOTT F, 1995, NUCLEIC ACIDS RES, V23, P2677, DOI 10.1093/nar/23.14.2677	42	18	19	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	1999	274	11					6835	6838		10.1074/jbc.274.11.6835	http://dx.doi.org/10.1074/jbc.274.11.6835			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	175DV	10066735	hybrid			2022-12-25	WOS:000079078400007
J	Hao, WS; Fong, HKW				Hao, WS; Fong, HKW			The endogenous chromophore of retinal G protein-coupled receptor opsin from the pigment epithelium	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING-PROTEIN; VITAMIN-A; BOVINE RETINA; RETINOCHROME; DEHYDROGENASE; RHODOPSIN; 11-CIS-RETINOL; CLONING; HOMOLOG; PINEAL	The recent identification of nonvisual opsins has revealed an expanding family of vertebrate opsin genes. The retinal pigment epithelium (RPE) and Muller cells contain a blue and UV light-absorbing opsin, the RPE retinal G protein-coupled receptor (RGR, or RGR opsin). The spectral properties of RGR purified from bovine RPE suggest that RGR is conjugated in vivo to a retinal chromophore through a covalent Schiff base bond. In this study, the isomeric structure of the endogenous chromophore of RGR was identified by the hydroxylamine derivatization method. The retinaloximes derived from RGR in the dark consisted predominantly of the all-trans isomer. Irradiation of RGR with 470-nm monochromatic or near-UV light resulted in stereospecific isomerization of the bound all-trans-retinal to an 11-cis configuration. The stereospecificity of photoisomerization of the all-trans-retinal chromophore of RGR was lost by denaturation of the protein in SDS. Under the in vitro conditions, the photosensitivity of RGR is at least 34% that of bovine rhodopsin. These results provide evidence that RGR is bound in vivo primarily to all-transretinal and is capable of operating as a stereospecific photoisomerase that generates 11-cis-retinal in the pigment epithelium.	Doheny Eye Inst, Los Angeles, CA 90033 USA; Univ So Calif, Sch Med, Dept Microbiol, Los Angeles, CA 90033 USA; Univ So Calif, Sch Med, Dept Ophthalmol, Los Angeles, CA 90033 USA	Doheny Eye Institute; University of Southern California; University of Southern California	Fong, HKW (corresponding author), Doheny Eye Inst, 1355 San Pablo St, Los Angeles, CA 90033 USA.	hfong@hsc.usc.edu			NATIONAL EYE INSTITUTE [R01EY008364, P30EY003040] Funding Source: NIH RePORTER; NEI NIH HHS [EY03040, EY08364] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		BARRY RJ, 1989, J BIOL CHEM, V264, P9231; BERMAN ER, 1985, CURR EYE RES, V4, P867, DOI 10.3109/02713688509095254; BLANER WS, 1987, J BIOL CHEM, V262, P53; BRIDGES CDB, 1976, EXP EYE RES, V22, P435, DOI 10.1016/0014-4835(76)90182-2; Dartnall H. J. A., 1972, HDB SENSORY PHYSIOLO, V7, P122; DEIGNER PS, 1989, SCIENCE, V244, P968, DOI 10.1126/science.2727688; DOWLING JE, 1960, NATURE, V188, P114, DOI 10.1038/188114a0; DRIESSEN CAGG, 1995, INVEST OPHTH VIS SCI, V36, P1988; FUTTERMAN S, 1977, J BIOL CHEM, V252, P3267; GROENENDIJK GWT, 1979, ANAL BIOCHEM, V99, P304, DOI 10.1016/S0003-2697(79)80011-1; GROENENDIJK GWT, 1980, BIOCHIM BIOPHYS ACTA, V617, P430, DOI 10.1016/0005-2760(80)90009-0; Hao WS, 1996, BIOCHEMISTRY-US, V35, P6251, DOI 10.1021/bi952420k; HARA T, 1982, METHOD ENZYMOL, V81, P190; HARA T, 1987, RETINAL PROTEINS, P457; HARANISHIMURA I, 1990, FEBS LETT, V271, P106, DOI 10.1016/0014-5793(90)80383-T; HONG K, 1982, METHOD ENZYMOL, V81, P144; HUBBARD R., 1971, Methods in Enzymology, V18C, P615, DOI 10.1016/S0076-6879(71)18045-7; JIANG M, 1993, INVEST OPHTH VIS SCI, V34, P3669; Mata NL, 1998, INVEST OPHTH VIS SCI, V39, P1312; MAX M, 1995, SCIENCE, V267, P1502, DOI 10.1126/science.7878470; OKANO T, 1994, NATURE, V372, P94, DOI 10.1038/372094a0; OZAKI K, 1986, VISION RES, V26, P691, DOI 10.1016/0042-6989(86)90083-0; OZAKI K, 1983, BIOPHYS J, V44, P127, DOI 10.1016/S0006-3495(83)84285-4; PANDEY S, 1994, EXP EYE RES, V58, P605, DOI 10.1006/exer.1994.1055; Provencio I, 1998, P NATL ACAD SCI USA, V95, P340, DOI 10.1073/pnas.95.1.340; RANDO RR, 1991, PROGR RETINAL RES, V10, P161; Saari J.C., 1990, Progress in Retinal Research, V9, P363, DOI 10.1016/0278-4327(90)90011-6; SAARI JC, 1989, J BIOL CHEM, V264, P8636; SAARI JC, 1987, J BIOL CHEM, V262, P7618; SHEN DW, 1994, BIOCHEMISTRY-US, V33, P13117, DOI 10.1021/bi00248a022; SIMON A, 1995, J BIOL CHEM, V270, P1107, DOI 10.1074/jbc.270.34.19979; Sun H, 1997, P NATL ACAD SCI USA, V94, P9893, DOI 10.1073/pnas.94.18.9893; TERAKITA A, 1989, VISION RES, V29, P639, DOI 10.1016/0042-6989(89)90026-6; TREHAN A, 1990, BIOCHEMISTRY-US, V29, P309, DOI 10.1021/bi00454a001; Winston A, 1998, BIOCHEMISTRY-US, V37, P2044, DOI 10.1021/bi971908d; YOUNG RW, 1969, J CELL BIOL, V42, P392, DOI 10.1083/jcb.42.2.392; ZIMMERMAN WF, 1974, VISION RES, V14, P795, DOI 10.1016/0042-6989(74)90143-6; ZIMMERMAN WF, 1976, EXP EYE RES, V23, P159, DOI 10.1016/0014-4835(76)90199-8	38	110	110	2	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	1999	274	10					6085	6090		10.1074/jbc.274.10.6085	http://dx.doi.org/10.1074/jbc.274.10.6085			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172BQ	10037690	hybrid			2022-12-25	WOS:000078902800012
J	Pinto, D; Robine, S; Jaisser, F; El Marjou, F; Louvard, D				Pinto, D; Robine, S; Jaisser, F; El Marjou, F; Louvard, D			Regulatory sequences of the mouse villin gene that efficiently drive transgenic expression in immature and differentiated epithelial cells of small and large intestines	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING-PROTEIN GENE; HORMONE FUSION GENES; CYTOSKELETAL PROTEIN; VISCERAL ENDODERM; GUT EPITHELIUM; REPORTER GENE; T-ANTIGEN; MICE; PATTERNS; TISSUE	Villin is an early marker of epithelial cells from the digestive and urogenital tracts. Indeed villin is expressed in the stem cells and the proliferative cells of the intestinal crypts, To investigate the underlying molecular mechanisms and particularly those responsible for the restricted tissue specificity, a large genomic region of the mouse villin gene has been analyzed, A 9-kilobase (kb) regulatory region of the mouse villin gene (harboring 3.5 kb upstream the transcription start site and 5.5 kb-of the first intron) was able to promote transcription of the LacZ reporter gene in the small and large intestines of transgenic mice, in a transmissible manner, and thus efficiently directed subsequent beta-gaIactosidase expression in epithelial cells along the entire crypt-villus axis. In the kidney, the transgene was also expressed in the epithelial cells of the proximal tubules but is likely sensitive to the site of integration. A construct lacking the first intron restricted beta-galactosidase expression to the small intestine, Thus, the 9-kb genomic region contains the necessary cis-acting elements to recapitulate the tissue-specific expression pattern of the endogenous villin gene, Hence, these regulatory sequences can be used to target heterologous genes in immature and differentiated epithelial cells of the small and/or large intestinal mucosa.	Inst Curie, CNRS, UMR 144, F-75248 Paris 05, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Sorbonne Universite	Louvard, D (corresponding author), Inst Curie, CNRS, UMR 144, 26 Rue Ulm, F-75248 Paris 05, France.		Jaisser, Frederic/P-4287-2017	Jaisser, Frederic/0000-0001-9051-1901				ARONOW BJ, 1992, MOL CELL BIOL, V12, P4170, DOI 10.1128/MCB.12.9.4170; BACCHI CE, 1991, LAB INVEST, V64, P418; BECKER PB, 1994, BIOESSAYS, V16, P541, DOI 10.1002/bies.950160807; BISAHA JG, 1995, J BIOL CHEM, V270, P19979, DOI 10.1074/jbc.270.34.19979; BOLLER K, 1988, DIFFERENTIATION, V39, P51, DOI 10.1111/j.1432-0436.1988.tb00080.x; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; BRY L, 1994, P NATL ACAD SCI USA, V91, P10335, DOI 10.1073/pnas.91.22.10335; CARBONI JM, 1987, AM J PATHOL, V129, P589; CARTIER N, 1993, J CELL SCI, V104, P695; CHENG H, 1974, AM J ANAT, V141, P461, DOI 10.1002/aja.1001410403; Cohen-Tannoudji M, 1998, MOL CELL BIOL, V18, P1444, DOI 10.1128/MCB.18.3.1444; COHN SM, 1992, J CELL BIOL, V119, P27, DOI 10.1083/jcb.119.1.27; CROSSMAN MW, 1994, J CELL BIOL, V126, P1547, DOI 10.1083/jcb.126.6.1547; CUI CQ, 1994, TRANSGENIC RES, V3, P182, DOI 10.1007/BF01973986; EFRAT S, 1988, P NATL ACAD SCI USA, V85, P9037, DOI 10.1073/pnas.85.23.9037; EZZELL RM, 1989, DEVELOPMENT, V106, P407; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; GORDON JI, 1994, CURR OPIN CELL BIOL, V6, P795, DOI 10.1016/0955-0674(94)90047-7; GREEN RP, 1992, DNA CELL BIOL, V11, P31, DOI 10.1089/dna.1992.11.31; HALL PA, 1994, J CELL SCI, V107, P3569; HANAHAN D, 1988, ANNU REV GENET, V22, P479, DOI 10.1146/annurev.ge.22.120188.002403; HAUFT SM, 1992, J CELL BIOL, V117, P825, DOI 10.1083/jcb.117.4.825; HERMISTON ML, 1993, P NATL ACAD SCI USA, V90, P8866, DOI 10.1073/pnas.90.19.8866; HERMISTON ML, 1995, J CELL BIOL, V129, P489, DOI 10.1083/jcb.129.2.489; KIM SH, 1993, J CELL BIOL, V123, P877, DOI 10.1083/jcb.123.4.877; MARKOWITZ AJ, 1993, AM J PHYSIOL, V265, pG526, DOI 10.1152/ajpgi.1993.265.3.G526; MAUNOURY R, 1988, EMBO J, V7, P3321, DOI 10.1002/j.1460-2075.1988.tb03203.x; MAUNOURY R, 1992, DEVELOPMENT, V115, P717; MOLL R, 1987, VIRCHOWS ARCH B, V54, P155, DOI 10.1007/BF02899208; PERRET C, 1991, GENE, V108, P227, DOI 10.1016/0378-1119(91)90438-H; PONDER BAJ, 1985, NATURE, V313, P689, DOI 10.1038/313689a0; POTTEN CS, 1990, DEVELOPMENT, V110, P1001; PRINGAULT E, 1991, P NATL ACAD SCI USA, V88, P10811, DOI 10.1073/pnas.88.23.10811; ROBINE S, 1993, J BIOL CHEM, V268, P11426; Robine S, 1997, AM J PHYSIOL-GASTR L, V273, pG759; ROBINE S, 1985, P NATL ACAD SCI USA, V82, P8488, DOI 10.1073/pnas.82.24.8488; ROTTMAN JN, 1993, J BIOL CHEM, V268, P11994; Sabourin JC, 1996, J BIOL CHEM, V271, P3469, DOI 10.1074/jbc.271.7.3469; SCHMIDT GH, 1985, CELL, V40, P425, DOI 10.1016/0092-8674(85)90156-4; Simon TC, 1997, J BIOL CHEM, V272, P10652; SIMON TC, 1995, P NATL ACAD SCI USA, V92, P8685, DOI 10.1073/pnas.92.19.8685; SWEETSER DA, 1988, P NATL ACAD SCI USA, V85, P9611, DOI 10.1073/pnas.85.24.9611; WEST AB, 1988, GASTROENTEROLOGY, V94, P343, DOI 10.1016/0016-5085(88)90421-0; WRIGHT NA, 1982, CELL TISSUE KINET, V15, P595, DOI 10.1111/j.1365-2184.1982.tb01066.x	44	122	126	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1999	274	10					6476	6482		10.1074/jbc.274.10.6476	http://dx.doi.org/10.1074/jbc.274.10.6476			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172BQ	10037740	hybrid			2022-12-25	WOS:000078902800062
J	Thuveson, M; Fries, E				Thuveson, M; Fries, E			Intracellular proteolytic processing of the heavy chain of rat pre-alpha-inhibitor - The COOH-terminal propeptide is required for coupling to bikunin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CUMULUS EXTRACELLULAR-MATRIX; COVALENTLY CROSS-LINKS; TRYPSIN-INHIBITOR; PRECURSOR PROTEINS; FAMILY; ENDOPROTEASE; BIOSYNTHESIS; HEPATOCYTES; CLEAVAGE; SEQUENCE	Pre-alpha-inhibitor is a serum protein consisting of two polypeptides named bikunin and heavy chain 3 (H3). Both polypeptides are synthesized in hepatocytes and while passing through the Golgi complex, bikunin, which carries a chondroitin sulfate chain, becomes covalently linked to the COOH-terminal amino acid residue of H3 via its polysaccharide. Immediately prior to this reaction, a COOH-terminal propeptide of 33 kDa is cleaved off from the heavy chain. Using COS-1 cells transfected with rat H3, we found that in the absence of bikunin, the cleaved propeptide remained bound to the heavy chain and that H3 lacking the propeptide sequence did not become linked to coexpressed bikunin. Sequencing of H3 secreted from COS-1 cells showed that part of the molecules had a 12-amino acid residue long NH2-terminal propeptide. Cleavage of this propeptide, which occurred in the endoplasmic reticulum, was found to require basic amino acid residues at P-1, P-2, and P-6 suggesting that it is mediated by a Golgi enzyme in transit. Deletion of the NH2-terminal propeptide or blocking of its release affected neither transport nor coupling of the heavy chain to bikunin.	Uppsala Univ, Dept Med Biochem & Microbiol, Uppsala, Sweden	Uppsala University	Thuveson, M (corresponding author), Box 575, S-75123 Uppsala, Sweden.	Thuveson@medkem.uu.se						Anderson ED, 1997, EMBO J, V16, P1508, DOI 10.1093/emboj/16.7.1508; Baker D, 1993, CURR OPIN CELL BIOL, V5, P966, DOI 10.1016/0955-0674(93)90078-5; BLOM A, 1995, J BIOL CHEM, V270, P9698, DOI 10.1074/jbc.270.17.9698; Blom AM, 1997, BIOCHEM J, V328, P185; BOURGUIGNON J, 1993, EUR J BIOCHEM, V212, P771, DOI 10.1111/j.1432-1033.1993.tb17717.x; BRATT T, 1994, FEBS LETT, V354, P57, DOI 10.1016/0014-5793(94)01087-0; CASTILLO GM, 1993, FEBS LETT, V318, P292, DOI 10.1016/0014-5793(93)80531-X; CHAN P, 1995, BIOCHEM J, V306, P505, DOI 10.1042/bj3060505; CHEN L, 1992, J BIOL CHEM, V267, P12380; CHEN L, 1994, J BIOL CHEM, V269, P28282; Chen Wen-Tien, 1992, Current Opinion in Cell Biology, V4, P802; Dayhoff MO, ATLAS PROTEIN SEQUEN; DENG WP, 1992, ANAL BIOCH, V200; ENGHILD JJ, 1991, J BIOL CHEM, V266, P747; GEBHARD W, 1989, EUR J BIOCHEM, V181, P571, DOI 10.1111/j.1432-1033.1989.tb14762.x; HALBAN PA, 1994, BIOCHEM J, V299, P1; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; MALEY F, 1989, ANAL BIOCHEM, V180, P195, DOI 10.1016/0003-2697(89)90115-2; MORELLE W, 1994, EUR J BIOCHEM, V221, P881, DOI 10.1111/j.1432-1033.1994.tb18803.x; Nakayama K, 1997, BIOCHEM J, V327, P625, DOI 10.1042/bj3270625; Seidah NG, 1997, CURR OPIN BIOTECH, V8, P602, DOI 10.1016/S0958-1669(97)80036-5; Siezen RJ, 1997, PROTEIN SCI, V6, P501; SJOBERG EM, 1992, ARCH BIOCHEM BIOPHYS, V295, P217, DOI 10.1016/0003-9861(92)90509-U; SWAIM MW, 1988, BIOCHEM J, V254, P171, DOI 10.1042/bj2540171; THOGERSEN IB, 1995, J BIOL CHEM, V270, P18700; VONHEIJNE G, 1983, EUR J BIOCHEM, V133, P17; Wisniewski HG, 1996, J IMMUNOL, V156, P1609	27	16	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	1999	274	10					6741	6746		10.1074/jbc.274.10.6741	http://dx.doi.org/10.1074/jbc.274.10.6741			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172BQ	10037773	hybrid			2022-12-25	WOS:000078902800095
J	van der Voort, R; Taher, TEI; Wielenga, VJM; Spaargaren, M; Prevo, R; Smit, L; David, G; Hartmann, G; Gherardi, E; Pals, ST				van der Voort, R; Taher, TEI; Wielenga, VJM; Spaargaren, M; Prevo, R; Smit, L; David, G; Hartmann, G; Gherardi, E; Pals, ST			Heparan sulfate-modified CD44 promotes hepatocyte growth factor scatter factor induced signal transduction through the receptor tyrosine kinase c-Met	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYMPHOCYTE HOMING RECEPTOR; FIBROBLAST GROWTH; CELL-ADHESION; EXTRACELLULAR-MATRIX; COLORECTAL-CANCER; EPITHELIAL-CELLS; VARIANT ISOFORMS; BINDING; HYALURONATE; EXPRESSION	CD44 has been implicated in tumor progression and metastasis, but the mechanism(s) involved is as yet poorly understood. Recent studies have shown that CD44 isoforms containing the alternatively spliced exon v3 carry heparan sulfate side chains and are able to bind heparin-binding growth factors. In the present study, we have explored the possibility of a physical and functional interaction between CD44 and hepatocyte growth factor/scatter factor (HGF/SF), the ligand of the receptor tyrosine kinase c-Met. The HGF/SF-c-Met pathway mediates cell growth and motility and has been implicated in tumor invasion and metastasis. We demonstrate that a CD44v3 splice variant efficiently binds HGF/SF via its heparan sulfate side chain. To address the functional relevance of this interaction, Namalwa Burkitt's lymphoma cells were stably co-transfected with c-Met and either CD44v3 or the isoform CD44s, which lacks heparan sulfate. We show that, as compared with CD44s, CD44v3 promotes: (i) HGF/SF-induced phosphorylation of c-Met, (ii) phosphorylation of several downstream proteins, and (iii) activation of the MAP kinases ERK1 and -2, By heparitinase treatment and the use of a mutant HGF/SF with greatly decreased affinity for heparan sulfate, we show that the enhancement of c-Met signal transduction induced by CD44v3 was critically dependent on heparan sulfate moieties, Our results identify heparan sulfate-modified CD44 (CD44-HS) as a functional co-receptor for HGF/SF which promotes signaling through the receptor tyrosine kinase c-Met, presumably by concentrating and presenting HGF/SF. As both CD44-HS and c-Met are overexpressed on several types of tumors, we propose that the observed functional collaboration might be instrumental in promoting tumor growth and metastasis.	Univ Amsterdam, Acad Med Ctr, Dept Pathol, NL-1105 AZ Amsterdam, Netherlands; Univ Leuven, Ctr Human Genet, B-3000 Leuven, Belgium; Univ Leuven VIB, B-3000 Leuven, Belgium; Univ Cambridge, Dept Oncol, Growth Factors Grp, Cambridge CB2 2QH, England	University of Amsterdam; Academic Medical Center Amsterdam; Vrije Universiteit Amsterdam; KU Leuven; Flanders Institute for Biotechnology (VIB); KU Leuven; University of Cambridge	Pals, ST (corresponding author), Univ Amsterdam, Acad Med Ctr, Dept Pathol, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands.	S.T.Pals@AMC.UVA.NL	Spaargaren, Marcel/AAU-1298-2021; Gherardi, Ermanno/AAB-9608-2022	Spaargaren, Marcel/0000-0002-3135-5109; Pals, Steven/0000-0002-1419-0939; GHERARDI, ERMANNO/0000-0002-0016-2945				ADAMS DH, 1994, P NATL ACAD SCI USA, V91, P7144, DOI 10.1073/pnas.91.15.7144; ARCH R, 1992, SCIENCE, V257, P682, DOI 10.1126/science.1496383; ARUFFO A, 1990, CELL, V61, P1303, DOI 10.1016/0092-8674(90)90694-A; ASHIKARI S, 1995, J BIOL CHEM, V270, P29586, DOI 10.1074/jbc.270.49.29586; AVIEZER D, 1994, J BIOL CHEM, V269, P114; BENNETT KL, 1995, J CELL BIOL, V128, P687, DOI 10.1083/jcb.128.4.687; BOROS P, 1995, LANCET, V345, P293, DOI 10.1016/S0140-6736(95)90279-1; BROWN TA, 1991, J CELL BIOL, V113, P207, DOI 10.1083/jcb.113.1.207; COOPER DL, 1995, NAT MED, V1, P635, DOI 10.1038/nm0795-635; Crepaldi T, 1997, J CELL BIOL, V138, P423, DOI 10.1083/jcb.138.2.423; DAVID G, 1992, J CELL BIOL, V119, P961, DOI 10.1083/jcb.119.4.961; DiGabriele AD, 1998, NATURE, V393, P812, DOI 10.1038/31741; DIRENZO MF, 1995, CANCER RES, V55, P1129; DIRENZO MF, 1995, CLIN CANCER RES, V1, P147; DOUGHERTY GJ, 1991, J EXP MED, V174, P1, DOI 10.1084/jem.174.1.1; Fixman ED, 1997, J BIOL CHEM, V272, P20167, DOI 10.1074/jbc.272.32.20167; FOX SB, 1993, LANCET, V342, P548, DOI 10.1016/0140-6736(93)91670-H; FURUKAWA T, 1995, AM J PATHOL, V147, P889; GALIMI F, 1994, J CELL BIOL, V127, P1743, DOI 10.1083/jcb.127.6.1743; GIORDANO S, 1993, P NATL ACAD SCI USA, V90, P649, DOI 10.1073/pnas.90.2.649; GUNTHERT U, 1991, CELL, V65, P13, DOI 10.1016/0092-8674(91)90403-L; Hartmann G, 1998, CURR BIOL, V8, P125, DOI 10.1016/S0960-9822(98)70059-4; HARTMANN G, 1992, P NATL ACAD SCI USA, V89, P11574, DOI 10.1073/pnas.89.23.11574; Herrera R, 1998, J CELL SCI, V111, P1039; HERRLICH P, 1993, IMMUNOL TODAY, V14, P395, DOI 10.1016/0167-5699(93)90141-7; Hughes PE, 1997, CELL, V88, P521, DOI 10.1016/S0092-8674(00)81892-9; JACKSON DG, 1992, J BIOL CHEM, V267, P4732; JACKSON DG, 1995, J CELL BIOL, V128, P673, DOI 10.1083/jcb.128.4.673; JALKANEN S, 1988, J IMMUNOL, V141, P1615; JALKANEN S, 1987, J CELL BIOL, V105, P983, DOI 10.1083/jcb.105.2.983; Jiang WG, 1995, BIOCHEM BIOPH RES CO, V217, P1062, DOI 10.1006/bbrc.1995.2877; KALOMIRIS EL, 1988, J CELL BIOL, V106, P319, DOI 10.1083/jcb.106.2.319; KAUFMANN M, 1995, LANCET, V345, P615, DOI 10.1016/S0140-6736(95)90521-9; Khwaja A, 1998, J BIOL CHEM, V273, P18793, DOI 10.1074/jbc.273.30.18793; KLAGSBRUN M, 1991, CELL, V67, P229, DOI 10.1016/0092-8674(91)90173-V; KMIECIK TE, 1992, BLOOD, V80, P2454; KOOPMAN G, 1993, J EXP MED, V177, P897, DOI 10.1084/jem.177.4.897; LACY BE, 1987, J CELL BIOL, V105, P1395, DOI 10.1083/jcb.105.3.1395; LESLEY J, 1993, ADV IMMUNOL, V54, P271, DOI 10.1016/S0065-2776(08)60537-4; LIU C, 1992, ONCOGENE, V7, P181; LYON M, 1994, J BIOL CHEM, V269, P11216; MACCARANA M, 1993, J BIOL CHEM, V268, P23898; MACKAY CR, 1994, J CELL BIOL, V124, P71, DOI 10.1083/jcb.124.1.71; Meng FY, 1998, EMBO J, V17, P4391, DOI 10.1093/emboj/17.15.4391; MIYAKE K, 1990, J EXP MED, V172, P69, DOI 10.1084/jem.172.1.69; MULDER JWR, 1994, LANCET, V344, P1470, DOI 10.1016/S0140-6736(94)90290-9; NAKAMURA T, 1986, P NATL ACAD SCI USA, V83, P6489, DOI 10.1073/pnas.83.17.6489; NISHINO T, 1995, BLOOD, V85, P3093, DOI 10.1182/blood.V85.11.3093.bloodjournal85113093; PALS ST, 1989, J IMMUNOL, V143, P851; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; Potempa S, 1998, MOL BIOL CELL, V9, P2185, DOI 10.1091/mbc.9.8.2185; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; RONG S, 1994, P NATL ACAD SCI USA, V91, P4731, DOI 10.1073/pnas.91.11.4731; Ropponen KM, 1998, SCAND J GASTROENTERO, V33, P301; ROSEN EM, 1994, J CELL BIOL, V127, P1783, DOI 10.1083/jcb.127.6.1783; RUOSLAHTI E, 1991, CELL, V64, P867, DOI 10.1016/0092-8674(91)90308-L; SAKSELA O, 1988, J CELL BIOL, V107, P743, DOI 10.1083/jcb.107.2.743; Schlaepfer DD, 1998, TRENDS CELL BIOL, V8, P151, DOI 10.1016/S0962-8924(97)01172-0; SCHLESSINGER J, 1995, CELL, V83, P357, DOI 10.1016/0092-8674(95)90112-4; Schmidt L, 1997, NAT GENET, V16, P68, DOI 10.1038/ng0597-68; SCREATON GR, 1992, P NATL ACAD SCI USA, V89, P12160, DOI 10.1073/pnas.89.24.12160; Smit L, 1997, CRIT REV ONCOGENESIS, V8, P359, DOI 10.1615/CritRevOncog.v8.i4.50; SPIVAKKROIZMAN T, 1994, CELL, V79, P1015, DOI 10.1016/0092-8674(94)90032-9; STAMENKOVIC I, 1991, EMBO J, V10, P343, DOI 10.1002/j.1460-2075.1991.tb07955.x; STAUDER R, 1995, BLOOD, V85, P2885, DOI 10.1182/blood.V85.10.2885.bloodjournal85102885; Taher TEI, 1996, J BIOL CHEM, V271, P2863, DOI 10.1074/jbc.271.5.2863; Takahashi K, 1996, J BIOL CHEM, V271, P9490, DOI 10.1074/jbc.271.16.9490; Takai K, 1997, BLOOD, V89, P1560, DOI 10.1182/blood.V89.5.1560.1560_1560_1565; Takayama H, 1997, P NATL ACAD SCI USA, V94, P701, DOI 10.1073/pnas.94.2.701; TANAKA Y, 1993, NATURE, V361, P79, DOI 10.1038/361079a0; Tanimura S, 1998, ONCOGENE, V17, P57, DOI 10.1038/sj.onc.1201905; TOLG C, 1993, NUCLEIC ACIDS RES, V21, P1225, DOI 10.1093/nar/21.5.1225; Tuck AB, 1996, AM J PATHOL, V148, P225; VANDERVOORT R, 1995, BIOCHEM BIOPH RES CO, V214, P137, DOI 10.1006/bbrc.1995.2267; vanderVoort R, 1997, J EXP MED, V185, P2121, DOI 10.1084/jem.185.12.2121; WEIDNER KM, 1990, J CELL BIOL, V111, P2097, DOI 10.1083/jcb.111.5.2097; Weidner KM, 1996, NATURE, V384, P173, DOI 10.1038/384173a0; Weimar IS, 1997, BLOOD, V89, P990, DOI 10.1182/blood.V89.3.990; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W; ZIONCHECK TF, 1995, J BIOL CHEM, V270, P16871, DOI 10.1074/jbc.270.28.16871; ZOLLER M, 1995, J MOL MED, V73, P425	81	187	198	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1999	274	10					6499	6506		10.1074/jbc.274.10.6499	http://dx.doi.org/10.1074/jbc.274.10.6499			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172BQ	10037743	hybrid			2022-12-25	WOS:000078902800065
J	Joyce, JG; Tung, JS; Przysiecki, CT; Cook, JC; Lehman, ED; Sands, JA; Jansens, KU; Keller, PM				Joyce, JG; Tung, JS; Przysiecki, CT; Cook, JC; Lehman, ED; Sands, JA; Jansens, KU; Keller, PM			The L1 major capsid protein of human papillomavirus type 11 recombinant virus-like particles interacts with heparin and cell-surface glycosaminoglycans on human keratinocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTRACELLULAR-SUPEROXIDE-DISMUTASE; CERVICAL INTRAEPITHELIAL NEOPLASIA; FIBROBLAST GROWTH-FACTOR; BETA-D-XYLOSIDES; SACCHAROMYCES-CEREVISIAE; SULFATE PROTEOGLYCANS; ANTITHROMBIN-III; INSECT CELLS; IN-VITRO; BINDING	The L1 major capsid protein of human papillomavirus (HPV) type 11, a 55-kDa polypeptide, forms particulate structures resembling native virus with an average particle diameter of 50-60 nm when expressed in the yeast Saccharomyces cerevisiae. me show in this report that these virus-like particles (VLPs) interact with heparin and with cell-surface glycosaminoglycans (GAGs) resembling heparin on keratinocytes and Chinese hamster ovary cells. The binding of VLPs to heparin is shown to exhibit an affinity comparable to that of other identified heparin-binding proteins. Immobilized heparin chromatography and surface plasmon resonance were used to show that this interaction can be specifically inhibited by free heparin and dextran sulfate and that the effectiveness of the inhibitor is related to its molecular weight and charge density. Sequence comparison of nine human L1 types revealed a conserved region of the carboxyl terminus containing clustered basic amino acids that bear resemblance to proposed heparin-binding motifs in unrelated proteins. Specific enzymatic cleavage of this region eliminated binding to both immobilized heparin and human keratinocyte (HaCaT) cells. Removal of heparan sulfate GAGs on keratinocytes by treatment with heparinase or heparitinase resulted in an 80-90% reduction of VLP binding, whereas treatment of cells with laminin, a substrate for cu, integrin receptors, provided minimal inhibition. Cells treated with chlorate or substituted beta-D-xylosides, resulting in under-sulfation or secretion of GAG chains, also showed a reduced affinity for VLPs. Similarly, binding of VLPs to a Chinese hamster ovary cell mutant deficient in GAG synthesis was shown to be only 10% that observed for wild type cells. This report establishes for the first time that the carboxyl-terminal portion of HPV L1 interacts with heparin, and that this region appears to be crucial for interaction with the cell surface.	Merck Res Labs, Dept Virus & Cell Biol, West Point, PA 19486 USA; Merck Res Labs, Dept Bioproc & Bioanalyt Res, Rahway, NJ 07065 USA; Lehigh Univ, Dept Biol Sci, Bethlehem, PA 18015 USA	Merck & Company; Merck & Company; Lehigh University	Joyce, JG (corresponding author), Merck Res Labs, Dept Virus & Cell Biol, Sumneytown Pike, West Point, PA 19486 USA.							ABBOTT NL, 1993, ACS SYM SER, V532, P53; BAKER TS, 1991, BIOPHYS J, V60, P1445, DOI 10.1016/S0006-3495(91)82181-6; BOOTH BA, 1995, GROWTH REGULAT, V5, P1; CARDIN AD, 1989, ARTERIOSCLEROSIS, V9, P21, DOI 10.1161/01.ATV.9.1.21; CARLSON TH, 1995, BLOOD COAGUL FIBRIN, V6, P474, DOI 10.1097/00001721-199507000-00016; CARTER JJ, 1991, VIROLOGY, V182, P513, DOI 10.1016/0042-6822(91)90592-Y; Choay J, 1981, Ann N Y Acad Sci, V370, P644, DOI 10.1111/j.1749-6632.1981.tb29770.x; DILLNER J, 1995, INT J CANCER, V60, P377; ESKO JD, 1985, P NATL ACAD SCI USA, V82, P3197, DOI 10.1073/pnas.82.10.3197; Evander M, 1997, J VIROL, V71, P2449, DOI 10.1128/JVI.71.3.2449-2456.1997; FAVRE M, 1975, J VIROL, V15, P1239, DOI 10.1128/JVI.15.5.1239-1247.1975; FRITZ TA, 1994, J BIOL CHEM, V269, P300; Fromm JR, 1997, ARCH BIOCHEM BIOPHYS, V343, P92, DOI 10.1006/abbi.1997.0147; GISSMANN L, 1983, P NATL ACAD SCI-BIOL, V80, P560, DOI 10.1073/pnas.80.2.560; HAGENSEE ME, 1993, J VIROL, V67, P315, DOI 10.1128/JVI.67.1.315-322.1993; HAGGERTY JG, 1994, J CELL PHYSIOL, V158, P39, DOI 10.1002/jcp.1041580106; HAUSEN HZ, 1991, SCIENCE, V254, P1167, DOI 10.1126/science.1659743; HOFMANN KJ, 1995, VIROLOGY, V209, P506, DOI 10.1006/viro.1995.1283; HORMIA M, 1995, J INVEST DERMATOL, V105, P557, DOI 10.1111/1523-1747.ep12323451; HOVINGH P, 1993, EUR J BIOCHEM, V211, P771, DOI 10.1111/j.1432-1033.1993.tb17608.x; HOWLEY PM, 1990, VIROLOGY, P1625; JACKSON RL, 1991, PHYSIOL REV, V71, P481, DOI 10.1152/physrev.1991.71.2.481; KARLSSON K, 1993, BIOCHEM J, V290, P623, DOI 10.1042/bj2900623; KIRNBAUER R, 1992, P NATL ACAD SCI USA, V89, P12180, DOI 10.1073/pnas.89.24.12180; KLUG A, 1965, J MOL BIOL, V11, P403, DOI 10.1016/S0022-2836(65)80066-3; KOUTSKY LA, 1992, NEW ENGL J MED, V327, P1272, DOI 10.1056/NEJM199210293271804; LIANG XP, 1993, VIROLOGY, V194, P233, DOI 10.1006/viro.1993.1254; Linker A., 1972, METHODS ENZYMOL, P902; Lowe RS, 1997, J INFECT DIS, V176, P1141, DOI 10.1086/514105; MACH H, 1993, BIOCHEMISTRY-US, V32, P5480, DOI 10.1021/bi00071a026; McCarthy MP, 1998, J VIROL, V72, P32, DOI 10.1128/JVI.72.1.32-41.1998; MEYERS C, 1992, SCIENCE, V257, P971, DOI 10.1126/science.1323879; MULLER M, 1995, J VIROL, V69, P948; MURRAY E, 1983, BIOCHIM BIOPHYS ACTA, V763, P299, DOI 10.1016/0167-4889(83)90138-6; Neeper MP, 1996, GENE, V180, P1, DOI 10.1016/S0378-1119(96)00388-5; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PFISTER H, 1994, INTERVIROLOGY, V37, P143, DOI 10.1159/000150372; PIEPKORN M, 1995, IN VITRO CELL DEV-AN, V31, P536; ROSE RC, 1993, J VIROL, V67, P1936, DOI 10.1128/JVI.67.4.1936-1944.1993; SANDSTROM J, 1993, BIOCHEM J, V294, P853, DOI 10.1042/bj2940853; SAPP M, 1995, J GEN VIROL, V76, P2407, DOI 10.1099/0022-1317-76-9-2407; SASAGAWA T, 1995, VIROLOGY, V206, P126, DOI 10.1016/S0042-6822(95)80027-1; SCHIFFMAN MH, 1993, JNCI-J NATL CANCER I, V85, P958, DOI 10.1093/jnci/85.12.958; Secchiero P, 1997, J VIROL, V71, P4571, DOI 10.1128/JVI.71.6.4571-4580.1997; SHEEHAN JP, 1994, P NATL ACAD SCI USA, V91, P5518, DOI 10.1073/pnas.91.12.5518; SLUZKY V, 1994, PHARMACEUT RES, V11, P485, DOI 10.1023/A:1018946011652; SMITH LH, 1995, J INVEST DERMATOL, V105, P438, DOI 10.1111/1523-1747.ep12321173; SPILLMANN D, 1994, CURR OPIN STRUC BIOL, V4, P677, DOI 10.1016/S0959-440X(94)90165-1; STENBERG E, 1991, J COLLOID INTERF SCI, V143, P513, DOI 10.1016/0021-9797(91)90284-F; TALSINGER R, 1995, J VIROL, V69, P4471, DOI 10.1128/JVI.69.7.4471-4483.1995; TOKUNAGA F, 1994, J BIOCHEM-TOKYO, V116, P1164, DOI 10.1093/oxfordjournals.jbchem.a124644; VOLPERS C, 1994, VIROLOGY, V200, P504, DOI 10.1006/viro.1994.1213; VOLPERS C, 1995, J VIROL, V69, P3258, DOI 10.1128/JVI.69.6.3258-3264.1995; WU HF, 1995, BLOOD, V85, P421; YOSHIDA T, 1993, POLYM J, V25, P1069, DOI 10.1295/polymj.25.1069; Zhu Z, 1995, NEUROLOGY, V45, pS15, DOI 10.1212/WNL.45.12_Suppl_8.S15	56	291	309	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 26	1999	274	9					5810	5822		10.1074/jbc.274.9.5810	http://dx.doi.org/10.1074/jbc.274.9.5810			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	170KG	10026203	hybrid			2022-12-25	WOS:000078804400074
J	Arriola, EL; Lopez, AR; Chresta, CM				Arriola, EL; Lopez, AR; Chresta, CM			Differential regulation of p21(waf-1/cip-1) and Mdm2 by etoposide: etoposide inhibits the p53-Mdm2 autoregulatory feedback loop	ONCOGENE			English	Article						testicular neoplasms; p53; Mdm2; etoposide; apoptosis	WILD-TYPE P53; CYCLE CHECKPOINT PATHWAY; HUMAN TESTICULAR-TUMORS; GERM-CELL TUMORS; INDUCED APOPTOSIS; TRANSCRIPTIONAL ACTIVITY; ONCOPROTEIN MDM2; UV-RADIATION; DNA-DAMAGE; IN-VIVO	The Mdm2 protein is frequently overexpressed in human non-seminomatous germ cell tumours and transitional carcinoma of the bladder where it may contribute to tolerance of wtp53. Mdm2 forms an autoregulatory feedback loop with p53; the Mdm2 gene is responsive to transactivation by p53 and once synthesized the Mdm2 protein terminates the p53 response, We show here that the topoisomerase poison etoposide, like ultra violet irradiation, inhibits Mdm2 synthesis. Cytotoxic concentrations of etoposide (IC90 for >3 h) result in inhibition of Mdm2 induction at both the RNA and protein level. Rapid apoptosis ensues, Global transcription is not inhibited: p21(saf-1/cip-1) and GADD45 expression increase in a dose dependent manner. Inhibition of Mdm2 synthesis depends on the continuous presence of etoposide, suggesting the DNA damage may prevent transcription. Downregulation of Mdm2 transcript occurs in cells expressing HPV16-E6 suggesting that inhibition of Mdm2 transcription is p53-independent, When cells are treated with a pulse (1 h) of etoposide and reincubated in drug free medium, Mdm2 synthesis commences immediately after damage is repaired (3 h) and the p53 response is attenuated, Induction of apoptosis and loss of clonogenicity are 3-5-fold lower under pulse treatment conditions. This is the first observation of inhibition of Mdm2 transcription following treatment with topoisomerase (topo II) poisons, a feature that may be useful in tumour types where p53 is tolerated by overexpression of Mdm2.	Univ Manchester, Sch Biol Sci, CRC, Mol & Cellular Pharmacol Res Grp, Manchester M13 9PT, Lancs, England	University of Manchester	Chresta, CM (corresponding author), Univ Manchester, Sch Biol Sci, CRC, Mol & Cellular Pharmacol Res Grp, B-38,Stopford Bldg, Manchester M13 9PT, Lancs, England.		Lopez, Andrea/GQQ-3059-2022					BARAK Y, 1994, GENE DEV, V8, P1739, DOI 10.1101/gad.8.15.1739; BARBARESCHI M, 1995, UROL RES, V22, P349, DOI 10.1007/BF00296873; BERTRAND R, 1991, CANCER RES, V51, P6280; Blaydes JP, 1997, ONCOGENE, V14, P1859, DOI 10.1038/sj.onc.1201018; Bottger A, 1997, CURR BIOL, V7, P860, DOI 10.1016/S0960-9822(06)00374-5; CANMAN CE, 1994, CANCER RES, V54, P5054; CHEN CY, 1994, P NATL ACAD SCI USA, V91, P2684, DOI 10.1073/pnas.91.7.2684; CHEN JD, 1995, MOL MED, V1, P142, DOI 10.1007/BF03401562; Chen JD, 1996, MOL CELL BIOL, V16, P2445; Chen LH, 1998, P NATL ACAD SCI USA, V95, P195, DOI 10.1073/pnas.95.1.195; Chresta CM, 1996, CANCER RES, V56, P1834; CORDONCARDO C, 1994, CANCER RES, V54, P794; De Jong S., 1997, Proceedings of the American Association for Cancer Research Annual Meeting, V38, P638; DubsPoterszman MC, 1995, ONCOGENE, V11, P2445; Erhardt P, 1997, J BIOL CHEM, V272, P15049, DOI 10.1074/jbc.272.24.15049; FAKHARZADEH SS, 1991, EMBO J, V10, P1565, DOI 10.1002/j.1460-2075.1991.tb07676.x; FINLAY CA, 1993, MOL CELL BIOL, V13, P301, DOI 10.1128/MCB.13.1.301; FLEISCHHACKER M, 1994, MODERN PATHOL, V7, P435; Guillou L, 1996, AM J PATHOL, V149, P1221; Haines DS, 1997, LEUKEMIA LYMPHOMA, V26, P227, DOI 10.3109/10428199709051772; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Haupt Y, 1996, EMBO J, V15, P1596, DOI 10.1002/j.1460-2075.1996.tb00504.x; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; Knippschild U, 1996, ONCOGENE, V13, P1387; Knippschild U, 1997, ONCOGENE, V15, P1727, DOI 10.1038/sj.onc.1201541; KOHN KW, 1976, BIOCHEMISTRY-US, V15, P4629, DOI 10.1021/bi00666a013; KONDO S, 1995, ONCOGENE, V10, P2001; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Landers JE, 1997, CANCER RES, V57, P3562; LEVINE AJ, 1990, VIROLOGY, V177, P419, DOI 10.1016/0042-6822(90)90505-L; LIANES P, 1994, J NATL CANCER I, V86, P1325, DOI 10.1093/jnci/86.17.1325; Ljungman M, 1996, ONCOGENE, V13, P823; Lu X, 1996, ONCOGENE, V13, P413; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; LUNA RMD, 1995, NATURE, V378, P203; Lutzker SG, 1996, NAT MED, V2, P804, DOI 10.1038/nm0796-804; Maki CG, 1997, MOL CELL BIOL, V17, P355, DOI 10.1128/MCB.17.1.355; MARTIN K, 1995, NATURE, V375, P691, DOI 10.1038/375691a0; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; PERRY ME, 1993, P NATL ACAD SCI USA, V90, P11623, DOI 10.1073/pnas.90.24.11623; REICH NC, 1983, MOL CELL BIOL, V3, P2143, DOI 10.1128/MCB.3.12.2143; Reinke V, 1997, RADIAT RES, V148, P115, DOI 10.2307/3579567; RIEGER KM, 1995, BRIT J CANCER, V72, P683, DOI 10.1038/bjc.1995.394; RIOU G, 1995, MOL CARCINOGEN, V12, P124, DOI 10.1002/mc.2940120303; RIOU JF, 1993, FEBS LETT, V334, P369, DOI 10.1016/0014-5793(93)80714-6; Shaulian E, 1997, ONCOGENE, V15, P2717, DOI 10.1038/sj.onc.1201453; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Sigalas I, 1996, NAT MED, V2, P912, DOI 10.1038/nm0896-912; Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471; WEINBERG R, 1993, NEURON, V11, P191, DOI 10.1016/0896-6273(93)90177-S; Wu L, 1997, MOL MED, V3, P441, DOI 10.1007/BF03401691; Xiao G, 1998, ONCOGENE, V16, P1171, DOI 10.1038/sj.onc.1201631; XIAO ZX, 1995, NATURE, V375, P694, DOI 10.1038/375694a0; [No title captured]	56	52	53	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 28	1999	18	4					1081	1091		10.1038/sj.onc.1202391	http://dx.doi.org/10.1038/sj.onc.1202391			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	165FT	10023685				2022-12-25	WOS:000078510600026
J	Duncan, EL; Reddel, RR				Duncan, EL; Reddel, RR			Downregulation of metallothionein-IIA expression occurs at immortalization	ONCOGENE			English	Article						metallothionein-IIA; immortalization; senescence; SV40	FRAUMENI SYNDROME FIBROBLASTS; HUMAN-DIPLOID FIBROBLASTS; GENE-EXPRESSION; MESSENGER-RNA; HUMAN-CELLS; P16(INK4) EXPRESSION; TELOMERASE ACTIVITY; EPITHELIAL-CELLS; INDUCTION; ZINC	Metallothioneins (MTs) may modulate a variety of cellular processes by regulating the activity of zinc-binding proteins, These proteins have been implicated in cell growth regulation, and their expression is abnormal in some tumors. In particular, MT-IIA is expressed 27-fold less in human colorectal tumors and tumor cell lines compared with normal tissue (Zhang et al,, 1997), Here we demonstrate that MT-IIA downregulation occurs when human cells become immortal, a key event in tumorigenesis, After immortalization MT-IIA expression remains inducible but the basal activity of the MT-IIA promoter is decreased, MT-IIA downregulation at immortalization is one of the most common immortalization-related changes identified to date, suggesting that MT-IIA has a role in this process.	Childrens Med Res Inst, Sydney, NSW 2145, Australia	Children's Medical Research Institute - Australia; University of Sydney	Reddel, RR (corresponding author), Childrens Med Res Inst, Locked Bag 23, Wentworthville, NSW 2145, Australia.		Reddel, Roger R/A-6635-2014	Reddel, Roger R/0000-0002-6302-6107				ANGEL P, 1986, MOL CELL BIOL, V6, P1760, DOI 10.1128/MCB.6.5.1760; BRYAN TM, 1994, CRIT REV ONCOGENESIS, V5, P331, DOI 10.1615/CritRevOncog.v5.i4.10; BRYAN TM, 1995, EMBO J, V14, P4240, DOI 10.1002/j.1460-2075.1995.tb00098.x; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; DESILVA R, 1993, CELL MOL BIOL RES, V39, P101; DESILVA R, 1994, EXP CELL RES, V213, P418, DOI 10.1006/excr.1994.1218; Duncan EL, 1997, BIOCHEMISTRY-MOSCOW+, V62, P1263; Garkavtsev I, 1997, MOL CELL BIOL, V17, P2014, DOI 10.1128/MCB.17.4.2014; Garkavtsev I, 1996, NAT GENET, V14, P415, DOI 10.1038/ng1296-415; GIRARDI AJ, 1965, J CELL COMPAR PHYSL, V65, P69, DOI 10.1002/jcp.1030650110; GONCHAROVA EI, 1994, CANCER RES, V54, P5318; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; HEGUY A, 1986, MOL CELL BIOL, V6, P2149, DOI 10.1128/MCB.6.6.2149; IMBRA RJ, 1987, MOL CELL BIOL, V7, P1358, DOI 10.1128/MCB.7.4.1358; JAHROUDI N, 1990, J BIOL CHEM, V265, P6506; KAGI JHR, 1991, METHOD ENZYMOL, V205, P613; KARIN M, 1983, P NATL ACAD SCI-BIOL, V80, P4040, DOI 10.1073/pnas.80.13.4040; KARIN M, 1987, MOL CELL BIOL, V7, P606, DOI 10.1128/MCB.7.2.606; KARIN M, 1982, NATURE, V299, P797, DOI 10.1038/299797a0; KARIN M, 1984, NATURE, V308, P513, DOI 10.1038/308513a0; KARIN M, 1981, EUR J BIOCHEM, V118, P527, DOI 10.1111/j.1432-1033.1981.tb05551.x; Lechner J F, 1985, J TISSUE CULT METHOD, V9, P43; LECHNER JF, 1985, P NATL ACAD SCI USA, V82, P3884, DOI 10.1073/pnas.82.11.3884; LI Y, 1994, CANCER RES, V54, P6078; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; LUCE MC, 1993, EXP GERONTOL, V28, P17, DOI 10.1016/0531-5565(93)90017-8; MACLEAN K, 1994, ONCOGENE, V9, P719; Noble JR, 1996, ONCOGENE, V13, P1259; OFNER D, 1994, VIRCHOWS ARCH, V425, P491; PEREIRASMITH OM, 1988, P NATL ACAD SCI USA, V85, P6042, DOI 10.1073/pnas.85.16.6042; ROGAN EM, 1995, MOL CELL BIOL, V15, P4745; SCHMIDT CJ, 1986, P NATL ACAD SCI USA, V83, P3346, DOI 10.1073/pnas.83.10.3346; Shibanuma M, 1997, MOL CELL BIOL, V17, P1224, DOI 10.1128/MCB.17.3.1224; STENNARD FA, 1994, BBA-GENE STRUCT EXPR, V1218, P357, DOI 10.1016/0167-4781(94)90189-9; THORNALLEY PJ, 1985, BIOCHIM BIOPHYS ACTA, V827, P36, DOI 10.1016/0167-4838(85)90098-6; UDOM AO, 1980, BIOCHEM J, V187, P329, DOI 10.1042/bj1870329; VALLEE BL, 1995, NEUROCHEM INT, V27, P23, DOI 10.1016/0197-0186(94)00165-Q; Waalkes MP, 1996, J PHARMACOL EXP THER, V277, P1026; WEST AK, 1990, GENOMICS, V8, P513, DOI 10.1016/0888-7543(90)90038-V; WILSON VL, 1983, SCIENCE, V220, P1054; ZENG J, 1991, FEBS LETT, V279, P310, DOI 10.1016/0014-5793(91)80175-3; Zhang L, 1997, SCIENCE, V276, P1268, DOI 10.1126/science.276.5316.1268	42	24	24	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 28	1999	18	4					897	903		10.1038/sj.onc.1202370	http://dx.doi.org/10.1038/sj.onc.1202370			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	165FT	10023665				2022-12-25	WOS:000078510600006
J	Tomizawa, Y; Kohno, T; Fujita, T; Kiyama, M; Saito, R; Noguchi, M; Matsuno, Y; Hirohashi, S; Yamaguchi, N; Nakajima, T; Yokota, J				Tomizawa, Y; Kohno, T; Fujita, T; Kiyama, M; Saito, R; Noguchi, M; Matsuno, Y; Hirohashi, S; Yamaguchi, N; Nakajima, T; Yokota, J			Correlation between the status of the p53 gene and survival in patients with stage I non-small cell lung carcinoma	ONCOGENE			English	Article						stage I NSCLC; p53 mutation; p53 expression; prognosis	TUMOR-SUPPRESSOR GENE; PROGNOSTIC-SIGNIFICANCE; POOR-PROGNOSIS; BREAST-CANCER; MUTANT P53; MUTATIONS; HETEROZYGOSITY; EXPRESSION; 17P13.3; TP53	The association of p53 abnormalities with the prognosis of patients,vith non-small cell lung carcinoma (NSCLC) has been extensively investigated to date, however, this association is still controversial, Therefore, we investigated the prognostic significance of p53 mutations through exons 2 to 11 and p53 protein expression in 103 cases of stage I NSCLC, p53 mutations were detected in 49 of 103 (48%) tumors, Two separate mutations were detected in four tumors giving a total of 53 unique mutations in 49 tumors. Ten (19%) of mutations occurred outside exons 5-8, Positive immunohistochemical staining of p53 protein was detected in 41 of 103 (40%) tumors. The concordance rate between mutations and protein overexpression,vas only 69%, p53 mutations, but not expression, were significantly associated with a shortened survival of patients (P < 0.001), Furthermore, we investigated the correlation between the types of p53 mutations and prognosis. p53 missense mutations rather than null mutations were associated with poor prognosis (P < 0.001 in missense mutations and P = 0.243 in null mutations), These results indicated that p53 mutations, in particular missense mutations, rather than p53 expression could be a useful molecular marker for the prognosis of patients with surgically resected stage I NSCLC.	Natl Canc Ctr, Res Inst, Div Biol, Chuo Ku, Tokyo 1040045, Japan; Natl Canc Ctr, Res Inst, Div Pathol, Chuo Ku, Tokyo 1040045, Japan; Natl Canc Ctr, Res Inst, Canc Informat & Epidemiol Div, Chuo Ku, Tokyo 1040045, Japan; Gunma Univ, Sch Med, Dept Pathol 2, Gunma 3718511, Japan; Hitachi Ltd, Adv Res Lab, Hatoyama, Saitama 3500395, Japan; Gunma Univ, Sch Med, Dept Internal Med 1, Gunma 3718511, Japan	National Cancer Center - Japan; National Cancer Center - Japan; National Cancer Center - Japan; Gunma University; Hitachi Limited; Gunma University	Yokota, J (corresponding author), Natl Canc Ctr, Res Inst, Div Biol, Chuo Ku, 1-1 Tsukiji, Tokyo 1040045, Japan.							BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BARTEK J, 1990, ONCOGENE, V5, P893; BODNER SM, 1992, ONCOGENE, V7, P743; BORRESEN AL, 1991, P NATL ACAD SCI USA, V88, P8405, DOI 10.1073/pnas.88.19.8405; CARBONE DP, 1994, CHEST, V106, pS377, DOI 10.1378/chest.106.6.377S; Casey G, 1996, ONCOGENE, V13, P1971; CHIBA I, 1990, ONCOGENE, V5, P1603; COLES C, 1990, LANCET, V336, P761, DOI 10.1016/0140-6736(90)93236-I; CORNELIS RS, 1994, CANCER RES, V54, P4200; deAnta JM, 1997, ONCOGENE, V15, P2951, DOI 10.1038/sj.onc.1201475; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FONG KM, 1995, CANCER RES, V55, P4268; Fukuyama Y, 1997, BRIT J CANCER, V75, P1125, DOI 10.1038/bjc.1997.194; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GREENBLATT MS, 1994, CANCER RES, V54, P4855; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HORIO Y, 1993, CANCER RES, V53, P1; IGGO R, 1990, LANCET, V335, P675, DOI 10.1016/0140-6736(90)90801-B; ISOBE T, 1994, JPN J CANCER RES, V85, P1240, DOI 10.1111/j.1349-7006.1994.tb02936.x; JONES MH, 1992, GENE CHROMOSOME CANC, V5, P89, DOI 10.1002/gcc.2870050113; KISHIMOTO Y, 1992, CANCER RES, V52, P4799; Kiyama M, 1996, BIOTECHNIQUES, V21, P710; LOHMANN D, 1993, DIAGN MOL PATHOL, V2, P36, DOI 10.1097/00019606-199300020-00006; MINNA JD, 1991, HARRISONS PRINCIPLES, P1102; Mitsudomi T, 1995, Ann Oncol, V6 Suppl 3, pS9; MITSUDOMI T, 1993, JNCI-J NATL CANCER I, V85, P2018, DOI 10.1093/jnci/85.24.2018; MOORE DF, 1996, LUNG CANC PRINCIPLES, P481; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; Ohno A, 1997, INT J ONCOL, V10, P521; OKAMOTO A, 1991, CANCER RES, V51, P5632; OKAMOTO A, 1991, CANCER RES, V51, P5157; RODRIGUES NR, 1990, P NATL ACAD SCI USA, V87, P7555, DOI 10.1073/pnas.87.19.7555; Sakamoto T, 1996, GYNECOL ONCOL, V63, P173, DOI 10.1006/gyno.1996.0302; SAMESHIMA Y, 1992, ONCOGENE, V7, P451; Schultz DC, 1996, CANCER RES, V56, P1997; Shiseki M, 1996, GENE CHROMOSOME CANC, V17, P71, DOI 10.1002/(SICI)1098-2264(199610)17:2<71::AID-GCC1>3.0.CO;2-Y; SOMMER SS, 1992, J NATL CANCER I, V84, P246, DOI 10.1093/jnci/84.4.246; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; THOMPSON AM, 1992, INT J CANCER, V50, P528, DOI 10.1002/ijc.2910500405; WALES MM, 1995, NAT MED, V1, P570, DOI 10.1038/nm0695-570; *WHO, 1981, HIST TYP LUNG TUM, V1; YOKOTA J, 1987, P NATL ACAD SCI USA, V84, P9252, DOI 10.1073/pnas.84.24.9252; YOKOTA J, 1993, FASEB J, V7, P920, DOI 10.1096/fasebj.7.10.8344488	43	72	76	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 28	1999	18	4					1007	1014		10.1038/sj.onc.1202384	http://dx.doi.org/10.1038/sj.onc.1202384			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	165FT	10023676				2022-12-25	WOS:000078510600017
J	Ackerman, MS; Bhate, M; Shenoy, N; Beck, K; Ramshaw, JAM; Brodsky, B				Ackerman, MS; Bhate, M; Shenoy, N; Beck, K; Ramshaw, JAM; Brodsky, B			Sequence dependence of the folding of collagen-like peptides - Single amino acids affect the rate of triple-helix nucleation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-Y TRIPLETS; BOND ISOMERIZATION; STABILITY; PROCOLLAGEN; STABILIZATION; MUTATIONS; RESIDUES; NMR	The refolding of thermally denatured model collagenlike peptides was studied for a set of 21 guest triplets embedded in a common host framework: acetyl-(Gly-Pro-Hyp)(3)-Gly-Xaa-Yaa-(Gly-Pro-Hyp)(4)-Gly The results show a strong dependence of the folding rate on the identity of the guest Gly-Xaa-Yaa triplet, with the half-times for refolding varying from 6 to 110 min (concentration = 1 mg/ml). All triplets of the form Gly-Xaa-Hyp promoted rapid folding, with the rate only marginally dependent on the residue in the Xaa position. In contrast, triplets of the form Gly-Pro-Yaa and Gly-Xaa-Yaa were slower and showed a wide range of half-times, varying with the identity of the residues in the triplet. At low concentrations, the folding can be described by third-order kinetics, suggesting nucleation is rate-limiting. Data on the relative nucleation ability of different Gly-Xaa-Yaa triplets support the favorable nature of imino acids, the importance of hydroxyproline, the varying effects of the same residue in the Xaa position versus the Yaa position, and the difficulties encountered when leucine or aspartic acid are in the Yaa position. Information on the relative propensities of different tripeptide sequences to promote nucleation of the triple-helix in peptides will aid in identification of nucleation sites in collagen sequences.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Biochem, Piscataway, NJ 08854 USA; CSIRO, Div Mol Sci, Parkville, Vic 3052, Australia	Rutgers State University New Brunswick; Rutgers State University Medical Center; Commonwealth Scientific & Industrial Research Organisation (CSIRO)	Brodsky, B (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Biochem, 675 Hoes Lane, Piscataway, NJ 08854 USA.	brodsky@rwja.umdnj.edu	Beck, Konrad/AAX-1351-2020; Ramshaw, John AM/A-9411-2011	Beck, Konrad/0000-0001-5098-9484; Ramshaw, John A.M./0000-0002-2131-3685	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR019626] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR19626] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BACHINGER HP, 1993, AM J MED GENET, V45, P152, DOI 10.1002/ajmg.1320450204; BACHINGER HP, 1987, J BIOL CHEM, V262, P17144; BACHINGER HP, 1980, EUR J BIOCHEM, V106, P619, DOI 10.1111/j.1432-1033.1980.tb04610.x; BACHINGER HP, 1978, EUR J BIOCHEM, V90, P605, DOI 10.1111/j.1432-1033.1978.tb12641.x; BANSAL M, 1977, INT J PEPT PROT RES, V9, P224; BANSAL M, 1988, BIOPOLYMERS, V27, P299, DOI 10.1002/bip.360270209; Baum J, 1997, FOLD DES, V2, pR53, DOI 10.1016/S1359-0278(97)00028-X; Beck K, 1998, J STRUCT BIOL, V122, P17, DOI 10.1006/jsbi.1998.3965; BELLA J, 1995, STRUCTURE, V3, P893, DOI 10.1016/S0969-2126(01)00224-6; BELLA J, 1994, SCIENCE, V266, P75, DOI 10.1126/science.7695699; Brodsky B, 1997, MATRIX BIOL, V15, P545, DOI 10.1016/S0945-053X(97)90030-5; BRODSKY B, 1990, PROTEIN FOLDING : DECIPHERING THE SECOND HALF OF THE GENETIC CODE, P55; Bulleid NJ, 1996, SEMIN CELL DEV BIOL, V7, P667, DOI 10.1006/scdb.1996.0081; Bulleid NJ, 1997, EMBO J, V16, P6694, DOI 10.1093/emboj/16.22.6694; Chan VC, 1997, J BIOL CHEM, V272, P31441, DOI 10.1074/jbc.272.50.31441; Eberhardt ES, 1996, J AM CHEM SOC, V118, P12261, DOI 10.1021/ja9623119; ENGEL J, 1991, ANNU REV BIOPHYS BIO, V20, P137, DOI 10.1146/annurev.biophys.20.1.137; FRASER RDB, 1979, J MOL BIOL, V129, P463, DOI 10.1016/0022-2836(79)90507-2; Lees JF, 1997, EMBO J, V16, P908, DOI 10.1093/emboj/16.5.908; Liu XY, 1996, BIOCHEMISTRY-US, V35, P4306, DOI 10.1021/bi952270d; Liu XY, 1998, BIOCHEMISTRY-US, V37, P15528, DOI 10.1021/bi981147u; LONG CG, 1993, BIOCHEMISTRY-US, V32, P11688, DOI 10.1021/bi00094a027; Mayo KH, 1996, BIOPOLYMERS, V40, P359, DOI 10.1002/(SICI)1097-0282(1996)40:4<359::AID-BIP2>3.0.CO;2-V; McLaughlin SH, 1998, MATRIX BIOL, V16, P369, DOI 10.1016/S0945-053X(98)90010-5; Nagata K, 1996, TRENDS BIOCHEM SCI, V21, P23, DOI 10.1016/0968-0004(96)80881-4; PIEZ KA, 1970, BIOCHEMISTRY-US, V9, P4134, DOI 10.1021/bi00823a016; PRIVALOV PL, 1982, ADV PROTEIN CHEM, V35, P1, DOI 10.1016/S0065-3233(08)60468-4; Ramshaw JAM, 1998, J STRUCT BIOL, V122, P86, DOI 10.1006/jsbi.1998.3977; RICH A, 1961, J MOL BIOL, V3, P483, DOI 10.1016/S0022-2836(61)80016-8; Richardson J. S., 1989, PREDICTION PROTEIN S, P1; SAKAKIBARA S, 1973, BIOCHIM BIOPHYS ACTA, V303, P198, DOI 10.1016/0005-2795(73)90164-5; Shah NK, 1996, BIOCHEMISTRY-US, V35, P10262, DOI 10.1021/bi960046y; SUTOH K, 1974, BIOPOLYMERS, V13, P2477, DOI 10.1002/bip.1974.360131207; VITAGLIANO L, 1993, BIOCHEMISTRY-US, V32, P7354, DOI 10.1021/bi00080a004; VONHIPPEL PH, 1959, BIOCHIM BIOPHYS ACTA, V36, P427, DOI 10.1016/0006-3002(59)90185-4; WEIDNER H, 1975, BIOPOLYMERS, V17, P763; WEIDNER H, 1974, PEPTIDES POLYPEPTIDE, P419; Wilson R, 1998, J BIOL CHEM, V273, P9637, DOI 10.1074/jbc.273.16.9637; Yang W, 1997, J BIOL CHEM, V272, P28837, DOI 10.1074/jbc.272.46.28837	39	70	70	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 19	1999	274	12					7668	7673		10.1074/jbc.274.12.7668	http://dx.doi.org/10.1074/jbc.274.12.7668			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	178LU	10075654	hybrid, Green Accepted			2022-12-25	WOS:000079268100013
J	Teuchert, M; Schafer, W; Berghofer, S; Hoflack, B; Klenk, HD; Garten, W				Teuchert, M; Schafer, W; Berghofer, S; Hoflack, B; Klenk, HD; Garten, W			Sorting of furin at the trans-Golgi network - Interaction of the cytoplasmic tail sorting signals with AP-1 Golgi-specific assembly proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MANNOSE 6-PHOSPHATE RECEPTORS; KINASE-II PHOSPHORYLATION; CLATHRIN-ASSOCIATED PROTEINS; HIGH-AFFINITY INTERACTION; COATED VESICLES; CELL-SURFACE; INTRACELLULAR TRAFFICKING; PROPROTEIN CONVERTASE; INVITRO BINDING; MEDIUM CHAINS	The eukaryotic subtilisin-like endoprotease furin is found predominantly in the trans-Golgi network (TGN) and cycles between this compartment, the cell surface, and the endosomes. There is experimental evidence for endocytosis from the plasma membrane and transport from endosomes to the TGN, but direct exit from the TGN to endosomes via clathrin-coated vesicles has only been discussed but not directly shown so far. Here we present data showing that expression of furin promotes the first step of clathrin-coat assembly at the TGN, the recruitment of the Golgis-specific assembly protein AP-I on Golgi membranes. Further, we report that furin indeed is present in isolated clathrin-coated vesicles, packaging into clathrin-coated vesicles requires signal components in the furin cytoplasmic domain which can be recognized by AP-1 assembly proteins. We found that besides depending on the phosphorylation state of a casein kinase II site, interaction of the furin tail with AP-1 and its mu 1subunit is mediated by a tyrosine motif and to less extent by a leucine-isoleucine signal, whereas a monophenylalanine motif is only involved in binding to the intact AP-1 complex. This study implies that high affinity interaction of AP-1 or mu 1 with the cytoplasmic tail of furin needs a complex interplay of signal components rather than one distinct signal.	Inst Pasteur, Inst Biol, EP 525, CNRS, F-59021 Lille, France; Univ Marburg, Inst Virol, D-35037 Marburg, Germany	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Philipps University Marburg	Garten, W (corresponding author), Inst Pasteur, Inst Biol, EP 525, CNRS, BP 447,1 Rue Prof Calmette, F-59021 Lille, France.		HOFLACK, Bernard/AAZ-6668-2020					ADAM SA, 1990, J CELL BIOL, V111, P807, DOI 10.1083/jcb.111.3.807; AHLE S, 1989, J BIOL CHEM, V264, P20089; Alconada A, 1996, EMBO J, V15, P6096, DOI 10.1002/j.1460-2075.1996.tb00998.x; BELTZER JP, 1991, EMBO J, V10, P3735, DOI 10.1002/j.1460-2075.1991.tb04942.x; Boge M, 1998, J BIOL CHEM, V273, P15773, DOI 10.1074/jbc.273.25.15773; Boll W, 1996, EMBO J, V15, P5789, DOI 10.1002/j.1460-2075.1996.tb00965.x; BOSSHART H, 1994, J CELL BIOL, V126, P1157, DOI 10.1083/jcb.126.5.1157; Bremnes T, 1998, J BIOL CHEM, V273, P8638, DOI 10.1074/jbc.273.15.8638; CAMPBELL C, 1984, BIOCHEMISTRY-US, V23, P4420, DOI 10.1021/bi00314a028; CHAPMAN RE, 1994, EMBO J, V13, P2305, DOI 10.1002/j.1460-2075.1994.tb06514.x; Dietrich J, 1997, J CELL BIOL, V138, P271, DOI 10.1083/jcb.138.2.271; Dittie AS, 1997, EMBO J, V16, P4859, DOI 10.1093/emboj/16.16.4859; DUNCAN JR, 1988, J CELL BIOL, V106, P617, DOI 10.1083/jcb.106.3.617; GLICKMAN JN, 1989, EMBO J, V8, P1041, DOI 10.1002/j.1460-2075.1989.tb03471.x; Heilker R, 1996, EMBO J, V15, P2893, DOI 10.1002/j.1460-2075.1996.tb00650.x; Hirst J, 1998, BBA-MOL CELL RES, V1404, P173, DOI 10.1016/S0167-4889(98)00056-1; Honing S, 1996, EMBO J, V15, P5230, DOI 10.1002/j.1460-2075.1996.tb00908.x; Honing S, 1997, J BIOL CHEM, V272, P19884, DOI 10.1074/jbc.272.32.19884; JONES BG, 1995, EMBO J, V14, P5869, DOI 10.1002/j.1460-2075.1995.tb00275.x; Kirchhausen T, 1997, CURR OPIN CELL BIOL, V9, P488, DOI 10.1016/S0955-0674(97)80024-5; KYHSEANDERSEN J, 1984, J BIOCHEM BIOPH METH, V10, P203, DOI 10.1016/0165-022X(84)90040-X; LeBorgne R, 1996, J BIOL CHEM, V271, P2162; LeBorgne R, 1997, J CELL BIOL, V137, P335; LEBORGNE R, 1993, J BIOL CHEM, V268, P22552; LUDWIG T, 1994, EMBO J, V13, P3430, DOI 10.1002/j.1460-2075.1994.tb06648.x; Mauxion F, 1996, J BIOL CHEM, V271, P2171, DOI 10.1074/jbc.271.4.2171; MOLLOY SS, 1994, EMBO J, V13, P18, DOI 10.1002/j.1460-2075.1994.tb06231.x; MOLLOY SS, 1992, J BIOL CHEM, V267, P16396; Nakayama K, 1997, BIOCHEM J, V327, P625, DOI 10.1042/bj3270625; NAKAYAMA Y, 1991, EUR J BIOCHEM, V202, P569, DOI 10.1111/j.1432-1033.1991.tb16409.x; NESTEROV A, 1995, J BIOL CHEM, V270, P6320, DOI 10.1074/jbc.270.11.6320; Ohno H, 1996, J BIOL CHEM, V271, P29009, DOI 10.1074/jbc.271.46.29009; OHNO H, 1995, SCIENCE, V269, P1872, DOI 10.1126/science.7569928; PEARSE BMF, 1988, EMBO J, V7, P3331, DOI 10.1002/j.1460-2075.1988.tb03204.x; Rapoport I, 1998, EMBO J, V17, P2148, DOI 10.1093/emboj/17.8.2148; Rodionov DG, 1998, J BIOL CHEM, V273, P6005, DOI 10.1074/jbc.273.11.6005; Salamero J, 1996, J BIOL CHEM, V271, P30318, DOI 10.1074/jbc.271.48.30318; Sambrook J., 2002, MOL CLONING LAB MANU; Sandoval Ignacio V., 1994, Trends in Cell Biology, V4, P292, DOI 10.1016/0962-8924(94)90220-8; SCHAFER W, 1995, EMBO J, V14, P2424, DOI 10.1002/j.1460-2075.1995.tb07240.x; SOSA MA, 1993, J BIOL CHEM, V268, P12537; STEINER DF, 1992, J BIOL CHEM, V267, P23435; TAKAHASHI S, 1995, J BIOL CHEM, V270, P28397; TRAUB LM, 1993, J CELL BIOL, V123, P561, DOI 10.1083/jcb.123.3.561; Traub LM, 1997, CURR OPIN CELL BIOL, V9, P527, DOI 10.1016/S0955-0674(97)80029-4; TROWBRIDGE IS, 1993, ANNU REV CELL BIOL, V9, P129, DOI 10.1146/annurev.cb.09.110193.001021; VOORHEES P, 1995, EMBO J, V14, P4961, DOI 10.1002/j.1460-2075.1995.tb00179.x; Wan L, 1998, CELL, V94, P205, DOI 10.1016/S0092-8674(00)81420-8; WOODMAN PG, 1991, J CELL BIOL, V112, P1133, DOI 10.1083/jcb.112.6.1133	49	43	44	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 19	1999	274	12					8199	8207		10.1074/jbc.274.12.8199	http://dx.doi.org/10.1074/jbc.274.12.8199			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	178LU	10075724	hybrid			2022-12-25	WOS:000079268100083
J	Hunt, AE; Lali, FV; Lord, JD; Nelson, BH; Miyazaki, T; Tracey, KJ; Foxwell, BMJ				Hunt, AE; Lali, FV; Lord, JD; Nelson, BH; Miyazaki, T; Tracey, KJ; Foxwell, BMJ			Role of interleukin (IL)-2 receptor beta-chain subdomains and Shc in p38 mitogen-activated protein (MAP) kinase and p54 MAP kinase (stress-activated protein kinase c-Jun N-terminal kinase) activation - IL-2-driven proliferation is independent of p38 and p54 MAP kinase activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P70 S6 KINASE; T-CELL LINE; GROWTH SIGNAL-TRANSDUCTION; MICE LACKING JAK3; IL-2 RECEPTOR; TYROSINE KINASE; TETRAVALENT GUANYLHYDRAZONE; ASSOCIATION; PHOSPHORYLATION; SUPPRESSION	We have shown recently that interleukin (IL)-2 activates the mitogen-activated protein (MAP) kinase family members p38 (HOG1/stress-activated protein kinase II) and p54 (c-Jun N-terminal kinase/stress-activated protein kinase I). Furthermore, the p38 MAP kinase inhibitor SB203580 inhibited IL-2-driven T cell proliferation, suggesting that p38 MAP kinase might be involved in mediating proliferative signals. In this study, using transfected BA/F3 cell lines, it is shown that both the acidic domain and the membrane-proximal serine-rich region of the IL-2R beta chain are required for p38 and p54 MAP kinase activation and that, as for p42/44 MAP kinase, this activation requires the Tyr(338) residue of the acidic domain, the binding site for She. It is well established that the acidic domain of the IL-2R beta chain is dispensable for IL-a-driven proliferation, and thus our observations suggest that neither p38 nor p54 MAP kinase activation is required for IL-a-driven proliferation of BA/F3 cells. In addition, the tetravalent guanylhydrazone inhibitor of proinflammatory cytokine production, CNI-1493, can block the activation of p54 and p38 MAP kinases by IL-2 but has no effect on IL-2-driven proliferation of BA/F3 cells, activated primary T cells, or a cytotoxic T cell line. Furthermore, our observations provide evidence for the existence of an additional, unknown target of the p38 MAP kinase inhibitor SB203580, the activation of which is essential for mitogenic signaling by IL-2.	Kennedy Inst Rheumatol, London W6 8LH, England; Virginia Mason Res Ctr, Seattle, WA 98101 USA; Univ Washington, Dept Immunol, Seattle, WA 98195 USA; Univ Tokyo, Grad Sch, Dept Immunol, Tokyo 113, Japan; Univ Tokyo, Fac Med, Tokyo 113, Japan; Picower Inst Med Res, Manhasset, NY 11030 USA	University of Oxford; Virginia Mason Medical Center; University of Washington; University of Washington Seattle; University of Tokyo; University of Tokyo; Northwell Health	Foxwell, BMJ (corresponding author), Kennedy Inst Rheumatol, 1 Aspenlea Rd, London W6 8LH, England.		Nelson, Brad H/K-2622-2014; Miyazaki, Tadaaki/D-9368-2012; Lali, Ferdinand/AAD-1946-2019; Ferdinand, Lali/AAH-4867-2020	Ferdinand, Lali/0000-0001-5890-9936; Nelson, Brad/0000-0002-4445-5539; Tracey, Kevin J/0000-0003-1884-6314				AUGUSTINE JA, 1991, MOL CELL BIOL, V11, P4431, DOI 10.1128/MCB.11.9.4431; Bianchi M, 1996, J EXP MED, V183, P927, DOI 10.1084/jem.183.3.927; BIANCHI M, 1995, MOL MED, V1, P254, DOI 10.1007/BF03401550; Bjork L, 1997, J INFECT DIS, V176, P1303; Brennan P, 1997, IMMUNITY, V7, P679, DOI 10.1016/S1074-7613(00)80388-X; CALVO V, 1992, P NATL ACAD SCI USA, V89, P7571, DOI 10.1073/pnas.89.16.7571; Clerk A, 1998, FEBS LETT, V426, P93, DOI 10.1016/S0014-5793(98)00324-X; Cohen PS, 1997, MOL MED, V3, P339, DOI 10.1007/BF03401812; Cohen PS, 1996, P NATL ACAD SCI USA, V93, P3967, DOI 10.1073/pnas.93.9.3967; Crawley JB, 1996, EUR J IMMUNOL, V26, P2717, DOI 10.1002/eji.1830261125; Crawley JB, 1997, J BIOL CHEM, V272, P15023, DOI 10.1074/jbc.272.23.15023; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; EVANS GA, 1995, J BIOL CHEM, V270, P28858, DOI 10.1074/jbc.270.48.28858; Finch A, 1997, FEBS LETT, V418, P144, DOI 10.1016/S0014-5793(97)01364-1; FRESHNEY NW, 1994, CELL, V78, P1039, DOI 10.1016/0092-8674(94)90278-X; Friedman MC, 1996, P NATL ACAD SCI USA, V93, P2077, DOI 10.1073/pnas.93.5.2077; FUJII H, 1995, P NATL ACAD SCI USA, V92, P5482, DOI 10.1073/pnas.92.12.5482; GOLDSMITH MA, 1995, J BIOL CHEM, V270, P21729, DOI 10.1074/jbc.270.37.21729; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HATAKEYAMA M, 1989, CELL, V59, P837, DOI 10.1016/0092-8674(89)90607-7; HATAKEYAMA M, 1991, SCIENCE, V252, P1523, DOI 10.1126/science.2047859; HATAKEYAMA M, 1989, SCIENCE, V244, P551, DOI 10.1126/science.2785715; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Higuchi M, 1996, EUR J IMMUNOL, V26, P1322, DOI 10.1002/eji.1830260622; Kemeny MM, 1998, P NATL ACAD SCI USA, V95, P4561, DOI 10.1073/pnas.95.8.4561; KUO CJ, 1992, NATURE, V358, P70, DOI 10.1038/358070a0; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; Lord JD, 1998, J IMMUNOL, V161, P4627; MERIDA I, 1991, J IMMUNOL, V147, P2202; MERIDA I, 1993, J BIOL CHEM, V268, P6765; MINAMI Y, 1995, IMMUNITY, V2, P89, DOI 10.1016/1074-7613(95)90081-0; MINAMI Y, 1994, J IMMUNOL, V152, P5680; MINAMI Y, 1993, EMBO J, V12, P759, DOI 10.1002/j.1460-2075.1993.tb05710.x; Miyazaki T, 1998, GENE DEV, V12, P770, DOI 10.1101/gad.12.6.770; MIYAZAKI T, 1995, CELL, V81, P223, DOI 10.1016/0092-8674(95)90332-1; MIYAZAKI T, 1994, SCIENCE, V266, P1045, DOI 10.1126/science.7973659; NOSAKA T, 1995, SCIENCE, V270, P800, DOI 10.1126/science.270.5237.800; PAGE TH, 1993, J IMMUNOL, V151, P4753; RAVICHANDRAN KS, 1994, J BIOL CHEM, V269, P1599; RAVICHANDRAN KS, 1995, MOL CELL BIOL, V15, P593; Reif K, 1997, J BIOL CHEM, V272, P14426, DOI 10.1074/jbc.272.22.14426; RUSSELL SM, 1994, SCIENCE, V266, P1042, DOI 10.1126/science.7973658; SATOH T, 1991, P NATL ACAD SCI USA, V88, P3314, DOI 10.1073/pnas.88.8.3314; SMITH KA, 1988, SCIENCE, V240, P1169, DOI 10.1126/science.3131876; Teglund S, 1998, CELL, V93, P841, DOI 10.1016/S0092-8674(00)81444-0; Theze J, 1996, IMMUNOL TODAY, V17, P481, DOI 10.1016/0167-5699(96)10057-C; THOMIS DC, 1995, SCIENCE, V270, P794, DOI 10.1126/science.270.5237.794; TURNER B, 1991, P NATL ACAD SCI USA, V88, P1227, DOI 10.1073/pnas.88.4.1227; TURNER M, 1995, NATURE, V378, P298, DOI 10.1038/378298a0; Whitmarsh AJ, 1997, MOL CELL BIOL, V17, P2360, DOI 10.1128/MCB.17.5.2360; WILLCOCKS JL, 1993, EUR J IMMUNOL, V23, P716, DOI 10.1002/eji.1830230322; ZMUIDZINAS A, 1991, MOL CELL BIOL, V11, P2794, DOI 10.1128/MCB.11.5.2794	53	35	35	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 12	1999	274	11					7591	7597		10.1074/jbc.274.11.7591	http://dx.doi.org/10.1074/jbc.274.11.7591			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	175DV	10066828	hybrid			2022-12-25	WOS:000079078400100
J	Affourtit, C; Albury, MS; Krab, K; Moore, AL				Affourtit, C; Albury, MS; Krab, K; Moore, AL			Functional expression of the plant alternative oxidase affects growth of the yeast Schizosaccharomyces pombe	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYANIDE-INSENSITIVE RESPIRATION; METABOLIC CONTROL ANALYSIS; QUINONE POOL; ELECTRON-TRANSFER; REDOX POISE; ACTIVE-SITE; MITOCHONDRIA; PROTEIN; PATHWAYS; KINETICS	We have investigated the extent to which functional expression of the plant alternative oxidase (from Sauromatum guttatum) in Schizosaccharomyces pombe affects yeast growth. When cells are cultured on glycerol, the maximum specific growth rate is decreased from 0.13 to 0.11 h(-1) while growth yield is lowered by 20% (from 1.14 x 10(8) to 9.12 x 10(7) cells ml(-1)). Kinetic studies suggest that the effect on growth is mitochondrial in origin. In isolated mitochondria we found that the alternative oxidase actively competes with the cytochrome pathway for reducing equivalents and contributes up to 24% to the overall respiratory activity. Metabolic control analysis reveals that the alternative oxidase exerts a considerable degree of control (22%) on total electron flux. Furthermore, the negative control exerted by the alternative oxidase on the flux ratio of electrons through the cytochrome and alternative pathways is comparable with the positive control exerted on this flux-ratio by the cytochrome pathway. To our knowledge, this is the first paper to report a phenotypic effect because of plant alternative oxidase expression. We suggest that the effect on growth is the result of high engagement of the non-protonmotive alternative oxidase in yeast respiration that, consequently, lowers the efficiency of energy conservation and hence growth.	Univ Sussex, Sch Biol Sci, Dept Biochem, Brighton BN1 9QG, E Sussex, England; Free Univ Amsterdam, IMBW, Microbiol Sect, NL-1081 HV Amsterdam, Netherlands	University of Sussex; Vrije Universiteit Amsterdam	Moore, AL (corresponding author), Univ Sussex, Sch Biol Sci, Dept Biochem, Brighton BN1 9QG, E Sussex, England.	a.l.moore@susx.ac.uk	Affourtit, Charles/I-3958-2019	Affourtit, Charles/0000-0003-1776-9943				Albury MS, 1998, J BIOL CHEM, V273, P30301, DOI 10.1074/jbc.273.46.30301; Albury MS, 1996, J BIOL CHEM, V271, P17062, DOI 10.1074/jbc.271.29.17062; Brand MD, 1996, J THEOR BIOL, V182, P351, DOI 10.1006/jtbi.1996.0174; DAY DA, 1995, AUST J PLANT PHYSIOL, V22, P497, DOI 10.1071/PP9950497; DRY IB, 1989, ARCH BIOCHEM BIOPHYS, V273, P148, DOI 10.1016/0003-9861(89)90173-2; FELL DA, 1992, BIOCHEM J, V286, P313, DOI 10.1042/bj2860313; GEIER BM, 1995, EUR J BIOCHEM, V227, P296, DOI 10.1111/j.1432-1033.1995.tb20388.x; GUTMAN, 1971, BIOCHEMISTRY-US, V10, P4763, DOI 10.1021/bi00801a025; Hiser C, 1996, PLANT PHYSIOL, V110, P277, DOI 10.1104/pp.110.1.277; HOEFNAGEL MHN, 1995, EUR J BIOCHEM, V233, P531, DOI 10.1111/j.1432-1033.1995.531_2.x; HOEFNAGEL MHN, 1995, ARCH BIOCHEM BIOPHYS, V318, P394, DOI 10.1006/abbi.1995.1245; JAULT JM, 1994, J BIOENERG BIOMEMBR, V26, P447, DOI 10.1007/BF00762785; KRAB K, 1995, J BIOENERG BIOMEMBR, V27, P387, DOI 10.1007/BF02110001; KRAB K, 1995, BIOCHEM SOC T, V23, pS289, DOI 10.1042/bst023289s; LJUNGDAHL PO, 1986, METHOD ENZYMOL, V126, P181; Millar AH, 1997, PLANT CELL ENVIRON, V20, P1273, DOI 10.1046/j.1365-3040.1997.d01-25.x; MOORE AL, 1988, FEBS LETT, V235, P76, DOI 10.1016/0014-5793(88)81237-7; MOORE AL, 1992, YEAST, V8, P923, DOI 10.1002/yea.320081103; MOORE AL, 1995, J BIOENERG BIOMEMBR, V27, P367, DOI 10.1007/BF02109999; MOORE AL, 1994, BBA-BIOENERGETICS, V1187, P145, DOI 10.1016/0005-2728(94)90101-5; MOORE AL, 1991, BIOCHIM BIOPHYS ACTA, V1059, P121, DOI 10.1016/S0005-2728(05)80197-5; MOORE AL, 1978, ARCH BIOCHEM BIOPHYS, V186, P298, DOI 10.1016/0003-9861(78)90439-3; MOORE AL, 1982, PLANT PHYSIOL, V70, P1271, DOI 10.1104/pp.70.5.1271; MURRAY JM, 1991, NUCLEIC ACIDS RES, V19, P3525, DOI 10.1093/nar/19.13.3525; OESTREIC.G, 1973, PLANT PHYSIOL, V52, P622, DOI 10.1104/pp.52.6.622; OKAZAKI K, 1990, NUCLEIC ACIDS RES, V18, P6485, DOI 10.1093/nar/18.22.6485; SIEDOW JN, 1995, FEBS LETT, V362, P10, DOI 10.1016/0014-5793(95)00196-G; SIEDOW JN, 1995, PLANT CELL, V7, P821, DOI 10.1105/tpc.7.7.821; SIEDOW JN, 1993, BIOCHIM BIOPHYS ACTA, V1142, P165, DOI 10.1016/0005-2728(93)90098-Z; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; UMBACH AL, 1993, PLANT PHYSIOL, V103, P845, DOI 10.1104/pp.103.3.845; UMBACH AL, 1994, FEBS LETT, V348, P181, DOI 10.1016/0014-5793(94)00600-8; VANDENBERGEN CWM, 1994, EUR J BIOCHEM, V226, P1071; VANLERBERGHE GC, 1994, PLANT PHYSIOL, V106, P1503, DOI 10.1104/pp.106.4.1503; Vanlerberghe GC, 1997, ANNU REV PLANT PHYS, V48, P703, DOI 10.1146/annurev.arplant.48.1.703; WAGNER AM, 1995, PHYSIOL PLANTARUM, V95, P318, DOI 10.1111/j.1399-3054.1995.tb00844.x; WESTERHOFF HV, 1987, BIOTECHNOL BIOENG, V30, P101, DOI 10.1002/bit.260300115	37	30	33	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	1999	274	10					6212	6218		10.1074/jbc.274.10.6212	http://dx.doi.org/10.1074/jbc.274.10.6212			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172BQ	10037707	hybrid, Green Published			2022-12-25	WOS:000078902800029
J	Bookchin, RM; Balazs, T				Bookchin, RM; Balazs, T			Polymer structure and solubility of deoxyhemoglobin S in the presence of high concentrations of volume-excluding 70-kDa dextran - Effects of non-S hemoglobins and inhibitors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SICKLE-CELL HEMOGLOBIN; CRYSTALLIZATION; MICROMETHOD; MUTANT	Earlier observations indicated that volume exclusion by admired non-hemoglobin macromolecules lowered the polymer solubility ("C-sat") of deoxyhemoglobin (Hb) S, presumably by increasing its activity. In view of the potential usefulness of these observations for in vitro studies of sickling-related polymerization, we examined the ultrastructure, solubility behavior, and phase distributions of deoxygenated mixtures of Hb S with 70-kDa dextran, a relatively inert, low ionic strength space-filling macromolecule. Increasing admixture of dextran progressively lowered the C-sat of deoxyHb S, With 12 g/dl dextran, a 5-fold decrease in apparent C-sat ("dextran-C-sat") was obtained together with acceptable sensitivity and proportionality with the standard C-sat when assessing the effects of non-S Hb admixtures (A, C, and F) or polymerization inhibitors (alkylureas or phenylalanine). The volume fraction of dextran excluding Hb was 70-75% of total deoxy Hb-dextran (12 g/dl) volumes. Electron microscopy showed polymer fibers and fiber-to-crystal transitions indistinguishable from those formed without dextran, Thus when Hb quantities are limited, as with genetically engineered recombinant Hbs or transgenic sickle mice, the dextran-C-sat provides convenient and reliable screening of effects of Hb S modifications on polymerization under near-physiological conditions, avoiding problems of high ionic strength.	Albert Einstein Coll Med, Dept Med, Bronx, NY 10461 USA; Univ Chicago, Dept Mol Genet & Cell Biol, Chicago, IL 60637 USA; Univ Cambridge, Physiol Lab, Cambridge CB2 3EG, England	Yeshiva University; Albert Einstein College of Medicine; University of Chicago; University of Cambridge	Bookchin, RM (corresponding author), Albert Einstein Coll Med, Dept Med, 1300 Morris Pk Ave, Bronx, NY 10461 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL022654, P01HL058512, R01HL028018] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL58512, HL28018, HL22654] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADACHI K, 1979, J BIOL CHEM, V254, P7765; ADACHI K, 1979, J BIOL CHEM, V254, P4079; BEHE MJ, 1978, BIOPHYS J, V23, P129, DOI 10.1016/S0006-3495(78)85438-1; BENESCH RE, 1978, ANAL BIOCHEM, V89, P162, DOI 10.1016/0003-2697(78)90737-6; BOOKCHIN RM, 1986, BLOOD, V67, P887; BOOKCHIN RM, 1994, J MOL BIOL, V244, P100, DOI 10.1006/jmbi.1994.1707; BOOKCHIN RM, 1973, SICKLE CELL DISEASE, P140; DELLANO JJM, 1993, P NATL ACAD SCI USA, V90, P918, DOI 10.1073/pnas.90.3.918; DELLANO JJM, 1994, PROTEIN SCI, V3, P1203; DRABKIN DL, 1946, J BIOL CHEM, V164, P703; Eaton W A, 1990, Adv Protein Chem, V40, P63, DOI 10.1016/S0065-3233(08)60287-9; FERRONE FA, 1998, HEMOGLOBINS BIOPHY C, P292; GOLDBERG MA, 1977, J BIOL CHEM, V252, P3414; GREAVES DR, 1990, NATURE, V343, P183, DOI 10.1038/343183a0; Himanen JP, 1996, J BIOL CHEM, V271, P25152, DOI 10.1074/jbc.271.41.25152; HOFRICHTER J, 1976, P NATL ACAD SCI USA, V73, P3035, DOI 10.1073/pnas.73.9.3035; ITANO HA, 1953, ARCH BIOCHEM BIOPHYS, V47, P148, DOI 10.1016/0003-9861(53)90444-5; Liao D, 1996, BIOPHYS J, V70, P2442, DOI 10.1016/S0006-3495(96)79815-6; MAGDOFFFAIRCHILD B, 1976, P NATL ACAD SCI USA, V73, P990, DOI 10.1073/pnas.73.4.990; NAGAI K, 1985, P NATL ACAD SCI USA, V82, P7252, DOI 10.1073/pnas.82.21.7252; PERUTZ MF, 1950, NATURE, V166, P677, DOI 10.1038/166677a0; POTEL MJ, 1984, J MOL BIOL, V177, P819, DOI 10.1016/0022-2836(84)90050-0; ROSS PD, 1979, BIOCHEM BIOPH RES CO, V88, P1308, DOI 10.1016/0006-291X(79)91123-9; ROTH EF, 1979, J LAB CLIN MED, V93, P867; RYAN TM, 1990, SCIENCE, V247, P566, DOI 10.1126/science.2154033; Sunshine HR, 1979, DEV THERAPEUTIC AGEN, P31; VASSAR RJ, 1982, J MOL BIOL, V157, P395, DOI 10.1016/0022-2836(82)90242-X; VEDVICK TS, 1998, CLIN BIOCHEM, V8, P288; WELLEMS TE, 1979, J MOL BIOL, V135, P651, DOI 10.1016/0022-2836(79)90170-0; WELLEMS TE, 1981, J MOL BIOL, V153, P1011, DOI 10.1016/0022-2836(81)90464-2; WISHNER BC, 1975, J MOL BIOL, V98, P179, DOI 10.1016/S0022-2836(75)80108-2; ZIMMERMAN SB, 1993, ANNU REV BIOPH BIOM, V22, P27, DOI 10.1146/annurev.bb.22.060193.000331	32	26	26	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1999	274	10					6689	6697		10.1074/jbc.274.10.6689	http://dx.doi.org/10.1074/jbc.274.10.6689			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172BQ	10037766	hybrid			2022-12-25	WOS:000078902800088
J	Daniels, RH; Zenke, FT; Bokoch, GM				Daniels, RH; Zenke, FT; Bokoch, GM			alpha Pix stimulates p21-activated kinase activity through exchange factor-dependent and -independent mechanisms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUANINE-NUCLEOTIDE EXCHANGE; DBL ONCOGENE PRODUCT; ACTIN STRESS FIBERS; PROTEIN-KINASE; RHO; PAK1; RAS; TRANSFORMATION; REGULATORS; PLECKSTRIN	Activation of pal-activated kinases (Paks) is achieved through binding of the GTPases Rac or Cdc42 to a conserved domain in the N-terminal regulatory region of Pak. Additional signaling components are also likely to be important in regulating Pak activation. Recently, a family of Pak-interacting guanine nucleotide exchange factors (Pix) have been identified and which are good candidates for regulating Pak activity. Using an active, truncated form of alpha Pix (amino acids 155-545), we observe stimulation of Pak1 kinase activity when alpha Pix(155-545) is co-expressed with Cdc42 and wild-type Pak1 in COS-1 cells. This activation does not occur when we co-express a Pak1 mutant unable to bind alpha Pix. The activation of wild-type Pak1 by alpha Pix(155-545) also requires that alpha Pix(155-545) retain functional exchange factor activity. However, the Pak1(H83,86L) mutant that does not bind Rac or Cdc42 is activated in the absence of GTPase by alpha Pix(155-545) and by a mutant of alpha Pix(155-545) that no longer has exchange factor activity. Pak1 activity stimulated in vitro using GTP gamma S-loaded Cdc42 was also enhanced by recombinant alpha Pix(155-545) in a binding-dependent manner. These data suggest that Pak activity can be modulated by physical interaction with alpha Pix and that this specific effect involves both exchange factor-dependent and -independent mechanisms.	Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA	Scripps Research Institute; Scripps Research Institute	Daniels, RH (corresponding author), Scripps Res Inst, Dept Immunol, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.			Zenke, Frank/0000-0002-2226-3755	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R03AR045738] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039434] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR45738] Funding Source: Medline; NIGMS NIH HHS [GM39434] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bagrodia S, 1998, J BIOL CHEM, V273, P23633, DOI 10.1074/jbc.273.37.23633; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOLLAG G, 1991, ANNU REV CELL BIOL, V7, P601, DOI 10.1146/annurev.cellbio.7.1.601; Cerione RA, 1996, CURR OPIN CELL BIOL, V8, P216, DOI 10.1016/S0955-0674(96)80068-8; Daniels RH, 1998, EMBO J, V17, P754, DOI 10.1093/emboj/17.3.754; Dharmawardhane S, 1997, J CELL BIOL, V138, P1265, DOI 10.1083/jcb.138.6.1265; Frost JA, 1998, J BIOL CHEM, V273, P28191, DOI 10.1074/jbc.273.43.28191; HART MJ, 1994, J BIOL CHEM, V269, P62; Hart MJ, 1996, J BIOL CHEM, V271, P25452, DOI 10.1074/jbc.271.41.25452; HART MJ, 1991, NATURE, V354, P311, DOI 10.1038/354311a0; HORII Y, 1994, EMBO J, V13, P4776, DOI 10.1002/j.1460-2075.1994.tb06803.x; Horiuchi H, 1997, CELL, V90, P1149, DOI 10.1016/S0092-8674(00)80380-3; Knaus UG, 1998, INT J BIOCHEM CELL B, V30, P857, DOI 10.1016/S1357-2725(98)00059-4; KNAUS UG, 1995, SCIENCE, V269, P221, DOI 10.1126/science.7618083; Manser E, 1998, MOL CELL, V1, P183, DOI 10.1016/S1097-2765(00)80019-2; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MCCOLLAM L, 1995, J BIOL CHEM, V270, P15954, DOI 10.1074/jbc.270.27.15954; MIKI T, 1993, NATURE, V362, P462, DOI 10.1038/362462a0; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Obermeier A, 1998, EMBO J, V17, P4328, DOI 10.1093/emboj/17.15.4328; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Sells MA, 1997, CURR BIOL, V7, P202, DOI 10.1016/S0960-9822(97)70091-5; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934; Zhao ZS, 1998, MOL CELL BIOL, V18, P2153, DOI 10.1128/MCB.18.4.2153; Zheng Y, 1996, J BIOL CHEM, V271, P19017, DOI 10.1074/jbc.271.32.19017; Zhou KM, 1998, J BIOL CHEM, V273, P16782, DOI 10.1074/jbc.273.27.16782	27	109	109	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1999	274	10					6047	6050		10.1074/jbc.274.10.6047	http://dx.doi.org/10.1074/jbc.274.10.6047			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172BQ	10037684	hybrid			2022-12-25	WOS:000078902800006
J	Hu, CA; Lin, WW; Obie, C; Valle, D				Hu, CA; Lin, WW; Obie, C; Valle, D			Molecular enzymology of mammalian Delta(1)-pyrroline-5-carboxylate synthase - Alternative splice donor utilization generates isoforms with different sensitivity to ornithine inhibition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUTAMYL-TRANSFERASE KINASE; L-PROLINE TRANSPORTER; FIRST 2 STEPS; SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; PYRROLINE-5-CARBOXYLATE SYNTHASE; CHROMOSOMAL LOCALIZATION; ARABIDOPSIS-THALIANA; SMALL-INTESTINE; GYRATE ATROPHY	Delta(1)-Pyrroline-5-carboxylate synthase (P5CS; EC not assigned), a mitochondrial inner membrane, ATP- and NADPH-dependent, bifunctional enzyme, catalyzes the reduction of glutamate to Delta(1)-pyrroline-5-carboxylate, a critical step in the de novo biosynthesis of proline and ornithine. We utilized published plant P5CS sequence to search the expressed sequence tag data base and cloned two full-length human P5CS cDNAs differing in length by 6 base pairs (bp) in the open reading frame. The short cDNA has a 2379-bp open reading frame encoding a protein of 793 residues; the long cDNA, generated by "exon sliding," a form of alternative splicing, contains an additional 6-bp insert following bp +711 of the short form resulting in inclusion of two additional amino acids in the region predicted to be the gamma-glutamyl kinase active site of P5CS, The long form predominates in all tissues examined except gut. We also isolated the corresponding long and short murine P5CS transcripts. To confirm the identity of the putative P5CS cDNAs, we expressed both human forms in gamma-glutamyl kinase- and gamma-glutamyl phosphate reductase-deficient strains of Saccharomyces cerevisiae and showed that they conferred the proline prototrophy. Additionally, we found expression of the murine putative P5CS cDNAs conferred proline prototrophy to P5CS-deficient Chinese hamster ovary cells (CHO-K1). We utilized stable CHO-K1 cell transformants to compare the biochemical characteristics of the long and short murine P5CS isoforms, We found that both confer P5CS activity and that the short isoform is inhibited by L-ornithine with a K-i of similar to 0.25 mM. Surprisingly, the long isoform is insensitive to ornithine inhibition. Thus, the two amino acid insert in the long isoform abolishes feedback inhibition of P5CS activity by L-ornithine.	Johns Hopkins Univ, Sch Med, Howard Hughes Med Inst, Dept Pediat, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Howard Hughes Med Inst, Inst Med Genet, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Predoctoral Training Program Human Genet, Baltimore, MD 21205 USA	Howard Hughes Medical Institute; Johns Hopkins University; Howard Hughes Medical Institute; Johns Hopkins University; Johns Hopkins University	Valle, D (corresponding author), Johns Hopkins Univ, Sch Med, Howard Hughes Med Inst, Dept Pediat, PCTB 802,725 N Wolfe St, Baltimore, MD 21205 USA.	dvalle@jhmi.edu			NEI NIH HHS [5RO1EY02948] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY002948] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Aral B, 1996, CR ACAD SCI III-VIE, V319, P171; BAUDIN A, 1993, NUCLEIC ACIDS RES, V21, P3329, DOI 10.1093/nar/21.14.3329; Blencowe BJ, 1998, GENE DEV, V12, P996, DOI 10.1101/gad.12.7.996; BRODY LC, 1992, J BIOL CHEM, V267, P3302; Chabot B, 1996, TRENDS GENET, V12, P472, DOI 10.1016/0168-9525(96)10037-8; Cooper TA, 1997, AM J HUM GENET, V61, P259, DOI 10.1086/514856; CRAIK CS, 1983, SCIENCE, V220, P1125, DOI 10.1126/science.6344214; De Jonge WJ, 1998, PEDIATR RES, V43, P442, DOI 10.1203/00006450-199804000-00002; DEUTCH AH, 1984, NUCLEIC ACIDS RES, V12, P6337, DOI 10.1093/nar/12.15.6337; FREMEAU RT, 1992, NEURON, V8, P915, DOI 10.1016/0896-6273(92)90206-S; FU XD, 1995, RNA, V1, P663; GarciaRios M, 1997, P NATL ACAD SCI USA, V94, P8249, DOI 10.1073/pnas.94.15.8249; Gilligan DM, 1997, GENOMICS, V43, P141, DOI 10.1006/geno.1997.4802; Graveley BR, 1998, MOL CELL, V1, P765, DOI 10.1016/S1097-2765(00)80076-3; HENDRICK JP, 1989, P NATL ACAD SCI USA, V86, P4056, DOI 10.1073/pnas.86.11.4056; HENSLEE JG, 1983, ARCH BIOCHEM BIOPHYS, V226, P693, DOI 10.1016/0003-9861(83)90340-5; Hertel KJ, 1997, CURR OPIN CELL BIOL, V9, P350, DOI 10.1016/S0955-0674(97)80007-5; HIRAMATSU T, 1994, AM J CLIN NUTR, V60, P207, DOI 10.1093/ajcn/60.2.207; HOROWITZ DS, 1994, TRENDS GENET, V10, P100, DOI 10.1016/0168-9525(94)90233-X; Hu CA, 1996, J BIOL CHEM, V271, P9795, DOI 10.1074/jbc.271.16.9795; HU CAA, 1992, P NATL ACAD SCI USA, V89, P9354, DOI 10.1073/pnas.89.19.9354; JONES C, 1975, SOMAT CELL GENET, V1, P345, DOI 10.1007/BF01538666; JONES ME, 1985, J NUTR, V115, P509, DOI 10.1093/jn/115.4.509; Kamoun P, 1998, B ACAD NAT MED PARIS, V182, P131; KAO F, 1967, GENETICS, V55, P511; KORNFELD K, 1989, GENE DEV, V3, P243, DOI 10.1101/gad.3.2.243; LI W, 1992, J BACTERIOL, V174, P4148, DOI 10.1128/jb.174.12.4148-4156.1992; LODATO RF, 1981, METABOLISM, V30, P908, DOI 10.1016/0026-0495(81)90070-6; Manley JL, 1996, GENE DEV, V10, P1569, DOI 10.1101/gad.10.13.1569; MARTIN D, 1992, EUR J PHARMACOL, V219, P59, DOI 10.1016/0014-2999(92)90580-W; MATSUZAWA T, 1994, J BIOCHEM-TOKYO, V116, P721, DOI 10.1093/oxfordjournals.jbchem.a124587; McRory JE, 1997, DNA CELL BIOL, V16, P95, DOI 10.1089/dna.1997.16.95; MILLER RG, 1995, J PEDIATR SURG, V30, P953, DOI 10.1016/0022-3468(95)90320-8; Miller RG, 1996, J SURG RES, V63, P199, DOI 10.1006/jsre.1996.0247; MITCHELL GA, 1989, P NATL ACAD SCI USA, V86, P197, DOI 10.1073/pnas.86.1.197; MUMBERG D, 1994, NUCLEIC ACIDS RES, V22, P5767, DOI 10.1093/nar/22.25.5767; NADLER JV, 1988, BRAIN RES, V456, P168; NAGAMINE Y, 1985, BIOCHEM BIOPH RES CO, V132, P563, DOI 10.1016/0006-291X(85)91170-2; NICKOLSON VJ, 1982, J NEUROCHEM, V38, P289, DOI 10.1111/j.1471-4159.1982.tb10885.x; NIGRO JM, 1992, MOL CELL BIOL, V12, P1357, DOI 10.1128/MCB.12.3.1357; OMORI K, 1993, J BACTERIOL, V175, P959, DOI 10.1128/JB.175.4.959-965.1993; OMORI K, 1991, J GEN MICROBIOL, V137, P509, DOI 10.1099/00221287-137-3-509; Pearson BM, 1996, YEAST, V12, P1021; Pietrokovski S, 1996, NUCLEIC ACIDS RES, V24, P197, DOI 10.1093/nar/24.1.197; POL S, 1989, HUM GENET, V83, P159, DOI 10.1007/BF00286710; Reed JC, 1997, CELL, V91, P559, DOI 10.1016/S0092-8674(00)80442-0; RIBY JE, 1990, PEDIATR RES, V28, P261, DOI 10.1203/00006450-199009000-00022; Rogaev EI, 1997, GENOMICS, V40, P415, DOI 10.1006/geno.1996.4523; ROISE D, 1988, J BIOL CHEM, V263, P4509; SAVOURE A, 1995, FEBS LETT, V372, P13, DOI 10.1016/0014-5793(95)00935-3; SCRUTTON NS, 1990, NATURE, V343, P38, DOI 10.1038/343038a0; SERINA L, 1995, BIOCHEMISTRY-US, V34, P5066, DOI 10.1021/bi00015a018; SHAFQAT S, 1995, MOL PHARMACOL, V48, P219; SHAPIRO MB, 1987, NUCLEIC ACIDS RES, V15, P7155, DOI 10.1093/nar/15.17.7155; SMITH CJ, 1984, J BACTERIOL, V157, P545, DOI 10.1128/JB.157.2.545-551.1984; SMITH LT, 1985, J BACTERIOL, V164, P1088, DOI 10.1128/JB.164.3.1088-1093.1985; SMITH RJ, 1979, J CELL PHYSIOL, V98, P475, DOI 10.1002/jcp.1040980306; SMITH RJ, 1980, P NATL ACAD SCI-BIOL, V77, P5221, DOI 10.1073/pnas.77.9.5221; TOMENCHOK DM, 1987, J BACTERIOL, V169, P5364, DOI 10.1128/jb.169.12.5364-5372.1987; Valle, 1995, METABOLIC MOL BASES, P1125; VALLE D, 1973, BIOCHEM BIOPH RES CO, V53, P1130, DOI 10.1016/0006-291X(73)90582-2; VALLE D, 1973, BIOCHEM BIOPH RES CO, V54, P1418, DOI 10.1016/0006-291X(73)91144-3; Valle D, 1995, METABOLIC MOL BASES, V1, P1147; Velaz-Faircloth M, 1995, J Biol Chem, V270, P15755; VONHEIJNE G, 1989, EUR J BIOCHEM, V180, P535; WAKABAYASHI Y, 1991, ARCH BIOCHEM BIOPHYS, V291, P1, DOI 10.1016/0003-9861(91)90097-3; WALSH CT, 1979, ENZYMATIC REACTION M; WANG T, 1995, NAT GENET, V11, P185, DOI 10.1038/ng1095-185; WINDMUELLER HG, 1975, ARCH BIOCHEM BIOPHYS, V171, P662, DOI 10.1016/0003-9861(75)90078-8; WU GY, 1994, BIOCHEM J, V299, P115, DOI 10.1042/bj2990115; WU GY, 1995, AM J PHYSIOL-REG I, V269, pR621, DOI 10.1152/ajpregu.1995.269.3.R621; YAMANAKA K, 1994, MOL GEN GENET, V243, P9, DOI 10.1007/BF00283870; YOSHIBA Y, 1995, PLANT J, V7, P751, DOI 10.1046/j.1365-313X.1995.07050751.x; Young SG, 1995, J CLIN INVEST, V96, P2932, DOI 10.1172/JCI118365; ZHANG CS, 1995, J BIOL CHEM, V270, P20491, DOI 10.1074/jbc.270.35.20491; Zhang MQ, 1998, HUM MOL GENET, V7, P919, DOI 10.1093/hmg/7.5.919	77	80	83	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	1999	274	10					6754	6762		10.1074/jbc.274.10.6754	http://dx.doi.org/10.1074/jbc.274.10.6754			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172BQ	10037775	hybrid			2022-12-25	WOS:000078902800097
J	Cens, T; Restituito, S; Galas, S; Charnet, P				Cens, T; Restituito, S; Galas, S; Charnet, P			Voltage and calcium use the same molecular determinants to inactivate calcium channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT CA2+ CHANNELS; BETA-SUBUNIT; XENOPUS-OOCYTES; CA2+-DEPENDENT INACTIVATION; ALPHA(1C) SUBUNIT; CA2+-SENSITIVE INACTIVATION; MEDIATED INACTIVATION; FUNCTIONAL EXPRESSION; SKELETAL-MUSCLE; SNAIL NEURONS	During sustained depolarization, voltage-gated Ca2+ channels progressively undergo a transition to a nonconducting, inactivated state, preventing Ca2+ overload of the cell. This transition can be triggered either by the membrane potential (voltage-dependent inactivation) or by the consecutive entry of Ca2+ (Ca2+-dependent inactivation), depending on the type of Ca2+ channel. These two types of inactivation are suspected to arise from distinct underlying mechanisms, relying on specific molecular sequences of the different pore-forming Ca2+ channel subunits. Here we report that the voltage-dependent inactivation (of the alpha(1A) Ca2+ channel) and the Ca2+-dependent inactivation (of the alpha(1C) Ca2+ channel) are similarly influenced by Ca2+ channel beta subunits. The same molecular determinants of the beta subunit, and therefore the same subunit interactions, influence both types of inactivation. These results strongly suggest that the voltage and the Ca2+-dependent transitions leading to channel inactivation use homologous structures of the different cu, subunits and occur through the same molecular process. A model of inactivation taking into account these new data is presented.	CNRS, UPR 1086, Ctr Rech Biochim Macromol, F-34293 Montpellier, France	Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier	Charnet, P (corresponding author), CNRS, UPR 1086, Ctr Rech Biochim Macromol, 1919 Route Mende, F-34293 Montpellier, France.	charnet@crbm.cnrs-mop.fr	Cens, Thierry/M-3337-2017; Galas, Simon/X-1312-2019	Cens, Thierry/0000-0002-4109-2779; Galas, Simon/0000-0002-1717-1266; Charnet, Pierre/0000-0003-4692-528X				Adams B, 1997, J GEN PHYSIOL, V110, P379, DOI 10.1085/jgp.110.4.379; ADAMS BA, 1994, J GEN PHYSIOL, V104, P985, DOI 10.1085/jgp.104.5.985; BEAN BP, 1991, AM J HYPERTENS, V4, pS406, DOI 10.1093/ajh/4.7.406S; BIRNBAUMER L, 1994, NEURON, V13, P505, DOI 10.1016/0896-6273(94)90021-3; BREHM P, 1980, J PHYSIOL-LONDON, V306, P193, DOI 10.1113/jphysiol.1980.sp013391; BROWN AM, 1984, J GEN PHYSIOL, V83, P751, DOI 10.1085/jgp.83.5.751; BROWN AM, 1986, MEMBRANE BIOCHEM, V6, P73, DOI 10.3109/09687688609065444; CARBONE E, 1989, PROG BIOPHYS MOL BIO, V54, P31, DOI 10.1016/0079-6107(89)90008-4; CASTELLANO A, 1993, J BIOL CHEM, V268, P12359; CASTELLANO A, 1993, J BIOL CHEM, V268, P3450; CATTERALL WA, 1995, ANNU REV BIOCHEM, V64, P493, DOI 10.1146/annurev.biochem.64.1.493; Cens T, 1996, FEBS LETT, V391, P232, DOI 10.1016/0014-5793(96)00704-1; Cens T, 1996, PFLUG ARCH EUR J PHY, V431, P771, DOI 10.1007/BF02253842; Cens T, 1998, PFLUG ARCH EUR J PHY, V435, P865, DOI 10.1007/s004240050595; CHAD J, 1989, COMP BIOCHEM PHYS A, V93, P95, DOI 10.1016/0300-9629(89)90196-5; CHAD JE, 1986, J PHYSIOL-LONDON, V378, P31, DOI 10.1113/jphysiol.1986.sp016206; CHARNET P, 1994, FEBS LETT, V344, P87, DOI 10.1016/0014-5793(94)00357-2; Chien AJ, 1998, J BIOL CHEM, V273, P23590, DOI 10.1074/jbc.273.36.23590; Chien AJ, 1996, J BIOL CHEM, V271, P26465, DOI 10.1074/jbc.271.43.26465; Cribbs LL, 1998, CIRC RES, V83, P103, DOI 10.1161/01.RES.83.1.103; DELEON M, 1995, SCIENCE, V270, P1502, DOI 10.1126/science.270.5241.1502; DeWaard M, 1996, FEBS LETT, V380, P272, DOI 10.1016/0014-5793(96)00007-5; DEWAARD M, 1995, J PHYSIOL-LONDON, V485, P619, DOI 10.1113/jphysiol.1995.sp020757; DEWAARD M, 1994, NEURON, V13, P495, DOI 10.1016/0896-6273(94)90363-8; DEWAARD M, 1995, J BIOL CHEM, V270, P12056, DOI 10.1074/jbc.270.20.12056; GUTNICK MJ, 1989, J PHYSIOL-LONDON, V412, P197, DOI 10.1113/jphysiol.1989.sp017611; HADLEY RW, 1998, J PHYSIOL-LONDON, V444, P257; Herlitze S, 1997, P NATL ACAD SCI USA, V94, P1512, DOI 10.1073/pnas.94.4.1512; Hofmann F, 1990, Curr Top Cell Regul, V31, P223; HOFMANN F, 1988, J CARDIOVASC PHARM, V12, pS25, DOI 10.1097/00005344-198806121-00005; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; HOSHI T, 1990, SCIENCE, V250, P533, DOI 10.1126/science.2122519; IMREDY JP, 1992, NEURON, V9, P197, DOI 10.1016/0896-6273(92)90159-B; IMREDY JP, 1994, NEURON, V12, P1301, DOI 10.1016/0896-6273(94)90446-4; LUX HD, 1984, SCIENCE, V225, P432, DOI 10.1126/science.6330896; Mangoni ME, 1997, RECEPTOR CHANNEL, V5, P1; MARTY A, 1989, TRENDS NEUROSCI, V12, P420, DOI 10.1016/0166-2236(89)90090-8; MCDONALD TF, 1994, PHYSIOL REV, V74, P365, DOI 10.1152/physrev.1994.74.2.365; MENTRARD D, 1984, J GEN PHYSIOL, V83, P105, DOI 10.1085/jgp.83.1.105; NAKAI J, 1994, P NATL ACAD SCI USA, V91, P1014, DOI 10.1073/pnas.91.3.1014; NASTAINCZYK W, 1990, GEN PHYSIOL BIOPHYS, V9, P321; NEELY A, 1994, BIOPHYS J, V66, P1895, DOI 10.1016/S0006-3495(94)80983-X; NISHIMURA S, 1993, FEBS LETT, V324, P283, DOI 10.1016/0014-5793(93)80135-H; OLCESE R, 1994, NEURON, V13, P1433, DOI 10.1016/0896-6273(94)90428-6; PARENT L, 1995, FEBS LETT, V360, P144, DOI 10.1016/0014-5793(95)00090-V; PELZER D, 1990, REV PHYSIOL BIOCH P, V114, P107; Perets T, 1996, FEBS LETT, V384, P189, DOI 10.1016/0014-5793(96)00303-1; Perez-Reyes E, 1998, NATURE, V391, P896, DOI 10.1038/36110; PEREZREYES E, 1995, KIDNEY INT, V48, P1111, DOI 10.1038/ki.1995.395; PRAGNELL M, 1994, NATURE, V368, P67, DOI 10.1038/368067a0; PRAGNELL M, 1991, FEBS LETT, V291, P253, DOI 10.1016/0014-5793(91)81296-K; Qin N, 1996, AM J PHYSIOL-CELL PH, V271, pC1539, DOI 10.1152/ajpcell.1996.271.5.C1539; Qin N, 1998, P NATL ACAD SCI USA, V95, P4690, DOI 10.1073/pnas.95.8.4690; REYES EP, 1992, J BIOL CHEM, V267, P1790; REYES EP, 1994, DRUG DEVELOP RES, V33, P295; SATHER WA, 1993, NEURON, V11, P291, DOI 10.1016/0896-6273(93)90185-T; SATHER WA, 1994, ANN NY ACAD SCI, V747, P294; SCHNEIDER T, 1994, RECEPTOR CHANNEL, V2, P255; SHIROKOV R, 1993, J GEN PHYSIOL, V102, P1005, DOI 10.1085/jgp.102.6.1005; SINGER D, 1991, SCIENCE, V253, P1553, DOI 10.1126/science.1716787; SINGERLAHAT D, 1994, RECEPTOR CHANNEL, V2, P215; Snutch T P, 1992, Curr Opin Neurobiol, V2, P247, DOI 10.1016/0959-4388(92)90111-W; Soldatov NM, 1997, J BIOL CHEM, V272, P3560, DOI 10.1074/jbc.272.6.3560; SOONG TW, 1993, SCIENCE, V260, P1133, DOI 10.1126/science.8388125; STARR TVB, 1991, P NATL ACAD SCI USA, V88, P5621, DOI 10.1073/pnas.88.13.5621; STEA A, 1993, NEUROPHARMACOLOGY, V32, P1103, DOI 10.1016/0028-3908(93)90005-N; STEA A, 1994, P NATL ACAD SCI USA, V91, P10576, DOI 10.1073/pnas.91.22.10576; TOMLINSON WJ, 1993, NEUROPHARMACOLOGY, V32, P1117, DOI 10.1016/0028-3908(93)90006-O; TSIEN RW, 1987, ANNU REV BIOPHYS BIO, V16, P265; TSIEN RW, 1991, TRENDS PHARMACOL SCI, V12, P349, DOI 10.1016/0165-6147(91)90595-J; VASSORT G, 1994, J CARDIOVASC ELECTR, V5, P376, DOI 10.1111/j.1540-8167.1994.tb01175.x; ZHANG JF, 1994, NATURE, V372, P97, DOI 10.1038/372097a0; ZHANG JF, 1993, NEUROPHARMACOLOGY, V32, P1075, DOI 10.1016/0028-3908(93)90003-L; Zhou JM, 1997, P NATL ACAD SCI USA, V94, P2301, DOI 10.1073/pnas.94.6.2301; Zong XG, 1996, FEBS LETT, V378, P121, DOI 10.1016/0014-5793(95)01434-9	75	85	86	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 26	1999	274	9					5483	5490		10.1074/jbc.274.9.5483	http://dx.doi.org/10.1074/jbc.274.9.5483			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	170KG	10026161	hybrid			2022-12-25	WOS:000078804400032
J	Gross, BS; Lee, JR; Clements, JL; Turner, M; Tybulewicz, VLJ; Findell, PR; Koretzky, GA; Watson, SP				Gross, BS; Lee, JR; Clements, JL; Turner, M; Tybulewicz, VLJ; Findell, PR; Koretzky, GA; Watson, SP			Tyrosine phosphorylation of SLP-76 is downstream of Syk following stimulation of the collagen receptor in platelets	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-CHAIN; PHOSPHOLIPASE C-GAMMA-2; MOLECULAR-CLONING; T-CELLS; ACTIVATION; PROTEIN; SUBSTRATE; INTERLEUKIN-2; PURIFICATION; PHOSPHATASE	Collagen-related peptide (CRP), a collagen homologue, induces platelet activation through a tyrosine kinase-dependent pathway, leading to sequential tyrosine phosphorylation of Pc receptor (FcR) gamma-chain, Syk, and phospholipase C-gamma(2). Here we report that CRP and the platelet low affinity immune receptor Fc gamma RIIA stimulate tyrosine phosphorylation of the T cell adapter SLP-76, whereas the G protein-coupled receptor agonist thrombin induces only minor tyrosine phosphorylation. This suggests that SLP-76 has a specific role downstream of receptors that signal via an immunoreceptor tyrosine-based activation motif, Immunoprecipitation studies demonstrate association of SLP-76 with SLAP-130, Vav, Fyn, Lyn, and the FcR gamma-chain in CRP-stimulated platelets. Several of these proteins, including SLP-76, undergo tyrosine phosphorylation in in vitro kinase assays performed on SLP-76 immunoprecipitates. Tyrosine phosphorylation of all of these proteins in the in vitro kinase assay was abrogated by the Src family kinase inhibitor PP1, suggesting that it is mediated by either Fyn or Lyn, The physiological significance of this is uncertain, however, since tyrosine phosphorylation of SLP-76 in vivo is not altered in either Fyn- or Lyn-deficient platelets, CRP stimulation of Syk-deficient platelets demonstrated that in vivo tyrosine phosphorylation of SLP-76 is downstream of Syk, The absence of Syk in the SLP-76 immunoprecipitates raises the possibility that another protein is responsible for bringing SLP-76 to Syk, Candidates for this include those proteins that co-immunoprecipitate with SLP-76, including the FcR gamma-chain, Tyrosine phosphorylation of PLC-gamma(2) and Ca2+ mobilization is markedly attenuated in SLP-76-deficient platelets following CRP stimulation, suggesting that the adapter plays a critical role in the regulation of the phospholipase. The increase in tyrosine phosphorylation of SLAP-130 in response to CRP is also inhibited in SLP-76-deficient platelets, placing it downstream of SLP-76, This work identifies SLP-76 as an important adapter molecule that is regulated by Syk and lies upstream of SLAP-130 and PLC-gamma(2) in CRP-stimulated platelets.	Univ Oxford, Dept Pharmacol, Oxford OX1 3QT, England; Univ Iowa, Coll Med, Dept Internal Med Physiol & Biophys, Iowa City, IA 52242 USA; Univ Iowa, Coll Med, Interdisciplinary Immunol Program, Iowa City, IA 52242 USA; Roche Biosci, Palo Alto, CA 94304 USA; Natl Inst Med Res, London NW7 1AA, England	University of Oxford; University of Iowa; University of Iowa; Roche Holding; MRC National Institute for Medical Research	Gross, BS (corresponding author), Univ Oxford, Dept Pharmacol, Mansfield Rd, Oxford OX1 3QT, England.	barbara.gross@users.jesus.ox.ac.uk	Turner, Martin/N-9976-2014; Watson, Stephen P/Q-6292-2016; Koretzky, Gary/AAU-5381-2021	Turner, Martin/0000-0002-3801-9896; Watson, Stephen P/0000-0002-7846-7423; GROSS, BARBARA/0000-0001-5566-0004				Asselin J, 1997, BLOOD, V89, P1235, DOI 10.1182/blood.V89.4.1235; BLAKE RA, 1993, BIOCHEM J, V290, P471, DOI 10.1042/bj2900471; BLAKE RA, 1994, FEBS LETT, V353, P212, DOI 10.1016/0014-5793(94)01037-4; Clements JL, 1998, SCIENCE, V281, P416, DOI 10.1126/science.281.5375.416; Ezumi Y, 1998, J EXP MED, V188, P267, DOI 10.1084/jem.188.2.267; Fang N, 1996, J IMMUNOL, V157, P3769; Francischetti IMB, 1998, ARCH BIOCHEM BIOPHYS, V353, P239, DOI 10.1006/abbi.1998.0598; FRANGIONI JV, 1993, ANAL BIOCHEM, V210, P179, DOI 10.1006/abio.1993.1170; Fu C, 1998, IMMUNITY, V9, P93, DOI 10.1016/S1074-7613(00)80591-9; Gibbins J, 1996, J BIOL CHEM, V271, P18095, DOI 10.1074/jbc.271.30.18095; Gibbins JM, 1997, FEBS LETT, V413, P255, DOI 10.1016/S0014-5793(97)00926-5; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; HendricksTaylor LR, 1997, J BIOL CHEM, V272, P1363, DOI 10.1074/jbc.272.2.1363; HIBBS ML, 1995, CELL, V83, P301, DOI 10.1016/0092-8674(95)90171-X; JACKMAN JK, 1995, J BIOL CHEM, V270, P7029, DOI 10.1074/jbc.270.13.7029; Kehrel B, 1998, BLOOD, V91, P491; Law CL, 1996, MOL CELL BIOL, V16, P1305; Mizuno K, 1996, J EXP MED, V184, P457, DOI 10.1084/jem.184.2.457; MORTON LF, 1995, BIOCHEM J, V306, P337, DOI 10.1042/bj3060337; Motto DG, 1996, J EXP MED, V183, P1937, DOI 10.1084/jem.183.4.1937; Musci MA, 1997, J IMMUNOL, V159, P1639; Musci MA, 1997, J BIOL CHEM, V272, P11674, DOI 10.1074/jbc.272.18.11674; Onodera H, 1996, J BIOL CHEM, V271, P22225, DOI 10.1074/jbc.271.36.22225; Pivniouk V, 1998, CELL, V94, P229, DOI 10.1016/S0092-8674(00)81422-1; Polgar J, 1997, J BIOL CHEM, V272, P13576, DOI 10.1074/jbc.272.21.13576; Poole A, 1997, EMBO J, V16, P2333, DOI 10.1093/emboj/16.9.2333; Raab M, 1997, IMMUNITY, V6, P155, DOI 10.1016/S1074-7613(00)80422-7; Robinson A, 1996, BLOOD, V88, P522, DOI 10.1182/blood.V88.2.522.bloodjournal882522; RodriguezLinares B, 1996, BIOCHEM J, V316, P93, DOI 10.1042/bj3160093; SCHNEIDER C, 1982, J BIOL CHEM, V257, P766; SILLMAN AL, 1995, J BIOL CHEM, V270, P11806, DOI 10.1074/jbc.270.20.11806; Tuosto L, 1996, J EXP MED, V184, P1161, DOI 10.1084/jem.184.3.1161; TURNER M, 1995, NATURE, V378, P298, DOI 10.1038/378298a0; Wardenburg JB, 1996, J BIOL CHEM, V271, P19641, DOI 10.1074/jbc.271.33.19641; Wu J, 1996, IMMUNITY, V4, P593, DOI 10.1016/S1074-7613(00)80485-9; Yablonski D, 1998, SCIENCE, V281, P413, DOI 10.1126/science.281.5375.413	37	101	102	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 26	1999	274	9					5963	5971		10.1074/jbc.274.9.5963	http://dx.doi.org/10.1074/jbc.274.9.5963			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	170KG	10026222	hybrid			2022-12-25	WOS:000078804400093
J	Zimmermann, B; Chiorini, JA; Ma, YL; Kotin, RM; Herberg, FW				Zimmermann, B; Chiorini, JA; Ma, YL; Kotin, RM; Herberg, FW			PrKX is a novel catalytic subunit of the cAMP-dependent protein kinase regulated by the regulatory subunit type I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; MOLECULAR-CLONING; INHIBITOR PROTEIN; IDENTIFICATION; EXPRESSION; NUCLEUS; DOMAINS; GENE; RESONANCE; STABILITY	The human X chromosome-encoded protein kinase X (PrKX) belongs to the family of cAMP-dependent protein kinases, The catalytically active recombinant enzyme expressed in COS cells phosphorylates the heptapeptide Kemptide (LRRASLG) with a specific activity of 1.5 mu mol/(min.mg). Using surface plasmon resonance, high affinity interactions were demonstrated with the regulatory subunit type I (RIalpha) of cAMP-dependent protein kinase (K-D = 10 nM) and the heat-stable protein kinase inhibitor (K-D = 15 nM), but not with the type II regulatory subunit (RIIalpha, K-D = 2.3 mu M) under physiological conditions. Kemptide and autophosphorylation activities of PrKX are strongly inhibited by the RIalpha subunit and by protein kinase inhibitor in vitro, but only weakly by the RIIalpha subunit. The inhibition by the RIalpha subunit is reversed by addition of nanomolar concentrations of cAMP (K-alpha = 40 nM), thus demonstrating that PrKX is a novel, type I cAMP-dependent protein kinase that is activated at lower cAMP concentrations than the holoenzyme with the C-alpha subunit of cAMP-dependent protein kinase. Microinjection data clearly indicate that the type I R subunit but not type II binds to PrKX in vivo, preventing the translocation of PrKX to the nucleus in the absence of cAMP. The RIIalpha subunit is an excellent substrate far PrKX and is phosphorylated in vitro in a cAMP-independent manner, me discuss how PrKX can modulate the cAMP-mediated signal transduction pathway by preferential binding to the RIalpha subunit and by phosphorylating the RIIalpha subunit in the absence of cAMP.	Ruhr Univ Bochum, Fak Med, Biochem Supramolek Syst Abt, Inst Physiol Chem 1, D-44801 Bochum, Germany; Univ Calif San Diego, Howard Hughes Med Inst, La Jolla, CA 92037 USA; Univ Calif San Diego, Dept Chem & Biochem, La Jolla, CA 92037 USA; NHLBI, Mol Hematol Branch, NIH, Bethesda, MD 20892 USA	Ruhr University Bochum; Howard Hughes Medical Institute; University of California System; University of California San Diego; University of California System; University of California San Diego; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Herberg, FW (corresponding author), Ruhr Univ Bochum, Fak Med, Biochem Supramolek Syst Abt, Inst Physiol Chem 1, MA 2-40, D-44801 Bochum, Germany.	friedrich.w.herberg@ruhr-uni-bochum.de	kotin, robert/B-8954-2008; Herberg, Friedrich W/B-5572-2015	Herberg, Friedrich W/0000-0001-7117-7653	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [Z01HL002231] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADAMS JA, 1995, BIOCHEMISTRY-US, V34, P2447, DOI 10.1021/bi00008a007; ARMSTRONG RN, 1979, BIOCHEMISTRY-US, V18, P1230, DOI 10.1021/bi00574a018; BEEBE SJ, 1990, MOL ENDOCRINOL, V4, P465, DOI 10.1210/mend-4-3-465; BROOKS SPJ, 1992, ANAL BIOCHEM, V201, P119, DOI 10.1016/0003-2697(92)90183-8; BUECHLER YJ, 1993, J BIOL CHEM, V268, P16495; CADD GG, 1990, J BIOL CHEM, V265, P19502; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; Chiorini JA, 1998, MOL CELL BIOL, V18, P5921, DOI 10.1128/MCB.18.10.5921; ChoChung YS, 1995, CRIT REV ONCOL HEMAT, V21, P33, DOI 10.1016/1040-8428(94)00166-9; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; COOK PF, 1982, BIOCHEMISTRY-US, V21, P5794, DOI 10.1021/bi00266a011; DOSKELAND SO, 1993, BIOCHIM BIOPHYS ACTA, V1178, P249, DOI 10.1016/0167-4889(93)90201-Y; FANTOZZI DA, 1994, J BIOL CHEM, V269, P2676; Faux MC, 1996, CELL, V85, P9, DOI 10.1016/S0092-8674(00)81075-2; Gibson RM, 1997, PROTEIN SCI, V6, P1825, DOI 10.1002/pro.5560060903; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HAGIWARA M, 1993, MOL CELL BIOL, V13, P4852, DOI 10.1128/MCB.13.8.4852; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HAROOTUNIAN AT, 1993, MOL BIOL CELL, V4, P993, DOI 10.1091/mbc.4.10.993; Herberg FW, 1997, PROTEIN SCI, V6, P569; HERBERG FW, 1993, PROTEIN ENG, V6, P771, DOI 10.1093/protein/6.7.771; HERBERG FW, 1993, BIOCHEMISTRY-US, V32, P14015, DOI 10.1021/bi00213a035; HERBERG FW, 1994, BIOCHEMISTRY-US, V33, P7485, DOI 10.1021/bi00189a057; HERBERG FW, 1996, BIOCHEMISTRY-US, V35, P29834; Hermanns J, 1997, J VIROL, V71, P6020, DOI 10.1128/JVI.71.8.6020-6027.1997; HOFMANN F, 1980, J BIOL CHEM, V255, P1559; Huang LJS, 1997, J BIOL CHEM, V272, P8057, DOI 10.1074/jbc.272.12.8057; KLINK A, 1995, HUM MOL GENET, V4, P869, DOI 10.1093/hmg/4.5.869; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; KREBS EG, 1979, ANNU REV BIOCHEM, V48, P923, DOI 10.1146/annurev.bi.48.070179.004423; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Macias MJ, 1996, NATURE, V382, P646, DOI 10.1038/382646a0; MELENDEZ A, 1995, GENETICS, V141, P1507; RANGELALDAO R, 1976, J BIOL CHEM, V251, P3375; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; ROSKOSKI R, 1983, METHOD ENZYMOL, V99, P3; SARASWAT LD, 1986, J BIOL CHEM, V261, P1091; Schiebel K, 1997, HUM MOL GENET, V6, P1985, DOI 10.1093/hmg/6.11.1985; SCHLESSINGER J, 1994, CURR OPIN GENET DEV, V4, P25, DOI 10.1016/0959-437X(94)90087-6; STENBERG E, 1991, J COLLOID INTERF SCI, V143, P513, DOI 10.1016/0021-9797(91)90284-F; Tasken K, 1997, ADV SEC MESS PHOSPH, V31, P191; TAYLOR SS, 1990, ANNU REV BIOCHEM, V59, P971, DOI 10.1146/annurev.bi.59.070190.004543; VANPATTEN SM, 1991, P NATL ACAD SCI USA, V88, P5383, DOI 10.1073/pnas.88.12.5383; Walsh D.A., 2018, PEPT PROT PHOSPH, P43; WEN W, 1995, CELL, V82, P463, DOI 10.1016/0092-8674(95)90435-2; WHITEHOUSE S, 1983, J BIOL CHEM, V258, P3682; YONEMOTO W, 1993, J BIOL CHEM, V268, P2348; YONEMOTO WM, 1991, METHOD ENZYMOL, V200, P581	48	79	86	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 26	1999	274	9					5370	5378		10.1074/jbc.274.9.5370	http://dx.doi.org/10.1074/jbc.274.9.5370			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	170KG	10026146	hybrid			2022-12-25	WOS:000078804400017
J	Hurd, C; Dinda, S; Khattree, N; Moudgil, VK				Hurd, C; Dinda, S; Khattree, N; Moudgil, VK			Estrogen-dependent and independent activation of the P1 promoter of the p53 gene in transiently transfected breast cancer cells	ONCOGENE			English	Article						breast cancer; tumor suppressors; p53; estrogen; antiestrogens; tamoxifen	TUMOR-SUPPRESSOR P53; C-MYC; TRANSCRIPTIONAL REPRESSION; INDUCED APOPTOSIS; RETINOBLASTOMA; PROTEIN; EXPRESSION; PRODUCT; PHOSPHORYLATION; FIBROBLASTS	Loss of p53 function by mutational inactivation is the most common marker of the cancerous phenotype, Previous studies from our laboratory have demonstrated 17 beta estradiol (E-2) induction of p53 protein expression in breast cancer cells. Although direct effects of E-2 on the expression of p53 gene are not known, the steroid is a potent regulator of c-Myc transcription. In the present studies, we have examined the ability of E-2 and antiestrogens to regulate the P1 promoter of the p53 gene which contains a c-Myc responsive element, Estrogen receptor (ER)-positive T47D and MCF-7 cells were transiently transfected with the P1CAT reporter plasmid and levels of CAT activity in response to serum, E-2 and antiestrogens were monitored. Factors in serum were noted to be the dominant inducers of chloramphenicol acetyltransferase (CAT) expression in MCF-7 cells. The levels of CAT were drastically reduced when cells were maintained in serum free medium (SFM). However, a subtle ER-mediated induction of CAT expression was detectable when MCF-7 cells, cultured in SFM, were treated with E-2, In serum-stimulated T47D cells, the CAT expression was minimal. The full ER antagonist, ICI 182 780 (ICI) had no effect. Treatment with E-2 or 4-hydroxy tamoxifen (OHT) resulted in P1CAT induction; OHT was more effective than E-2. Consistent with c-Myc regulation of the P1 promoter, E-2 stimulated endogenous c-Myc in both cell lines. Two forms of c-Myc were expressed independent of E-2 stimuli. The expression of a third more rapidly migrating form was E-2-dependent and ER-mediated since it was blocked by the full ER antagonist, ICI, but not by the ER agonist/antagonist OHT, These data demonstrate both ER-mediated and ER-independent regulation of c-Myc and the P1 promoter of the p53 gene, and show differential effects of the two classes of antiestrogens in their ability to induce the P1 promoter of the p53 gene in breast cancer cells.	Oakland Univ, Dept Biol Sci, Rochester, MI 48309 USA; Oakland Univ, Ctr Biomed Res, Rochester, MI 48309 USA	Oakland University; Oakland University	Moudgil, VK (corresponding author), Oakland Univ, Dept Biol Sci, Rochester, MI 48309 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK020893] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 20893] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Altucci L, 1996, ONCOGENE, V12, P2315; DEFFIE A, 1993, MOL CELL BIOL, V13, P3415, DOI 10.1128/MCB.13.6.3415; DONEHOWER LA, 1993, BIOCHIM BIOPHYS ACTA, V1155, P181, DOI 10.1016/0304-419X(93)90004-V; DUBIK D, 1988, J BIOL CHEM, V263, P12705; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Foster JS, 1996, MOL ENDOCRINOL, V10, P488, DOI 10.1210/me.10.5.488; HAASKOGAN DA, 1995, EMBO J, V14, P461, DOI 10.1002/j.1460-2075.1995.tb07022.x; HAMEL PA, 1992, MOL CELL BIOL, V12, P3431, DOI 10.1128/MCB.12.8.3431; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; HURD C, 1995, J BIOL CHEM, V270, P28507, DOI 10.1074/jbc.270.48.28507; Hurd C, 1997, ONCOGENE, V15, P991, DOI 10.1038/sj.onc.1201233; Hurd C, 1998, HANDBK PHYS, V1, P383; Kang Y, 1996, J NATL CANCER I, V88, P279, DOI 10.1093/jnci/88.5.279; KODALI S, 1994, BIOCHEM BIOPH RES CO, V202, P1413, DOI 10.1006/bbrc.1994.2088; LOWE SW, 1994, SCIENCE, V266, P807, DOI 10.1126/science.7973635; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; Lukas J, 1996, MOL CELL BIOL, V16, P6917; McCormack SJ, 1998, ONCOGENE, V16, P2755, DOI 10.1038/sj.onc.1201804; PlanasSilva MD, 1997, MOL CELL BIOL, V17, P4059, DOI 10.1128/MCB.17.7.4059; Prall OWJ, 1997, J BIOL CHEM, V272, P10882; REISMAN D, 1988, P NATL ACAD SCI USA, V85, P5146, DOI 10.1073/pnas.85.14.5146; ROY B, 1994, MOL CELL BIOL, V14, P7805, DOI 10.1128/MCB.14.12.7805; RUSTGI AK, 1991, NATURE, V352, P541, DOI 10.1038/352541a0; UITTENBOGAARD MN, 1995, J BIOL CHEM, V270, P28503, DOI 10.1074/jbc.270.48.28503; WU HY, 1994, J BIOL CHEM, V269, P20067	26	33	34	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 28	1999	18	4					1067	1072		10.1038/sj.onc.1202398	http://dx.doi.org/10.1038/sj.onc.1202398			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	165FT	10023683				2022-12-25	WOS:000078510600024
J	Kishida, M; Koyama, S; Kishida, S; Matsubara, K; Nakashima, S; Higano, K; Takada, R; Takada, S; Kikuchi, A				Kishida, M; Koyama, S; Kishida, S; Matsubara, K; Nakashima, S; Higano, K; Takada, R; Takada, S; Kikuchi, A			Axin prevents Wnt-3a-induced accumulation of beta-catenin	ONCOGENE			English	Article						Axin; Wnt; beta-catenin; APC; GSK-3 beta	GLYCOGEN-SYNTHASE KINASE-3; MOUSE FUSED LOCUS; INT-1 PROTOONCOGENE; SIGNALING PATHWAY; XENOPUS EMBRYOS; MAMMALIAN-CELLS; WNT GENES; PROTEIN; COMPLEX; APC	When Axin, a negative regulator of the Wnt signaling pathway, was expressed in COS cells, it coeluted with glycogen synthase kinase-3 beta (GSK-3 beta), beta-catenin, and adenomatous polyposis coli protein (APC) in a high molecular weight fraction on gel filtration column chromatography. In this fraction, GSK-3 beta, beta-catenin, and APC were co-precipitated with Axin. Although beta-catenin was detected in the high molecular weight fraction in L cells on gel filtration column chromatography, addition of conditioned medium expressing Wnt-3a to the cells increased beta-catenin in the low molecular weight fraction. However, Wnt-3a-dependent accumulation of beta-catenin was greatly inhibited in L cells stably expressing Axin, Axin also suppressed Wnt-3a-dependent activation of Tcf-4 which binds to beta-catenin and acts as a transcription factor. These results suggest that Axin forms a complex with GSK-3 beta, beta-catenin, and APC, resulting in the stimulation of the degradation of beta-catenin and that Wnt-3a induces the dissociation of beta-catenin from the Axin complex and accumulates beta-catenin.	Hiroshima Univ, Sch Med, Dept Biochem, Minami Ku, Hiroshima 7348551, Japan; Kyoto Univ, Fac Sci, Ctr Mol & Dev Biol, Sakyo Ku, Kyoto 6068502, Japan	Hiroshima University; Kyoto University	Kikuchi, A (corresponding author), Hiroshima Univ, Sch Med, Dept Biochem, Minami Ku, 1-2-3 Kasumi, Hiroshima 7348551, Japan.			kishida, shosei/0000-0003-0405-851X; Takada, Shinji/0000-0003-4125-6056; Takada, Ritsuko/0000-0002-1615-056X				Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Behrens J, 1998, SCIENCE, V280, P596, DOI 10.1126/science.280.5363.596; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; BRADLEY RS, 1995, MOL CELL BIOL, V15, P4616; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; Cook D, 1996, EMBO J, V15, P4526, DOI 10.1002/j.1460-2075.1996.tb00830.x; GLUECKSOHNSCHOENHEIMER S, 1949, J EXP ZOOL, V110, P47, DOI 10.1002/jez.1401100105; Hart MJ, 1998, CURR BIOL, V8, P573, DOI 10.1016/S0960-9822(98)70226-X; HE X, 1995, NATURE, V374, P617, DOI 10.1038/374617a0; HINCK L, 1994, J CELL BIOL, V124, P729, DOI 10.1083/jcb.124.5.729; HOSCHUETZKY H, 1994, J CELL BIOL, V127, P1375, DOI 10.1083/jcb.127.5.1375; Ikeda S, 1998, EMBO J, V17, P1371, DOI 10.1093/emboj/17.5.1371; Ikeya M, 1997, NATURE, V389, P966, DOI 10.1038/40146; Itoh K, 1998, CURR BIOL, V8, P591, DOI 10.1016/S0960-9822(98)70229-5; JACOBSCOHEN RJ, 1984, GENET RES, V43, P43, DOI 10.1017/S0016672300025702; Kishida S, 1998, J BIOL CHEM, V273, P10823, DOI 10.1074/jbc.273.18.10823; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Korinek V, 1998, MOL CELL BIOL, V18, P1248, DOI 10.1128/MCB.18.3.1248; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; Miller JR, 1996, GENE DEV, V10, P2527, DOI 10.1101/gad.10.20.2527; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; MUNEMITSU S, 1995, P NATL ACAD SCI USA, V92, P3046, DOI 10.1073/pnas.92.7.3046; NAGAFUCHI A, 1987, NATURE, V329, P341, DOI 10.1038/329341a0; NUSSE R, 1992, CELL, V69, P1073, DOI 10.1016/0092-8674(92)90630-U; PAPKOFF J, 1987, MOL CELL BIOL, V7, P3978, DOI 10.1128/MCB.7.11.3978; Papkoff J, 1996, MOL CELL BIOL, V16, P2128; PARR BA, 1993, DEVELOPMENT, V119, P247; PERRY WL, 1995, GENETICS, V141, P321; PIERCE SB, 1995, DEVELOPMENT, V121, P755; Porfiri E, 1997, ONCOGENE, V15, P2833, DOI 10.1038/sj.onc.1201462; Rajasekaran AK, 1996, J CELL BIOL, V132, P451, DOI 10.1083/jcb.132.3.451; Reed SC, 1937, GENETICS, V22, P1; ROELINK H, 1990, P NATL ACAD SCI USA, V87, P4519, DOI 10.1073/pnas.87.12.4519; Rubinfeld B, 1996, SCIENCE, V272, P1023, DOI 10.1126/science.272.5264.1023; Sakanaka C, 1998, P NATL ACAD SCI USA, V95, P3020, DOI 10.1073/pnas.95.6.3020; SHIBAMOTO S, 1999, IN PRESS GENES CELLS; Shimizu H, 1997, CELL GROWTH DIFFER, V8, P1349; SMOLICH BD, 1993, MOL BIOL CELL, V4, P1267, DOI 10.1091/mbc.4.12.1267; Stewart DB, 1997, J BIOL CHEM, V272, P29652, DOI 10.1074/jbc.272.47.29652; TAKADA S, 1994, GENE DEV, V8, P174, DOI 10.1101/gad.8.2.174; Tao YS, 1996, J CELL BIOL, V134, P1271, DOI 10.1083/jcb.134.5.1271; THOMAS KR, 1990, NATURE, V346, P847, DOI 10.1038/346847a0; VANLEEUWEN F, 1994, NATURE, V368, P342, DOI 10.1038/368342a0; Yamamoto H, 1998, MOL CELL BIOL, V18, P2867, DOI 10.1128/MCB.18.5.2867; YOST C, 1996, GENE DEV, V10, P143; Zeng L, 1997, CELL, V90, P181, DOI 10.1016/S0092-8674(00)80324-4	47	116	120	1	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 28	1999	18	4					979	985		10.1038/sj.onc.1202388	http://dx.doi.org/10.1038/sj.onc.1202388			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	165FT	10023673				2022-12-25	WOS:000078510600014
J	Bateson, M; Devenish, RJ; Nagley, P; Prescott, M				Bateson, M; Devenish, RJ; Nagley, P; Prescott, M			Single copies of subunits d, oligomycin-sensitivity conferring protein, and b are present in the Saccharomyces cerevisiae mitochondrial ATP synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BEEF-HEART MITOCHONDRIA; ESCHERICHIA-COLI; H+-ATPASE; CROSS-LINKING; COMPLEX; YEAST; STOICHIOMETRY; OSCP; F1; REGION	In the mitochondrial ATP synthase (mtATPase) of the yeast Saccharomyces cerevisiae, the stoichiometry of subunits d, oligomycin-sensitivity conferring protein (OSCP), and b is poorly defined. We have investigated the stoichiometry of these subunits by the application of hexahistidine affinity purification technology, We have previously demonstrated that intact mtATPase complexes incorporating a Hex(6)-tagged subunit can be isolated via Ni2+-nitrilotriacetic acid affinity chromatography (Bateson, RI., Devenish, R, J., Nagley, P., and Prescott, M, (1996) Anal. Biochem. 238, 14-18), Strains were constructed in which Hex(6)-tagged versions of subunits d, OSCP, and b were coexpressed with the corresponding wild-type subunit. This coexpression resulted in a mixed population of mtATPase complexes containing untagged wild-type and Hex(6)-tagged subunits, The stoichiometry of each subunit was then assessed by determining whether or not the untagged wild-type subunit could be recovered from Ni2+-nitrilotriacetic acid purifications as an integral component of those complexes absorbed by virtue of the Hex(6)-tagged subunit, As only the Hex(6)-tagged subunit was recovered from such purifications, we demonstrate that the stoichiometry of subunits d, OSCP, and b in yeast is 1 in each case.	Monash Univ, Dept Biochem & Mol Biol, Melbourne, Vic 3168, Australia	Monash University	Devenish, RJ (corresponding author), Monash Univ, Dept Biochem & Mol Biol, Melbourne, Vic 3168, Australia.	Rodney.Devenish@med.monash.edu.au						ARIS JP, 1983, J BIOL CHEM, V258, P4599; Bateson M, 1996, ANAL BIOCHEM, V238, P14, DOI 10.1006/abio.1996.0242; BELOGRUDOV GI, 1995, J BIOL CHEM, V270, P2053, DOI 10.1074/jbc.270.5.2053; BOYER PD, 1993, BIOCHIM BIOPHYS ACTA, V1140, P215, DOI 10.1016/0005-2728(93)90063-L; Collinson IR, 1996, BIOCHEMISTRY-US, V35, P12640, DOI 10.1021/bi960969t; DUNN SD, 1992, J BIOL CHEM, V267, P7630; Dunn SD, 1998, J BIOL CHEM, V273, P8646, DOI 10.1074/jbc.273.15.8646; FOSTER DL, 1982, J BIOL CHEM, V257, P2009; Gray R E, 1996, Methods Enzymol, V264, P369, DOI 10.1016/S0076-6879(96)64035-X; HADIKUSUMO RG, 1988, BIOCHIM BIOPHYS ACTA, V933, P212, DOI 10.1016/0005-2728(88)90072-2; HAMES BD, 1990, GEL ELECTROPHORESIS, P30; HEKMAN C, 1991, J BIOL CHEM, V266, P13564; HERMOLIN J, 1983, J BIOL CHEM, V258, P4550; Law RHP, 1995, METHOD ENZYMOL, V260, P133, DOI 10.1016/0076-6879(95)60135-X; LIPPE G, 1988, J BIOL CHEM, V263, P18627; McLachlin DT, 1998, J BIOL CHEM, V273, P15162, DOI 10.1074/jbc.273.24.15162; Noji H, 1997, NATURE, V386, P299, DOI 10.1038/386299a0; NORAIS N, 1991, J BIOL CHEM, V266, P16541; Ogilvie I, 1997, J BIOL CHEM, V272, P16652, DOI 10.1074/jbc.272.26.16652; OVCHINNIKOV YA, 1984, FEBS LETT, V175, P109, DOI 10.1016/0014-5793(84)80580-3; PAPAKONSTANTINOU T, 1993, BIOCHIM BIOPHYS ACTA, V1144, P22, DOI 10.1016/0005-2728(93)90026-C; PENIN F, 1985, BIOCHIM BIOPHYS ACTA, V810, P346, DOI 10.1016/0005-2728(85)90220-8; PRESCOTT M, 1995, BIOCHEM BIOPH RES CO, V207, P943, DOI 10.1006/bbrc.1995.1276; ROBERTS H, 1979, FEBS LETT, V108, P501, DOI 10.1016/0014-5793(79)80597-9; Rodgers AJW, 1998, J BIOL CHEM, V273, P29406, DOI 10.1074/jbc.273.45.29406; ROTT R, 1981, J BIOL CHEM, V256, P9224; Straffon AFL, 1998, BBA-BIOMEMBRANES, V1371, P157, DOI 10.1016/S0005-2736(98)00034-0; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2	29	23	23	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 12	1999	274	11					7462	7466		10.1074/jbc.274.11.7462	http://dx.doi.org/10.1074/jbc.274.11.7462			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	175DV	10066811	hybrid			2022-12-25	WOS:000079078400083
J	Delhaize, E; Hebb, DM; Richards, KD; Lin, JM; Ryan, PR; Gardner, RC				Delhaize, E; Hebb, DM; Richards, KD; Lin, JM; Ryan, PR; Gardner, RC			Cloning and expression of a wheat (Triticum aestivum L.) phosphatidylserine synthase cDNA - Overexpression in plants alters the composition of phospholipids	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLCHOLINE SYNTHESIS; SACCHAROMYCES-CEREVISIAE; ARABIDOPSIS-THALIANA; YEAST; BIOSYNTHESIS; ALUMINUM; MUTANT; GENES; TRANSFORMATION; MEMBRANES	We describe the cloning of a wheat cDNA (TaPSS1) that encodes a phosphatidylserine synthase (PSS) and provides the first strong evidence for the existence of this enzyme in a higher eukaryotic cell, The cDNA was isolated on its ability to confer increased resistance to aluminum toxicity when expressed in yeast, The sequence of the predicted protein encoded by TaPSS1 shows homology to PSS from both yeast and bacteria but is distinct from the animal PSS enzymes that catalyze base-exchange reactions. In wheat, Southern blot analysis identified the presence of a small family of genes that cross-hybridized to TaPSS1, and Northern blots showed that aluminum induced TaPSS1 expression in root apices, Expression of TaPSS1 complemented the yeast cho1 mutant that lacks PSS activity and altered the phospholipid composition of wild type yeast, with the most marked effect being increased abundance of phosphatidylserine (PS). Arabidopsis thaliana leaves overexpressing TaPSS1 showed a marked enhancement in PSS activity, which was associated with increased biosynthesis of PS at the expense of bo th phosphatidylinositol and phosphatidylglycerol, Unlike mammalian cells where PS accumulation is tightly regulated even when the capacity for PS biosynthesis is increased, plant cells accumulated large amounts of PS when TaPSS1 was overexpressed. High levels of TaPSS1 expression in Arabidopsis and tobacco (Nicotiana tabacum) led to the appearance of necrotic lesions on leaves, which may have resulted from the excessive accumulation of PS, The cloning of TaPSS1 now provides evidence that the yeast pathway for PS synthesis exists in some plant tissues and provides a tool for understanding the pathways of phospholipid biosynthesis and their regulation in plants.	CSIRO, Canberra, ACT 2601, Australia; Univ Auckland, Sch Biol Sci, Ctr Gene Technol, Auckland 1, New Zealand	Commonwealth Scientific & Industrial Research Organisation (CSIRO); University of Auckland	Delhaize, E (corresponding author), CSIRO, GPO Box 1600, Canberra, ACT 2601, Australia.		Ryan, Peter R/I-4651-2012; Gardner, Richard C/C-9002-2009; Delhaize, Emmanuel/I-6536-2013	Ryan, Peter R/0000-0002-1376-9543; Lin, Jian/0000-0002-8362-6951				APPELS R, 1982, THEOR APPL GENET, V63, P361, DOI 10.1007/BF00303907; ATKINSON K, 1980, J BIOL CHEM, V255, P6653; ATKINSON KD, 1980, J BACTERIOL, V141, P558, DOI 10.1128/JB.141.2.558-564.1980; Aussel C, 1998, FEBS LETT, V431, P195, DOI 10.1016/S0014-5793(98)00748-0; Carman GM, 1996, J BIOL CHEM, V271, P13293, DOI 10.1074/jbc.271.23.13293; CHANDLER PM, 1983, PLANT PHYSIOL, V71, P47, DOI 10.1104/pp.71.1.47; Choi SB, 1997, MOL CELLS, V7, P58; DATKO AH, 1988, PLANT PHYSIOL, V88, P1338, DOI 10.1104/pp.88.4.1338; DELHAIZE E, 1993, PLANT PHYSIOL, V103, P695, DOI 10.1104/pp.103.3.695; DELHAIZE E, 1995, PLANT PHYSIOL, V107, P207, DOI 10.1104/pp.107.1.207; DEVAUX PF, 1991, BIOCHEMISTRY-US, V30, P1163, DOI 10.1021/bi00219a001; Dowhan W, 1997, ANNU REV BIOCHEM, V66, P199, DOI 10.1146/annurev.biochem.66.1.199; Doyle J.J., 1990, FOCUS, V12, P13, DOI DOI 10.2307/2419362; FADOK VA, 1992, J IMMUNOL, V148, P2207; Fadok VA, 1998, CELL DEATH DIFFER, V5, P551, DOI 10.1038/sj.cdd.4400404; Galliard T., 1973, FORM FUNCTION PHOSPH, P253; GIETZ RD, 1995, YEAST, V11, P355, DOI 10.1002/yea.320110408; GISH W, 1993, NAT GENET, V3, P266, DOI 10.1038/ng0393-266; GLEAVE AP, 1992, PLANT MOL BIOL, V20, P1203, DOI 10.1007/BF00028910; HOMANN MJ, 1987, J BACTERIOL, V169, P533, DOI 10.1128/jb.169.2.533-539.1987; HORSCH RB, 1985, SCIENCE, V227, P1229, DOI 10.1126/science.227.4691.1229; Jones DL, 1997, FEBS LETT, V400, P51, DOI 10.1016/S0014-5793(96)01319-1; KINNEY AJ, 1987, PLANT PHYSIOL, V84, P78, DOI 10.1104/pp.84.1.78; Kuge O, 1998, P NATL ACAD SCI USA, V95, P4199, DOI 10.1073/pnas.95.8.4199; Kuge O, 1997, BBA-LIPID LIPID MET, V1348, P151, DOI 10.1016/S0005-2760(97)00137-9; LETTS VA, 1983, P NATL ACAD SCI-BIOL, V80, P7279, DOI 10.1073/pnas.80.23.7279; MacDiarmid CW, 1996, PLANT PHYSIOL, V112, P1101, DOI 10.1104/pp.112.3.1101; MARSHALL MO, 1974, CAN J BIOCHEM CELL B, V52, P469, DOI 10.1139/o74-071; MOORE TS, 1975, PLANT PHYSIOL, V56, P177, DOI 10.1104/pp.56.2.177; MOORE TS, 1982, ANNU REV PLANT PHYS, V33, P235, DOI 10.1146/annurev.pp.33.060182.001315; Nishida I, 1996, PLANT MOL BIOL, V31, P205, DOI 10.1007/BF00021784; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; O'Brien IEW, 1998, PLANT J, V13, P803, DOI 10.1046/j.1365-313X.1998.00087.x; PIETRZAK M, 1986, NUCLEIC ACIDS RES, V14, P5857, DOI 10.1093/nar/14.14.5857; Richardson K, 1998, AUST J PLANT PHYSIOL, V25, P125, DOI 10.1071/PP97109; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHROIT AJ, 1991, BIOCHIM BIOPHYS ACTA, V1071, P313, DOI 10.1016/0304-4157(91)90019-S; SMITH FW, 1995, P NATL ACAD SCI USA, V92, P9373, DOI 10.1073/pnas.92.20.9373; SNOWDEN KC, 1993, PLANT PHYSIOL, V103, P855, DOI 10.1104/pp.103.3.855; SPERKAGOTTLIEB C, 1990, YEAST, V6, P331, DOI 10.1002/yea.320060406; Stone SJ, 1998, J BIOL CHEM, V273, P7293, DOI 10.1074/jbc.273.13.7293; SURIN B, 1912, P 4 AS PAC C AGR BIO; Uchida K, 1998, J BIOCHEM-TOKYO, V123, P1073; Yamashita S, 1997, BBA-LIPID LIPID MET, V1348, P228, DOI 10.1016/S0005-2760(97)00102-1; Zhang GH, 1997, BIOTECHNIQUES, V23, P525, DOI 10.2144/97233pf01; [No title captured]	47	71	79	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 12	1999	274	11					7082	7088		10.1074/jbc.274.11.7082	http://dx.doi.org/10.1074/jbc.274.11.7082			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	175DV	10066765	hybrid			2022-12-25	WOS:000079078400037
J	Helmerhorst, EJ; Breeuwer, P; van't Hof, W; Walgreen-Weterings, E; Oomen, LCJM; Veerman, ECI; Amerongen, AVN; Abee, T				Helmerhorst, EJ; Breeuwer, P; van't Hof, W; Walgreen-Weterings, E; Oomen, LCJM; Veerman, ECI; Amerongen, AVN; Abee, T			The cellular target of histatin 5 on Candida albicans is the energized mitochondrion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-PAROTID SECRETION; NEUTROPHIL DEFENSINS; PEPTIDE; IMPORT; MECHANISM; PROTEIN; PRESEQUENCES; RESPIRATION; MODULATION; SURFACE	Histatin 5 is a human basic salivary peptide with strong fungicidal properties in vitro. To elucidate the mechanism of action, the effect of histatin 5 on the viability of Candida albicans cells was studied in relation to its membrane perturbing properties. It was found that both the killing activity and the membrane perturbing activity, studied by the influx of a DNA-specific marker propidium iodide, were inhibited by high salt conditions and by metabolic inhibitors, like sodium azide, In addition, exposure to histatin 5 resulted in a loss of the mitochondrial transmembrane potential in situ, measured by the release of the potential-dependent distributional probe rhodamine 123, Localization studies using tetramethylrhodamine isothiocyanate-labeled histatin 5 or fluorescein isothiocyanate-labeled histatin 5 showed a granular intracellular distribution of the peptide, which co-localized with mitotracker orange, a permeant mitochondria-specific probe. Like the biological effects, uptake of labeled histatin 5 was inhibited by mitochondrial inhibitors and high salt conditions. Our data indicate that histatin 5 is internalized, and targets to the energized mitochondrion.	Free Univ Amsterdam, Dept Oral Biochem, Acad Ctr Dent, NL-1081 BT Amsterdam, Netherlands; Wageningen Univ & Res Ctr, Dept Food Technol & Nutr Sci, Food Sci Grp, NL-6703 HD Wageningen, Netherlands; Netherlands Canc Inst, Dept Biophys, NL-1066 CX Amsterdam, Netherlands	Academic Center for Dentistry Amsterdam; Vrije Universiteit Amsterdam; Wageningen University & Research; Netherlands Cancer Institute	Helmerhorst, EJ (corresponding author), Free Univ Amsterdam, Dept Oral Biochem, Acad Ctr Dent, Van der Boechorststr 7, NL-1081 BT Amsterdam, Netherlands.			Helmerhorst, Eva/0000-0002-4803-3018				BJERKNES R, 1984, J IMMUNOL METHODS, V72, P229, DOI 10.1016/0022-1759(84)90451-4; Costilow R. N, 1981, MANUAL METHODS GENER, P66; FURUYA S, 1991, EMBO J, V10, P1759, DOI 10.1002/j.1460-2075.1991.tb07700.x; Hancock REW, 1998, TRENDS BIOTECHNOL, V16, P82, DOI 10.1016/S0167-7799(97)01156-6; Hancock REW, 1997, LANCET, V349, P418, DOI 10.1016/S0140-6736(97)80051-7; HARLOW E, 1988, ANTIBODIES LABORATOR, P354; Helmerhorst EJ, 1997, BIOCHEM J, V326, P39, DOI 10.1042/bj3260039; HENRY MF, 1975, SUB-CELL BIOCHEM, V4, P1; Hristova K, 1997, J BIOL CHEM, V272, P24224, DOI 10.1074/jbc.272.39.24224; HUGOSSON M, 1994, EUR J BIOCHEM, V223, P1027, DOI 10.1111/j.1432-1033.1994.tb19081.x; IIJIMA R, 1993, J BIOL CHEM, V268, P12055; LEHRER RI, 1988, J CLIN INVEST, V81, P1829, DOI 10.1172/JCI113527; LEHRER RI, 1989, J CLIN INVEST, V84, P553, DOI 10.1172/JCI114198; LEHRER RI, 1991, CELL, V64, P229, DOI 10.1016/0092-8674(91)90632-9; Lendenmann Urs, 1998, P198; LICHTENSTEIN AK, 1988, J IMMUNOL, V140, P2686; MADUKE M, 1993, SCIENCE, V260, P364, DOI 10.1126/science.8385804; Margulis L, 1996, P NATL ACAD SCI USA, V93, P1071, DOI 10.1073/pnas.93.3.1071; MATSUZAKI K, 1995, BIOCHEMISTRY-US, V34, P6521, DOI 10.1021/bi00019a033; Matsuzaki K, 1997, BIOCHEMISTRY-US, V36, P2104, DOI 10.1021/bi961870p; McAuliffe O, 1998, APPL ENVIRON MICROB, V64, P439; MCCARTHY DM, 1987, APPL ENVIRON MICROB, V53, P345, DOI 10.1128/AEM.53.2.345-351.1987; NICOLAY K, 1994, J BIOENERG BIOMEMBR, V26, P327, DOI 10.1007/BF00763104; OLSON VL, 1977, CAN J MICROBIOL, V23, P166, DOI 10.1139/m77-024; OPPENHEIM FG, 1988, J BIOL CHEM, V263, P7472; OPPENHEIM FG, 1986, J BIOL CHEM, V261, P1177; POLLOCK JJ, 1984, INFECT IMMUN, V44, P702, DOI 10.1128/IAI.44.3.702-707.1984; ROISE D, 1992, P NATL ACAD SCI USA, V89, P608, DOI 10.1073/pnas.89.2.608; SHEPHERD MG, 1978, ARCH MICROBIOL, V116, P61, DOI 10.1007/BF00408734; VANTHOF W, 1991, MOL IMMUNOL, V28, P1225, DOI 10.1016/0161-5890(91)90009-9; WESTERHOFF HV, 1989, BIOCHIM BIOPHYS ACTA, V975, P361, DOI 10.1016/S0005-2728(89)80344-5; WESTERHOFF HV, 1989, P NATL ACAD SCI USA, V86, P6597, DOI 10.1073/pnas.86.17.6597; ZASLOFF M, 1987, P NATL ACAD SCI USA, V84, P5549	33	217	220	1	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 12	1999	274	11					7286	7291		10.1074/jbc.274.11.7286	http://dx.doi.org/10.1074/jbc.274.11.7286			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	175DV	10066791	hybrid			2022-12-25	WOS:000079078400063
J	Miura, S; Feng, YH; Husain, A; Karnik, SS				Miura, S; Feng, YH; Husain, A; Karnik, SS			Role of aromaticity of agonist switches of angiotensin II in the activation of the AT(1) receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSMEMBRANE DOMAIN; RESIDUES; BINDING; ANTAGONISTS; MUTATION; AFFINITY; SITE	We have shown previously that the octapeptide angiotensin II (Ang II) activates the AT, receptor through an induced-fit mechanism (Noda, K,, Feng, Y. H., Liu, X. P., Saad, Y,, Husain, A., and Karnik, S, S. (1996) Biochemistry 35, 16435-16442). In this activation process, interactions between Tyr(4) and Phe(8) of Ang II with Asn(111) and His(256) Of the AT(1) receptor, respectively, are essential for agonism, Here we show that aromaticity, primarily, and size, secondarily, of the Tyr(4) side chain are important in activating the receptor. Activation analysis of AT(1) receptor position 111 mutants by various Ang II position 4 analogues suggests that an amino-aromatic bonding interaction operates between the residue Asn(111) of the AT(1) receptor and Ty(r)4 of Ang II. Degree and potency of AT(1) receptor activation by Ang II can be recreated by a reciprocal exchange of aromatic and amide groups between positions 4 and 111 of Ang II and the AT(1) receptor, respectively. In several other bonding combinations, set up between Ang II position 4 analogues and receptor mutants, the gain of affinity is not accompanied by gain of function, Activation analysis of position 256 receptor mutants by Ang II position 8 analogues suggests that aromaticity of Phe(8) and His256 Side chains is crucial for receptor activation; however, a stacked rather than an amino-aromatic interaction appears to operate at this switch locus. Interaction between these residues, unlike the Tyr(4):Asn(111) interaction, plays an insignificant role in ligand docking.	Cleveland Clin Fdn, Lerner Res Inst, Dept Mol Cardiol, Cleveland, OH 44195 USA	Cleveland Clinic Foundation	Karnik, SS (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, Dept Mol Cardiol, 9500 Euclid Ave, Cleveland, OH 44195 USA.	karniks@cesmtp.ccf.org	Karnik, Sadashiva/Y-2477-2019; Husain, Ahsan/J-6861-2012	Karnik, Sadashiva/0000-0003-0746-2753; Husain, Ahsan/0000-0003-3426-3469	NEI NIH HHS [EY09704] Funding Source: Medline; NHLBI NIH HHS [R01 HL064845, HL57470, R01 HL057470] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY009704] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL057470] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARMSTRONG KM, 1993, J MOL BIOL, V230, P284, DOI 10.1006/jmbi.1993.1142; Balmforth AJ, 1997, J BIOL CHEM, V272, P4245, DOI 10.1074/jbc.272.7.4245; BIHOREAU C, 1993, P NATL ACAD SCI USA, V90, P5133, DOI 10.1073/pnas.90.11.5133; BUMPUS FM, 1977, HYPERTENSION PHYSIOP, P183; CREIGHTON TE, 1984, PROTEINS STRUCTURAL, P2; DOUGHERTY DA, 1990, SCIENCE, V250, P1558, DOI 10.1126/science.2274786; FENG YH, 1995, J BIOL CHEM, V270, P12846, DOI 10.1074/jbc.270.21.12846; Feng YH, 1998, BIOCHEMISTRY-US, V37, P15791, DOI 10.1021/bi980863t; Gether U, 1998, J BIOL CHEM, V273, P17979, DOI 10.1074/jbc.273.29.17979; Groblewski T, 1997, J BIOL CHEM, V272, P1822, DOI 10.1074/jbc.272.3.1822; GUILLEMETTE G, 1984, J MED CHEM, V27, P315, DOI 10.1021/jm00369a015; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Karnik SS, 1996, CLIN EXP PHARMACOL P, V23, pS58, DOI 10.1111/j.1440-1681.1996.tb02815.x; LEVITT M, 1988, J MOL BIOL, V201, P751, DOI 10.1016/0022-2836(88)90471-8; MARIE J, 1994, J BIOL CHEM, V269, P20815; MARSHALL GR, 1974, RECENT ADV RENAL PHY, P215; MITCHELL JBO, 1994, J MOL BIOL, V239, P315, DOI 10.1006/jmbi.1994.1370; Monnot C, 1996, J BIOL CHEM, V271, P1507, DOI 10.1074/jbc.271.3.1507; Nicholls A.J., 1993, GRASP MANUAL; NIKIFOROVICH GV, 1994, BIOCHEMISTRY-US, V33, P3591, DOI 10.1021/bi00178a016; NODA K, 1995, J BIOL CHEM, V270, P28511, DOI 10.1074/jbc.270.48.28511; NODA K, 1995, J BIOL CHEM, V270, P2284, DOI 10.1074/jbc.270.5.2284; NODA K, 1994, J BIOL CHEM, V269, P6743; PERLMAN S, 1995, J BIOL CHEM, V270, P1493, DOI 10.1074/jbc.270.4.1493; SAMANEN J, 1989, J MED CHEM, V32, P1366, DOI 10.1021/jm00126a037; SAMANEN J, 1994, ANGIOTENSIN 2 RECEPT, V2, P11; STRADER CD, 1994, ANNU REV BIOCHEM, V63, P101, DOI 10.1146/annurev.bi.63.070194.000533; TIMMERMANS PBMWM, 1993, PHARMACOL REV, V45, P205; Underwood D J, 1994, Chem Biol, V1, P211, DOI 10.1016/1074-5521(94)90013-2; WALKSMAN G, 1992, NATURE, V358, P646; YAMANO Y, 1992, BIOCHEM BIOPH RES CO, V187, P1426, DOI 10.1016/0006-291X(92)90461-S	31	95	97	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	1999	274	11					7103	7110		10.1074/jbc.274.11.7103	http://dx.doi.org/10.1074/jbc.274.11.7103			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	175DV	10066768	hybrid			2022-12-25	WOS:000079078400040
J	Strumberg, D; Nitiss, JL; Rose, A; Nicklaus, MC; Pommier, Y				Strumberg, D; Nitiss, JL; Rose, A; Nicklaus, MC; Pommier, Y			Mutation of a conserved serine residue in a quinolone-resistant type II topoisomerase alters the enzyme-DNA and drug interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EUKARYOTIC TOPOISOMERASE; ESCHERICHIA-COLI; CLEAVAGE; YEAST; DERIVATIVES; INHIBITORS; MECHANISM; COMPLEX; BINDING; GYRASE	A Ser(740) --> Trp mutation in yeast topoisomerase II (top2) and of the equivalent Ser(83) in gyrase results in resistance to quinolones and confers hypersensitivity to etoposide (VP-16), We characterized the cleavage complexes induced by the top2(S740W) in the human c-myc gene. In addition to resistance to the fluoroquinolone CP-115,953, top2(S740W) induced novel DNA cleavage sites in the presence of VP-16, azatoxin, amsacrine, and mitoxantrone, Analysis of the VP-16 sites indicated that the changes in the cleavage pattern were reflected by alterations in base preference. C at position -2 and G at position +6 were observed for the top(2S740W) in addition to the previously reported C-1 and G+5 for the wildtype top2, The VP-16-induced top(2S740W) cleavage complexes were also more stable. The most stable sites had strong preference for C-l, whereas the most reversible sites showed no base preference at positions -1 or -2, Different patterns of DNA cleavage were also observed in the absence of drug and in the presence of calcium. These results indicate that the Ser(740) --> Trp mutation alters the DNA recognition of top2, enhances its DNA binding, and markedly affects its interactions with inhibitors. Thus, residue 740 of top2 appears critical for both DNA and drug interactions.	NCI, Mol Pharmacol Lab, NIH, Bethesda, MD 20892 USA; NCI, Med Chem Lab, Div Basic Sci, NCI, Bethesda, MD 20892 USA; St Jude Childrens Res Hosp, Dept Mol Pharmacol, Memphis, TN 38105 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); St Jude Children's Research Hospital	Pommier, Y (corresponding author), NCI, Mol Pharmacol Lab, NIH, Blg 37,Rom 5D02, Bethesda, MD 20892 USA.		Nitiss, John/E-9974-2010; Nicklaus, Marc/N-4183-2014	Nitiss, John/0000-0002-1013-4972; Strumberg, Dirk/0000-0001-7053-8365; Nicklaus, Marc/0000-0002-4775-7030	NCI NIH HHS [CA52814] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA052814] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Beck W T, 1994, Adv Pharmacol, V29B, P145; Beck WT, 1997, ADV ENZYME REGUL, V37, P17, DOI 10.1016/S0065-2571(96)00024-6; Berger JM, 1996, CURR OPIN STRUC BIOL, V6, P84, DOI 10.1016/S0959-440X(96)80099-6; Berger JM, 1998, CURR OPIN STRUC BIOL, V8, P26, DOI 10.1016/S0959-440X(98)80006-7; Berger JM, 1996, NATURE, V379, P225, DOI 10.1038/379225a0; BIGIONI M, 1994, NUCLEIC ACIDS RES, V22, P2274, DOI 10.1093/nar/22.12.2274; Burden DA, 1996, J BIOL CHEM, V271, P29238, DOI 10.1074/jbc.271.46.29238; Cabral JHM, 1997, NATURE, V388, P903, DOI 10.1038/42294; Capranico G, 1997, TRENDS PHARMACOL SCI, V18, P323; CAPRANICO G, 1990, BIOCHEMISTRY-US, V29, P562, DOI 10.1021/bi00454a033; Capranico G, 1997, CANCER CHEMOTHER BIO, V17, P114; Conrad S, 1996, J ANTIMICROB CHEMOTH, V38, P443, DOI 10.1093/jac/38.3.443; Cozzarelli N.R., 1990, DNA TOPOLOGY ITS BIO; D'Arpa P, 1994, Adv Pharmacol, V29B, P127; Elsea SH, 1997, BIOCHEMISTRY-US, V36, P2919, DOI 10.1021/bi962488f; ELSEA SH, 1993, ANTIMICROB AGENTS CH, V37, P2179, DOI 10.1128/AAC.37.10.2179; ELSEA SH, 1995, J BIOL CHEM, V270, P1913, DOI 10.1074/jbc.270.4.1913; ELSEA SH, 1992, J BIOL CHEM, V267, P13150; Gmunder H, 1997, NUCLEIC ACIDS RES, V25, P604, DOI 10.1093/nar/25.3.604; Hsiung Y, 1996, CANCER RES, V56, P91; HSIUNG YC, 1995, J BIOL CHEM, V270, P20359, DOI 10.1074/jbc.270.35.20359; Hung F, 1996, FEBS LETT, V380, P127, DOI 10.1016/0014-5793(96)00035-X; LEE MP, 1992, NUCLEIC ACIDS RES, V20, P5027, DOI 10.1093/nar/20.19.5027; LETEURTRE F, 1994, BIOCHEM BIOPH RES CO, V203, P1259, DOI 10.1006/bbrc.1994.2318; LETEURTRE F, 1994, J BIOL CHEM, V269, P7893; LETEURTRE F, 1992, CANCER RES, V52, P4478; Lewis RJ, 1996, BIOESSAYS, V18, P661, DOI 10.1002/bies.950180810; Li W, 1997, J BIOL CHEM, V272, P31190, DOI 10.1074/jbc.272.49.31190; LINDSLEY JE, 1991, P NATL ACAD SCI USA, V88, P10485, DOI 10.1073/pnas.88.23.10485; LIU L, 1994, DNA TOPOISOMERASES T; Liu QY, 1998, J BIOL CHEM, V273, P20252, DOI 10.1074/jbc.273.32.20252; LIU YX, 1994, CANCER RES, V54, P2943; Neu H C, 1994, Adv Pharmacol, V29A, P227; OSHEROFF N, 1987, BIOCHEMISTRY-US, V26, P4303, DOI 10.1021/bi00388a018; PENG H, 1995, J BIOL CHEM, V270, P25286, DOI 10.1074/jbc.270.42.25286; POMMIER Y, 1991, NUCLEIC ACIDS RES, V19, P5973, DOI 10.1093/nar/19.21.5973; POMMIER Y, 1994, CANCER INVEST, V12, P530, DOI 10.3109/07357909409021413; Pommier Yves, 1997, P153; ROBINSON MJ, 1992, ANTIMICROB AGENTS CH, V36, P751, DOI 10.1128/AAC.36.4.751; ROBINSON MJ, 1991, J BIOL CHEM, V266, P14585; ROBLEDOLUIGGI C, 1991, BIOPOLYMERS, V31, P907, DOI 10.1002/bip.360310710; SARTORIUS J, 1995, FEBS LETT, V374, P387, DOI 10.1016/0014-5793(95)01158-B; TANIZAWA A, 1993, NUCLEIC ACIDS RES, V21, P5157, DOI 10.1093/nar/21.22.5157; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; WASSERMAN RA, 1994, J BIOL CHEM, V269, P20943; WIGLEY DB, 1995, ANNU REV BIOPH BIOM, V24, P185, DOI 10.1146/annurev.bb.24.060195.001153; WILLMOTT CJR, 1993, ANTIMICROB AGENTS CH, V37, P126, DOI 10.1128/AAC.37.1.126; WORLAND ST, 1989, J BIOL CHEM, V264, P4412	48	21	21	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 12	1999	274	11					7292	7301		10.1074/jbc.274.11.7292	http://dx.doi.org/10.1074/jbc.274.11.7292			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	175DV	10066792	hybrid			2022-12-25	WOS:000079078400064
J	Arner, EC; Pratta, MA; Trzaskos, JM; Decicco, CP; Tortorella, MD				Arner, EC; Pratta, MA; Trzaskos, JM; Decicco, CP; Tortorella, MD			Generation and characterization of aggrecanase - A soluble, cartilage-derived aggrecan-degrading activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ARTICULAR-CARTILAGE; NECROSIS-FACTOR-ALPHA; HUMAN SYNOVIAL-FLUID; C-TERMINAL DOMAIN; INTERGLOBULAR DOMAIN; MATRIX METALLOPROTEINASE; TISSUE INHIBITORS; CLEAVAGE SITE; GELATINASE-A; CATABOLISM	A method was developed for generating soluble, active "aggreeanase" in conditioned media from interleukin-1-stimulated bovine nasal cartilage cultures, Using bovine nasal cartilage conditioned media as a source of the aggrecanase enzyme, an enzymatic assay was established employing purified aggrecan monomers as a substrate and monitoring specific aggrecanase-mediated cleavage products by Western analysis using the monoclonal antibody, BC-3 (which recognizes the new N terminus, ARGS, on fragments produced by cleavage between amino acid residues Glu(373 an)d Ala(374)). Using this assay we have characterized cartilage aggrecanase with respect to assay kinetics, pH; and salt optima, heat sensitivity, and stability upon storage. Aggrecanase activity was inhibited by the metalloprotease inhibitor, EDTA, while a panel of inhibitors of serine, cysteine, and aspartic proteinases had no effect, suggesting that aggrecanase is a metalloproteinase, Sensitivity to known matrix metalloproteinase inhibitors as well as to the endogenous tissue inhibitor of metalloproteinases, TIMP-1, further support the notion that aggrecanase is a metalloproteinase potentially related to the ADAM family or MMP family of proteases previously implicated in the catabolism of the extracellular matrix.	DuPont Pharmaceut Co, Inflammatory Dis Res, Expt Stn E400 4239, Wilmington, DE 19880 USA; DuPont Pharmaceut Co, Chem & Phys Sci, Wilmington, DE 19880 USA	DuPont; DuPont	Arner, EC (corresponding author), DuPont Pharmaceut Co, Inflammatory Dis Res, Expt Stn E400 4239, POB 400, Wilmington, DE 19880 USA.							Arner EC, 1997, J BIOL CHEM, V272, P9294; Arner EC, 1998, OSTEOARTHR CARTILAGE, V6, P214, DOI 10.1053/joca.1998.0114; Billington CJ, 1998, BIOCHEM J, V336, P207, DOI 10.1042/bj3360207; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; CAMPION C, 1989, PCTGB8901399; FARNDALE RW, 1982, CONNECT TISSUE RES, V9, P247, DOI 10.3109/03008208209160269; FLANNERY CR, 1992, J BIOL CHEM, V267, P1008; FLANNERY CR, 1993, T ORTHOP RES SOC, V18, P190; FOSANG AJ, 1991, J BIOL CHEM, V266, P15579; FOSANG AJ, 1992, J BIOL CHEM, V267, P19470; Fosang AJ, 1996, J CLIN INVEST, V98, P2292, DOI 10.1172/JCI119040; FOSANG AJ, 1993, BIOCHEM J, V295, P273, DOI 10.1042/bj2950273; Fosang AJ, 1996, FEBS LETT, V380, P17, DOI 10.1016/0014-5793(95)01539-6; HARDINGHAM TE, 1992, ARTICULAR CARTILAGE AND OSTEOARTHRITIS, P5; HARDINGHAM TE, 1972, BIOCHIM BIOPHYS ACTA, V279, P401, DOI 10.1016/0304-4165(72)90160-2; HARDINGHAM TE, 1979, BIOCHEM J, V177, P237, DOI 10.1042/bj1770237; HASCALL VC, 1969, J BIOL CHEM, V244, P2384; HEINEGARD D, 1974, J BIOL CHEM, V249, P4250; HUANG JJ, 1987, MOL BIOL MED, V4, P169; Hughes CE, 1997, J BIOL CHEM, V272, P20269, DOI 10.1074/jbc.272.32.20269; HUGHES CE, 1995, BIOCHEM J, V305, P799, DOI 10.1042/bj3050799; Hughes CE, 1998, J BIOL CHEM, V273, P30576, DOI 10.1074/jbc.273.46.30576; ILIC MZ, 1995, ARCH BIOCHEM BIOPHYS, V322, P22, DOI 10.1006/abbi.1995.1431; ILIC MZ, 1992, ARCH BIOCHEM BIOPHYS, V294, P115, DOI 10.1016/0003-9861(92)90144-L; Lark MW, 1997, J CLIN INVEST, V100, P93, DOI 10.1172/JCI119526; LARK MW, 1995, J BIOL CHEM, V270, P2550, DOI 10.1074/jbc.270.6.2550; LEULAKIS P, 1992, BIOCHEM J, V264, P589; LOHMANDER LS, 1993, ARTHRITIS RHEUM, V36, P1214; Moss ML, 1997, NATURE, V385, P733, DOI 10.1038/385733a0; MURPHY G, 1992, BIOCHEM J, V283, P637, DOI 10.1042/bj2830637; MURPHY G, 1992, J BIOL CHEM, V267, P9612; NGUYEN Q, 1994, BIOCHEMISTRY-US, V33, P2089, DOI 10.1021/bi00174a015; PAULSSON M, 1987, BIOCHEM J, V245, P763, DOI 10.1042/bj2450763; Sandy JD, 1995, ACTA ORTHOP SCAND, V66, P26, DOI 10.3109/17453679509157643; SANDY JD, 1992, J CLIN INVEST, V89, P1512, DOI 10.1172/JCI115742; SANDY JD, 1991, J BIOL CHEM, V266, P8683; SANDY JD, 1991, J BIOL CHEM, V266, P8198; Tortorella MD, 1998, J BIOL CHEM, V273, P5846, DOI 10.1074/jbc.273.10.5846; Tortorella MD, 1997, INFLAMM RES, V46, pS122; TORTORELLA MD, 1996, T ORTHOP RES SOC, V20, P341; TORTORELLA MD, 1996, T ORTHOP RES SOC, V21, P148; Wolfsberg TG, 1996, DEV BIOL, V180, P389, DOI 10.1006/dbio.1996.0313; XUE CB, 1997, Patent No. 9718207	43	117	123	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1999	274	10					6594	6601		10.1074/jbc.274.10.6594	http://dx.doi.org/10.1074/jbc.274.10.6594			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172BQ	10037754	hybrid			2022-12-25	WOS:000078902800076
J	Grainge, I; Sherratt, DJ				Grainge, I; Sherratt, DJ			Xer site-specific recombination - DNA strand rejoining by recombinase XerC	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; FLP RECOMBINASE; IN-VITRO; BACTERIOPHAGE-LAMBDA; HOLLIDAY STRUCTURES; PROTEIN; RESOLUTION; HOMOLOGY; DIF; INTEGRASE	Xer site-specific recombination functions in the stable maintenance of circular replicons in Escherichia coli. Each of two related recombinase proteins, XerC and XerD, cleaves a specific pair of DNA strands, exchanges them, and rejoins them to the partner DNA molecule during a complete recombination reaction. The rejoining activity of recombinase XerC has been analyzed using isolated covalent XerC-DNA complexes resulting from DNA cleavage reactions upon Holliday junction substrates, These covalent protein-DNA complexes are competent in the rejoining reaction, demonstrating that covalently bound XerC can catalyze strand rejoining in the absence of other proteins. This contrasts with a recombinase-mediated cleavage reaction, which requires the presence of both recombinases, the recombinase mediating catalysis at any given time requiring activation by the partner recombinase, In a recombining nucleoprotein complex, both cleavage and rejoining can occur prior to dissociation of the complex.	Univ Oxford, Dept Biochem, Div Mol Genet, Oxford OX1 3QU, England	University of Oxford	Sherratt, DJ (corresponding author), Univ Oxford, Dept Biochem, Div Mol Genet, S Parks Rd, Oxford OX1 3QU, England.	sherratt@bioch.ox.ac.uk	Grainge, Ian RF/A-9031-2010	Grainge, Ian RF/0000-0001-8268-583X				ARCISZEWSKA L, 1995, EMBO J, V14, P2651, DOI 10.1002/j.1460-2075.1995.tb07263.x; ARCISZEWSKA LK, 1995, EMBO J, V14, P2112, DOI 10.1002/j.1460-2075.1995.tb07203.x; Azaro MA, 1997, EMBO J, V16, P3744, DOI 10.1093/emboj/16.12.3744; BLAKELY G, 1993, CELL, V75, P351, DOI 10.1016/0092-8674(93)80076-Q; Blakely GW, 1997, J MOL BIOL, V265, P30, DOI 10.1006/jmbi.1996.0709; BLAKELY GW, 1994, NUCLEIC ACIDS RES, V22, P5613; CHEN JW, 1992, CELL, V69, P647, DOI 10.1016/0092-8674(92)90228-5; Colloms SD, 1997, CELL, V88, P855, DOI 10.1016/S0092-8674(00)81931-5; Colloms SD, 1996, EMBO J, V15, P1172, DOI 10.1002/j.1460-2075.1996.tb00456.x; CORNET F, 1994, J BACTERIOL, V176, P3188, DOI 10.1128/jb.176.11.3188-3195.1994; Cornet F, 1997, J BIOL CHEM, V272, P21927, DOI 10.1074/jbc.272.35.21927; DIXON JE, 1994, J MOL BIOL, V243, P199, DOI 10.1006/jmbi.1994.1647; Esposito D, 1997, NUCLEIC ACIDS RES, V25, P3605, DOI 10.1093/nar/25.18.3605; Gopaul DN, 1998, EMBO J, V17, P4175, DOI 10.1093/emboj/17.14.4175; Guo F, 1997, NATURE, V389, P40, DOI 10.1038/37925; HOESS R, 1987, P NATL ACAD SCI USA, V84, P6840, DOI 10.1073/pnas.84.19.6840; HSU PL, 1984, NATURE, V311, P721, DOI 10.1038/311721a0; JAYARAM M, 1988, P NATL ACAD SCI USA, V85, P7902, DOI 10.1073/pnas.85.21.7902; KITTS PA, 1987, NATURE, V329, P346, DOI 10.1038/329346a0; KITTS PA, 1988, J MOL BIOL, V204, P95, DOI 10.1016/0022-2836(88)90602-X; KUEMPEL PL, 1991, NEW BIOL, V3, P799; LEE J, 1995, J BIOL CHEM, V270, P4042, DOI 10.1074/jbc.270.8.4042; MCCULLOCH R, 1994, EMBO J, V13, P1844, DOI 10.1002/j.1460-2075.1994.tb06453.x; MEYERLEON L, 1990, MOL CELL BIOL, V10, P235, DOI 10.1128/MCB.10.1.235; Nunes-Duby SE, 1998, NUCLEIC ACIDS RES, V26, P391, DOI 10.1093/nar/26.2.391; NUNESDUBY SE, 1987, CELL, V50, P779, DOI 10.1016/0092-8674(87)90336-9; NUNESDUBY SE, 1995, CURR BIOL, V5, P139, DOI 10.1016/S0960-9822(95)00035-2; PAN GH, 1993, MOL CELL BIOL, V13, P3167, DOI 10.1128/MCB.13.6.3167; PAN GH, 1992, J BIOL CHEM, V267, P12397; SHERRATT DJ, 1995, PHILOS T ROY SOC B, V347, P37, DOI 10.1098/rstb.1995.0006; Sherratt DJ, 1998, CELL, V93, P149, DOI 10.1016/S0092-8674(00)81566-4; Subramanya HS, 1997, EMBO J, V16, P5178, DOI 10.1093/emboj/16.17.5178; SUMMERS DK, 1984, CELL, V36, P1097, DOI 10.1016/0092-8674(84)90060-6; SUMMERS DK, 1989, EMBO J, V8, P309, DOI 10.1002/j.1460-2075.1989.tb03378.x; ZHU XD, 1995, J BIOL CHEM, V270, P11646, DOI 10.1074/jbc.270.19.11646	35	7	8	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1999	274	10					6763	6769		10.1074/jbc.274.10.6763	http://dx.doi.org/10.1074/jbc.274.10.6763			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172BQ	10037776	hybrid			2022-12-25	WOS:000078902800098
J	Gutknecht, R; Flukiger, K; Lanz, R; Erni, B				Gutknecht, R; Flukiger, K; Lanz, R; Erni, B			Mechanism of phosphoryl transfer in the dimeric IIAB(Man) subunit of the Escherichia coli mannose transporter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUGAR PHOSPHOTRANSFERASE SYSTEM; MANNITOL TRANSPORT; ENZYME-III; SALMONELLA-TYPHIMURIUM; BACILLUS-SUBTILIS; ANTITERMINATOR PROTEIN; KLEBSIELLA-PNEUMONIAE; GLUCOSE-TRANSPORT; SITE MUTANTS; PHOSPHOENOLPYRUVATE	The mannose transporter of bacterial phosphoenolpyruvate:sugar phosphotransferase system (PTS) mediates uptake of mannose, glucose, and related hexoses by a mechanism that couples translocation with phosphorylation of the substrate. It consists of the transmembrane IICMan IIDMan complex and the cytoplasmic ILAB(Man) subunit. IIAB(Man) has two domains (IIA and IIB) that are linked by a 60-Angstrom long alanine-proline-rich linker. ILAB(Man) transfers phosphoryl groups from the phospho-histidine-containing phospho-carrier protein of the PTS to His-10 on IIA, hence to His-175 on IIB, and finally to the 6'-OH of the transported hexose. IIAB(Man) occurs as a stable homodimer. The subunit contact is mediated by a swap of beta-strands and an extensive contact area between the IIA domains. The H10C and H175C single and the H10C/H175C double mutants were used to characterize the phosphoryl transfer between IIA to IIB. Subunits do not exchange between dimers under physiological conditions, but slow phosphoryl transfer can take place between subunits from different dimers. Heterodimers of different subunits were produced in vitro by GuHCl-induced unfolding and refolding of mixtures of two different homodimers. With respect to wild-type homodimers, the heterodimers have the following activities: wild-type.H10C, 50%; wild-type.H175C 45%; H10C.H175C, 37%; and wild-type.H1OC/H175C (double mutant), 29%. Taken together, this indicates that both cis and trans pathways contribute to the maximal phosphotransferase activity of IIAB(Man). A phosphoryl group on a IIA domain can be transferred either to the IIB domain on the same or on the second subunit in the dimer, and interruption of one of the two pathways results in a reduction of the activity to 70-80% of the control.	Univ Bern, Dept Biochem & Chem, CH-3012 Bern, Switzerland	University of Bern	Erni, B (corresponding author), Univ Bern, Dept Biochem & Chem, Freiestr 3, CH-3012 Bern, Switzerland.	erni@ibc.unibe.ch						BOER H, 1995, BIOCHEMISTRY-US, V34, P3239, DOI 10.1021/bi00010a013; BOER H, 1994, J BIOL CHEM, V269, P17863; Boer H, 1996, BIOCHEMISTRY-US, V35, P12901, DOI 10.1021/bi9611016; Bouma CL, 1996, J BIOL CHEM, V271, P33457, DOI 10.1074/jbc.271.52.33457; CANTOR CR, 1980, BIOPHYSICAL CHEM 2, P557; Chen Q, 1998, BIOCHEMISTRY-US, V37, P8714, DOI 10.1021/bi9731652; DEAN DA, 1990, J BIOL CHEM, V265, P21005; DEBARBOUILLE M, 1991, P NATL ACAD SCI USA, V88, P2212, DOI 10.1073/pnas.88.6.2212; Eberstadt M, 1996, BIOCHEMISTRY-US, V35, P11286, DOI 10.1021/bi960492l; ERNI B, 1985, J BIOL CHEM, V260, P5495; ERNI B, 1992, INT REV CYTOL, V137A, P127; ERNI B, 1989, FEMS MICROBIOL LETT, V63, P13, DOI 10.1016/0168-6445(89)90004-1; ERNI B, 1989, J BIOL CHEM, V264, P18733; ERNI B, 1987, J BIOL CHEM, V262, P5238; FERSHT AR, 1985, ENZYME STRUCTURE MEC, P308; Gutknecht R, 1998, J BIOL CHEM, V273, P12234, DOI 10.1074/jbc.273.20.12234; Huber F, 1996, EUR J BIOCHEM, V239, P810, DOI 10.1111/j.1432-1033.1996.0810u.x; HURLEY JH, 1993, SCIENCE, V259, P673, DOI 10.1126/science.8430315; JIA ZC, 1993, J BIOL CHEM, V268, P22490; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lanz R, 1998, J BIOL CHEM, V273, P12239, DOI 10.1074/jbc.273.20.12239; MAO QC, 1995, J BIOL CHEM, V270, P5258, DOI 10.1074/jbc.270.10.5258; MARKOVICHOUSLEY Z, 1994, BIOCHEMISTRY-US, V33, P10977, DOI 10.1021/bi00202a017; Martin-Verstraete I, 1998, MOL MICROBIOL, V28, P293, DOI 10.1046/j.1365-2958.1998.00781.x; MARTINVERSTRAETE I, 1994, J MOL BIOL, V241, P178, DOI 10.1006/jmbi.1994.1487; MEADOW ND, 1990, ANNU REV BIOCHEM, V59, P497, DOI 10.1146/annurev.biochem.59.1.497; Meijberg W, 1996, BIOCHEMISTRY-US, V35, P2759, DOI 10.1021/bi952567b; Meijberg W, 1998, J BIOL CHEM, V273, P7949, DOI 10.1074/jbc.273.14.7949; MEINS M, 1988, J BIOL CHEM, V263, P12986; Nunn RS, 1996, J MOL BIOL, V259, P502, DOI 10.1006/jmbi.1996.0335; OSUMI T, 1982, P NATL ACAD SCI-BIOL, V79, P1457, DOI 10.1073/pnas.79.5.1457; PERHAM RN, 1991, BIOCHEMISTRY-US, V30, P8501, DOI 10.1021/bi00099a001; PETERKOFSKY A, 1993, PROG NUCLEIC ACID RE, V44, P31, DOI 10.1016/S0079-6603(08)60216-0; PETERKOFSKY A, 1995, BIOCHEMISTRY-US, V34, P8950, DOI 10.1021/bi00028a003; Postma P.W., 1996, ESCHERICHIA COLI SAL, P1149; POSTMA PW, 1993, MICROBIOL REV, V57, P543, DOI 10.1128/MMBR.57.3.543-594.1993; RHIEL E, 1994, BIOL CHEM H-S, V375, P551, DOI 10.1515/bchm3.1994.375.8.551; SAIER MH, 1983, J BACTERIOL, V155, P1351, DOI 10.1128/JB.155.3.1351-1357.1983; Schauder S, 1998, J MOL BIOL, V276, P591, DOI 10.1006/jmbi.1997.1544; SCHNETZ K, 1990, P NATL ACAD SCI USA, V87, P5074, DOI 10.1073/pnas.87.13.5074; Schnetz K, 1996, J BACTERIOL, V178, P1971, DOI 10.1128/jb.178.7.1971-1979.1996; Sliz P, 1997, STRUCTURE, V5, P775, DOI 10.1016/S0969-2126(97)00232-3; STOLZ B, 1993, J BIOL CHEM, V268, P27094; Stulke J, 1998, MOL MICROBIOL, V28, P865, DOI 10.1046/j.1365-2958.1998.00839.x; VANDERVLAG J, 1995, MOL GEN GENET, V248, P236, DOI 10.1007/BF02190806; VANDERVLAG J, 1994, J BACTERIOL, V176, P3518, DOI 10.1128/JB.176.12.3518-3526.1994; vanMontfort RLM, 1997, STRUCTURE, V5, P217, DOI 10.1016/S0969-2126(97)00180-9; VANWEEGHEL RP, 1991, BIOCHEMISTRY-US, V30, P9478, DOI 10.1021/bi00103a013; VANWEEGHEL RP, 1991, BIOCHEMISTRY-US, V30, P1768, DOI 10.1021/bi00221a006; VEYRAT A, 1994, MICROBIOL-UK, V140, P1141, DOI 10.1099/13500872-140-5-1141; VOGLER AP, 1988, MOL GEN GENET, V213, P175, DOI 10.1007/BF00333417; VOGLER AP, 1988, MOL MICROBIOL, V2, P719, DOI 10.1111/j.1365-2958.1988.tb00082.x; WEHMEIER UF, 1994, BBA-PROTEIN STRUCT M, V1208, P348, DOI 10.1016/0167-4838(94)90124-4; WOOTTON JC, 1989, PROTEIN ENG, V2, P535, DOI 10.1093/protein/2.7.535	54	17	17	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	1999	274	10					6091	6096		10.1074/jbc.274.10.6091	http://dx.doi.org/10.1074/jbc.274.10.6091			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172BQ	10037691	hybrid			2022-12-25	WOS:000078902800013
J	Masuko, N; Makino, K; Kuwahara, H; Fukunaga, K; Sudo, T; Araki, N; Yamamoto, H; Yamada, Y; Miyamoto, E; Saya, H				Masuko, N; Makino, K; Kuwahara, H; Fukunaga, K; Sudo, T; Araki, N; Yamamoto, H; Yamada, Y; Miyamoto, E; Saya, H			Interaction of NE-dlg/SAP102, a neuronal and endocrine tissue-specific membrane-associated guanylate kinase protein, with calmodulin and PSD-95/SAP90 - A possible regulatory role in molecular clustering at synaptic sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POSTSYNAPTIC DENSITY PROTEIN; TUMOR-SUPPRESSOR PROTEIN; NMDA RECEPTOR; BINDING DOMAIN; PDZ DOMAINS; FAMILY; IDENTIFICATION; RECOGNITION; SUBSTRATE; HOMOLOG	NE-dlg/SAP102, a neuronal and endocrine tissue-specific membrane-associated guanylate kinase family protein, is known to bind to C-terminal ends of N-methyl-D-aspartate receptor 2B (NR2B) through its PDZ (PSD-95/Dlg/ZO-1) domains. NE-dlg/SAP102 and NR2B colocalize at synaptic sites in cultured rat hippocampal neurons, and their expressions increase in parallel with the onset of synaptogenesis, me have identified that NE-dlg/SAP102 interacts with calmodulin in a Ca2+-dependent manner. The binding site for calmodulin has been determined to he at the putative basic cr-helix region located around the src homology 3 (SH3) domain of NE-dlg/SAP102. Using a surface plasmon resonance measurement system, we detected specific binding of recombinant NE-dlg/SAP102 to the immobilized calmodulin with a K-d value of 44 nM. However, the binding of Ca2+/calmodulin to NE-dlg/SAP102 did not modulate the interaction between PDZ domains of NE-dlg/SAP102 and the C-terminal end of rat NR2B. We have also identified that the region near the calmodulin binding site of NE-dlg/SAP102 interacts with the GUK-like domain of PSD-95/SAP90 by two-hybrid screening. Pull down assay revealed that NE-dlg/SAP102 can interact with PSD-95/SAP90 in the presence of both Ca2+ and calmodulin. These findings suggest that the Ca2+/calmodulin modulates interaction of neuronal membrane-associated guanylate kinase proteins and regulates clustering of neurotransmitter receptors at central synapses.	Kumamoto Univ, Sch Med, Dept Tumor Genet & Biol, Kumamoto 8600811, Japan; Kumamoto Univ, Sch Med, Dept Pharmacol, Kumamoto 8600811, Japan; Taisho Pharmaceut Co Ltd, Hanno Res Ctr, Canc Res Lab, Hanno, Saitama 3578527, Japan	Kumamoto University; Kumamoto University; Taisho Pharmaceutical Holdings Co Ltd	Saya, H (corresponding author), Kumamoto Univ, Sch Med, Dept Tumor Genet & Biol, 2-2-1 Honjo, Kumamoto 8600811, Japan.	hsaya@gpo.kumamoto-u.ac.jp	Saya, Hideyuki/J-4325-2013					ALEXANDROPOULOS K, 1995, P NATL ACAD SCI USA, V92, P3110, DOI 10.1073/pnas.92.8.3110; BABU YS, 1985, NATURE, V315, P37, DOI 10.1038/315037a0; Baird DH, 1996, J NEUROSCI, V16, P2642; BASARSKY TA, 1994, J NEUROSCI, V14, P6402; BECKER DM, 1991, METHOD ENZYMOL, V194, P182; Brenman JE, 1996, CELL, V84, P757, DOI 10.1016/S0092-8674(00)81053-3; Cabral JHM, 1996, NATURE, V382, P649, DOI 10.1038/382649a0; CARLIN RK, 1981, J CELL BIOL, V89, P449, DOI 10.1083/jcb.89.3.449; CHO KO, 1992, NEURON, V9, P929, DOI 10.1016/0896-6273(92)90245-9; Constantine-Paton M, 1998, CURR OPIN NEUROBIOL, V8, P139, DOI 10.1016/S0959-4388(98)80017-2; Doyle DA, 1996, CELL, V85, P1067, DOI 10.1016/S0092-8674(00)81307-0; Ehlers MD, 1996, CELL, V84, P745, DOI 10.1016/S0092-8674(00)81052-1; FEILOTTER HE, 1994, NUCLEIC ACIDS RES, V22, P1502, DOI 10.1093/nar/22.8.1502; FUKUNAGA K, 1992, J BIOL CHEM, V267, P22527; Gomperts SN, 1996, CELL, V84, P659, DOI 10.1016/S0092-8674(00)81043-0; GOPALAKRISHNA R, 1982, BIOCHEM BIOPH RES CO, V104, P830, DOI 10.1016/0006-291X(82)90712-4; KELLY GM, 1991, J BIOL CHEM, V266, P12469; KELLY PT, 1978, J CELL BIOL, V79, P173, DOI 10.1083/jcb.79.1.173; KENNEDY MB, 1983, P NATL ACAD SCI-BIOL, V80, P7357, DOI 10.1073/pnas.80.23.7357; Kim E, 1997, J CELL BIOL, V136, P669, DOI 10.1083/jcb.136.3.669; Kim E, 1996, NEURON, V17, P103, DOI 10.1016/S0896-6273(00)80284-6; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; LAHEY T, 1994, NEURON, V13, P823, DOI 10.1016/0896-6273(94)90249-6; Lin SY, 1998, J NEUROSCI, V18, P3725; Makino K, 1997, ONCOGENE, V14, P2425, DOI 10.1038/sj.onc.1201087; Muller BM, 1996, NEURON, V17, P255, DOI 10.1016/S0896-6273(00)80157-9; OROURKE NA, 1994, NEURON, V12, P921, DOI 10.1016/0896-6273(94)90343-3; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; REXACH M, 1995, CELL, V83, P683, DOI 10.1016/0092-8674(95)90181-7; Rhoads AR, 1997, FASEB J, V11, P331, DOI 10.1096/fasebj.11.5.9141499; Satoh K, 1997, GENES CELLS, V2, P415, DOI 10.1046/j.1365-2443.1997.1310329.x; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; STEHLE T, 1992, J MOL BIOL, V224, P1127, DOI 10.1016/0022-2836(92)90474-X; TAKESHIMA H, 1994, ONCOGENE, V9, P2135; Takeuchi M, 1997, J BIOL CHEM, V272, P11943, DOI 10.1074/jbc.272.18.11943; WALSH MJ, 1992, J NEUROCHEM, V59, P667, DOI 10.1111/j.1471-4159.1992.tb09421.x; WENG ZG, 1994, MOL CELL BIOL, V14, P4509, DOI 10.1128/MCB.14.7.4509; WENG ZG, 1995, MOL CELL BIOL, V15, P5627; WOODS DF, 1993, MECH DEVELOP, V44, P85, DOI 10.1016/0925-4773(93)90059-7; Wyszynski M, 1997, NATURE, V385, P439, DOI 10.1038/385439a0	40	77	79	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 26	1999	274	9					5782	5790		10.1074/jbc.274.9.5782	http://dx.doi.org/10.1074/jbc.274.9.5782			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	170KG	10026200	hybrid			2022-12-25	WOS:000078804400071
J	Yan, D; Schulte, MK; Bloom, KE; White, MM				Yan, D; Schulte, MK; Bloom, KE; White, MM			Structural features of the ligand-binding domain of the serotonin 5HT(3) receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NICOTINIC ACETYLCHOLINE-RECEPTOR; N1E-115 NEUROBLASTOMA-CELLS; GATED ION-CHANNEL; FUNCTIONAL EXPRESSION; SEQUENCE; SUBUNIT; SITES	The nicotinic acetylcholine receptor (AChR) and the serotonin type 3 receptor (5HT(3)R) are members of the Ligand-gated ion channel gene family, Both receptors are inhibited by nanomolar concentrations of d-tubocurarine (curare) in a competitive fashion. Chemical labeling studies on the AChR have identified tryptophan residues on the gamma (gamma Trp-55) and delta (delta Trp-57) subunits that interact with curare, Comparison of the sequences of these two subunits with the 5HT(3)R shows that a tryptophan residue is found in the homologous position in the 5HT(3)R (Trp-89), suggesting that this residue may be involved in curare-5HT(3)R interactions. Site-directed mutagenesis at position Trp-89 markedly reduces the affinity of the 5HT(3)R for the antagonists curare and granisetron but has little effect on the affinity for the agonist serotonin, To further examine the role of this region of the receptor in ligand-receptor interactions, alanine-scanning mutagenesis analysis of the region centered on Trp-89 (Thr-85 to Trp-94) was carried out, and the ligand binding properties of the mutant receptors were determined. Within this region of the receptor, curare affinity is reduced by substitution only at Trp-89, whereas serotonin affinity is reduced only by substitution at Arg-91, On the other hand, granisetron affinity is reduced by substitutions at Trp-89, Arg-91, and Tyr-93, This differential effect of substitutions on ligand affinity suggests that different ligands may have different points of interaction within the ligand-binding pocket. In addition, the every-other-residue periodicity of the effects on granisetron affinity strongly suggests that this region of the ligand-binding site of the 5HT(3)R (and by inference, other members of the ligand-gated ion channel family) is in a beta-strand conformation.	Med Coll Penn & Hahnemann Univ, Dept Pharmacol, Philadelphia, PA 19129 USA; Med Coll Penn & Hahnemann Univ, Dept Physiol, Philadelphia, PA 19129 USA	Drexel University; Drexel University	White, MM (corresponding author), Med Coll Penn & Hahnemann Univ, Dept Pharmacol, 3300 Henry Ave, Philadelphia, PA 19129 USA.			Schulte, Marvin/0000-0002-8141-041X	NINDS NIH HHS [T32 NS09618, R01 NS23885] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS023885] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BLOUNT P, 1989, NEURON, V3, P349, DOI 10.1016/0896-6273(89)90259-6; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; Chiara DC, 1998, FEBS LETT, V423, P223, DOI 10.1016/S0014-5793(98)00093-3; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; CUNNINGHAM BC, 1989, SCIENCE, V244, P1081, DOI 10.1126/science.2471267; DEVILLERSTHIERY A, 1993, J MEMBRANE BIOL, V136, P97, DOI 10.1007/BF02505755; EISELE JL, 1993, NATURE, V366, P479, DOI 10.1038/366479a0; GAMIER J, 1978, J MOL BIOL, V120, P97; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HOPE AG, 1993, EUR J PHARM-MOLEC PH, V245, P187, DOI 10.1016/0922-4106(93)90128-V; Karlin A, 1993, Curr Opin Neurobiol, V3, P299, DOI 10.1016/0959-4388(93)90121-E; Karlin A, 1995, NEURON, V15, P1231, DOI 10.1016/0896-6273(95)90004-7; LUMMIS SCR, 1993, EUR J PHARMACOL, V243, P7, DOI 10.1016/0014-2999(93)90160-J; MARICQ AV, 1991, SCIENCE, V254, P432, DOI 10.1126/science.1718042; MIQUEL MC, 1991, BIOCHEM PHARMACOL, V42, P1453, DOI 10.1016/0006-2952(91)90459-I; OELARY ME, 1994, AM J PHYSIOL, V266, pC648; OLEARY ME, 1992, J BIOL CHEM, V267, P8360; ORTELLS MO, 1995, TRENDS NEUROSCI, V18, P121, DOI 10.1016/0166-2236(95)93887-4; PEDERSEN SE, 1990, P NATL ACAD SCI USA, V87, P2785, DOI 10.1073/pnas.87.7.2785; PETERS JA, 1990, NEUROSCI LETT, V110, P107, DOI 10.1016/0304-3940(90)90796-C; Tsigelny I, 1997, BIOPHYS J, V73, P52, DOI 10.1016/S0006-3495(97)78047-0; UNWIN N, 1993, NEURON S, V10, P31; Yan D, 1998, NEUROPHARMACOLOGY, V37, P251, DOI 10.1016/S0028-3908(98)00010-0	23	72	72	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 26	1999	274	9					5537	5541		10.1074/jbc.274.9.5537	http://dx.doi.org/10.1074/jbc.274.9.5537			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	170KG	10026168	hybrid			2022-12-25	WOS:000078804400039
J	Ritchie, A; Braun, SE; He, J; Broxmeyer, HE				Ritchie, A; Braun, SE; He, J; Broxmeyer, HE			Thrombopoietin-induced conformational change in p53 lies downstream of the p44/p42 mitogen activated protein kinase cascade in the human growth factor-dependent cell line M07e	ONCOGENE			English	Article						MAPK; p53 conformation; thrombopoietin; apoptosis; M07e	WILD-TYPE P53; FACTOR RECEPTOR SUPERFAMILY; TUMOR-SUPPRESSOR PROTEIN; MPL CYTOPLASMIC DOMAIN; C-KIT LIGAND; TYROSINE-PHOSPHORYLATION; HEMATOPOIETIC-CELLS; MEGAKARYOCYTIC DIFFERENTIATION; SHC PHOSPHORYLATION; SIGNALING MOLECULES	Thrombopoietin is a cytokine with potent megakaryocytopoietic and thrombopoietic activities in who. Wild-type p53 is a conformationally flexible, anti-oncogenic transcription factor that plays a principal role in mediating growth factor withdrawal-induced apoptosis in factor-dependent hematopoietic cells. We recently reported that Tpo induces a conformational change in and functional inactivation of p53, coincident with its anti-apoptotic effects, in the human factor-dependent cell line M07e. In an effort to identify potential signaling cascades through which Tpo illicits these effects on p53, we report here that treating M07e cells with MAPK kinase inhibitor PD98059 dramatically suppressed Tpo-induced conformational change in p53 as well as Tpo-enhanced viability in M07e cells in a p53-dependent manner. Furthermore, the expression of constitutively active Raf1 in M07e cells induced conformational change in p53 independent of Tpo stimulation. Inhibition of the JAK/STAT pathway revealed that JAK/STAT signaling plays an insignificant role in conformational modulation of p53 and apoptosis suppression. Inhibition of phosphatidylinositol-3 kinase did not have a significant effect on p53 conformation but did have a weak but significant effect on Tpo-enhanced viability. Cytokine-induced activation of the MAPK pathway and the subsequent functional neutralization of p53, may be an event by which apoptosis is commonly suppressed in hematopoiesis.	Indiana Univ, Sch Med, Dept Microbiol Immunol, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Dept Med Hematol Oncol, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Walther Oncol Ctr, Indianapolis, IN 46202 USA; Walther Canc Inst, Indianapolis, IN 46208 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute; Walther Cancer Institute	Broxmeyer, HE (corresponding author), Indiana Univ, Sch Med, Dept Microbiol Immunol, Indianapolis, IN 46202 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054037, R01HL056416] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053674] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL 54037, R01 HL 56416] Funding Source: Medline; NIDDK NIH HHS [R01 DK 53674] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABRAHAMSON JLA, 1995, MOL CELL BIOL, V15, P6953; Alexander WS, 1996, EMBO J, V15, P6531, DOI 10.1002/j.1460-2075.1996.tb01044.x; AVANZI GC, 1988, BRIT J HAEMATOL, V69, P359, DOI 10.1111/j.1365-2141.1988.tb02374.x; BACON CM, 1995, FEBS LETT, V370, P63, DOI 10.1016/0014-5793(95)00796-C; BI S, 1993, LEUKEMIA, V7, P1840; BLANDINO G, 1995, ONCOGENE, V10, P731; Brizzi MF, 1996, ONCOGENE, V13, P2067; BROUDY VC, 1995, BLOOD, V85, P1719, DOI 10.1182/blood.V85.7.1719.bloodjournal8571719; CarverMoore K, 1996, BLOOD, V88, P803; Chung JK, 1997, MOL CELL BIOL, V17, P6508, DOI 10.1128/MCB.17.11.6508; CohenSolal K, 1997, THROMB HAEMOSTASIS, V78, P37; Diaz B, 1997, MOL CELL BIOL, V17, P4509, DOI 10.1128/MCB.17.8.4509; Dorsch M, 1997, J EXP MED, V186, P1947, DOI 10.1084/jem.186.12.1947; Drachman JG, 1997, P NATL ACAD SCI USA, V94, P2350, DOI 10.1073/pnas.94.6.2350; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Fukada T, 1996, IMMUNITY, V5, P449, DOI 10.1016/S1074-7613(00)80501-4; Gotoh A, 1997, ANN HEMATOL, V75, P207, DOI 10.1007/s002770050344; GURNEY AL, 1995, P NATL ACAD SCI USA, V92, P5292, DOI 10.1073/pnas.92.12.5292; HAINAUT P, 1993, CANCER RES, V53, P1739; HAINAUT P, 1993, CANCER RES, V53, P4469; HARLOW E, 1985, MOL CELL BIOL, V5, P1601, DOI 10.1128/MCB.5.7.1601; HENDRIE PC, 1991, EXP HEMATOL, V19, P1031; KAUSHANSKY K, 1995, P NATL ACAD SCI USA, V92, P3234, DOI 10.1073/pnas.92.8.3234; Kinoshita T, 1997, ONCOGENE, V15, P619, DOI 10.1038/sj.onc.1201234; Melemed AS, 1997, BLOOD, V90, P3462, DOI 10.1182/blood.V90.9.3462; Meydan N, 1996, NATURE, V379, P645, DOI 10.1038/379645a0; MILLER AD, 1986, MOL CELL BIOL, V6, P2895, DOI 10.1128/MCB.6.8.2895; MILNE DM, 1994, J BIOL CHEM, V269, P9253; MILNER J, 1991, P ROY SOC B-BIOL SCI, V245, P139, DOI 10.1098/rspb.1991.0100; MILNER J, 1990, ONCOGENE, V5, P1683; MIYASHITA T, 1995, CELL, V80, P293; MIYAZAWA K, 1991, EXP HEMATOL, V19, P1110; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Morita H, 1996, FEBS LETT, V395, P228, DOI 10.1016/0014-5793(96)01047-2; MURAKAMI M, 1991, P NATL ACAD SCI USA, V88, P11349, DOI 10.1073/pnas.88.24.11349; Nagata Y, 1995, FEBS LETT, V377, P497, DOI 10.1016/0014-5793(95)01386-5; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; Parrizas M, 1997, J BIOL CHEM, V272, P154; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; PICKSLEY SM, 1992, ONCOGENE, V7, P1649; Porteu F, 1996, MOL CELL BIOL, V16, P2473; RAINWATER R, 1995, MOL CELL BIOL, V15, P3892; Ramsfjell V, 1997, J IMMUNOL, V158, P5169; Reid S, 1996, J IMMUNOL METHODS, V192, P43, DOI 10.1016/0022-1759(96)00004-X; Ritchie A, 1997, BLOOD, V90, P4394; Ritchie A, 1996, STEM CELLS, V14, P330, DOI 10.1002/stem.140330; Rouyez MC, 1997, MOL CELL BIOL, V17, P4991, DOI 10.1128/MCB.17.9.4991; SASAKI K, 1995, BIOCHEM BIOPH RES CO, V216, P338, DOI 10.1006/bbrc.1995.2629; Sattler M, 1997, J CELL PHYSIOL, V171, P28; Sitnicka E, 1996, BLOOD, V87, P4998, DOI 10.1182/blood.V87.12.4998.bloodjournal87124998; SKODA RC, 1993, EMBO J, V12, P2645, DOI 10.1002/j.1460-2075.1993.tb05925.x; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; Takahira H, 1997, BLOOD, V89, P1574, DOI 10.1182/blood.V89.5.1574.1574_1574_1584; TAUCHI T, 1994, J BIOL CHEM, V269, P25206; TORTOLANI PJ, 1995, BLOOD, V85, P3444, DOI 10.1182/blood.V85.12.3444.bloodjournal85123444; VIGON I, 1992, P NATL ACAD SCI USA, V89, P5640, DOI 10.1073/pnas.89.12.5640; WELHAM MJ, 1992, J IMMUNOL, V149, P1683; WILLIAMS GT, 1990, NATURE, V343, P76, DOI 10.1038/343076a0; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; YAMADA M, 1995, BIOCHEM BIOPH RES CO, V217, P230, DOI 10.1006/bbrc.1995.2768; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; Zauli G, 1997, BLOOD, V89, P883, DOI 10.1182/blood.V89.3.883; ZERRAHN J, 1992, ONCOGENE, V7, P1371; ZHANG W, 1992, ONCOGENE, V7, P1645; ZHANG W, 1994, LEUKEMIA LYMPHOMA, V14, P251, DOI 10.3109/10428199409049675; ZHU YM, 1994, BRIT J CANCER, V69, P468, DOI 10.1038/bjc.1994.85	70	20	20	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 18	1999	18	7					1465	1477		10.1038/sj.onc.1202439	http://dx.doi.org/10.1038/sj.onc.1202439			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	167UK	10050883				2022-12-25	WOS:000078651600008
J	Ghorbel, MT; Seugnet, I; Hadj-Sahraoui, N; Topilko, P; Levi, G; Demeneix, B				Ghorbel, MT; Seugnet, I; Hadj-Sahraoui, N; Topilko, P; Levi, G; Demeneix, B			Thyroid hormone effects on Krox-24 transcription in the post-natal mouse brain are developmentally regulated but are not correlated with mitosis	ONCOGENE			English	Article						non viral gene transfer; polyethylenimine; thyroid hormone; Krox-24; mouse; central nervous system	A GENE-EXPRESSION; NGFI-A; GROWTH-FACTORS; RAT-BRAIN; IN-VIVO; DIFFERENTIATION; RECEPTOR; CELLS; POLYETHYLENIMINE; PROLIFERATION	Krox-24 (NGFI-A, Egr-1) is an immediate-early gene encoding a zinc finger transcription factor. As Krox-24 is expressed in brain areas showing post-natal neurogenesis during a thyroid hormone (T-3)-sensitive period, we followed T-3 effects on Krox-24 expression in newborn mice. We analysed whether regulation was associated,vith changes in mitotic activity in the subventricular zone and the cerebellum, In vivo T-3-dependent Krox-24 transcription was studied by polyethylenimine-based gene transfer. T-3 increased transcription from the Krox-24 promoter in both areas studied at post-natal day 2, but was without effect at day 6, An intact thyroid hormone response element (TRE) in the Krox-24 promoter was necessary for these inductions. These stage-dependent effects were also seen in endogenous Krox-24 mRNA levels: activation at day 2 and no effect at day 6, Moreover, similar results were obtained by examining beta-galactosidase expression in heterozygous mice in which one allele of the Krox-24 gene was disrupted with an in-frame Lac-Z insertion. However, bromodeoxyuridine incorporation showed mitosis to continue through to day 6. We conclude first, that T-3 activates Krox-24 transcription during early post-natal mitosis but that this effect is extinguished as development proceeds and second, loss of T-3-dependent Krox-24 expression is not correlated with loss of mitotic activity.	Museum Natl Hist Nat, Lab Physiol Gen & Comparee, CNRS, URA 90, F-75231 Paris 5, France; Ecole Normale Super, INSERM, U368, F-75230 Paris, France; IST, CBA, Mol Biol Lab, Genoa, Italy	Centre National de la Recherche Scientifique (CNRS); Museum National d'Histoire Naturelle (MNHN); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; Ecole Normale Superieure (ENS)	Demeneix, B (corresponding author), Museum Natl Hist Nat, Lab Physiol Gen & Comparee, CNRS, URA 90, F-75231 Paris 5, France.		Levi, Giovanni/B-4416-2013	Levi, Giovanni/0000-0002-7041-6787				Abdallah B, 1996, HUM GENE THER, V7, P1947, DOI 10.1089/hum.1996.7.16-1947; Ausubel FM, 1994, CURRENT PROTOCOLS MO; BOUSSIF O, 1995, P NATL ACAD SCI USA, V92, P7297, DOI 10.1073/pnas.92.16.7297; BRADLEY DJ, 1992, J NEUROSCI, V12, P2288; CHRISTY B, 1989, P NATL ACAD SCI USA, V86, P8737, DOI 10.1073/pnas.86.22.8737; DEMENEIX BA, 1978, GEN COMP ENDOCR, V35, P77, DOI 10.1016/0016-6480(78)90170-3; FORREST D, 1994, SEMIN CANCER BIOL, V5, P167; GASHLER A, 1995, PROG NUCLEIC ACID RE, V50, P191, DOI 10.1016/S0079-6603(08)60815-6; Ghorbel M, 1997, NEUROSCI LETT, V231, P127, DOI 10.1016/S0304-3940(97)00541-7; GIUS D, 1990, MOL CELL BIOL, V10, P4243, DOI 10.1128/MCB.10.8.4243; GLASS CK, 1989, CELL, V59, P697, DOI 10.1016/0092-8674(89)90016-0; GLASS CK, 1994, ENDOCR REV, V15, P391, DOI 10.1210/er.15.3.391; GUISSOUMA H, IN PRESS FASEB J; KOENIG RJ, 1989, NATURE, V337, P659, DOI 10.1038/337659a0; Lebel JM, 1994, CURR OPIN ENDOCRINOL, V1, P167; Lee SL, 1996, MOL CELL BIOL, V16, P4566; LEE SL, 1995, J BIOL CHEM, V270, P9971, DOI 10.1074/jbc.270.17.9971; LEMAIRE P, 1988, P NATL ACAD SCI USA, V85, P4691, DOI 10.1073/pnas.85.13.4691; LEZOUALCH F, 1992, MOL ENDOCRINOL, V6, P1797, DOI 10.1210/me.6.11.1797; LUSKIN MB, 1993, NEURON, V11, P173, DOI 10.1016/0896-6273(93)90281-U; MELLSTROM B, 1994, ENDOCRINOLOGY, V135, P583, DOI 10.1210/en.135.2.583; MILBRANDT J, 1987, SCIENCE, V238, P797, DOI 10.1126/science.3672127; MORRIS CHT, 1988, NUCLEIC ACIDS RES, V16, P8835, DOI 10.1093/nar/16.18.8835; NICHOLSO.JL, 1972, BRAIN RES, V44, P13, DOI 10.1016/0006-8993(72)90362-9; PIPAON C, 1992, J BIOL CHEM, V267, P21, DOI 10.1016/S0021-9258(18)48449-9; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; ROHRER H, 1990, EUR J NEUROSCI, V2, P1005, DOI 10.1111/j.1460-9568.1990.tb00013.x; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; SUKHATME VP, 1987, ONCOGENE RES, V1, P343; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; Topilko P, 1998, MOL ENDOCRINOL, V12, P107, DOI 10.1210/mend.12.1.0049; Wolffe AP, 1997, NATURE, V387, P16, DOI 10.1038/387016a0; ZHU N, 1993, SCIENCE, V261, P209, DOI 10.1126/science.7687073	33	21	22	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 28	1999	18	4					917	924		10.1038/sj.onc.1202378	http://dx.doi.org/10.1038/sj.onc.1202378			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	165FT	10023667	Bronze			2022-12-25	WOS:000078510600008
J	Perez, M; Haschke, B; Donato, NJ				Perez, M; Haschke, B; Donato, NJ			Differential expression and translocation of protein tyrosine phosphatase 1B-related proteins in ME-180 tumor cells expressing apoptotic sensitivity and resistance to tumor necrosis factor: potential interaction with epidermal growth factor receptor	ONCOGENE			English	Article						apoptosis; protein tyrosine; phosphate; TNF	FAS-MEDIATED APOPTOSIS; MANGANOUS SUPEROXIDE-DISMUTASE; RADIATION-INDUCED APOPTOSIS; KAPPA-B ACTIVATION; CARCINOMA-CELLS; FACTOR-ALPHA; TRANSCRIPTION FACTOR; CELLULAR-RESISTANCE; SIGNAL-TRANSDUCTION; GAMMA-RADIATION	Tumor necrosis factor (TNF)-induced apoptosis can be inhibited by overexpression of specific tyrosine kinases or activation of tyrosine kinase cascades, suggesting potential antagonism between apoptotic and tyrosine kinase signaling processes. In this report, the effects of TNF on EGF receptor tyrosine phosphorylation in ME-180 cell variants selected for apoptotic sensitivity (Sen) or resistance (Res) to TNF, previously shown to differentially express EGFr, were examined, Prior to the onset of apoptosis, TNF caused a significant reduction in the level of EGFr tyrosine phosphorylation in Sen cells but mediated only limited suppression of EGFr tyrosine phosphorylation in apoptotically resistant Res cells, In vitro incubation of cellular membranes with TNF derived from Sen cells stimulated a resident protein tyrosine phosphatase (PTP) activity which was able to dephosphorylate EGFr or tyrosine phosphopeptides mimicking an EGFr autophosphorylation site, In membrane preparations, PTP1B complexed with tyrosine phosphorylated EGFr and this association was disrupted by TNF through an apparent stimulation of PTP activity and turnover of phosphotyrosine, Intrinsic enzymatic activity of PTP1B was 2-3-fold higher in Sen versus Res cell lysates and a family of PTP1B-related proteins with altered C-termini was found to be highly expressed in Sen cells but absent or expressed at reduced levels in Res cells, Cytoplasmic extracts of Sen cells contained PTP1B-like proteins and TNF incubation resulted in the time dependent accumulation of PTP1B-like proteins in Sen cells but did not effect these proteins in Res cells, Together, these results suggest that specific changes in expression and subcellular distribution of phosphotyrosine modulatory proteins may play a role in conveying intrinsic apoptotic sensitivity to TNF in some tumor cell types.	Univ Texas, MD Anderson Canc Ctr, Dept Bioimmunotherapy & Drug Carriers, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Donato, NJ (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Bioimmunotherapy & Drug Carriers, Box 44,1515 Holcombe Blvd, Houston, TX 77030 USA.				NATIONAL CANCER INSTITUTE [R01CA073018, R29CA048906, R01CA048906] Funding Source: NIH RePORTER; NCI NIH HHS [CA48906, CA73018] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AGGARWAL BB, 1994, FEBS LETT, V345, P219, DOI 10.1016/0014-5793(94)00441-2; Atherton E., 1990, SOLID PHASE PEPTIDE; Bandyopadhyay D, 1997, J BIOL CHEM, V272, P1639, DOI 10.1074/jbc.272.3.1639; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Byon JCH, 1997, P SOC EXP BIOL MED, V216, P1; CARSON DA, 1993, LANCET, V341, P1251, DOI 10.1016/0140-6736(93)91154-E; CHANG DJ, 1992, BIOCHEM BIOPH RES CO, V188, P538, DOI 10.1016/0006-291X(92)91089-9; Chen YR, 1996, J BIOL CHEM, V271, P31929, DOI 10.1074/jbc.271.50.31929; Chen YR, 1996, J BIOL CHEM, V271, P631, DOI 10.1074/jbc.271.2.631; CLEVELAND JL, 1995, CELL, V81, P479, DOI 10.1016/0092-8674(95)90068-3; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; DONATO NJ, 1992, CELL GROWTH DIFFER, V3, P259; DONATO NJ, 1993, CELL GROWTH DIFFER, V4, P411; Donato NJ, 1998, J BIOL CHEM, V273, P5067, DOI 10.1074/jbc.273.9.5067; DOWD DR, 1995, ADV SEC MESS PHOSPH, V30, P255; Dubrez L, 1996, EMBO J, V15, P5504, DOI 10.1002/j.1460-2075.1996.tb00935.x; EASTMAN A, 1995, SEMIN CANCER BIOL, V6, P45, DOI 10.1006/scbi.1995.0006; EISCHEN CM, 1994, J IMMUNOL, V153, P1947; Enari M, 1996, NATURE, V380, P723, DOI 10.1038/380723a0; Flint AJ, 1997, P NATL ACAD SCI USA, V94, P1680, DOI 10.1073/pnas.94.5.1680; FLINT AJ, 1993, EMBO J, V12, P1937, DOI 10.1002/j.1460-2075.1993.tb05843.x; FRANGIONI JV, 1992, CELL, V68, P545, DOI 10.1016/0092-8674(92)90190-N; FRANGIONI JV, 1993, EMBO J, V12, P4843, DOI 10.1002/j.1460-2075.1993.tb06174.x; Fraser A, 1996, CELL, V85, P781, DOI 10.1016/S0092-8674(00)81005-3; FREEMAN BA, 1982, LAB INVEST, V47, P412; GAGLIARDINI V, 1994, SCIENCE, V263, P826, DOI 10.1126/science.8303301; GarciaLloret MI, 1996, J CELL PHYSIOL, V167, P324, DOI 10.1002/(SICI)1097-4652(199605)167:2<324::AID-JCP17>3.0.CO;2-7; Gardner AM, 1996, J BIOL CHEM, V271, P14560, DOI 10.1074/jbc.271.24.14560; GOOSSENS V, 1995, P NATL ACAD SCI USA, V92, P8115, DOI 10.1073/pnas.92.18.8115; Henkart PA, 1996, IMMUNITY, V4, P195, DOI 10.1016/S1074-7613(00)80428-8; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; HUDZIAK RM, 1988, P NATL ACAD SCI USA, V85, P5102, DOI 10.1073/pnas.85.14.5102; JAATTELA M, 1995, ONCOGENE, V10, P2297; Kenner KA, 1996, J BIOL CHEM, V271, P19810, DOI 10.1074/jbc.271.33.19810; KORSMEYER SJ, 1995, TRENDS GENET, V11, P101, DOI 10.1016/S0168-9525(00)89010-1; Krippner A, 1996, J BIOL CHEM, V271, P21629, DOI 10.1074/jbc.271.35.21629; LAMMERS R, 1993, J BIOL CHEM, V268, P22456; Liles WC, 1996, J EXP MED, V184, P429, DOI 10.1084/jem.184.2.429; Liu F, 1997, BIOCHEM J, V327, P139, DOI 10.1042/bj3270139; Liu F, 1996, J BIOL CHEM, V271, P31290, DOI 10.1074/jbc.271.49.31290; Liu F, 1998, MOL CELL BIOL, V18, P250, DOI 10.1128/MCB.18.1.250; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Lumelsky NL, 1996, CANCER RES, V56, P3909; MAEGAWA H, 1995, J BIOL CHEM, V270, P7724, DOI 10.1074/jbc.270.13.7724; MERLO GR, 1995, J CELL BIOL, V128, P1185, DOI 10.1083/jcb.128.6.1185; MIGITA K, 1995, IMMUNOLOGY, V85, P550; MILARSKI KL, 1993, J BIOL CHEM, V268, P23634; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; NICOTERA P, 1992, ANNU REV PHARMACOL, V32, P449, DOI 10.1146/annurev.pa.32.040192.002313; NISHIKAWA K, 1994, LYMPHOKINE CYTOK RES, V13, P37; Perez M, 1996, J INTERF CYTOK RES, V16, P307, DOI 10.1089/jir.1996.16.307; Rock MT, 1997, J BIOL CHEM, V272, P33377, DOI 10.1074/jbc.272.52.33377; Santana P, 1996, CELL, V86, P189, DOI 10.1016/S0092-8674(00)80091-4; SCHIEVEN GL, 1995, J BIOL CHEM, V270, P20824, DOI 10.1074/jbc.270.35.20824; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SHEPARD HM, 1988, J CLIN IMMUNOL, V8, P333, DOI 10.1007/BF00917148; Shifrin VI, 1997, J BIOL CHEM, V272, P2957, DOI 10.1074/jbc.272.5.2957; Stefanis L, 1996, J BIOL CHEM, V271, P30663, DOI 10.1074/jbc.271.48.30663; SU X, 1995, IMMUNITY, V2, P353, DOI 10.1016/1074-7613(95)90143-4; SUGARMAN BJ, 1987, CANCER RES, V47, P781; TEWARI M, 1995, J BIOL CHEM, V270, P3255, DOI 10.1074/jbc.270.7.3255; TILLY JL, 1992, MOL ENDOCRINOL, V6, P1942, DOI 10.1210/me.6.11.1942; TONKS NK, 1988, J BIOL CHEM, V263, P6722; Tonks NK, 1996, CELL, V87, P365, DOI 10.1016/S0092-8674(00)81357-4; WARREN S, 1993, LYMPHOKINE CYTOK RES, V12, P75; WIENER JR, 1994, J NATL CANCER I, V86, P372, DOI 10.1093/jnci/86.5.372; WONG GHW, 1989, CELL, V58, P923, DOI 10.1016/0092-8674(89)90944-6; WOODFORDTHOMAS TA, 1992, J CELL BIOL, V117, P401, DOI 10.1083/jcb.117.2.401; WU XP, 1995, J CLIN INVEST, V95, P1897, DOI 10.1172/JCI117871; Wu YL, 1996, J CELL PHYSIOL, V168, P499, DOI 10.1002/(SICI)1097-4652(199609)168:3<499::AID-JCP2>3.0.CO;2-K; YOUSEFI S, 1994, P NATL ACAD SCI USA, V91, P10868, DOI 10.1073/pnas.91.23.10868; ZHAI YF, 1993, CANCER RES, V53, P2272; ZIMMERMAN RJ, 1989, CANCER RES, V49, P164	76	15	15	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 28	1999	18	4					967	978		10.1038/sj.onc.1202368	http://dx.doi.org/10.1038/sj.onc.1202368			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	165FT	10023672				2022-12-25	WOS:000078510600013
J	Morrison, EE; Wardleworth, BN; Askham, JM; Markham, AF; Meredith, DM				Morrison, EE; Wardleworth, BN; Askham, JM; Markham, AF; Meredith, DM			EB1, a protein which interacts with the APC tumour suppressor, is associated with the microtubule cytoskeleton throughout the cell cycle	ONCOGENE			English	Article						EB1; APC; microtubules; mitosis; cancer	ADENOMATOUS POLYPOSIS; BETA-CATENIN; IN-VITRO; DYNAMICS; BINDING; GENE; EXPRESSION; MUTATIONS; MIGRATION; HOMOLOG	The characteristics of the adenomatous polyposis coli (APC) associated protein EB1 were examined in mammalian cells. By immunocytochemistry EB1 was shown to be closely associated with the microtubule cytoskeleton throughout the cell cycle, In interphase cells EB1 was associated with microtubules along their full length but was often particularly concentrated at their tips, During early mitosis, EB1 was localized to separating centrosomes and associated microtubules, while at metaphase it was associated with the spindle poles and associated microtubules. During cytokinesis EB1 was strongly associated with the midbody microtubules, Treatment with nocodazole caused a diffuse redistribution of EB1 immunoreactivity, whereas treatment with cytochalasin D had no effect. Interestingly, treatment with taxol abolished the EB1 association with microtubules, In nocodazole washout experiments EB1 rapidly became associated with the centrosome and repolymerizing microtubules. In taxol wash-out experiments EB1 rapidly re-associated with the microtubule cytoskeleton, resembling untreated control cells within 10 min, Immunostaining of SW480 cells, which contain truncated APC incapable of interaction with EEL, showed that the association of EB1 with microtubules throughout the cell cycle was not dependent upon an interaction with APC. These results suggest a role for EB1 in the control of microtubule dynamics in mammalian cells.	Univ Leeds, St James Hosp, Mol Med Unit, Leeds LS9 7TF, W Yorkshire, England	Saint James's University Hospital; University of Leeds	Morrison, EE (corresponding author), Univ Leeds, St James Hosp, Mol Med Unit, Clin Sci Bldg, Leeds LS9 7TF, W Yorkshire, England.							Beinhauer JD, 1997, J CELL BIOL, V139, P717, DOI 10.1083/jcb.139.3.717; GRODEN J, 1993, AM J HUM GENET, V52, P263; Gumbiner BM, 1997, CURR BIOL, V7, pR443, DOI 10.1016/S0960-9822(06)00214-4; Jordan MA, 1998, CURR OPIN CELL BIOL, V10, P123, DOI 10.1016/S0955-0674(98)80095-1; JORDAN MA, 1992, J CELL SCI, V102, P401; Lengauer C, 1997, NATURE, V386, P623, DOI 10.1038/386623a0; LEVY DB, 1994, CANCER RES, V54, P5953; Matsumine A, 1996, SCIENCE, V272, P1020, DOI 10.1126/science.272.5264.1020; Morin PJ, 1996, P NATL ACAD SCI USA, V93, P7950, DOI 10.1073/pnas.93.15.7950; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Morrison EE, 1997, NEUROSCI LETT, V235, P129, DOI 10.1016/S0304-3940(97)00739-8; Morrison EE, 1997, NEUROSCIENCE, V81, P553, DOI 10.1016/S0306-4522(97)00099-7; MUNEMITSU S, 1994, CANCER RES, V54, P3676; Nathke IS, 1996, J CELL BIOL, V134, P165, DOI 10.1083/jcb.134.1.165; OSHIMA M, 1995, P NATL ACAD SCI USA, V92, P4482, DOI 10.1073/pnas.92.10.4482; Pollack AL, 1997, J CELL BIOL, V137, P1651, DOI 10.1083/jcb.137.7.1651; Renner C, 1997, J IMMUNOL, V159, P1276; Schwartz K, 1997, MOL BIOL CELL, V8, P2677, DOI 10.1091/mbc.8.12.2677; SMITH KJ, 1994, CANCER RES, V54, P3672; SU LK, 1995, CANCER RES, V55, P2972; SU LK, 1998, P AM ASS CANC RES, V39; Trzepacz C, 1997, J BIOL CHEM, V272, P21681, DOI 10.1074/jbc.272.35.21681; Wong MH, 1996, P NATL ACAD SCI USA, V93, P9588, DOI 10.1073/pnas.93.18.9588; Zhang KZ, 1996, P NATL ACAD SCI USA, V93, P4504, DOI 10.1073/pnas.93.9.4504	24	191	194	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 31	1998	17	26					3471	3477		10.1038/sj.onc.1202247	http://dx.doi.org/10.1038/sj.onc.1202247			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	157XD	10030671				2022-12-25	WOS:000078086200008
J	Dornberger, U; Leijon, M; Fritzsche, H				Dornberger, U; Leijon, M; Fritzsche, H			High base pair opening rates in tracts of GC base pairs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTON-EXCHANGE; B-DNA; NMR-SPECTROSCOPY; SEQUENCE; METHYLTRANSFERASE; OLIGONUCLEOTIDES; RESONANCES; EXCITATION; COMPLEXES; CRYSTALS	Sequence-dependent structural features of the DNA double helix have a strong influence on the base pair opening dynamics. Here we report a detailed study of the kinetics of base pair breathing in tracts of GC base pairs in DNA duplexes derived from H-1 NMR measurements of the imino proton exchange rates upon titration with the exchange catalyst ammonia. In the limit of infinite exchange catalyst concentration, the exchange times of the guanine imino protons of the GC tracts extrapolate to much shorter base pair lifetimes than commonly observed for isolated GC base pairs. The base pair lifetimes in the GC tracts are below 5 ms for almost all of the base pairs. The unusually rapid base pair opening dynamics of GC tracts are in striking contrast to the behavior of AT tracts, where very long base pair lifetimes are observed, The implication of these findings for the structural principles governing spontaneous helix opening as well as the DNA-binding specificity of the cytosine-5-methyltransferases, where flipping of the cytosine base has been observed, are discussed.	Stockholm Univ, Arrhenius Lab, Dept Biophys, S-10691 Stockholm, Sweden; Univ Jena, Inst Mol Biol, D-07745 Jena, Germany	Stockholm University; Friedrich Schiller University of Jena	Leijon, M (corresponding author), Stockholm Univ, Arrhenius Lab, Dept Biophys, S-10691 Stockholm, Sweden.	leijon@biophys.su.se		Leijon, Mikael/0000-0001-8701-9887				BAUER C, 1984, J MAGN RESON, V58, P442, DOI 10.1016/0022-2364(84)90148-3; BOELENS R, 1985, J MAGN RESON, V62, P378, DOI 10.1016/0022-2364(85)90207-0; Cheng XD, 1996, STRUCTURE, V4, P639, DOI 10.1016/S0969-2126(96)00068-8; Dickerson RE, 1996, J MOL BIOL, V256, P108, DOI 10.1006/jmbi.1996.0071; Dornberger U, 1998, J MOL BIOL, V284, P1453, DOI 10.1006/jmbi.1998.2261; Dornberger U, 1997, NUCLEIC ACIDS RES, V25, P822, DOI 10.1093/nar/25.4.822; FOLTASTOGNIEW E, 1994, BIOCHEMISTRY-US, V33, P11016, DOI 10.1021/bi00202a022; Garcia RA, 1996, P NATL ACAD SCI USA, V93, P7618, DOI 10.1073/pnas.93.15.7618; GEEN H, 1991, J MAGN RESON, V93, P93, DOI 10.1016/0022-2364(91)90034-Q; GMEINER WH, 1995, MAGN RESON CHEM, V33, P449, DOI 10.1002/mrc.1260330607; Gueron M, 1995, METHOD ENZYMOL, V261, P383; GUERON M, 1992, NUCLEIC ACIDS MOL BI, V6, P1; GUERON M, 1990, STRUCTURE METHODS, V3, P113; HEINEMANN U, 1992, EMBO J, V11, P1931, DOI 10.1002/j.1460-2075.1992.tb05246.x; HEINEMANN U, 1989, J MOL BIOL, V210, P369, DOI 10.1016/0022-2836(89)90337-9; HEINEMANN U, 1992, J BIOL CHEM, V267, P7332; KLIMASAUSKAS S, 1995, GENE, V157, P163, DOI 10.1016/0378-1119(94)00624-2; Klimasauskas S, 1998, EMBO J, V17, P317, DOI 10.1093/emboj/17.1.317; KLIMASAUSKAS S, 1994, CELL, V76, P357, DOI 10.1016/0092-8674(94)90342-5; KOCHOYAN M, 1987, J MOL BIOL, V196, P599, DOI 10.1016/0022-2836(87)90036-2; Leijon M, 1996, J MAGN RESON SER B, V112, P181, DOI 10.1006/jmrb.1996.0127; Leijon M, 1997, J MOL BIOL, V271, P438, DOI 10.1006/jmbi.1997.1153; Leijon M, 1997, BIOCHIMIE, V79, P775, DOI 10.1016/S0300-9084(97)86936-2; LEROY JL, 1992, BIOCHEMISTRY-US, V31, P1407, DOI 10.1021/bi00120a017; LEROY JL, 1991, BIOCHEMISTRY-US, V30, P5653, DOI 10.1021/bi00237a003; LEROY JL, 1988, BIOCHEMISTRY-US, V27, P8894, DOI 10.1021/bi00425a004; NELSON HCM, 1987, NATURE, V330, P221, DOI 10.1038/330221a0; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; PLATEAU P, 1982, J AM CHEM SOC, V104, P7310, DOI 10.1021/ja00389a067; REINISCH KM, 1995, CELL, V82, P143, DOI 10.1016/0092-8674(95)90060-8; Sarkar M, 1997, BIOCHEMISTRY-US, V36, P15463, DOI 10.1021/bi9702243; STEITZ TA, 1990, Q REV BIOPHYS, V23, P205, DOI 10.1017/S0033583500005552; TIMSIT Y, 1989, NATURE, V341, P459, DOI 10.1038/341459a0; TIMSIT Y, 1991, NATURE, V354, P167, DOI 10.1038/354167a0; YANG AS, 1995, NUCLEIC ACIDS RES, V23, P1380, DOI 10.1093/nar/23.8.1380	35	121	122	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 12	1999	274	11					6957	6962		10.1074/jbc.274.11.6957	http://dx.doi.org/10.1074/jbc.274.11.6957			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	175DV	10066749	hybrid			2022-12-25	WOS:000079078400021
J	Huwiler, A; Pfeilschifter, J; van den Bosch, H				Huwiler, A; Pfeilschifter, J; van den Bosch, H			Nitric oxide donors induce stress signaling via ceramide formation in rat renal mesangial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; STIMULATED PHOSPHOINOSITIDE HYDROLYSIS; EXTRACELLULAR ATP; INDUCED APOPTOSIS; PROSTAGLANDIN SYNTHESIS; FEEDBACK INHIBITION; ENDOTHELIAL-CELLS; INVOLVEMENT; SYNTHASE; ALPHA	Exogenous NO is able to trigger apoptosis of renal mesangial cells, and thus may contribute to acute lytic phases as well as to resolution of glomerulonephritis. However, the mechanism involved in these events is still unclear. We report here that chronic exposure of renal mesangial cells for 24 h to compounds releasing NO, including spermine-NO, (Z)-1-(N-methyl-N-[6-(N-methylammoniohexyl)-amino])diazen-1-ium-1,2-diolate (MAHMA-NO), S-nitrosoglutathione (GS-NO), and S-nitroso-N-acetyl-D,L-penicillamine (SNAP) results in a potent and dose-dependent increase in the lipid signaling molecule ceramide, Time courses reveal that significant effects occur after 2-4 h of stimulation with NO donors and reach maximal levels after 24 h of stimulation, No acute (within minutes) ceramide production can be detected. When cells were stimulated with NO donors in the presence of phorbol ester, a direct activator of protein kinase C, both ceramide production and DNA fragmentation are completely abolished. Furthermore, addition of exogenous ceramide partially reversed the inhibitory effect of phorbol ester on apoptosis, thus suggesting a negative regulation of protein kinase C on ceramide formation and apoptosis, In contrast to exogenous NO, tumor necrosis factor (TNF)-alpha stimulates a very rapid and transient increase in ceramide levels within minutes but fails to induce the late-phase ceramide formation. Moreover, TNF fails to induce apoptosis in mesangial cells. Interestingly, NO and TNF alpha cause a chronic activation of acidic and neutral sphingomyelinases, the ceramide-generating enzymes, whereas acidic and neutral ceramidases, the ceramide-metabolizing enzymes, are inhibited by NO, but potently stimulated by TNF alpha, Furthermore, in the presence of an acidic ceramidase inhibitor, N-oleoylethanolamine, TNF alpha leads to a sustained accumulation of ceramide and in parallel induces DNA fragmentation. In summary, our data demonstrate that exogenous NO causes a chronic up-regulation of ceramide levels in mesangial cells by activating sphingomyelinases and concomitantly inhibiting ceramidases, and that particularly the late-phase of ceramide generation may be responsible for the further processing of a proapoptotic signal.	Univ Frankfurt Klinikum, Zentrum Pharmakol, Inst Pharmacol & Toxicol, D-60590 Frankfurt, Germany; Univ Utrecht, Ctr Biomembranes & Lipid Enzymol, NL-3584 CH Utrecht, Netherlands	Goethe University Frankfurt; Goethe University Frankfurt Hospital; Utrecht University	Huwiler, A (corresponding author), Univ Frankfurt Klinikum, Zentrum Pharmakol, Inst Pharmacol & Toxicol, Theodor Stern Kai 7, D-60590 Frankfurt, Germany.	huwiler@em.uni-frankfurt.de						ALBINA JE, 1993, J IMMUNOL, V150, P5080; Beckman JS, 1996, AM J PHYSIOL-CELL PH, V271, pC1424; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Cattell V, 1995, Curr Opin Nephrol Hypertens, V4, P359, DOI 10.1097/00041552-199507000-00013; CATTELL V, 1993, EXP NEPHROL, V1, P265; COHEN JJ, 1993, IMMUNOL TODAY, V14, P126, DOI 10.1016/0167-5699(93)90214-6; Dawson VL, 1996, J NEUROSCI, V16, P2479; Dimmeler S, 1997, J EXP MED, V185, P601, DOI 10.1084/jem.185.4.601; FEHSEL K, 1995, J IMMUNOL, V155, P2858; HANNUN YA, 1995, TRENDS BIOCHEM SCI, V20, P73, DOI 10.1016/S0968-0004(00)88961-6; Huwiler A, 1998, BIOCHEMISTRY-US, V37, P14556, DOI 10.1021/bi981401i; Huwiler A, 1997, KIDNEY INT, V52, P329, DOI 10.1038/ki.1997.338; HUWILER A, 1991, BIOCHEM J, V279, P441, DOI 10.1042/bj2790441; HUWILER A, 1992, FEBS LETT, V300, P259, DOI 10.1016/0014-5793(92)80858-E; IGNARRO LJ, 1990, ANNU REV PHARMACOL, V30, P535, DOI 10.1146/annurev.pa.30.040190.002535; KNOWLES RG, 1994, BIOCHEM J, V298, P249, DOI 10.1042/bj2980249; KRONCKE KD, 1995, BIOL CHEM H-S, V376, P327; Lander HM, 1996, J BIOL CHEM, V271, P19705, DOI 10.1074/jbc.271.33.19705; LIPTON SA, 1993, NATURE, V364, P626, DOI 10.1038/364626a0; LUCAS M, 1995, GEN PHARMACOL, V26, P881, DOI 10.1016/0306-3623(94)00295-X; MESSMER UK, 1995, MOL PHARMACOL, V47, P757; Messmer UK, 1996, ARCH BIOCHEM BIOPHYS, V327, P1, DOI 10.1006/abbi.1996.0085; MONCADA S, 1991, PHARMACOL REV, V43, P109; Muhl H, 1996, EUR J PHARMACOL, V317, P137, DOI 10.1016/S0014-2999(96)00701-7; MULSCH A, 1991, METHOD ENZYMOL, V195, P377; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; NikolovaKarakashian M, 1997, J BIOL CHEM, V272, P18718, DOI 10.1074/jbc.272.30.18718; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; Nitsch DD, 1997, AM J PATHOL, V150, P889; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; OCHSNER M, 1993, EUR J PHARM-MOLEC PH, V245, P15, DOI 10.1016/0922-4106(93)90164-5; Pena LA, 1997, BIOCHEM PHARMACOL, V53, P615, DOI 10.1016/S0006-2952(96)00834-9; PFEILSCHIFTE RJ, 1995, KIDNEY INT, V51, pS50; PFEILSCHIFTER J, 1990, BIOCHEM J, V272, P469, DOI 10.1042/bj2720469; PFEILSCHIFTER J, 1990, CELL SIGNAL, V2, P129; PFEILSCHIFTER J, 1992, EUR J BIOCHEM, V203, P251, DOI 10.1111/j.1432-1033.1992.tb19854.x; PFEILSCHIFTER J, 1990, FEBS LETT, V273, P185, DOI 10.1016/0014-5793(90)81080-8; Pfeilschifter J, 1998, KIDNEY INT, V54, pS34, DOI 10.1046/j.1523-1755.1998.06707.x; Pfeilschifter J, 1996, FEBS LETT, V396, P67, DOI 10.1016/0014-5793(96)01070-8; Sandau K, 1996, CELL SIGNAL, V8, P173, DOI 10.1016/0898-6568(95)02051-9; SCHMIDT HHHW, 1993, BIOCHIM BIOPHYS ACTA, V1178, P153, DOI 10.1016/0167-4889(93)90006-B; STAMLER JS, 1994, CELL, V78, P931, DOI 10.1016/0092-8674(94)90269-0; SUGITA M, 1975, BIOCHIM BIOPHYS ACTA, V398, P125, DOI 10.1016/0005-2760(75)90176-9; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; Zhivotovsky B, 1997, BIOCHEM BIOPH RES CO, V230, P481, DOI 10.1006/bbrc.1996.6016	45	102	107	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	1999	274	11					7190	7195		10.1074/jbc.274.11.7190	http://dx.doi.org/10.1074/jbc.274.11.7190			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	175DV	10066779	hybrid			2022-12-25	WOS:000079078400051
J	Kruth, HS; Zhang, WY; Skarlatos, SI; Chao, FF				Kruth, HS; Zhang, WY; Skarlatos, SI; Chao, FF			Apolipoprotein B stimulates formation of monocyte-macrophage surface-connected compartments and mediates uptake of low density lipoprotein-derived liposomes into these compartments	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE PERITONEAL-MACROPHAGES; RECEPTOR-RELATED PROTEIN; RICH LIPID PARTICLES; HUMAN ATHEROSCLEROTIC LESIONS; UNESTERIFIED CHOLESTEROL; FAMILIAL HYPERCHOLESTEROLEMIA; MONOCLONAL-ANTIBODIES; HYPERLIPIDEMIC RABBIT; BETA-VLDL; ACCUMULATION	Much of the cholesterol that accumulates in atherosclerotic plaques is found within monocyte-macrophages transforming these cells into "foam cells." Native low density lipoprotein (LDL) does not cause foam cell formation. Treatment of LDL with cholesterol esterase converts LDL into cholesterol-rich liposomes having >90% cholesterol in unesterified form. Similar cholesterol-rich liposomes are found in early developing atherosclerotic plaques surrounding foam cells. We now show that cholesterol-rich liposomes produced from cholesterol esterase-treated LDL can cause human monocyte-macrophage foam cell formation inducing a 3-5-fold increase in macrophage cholesterol content of which >60% is esterified. Although cytochalasin D inhibited LDL liposome-induced macrophage cholesteryl ester accumulation, LDL liposomes did not enter macrophages by phagocytosis. Rather, the LDL liposomes induced and entered surface-connected compartments within the macrophages, a unique endocytic pathway in these cells that we call patocytosis, LDL liposome apoB rather than LDL liposome lipid mediated LDL liposome uptake by macrophages, This was shown by the findings that: 1) protease treatment of the LDL liposomes prevented macrophage cholesterol accumulation; 2) liposomes prepared from LDL lipid extracts did not cause macrophage cholesterol accumulation; and 3) purified apoB induced and accumulated within macrophage surface-connected compartments. Although apoB mediated the macrophage uptake of LDL liposomes, this uptake did not occur through LDL, LDL receptor-related protein, or scavenger receptors, Also, LDL liposome uptake was not sensitive to treatment of macrophages with trypsin or heparinase, Cholesterol esterase-mediated transformation of LDL into cholesterol-rich liposomes is an LDL modification that: 1) stimulates uptake of LDL cholesterol by apoB-dependent endocytosis into surface-connected compartments, and 2) causes human monocyte-macrophage foam cell formation.	NHLBI, Sect Expt Atherosclerosis, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Kruth, HS (corresponding author), NHLBI, Sect Expt Atherosclerosis, NIH, Bldg 10,Rm 5N-113,10 Ctr Dr,MSC 1422, Bethesda, MD 20892 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [Z01HL002832, ZIAHL002832] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AVIRAM M, 1991, J BIOL CHEM, V266, P11567; BEISIEGEL U, 1981, J BIOL CHEM, V256, P1923; BHAKDI S, 1995, J EXP MED, V182, P1959, DOI 10.1084/jem.182.6.1959; CAREW TE, 1978, BIOCHIM BIOPHYS ACTA, V529, P171, DOI 10.1016/0005-2760(78)90115-7; CHAO FF, 1988, AM J PATHOL, V131, P73; CHAO FF, 1992, J BIOL CHEM, V267, P4992; CHAO FF, 1994, J LIPID RES, V35, P71; CHAO FF, 1990, AM J PATHOL, V136, P169; FOLCH J, 1957, J BIOL CHEM, V226, P497; GAMBLE W, 1978, J LIPID RES, V19, P1068; GREVE H, 1988, J BIOL CHEM, V263, P12886; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; HOFF HF, 1991, ARTERIOSCLER THROMB, V11, P1209, DOI 10.1161/01.ATV.11.5.1209; KAWABE Y, 1994, ARCH BIOCHEM BIOPHYS, V310, P489, DOI 10.1006/abbi.1994.1197; KHOO JC, 1988, ARTERIOSCLEROSIS, V8, P348, DOI 10.1161/01.ATV.8.4.348; KOO C, 1988, J CLIN INVEST, V81, P1332, DOI 10.1172/JCI113460; KRIEGER M, 1994, ANNU REV BIOCHEM, V63, P601, DOI 10.1146/annurev.bi.63.070194.003125; Kruth H S, 1997, Subcell Biochem, V28, P319; KRUTH HS, 1984, AM J PATHOL, V114, P201; KRUTH HS, 1985, ATHEROSCLEROSIS, V57, P337, DOI 10.1016/0021-9150(85)90045-0; KRUTH HS, 1995, J CELL BIOL, V129, P133, DOI 10.1083/jcb.129.1.133; KRUTH HS, 1994, J BIOL CHEM, V269, P24511; Li F, 1997, J BIOL CHEM, V272, P28666, DOI 10.1074/jbc.272.45.28666; LUFT JH, 1971, ANAT REC, V171, P347, DOI 10.1002/ar.1091710302; LUNDBERG B, 1984, J LIPID RES, V25, P550; MAEBA R, 1994, BBA-LIPID LIPID MET, V1215, P79, DOI 10.1016/0005-2760(94)90094-9; MORA R, 1990, J LIPID RES, V31, P1793; MYERS JN, 1993, J CELL BIOL, V123, P1389, DOI 10.1083/jcb.123.6.1389; NARUSZEWICZ M, 1994, NUTR METAB CARDIOVAS, V4, P70; OBUNIKE JC, 1994, J BIOL CHEM, V269, P13129; RUMSEY SC, 1992, J CLIN INVEST, V90, P1504, DOI 10.1172/JCI116018; Seo T, 1997, J LIPID RES, V38, P765; Shamir R, 1996, J CLIN INVEST, V97, P1696, DOI 10.1172/JCI118596; SHECHTER I, 1981, J LIPID RES, V22, P63; SIMIONESCU N, 1986, AM J PATHOL, V123, P109; STRICKLAND DK, 1995, FASEB J, V9, P890, DOI 10.1096/fasebj.9.10.7615159; SUITS AG, 1989, P NATL ACAD SCI USA, V86, P2713, DOI 10.1073/pnas.86.8.2713; TABAS I, 1991, J CELL BIOL, V115, P1547, DOI 10.1083/jcb.115.6.1547; TABAS I, 1994, J BIOL CHEM, V269, P22547; TERTOV VV, 1992, CIRC RES, V71, P218, DOI 10.1161/01.RES.71.1.218; VANLENTEN BJ, 1983, J BIOL CHEM, V258, P5151; WALSH MT, 1983, BIOCHEMISTRY-US, V22, P3170, DOI 10.1021/bi00282a021; WIKLUND O, 1985, J BIOL CHEM, V260, P956; Wu SM, 1996, ARCH BIOCHEM BIOPHYS, V326, P39, DOI 10.1006/abbi.1996.0044; XU XX, 1991, J BIOL CHEM, V266, P24849; Zhang WY, 1997, J BIOL CHEM, V272, P31700, DOI 10.1074/jbc.272.50.31700	46	23	23	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 12	1999	274	11					7495	7500		10.1074/jbc.274.11.7495	http://dx.doi.org/10.1074/jbc.274.11.7495			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	175DV	10066816	hybrid			2022-12-25	WOS:000079078400088
J	Magyar, A; Zhang, XD; Abdi, F; Kohn, H; Widger, WR				Magyar, A; Zhang, XD; Abdi, F; Kohn, H; Widger, WR			Identifying the bicyclomycin binding domain through biochemical analysis of antibiotic-resistant Rho proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TERMINATION FACTOR-RHO; DEPENDENT TRANSCRIPTION TERMINATION; RNP1-LIKE SEQUENCE MOTIF; ESCHERICHIA-COLI; OLIGONUCLEOTIDE COFACTORS; BIOLOGICAL PROPERTIES; MICROCOCCUS-LUTEUS; HELICASE ACTIVITY; ATPASE ACTIVITY; RNA	Mutations M219K, S266A, and G337S in transcription termination factor Rho have been shown to confer resistance to the antibiotic bicyclomycin (BCM). All three His-tagged mutant Rho proteins exhibited similar K-m values for ATP; however, the V-max values at infinite ATP concentrations were one-fourth to one-third that for the His-tagged wild-type enzyme. BCM inhibition kinetics of poly(C)-dependent ATPase activity for the mutant proteins were non-competitive with respect to ATP (altering catalytic function but not ATP binding) and showed increased K-i values compared with His-tagged wildtype Rho, M219K and G337S exhibited increased ratios of poly(U)/poly(C)-stimulated ATPase activity and lower apparent K-m values for ribo(C)(10) in the poly(dC) ribo(C)(10)ependent ATPase assay compared with His-tagged wild-type Rho. The S266A mutation did not show an increased poly(U)/poly(C) ATPase activity ratio and maintained approximately the same K-m for ribo(C)(10) in the poly(dC). ribo(C)(10)- dependent ATPase assay, The kinetic studies indicated that M219K and G337S altered the secondary RNA binding domain in Rho whereas the S266A mutation did not. Transcription termination assays for each mutant showed different patterns of Rho-terminated transcripts. Tyrosine substitution of Ser-266 led to BCM sensitivity intimating that an OH (hydroxyl) moiety at this position is needed for BCM (binding) inhibition. Our results suggest BCM binds to Rho at a site distinct from both the ATP and the primary RNA binding domains but close to the secondary RNA-binding (tracking) site and the ATP hydrolysis pocket.	Univ Houston, Dept Chem, Houston, TX 77204 USA; Univ Houston, Dept Biol & Biochem, Houston, TX 77204 USA	University of Houston System; University of Houston; University of Houston System; University of Houston	Widger, WR (corresponding author), Univ Houston, Dept Chem, Univ Pk, Houston, TX 77204 USA.	hkohn@uh.edu; widger@uh.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037934] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 37934] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; Allison TJ, 1998, NAT STRUCT BIOL, V5, P352, DOI 10.1038/nsb0598-352; BEAR DG, 1985, P NATL ACAD SCI USA, V82, P1191; BRENNAN CA, 1987, CELL, V48, P945, DOI 10.1016/0092-8674(87)90703-3; BRENNAN CA, 1991, J BIOL CHEM, V266, P17296; Briercheck DM, 1998, NAT STRUCT BIOL, V5, P393, DOI 10.1038/nsb0598-393; Carrano L, 1998, ANTIMICROB AGENTS CH, V42, P571, DOI 10.1128/AAC.42.3.571; Cho HJ, 1997, J ORG CHEM, V62, P5432, DOI 10.1021/jo970575n; DOMBROSKI AJ, 1988, J BIOL CHEM, V263, P18802; DOMBROSKI AJ, 1988, P NATL ACAD SCI USA, V85, P2538, DOI 10.1073/pnas.85.8.2538; DOMBROSKI AJ, 1988, J BIOL CHEM, V263, P18810; GALLUPPI GR, 1980, J MOL BIOL, V138, P513, DOI 10.1016/S0022-2836(80)80016-7; Horiguchi T, 1997, J MOL BIOL, V269, P514, DOI 10.1006/jmbi.1997.1059; ISEKI M, 1980, J ANTIBIOT, V33, P488, DOI 10.7164/antibiotics.33.488; JIN DJ, 1992, P NATL ACAD SCI USA, V89, P1453, DOI 10.1073/pnas.89.4.1453; KAMIYA T, 1972, J ANTIBIOT, V25, P576, DOI 10.7164/antibiotics.25.576; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Magyar A, 1996, J BIOL CHEM, V271, P25369, DOI 10.1074/jbc.271.41.25369; Martinez A, 1996, J MOL BIOL, V257, P895, DOI 10.1006/jmbi.1996.0210; Martinez A, 1996, J MOL BIOL, V257, P909, DOI 10.1006/jmbi.1996.0211; MIWA Y, 1995, J MOL BIOL, V254, P815, DOI 10.1006/jmbi.1995.0658; MIYAMURA S, 1973, J ANTIBIOT, V26, P479, DOI 10.7164/antibiotics.26.479; MIYAMURA S, 1972, J ANTIBIOT, V25, P610, DOI 10.7164/antibiotics.25.610; MIYOSHI T, 1980, J ANTIBIOT, V33, P480, DOI 10.7164/antibiotics.33.480; MODRAK D, 1994, BIOCHEMISTRY-US, V33, P8292, DOI 10.1021/bi00193a016; MORI H, 1989, J MOL BIOL, V210, P39, DOI 10.1016/0022-2836(89)90289-1; NISHIDA M, 1972, J ANTIBIOT, V25, P594, DOI 10.7164/antibiotics.25.594; NISHIDA M, 1972, J ANTIBIOT, V25, P582, DOI 10.7164/antibiotics.25.582; Nowatzke WL, 1996, J BIOL CHEM, V271, P742, DOI 10.1074/jbc.271.2.742; Nowatzke WL, 1997, J BACTERIOL, V179, P5238, DOI 10.1128/jb.179.16.5238-5240.1997; Park H, 1996, J ORG CHEM, V61, P7764, DOI 10.1021/jo961004i; Park H, 1996, J ORG CHEM, V61, P7750, DOI 10.1021/jo961002y; PARK HG, 1995, ARCH BIOCHEM BIOPHYS, V323, P447, DOI 10.1006/abbi.1995.0066; PEREIRA S, 1995, J MOL BIOL, V251, P30, DOI 10.1006/jmbi.1995.0413; Pereira S, 1995, J BIOL CHEM, V270, P30401, DOI 10.1074/jbc.270.51.30401; PINKHAM JL, 1983, NUCLEIC ACIDS RES, V11, P3531, DOI 10.1093/nar/11.11.3531; PLATT T, 1994, MOL MICROBIOL, V11, P983, DOI 10.1111/j.1365-2958.1994.tb00376.x; Riba I, 1998, J BIOL CHEM, V273, P34033, DOI 10.1074/jbc.273.51.34033; RICHARDSON JP, 1982, J BIOL CHEM, V257, P5760; Richardson JP, 1996, J BIOL CHEM, V271, P1251, DOI 10.1074/jbc.271.3.1251; RICHARDSON JP, 1990, BIOCHIM BIOPHYS ACTA, V1048, P127, DOI 10.1016/0167-4781(90)90048-7; Richardson LV, 1996, J BIOL CHEM, V271, P21597, DOI 10.1074/jbc.271.35.21597; Santillan A, 1998, J MED CHEM, V41, P1185, DOI 10.1021/jm9708386; Santillan A, 1996, J ORG CHEM, V61, P7756, DOI 10.1021/jo961003q; SEIFRIED SE, 1992, P NATL ACAD SCI USA, V89, P10454, DOI 10.1073/pnas.89.21.10454; SHARP JA, 1983, J BIOL CHEM, V258, P3482; STEINMETZ EJ, 1994, P NATL ACAD SCI USA, V91, P1401, DOI 10.1073/pnas.91.4.1401; TSURUSHITA N, 1984, MOL GEN GENET, V196, P458, DOI 10.1007/BF00436193; TSURUSHITA N, 1989, J MOL BIOL, V210, P23, DOI 10.1016/0022-2836(89)90288-X; VONHIPPEL PH, 1984, ANNU REV BIOCHEM, V53, P389, DOI 10.1146/annurev.bi.53.070184.002133; WANG Y, 1993, J BIOL CHEM, V268, P13940; WANG Y, 1993, J BIOL CHEM, V268, P13947; WILLIAMS RM, 1988, CHEM REV, V88, P511, DOI 10.1021/cr00085a004; WU AM, 1981, P NATL ACAD SCI-BIOL, V78, P2913, DOI 10.1073/pnas.78.5.2913; YAGER TD, 1998, MOL CELL BIOL E COLI, P1241; ZHANG Z, 1994, J CHEM SOC CHEM COMM, P1334; ZWIEFKA A, 1993, BIOCHEMISTRY-US, V32, P3564, DOI 10.1021/bi00065a007	57	40	40	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 12	1999	274	11					7316	7324		10.1074/jbc.274.11.7316	http://dx.doi.org/10.1074/jbc.274.11.7316			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	175DV	10066795	hybrid			2022-12-25	WOS:000079078400067
J	Woodrow, CJ; Penny, JI; Krishna, S				Woodrow, CJ; Penny, JI; Krishna, S			Intraerythrocytic Plasmodium falciparum expresses a high affinity facilitative hexose transporter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUT1 GLUCOSE-TRANSPORTER; POLYMERASE-CHAIN-REACTION; EXOFACIAL LIGAND-BINDING; INFECTED ERYTHROCYTES; MALARIA PARASITE; XENOPUS OOCYTES; MEMBRANE; CHANNEL; INVITRO; ACID	Asexual stages of Plasmodium falciparum cause severe malaria and are dependent upon host glucose for energy. We have identified a glucose transporter of P. falciparum (PfHT1) and studied its function and expression during parasite development in vitro. PfHT1 is a saturable, sodium-independent, and stereospecific transporter, which is inhibited by cytochalasin B, and has a relatively high affinity for glucose (K-m = 0.48 mM) when expressed in Xenopus laevis oocytes, Competition experiments with glucose analogues show that hydroxyl groups at positions C-3 and C-4 are important for ligand binding. mRNA levels for PfHT1, assessed by the quantitative technique of tandem competitive polymerase chain reaction, are highest during the small ring stages of infection and lowest in gametocytes. Confocal immunofluorescence microscopy localizes PfHT1 to the region of the parasite plasma membrane and not to host structures. These findings have implications for development of new drug targets in malaria as well as for understanding of the pathophysiology of severe infection. When hypoglycemia complicates malaria, modeling studies suggest that the high affinity of PfHT1 is likely to increase the relative proportion of glucose taken up by parasites and thereby worsen the clinical condition.	St George Hosp, Sch Med, Dept Infect Dis, London SW17 0RE, England	St Georges University London	Krishna, S (corresponding author), St George Hosp, Sch Med, Dept Infect Dis, Cranmer Terrace, London SW17 0RE, England.			Krishna, Sanjeev/0000-0003-0066-0634; Woodrow, Charles/0000-0002-5134-7165				BURANT CF, 1992, BIOCHEMISTRY-US, V31, P10414, DOI 10.1021/bi00157a032; DESAI SA, 1993, NATURE, V362, P643, DOI 10.1038/362643a0; GARCIA JC, 1992, J BIOL CHEM, V267, P7770; Goodyer ID, 1997, MOL BIOCHEM PARASIT, V84, P229, DOI 10.1016/S0166-6851(96)02802-2; GOULD GW, 1989, BIOCHEMISTRY-US, V28, P9447, DOI 10.1021/bi00450a030; GOULD GW, 1993, BIOCHEM J, V295, P329, DOI 10.1042/bj2950329; HASHIRAMOTO M, 1992, J BIOL CHEM, V267, P17502; HEDIGER MA, 1987, NATURE, V330, P379, DOI 10.1038/330379a0; KIRK K, 1994, J BIOL CHEM, V269, P3339; Kirk K, 1996, MOL BIOCHEM PARASIT, V82, P195, DOI 10.1016/0166-6851(96)02734-X; Lauer SA, 1997, SCIENCE, V276, P1122, DOI 10.1126/science.276.5315.1122; MUECKLER M, 1994, J BIOL CHEM, V269, P20533; MUECKLER M, 1985, SCIENCE, V229, P941, DOI 10.1126/science.3839598; Newton CRJC, 1998, PHARMACOL THERAPEUT, V79, P1, DOI 10.1016/S0163-7258(98)00008-4; Pardridge William M., 1993, P395; Penny JI, 1998, MOL BIOCHEM PARASIT, V93, P81, DOI 10.1016/S0166-6851(98)00024-3; Pinder JC, 1998, J CELL SCI, V111, P1831; POUVELLE B, 1991, NATURE, V353, P73, DOI 10.1038/353073a0; Price R, 1997, MOL BIOCHEM PARASIT, V85, P161, DOI 10.1016/S0166-6851(96)02822-8; SHERMAN IW, 1979, MICROBIOL REV, V43, P453, DOI 10.1128/MMBR.43.4.453-495.1979; TAMORI Y, 1994, J BIOL CHEM, V269, P2982; TERKUILE F, 1993, EXP PARASITOL, V76, P85, DOI 10.1006/expr.1993.1010; TRAGER W, 1992, P NATL ACAD SCI USA, V89, P5351, DOI 10.1073/pnas.89.12.5351; VIRDI AS, 1992, MOL CELL PROBE, V6, P375, DOI 10.1016/0890-8508(92)90030-2; WHITE NJ, 1992, J ANTIMICROB CHEMOTH, V30, P571, DOI 10.1093/jac/30.5.571; ZOLG JW, 1984, IN VITRO CELL DEV B, V20, P205, DOI 10.1007/BF02618189	26	103	108	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 12	1999	274	11					7272	7277		10.1074/jbc.274.11.7272	http://dx.doi.org/10.1074/jbc.274.11.7272			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	175DV	10066789	hybrid, Green Published			2022-12-25	WOS:000079078400061
J	Coccia, EM; Passini, N; Battistini, A; Pini, C; Sinigaglia, F; Rogge, L				Coccia, EM; Passini, N; Battistini, A; Pini, C; Sinigaglia, F; Rogge, L			Interleukin-12 induces expression of interferon regulatory factor-1 via signal transducer and activator of transcription-4 in human T helper type 1 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-BETA-CHAIN; NF-KAPPA-B; TH2 CELLS; FACTOR-I; IMMUNE-RESPONSES; NATURAL-KILLER; TYROSINE PHOSPHORYLATION; GENE-EXPRESSION; FACTOR IRF-1; IL-12	IRF-1-deficient mice show a striking defect in the development of T helper 1 (Th1) cells. In the present report, we investigate the expression of IRF-1 during differentiation of human T helper cells. No significant differences of IRF-1 mRNA expression were found in established Th1 and Th2 cells; however, interleukin 12 (IL-12) induced a strong up-regulation of IRF-1 transcripts in Th1 but not in Th2 cells. We demonstrate that IL-12-induced up-regulation of IRF-1 is mediated by signal transducer and activator of transcription-4, which binds to the interferon (IFN)-gamma-activated sequence present in the promoter of the IRF-1 gene. Strong IL-12-dependent activation of a reporter gene construct containing the IRF-1 IFN-gamma-activated sequence element provides further evidence for the key role of signal transducer and activator of transcription-4 in the IL-12-induced up-regulation of IRF-1 transcripts in T cells. IRF-1 expression was strongly induced after stimulation of naive CD4(+) T cells via the T cell receptor, irrespective of the cytokines present at priming, indicating that this transcription factor does not play a major role in initiating a Th1-specific transcriptional cascade in differentiating helper T cells. However, our finding that IRF-1 is a target gene of IL-12 suggests that some of the IL-12-induced effector functions of Th1 cells may be mediated by IRF-1.	Roche Milano Ric, I-20132 Milan, Italy; Ist Super Sanita, Immunol Lab, I-00161 Rome, Italy; Ist Super Sanita, Virol Lab, I-00161 Rome, Italy	Roche Holding; Istituto Superiore di Sanita (ISS); Istituto Superiore di Sanita (ISS)	Rogge, L (corresponding author), Roche Milano Ric, Via Olgettina 58, I-20132 Milan, Italy.		BATTISTINI, ANGELA/C-2944-2016; Rogge, Lars/GYJ-6142-2022; Coccia, Eliana M/B-4752-2013	Coccia, Eliana M/0000-0002-1606-2949; Rogge, Lars/0000-0003-1262-9204				Abbas AK, 1996, NATURE, V383, P787, DOI 10.1038/383787a0; BACH EA, 1995, SCIENCE, V270, P1215, DOI 10.1126/science.270.5239.1215; BACON CM, 1995, P NATL ACAD SCI USA, V92, P7307, DOI 10.1073/pnas.92.16.7307; Cho SS, 1996, J IMMUNOL, V157, P4781; Duncan GS, 1996, J EXP MED, V184, P2043, DOI 10.1084/jem.184.5.2043; Gately MK, 1998, ANNU REV IMMUNOL, V16, P495, DOI 10.1146/annurev.immunol.16.1.495; Groux H, 1997, J IMMUNOL, V158, P5627; HARADA H, 1994, MOL CELL BIOL, V14, P1500, DOI 10.1128/MCB.14.2.1500; HARROCH S, 1994, EMBO J, V13, P1942, DOI 10.1002/j.1460-2075.1994.tb06463.x; Hilkens CMU, 1996, J IMMUNOL, V157, P4316; Ho IC, 1996, CELL, V85, P973, DOI 10.1016/S0092-8674(00)81299-4; Hodge MR, 1996, SCIENCE, V274, P1903, DOI 10.1126/science.274.5294.1903; HOU JZ, 1994, SCIENCE, V265, P1701, DOI 10.1126/science.8085155; HSIEH CS, 1993, SCIENCE, V260, P547, DOI 10.1126/science.8097338; HSIEH CS, 1992, P NATL ACAD SCI USA, V89, P6065, DOI 10.1073/pnas.89.13.6065; Huang H, 1998, J EXP MED, V187, P1305, DOI 10.1084/jem.187.8.1305; JACOBSON NG, 1995, J EXP MED, V181, P1755, DOI 10.1084/jem.181.5.1755; Kaplan MH, 1996, IMMUNITY, V4, P313, DOI 10.1016/S1074-7613(00)80439-2; Kaplan MH, 1996, NATURE, V382, P174, DOI 10.1038/382174a0; LANZAVECCHIA A, 1987, EUR J IMMUNOL, V17, P105, DOI 10.1002/eji.1830170118; Lohoff M, 1997, IMMUNITY, V6, P681, DOI 10.1016/S1074-7613(00)80444-6; Ma XJ, 1996, J EXP MED, V183, P147, DOI 10.1084/jem.183.1.147; MANETTI R, 1993, J EXP MED, V177, P1199, DOI 10.1084/jem.177.4.1199; MOSMANN TR, 1986, J IMMUNOL, V136, P2348; MURPHY TL, 1995, MOL CELL BIOL, V15, P5258; Nguyen Hannah, 1997, Cytokine and Growth Factor Reviews, V8, P293, DOI 10.1016/S1359-6101(97)00019-1; O'Garra A, 1998, IMMUNITY, V8, P275, DOI 10.1016/S1074-7613(00)80533-6; Ogasawara K, 1998, NATURE, V391, P700, DOI 10.1038/35636; Ohteki T, 1998, J EXP MED, V187, P967, DOI 10.1084/jem.187.6.967; Penninger JM, 1997, IMMUNITY, V7, P243, DOI 10.1016/S1074-7613(00)80527-0; PERNIS A, 1995, SCIENCE, V269, P245, DOI 10.1126/science.7618088; Presky DH, 1996, P NATL ACAD SCI USA, V93, P14002, DOI 10.1073/pnas.93.24.14002; Rincon M, 1997, CURR BIOL, V7, pR729, DOI 10.1016/S0960-9822(06)00368-X; Rogge L, 1997, J EXP MED, V185, P825, DOI 10.1084/jem.185.5.825; Rogge L, 1998, J IMMUNOL, V161, P6567; ROMAGNANI S, 1994, ANNU REV IMMUNOL, V12, P227, DOI 10.1146/annurev.iy.12.040194.001303; ROONEY JW, 1995, IMMUNITY, V2, P473, DOI 10.1016/1074-7613(95)90028-4; SCHINDLER C, 1994, EMBO J, V13, P1350, DOI 10.1002/j.1460-2075.1994.tb06388.x; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SEDER RA, 1994, ANNU REV IMMUNOL, V12, P635, DOI 10.1146/annurev.iy.12.040194.003223; SEDER RA, 1992, J EXP MED, V176, P1091, DOI 10.1084/jem.176.4.1091; SEDER RA, 1993, P NATL ACAD SCI USA, V90, P10188, DOI 10.1073/pnas.90.21.10188; Shimoda K, 1996, NATURE, V380, P630, DOI 10.1038/380630a0; Sica A, 1997, J BIOL CHEM, V272, P30412, DOI 10.1074/jbc.272.48.30412; SIMS SH, 1993, MOL CELL BIOL, V13, P690, DOI 10.1128/MCB.13.1.690; SZABO SJ, 1995, IMMUNITY, V2, P665, DOI 10.1016/1074-7613(95)90011-X; Szabo SJ, 1997, J EXP MED, V185, P817, DOI 10.1084/jem.185.5.817; Takeda K, 1996, NATURE, V380, P627, DOI 10.1038/380627a0; Taki S, 1997, IMMUNITY, V6, P673, DOI 10.1016/S1074-7613(00)80443-4; TANAKA N, 1993, MOL CELL BIOL, V13, P4531, DOI 10.1128/MCB.13.8.4531; Taniguchi T, 1997, J CELL PHYSIOL, V173, P128, DOI 10.1002/(SICI)1097-4652(199711)173:2<128::AID-JCP8>3.0.CO;2-P; TANIGUCHI T, 1997, BIOCHIM BIOPHYS ACTA, V1333, P9; Thierfelder WE, 1996, NATURE, V382, P171, DOI 10.1038/382171a0; TRINCHIERI G, 1995, ANNU REV IMMUNOL, V13, P251, DOI 10.1146/annurev.immunol.13.1.251; White LC, 1996, IMMUNITY, V5, P365, DOI 10.1016/S1074-7613(00)80262-9; Xu XA, 1996, SCIENCE, V273, P794, DOI 10.1126/science.273.5276.794; Yamamoto K, 1997, BIOCHEM BIOPH RES CO, V233, P126, DOI 10.1006/bbrc.1997.6415; YUAN JP, 1994, MOL CELL BIOL, V14, P1657, DOI 10.1128/MCB.14.3.1657; Zheng WP, 1997, CELL, V89, P587, DOI 10.1016/S0092-8674(00)80240-8	59	65	67	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1999	274	10					6698	6703		10.1074/jbc.274.10.6698	http://dx.doi.org/10.1074/jbc.274.10.6698			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172BQ	10037767	hybrid			2022-12-25	WOS:000078902800089
J	Suschek, CV; Krischel, V; Bruch-Gerharz, D; Berendji, D; Krutmann, J; Kroncke, KD; Kolb-Bachofen, V				Suschek, CV; Krischel, V; Bruch-Gerharz, D; Berendji, D; Krutmann, J; Kroncke, KD; Kolb-Bachofen, V			Nitric oxide fully protects against UVA-induced apoptosis in tight correlation with Bcl-2 up-regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AORTIC ENDOTHELIAL-CELLS; TUMOR-NECROSIS-FACTOR; ULTRAVIOLET-LIGHT; CYTOCHROME-C; CYTOSKELETAL DAMAGE; INTERFERON-GAMMA; STRAND BREAKS; IN-VITRO; SYNTHASE; INHIBITION	A variety of toxic and modulating events induced by WA exposure are described to cause cell death via apoptosis, Recently, we found that UV irradiation of human skin leads to inducible nitric-oxide synthase (iNOS) expression in keratinocytes and endothelial cells (ECs). We have now searched for the role of MOS expression and nitric oxide (NO) synthesis in UVA-induced apoptosis as detected by DNA-specific fluorochrome labeling and in DNA fragmentation visualized by in situ nick translation in ECs, Activation with proinflammatory cytokines 24 h before WA exposure leading to iNOS expression and endogenous NO synthesis fully protects ECs from the onset of apoptosis. This protection was completely abolished in the presence of the iNOS inhibitor L-N-5-(1-iminoethyl)-ornithine (0.25 mM). Additionally, preincubation of cells with the NO donor (Z)-1-[N(2-aminoethyl) -N-(2-ammonioethyl)amino] diazen-1-ium-1,2-diolate at concentrations from 10 to 1000 mu M as an exogenous NO-generating source before UVA irradiation led to a dose-dependent inhibition of both DNA strand breaks and apoptosis, In search of the molecular mechanism responsible for the protective effect, we find that protection from UVA-induced apoptosis is tightly correlated with NO-mediated increases in Bcl-2 expression and a concomitant inhibition of WA-induced overexpression of Bar protein. In conclusion, we present evidence for a protective role of iNOS-derived NO in skin biology, because NO either endogenously produced or exogenously applied fully protects against WA-induced cell damage and death. me also show that the NO-mediated expression modulation of proteins of the Bcl-2 family, an event upstream of caspase activation, appears to be the molecular mechanism underlying this protection.	Univ Dusseldorf, Inst Immunobiol, Res Grp Immunobiol, D-40001 Dusseldorf, Germany; Univ Dusseldorf, Dept Dermatol, D-40001 Dusseldorf, Germany	Heinrich Heine University Dusseldorf; Heinrich Heine University Dusseldorf	Kolb-Bachofen, V (corresponding author), Univ Dusseldorf, Inst Immunobiol, Res Grp Immunobiol, Geb 14-80,POB 10 10 07, D-40001 Dusseldorf, Germany.							Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Antonsson B, 1997, SCIENCE, V277, P370, DOI 10.1126/science.277.5324.370; Berendji D, 1997, FEBS LETT, V405, P37, DOI 10.1016/S0014-5793(97)00150-6; BLACK HS, 1987, PHOTOCHEM PHOTOBIOL, V46, P213, DOI 10.1111/j.1751-1097.1987.tb04759.x; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CORBETT JA, 1993, P NATL ACAD SCI USA, V90, P1731, DOI 10.1073/pnas.90.5.1731; CUNNINGHAM ML, 1985, PHOTOCHEM PHOTOBIOL, V42, P125, DOI 10.1111/j.1751-1097.1985.tb01549.x; DELICONSTANTINOS G, 1995, BRIT J PHARMACOL, V114, P1257, DOI 10.1111/j.1476-5381.1995.tb13341.x; Dimmeler S, 1997, J EXP MED, V185, P601, DOI 10.1084/jem.185.4.601; FEHSEL K, 1991, AM J PATHOL, V139, P251; FEHSEL K, 1995, J IMMUNOL, V155, P2858; FINTER NB, 1969, J GEN VIROL, V5, P419, DOI 10.1099/0022-1317-5-3-419; FORSTERMANN U, 1994, HYPERTENSION, V23, P1121, DOI 10.1161/01.HYP.23.6.1121; GENARO AM, 1995, J CLIN INVEST, V95, P1884, DOI 10.1172/JCI117869; GODAR DE, 1995, PHOTOCHEM PHOTOBIOL, V62, P108, DOI 10.1111/j.1751-1097.1995.tb05246.x; GODAR DE, 1993, PHOTOCHEM PHOTOBIOL, V57, P1018, DOI 10.1111/j.1751-1097.1993.tb02965.x; GODAR DE, 1992, BIOL RESPONSES ULTRA, P65; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; Hale AJ, 1996, EUR J BIOCHEM, V236, P1, DOI 10.1111/j.1432-1033.1996.00001.x; HOLT PG, 1993, J EXP MED, V177, P397, DOI 10.1084/jem.177.2.397; KILBOURN RG, 1992, J NATL CANCER I, V84, P827, DOI 10.1093/jnci/84.11.827; KILBOURN RG, 1990, J NATL CANCER I, V82, P772, DOI 10.1093/jnci/82.9.772; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; KOLB H, 1992, DIABETOLOGIA, V35, P796; Kothakota S, 1997, SCIENCE, V278, P294, DOI 10.1126/science.278.5336.294; KRAJEWSKI S, 1993, CANCER RES, V53, P4701; Kroemer G, 1997, NAT MED, V3, P614, DOI 10.1038/nm0697-614; KRONCKE KD, 1995, BIOL CHEM H-S, V376, P327; Kroncke KD, 1997, NITRIC OXIDE-BIOL CH, V1, P107, DOI 10.1006/niox.1997.0118; Kuhn A, 1998, J INVEST DERMATOL, V111, P149, DOI 10.1046/j.1523-1747.1998.00253.x; LAMAS S, 1992, J CLIN INVEST, V90, P879, DOI 10.1172/JCI115963; Laurent M, 1996, BIOCHEM J, V314, P109, DOI 10.1042/bj3140109; LAZEBNIK YA, 1993, J CELL BIOL, V123, P7, DOI 10.1083/jcb.123.1.7; Liew FY, 1991, IMMUNOL TODAY, V12, P17; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Mannick JB, 1997, J BIOL CHEM, V272, P24125, DOI 10.1074/jbc.272.39.24125; MARAGOS CM, 1993, CANCER RES, V53, P564; MCGUIRE PG, 1987, LAB INVEST, V57, P94; MILLS CD, 1991, J IMMUNOL, V146, P2719; Mohr S, 1997, BIOCHEM BIOPH RES CO, V238, P387, DOI 10.1006/bbrc.1997.7304; OITVAI ZN, 1993, CELL, V74, P609; PEAK JG, 1991, MUTAT RES, V246, P187, DOI 10.1016/0027-5107(91)90121-4; PROBER JS, 1990, PHYSIOL REV, V70, P427; ROBINSON AP, 1986, IMMUNOLOGY, V57, P231; ROSHCHUPKIN DI, 1975, PHOTOCHEM PHOTOBIOL, V21, P63, DOI 10.1111/j.1751-1097.1975.tb06629.x; Rowan S, 1997, LEUKEMIA, V11, P457, DOI 10.1038/sj.leu.2400626; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SEDLAK TW, 1995, P NATL ACAD SCI USA, V92, P7834, DOI 10.1073/pnas.92.17.7834; SIRSJO A, 1994, FEBS LETT, V338, P191, DOI 10.1016/0014-5793(94)80363-3; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; SUSCHEK C, 1993, J IMMUNOL, V151, P3283; SUSCHEK C, 1994, AM J PATHOL, V145, P685; THOMAS DP, 1991, P 49 ANN M EL MICR S, P104; TILLY JL, 1995, ENDOCRINOLOGY, V136, P232, DOI 10.1210/en.136.1.232; TYRRELL RM, 1990, J PHOTOCH PHOTOBIO B, V4, P349, DOI 10.1016/1011-1344(90)85014-N; Tzeng E, 1997, SURGERY, V122, P255, DOI 10.1016/S0039-6060(97)90016-7; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; Wink DA, 1996, CURR TOP CELL REGUL, V34, P159, DOI 10.1016/S0070-2137(96)80006-9; WOOD KS, 1990, BIOCHEM BIOPH RES CO, V170, P80, DOI 10.1016/0006-291X(90)91243-L; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; ZAMANSKY GB, 1987, J INVEST DERMATOL, V89, P603, DOI 10.1111/1523-1747.ep12461366	61	145	151	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1999	274	10					6130	6137		10.1074/jbc.274.10.6130	http://dx.doi.org/10.1074/jbc.274.10.6130			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172BQ	10037696	hybrid			2022-12-25	WOS:000078902800018
J	Holthofer, H; Kretzler, M; Haltia, A; Solin, ML; Taanman, JW; Schagger, H; Kriz, W; Kerjaschki, D; Schlondorff, D				Holthofer, H; Kretzler, M; Haltia, A; Solin, ML; Taanman, JW; Schagger, H; Kriz, W; Kerjaschki, D; Schlondorff, D			Altered gene expression and functions of mitochondria in human nephrotic syndrome	FASEB JOURNAL			English	Article						proteinuria; congenital nephrotic syndrome; glomerular disease; differential display; cytochrome c oxidase	CYTOCHROME-C-OXIDASE; BLUE NATIVE ELECTROPHORESIS; COMPLEX-I DEFICIENCY; FINNISH TYPE; OXIDATIVE-PHOSPHORYLATION; MOLECULAR MECHANISMS; LIPID-PEROXIDATION; GLOMERULAR INJURY; HEYMANN NEPHRITIS; MESSENGER-RNA	The molecular basis of glomerular permselectivity remains largely unknown. The congenital nephrotic syndrome of the Finnish type (CNF) characterized by massive proteinuria already present but without extrarenal symptoms is a unique human disease model of pure proteinuria, In search of genes and pathophysiologic mechanisms associated with proteinuria, we used differential display-PCR to identify differences in gene expression between glomeruli from CNF and control kidneys, A distinctly underexpressed PCR product of the CNF kidneys showed over 98% identity with a mitochondrially encoded cytochrome c oxidase (COX I), Using a full-length COX I cDNA probe, we verified down-regulation of COX I mRNA to 1/4 of normal kidney values on Northern blots, In addition, transcripts of other mitochondrially encoded respiratory chain complexes showed a similar down-regulation whereas the respective nuclearly encoded complexes were expressed at comparable levels, Additional studies using histochemical, immunohistochemical, in situ hybridization, RT-PCR, and biochemical and electron microscopic methods all showed a mitochondrial involvement in the diseased kidneys but not in extrarenal blood vessels, As a secondary sign of mitochondrial dysfunction, excess lipid peroxidation products were found in glomerular structures in CNF samples, Our data suggest that mitochondrial dysfunction occurs in the kidneys of patients with CNF, with subsequent lipid peroxidation at the glomerular basement membrane, Our additional studies have revealed similar down-regulation of mitochondrial functions in experimental models of proteinuria, Thus, mitochondrial dysfunction may be a crucial pathophysiologic factor in this symptom.	Univ Helsinki, Div Bacteriol & Immunol, Haartman Inst, Dept Bacteriol & Immunol, FIN-00014 Helsinki, Finland; Univ Munich, Med Poliklin, D-8000 Munich, Germany; Univ Vienna, Dept Pathol, Vienna, Austria; Univ London, Dept Clin Neurosci, London, England; Univ Frankfurt, D-6000 Frankfurt, Germany; Univ Heidelberg, Dept Anat, Heidelberg, Germany	University of Helsinki; University of Munich; University of Vienna; University of London; Goethe University Frankfurt; Ruprecht Karls University Heidelberg	Holthofer, H (corresponding author), Univ Helsinki, Div Bacteriol & Immunol, Haartman Inst, Dept Bacteriol & Immunol, PB 21,Haartmaninkatu 3, FIN-00014 Helsinki, Finland.	Harry.Holthofer@Helsinki.fi	Taanman, Jan W/A-5379-2011	Taanman, Jan W/0000-0002-5476-9785				ANTHONY G, 1993, P NATL ACAD SCI USA, V90, P1652, DOI 10.1073/pnas.90.5.1652; BANCROFT JD, 1975, HISTOCHEMICAL TECHNI, P280; BENTLAGE H, 1995, EUR J BIOCHEM, V227, P909, DOI 10.1111/j.1432-1033.1995.tb20218.x; BRESOLIN N, 1994, MITOCHONDRIA DNA PRO, P221; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DIAMOND JR, 1992, AM J KIDNEY DIS, V19, P292, DOI 10.1016/S0272-6386(13)80013-3; GABAI VL, 1993, FEBS LETT, V327, P247, DOI 10.1016/0014-5793(93)80997-9; HALLIWELL B, 1994, LANCET, V344, P721, DOI 10.1016/S0140-6736(94)92211-X; HALLMAN NIILO, 1967, ACTA PAEDIAT SCAND SUPPL, V172., P75; Haltia A, 1996, PEDIATR RES, V40, P652, DOI 10.1203/00006450-199611000-00002; HOLMBERG C, 1995, PEDIATR NEPHROL, V9, P87, DOI 10.1007/BF00858984; HOLTHOFER H, 1994, KIDNEY INT, V45, P123, DOI 10.1038/ki.1994.14; Hsieh F, 1996, J AM SOC NEPHROL, V7, P647; JOHNS DR, 1995, NEW ENGL J MED, V333, P638, DOI 10.1056/NEJM199509073331007; JOHNSON RJ, 1994, KIDNEY INT, V45, P352, DOI 10.1038/ki.1994.45; KANWAR YS, 1991, SEMIN NEPHROL, V11, P390; KERJASCHKI D, 1994, KIDNEY INT, V45, P300, DOI 10.1038/ki.1994.39; Kerjaschki D, 1996, J AM SOC NEPHROL, V7, P2518; Kestila M, 1998, MOL CELL, V1, P575, DOI 10.1016/S1097-2765(00)80057-X; KIM K, 1995, BIOCHEM J, V306, P353, DOI 10.1042/bj3060353; KRETZLER M, 1996, AM J PHYSIOL, V271, P770; LANG H, 1994, BIOCHEM J, V299, P393, DOI 10.1042/bj2990393; LARSSON NG, 1990, PEDIATR RES, V28, P131, DOI 10.1203/00006450-199028020-00011; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; Luo XP, 1997, J CLIN INVEST, V99, P2877, DOI 10.1172/JCI119481; MANDEL LJ, 1993, NATURE, V361, P552, DOI 10.1038/361552a0; Mannikko M, 1996, J AM SOC NEPHROL, V7, P2700; MAYER A, 1995, CELL, V80, P127, DOI 10.1016/0092-8674(95)90457-3; MCCORMACK JG, 1994, MITOCHONDRIA DNA PRO, P221; MOGGIO M, 1989, INT J DEV NEUROSCI, V7, P5, DOI 10.1016/0736-5748(89)90040-3; Montine TJ, 1996, AM J PATHOL, V148, P89; NAGLEY P, 1991, TRENDS GENET, V7, P1, DOI 10.1016/0168-9525(91)90002-8; NEALE TJ, 1994, J CLIN INVEST, V94, P1577, DOI 10.1172/JCI117499; PABST R, 1983, KIDNEY INT, V24, P626, DOI 10.1038/ki.1983.203; Pitkanen S, 1996, J CLIN INVEST, V98, P345, DOI 10.1172/JCI118798; RAPOLA J, 1987, PEDIATR NEPHROL, V1, P441, DOI 10.1007/BF00849252; RENNKE HG, 1994, KIDNEY INT, V45, pS58; Sambrook J., 1989, MOL CLONING, pA1; Scarpulla RC, 1997, J BIOENERG BIOMEMBR, V29, P109, DOI 10.1023/A:1022681828846; SCHAGGER H, 1995, ELECTROPHORESIS, V16, P763, DOI 10.1002/elps.11501601125; SCHAGGER H, 1991, ANAL BIOCHEM, V199, P223, DOI 10.1016/0003-2697(91)90094-A; SCHAPIRA AHV, 1994, MITOCHONDRIA DNA PRO, P241; Shirato I, 1996, AM J PATHOL, V148, P1283; Taanman JW, 1997, HUM MOL GENET, V6, P935, DOI 10.1093/hmg/6.6.935; TAANMAN JW, 1993, BIOCHIM BIOPHYS ACTA, V1225, P95, DOI 10.1016/0925-4439(93)90128-N; Taanman JW, 1996, BBA-MOL BASIS DIS, V1315, P199, DOI 10.1016/0925-4439(95)00127-1; VANBIERVLIET JPGM, 1977, PEDIATR RES, V11, P1088, DOI 10.1203/00006450-197711100-00005; VOOS W, 1994, MITOCHONDRIA DNA PRO, P221; WALLACE DC, 1995, AM J HUM GENET, V57, P201	49	47	48	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	1999	13	3					523	532		10.1096/fasebj.13.3.523	http://dx.doi.org/10.1096/fasebj.13.3.523			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	174CF	10064619				2022-12-25	WOS:000079016000012
J	Jackson, M; Howie, SEM; Weller, R; Sabin, E; Hunter, JAA; McKenzie, RC				Jackson, M; Howie, SEM; Weller, R; Sabin, E; Hunter, JAA; McKenzie, RC			Psoriatic keratinocytes show reduced IRF-1 and STAT-1 alpha activation in response to gamma-IFN	FASEB JOURNAL			English	Article						psoriasis; gamma-interferon; fibronectin; KC; GAS sites	REGULATORY FACTOR-I; RECOMBINANT INTERFERON-GAMMA; STAT SIGNALING PATHWAY; NITRIC-OXIDE SYNTHASE; GROWTH-INHIBITION; T-LYMPHOCYTES; EXPRESSION; RECEPTOR; SKIN; APOPTOSIS	Psoriasis is a chronic inflammatory dermatosis characterized by hyperproliferative keratinocytes (MC), The skin lesions are infiltrated by T cells, which secrete gamma interferon (gamma-IFN) and are believed to be necessary to maintain the psoriatic phenotype, In normal KC, gamma-IFN is a potent inhibitor of proliferation, but proliferation of KC persists in psoriatic plaques despite the presence of gamma-lFN, Immunostaining of interferon regulatory factor-1 (IRF-1) revealed that IRF-1 was localized to the basal cells of the epidermis in normal and in nonlesional psoriatic skin, but was suprabasal or completely absent in lesional psoriatic skin. This finding led to the hypothesis that abnormal signaling in the gamma-IFN pathway may occur in psoriatic KC. To test this hypothesis, we measured activation of IRF-1 and signal transducer and activator of transcription (STAT)-1 alpha transcription factors in KC after stimulation with gamma-IFN, Primary cultures of KC from normal and nonlesional psoriatic skin were stimulated with gamma-IFN and subsequent transcription factor activation was measured by electrophoretic mobility shift assay, Psoriatic KC showed a reduced induction of IRF-1 and STAT-1 alpha activation after stimulation with gamma-IFN, compared with normal KC, Reduced activation of IRF-1 and STAT-lar in response to gamma-IFN indicates a fundamental defect in the growth and differentiation control of psoriatic KC in the absence of the influence of other cell types.	Univ Edinburgh, Dept Dermatol, RIE, Edinburgh EH3 9YW, Midlothian, Scotland; Univ Edinburgh, Dept Pathol, Edinburgh EH3 9YW, Midlothian, Scotland	Royal Infirmary of Edinburgh; University of Edinburgh; University of Edinburgh	McKenzie, RC (corresponding author), Univ Edinburgh, Dept Dermatol, RIE, Lauriston Bldg, Edinburgh EH3 9YW, Midlothian, Scotland.							ABDOLLAHI A, 1991, CELL GROWTH DIFFER, V2, P401; Bach EA, 1997, ANNU REV IMMUNOL, V15, P563, DOI 10.1146/annurev.immunol.15.1.563; BAKER BS, 1988, SCAND J IMMUNOL, V28, P735, DOI 10.1111/j.1365-3083.1988.tb01507.x; BARKER J N W N, 1991, Journal of Dermatological Science, V2, P106, DOI 10.1016/0923-1811(91)90019-T; BARKER JNWN, 1993, AM J PATHOL, V142, P1091; Chin YE, 1997, MOL CELL BIOL, V17, P5328, DOI 10.1128/MCB.17.9.5328; Chin YE, 1996, SCIENCE, V272, P719, DOI 10.1126/science.272.5262.719; Christophers E, 1996, INT ARCH ALLERGY IMM, V110, P199, DOI 10.1159/000237288; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Duhe RJ, 1998, P NATL ACAD SCI USA, V95, P126, DOI 10.1073/pnas.95.1.126; ELDER JT, 1994, ARCH DERMATOL, V130, P216, DOI 10.1001/archderm.130.2.216; FARRAR MA, 1993, ANNU REV IMMUNOL, V11, P571, DOI 10.1146/annurev.iy.11.040193.003035; FIERLBECK G, 1990, ARCH DERMATOL, V126, P351, DOI 10.1001/archderm.126.3.351; Gobert S, 1996, EMBO J, V15, P2434, DOI 10.1002/j.1460-2075.1996.tb00601.x; GREENLUND AC, 1994, EMBO J, V13, P1591, DOI 10.1002/j.1460-2075.1994.tb06422.x; HARADA H, 1993, SCIENCE, V259, P971, DOI 10.1126/science.8438157; HARADA H, 1989, CELL, V58, P729, DOI 10.1016/0092-8674(89)90107-4; Hobart M, 1997, J IMMUNOL, V158, P4260; Howie SEM, 1996, J INVEST DERMATOL, V106, P1218, DOI 10.1111/1523-1747.ep12348507; JONES JL, 1994, J PATHOL, V174, P77, DOI 10.1002/path.1711740203; KOTENKO SV, 1995, J BIOL CHEM, V270, P20915, DOI 10.1074/jbc.270.36.20915; KRUEGER GG, 1981, J CLIN INVEST, V68, P1548, DOI 10.1172/JCI110409; LIU SCC, 1983, J INVEST DERMATOL, V81, P54, DOI 10.1111/1523-1747.ep12538884; LOOK DC, 1994, J BIOL CHEM, V269, P8952; LORRE K, 1994, CLIN IMMUNOL IMMUNOP, V70, P81, DOI 10.1006/clin.1994.1014; Meraz MA, 1996, CELL, V84, P431, DOI 10.1016/S0092-8674(00)81288-X; MORHENN VB, 1987, ARCH DERMATOL, V123, P1633, DOI 10.1001/archderm.123.12.1633; NICKOLOFF BJ, 1989, BRIT J DERMATOL, V121, P161, DOI 10.1111/j.1365-2133.1989.tb01795.x; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; Sato T, 1997, BLOOD, V90, P4749, DOI 10.1182/blood.V90.12.4749.4749_4749_4758; Saunders N, 1996, J DERMATOL SCI, V13, P98, DOI 10.1016/S0923-1811(96)00535-X; SCHEYNIUS A, 1992, J INVEST DERMATOL, V98, P255, DOI 10.1111/1523-1747.ep12556086; Sirsjo A, 1996, BRIT J DERMATOL, V134, P643, DOI 10.1111/j.1365-2133.1996.tb06963.x; Spink J, 1997, J BIOL CHEM, V272, P24417, DOI 10.1074/jbc.272.39.24417; TAMURA T, 1995, NATURE, V376, P596, DOI 10.1038/376596a0; TANAKA N, 1994, CELL, V77, P829, DOI 10.1016/0092-8674(94)90132-5; VANDENOORD JJ, 1995, PATHOL RES PRACT, V191, P530, DOI 10.1016/S0344-0338(11)80872-1; WATANABE N, 1991, NUCLEIC ACIDS RES, V19, P4421, DOI 10.1093/nar/19.16.4421	38	40	43	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	1999	13	3					495	502		10.1096/fasebj.13.3.495	http://dx.doi.org/10.1096/fasebj.13.3.495			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	174CF	10064616				2022-12-25	WOS:000079016000009
J	Shiratsuchi, A; Kawasaki, Y; Ikemoto, M; Arai, H; Nakanishi, Y				Shiratsuchi, A; Kawasaki, Y; Ikemoto, M; Arai, H; Nakanishi, Y			Role of class B scavenger receptor type I in phagocytosis of apoptotic rat spermatogenic cells by Sertoli cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-DENSITY-LIPOPROTEIN; MALE GERM-CELLS; SR-BI; TESTICULAR CELLS; PRIMARY CULTURE; TESTIS; PHOSPHATIDYLSERINE; RECOGNITION; SURFACE; DIFFERENTIATION	Rat Sertoli cells phagocytose apoptotic spermatogenic cells, which consist mostly of spermatocytes, in primary culture by recognizing phosphatidylserine (PS) exposed on the surface of degenerating spermatogenic cells. We compared the mode of phagocytosis using spermatogenic cells at different stages of spermatogenesis. Spermatogenic cells were separated into several groups based on their ploidy, with purities of 60-90%. When the fractionated spermatogenic cell populations were subjected to a phagocytosis assay, cells with ploidies of In, 2n, and 4n were almost equally phagocytosed by Sertoli cells, AU the cell populations exposed PS on the cell surface, and phagocytosis of all cell populations was similarly inhibited by the addition of PS-containing liposomes, Class B scavenger receptor type I (SR-BI), a candidate for the PS receptor, was detected in Sertoli cells. Overexpression of the rat SR-BI cDNA increased the PS-mediated phagocytic activity of Sertoli cell-derived cell lines. Moreover, phagocytosis of spermatogenic cells by Sertoli cells was inhibited in the presence of an anti-SR-BI antibody. Finally, the addition of high density lipoprotein, a ligand specific for SR-BI, decreased both phagocytosis of spermatogenic cells and incorporation of PS-containing liposomes by Sertoli cells. In conclusion, SR-BI functions at least partly as a PS receptor, enabling Sertoli cells to recognize and phagocytose apoptotic spermatogenic cells at all stages of differentiation.	Kanazawa Univ, Fac Pharmaceut Sci, Kanazawa, Ishikawa 9200934, Japan; Kanazawa Univ, Grad Sch Nat Sci & Technol, Kanazawa, Ishikawa 9200934, Japan; Univ Tokyo, Grad Sch Pharmaceut Sci, Tokyo 1130033, Japan	Kanazawa University; Kanazawa University; University of Tokyo	Nakanishi, Y (corresponding author), Kanazawa Univ, Fac Pharmaceut Sci, 13-1 Takara Machi, Kanazawa, Ishikawa 9200934, Japan.	nakanaka@kenroku.kanazawa-u.ac.jp	Eckhardt, Erik/G-1567-2010; Shiratsuchi, Akiko/D-8391-2015; Nakanishi, Yoshinobu/D-4602-2014	Shiratsuchi, Akiko/0000-0002-7811-4409; Nakanishi, Yoshinobu/0000-0002-8767-3587				Acton S, 1996, SCIENCE, V271, P518, DOI 10.1126/science.271.5248.518; ACTON SL, 1994, J BIOL CHEM, V269, P21003; Allan D.J., 1987, P229; ALLAN DJ, 1992, CELL PROLIFERAT, V25, P241, DOI 10.1111/j.1365-2184.1992.tb01399.x; BASU SK, 1976, P NATL ACAD SCI USA, V73, P3178, DOI 10.1073/pnas.73.9.3178; BENNETT MR, 1995, CIRC RES, V77, P1136, DOI 10.1161/01.RES.77.6.1136; Braun RE, 1998, NAT GENET, V18, P202, DOI 10.1038/ng0398-202; BRINKWORTH MH, 1995, J REPROD FERTIL, V105, P25, DOI 10.1530/jrf.0.1050025; Byers S., 1993, SERTOLI CELL, P461; CALLARD GV, 1995, DEV GENET, V16, P140, DOI 10.1002/dvg.1020160207; CasciolaRosen L, 1996, P NATL ACAD SCI USA, V93, P1624, DOI 10.1073/pnas.93.4.1624; CHEMES H, 1986, ENDOCRINOLOGY, V119, P1673, DOI 10.1210/endo-119-4-1673; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Dunkel L, 1997, CELL DEATH DIFFER, V4, P171, DOI 10.1038/sj.cdd.4400234; DYM M, 1994, P NATL ACAD SCI USA, V91, P11287, DOI 10.1073/pnas.91.24.11287; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; FADOK VA, 1992, J IMMUNOL, V148, P2207; Fadok VA, 1998, CELL DEATH DIFFER, V5, P551, DOI 10.1038/sj.cdd.4400404; Fujimoto I, 1998, CELL DEATH DIFFER, V5, P426, DOI 10.1038/sj.cdd.4400362; Fukasawa M, 1996, EXP CELL RES, V222, P246, DOI 10.1006/excr.1996.0030; Grandjean V, 1997, DEV BIOL, V184, P165, DOI 10.1006/dbio.1997.8518; HUCKINS C, 1978, ANAT REC, V190, P905, DOI 10.1002/ar.1091900410; JOKINEN EV, 1994, J BIOL CHEM, V269, P26411; KERR JB, 1992, J REPROD FERTIL, V95, P825, DOI 10.1530/jrf.0.0950825; KIKUCHI H, 1993, BIOCHIM BIOPHYS ACTA, V1162, P171, DOI 10.1016/0167-4838(93)90144-G; KOOPMAN G, 1994, BLOOD, V84, P1415, DOI 10.1182/blood.V84.5.1415.1415; Landschulz KT, 1996, J CLIN INVEST, V98, P984, DOI 10.1172/JCI118883; Liles WC, 1996, J EXP MED, V184, P429, DOI 10.1084/jem.184.2.429; Martin Seamus J., 1996, P107; MARTIN SJ, 1995, J EXP MED, V182, P1545, DOI 10.1084/jem.182.5.1545; Martin SJ, 1996, J BIOL CHEM, V271, P28753, DOI 10.1074/jbc.271.46.28753; MATHER JP, 1982, ANN NY ACAD SCI, V383, P44, DOI 10.1111/j.1749-6632.1982.tb23161.x; MIETHING A, 1992, CELL TISSUE RES, V267, P583, DOI 10.1007/BF00319381; Mizuno K, 1996, CELL DEATH DIFFER, V3, P119; Mizutani T, 1997, BIOCHEM BIOPH RES CO, V234, P499, DOI 10.1006/bbrc.1997.6646; MOROHASHI K, 1993, MOL ENDOCRINOL, V7, P1196, DOI 10.1210/me.7.9.1196; Murao K, 1997, J BIOL CHEM, V272, P17551, DOI 10.1074/jbc.272.28.17551; NAGAO Y, 1989, IN VITRO CELL DEV B, V25, P1088, DOI 10.1007/BF02621259; NISHIKAWA K, 1990, J BIOL CHEM, V265, P5226; Oka K, 1998, P NATL ACAD SCI USA, V95, P9535, DOI 10.1073/pnas.95.16.9535; PINEAU C, 1991, CELL TISSUE RES, V264, P589, DOI 10.1007/BF00319048; RASSOULZADEGAN M, 1993, CELL, V75, P997, DOI 10.1016/0092-8674(93)90543-Y; Ren Y, 1998, CELL DEATH DIFFER, V5, P563, DOI 10.1038/sj.cdd.4400407; RIGOTTI A, 1995, J BIOL CHEM, V270, P16221, DOI 10.1074/jbc.270.27.16221; Rigotti A, 1997, CURR OPIN LIPIDOL, V8, P181, DOI 10.1097/00041433-199706000-00009; RUSSELL LD, 1977, ANAT RECORD, V187, P347, DOI 10.1002/ar.1091870307; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Savill J, 1997, BRIT MED BULL, V53, P491; SAVILL J, 1993, IMMUNOL TODAY, V14, P131, DOI 10.1016/0167-5699(93)90215-7; SHIKONE T, 1994, BIOL REPROD, V51, P865, DOI 10.1095/biolreprod51.5.865; Shiratsuchi A, 1998, BIOCHEM BIOPH RES CO, V246, P549, DOI 10.1006/bbrc.1998.8663; Shiratsuchi A, 1997, J BIOL CHEM, V272, P2354, DOI 10.1074/jbc.272.4.2354; TAMARU M, 1990, BIOCHIM BIOPHYS ACTA, V1049, P331, DOI 10.1016/0167-4781(90)90106-C; TOKUDA N, 1992, J UROLOGY, V147, P278, DOI 10.1016/S0022-5347(17)37213-0; UEYAMA H, 1984, MOL CELL BIOL, V4, P1073, DOI 10.1128/MCB.4.6.1073; Varban ML, 1998, P NATL ACAD SCI USA, V95, P4619, DOI 10.1073/pnas.95.8.4619; VERHOVEN B, 1995, J EXP MED, V182, P1597, DOI 10.1084/jem.182.5.1597; Webb NR, 1998, J BIOL CHEM, V273, P15241, DOI 10.1074/jbc.273.24.15241; WOLGEMUTH DJ, 1985, GAMETE RES, V12, P1, DOI 10.1002/mrd.1120120102; Wyllie A H, 1980, Int Rev Cytol, V68, P251; ZACHOWSKI A, 1993, BIOCHEM J, V294, P1; Zwaal RFA, 1997, BLOOD, V89, P1121, DOI 10.1182/blood.V89.4.1121	62	131	133	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 26	1999	274	9					5901	5908		10.1074/jbc.274.9.5901	http://dx.doi.org/10.1074/jbc.274.9.5901			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	170KG	10026214	hybrid			2022-12-25	WOS:000078804400085
J	Suttles, J; Milhorn, DM; Miller, RW; Poe, JC; Wahl, LM; Stout, RD				Suttles, J; Milhorn, DM; Miller, RW; Poe, JC; Wahl, LM; Stout, RD			CD40 signaling of monocyte inflammatory cytokine synthesis through an ERK1/2-dependent pathway - A target of interleukin (IL)-4 and IL-10 anti-inflammatory action	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; NECROSIS-FACTOR-ALPHA; N-TERMINAL KINASE; EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; CD40-CD40 LIGAND INTERACTIONS; COLLAGEN-INDUCED ARTHRITIS; CROSS-LINKING CD40; HYPER-IGM SYNDROME; T-CELL; B-CELLS	Ligation of CD40 on monocytes through its interaction with CD40 ligand (CD154) present on activated T helper cells, results in activation of monocyte inflammatory cytokine synthesis and rescue of monocytes from apoptosis induced through serum deprivation, Both of these consequences of CD40 stimulation have been shown to be dependent on the induction of protein tyrosine kinase activity, CD40-mediated activation of protein tyrosine kinase activity and subsequent inflammatory cytokine production are abrogated by treatment of monocytes with the T helper type 2 cytokines interleukin 4 (IL-4) and interleukin 10 (IL-10), In the current study we demonstrate that stimulation of monocytes through CD40 resulted in the phosphorylation and activation of the extracellular signal-regulated kinases 1 and 2 (ERK1/2) mitogen-activated protein kinases, whereas phosphorylation of mitogen-activated protein kinases family members p38 and c-Jun N-terminal kinase was not observed in response to this stimuli over the time course examined, PD98059, an inhibitor of the upstream activator of ERK1/2, the MAP/ERK kinase MEK1/2, suppressed IL-1 beta and tumor necrosis factor-alpha production in a dose-dependent fashion, Pretreatment of monocytes with IL-4 and IL-10 inhibited CD40-mediated activation of ERK1/2 kinase activity when used individually, and are enhanced in effectiveness when used in combination. Together, the data demonstrate that CD40-mediated induction of IL-1 beta and tumor necrosis factor-a synthesis is dependent on a MEK/ERK pathway which is obstructed by signals generated through the action of IL-4 and IL-10.	E Tennessee State Univ, Quillen Dishner Coll Med, Dept Biochem & Mol Biol, Johnson City, TN 37614 USA; E Tennessee State Univ, Quillen Dishner Coll Med, Dept Microbiol, Johnson City, TN 37614 USA; NIDR, NIH, Immunopathol Sect, Bethesda, MD 20892 USA	East Tennessee State University; East Tennessee State University; National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	Suttles, J (corresponding author), E Tennessee State Univ, Quillen Dishner Coll Med, Dept Biochem & Mol Biol, Box 70581, Johnson City, TN 37614 USA.			Poe, Jonathan/0000-0002-7789-1564	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI034875] Funding Source: NIH RePORTER; NIAID NIH HHS [AI34875] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AagaardTillery KM, 1996, J IMMUNOL, V156, P4543; ALDERSON MR, 1993, J EXP MED, V178, P669, DOI 10.1084/jem.178.2.669; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; ARUFFO A, 1993, CELL, V72, P291, DOI 10.1016/0092-8674(93)90668-G; BANCHEREAU J, 1994, ANNU REV IMMUNOL, V12, P881, DOI 10.1146/annurev.iy.12.040194.004313; Berberich I, 1996, EMBO J, V15, P92, DOI 10.1002/j.1460-2075.1996.tb00337.x; BERBERICH I, 1994, J IMMUNOL, V153, P4357; CALLARD RE, 1993, IMMUNOL TODAY, V14, P559, DOI 10.1016/0167-5699(93)90188-Q; Carayanniotis G, 1997, IMMUNOLOGY, V90, P421, DOI 10.1111/j.1365-2567.1997.00421.x; CAUX C, 1994, J EXP MED, V180, P1263, DOI 10.1084/jem.180.4.1263; CHENG GH, 1995, SCIENCE, V267, P1494, DOI 10.1126/science.7533327; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; Denfeld RW, 1996, EUR J IMMUNOL, V26, P2329, DOI 10.1002/eji.1830261009; DURIE FH, 1993, SCIENCE, V261, P1328, DOI 10.1126/science.7689748; Falcone M, 1998, J IMMUNOL, V160, P4822; FARIS M, 1994, J EXP MED, V179, P1923, DOI 10.1084/jem.179.6.1923; FINBLOOM DS, 1995, J IMMUNOL, V155, P1079; FRANCIS DA, 1995, INT IMMUNOL, V7, P151, DOI 10.1093/intimm/7.2.151; GENG Y, 1994, P NATL ACAD SCI USA, V91, P8602, DOI 10.1073/pnas.91.18.8602; Gerritse K, 1996, P NATL ACAD SCI USA, V93, P2499, DOI 10.1073/pnas.93.6.2499; Grewal IS, 1996, SCIENCE, V273, P1864, DOI 10.1126/science.273.5283.1864; Hambleton J, 1996, P NATL ACAD SCI USA, V93, P2774, DOI 10.1073/pnas.93.7.2774; Hanissian SH, 1997, IMMUNITY, V6, P379, DOI 10.1016/S1074-7613(00)80281-2; HART PH, 1989, P NATL ACAD SCI USA, V86, P3803, DOI 10.1073/pnas.86.10.3803; HISCOTT J, 1993, MOL CELL BIOL, V13, P6231, DOI 10.1128/MCB.13.10.6231; Hogaboam CM, 1997, J CLIN INVEST, V100, P2766, DOI 10.1172/JCI119823; Horsfall AC, 1997, J IMMUNOL, V159, P5687; Hsu YM, 1997, J BIOL CHEM, V272, P911, DOI 10.1074/jbc.272.2.911; HU HM, 1994, J BIOL CHEM, V269, P30069; IKEJIMA T, 1990, J INFECT DIS, V162, P215, DOI 10.1093/infdis/162.1.215; Karras JG, 1997, J IMMUNOL, V159, P4350; Kashiwada M, 1996, EUR J IMMUNOL, V26, P1451, DOI 10.1002/eji.1830260708; Kashiwada M, 1998, J EXP MED, V187, P237, DOI 10.1084/jem.187.2.237; KOMINATO Y, 1995, MOL CELL BIOL, V15, P59; KORTHAUER U, 1993, NATURE, V361, P539, DOI 10.1038/361539a0; LALMANACHGIRARD AC, 1993, J EXP MED, V177, P1215, DOI 10.1084/jem.177.4.1215; Lebeaut A, 1997, EUR CYTOKINE NETW, V8, P303; Leonard WJ, 1998, ANNU REV IMMUNOL, V16, P293, DOI 10.1146/annurev.immunol.16.1.293; Li YY, 1996, J IMMUNOL, V157, P1440; Mach F, 1997, P NATL ACAD SCI USA, V94, P1931, DOI 10.1073/pnas.94.5.1931; MOORE KW, 1993, ANNU REV IMMUNOL, V11, P165, DOI 10.1146/annurev.immunol.11.1.165; Moreland LW, 1997, NEW ENGL J MED, V337, P141, DOI 10.1056/NEJM199707173370301; NAKAJIMA T, 1993, P NATL ACAD SCI USA, V90, P2207, DOI 10.1073/pnas.90.6.2207; Narula SK, 1998, AGENT ACTION SUPPL, V49, P57; Nicholson SE, 1998, J LEUKOCYTE BIOL, V63, P665, DOI 10.1002/jlb.63.6.665; Padmore L, 1997, CELL IMMUNOL, V177, P119, DOI 10.1006/cimm.1997.1102; Poe JC, 1997, J IMMUNOL, V159, P846; Purkerson JM, 1998, J IMMUNOL, V160, P2121; Reinhard C, 1997, EMBO J, V16, P1080, DOI 10.1093/emboj/16.5.1080; RHOADES KL, 1992, J BIOL CHEM, V267, P22102; Ridge JP, 1998, NATURE, V393, P474, DOI 10.1038/30989; Ridley SH, 1997, J IMMUNOL, V158, P3165; ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0; Roulston A, 1998, J BIOL CHEM, V273, P10232, DOI 10.1074/jbc.273.17.10232; Sacca R, 1997, CURR OPIN IMMUNOL, V9, P851, DOI 10.1016/S0952-7915(97)80189-6; Sakata N, 1995, J BIOL CHEM, V270, P30823, DOI 10.1074/jbc.270.51.30823; Sanghera JS, 1996, J IMMUNOL, V156, P4457; Shaw MK, 1997, J EXP MED, V185, P1711, DOI 10.1084/jem.185.9.1711; SLUSS HK, 1994, MOL CELL BIOL, V14, P8376, DOI 10.1128/MCB.14.12.8376; Soong L, 1996, IMMUNITY, V4, P263, DOI 10.1016/S1074-7613(00)80434-3; STOUT RD, 1993, CURR OPIN IMMUNOL, V5, P398, DOI 10.1016/0952-7915(93)90059-2; Stout RD, 1996, IMMUNOL TODAY, V17, P487, DOI 10.1016/0167-5699(96)10060-I; Stout RD, 1996, J IMMUNOL, V156, P8; Sutherland CL, 1996, J IMMUNOL, V157, P3381; Suttles J, 1996, J LEUKOCYTE BIOL, V60, P651, DOI 10.1002/jlb.60.5.651; Swantek JL, 1997, MOL CELL BIOL, V17, P6274, DOI 10.1128/MCB.17.11.6274; Tanaka Y, 1996, INFLAMM RES, V45, P283, DOI 10.1007/BF02280992; TIAN LC, 1995, EUR J IMMUNOL, V25, P306, DOI 10.1002/eji.1830250152; TSUKADA J, 1994, MOL CELL BIOL, V14, P7285, DOI 10.1128/MCB.14.11.7285; UCKUN FM, 1991, J BIOL CHEM, V266, P17478; VANNIER E, 1992, P NATL ACAD SCI USA, V89, P4076, DOI 10.1073/pnas.89.9.4076; WAGNER DH, 1994, EUR J IMMUNOL, V24, P3148, DOI 10.1002/eji.1830241235; WAHL LM, 1984, CELL IMMUNOL, V85, P373, DOI 10.1016/0008-8749(84)90251-X; Whitmarsh AJ, 1996, J MOL MED-JMM, V74, P589, DOI 10.1007/s001090050063; Yao J, 1997, J BIOL CHEM, V272, P17795, DOI 10.1074/jbc.272.28.17795; YELLIN MJ, 1991, J IMMUNOL, V147, P3389; YELLIN MJ, 1995, J LEUKOCYTE BIOL, V58, P209, DOI 10.1002/jlb.58.2.209; YELLIN MJ, 1995, J EXP MED, V182, P1857, DOI 10.1084/jem.182.6.1857; YELLIN MJ, 1994, J IMMUNOL, V153, P666	80	97	97	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 26	1999	274	9					5835	5842		10.1074/jbc.274.9.5835	http://dx.doi.org/10.1074/jbc.274.9.5835			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	170KG	10026206	hybrid			2022-12-25	WOS:000078804400077
J	Hagemann, D; Troppmair, J; Rapp, UR				Hagemann, D; Troppmair, J; Rapp, UR			Cot protooncoprotein activates the dual specificity kinases MEK-1 and SEK-1 and induces differentiation of PC12 cells	ONCOGENE			English	Article						cot; classic cytoplasmic cascade; stress kinase pathway; transformation; differentiation	PROTEIN-KINASE; SIGNAL-TRANSDUCTION; C-JUN; MAMMALIAN-CELLS; GENE-PRODUCT; MAP KINASES; RAF; GROWTH; TPL-2; TRANSFORMATION	Mitogenic signals initiated at the plasma membrane are transmitted to the nucleus through an intricate signalling network. We identified the protooncoprotein Cot as a new component of mitogenic signalling cascades, which activates both the classic cytoplasmic cascade and the SAFE stress pathway. Wildtype and activated Cot phosphorylate and activate MEK-1 and SEK-1 in vitro. These findings are consistent with the sequence homology between Cot and the rat gene Tpl-2. Expression of oncogenic Cot in 293, NIH3T3 and PC12 cells leads to in vivo phosphorylation of endogenous c-Jun and Erk-1/2 suggesting that the serine/threonine kinase Cot functions beside c-Raf-l and Mos asa direct activator of MEK-1. Furthermore, we have examined the biological effects of Cot on the phenotype of fibroblastic and neuronal cells. In order to test a potential c-Raf-l dependency of Cot transformation, the effect of oncogenic Cot on Raf revertant CHP25 cells was determined. Cot could restore the transformed phenotype indicating that Cot transformation is not dependent on active c-Raf-l and that Cot is not a target for the putative Raf inhibitor, which is presumably active in the revertant cell line. Expression of oncogenic versions of Raf as well as v-Mos leads to differentiation of PC12 cells. Cot also induces neurite outgrowth of PC12 cells. These data are consistent with the role of Cot in the classic mitogenic cascade and suggest that the simultaneously activated JNK/SAPK stress pathway has no antagonistic effects in this context.	Univ Wurzburg, Inst Med Strahlenkunde & Zellforsch, D-97078 Wurzburg, Germany	University of Wurzburg	Rapp, UR (corresponding author), Univ Wurzburg, Inst Med Strahlenkunde & Zellforsch, Versbacher Str 5, D-97078 Wurzburg, Germany.			Troppmair, Jakob/0000-0002-0611-3837				ALESSI DR, 1994, EMBO J, V13, P1610, DOI 10.1002/j.1460-2075.1994.tb06424.x; AOKI M, 1993, J BIOL CHEM, V268, P22723; AVRUCH J, 1994, TRENDS BIOCHEM SCI, V19, P279, DOI 10.1016/0968-0004(94)90005-1; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; Cai H, 1997, MOL CELL BIOL, V17, P732, DOI 10.1128/MCB.17.2.732; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CREWS CM, 1992, P NATL ACAD SCI USA, V89, P8205, DOI 10.1073/pnas.89.17.8205; DAUM G, 1994, TRENDS BIOCHEM SCI, V19, P474, DOI 10.1016/0968-0004(94)90133-3; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; Fanger GR, 1997, CURR OPIN GENET DEV, V7, P67, DOI 10.1016/S0959-437X(97)80111-6; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HEIDECKER G, 1989, GENES SIGNAL TRANSDU, P339; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Kerkhoff E, 1997, MOL CELL BIOL, V17, P2576, DOI 10.1128/MCB.17.5.2576; KOLCH W, 1993, ONCOGENE, V8, P361; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Leppa S, 1998, EMBO J, V17, P4404, DOI 10.1093/emboj/17.15.4404; Ludwig S, 1996, MOL CELL BIOL, V16, P6687; MAKRIS A, 1993, J VIROL, V67, P4283, DOI 10.1128/JVI.67.7.4283-4289.1993; MCCARTHY SA, 1995, GENE DEV, V9, P1953, DOI 10.1101/gad.9.16.1953; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MIYOSHI J, 1991, MOL CELL BIOL, V11, P4088, DOI 10.1128/MCB.11.8.4088; Morrison DK, 1997, CURR OPIN CELL BIOL, V9, P174, DOI 10.1016/S0955-0674(97)80060-9; PATRIOTIS C, 1994, P NATL ACAD SCI USA, V91, P9755, DOI 10.1073/pnas.91.21.9755; PATRIOTIS C, 1993, P NATL ACAD SCI USA, V90, P2251, DOI 10.1073/pnas.90.6.2251; RAPP UR, 1988, COLD SPRING HARB SYM, V53, P173, DOI 10.1101/SQB.1988.053.01.023; RAPP UR, 1991, ONCOGENE, V6, P495; RAPP UR, 1983, P NATL ACAD SCI-BIOL, V80, P4218, DOI 10.1073/pnas.80.14.4218; RAPP UR, 1983, J VIROL, V45, P914, DOI 10.1128/JVI.45.3.914-924.1983; RAPP UR, 1978, P NATL ACAD SCI USA, V75, P2468, DOI 10.1073/pnas.75.5.2468; RAPP UR, 1988, HDB ONCOGENES, P213; RAPP UR, 1994, FOS JUN FAMILIES TRA, P221; ROBBINS DJ, 1993, J BIOL CHEM, V268, P5097; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; Salmeron A, 1996, EMBO J, V15, P817, DOI 10.1002/j.1460-2075.1996.tb00417.x; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SLUPSKY JR, 1998, CELL GROWTH ONCOGENE, P75; TROPPMAIR J, 1994, J BIOL CHEM, V269, P7030; Wixler V, 1996, FEBS LETT, V385, P131, DOI 10.1016/0014-5793(96)00363-8; Woodgett JR, 1996, CANCER SURV, V27, P127; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; YAN MH, 1994, NATURE, V372, P798	45	37	39	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 18	1999	18	7					1391	1400		10.1038/sj.onc.1202431	http://dx.doi.org/10.1038/sj.onc.1202431			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	167UK	10050876				2022-12-25	WOS:000078651600001
J	Gatti, A; Huang, ZD; Tuazon, PT; Traugh, JA				Gatti, A; Huang, ZD; Tuazon, PT; Traugh, JA			Multisite autophosphorylation of p21-activated protein kinase gamma-PAK as a function of activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYACRYLAMIDE-GEL ELECTROPHORESIS; MOLECULAR-CLONING; IDENTIFICATION; CLEAVAGE; GTPASES; FAMILY; PHOSPHORYLATION; RECEPTOR; PEPTIDES; STE20	p21-activated protein kinase (PAK) is a family of serine/threonine kinases whose activity is stimulated by binding to small G-proteins such as Cdc42 and subsequent autophosphorylation, Focusing on the ubiquitous gamma-isoform of PAK in this study, baculovirus-infected insect cells were used to obtain recombinant gamma-PAK, while native gamma-PAK was isolated from rabbit reticulocytes, Two-dimensional gel electrophoresis of gamma-PAK followed by immunoblot analysis revealed a similar profile for native and recombinant gamma-PAK, both consisting of multiple protein spots. Following Cdc42-stimulated autophosphorylation, the two-dimensional profiles of native and recombinant gamma-PAK were characterized by a similar acidic shift, suggesting a common response to Cdc42. To understand the effect of differential phosphorylation on its activation status, gamma-PAK autophosphorylation was conducted in the presence or absence of activators such as Cdc42 and histone II-AS, followed by tryptic digestion and comparative two-dimensional phosphopeptide mapping. The major phosphopeptides were subjected to a combination of manual and automated amino acid sequencing. Overall, eight autophosphorylation sites were identified in Cdc42-activated gamma-PAK, six of which are in common with those previously reported in alpha-PAK, while Ser-19 and Ser-165 appear to be uniquely phosphorylated in the gamma-form, Further, the phosphorylation of Ser-141, Ser-165, and Thr-402 was found to correlate with gamma-PAK activation.	Univ Calif Riverside, Dept Biochem, Riverside, CA 92521 USA	University of California System; University of California Riverside	Traugh, JA (corresponding author), Univ Calif Riverside, Dept Biochem, Riverside, CA 92521 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026738] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM26738] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allen KM, 1998, NAT GENET, V20, P25, DOI 10.1038/1675; BAGRODIA S, 1995, J BIOL CHEM, V270, P22731, DOI 10.1074/jbc.270.39.22731; Bokoch GM, 1998, J BIOL CHEM, V273, P8137, DOI 10.1074/jbc.273.14.8137; Brown JL, 1996, CURR BIOL, V6, P598, DOI 10.1016/S0960-9822(02)00546-8; Daniels RH, 1998, EMBO J, V17, P754, DOI 10.1093/emboj/17.3.754; Dharmawardhane S, 1997, J CELL BIOL, V138, P1265, DOI 10.1083/jcb.138.6.1265; Galisteo ML, 1996, J BIOL CHEM, V271, P20997, DOI 10.1074/jbc.271.35.20997; Gatti A, 1997, EUR J BIOCHEM, V249, P92, DOI 10.1111/j.1432-1033.1997.t01-1-00092.x; Gatti A, 1999, ANAL BIOCHEM, V266, P198, DOI 10.1006/abio.1998.2955; HILLIARD GM, 1994, BIOCHEMISTRY-US, V33, P4300, DOI 10.1021/bi00180a026; Jakobi R, 1996, J BIOL CHEM, V271, P6206, DOI 10.1074/jbc.271.11.6206; JAKOBI R, 1998, FASEB J, V12, P343; KNAUS UG, 1995, SCIENCE, V269, P221, DOI 10.1126/science.7618083; KOZMA SC, 1993, J BIOL CHEM, V268, P7134; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee N, 1997, P NATL ACAD SCI USA, V94, P13642, DOI 10.1073/pnas.94.25.13642; Lim L, 1996, EUR J BIOCHEM, V242, P171, DOI 10.1111/j.1432-1033.1996.0171r.x; Lui M, 1996, ANAL BIOCHEM, V241, P156, DOI 10.1006/abio.1996.0393; MANSER E, 1995, J BIOL CHEM, V270, P25070, DOI 10.1074/jbc.270.42.25070; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; Manser E, 1997, MOL CELL BIOL, V17, P1129, DOI 10.1128/MCB.17.3.1129; MARTIN GA, 1995, EMBO J, V14, P1970, DOI 10.1002/j.1460-2075.1995.tb07189.x; MCDONALD JIS, 1994, J BIOL CHEM, V269, P10529; MEYER HE, 1986, FEBS LETT, V204, P61, DOI 10.1016/0014-5793(86)81388-6; Rooney RD, 1996, J BIOL CHEM, V271, P21498, DOI 10.1074/jbc.271.35.21498; Rudel T, 1997, SCIENCE, V276, P1571, DOI 10.1126/science.276.5318.1571; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Sells MA, 1997, TRENDS CELL BIOL, V7, P162, DOI 10.1016/S0962-8924(97)01003-9; SULLIVAN S, 1991, ANAL BIOCHEM, V197, P65, DOI 10.1016/0003-2697(91)90356-X; TAHARA SM, 1981, J BIOL CHEM, V256, P1558; TAHARA SM, 1982, EUR J BIOCHEM, V126, P395; TEO M, 1995, J BIOL CHEM, V270, P26690, DOI 10.1074/jbc.270.44.26690; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Tuazon PT, 1998, BIOCHEMISTRY-US, V37, P17024, DOI 10.1021/bi982103o; Tuazon PT, 1997, BIOCHEMISTRY-US, V36, P16059, DOI 10.1021/bi9717845; Walter BN, 1998, J BIOL CHEM, V273, P28733, DOI 10.1074/jbc.273.44.28733; WEST MHP, 1984, ELECTROPHORESIS, V5, P133, DOI 10.1002/elps.1150050302; Yu JS, 1998, BIOCHEM J, V334, P121, DOI 10.1042/bj3340121; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934	39	88	90	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 19	1999	274	12					8022	8028		10.1074/jbc.274.12.8022	http://dx.doi.org/10.1074/jbc.274.12.8022			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	178LU	10075701	hybrid			2022-12-25	WOS:000079268100060
J	Gurrola, GB; Arevalo, C; Sreekumar, R; Lokuta, AJ; Walker, JW; Valdivia, HH				Gurrola, GB; Arevalo, C; Sreekumar, R; Lokuta, AJ; Walker, JW; Valdivia, HH			Activation of ryanodine receptors by imperatoxin A and a peptide segment of the II-III loop of the dihydropyridine receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SKELETAL-MUSCLE; SARCOPLASMIC-RETICULUM; FK506-BINDING PROTEIN; RELEASE; CHANNEL; CALCIUM; VENOM; ACID; REGIONS; MUTANT	Excitation-contraction coupling in skeletal muscle is believed to be triggered by direct protein-protein interactions between the sarcolemmal dihydropyridine-sensitive Ca2+ channel and the Ca2+ release channel/ryanodine receptor (RyR) of sarcoplasmic reticulum. A 138-amino acid cytoplasmic loop between repeats II and III of the (alpha(1), subunit of the skeletal dihydropyridine receptor (the II-III loop) interacts with a region of the RyR to elicit Ca2+ release. In addition, small segments (10-20 amino acid residues) of the II-III loop retain the capacity to activate Ca2+ release. Imperatoxin A, a 33-amino acid peptide from the scorpion Pandinus imperator, binds directly to the RyR and displays structural and functional homology with an activating segment of the II-III loop (Glu(666)-Leu(690)), Mutations in a structural motif composed of a cluster of basic amino acids followed by Ser or Thr dramatically reduce or completely abolish the capacity of the peptides to activate RyRs, Thus, the Imperatoxin A-RyR interaction mimics critical molecular characteristics of the II-III loop-RyR interaction and may be a useful tool to elucidate the molecular mechanism that couples membrane depolarization to sarcoplasmic reticulum Ca2+ release in vivo.	Univ Wisconsin, Sch Med, Dept Physiol, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Valdivia, HH (corresponding author), Univ Wisconsin, Sch Med, Dept Physiol, 1300 Univ Ave, Madison, WI 53706 USA.	valdivia@physiology.wisc.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL055438, P01HL047053] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01 HL47053, HL55438] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARMSTRONG CM, 1972, BIOCHIM BIOPHYS ACTA, V267, P605, DOI 10.1016/0005-2728(72)90194-6; BERS DM, 1991, EXCITATION CONTRACTI; Beurg M, 1998, BIOPHYS J, V74, pA235; BLOCK BA, 1988, J CELL BIOL, V107, P2587, DOI 10.1083/jcb.107.6.2587; BRILLANTES AMB, 1994, CELL, V77, P513, DOI 10.1016/0092-8674(94)90214-3; CHANDLER WK, 1976, J PHYSIOL-LONDON, V254, P285, DOI 10.1113/jphysiol.1976.sp011233; CORDEIRO MD, 1992, FEBS LETT, V310, P153, DOI 10.1016/0014-5793(92)81318-G; Dudley SC, 1995, BIOPHYS J, V69, P1657, DOI 10.1016/S0006-3495(95)80045-7; El-Hayek R, 1998, BIOCHEMISTRY-US, V37, P7015, DOI 10.1021/bi972907o; ELHAYEK R, 1995, J BIOL CHEM, V270, P28696, DOI 10.1074/jbc.270.48.28696; ELHAYEK R, 1995, J BIOL CHEM, V270, P22116, DOI 10.1074/jbc.270.38.22116; FABIATO A, 1985, J GEN PHYSIOL, V85, P247, DOI 10.1085/jgp.85.2.247; HAGIWARA K, 1990, BIOMED RES-TOKYO, V11, P181, DOI 10.2220/biomedres.11.181; HIDALGO P, 1995, SCIENCE, V268, P307, DOI 10.1126/science.7716527; HIGASHIJIMA T, 1988, J BIOL CHEM, V263, P6491; HILLYARD DR, 1992, NEURON, V9, P69, DOI 10.1016/0896-6273(92)90221-X; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; Leong P, 1998, J BIOL CHEM, V273, P7791, DOI 10.1074/jbc.273.14.7791; LINDSAY ARG, 1994, J GEN PHYSIOL, V104, P425, DOI 10.1085/jgp.104.3.425; LU XY, 1995, J BIOL CHEM, V270, P18459, DOI 10.1074/jbc.270.31.18459; LU XY, 1994, J BIOL CHEM, V269, P6511; Manjunatha B, 1997, J GEN PHYSIOL, V110, P749, DOI 10.1085/jgp.110.6.749; MENEZ A, 1992, P ROY SOC EDINB B, V99, P83, DOI 10.1017/S0269727000013075; Nakai J, 1998, J BIOL CHEM, V273, P13403, DOI 10.1074/jbc.273.22.13403; Nakai J, 1998, J BIOL CHEM, V273, P24983, DOI 10.1074/jbc.273.39.24983; PALADE P, 1987, J BIOL CHEM, V262, P6135; RIOS E, 1991, PHYSIOL REV, V71, P849, DOI 10.1152/physrev.1991.71.3.849; Slavik KJ, 1997, AM J PHYSIOL-CELL PH, V272, pC1475, DOI 10.1152/ajpcell.1997.272.5.C1475; TANABE T, 1990, NATURE, V344, P451, DOI 10.1038/344451a0; TANABE T, 1990, NATURE, V346, P567, DOI 10.1038/346567a0; Tripathy A, 1998, J GEN PHYSIOL, V111, P679, DOI 10.1085/jgp.111.5.679; Wilson CJ, 1997, BIOCHEMISTRY-US, V36, P4542, DOI 10.1021/bi962299x; Xiao RP, 1997, J PHYSIOL-LONDON, V500, P343, DOI 10.1113/jphysiol.1997.sp022025; Yamazawa T, 1997, J BIOL CHEM, V272, P8161, DOI 10.1074/jbc.272.13.8161; Zamudio FZ, 1997, FEBS LETT, V405, P385, DOI 10.1016/S0014-5793(97)00227-5; Zucchi R, 1997, PHARMACOL REV, V49, P1	36	80	80	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	1999	274	12					7879	7886		10.1074/jbc.274.12.7879	http://dx.doi.org/10.1074/jbc.274.12.7879			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	178LU	10075681	hybrid			2022-12-25	WOS:000079268100040
J	Ancsin, JB; Kisilevsky, R				Ancsin, JB; Kisilevsky, R			The heparin heparan sulfate-binding site on apo serum amyloid A - Implications for the therapeutic intervention of amyloidosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-DENSITY-LIPOPROTEIN; CELLULAR CHOLESTEROL EFFLUX; FIBROBLAST GROWTH-FACTOR; HUMAN ANTITHROMBIN-III; HUMAN APOLIPOPROTEIN-E; ACUTE-PHASE PROTEIN; BASIC-AMINO-ACIDS; CONGO RED; PRP ACCUMULATION; A SAA	Serum amyloid A isoforms, apoSAA1 and apoSAA2, are apolipoproteins of unknown function that become major components of high density lipoprotein (HDL) during the acute phase of an inflammatory response, ApoSAA is also the precursor of inflammation-associated amyloid, and there is strong evidence that the formation of inflammation-associated and other types of amyloid is promoted by heparan sulfate (HS). Data presented herein demonstrate that both mouse and human apoSAA contain binding sites that are specific for heparin and HS, with no binding for the other major glycosaminoglycans detected. Cyanogen bromide-generated peptides of mouse apoSAA1 and apoSAA2 were screened for heparin binding activity. Two peptides, an apoSAA1-derived 80-mer (residues 24-103) and a smaller carboxyl-terminal 27-mer peptide of apoSAA2 (residues 77-103), were retained by a heparin column. A synthetic peptide corresponding to the CNBr-generated 27-mer also bound heparin, and by substituting or deleting one or more of its six basic residues (Arg-83, His-84, Arg-86, Lys-89, Arg-95, and Lys-102), their relative importance for heparin and HS binding was determined. The Lys-102 residue appeared to be required only for HS binding. The residues Arg-86, Lys-89, Arg-95, and Lys-102 are phylogenetically conserved suggesting that the heparin/HS binding activity may be an important aspect of the function of apoSAA HS linked by its carboxyl groups to an Affi-Gel column or treated with carbodiimide to block its carboxyl groups lost the ability to bind apoSAA. HDL-apoSAA did not bind to heparin; however, it did bind to HS, an interaction to which apoA-I contributed. Results from binding experiments with Congo Red-Sepharose 4B columns support the conclusions of a recent structural study which found that heparin binding domains have a common spatial distance of about 20 Angstrom between their two outer basic residues. Our present work provides direct evidence that apoSAA can associate with HS (and heparin) and that the occupation of its binding site by HS, and HS analogs, likely caused the previously reported increase in amyloidogenic conformation (beta-sheet) of apoSAA2 (McCubbin, W. D., Kay, C. M., Narindrasorasak, S., and Kisilevsky, R. (1988) Biochem. J. 256, 775-783) and their amyloid-suppressing effects in vivo (Kisilevsky, R., Lemieux, L. J., Fraser, P. E., Kong, X., Hultin, P. G., and Szarek, W. A. (1995) Not. Med. 1, 143-147), respectively.	Queens Univ, Dept Pathol, Kingston, ON K7L 3N6, Canada; Kingston Gen Hosp, Syl & Molly Apps Res Ctr, Kingston, ON K7L 3N6, Canada	Queens University - Canada; Queens University - Canada	Kisilevsky, R (corresponding author), Queens Univ, Dept Pathol, Kingston, ON K7L 3N6, Canada.	Kisilevsky@cliff.path.queensu.ca						Acton S, 1996, SCIENCE, V271, P518, DOI 10.1126/science.271.5248.518; AILLES L, 1993, LAB INVEST, V69, P443; Ancsin JB, 1997, J BIOL CHEM, V272, P406; AXELRAD MA, 1982, LAB INVEST, V47, P139; BADOLATO R, 1995, J IMMUNOL, V155, P4004; BAIRD A, 1988, P NATL ACAD SCI USA, V85, P2324, DOI 10.1073/pnas.85.7.2324; BANKA CL, 1995, J LIPID RES, V36, P1058; BARKALOW FJB, 1991, J BIOL CHEM, V266, P7812; BENDITT EP, 1977, P NATL ACAD SCI USA, V74, P4025, DOI 10.1073/pnas.74.9.4025; BITTER T, 1966, J CLIN INVEST, V45, P963, DOI 10.1172/JCI105412; BRISSETTE L, 1989, J BIOL CHEM, V264, P19327; Caldwell EEO, 1996, INT J BIOCHEM CELL B, V28, P203, DOI 10.1016/1357-2725(95)00123-9; CARDIN AD, 1986, BIOCHEM BIOPH RES CO, V134, P783, DOI 10.1016/S0006-291X(86)80489-2; CARDIN AD, 1989, ARTERIOSCLEROSIS, V9, P21, DOI 10.1161/01.ATV.9.1.21; Castillo GM, 1998, DIABETES, V47, P612, DOI 10.2337/diabetes.47.4.612; CAUGHEY B, 1994, J VIROL, V68, P2135, DOI 10.1128/JVI.68.4.2135-2141.1994; CAUGHEY B, 1992, J NEUROCHEM, V59, P768, DOI 10.1111/j.1471-4159.1992.tb09437.x; CAUGHEY B, 1993, J VIROL, V67, P643, DOI 10.1128/JVI.67.2.643-650.1993; COETZEE GA, 1986, J BIOL CHEM, V261, P9644; DALFERES ER, 1967, ARCH BIOCHEM BIOPHYS, V118, P284, DOI 10.1016/0003-9861(67)90350-5; DEBEER MC, 1993, J BIOL CHEM, V268, P20606; FIELDING CJ, 1995, J LIPID RES, V36, P211; FRASER PE, 1992, J NEUROCHEM, V59, P1531, DOI 10.1111/j.1471-4159.1992.tb08470.x; Fromm JR, 1997, ARCH BIOCHEM BIOPHYS, V343, P92, DOI 10.1006/abbi.1997.0147; FROMM JR, 1995, ARCH BIOCHEM BIOPHYS, V323, P279, DOI 10.1006/abbi.1995.9963; GABIZON R, 1993, J CELL PHYSIOL, V157, P319, DOI 10.1002/jcp.1041570215; GITEL SN, 1985, BLOOD, V65, P902; GOLDBERGER G, 1987, J IMMUNOL, V138, P3967; GOLDSMITH MR, 1979, ANAL BIOCHEM, V99, P33, DOI 10.1016/0003-2697(79)90041-1; HANDIN RI, 1976, J BIOL CHEM, V251, P4273; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; HIDAKA H, 1992, BIOCHEM J, V284, P161, DOI 10.1042/bj2840161; HIROSE N, 1987, BIOCHEMISTRY-US, V26, P5505, DOI 10.1021/bi00391a044; HUSBY G, 1994, AMYLOID, V1, P119, DOI 10.3109/13506129409148635; HUSBY G, 1973, NATURE, V244, P362, DOI 10.1038/244362a0; HUSHNER I, 1994, CLIN RHEUMATOL, P513; Inoue S, 1996, LAB INVEST, V74, P1081; JACKSON RL, 1991, PHYSIOL REV, V71, P481, DOI 10.1152/physrev.1991.71.2.481; Jensen LE, 1997, J IMMUNOL, V158, P384; Ji Y, 1997, J BIOL CHEM, V272, P20982, DOI 10.1074/jbc.272.34.20982; KAGAN DZ, 1974, PROBL TUBERK, V40, P72; KAZATCHKINE MD, 1993, B WORLD HEALTH ORGAN, V71, P105; KISILEVSKY R, 1995, NAT MED, V1, P143, DOI 10.1038/nm0295-143; Kisilevsky R, 1997, CRIT REV BIOCHEM MOL, V32, P361, DOI 10.3109/10409239709082674; KISILEVSKY R, 1992, LAB INVEST, V66, P778; Kisilevsky R, 1996, CIBA F SYMP, V199, P58; KISILEVSKY R, 1997, Patent No. 5643562; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; KLUNK WE, 1989, J HISTOCHEM CYTOCHEM, V37, P1273, DOI 10.1177/37.8.2666510; LEVEUGLE B, 1994, NEUROREPORT, V5, P1389, DOI 10.1097/00001756-199406000-00025; LEVIN M, 1973, J EXP MED, V138, P373, DOI 10.1084/jem.138.2.373; Linhardt R. J., 1997, CARBOHYDRATES DRUG D, P277; LINKE RP, 1991, BIOCHEM BIOPH RES CO, V176, P1100, DOI 10.1016/0006-291X(91)90397-P; LIU CS, 1987, J BIOL CHEM, V262, P17356; LOSCALZO J, 1985, ARCH BIOCHEM BIOPHYS, V240, P446, DOI 10.1016/0003-9861(85)90049-9; LOWELL CA, 1986, J BIOL CHEM, V261, P8453; Magnus JH, 1997, AMYLOID, V4, P121, DOI 10.3109/13506129708995282; Mahley RW, 1996, ISRAEL J MED SCI, V32, P414; MARGALIT H, 1993, J BIOL CHEM, V268, P19228; MCADAM KPWJ, 1976, J EXP MED, V144, P1121, DOI 10.1084/jem.144.4.1121; MCCUBBIN WD, 1988, BIOCHEM J, V256, P775, DOI 10.1042/bj2560775; MCKNIGHT GL, 1992, J BIOL CHEM, V267, P12131; NARINDRASORASAK S, 1991, J BIOL CHEM, V266, P12878; NICHOLS WC, 1988, BIOCHEM BIOPH RES CO, V156, P534; OSBORNE JC, 1986, METHOD ENZYMOL, V128, P213; PreciadoPatt L, 1996, INT J PEPT PROT RES, V48, P503; PRIOLA SA, 1994, MOL NEUROBIOL, V8, P113, DOI 10.1007/BF02780661; PUCHTLER H, 1983, HISTOCHEMISTRY, V77, P431, DOI 10.1007/BF00495799; ROCKEN C, 1997, INT J EXP CLIN INVES, V4, P259; Salmivirta M, 1996, FASEB J, V10, P1270, DOI 10.1096/fasebj.10.11.8836040; SCOPES RK, 1986, J CHROMATOGR, V376, P131, DOI 10.1016/S0378-4347(00)80830-0; SERGREST JP, 1976, BIOCHEMISTRY-US, V15, P3187; SINAY P, 1984, CARBOHYD RES, V132, pC5, DOI 10.1016/0008-6215(84)85236-2; SIPE JD, 1994, CRIT REV CL LAB SCI, V31, P325, DOI 10.3109/10408369409084679; SMITH PK, 1980, ANAL BIOCHEM, V109, P466, DOI 10.1016/0003-2697(80)90679-X; SNOW AD, 1987, LAB INVEST, V56, P665; SNOW AD, 1987, LAB INVEST, V57, P687; SNOW AD, 1991, J HISTOCHEM CYTOCHEM, V39, P1321, DOI 10.1177/39.10.1940305; SOBEL M, 1992, J BIOL CHEM, V267, P8857; STEEL DM, 1994, IMMUNOL TODAY, V15, P81, DOI 10.1016/0167-5699(94)90138-4; SUN XJ, 1989, J BIOL CHEM, V264, P11288; UHLAR CM, 1994, GENOMICS, V19, P228, DOI 10.1006/geno.1994.1052; Van der Westhuyzen D., 1986, AMYLOIDOSIS, P115; Watson DJ, 1997, J BIOL CHEM, V272, P31617, DOI 10.1074/jbc.272.50.31617; WEISGRABER KH, 1986, J BIOL CHEM, V261, P2068; WEISGRABER KH, 1987, J BIOL CHEM, V262, P11097; Williams KJ, 1997, CURR OPIN LIPIDOL, V8, P253	87	135	146	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 12	1999	274	11					7172	7181		10.1074/jbc.274.11.7172	http://dx.doi.org/10.1074/jbc.274.11.7172			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	175DV	10066777	hybrid			2022-12-25	WOS:000079078400049
J	Anis, Y; Nurnberg, B; Visochek, L; Reiss, N; Naor, Z; Cohen-Armon, M				Anis, Y; Nurnberg, B; Visochek, L; Reiss, N; Naor, Z; Cohen-Armon, M			Activation of G(o)-proteins by membrane depolarization traced by in situ photoaffinity labeling of G(alpha o)-proteins with [alpha P-32]GTP-azidoanilide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HETEROTRIMERIC G-PROTEINS; GTP-BINDING PROTEINS; CATALYZED ADP-RIBOSYLATION; ALPHA-SUBUNITS; MUSCARINIC RECEPTORS; SODIUM-CHANNELS; RAT-BRAIN; LIPID MODIFICATIONS; NA+ CHANNELS; PHOSPHOLIPID-VESICLES	Evidence for depolarization-induced activation of G-proteins in membranes of rat brain synaptoneurosomes has been previously reported (Cohen-Armon, RI,, and Sokolovsky, M. (1991) J, Biol, Chem, 266, 2595-2605; Cohen-Armon, RI., and Sokolovsky, M. (1993) J, Biol, Chem, 268, 9824-9838). In the present work we identify the activated G-proteins as G(o)-proteins by tracing their depolarization-induced in situ photoaffinity labeling with [alpha(32)P]GTP-azidoanilide (GTPAA), Labeled GTPAA was introduced into transiently permeabilized rat brainstem synaptoneurosomes. The resealed synaptoneurosomes, while being UV-irradiated, were depolarized. Relative to synaptoneurosomes at resting potential, the covalent binding of [alpha(32)P]GTPAA to G alpha(o1)- and G alpha(o3)-proteins, but not to G alpha(o2)- isoforms, was enhanced by 5- to 7-fold in depolarized synaptoneurosomes, thereby implying an accelerated exchange of GDP for [alpha(32)P]GT-PAA. Their depolarization-induced photoaffinity labeling was independent of stimulation of G(o)-proteincoupled receptors and could be reversed by membrane repolarization, thus excluding induction by transmitters release. It was, however, dependent on depolarization-induced activation of the voltage-gated sodium channels (VGSC), regardless of Na+ current. The alpha subunit of VGSC was cross-linked and co-immunoprecipitated with G alpha(o)-proteins in depolarized brain-stem and cortical synaptoneurosomes. VGSC alpha subunit most efficiently cross-linked with guanosine 5'-O2-thiodiphosphate-bound rather than to guanosine 5'-O-(3-thiotriphosphate)-bound G alpha(o)-proteins in isolated synaptoneurosomal membranes. These findings support a possible involvement of VGSC in depolarization-induced activation of G(o)-proteins.	Tel Aviv Univ, Sackler Sch Med, Dept Physiol, IL-69978 Tel Aviv, Israel; Tel Aviv Univ, Sackler Sch Med, Cardiac Res Inst, IL-69978 Tel Aviv, Israel; Tel Aviv Univ, George S Wise Fac Life Sci, Dept Biochem, IL-69978 Tel Aviv, Israel; Free Univ Berlin, Inst Pharmakol, D-14195 Berlin, Germany	Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv University; Free University of Berlin	Cohen-Armon, M (corresponding author), Tel Aviv Univ, Sackler Sch Med, Dept Physiol, IL-69978 Tel Aviv, Israel.	marmon@post.tau.ac.il		Nurnberg, Bernd/0000-0002-5995-6555				AVIGAN J, 1992, BIOCHEMISTRY-US, V31, P7736, DOI 10.1021/bi00148a039; BANNO Y, 1987, BIOCHEM BIOPH RES CO, V146, P861, DOI 10.1016/0006-291X(87)90610-3; BETZ H, 1990, BIOCHEMISTRY-US, V29, P3591, DOI 10.1021/bi00467a001; BIGAY J, 1994, BIOCHEMISTRY-US, V33, P14081, DOI 10.1021/bi00251a017; BOBAK DA, 1990, ADP RIBOSYLATING TOX, P439; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; CASEY PJ, 1995, SCIENCE, V268, P221, DOI 10.1126/science.7716512; CASEY PJ, 1994, CURR OPIN CELL BIOL, V6, P219, DOI 10.1016/0955-0674(94)90139-2; CASSEL D, 1978, P NATL ACAD SCI USA, V75, P4155, DOI 10.1073/pnas.75.9.4155; CATTERALL WA, 1992, PHYSIOL REV, V72, P15; CERIONE RA, 1986, J BIOL CHEM, V261, P3901; CHENG K, 1980, J MEMBRANE BIOL, V56, P191, DOI 10.1007/BF01869476; COHEN-ARMON M, 1985, BIOCHEM BIOPH RES CO, V127, P326, DOI 10.1016/S0006-291X(85)80162-5; COHEN-ARMON M, 1986, J BIOL CHEM, V261, P2498; COHEN-ARMON M, 1991, NEUROSCI LETT, V126, P87, DOI 10.1016/0304-3940(91)90378-7; COHEN-ARMON M, 1993, J BIOL CHEM, V268, P9824; COHEN-ARMON M, 1991, J BIOL CHEM, V266, P2595; COULTER S, 1992, P NATL ACAD SCI USA, V89, P5842, DOI 10.1073/pnas.89.13.5842; DALY JW, 1982, J TOXICOL-TOXIN REV, V1, P33, DOI 10.3109/15569548209016467; DENKER BM, 1995, BIOCHEMISTRY-US, V34, P5544, DOI 10.1021/bi00016a028; DRAPEAU P, 1983, J NEUROSCI, V3, P703; DRATZ EA, 1993, NATURE, V363, P276, DOI 10.1038/363276a0; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; FABIATO A, 1981, J GEN PHYSIOL, V78, P457, DOI 10.1085/jgp.78.5.457; FERROLUZZI AG, 1976, BIOCHEMISTRY-US, V15, P617; FLORIO VA, 1989, J BIOL CHEM, V264, P3909; GILMAN AG, 1995, BIOSCIENCE REP, V15, P65, DOI 10.1007/BF01200143; GOLDSMITH P, 1988, J BIOL CHEM, V263, P6476; GURWITZ D, 1985, MOL PHARMACOL, V28, P297; Hamm HE, 1996, CURR OPIN CELL BIOL, V8, P189, DOI 10.1016/S0955-0674(96)80065-2; HEPLER JR, 1992, TRENDS BIOCHEM SCI, V17, P383, DOI 10.1016/0968-0004(92)90005-T; HODGKIN AL, 1952, J PHYSIOL-LONDON, V117, P500, DOI 10.1113/jphysiol.1952.sp004764; HOLLINGSWORTH EB, 1985, J NEUROSCI, V5, P2240; Iniguez-Lluhi Jorge, 1993, Trends in Cell Biology, V3, P230, DOI 10.1016/0962-8924(93)90122-H; ISOM LL, 1995, CELL, V83, P433, DOI 10.1016/0092-8674(95)90121-3; ITOH H, 1986, P NATL ACAD SCI USA, V83, P3776, DOI 10.1073/pnas.83.11.3776; KHODOROV BI, 1985, PROG BIOPHYS MOL BIO, V45, P57, DOI 10.1016/0079-6107(85)90005-7; KLEUSS C, 1994, P NATL ACAD SCI USA, V91, P9828, DOI 10.1073/pnas.91.21.9828; KLEUSS C, 1991, NATURE, V353, P43, DOI 10.1038/353043a0; Klink R, 1997, J NEUROPHYSIOL, V77, P1813, DOI 10.1152/jn.1997.77.4.1813; KRAPIVINSKY G, 1995, J BIOL CHEM, V270, P29059, DOI 10.1074/jbc.270.49.29059; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MA JY, 1994, P NATL ACAD SCI USA, V91, P12351, DOI 10.1073/pnas.91.25.12351; MILLIGAN G, 1995, TRENDS BIOCHEM SCI, V20, P181, DOI 10.1016/S0968-0004(00)89004-0; MOORE JW, 1967, J GEN PHYSIOL, V50, P1401, DOI 10.1085/jgp.50.5.1401; MUMBY SM, 1994, P NATL ACAD SCI USA, V91, P2800, DOI 10.1073/pnas.91.7.2800; NEER EJ, 1994, PROTEIN SCI, V3, P3; NEUBIG RR, 1994, FASEB J, V8, P939, DOI 10.1096/fasebj.8.12.8088459; NODA M, 1986, NATURE, V322, P826, DOI 10.1038/322826a0; NURNBERG B, 1994, BIOCHEM J, V300, P387; OFFERMANS S, 1990, FEBS LETT, V260, P14, DOI 10.1016/0014-5793(90)80054-M; PFAFFINGER PJ, 1985, NATURE, V317, P536, DOI 10.1038/317536a0; PFEUFFER T, 1977, J BIOL CHEM, V252, P7224; RENSDOMIANO S, 1995, FASEB J, V9, P1059, DOI 10.1096/fasebj.9.11.7649405; ROMEY G, 1987, P NATL ACAD SCI USA, V84, P896, DOI 10.1073/pnas.84.3.896; ROSS EM, 1989, NEURON, V3, P141, DOI 10.1016/0896-6273(89)90027-5; Sheng M, 1996, CURR OPIN NEUROBIOL, V6, P602, DOI 10.1016/S0959-4388(96)80091-2; Slutsky I, 1998, EUR J NEUROSCI, V10, P174; SPICHER K, 1994, BIOCHEM BIOPH RES CO, V198, P906, DOI 10.1006/bbrc.1994.1129; SPICHER K, 1991, BIOCHEM BIOPH RES CO, V175, P473, DOI 10.1016/0006-291X(91)91588-4; SPIEGEL AM, 1990, ADP RIBOSYLATION TOX, P207; STEHNOBITTEL L, 1995, J BIOL CHEM, V270, P30068; STRITTMATTER SM, 1990, NATURE, V344, P836, DOI 10.1038/344836a0; SUDO Y, 1992, EMBO J, V11, P2095, DOI 10.1002/j.1460-2075.1992.tb05268.x; TASAKI I, 1967, AM J PHYSIOL, V213, P1465, DOI 10.1152/ajplegacy.1967.213.6.1465; THOMAS TC, 1993, P NATL ACAD SCI USA, V90, P10295, DOI 10.1073/pnas.90.21.10295; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Trainer VL, 1996, J BIOL CHEM, V271, P11261, DOI 10.1074/jbc.271.19.11261; Urenjak J, 1996, PHARMACOL REV, V48, P21; vanBiesen T, 1996, J BIOL CHEM, V271, P1266, DOI 10.1074/jbc.271.3.1266; WALKER GR, 1995, J NIH RES, V7, P76; WEDEGAERTNER PB, 1995, J BIOL CHEM, V270, P503, DOI 10.1074/jbc.270.2.503; WEDEGAERTNER PB, 1994, CELL, V77, P1063, DOI 10.1016/0092-8674(94)90445-6; WILCOX MD, 1995, J BIOL CHEM, V270, P4189, DOI 10.1074/jbc.270.9.4189	74	14	14	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	1999	274	11					7431	7440		10.1074/jbc.274.11.7431	http://dx.doi.org/10.1074/jbc.274.11.7431			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	175DV	10066808	hybrid			2022-12-25	WOS:000079078400080
J	Cole, AR; Hall, NE; Treutlein, HR; Eddes, JS; Reid, GE; Moritz, RL; Simpson, RJ				Cole, AR; Hall, NE; Treutlein, HR; Eddes, JS; Reid, GE; Moritz, RL; Simpson, RJ			Disulfide bond structure and N-glycosylation sites of the extracellular domain of the human interleukin-6 receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; HUMAN IL-6 RECEPTOR; SOLUBLE CYTOKINE RECEPTORS; HIGH-AFFINITY BINDING; HUMAN GROWTH-HORMONE; FLAVOBACTERIUM-MENINGOSEPTICUM; SIGNAL-TRANSDUCTION; CRYSTAL-STRUCTURE; 3-DIMENSIONAL STRUCTURES; ACETYLGLUCOSAMINIDASE-F	The high affinity interleukin-6 (IL-6) receptor is a hexameric complex consisting of two molecules each of IL-6, IL-6 receptor (IL-6R), and the high affinity converter and signaling molecule, gp130, The extracellular "soluble" part of the IL-GR (sIL-6R) consists of three domains: an amino-terminal Ig-like domain and two fibronectin-type III (FN III) domains. The two FN III domains comprise the cytokine-binding domain defined by a set of 4 conserved cysteine residues and a WSXWS sequence motif. Here, we have determined the disulfide structure of the human sIL-6R by peptide mapping in the absence and presence of reducing agent. Mass spectrometric analysis of these peptides revealed four disulfide bonds and two free cysteines. The disulfides Cys(102)-Cys(113) and Cys(146)-Cys(157),, consistent with known cytokine-binding domain motifs, and Cys(28)-Cys(77) With known Ig superfamily domains. An unusual cysteine connectivity between Cys(6)-Cys(174), which links the Ig-like and NH2-rminal FN III domains causing them to fold back onto each other, has not previously been observed among cytokine receptors, The two free cysteines (Cys(192) and Cys(258)) were detected as cysteinyl-cysteines, although a small proportion of Cys(258) was reactive with the alkylating agent 4-vinylpyridine. Of the four potential N-glycosylation sites, carbohydrate moieties were identified on Asn(36), Asn(74), and Asn(202), but not on Asn(226).	Walter & Eliza Hall Inst Med Res, Parkville, Vic 3050, Australia; Ludwig Inst Canc Res, Melbourne Tumour Biol Branch, Joint Prot Struct Lab, Parkville, Vic 3050, Australia; Cooperat Res Ctr Cellular Growth Factors, Parkville, Vic 3050, Australia	Walter & Eliza Hall Institute; Ludwig Institute for Cancer Research	Simpson, RJ (corresponding author), Royal Melbourne Hosp, Ludwig Inst Canc Res, Joint Prot Struct Lab, POB 2008, Parkville, Vic 3050, Australia.	Richard.simpson@ludwig.edu.au	Treutlein, Herbert Rudolf/AAC-7648-2021; Eddes, James/F-1670-2011; Cole, Adam/B-9785-2011; Moritz, Robert L/B-9222-2011	Treutlein, Herbert Rudolf/0000-0001-5553-5553; Reid, Gavin/0000-0002-9675-1444; Simpson, Richard/0000-0002-9834-0796; Hall, Nathan/0000-0001-8942-0498				AKIRA S, 1993, ADV IMMUNOL, V54, P1, DOI 10.1016/S0065-2776(08)60532-5; Bagley CJ, 1997, BLOOD, V89, P1471, DOI 10.1182/blood.V89.5.1471.1471_1471_1482; BAUMANN M, 1990, J BIOL CHEM, V265, P19853; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BORK P, 1994, J MOL BIOL, V242, P309, DOI 10.1006/jmbi.1994.1582; BRADEN BC, 1994, J MOL BIOL, V243, P767, DOI 10.1016/0022-2836(94)90046-9; Bravo J, 1998, EMBO J, V17, P1665, DOI 10.1093/emboj/17.6.1665; CHEREL M, 1995, BLOOD, V86, P2534; CLOGSTON CL, 1989, ARCH BIOCHEM BIOPHYS, V272, P144, DOI 10.1016/0003-9861(89)90205-1; Courchesne PL, 1998, ELECTROPHORESIS, V19, P956, DOI 10.1002/elps.1150190611; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; ELDER JH, 1982, P NATL ACAD SCI-BIOL, V79, P4540, DOI 10.1073/pnas.79.15.4540; Elson GCA, 1998, J IMMUNOL, V161, P1371; FRIELING JTM, 1994, CYTOKINE, V6, P376, DOI 10.1016/1043-4666(94)90061-2; FUH G, 1990, J BIOL CHEM, V265, P3111; GAILLARD JP, 1993, EUR J IMMUNOL, V23, P820, DOI 10.1002/eji.1830230408; Gaillard JP, 1996, IMMUNOLOGY, V89, P135, DOI 10.1046/j.1365-2567.1996.d01-709.x; GRAY WR, 1993, PROTEIN SCI, V2, P1732, DOI 10.1002/pro.5560021017; Grotzinger J, 1997, PROTEINS, V27, P96; Haniu M, 1996, BIOCHEMISTRY-US, V35, P13040, DOI 10.1021/bi960213u; Heaney ML, 1996, BLOOD, V87, P847, DOI 10.1182/blood.V87.3.847.bloodjournal873847; Heinrich PC, 1998, BIOCHEM J, V334, P297, DOI 10.1042/bj3340297; HILTON DJ, 1994, EMBO J, V13, P4765, DOI 10.1002/j.1460-2075.1994.tb06802.x; HIRAOKA O, 1994, J BIOL CHEM, V269, P22412; HIRATA Y, 1989, J IMMUNOL, V143, P2900; HONDA M, 1992, J IMMUNOL, V148, P2175; HORIUCHI S, 1994, EUR J IMMUNOL, V24, P1945, DOI 10.1002/eji.1830240837; JONES SS, 1990, BLOOD, V76, P31; Kalai M, 1996, EUR J BIOCHEM, V238, P714, DOI 10.1111/j.1432-1033.1996.0714w.x; Kalai M, 1997, BLOOD, V89, P1319, DOI 10.1182/blood.V89.4.1319; KISHIMOTO T, 1994, CELL, V76, P253, DOI 10.1016/0092-8674(94)90333-6; KISHIMOTO T, 1995, BLOOD, V86, P1243, DOI 10.1182/blood.V86.4.1243.bloodjournal8641243; KLEIN B, 1995, BLOOD, V85, P863, DOI 10.1182/blood.V85.4.863.bloodjournal854863; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Livnah O, 1996, SCIENCE, V273, P464, DOI 10.1126/science.273.5274.464; LUST JA, 1992, CYTOKINE, V4, P96, DOI 10.1016/1043-4666(92)90043-Q; Menziani MC, 1997, PROTEINS, V29, P528; MIURA O, 1993, ARCH BIOCHEM BIOPHYS, V306, P200, DOI 10.1006/abbi.1993.1501; Moritz RL, 1996, ELECTROPHORESIS, V17, P907, DOI 10.1002/elps.1150170512; MULLBERG J, 1993, EUR J IMMUNOL, V23, P473, DOI 10.1002/eji.1830230226; MURAKAMI M, 1993, SCIENCE, V260, P1808, DOI 10.1126/science.8511589; NARAZAKI M, 1993, BLOOD, V82, P1120, DOI 10.1182/blood.V82.4.1120.bloodjournal8241120; NOVICK D, 1989, J EXP MED, V170, P1409, DOI 10.1084/jem.170.4.1409; Ozbek S, 1998, J BIOL CHEM, V273, P21374, DOI 10.1074/jbc.273.33.21374; PAONESSA G, 1995, EMBO J, V14, P1942, DOI 10.1002/j.1460-2075.1995.tb07186.x; PLUMMER TH, 1984, J BIOL CHEM, V259, P700; RICHARDSON JS, 1977, NATURE, V268, P495, DOI 10.1038/268495a0; ROSEJOHN S, 1994, BIOCHEM J, V300, P281, DOI 10.1042/bj3000281; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Sanchez R, 1997, PROTEINS, P50; SIMPSON RJ, 1988, BIOCHEM BIOPH RES CO, V157, P364, DOI 10.1016/S0006-291X(88)80056-1; Simpson RJ, 1997, PROTEIN SCI, V6, P929, DOI 10.1002/pro.5560060501; SIPPL MJ, 1993, PROTEINS, V17, P355, DOI 10.1002/prot.340170404; Smith DK, 1998, PROTEIN SCI, V7, P886; Somers W, 1997, EMBO J, V16, P989, DOI 10.1093/emboj/16.5.989; SOMERS W, 1994, NATURE, V372, P478, DOI 10.1038/372478a0; Stomski FC, 1998, J BIOL CHEM, V273, P1192, DOI 10.1074/jbc.273.2.1192; Stomski FC, 1996, MOL CELL BIOL, V16, P3035; STOYAN T, 1993, EUR J BIOCHEM, V216, P239, DOI 10.1111/j.1432-1033.1993.tb18138.x; STUBER D, 1993, BIOCHEMISTRY-US, V32, P2423; SUGITA T, 1990, J EXP MED, V171, P2001, DOI 10.1084/jem.171.6.2001; TARENTINO AL, 1994, METHOD ENZYMOL, V230, P44; TRIMBLE RB, 1991, J BIOL CHEM, V266, P1646; Vaughn DE, 1996, NEURON, V16, P261, DOI 10.1016/S0896-6273(00)80045-8; Vollmer P, 1996, J IMMUNOL METHODS, V199, P47, DOI 10.1016/S0022-1759(96)00163-9; WALTER MR, 1995, NATURE, V376, P230, DOI 10.1038/376230a0; WARD LD, 1994, J BIOL CHEM, V269, P23286; WARD LD, 1995, BIOCHEMISTRY-US, V34, P2901, DOI 10.1021/bi00009a021; WARD LD, 1994, TECHNIQUES IN PROTEIN CHEMISTRY V, P331; YAMASAKI K, 1988, SCIENCE, V241, P825, DOI 10.1126/science.3136546; YASUKAWA K, 1990, J BIOCHEM-TOKYO, V108, P673, DOI 10.1093/oxfordjournals.jbchem.a123261; YAWATA H, 1993, EMBO J, V12, P1705, DOI 10.1002/j.1460-2075.1993.tb05815.x	73	28	29	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	1999	274	11					7207	7215		10.1074/jbc.274.11.7207	http://dx.doi.org/10.1074/jbc.274.11.7207			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	175DV	10066782	hybrid			2022-12-25	WOS:000079078400054
J	Lu, ZL; Hulme, EC				Lu, ZL; Hulme, EC			The functional topography of transmembrane domain 3 of the M-1 muscarinic acetylcholine receptor, revealed by scanning mutagenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; SITE-DIRECTED MUTAGENESIS; CONSTITUTIVELY ACTIVE MUTANTS; BETA-ADRENERGIC-RECEPTOR; TERNARY COMPLEX MODEL; ANTAGONIST BINDING; ARGININE RESIDUE; ACTIVATION; RHODOPSIN; ASPARTATE	Alanine-scanning mutagenesis has been applied to residues 100-121 in transmembrane domain 3 of the M-1 muscarinic acetylcholine receptor, This study complements a previous investigation of the triad Asp(122)-Arg(123)-Tyr(124) (Lu, Z-L., Curtis, C, A,, Jones, P. G,, Pavia, J., and Hulme, E. C. (1997) Mol. Pharmacol 51, 234-241), The results demonstrate the alpha-helical secondary structure of the domain and suggest its orientation with respect to the other transmembrane domains. The C-terminal part of the helix appears to be largely buried within the receptor structure. On its surface, there is a patch of three residues, Val(113), Leu(116), and Ser(120), which may form intramolecular contacts that help to stabilize the inactive ground state of the receptor. Mutagenic disruption of these increased agonist affinity and signaling efficacy. In two cases (L116A and S120A), this led to constitutive activation of the receptor. Parallel to the helix axis and spanning the whole transmembrane region, a distinct strip of residues on one face of transmembrane domain 3 forms intermolecular (acetylcholine-receptor, receptor-G; protein) or intrareceptor beads that contribute to the activated state. The binding of acetylcholine may destabilize the first set of contacts while favoring the formation of the second.	Natl Inst Med Res, Div Phys Biochem, London NW7 1AA, England	MRC National Institute for Medical Research	Hulme, EC (corresponding author), Natl Inst Med Res, Div Phys Biochem, Mill Hill, London NW7 1AA, England.			Lu, Zhiliang/0000-0002-3442-1415				Baldwin JM, 1997, J MOL BIOL, V272, P144, DOI 10.1006/jmbi.1997.1240; Ballesteros J, 1998, J BIOL CHEM, V273, P10445, DOI 10.1074/jbc.273.17.10445; BLACK JW, 1983, PROC R SOC SER B-BIO, V220, P141, DOI 10.1098/rspb.1983.0093; Burstein ES, 1998, J BIOL CHEM, V273, P24322, DOI 10.1074/jbc.273.38.24322; CLACKSON T, 1995, SCIENCE, V267, P383, DOI 10.1126/science.7529940; COHEN GB, 1993, BIOCHEMISTRY-US, V32, P6111, DOI 10.1021/bi00074a024; DELEAN A, 1980, J BIOL CHEM, V255, P7108; DONNELLY D, 1994, RECEPTOR CHANNEL, V2, P61; Dougherty DA, 1996, SCIENCE, V271, P163, DOI 10.1126/science.271.5246.163; FAHMY K, 1993, BIOCHEMISTRY-US, V32, P7229, DOI 10.1021/bi00079a020; FARAHBAKHSH ZT, 1995, BIOCHEMISTRY-US, V34, P8812, DOI 10.1021/bi00027a033; Farrens DL, 1996, SCIENCE, V274, P768, DOI 10.1126/science.274.5288.768; Gether U, 1998, J BIOL CHEM, V273, P17979, DOI 10.1074/jbc.273.29.17979; HIBERT MF, 1991, MOL PHARMACOL, V40, P8; Hulme EC, 1998, J PHYSIOLOGY-PARIS, V92, P269, DOI 10.1016/S0928-4257(98)80031-4; JAVITCH JA, 1995, NEURON, V14, P825, DOI 10.1016/0896-6273(95)90226-0; JONES PG, 1995, EUR J PHARM-MOLEC PH, V288, P251, DOI 10.1016/0922-4106(95)90036-5; KURTENBACH E, 1990, J BIOL CHEM, V265, P13702; Lu ZL, 1997, MOL PHARMACOL, V51, P234, DOI 10.1124/mol.51.2.234; MATSUI H, 1995, MOL PHARMACOL, V47, P88; PAGE KM, 1995, EUR J PHARM-MOLEC PH, V289, P429, DOI 10.1016/0922-4106(95)90151-5; ROBINSON PR, 1992, NEURON, V9, P719, DOI 10.1016/0896-6273(92)90034-B; SAMAMA P, 1993, J BIOL CHEM, V268, P4625; SAVARESE TM, 1992, J BIOL CHEM, V267, P11439; Scheer A, 1996, EMBO J, V15, P3566, DOI 10.1002/j.1460-2075.1996.tb00726.x; Sheikh SP, 1996, NATURE, V383, P347, DOI 10.1038/383347a0; SPALDING TA, 1994, J BIOL CHEM, V269, P4092; Spalding TA, 1997, BIOCHEMISTRY-US, V36, P10109, DOI 10.1021/bi970565g; WARD WHJ, 1990, TRENDS PHARMACOL SCI, V11, P280, DOI 10.1016/0165-6147(90)90009-W; WESS J, 1991, EMBO J, V10, P3729, DOI 10.1002/j.1460-2075.1991.tb04941.x; WHALEY BS, 1994, MOL PHARMACOL, V45, P481; ZHU SZ, 1994, MOL PHARMACOL, V45, P517	32	83	88	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 12	1999	274	11					7309	7315		10.1074/jbc.274.11.7309	http://dx.doi.org/10.1074/jbc.274.11.7309			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	175DV	10066794	hybrid			2022-12-25	WOS:000079078400066
J	Sung, JZ; Qian, YM; Chen, Z; Marfurt, J; Hamilton, AD; Sebti, SM				Sung, JZ; Qian, YM; Chen, Z; Marfurt, J; Hamilton, AD; Sebti, SM			The geranylgeranyltransferase I inhibitor GGTI-298 induces hypophosphorylation of retinoblastoma and partner switching of cyclin-dependent kinase inhibitors - A potential mechanism for GGTI-298 antitumor activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN GERANYLGERANYLATION; RAS TRANSFORMATION; CDK INHIBITORS; FARNESYLATION; FIBROBLASTS; PRENYLATION; CELLS; G(1); RHO	The geranylgeranyltransferase I inhibitor GGTI-298 has recently been shown to arrest human tumor cells in the G(1) phase of the cell cycle, induce apoptosis, and inhibit tumor growth in nude mice. In the present manuscript, we provide a possible mechanism by which GGTI-298 mediates its tumor growth arrest. Treatment of the human lung carcinoma cell line Calu-1 with GGTI-298 results in inhibition of the phosphorylation of retinoblastoma protein, a critical step for G(1)/S transition. The kinase activities of two G(1)/S cyclin-dependent kinases, CDK2 and CDK4, are inhibited in Calu-1 cells treated with GGTI-298, Furthermore, GGTI-298 has little effect on the expression levels of CDK2, CDK4, CDK6, cyclins D1 and E, but decreases the levels of cyclin A. GGTI-298 increases the levels of the cyclin-dependent kinase inhibitors p21 and p15 and had little effect on those of p27 and p16, Most interesting is the ability of GGTI-298 to induce partner switching for several CDK inhibitors. GGTI-298 promotes binding of p21 and p27 to CDK2 while decreasing their binding to CDK6, Reversal of partner switching and G(1) block was observed after removal of GGTI-298, Furthermore, GGTI-298 treatment results in an increased binding of p15 to CDK4, which is paralleled with decreased binding to p27, The results demonstrate that the GGTI-298-mediated G(1) block in Calu-1 cells involves increased expression and partner switching of CDK inhibitors resulting in inhibition of CDK2 and CDK4, and retinoblastoma protein phosphorylation.	Univ S Florida, Dept Biochem & Mol Biol, Drug Discovery Program, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA; Yale Univ, Dept Chem, New Haven, CT 06511 USA	H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; Yale University	Sebti, SM (corresponding author), Univ S Florida, Dept Biochem & Mol Biol, Drug Discovery Program, H Lee Moffitt Canc Ctr & Res Inst, 12902 Magnolia Dr, Tampa, FL 33612 USA.				NATIONAL CANCER INSTITUTE [U19CA067771] Funding Source: NIH RePORTER; NCI NIH HHS [CA-67771] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adnane J, 1998, MOL CELL BIOL, V18, P6962, DOI 10.1128/MCB.18.12.6962; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; Blain SW, 1997, J BIOL CHEM, V272, P25863, DOI 10.1074/jbc.272.41.25863; BOOTA A, 1998, AM J PHYSIOL, V275, pL55; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; Finder JD, 1997, J BIOL CHEM, V272, P13484, DOI 10.1074/jbc.272.21.13484; Irani K, 1997, SCIENCE, V275, P1649, DOI 10.1126/science.275.5306.1649; JACKSON JH, 1990, P NATL ACAD SCI USA, V87, P3042, DOI 10.1073/pnas.87.8.3042; Katz ME, 1997, CURR OPIN GENET DEV, V7, P75, DOI 10.1016/S0959-437X(97)80112-8; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; LERNER EC, 1995, J BIOL CHEM, V270, P26802, DOI 10.1074/jbc.270.45.26802; McGuire TF, 1996, J BIOL CHEM, V271, P27402, DOI 10.1074/jbc.271.44.27402; Miguel K., 1997, CANCER RES, V57, P1846; MUSUNURU K, 1997, CELL CYCLE REGULATOR; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; QIU RG, 1995, P NATL ACAD SCI USA, V92, P11781, DOI 10.1073/pnas.92.25.11781; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; Sebti SM, 1997, PHARMACOL THERAPEUT, V74, P103, DOI 10.1016/S0163-7258(97)00014-4; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; STARK WW, 1999, IN PRESS AM J PHYSL; SUN JZ, 1995, CANCER RES, V55, P4243; Sun JZ, 1998, ONCOGENE, V16, P1467, DOI 10.1038/sj.onc.1201656; Tapon N, 1998, EMBO J, V17, P1395, DOI 10.1093/emboj/17.5.1395; Vogt A, 1997, J BIOL CHEM, V272, P27224, DOI 10.1074/jbc.272.43.27224; Vogt A, 1996, ONCOGENE, V13, P1991; Weber JD, 1997, J BIOL CHEM, V272, P32966, DOI 10.1074/jbc.272.52.32966; Zhang FL, 1996, ANNU REV BIOCHEM, V65, P241, DOI 10.1146/annurev.bi.65.070196.001325; Zujewski J., 1998, Proceedings of the American Association for Cancer Research Annual Meeting, V39, P270	29	6	6	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 12	1999	274	11					6930	6934						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	175DV	10066746				2022-12-25	WOS:000079078400018
J	Brophy, CM; Dickinson, M; Woodrum, D				Brophy, CM; Dickinson, M; Woodrum, D			Phosphorylation of the small heat shock-related protein, HSP20, in vascular smooth muscles is associated with changes in the macromolecular associations of HSP20	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESOLUTION 2-DIMENSIONAL ELECTROPHORESIS; ALPHA-B-CRYSTALLIN; CONTRACTION; FORM	Cyclic nucleotide-dependent vasorelaxation is associated with increases in the phosphorylation of a small heat shock-related protein, HSP20, We hypothesized that phosphorylation of HSP20 in vascular smooth muscles is associated with alterations in the macromolecular associations of HSP20, Treatment of bovine carotid artery smooth muscles with the phosphodiesterase inhibitor, 3-isobutyl-1-methylxanthine, and the adenylate cyclase activator, forskolin, led to increases in the phosphorylation of HSP20 and dissociation of macromolecular aggregates of HSP20, However, 3-isobutyl-1-methylxanthine and forskolin treatment of a muscle that is uniquely refractory to cyclic nucleotide-dependent vasorelaxation, human umbilical artery smooth muscle, did not result in increases in the phosphorylation of HSP20 or to dissociation of macromolecular aggregates. HSP20 can be phosphorylated in vitro by the catalytic subunit of cAMP-dependent protein kinase (PKA) in both carotid and umbilical arteries and this phosphorylation of HSP20 is associated with dissociation of macromolecular aggregates of HSP20. Activation of cyclic nucleotide-dependent signaling pathways does not lead to changes in the macromolecular associations of another small heat shock protein, HSP27. interestingly, the myosin light chains (MLC20) are in similar fractions as the HSP20, and phosphorylation of HSP20 is associated with changes in the macromolecular associations of MLC20. These data suggest that increases in the phosphorylation of HSP20 are associated with changes in the macromolecular associations of HSP20. HSP20 may regulate vasorelaxation through a direct interaction with specific contractile regulatory proteins.	Med Coll Georgia, Inst Mol Med & Genet, Dept Med, Augusta, GA 30912 USA; Med Coll Georgia, Dept Surg, Augusta, GA 30912 USA; Med Coll Georgia, Dept Cell Biol & Anat, Augusta, GA 30912 USA; Vet Adm Med Ctr, Augusta, GA 30910 USA	University System of Georgia; Augusta University; University System of Georgia; Augusta University; University System of Georgia; Augusta University; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Brophy, CM (corresponding author), Med Coll Georgia, Inst Mol Med & Genet, Dept Med, 1120 15th St, Augusta, GA 30912 USA.				NHLBI NIH HHS [R01 HL58027-01] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058027] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Beall AC, 1997, J BIOL CHEM, V272, P11283; BERGH CM, 1995, AM J PHYSIOL-HEART C, V268, pH202, DOI 10.1152/ajpheart.1995.268.1.H202; BITAR KN, 1991, BIOCHEM BIOPH RES CO, V181, P1192, DOI 10.1016/0006-291X(91)92065-R; Brophy CM, 1997, BIOL REPROD, V57, P1354, DOI 10.1095/biolreprod57.6.1354; Brophy CM, 1998, J VASC SURG, V27, P963, DOI 10.1016/S0741-5214(98)70279-4; BROPHY CM, 1999, IN PRESS J VASC SURG; Guay J, 1997, J CELL SCI, V110, P357; HOCHSTRASSER DF, 1988, ANAL BIOCHEM, V173, P424, DOI 10.1016/0003-2697(88)90209-6; JERIUS H, 1999, IN PRESS J VASC SURG; KATO K, 1994, J BIOL CHEM, V269, P11274; KATO K, 1994, J BIOL CHEM, V269, P15302; LARSEN JK, 1997, AM J PHYSIOL, V273, P930; LAVOIE JN, 1995, MOL CELL BIOL, V15, P505, DOI 10.1128/MCB.15.1.505; MILLERHANCE WC, 1988, J BIOL CHEM, V263, P13979; NEUHOFF V, 1988, ELECTROPHORESIS, V9, P255, DOI 10.1002/elps.1150090603; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; OFARRELL PZ, 1977, CELL, V12, P1133, DOI 10.1016/0092-8674(77)90176-3; Schafer C, 1998, J BIOL CHEM, V273, P24173, DOI 10.1074/jbc.273.37.24173; Welsh MJ, 1996, BIOL REPROD, V55, P141, DOI 10.1095/biolreprod55.1.141; ZANTEMA A, 1992, J BIOL CHEM, V267, P12936	20	56	60	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1999	274	10					6324	6329		10.1074/jbc.274.10.6324	http://dx.doi.org/10.1074/jbc.274.10.6324			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172BQ	10037721	hybrid			2022-12-25	WOS:000078902800043
J	Moss, JM; Reid, GE; Mullin, KA; Zawadzki, JL; Simpson, RJ; McConville, MJ				Moss, JM; Reid, GE; Mullin, KA; Zawadzki, JL; Simpson, RJ; McConville, MJ			Characterization of a novel GDP-mannose : Serine-protein mannose-l-phosphotransferase from Leishmania mexicana	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SECRETED ACID-PHOSPHATASE; LIPOPHOSPHOGLYCAN; BIOSYNTHESIS; PROTEOPHOSPHOGLYCAN; AMASTIGOTES; PARASITES; PROMASTIGOTES; PURIFICATION; DONOVANI; EPITOPES	Protozoan parasites of the genus Leishmania secrete a number of glycoproteins and mucin-like proteoglycans that appear to be important parasite virulence factors. We have previously proposed that the polypeptide backbones of these molecules are extensively modified with a complex array of phosphoglycan chains that are linked to Ser/Thr-rich domains via a common Man alpha 1-PO4-Ser Linkage (Ilg, T., Overath, P., Ferguson, M. A J., Rutherford, T,, Campbell, D, G,, and McConville, M, J, (1994) J, Biol. Chem, 269, 24073-24081), In this study, we show that Leishmania mexicana promastigotes contain a peptide-specific mannose-l-phosphotransferase (pep-MPT) activity that adds Man alpha 1-P to serine residues in a range of defined peptides, The presence and location of the Man alpha 1-PO4-Ser linkage in these peptides were determined by electrospray ionization mass spectrometry and chemical and enzymatic treatments. The pep-MPT activity was solubilized in non-ionic detergents, was dependent on Mn2+, utilized GDP-Man as the mannose donor, and was expressed in all developmental stages of the parasite. The pep-MPT activity was maximal against peptides containing Ser/Thr-rich domains of the endogenous accepters and, based on competition assays with oligosaccharide accepters, was distinct from other leishmanial MPTs involved in the initiation and elongation of lipid-linked phosphoglycan chains. In subcellular fractionation experiments, pep-MPT was resolved from the endoplasmic reticulum marker BiP, but had an overlapping distribution with the cis-Golgi marker Rab1, Although Man-PO4 residues in the mature secreted glycoproteins are extensively modified with mannose oligosaccharides and phosphoglycan chains, similar modifications were not added to peptide-linked Man-PO4 residues in the in vitro assays, Similarly, Man-PO4 residues on endogenous polypeptide accepters were also poorly extended, although the elongating enzymes were still active, suggesting that the pep-MPT activity and elongating enzymes may be present in separate subcellular compartments.	Univ Melbourne, Dept Biochem & Mol Biol, Parkville, Vic 3052, Australia; Ludwig Inst Canc Res, Joint Prot Struct Lab, Parkville, Vic 3050, Australia; Walter & Eliza Hall Inst Med Res, Parkville, Vic 3050, Australia	University of Melbourne; Ludwig Institute for Cancer Research; Walter & Eliza Hall Institute	McConville, MJ (corresponding author), Univ Melbourne, Dept Biochem & Mol Biol, Parkville, Vic 3052, Australia.	m.mcconville@biochemistry.unimelb.edu.au		Reid, Gavin/0000-0002-9675-1444; Simpson, Richard/0000-0002-9834-0796				Annan RS, 1996, ANAL CHEM, V68, P3413, DOI 10.1021/ac960221g; BANGS JD, 1993, J CELL SCI, V105, P1101; BATES PA, 1990, MOL BIOCHEM PARASIT, V39, P247, DOI 10.1016/0166-6851(90)90063-R; BATES PA, 1992, PARASITOLOGY, V105, P193, DOI 10.1017/S0031182000074102; BRAELL WA, 1976, ANAL BIOCHEM, V74, P484, DOI 10.1016/0003-2697(76)90229-3; Brown GM, 1996, EUR J BIOCHEM, V242, P410, DOI 10.1111/j.1432-1033.1996.0410r.x; CAPPAI R, 1993, MOL BIOCHEM PARASIT, V62, P73, DOI 10.1016/0166-6851(93)90179-2; CARVER MA, 1991, J BIOL CHEM, V266, P10974; Ha DS, 1996, MOL BIOCHEM PARASIT, V77, P57, DOI 10.1016/0166-6851(96)02580-7; Haynes PA, 1998, GLYCOBIOLOGY, V8, P1, DOI 10.1093/glycob/8.1.1; ILG T, 1993, EUR J BIOCHEM, V217, P603, DOI 10.1111/j.1432-1033.1993.tb18283.x; ILG T, 1995, EUR J CELL BIOL, V66, P205; Ilg T, 1998, J BIOL CHEM, V273, P13509, DOI 10.1074/jbc.273.22.13509; ILG T, 1994, J BIOL CHEM, V269, P24073; ILG T, 1991, P NATL ACAD SCI USA, V88, P8774, DOI 10.1073/pnas.88.19.8774; Ilg T, 1996, J BIOL CHEM, V271, P21583, DOI 10.1074/jbc.271.35.21583; ILG T, 1994, PARASITOLOGY, V108, pS63, DOI 10.1017/S0031182000075739; JAFFE CL, 1990, MOL BIOCHEM PARASIT, V41, P233, DOI 10.1016/0166-6851(90)90186-P; Ma DQ, 1997, J BIOL CHEM, V272, P3799, DOI 10.1074/jbc.272.6.3799; MCCONVILLE MJ, 1993, BIOCHEM J, V294, P305, DOI 10.1042/bj2940305; MCCONVILLE MJ, 1995, BIOCHEM J, V310, P807, DOI 10.1042/bj3100807; MCCONVILLE MJ, 1990, J BIOL CHEM, V265, P19611; Mehta DP, 1996, J BIOL CHEM, V271, P10897, DOI 10.1074/jbc.271.18.10897; Mengeling BJ, 1997, GLYCOBIOLOGY, V7, P847, DOI 10.1093/glycob/7.6.847; Mengeling BJ, 1997, GLYCOBIOLOGY, V7, P873, DOI 10.1093/glycob/7.7.873-c; MORITZ RL, 1992, J CHROMATOGR, V599, P119; Moritz RL, 1996, ELECTROPHORESIS, V17, P907, DOI 10.1002/elps.1150170512; NG K, 1994, GLYCOBIOLOGY, V4, P845, DOI 10.1093/glycob/4.6.845; Peters C, 1997, EUR J IMMUNOL, V27, P2666, DOI 10.1002/eji.1830271028; Peters C, 1997, INFECT IMMUN, V65, P783, DOI 10.1128/IAI.65.2.783-786.1997; PIND SN, 1994, J CELL BIOL, V125, P239, DOI 10.1083/jcb.125.2.239; RUSH JS, 1993, J BIOL CHEM, V268, P13110; SCHNEIDER P, 1993, ANAL BIOCHEM, V210, P106, DOI 10.1006/abio.1993.1158; STIERHOF YD, 1994, J CELL BIOL, V125, P321, DOI 10.1083/jcb.125.2.321; TACK BF, 1980, J BIOL CHEM, V255, P8842; TURCO SJ, 1992, ANNU REV MICROBIOL, V46, P65, DOI 10.1146/annurev.mi.46.100192.000433; WEISE M, 1995, EMBO J, V14, P1067; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6	38	17	19	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1999	274	10					6678	6688		10.1074/jbc.274.10.6678	http://dx.doi.org/10.1074/jbc.274.10.6678			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172BQ	10037765	hybrid			2022-12-25	WOS:000078902800087
J	Hageman, GS; Mullins, RF; Russell, SR; Johnson, LV; Anderson, DH				Hageman, GS; Mullins, RF; Russell, SR; Johnson, LV; Anderson, DH			Vitronectin is a constituent of ocular drusen and the vitronectin gene is expressed in human retinal pigmented epithelial cells	FASEB JOURNAL			English	Article						age-related macular degeneration; retinal pigment epithelium; extracellular matrix; heparan sulfate proteoglycan	AGE-RELATED MACULOPATHY; MACULAR DEGENERATION; BRUCHS MEMBRANE; MULTIMERIC VITRONECTIN; ELECTRON-MICROSCOPY; RISK-FACTORS; S-PROTEIN; BINDING; TISSUE; NEOVASCULARIZATION	Age-related macular degeneration (AMD) leads to dysfunction and degeneration of retinal photoreceptor cells. This disease is characterized, in part, by the development of extracellular deposits called drusen, The presence of drusen is correlated with the development of AMD, although little is known about drusen composition or biogenesis, Drusen form within Bruch's membrane, a stratified extracellular matrix situated between the retinal pigmented epithelium and choriocapillaris. Because of this association, we sought to determine whether drusen contain known extracellular matrix constituents. Antibodies directed against a battery of extracellular matrix molecules were screened on drusen-containing sections from human donor eyes, including donors with clinically documented AMD, Antibodies directed against vitronectin, a plasma protein and extracellular matrix component, exhibit intense and consistent reactivity with drusen; antibodies to the conformationally distinct, heparin binding form of human vitronectin are similarly immunoreactive, No differences in vitronectin immunoreactivity between hard and soft drusen, or between macular and extra macular regions, have been observed. RT-PCR analyses revealed that vitronectin mRNA is expressed in the retinal pigmented epithelium (RPE)-choroidal complex and cultured RPE cells. These data document that vitronectin is a major constituent of human ocular drusen and that vitronectin mRNA is synthesized locally, Based on these data,we propose that vitronectin may participate in the pathogenesis of AMD.	Univ Iowa, Dept Ophthalmol & Visual Sci, Ctr Macular Degenerat, Iowa City, IA 52242 USA; Univ Calif Santa Barbara, Neurosci Res Inst, Ctr Study Macular Degenerat, Santa Barbara, CA 93106 USA	University of Iowa; University of California System; University of California Santa Barbara	Hageman, GS (corresponding author), Univ Iowa, Dept Ophthalmol & Visual Sci, 11190E PFP,200 Hawkins Dr, Iowa City, IA 52240 USA.	gregory_hagerman@uiowa.edu	Mullins, Robert F/I-6717-2013	Mullins, Robert/0000-0002-5006-0891; Russell, Stephen/0000-0003-3776-1367				AKIYAMA H, 1991, J NEUROIMMUNOL, V32, P19, DOI 10.1016/0165-5728(91)90067-H; BIRD AC, 1992, BRIT J OPHTHALMOL, V76, P166, DOI 10.1136/bjo.76.3.166; BITTORF SV, 1993, J BIOL CHEM, V268, P24838; BLUMENKRANZ MS, 1986, OPHTHALMOLOGY, V93, P552; BRESSLER NM, 1994, RETINA-J RET VIT DIS, V14, P130, DOI 10.1097/00006982-199414020-00006; BRESSLER SB, 1990, ARCH OPHTHALMOL-CHIC, V108, P1442, DOI 10.1001/archopht.1990.01070120090035; Burns R P, 1980, Trans Am Ophthalmol Soc, V78, P206; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DAHLBACK K, 1988, ACTA DERM-VENEREOL, V68, P107; DAHLBACK K, 1993, J INVEST DERMATOL, V100, P166, DOI 10.1111/1523-1747.ep12462792; FARKAS TG, 1971, AM J OPHTHALMOL, V71, P1196, DOI 10.1016/0002-9394(71)90963-9; FEENEYBURNS L, 1985, AM J OPHTHALMOL, V100, P686, DOI 10.1016/0002-9394(85)90625-7; FEENEYBURNS L, 1988, INVEST OPHTH VIS SCI, V29, P708; FINE BS, 1981, AM J OPHTHALMOL, V91, P469, DOI 10.1016/0002-9394(81)90234-8; GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519; GREEN WR, 1985, OPHTHALMOLOGY, V92, P615; HALE IL, 1993, METHOD CELL BIOL, V38, P289; HAYMAN EG, 1983, P NATL ACAD SCI-BIOL, V80, P4003, DOI 10.1073/pnas.80.13.4003; HEIBA IM, 1994, GENET EPIDEMIOL, V11, P51, DOI 10.1002/gepi.1370110106; HOGASEN K, 1992, J BIOL CHEM, V267, P23076; Hyman L, 1992, AGE RELATED MACULAR, P1; ISHIBASHI T, 1986, AM J OPHTHALMOL, V101, P342, DOI 10.1016/0002-9394(86)90830-5; JANSEN JH, 1993, AM J PATHOL, V143, P1356; JOHNSON LV, 1984, CURR EYE RES, V3, P969, DOI 10.3109/02713688409167215; KINCAID M, 1992, AGE RELATED MACULAR; KLEIN ML, 1994, ARCH OPHTHALMOL-CHIC, V112, P932, DOI 10.1001/archopht.1994.01090190080025; KLEIN R, 1995, OPHTHALMOLOGY, V102, P371; KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128; Kliffen M, 1996, ARCH OPHTHALMOL-CHIC, V114, P1009, DOI 10.1001/archopht.1996.01100140217021; LEWIS H, 1986, OPHTHALMOLOGY, V93, P1098; Mullins RF, 1997, OPHTHALMOLOGY, V104, P288, DOI 10.1016/S0161-6420(97)30322-4; NEWSOME DA, 1987, AM J OPHTHALMOL, V104, P373, DOI 10.1016/0002-9394(87)90227-3; NICULESCU F, 1989, ATHEROSCLEROSIS, V78, P197, DOI 10.1016/0021-9150(89)90223-2; PAULEIKHOFF D, 1992, OPHTHALMOLOGY, V99, P1548; Pauleikhoff D., 1994, Ophthalmologe, V91, P730; PAULEIKHOFF D, 1990, AM J OPHTHALMOL, V109, P38, DOI 10.1016/S0002-9394(14)75576-X; PREISSNER KT, 1991, ANNU REV CELL BIOL, V7, P275, DOI 10.1146/annurev.cellbio.7.1.275; SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106; SARKS S, 1989, RETINA, V2; SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324; SARKS SH, 1980, T OPHTHAL SOC UK, V100, P414; SEIFFERT D, 1994, J BIOL CHEM, V269, P19836; SOLEM M, 1991, MOL CELL BIOCHEM, V100, P141; STOCKMANN A, 1993, J BIOL CHEM, V268, P22874; STONE E, 1993, MOL GENETICS INHERIT; Tomasini B R, 1991, Prog Hemost Thromb, V10, P269; VANDERSCHAFT TL, 1992, OPHTHALMOLOGY, V99, P278; VANDERSCHAFT TL, 1993, BRIT J OPHTHALMOL, V77, P657, DOI 10.1136/bjo.77.10.657; VANDERSCHAFT TL, 1994, GRAEF ARCH CLIN EXP, V232, P40, DOI 10.1007/BF00176436; VINDING T, 1990, ACTA OPHTHALMOL, V68, P410; VINGERLING JR, 1995, AM J EPIDEMIOL, V142, P404, DOI 10.1093/oxfordjournals.aje.a117648; VOLKER W, 1993, J HISTOCHEM CYTOCHEM, V41, P1823, DOI 10.1177/41.12.7504009; YASUMITSU H, 1993, IN VITRO CELL DEV-AN, V29A, P403; YOUNG RW, 1987, SURV OPHTHALMOL, V31, P291, DOI 10.1145/1165387.275645	54	158	168	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	1999	13	3					477	484		10.1096/fasebj.13.3.477	http://dx.doi.org/10.1096/fasebj.13.3.477			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	174CF	10064614				2022-12-25	WOS:000079016000007
J	Li, J; Gilmour, RS; Saunders, JC; Dauncey, MJ; Fowden, AL				Li, J; Gilmour, RS; Saunders, JC; Dauncey, MJ; Fowden, AL			Activation of the adult mode of ovine growth hormone receptor gene expression by cortisol during late fetal development	FASEB JOURNAL			English	Article						fetus; GHR; fetal plasma cortisol; GH binding; riboprobe; insulin-like growth factor; glucocorticoid response element	MESSENGER-RIBONUCLEIC-ACID; GH-BINDING-PROTEIN; LIVER-SPECIFIC PROMOTER; FACTOR-I GENE; RNA EXPRESSION; SHEEP FETUS; IGF-I; ONTOGENY; MECHANISMS; GESTATION	The developmental and tissue-specific regulation of growth hormone receptor (GI-W) mRNA expression is complex and involves alternate leader exon usage. The transcript composition of hepatic GHR mRNA has therefore been determined in fetal sheep during late gestation and after experimental manipulation of fetal plasma cortisol levels by fetal adrenalectomy and exogenous cortisol infusion, using RNase protection assays and a riboprobe containing exons 1A, 2, and 3 of the ovine GHR gene, Expression of the adult liver-specific GHR mRNA transcript containing exon 1A was not detected earlier than 138 days of gestation (term 145 +/- 2 days). Thereafter, expression of this leader exon increased and accounted for 25-30% of the total GHR mRNA in the fetal liver at term, Hepatic GHR mRNA derived from leader exons other than 1A was detectable at 97 days and increased in abundance toward term in parallel with the normal prepartum rise in fetal plasma cortisol, Abolition of this cortisol surge by fetal adrenalectomy prevented both the activation of exon 1A expression and the prepartum rise in GHR mRNA derived from the other leader exons in fetal ovine liver. Conversely, raising cortisol levels by exogenous infusion earlier in gestation prematurely activated exon 1A expression and enhanced the abundance of GHR mRNA transcripts derived from the other leader exons, Cortisol therefore appears to activate the adult mode of GHR gene expression in fetal ovine liver during late gestation. These observations have important implications for the maturation of the somatotrophic axis and for the onset of GH-dependent growth after birth.	Univ Cambridge, Dept Physiol, Cambridge CB2 3EG, England; Babraham Inst, Dept Cellular Physiol, Cambridge CB2 4AT, England	University of Cambridge; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute	Fowden, AL (corresponding author), Univ Cambridge, Dept Physiol, Downing St, Cambridge CB2 3EG, England.							ADAMS TE, 1995, MOL CELL ENDOCRINOL, V108, P23, DOI 10.1016/0303-7207(95)92575-9; ADAMS TE, 1990, MOL CELL ENDOCRINOL, V73, P135, DOI 10.1016/0303-7207(90)90126-S; Armitage P., 1971, STAT METHODS MED RES, V1; BAKER J, 1993, CELL, V75, P73, DOI 10.1016/0092-8674(93)90680-O; BAUMBACH WR, 1995, ENDOCRINOLOGY, V136, P749, DOI 10.1210/en.136.2.749; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COMLINE RS, 1972, J PHYSIOL-LONDON, V222, P233, DOI 10.1113/jphysiol.1972.sp009795; DARVEAU A, 1985, P NATL ACAD SCI USA, V82, P2315, DOI 10.1073/pnas.82.8.2315; Duchamp C, 1996, EUR J ENDOCRINOL, V134, P524, DOI 10.1530/eje.0.1340524; FOWDEN AL, 1995, REPROD FERT DEVELOP, V7, P351, DOI 10.1071/RD9950351; Fowden AL, 1998, P NUTR SOC, V57, P113, DOI 10.1079/PNS19980017; GABRIELSSON BG, 1995, ENDOCRINOLOGY, V136, P209, DOI 10.1210/en.136.1.209; GARCIA E, 1992, FOCUS DIVERSITY, V1, P1; GLUCKMAN PD, 1983, ENDOCRINOLOGY, V112, P1607, DOI 10.1210/endo-112-5-1607; GLUCKMAN PD, 1995, FETUS NEONATE PHYSL, V3, P971; HAUSER SD, 1990, MOL CELL ENDOCRINOL, V72, P187, DOI 10.1016/0303-7207(90)90143-V; HERINGTON AC, 1994, MOL CELL ENDOCRINOL, V100, P39, DOI 10.1016/0303-7207(94)90276-3; HILL DJ, 1992, J CLIN ENDOCR METAB, V75, P646, DOI 10.1210/jc.75.2.646; KLEMPT M, 1993, ENDOCRINOLOGY, V132, P1071, DOI 10.1210/en.132.3.1071; LEE CY, 1993, MOL CELL ENDOCRINOL, V93, P71, DOI 10.1016/0303-7207(93)90141-6; Li J, 1996, ENDOCRINOLOGY, V137, P1650, DOI 10.1210/en.137.5.1650; LI J, 1997, J ENDOCRINOL S, V152, P123; MAES M, 1983, ENDOCRINOLOGY, V113, P1325, DOI 10.1210/endo-113-4-1325; Martini JF, 1997, J BIOL CHEM, V272, P18951, DOI 10.1074/jbc.272.30.18951; MESIANO S, 1989, ENDOCRINOLOGY, V124, P1485, DOI 10.1210/endo-124-3-1485; Min SH, 1996, ENDOCRINOLOGY, V137, P1129, DOI 10.1210/en.137.3.1129; OMAHONEY JV, 1994, MOL CELL ENDOCRINOL, V101, P129, DOI 10.1016/0303-7207(94)90227-5; PEKHLETSKY RI, 1992, MOL CELL ENDOCRINOL, V90, P103, DOI 10.1016/0303-7207(92)90107-H; PRATT SL, 1995, ENDOCRINOLOGY, V136, P2150, DOI 10.1210/en.136.5.2150; SAUNDERS JC, 1991, J MOL ENDOCRINOL, V7, P233, DOI 10.1677/jme.0.0070233; SchnoebelenCombes S, 1996, J ENDOCRINOL, V148, P249, DOI 10.1677/joe.0.1480249; SOUTHARD JN, 1995, ENDOCRINOLOGY, V136, P2913, DOI 10.1210/en.136.7.2913; WELLER PA, 1994, AM J PHYSIOL, V266, pE776, DOI 10.1152/ajpendo.1994.266.5.E776; YMER SI, 1992, MOL CELL ENDOCRINOL, V83, P39, DOI 10.1016/0303-7207(92)90193-A; Zogopoulos G, 1996, J CLIN ENDOCR METAB, V81, P775, DOI 10.1210/jc.81.2.775; Zogopoulos G, 1996, CANCER RES, V56, P2949; Zou LL, 1997, ENDOCRINOLOGY, V138, P1771, DOI 10.1210/en.138.4.1771	37	26	27	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	1999	13	3					545	552		10.1096/fasebj.13.3.545	http://dx.doi.org/10.1096/fasebj.13.3.545			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	174CF	10064621				2022-12-25	WOS:000079016000014
J	Ichtchenko, K; Bittner, MA; Krasnoperov, V; Little, AR; Chepurny, O; Holz, RW; Petrenko, AG				Ichtchenko, K; Bittner, MA; Krasnoperov, V; Little, AR; Chepurny, O; Holz, RW; Petrenko, AG			A novel ubiquitously expressed alpha-latrotoxin receptor is a member of the CIRL family of G-protein-coupled receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WIDOW SPIDER VENOM; TRANSMITTER RELEASE; TOXIN; DEPENDENCE; CATIONS	Poisoning with alpha-latrotoxin, a neurotoxic protein from black widow spider venom, results in a robust increase of spontaneous synaptic transmission and subsequent degeneration of affected nerve terminals. The neurotoxic action of alpha-latrotoxin involves extracellular binding to its high affinity receptors as a first step. One of these proteins, GIRL, is a neuronal G-protein-coupled receptor implicated in the regulation of secretion. We now demonstrate that GIRL has two close homologs with a similar domain structure and high degree of overall identity. These novel receptors, which we propose to name CIRL-2 and CIRL-3, together with CIRL (CIRL-1) belong to a recently identified subfamily of large orphan receptors with structural features typical of both G-protein-coupled receptors and cell adhesion proteins. Northern blotting experiments indicate that CIRL-2 is expressed ubiquitously with highest concentrations found in placenta, kidney, spleen, ovary, heart, and lung whereas CIRL-3 is expressed predominantly in brain similarly to CIRL-1, It appears that CIRL-2 can also bind alpha-latrotoxin, although its affinity to the toxin is about 14 times less than that of CIRL-1, When overexpressed in chromaffin cells, CIRL-2 increases their sensitivity to alpha-latrotoxin stimulation but also inhibits Ca2+-regulated secretion, Thus, CIRL-2 is a functionally competent receptor of alpha-latrotoxin. Our findings suggest that although the nervous system is the primary target of low doses of alpha-latrotoxin, cells of other tissues are also susceptible to the toxic effects of alpha-latrotoxin because of the presence of CIRL-2, a low affinity receptor of the toxin.	NYU, Med Ctr, Dept Pharmacol, New York, NY 10016 USA; NYU, Med Ctr, Dept Physiol & Neurosci, New York, NY 10016 USA; Univ Michigan, Sch Med, Dept Pharmacol, Ann Arbor, MI 48109 USA; NYU, Med Ctr, Dept Environm Med, New York, NY 10016 USA	New York University; New York University; University of Michigan System; University of Michigan; New York University	Ichtchenko, K (corresponding author), NYU, Med Ctr, Dept Pharmacol, 550 1st Ave,MSB-202, New York, NY 10016 USA.		Little, A/O-6191-2014	Little, A/0000-0001-6831-0177; Petrenko, Alexander/0000-0002-6689-6546; Ichtchenko, Konstantin/0000-0002-2198-1325	NIDDK NIH HHS [R01DK27959] Funding Source: Medline; NINDS NIH HHS [R01NS34937, R01NS35098] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK027959] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS035098, R01NS034937] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Barnett DW, 1996, PFLUG ARCH EUR J PHY, V432, P1039, DOI 10.1007/s004240050232; Bittner MA, 1998, J NEUROSCI, V18, P2914; Capogna M, 1996, J NEUROPHYSIOL, V76, P3149, DOI 10.1152/jn.1996.76.5.3149; CLARK AW, 1970, NATURE, V225, P703, DOI 10.1038/225703a0; FRONTALI N, 1976, J CELL BIOL, V68, P462, DOI 10.1083/jcb.68.3.462; Geppert M, 1998, J BIOL CHEM, V273, P1705, DOI 10.1074/jbc.273.3.1705; GRASSO A, 1980, NATURE, V283, P774, DOI 10.1038/283774a0; GRASSO A, 1976, BIOCHIM BIOPHYS ACTA, V439, P406, DOI 10.1016/0005-2795(76)90077-5; Gray JX, 1996, J IMMUNOL, V157, P5438; KIYATKIN NI, 1990, FEBS LETT, V270, P127, DOI 10.1016/0014-5793(90)81250-R; Krasnoperov V, 1999, J BIOL CHEM, V274, P3590, DOI 10.1074/jbc.274.6.3590; Krasnoperov VG, 1997, NEURON, V18, P925, DOI 10.1016/S0896-6273(00)80332-3; Lang JC, 1998, EMBO J, V17, P648, DOI 10.1093/emboj/17.3.648; Lelianova VG, 1997, J BIOL CHEM, V272, P21504, DOI 10.1074/jbc.272.34.21504; MELDOLESI J, 1982, J NEUROCHEM, V38, P1559, DOI 10.1111/j.1471-4159.1982.tb06633.x; MISLER S, 1987, AM J PHYSIOL, V253, pC469, DOI 10.1152/ajpcell.1987.253.3.C469; Nishimori H, 1997, ONCOGENE, V15, P2145, DOI 10.1038/sj.onc.1201542; Petrenko AG, 1996, J NEUROSCI, V16, P4360; PETRENKO AG, 1990, EMBO J, V9, P2023, DOI 10.1002/j.1460-2075.1990.tb08331.x; PETRENKO AG, 1998, CELLULAR MOL MECH TO, P185; ROSENTHAL L, 1990, MOL PHARMACOL, V38, P917; ROSENTHAL L, 1989, PHARMACOL THERAPEUT, V42, P115, DOI 10.1016/0163-7258(89)90024-7; Shiratsuchi T, 1997, CYTOGENET CELL GENET, V79, P103, DOI 10.1159/000134693; USHKARYOV YA, 1992, SCIENCE, V257, P50, DOI 10.1126/science.1621094; VALTORTA F, 1984, J CELL BIOL, V99, P124, DOI 10.1083/jcb.99.1.124	25	86	95	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 26	1999	274	9					5491	5498		10.1074/jbc.274.9.5491	http://dx.doi.org/10.1074/jbc.274.9.5491			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	170KG	10026162	hybrid			2022-12-25	WOS:000078804400033
J	Shinoda, E; Yui, Y; Hattori, R; Tanaka, M; Inoue, R; Aoyama, T; Takimoto, Y; Mitsui, Y; Miyahara, K; Shizuta, Y; Sasayama, S				Shinoda, E; Yui, Y; Hattori, R; Tanaka, M; Inoue, R; Aoyama, T; Takimoto, Y; Mitsui, Y; Miyahara, K; Shizuta, Y; Sasayama, S			Tissue factor pathway inhibitor-2 is a novel mitogen for vascular smooth muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR XA; EXPRESSION; CLONING; INJURY	A mitogen for growth-arrested cultured bovine aortic smooth muscle cells was purified to homogeneity from the supernatant of cultured human umbilical vein endothelial cells by heparin affinity chromatography and reverse-phase high performance liquid chromatography, This mitogen was revealed to be tissue factor pathway inhibitor-2 (TFPI-2), which is a Kunitz-type serine protease inhibitor. TFPI-2 was expressed in baby hamster kidney cells using a mammalian expression vector. Recombinant TFPI-2 (rTFPI-2) stimulated DNA synthesis and cell proliferation in a dose-dependent manner (1-500 nM). rTFPI-2 activated mitogen-activated protein kinase (MAPK) activity and stimulated early proto-oncogene c-fos mRNA expression in smooth muscle cells. MAPK, c-fos expression and the mitogenic activity were inhibited by a specific inhibitor of MAPK kinase, PD098059, Thus, the mitogenic function of rTFPI-2 is considered to be mediated through MAPK pathway, TFPI has been reported to exhibit antiproliferative action after vascular smooth muscle injury in addition to the ability to inhibit activation of the extrinsic coagulation cascade. However, structurally similar TFPI-2 was found to have a mitogenic activity for the smooth muscle cell.	Kyoto Univ Hosp, Dept Internal Med, Div 3, Kyoto 6068507, Japan; Agcy Ind Sci & Technol, Natl Inst Biosci & Human Technol, Tsukuba, Ibaraki 3058566, Japan; Kochi Med Sch, Dept Med Chem, Nanko Ku, Kochi 7838505, Japan	Kyoto University; National Institute of Advanced Industrial Science & Technology (AIST); Kochi University	Yui, Y (corresponding author), 26-4 Maehagicho,Sakyo Ku, Kyoto 6060833, Japan.							Brown DM, 1996, ARCH SURG-CHICAGO, V131, P1086; JANG YS, 1995, CIRCULATION, V92, P3041, DOI 10.1161/01.CIR.92.10.3041; JESTY J, 1994, BIOCHEMISTRY-US, V33, P12686, DOI 10.1021/bi00208a020; Kamikubo Y, 1997, FEBS LETT, V407, P116, DOI 10.1016/S0014-5793(97)00312-8; Ko FN, 1996, J CLIN INVEST, V98, P1493, DOI 10.1172/JCI118938; MIYAGI Y, 1994, J BIOCHEM-TOKYO, V116, P939, DOI 10.1093/oxfordjournals.jbchem.a124648; Muller JN, 1997, J BIOL CHEM, V272, P23435, DOI 10.1074/jbc.272.37.23435; NIIDOME T, 1994, BIOCHEM BIOPH RES CO, V203, P1821, DOI 10.1006/bbrc.1994.2399; Oltrona L, 1997, CIRCULATION, V96, P646; Petersen LC, 1996, BIOCHEMISTRY-US, V35, P266, DOI 10.1021/bi951501d; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; SEIICHIRO W, 1995, BIOCHEM BIOPH RES CO, V216, P729; SHIROTANI M, 1991, J PHARMACOL EXP THER, V259, P738; SPRECHER CA, 1994, P NATL ACAD SCI USA, V91, P3353, DOI 10.1073/pnas.91.8.3353; STRAATEN F, 1983, P NATL ACAD SCI USA, V80, P3183; Yamakawa T, 1998, HYPERTENSION, V31, P248, DOI 10.1161/01.HYP.31.1.248	16	29	33	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 26	1999	274	9					5379	5384		10.1074/jbc.274.9.5379	http://dx.doi.org/10.1074/jbc.274.9.5379			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	170KG	10026147	Green Submitted, hybrid			2022-12-25	WOS:000078804400018
J	Stemmer, C; Quesnel, A; Prevost-Blondel, A; Zimmermann, C; Muller, S; Briand, JP; Pircher, H				Stemmer, C; Quesnel, A; Prevost-Blondel, A; Zimmermann, C; Muller, S; Briand, JP; Pircher, H			Protection against lymphocytic choriomeningitis virus infection induced by a reduced peptide bond analogue of the H-2D(b)-restricted CD8(+) T cell epitope GP33	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETRO-INVERSO-PEPTIDOMIMETICS; PSEUDOPEPTIDE ANALOGS; ANTIGENIC PEPTIDES; LIVING CELLS; MOLECULES; SELECTION; BINDING; REQUIREMENTS; EXPLORATION; HEXAPEPTIDE	Recent investigations have suggested that pseudopeptides containing modified peptide bonds might advantageously replace natural peptides in therapeutic strategies. We have generated eight reduced peptide bond psi(CH2-NH) analogues corresponding to the H-2D(b)-restricted CD8(+) T cell epitope (called GP33) of the glycoprotein of the lymphocytic choriomeningitis virus. One of these pseudopeptides, containing a reduced peptide bond between residues 6 and 7 (psi(6-7)), displayed very similar properties of binding to major histocompatibility complex (MHC) and recognition by T cell receptor transgenic T cells specific for GP33 when compared with the parent peptide. We assessed in vitro and in vivo the proteolytic resistance of GP33 and psi(6-7) and analyzed its contribution to the priming properties of these peptides. The psi(6-7) analogue exhibited a dramatically increased proteolytic resistance when compared with GP33, and we show for the first time that MHC-peptide complexes formed in vivo with a pseudopeptide display a sustained half-life compared with the complexes formed with the natural peptide. Furthermore, in contrast to immunizations with GP33, three injections of psi(6-7) in saline induced significant antiviral protection in mice. The enhanced ability of psi(6-7) to induce antiviral protection may result from the higher stability of the analogue and/or of the MHC-analogue complexes.	Univ Freiburg, Dept Immunol, Inst Med Microbiol & Hyg, D-79104 Freiburg, Germany; CNRS, UPR 9021, Inst Biol Mol & Cellulaire, F-67000 Strasbourg, France	University of Freiburg; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Pircher, H (corresponding author), Univ Freiburg, Dept Immunol, Inst Med Microbiol & Hyg, Hermann Herder Str 11, D-79104 Freiburg, Germany.	pircher@ukl.uni-freiburg.de	Prevost-Blondel, Armelle/N-7643-2017; Muller, Sylviane/J-5319-2014	Prevost-Blondel, Armelle/0000-0002-7268-5905				AICHELE P, 1995, J EXP MED, V182, P261, DOI 10.1084/jem.182.1.261; Azay J, 1998, PEPTIDES, V19, P57, DOI 10.1016/S0196-9781(97)00275-1; BATTEGAY M, 1991, J VIROL METHODS, V33, P191, DOI 10.1016/0166-0934(91)90018-U; Benkirane N, 1996, J BIOL CHEM, V271, P33218, DOI 10.1074/jbc.271.52.33218; Bianco A, 1998, J BIOL CHEM, V273, P28759, DOI 10.1074/jbc.273.44.28759; Briand JP, 1997, P NATL ACAD SCI USA, V94, P12545, DOI 10.1073/pnas.94.23.12545; Buss JE, 1995, CHEM BIOL, V2, P787, DOI 10.1016/1074-5521(95)90083-7; Cotton J, 1998, INT IMMUNOL, V10, P159, DOI 10.1093/intimm/10.2.159; Eberl G, 1996, EUR J IMMUNOL, V26, P1993, DOI 10.1002/eji.1830260904; Ettouati L, 1996, PEPTIDE RES, V9, P248; FAUCHERE JL, 1992, ADV DRUG RES, V23, P127; GANTE J, 1994, ANGEW CHEM INT EDIT, V33, P1699, DOI 10.1002/anie.199416991; GUICHARD G, 1995, J BIOL CHEM, V270, P26057, DOI 10.1074/jbc.270.44.26057; GUICHARD G, 1994, PEPTIDE RES, V7, P308; GUICHARD G, 1994, P NATL ACAD SCI USA, V91, P9765, DOI 10.1073/pnas.91.21.9765; Guichard G, 1996, J MED CHEM, V39, P2030, DOI 10.1021/jm9509511; HAMMERLING GJ, 1979, IMMUNOGENETICS, V8, P433, DOI 10.1007/BF01561454; HILL CM, 1994, J IMMUNOL, V152, P2890; Kagi D, 1996, CURR OPIN IMMUNOL, V8, P472, DOI 10.1016/S0952-7915(96)80033-1; Liu MA, 1998, NAT MED, V4, P515, DOI 10.1038/nm0598supp-515; LUESCHER IF, 1992, J IMMUNOL, V148, P1003; Meziere C, 1997, J IMMUNOL, V159, P3230; MOURITSEN S, 1992, J IMMUNOL, V149, P1987; Muller S., 1998, Research in Immunology, V149, P55, DOI 10.1016/S0923-2494(98)80046-1; Ostankovitch M, 1998, J IMMUNOL, V161, P200; PIRCHER H, 1990, NATURE, V346, P629, DOI 10.1038/346629a0; PIRCHER H, 1989, NATURE, V342, P559, DOI 10.1038/342559a0; Quesnel A, 1998, J PEPT RES, V52, P107; ROMERO P, 1991, J EXP MED, V174, P603, DOI 10.1084/jem.174.3.603; Sebzda E, 1996, J EXP MED, V183, P1093, DOI 10.1084/jem.183.3.1093; SLOANLANCASTER J, 1995, CURR OPIN IMMUNOL, V7, P103, DOI 10.1016/0952-7915(95)80035-2; Stemmer C, 1998, EXPERT OPIN THER PAT, V8, P819, DOI 10.1517/13543776.8.7.819; Teal PEA, 1997, REGUL PEPTIDES, V72, P161, DOI 10.1016/S0167-0115(97)01053-7; TOWNSEND A, 1989, NATURE, V340, P443, DOI 10.1038/340443a0; VERDINI AS, 1991, J MED CHEM, V34, P3372, DOI 10.1021/jm00116a005; YOUNG ACM, 1994, CELL, V76, P39, DOI 10.1016/0092-8674(94)90171-6; ZINKERNAGEL RM, 1985, J EXP MED, V162, P2125, DOI 10.1084/jem.162.6.2125	38	27	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 26	1999	274	9					5550	5556		10.1074/jbc.274.9.5550	http://dx.doi.org/10.1074/jbc.274.9.5550			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	170KG	10026170	hybrid			2022-12-25	WOS:000078804400041
J	Sun, SC; Maggirwar, SB; Harhaj, EW; Uhlik, M				Sun, SC; Maggirwar, SB; Harhaj, EW; Uhlik, M			Binding of c-Rel to STAT5 target sequences in HTLV-I-transformed T cells	ONCOGENE			English	Article						HTLV-I; c-Rel; STAT; T-cell transformation; NF-kappa B	NF-KAPPA-B; VIRUS TYPE-I; LEUKEMIA-LYMPHOMA VIRUS; LONG TERMINAL REPEAT; JAK-3 JANUS KINASE; TAX PROTEIN; TRANSCRIPTIONAL ACTIVATION; CONSTITUTIVE ACTIVATION; SIGNAL; PHOSPHORYLATION	The type I human T-cell leukemia virus (HTLV-I) induces abnormal growth and subsequent transformation of T cells, which is associated with the development of an acute T-cell malignancy termed adult T-cell leukemia, A characteristic of HTLV-I-transformed T cells is the constitutive nuclear expression of NF-kappa B/Rel family of transcription factors, which appears to be essential for the growth of these transformed cells. Although NF-kappa B/Rel factors are known to induce the expression of T-cell growth factor interleukin (IL)-2, it is unclear how they participate in the IL-2-independent growth of HTLV-1-transformed cells, In this study, we show that certain NF-kappa B/Rel members, predominantly c-Rel, interact with enhancer sequences for STAT5, a key transcription factor mediating IL-2-induced T-cell proliferation. Reporter gene assays reveal that the binding of c-Rel to the STAT5 site present in the Fc gamma 1 gene leads to potent transactivation of this enhancer. Binding of c-Rel to the Fc gamma R1 STAT site also occurs in human peripheral blood T cells immortalized with HTLV-I in vitro and is correlated with enhanced levels of proliferation of these cells. These results raise the possibility that NF-kappa B/Rel may participate in the growth control of HTLV-I-transformed T cells by regulating genes driven by both kappa B and certain STAT enhancers.	Penn State Univ, Coll Med, Hershey Med Ctr, Dept Microbiol & Immunol, Hershey, PA 17033 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Sun, SC (corresponding author), Penn State Univ, Coll Med, Hershey Med Ctr, Dept Microbiol & Immunol, POB 850, Hershey, PA 17033 USA.				NCI NIH HHS [1 R01 CA68471-03, 5 T32 CA 6039-5] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA068471] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akagi T, 1997, ONCOGENE, V14, P2071, DOI 10.1038/sj.onc.1201045; Becker S, 1998, NATURE, V394, P145, DOI 10.1038/28101; BEG AA, 1993, GENE DEV, V7, P2064, DOI 10.1101/gad.7.11.2064; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DOERRE S, 1993, P NATL ACAD SCI USA, V90, P1023, DOI 10.1073/pnas.90.3.1023; FEUER G, 1992, BIOCHIM BIOPHYS ACTA, V1114, P223, DOI 10.1016/0304-419X(92)90017-S; FUJII H, 1995, P NATL ACAD SCI USA, V92, P5482, DOI 10.1073/pnas.92.12.5482; GANCHI PA, 1992, MOL BIOL CELL, V3, P1339, DOI 10.1091/mbc.3.12.1339; GAZDAR AF, 1980, BLOOD, V55, P409; GILMORE TD, 1990, CELL, V62, P841, DOI 10.1016/0092-8674(90)90257-F; Good LF, 1996, J VIROL, V70, P2730, DOI 10.1128/JVI.70.5.2730-2735.1996; HOLBROOK NJ, 1987, VIROLOGY, V157, P211, DOI 10.1016/0042-6822(87)90330-8; HOLLSBERG P, 1992, J IMMUNOL, V148, P3256; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; JOHNSTON JA, 1994, NATURE, V370, P151, DOI 10.1038/370151a0; JOHNSTON JA, 1995, P NATL ACAD SCI USA, V92, P8705, DOI 10.1073/pnas.92.19.8705; KANNO T, 1994, MOL CELL BIOL, V14, P6443, DOI 10.1128/MCB.14.10.6443; KITAJIMA I, 1992, SCIENCE, V258, P1792, DOI 10.1126/science.1299224; KOEFFLER HP, 1984, BLOOD, V64, P482; KONTGEN F, 1995, GENE DEV, V9, P1965, DOI 10.1101/gad.9.16.1965; LACOSTE J, 1995, J VIROL, V69, P564, DOI 10.1128/JVI.69.1.564-569.1995; LI CCH, 1993, J VIROL, V67, P4205, DOI 10.1128/JVI.67.7.4205-4213.1993; LIN JX, 1995, IMMUNITY, V2, P331, DOI 10.1016/1074-7613(95)90141-8; McKinsey TA, 1996, MOL CELL BIOL, V16, P2083; MERL S, 1984, BLOOD, V64, P967; MIGONE TS, 1995, SCIENCE, V269, P79, DOI 10.1126/science.7604283; MIYOSHI I, 1981, GANN, V72, P978; MUI ALF, 1995, EMBO J, V14, P1166, DOI 10.1002/j.1460-2075.1995.tb07100.x; Mulloy JC, 1998, J VIROL, V72, P4408, DOI 10.1128/JVI.72.5.4408-4412.1998; Nakajima K, 1996, EMBO J, V15, P3651, DOI 10.1002/j.1460-2075.1996.tb00734.x; OShea JJ, 1997, IMMUNITY, V7, P1, DOI 10.1016/S1074-7613(00)80505-1; PERSAUD D, 1995, J VIROL, V69, P6297, DOI 10.1128/JVI.69.10.6297-6303.1995; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; Ressler S, 1996, FEMS MICROBIOL LETT, V140, P99, DOI 10.1016/0378-1097(96)00166-8; SALAHUDDIN SZ, 1983, VIROLOGY, V129, P51, DOI 10.1016/0042-6822(83)90395-1; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SCHWARTZ RH, 1990, SCIENCE, V248, P1349, DOI 10.1126/science.2113314; Shen CH, 1998, MOL CELL BIOL, V18, P3395, DOI 10.1128/MCB.18.6.3395; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; SMITH MR, 1991, J CLIN INVEST, V87, P761, DOI 10.1172/JCI115078; SODROSKI J, 1992, BIOCHIM BIOPHYS ACTA, V1114, P19, DOI 10.1016/0304-419X(92)90003-H; Stancovski I, 1997, CELL, V91, P299, DOI 10.1016/S0092-8674(00)80413-4; SUN SC, 1994, MOL CELL BIOL, V14, P7377, DOI 10.1128/MCB.14.11.7377; Takemoto S, 1997, P NATL ACAD SCI USA, V94, P13897, DOI 10.1073/pnas.94.25.13897; Uchiyama T, 1997, ANNU REV IMMUNOL, V15, P15, DOI 10.1146/annurev.immunol.15.1.15; WITTHUHN BA, 1994, NATURE, V370, P153, DOI 10.1038/370153a0; XU X, 1995, J CLIN INVEST, V96, P1548, DOI 10.1172/JCI118193; Yamaoka S, 1996, EMBO J, V15, P873, DOI 10.1002/j.1460-2075.1996.tb00422.x; YOSHIDA M, 1995, J CANCER RES CLIN, V121, P521, DOI 10.1007/BF01197764; YOSHIDA M, 1982, P NATL ACAD SCI-BIOL, V79, P2031, DOI 10.1073/pnas.79.6.2031	52	13	14	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 18	1999	18	7					1401	1409		10.1038/sj.onc.1202430	http://dx.doi.org/10.1038/sj.onc.1202430			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	167UK	10050877				2022-12-25	WOS:000078651600002
J	Davis, JN; Williams, BJ; Herron, JT; Galiano, FJ; Meyers, S				Davis, JN; Williams, BJ; Herron, JT; Galiano, FJ; Meyers, S			ETO-2, a new member of the ETO-family of nuclear proteins	ONCOGENE			English	Article						ETO family; MTG8; (8;21) translocation; nuclear; dimerization	ACUTE MYELOID-LEUKEMIA; DROSOPHILA SEGMENTATION GENE; T(8-21) FUSION PROTEIN; CORE-BINDING FACTOR; TRANSCRIPTIONAL REGULATION; MOLECULAR-CLONING; AML1 GENE; CELL-LINE; RUNT; IDENTIFICATION	The t(8;21) is associated with 12-15% of acute myelogenous leukemias of the M2 subtype, the translocation results in the fusion of two genes, AML1 (CBFA2) on chromosome 21 and ETO (MTG8) on chromosome 8, AML1 encodes a DNA binding factor; the ETO protein product is less well characterized, but is thought to be a transcription factor. Here we describe the isolation and characterization of ETO-2, a murine cDNA that encodes a new member of the ETO family of proteins. ETO-2 is 75% identical to murine ETO and shares very high sequence identities over four regions of the protein with ETO (domain I-III and zinc-finger). Northern analysis identifies ETO-2 transcripts in many of the murine tissues analysed and in the developing mouse embryo. ETO-2 is also expressed in myeloid and erythroid cell lines. We confirmed the nuclear localization of ETO-2 and demonstrated that domain III and the zinc-finger region are not required for nuclear localization. We further showed that a region within ETO, containing domain II, mediates dimerization among family members. This region is conserved in the oncoprotein AML-1/ETO. The recent identification of another ETO-like protein, myeloid translocation gene-related protein 1, together with the data presented here, demonstrates that at least three ETO proteins exist with the potential to form dimers in the cell nucleus.	Louisiana State Univ, Med Ctr, Dept Biochem & Mol Biol, Shreveport, LA 71130 USA; Louisiana State Univ, Med Ctr, Dept Urol, Shreveport, LA 71130 USA; Louisiana State Univ, Med Ctr, Feist Weiller Canc Ctr, Shreveport, LA 71130 USA	Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport; Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport; Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport	Meyers, S (corresponding author), Louisiana State Univ, Med Ctr, Dept Biochem & Mol Biol, Shreveport, LA 71130 USA.				NATIONAL CANCER INSTITUTE [R29CA076186] Funding Source: NIH RePORTER; NCI NIH HHS [R29-CA76186] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ASKEW DS, 1993, HEMATOL PATHOL, V7, P1; BAE SC, 1994, MOL CELL BIOL, V14, P3242, DOI 10.1128/MCB.14.5.3242; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; DICKSTEIN R, 1996, CELL, V87, P137; ERICKSON P, 1992, BLOOD, V80, P1825; ERICKSON PF, 1994, CANCER RES, V54, P1782; Erickson PF, 1996, BLOOD, V88, P1813; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FEINSTEIN PG, 1995, GENETICS, V140, P573; Frank R, 1995, ONCOGENE, V11, P2667; Fuchs E, 1998, SCIENCE, V279, P514, DOI 10.1126/science.279.5350.514; Gamou T, 1998, BLOOD, V91, P4028, DOI 10.1182/blood.V91.11.4028.411a45_4028_4037; GOLUB TR, 1995, P NATL ACAD SCI USA, V92, P4917, DOI 10.1073/pnas.92.11.4917; Gross CT, 1996, EMBO J, V15, P1961, DOI 10.1002/j.1460-2075.1996.tb00547.x; Hiebert SW, 1996, CURR TOP MICROBIOL, V211, P253; HOEY T, 1993, CELL, V72, P247, DOI 10.1016/0092-8674(93)90664-C; Hwang I, 1997, J IMMUNOL, V158, P1165; Jousset C, 1997, EMBO J, V16, P69, DOI 10.1093/emboj/16.1.69; KAGOSHIMA H, 1993, TRENDS GENET, V9, P338, DOI 10.1016/0168-9525(93)90026-E; KANIA MA, 1990, GENE DEV, V4, P1701, DOI 10.1101/gad.4.10.1701; Kitabayashi I, 1998, MOL CELL BIOL, V18, P846, DOI 10.1128/MCB.18.2.846; KOZU T, 1993, BLOOD, V82, P1270; Kozu Tomoko, 1997, Leukemia (Basingstoke), V11, P297; LEE JC, 1982, J IMMUNOL, V128, P2393; LENNY N, 1995, ONCOGENE, V11, P1761; LEVANON D, 1994, GENOMICS, V23, P425, DOI 10.1006/geno.1994.1519; Mackay JP, 1998, TRENDS BIOCHEM SCI, V23, P1, DOI 10.1016/S0968-0004(97)01168-7; MELNIKOVA IN, 1993, J VIROL, V67, P2408, DOI 10.1128/JVI.67.4.2408-2411.1993; MEYERS S, 1995, MOL CELL BIOL, V15, P1974; Meyers S, 1995, CRIT REV EUKAR GENE, V5, P365, DOI 10.1615/CritRevEukarGeneExpr.v5.i3-4.70; MEYERS S, 1993, MOL CELL BIOL, V13, P6336, DOI 10.1128/MCB.13.10.6336; MIYOSHI H, 1991, P NATL ACAD SCI USA, V88, P10431, DOI 10.1073/pnas.88.23.10431; MIYOSHI H, 1993, EMBO J, V12, P2715, DOI 10.1002/j.1460-2075.1993.tb05933.x; OGAWA E, 1993, P NATL ACAD SCI USA, V90, P6859, DOI 10.1073/pnas.90.14.6859; OWENS GP, 1991, MOL CELL BIOL, V11, P4177, DOI 10.1128/MCB.11.8.4177; ROWLEY JD, 1984, CANCER RES, V44, P3159; SELLS MA, 1995, GENE, V152, P187, DOI 10.1016/0378-1119(94)00685-L; Speck NA, 1995, CRIT REV EUKAR GENE, V5, P337, DOI 10.1615/CritRevEukarGeneExpr.v5.i3-4.60; Tanese N, 1996, P NATL ACAD SCI USA, V93, P13611, DOI 10.1073/pnas.93.24.13611; WANG SW, 1993, MOL CELL BIOL, V13, P3324, DOI 10.1128/MCB.13.6.3324; WANG SW, 1992, MOL CELL BIOL, V12, P89, DOI 10.1128/MCB.12.1.89; WHEELER EF, 1987, MOL CELL BIOL, V7, P1673, DOI 10.1128/MCB.7.5.1673; Zeng CM, 1997, P NATL ACAD SCI USA, V94, P6746, DOI 10.1073/pnas.94.13.6746; Zhang DE, 1996, CURR TOP MICROBIOL, V211, P137	44	35	38	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 11	1999	18	6					1375	1383		10.1038/sj.onc.1202412	http://dx.doi.org/10.1038/sj.onc.1202412			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	165FW	10022820				2022-12-25	WOS:000078510900014
J	Ferrier, R; Nougarede, R; Doucet, S; Kahn-Perles, B; Imbert, J; Mathieu-Mahul, D				Ferrier, R; Nougarede, R; Doucet, S; Kahn-Perles, B; Imbert, J; Mathieu-Mahul, D			Physical interaction of the bHLH LYL1 protein and NF-kappa B1 p105	ONCOGENE			English	Article						bHLH; LYL1; NF-kappa b	NF-KAPPA-B; T-CELL LEUKEMIA; LOOP-HELIX PROTEINS; ACUTE LYMPHOBLASTIC-LEUKEMIA; DNA-BINDING PROPERTIES; SCL GENE-PRODUCT; TRANSGENIC MICE; ERYTHROID-DIFFERENTIATION; HEMATOPOIETIC LINEAGES; ENHANCER-BINDING	The LYL1 gene was first identified upon the molecular characterization of the t(7;9)(q35;p13) translocation associated with some human T-cell acute leukemias (T-ALLs), In adult tissues, LYL1 expression is restricted to hematopoietic cells with the notable exclusion of the T cell lineage. LYL1 encodes a basic helix-loop-helix (bHLH) protein highly related to TAL-1, whose activation is also associated with a high proportion of human T-ALLs. A yeast two-hybrid system was used to identify proteins that specifically interact with LYL1 and might mediate its activities. We found that p105, the precursor of NF-kappa B1 p50, was the major LYL1-interacting protein in this system. The association between LYL1 and p105 was confirmed both in vitro and in vivo in mammalian cells. Biochemical studies indicated that the interaction was mediated by the bHLH motif of LYL1 and the ankyrin-like motifs of p105. Ectopic expression of LYL1 in a human T cell line caused a significant decrease in NF-kappa B-dependent transcription, associated with a reduced level of NF-kappa B1 proteins.	Inst Genet Mol, UMR 5535, F-34293 Montpellier, France; Inst J Paoli I Calmettes, INSERM, U119, F-13009 Marseille, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Montpellier; Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Institut Paoli-Calmette (IPC)	Mathieu-Mahul, D (corresponding author), Inst Genet Mol, UMR 5535, 1919 Route Mende, F-34293 Montpellier, France.		Imbert, Jean/G-3248-2013; Imbert, Jean/AAG-1165-2020; Mathieu, Daniele/G-6092-2012; Kahn-Perlès, Brigitte/M-3513-2016	Imbert, Jean/0000-0002-0478-9593; Imbert, Jean/0000-0002-0478-9593; Kahn-Perlès, Brigitte/0000-0001-5673-5901				ABBADIE C, 1993, CELL, V75, P899, DOI 10.1016/0092-8674(93)90534-W; APLAN PD, 1992, EMBO J, V11, P4073, DOI 10.1002/j.1460-2075.1992.tb05500.x; BAER R, 1993, SEMIN CANCER BIOL, V4, P341; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Baichwal V. R., 1997, CURR BIOL, V7, P94; BAIN G, 1994, CELL, V79, P885, DOI 10.1016/0092-8674(94)90077-9; BASH RO, 1995, BLOOD, V86, P666, DOI 10.1182/blood.V86.2.666.bloodjournal862666; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BEGLEY CG, 1989, P NATL ACAD SCI USA, V86, P10128, DOI 10.1073/pnas.86.24.10128; BERNARD O, 1990, GENE CHROMOSOME CANC, V1, P194, DOI 10.1002/gcc.2870010303; BERNARD O, 1991, ONCOGENE, V6, P1477; Boothby MR, 1997, J EXP MED, V185, P1897, DOI 10.1084/jem.185.11.1897; BROWN L, 1990, EMBO J, V9, P3343, DOI 10.1002/j.1460-2075.1990.tb07535.x; Carrasco D, 1996, EMBO J, V15, P3640, DOI 10.1002/j.1460-2075.1996.tb00733.x; CHANG CC, 1995, MOL CELL BIOL, V15, P5180; CHEN Q, 1990, EMBO J, V9, P415, DOI 10.1002/j.1460-2075.1990.tb08126.x; Condorelli GL, 1997, MOL CELL BIOL, V17, P2954, DOI 10.1128/MCB.17.5.2954; Condorelli GL, 1996, CANCER RES, V56, P5113; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FINCH E, 1995, ADDICT RES, V3, P63, DOI 10.3109/16066359509005223; FUJIMOTO K, 1995, GENE, V165, P183, DOI 10.1016/0378-1119(95)00507-3; Gilmore TD, 1996, ONCOGENE, V13, P1367; GOLDFARB AN, 1992, BLOOD, V80, P2658; GREEN AR, 1991, ONCOGENE, V6, P475; GREEN AR, 1991, EMBO J, V10, P4153, DOI 10.1002/j.1460-2075.1991.tb04993.x; Grilli M, 1996, SCIENCE, V274, P1383, DOI 10.1126/science.274.5291.1383; Grimm S, 1996, J CELL BIOL, V134, P13, DOI 10.1083/jcb.134.1.13; HSU HL, 1994, P NATL ACAD SCI USA, V91, P3181, DOI 10.1073/pnas.91.8.3181; HSU HL, 1994, P NATL ACAD SCI USA, V91, P5947, DOI 10.1073/pnas.91.13.5947; HSU HL, 1991, MOL CELL BIOL, V11, P3037, DOI 10.1128/MCB.11.6.3037; HSU HL, 1994, MOL CELL BIOL, V14, P1256, DOI 10.1128/MCB.14.2.1256; KALLIANPUR AR, 1994, BLOOD, V83, P1200; KANG SM, 1992, SCIENCE, V256, P1452, DOI 10.1126/science.1604322; Kelliher MA, 1996, EMBO J, V15, P5160, DOI 10.1002/j.1460-2075.1996.tb00900.x; KLEIN ES, 1993, GENE DEV, V7, P55, DOI 10.1101/gad.7.1.55; LEROYVIARD K, 1995, EMBO J, V14, P2341, DOI 10.1002/j.1460-2075.1995.tb07229.x; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; MacKichan ML, 1996, J BIOL CHEM, V271, P6084, DOI 10.1074/jbc.271.11.6084; Mahajan MA, 1996, ONCOGENE, V12, P2343; MELLENTIN JD, 1989, CELL, V58, P77, DOI 10.1016/0092-8674(89)90404-2; MIGLIAZZA A, 1994, BLOOD, V84, P3850, DOI 10.1182/blood.V84.11.3850.bloodjournal84113850; Miyamoto A, 1996, MOL CELL BIOL, V16, P2394; MOUTHON MA, 1993, BLOOD, V81, P647; MUNOZ E, 1994, J VIROL, V68, P8035; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; Ono Y, 1997, J BIOL CHEM, V272, P4576, DOI 10.1074/jbc.272.7.4576; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; Porcher C, 1996, CELL, V86, P47, DOI 10.1016/S0092-8674(00)80076-8; PULFORD K, 1995, BLOOD, V85, P675, DOI 10.1182/blood.V85.3.675.bloodjournal853675; ROBB L, 1995, P NATL ACAD SCI USA, V92, P7075, DOI 10.1073/pnas.92.15.7075; Robb L, 1996, EMBO J, V15, P4123, DOI 10.1002/j.1460-2075.1996.tb00787.x; Rousset R, 1996, NATURE, V381, P328, DOI 10.1038/381328a0; SHIVDASANI RA, 1995, NATURE, V373, P432, DOI 10.1038/373432a0; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TEN RM, 1992, EMBO J, V11, P195, DOI 10.1002/j.1460-2075.1992.tb05042.x; VALGEARCHER VE, 1994, P NATL ACAD SCI USA, V91, P8617, DOI 10.1073/pnas.91.18.8617; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; VISVADER J, 1991, ONCOGENE, V6, P187; WADMAN I, 1994, EMBO J, V13, P4831, DOI 10.1002/j.1460-2075.1994.tb06809.x; Wadman IA, 1997, EMBO J, V16, P3145, DOI 10.1093/emboj/16.11.3145; XIA Y, 1994, ONCOGENE, V9, P1437; XIA Y, 1991, P NATL ACAD SCI USA, V88, P11416, DOI 10.1073/pnas.88.24.11416	62	31	33	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 28	1999	18	4					995	1005		10.1038/sj.onc.1202374	http://dx.doi.org/10.1038/sj.onc.1202374			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	165FT	10023675				2022-12-25	WOS:000078510600016
J	Regev, A; Cohen, S; Cohen, E; Bar-Am, I; Lavi, S				Regev, A; Cohen, S; Cohen, E; Bar-Am, I; Lavi, S			Telomeric repeats on small polydisperse circular DNA (spcDNA) and genomic instability	ONCOGENE			English	Article						genomic instability; spcDNA; telomeres; mutator phenotype; two dimensional electrophoresis; cancer	GENE AMPLIFICATION; CHROMOSOMAL-ABERRATIONS; HUMAN-CELLS; SEQUENCES; RECOMBINATION; INVOLVEMENT; RESISTANCE; EXCISION; FAMILY; VIRUS	Small polydisperse circular DNA (spcDNA) is a heterogeneous population of extrachromosomal circular molecules present in a large variety of eukaryotic cells. Elevated amounts of total spcDNA are related to endogenous and induced genomic instability in rodent and human cells, We suggested spcDNA as a novel marker for genomic instability, and speculated that spcDNA might serve as a mutator, In this study, we examine the presence of telomeric sequences on spcDNA, We report for the first time the appearance of telomeric repeats in spcDNA molecules (tel-spcDNA) in rodent and human cells. Restriction enzyme analysis indicates that tel-spcDNA molecules harbor mostly, if not exclusively, telomeric repeats, In rodent cells, tel-spcDNA levels are higher in transformed than in normal cells and are enhanced by treatment with carcinogen, Tel-spcDNA is also detected in some human tumors and cell lines, but not in others. We suggest, that its levels in human cells may be primarily related to the amount of the chromosomal telomeric sequences. Tel-spcDNA may serve as a unique mutator, through specific mechanisms related to the telomeric repeats, which distinguish it from the total heterogeneous spcDNA population. It may affect telomere dynamics and genomic instability by clastogenic events, alterations of telomere size and sequestration of telomeric proteins.	Tel Aviv Univ, George S Wise Fac Life Sci, Dept Cell Res & Immunol, IL-69978 Tel Aviv, Israel	Tel Aviv University	Lavi, S (corresponding author), Tel Aviv Univ, George S Wise Fac Life Sci, Dept Cell Res & Immunol, IL-69978 Tel Aviv, Israel.							Autexier C, 1996, TRENDS BIOCHEM SCI, V21, P387, DOI 10.1016/S0968-0004(96)90128-0; Balajee AS, 1996, MUTAT RES-FUND MOL M, V372, P163, DOI 10.1016/S0027-5107(96)00136-4; BARAM I, 1992, GENE CHROMOSOME CANC, V4, P314, DOI 10.1002/gcc.2870040407; Bassham S, 1998, MOL CELL BIOL, V18, P269, DOI 10.1128/MCB.18.1.269; BERTONI L, 1994, GENOMICS, V24, P53, DOI 10.1006/geno.1994.1581; Bouffler SD, 1996, MUTAT RES-REV GENET, V366, P129, DOI 10.1016/S0165-1110(96)90033-0; BREWER BJ, 1987, CELL, V51, P463, DOI 10.1016/0092-8674(87)90642-8; BRITTEN RJ, 1968, SCIENCE, V161, P529, DOI 10.1126/science.161.3841.529; BRYAN TM, 1995, EMBO J, V14, P4240, DOI 10.1002/j.1460-2075.1995.tb00098.x; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; Cohen S, 1997, ONCOGENE, V14, P977, DOI 10.1038/sj.onc.1200917; Cohen S, 1996, MOL CELL BIOL, V16, P2002; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; DENIS N, 1991, ONCOGENE, V6, P1453; Friedman SL, 1997, ONCOGENE, V15, P63, DOI 10.1038/sj.onc.1201149; GAUBATZ JW, 1990, MUTAT RES, V237, P271, DOI 10.1016/0921-8734(90)90009-G; HANISH JP, 1994, P NATL ACAD SCI USA, V91, P8861, DOI 10.1073/pnas.91.19.8861; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; JONES RS, 1985, NUCLEIC ACIDS RES, V13, P1027, DOI 10.1093/nar/13.3.1027; KIM RA, 1989, CELL, V57, P975, DOI 10.1016/0092-8674(89)90336-X; KIYAMA R, 1987, J MOL BIOL, V198, P589, DOI 10.1016/0022-2836(87)90202-6; LAVI S, 1981, P NATL ACAD SCI-BIOL, V78, P6144, DOI 10.1073/pnas.78.10.6144; Mirabella A, 1997, EMBO J, V16, P523, DOI 10.1093/emboj/16.3.523; Ohki R, 1995, NUCLEIC ACIDS RES, V23, P4971, DOI 10.1093/nar/23.24.4971; OKUMURA K, 1987, NUCLEIC ACIDS RES, V15, P7477, DOI 10.1093/nar/15.18.7477; PANDITA TK, 1995, CYTOGENET CELL GENET, V68, P95, DOI 10.1159/000133899; RENAULT S, 1993, GENOME, V36, P244, DOI 10.1139/g93-034; Sinclair DA, 1997, CELL, V91, P1033, DOI 10.1016/S0092-8674(00)80493-6; SUNNERHAGEN P, 1989, SOMAT CELL MOLEC GEN, V15, P61, DOI 10.1007/BF01534670; WELLS RA, 1990, GENOMICS, V8, P699, DOI 10.1016/0888-7543(90)90257-U; WINOCOUR E, 1992, VIROLOGY, V190, P316, DOI 10.1016/0042-6822(92)91218-J	31	57	60	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 31	1998	17	26					3455	3461		10.1038/sj.onc.1202250	http://dx.doi.org/10.1038/sj.onc.1202250			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	157XD	10030669				2022-12-25	WOS:000078086200006
J	Tran, Y; Benbatoul, K; Gorse, K; Rempel, S; Futreal, A; Green, M; Newsham, I				Tran, Y; Benbatoul, K; Gorse, K; Rempel, S; Futreal, A; Green, M; Newsham, I			Novel regions of allelic deletion on chromosome 18p in tumors of the lung, brain and breast	ONCOGENE			English	Article						loss of heterozygosity; chromosome 18p; Non-small cell lung cancer; breast cancer; glioblastoma	MICROSATELLITE INSTABILITY; COMMON REGION; HETEROZYGOSITY; CANCER; CARCINOMAS; ABNORMALITIES; PROGRESSION; SEQUENCES; LOCUS; PANEL	Lung cancer is now the number one cause of cancer death for both men and women. An age-adjusted analysis over the past 25 gears shows that in women specifically, lung cancer incidence is on the rise. It is estimated that 10-20 genetic events including the alteration of oncogenes and tumor suppressor genes will have occurred by the time a lung tumor becomes clinically evident. In an effort to identify regions containing novel cancer genes, chromosome 18p11, a band not previously implicated in disease, was examined for loss of heterozygosity (LOH). In this study, 50 matched normal and NSCLC tumor samples were examined using sis 18p11 and one 18q12.3 PCR-based polymorphic markers. In addition, LOH was examined in 29 glioblastoma pairs and 14 paired breast carcinomas. This analysis has revealed potentially two regions of LOH in 18p11 in up to 38% of the tumor samples examined, The regions of LOH identified included a 2 cm area between markers D18S59 and D18S476, and a more proximal, 25 cm region of intermediate frequency between D18S452 and D18S453, These results provide evidence for the presence of one or more potential tumor suppressor genes on the short arm of chromosome 18 which may be involved in NSCLC, brain tumors and possibly breast carcinomas as well.	Univ Calif San Diego, Dept Med, Theodore Gildred Canc Ctr, La Jolla, CA 92093 USA; Virginia Commonwealth Univ, Med Coll Virginia, Dept Anat, Richmond, VA 23298 USA; Henry Ford Hosp, Dept Neurosurg, Detroit, MI 48202 USA; Duke Univ, Dept Surg, Durham, NC 27710 USA; Med Univ S Carolina, Med Ctr, Hollings Canc Ctr, Charleston, SC 29425 USA	University of California System; University of California San Diego; Virginia Commonwealth University; Henry Ford Health System; Henry Ford Hospital; Duke University; Medical University of South Carolina	Newsham, I (corresponding author), Univ Calif San Diego, Dept Med, Theodore Gildred Canc Ctr, La Jolla, CA 92093 USA.				NATIONAL CANCER INSTITUTE [P20CA066215, R29CA077730, P30CA023100] Funding Source: NIH RePORTER; NCI NIH HHS [R29-CA77730-02, 5-P30-CA23100-13, 1 P20-CA66215-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADACHI J, 1995, GENE CHROMOSOME CANC, V14, P301, DOI 10.1002/gcc.2870140409; BEPLER G, 1994, P NATL ACAD SCI USA, V91, P5513, DOI 10.1073/pnas.91.12.5513; BesnardGuerin C, 1996, HUM GENET, V97, P163, DOI 10.1007/BF02265259; BUETOW KH, 1994, NAT GENET, V6, P391, DOI 10.1038/ng0494-391; CENTER R, 1993, GENE CHROMOSOME CANC, V7, P47, DOI 10.1002/gcc.2870070108; FONG KM, 1995, CANCER RES, V55, P4268; FONG KM, 1995, CANCER RES, V55, P220; GYAPAY G, 1994, NAT GENET, V7, P246, DOI 10.1038/ng0694supp-246; HAMPTON GM, 1994, CANCER RES, V54, P4586; HUANG THM, 1995, DIAGN MOL PATHOL, V4, P6672; HUNG J, 1995, JAMA-J AM MED ASSOC, V273, P558, DOI 10.1001/jama.273.7.558; KISHIMOTO Y, 1995, JNCI-J NATL CANCER I, V87, P1224, DOI 10.1093/jnci/87.16.1224; KLEIHUES P, 1993, BRAIN PATHOL, V3, P255, DOI 10.1111/j.1750-3639.1993.tb00752.x; LUKEIS R, 1993, GENE CHROMOSOME CANC, V8, P262, DOI 10.1002/gcc.2870080409; MERLENS F, 1997, CANCER RES, V57, P2765; Nagatake M, 1996, CANCER RES, V56, P1886; Nagatake M, 1996, CANCER RES, V56, P2718; Parker SL, 1997, CA-CANCER J CLIN, V47, P5, DOI 10.3322/canjclin.47.1.5; RABBITTS P, 1989, GENE CHROMOSOME CANC, V1, P95, DOI 10.1002/gcc.2870010115; RASIO D, 1995, CANCER RES, V55, P3988; REMPEL SA, 1993, CANCER RES, V53, P2386; ROJAS K, 1995, GENOMICS, V25, P329, DOI 10.1016/0888-7543(95)80153-D; Shiseki M, 1996, GENE CHROMOSOME CANC, V17, P71, DOI 10.1002/(SICI)1098-2264(199610)17:2<71::AID-GCC1>3.0.CO;2-Y; SHRIDHAR V, 1994, CANCER RES, V54, P2084; TESTA JR, 1992, CANCER RES, V52, pS2702; TESTA JR, 1994, GENE CHROMOSOME CANC, V11, P178, DOI 10.1002/gcc.2870110307; Tran YK, 1996, CANCER RES, V56, P2916; WINQVIST R, 1995, CANCER RES, V55, P2660; Zhu JG, 1996, ONCOGENE, V12, P1417	29	46	50	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 31	1998	17	26					3499	3505		10.1038/sj.onc.1202258	http://dx.doi.org/10.1038/sj.onc.1202258			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	157XD	10030674				2022-12-25	WOS:000078086200011
J	Mohana-Borges, R; Silva, JL; de Prat-Gay, G				Mohana-Borges, R; Silva, JL; de Prat-Gay, G			Protein folding in the absence of chemical denaturants - Reversible pressure denaturation of the noncovalent complex formed by the association of two protein fragments	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BARLEY CHYMOTRYPSIN INHIBITOR-2; TRANSITION-STATE; HYDROPHOBIC CORE; ARC REPRESSOR; DISSOCIATION; FLUORESCENCE; SPECTROSCOPY; EQUILIBRIUM; STABILITY; NUCLEASE	Small monomeric proteins are the best models for studying protein folding, but they are often too stable for denaturation using pressure as the sole perturbant. In the present work we subject [CI-2(1-40).(41-64)], a noncovalent complex formed by the association of two complementary fragments of the chymotrypsin inhibitor-2, to high pressure to investigate the folding mechanism of a model protein. Pressures up to 3.5 kilobar do not affect the intact protein, but it can be unfolded reversibly by pressure in the presence of subdenaturing concentrations of guanidine chloride, with free energy and molar volume changes of 2.5 kcal mol(-1) and 42.5 ml mol(-1), respectively. In contrast, the complex can be reversibly denatured by high pressure without the addition of chemical denaturants. However, the process is clearly independent of the protein concentration, indicating lack of dissociation. We determined a change in the free energy of 1.4 kcal mol(-1) and a molar volume change of 35 ml mol(-1) for the pressure denaturation of the complex. A persistent quenching of the tryptophan adds further evidence for the presence of residual structure in the high pressure-denatured state. This state also appears to be compact as the small volume change indicates, compared with pressure denaturation of naturally occurring dimers, Based on observations of a number of pressure-denatured states and on characteristics of large CI-2 fragments with a solvent accessible core but maintaining tertiary interactions, the structure of the pressure-denatured state of the CI-2 complex could be explained by an ordered molten globule-like conformation.	Fdn Campomar, Inst Invest Bioquim, RA-1405 Buenos Aires, DF, Argentina; Univ Fed Rio de Janeiro, Dept Bioquim Med, ICB, Ctr Nacl Ressonancia Magnet Nucl Macromol, BR-21941590 Rio De Janeiro, Brazil	Leloir Institute; Universidade Federal do Rio de Janeiro	de Prat-Gay, G (corresponding author), Fdn Campomar, Inst Invest Bioquim, Av Patricias Argentinas 435, RA-1405 Buenos Aires, DF, Argentina.	pratgay@iris.iib.uba.ar	Silva, Jerson/J-8984-2014; Borges, Ronaldo S Mohana/C-5575-2013; SILVA, JERSON Lima/GRF-1442-2022	Silva, Jerson/0000-0001-9523-9441; SILVA, JERSON Lima/0000-0001-9523-9441; Prat Gay, Gonzalo/0000-0001-5748-6863				de Prat Gay G, 1994, Proc Natl Acad Sci U S A, V91, P10943; DEPRATGAY G, 1996, ARCH BIOCHEM BIOPHYS, V334, P1; EFTINK MR, 1991, BIOCHEMISTRY-US, V30, P1193, DOI 10.1021/bi00219a005; Foguel D, 1998, J BIOL CHEM, V273, P9050, DOI 10.1074/jbc.273.15.9050; GAY GD, 1994, BIOCHEMISTRY-US, V33, P7957, DOI 10.1021/bi00191a024; GAY GD, 1995, P NATL ACAD SCI USA, V92, P3683, DOI 10.1073/pnas.92.9.3683; GAY GD, 1995, J MOL BIOL, V254, P968, DOI 10.1006/jmbi.1995.0669; GAY GD, 1994, PROTEIN ENG, V7, P103; GAY GD, 1994, BIOCHEMISTRY-US, V33, P7964, DOI 10.1021/bi00191a025; GROSS M, 1994, EUR J BIOCHEM, V221, P617, DOI 10.1111/j.1432-1033.1994.tb18774.x; HEREMANS K, 1982, ANNU REV BIOPHYS BIO, V11, P1, DOI 10.1146/annurev.bb.11.060182.000245; ITZHAKI LS, 1995, J MOL BIOL, V254, P260, DOI 10.1006/jmbi.1995.0616; JACKSON SE, 1993, BIOCHEMISTRY-US, V32, P11270, DOI 10.1021/bi00093a002; JACKSON SE, 1991, BIOCHEMISTRY-US, V30, P10428, DOI 10.1021/bi00107a010; JACKSON SE, 1993, BIOCHEMISTRY-US, V32, P11259, DOI 10.1021/bi00093a001; JONAS J, 1994, ANNU REV BIOPH BIOM, V23, P287, DOI 10.1146/annurev.bb.23.060194.001443; LETILLY V, 1992, EUR J BIOCHEM, V205, P1061; LI TM, 1976, BIOCHEMISTRY-US, V15, P5571, DOI 10.1021/bi00670a023; LUDVIGSEN S, 1991, J MOL BIOL, V222, P621, DOI 10.1016/0022-2836(91)90500-6; MCPHALEN CA, 1987, BIOCHEMISTRY-US, V26, P261, DOI 10.1021/bi00375a036; Mok YK, 1996, PROTEIN SCI, V5, P310; Mozhaev VV, 1996, PROTEINS, V24, P81, DOI 10.1002/(SICI)1097-0134(199601)24:1<81::AID-PROT6>3.0.CO;2-R; Neira JL, 1996, FOLD DES, V1, P189, DOI 10.1016/S1359-0278(96)00031-4; Neira JL, 1997, J MOL BIOL, V268, P185, DOI 10.1006/jmbi.1997.0932; OTZEN DE, 1994, P NATL ACAD SCI USA, V91, P10422, DOI 10.1073/pnas.91.22.10422; PALADINI AA, 1994, ANAL BIOCHEM, V218, P364, DOI 10.1006/abio.1994.1193; PALADINI AA, 1981, REV SCI INSTRUM, V52, P419, DOI 10.1063/1.1136596; Panick G, 1998, J MOL BIOL, V275, P389, DOI 10.1006/jmbi.1997.1454; PENG XD, 1994, BIOCHEMISTRY-US, V33, P8323, DOI 10.1021/bi00193a020; PREVELIGE PE, 1994, BIOPHYS J, V66, P1631, DOI 10.1016/S0006-3495(94)80955-5; ROYER CA, 1993, BIOCHEMISTRY-US, V32, P5222, DOI 10.1021/bi00070a034; Royer CA, 1995, METHOD ENZYMOL, V259, P357; RUIZSANZ J, 1995, BIOCHEMISTRY-US, V34, P1695, DOI 10.1021/bi00005a026; SAMARASINGHE SD, 1992, BIOCHEMISTRY-US, V31, P7773, DOI 10.1021/bi00149a005; SCHELLMAN JA, 1978, BIOPOLYMERS, V17, P1305, DOI 10.1002/bip.1978.360170515; Silva JL, 1996, CURR OPIN STRUC BIOL, V6, P166, DOI 10.1016/S0959-440X(96)80071-6; SILVA JL, 1993, ANNU REV PHYS CHEM, V44, P89, DOI 10.1146/annurev.pc.44.100193.000513; SILVA JL, 1992, J MOL BIOL, V223, P545, DOI 10.1016/0022-2836(92)90669-B; Weber G., 1992, PROTEIN INTERACTIONS	39	25	25	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	1999	274	12					7732	7740		10.1074/jbc.274.12.7732	http://dx.doi.org/10.1074/jbc.274.12.7732			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	178LU	10075663	hybrid			2022-12-25	WOS:000079268100022
J	Humphreys, DT; Carver, JA; Easterbrook-Smith, SB; Wilson, MR				Humphreys, DT; Carver, JA; Easterbrook-Smith, SB; Wilson, MR			Clusterin has chaperone-like activity similar to that of small heat shock proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SULFATED GLYCOPROTEIN-2; HUMAN PLASMA; APOLIPOPROTEIN-J/CLUSTERIN; ALPHA-CRYSTALLIN; EPITHELIAL-CELLS; TESTIS FLUID; COMPLEMENT; STRESS; DEATH; EXPRESSION	Clusterin is a highly conserved protein which is expressed at increased levels by many cell types in response to a broad variety of stress conditions. A genuine physiological function for clusterin has not yet been established. The results presented here demonstrate for the first time that clusterin has chaperone-like activity. At physiological concentrations, clusterin potently protected glutathione S-transferase and catalase from heat-induced precipitation and alpha-lactalbumin and bovine serum albumin from precipitation induced by reduction with dithiothreitol. Enzyme-linked immunosorbent assay data showed that clusterin bound preferentially to heat-stressed glutathione S-transferase and to dithiothreitol-treated bovine serum albumin and alpha-lactalbumin. Size exclusion chromatography and SDS-polyacrylamide gel electrophoresis analyses showed that clusterin formed high molecular weight complexes (HMW) with all four proteins tested. Small heat shock proteins (sHSP) also act in this way to prevent protein precipitation and protect cells from heat and other stresses. The stoichiometric subunit molar ratios of clusterin:stressed protein during formation of HMW complexes (which for the four proteins tested ranged from 1.0:1.3 to 1.0:11) is less than the reported ratios for sHSP-mediated formation of HMW complexes (1.0:1.0 or greater), indicating that clusterin is a very efficient chaperone. Our results suggest that clusterin may play a sHSP-like role in cytoprotection.	Univ Wollongong, Dept Sci Biol, Wollongong, NSW 2522, Australia; Univ Wollongong, Dept Chem, Wollongong, NSW 2522, Australia; Univ Sydney, Dept Biochem, Sydney, NSW 2006, Australia	University of Wollongong; University of Wollongong; University of Sydney	Wilson, MR (corresponding author), Univ Wollongong, Dept Sci Biol, Northfields Ave, Wollongong, NSW 2522, Australia.	Mark_Wilson@uow.edu.au	Carver, John Adrian/J-3825-2014; Wilson, Mark R/B-3254-2018	Carver, John Adrian/0000-0002-2441-8108; Wilson, Mark R/0000-0002-9551-7445; Humphreys, David/0000-0003-4140-0089				Akesson P, 1996, J BIOL CHEM, V271, P1081, DOI 10.1074/jbc.271.2.1081; Arrigo AP, 1998, BIOL CHEM, V379, P19; BLASCHUK O, 1983, J BIOL CHEM, V258, P7714; BUTTYAN R, 1989, MOL CELL BIOL, V9, P3473, DOI 10.1128/MCB.9.8.3473; CARVER JA, 1994, BBA-PROTEIN STRUCT M, V1204, P195, DOI 10.1016/0167-4838(94)90009-4; CARVER JA, 1995, BBA-PROTEIN STRUCT M, V1252, P251, DOI 10.1016/0167-4838(95)00146-L; CHOI NH, 1989, MOL IMMUNOL, V26, P835; Clark AM, 1997, J ANDROL, V18, P257; DESILVA HV, 1990, J BIOL CHEM, V265, P13240; DESILVA HV, 1990, BIOCHEMISTRY-US, V29, P5380, DOI 10.1021/bi00474a025; EHRNSPERGER M, 1997, MOL CHAPERONES LIFE; FARAHBAKHSH ZT, 1995, BIOCHEMISTRY-US, V34, P509, DOI 10.1021/bi00002a015; FRENCH LE, 1994, J CLIN INVEST, V93, P877, DOI 10.1172/JCI117043; FRITZ IB, 1993, TRENDS ENDOCRIN MET, V4, P41, DOI 10.1016/S1043-2760(05)80013-X; Gelissen IC, 1998, BIOCHEM J, V331, P231, DOI 10.1042/bj3310231; Heuer KH, 1996, BIOCHEMISTRY-US, V35, P9069, DOI 10.1021/bi952817o; Hook DWA, 1997, EUR J BIOCHEM, V247, P380, DOI 10.1111/j.1432-1033.1997.00380.x; HORWITZ J, 1992, P NATL ACAD SCI USA, V89, P1049; Humphreys D, 1997, BIOCHEMISTRY-US, V36, P15233, DOI 10.1021/bi9703507; JENNE DE, 1991, J BIOL CHEM, V266, P11030; JENNE DE, 1992, TRENDS BIOCHEM SCI, V17, P154, DOI 10.1016/0968-0004(92)90325-4; JENNE DE, 1989, P NATL ACAD SCI USA, V86, P7123, DOI 10.1073/pnas.86.18.7123; Kapron JT, 1997, PROTEIN SCI, V6, P2120; KELSO GJ, 1994, BIOCHEMISTRY-US, V33, P832, DOI 10.1021/bi00169a026; Kimura K, 1997, CELL BIOCHEM FUNCT, V15, P251, DOI 10.1002/(SICI)1099-0844(199712)15:4<251::AID-CBF748>3.0.CO;2-3; KOUNNAS MZ, 1995, J BIOL CHEM, V270, P13070, DOI 10.1074/jbc.270.22.13070; Lindner RA, 1998, EUR J BIOCHEM, V258, P170, DOI 10.1046/j.1432-1327.1998.2580170.x; Michel D, 1997, BIOCHEM J, V328, P45, DOI 10.1042/bj3280045; Michel D, 1997, J CELL SCI, V110, P1635; OBRYAN MK, 1990, J CLIN INVEST, V85, P1477, DOI 10.1172/JCI114594; ODA T, 1995, EXP NEUROL, V136, P22, DOI 10.1006/exnr.1995.1080; Pankhurst GJ, 1998, BIOCHEMISTRY-US, V37, P4823, DOI 10.1021/bi972367v; Partridge SR, 1996, INFECT IMMUN, V64, P4324, DOI 10.1128/IAI.64.10.4324-4329.1996; RAO PV, 1993, BIOCHEM BIOPH RES CO, V190, P786, DOI 10.1006/bbrc.1993.1118; Reddy KB, 1996, BIOCHEMISTRY-US, V35, P6157, DOI 10.1021/bi952981b; SENSIBAR JA, 1995, CANCER RES, V55, P2431; Silkensen JR, 1995, J CLIN INVEST, V96, P2646, DOI 10.1172/JCI118330; SILKENSEN JR, 1994, BIOCHEM CELL BIOL, V72, P483, DOI 10.1139/o94-065; TSCHOPP J, 1993, J IMMUNOL, V151, P2159; TSURUTA JK, 1990, BIOCHEM J, V268, P571, DOI 10.1042/bj2680571; WILSON MR, 1992, BIOCHIM BIOPHYS ACTA, V1159, P319, DOI 10.1016/0167-4838(92)90062-I; WILSON MR, 1993, ANAL BIOCHEM, V209, P183, DOI 10.1006/abio.1993.1100; WILSON MR, 1995, MECH INDUCTION FUNCT, P75; [No title captured]	44	359	368	0	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 12	1999	274	11					6875	6881		10.1074/jbc.274.11.6875	http://dx.doi.org/10.1074/jbc.274.11.6875			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	175DV	10066740	hybrid			2022-12-25	WOS:000079078400012
J	Malin, G; Iakobashvili, R; Lapidot, A				Malin, G; Iakobashvili, R; Lapidot, A			Effect of tetrahydropyrimidine derivatives on protein nucleic acids interaction - Type II restriction endonucleases as a model system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHROMATOGRAPHY-MASS-SPECTROMETRY; PRODUCER STREPTOMYCES-PARVULUS; ECO-RI ENDONUCLEASE; ESCHERICHIA-COLI; CORYNEBACTERIUM-GLUTAMICUM; HALOPHILIC EUBACTERIA; COMPATIBLE SOLUTES; MAGNETIC-RESONANCE; DNA RECOGNITION; STRESS	2-Methyl-4-carboxy,5-hydroxy-3,4,5,6-tetrahydropyrimidine (THP(A) or hydroxyectoine) and 2-methyl,4-carboxy-3, 4,5,6-tetrahydropyrimidine (THP(B) or ectoine) are now recognized as ubiquitous bacterial osmoprotectants, To evaluate the impact of tetrahydropyrimidine derivatives (THPs) on protein-DNA interaction and on restriction-modification systems, we have examined their effect on the cleavage of plasmid DNA by 10 type II restriction endonucleases. THP(A) completely arrested the cleavage of plasmid and bacteriophage A DNA by EcoRI endonuclease at 0.4 mM and the oligonucleotide (d(CGCGAATTCGCG))(2) at about 4.0 mM. THP(B) was 10-fold less effective than THP(A), whereas for betaine and proline, a notable inhibition was observed only at 100 mM, Similar effects of THP(A) were observed for all tested restriction endonucleases, except for SmaI and PvuII, which were inhibited only partially at 50 mM THP(A), No effect of THP(A) on the activity of DNase I, RNase A, and Tag DNA polymerase was noticed. Gel-shift assays showed that THP(A) inhibited the EcoRI-(d-(CGCGAATTCGCG))(2) complex formation, whereas facilitated diffusion of EcoRI along the DNA was not affected. Methylation of the carboxy group significantly decreased the activity of THPs, suggesting that their zwitterionic character is essential for the inhibition effect. Possible mechanisms of inhibition, the role of THPs in the modulation of the protein-DNA interaction, and the in vivo relevance of the observed phenomena are discussed.	Weizmann Inst Sci, Dept Organ Chem, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Lapidot, A (corresponding author), Weizmann Inst Sci, Dept Organ Chem, IL-76100 Rehovot, Israel.	colapidot@wiccmail.weizmann.ac.il						BAILEY CR, 1986, J GEN MICROBIOL, V132, P2945; BUCHE A, 1993, J BIOMOL STRUCT DYN, V11, P95, DOI 10.1080/07391102.1993.10508712; Canovas D, 1997, J BIOL CHEM, V272, P25794, DOI 10.1074/jbc.272.41.25794; Capp MW, 1996, J MOL BIOL, V258, P25, DOI 10.1006/jmbi.1996.0231; CHENG XD, 1994, EMBO J, V13, P3927, DOI 10.1002/j.1460-2075.1994.tb06708.x; Connolly B A, 1994, Methods Mol Biol, V30, P371; CORNISHB.A, 1974, BIOCHEM J, V137, P143, DOI 10.1042/bj1370143; CORNISHBOWDEN A, 1979, FUNDAMENTALS ENZYME, P78; Csonka L. N., 1996, ESCHERICHIA COLI SAL, P1210; CSONKA LN, 1991, ANNU REV MICROBIOL, V45, P569, DOI 10.1146/annurev.mi.45.100191.003033; CSONKA LN, 1989, MICROBIOL REV, V53, P121, DOI 10.1128/MMBR.53.1.121-147.1989; CUNDLIFFE E, 1989, ANNU REV MICROBIOL, V43, P207, DOI 10.1146/annurev.micro.43.1.207; DIXON M, 1953, BIOCHEM J, V55, P170, DOI 10.1042/bj0550170; EHBRECHT HJ, 1985, J BIOL CHEM, V260, P6160; ENGEL P, 1987, APPL ENVIRON MICROB, V53, P1; Eom SH, 1996, NATURE, V382, P278, DOI 10.1038/382278a0; FARWICK M, 1995, J BACTERIOL, V177, P4690, DOI 10.1128/jb.177.16.4690-4695.1995; Flock S, 1996, BIOPHYS J, V71, P1519, DOI 10.1016/S0006-3495(96)79354-2; FONTECILLACAMPS JC, 1994, J BIOL CHEM, V269, P21526; GALINSKI EA, 1993, EXPERIENTIA, V49, P487, DOI 10.1007/BF01955150; GALINSKI EA, 1985, EUR J BIOCHEM, V149, P135, DOI 10.1111/j.1432-1033.1985.tb08903.x; GALINSKI EA, 1991, NATO ADV SCI I A-LIF, V201, P351; GREENE PJ, 1975, J MOL BIOL, V99, P237, DOI 10.1016/S0022-2836(75)80143-4; HALFORD SE, 1983, BIOCHEM J, V211, P405, DOI 10.1042/bj2110405; HAMANA K, 1987, FEMS MICROBIOL LETT, V41, P211; HEITMAN J, 1989, P NATL ACAD SCI USA, V86, P2281, DOI 10.1073/pnas.86.7.2281; INBAR L, 1988, J BIOL CHEM, V263, P16014; INBAR L, 1988, J BACTERIOL, V170, P4055, DOI 10.1128/jb.170.9.4055-4064.1988; INBAR L, 1991, J BACTERIOL, V173, P7790, DOI 10.1128/jb.173.24.7790-7801.1991; INBAR L, 1993, EUR J BIOCHEM, V214, P897, DOI 10.1111/j.1432-1033.1993.tb17993.x; JEBBAR M, 1992, J BACTERIOL, V174, P5027, DOI 10.1128/JB.174.15.5027-5035.1992; Jeltsch A, 1996, EMBO J, V15, P5104, DOI 10.1002/j.1460-2075.1996.tb00891.x; JenJacobson L, 1997, BIOPOLYMERS, V44, P153; LAHM A, 1991, J MOL BIOL, V222, P645, DOI 10.1016/0022-2836(91)90502-W; LAI MC, 1991, J BACTERIOL, V173, P5352, DOI 10.1128/jb.173.17.5352-5358.1991; LAPIDOT A, 1998, Patent No. 123256; LESSER DR, 1990, SCIENCE, V250, P776, DOI 10.1126/science.2237428; Louis P, 1997, MICROBIOL-UK, V143, P1141, DOI 10.1099/00221287-143-4-1141; Malin G, 1996, J BACTERIOL, V178, P385, DOI 10.1128/jb.178.2.385-395.1996; OLLER AR, 1991, BIOCHEMISTRY-US, V30, P2543, DOI 10.1021/bi00223a035; PINGOUD A, 1984, BIOCHEMISTRY-US, V23, P5697, DOI 10.1021/bi00319a006; Pingoud A, 1997, EUR J BIOCHEM, V246, P1, DOI 10.1111/j.1432-1033.1997.t01-6-00001.x; Rajendrakumar CSV, 1997, FEBS LETT, V410, P201, DOI 10.1016/S0014-5793(97)00588-7; REES WA, 1993, BIOCHEMISTRY-US, V32, P137, DOI 10.1021/bi00052a019; RODRIGUEZ RJ, 1993, ANAL BIOCHEM, V209, P291, DOI 10.1006/abio.1993.1122; Sambrook J., 1989, MOL CLONING, pA1; SCHAFER A, 1994, J BACTERIOL, V176, P7309; SCHOBERT B, 1978, BIOCHIM BIOPHYS ACTA, V541, P270, DOI 10.1016/0304-4165(78)90400-2; SPOLAR RS, 1994, SCIENCE, V263, P777, DOI 10.1126/science.8303294; TABOR CW, 1985, MICROBIOL REV, V49, P81, DOI 10.1128/MMBR.49.1.81-99.1985; TALIBART R, 1994, J BACTERIOL, V176, P5210, DOI 10.1128/JB.176.17.5210-5217.1994; TERRY BJ, 1985, J BIOL CHEM, V260, P3130; Timasheff SN, 1998, ADV PROTEIN CHEM, V51, P355; VONHIPPEL PH, 1989, J BIOL CHEM, V264, P675; WELLS RD, 1981, ENZYMES A, V14, P157; WHATMORE AM, 1990, J GEN MICROBIOL, V136, P2527, DOI 10.1099/00221287-136-12-2527; Winkler F. K., 1992, CURR OPIN STRUC BIOL, V2, P93; WITHERS BE, 1995, J BIOL CHEM, V270, P6496, DOI 10.1074/jbc.270.12.6496; WOHLFARTH A, 1990, J GEN MICROBIOL, V136, P705, DOI 10.1099/00221287-136-4-705	59	33	45	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	1999	274	11					6920	6929		10.1074/jbc.274.11.6920	http://dx.doi.org/10.1074/jbc.274.11.6920			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	175DV	10066745	hybrid			2022-12-25	WOS:000079078400017
J	Sutor, SL; Vroman, BT; Armstrong, EA; Abraham, RT; Karnitz, LM				Sutor, SL; Vroman, BT; Armstrong, EA; Abraham, RT; Karnitz, LM			A phosphatidylinositol 3-kinase-dependent pathway that differentially regulates c-Raf and A-Raf	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; T-CELL LINE; SIGNAL-TRANSDUCTION; HEMATOPOIETIC-CELLS; B-RAF; 3-KINASE; PHOSPHORYLATION; FAMILY; AKT; INHIBITION	Cytokines trigger the rapid assembly of multimolecular signaling complexes that direct the activation of downstream protein kinase cascades. Two protein kinases that have been linked to growth factor-regulated proliferation and survival are mitogen-activated protein/ERK kinase (MEK) and its downstream target Erk, a member of the mitogen-activated protein kinase family. Using complementary pharmacological and genetic ap preaches, we demonstrate that MEK and Erk activation requires a phosphatidylinositol 3-kinase (PI3-K)-generated signal in an interleukin (IL)-3-dependent myeloid progenitor cell line. Analysis of the upstream pathway leading to MEK activation revealed that inhibition of PI3-K did not block c-Raf activation, whereas MEK activation was effectively blocked under these conditions. Furthermore, agents that elevated cAMP suppressed IL-3-induced c-Raf activation but did not inhibit MEK activation. Because c-Raf activation and MEK activation were inversely affected by PI3-K- and cAMP-dependent pathways, we examined whether IL-3 activated the alternative Raf isoforms A-Raf and B-Raf, Although IL-3 did not activate B-Raf, A-Raf was activated by the cytokine, Moreover, A-Raf activation, like MEK activation, was blocked by inhibition of PI3-K but was insensitive to cAMP. Experiments with dominant negative mutants of the Raf isoforms showed that overexpression of dominant negative c-Raf did not prevent MEK activation. However, dominant negative A-Raf effectively blocked MEK activation, suggesting that activation of the MEK-Erk signaling cascade is mediated through A-Raf Taken together, these results suggest that IL-3 receptors engage and activate both c-Raf and A-Raf in hemopoietic cells. However, these intermediates are differentially regulated by upstream signaling cascades and selectively coupled to downstream signaling pathways.	Mayo Clin & Mayo Fdn, Div Radiat Oncol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Div Oncol Res, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Immunol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Pharmacol, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic	Karnitz, LM (corresponding author), Mayo Clin & Mayo Fdn, Div Radiat Oncol, Guggenheim 13,200 1st St SW, Rochester, MN 55905 USA.	karnitz.larry@mayo.edu			NCI NIH HHS [CA73622, CA52995] Funding Source: Medline; NIGMS NIH HHS [GM73161] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA073622, U19CA052995, U01CA052995] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABRAHAM RT, 1986, J TISSUE CULTURE MET, V10, P93; Akimoto K, 1996, EMBO J, V15, P788, DOI 10.1002/j.1460-2075.1996.tb00414.x; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; CROSS DAE, 1994, BIOCHEM J, V303, P21, DOI 10.1042/bj3030021; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; delPeso L, 1997, SCIENCE, V278, P687; EYCHENE A, 1995, ONCOGENE, V10, P1159; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Ghosh S, 1996, J BIOL CHEM, V271, P8472, DOI 10.1074/jbc.271.14.8472; Gingras AC, 1998, GENE DEV, V12, P502, DOI 10.1101/gad.12.4.502; HARA K, 1994, P NATL ACAD SCI USA, V91, P7415, DOI 10.1073/pnas.91.16.7415; Hara T, 1996, STEM CELLS, V14, P605, DOI 10.1002/stem.140605; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Jelinek T, 1996, MOL CELL BIOL, V16, P1027; KARNITZ L, 1992, MOL CELL BIOL, V12, P4521, DOI 10.1128/MCB.12.10.4521; KARNITZ LM, 1995, CURR OPIN IMMUNOL, V7, P320, DOI 10.1016/0952-7915(95)80105-7; KARNITZ LM, 1995, MOL CELL BIOL, V15, P3049; KARNITZ LM, 1994, J EXP MED, V179, P1799, DOI 10.1084/jem.179.6.1799; Knall C, 1996, J BIOL CHEM, V271, P2832, DOI 10.1074/jbc.271.5.2832; LOPEZ AF, 1992, IMMUNOL TODAY, V13, P495, DOI 10.1016/0167-5699(92)90025-3; Marais R, 1997, J BIOL CHEM, V272, P4378, DOI 10.1074/jbc.272.7.4378; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; Morrison DK, 1997, CURR OPIN CELL BIOL, V9, P174, DOI 10.1016/S0955-0674(97)80060-9; Muller G, 1998, EMBO J, V17, P732, DOI 10.1093/emboj/17.3.732; MUSZYNSKI KW, 1995, J EXP MED, V181, P2189, DOI 10.1084/jem.181.6.2189; OKADA T, 1994, J BIOL CHEM, V269, P3563; POWIS G, 1994, CANCER RES, V54, P2419; Pullen N, 1998, SCIENCE, V279, P707, DOI 10.1126/science.279.5351.707; Scheid MP, 1996, J BIOL CHEM, V271, P18134, DOI 10.1074/jbc.271.30.18134; Stephens L, 1998, SCIENCE, V279, P710, DOI 10.1126/science.279.5351.710; STORM SM, 1990, ONCOGENE, V5, P345; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; TOKER A, 1994, J BIOL CHEM, V269, P32358; Vanhaesebroeck B, 1997, TRENDS BIOCHEM SCI, V22, P267, DOI 10.1016/S0968-0004(97)01061-X; Wang HG, 1996, CELL, V87, P629, DOI 10.1016/S0092-8674(00)81383-5; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366; Xia K, 1996, P NATL ACAD SCI USA, V93, P11681, DOI 10.1073/pnas.93.21.11681; YAO B, 1995, NATURE, V378, P307, DOI 10.1038/378307a0; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3	44	67	68	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 12	1999	274	11					7002	7010		10.1074/jbc.274.11.7002	http://dx.doi.org/10.1074/jbc.274.11.7002			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	175DV	10066754	hybrid			2022-12-25	WOS:000079078400026
J	Diaz, V; Rojo, F; Martinez, C; Alonso, JC; Bernad, A				Diaz, V; Rojo, F; Martinez, C; Alonso, JC; Bernad, A			The prokaryotic beta-recombinase catalyzes site-specific recombination in mammalian cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PYOGENES PLASMID PSM19035; DNA RECOMBINATION; BACILLUS-SUBTILIS; CRE RECOMBINASE; TRANSGENIC MICE; PROTEIN HBSU; MOUSE GENOME; T-CELLS; LOX; PURIFICATION	The development of new strategies for the in vivo modification of eukaryotic genomes has become an important objective of current research. Site-specific recombination has proven useful, as it allows controlled manipulation of murine, plant, and yeast genomes, Here we provide the first evidence that the prokaryotic site-specific recombinase (beta-recombinase), which catalyzes only intramolecular recombination, is active in eukaryotic environments. beta-Recombinase, encoded by the beta gene of the Gram-positive broad host range plasmid pSM19035, has been functionally expressed in eukaryotic cell lines, demonstrating high avidity for the nuclear compartment and forming a clear speckled pattern when assayed by indirect immunofluorescence, In simian COS-1 cells, transient beta-recombinase expression promoted deletion of a DNA fragment lying between two directly oriented specific recognition/crossing over sequences (six sites) located as an extrachromosomal DNA substrate. The same result was obtained in a recombination-dependent lacZ activation system tested in a cell Line that stably expresses the beta-recombinase protein. In stable NIH/3T3 clones bearing different number of copies of the target sequences integrated at distinct chromosomal locations, transient beta-recombinase expression also promoted deletion of the intervening DNA, independently of the insertion position of the target sequences. The utility of this new recombination tool for the manipulation of eukaryotic genomes, used either alone or in combination with the other recombination systems currently in use, is discussed.	CSIC, Dept Inmunol & Oncol, E-28049 Madrid, Spain; CSIC, Dept Biotecnol Microbiana, Ctr Nacl Biotecnol, E-28049 Madrid, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB)	Bernad, A (corresponding author), CSIC, Dept Inmunol & Oncol, Campus Univ Autonoma Madrid, E-28049 Madrid, Spain.	abernad@cnb.uam.es	Bernad, Antonio/P-8573-2017; Rojo, Fernando/A-7038-2008; Alonso, Juan Carlos/D-2595-2009	Rojo, Fernando/0000-0003-1848-7745; Alonso, Juan Carlos/0000-0002-5178-7179; Bernad, Antonio/0000-0003-0620-9668				ABREMSKI K, 1984, J BIOL CHEM, V259, P1509; ALONSO JC, 1995, MOL MICROBIOL, V18, P471, DOI 10.1111/j.1365-2958.1995.mmi_18030471.x; ALONSO JC, 1995, J BIOL CHEM, V270, P2938, DOI 10.1074/jbc.270.7.2938; BRANDON EP, 1995, CURR BIOL, V5, P625, DOI 10.1016/S0960-9822(95)00127-8; BRANDON EP, 1995, CURR BIOL, V5, P758, DOI 10.1016/S0960-9822(95)00152-7; CEGLOWSKI P, 1993, GENE, V136, P1, DOI 10.1016/0378-1119(93)90441-5; DISANTO JP, 1995, P NATL ACAD SCI USA, V92, P377, DOI 10.1073/pnas.92.2.377; DRANOFF G, 1994, SCIENCE, V264, P713, DOI 10.1126/science.8171324; Dymecki SM, 1996, P NATL ACAD SCI USA, V93, P6191, DOI 10.1073/pnas.93.12.6191; FUKUSHIGE S, 1992, P NATL ACAD SCI USA, V89, P7905, DOI 10.1073/pnas.89.17.7905; Grasser KD, 1997, EUR J BIOCHEM, V249, P70; GRINDLEY NDF, 1994, NUCLEIC ACIDS MOL BI, V8, P236; GU H, 1994, SCIENCE, V265, P103, DOI 10.1126/science.8016642; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; IOFFE E, 1994, P NATL ACAD SCI USA, V91, P728, DOI 10.1073/pnas.91.2.728; KILBY NJ, 1993, TRENDS GENET, V9, P413, DOI 10.1016/0168-9525(93)90104-P; KUHN R, 1991, SCIENCE, V254, P707, DOI 10.1126/science.1948049; KUHN R, 1995, SCIENCE, V269, P1427, DOI 10.1126/science.7660125; Maniatis T., 1982, MOL CLONING LAB MANU; MEDBERRY SL, 1995, NUCLEIC ACIDS RES, V23, P485, DOI 10.1093/nar/23.3.485; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; MULLIGAN RC, 1979, NATURE, V277, P108, DOI 10.1038/277108a0; Nash H, 1996, ESCHERICHIA COLI SAL, P2363; NATH ST, 1990, MOL CELL BIOL, V10, P4139, DOI 10.1128/MCB.10.8.4139; ORBAN PC, 1992, P NATL ACAD SCI USA, V89, P6861, DOI 10.1073/pnas.89.15.6861; OSBORNE BI, 1995, PLANT J, V7, P687, DOI 10.1046/j.1365-313X.1995.7040687.x; PICHEL JG, 1993, ONCOGENE, V8, P3333; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; ROJO F, 1995, NUCLEIC ACIDS RES, V23, P3181, DOI 10.1093/nar/23.16.3181; ROJO F, 1993, FEBS LETT, V328, P169, DOI 10.1016/0014-5793(93)80987-6; ROJO F, 1994, J MOL BIOL, V238, P159, DOI 10.1006/jmbi.1994.1278; SAUER B, 1993, METHOD ENZYMOL, V225, P890; SAUER B, 1990, New Biologist, V2, P441; SCHORLE H, 1991, NATURE, V352, P621, DOI 10.1038/352621a0; VANDEURSEN J, 1995, P NATL ACAD SCI USA, V92, P7376, DOI 10.1073/pnas.92.16.7376	35	26	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	1999	274	10					6634	6640		10.1074/jbc.274.10.6634	http://dx.doi.org/10.1074/jbc.274.10.6634			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172BQ	10037759	hybrid			2022-12-25	WOS:000078902800081
J	Knapp, JE; Oliveira, MA; Xie, Q; Ernst, SR; Riggs, AF; Hackert, ML				Knapp, JE; Oliveira, MA; Xie, Q; Ernst, SR; Riggs, AF; Hackert, ML			The structural and functional analysis of the hemoglobin D component from chicken	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-STRUCTURE REFINEMENT; OXYGEN-AFFINITY; CRYSTAL-STRUCTURE; HUMAN DEOXYHEMOGLOBIN; ORGANIC-PHOSPHATES; AREA DETECTOR; BLOOD; RESOLUTION; BINDING; ASSOCIATION	Oxygen binding by chicken blood shows enhanced cooperativity at high levels of oxygen saturation. This implies that deoxy hemoglobin tetramers self-associate. The crystal structure of an R-state form of chicken hemoglobin D has been solved to 2.3-Angstrom resolution using molecular replacement phases derived from human oxyhemoglobin. The model consists of an alpha(2)beta(2) tetramer in the asymmetric unit and has been refined to a R-factor of 0.222 (R-free = 0.257) for 29,702 reflections between 10,0- and 2.3-Angstrom resolution. Chicken Hb D differs most from human oxyhemoglobin in the AB and GH corners of the alpha subunits and the EF corner of the beta subunits, Reanalysis of published oxygen binding data for chicken Hbs shows that both chicken Hb A and Hb D possess enhanced cooperativity in vitro when inositol hexaphosphate is present. The electrostatic surface potential for a calculated model of chicken deoxy-Hb D tetramers shows a pronounced hydrophobic patch that involves parts of the D and E helices of the beta subunits, This hydrophobic patch is a promising candidate for a tetramer-tetramer interface that could regulate oxygen binding via the distal histidine.	Univ Texas, Dept Chem & Biochem, Austin, TX 78712 USA; Univ Texas, Dept Zool, Austin, TX 78712 USA	University of Texas System; University of Texas Austin; University of Texas System; University of Texas Austin	Hackert, ML (corresponding author), Univ Texas, Dept Chem & Biochem, Austin, TX 78712 USA.							ANDERSEN ME, 1971, J BIOL CHEM, V246, P4800; ANDERSEN ME, 1971, J BIOL CHEM, V246, P4790; [Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; ARNONE A, 1974, NATURE, V249, P34, DOI 10.1038/249034a0; BALDWIN JM, 1980, J MOL BIOL, V136, P103, DOI 10.1016/0022-2836(80)90308-3; Bardgard A, 1997, COMP BIOCHEM PHYS B, V117, P225, DOI 10.1016/S0305-0491(97)00094-1; BAUMANN R, 1982, J APPL PHYSIOL, V53, P1439, DOI 10.1152/jappl.1982.53.6.1439; BEHLKE J, 1970, FEBS LETT, V7, P177, DOI 10.1016/0014-5793(70)80150-8; BENESCH R, 1967, BIOCHEM BIOPH RES CO, V26, P162, DOI 10.1016/0006-291X(67)90228-8; BENSON DA, 1994, NUCLEIC ACIDS RES, V22, P3441, DOI 10.1093/nar/22.17.3441; BERNER NJ, 1988, J EXP BIOL, V140, P437; BOLTON W, 1968, J MOL BIOL, V33, P283, DOI 10.1016/0022-2836(68)90294-5; BRIEHL RW, 1963, J BIOL CHEM, V238, P2361; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P585, DOI 10.1107/S0108767390002355; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P46, DOI 10.1107/S0108767389009633; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; BRUNGER AT, 1992, XPLOR MANUAL VERSION; BRYGIER J, 1975, EUR J BIOCHEM, V60, P379, DOI 10.1111/j.1432-1033.1975.tb21013.x; CHENG B, 1994, INORG CHEM, V33, P1319, DOI 10.1021/ic00085a018; COBB JA, 1992, J BIOL CHEM, V267, P1183; de Bruin S H, 1974, Biochem Biophys Res Commun, V58, P204, DOI 10.1016/0006-291X(74)90912-7; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; FERMI G, 1984, J MOL BIOL, V175, P159, DOI 10.1016/0022-2836(84)90472-8; GILL SJ, 1978, SCIENCE, V201, P362, DOI 10.1126/science.663663; Harrington DJ, 1997, J MOL BIOL, V272, P398, DOI 10.1006/jmbi.1997.1253; HEIDNER EJ, 1976, J MOL BIOL, V104, P707, DOI 10.1016/0022-2836(76)90130-3; HIRSOWITZ LA, 1977, RESP PHYSIOL, V31, P51, DOI 10.1016/0034-5687(77)90064-0; HODEL A, 1992, ACTA CRYSTALLOGR A, V48, P851, DOI 10.1107/S0108767392006044; HOLLAND RAB, 1994, ADV EXP MED BIOL, V345, P159; HOLLAND RAB, 1988, RESP PHYSIOL, V73, P69, DOI 10.1016/0034-5687(88)90128-4; HOLLAND RAB, 1991, P AUST PHYSL PHARM S, V22, pP117; HOWARD AJ, 1985, METHOD ENZYMOL, V114, P452; ISAACKS RE, 1980, AM ZOOL, V20, P115; ISAACKS RE, 1976, ARCH BIOCHEM BIOPHYS, V173, P114, DOI 10.1016/0003-9861(76)90240-X; JANCARIK J, 1991, J APPL CRYSTALLOGR, V24, P409, DOI 10.1107/S0021889891004430; JANIN J, 1990, J BIOL CHEM, V265, P16027; JANIN J, 1988, J MOL BIOL, V204, P155, DOI 10.1016/0022-2836(88)90606-7; JOHANSEN K, 1987, PHYSIOL ZOOL, V60, P269, DOI 10.1086/physzool.60.2.30158651; JOHANSEN K, 1980, J COMP PHYSIOL, V136, P71, DOI 10.1007/BF00688625; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kleywegt GJ, 1996, ACTA CRYSTALLOGR D, V52, P842, DOI 10.1107/S0907444995016477; KORBER FCF, 1991, J CHEM SOC DALTON, P3291, DOI 10.1039/dt9910003291; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LADNER RC, 1977, J MOL BIOL, V114, P385, DOI 10.1016/0022-2836(77)90256-X; LAPENNAS GN, 1983, RESP PHYSIOL, V52, P27, DOI 10.1016/0034-5687(83)90134-2; LAPENNAS GN, 1983, RESP PHYSIOL, V52, P13, DOI 10.1016/0034-5687(83)90133-0; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; LIAN CY, 1971, BIOCHEM BIOPH RES CO, V45, P151, DOI 10.1016/0006-291X(71)90063-5; LONGMUIR IS, 1970, J APPL PHYSIOL, V28, P343; LUTZ PL, 1974, RESP PHYSIOL, V20, P325, DOI 10.1016/0034-5687(74)90029-2; LYKKEBOE G, 1978, RESP PHYSIOL, V35, P119, DOI 10.1016/0034-5687(78)90017-8; MACMAHON JA, 1975, COMP BIOCHEM PHYS A, V51, P59, DOI 10.1016/0300-9629(75)90413-2; MCPHERSON A, 1990, EUR J BIOCHEM, V189, P1, DOI 10.1111/j.1432-1033.1990.tb15454.x; MOSS BA, 1969, AUST J BIOL SCI, V22, P1455, DOI 10.1071/BI9691455; MUIRHEAD H, 1963, NATURE, V199, P633, DOI 10.1038/199633a0; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Perutz M. F., 1970, NATURE, V228, P734; PERUTZ MF, 1970, NATURE, V228, P726, DOI 10.1038/228726a0; PERUTZ MF, 1960, NATURE, V185, P416, DOI 10.1038/185416a0; PERUTZ MF, 1987, ACCOUNTS CHEM RES, V20, P309, DOI 10.1021/ar00141a001; POWELL MJD, 1976, MATH PROGRAM, V11, P42, DOI 10.1007/BF01580369; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; ROLLEMA HS, 1979, J BIOL CHEM, V254, P2038; SHAANAN B, 1983, J MOL BIOL, V171, P31, DOI 10.1016/S0022-2836(83)80313-1; SILVA MM, 1992, J BIOL CHEM, V267, P17248; SMITH T, 1992, J APPL CRYSTALLOGR, V26, P496; STEIGEMANN W, 1979, J MOL BIOL, V127, P309, DOI 10.1016/0022-2836(79)90332-2; TAM LT, 1984, J BIOL CHEM, V259, P2610; VORGER P, 1987, COMP BIOCHEM PHYS A, V88, P613, DOI 10.1016/0300-9629(87)90672-4; VORGER P, 1994, COMP BIOCHEM PHYS B, V109, P391, DOI 10.1016/0305-0491(94)90022-1; XUONG NH, 1985, J APPL CRYSTALLOGR, V18, P342, DOI 10.1107/S0021889885010433; Zhang J, 1996, J MOL BIOL, V255, P484, DOI 10.1006/jmbi.1996.0040	74	52	55	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1999	274	10					6411	6420		10.1074/jbc.274.10.6411	http://dx.doi.org/10.1074/jbc.274.10.6411			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172BQ	10037733	hybrid			2022-12-25	WOS:000078902800055
J	Paolillo, M; Feliciello, A; Porcellini, A; Garbi, C; Bifulco, M; Schinelli, S; Ventra, C; Stabile, E; Ricciardelli, G; Schettini, G; Avvedimento, EV				Paolillo, M; Feliciello, A; Porcellini, A; Garbi, C; Bifulco, M; Schinelli, S; Ventra, C; Stabile, E; Ricciardelli, G; Schettini, G; Avvedimento, EV			The type and the localization of cAMP-dependent protein kinase regulate transmission of cAMP signals to the nucleus in cortical and cerebellar granule cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG-TERM-MEMORY; C-FOS TRANSCRIPTION; GENE-EXPRESSION; CYCLIC-AMP; II-BETA; CREB PHOSPHORYLATION; ANCHORING PROTEINS; BINDING-PROTEIN; SUBUNIT; NEURONS	cAMP signals are received and transmitted by multiple isoforms of cAMP-dependent protein kinases, typically determined by their specific regulatory subunits. In the brain the major regulatory isoform RII beta and the RII-anchor protein, AKAP150 (rat) or 75 (bovine), are differentially expressed. Cortical neurons express RII beta and AKAP75; conversely, granule cerebellar cells express predominantly RI alpha and RII alpha Cortical neurons accumulate PKA catalytic subunit and phosphorylated cAMP responsive element binding protein very efficiently into nuclei upon cAMP induction, whereas granule cerebellar cells fail to do so. Down-regulation of RII beta synthesis by antisense oligonucleotides inhibited cAMP-induced nuclear signaling in cortical neurons. Expression in cerebellar granule cells of RII beta and ARAP75 genes by microinjection of specific expression vectors, markedly stimulated cAMP-induced transcription of the lacZ gene driven by a cAMP-responsive element promoter. These data indicate that the composition of PKA in cortical and granule cells underlies the differential ability of these cells to transmit cAMP signals to the nucleus.	Univ Naples Federico II, Fac Med, Dipartimento Biol & Patol Cellulare & Mol, CNR,CEOS, I-80131 Naples, Italy; Univ Pavia, Fac Farm, Ist Farmacol, I-27100 Pavia, Italy; Univ Naples Federico II, Fac Med, Dipartimento Biochim & Biotecnol Med, I-80131 Naples, Italy; Fac Med, Ist Farmacol, Genoa, Italy; CBA, IST, Serv Farmacol & Neurosci, Genoa, Italy; Univ Catanzaro, Fac Med Catanzaro, Dipartimento Med Sperimentale, Catanzaro, Italy	Consiglio Nazionale delle Ricerche (CNR); University of Naples Federico II; University of Pavia; University of Naples Federico II; Magna Graecia University of Catanzaro	Avvedimento, EV (corresponding author), Univ Naples Federico II, Fac Med, Dipartimento Biol & Patol Cellulare & Mol, CNR,CEOS, Torre Biol 14 Fl,Via S Pansini 5, I-80131 Naples, Italy.		Porcellini, Antonio/AAC-6097-2019; Paolillo, Mayra/N-2615-2015; Porcellini, Antonio/E-1900-2011	Paolillo, Mayra/0000-0002-7751-3336; Porcellini, Antonio/0000-0001-6882-9518; Feliciello, Antonio/0000-0002-7932-2170; stabile, eugenio/0000-0002-4544-3142; Bifulco, Maurizio/0000-0002-1771-4531; stabile, eugenio/0000-0001-9763-6010				Abel T, 1997, CELL, V88, P615, DOI 10.1016/S0092-8674(00)81904-2; Adams MR, 1997, P NATL ACAD SCI USA, V94, P12157, DOI 10.1073/pnas.94.22.12157; BEEBE SJ, 1986, ENZYMES, V17, P43; Bito H, 1996, CELL, V87, P1203, DOI 10.1016/S0092-8674(00)81816-4; BOURTCHULADZE R, 1994, CELL, V79, P59, DOI 10.1016/0092-8674(94)90400-6; Brandon EP, 1998, J NEUROSCI, V18, P3639; BREGMAN DB, 1989, J BIOL CHEM, V264, P4648; CADD G, 1989, NEURON, V3, P71, DOI 10.1016/0896-6273(89)90116-5; Carew TJ, 1996, NEURON, V16, P5, DOI 10.1016/S0896-6273(00)80016-1; CARR DW, 1992, J BIOL CHEM, V267, P16816; CARR DW, 1993, J BIOL CHEM, V268, P20729; Cassano S, 1996, J BIOL CHEM, V271, P29870, DOI 10.1074/jbc.271.47.29870; CIARDIELLO F, 1990, J BIOL CHEM, V265, P1016; DAY RN, 1989, J BIOL CHEM, V264, P431; Deisseroth K, 1996, NEURON, V16, P89, DOI 10.1016/S0896-6273(00)80026-4; Faux MC, 1996, TRENDS BIOCHEM SCI, V21, P312, DOI 10.1016/0968-0004(96)10040-2; Feliciello A, 1997, CURR BIOL, V7, P1011, DOI 10.1016/S0960-9822(06)00424-6; Feliciello A, 1996, J BIOL CHEM, V271, P25350, DOI 10.1074/jbc.271.41.25350; FRANK DA, 1994, CELL, V79, P5, DOI 10.1016/0092-8674(94)90394-8; GALLO A, 1992, GENE DEV, V6, P1621, DOI 10.1101/gad.6.9.1621; GINTY DD, 1993, SCIENCE, V260, P238, DOI 10.1126/science.8097062; Ginty DD, 1997, NEURON, V18, P183, DOI 10.1016/S0896-6273(00)80258-5; GINTY DD, 1994, CELL, V77, P713, DOI 10.1016/0092-8674(94)90055-8; GLANTZ SB, 1993, J BIOL CHEM, V268, P12796; GLANTZ SB, 1992, MOL BIOL CELL, V3, P1215, DOI 10.1091/mbc.3.11.1215; HAGIWARA M, 1993, MOL CELL BIOL, V13, P4852, DOI 10.1128/MCB.13.8.4852; HAROOTUNIAN AT, 1993, MOL BIOL CELL, V4, P993, DOI 10.1091/mbc.4.10.993; HIRSCH AH, 1992, J BIOL CHEM, V267, P2131; HOFMANN F, 1975, J BIOL CHEM, V250, P7795; Impey S, 1996, NEURON, V16, P973, DOI 10.1016/S0896-6273(00)80120-8; KAANG BK, 1993, NEURON, V10, P427, DOI 10.1016/0896-6273(93)90331-K; KAANG BK, 1992, P NATL ACAD SCI USA, V89, P1133, DOI 10.1073/pnas.89.3.1133; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LEISER M, 1986, J BIOL CHEM, V261, P1904; Li Y, 1996, J BIOL CHEM, V271, P16862, DOI 10.1074/jbc.271.28.16862; MELLON PL, 1989, P NATL ACAD SCI USA, V86, P4887, DOI 10.1073/pnas.86.13.4887; MOCHLYROSEN D, 1995, SCIENCE, V268, P247, DOI 10.1126/science.7716516; MONTMINY MR, 1990, TRENDS NEUROSCI, V13, P184, DOI 10.1016/0166-2236(90)90045-C; NDUBUKA C, 1993, J BIOL CHEM, V268, P7621; OBAR RA, 1989, NEURON, V3, P639, DOI 10.1016/0896-6273(89)90274-2; RUBIN CS, 1994, BBA-MOL CELL RES, V1224, P467; RUBINO HM, 1989, NEURON, V3, P631, DOI 10.1016/0896-6273(89)90273-0; SCHINELLI S, 1994, J NEUROCHEM, V62, P944; Schulman H, 1993, CURR OPIN CELL BIOL, V5, P247, DOI 10.1016/0955-0674(93)90111-3; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; THOMPSON MA, 1995, J BIOL CHEM, V270, P4224, DOI 10.1074/jbc.270.9.4224; Ventra C, 1996, J NEUROCHEM, V66, P1752	47	30	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1999	274	10					6546	6552		10.1074/jbc.274.10.6546	http://dx.doi.org/10.1074/jbc.274.10.6546			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172BQ	10037748	hybrid			2022-12-25	WOS:000078902800070
J	Tolwinski, NS; Shapiro, PS; Goueli, S; Ahn, NG				Tolwinski, NS; Shapiro, PS; Goueli, S; Ahn, NG			Nuclear localization of mitogen-activated protein kinase kinase 1 (MKK1) is promoted by serum stimulation and G2-M progression - Requirement for phosphorylation at the activation lip and signaling downstream of MKK	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							XENOPUS EGG EXTRACTS; SPINDLE ASSEMBLY CHECKPOINT; MAP KINASE; CYTOPLASMIC LOCALIZATION; EXPORT; TRANSLOCATION; MITOSIS; CRM1; DIFFERENTIATION; RAF-1	Stimulation of mammalian cells results in subcellular relocalization of Ras pathway enzymes, in which extracellular signal-regulated protein kinases rapidly translocate to nuclei. In this study, we define conditions for nuclear localization of mitogen-activated protein kinase kinase 1 (MKK1) by examining effects of perturbing the nuclear export signal (NES), the regulatory phosphorylation sites Ser(218) and Ser(222), and a regulatory domain at the N terminus. After disrupting the NES (Delta 32-37), nuclear uptake of MKK was enhanced when quiescent cells were activated with serum-phorbol 12-myristate 13-acetate or BXB-Raf-1 cotransfection. Uptake was enhanced by mutation of Ser(218) and Ser(222) to Glu and Asp, respectively, and blocked by mutation of these residues to Ala, although mutation of Lys(97) to Met, which renders MKK catalytically inactive, did not interfere with uptake. Therefore, nuclear uptake of MKK requires incorporation of phosphate or negatively charged residues at the activation lip but not enzyme activity. On the other hand, uptake of an active MKK mutant with disrupted NES (Delta 32-51) was elevated in quiescent as well as stimulated cells, and pretreatment of cells with the MKK inhibitor 1,4-diamino-2,3-dicyano-1,4-bis[2-aminophenylthio]butadiene blocked nuclear uptake. Thus, signaling downstream of MKK is also necessary for translocation. Finally, wild type MKK containing an intact NES translocates to nuclei during mitosis before envelope breakdown. Comparison of mutants with Ser to Glu and Asp or Ala substitutions indicates that Ser phosphorylation is also required for mitotic nuclear uptake of MKK.	Univ Colorado, Dept Chem & Biochem, Boulder, CO 80309 USA; Univ Colorado, Howard Hughes Med Inst, Boulder, CO 80309 USA; Promega Corp, Madison, WI 53711 USA	University of Colorado System; University of Colorado Boulder; Howard Hughes Medical Institute; University of Colorado System; University of Colorado Boulder; Promega Corporation	Ahn, NG (corresponding author), Univ Colorado, Dept Chem & Biochem, Campus Box 215, Boulder, CO 80309 USA.	ahnn@spot.colorado.edu	Tolwinski, Nicholas/Q-5782-2019; Tolwinski, Nicholas/D-1481-2014	Tolwinski, Nicholas/0000-0002-8507-2737; 	NIGMS NIH HHS [R01-GM48521, F32 GM18151] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048521, F32GM018151] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abrieu A, 1996, J CELL SCI, V109, P239; CHENG HN, 1992, MAKROMOL CHEM-THEOR, V1, P415; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Fukuda M, 1996, J BIOL CHEM, V271, P20024, DOI 10.1074/jbc.271.33.20024; Fukuda M, 1997, NATURE, V390, P308, DOI 10.1038/36894; Fukuda M, 1997, J BIOL CHEM, V272, P32642, DOI 10.1074/jbc.272.51.32642; Fukuda M, 1997, EMBO J, V16, P1901, DOI 10.1093/emboj/16.8.1901; GONZALEZ FA, 1993, J CELL BIOL, V122, P1089, DOI 10.1083/jcb.122.5.1089; Gorbsky GJ, 1997, BIOESSAYS, V19, P193, DOI 10.1002/bies.950190303; GOTOH Y, 1990, EUR J BIOCHEM, V193, P661, DOI 10.1111/j.1432-1033.1990.tb19384.x; Jaaro H, 1997, P NATL ACAD SCI USA, V94, P3742, DOI 10.1073/pnas.94.8.3742; Khokhlatchev AV, 1998, CELL, V93, P605, DOI 10.1016/S0092-8674(00)81189-7; Kudo N, 1997, J BIOL CHEM, V272, P29742, DOI 10.1074/jbc.272.47.29742; LAIRD AD, 1995, J BIOL CHEM, V270, P26742, DOI 10.1074/jbc.270.45.26742; LENORMAND P, 1993, J CELL BIOL, V122, P1079, DOI 10.1083/jcb.122.5.1079; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; Mansour SJ, 1996, BIOCHEMISTRY-US, V35, P15529, DOI 10.1021/bi961854s; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MINSHULL J, 1994, CELL, V79, P475, DOI 10.1016/0092-8674(94)90256-9; OssarehNazari B, 1997, SCIENCE, V278, P141, DOI 10.1126/science.278.5335.141; Pathan NI, 1996, J BIOL CHEM, V271, P30315, DOI 10.1074/jbc.271.48.30315; QIU MS, 1992, NEURON, V9, P705, DOI 10.1016/0896-6273(92)90033-A; ROBBINS DJ, 1993, J BIOL CHEM, V268, P5097; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; ROCHE S, 1995, SCIENCE, V269, P1567, DOI 10.1126/science.7545311; Shapiro PS, 1998, J CELL BIOL, V142, P1533, DOI 10.1083/jcb.142.6.1533; Takenaka K, 1997, J CELL BIOL, V136, P1091, DOI 10.1083/jcb.136.5.1091; TRAVERSE S, 1992, BIOCHEM J, V288, P351, DOI 10.1042/bj2880351; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; Walter SA, 1997, MOL BIOL CELL, V8, P2157, DOI 10.1091/mbc.8.11.2157; WEN W, 1995, CELL, V82, P463, DOI 10.1016/0092-8674(95)90435-2; Whalen AM, 1997, MOL CELL BIOL, V17, P1947, DOI 10.1128/MCB.17.4.1947; ZHENG CF, 1994, J BIOL CHEM, V269, P19947	34	69	69	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	1999	274	10					6168	6174		10.1074/jbc.274.10.6168	http://dx.doi.org/10.1074/jbc.274.10.6168			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172BQ	10037701	hybrid			2022-12-25	WOS:000078902800023
J	Fitzgerald, J; Hughes-Fulford, M				Fitzgerald, J; Hughes-Fulford, M			Mechanically induced c-fos expression is mediated by cAMP in MC3T3-E1 osteoblasts	FASEB JOURNAL			English	Article						gene expression; signal transduction; gravity; mechanical stimulation; PGE(2) synthesis	MESSENGER-RNA EXPRESSION; GENE-EXPRESSION; TRANSGENIC MICE; CELLS; BONE; DIFFERENTIATION; HYPERGRAVITY; RESPONSES; INVITRO	In serum-deprived MC3T3-E1 osteoblasts, mechanical stimulation caused by mild (287 x g) centrifugation induced a 10-fold increase in mRNA levels of the proto-oncogene, c-fos, Induction of c-fos was abolished by the cAMP-dependent protein kinase inhibitor H-89, suggesting that the transient c-fos mRNA increase is mediated by cAMP, Down-regulation of protein kinase C (PKC) activity by chronic TPA treatment failed to significantly reduce c-fos induction, suggesting that TPA-sensitive isoforms of PKC are not responsible for c-fos up regulation, In addition, 287 x g centrifugation increased intracellular prostaglandin E-2 (PGE(2)) levels 2.8-fold (P < 0.005), Since we have previously shown that prostaglandin E-2 (PGE(2)) can induce c-fos expression via a cAMP-mediated mechanism, we asked whether the increase in c-fos mRNA was due to centrifugation-induced PGE(2) release. Pretreatment with the cyclooxygenase inhibitors indomethacin and flurbiprofen did not hinder the early induction of c-fos by mechanical stimulation, We conclude that c-fos expression induced by mild mechanical loading is dependent primarily on cAMP, not PKC, and initial induction of c-fos is not necessarily dependent on the action of newly synthesized PGE(2).	Vet Affairs Med Ctr, Dept Med, Lab Cell Growth, San Francisco, CA 94121 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA)	Hughes-Fulford, M (corresponding author), Vet Affairs Med Ctr, Dept Med, Lab Cell Growth, Mail Code 151F,4150 Clement St, San Francisco, CA 94121 USA.			Hughes-Fulford, Millie/0000-0002-0756-068X				CARVALHO RS, 1995, ARCH ORAL BIOL, V40, P257, DOI 10.1016/0003-9969(95)98814-F; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLOHISY JC, 1992, MOL ENDOCRINOL, V6, P1834, DOI 10.1210/me.6.11.1834; CLOSS EI, 1990, J CELL BIOL, V111, P1313, DOI 10.1083/jcb.111.3.1313; DANESCH U, 1994, J BIOL CHEM, V269, P27258; Fitzgerald J, 1996, EXP CELL RES, V228, P168, DOI 10.1006/excr.1996.0313; GRIGORIADIS AE, 1993, J CELL BIOL, V122, P685, DOI 10.1083/jcb.122.3.685; GRIGORIADIS AE, 1994, SCIENCE, V266, P443, DOI 10.1126/science.7939685; HARTER LV, 1995, ENDOCRINOLOGY, V136, P528, DOI 10.1210/en.136.2.528; INAOKA T, 1995, BIOCHEM BIOPH RES CO, V217, P264, DOI 10.1006/bbrc.1995.2773; JANKNECHT R, 1995, CARCINOGENESIS, V16, P443, DOI 10.1093/carcin/16.3.443; JEE WSS, 1985, CALCIFIED TISSUE INT, V37, P148, DOI 10.1007/BF02554834; JOHNSON RS, 1992, CELL, V71, P577, DOI 10.1016/0092-8674(92)90592-Z; KUMEI Y, 1989, J CELL SCI, V93, P221; NOSE K, 1994, EXP CELL RES, V211, P168, DOI 10.1006/excr.1994.1073; RAABCULLEN DM, 1994, CALCIFIED TISSUE INT, V55, P473, DOI 10.1007/BF00298562; RODRIGUEZPENA A, 1984, BIOCHEM BIOPH RES CO, V120, P1053, DOI 10.1016/S0006-291X(84)80213-2; RUTHER U, 1987, NATURE, V325, P412, DOI 10.1038/325412a0; SADOSHIMA J, 1993, EMBO J, V12, P1681, DOI 10.1002/j.1460-2075.1993.tb05813.x; Shanfeld J L, 1985, Prog Clin Biol Res, V187, P331; SIMONSON MS, 1994, EXP CELL RES, V215, P137, DOI 10.1006/excr.1994.1325; STANFORD CM, 1995, J ORTHOPAED RES, V13, P664, DOI 10.1002/jor.1100130505; SUDO H, 1983, J CELL BIOL, V96, P191, DOI 10.1083/jcb.96.1.191; Tjandrawinata RR, 1997, FASEB J, V11, P493, DOI 10.1096/fasebj.11.6.9194530; TREISMAN R, 1995, EMBO J, V14, P4905, DOI 10.1002/j.1460-2075.1995.tb00173.x; WANG ZQ, 1992, NATURE, V360, P741, DOI 10.1038/360741a0; ZAMAN G, 1992, CALCIFIED TISSUE INT, V51, P132, DOI 10.1007/BF00298501	27	40	53	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	1999	13	3					553	557		10.1096/fasebj.13.3.553	http://dx.doi.org/10.1096/fasebj.13.3.553			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	174CF	10064622				2022-12-25	WOS:000079016000015
J	Gemel, J; Jacobsen, C; MacArthur, CA				Gemel, J; Jacobsen, C; MacArthur, CA			Fibroblast growth factor-8 expression is regulated by intronic engrailed and Pbx1-binding sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EMBRYONAL CARCINOMA-CELLS; INT-2 GENE; GROWTH-FACTOR-4 ENHANCER; SEQUENCE HOMOLOGY; MOUSE DEVELOPMENT; BINDING PROTEINS; VERTEBRATE LIMB; MESSENGER-RNA; STEM-CELLS; FGF-8 GENE	Fibroblast growth factor-8 (FGF8) plays a critical role in vertebrate development and is expressed normally in temporally and spatially restricted regions of the vertebrate embryo. We now report on the identification of regions of Fgf8 important for its transcriptional regulation in murine ES cell-derived embryoid bodies. Stable transfection of ES cells, using a human growth hormone reporter gene, was employed to identify regions of the Fgf8 gene with promoter/enhancer activity. A 2-kilobase 5' region of Fgf8 was shown to contain promoter activity. A 0.8-kilobase fragment derived from the large intron of Fgf8 was found to enhance human growth hormone expressed from the Fgf8 promoter 3-4-fold in an orientation dependent manner. The intronic fragment contains DNA-binding sites for the AP2, Pbx1, and Engrailed transcription factors. Gel shift and Western blot experiments documented the presence of these transcription factors in nuclear extracts from ES cell embryoid bodies. In vitro mutagenesis of the Engrailed or Pbx1 site demonstrated that these sites modulate the activity of the intronic fragment. In addition, in vitro mutagenesis of both Engrailed and Pbx1 sites indicated that other unidentified sites are responsible for the transcriptional enhancement observed with the intronic fragment.	Washington Univ, Sch Med, Dept Pediat & Pathol, St Louis, MO 63110 USA	Washington University (WUSTL)	MacArthur, CA (corresponding author), Washington Univ, Sch Med, Dept Pediat & Pathol, Campus Box 8116,1 Childrens Pl, St Louis, MO 63110 USA.				NATIONAL CANCER INSTITUTE [R01CA070106] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA 70106] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ACLAND P, 1990, NATURE, V343, P662, DOI 10.1038/343662a0; Ambrosetti DC, 1997, MOL CELL BIOL, V17, P6321, DOI 10.1128/MCB.17.11.6321; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; AUSUBEL FA, 1995, CURRENT PROTOCOLS MO, V2; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; Crossley PH, 1996, NATURE, V380, P66, DOI 10.1038/380066a0; Crossley PH, 1996, CELL, V84, P127, DOI 10.1016/S0092-8674(00)80999-X; CROSSLEY PH, 1995, DEVELOPMENT, V121, P439; CURATOLA AM, 1990, MOL CELL BIOL, V10, P2475, DOI 10.1128/MCB.10.6.2475; DAILEY L, 1994, MOL CELL BIOL, V14, P7758, DOI 10.1128/MCB.14.12.7758; DAVIS CA, 1988, GENE DEV, V2, P1736, DOI 10.1101/gad.2.12b.1736; DAVIS CA, 1991, DEVELOPMENT, V111, P287; DOETSCHMAN TC, 1985, J EMBRYOL EXP MORPH, V87, P27; Gemel J, 1996, GENOMICS, V35, P253, DOI 10.1006/geno.1996.0349; GRINBERG D, 1991, CELL GROWTH DIFFER, V2, P137; HANKS M, 1995, SCIENCE, V269, P679, DOI 10.1126/science.7624797; HEIKINHEIMO M, 1994, MECH DEVELOP, V48, P129, DOI 10.1016/0925-4773(94)90022-1; Hogan B, 1994, MANIPULATING MOUSE E; JOYNER AL, 1987, GENE DEV, V1, P29, DOI 10.1101/gad.1.1.29; JOYNER AL, 1985, CELL, V43, P29, DOI 10.1016/0092-8674(85)90009-1; JOYNER AL, 1991, SCIENCE, V251, P1239, DOI 10.1126/science.1672471; Lee SMK, 1997, DEVELOPMENT, V124, P959; Loomis CA, 1996, NATURE, V382, P360, DOI 10.1038/382360a0; LORENZI MV, 1995, ONCOGENE, V10, P2051; LOZANO G, 1991, MOL CARCINOGEN, V4, P3, DOI 10.1002/mc.2940040103; MacArthur CA, 1997, GENOMICS, V42, P137, DOI 10.1006/geno.1997.4353; MACARTHUR CA, 1995, DEVELOPMENT, V121, P3603; MACARTHUR CA, 1995, J VIROL, V69, P2501, DOI 10.1128/JVI.69.4.2501-2507.1995; MAGIN TM, 1992, GENE, V122, P289, DOI 10.1016/0378-1119(92)90217-D; MAHMOOD R, 1995, CURR BIOL, V5, P797, DOI 10.1016/S0960-9822(95)00157-6; MANSOUR SL, 1988, EMBO J, V7, P2035, DOI 10.1002/j.1460-2075.1988.tb03043.x; McEwen DG, 1998, J BIOL CHEM, V273, P5349, DOI 10.1074/jbc.273.9.5349; MCMAHON AP, 1992, CELL, V69, P581, DOI 10.1016/0092-8674(92)90222-X; Meyers EN, 1998, NAT GENET, V18, P136, DOI 10.1038/ng0298-136; MURRE C, 1991, MOL CELL BIOL, V11, P1156, DOI 10.1128/MCB.11.2.1156; MYERS RL, 1995, J BIOL CHEM, V270, P8257, DOI 10.1074/jbc.270.14.8257; MYERS RL, 1993, ONCOGENE, V8, P341; OHUCHI H, 1994, BIOCHEM BIOPH RES CO, V204, P882, DOI 10.1006/bbrc.1994.2542; PARI G, 1991, MOL CELL BIOL, V11, P4796, DOI 10.1128/MCB.11.9.4796; Payson RA, 1996, ONCOGENE, V13, P47; Peltenburg LTC, 1996, EMBO J, V15, P3385, DOI 10.1002/j.1460-2075.1996.tb00704.x; Peltenburg LTC, 1997, DEVELOPMENT, V124, P1089; Pinsonneault J, 1997, EMBO J, V16, P2032, DOI 10.1093/emboj/16.8.2032; Ray SK, 1997, J BIOL CHEM, V272, P7546, DOI 10.1074/jbc.272.11.7546; ROBERTSON E, 1987, TERATOCARCINOMA EMBR; Rohrer J, 1998, BLOOD, V91, P214, DOI 10.1182/blood.V91.1.214.214_214_221; SMITH R, 1988, EMBO J, V7, P1013, DOI 10.1002/j.1460-2075.1988.tb02908.x; SOUDAIS C, 1995, DEVELOPMENT, V121, P3877; TOBIAS KE, 1995, ONCOGENE, V11, P1721; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; Valve E, 1997, BIOCHEM BIOPH RES CO, V232, P173, DOI 10.1006/bbrc.1997.6256; Vogel A, 1996, DEVELOPMENT, V122, P1737; WILSON DB, 1990, MOL CELL BIOL, V10, P4854, DOI 10.1128/MCB.10.9.4854; WURST W, 1994, DEVELOPMENT, V120, P2065; YUAN HB, 1995, GENE DEV, V9, P2635, DOI 10.1101/gad.9.21.2635	55	44	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 26	1999	274	9					6020	6026		10.1074/jbc.274.9.6020	http://dx.doi.org/10.1074/jbc.274.9.6020			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	170KG	10026229	hybrid			2022-12-25	WOS:000078804400100
J	Wu, TH; Marinus, MG				Wu, TH; Marinus, MG			Deletion mutation analysis of the mutS gene in Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BASE PAIRS; MISMATCH REPAIR; GENOME INSTABILITY; ATP HYDROLYSIS; PROTEIN; BINDS	The MutS protein is part of the dam-directed MutHLS mismatch repair pathway in Escherichia coli. We have constructed deletion derivatives in the mutS gene, which retain the P-loop coding region for ATP binding. The mutant proteins were assayed for ATP hydrolysis, heteroduplex DNA binding, heterodimer mutS formation, and the ability to interact with MutL. Dimerization was assayed by expressing His(6)-tagged wild-type and non-tagged deletion mutant proteins in the same cell and isolating the His(6)-tagged protein followed by MutS immunoblotting after SDS-polyacrylamide gel electrophoresis. MutS-MutL interaction was measured using the same technique except that the MutL protein carried the His, tag. Our results indicate that DNA binding ability resides in the N-terminal end of MutS, and dimerization and MutL interactions are located in the C-terminal end. Given the extensive amino acid homology in the MutS family our results with E. coli should be applicable to MutS homologues in other prokaryotes and eukaryotes.	Univ Massachusetts, Sch Med, Dept Mol Pharmacol & Toxicol, Worcester, MA 01655 USA	University of Massachusetts System; University of Massachusetts Worcester	Marinus, MG (corresponding author), Univ Massachusetts, Sch Med, Dept Mol Pharmacol & Toxicol, 55 Lake Ave, Worcester, MA 01655 USA.	Martin.Marinus@ummed.edu			NIGMS NIH HHS [GM33233] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033233] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alani E, 1997, MOL CELL BIOL, V17, P2436, DOI 10.1128/MCB.17.5.2436; Alani E, 1996, MOL CELL BIOL, V16, P5604; Allen DJ, 1997, EMBO J, V16, P4467, DOI 10.1093/emboj/16.14.4467; Drotschmann K, 1998, NUCLEIC ACIDS RES, V26, P948, DOI 10.1093/nar/26.4.948; Eisen JA, 1998, NUCLEIC ACIDS RES, V26, P4291, DOI 10.1093/nar/26.18.4291; Gradia S, 1997, CELL, V91, P995, DOI 10.1016/S0092-8674(00)80490-0; GRILLEY M, 1989, J BIOL CHEM, V264, P1000; Horst JP, 1999, TRENDS MICROBIOL, V7, P29, DOI 10.1016/S0966-842X(98)01424-3; KARRAN P, 1994, BIOESSAYS, V16, P833, DOI 10.1002/bies.950161110; Kolodner R, 1996, GENE DEV, V10, P1433, DOI 10.1101/gad.10.12.1433; Malkov VA, 1997, J BIOL CHEM, V272, P23811, DOI 10.1074/jbc.272.38.23811; MODRICH P, 1991, ANNU REV GENET, V25, P229, DOI 10.1146/annurev.ge.25.120191.001305; Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533; SU SS, 1986, P NATL ACAD SCI USA, V83, P5057, DOI 10.1073/pnas.83.14.5057; Tachiki H, 1998, NUCLEIC ACIDS RES, V26, P4153, DOI 10.1093/nar/26.18.4153; Umar A, 1996, EUR J BIOCHEM, V238, P297, DOI 10.1111/j.1432-1033.1996.0297z.x; WEINSTOCK GM, 1981, J BIOL CHEM, V256, P8829; WU TH, 1994, J BACTERIOL, V176, P5393, DOI 10.1128/JB.176.17.5393-5400.1994; WU TH, 1990, GENE, V87, P1, DOI 10.1016/0378-1119(90)90488-D; Yamaguchi M, 1998, J BIOL CHEM, V273, P9197, DOI 10.1074/jbc.273.15.9197	20	46	46	2	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 26	1999	274	9					5948	5952		10.1074/jbc.274.9.5948	http://dx.doi.org/10.1074/jbc.274.9.5948			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	170KG	10026220	hybrid			2022-12-25	WOS:000078804400091
J	Laudet, V; Hanni, C; Stehelin, D; Duterque-Coquillaud, M				Laudet, V; Hanni, C; Stehelin, D; Duterque-Coquillaud, M			Molecular phylogeny of the ETS gene family	ONCOGENE			English	Article						phylogeny; ETS family; transcription factors; DNA binding domains	EWINGS-SARCOMA TRANSLOCATION; DNA-BINDING SPECIFICITIES; TRANSCRIPTION FACTOR PU.1; C-FOS; CHROMOSOMAL TRANSLOCATION; DOMAIN PROTEIN; FACTORS ELK-1; MURINE ETS-1; HOX GENES; EWS GENE	We have constructed a molecular phylogeny of the ETS gene family, By distance and parsimony analysis of the ETS conserved domains we show that the family containing so far 29 different genes in vertebrates can be divided into 13 groups of genes namely ETS, ER71, GABP, PEA3, ERG, ERF, ELK, DETS4, ELF, ESE, TEL, YAN, SPI, Since the three dimensional structure of the ETS domain has revealed a similarity with the winged-helix - turn- helix proteins, we used two of them (CAP and HSF) to root the tree. This allowed us to show that the family can be divided into five subfamilies: ETS, DETS4, ELF, TEL and SPI, The ETS subfamily comprises the ETS, ER71, GABP, PEA3, ERG, ERF and the ELK groups which appear more related to each other than to any other ETS family members. The fact that some members of these subfamilies were identified in early metazoans such as diploblasts and sponges suggests that the diversification of ETS family genes predates the diversification of metazoans. By the combined analysis of both the ETS and the PNT domains, which are conserved in some members of the family, we showed that the GABP group, and not the ERG group, is the one most closely related to the ETS group. We also observed that the speed of accumulation of mutations in the various genes of the family is highly variable, Noticeably, paralogous members of the ELK group exhibit strikingly different evolutionary speed suggesting that the evolutionary pressure they support is very different.	Ecole Normale Super Lyon, UMR 49 CNRS, F-69364 Lyon 07, France; Inst Biol Lille, CNRS UMR 319, F-59021 Lille, France; Univ Lyon 1, CGMC, UMR CNRS 5534, F-69962 Villeurbanne, France	Ecole Normale Superieure de Lyon (ENS de LYON); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Claude Bernard Lyon 1	Laudet, V (corresponding author), Ecole Normale Super Lyon, UMR 49 CNRS, 46 Allee Italie, F-69364 Lyon 07, France.			Duterque-Coquillaud, Martine/0000-0003-3943-5629				Alkema MJ, 1997, GENE DEV, V11, P226, DOI 10.1101/gad.11.2.226; Averof M, 1997, CURR BIOL, V7, pR634, DOI 10.1016/S0960-9822(06)00321-6; BASSUK AG, 1995, IMMUNITY, V3, P223, DOI 10.1016/1074-7613(95)90092-6; Basuyaux JP, 1997, J BIOL CHEM, V272, P26188, DOI 10.1074/jbc.272.42.26188; Beitel GJ, 1995, GENE DEV, V9, P3149, DOI 10.1101/gad.9.24.3149; BENDAVID Y, 1991, GENE DEV, V5, P908, DOI 10.1101/gad.5.6.908; BORIES JC, 1995, NATURE, V377, P635, DOI 10.1038/377635a0; Bornemann D, 1996, DEVELOPMENT, V122, P1621; Buttice G, 1996, ONCOGENE, V13, P2297; Carrere S, 1998, ONCOGENE, V16, P3261, DOI 10.1038/sj.onc.1201868; CHEN T, 1992, DEV BIOL, V151, P176, DOI 10.1016/0012-1606(92)90225-6; CREPIEUX P, 1994, CRIT REV ONCOGENESIS, V5, P615; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; DEGNAN BM, 1993, NUCLEIC ACIDS RES, V21, P3479, DOI 10.1093/nar/21.15.3479; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; DONALDSON LW, 1994, BIOCHEMISTRY-US, V33, P13509, DOI 10.1021/bi00250a001; Donaldson LW, 1996, EMBO J, V15, P125, DOI 10.1002/j.1460-2075.1996.tb00340.x; DUTERQUECOQUILLAUD M, 1993, ONCOGENE, V8, P1865; Escriva H, 1997, P NATL ACAD SCI USA, V94, P6803, DOI 10.1073/pnas.94.13.6803; Fitzsimmons D, 1996, GENE DEV, V10, P2198, DOI 10.1101/gad.10.17.2198; GOLUB TR, 1994, CELL, V77, P307, DOI 10.1016/0092-8674(94)90322-0; Graves BJ, 1998, ADV CANCER RES, V75, P1, DOI 10.1016/S0065-230X(08)60738-1; HIPSKIND RA, 1991, NATURE, V354, P531, DOI 10.1038/354531a0; Holland PWH, 1996, DEV BIOL, V173, P382, DOI 10.1006/dbio.1996.0034; JEON IS, 1995, ONCOGENE, V10, P1229; Jousset C, 1997, EMBO J, V16, P69, DOI 10.1093/emboj/16.1.69; KARIM FD, 1990, GENE DEV, V4, P1451, DOI 10.1101/gad.4.9.1451; Kasahara M, 1996, P NATL ACAD SCI USA, V93, P9096, DOI 10.1073/pnas.93.17.9096; Katsanis N, 1996, GENOMICS, V35, P101, DOI 10.1006/geno.1996.0328; Kherrouche Z, 1998, ONCOGENE, V16, P1357, DOI 10.1038/sj.onc.1201650; KLAMBT C, 1993, DEVELOPMENT, V117, P163; Kodandapani R, 1996, NATURE, V380, P456, DOI 10.1038/380456a0; LANDSMAN D, 1995, TRENDS BIOCHEM SCI, V20, P225, DOI 10.1016/S0968-0004(00)89021-0; Laudet V, 1997, J MOL ENDOCRINOL, V19, P207, DOI 10.1677/jme.0.0190207; LAUDET V, 1993, BIOCHEM BIOPH RES CO, V190, P8, DOI 10.1006/bbrc.1993.1002; LAUTENBERGER JA, 1992, ONCOGENE, V7, P1713; LEPRINCE D, 1983, NATURE, V306, P395, DOI 10.1038/306395a0; LIANG H, 1994, NAT STRUCT BIOL, V1, P871, DOI 10.1038/nsb1294-871; Maira SM, 1996, EMBO J, V15, P5849, DOI 10.1002/j.1460-2075.1996.tb00972.x; MCKAY DB, 1981, NATURE, V290, P744, DOI 10.1038/290744a0; MOREAUGACHELIN F, 1989, ONCOGENE, V4, P1449; MUTHUSAMY N, 1995, NATURE, V377, P639, DOI 10.1038/377639a0; NUNN MF, 1983, NATURE, V306, P391, DOI 10.1038/306391a0; Ohno S., 1970, EVOLUTION GENE DUPLI; PAPADOPOULOS P, 1995, CANCER RES, V55, P34; Peter M, 1997, ONCOGENE, V14, P1159, DOI 10.1038/sj.onc.1200933; PHILIPPE H, 1994, DEVELOPMENT, P15; PONGUBALA JMR, 1992, MOL CELL BIOL, V12, P368, DOI 10.1128/MCB.12.1.368; Pongubala JMR, 1997, P NATL ACAD SCI USA, V94, P127, DOI 10.1073/pnas.94.1.127; PRICE MA, 1995, EMBO J, V14, P2589, DOI 10.1002/j.1460-2075.1995.tb07257.x; RAO VN, 1987, SCIENCE, V237, P635, DOI 10.1126/science.3299708; RAO VN, 1988, ONCOGENE, V3, P497; RIVERA RR, 1993, MOL CELL BIOL, V13, P7163, DOI 10.1128/MCB.13.11.7163; RORTH P, 1990, NUCLEIC ACIDS RES, V18, P5009, DOI 10.1093/nar/18.17.5009; SCOTT EW, 1994, SCIENCE, V265, P1573, DOI 10.1126/science.8079170; SETH A, 1990, ONCOGENE, V5, P1761; SGOURAS DN, 1995, EMBO J, V14, P4781, DOI 10.1002/j.1460-2075.1995.tb00160.x; SHIMIZU K, 1993, P NATL ACAD SCI USA, V90, P10280, DOI 10.1073/pnas.90.21.10280; SHORE P, 1995, NUCLEIC ACIDS RES, V23, P4698, DOI 10.1093/nar/23.22.4698; SORENSEN PHB, 1994, NAT GENET, V6, P146, DOI 10.1038/ng0294-146; Tondravi MM, 1997, NATURE, V386, P81, DOI 10.1038/386081a0; Urano F, 1996, BIOCHEM BIOPH RES CO, V219, P608, DOI 10.1006/bbrc.1996.0281; VANDENBUNDER B, 1989, DEVELOPMENT, V106, P265; VERNIER P, 1995, TRENDS PHARMACOL SCI, V16, P375, DOI 10.1016/S0165-6147(00)89078-1; WANG CY, 1992, J EXP MED, V175, P1391, DOI 10.1084/jem.175.5.1391; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WASYLYK C, 1991, EMBO J, V10, P1127, DOI 10.1002/j.1460-2075.1991.tb08053.x; WATSON DK, 1988, P NATL ACAD SCI USA, V85, P7862, DOI 10.1073/pnas.85.21.7862; ZUCMAN J, 1993, EMBO J, V12, P4481, DOI 10.1002/j.1460-2075.1993.tb06137.x	69	115	118	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 11	1999	18	6					1351	1359		10.1038/sj.onc.1202444	http://dx.doi.org/10.1038/sj.onc.1202444			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	165FW	10022817				2022-12-25	WOS:000078510900011
J	Dunn, J; Garde, J; Dolan, K; Gosney, JR; Sutton, R; Meltzer, SJ; Field, JK				Dunn, J; Garde, J; Dolan, K; Gosney, JR; Sutton, R; Meltzer, SJ; Field, JK			Multiple target sites of allelic imbalance on chromosome 17 in Barrett's oesophageal cancer	ONCOGENE			English	Article						Barrett's adenocarcinoma; deletion mapping; chromosome 17; target regions	TUMOR-SUPPRESSOR GENE; EPITHELIAL OVARIAN-TUMORS; HUMAN BREAST CARCINOMAS; ESOPHAGEAL ADENOCARCINOMA; PROGNOSTIC VALUE; PROSTATE-CANCER; P53 MUTATIONS; FREQUENT LOSS; HETEROZYGOSITY; REGIONS	Twelve Barrett's adenocarcinomas have been analysed for the occurrence of allelic imbalance (LOH) on chromosome 17 using 41 microsatellite markers. This study provides evidence for 13 minimal regions of LOH, six on 17p and seven on 17q. Four of these centre in the vicinity of the known tumour suppressor genes (TSGs) TP53 (17p13.1), NF1 (17q11.2), BRCA1 (17q21.1), and a putative TSG (17p13.3), The tumours all displayed relatively small regions of LOH (1-10 cM), and in several tumours extensive regions of LOH were detected. One tumour displayed only two very small regions of LOH; 17p11.2 and 17p13.1. The frequency of allelic imbalance has been calculated based on the LOH encompassing only one minimal region, and based on all the LOH observations. By both evaluations the highest LOH frequencies were found for regions II (p53), III (17p13.1 centromeric to p53), IV (17p12), V (17p11.2) and VII (NF1, 17q11.2). Our data supports the existence of multiple TSGs on chromosome 17 and challenges the view that p53 is the sole target of LOH on 17p in Barrett's adenocarcinoma.	Univ Liverpool, Mol Genet & Oncol Grp, Liverpool L69 3BX, Merseyside, England; Thameside Gen Hosp, Dept Surg, Ashton Under Lyne OL6 9RW, Greater Manches, England; Univ Liverpool, Dept Pathol, Liverpool L69 3BX, Merseyside, England; Univ Liverpool, Dept Surg, Liverpool L69 3BX, Merseyside, England; Univ Maryland, Baltimore, MD 21201 USA; Vet Affairs Hosp, Baltimore, MD 21201 USA	University of Liverpool; University of Liverpool; University of Liverpool; University System of Maryland; University of Maryland Baltimore	Field, JK (corresponding author), Univ Liverpool, Mol Genet & Oncol Grp, Liverpool L69 3BX, Merseyside, England.		Sutton, Robert/I-3587-2016; Field, John K./AAD-5674-2020	Sutton, Robert/0000-0001-6600-562X; Field, John K./0000-0003-3951-6365				ABERLE H, 1995, P NATL ACAD SCI USA, V92, P6384, DOI 10.1073/pnas.92.14.6384; ALESSANDRA V, 1995, CANCER RES, V55, P2645; ALKASSPOOLES M, 1993, INT J CANCER, V54, P213, DOI 10.1002/ijc.2910540209; ATKIN NB, 1989, CANCER GENET CYTOGEN, V37, P229, DOI 10.1016/0165-4608(89)90053-8; Audrezet MP, 1996, HUM MUTAT, V7, P109, DOI 10.1002/(SICI)1098-1004(1996)7:2<109::AID-HUMU4>3.0.CO;2-7; Barrett MT, 1996, ONCOGENE, V12, P1873; Barrett MT, 1996, ONCOGENE, V13, P1867; BLOUNT PL, 1993, P NATL ACAD SCI USA, V90, P3221, DOI 10.1073/pnas.90.8.3221; BLOUNT PL, 1994, CANCER RES, V54, P2292; CAMERON AJ, 1995, GASTROENTEROLOGY, V109, P1541, DOI 10.1016/0016-5085(95)90642-8; CAMERON AJ, 1993, ENDOSCOPY, V25, P635, DOI 10.1055/s-2007-1010420; CAMERON AJ, 1992, GASTROENTEROLOGY, V103, P1241, DOI 10.1016/0016-5085(92)91510-B; Campomenosi P, 1996, CANCER EPIDEM BIOMAR, V5, P559; CASSON AG, 1994, AM J SURG, V167, P52, DOI 10.1016/0002-9610(94)90053-1; Chekmareva MA, 1997, PROSTATE, V33, P271; COGEN PH, 1992, AM J HUM GENET, V50, P584; CORNELIS RS, 1993, ONCOGENE, V8, P781; CORNELIS RS, 1994, CANCER RES, V54, P4200; CROPP CS, 1993, CANCER RES, V53, P5617; FENNERTY MB, 1993, ALIMENT PHARM THER, V7, P339; FILIPE MI, 1993, ENDOSCOPY, V25, P637, DOI 10.1055/s-2007-1010421; FLEJOU JF, 1994, PATHOL RES PRACT, V190, P1141, DOI 10.1016/S0344-0338(11)80440-1; FONG KM, 1995, CANCER RES, V55, P4268; FUTREAL PA, 1992, CANCER RES, V52, P2624; Galipeau PC, 1996, P NATL ACAD SCI USA, V93, P7081, DOI 10.1073/pnas.93.14.7081; GAO X, 1995, ONCOGENE, V11, P1241; GLEESON CM, 1995, CANCER RES, V55, P3406; Gonzalez MV, 1997, J CLIN PATHOL, V50, P212, DOI 10.1136/jcp.50.3.212; GREENWALD BD, 1992, INT J ONCOL, V1, P271; Gullick W J, 1990, Int J Cancer Suppl, V5, P55; HARRIS CC, 1993, NEW ENGL J MED, V329, P1318, DOI 10.1056/NEJM199310283291807; HUANG Y, 1993, CANCER RES, V53, P1889; HUANG Y, 1992, CANCER RES, V52, P6525; Kelsell DP, 1996, HUM MOL GENET, V5, P857, DOI 10.1093/hmg/5.6.857; Kerangueven F, 1997, ONCOGENE, V14, P339, DOI 10.1038/sj.onc.1200818; KIRCHWEGER R, 1994, INT J CANCER, V56, P193, DOI 10.1002/ijc.2910560208; KNUDSON AG, 1993, P NATL ACAD SCI USA, V90, P10914, DOI 10.1073/pnas.90.23.10914; KRISHNADATH KK, 1995, EUR J GASTROEN HEPAT, V7, P81; MORI T, 1994, CANCER RES, V54, P1638; NAGAI MA, 1995, CANCER RES, V55, P112; NAKAMURA T, 1994, CANCER-AM CANCER SOC, V73, P1785, DOI 10.1002/1097-0142(19940401)73:7<1785::AID-CNCR2820730703>3.0.CO;2-0; NEIDERACHER D, 1997, GENES CHROM CANC, V18, P181; NESHAT K, 1994, GASTROENTEROLOGY, V106, P1589, DOI 10.1016/0016-5085(94)90415-4; Phelan CM, 1998, CANCER RES, V58, P1004; PHILLIPS N, 1993, INT J CANCER, V54, P85, DOI 10.1002/ijc.2910540115; PIERETTI M, 1995, HUM PATHOL, V26, P393, DOI 10.1016/0046-8177(95)90139-6; Plummer SJ, 1997, ONCOGENE, V14, P2339, DOI 10.1038/sj.onc.1201073; RISK JM, 1994, NAT GENET, V8, P319, DOI 10.1038/ng1294-319; SAITO H, 1993, CANCER RES, V53, P3382; SATO T, 1992, CANCER RES, V52, P1643; SAUNTER ER, 1995, J SURG ONCOL, V58, P269; SAXENA A, 1992, CANCER RES, V52, P6716; SCHULTZ DC, 1996, CANCER RES, V56, P2002; SEIZINGER BR, 1993, NAT GENET, V3, P97, DOI 10.1038/ng0293-97; Stein Hubert J., 1993, Dysphagia, V8, P276, DOI 10.1007/BF01354551; SWIFT A, 1995, BRIT J CANCER, V71, P995, DOI 10.1038/bjc.1995.191; VONBREVERN M, 1998, IN PRESS ONCOGENE; WALES MM, 1995, NAT MED, V1, P570, DOI 10.1038/nm0695-570; Wang TH, 1996, J FORMOS MED ASSOC, V95, P509; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; Wertheim I, 1996, ONCOGENE, V12, P2147; White GRM, 1996, BRIT J CANCER, V74, P863, DOI 10.1038/bjc.1996.449; WRIGHT TA, 1994, EUR J GASTROEN HEPAT, V6, P656, DOI 10.1097/00042737-199408000-00003	63	31	32	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 28	1999	18	4					987	993		10.1038/sj.onc.1202371	http://dx.doi.org/10.1038/sj.onc.1202371			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	165FT	10023674				2022-12-25	WOS:000078510600015
J	Joh, T; Hosokawa, Y; Suzuki, R; Takahashi, T; Seto, M				Joh, T; Hosokawa, Y; Suzuki, R; Takahashi, T; Seto, M			Establishment of an inducible expression system of chimeric MLL-LTG9 protein and inhibition of Hox a7, Hox b7 and Hox c9 expression by MLL-LTG9 in 32Dc13 cells	ONCOGENE			English	Article						translocation; 11q23; MLL; LTGB; Hox; leukemogenesis	ACUTE-LEUKEMIA; DROSOPHILA-TRITHORAX; 11Q23 TRANSLOCATIONS; ALL-1 GENE; POLYCOMB; PRODUCTS; MICE; MLL; ABNORMALITIES; HOMOLOG	The MLL (HRX/ALL-1 gene is frequently disrupted in infantile leukemias and therapy-related leukemias and fused to various translocation partner genes, We previously showed that chimeric MLL proteins localize in the nuclei in a fashion similar to that of MLL protein even if the partner gene encodes a cytoplasmic protein and indicated the importance of the IV-terminal portion of MLL common to various MLL translocations, This time we established an inducible expression system for chimeric MLL-LTG9 and truncated N-terminal MLL proteins (MLL-Zf(-)) in 32Dc13 cells. By utilizing this system, we were able to show inhibition of Hox a7, Hox b7 and Hox c9 genes' expression by induced MLL-LTG9 and MLL-Zf(-). Up-regulation of Hox a7, Hox b7 and Hox c9 was observed when 32Dc13 cells were cultured with granulocyte colony stimulating factor (G-CSF) in place of interleukin 3 and induction of MLL-LTG9 and MLL-Zf(-) was shown to suppress this upregulation. At the same time, expression of two mammalian Polycomb group genes, M33 and mel-18, which both reportedly affect Hox genes' expression, was not inhibited by MLL-LTG9 and MLL-Zf(-) induction. These results indicate that MLL has an important effect on the expression of at least some Hox genes in hematopoietic cells and suggest that inhibition of the proper expression of Hox genes by chimeric MLL proteins may dysregulate hematopoietic cell differentiation and proliferation, which then can lead to leukemogenesis.	Aichi Canc Ctr, Res Inst, Lab Chemotherapy, Nagoya, Aichi 4648681, Japan; Aichi Canc Ctr, Res Inst, Immunol Lab, Nagoya, Aichi 4648681, Japan	Aichi Cancer Center; Aichi Cancer Center	Seto, M (corresponding author), Aichi Canc Ctr, Res Inst, Lab Chemotherapy, Nagoya, Aichi 4648681, Japan.			Suzuki, Ritsuro/0000-0002-5974-7614				ABE R, 1984, CANCER GENET CYTOGEN, V13, P121, DOI 10.1016/0165-4608(84)90053-0; Akasaka T, 1996, DEVELOPMENT, V122, P1513; Arakawa H, 1998, P NATL ACAD SCI USA, V95, P4573, DOI 10.1073/pnas.95.8.4573; Core N, 1997, DEVELOPMENT, V124, P721; Corral J, 1996, CELL, V85, P853, DOI 10.1016/S0092-8674(00)81269-6; GU Y, 1992, CELL, V71, P701, DOI 10.1016/0092-8674(92)90603-A; IIDA S, 1993, ONCOGENE, V8, P3085; Joh T, 1997, ONCOGENE, V15, P1681, DOI 10.1038/sj.onc.1201332; Joh T, 1996, ONCOGENE, V13, P1945; KANEKO Y, 1986, BLOOD, V67, P484; Kennison JA, 1995, ANNU REV GENET, V29, P289, DOI 10.1146/annurev.ge.29.120195.001445; Lavau C, 1997, EMBO J, V16, P4226, DOI 10.1093/emboj/16.14.4226; LAWRENCE HJ, 1992, BLOOD, V80, P2445; MA Q, 1993, P NATL ACAD SCI USA, V90, P6350, DOI 10.1073/pnas.90.13.6350; MAVILIO F, 1989, ONCOGENE, V4, P301; NAKAMURA T, 1993, P NATL ACAD SCI USA, V90, P4631, DOI 10.1073/pnas.90.10.4631; PUI CH, 1989, NEW ENGL J MED, V321, P136, DOI 10.1056/NEJM198907203210302; PUI CH, 1991, BLOOD, V77, P440; SAUVAGEAU G, 1994, P NATL ACAD SCI USA, V91, P12223, DOI 10.1073/pnas.91.25.12223; SCHICHMAN SA, 1994, P NATL ACAD SCI USA, V91, P6236, DOI 10.1073/pnas.91.13.6236; SIMON J, 1992, DEVELOPMENT, V114, P493; TKACHUK DC, 1992, CELL, V71, P691, DOI 10.1016/0092-8674(92)90602-9; TRENT JM, 1989, CYTOGENET CELL GENET, V51, P533, DOI 10.1159/000132807; Waring PM, 1997, CURR TOP MICROBIOL, V220, P1; YAMAMOTO K, 1993, ONCOGENE, V8, P479; YAMAMOTO K, 1993, ONCOGENE, V8, P2617; YU BD, 1995, NATURE, V378, P505, DOI 10.1038/378505a0	27	24	25	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 28	1999	18	4					1125	1130		10.1038/sj.onc.1202400	http://dx.doi.org/10.1038/sj.onc.1202400			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	165FT	10023690				2022-12-25	WOS:000078510600031
J	Chavez, RA; Gray, AT; Zhao, BB; Kindler, CH; Mazurek, MJ; Mehta, Y; Forsayeth, JR; Yost, CS				Chavez, RA; Gray, AT; Zhao, BB; Kindler, CH; Mazurek, MJ; Mehta, Y; Forsayeth, JR; Yost, CS			TWIK-2, a new weak inward rectifying member of the tandem pore domain potassium channel family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC ACINAR-CELLS; RECTIFIER K+ CHANNEL; SUBUNIT STOICHIOMETRY; PH	Potassium channels are found in all mammalian cell types, and they perform many distinct functions in both excitable and non-excitable cells. These functions are subserved by several different families of potassium channels distinguishable by primary sequence features as well as by physiological characteristics. Of these families, the tandem pore domain potassium channels are a new and distinct class, primarily distinguished by the presence of two pore-forming domains within a single polypeptide chain. We have cloned a new member of this family, TWIK-2, from a human brain cDNA library. Primary sequence analysis of TWIK-2 shows that it is most closely related to TWIK-1, especially in the pore-forming domains. Northern blot analysis reveals the expression of TWIK-2 in all human tissues assayed except skeletal muscle. Human TWIK-2 expressed heterologously in Xenopus oocytes is a non-inactivating weak inward rectifier with channel properties similar to TWIK-1, Pharmacologically, TWIK-2 channels are distinct from TWIK-1 channels in their response to quinidine, quinine, and barium. TWIK-2 is inhibited by intracellular, but not extracellular, acidification. This new clone reveals the existence of a subfamily in the tandem pore domain potassium channel family with weak inward rectification properties.	Elan Pharmaceut, Menlo Park, CA 94025 USA; Univ Calif San Francisco, Sch Med, Dept Anesthesia & Perioperat Care, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Yost, CS (corresponding author), Univ Calif San Francisco, Sch Med, Dept Anesthesia, 513 Parnassus Ave,Box 0542,Rm S261, San Francisco, CA 94143 USA.			Chavez, Raymond/0000-0002-3006-0325	NIGMS NIH HHS [GM57740, GM51372] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM051372] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Di Stefano A, 1998, CELL PHYSIOL BIOCHEM, V8, P89, DOI 10.1159/000016273; DOUPNIK CA, 1995, CURR OPIN NEUROBIOL, V5, P268, DOI 10.1016/0959-4388(95)80038-7; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; Duprat F, 1997, EMBO J, V16, P5464, DOI 10.1093/emboj/16.17.5464; FICKER E, 1994, SCIENCE, V266, P1068, DOI 10.1126/science.7973666; Fink M, 1998, EMBO J, V17, P3297, DOI 10.1093/emboj/17.12.3297; Fink M, 1996, EMBO J, V15, P6854, DOI 10.1002/j.1460-2075.1996.tb01077.x; GUILLEMARE E, 1995, MOL PHARMACOL, V47, P588; Jegla T, 1997, J NEUROSCI, V17, P32, DOI 10.1523/JNEUROSCI.17-01-00032.1997; KETCHUM KA, 1995, NATURE, V376, P690, DOI 10.1038/376690a0; KIBBLE JD, 1995, AM J PHYSIOL-RENAL, V268, pF778, DOI 10.1152/ajprenal.1995.268.4.F778; Leonoudakis D, 1998, J NEUROSCI, V18, P868; Lesage F, 1996, EMBO J, V15, P6400, DOI 10.1002/j.1460-2075.1996.tb01031.x; Lesage F, 1997, FEBS LETT, V402, P28, DOI 10.1016/S0014-5793(96)01491-3; Lesage F, 1996, EMBO J, V15, P1004, DOI 10.1002/j.1460-2075.1996.tb00437.x; Lesage F, 1996, J BIOL CHEM, V271, P4183; MACKINNON R, 1991, NATURE, V350, P232, DOI 10.1038/350232a0; Salkoff Lawrence, 1997, Pfluegers Archiv European Journal of Physiology, V434, pR79; SCHMID A, 1995, J PHYSIOL-LONDON, V484, P661, DOI 10.1113/jphysiol.1995.sp020694; Schmid A, 1997, J PHYSIOL-LONDON, V504, P259, DOI 10.1111/j.1469-7793.1997.259be.x; Shepard AR, 1997, NUCLEIC ACIDS RES, V25, P3183, DOI 10.1093/nar/25.15.3183; Slawik M, 1996, PFLUG ARCH EUR J PHY, V432, P112, DOI 10.1007/s004240050112; TABEI K, 1995, AM J PHYSIOL-RENAL, V268, pF490, DOI 10.1152/ajprenal.1995.268.3.F490; TAKANASHI H, 1994, J CELL PHYSIOL, V161, P537, DOI 10.1002/jcp.1041610317; Tare M, 1998, J PHYSIOL-LONDON, V506, P303, DOI 10.1111/j.1469-7793.1998.303bw.x; Wei A, 1996, NEUROPHARMACOLOGY, V35, P805, DOI 10.1016/0028-3908(96)00126-8; Yang J, 1995, NEURON, V15, P1441, DOI 10.1016/0896-6273(95)90021-7	28	111	117	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 19	1999	274	12					7887	7892		10.1074/jbc.274.12.7887	http://dx.doi.org/10.1074/jbc.274.12.7887			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	178LU	10075682	hybrid			2022-12-25	WOS:000079268100041
J	Sabo, SL; Lanier, LM; Ikin, AF; Khorkova, O; Sahasrabudhe, S; Greengard, P; Buxbaum, JD				Sabo, SL; Lanier, LM; Ikin, AF; Khorkova, O; Sahasrabudhe, S; Greengard, P; Buxbaum, JD			Regulation of beta-amyloid secretion by FE65, an amyloid protein precursor-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALZHEIMERS-DISEASE; KINASE-C; CYTOPLASMIC DOMAIN; PEPTIDE; CLEAVAGE; TRAFFICKING; PHOSPHORYLATION; INTERNALIZATION; LOCALIZATION; COMPARTMENT	The principal component of Alzheimer's amyloid plaques, A beta, derives from proteolytic processing of the Alzheimer's amyloid protein precursor (APP), FE65 is a brain-enriched protein that binds to APP, Although several laboratories have characterized the APP-FE65 interaction in vitro, the possible relevance of this interaction to Alzheimer's disease has remained unclear. We demonstrate here that APP and FE65 co-localize in the endoplasmic reticulum/Golgi and possibly in endosomes, Moreover, FE65 increases translocation of APP to the cell surface, as well as both alpha APP(s) and A beta secretion. The dramatic (4-fold) FE65-dependent increase in A beta secretion suggests that agents which inhibit the interaction of FE65 with APP might reduce A beta secretion in the brain and therefore be useful for preventing or slowing amyloid plaque formation.	CUNY Mt Sinai Sch Med, Dept Psychiat, Lab Mol Neuropsychiat, New York, NY 10029 USA; CUNY Mt Sinai Sch Med, Dept Neurobiol, Lab Mol Neuropsychiat, New York, NY 10029 USA; Rockefeller Univ, Mol & Cellular Neurosci Lab, New York, NY 10021 USA; Rockefeller Univ, Zachary & Elizabeth M Fisher Ctr, New York, NY 10021 USA; Hoeschst Marion Roussel, Biotechnol Grp, Bridgewater, NJ 08807 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; Rockefeller University; Rockefeller University	Buxbaum, JD (corresponding author), CUNY Mt Sinai Sch Med, Dept Psychiat, Lab Mol Neuropsychiat, New York, NY 10029 USA.		Buxbaum, Joseph D/G-6001-2010	khorkova, olga/0000-0002-1848-2365; Buxbaum, Joseph/0000-0001-8898-8313; Sabo, Shasta/0000-0001-6386-7443	NATIONAL INSTITUTE OF MENTAL HEALTH [T32MH015125] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG009464, R55AG014996, R01AG014996] Funding Source: NIH RePORTER; NIA NIH HHS [AG09464, AG14996] Funding Source: Medline; NIMH NIH HHS [MH15125] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ANDERSON JP, 1991, NEUROSCI LETT, V128, P126, DOI 10.1016/0304-3940(91)90775-O; Borg JP, 1996, MOL CELL BIOL, V16, P6229; BORK P, 1995, CELL, V80, P693, DOI 10.1016/0092-8674(95)90347-X; BORK P, 1994, TRENDS BIOCHEM SCI, V19, P531, DOI 10.1016/0968-0004(94)90053-1; Bressler SL, 1996, HUM MOL GENET, V5, P1589, DOI 10.1093/hmg/5.10.1589; BUXBAUM JD, 1990, P NATL ACAD SCI USA, V87, P6003, DOI 10.1073/pnas.87.15.6003; BUXBAUM JD, 1994, P NATL ACAD SCI USA, V91, P4489, DOI 10.1073/pnas.91.10.4489; BUXBAUM JD, 1993, P NATL ACAD SCI USA, V90, P9195, DOI 10.1073/pnas.90.19.9195; CAPORASO GL, 1994, J NEUROSCI, V14, P3122; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; Desdouits F, 1996, J BIOL CHEM, V271, P24670, DOI 10.1074/jbc.271.40.24670; DESTROOPER B, 1993, J CELL BIOL, V121, P295, DOI 10.1083/jcb.121.2.295; DUILIO A, 1991, NUCLEIC ACIDS RES, V19, P5269, DOI 10.1093/nar/19.19.5269; Ermekova KS, 1997, J BIOL CHEM, V272, P32869, DOI 10.1074/jbc.272.52.32869; ESCH FS, 1990, SCIENCE, V248, P1122, DOI 10.1126/science.2111583; Fiore F, 1995, J BIOL CHEM, V270, P30853, DOI 10.1074/jbc.270.52.30853; GABUZDA D, 1993, J NEUROCHEM, V61, P2326, DOI 10.1111/j.1471-4159.1993.tb07479.x; Gertler FB, 1996, CELL, V87, P227, DOI 10.1016/S0092-8674(00)81341-0; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; GOLDGABER D, 1987, SCIENCE, V235, P877, DOI 10.1126/science.3810169; GRAHAM J, 1994, ANAL BIOCHEM, V220, P367, DOI 10.1006/abio.1994.1351; Guenette SY, 1996, P NATL ACAD SCI USA, V93, P10832, DOI 10.1073/pnas.93.20.10832; HAASS C, 1993, J BIOL CHEM, V268, P3021; HAASS C, 1992, NATURE, V357, P500, DOI 10.1038/357500a0; HAASS C, 1994, P NATL ACAD SCI USA, V91, P1564, DOI 10.1073/pnas.91.4.1564; Hardy J, 1997, TRENDS NEUROSCI, V20, P154, DOI 10.1016/S0166-2236(96)01030-2; HUNG AY, 1993, J BIOL CHEM, V268, P22959; JACOBSEN JS, 1994, J BIOL CHEM, V269, P8376; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; Koo EH, 1996, J CELL SCI, V109, P991; KOO EH, 1994, J BIOL CHEM, V269, P17386; LAI A, 1995, J BIOL CHEM, V270, P3565, DOI 10.1074/jbc.270.8.3565; MANNAERTS GP, 1982, BIOCHEM J, V204, P17, DOI 10.1042/bj2040017; MASTERS CL, 1985, P NATL ACAD SCI USA, V82, P4245, DOI 10.1073/pnas.82.12.4245; MU FT, 1995, J BIOL CHEM, V270, P13503, DOI 10.1074/jbc.270.22.13503; REFOLO LM, 1995, J NEUROSCI RES, V40, P694, DOI 10.1002/jnr.490400515; SAMBAMURTI K, 1992, ANN NY ACAD SCI, V674, P118, DOI 10.1111/j.1749-6632.1992.tb27481.x; SEUBERT P, 1992, NATURE, V359, P325, DOI 10.1038/359325a0; SILVA OABDE, 1993, NEUROSCIENCE, V57, P873, DOI 10.1016/0306-4522(93)90031-A; Thinakaran G, 1998, NEUROBIOL DIS, V4, P438, DOI 10.1006/nbdi.1998.0171; TOMIMOTO H, 1995, ACTA NEUROPATHOL, V90, P608; Ullrich O, 1996, J CELL BIOL, V135, P913, DOI 10.1083/jcb.135.4.913; WEIDEMANN A, 1989, CELL, V57, P115, DOI 10.1016/0092-8674(89)90177-3; Yamazaki T, 1996, J CELL SCI, V109, P999; Zambrano N, 1997, J BIOL CHEM, V272, P6399, DOI 10.1074/jbc.272.10.6399	45	189	192	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 19	1999	274	12					7952	7957		10.1074/jbc.274.12.7952	http://dx.doi.org/10.1074/jbc.274.12.7952			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	178LU	10075692	hybrid			2022-12-25	WOS:000079268100051
J	Saiki, Y; El-Hayek, R; Ikemoto, N				Saiki, Y; El-Hayek, R; Ikemoto, N			Involvement of the Glu(724)-Pro(760) region of the dihydropyridine receptor II-III loop in skeletal muscle-type excitation-contraction coupling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							JUNCTIONAL FOOT PROTEIN; INDUCED CA2+ RELEASE; SARCOPLASMIC-RETICULUM; CALCIUM-RELEASE; TRANSVERSE TUBULE; CA-2+ RELEASE; DEPOLARIZATION; CHANNEL; ACTIVATION; FIBERS	Our previous study (El-Hayek, R., Antoniu, B,, Wang, J, P,, Hamilton, S, L,, and Ikemoto, N, (1995) J, Biol, Chem, 270, 22116-22118) suggested the hypothesis that skeletal muscle-type excitation-contraction coupling is regulated by two domains (activating and blocking) of the Ii-III loop of the dihydropyridine receptor alpha 1 subunit. We investigated this hypothesis by examining conformational changes in the ryanodine receptor induced by synthetic peptides and by transverse tubular system (T-tubule) depolarization. Peptide A, corresponding to the Thr(671)-Leu(690) region, rapidly changed the ryanodine receptor conformation from a blocked state (low fluorescence of the conformational probe, methyl coumarin acetamide, attached specifically to the ryanodine receptor) to an activated state (high methyl coumarin acetamide fluorescence) as T-tubule depolarization did. Peptide C, corresponding to the Glu(724)-Pro(760) region, blocked both conformational changes induced by peptide A and T-tubule depolarization, Its ability to block peptide A-induced and depolarization-induced activation was considerably impaired by replacing the portion of peptide C corresponding to the Phe(725)-pro(742) region of the loop with cardiac muscle-type sequence. These results are consistent with the model that depolarization-induced activation of excitation-contraction coupling and blocking/repriming are mediated by the peptide A region and the peptide C region (containing the critical phe(725)-Pro(742) sequence) of the II-III loop, respectively.	Boston Biomed Res Inst, Boston, MA 02114 USA; Harvard Univ, Sch Med, Dept Neurol, Boston, MA 02115 USA	Boston Biomedical Research Institute; Harvard University; Harvard Medical School	Ikemoto, N (corresponding author), Boston Biomed Res Inst, 20 Staniford St, Boston, MA 02114 USA.	Ikemoto@bbri.org			NIAMS NIH HHS [AR16922] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR016922] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ASHLEY CC, 1991, Q REV BIOPHYS, V24, P1, DOI 10.1017/S0033583500003267; BLOCK BA, 1988, J CELL BIOL, V107, P2587, DOI 10.1083/jcb.107.6.2587; CIFUENTES ME, 1989, ARCH BIOCHEM BIOPHYS, V273, P554, DOI 10.1016/0003-9861(89)90515-8; El-Hayek R, 1998, BIOCHEMISTRY-US, V37, P7015, DOI 10.1021/bi972907o; ELHAYEK R, 1995, J BIOL CHEM, V270, P15634, DOI 10.1074/jbc.270.26.15634; ELHAYEK R, 1993, BIOPHYS J, V65, P779, DOI 10.1016/S0006-3495(93)81101-9; ELHAYEK R, 1995, J BIOL CHEM, V270, P22116, DOI 10.1074/jbc.270.38.22116; FLEISCHER S, 1989, ANNU REV BIOPHYS BIO, V18, P333, DOI 10.1146/annurev.bb.18.060189.002001; FRANZINIARMSTRONG C, 1995, J MUSCLE RES CELL M, V16, P319, DOI 10.1007/BF00121140; FRANZINIARMSTRONG C, 1994, ANNU REV PHYSIOL, V56, P509, DOI 10.1146/annurev.ph.56.030194.002453; IKEMOTO N, 1994, BIOCHEMISTRY-US, V33, P10961, DOI 10.1021/bi00202a015; Ikemoto N, 1996, FEBS LETT, V394, P330, DOI 10.1016/0014-5793(96)00973-8; IKEMOTO N, 1988, METHOD ENZYMOL, V157, P469; KANG JJ, 1992, BIOCHEMISTRY-US, V31, P3298; LAMB GD, 1990, J PHYSIOL-LONDON, V423, P519, DOI 10.1113/jphysiol.1990.sp018037; LAMB GD, 1990, J PHYSIOL-LONDON, V423, P495, DOI 10.1113/jphysiol.1990.sp018036; Leong P, 1998, J BIOL CHEM, V273, P7791, DOI 10.1074/jbc.273.14.7791; Lu Xiangyang, 1995, Biophysical Journal, V68, pA372; LU XY, 1994, J BIOL CHEM, V269, P6511; MEISSNER G, 1994, ANNU REV PHYSIOL, V56, P485, DOI 10.1146/annurev.ph.56.030194.002413; MELZER W, 1995, BBA-REV BIOMEMBRANES, V1241, P59, DOI 10.1016/0304-4157(94)00014-5; Nakai J, 1998, J BIOL CHEM, V273, P24983, DOI 10.1074/jbc.273.39.24983; Nakai J., 1995, Biophysical Journal, V68, pA14; PALADE P, 1989, J BIOENERG BIOMEMBR, V21, P295, DOI 10.1007/BF00812074; RIOS E, 1992, ANNU REV PHYSIOL, V54, P109, DOI 10.1146/annurev.ph.54.030192.000545; RIOS E, 1991, PHYSIOL REV, V71, P849, DOI 10.1152/physrev.1991.71.3.849; SCHNEIDER MF, 1994, ANNU REV PHYSIOL, V56, P463, DOI 10.1146/annurev.ph.56.030194.002335; TANABE T, 1990, NATURE, V346, P567, DOI 10.1038/346567a0; TANABE T, 1988, NATURE, V336, P134, DOI 10.1038/336134a0; THEVENIN BJM, 1992, EUR J BIOCHEM, V206, P471, DOI 10.1111/j.1432-1033.1992.tb16949.x; WYSKOVSKY W, 1990, EUR J BIOCHEM, V194, P549, DOI 10.1111/j.1432-1033.1990.tb15651.x; YANO M, 1995, J BIOL CHEM, V270, P3017, DOI 10.1074/jbc.270.7.3017	32	28	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	1999	274	12					7825	7832		10.1074/jbc.274.12.7825	http://dx.doi.org/10.1074/jbc.274.12.7825			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	178LU	10075674	hybrid			2022-12-25	WOS:000079268100033
J	Chien, MM; Zahradka, KE; Newell, MK; Freed, JH				Chien, MM; Zahradka, KE; Newell, MK; Freed, JH			Fas-induced B cell apoptosis requires an increase in free cytosolic magnesium as an early event	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINOPHOSPHOLIPID TRANSLOCASE; INTRACELLULAR MAGNESIUM; THYMOCYTE APOPTOSIS; RAT HEPATOCYTES; LYMPHOCYTES; CALCIUM; PHOSPHATIDYLSERINE; ANTIGEN; LIGATION; DEATH	Ligation of the Fas molecule expressed on the surface of a cell initiates multiple signaling pathways that result in the apoptotic death of that cell. We have examined Mg2+ mobilization as well as Ca2+ mobilization in B cells undergoing Fas-initiated apoptosis, Our results indicate that cytosolic levels of free (non-complexed) Mg2+ ([M2+](i)) and Ca2+ ([Ca2+](i)) increase in cells undergoing apoptosis, Furthermore, the percentages of cells mobilizing Mg2+, fragmenting DNA, or externalizing phosphatidylserine (PS) increase in parallel as the concentration of anti-Fas monoclonal antibody is raised. Kinetic analysis suggests that Mg2+ mobilization is an early event in apoptosis, clearly preceding DNA fragmentation and probably occurring prior to externalization of PS as well. The source of Mg2+ that produces the increases in [Mg2+](i) is intracellular and most likely is the mitochondria. Extended pretreatment of B cells with carbonyl cyanide m-chlorophenylhydrazone, an inhibitor of mitochondrial oxidative phosphorylation, produces proportional decreases in the percentage of cells mobilizing Mg2+, fragmenting DNA, and externalizing PS in response to anti-Fas monoclonal antibody treatment. These observations are consistent with the hypothesis that elevated [Mg2+](i) is required for apoptosis. Furthermore, we propose that the increases in [Mg2+](i) function not only as cofactors for Mg2+-dependent endonucleases, but also to facilitate the release of cytochrome c from the mitochondria, which drives many of the post-mitochondrial, caspase-mediated events in apoptotic cells.	Natl Jewish Med & Res Ctr, Dept Med, Div Basic Immunol, Denver, CO 80206 USA; Univ Colorado, Hlth Sci Ctr, Dept Immunol, Denver, CO 80262 USA	National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Freed, JH (corresponding author), Natl Jewish Med & Res Ctr, Dept Med, Div Basic Immunol, 1400 Jackson St, Denver, CO 80206 USA.	freedj@njc.org			NIAID NIH HHS [AI37523, AI33470] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI033470, R15AI133470, R01AI037523] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AULAND ME, 1994, P NATL ACAD SCI USA, V91, P10938, DOI 10.1073/pnas.91.23.10938; BANCHEREAU J, 1994, ANNU REV IMMUNOL, V12, P881, DOI 10.1146/annurev.iy.12.040194.004313; Berridge MJ, 1998, NATURE, V395, P645, DOI 10.1038/27094; BITBOL M, 1987, BIOCHIM BIOPHYS ACTA, V904, P268, DOI 10.1016/0005-2736(87)90376-2; BOND M, 1987, J BIOL CHEM, V262, P15630; Bossy-Wetzel E, 1998, EMBO J, V17, P37, DOI 10.1093/emboj/17.1.37; Bratton DL, 1997, J BIOL CHEM, V272, P26159, DOI 10.1074/jbc.272.42.26159; Cai JY, 1998, BBA-BIOENERGETICS, V1366, P139, DOI 10.1016/S0005-2728(98)00109-1; CHEEK TR, 1989, J CELL SCI, V93, P211; Cittadini A, 1991, Magnes Res, V4, P23; CORKEY BE, 1986, J BIOL CHEM, V261, P2567; Dao T, 1997, J IMMUNOL, V159, P4261; Depraetere V, 1997, Semin Immunol, V9, P93, DOI 10.1006/smim.1997.0062; Eskes R, 1998, J CELL BIOL, V143, P217, DOI 10.1083/jcb.143.1.217; Foote LC, 1996, J IMMUNOL, V157, P1878; GAIDO ML, 1991, J BIOL CHEM, V266, P18580; GARRONE P, 1995, J EXP MED, V182, P1265, DOI 10.1084/jem.182.5.1265; HEATH AW, 1994, EUR J IMMUNOL, V24, P1828, DOI 10.1002/eji.1830240816; JUSTEMENT LB, 1990, NONINVASIVE TECHNIQU, P353; KAWABATA H, 1993, BIOCHEM BIOPH RES CO, V191, P247, DOI 10.1006/bbrc.1993.1209; Khodarev NN, 1996, J IMMUNOL, V156, P922; Kroemer G, 1997, IMMUNOL TODAY, V18, P44, DOI 10.1016/S0167-5699(97)80014-X; LATTANZIO FA, 1991, BIOCHEM BIOPH RES CO, V177, P184, DOI 10.1016/0006-291X(91)91966-G; LI HY, 1993, BIOCHIM BIOPHYS ACTA, V1181, P307, DOI 10.1016/0925-4439(93)90037-2; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; LIU YJ, 1995, IMMUNITY, V2, P239, DOI 10.1016/1074-7613(95)90048-9; LONDON RE, 1991, ANNU REV PHYSIOL, V53, P241, DOI 10.1146/annurev.physiol.53.1.241; MARTIN SJ, 1995, J EXP MED, V182, P1545, DOI 10.1084/jem.182.5.1545; McConkey DJ, 1997, BIOCHEM BIOPH RES CO, V239, P357, DOI 10.1006/bbrc.1997.7409; MIYAWAKI T, 1992, J IMMUNOL, V149, P3753; MORROT G, 1990, FEBS LETT, V266, P29, DOI 10.1016/0014-5793(90)81498-D; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; NEWELL MK, 1993, P NATL ACAD SCI USA, V90, P10459, DOI 10.1073/pnas.90.22.10459; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; NICOTERA P, 1994, PEZ FDN SYM, V5, P97; PATEL T, 1994, J CLIN INVEST, V94, P2183, DOI 10.1172/JCI117579; QUAMME GA, 1993, AM J PHYSIOL, V265, pH281, DOI 10.1152/ajpheart.1993.265.1.H281; RIJKERS GT, 1993, BIOCHEM J, V289, P373, DOI 10.1042/bj2890373; ROTHSTEIN TL, 1995, NATURE, V374, P163, DOI 10.1038/374163a0; SCHATTNER EJ, 1995, J EXP MED, V182, P1557, DOI 10.1084/jem.182.5.1557; SEILIEV AA, 1992, RADIAT ENVIRON BIOPH, V31, P123, DOI 10.1007/BF01211210; SQUIER MKT, 1994, J CELL PHYSIOL, V159, P229, DOI 10.1002/jcp.1041590206; Squier MKT, 1997, J IMMUNOL, V158, P3690; SUN XM, 1994, J BIOL CHEM, V269, P14857; Susin SA, 1997, J EXP MED, V186, P25, DOI 10.1084/jem.186.1.25; VELLA AT, 1995, IMMUNITY, V2, P261, DOI 10.1016/1074-7613(95)90050-0; VERHOVEN B, 1995, J EXP MED, V182, P1597, DOI 10.1084/jem.182.5.1597; Yoshida A, 1998, CANCER RES, V58, P2576	48	48	56	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	1999	274	11					7059	7066		10.1074/jbc.274.11.7059	http://dx.doi.org/10.1074/jbc.274.11.7059			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	175DV	10066762	hybrid			2022-12-25	WOS:000079078400034
J	Lam, MHC; Briggs, LJ; Hu, W; Martin, TJ; Gillespie, MT; Jans, DA				Lam, MHC; Briggs, LJ; Hu, W; Martin, TJ; Gillespie, MT; Jans, DA			Importin beta recognizes parathyroid hormone-related protein with high affinity and mediates its nuclear import in the absence of importin alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; LOCALIZATION SEQUENCE; CYTOKINE INTERLEUKIN-5; BONE-RESORPTION; IN-VITRO; PEPTIDE; SIGNAL; LINE; RECEPTOR; GROWTH	Parathyroid hormone-related protein (PTHrP), expressed in a range of tumors, has endocrine, autocrine/paracrine, and intracrine actions, some of which relate to its ability to localize in the nucleus. Here we show for the first time that extracellularly added human PTHrP (amino acids 1-108) can be taken up specifically by receptor-expressing UMR106.01 osteogenic sarcoma cells and accumulate to quite high levels in the nucleus and nucleolus within 40 min. Quantitation of recognition by the nuclear localization sequence (NLS)-binding importin subunits indicated that in contrast to proteins containing conventional NLSs, PTHrP is recognized exclusively by importin beta and not by importin alpha. The sequence of PTHrP responsible for binding was mapped to amino acids 66-94, which includes an SV40 large tumor-antigen NLS-like sequence, although sequence determinants amino-terminal to this region were also necessary for high affinity binding (apparent dissociation constant of similar to 2 nM for importin beta), Nuclear import of PTHrP was assessed in vitro using purified components, demonstrating that importin beta, together with the GTP-binding protein Ran, was able to mediate efficient nuclear accumulation in the absence of importin alpha, whereas the addition of nuclear transport factor NTF2 reduced transport, The polypeptide ligand PTHrP thus appears to be accumulated in the nucleus/nucleolus through a novel, NLS-dependent nuclear import pathway independent of importin a and perhaps also of NTF2.	Australian Natl Univ, John Curtin Sch Med Res, Div Biochem & Mol Biol, Canberra, ACT 2601, Australia; St Vincents Inst Med Res, Fitzroy, Vic 3065, Australia	Australian National University; John Curtin School of Medical Research; St. Vincent's Institute of Medical Research	Jans, DA (corresponding author), Australian Natl Univ, John Curtin Sch Med Res, Div Biochem & Mol Biol, POB 334, Canberra, ACT 2601, Australia.		Briggs, Lyndall J/A-7549-2011	Jans, David/0000-0001-5115-4745; Gillespie, Matthew/0000-0001-6543-8909				BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Briggs LJ, 1998, J BIOL CHEM, V273, P22745, DOI 10.1074/jbc.273.35.22745; BURTIS WJ, 1992, CLIN CHEM, V38, P2171; Chan CK, 1998, GENE THER, V5, P1204, DOI 10.1038/sj.gt.3300708; Chi NC, 1996, J CELL BIOL, V135, P559, DOI 10.1083/jcb.135.3.559; DASSO M, 1994, EMBO J, V13, P5732, DOI 10.1002/j.1460-2075.1994.tb06911.x; Efthymiadis A, 1997, J BIOL CHEM, V272, P22134, DOI 10.1074/jbc.272.35.22134; Efthymiadis A, 1998, J BIOL CHEM, V273, P1623, DOI 10.1074/jbc.273.3.1623; Fagotto F, 1998, CURR BIOL, V8, P181, DOI 10.1016/S0960-9822(98)70082-X; FENTON AJ, 1991, ENDOCRINOLOGY, V129, P1762, DOI 10.1210/endo-129-4-1762; FENTON AJ, 1991, ENDOCRINOLOGY, V129, P3424, DOI 10.1210/endo-129-6-3424; GOERLICH D, 1995, NATURE, V377, P246; GRILL V, 1991, J CLIN ENDOCR METAB, V73, P1309, DOI 10.1210/jcem-73-6-1309; HAMMONDS RG, 1989, J BIOL CHEM, V264, P14806; Henderson BR, 1997, J MOL BIOL, V274, P693, DOI 10.1006/jmbi.1997.1420; HENDERSON JE, 1995, MOL CELL BIOL, V15, P4064; Hubner S, 1997, J BIOL CHEM, V272, P17191, DOI 10.1074/jbc.272.27.17191; Jans DA, 1998, MED RES REV, V18, P189, DOI 10.1002/(SICI)1098-1128(199807)18:4<189::AID-MED1>3.3.CO;2-Z; Jans DA, 1997, FEBS LETT, V410, P368, DOI 10.1016/S0014-5793(97)00622-4; Jans DA, 1998, BIOESSAYS, V20, P400, DOI 10.1002/(SICI)1521-1878(199805)20:5<400::AID-BIES7>3.0.CO;2-R; Jans DA, 1997, FEBS LETT, V406, P315, DOI 10.1016/S0014-5793(97)00293-7; JANS DA, 1995, BIOCHEM J, V311, P705, DOI 10.1042/bj3110705; JANS DA, 1991, J CELL BIOL, V115, P1203, DOI 10.1083/jcb.115.5.1203; JANS DA, 1994, FASEB J, V8, P841, DOI 10.1096/fasebj.8.11.8070633; KAISER SM, 1992, J BIOL CHEM, V267, P13623; KAISER SM, 1994, MOL ENDOCRINOL, V8, P139, DOI 10.1210/me.8.2.139; Lam MHC, 1997, J CELL PHYSIOL, V173, P433, DOI 10.1002/(SICI)1097-4652(199712)173:3<433::AID-JCP16>3.0.CO;2-C; Maher PA, 1996, J CELL BIOL, V134, P529, DOI 10.1083/jcb.134.2.529; Martin TJ, 1997, J ENDOCRINOL, V154, pS23; MARTIN TJ, 1991, CRIT REV BIOCHEM MOL, V26, P377, DOI 10.3109/10409239109114073; Massfelder T, 1997, P NATL ACAD SCI USA, V94, P13630, DOI 10.1073/pnas.94.25.13630; Michael WM, 1997, EMBO J, V16, P3587, DOI 10.1093/emboj/16.12.3587; MOORE MS, 1994, P NATL ACAD SCI USA, V91, P10212, DOI 10.1073/pnas.91.21.10212; MOSELEY JM, 1995, CRIT REV CL LAB SCI, V32, P299, DOI 10.3109/10408369509084687; MOSELEY JM, 1987, P NATL ACAD SCI USA, V84, P5048, DOI 10.1073/pnas.84.14.5048; OKANO K, 1995, ENDOCRINOLOGY, V136, P1782, DOI 10.1210/en.136.4.1782; PASCHAL BM, 1995, J CELL BIOL, V129, P925, DOI 10.1083/jcb.129.4.925; PEARSON RB, 1993, PROTEIN PHOSPHORYLAT, P265; Philbrick WM, 1996, PHYSIOL REV, V76, P127, DOI 10.1152/physrev.1996.76.1.127; Pollard VW, 1996, CELL, V86, P985, DOI 10.1016/S0092-8674(00)80173-7; REXACH M, 1995, CELL, V83, P683, DOI 10.1016/0092-8674(95)90181-7; Roskams T, 1997, AM J PATHOL, V150, P779; Rout MP, 1997, CELL, V89, P715, DOI 10.1016/S0092-8674(00)80254-8; Stade K, 1997, CELL, V90, P1041, DOI 10.1016/S0092-8674(00)80370-0; Tachibana T, 1996, FEBS LETT, V397, P177, DOI 10.1016/S0014-5793(96)01180-5; Tiganis T, 1997, J BIOL CHEM, V272, P21548, DOI 10.1074/jbc.272.34.21548; WATERS MJ, 1994, P SOC EXP BIOL MED, V206, P216; Xiao CY, 1996, J BIOL CHEM, V271, P6451, DOI 10.1074/jbc.271.11.6451; Xiao CY, 1997, J BIOL CHEM, V272, P22191, DOI 10.1074/jbc.272.35.22191	49	172	175	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 12	1999	274	11					7391	7398		10.1074/jbc.274.11.7391	http://dx.doi.org/10.1074/jbc.274.11.7391			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	175DV	10066803	hybrid			2022-12-25	WOS:000079078400075
J	Pfister, T; Wimmer, E				Pfister, T; Wimmer, E			Characterization of the nucleoside triphosphatase activity of poliovirus protein 2C reveals a mechanism by which guanidine inhibits poliovirus replication	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEGATIVE-STRAND RNA; DNA-BINDING PROTEIN; ESCHERICHIA-COLI; VIRAL-RNA; ATPASE ACTIVITY; POLYPEPTIDE 2C; MEMBRANE PROLIFERATION; HUMAN PAPILLOMAVIRUS; E1 PROTEIN; CELL-FREE	The highly conserved non-structural protein 2C of picornaviruses is involved in viral genome replication and encapsidation and in the rearrangement of intracellular structures. 2C binds RNA, has nucleoside triphosphatase activity, and shares three motifs with superfamily III helicases, Motifs "A" and "B" are involved in nucleotide triphosphate (NTP) binding and hydrolysis, whereas a function for motif "C" has not yet been demonstrated. Poliovirus RNA replication is inhibited by millimolar concentrations of guanidine hydrochloride (GdnHCl). Resistance and dependence to GdnHCl map to 2C, To characterize the nucleoside triphosphatase activity of 2C, we purified poliovirus recombinant 2C fused to glutathione S-transferase (GST-PC) from Escherichia coli. GST-SC hydrolyzed ATP with a K-m of 0.7 mM. Other NTPs, including GTP, competed with ATP for binding to 2C but were poor substrates for hydrolysis, Mutation of conserved residues in motif A and B abolished ATPase activity, as did mutation of the conserved asparagine residue in motif C, an observation indicating the involvement of this motif in ATP hydrolysis, GdnHCl at millimolar concentrations inhibited ATP hydrolysis. Mutations in 2C that confer poliovirus resistant to or dependent on GdnHCl increased the tolerance to GdnHCl up to 100-fold.	SUNY Stony Brook, Dept Mol Genet & Microbiol, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Wimmer, E (corresponding author), SUNY Stony Brook, Dept Mol Genet & Microbiol, Stony Brook, NY 11794 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI015122, R01AI032100, R01AI015122] Funding Source: NIH RePORTER; NIAID NIH HHS [AI3210007, AI1512225] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alberts B., 1994, MOL BIOL CELL; ALDABE R, 1995, BIOCHEM BIOPH RES CO, V206, P64, DOI 10.1006/bbrc.1995.1010; Aldabe R, 1996, J BIOL CHEM, V271, P23134, DOI 10.1074/jbc.271.38.23134; BALTIMORE D, 1963, P NATL ACAD SCI USA, V49, P843, DOI 10.1073/pnas.49.6.843; Banerjee R, 1997, J VIROL, V71, P9570, DOI 10.1128/JVI.71.12.9570-9578.1997; BARCO A, 1995, EMBO J, V14, P3349, DOI 10.1002/j.1460-2075.1995.tb07341.x; Barton DJ, 1997, J VIROL, V71, P8482, DOI 10.1128/JVI.71.11.8482-8489.1997; BIENZ K, 1992, J VIROL, V66, P2740, DOI 10.1128/JVI.66.5.2740-2747.1992; BIENZ K, 1983, VIROLOGY, V131, P39, DOI 10.1016/0042-6822(83)90531-7; BIENZ K, 1987, VIROLOGY, V160, P220, DOI 10.1016/0042-6822(87)90063-8; BIENZ K, 1980, VIROLOGY, V100, P390, DOI 10.1016/0042-6822(80)90530-9; BIENZ K, 1990, J VIROL, V64, P1156, DOI 10.1128/JVI.64.3.1156-1163.1990; BLANCO L, 1989, J BIOL CHEM, V264, P8935; Brodsky JL, 1998, J VIROL, V72, P5329, DOI 10.1128/JVI.72.7.5329-5334.1998; CALIGUIRI LA, 1974, VIROLOGY, V58, P526, DOI 10.1016/0042-6822(74)90086-5; CALIGUIRI LA, 1970, VIROLOGY, V42, P112, DOI 10.1016/0042-6822(70)90243-6; CALIGUIRI LA, 1973, SELECTIVE INHIBITORS, P257; CAO XM, 1993, J VIROL, V67, P5572, DOI 10.1128/JVI.67.9.5572-5578.1993; Castellino AM, 1997, J VIROL, V71, P7549, DOI 10.1128/JVI.71.10.7549-7559.1997; CHO MW, 1994, VIROLOGY, V202, P129, DOI 10.1006/viro.1994.1329; CHO MW, 1993, J VIROL, V67, P3010, DOI 10.1128/JVI.67.6.3010-3018.1993; CROWTHER D, 1961, VIROLOGY, V15, P65, DOI 10.1016/0042-6822(61)90078-2; Cuconati A, 1998, J VIROL, V72, P6456, DOI 10.1128/JVI.72.8.6456-6464.1998; Cuconati A, 1998, J VIROL, V72, P1297, DOI 10.1128/JVI.72.2.1297-1307.1998; DALES S, 1965, VIROLOGY, V26, P379, DOI 10.1016/0042-6822(65)90001-2; DATTA AK, 1995, NUCLEIC ACIDS RES, V23, P4530, DOI 10.1093/nar/23.21.4530; Dekker J, 1997, EMBO J, V16, P1455, DOI 10.1093/emboj/16.6.1455; DOEDENS JR, 1995, EMBO J, V14, P894, DOI 10.1002/j.1460-2075.1995.tb07071.x; Duggal R, 1997, P NATL ACAD SCI USA, V94, P13786, DOI 10.1073/pnas.94.25.13786; ECHEVERRI AC, 1995, VIROLOGY, V208, P540, DOI 10.1006/viro.1995.1185; Egger D, 1996, J VIROL, V70, P8675, DOI 10.1128/JVI.70.12.8675-8683.1996; ETCHISON D, 1981, VIROLOGY, V111, P33, DOI 10.1016/0042-6822(81)90651-6; FERNANDEZ A, 1995, NUCLEIC ACIDS RES, V23, P1327, DOI 10.1093/nar/23.8.1327; Georgopoulos C.M., 1994, BIOL HEAT SHOCK PROT; GORBALENYA AE, 1989, NUCLEIC ACIDS RES, V17, P8413, DOI 10.1093/nar/17.21.8413; GORBALENYA AE, 1990, FEBS LETT, V262, P145, DOI 10.1016/0014-5793(90)80175-I; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; Guenther B, 1997, CELL, V91, P335, DOI 10.1016/S0092-8674(00)80417-1; Hu JM, 1997, EMBO J, V16, P59, DOI 10.1093/emboj/16.1.59; HUGHES FJ, 1993, NUCLEIC ACIDS RES, V21, P5817, DOI 10.1093/nar/21.25.5817; Jenkins O, 1996, J GEN VIROL, V77, P1805, DOI 10.1099/0022-1317-77-8-1805; JINDAL HK, 1994, J BIOL CHEM, V269, P3283; Kadare G, 1997, J VIROL, V71, P2583; KITAMURA N, 1981, NATURE, V291, P547, DOI 10.1038/291547a0; Kusov YY, 1998, ARCH VIROL, V143, P931, DOI 10.1007/s007050050343; LAMA J, 1992, J BIOL CHEM, V267, P15932; LI JP, 1988, J VIROL, V62, P4016, DOI 10.1128/JVI.62.11.4016-4021.1988; LI JP, 1990, J VIROL, V64, P1102, DOI 10.1128/JVI.64.3.1102-1107.1990; Mansky KC, 1997, J VIROL, V71, P7600, DOI 10.1128/JVI.71.10.7600-7608.1997; MELNICK JL, 1996, FIELDS VIROLOGY, V1, P655; MIRZAYAN C, 1994, VIROLOGY, V199, P176, DOI 10.1006/viro.1994.1110; MIRZAYAN C, 1992, VIROLOGY, V189, P547, DOI 10.1016/0042-6822(92)90578-D; MOLLA A, 1991, SCIENCE, V254, P1647, DOI 10.1126/science.1661029; Nickel W, 1997, FEBS LETT, V413, P395, DOI 10.1016/S0014-5793(97)00939-3; Noble S, 1997, J VIROL, V71, P2182, DOI 10.1128/JVI.71.3.2182-2191.1997; Paul AV, 1998, NATURE, V393, P280, DOI 10.1038/30529; PAUL AV, 1994, VIROLOGY, V199, P188, DOI 10.1006/viro.1994.1111; PFISTER T, 1996, KEYST S VIR GEN REPL; PINCUS SE, 1987, VIROLOGY, V157, P83, DOI 10.1016/0042-6822(87)90316-3; PINCUS SE, 1986, J VIROL, V57, P638, DOI 10.1128/JVI.57.2.638-646.1986; PINCUS SE, 1986, J VIROL, V60, P793, DOI 10.1128/JVI.60.2.793-796.1986; PLOTCH SJ, 1995, J VIROL, V69, P7169, DOI 10.1128/JVI.69.11.7169-7179.1995; RIGHTSEL WA, 1961, SCIENCE, V134, P558, DOI 10.1126/science.134.3478.558; RODRIGUEZ PL, 1995, J BIOL CHEM, V270, P10105, DOI 10.1074/jbc.270.17.10105; RODRIGUEZ PL, 1993, J BIOL CHEM, V268, P8105; ROY P, 1970, J VIROL, V6, P604, DOI 10.1128/JVI.6.5.604-609.1970; SALAS M, 1991, ANNU REV BIOCHEM, V60, P39, DOI 10.1146/annurev.bi.60.070191.000351; Sambrook J., 2002, MOL CLONING LAB MANU; Schlegel A, 1996, J VIROL, V70, P6576, DOI 10.1128/JVI.70.10.6576-6588.1996; TAKEGAMI T, 1983, VIROLOGY, V128, P33, DOI 10.1016/0042-6822(83)90316-1; TAKEGAMI T, 1983, P NATL ACAD SCI-BIOL, V80, P7447, DOI 10.1073/pnas.80.24.7447; TETERINA NL, 1992, J GEN VIROL, V73, P1977, DOI 10.1099/0022-1317-73-8-1977; Teterina NL, 1997, J VIROL, V71, P8962, DOI 10.1128/JVI.71.12.8962-8972.1997; TOLSKAYA EA, 1994, J MOL BIOL, V236, P1310, DOI 10.1016/0022-2836(94)90060-4; Vance LM, 1997, J VIROL, V71, P8759, DOI 10.1128/JVI.71.11.8759-8765.1997; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WIMMER E, 1993, ANNU REV GENET, V27, P353, DOI 10.1146/annurev.ge.27.120193.002033; Woodman PG, 1997, BBA-MOL CELL RES, V1357, P155, DOI 10.1016/S0167-4889(97)00039-6; ZIJDERVELD DC, 1994, J VIROL, V68, P1158, DOI 10.1128/JVI.68.2.1158-1164.1994	79	132	135	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 12	1999	274	11					6992	7001		10.1074/jbc.274.11.6992	http://dx.doi.org/10.1074/jbc.274.11.6992			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	175DV	10066753	hybrid			2022-12-25	WOS:000079078400025
J	Rossig, L; Fichtlscherer, B; Breitschopf, K; Haendeler, J; Zeiher, AM; Mulsch, A; Dimmeler, S				Rossig, L; Fichtlscherer, B; Breitschopf, K; Haendeler, J; Zeiher, AM; Mulsch, A; Dimmeler, S			Nitric oxide inhibits caspase-3 by S-nitrosation in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED APOPTOSIS; INTERLEUKIN-1-BETA-CONVERTING ENZYME; IN-VIVO; NITROSYLATION; PROTEASE; DEATH	In cultured human endothelial cells, physiological levels of NO prevent apoptosis and interfere with the activation of the caspase cascade. In vitro data have demonstrated that NO inhibits the activity of caspase-3 by S-nitrosation of the enzyme. Here we present evidence for the in vivo occurrence and functional relevance of this novel antiapoptotic mechanism. To demonstrate that the cysteine residue Cys-163 of caspase-3 is S-nitrosated, cells were transfected with the Myc-tagged p17 subunit of caspase-3. After incubation of the transfected cells with different NO donors, Myc-tagged p17 was immunoprecipitated with anti-Myc antibody. S-Nitroso-thiol was detected in the immunoprecipitate by electron spin resonance spectroscopy after liberation and spin trapping of NO by N-methyl-D-glucamine-dithiocarbamate-iron complex. Transfection of cells with a p17 mutant, where the essential Cys-163 was mutated into alanine, completely prevented S-nitrosation of the enzyme. As a functional correlate, in human umbilical vein endothelial cells the NO donors sodium nitroprusside or PAPA NONOate (50 mu M) significantly reduced the increase in caspase-3-like activity induced by overexpressing caspase-3 by 75 and 70%, respectively. When human umbilical vein endothelial cells were cotransfected with P-galactosidase, morphological analysis of stained cells revealed that cell death induction by overexpression of caspase-3 was completely suppressed in the presence of sodium nitroprusside, PAPA NONOate, or S-nitroso-L-cysteine (50 mu M). Thus, NO supplied by exogenous NO donors serves in vivo as an antiapoptotic regulator of caspase activity via S-nitrosation of the Cys-163 residue of caspase-3.	Univ Frankfurt, Dept Internal Med 4, D-60590 Frankfurt, Germany; Univ Frankfurt, Inst Cardiovasc Physiol, D-60590 Frankfurt, Germany	Goethe University Frankfurt; Goethe University Frankfurt	Dimmeler, S (corresponding author), Univ Frankfurt, Dept Internal Med 4, Theodor Stern Kai 7, D-60590 Frankfurt, Germany.			Dimmeler, Stefanie/0000-0002-1045-2436; Haendeler, Judith/0000-0001-8507-4540				ALBINA JE, 1993, J IMMUNOL, V150, P5080; Arnelle DR, 1997, NITRIC OXIDE-BIOL CH, V1, P56, DOI 10.1006/niox.1996.0107; Burney S, 1997, NITRIC OXIDE-BIOL CH, V1, P130, DOI 10.1006/niox.1996.0114; Dimmeler S, 1997, NITRIC OXIDE-BIOL CH, V1, P275, DOI 10.1006/niox.1997.0133; Dimmeler S, 1997, J EXP MED, V185, P601, DOI 10.1084/jem.185.4.601; Dimmeler S, 1998, CELL GROWTH DIFFER, V9, P415; Dimmeler S, 1998, CIRC RES, V83, P334, DOI 10.1161/01.RES.83.3.334; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; Estevez AG, 1998, J NEUROSCI, V18, P3708; GENG YJ, 1995, AM J PATHOL, V147, P251; Haendeler J, 1997, NITRIC OXIDE-BIOL CH, V1, P282, DOI 10.1006/niox.1997.0134; Haunstetter A, 1998, CIRC RES, V82, P1111, DOI 10.1161/01.RES.82.11.1111; Hausladen A, 1996, CELL, V86, P719, DOI 10.1016/S0092-8674(00)80147-6; Hebestreit H, 1998, J EXP MED, V187, P415, DOI 10.1084/jem.187.3.415; Kim YM, 1997, J BIOL CHEM, V272, P1402, DOI 10.1074/jbc.272.2.1402; LAI CS, 1994, FEBS LETT, V345, P120, DOI 10.1016/0014-5793(94)00422-6; Li JR, 1997, BIOCHEM BIOPH RES CO, V240, P419, DOI 10.1006/bbrc.1997.7672; Mannick JB, 1997, J BIOL CHEM, V272, P24125, DOI 10.1074/jbc.272.39.24125; MANNICK JB, 1994, CELL, V79, P1137, DOI 10.1016/0092-8674(94)90005-1; Messmer UK, 1996, BIOCHEM J, V319, P299, DOI 10.1042/bj3190299; Mikoyan VD, 1997, BBA-GEN SUBJECTS, V1336, P225, DOI 10.1016/S0304-4165(97)00032-9; MONCADA S, 1993, NEW ENGL J MED, V329, P2002; Moroi M, 1998, J CLIN INVEST, V101, P1225, DOI 10.1172/JCI1293; MULSCH A, 1995, CIRCULATION, V92, P1876, DOI 10.1161/01.CIR.92.7.1876; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; NGUYEN T, 1992, P NATL ACAD SCI USA, V89, P3030, DOI 10.1073/pnas.89.7.3030; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Nicotera P, 1997, TRENDS PHARMACOL SCI, V18, P189, DOI 10.1016/S0165-6147(97)90619-2; Shen YH, 1998, FEBS LETT, V433, P125, DOI 10.1016/S0014-5793(98)00844-8; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P444, DOI 10.1073/pnas.89.1.444; STAMLER JS, 1994, CELL, V78, P931, DOI 10.1016/0092-8674(94)90269-0; Tsuchiya K, 1996, FREE RADICAL BIO MED, V21, P733, DOI 10.1016/0891-5849(96)00221-3; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1	33	358	366	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 12	1999	274	11					6823	6826		10.1074/jbc.274.11.6823	http://dx.doi.org/10.1074/jbc.274.11.6823			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	175DV	10066732	hybrid			2022-12-25	WOS:000079078400004
J	Gregoire, JM; Romeo, PH				Gregoire, JM; Romeo, PH			T-cell expression of the human GATA-3 gene is regulated by a non-lineage-specific silencer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR GATA-3; TISSUE-SPECIFIC EXPRESSION; LOOP-HELIX PROTEINS; DNA-BINDING PROTEIN; TRANSGENIC MICE; LYMPHOCYTE DEVELOPMENT; GLOBIN GENE; ELEMENTS; HEMATOPOIESIS; RECEPTOR	The GATA-3 transcription factor is required for development of the T-cell lineage and Th2 cytokine gene expression in CD4 T-cells, We have mapped the DNase-I-hypersensitive (HS) regions of the human GATA-3 gene in T-cells and non-T-cells and studied their transcriptional activities. HS I-III, located 5' from the transcriptional initiation site, were found in hematopoietic and non-hematopoietic cells, whereas HS IV-VII, located 3' from the transcriptional start site, were exclusively observed in T-cells, Among these hypersensitive sites, two transcriptional control elements were found, one in the first intron of the GATA-3 gene and the other between 8.3 and 5.9 kilobases 5' from the GATA-3 transcriptional initiation site. The first intron acted as a strong transcriptional activator in a position-dependent manner and with no cell-type specificity, The upstream regulatory element could confer T-cell specificity to the GATA-3 promoter activity, and analysis of this region revealed a 707-base pair silencer that drastically inhibited GATA-3 promoter activity in non-T-cells. Two CAG-GTG; E-boxes, located at the 5'- and 3'-ends of the silencer, were necessary for this silencer activity. The 3'-CAGGTG E-box could bind USF proteins, the ubiquitous repressor ZEE, or the basic helix-loop-helix proteins E2A and HEB, and we showed that a competition between ZEE and EBA/HEB proteins is involved in the silencer activity.	Hop Henri Mondor, INSERM, U474, F-94010 Creteil, France	Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm)	Romeo, PH (corresponding author), Hop Henri Mondor, INSERM, U474, F-94010 Creteil, France.		Romeo, Paul-Henri/L-5989-2017	Romeo, Paul-Henri/0000-0002-8294-0367				Arnone MI, 1997, DEVELOPMENT, V124, P1851; Ausubel FM, 1989, CURRENT PROTOCOLS MO, V1-3; BIASSONI R, 1993, EUR J IMMUNOL, V23, P1083, DOI 10.1002/eji.1830230516; BONIFER C, 1990, EMBO J, V9, P2843, DOI 10.1002/j.1460-2075.1990.tb07473.x; COONEY AJ, 1992, MOL CELL BIOL, V12, P4153, DOI 10.1128/MCB.12.9.4153; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; Galvin KM, 1997, MOL CELL BIOL, V17, P3723, DOI 10.1128/MCB.17.7.3723; GENETTA T, 1994, MOL CELL BIOL, V14, P6153, DOI 10.1128/MCB.14.9.6153; GEORGE KM, 1994, DEVELOPMENT, V120, P2673; GORAYA TY, 1994, NUCLEIC ACIDS RES, V22, P1194, DOI 10.1093/nar/22.7.1194; GROSVELD F, 1987, CELL, V51, P975, DOI 10.1016/0092-8674(87)90584-8; HSU HL, 1994, MOL CELL BIOL, V14, P1256, DOI 10.1128/MCB.14.2.1256; ISHIHARA H, 1995, J BIOCHEM-TOKYO, V3, P499; JOULIN V, 1991, EMBO J, V10, P1809, DOI 10.1002/j.1460-2075.1991.tb07706.x; LABASTIE MC, 1994, GENOMICS, V21, P1, DOI 10.1006/geno.1994.1217; Lieuw KH, 1997, DEV BIOL, V188, P1, DOI 10.1006/dbio.1997.8575; LIU ZY, 1994, DEV BIOL, V166, P159, DOI 10.1006/dbio.1994.1304; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; Markowitz AJ, 1995, AM J PHYSIOL-GASTR L, V269, pG925, DOI 10.1152/ajpgi.1995.269.6.G925; MARTIN DIK, 1990, NATURE, V344, P444, DOI 10.1038/344444a0; Meng AM, 1997, P NATL ACAD SCI USA, V94, P6267, DOI 10.1073/pnas.94.12.6267; MOUTHON MA, 1993, BLOOD, V81, P647; MURRELL AM, 1995, ONCOGENE, V10, P631; ORKIN SH, 1992, BLOOD, V80, P575; PANDOLFI PP, 1995, NAT GENET, V11, P40, DOI 10.1038/ng0995-40; PEVNY L, 1991, NATURE, V349, P257, DOI 10.1038/349257a0; Postigo AA, 1997, EMBO J, V16, P3924, DOI 10.1093/emboj/16.13.3924; Postigo AA, 1997, EMBO J, V16, P3935, DOI 10.1093/emboj/16.13.3935; ROMEO PH, 1990, NATURE, V344, P447, DOI 10.1038/344447a0; ROSENTHAL N, 1987, METHOD ENZYMOL, V152, P704; SAKSELA K, 1993, MOL CELL BIOL, V13, P3698, DOI 10.1128/MCB.13.6.3698; SAWADA S, 1993, MOL CELL BIOL, V13, P5620, DOI 10.1128/MCB.13.9.5620; SAWADA S, 1994, CELL, V77, P917, DOI 10.1016/0092-8674(94)90140-6; SCHRODER FH, 1989, PROSTATE, P17; SEKIDO R, 1994, MOL CELL BIOL, V14, P5692, DOI 10.1128/MCB.14.9.5692; Shivdasani RA, 1996, BLOOD, V87, P4025, DOI 10.1182/blood.V87.10.4025.bloodjournal87104025; Ting CN, 1996, NATURE, V384, P474, DOI 10.1038/384474a0; TSAI FY, 1994, NATURE, V371, P221, DOI 10.1038/371221a0; TSAI SF, 1989, NATURE, V339, P446, DOI 10.1038/339446a0; VITALE M, 1994, BIOCHEM BIOPH RES CO, V204, P413, DOI 10.1006/bbrc.1994.2474; WINOTO A, 1989, CELL, V59, P649, DOI 10.1016/0092-8674(89)90010-X; YAMAMOTO M, 1990, GENE DEV, V4, P1650, DOI 10.1101/gad.4.10.1650; Zheng WP, 1997, CELL, V89, P587, DOI 10.1016/S0092-8674(00)80240-8; Zhuang Y, 1996, MOL CELL BIOL, V16, P2898	44	61	66	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	1999	274	10					6567	6578		10.1074/jbc.274.10.6567	http://dx.doi.org/10.1074/jbc.274.10.6567			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172BQ	10037751	hybrid			2022-12-25	WOS:000078902800073
J	Kida, M; Souri, M; Yamamoto, M; Saito, H; Ichinose, A				Kida, M; Souri, M; Yamamoto, M; Saito, H; Ichinose, A			Transcriptional regulation of cell type-specific expression of the TATA-less A subunit gene for human coagulation factor XIII	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE TRANSGLUTAMINASE GENE; AMINO-ACID SEQUENCE; ZINC-FINGER GENE; BLOOD-COAGULATION; B-SUBUNIT; RESPONSE ELEMENT; HUMAN-MONOCYTES; FACTOR GATA-1; A-SUBUNIT; IIB GENE	To study the mechanism of gene regulation for coagulation factor WI A subunit (FXIIIA), we characterized its 5'-flanking region using a monocytoid (U937), a megakaryocytoid (MEG-01), and other cells. Our results confirmed that U937 and MEG-01 contained FXIIIA mRNA. A tentative transcription start site was determined to be 76 bases upstream from the first exon/intron boundary. Reporter gene assays revealed that a 5'-fragment (-2331 to +75) was sufficient to support basal expression in U937 and MEG-01 but not in the other cells. Deletion analysis confined a minimal promoter sequence from -114 to +75. DNase footprinting, electrophoretic mobility shift, and reporter gene assays demonstrated that promoter elements for a myeloid-enriched transcription factor (MZF-1-like protein) and two ubiquitous transcription factors (NF-1 and SP-1) in this region were important for the basal FXIII expression. It was also revealed that an upstream region (-806 to -290) had enhancer activity in MEG-01 but silencer activity in U937. DNA sequences for binding of myeloid-enriched factors (GATA-1 and Ets-1) were recognized in this region, and the GATA-1 element was found to be responsible for the enhancer activity. These transcription factors play a major role in the cell type-specific expression of FXIIIA, which differs from other transglutaminases.	Yamagata Univ, Sch Med, Dept Mol Pathol Biochem & Biol, Yamagata 9909585, Japan; Univ Tsukuba, Sch Med, Dept Mol Dev Biol, Tsukuba, Ibaraki 305, Japan; Nagoya Univ, Sch Med, Dept Med 1, Nagoya, Aichi 466, Japan	Yamagata University; University of Tsukuba; Nagoya University	Ichinose, A (corresponding author), Yamagata Univ, Sch Med, Dept Mol Pathol Biochem & Biol, Iida Nishi 2-2-2, Yamagata 9909585, Japan.	aichinos@med.id.yamagata-u.ac.jp	Yamamoto, Masayuki/A-4873-2010	Yamamoto, Masayuki/0000-0002-9073-9436				Adany R, 1996, THROMB HAEMOSTASIS, V76, P74; ADANY R, 1988, J CLIN PATHOL, V41, P49, DOI 10.1136/jcp.41.1.49; ADANY R, 1985, EUR J CELL BIOL, V38, P171; Bastian LS, 1996, J BIOL CHEM, V271, P18554, DOI 10.1074/jbc.271.31.18554; Block KL, 1996, BLOOD, V88, P2071, DOI 10.1182/blood.V88.6.2071.bloodjournal8862071; BOARD PG, 1988, CYTOGENET CELL GENET, V48, P25, DOI 10.1159/000132580; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; BUTTICE G, 1993, J BIOL CHEM, V268, P7196; Deveaux S, 1996, BLOOD, V87, P4678, DOI 10.1182/blood.V87.11.4678.bloodjournal87114678; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Garlatti M, 1996, J BIOL CHEM, V271, P32629, DOI 10.1074/jbc.271.51.32629; GREENBERG CS, 1991, FASEB J, V5, P3071, DOI 10.1096/fasebj.5.15.1683845; GRUNDMANN U, 1986, P NATL ACAD SCI USA, V83, P8024, DOI 10.1073/pnas.83.21.8024; HENRIKSSON P, 1985, J CLIN INVEST, V76, P528, DOI 10.1172/JCI112002; HO KC, 1992, J BIOL CHEM, V267, P12660; HROMAS R, 1991, J BIOL CHEM, V266, P14183; ICHINOSE A, 1986, BIOCHEMISTRY-US, V25, P4633, DOI 10.1021/bi00364a027; Ichinose A, 1998, BRIT J HAEMATOL, V101, P264, DOI 10.1046/j.1365-2141.1998.00698.x; ICHINOSE A, 1986, BIOCHEMISTRY-US, V25, P6900, DOI 10.1021/bi00370a025; ICHINOSE A, 1988, P NATL ACAD SCI USA, V85, P5829, DOI 10.1073/pnas.85.16.5829; ICHINOSE A, 1990, J BIOL CHEM, V265, P13411; ICHINOSE A, 1994, HAEMOSTASIS THROMBOS, P531; ITO E, 1993, NATURE, V362, P466, DOI 10.1038/362466a0; Izumi T, 1998, THROMB HAEMOSTASIS, V79, P479; KACZMAREK E, 1995, BBA-PROTEIN STRUCT M, V1247, P127, DOI 10.1016/0167-4838(94)00167-F; Kaetsu H, 1996, J BIOCHEM-TOKYO, V119, P961; KIESSELBACH TH, 1972, ANN NY ACAD SCI, V202, P318, DOI 10.1111/j.1749-6632.1972.tb16344.x; KRADIN RL, 1987, BLOOD, V69, P778; Lee JH, 1996, J BIOL CHEM, V271, P4561; LEMARCHANDEL V, 1993, MOL CELL BIOL, V13, P668, DOI 10.1128/MCB.13.1.668; Lorand L, 1980, Prog Hemost Thromb, V5, P245; Lu S, 1997, P NATL ACAD SCI USA, V94, P4692, DOI 10.1073/pnas.94.9.4692; LU S, 1995, J BIOL CHEM, V270, P9748, DOI 10.1074/jbc.270.17.9748; Mariniello L, 1995, J BIOL CHEM, V270, P31358, DOI 10.1074/jbc.270.52.31358; MORRIS JF, 1995, BLOOD, V86, P3640; MORRIS JF, 1994, MOL CELL BIOL, V14, P1786, DOI 10.1128/MCB.14.3.1786; MUSZBEK L, 1985, THROMB RES, V37, P401, DOI 10.1016/0049-3848(85)90069-6; NAGY JA, 1986, BLOOD, V68, P1272; Nagy L, 1996, J BIOL CHEM, V271, P4355; PAN JL, 1993, J BIOL CHEM, V268, P22600; POLYMEROPOULOS MH, 1991, NUCLEIC ACIDS RES, V19, P4306, DOI 10.1093/nar/19.15.4306-a; POON MC, 1989, J CLIN INVEST, V84, P787, DOI 10.1172/JCI114237; Prandini MH, 1996, BLOOD, V88, P2062, DOI 10.1182/blood.V88.6.2062.bloodjournal8862062; SCHWARTZ ML, 1973, J BIOL CHEM, V248, P1395; Takahashi N, 1998, BLOOD, V91, P2830, DOI 10.1182/blood.V91.8.2830.2830_2830_2838; THACHER SM, 1985, CELL, V40, P685, DOI 10.1016/0092-8674(85)90217-X; TRIMBLE CL, 1992, VIRCHOWS ARCH A, V420, P513, DOI 10.1007/BF01600256; TSAI SF, 1991, GENE DEV, V5, P919, DOI 10.1101/gad.5.6.919; WEISBERG LJ, 1987, BLOOD, V70, P579; WEISBERG LJ, 1987, J CLIN INVEST, V79, P649, DOI 10.1172/JCI112862	50	29	29	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	1999	274	10					6138	6147		10.1074/jbc.274.10.6138	http://dx.doi.org/10.1074/jbc.274.10.6138			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172BQ	10037697	hybrid			2022-12-25	WOS:000078902800019
J	Fukuhara, S; Murga, C; Zohar, M; Igishi, T; Gutkind, JS				Fukuhara, S; Murga, C; Zohar, M; Igishi, T; Gutkind, JS			A novel PDZ domain containing guanine nucleotide exchange factor links heterotrimeric G proteins to Rho	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VAV PROTOONCOGENE PRODUCT; GTP-BINDING PROTEIN; PLECKSTRIN HOMOLOGY DOMAIN; DBL ONCOGENE PRODUCT; NIH 3T3 CELLS; ALPHA-SUBUNIT; SIGNAL-TRANSDUCTION; TYROSINE PHOSPHORYLATION; CELLULAR-TRANSFORMATION; ACTIN CYTOSKELETON	Small GTP-binding proteins of the Rho family play a critical role in signal transduction. However, there is still very limited information on how they are activated by cell surface receptors. Here, we used a consensus sequence for Dbl domains of Rho guanine nucleotide exchange factors (GEFs) to search DNA data bases, and identified a novel human GEF for Rho-related GTPases harboring structural features indicative of its possible regulatory mechanism(s). This protein contained a tandem DH/PH domain closely related to those of Rho-specific GEFs, a PDZ domain, a proline-rich domain, and an area of homology to Lsc, p115-RhoGEF, and a Drosophila RhoGEF that was termed Lsc-homology (LH) domain. This novel molecule, designated PDZ-RhoGEF, activated biological and biochemical pathways specific for Rho, and activation of these pathways required an intact DH and PH domain. However, the PDZ domain was dispensable for these functions, and mutants lacking the LH domain were more active, suggesting a negative regulatory role for the LII domain. A search for additional molecules exhibiting an LH domain revealed a limited homology with the catalytic region of a newly identified GTPase-activating protein for heterotrimeric G proteins, RGS14. This prompted us to investigate whether PDZ-RhoGEF could interact with representative members of each G protein family We found that PDZ-RhoGEF was able to form, in vivo, stable complexes with two members of the G alpha(12) family, G alpha(12) and G alpha(13) and that this interaction was mediated by the LR domain. Furthermore, we obtained evidence to suggest that PDZ-Rho-GEF mediates the activation of Rho by G alpha(12) and G alpha(13). Together, these findings suggest the existence of a novel mechanism whereby the large family of cell surface receptors that transmit signals through heterotrimeric G proteins activate Rho-dependent pathways: by stimulating the activity of members of the G alpha(12) family which, in turn, activate an exchange factor acting on Rho.	NIDCR, NIH, Oral & Pharyngeal Canc Branch, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	Gutkind, JS (corresponding author), NIDCR, NIH, Oral & Pharyngeal Canc Branch, 30 Convent Dr,Bldg 30,Rm 212, Bethesda, MD 20892 USA.		Gutkind, J. Silvio/A-1053-2009; Gutkind, J. Silvio/J-1201-2016; Murga, Cristina/E-1965-2014	Gutkind, J. Silvio/0000-0002-5150-4482; Murga, Cristina/0000-0002-8964-4077				AKTORIES K, 1989, TRENDS PHARMACOL SCI, V10, P415, DOI 10.1016/0165-6147(89)90191-0; An SZ, 1997, BIOCHEM BIOPH RES CO, V231, P619, DOI 10.1006/bbrc.1997.6150; ARAGAY AM, 1995, J BIOL CHEM, V270, P20073, DOI 10.1074/jbc.270.34.20073; Barrett K, 1997, CELL, V91, P905, DOI 10.1016/S0092-8674(00)80482-1; Berman DM, 1998, J BIOL CHEM, V273, P1269, DOI 10.1074/jbc.273.3.1269; BIRNBAUMER L, 1995, J RECEPT SIGNAL TR R, V15, P213; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BONFINI L, 1992, SCIENCE, V255, P603, DOI 10.1126/science.1736363; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BUHL AM, 1995, J BIOL CHEM, V270, P24631, DOI 10.1074/jbc.270.42.24631; Bustelo XR, 1996, CRIT REV ONCOGENESIS, V7, P65, DOI 10.1615/CritRevOncog.v7.i1-2.50; BUSTELO XR, 1992, SCIENCE, V256, P1196, DOI 10.1126/science.256.5060.1196; CHO KO, 1992, NEURON, V9, P929, DOI 10.1016/0896-6273(92)90245-9; Collins LR, 1997, ONCOGENE, V15, P595, DOI 10.1038/sj.onc.1201220; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; COSO OA, 1995, J BIOL CHEM, V270, P5620, DOI 10.1074/jbc.270.10.5620; COSTA M, 1994, CELL, V76, P1075, DOI 10.1016/0092-8674(94)90384-0; Crespo P, 1997, NATURE, V385, P169, DOI 10.1038/385169a0; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; Dhanasekaran N, 1996, CELL SIGNAL, V8, P235, DOI 10.1016/0898-6568(96)00048-4; Fanning AS, 1996, CURR BIOL, V6, P1385, DOI 10.1016/S0960-9822(96)00737-3; Fromm C, 1997, P NATL ACAD SCI USA, V94, P10098, DOI 10.1073/pnas.94.19.10098; Glaven JA, 1996, J BIOL CHEM, V271, P27374, DOI 10.1074/jbc.271.44.27374; Gohla A, 1998, J BIOL CHEM, V273, P4653, DOI 10.1074/jbc.273.8.4653; Gutkind JS, 1998, J BIOL CHEM, V273, P1839, DOI 10.1074/jbc.273.4.1839; HABETS GGM, 1995, ONCOGENE, V10, P1371; Hacker U, 1998, GENE DEV, V12, P274, DOI 10.1101/gad.12.2.274; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; HART MJ, 1994, J BIOL CHEM, V269, P62; Hart MJ, 1996, J BIOL CHEM, V271, P25452, DOI 10.1074/jbc.271.41.25452; HART MJ, 1991, NATURE, V354, P311, DOI 10.1038/354311a0; Hart MJ, 1998, SCIENCE, V280, P2112, DOI 10.1126/science.280.5372.2112; Hecht JH, 1996, J CELL BIOL, V135, P1071, DOI 10.1083/jcb.135.4.1071; HERMOUET S, 1991, P NATL ACAD SCI USA, V88, P10455, DOI 10.1073/pnas.88.23.10455; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; HORII Y, 1994, EMBO J, V13, P4776, DOI 10.1002/j.1460-2075.1994.tb06803.x; Hotchin NA, 1996, CANCER SURV, V27, P311; KALINEC G, 1992, MOL CELL BIOL, V12, P4687, DOI 10.1128/MCB.12.10.4687; Kozasa T, 1998, SCIENCE, V280, P2109, DOI 10.1126/science.280.5372.2109; LAMARCHE N, 1994, TRENDS GENET, V10, P436, DOI 10.1016/0168-9525(94)90114-7; LAMBRIGHT DG, 1994, NATURE, V369, P621, DOI 10.1038/369621a0; Lemmon MA, 1996, CELL, V85, P621, DOI 10.1016/S0092-8674(00)81022-3; MARGOLIS B, 1992, NATURE, V356, P71, DOI 10.1038/356071a0; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MARSHALL M, 1995, MOL REPROD DEV, V42, P493, DOI 10.1002/mrd.1080420418; Michiels F, 1997, J CELL BIOL, V137, P387, DOI 10.1083/jcb.137.2.387; MUSACCHIO A, 1993, TRENDS BIOCHEM SCI, V18, P343, DOI 10.1016/0968-0004(93)90071-T; Narumiya S, 1997, FEBS LETT, V410, P68, DOI 10.1016/S0014-5793(97)00317-7; Narumiya S, 1996, J BIOCHEM-TOKYO, V120, P215; OFFERMANNS S, 1994, P NATL ACAD SCI USA, V91, P504, DOI 10.1073/pnas.91.2.504; PARKS S, 1991, CELL, V64, P447, DOI 10.1016/0092-8674(91)90652-F; PATERSON HF, 1990, J CELL BIOL, V111, P1001, DOI 10.1083/jcb.111.3.1001; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; SCHLESSINGER J, 1993, TRENDS BIOCHEM SCI, V18, P273, DOI 10.1016/0968-0004(93)90031-H; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; Shaw G, 1996, BIOESSAYS, V18, P35, DOI 10.1002/bies.950180109; SHOU C, 1992, NATURE, V358, P351, DOI 10.1038/358351a0; Snow BE, 1997, BIOCHEM BIOPH RES CO, V233, P770, DOI 10.1006/bbrc.1997.6537; SRIVASTAVA SK, 1986, P NATL ACAD SCI USA, V83, P8868, DOI 10.1073/pnas.83.23.8868; STRATHMANN MP, 1991, P NATL ACAD SCI USA, V88, P5582, DOI 10.1073/pnas.88.13.5582; Tapon N, 1997, CURR OPIN CELL BIOL, V9, P86, DOI 10.1016/S0955-0674(97)80156-1; Teramoto H, 1997, J BIOL CHEM, V272, P10751; Teramoto H, 1996, J BIOL CHEM, V271, P27225, DOI 10.1074/jbc.271.44.27225; VanAelst L, 1997, GENE DEV, V11, P2295, DOI 10.1101/gad.11.18.2295; Whitehead IP, 1997, BBA-REV CANCER, V1332, pF1, DOI 10.1016/S0304-419X(96)00040-6; Whitehead IP, 1996, J BIOL CHEM, V271, P18643, DOI 10.1074/jbc.271.31.18643; XU NZ, 1993, P NATL ACAD SCI USA, V90, P6741, DOI 10.1073/pnas.90.14.6741; XU NZ, 1994, BIOCHEM BIOPH RES CO, V201, P603, DOI 10.1006/bbrc.1994.1744	70	327	333	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 26	1999	274	9					5868	5879		10.1074/jbc.274.9.5868	http://dx.doi.org/10.1074/jbc.274.9.5868			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	170KG	10026210	hybrid			2022-12-25	WOS:000078804400081
J	Watowich, SS; Liu, KD; Xie, XL; Lai, SY; Mikami, A; Longmore, GD; Goldsmith, MA				Watowich, SS; Liu, KD; Xie, XL; Lai, SY; Mikami, A; Longmore, GD; Goldsmith, MA			Oligomerization and scaffolding functions of the erythropoietin receptor cytoplasmic tail	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEVERE COMBINED IMMUNODEFICIENCY; TYROSINE KINASE DOMAIN; DNA-BINDING ACTIVITY; SIGNAL-TRANSDUCTION; BETA-CHAIN; STAT5 ACTIVATION; EPO RECEPTOR; CELL-PROLIFERATION; GAMMA(C) SUBUNIT; PROTEIN HORMONE	Signal transduction by the erythropoietin receptor (EPOR) is activated by ligand-mediated receptor homodimerization. However, the relationship between extracellular and intracellular domain oligomerization remains poorly understood. To assess the requirements for dimerization of receptor cytoplasmic sequences for signaling, we overexpressed mutant EPORs in combination with wild-type (WT) EPOR to drive formation of heterodimeric (i.e. WT-mutant) receptor complexes. Dimerization of the membrane proximal portion of the EPOR cytoplasmic region was found to be critical for the initiation of mitogenic signaling. However, dimerization of the entire EPOR cytoplasmic region was not required. To examine this process more closely, we generated chimeras between the intracellular and transmembrane portions of the EPOR and the extracellular domains of the interleukin-2 receptor beta and gamma(c), chains. These chimeras allowed us to assess more precisely the signaling role of each receptor chain because only heterodimers of WT and mutant receptor chimeras form in the presence of interleukin-2. Coexpression studies demonstrated that a functional receptor complex requires the membrane-proximal region of each receptor subunit in the oligomer to permit activation of JAK2 but only one membrane-distal tail to activate STAT5 and to support cell proliferation. Thus, this study defines key relationships involved in the assembly and activation of the EPOR signal transduction complex which may be applicable to other homodimeric cytokine receptors.	Gladstone Inst Virol & Immunol, San Francisco, CA 94141 USA; Univ Texas, MD Anderson Cancer Ctr, Dept Immunol, Houston, TX 77030 USA; Univ Calif San Francisco, Sch Med, Dept Med, San Francisco, CA 94143 USA; Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Cell Biol, St Louis, MO 63110 USA	University of California System; University of California San Francisco; The J David Gladstone Institutes; University of Texas System; UTMD Anderson Cancer Center; University of California System; University of California San Francisco; Washington University (WUSTL); Washington University (WUSTL)	Goldsmith, MA (corresponding author), Gladstone Inst Virol & Immunol, POB 419100, San Francisco, CA 94141 USA.	mgoldsmith@gladstane.ucsf.edu		Lai, Stephen/0000-0001-8301-7286; Watowich, Stephanie/0000-0003-1969-659X	NCI NIH HHS [CA-77447, R01 CA077447-03, R01 CA077447-02] Funding Source: Medline; NHLBI NIH HHS [HL32262, P01 HL032262] Funding Source: Medline; NIGMS NIH HHS [R01 GM054351, GM-54351] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA077447] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL032262] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054351] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AZAM M, 1995, EMBO J, V14, P1402, DOI 10.1002/j.1460-2075.1995.tb07126.x; Barber DL, 1997, BLOOD, V89, P55, DOI 10.1182/blood.V89.1.55.55_55_64; BARBER DL, 1994, MOL CELL BIOL, V14, P2257, DOI 10.1128/MCB.14.4.2257; Bauer JH, 1998, J BIOL CHEM, V273, P9255, DOI 10.1074/jbc.273.15.9255; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; Chin H, 1996, BLOOD, V88, P4415, DOI 10.1182/blood.V88.12.4415.bloodjournal88124415; COSMAN D, 1990, TRENDS BIOCHEM SCI, V15, P265, DOI 10.1016/0968-0004(90)90051-C; DAMEN JE, 1995, J BIOL CHEM, V270, P23402, DOI 10.1074/jbc.270.40.23402; DAMEN JE, 1995, EMBO J, V14, P5557, DOI 10.1002/j.1460-2075.1995.tb00243.x; DANDREA AD, 1991, MOL CELL BIOL, V11, P1980, DOI 10.1128/MCB.11.4.1980; DEXTER TM, 1980, J EXP MED, V152, P1036, DOI 10.1084/jem.152.4.1036; Endo TA, 1997, NATURE, V387, P921, DOI 10.1038/43213; Gaffen Sarah L., 1998, P73; Gaffen SL, 1996, J BIOL CHEM, V271, P21381, DOI 10.1074/jbc.271.35.21381; GAFFEN SL, 1995, P NATL ACAD SCI USA, V92, P7192, DOI 10.1073/pnas.92.16.7192; Gobert S, 1996, EMBO J, V15, P2434, DOI 10.1002/j.1460-2075.1996.tb00601.x; GOLDSMITH MA, 1995, J BIOL CHEM, V270, P21729, DOI 10.1074/jbc.270.37.21729; HONEGGER AM, 1990, MOL CELL BIOL, V10, P4035, DOI 10.1128/MCB.10.8.4035; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; Ihle JN, 1995, ADV IMMUNOL, V60, P1, DOI 10.1016/S0065-2776(08)60582-9; Klingmuller U, 1996, P NATL ACAD SCI USA, V93, P8324, DOI 10.1073/pnas.93.16.8324; KLINGMULLER U, 1995, CELL, V80, P729, DOI 10.1016/0092-8674(95)90351-8; KRANTZ SB, 1991, BLOOD, V77, P419; Lai SY, 1997, J CLIN INVEST, V99, P169, DOI 10.1172/JCI119144; Lai SY, 1996, P NATL ACAD SCI USA, V93, P231, DOI 10.1073/pnas.93.1.231; LATCHMAN DS, 1993, PRACTICAL APPROACH S, P1; Leonard WJ, 1996, ANNU REV MED, V47, P229; Lin CS, 1996, GENE DEV, V10, P154, DOI 10.1101/gad.10.2.154; Lin JX, 1996, J BIOL CHEM, V271, P10738, DOI 10.1074/jbc.271.18.10738; Liu KD, 1997, CURR BIOL, V7, P817, DOI 10.1016/S0960-9822(06)00369-1; Livnah O, 1996, SCIENCE, V273, P464, DOI 10.1126/science.273.5274.464; Livnah O, 1998, NAT STRUCT BIOL, V5, P993, DOI 10.1038/2965; LONGMORE GD, 1991, CELL, V67, P1089, DOI 10.1016/0092-8674(91)90286-8; Matsumoto A, 1997, BLOOD, V89, P3148, DOI 10.1182/blood.V89.9.3148; MIURA O, 1993, MOL CELL BIOL, V13, P1788, DOI 10.1128/MCB.13.3.1788; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; Mohammadi M, 1996, CELL, V86, P577, DOI 10.1016/S0092-8674(00)80131-2; MUI ALF, 1995, EMBO J, V14, P1166, DOI 10.1002/j.1460-2075.1995.tb07100.x; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; Naka T, 1997, NATURE, V387, P924, DOI 10.1038/43219; Nakamura N, 1996, J BIOL CHEM, V271, P19483, DOI 10.1074/jbc.271.32.19483; NAKAMURA Y, 1994, NATURE, V369, P330, DOI 10.1038/369330a0; NELSON BH, 1994, NATURE, V369, P333, DOI 10.1038/369333a0; PHARR PN, 1993, P NATL ACAD SCI USA, V90, P938, DOI 10.1073/pnas.90.3.938; Philo JS, 1996, BIOCHEMISTRY-US, V35, P1681, DOI 10.1021/bi9524272; SAKAI I, 1995, J BIOL CHEM, V270, P18420, DOI 10.1074/jbc.270.31.18420; Starr R, 1997, NATURE, V387, P917, DOI 10.1038/43206; Tarr K, 1997, J BIOL CHEM, V272, P9099; Tilbrook PA, 1997, EMBO J, V16, P1610, DOI 10.1093/emboj/16.7.1610; WATOWICH SS, 1994, MOL CELL BIOL, V14, P3535, DOI 10.1128/MCB.14.6.3535; WATOWICH SS, 1992, P NATL ACAD SCI USA, V89, P2140, DOI 10.1073/pnas.89.6.2140; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; Wrighton NC, 1996, SCIENCE, V273, P458, DOI 10.1126/science.273.5274.458; WU H, 1995, CELL, V83, P59, DOI 10.1016/0092-8674(95)90234-1; YOSHIMURA A, 1990, NATURE, V348, P647, DOI 10.1038/348647a0; YOSHIMURA A, 1995, EMBO J, V14, P2816, DOI 10.1002/j.1460-2075.1995.tb07281.x	57	24	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 26	1999	274	9					5415	5421		10.1074/jbc.274.9.5415	http://dx.doi.org/10.1074/jbc.274.9.5415			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	170KG	10026152	Green Accepted, hybrid			2022-12-25	WOS:000078804400023
J	Wu, LT; Chen, P; Hwang, JJ; Barsky, LW; Weinberg, KI; Jong, A; Starnes, VA				Wu, LT; Chen, P; Hwang, JJ; Barsky, LW; Weinberg, KI; Jong, A; Starnes, VA			RNA antisense abrogation of MAT1 induces G(1) phase arrest and triggers apoptosis in aortic smooth muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE-ACTIVATING KINASE; RETINOBLASTOMA GENE-PRODUCT; TRANSCRIPTION FACTOR TFIIH; FIBROBLAST GROWTH-FACTOR; HUMAN OSTEOSARCOMA CELLS; RING FINGER PROTEIN; D-TYPE CYCLINS; DNA-REPAIR; NEOINTIMA FORMATION; CATALYTIC SUBUNIT	The human MAT1 gene (menage a trois I) is an assembly factor and a targeting subunit of cyclin-dependent kinase (CDK)-activating kinase. The novel mechanisms by which MAT1 forms an active CDH-activating kinase and determines substrate specificity of CDK7-cyclin H are involved in the cell cycle, DNA repair, and transcription. Hyperplasia of vascular smooth muscle cells (SMC) is a fundamental pathologic feature of luminal narrowing in vascular occlusive diseases, and nothing is yet known regarding the cell cycle phase specificity of the MAT1 gene in its involvement in SMC proliferation. To investigate such novel regulatory pathways, MAT1 expression was abrogated by retrovirus-mediated gene transfer of antisense MAT1 RNA in cultured rat aortic SMCs. We show that abrogation of MAT1 expression retards SMC proliferation and inhibits cell activation from a nonproliferative state. Furthermore, we have demonstrated that these effects are due to G(1) phase arrest and apoptotic cell death. Our studies indicate a link between cell cycle control and apoptosis and reveal a potential mechanism for coupling the regulation of MAT1 with G(1) exit and prevention of apoptosis.	Univ So Calif, Sch Med, Childrens Hosp Los Angeles, Res Inst,Div Cardiothorac Surg, Los Angeles, CA 90027 USA; Univ So Calif, Sch Med, Childrens Hosp Los Angeles, Res Inst,Div Res Immunol,BMT, Los Angeles, CA 90027 USA; Univ So Calif, Sch Med, Childrens Hosp Los Angeles, Res Inst,Div Hematol Oncol, Los Angeles, CA 90027 USA; Univ So Calif, Sch Med, Dept Biochem & Mol Biol, Los Angeles, CA 90033 USA	Children's Hospital Los Angeles; University of Southern California; Children's Hospital Los Angeles; University of Southern California; Children's Hospital Los Angeles; University of Southern California; University of Southern California	Wu, LT (corresponding author), Univ So Calif, Sch Med, Childrens Hosp Los Angeles, Res Inst,Div Cardiothorac Surg, Smith Res Tower,MS 103,4650 Sunset Blvd, Los Angeles, CA 90027 USA.	lingtaow@hsc.usc.edu						BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; BILLINGHAM ME, 1994, CLIN TRANSPLANT, V8, P289; CHALUT C, 1994, BIOESSAYS, V16, P651, DOI 10.1002/bies.950160910; CHANG MW, 1995, SCIENCE, V267, P518, DOI 10.1126/science.7824950; COMPTON MM, 1992, CANCER METAST REV, V11, P105, DOI 10.1007/BF00048058; DEVAULT A, 1995, EMBO J, V14, P5027, DOI 10.1002/j.1460-2075.1995.tb00185.x; DRAPKIN R, 1994, TRENDS BIOCHEM SCI, V19, P504, DOI 10.1016/0968-0004(94)90139-2; Drapkin R, 1996, P NATL ACAD SCI USA, V93, P6488, DOI 10.1073/pnas.93.13.6488; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FESQUET D, 1993, EMBO J, V12, P3111, DOI 10.1002/j.1460-2075.1993.tb05980.x; FISHER RP, 1995, CELL, V83, P47, DOI 10.1016/0092-8674(95)90233-3; FISHER RP, 1994, CELL, V78, P713, DOI 10.1016/0092-8674(94)90535-5; FOTEDAR R, 1995, MOL CELL BIOL, V15, P932; Fox JC, 1996, J BIOL CHEM, V271, P12578, DOI 10.1074/jbc.271.21.12578; Geary RL, 1996, ARTERIOSCL THROM VAS, V16, P34, DOI 10.1161/01.ATV.16.1.34; Gibbons GH, 1996, SCIENCE, V272, P689, DOI 10.1126/science.272.5262.689; GOODRICH JA, 1994, CELL, V77, P145, DOI 10.1016/0092-8674(94)90242-9; GORCZYCA W, 1993, CANCER RES, V53, P3186; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; Hwang JJ, 1996, J VIROL, V70, P8138, DOI 10.1128/JVI.70.11.8138-8141.1996; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; KATO J, 1993, GENE DEV, V7, P331; Ko LJ, 1997, MOL CELL BIOL, V17, P7220, DOI 10.1128/MCB.17.12.7220; KREK W, 1991, EMBO J, V10, P3331, DOI 10.1002/j.1460-2075.1991.tb04897.x; LI CJ, 1995, SCIENCE, V268, P429, DOI 10.1126/science.7716549; Martinez AM, 1997, EMBO J, V16, P343, DOI 10.1093/emboj/16.2.343; MIANO JM, 1993, ARTERIOSCLER THROMB, V13, P211, DOI 10.1161/01.ATV.13.2.211; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; MORISHITA R, 1993, P NATL ACAD SCI USA, V90, P8474, DOI 10.1073/pnas.90.18.8474; Nasmyth K, 1996, SCIENCE, V274, P1643, DOI 10.1126/science.274.5293.1643; Nigg EA, 1996, CURR OPIN CELL BIOL, V8, P312, DOI 10.1016/S0955-0674(96)80003-2; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; Peter ME, 1997, P NATL ACAD SCI USA, V94, P12736, DOI 10.1073/pnas.94.24.12736; POON RYC, 1994, J CELL SCI, V107, P2789; POON RYC, 1993, EMBO J, V12, P3123, DOI 10.1002/j.1460-2075.1993.tb05981.x; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; RAINES EW, 1993, BRIT HEART J, V69, pS30; Reardon JT, 1996, P NATL ACAD SCI USA, V93, P6482, DOI 10.1073/pnas.93.13.6482; REKHTER M, 1993, ARTERIOSCLER THROMB, V13, P609, DOI 10.1161/01.ATV.13.4.609; Rossignol M, 1997, EMBO J, V16, P1628, DOI 10.1093/emboj/16.7.1628; ROY R, 1994, CELL, V79, P1093, DOI 10.1016/0092-8674(94)90039-6; SCHWARTZ SM, 1995, CIRC RES, V77, P445, DOI 10.1161/01.RES.77.3.445; SERIZAWA H, 1995, NATURE, V374, P280, DOI 10.1038/374280a0; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SHI L, 1994, SCIENCE, V263, P1143, DOI 10.1126/science.8108732; SHIEKHATTAR R, 1995, NATURE, V374, P283, DOI 10.1038/374283a0; Smith RC, 1997, CIRCULATION, V96, P1899, DOI 10.1161/01.CIR.96.6.1899; SOLOMON MJ, 1993, EMBO J, V12, P3133, DOI 10.1002/j.1460-2075.1993.tb05982.x; TASSAN JP, 1995, EMBO J, V14, P5608, DOI 10.1002/j.1460-2075.1995.tb00248.x; Vaux DL, 1996, P NATL ACAD SCI USA, V93, P2239, DOI 10.1073/pnas.93.6.2239; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; WU LT, 1994, ONCOL REP, V1, P705; WU LT, 1994, ONCOGENE, V9, P2089; WU LT, 1993, INT J ONCOL, V3, P859; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; WYLLIE AH, 1984, J PATHOL, V142, P66; YAMADA T, 1995, HEART VESSELS, V10, P41, DOI 10.1007/BF01745076; Yang ZY, 1996, P NATL ACAD SCI USA, V93, P7905, DOI 10.1073/pnas.93.15.7905; Yankulov KY, 1997, EMBO J, V16, P1638, DOI 10.1093/emboj/16.7.1638; YASUDA T, 1995, J NEUROSCI RES, V40, P306, DOI 10.1002/jnr.490400304; Ye KQ, 1998, P NATL ACAD SCI USA, V95, P1601, DOI 10.1073/pnas.95.4.1601; Yee A, 1996, J BIOL CHEM, V271, P471, DOI 10.1074/jbc.271.1.471; YEE A, 1995, CANCER RES, V55, P6058; Zhu NL, 1997, CIRCULATION, V96, P628	67	23	27	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 26	1999	274	9					5564	5572		10.1074/jbc.274.9.5564	http://dx.doi.org/10.1074/jbc.274.9.5564			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	170KG	10026172	hybrid			2022-12-25	WOS:000078804400043
J	Zhu, A; Haller, S; Li, H; Chaudhuri, A; Blancher, A; Suyama, K				Zhu, A; Haller, S; Li, H; Chaudhuri, A; Blancher, A; Suyama, K			Use of RhD fusion protein expressed on K562 cell surface in the study of molecular basis for D antigenic epitopes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLOOD-GROUP ANTIGEN; PLASMODIUM-VIVAX; POLYPEPTIDES; CDNA; GLYCOPROTEIN; PHENOTYPES; RECEPTOR; SUBUNITS; REGION	The human D antigens, one of the most clinically important blood groups, are presented by RhD protein with a putative 12 transmembrane topology. To understand the molecular basis for the complex antigenic profile of RhD protein, we expressed a series of RhD fusion proteins using different portions of Duffy protein as a tag in erythroleukemic K562 cells. Because the reactivity of monoclonal anti-RhD antibody, LOR15C9, depends mainly on the sequence coded by exon 7 of RhD, we altered DNA sequence corresponding to the amino acid residues 323-331(A) and 350-354(B) in the exon 7. The mutation in region B resulted in a severe reduction in LOR15C9 binding by flow cytometry analysis, suggesting that region B may play an important role in constituting antigen epitopes recognized by LOR15C9, On the other hand, a slight decrease in the antibody binding was observed for the region A mutant, suggesting that the intracellularly located region A may elicit a long distance effect on the formation of exofacial antigen epitopes, In addition, using various monoclonal. antibodies against RhD, we compared the antigenic profile of expressed RhD fusion protein with that of endogenous RhD in K562 cells as well as in erythrocytes.	New York Blood Ctr, Lindsley F Kimball Res Inst, New York, NY 10021 USA; Univ Toulouse 3, Hop Purpan, Immunogenet Mol Lab, F-31059 Toulouse, France	New York Blood Center; CHU de Toulouse; Universite de Toulouse; Universite Toulouse III - Paul Sabatier	Zhu, A (corresponding author), New York Blood Ctr, Lindsley F Kimball Res Inst, 310 E 67 St, New York, NY 10021 USA.							Apoil PA, 1997, BRIT J HAEMATOL, V98, P365, DOI 10.1046/j.1365-2141.1997.2183041.x; Avent ND, 1996, J BIOL CHEM, V271, P14233, DOI 10.1074/jbc.271.24.14233; BLANCHER A, 1997, RHESUS SYSTEM MOL BI, P147; Chang TY, 1998, BLOOD, V91, P3066, DOI 10.1182/blood.V91.8.3066.3066_3066_3078; CHAUDHURI A, 1993, P NATL ACAD SCI USA, V90, P10793, DOI 10.1073/pnas.90.22.10793; CHAUDHURI A, 1994, J BIOL CHEM, V269, P7835; CHERIFZAHAR B, 1991, HUM GENET, V86, P398, DOI 10.1007/BF00201843; Chitnis CE, 1996, J EXP MED, V184, P1531, DOI 10.1084/jem.184.4.1531; EYERS SAC, 1994, J BIOL CHEM, V269, P6417; HARTELSCHENK S, 1992, J BIOL CHEM, V267, P5569; HERMAND P, 1993, BLOOD, V82, P669; Huang C H, 1997, Curr Opin Hematol, V4, P94; LOMAS C, 1993, TRANSFUSION MED, V3, P67, DOI 10.1111/j.1365-3148.1993.tb00106.x; MOURO I, 1994, BLOOD, V83, P1129, DOI 10.1182/blood.V83.4.1129.bloodjournal8341129; NUNOKI K, 1994, J BIOL CHEM, V269, P24138; RAJASEKARAN AK, 1994, MOL BIOL CELL, V5, P1093, DOI 10.1091/mbc.5.10.1093; RIDGWELL K, 1992, BIOCHEM J, V287, P223, DOI 10.1042/bj2870223; Roubinet F, 1996, TRANSFUS CLIN BIOL, V3, P247, DOI 10.1016/S1246-7820(96)80004-8; ROUILLAC C, 1995, BLOOD, V85, P2937, DOI 10.1182/blood.V85.10.2937.bloodjournal85102937; Scott M, 1996, TRANSFUS CLIN BIOL, V3, P333, DOI 10.1016/S1246-7820(96)80040-1; Smythe JS, 1996, BLOOD, V87, P2968, DOI 10.1182/blood.V87.7.2968.bloodjournal8772968; SUYAMA K, 1994, BLOOD, V84, P1975, DOI 10.1182/blood.V84.6.1975.bloodjournal8461975; SUYAMA K, 1993, BLOOD, V82, P1006; Zhu A, 1996, EUR J BIOCHEM, V235, P332, DOI 10.1111/j.1432-1033.1996.00332.x	24	19	22	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 26	1999	274	9					5731	5737		10.1074/jbc.274.9.5731	http://dx.doi.org/10.1074/jbc.274.9.5731			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	170KG	10026193	hybrid			2022-12-25	WOS:000078804400064
J	Okamoto, I; Kawano, Y; Tsuiki, H; Sasaki, J; Nakao, M; Matsumoto, M; Suga, M; Ando, M; Nakajima, M; Saya, H				Okamoto, I; Kawano, Y; Tsuiki, H; Sasaki, J; Nakao, M; Matsumoto, M; Suga, M; Ando, M; Nakajima, M; Saya, H			CD44 cleavage induced by a membrane-associated metalloprotease plays a critical role in tumor cell migration	ONCOGENE			English	Article						CD44; cleavage; metalloprotease; hyaluronic acid; tumor cell migration	LYMPHOCYTE HOMING RECEPTOR; MATRIX METALLOPROTEINASE; HYALURONATE BINDING; CARCINOMA-CELLS; MELANOMA-CELLS; CYTOPLASMIC DOMAIN; GLYCOPROTEIN CD44; BREAST-CARCINOMA; COLON CARCINOMAS; SPLICED EXONS	CD44 is a cell surface receptor for hyaluronate, a component of the extracellular matrix (ECM), Although CD44 has been implicated in tumor invasion and metastasis, the molecular mechanisms remain to be elucidated. Here we find that CD44 expressed in cancer cells is cleaved at the membrane-proximal region of the ectodomain and the membrane-bound cleavage product can be detected using an antibody against the cytoplasmic domain of CD44, Furthermore, we report that CD44 cleavage is mediated by a membrane-associated metalloprotease expressed in cancer cells, A tissue inhibitor of metalloproteases-l (TIMP-1), as well as metalloprotease inhibitor's, inhibit CD44 cleavage in the cell-free assay. Contrary, serine protease inhibitors enhance CD44 cleavage, and the enhancement can be prevented by pretreatment with a metalloprotease inhibitor. Thus, CD44 cleavage is regulated by an intricate balance between some proteases and their inhibitors. Interestingly, treatment with the metalloprotease blocker l,10-phenanthroline, which strongly prevent the CD44 cleavage, suppressed RERF-LC-OK lung cancer cell migration on a hyaluronate substrate, but not on several other substrates. These results suggest that CD44 cleavage plays a critical role in an efficient cell-detachment from a hyaluronate substrate during the cell migration and consequently promotes CD44-mediated cancer cell migration. Our present data indicate that CD44, not only ECM per se, is one of the targets of pericellular proteolysis involved in tumor invasion and metastasis.	Kumamoto Univ, Sch Med, Dept Tumor Genet & Biol, Kumamoto 8600811, Japan; Novartis Pharma KK, Oncol Res, Takarazuka, Hyogo 6650042, Japan	Kumamoto University; Novartis	Saya, H (corresponding author), Kumamoto Univ, Sch Med, Dept Tumor Genet & Biol, 2-2-1 Honjo, Kumamoto 8600811, Japan.		Saya, Hideyuki/J-4325-2013					ALBELDA SM, 1993, LAB INVEST, V68, P4; ARCH R, 1992, SCIENCE, V257, P682, DOI 10.1126/science.1496383; ARUFFO A, 1990, CELL, V61, P1303, DOI 10.1016/0092-8674(90)90694-A; BARTOLAZZI A, 1995, J CELL SCI, V108, P1723; Bartolazzi A, 1996, J CELL BIOL, V132, P1199, DOI 10.1083/jcb.132.6.1199; BARTOLAZZI A, 1994, J EXP MED, V180, P53, DOI 10.1084/jem.180.1.53; BAZIL V, 1994, J IMMUNOL, V152, P1314; BENNETT KL, 1995, J CELL BIOL, V131, P1623, DOI 10.1083/jcb.131.6.1623; Chambers AF, 1997, J NATL CANCER I, V89, P1260, DOI 10.1093/jnci/89.17.1260; CULTY M, 1990, J CELL BIOL, V111, P2765, DOI 10.1083/jcb.111.6.2765; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; Friedl P, 1997, CANCER RES, V57, P2061; Goebeler M, 1996, J CELL SCI, V109, P1957; GOLDSTEIN LA, 1989, CELL, V56, P1063, DOI 10.1016/0092-8674(89)90639-9; Gunthert AR, 1996, J CELL BIOL, V134, P1089, DOI 10.1083/jcb.134.4.1089; GUNTHERT U, 1991, CELL, V65, P13, DOI 10.1016/0092-8674(91)90403-L; Hirao M, 1996, J CELL BIOL, V135, P37, DOI 10.1083/jcb.135.1.37; Hooper NM, 1997, BIOCHEM J, V321, P265, DOI 10.1042/bj3210265; ISACKE CM, 1994, J CELL SCI, V107, P2353; Iwamura T, 1997, CANCER RES, V57, P1206; JACKSON DG, 1992, J BIOL CHEM, V267, P4732; KATOH S, 1995, J EXP MED, V182, P419, DOI 10.1084/jem.182.2.419; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; LESLEY J, 1995, J EXP MED, V182, P431, DOI 10.1084/jem.182.2.431; Matsui T, 1998, J CELL BIOL, V140, P647, DOI 10.1083/jcb.140.3.647; MATSUMURA Y, 1992, LANCET, V340, P1053, DOI 10.1016/0140-6736(92)93077-Z; Okamoto I, 1998, J NATL CANCER I, V90, P307, DOI 10.1093/jnci/90.4.307; Palecek SP, 1997, NATURE, V385, P537, DOI 10.1038/385537a0; Puente XS, 1996, CANCER RES, V56, P944; PURE E, 1995, J EXP MED, V181, P55, DOI 10.1084/jem.181.1.55; Sasaki J, 1998, INT J ONCOL, V12, P525; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; SCREATON GR, 1992, P NATL ACAD SCI USA, V89, P12160, DOI 10.1073/pnas.89.24.12160; Sheng Y, 1997, INT J CANCER, V73, P850, DOI 10.1002/(SICI)1097-0215(19971210)73:6<850::AID-IJC15>3.0.CO;2-8; Sleeman J, 1996, J CELL BIOL, V135, P1139, DOI 10.1083/jcb.135.4.1139; STAMENKOVIC I, 1991, EMBO J, V10, P343, DOI 10.1002/j.1460-2075.1991.tb07955.x; SY MS, 1991, J EXP MED, V174, P859, DOI 10.1084/jem.174.4.859; Takahashi K, 1995, ONCOGENE, V11, P2223; Takahashi K, 1997, J BIOL CHEM, V272, P23371, DOI 10.1074/jbc.272.37.23371; TAKINO T, 1995, J BIOL CHEM, V270, P23013, DOI 10.1074/jbc.270.39.23013; Talbot DC, 1996, EUR J CANCER, V32A, P2528; TANABE KK, 1993, LANCET, V341, P725, DOI 10.1016/0140-6736(93)90490-8; TANABE KK, 1993, MOL CARCINOGEN, V7, P212, DOI 10.1002/mc.2940070403; THOMAS L, 1992, J CELL BIOL, V118, P971, DOI 10.1083/jcb.118.4.971; ToyamaSorimachi N, 1997, J BIOL CHEM, V272, P26714, DOI 10.1074/jbc.272.42.26714; TSUKITA S, 1994, J CELL BIOL, V126, P391, DOI 10.1083/jcb.126.2.391; Walcheck B, 1996, NATURE, V380, P720, DOI 10.1038/380720a0; Werb Z, 1997, CELL, V91, P439, DOI 10.1016/S0092-8674(00)80429-8; WILL H, 1995, EUR J BIOCHEM, V231, P602, DOI 10.1111/j.1432-1033.1995.0602d.x	49	199	203	1	11	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 18	1999	18	7					1435	1446		10.1038/sj.onc.1202447	http://dx.doi.org/10.1038/sj.onc.1202447			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	167UK	10050880				2022-12-25	WOS:000078651600005
J	Sugihara, K; Nakatsuji, N; Nakamura, K; Nakao, K; Hashimoto, R; Otani, H; Sakagami, H; Kondo, H; Nozawa, S; Aiba, A; Katsuki, M				Sugihara, K; Nakatsuji, N; Nakamura, K; Nakao, K; Hashimoto, R; Otani, H; Sakagami, H; Kondo, H; Nozawa, S; Aiba, A; Katsuki, M			Rac1 is required for the formation of three germ layers during gastrulation	ONCOGENE			English	Article						Rac1; gene targeting; cell adhesion; motility; early development	GTP-BINDING PROTEIN; ACTIN STRESS FIBERS; NADPH OXIDASE; RAS TRANSFORMATION; EXCHANGE PROTEINS; PRIMITIVE-STREAK; CDC42 GTPASES; CELL-DEATH; RHO-FAMILY; ACTIVATION	The Rad, a member of the Rho family proteins, regulates actin organization of cytoskeleton and cell adhesion. We used genetic analysis to elucidate the role of Rad in mouse embryonic development. The rac1 deficient embryos showed numerous cell deaths in the space between the embryonic ectoderm and endoderm at the primitive streak stage. Investigation of the primary epiblast culture isolated from rac1 deficient embryos indicated that Rad is involved in lamellipodia formation, cell adhesion and cell migration in vivo. These results suggest that Rad-mediated cell adhesion is essential for the formation of three germ layers during gastrulation.	Univ Tokyo, Inst Med Sci, Ctr Med Expt, Div DNA Biol & Embryo Engn,Minato Ku, Tokyo 1088639, Japan; Univ Tokyo, CREST, Minato Ku, Tokyo 1088639, Japan; Keio Univ, Sch Med, Dept Obstet & Gynecol, Shinjuku Ku, Tokyo 1608582, Japan; Natl Inst Genet, Mammalian Dev Lab, Mishima, Shizuoka 4118540, Japan; Shimane Med Univ, Dept Anat, Izumo, Shimane 6938501, Japan; Tohoku Univ, Grad Sch Med Sci, Dept Cell Biol, Div Histol,Aoba Ku, Sendai, Miyagi 9808575, Japan	University of Tokyo; Japan Science & Technology Agency (JST); University of Tokyo; Keio University; Research Organization of Information & Systems (ROIS); National Institute of Genetics (NIG) - Japan; Shimane University; Tohoku University	Katsuki, M (corresponding author), Univ Tokyo, Inst Med Sci, Ctr Med Expt, Div DNA Biol & Embryo Engn,Minato Ku, 4-6-1 Shirokanedai, Tokyo 1088639, Japan.			Aiba, Atsu/0000-0002-8192-0778; zhong wei, he gui/0000-0002-3066-3564				ABO A, 1991, NATURE, V353, P668, DOI 10.1038/353668a0; ANDO S, 1992, J BIOL CHEM, V267, P25709; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; Braga VMM, 1997, J CELL BIOL, V137, P1421, DOI 10.1083/jcb.137.6.1421; CHANT J, 1995, CELL, V81, P1, DOI 10.1016/0092-8674(95)90363-1; EATON S, 1995, J CELL BIOL, V131, P151, DOI 10.1083/jcb.131.1.151; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Haataja L, 1997, J BIOL CHEM, V272, P20384, DOI 10.1074/jbc.272.33.20384; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; HASHIMOTO K, 1987, DEVELOPMENT, V100, P587; Hotchin NA, 1995, J CELL BIOL, V131, P1857, DOI 10.1083/jcb.131.6.1857; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; KNAUS UG, 1991, SCIENCE, V254, P1512, DOI 10.1126/science.1660188; KOTANI K, 1995, BIOCHEM BIOPH RES CO, V208, P985, DOI 10.1006/bbrc.1995.1431; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; MACKAY DJG, 1995, TRENDS NEUROSCI, V18, P496, DOI 10.1016/0166-2236(95)92773-J; MICHIELS F, 1995, NATURE, V375, P338, DOI 10.1038/375338a0; MIZUNO T, 1992, J BIOL CHEM, V267, P10215; MOLL J, 1991, ONCOGENE, V6, P863; NAKATSUJI N, 1986, J EMBRYOL EXP MORPH, V96, P99; NISHIYAMA T, 1994, MOL CELL BIOL, V14, P2447, DOI 10.1128/MCB.14.4.2447; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Nomura M, 1998, NATURE, V393, P786, DOI 10.1038/31693; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; PATERSON HF, 1990, J CELL BIOL, V111, P1001, DOI 10.1083/jcb.111.3.1001; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; RANKIN S, 1994, FEBS LETT, V354, P315, DOI 10.1016/0014-5793(94)01148-6; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Robertson EJ, 1987, TERATOCARCINOMAS EMB, P71; RUOSLAHTI E, 1994, CELL, V77, P477, DOI 10.1016/0092-8674(94)90209-7; Sanders EJ, 1997, ANAT EMBRYOL, V195, P147, DOI 10.1007/s004290050033; TAKAI Y, 1992, INT REV CYTOL, V133, P187, DOI 10.1016/S0074-7696(08)61861-6; Takaishi K, 1997, J CELL BIOL, V139, P1047, DOI 10.1083/jcb.139.4.1047; Tam PPL, 1997, MECH DEVELOP, V68, P3, DOI 10.1016/S0925-4773(97)00123-8; VanAelst L, 1997, GENE DEV, V11, P2295, DOI 10.1101/gad.11.18.2295	37	258	260	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 31	1998	17	26					3427	3433		10.1038/sj.onc.1202595	http://dx.doi.org/10.1038/sj.onc.1202595			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	157XD	10030666				2022-12-25	WOS:000078086200003
J	Bessette, PH; Cotto, JJ; Gilbert, HF; Georgiou, G				Bessette, PH; Cotto, JJ; Gilbert, HF; Georgiou, G			In vivo and in vitro function of the Escherichia coli periplasmic cysteine oxidoreductase DsbG	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN DISULFIDE-ISOMERASE; PANCREATIC TRYPSIN-INHIBITOR; IN-VIVO; BOND FORMATION; REDOX PROPERTIES; CELL-ENVELOPE; C-TYPE; THIOREDOXIN; STATES; BIOGENESIS	We have characterized in vivo and in vitro the recently identified DsbG from Escherichia coli, In addition to sharing sequence homology with the thiol disulfide exchange protein DsbC, DsbG: likewise was shown to form a stable periplasmic dimer, and it displays an equilibrium constant with glutathione comparable with DsbA and DsbC, DsbG was found to be expressed at approximately 25% the level of DsbC. In contrast to earlier results (Andersen, C, L,, Matthey-Dupraz, A., Missiakas, D., and Raina, S. (1997) Mel. Microbiol. 26, 121-132), we showed that dsbG is not essential for growth and that dsbG null mutants display no defect in folding of multiple disulfide-containing heterologous proteins. Overexpression of DsbG:, however, was able to restore the ability of dsbC mutants to express heterologous multidisulfide proteins, namely bovine pancreatic trypsin inhibitor, a protein with three disulfides, and to a lesser extent, mouse urokinase (12 disulfides), As in DsbC, the putative active site thiols in DsbG are completely reduced in vivo in a dsbD-dependent fashion, as would be expected if DsbG is acting as a disulfide isomerase or reductase. However, the latter is not likely because DsbG could not catalyze insulin reduction in vitro. Overall, our results indicate that DsbC functions primarily as a periplasmic disulfide isomerase with a narrower substrate specificity than DsbC.	Univ Texas, Dept Chem Engn, Austin, TX 78712 USA; Baylor Coll Med, Dept Biochem, Houston, TX 77030 USA	University of Texas System; University of Texas Austin; Baylor College of Medicine	Georgiou, G (corresponding author), Univ Texas, Dept Chem Engn, Dean Keaton & Speedway, Austin, TX 78758 USA.	gg@che.utexas.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047520] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-47520] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Andersen CL, 1997, MOL MICROBIOL, V26, P121, DOI 10.1046/j.1365-2958.1997.5581925.x; Ausubel F.M., 1989, CURRENT PROTOCOLS MO, V2; Bader M, 1998, J BIOL CHEM, V273, P10302, DOI 10.1074/jbc.273.17.10302; BANEYX F, 1990, J BACTERIOL, V172, P491, DOI 10.1128/JB.172.1.491-494.1990; BERGLUND O, 1975, J BIOL CHEM, V250, P2778; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; CREIGHTON TE, 1990, BIOCHEM J, V270, P1; DUVOISIN RM, 1986, GENE, V45, P193, DOI 10.1016/0378-1119(86)90254-4; Fabianek RA, 1998, J BACTERIOL, V180, P1947, DOI 10.1128/JB.180.7.1947-1950.1998; Fabianek RA, 1997, J BIOL CHEM, V272, P4467, DOI 10.1074/jbc.272.7.4467; GLEASON FK, 1992, PROTEIN SCI, V1, P609, DOI 10.1002/pro.5560010507; GOLDENBERG DP, 1988, BIOCHEMISTRY-US, V27, P2481, DOI 10.1021/bi00407a034; HAWKINS HC, 1991, BIOCHEM J, V275, P341, DOI 10.1042/bj2750341; HOLMGREN A, 1972, J BIOL CHEM, V247, P1992; HOLMGREN A, 1979, J BIOL CHEM, V254, P9627; Joly JC, 1997, BIOCHEMISTRY-US, V36, P10067, DOI 10.1021/bi9707739; Joly JC, 1998, P NATL ACAD SCI USA, V95, P2773, DOI 10.1073/pnas.95.6.2773; JOLY JC, 1994, BIOCHEMISTRY-US, V33, P4231, DOI 10.1021/bi00180a017; KISHIGAMI S, 1995, FEBS LETT, V364, P55, DOI 10.1016/0014-5793(95)00354-C; Kobayashi T, 1997, P NATL ACAD SCI USA, V94, P11857, DOI 10.1073/pnas.94.22.11857; KOHARA Y, 1987, CELL, V50, P495, DOI 10.1016/0092-8674(87)90503-4; LIN TY, 1989, BIOCHEMISTRY-US, V28, P5282, DOI 10.1021/bi00438a054; LYLES MM, 1991, BIOCHEMISTRY-US, V30, P613, DOI 10.1021/bi00217a004; LYLES MM, 1994, J BIOL CHEM, V269, P30946; MILLER JH, 1992, SHORT COURSE BACTERI, P268; Missiakas D, 1997, J BACTERIOL, V179, P2465, DOI 10.1128/jb.179.8.2465-2471.1997; Missiakas D, 1997, TRENDS BIOCHEM SCI, V22, P59, DOI 10.1016/S0968-0004(96)10072-4; Ostermeier M, 1996, J BIOL CHEM, V271, P10616, DOI 10.1074/jbc.271.18.10616; OSTERMEIER M, 1994, J BIOL CHEM, V269, P21072; OSTERMEIER MA, 1996, THESIS U TEXAS AUSTI; Page MD, 1997, MOL MICROBIOL, V24, P977, DOI 10.1046/j.1365-2958.1997.4061775.x; Raina S, 1997, ANNU REV MICROBIOL, V51, P179, DOI 10.1146/annurev.micro.51.1.179; Rietsch A, 1997, J BACTERIOL, V179, P6602, DOI 10.1128/jb.179.21.6602-6608.1997; Rietsch A, 1996, P NATL ACAD SCI USA, V93, P13048, DOI 10.1073/pnas.93.23.13048; RUSSELL CB, 1989, J BACTERIOL, V171, P2609, DOI 10.1128/jb.171.5.2609-2613.1989; Sone M, 1997, J BIOL CHEM, V272, P10349; STRAUCH KL, 1989, J BACTERIOL, V171, P2689, DOI 10.1128/jb.171.5.2689-2696.1989; Thorstenson YR, 1997, J BACTERIOL, V179, P5333, DOI 10.1128/jb.179.17.5333-5339.1997; WALKER KW, 1994, J BIOL CHEM, V269, P28487; WULFING C, 1994, MOL MICROBIOL, V12, P685, DOI 10.1111/j.1365-2958.1994.tb01056.x; WUNDERLICH M, 1993, PROTEIN SCI, V2, P717, DOI 10.1002/pro.5560020503; Zander T, 1998, METHOD ENZYMOL, V290, P59, DOI 10.1016/S0076-6879(98)90007-6; ZAPUN A, 1995, BIOCHEMISTRY-US, V34, P5075, DOI 10.1021/bi00015a019; ZAPUN A, 1993, BIOCHEMISTRY-US, V32, P5083, DOI 10.1021/bi00070a016	45	137	145	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	1999	274	12					7784	7792		10.1074/jbc.274.12.7784	http://dx.doi.org/10.1074/jbc.274.12.7784			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	178LU	10075670	hybrid			2022-12-25	WOS:000079268100029
J	Kapus, A; Szaszi, K; Sun, JG; Rizoli, S; Rotstein, OD				Kapus, A; Szaszi, K; Sun, JG; Rizoli, S; Rotstein, OD			Cell shrinkage regulates Src kinases and induces tyrosine phosphorylation of cortactin, independent of the osmotic regulation of Na+/H+ exchangers	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; EPIDERMAL GROWTH-FACTOR; THICK ASCENDING LIMB; HAMSTER OVARY CELLS; C-SRC; ACTIN CYTOSKELETON; OXIDATIVE STRESS; FAMILY KINASES; SUBSTRATE; TRANSLOCATION	The signaling pathways by which cell volume regulates ion transporters, e.g. Na+/H+ exchangers (NHEs), and affects cytoskeletal organization are poorly understood, We have previously shown that shrinkage induces tyrosine phosphorylation in CHO cells, predominantly in an 85-kDa band. To identify volume-sensitive kinases and their substrates, we investigated the effect of hypertonicity on members of the Src kinase family. Hyperosmolarity stimulated Fyn and inhibited Src, Fyn activation was also observed in nystatin-permeabilized cells, where shrinkage cannot induce intracellular alkalinization, In contrast, osmotic inhibition of Src was prevented by permeabilization or by inhibiting NHE-1, PPI, a selective Src family inhibitor, strongly reduced the hypertonicity-induced tyrosine phosphorylation. We identified one of the major targets of the osmotic stress-elicited phosphorylation as cortactin, an 85-kDa actin-binding protein and well known Src family substrate. Cortactin phosphorylation was triggered by shrinkage and not by changes in osmolarity or pH(i) and was abrogated by PP1, Hyperosmotic cortactin phosphorylation was reduced in Fyn-deficient fibroblasts but remained intact in Src-deficient fibroblasts, To address the potential role of the Src family in the osmotic regulation of NHEs, we used PP1. The drug affected neither the hyperosmotic stimulation of NHE-1 nor the inhibition of NHE-3, Thus, members of the Src family are volume-sensitive enzymes that may participate in the shrinkage-related reorganization of the cytoskeleton but are probably not responsible for the osmotic regulation of NHE.	Toronto Hosp, Dept Surg, Toronto, ON M5G 1L7, Canada; Semmelweis Univ Med, Dept Physiol, H-1444 Budapest 8, Hungary; Univ Toronto, Toronto, ON M5G 1L7, Canada; Semmelweis Univ Med, Lab Cellular & Mol Physiol, H-1444 Budapest, Hungary	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Semmelweis University; University of Toronto; Semmelweis University	Kapus, A (corresponding author), Toronto Hosp, Dept Surg, Rm CCRW 2-850,101 Coll St, Toronto, ON M5G 1L7, Canada.	akapus@transplantunit.org	Szaszi, Katalin/J-7522-2012	Szaszi, Katalin/0000-0002-2490-8422				Abe J, 1997, J BIOL CHEM, V272, P20389, DOI 10.1074/jbc.272.33.20389; Amoui M, 1997, EUR J IMMUNOL, V27, P1881, DOI 10.1002/eji.1830270810; BIANCHINI L, 1995, AM J PHYSIOL-CELL PH, V269, pC998, DOI 10.1152/ajpcell.1995.269.4.C998; Bianchini L, 1997, J BIOL CHEM, V272, P271; Burridge K, 1996, ANNU REV CELL DEV BI, V12, P463, DOI 10.1146/annurev.cellbio.12.1.463; CALAUTTI E, 1995, GENE DEV, V9, P2279, DOI 10.1101/gad.9.18.2279; CHANG JH, 1995, J CELL BIOL, V130, P355, DOI 10.1083/jcb.130.2.355; CHENG HC, 1992, J BIOL CHEM, V267, P9248; CHOWDHURY S, 1992, J CELL BIOL, V118, P561, DOI 10.1083/jcb.118.3.561; DeCorte V, 1997, FEBS LETT, V401, P191, DOI 10.1016/S0014-5793(96)01471-8; DeFranceschi L, 1997, J CLIN INVEST, V99, P220, DOI 10.1172/JCI119150; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; Dove SK, 1997, NATURE, V390, P187, DOI 10.1038/36613; DURIEUTRAUTMANN O, 1994, J BIOL CHEM, V269, P12536; ElHillal O, 1997, P NATL ACAD SCI USA, V94, P1919, DOI 10.1073/pnas.94.5.1919; ERPEL T, 1995, CURR OPIN CELL BIOL, V7, P176, DOI 10.1016/0955-0674(95)80025-5; Fincham VJ, 1996, J CELL BIOL, V135, P1551, DOI 10.1083/jcb.135.6.1551; FOSKETT JK, 1985, AM J PHYSIOL, V248, pC27, DOI 10.1152/ajpcell.1985.248.1.C27; Gao J, 1997, EMBO J, V16, P6414, DOI 10.1093/emboj/16.21.6414; Gatsios P, 1998, J BIOL CHEM, V273, P22962, DOI 10.1074/jbc.273.36.22962; GOOD DW, 1995, J BIOL CHEM, V270, P9883, DOI 10.1074/jbc.270.17.9883; HALLOWS KR, 1991, AM J PHYSIOL, V261, pC1154, DOI 10.1152/ajpcell.1991.261.6.C1154; HANDLER JS, 1993, AM J PHYSIOL, V265, pC1449, DOI 10.1152/ajpcell.1993.265.6.C1449; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Haussinger D, 1996, BIOCHEM J, V313, P697; He H, 1998, MOL CELL BIOL, V18, P3829, DOI 10.1128/MCB.18.7.3829; HORVATH AR, 1992, EMBO J, V11, P855, DOI 10.1002/j.1460-2075.1992.tb05123.x; Huang C, 1997, J BIOL CHEM, V272, P13911, DOI 10.1074/jbc.272.21.13911; Junger WG, 1998, J CLIN INVEST, V101, P2768, DOI 10.1172/JCI1354; KAPUS A, 1994, J BIOL CHEM, V269, P23544; Kim L, 1998, J BIOL CHEM, V273, P23542, DOI 10.1074/jbc.273.36.23542; Krump E, 1997, J BIOL CHEM, V272, P17303, DOI 10.1074/jbc.272.28.17303; Lang F, 1998, PHYSIOL REV, V78, P247, DOI 10.1152/physrev.1998.78.1.247; Lepple-Wienhues A, 1998, J CELL BIOL, V141, P281, DOI 10.1083/jcb.141.1.281; Liu MY, 1996, J BIOL CHEM, V271, P7066, DOI 10.1074/jbc.271.12.7066; MAA MC, 1992, ONCOGENE, V7, P2429; Maruyama S, 1996, J BIOL CHEM, V271, P6631, DOI 10.1074/jbc.271.12.6631; NADA S, 1994, ONCOGENE, V9, P3571; Nath SK, 1996, AM J PHYSIOL-GASTR L, V270, pG431, DOI 10.1152/ajpgi.1996.270.3.G431; Okazaki T, 1997, J BIOL CHEM, V272, P32274, DOI 10.1074/jbc.272.51.32274; Patel AS, 1998, ONCOGENE, V16, P3227, DOI 10.1038/sj.onc.1201850; Qin SF, 1997, J BIOL CHEM, V272, P2098; Qin SF, 1998, BIOCHEMISTRY-US, V37, P5481, DOI 10.1021/bi9729460; Rivero F, 1996, J CELL SCI, V109, P2679; Rosette C, 1996, SCIENCE, V274, P1194, DOI 10.1126/science.274.5290.1194; SARTOR O, 1993, J BIOL CHEM, V268, P21014; Sato K, 1997, FEBS LETT, V410, P136, DOI 10.1016/S0014-5793(97)00539-5; Shrode LD, 1997, J BIOL CHEM, V272, P13653, DOI 10.1074/jbc.272.21.13653; SHRODE LD, 1995, AM J PHYSIOL-CELL PH, V269, pC257, DOI 10.1152/ajpcell.1995.269.1.C257; SOLEIMANI M, 1994, J BIOL CHEM, V269, P15613; Susztak K, 1997, BIOCHEM J, V325, P501, DOI 10.1042/bj3250501; Szaszi K, 1997, J BIOL CHEM, V272, P16670, DOI 10.1074/jbc.272.26.16670; THOMAS SM, 1995, NATURE, V376, P267, DOI 10.1038/376267a0; TILLY BC, 1993, J BIOL CHEM, V268, P19919; Tilly BC, 1996, MOL BIOL CELL, V7, P1419, DOI 10.1091/mbc.7.9.1419; Tominaga T, 1998, MOL BIOL CELL, V9, P2287, DOI 10.1091/mbc.9.8.2287; VUORI K, 1995, J BIOL CHEM, V270, P22259, DOI 10.1074/jbc.270.38.22259; Waldegger S, 1997, P NATL ACAD SCI USA, V94, P4440, DOI 10.1073/pnas.94.9.4440; WATTS BA, 1994, J BIOL CHEM, V269, P20250; Weed SA, 1998, J CELL SCI, V111, P2433; WEERNINK PAO, 1995, J BIOL CHEM, V270, P2264, DOI 10.1074/jbc.270.5.2264; Wesselborg S, 1997, J BIOL CHEM, V272, P12422, DOI 10.1074/jbc.272.19.12422; Wiese S, 1998, BIOL CHEM, V379, P667, DOI 10.1515/bchm.1998.379.6.667; WU H, 1991, MOL CELL BIOL, V11, P5113, DOI 10.1128/MCB.11.10.5113; WU H, 1993, J CELL BIOL, V120, P1417, DOI 10.1083/jcb.120.6.1417; YAMAJI Y, 1995, P NATL ACAD SCI USA, V92, P6274, DOI 10.1073/pnas.92.14.6274; Yamaji Y, 1997, AM J PHYSIOL-CELL PH, V272, pC886, DOI 10.1152/ajpcell.1997.272.3.C886; ZHAN X, 1994, J BIOL CHEM, V269, P20221	68	140	143	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 19	1999	274	12					8093	8102		10.1074/jbc.274.12.8093	http://dx.doi.org/10.1074/jbc.274.12.8093			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	178LU	10075710	hybrid			2022-12-25	WOS:000079268100069
J	Pellaud, J; Schote, U; Arvinte, T; Seelig, J				Pellaud, J; Schote, U; Arvinte, T; Seelig, J			Conformation and self-association of human recombinant transforming growth factor-beta 3 in aqueous solutions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-BETA; CRYSTAL-STRUCTURE; BIOLOGICAL-ACTIVITIES; RECEPTOR-BINDING; GROWTH-FACTOR-BETA-2; ACTIVATION; EXPRESSION; REPAIR; BONE; PURIFICATION	The transforming growth factors-beta (TGF-beta) are important regulatory peptides for cell growth and differentiation with therapeutic potential for wound healing. Among the several TGF-beta isoforms TGF-beta 3 has a particularly low solubility at physiological pH and easily forms aggregates. A spectroscopic structural analysis of TGF-beta 3 in solution has thus been difficult. In this study, circular dichroism spectroscopy was used to determine the secondary structural elements of TGF-beta 3, In addition, the aggregation of TGF-beta 3 was investigated systematically as a function of pH and salt concentration using a rapid screening method, Sedimentation equilibrium and sedimentation velocity analysis revealed that TGF-beta S exists predominantly in two major forms: (i) monomers in solution at low pH and (ii) large precipitating aggregates at physiological pH, Under acidic conditions (pH < 3.8) the protein was not aggregated, At pH similar to 3.9, a monomer reversible arrow dimer equilibrium could be detected that transformed into larger aggregates at pH > 4.1, Aggregation was pronounced in the pH range of 4.3 < pH < 9.8 with the aggregation maximum between pH 6.5 and 8.5. The aggregation process was accompanied by a structural change of the protein, The CD spectra were characterized by an isodichroic point at 209.5 nm indicating a two-state equilibrium between TGF-beta 3 dissolved in solution and aggregated TGF-beta 3. Aggregated TGF-beta S showed a higher beta-sheet content and lower beta-turn and random coil contributions compared with monomeric TGF-beta 3, Both the solution structure and the aggregate structure of TGF-beta 3 were different from the crystal structure. This was in contrast to TGF-beta 2, which showed very similar crystal and solution structures. Under alkaline conditions (pH > 9.8) the turbidity disappeared and a further conformational change was induced, The pH dependence of the TGF-beta S conformation in solution in the range of 2.3 < pH < 11.0 was reversible. Aggregation of TGF-beta S was, furthermore, influenced by the presence of salt. For pH > 3.8 the addition of salt greatly enhanced the tendency to aggregate, even in the very basic domain. Under physiological conditions (pH 7,4, c(NaCl) = 164 mM) TGF-beta 3 has almost the highest tendency to aggregate and will remain in solution only at nanomolar concentrations.	Univ Basel, Bioctr, Dept Biophys Chem, CH-4056 Basel, Switzerland; Novartis Pharma AG, Pharmaceut & Analyt Dev, CH-4002 Basel, Switzerland	University of Basel; Novartis	Seelig, J (corresponding author), Univ Basel, Bioctr, Dept Biophys Chem, Klingelbergstr 70, CH-4056 Basel, Switzerland.	seelig1@ubaclu.unibas.ch						Abe M, 1998, J CELL PHYSIOL, V174, P186, DOI 10.1002/(SICI)1097-4652(199802)174:2<186::AID-JCP6>3.0.CO;2-K; ARCHER SJ, 1993, BIOCHEMISTRY-US, V32, P1164, DOI 10.1021/bi00055a022; ARCHER SJ, 1993, BIOCHEMISTRY-US, V32, P1152, DOI 10.1021/bi00055a021; Bailly S, 1997, J BIOL CHEM, V272, P16329, DOI 10.1074/jbc.272.26.16329; Bonewald LF, 1997, ENDOCRINOLOGY, V138, P657, DOI 10.1210/en.138.2.657; BORDER WA, 1992, J CLIN INVEST, V90, P1, DOI 10.1172/JCI115821; Chambaz EM, 1996, HORM RES, V45, P222; CHERVENKA CH, 1970, MANUAL METHODS ANAL; COX DA, 1995, CELL BIOL INT, V19, P357, DOI 10.1006/cbir.1995.1082; DAOPIN S, 1992, SCIENCE, V257, P369, DOI 10.1126/science.1631557; Daopin Sun, 1993, Proteins Structure Function and Genetics, V17, P176, DOI 10.1002/prot.340170207; Frank S, 1996, J BIOL CHEM, V271, P10188, DOI 10.1074/jbc.271.17.10188; Gleizes PE, 1997, STEM CELLS, V15, P190, DOI 10.1002/stem.150190; GRAINGER DJ, 1994, NATURE, V370, P460, DOI 10.1038/370460a0; Grande JP, 1997, P SOC EXP BIOL MED, V214, P27; GRAYCAR JL, 1989, MOL ENDOCRINOL, V3, P1977, DOI 10.1210/mend-3-12-1977; Hinck AP, 1996, BIOCHEMISTRY-US, V35, P8517, DOI 10.1021/bi9604946; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; Kloen P, 1997, CANCER, V80, P2230; KOPPA SD, 1994, DRUG THER, V24, P34; LEBERMAN R, 1991, FEBS LETT, V284, P293, DOI 10.1016/0014-5793(91)80707-A; LEVINE JH, 1993, AM J PATHOL, V143, P368; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MIHALYI E, 1968, J CHEM ENG DATA, V13, P179, DOI 10.1021/je60037a011; Mittl PRE, 1996, PROTEIN SCI, V5, P1261, DOI 10.1002/pro.5560050705; MIYAZONO K, 1989, NATURE, V338, P158, DOI 10.1038/338158a0; MOSES HL, 1990, CELL, V63, P245, DOI 10.1016/0092-8674(90)90155-8; Naef M, 1997, INT J CANCER, V71, P131; OGAWA Y, 1992, J BIOL CHEM, V267, P2325; Roth DA, 1997, PLAST RECONSTR SURG, V99, P300, DOI 10.1097/00006534-199702000-00002; RUNSER S, 1995, BIOTECHNOL APPL BIOC, V22, P39; SCHLUNEGGER MP, 1993, J MOL BIOL, V231, P445, DOI 10.1006/jmbi.1993.1293; SCHLUNEGGER MP, 1992, FEBS LETT, V303, P91, DOI 10.1016/0014-5793(92)80484-X; SCHLUNEGGER MP, 1992, NATURE, V358, P430, DOI 10.1038/358430a0; SCHMID P, 1993, J PATHOL, V171, P191, DOI 10.1002/path.1711710307; SCHULTZCHERRY S, 1995, J BIOL CHEM, V270, P7304, DOI 10.1074/jbc.270.13.7304; SPORN MB, 1987, J CELL BIOL, V105, P1039, DOI 10.1083/jcb.105.3.1039; TENDIJKE P, 1990, MOL CELL BIOL, V10, P4473, DOI 10.1128/MCB.10.9.4473; YANG JT, 1986, METHOD ENZYMOL, V130, P208; Yang NN, 1996, ENDOCRINOLOGY, V137, P2075, DOI 10.1210/en.137.5.2075	40	50	51	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 19	1999	274	12					7699	7704		10.1074/jbc.274.12.7699	http://dx.doi.org/10.1074/jbc.274.12.7699			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	178LU	10075659	hybrid			2022-12-25	WOS:000079268100018
J	Buse, P; Tran, SH; Luther, E; Phu, PT; Aponte, GW; Firestone, GL				Buse, P; Tran, SH; Luther, E; Phu, PT; Aponte, GW; Firestone, GL			Cell cycle and hormonal control of nuclear-cytoplasmic localization of the serum- and glucocorticoid-inducible protein kinase, Sgk, in mammary tumor cells - A novel convergence point of anti-proliferative and proliferative cell signaling pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-ALPHA; RAT HEPATOMA-CELLS; GENE-EXPRESSION; 3T3 FIBROBLASTS; TRANSCRIPTION FACTORS; ANCHORING PROTEINS; PROMOTER ACTIVITY; DNA-BINDING; S6 KINASE; RECEPTOR	The serum- and glucocorticoid-inducible kinase (sgk) is a novel serine/threonine protein kinase that is transcriptionally regulated in rat mammary tumor cells by serum under proliferative conditions or by glucocorticoids that induce a G(1) cell cycle arrest, Our results establish that the subcellular distribution of Sgk is under stringent cell cycle and hormonal control. Sgk is localized to the perinuclear or cytoplasmic compartment as a 50-kDa hypophosphorylated protein in cells arrested in G(1) by treatment with the synthetic glucocorticoid dexamethasone, In serum-stimulated cells, Sgk was transiently hyperphosphorylated and resided in the nucleus. Laser scanning cytometry, which monitors Sgk localization and DNA content in individual mammary tumor cells of an asynchronously growing population, revealed that Sgk actively shuttles between the nucleus (in S and G(2)/M) and the cytoplasm (in G(1)) in synchrony with the cell cycle. In cells synchronously released from the G(1)/S boundary, Sgk localized to the nucleus during progression through S phase. The forced retention of exogenous Sgk in either the cytoplasmic compartment, using a wild type sgk gene, or the nucleus, using a nuclear localization signal-containing sgk gene (NLS-Sgk), suppressed the growth and DNA synthesis of serum-stimulated cells, Thus, our study implicates the nuclear-cytoplasmic shuttling of sgk as a requirement for cell cycle progression and represents a novel convergence point of anti-proliferative and proliferative signaling in mammary tumor cells.	Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA; Univ Calif Berkeley, Canc Res Lab, Berkeley, CA 94720 USA; CompuCyte Corp, Cambridge, MA 02139 USA; Univ Calif Berkeley, Dept Nutr Sci, Berkeley, CA 94720 USA	University of California System; University of California Berkeley; University of California System; University of California Berkeley; University of California System; University of California Berkeley	Firestone, GL (corresponding author), Univ Calif Berkeley, Dept Mol & Cell Biol, 591 LSA, Berkeley, CA 94720 USA.		Luther, Ed/AAO-7064-2020; Luther, Ed/AAA-2536-2021		NATIONAL CANCER INSTITUTE [R01CA071514] Funding Source: NIH RePORTER; NCI NIH HHS [CA-71514] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALEXANDER DB, 1993, CANCER RES, V53, P1808; Alliston TN, 1997, MOL ENDOCRINOL, V11, P1934, DOI 10.1210/me.11.13.1934; Almawi WY, 1996, J LEUKOCYTE BIOL, V60, P563, DOI 10.1002/jlb.60.5.563; Bamberger CM, 1996, ENDOCR REV, V17, P245, DOI 10.1210/er.17.3.245; Beato M, 1996, ENDOCR REV, V17, P587, DOI 10.1210/er.17.6.587; BOULIKAS T, 1995, CRIT REV EUKAR GENE, V5, P1; Boulikas Teni, 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P193; BUSE P, 1995, J BIOL CHEM, V270, P6505, DOI 10.1074/jbc.270.12.6505; BUSE P, 1995, J BIOL CHEM, V270, P28223; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; Cheng JQ, 1997, ONCOGENE, V14, P2793, DOI 10.1038/sj.onc.1201121; CHOI KY, 1994, CELL, V78, P499; CHOI PM, 1990, MOL CELL BIOL, V10, P4650, DOI 10.1128/MCB.10.9.4650; COOK PW, 1988, MOL CELL BIOL, V8, P1449, DOI 10.1128/MCB.8.4.1449; CROSS M, 1991, CELL, V64, P271, DOI 10.1016/0092-8674(91)90638-F; Denhardt DT, 1996, BIOCHEM J, V318, P729, DOI 10.1042/bj3180729; Dickens M, 1997, SCIENCE, V277, P693, DOI 10.1126/science.277.5326.693; Dowd DR, 1997, MOL CELL ENDOCRINOL, V128, P29, DOI 10.1016/S0303-7207(96)04012-9; Edelmann HML, 1996, J BIOL CHEM, V271, P963, DOI 10.1074/jbc.271.2.963; Fode C, 1996, MOL CELL BIOL, V16, P4665; GERADTS J, 1986, CANCER RES, P1920; GOODNIGHT J, 1995, J BIOL CHEM, V270, P9991, DOI 10.1074/jbc.270.17.9991; Gorlich D, 1997, CURR OPIN CELL BIOL, V9, P412, DOI 10.1016/S0955-0674(97)80015-4; GOYA L, 1993, CANCER RES, V53, P1816; GOYA L, 1993, MOL ENDOCRINOL, V7, P1121, DOI 10.1210/me.7.9.1121; Hansson A, 1996, CELL BIOCHEM FUNCT, V14, P121; HARAGUCHI T, 1991, J BIOL CHEM, V266, P18299; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; HEDLEY ML, 1995, P NATL ACAD SCI USA, V92, P11524, DOI 10.1073/pnas.92.25.11524; HERNANDEZSOTOMAYOR SMT, 1992, J MEMBRANE BIOL, V128, P81; HOUSEY GM, 1988, CELL, V52, P343, DOI 10.1016/S0092-8674(88)80027-8; Hubner S, 1997, J BIOL CHEM, V272, P17191, DOI 10.1074/jbc.272.27.17191; IRESTONE GL, 1995, HORMONES AGING, P325; JOHNSON GL, 1994, CURR OPIN CELL BIOL, V6, P230, DOI 10.1016/0955-0674(94)90141-4; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491; Klauck TM, 1996, SCIENCE, V271, P1589, DOI 10.1126/science.271.5255.1589; Koli K, 1996, ADV CANCER RES, V70, P63, DOI 10.1016/S0065-230X(08)60872-6; Krstic MD, 1997, MOL CELL BIOL, V17, P3947, DOI 10.1128/MCB.17.7.3947; LEHEL C, 1994, J BIOL CHEM, V269, P4761; Maiyar AC, 1996, J BIOL CHEM, V271, P12414, DOI 10.1074/jbc.271.21.12414; Maiyar AC, 1997, MOL ENDOCRINOL, V11, P312, DOI 10.1210/me.11.3.312; Manni A, 1996, CELL GROWTH DIFFER, V7, P1187; MCCORMICK F, 1995, MOL REPROD DEV, V42, P500, DOI 10.1002/mrd.1080420419; McEwan IJ, 1997, BIOESSAYS, V19, P153, DOI 10.1002/bies.950190210; MCNEILL RB, 1995, J BIOL CHEM, V270, P10043, DOI 10.1074/jbc.270.17.10043; MEINKOTH JL, 1993, MOL CELL BIOCHEM, V128, P179, DOI 10.1007/BF01076769; MOCHLYROSEN D, 1995, SCIENCE, V268, P247, DOI 10.1126/science.7716516; Monfar M, 1996, MOL ENDOCRINOL, V10, P1107, DOI 10.1210/me.10.9.1107; MURPHY LJ, 1994, J STEROID BIOCHEM, V48, P419, DOI 10.1016/0960-0760(94)90189-9; MUSGROVE EA, 1994, SEMIN CANCER BIOL, V5, P381; Nigg EA, 1997, NATURE, V386, P779, DOI 10.1038/386779a0; NORDEEN SK, 1994, ENDOCRINOLOGY, V134, P1723, DOI 10.1210/en.134.4.1723; Ohno M, 1998, CELL, V92, P327, DOI 10.1016/S0092-8674(00)80926-5; PAWSON T, 1993, DEV GENET, V14, P333, DOI 10.1002/dvg.1020140502; Price MA, 1996, EMBO J, V15, P6552, DOI 10.1002/j.1460-2075.1996.tb01046.x; Ramos RA, 1996, MOL CELL BIOL, V16, P5288; REINHARD C, 1994, EMBO J, V13, P1557, DOI 10.1002/j.1460-2075.1994.tb06418.x; RHEE K, 1995, CANCER RES, V55, P4188; Rider LG, 1996, J IMMUNOL, V157, P2374; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; Rogatsky I, 1997, MOL CELL BIOL, V17, P3181, DOI 10.1128/MCB.17.6.3181; SCHLESSINGER J, 1994, CURR OPIN GENET DEV, V4, P25, DOI 10.1016/0959-437X(94)90087-6; SCOTT JD, 1994, MOL ENDOCRINOL, V8, P5, DOI 10.1210/me.8.1.5; SEGER R, 1995, FASEB J, V9, P727; TRUSS M, 1993, ENDOCR REV, V14, P459, DOI 10.1210/er.14.4.459; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.biochem.63.1.451; WAHLI W, 1991, FASEB J, V5, P2243, DOI 10.1096/fasebj.5.9.1860615; WEBSTER MK, 1993, MOL CELL BIOL, V13, P2031, DOI 10.1128/MCB.13.4.2031; WEBSTER MK, 1990, J BIOL CHEM, V265, P4831; WEBSTER MK, 1991, CANCER RES, V51, P6031; WEBSTER MK, 1993, J BIOL CHEM, V268, P11482; Xiao CY, 1996, J BIOL CHEM, V271, P6451, DOI 10.1074/jbc.271.11.6451; ZILLIACUS J, 1995, MOL ENDOCRINOL, V9, P389, DOI 10.1210/me.9.4.389	74	113	124	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 12	1999	274	11					7253	7263		10.1074/jbc.274.11.7253	http://dx.doi.org/10.1074/jbc.274.11.7253			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	175DV	10066787	hybrid			2022-12-25	WOS:000079078400059
J	Fillebeen, C; Descamps, L; Dehouck, MP; Fenart, L; Benaissa, M; Spik, G; Cecchelli, R; Pierce, A				Fillebeen, C; Descamps, L; Dehouck, MP; Fenart, L; Benaissa, M; Spik, G; Cecchelli, R; Pierce, A			Receptor-mediated transcytosis of lactoferrin through the blood-brain barrier	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DENSITY-LIPOPROTEIN RECEPTOR; PROTEIN ALPHA(2)-MACROGLOBULIN RECEPTOR; HYDROXYL-RADICAL PRODUCTION; VASCULAR SMOOTH-MUSCLE; ENDOTHELIAL-CELLS; LDL-RECEPTOR; ALPHA-2-MACROGLOBULIN RECEPTOR; CAPILLARY-PERMEABILITY; PLASMINOGEN-ACTIVATOR; CEREBROSPINAL-FLUID	Lactoferrin (Lf) is an iron-binding protein involved in host defense against infection and severe inflammation; it accumulates in the brain during neurodegenerative disorders. Before determining Lf function in brain tissue, we investigated its origin and demonstrate here that it crosses the blood-brain barrier. An in vitro model of the blood-brain barrier was used to examine the mechanism of Lf transport to the brain. We report that differentiated bovine brain capillary endothelial cells exhibited specific high (K-d = 37.5 nM; n = 90,000/cell) and low (K-d = 2 mu M; n = 900,000 sites/cell) affinity binding sites. Only the latter were present on nondifferentiated cells. The surface-bound Lf was internalized only by the differentiated cell population leading to the conclusion that Lf receptors were acquired during cell differentiation. A specific unidirectional transport then occurred via a receptor-mediated process with no apparent intraendothelial degradation. We further report that iron may cross the bovine brain capillary endothelial cells as a complex with Lf, Finally, we show that the low density lipoprotein receptor-related protein might be involved in this process because its specific antagonist, the receptor-associated protein, inhibits 70% of Lf transport.	Univ Sci & Technol Lille, Chim Biol Lab, CNRS, UMR 111, F-59655 Villeneuve Dascq, France; Inst Pasteur, Serv Etud & Rech Lipoprot & Atherosclerose, INSERM, U325, F-59019 Lille, France; Univ Artois, Fac Jean Perrin, F-62307 Lens, France	Centre National de la Recherche Scientifique (CNRS); Universite de Lille - ISITE; Universite de Lille; Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Universite d'Artois	Pierce, A (corresponding author), Univ Sci & Technol Lille, Chim Biol Lab, CNRS, UMR 111, F-59655 Villeneuve Dascq, France.			Fenart, Laurence/0000-0001-9285-0579				AMBRUSO DR, 1981, J CLIN INVEST, V67, P352, DOI 10.1172/JCI110042; Bi BY, 1996, EUR J CELL BIOL, V69, P288; BOOHER J, 1972, Neurobiology (Copenhagen), V2, P97; BORSTEIN MB, 1958, LAB INVEST, V7, P134; BRITIGAN BE, 1989, BIOCHEM J, V264, P447, DOI 10.1042/bj2640447; BU GJ, 1994, J BIOL CHEM, V269, P18521; BU GJ, 1995, EMBO J, V14, P2269, DOI 10.1002/j.1460-2075.1995.tb07221.x; CHERON A, 1977, CR ACAD SCI D NAT, V284, P585; CONNOR JR, 1992, J NEUROSCI RES, V31, P75, DOI 10.1002/jnr.490310111; CONNOR JR, 1992, ANN NEUROL S, V32, P51; Dehouck B, 1997, J CELL BIOL, V138, P877, DOI 10.1083/jcb.138.4.877; DEHOUCK B, 1994, J CELL BIOL, V126, P465, DOI 10.1083/jcb.126.2.465; DEHOUCK M-P, 1990, Circulation et Metabolisme du Cerveau, V7, P151; Descamps L, 1997, J NEUROIMMUNOL, V74, P173, DOI 10.1016/S0165-5728(96)00226-3; Descamps L, 1996, AM J PHYSIOL-HEART C, V270, pH1149, DOI 10.1152/ajpheart.1996.270.4.H1149; FAUCHEUX BA, 1995, P NATL ACAD SCI USA, V92, P9603, DOI 10.1073/pnas.92.21.9603; FAUCHEUX BA, 1993, J NEUROCHEM, V60, P2338, DOI 10.1111/j.1471-4159.1993.tb03527.x; FILLEBEEN C, 1998, ADV LACTOFERRIN RES, P296; GLIEMANN J, 1994, ANN NY ACAD SCI, V737, P20, DOI 10.1111/j.1749-6632.1994.tb44299.x; GOAVEC M, 1985, CR ACAD SCI III-VIE, V301, P689; GROBMYER SR, 1993, J BIOL CHEM, V268, P13291; HALLGREN R, 1982, INFLAMMATION, V6, P291, DOI 10.1007/BF00916410; HERZ J, 1991, J BIOL CHEM, V266, P21232; HUTTINGER M, 1992, J BIOL CHEM, V267, P18551; JENNER P, 1996, NEUROLOGY S3, V47, P161; KAWAMATA T, 1993, AM J PATHOL, V142, P1574; KELLER KM, 1989, BIOCHEMISTRY-US, V28, P8100, DOI 10.1021/bi00446a021; KING GL, 1985, SCIENCE, V227, P1583, DOI 10.1126/science.3883490; LAMAZE C, 1995, CURR OPIN CELL BIOL, V7, P573, DOI 10.1016/0955-0674(95)80015-8; Legrand D, 1997, BIOCHEM J, V327, P841, DOI 10.1042/bj3270841; LEVEUGLE B, 1994, BRAIN RES, V650, P20, DOI 10.1016/0006-8993(94)90202-X; Leveugle B, 1996, ACTA NEUROPATHOL, V91, P566, DOI 10.1007/s004010050468; LEVEUGLE B, 1993, EUR J BIOCHEM, V213, P1205, DOI 10.1111/j.1432-1033.1993.tb17871.x; Masson P., 1970, LACTOFERRINE PROTEIN, P93; MASSON PL, 1969, J EXP MED, V130, P643, DOI 10.1084/jem.130.3.643; MAZURIER J, 1989, EUR J BIOCHEM, V179, P481, DOI 10.1111/j.1432-1033.1989.tb14578.x; MEILINGER M, 1995, FEBS LETT, V360, P70, DOI 10.1016/0014-5793(95)00082-K; MERESSE S, 1989, J NEUROCHEM, V53, P1363, DOI 10.1111/j.1471-4159.1989.tb08526.x; MIKOGAMI T, 1995, BIOCHEM J, V308, P391, DOI 10.1042/bj3080391; MIKOGAMI T, 1994, AM J PHYSIOL, V267, P308; MILICI AJ, 1987, J CELL BIOL, V105, P2303; MONTREUIL J, 1960, BIOCHIM BIOPHYS ACTA, V45, P413, DOI 10.1016/0006-3002(60)91478-5; NILLESSE N, 1994, BIOL CELL, V82, P149, DOI 10.1016/S0248-4900(94)80017-0; Nuijens JH, 1996, J MAMMARY GLAND BIOL, V1, P285, DOI 10.1007/BF02018081; OSMAND AP, 1991, ALZHEIMERS DISEASE : BASIC MECHANISMS, DIAGNOSIS AND THERAPEUTIC STRATEGIES, P219; REBECK GW, 1995, ANN NEUROL, V37, P211, DOI 10.1002/ana.410370212; SCHNITZER JE, 1994, J BIOL CHEM, V269, P6072; SCHNITZER JE, 1994, J CELL BIOL, V127, P1217, DOI 10.1083/jcb.127.5.1217; SEVERS NJ, 1986, LAB INVEST, V55, P295; Siebert PD, 1997, P NATL ACAD SCI USA, V94, P2198, DOI 10.1073/pnas.94.6.2198; SOFIC E, 1988, J NEURAL TRANSM, V74, P199, DOI 10.1007/BF01244786; SPIK G, 1993, NEW PERSPECTIVES INF, P77; STRICKLAND DK, 1994, FIBRINOLYSIS, V8, P204, DOI 10.1016/0268-9499(94)90718-8; STRICKLAND DK, 1991, J BIOL CHEM, V266, P13364; TERENT A, 1981, STROKE, V12, P40, DOI 10.1161/01.STR.12.1.40; TOOYAMA I, 1995, BRAIN RES, V691, P235, DOI 10.1016/0006-8993(95)00735-9; vanBerkel PHC, 1997, BIOCHEM J, V328, P145, DOI 10.1042/bj3280145; Warshawsky I, 1996, EUR J CELL BIOL, V69, P156; Willnow TE, 1996, EMBO J, V15, P2632, DOI 10.1002/j.1460-2075.1996.tb00623.x; WILLNOW TE, 1992, J BIOL CHEM, V267, P26172; Ziere GJ, 1996, BIOCHEM J, V313, P289, DOI 10.1042/bj3130289; ZIERE GJ, 1993, J BIOL CHEM, V268, P27069	62	290	330	1	29	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 12	1999	274	11					7011	7017		10.1074/jbc.274.11.7011	http://dx.doi.org/10.1074/jbc.274.11.7011			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	175DV	10066755	hybrid			2022-12-25	WOS:000079078400027
J	Shi, Y; Wang, SL; Krueger, S; Schwarz, FP				Shi, Y; Wang, SL; Krueger, S; Schwarz, FP			Effect of mutations at the monomer-monomer interface of cAMP receptor protein on specific DNA binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE ACTIVATOR PROTEIN; CYCLIC-AMP RECEPTOR; ESCHERICHIA-COLI; REGULATORY PROTEIN; THERMODYNAMICS; COMPLEX; SITE; CAP; TRANSCRIPTION; ASSOCIATION	To determine the thermodynamic role of binding of an operon to cAMP receptor protein (CRP) in the activation of transcription, isothermal titration calorimetry measurements were performed on the binding of three 40-base pair DNA sequences to the cyclic nucleoside complexes of CRP and its mutants at 296 K, The three 40-base pair sequences consisted of a consensus DNA (conDNA) duplex derived from the CRP-binding site sequences of the operons activated by CRP and two DNA sequences based on the CRP-binding site sequences of the lac operon (lacDNA) and of the gal operon (galDNA), The mutants of CRP consisted of a T127L mutant, a S128A mutant, and a mutant containing both mutations (CRP*) which not only alter the transcriptional activity of the CRP complexes but also are involved in the monomer-monomer interfacial interactions of the CRP dimer, The binding reactions of the DNA duplexes to the fully cNMP-ligated CRP-mutant complexes were endothermic with binding constants as high as 6.6 +/- 1.1 x 10(6) M-1 (conDNA . CRP(cAMP)(2)). ConDNA binding to the unligated T127L and CRP* mutants was observed as well as conDNA and lacDNA binding to CRP with cAMP bound to only one monomer. The reduction of the binding constants with increase in KCl concentration indicated the formation of two ion pairs for the cAMP-ligated CRP and S128A complexes and four ion pairs for the cAMP-ligated T127L and CRP* complexes. Reduction of the DNA binding constants upon substitution of D2O for H2O in the buffer, the large heat capacity changes, and the enthalpy-entropy compensation exhibited by the binding reactions indicate the importance of dehydration in the binding reaction. Small angle neutron scattering measurements on the lacDNA . CRP(cAMP)(2) complex in D2O/ H2O mixtures show that the DNA is bent around the cAMP-ligated protein in solution.	Natl Inst Stand & Technol, Ctr Adv Res Biotechnol, Rockville, MD 20850 USA	National Institute of Standards & Technology (NIST) - USA	Schwarz, FP (corresponding author), Natl Inst Stand & Technol, Ctr Adv Res Biotechnol, Rockville, MD 20850 USA.							ANDERSON WB, 1971, J BIOL CHEM, V246, P5929; BERG OG, 1988, J MOL BIOL, V200, P709, DOI 10.1016/0022-2836(88)90482-2; BROWN AM, 1989, P NATL ACAD SCI USA, V86, P7387, DOI 10.1073/pnas.86.19.7387; CHERVENAK MC, 1994, J AM CHEM SOC, V116, P10533, DOI 10.1021/ja00102a021; CONNELLY PR, 1993, BIOCHEMISTRY-US, V32, P5583, DOI 10.1021/bi00072a013; CROMBRUGGHE B, 1984, SCIENCE, V224, P831; EBRIGHT RH, 1989, NUCLEIC ACIDS RES, V17, P10295, DOI 10.1093/nar/17.24.10295; FRIED MG, 1984, J MOL BIOL, V172, P241, DOI 10.1016/S0022-2836(84)80025-X; GARGES S, 1988, J BACTERIOL, V170, P1417, DOI 10.1128/jb.170.4.1417-1422.1988; GORSHKOVA I, 1995, J BIOL CHEM, V270, P21679, DOI 10.1074/jbc.270.37.21679; GUNASEKERA A, 1992, J BIOL CHEM, V267, P14713; Hubbard SJ, 1993, NACCESS COMPUTER PRO; Krueger S, 1998, J BIOL CHEM, V273, P20001, DOI 10.1074/jbc.273.32.20001; Krueger S, 1997, PHYSICA B, V241, P1131, DOI 10.1016/S0921-4526(97)00809-0; LIUJOHNSON HN, 1986, CELL, V47, P995, DOI 10.1016/0092-8674(86)90814-7; Lundback T, 1996, P NATL ACAD SCI USA, V93, P4754, DOI 10.1073/pnas.93.10.4754; Moore JL, 1996, J BIOL CHEM, V271, P21273, DOI 10.1074/jbc.271.35.21273; MOORE JL, 1993, THESIS G WASHINGTON; MULLER N, 1991, J SOLUTION CHEM, V20, P669, DOI 10.1007/BF00650715; Parkinson G, 1996, J MOL BIOL, V260, P395, DOI 10.1006/jmbi.1996.0409; PORTE D, 1995, J BIOL CHEM, V270, P22721, DOI 10.1074/jbc.270.39.22721; RECORD MT, 1978, Q REV BIOPHYS, V11, P103, DOI 10.1017/S003358350000202X; RICHEY B, 1987, J BIOL CHEM, V262, P7157; SCHULTZ SC, 1991, SCIENCE, V253, P1001, DOI 10.1126/science.1653449; SCHWARZ FP, 1993, J BIOL CHEM, V268, P7668; SPOLAR RS, 1994, SCIENCE, V263, P777, DOI 10.1126/science.8303294; TAKAHASHI M, 1989, J MOL BIOL, V207, P783, DOI 10.1016/0022-2836(89)90244-1; TAKEDA Y, 1992, P NATL ACAD SCI USA, V89, P8180, DOI 10.1073/pnas.89.17.8180; Vossen KM, 1997, BIOCHEMISTRY-US, V36, P11640, DOI 10.1021/bi971193e; WEBER IT, 1984, P NATL ACAD SCI-BIOL, V81, P3973, DOI 10.1073/pnas.81.13.3973; WEBER IT, 1987, J MOL BIOL, V198, P311, DOI 10.1016/0022-2836(87)90315-9; WISEMAN T, 1989, ANAL BIOCHEM, V179, P131, DOI 10.1016/0003-2697(89)90213-3; YANG CP, 1990, OMEGA DATA ORIGIN, P66; ZHANG XP, 1992, J BIOL CHEM, V267, P8136	34	22	22	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	1999	274	11					6946	6956		10.1074/jbc.274.11.6946	http://dx.doi.org/10.1074/jbc.274.11.6946			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	175DV	10066748	hybrid			2022-12-25	WOS:000079078400020
J	Miyata, S; Ruggeri, ZM				Miyata, S; Ruggeri, ZM			Distinct structural attributes regulating von Willebrand factor A1 domain interaction with platelet glycoprotein Ib alpha under flow	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VONWILLEBRAND-FACTOR-BINDING; AMINO-ACID-SEQUENCE; ACUTE CORONARY SYNDROMES; BOTHROPS-JARARACA; ARTERY DISEASE; RNA-POLYMERASE; FACTOR VWF; BOTROCETIN; VENOM; COMPLEX	We have used recombinant von Willebrand factor (vWF) fragments to investigate the properties regulating A1 domain interaction with platelet glycoprotein (GP) Ib alpha. One fragment, rvWF(508-704), represented the main portion of domain Al (mature subunit residues 497-716) within the Cys(509)-Cys(695) disulfide loop. The other, rvWF(445-733), included the carboxyl-terminal region of domain D3, preceding A1, and corresponded to the proteolytic fragment originally identified as the GP Ib alpha-binding site (residues 449-728), Conformational changes were induced by reduction and alkylation of the Cys509-Cys695 bond and/or exposure to acidic pH, The cyclic, rvWF(445-733) fragment exhibited the function of native VWF A1 domain. When immobilized onto a surface, it tethered platelets at shear rates up to 6,300 s(-1) mediating low velocity translocation but not stable attachment; in solution, it exhibited limited interaction with GP Ib alpha. In contrast, fragments with perturbed conformation could not tether platelets at high shear rates but promoted stable adhesion at lower shear and bound tightly to GP Ib alpha. Only in the presence of the exogenous modulator, botrocetin, did cyclic rvWF(445-733) mediate irreversible adhesion. Thus, conformational transitions in the VWF A1 domain may influence differentially the efficiency of bond formation with GP Ib alpha and the stability of binding.	Scripps Res Inst, Dept Mol & Expt Med, Div Expt Hemostasis & Thrombosis, Roon Res Ctr Arteriosclerosis & Thrombosis, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Vasc Biol, La Jolla, CA 92037 USA	Scripps Research Institute; Scripps Research Institute	Ruggeri, ZM (corresponding author), Scripps Res Inst, Dept Mol & Expt Med, Div Expt Hemostasis & Thrombosis, Roon Res Ctr Arteriosclerosis & Thrombosis, SBR-8,10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL048728, P01HL031950, R01HL042846, R37HL042846] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-42846, HL-48728, HL-31950] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDREWS RK, 1989, BIOCHEMISTRY-US, V28, P8317, DOI 10.1021/bi00447a009; BACK LD, 1977, J BIOMECH, V10, P339, DOI 10.1016/0021-9290(77)90006-9; BAUMGARTNER HR, 1977, THROMB HAEMOSTASIS, V37, P17; Celikel R, 1998, NAT STRUCT BIOL, V5, P189, DOI 10.1038/nsb0398-189; CRUZ MA, 1995, J BIOL CHEM, V270, P10822, DOI 10.1074/jbc.270.18.10822; DEGROOT PG, 1988, J CLIN INVEST, V82, P65, DOI 10.1172/JCI113602; DENT JA, 1990, P NATL ACAD SCI USA, V87, P6306, DOI 10.1073/pnas.87.16.6306; DISE CA, 1982, J BIOL CHEM, V257, P4701; EY PL, 1978, IMMUNOCHEMISTRY, V15, P429, DOI 10.1016/0161-5890(78)90070-6; FOWLER WE, 1985, J CLIN INVEST, V76, P1491, DOI 10.1172/JCI112129; FUJIMURA Y, 1991, BLOOD, V77, P113; FUJIMURA Y, 1991, BIOCHEMISTRY-US, V30, P1957, DOI 10.1021/bi00221a032; FUSTER V, 1992, NEW ENGL J MED, V326, P242, DOI 10.1056/NEJM199201233260406; FUSTER V, 1992, NEW ENGL J MED, V326, P310; GOLDSMITH HL, 1986, THROMB HAEMOSTASIS, V55, P415; GOTO S, 1995, J BIOL CHEM, V270, P23352, DOI 10.1074/jbc.270.40.23352; HANDA M, 1986, J BIOL CHEM, V261, P2579; HOWARD MA, 1971, THROMB DIATH HAEMOST, V26, P362; KATAYAMA M, 1995, J BIOCHEM-TOKYO, V117, P331, DOI 10.1093/jb/117.2.331; Kawasaki T, 1996, J BIOL CHEM, V271, P10635, DOI 10.1074/jbc.271.18.10635; MARTI T, 1987, BIOCHEMISTRY-US, V26, P8099, DOI 10.1021/bi00399a013; Miyata S, 1996, J BIOL CHEM, V271, P9046, DOI 10.1074/jbc.271.15.9046; NIIYA K, 1987, BLOOD, V70, P475; PARETI FI, 1987, J BIOL CHEM, V262, P13835; PRIOR CP, 1993, BIO-TECHNOL, V11, P709, DOI 10.1038/nbt0693-709; READ MS, 1978, P NATL ACAD SCI USA, V75, P4514, DOI 10.1073/pnas.75.9.4514; READ MS, 1989, BLOOD, V74, P1031; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; Ruggeri ZM, 1997, J CLIN INVEST, V99, P559, DOI 10.1172/JCI119195; RUGGERI ZM, 1983, J CLIN INVEST, V72, P1, DOI 10.1172/JCI110946; RUGGERI ZM, 1993, FASEB J, V7, P308, DOI 10.1096/fasebj.7.2.8440408; Savage B, 1996, CELL, V84, P289, DOI 10.1016/S0092-8674(00)80983-6; SAVAGE B, 1992, J BIOL CHEM, V267, P11300; SCOTT JP, 1991, J BIOL CHEM, V266, P8149; Siedlecki CA, 1996, BLOOD, V88, P2939, DOI 10.1182/blood.V88.8.2939.bloodjournal8882939; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; SUGIMOTO M, 1993, J BIOL CHEM, V268, P12185; SUGIMOTO M, 1991, J BIOL CHEM, V266, P18172; TANGELDER GJ, 1988, AM J PHYSIOL, V254, pH1059, DOI 10.1152/ajpheart.1988.254.6.H1059; TITANI K, 1987, P NATL ACAD SCI USA, V84, P5610, DOI 10.1073/pnas.84.16.5610; TITANI K, 1986, BIOCHEMISTRY-US, V25, P3171, DOI 10.1021/bi00359a015; USAMI S, 1993, ANN BIOMED ENG, V21, P77, DOI 10.1007/BF02368167; USAMI Y, 1993, P NATL ACAD SCI USA, V90, P928, DOI 10.1073/pnas.90.3.928; ZIMMERMAN TS, 1986, J CLIN INVEST, V77, P947, DOI 10.1172/JCI112394	45	54	55	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1999	274	10					6586	6593		10.1074/jbc.274.10.6586	http://dx.doi.org/10.1074/jbc.274.10.6586			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172BQ	10037753	hybrid			2022-12-25	WOS:000078902800075
J	Torres, GE; Egan, TM; Voigt, MM				Torres, GE; Egan, TM; Voigt, MM			Hetero-oligomeric assembly of P2X receptor subunits - Specificities exist with regard to possible partners	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GATED ION CHANNELS; SENSORY NEURONS; ATP; RAT; PURINOCEPTORS; EXPRESSION; CLONING	P2X receptors are a distinct family of Ligand-gated ion channels activated by extracellular ATP, Each of the seven identified subunit proteins (P2X(1) through P2X(7)) has been reported to form functional homo-oligomeric channels when expressed in heterologous systems. Functional studies of native receptors, together with patterns of subunit gene expression, suggest that hetero-oligomeric assembly among members of this family may also occur. This prediction is supported by reports describing hetero-oligomeric assembly for three different recombinant subunit combinations. In this report, we systematically examined the ability of all members of the P2X receptor family to interact using a co-immunoprecipitation assay. The seven P2X receptor subunits were differentially epitope-tagged and expressed in various combinations in human embryonic kidney 293 cells. It was found that six of the seven subunits formed homooligomeric complexes, the exception being P2X(6). When co-assembly between pairs of subunits was examined, all were able to form hetero-oligomeric assemblies with the exception of P2X(7). Whereas P2X(1), P2X(2), P2X(5), and P2X(6) were able to assemble with most subunits, P2X(3) and P2X(4) presented a more restricted pattern of co-association, These results suggest that hetero-oligomeric assembly might underlie functional discrepancies observed between P2X responses seen in the native and recombinant settings, while providing for an increased diversity of signaling by ATP.	St Louis Univ, Sch Med, Dept Pharmacol & Physiol Sci, St Louis, MO 63104 USA	Saint Louis University	Voigt, MM (corresponding author), St Louis Univ, Sch Med, Dept Pharmacol & Physiol Sci, 1402 S Grand Blvd, St Louis, MO 63104 USA.	voigtm@slu.edu		Egan, Terrance/0000-0002-7249-3161	NHLBI NIH HHS [HL56236] Funding Source: Medline; NINDS NIH HHS [NS35534] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL056236] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS035534] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bardoni R, 1997, J NEUROSCI, V17, P5297; Barnard EA, 1998, PHARMACOL REV, V50, P291; BARNARD EA, 1992, TRENDS BIOCHEM SCI, V17, P368, DOI 10.1016/0968-0004(92)90002-Q; Burnstock G, 1996, CIBA F SYMP, V198, P1; CANESSA CM, 1994, NATURE, V367, P463, DOI 10.1038/367463a0; Cario-Toumaniantz C, 1998, CIRC RES, V83, P196, DOI 10.1161/01.RES.83.2.196; Cheng C, 1998, J BIOL CHEM, V273, P22693, DOI 10.1074/jbc.273.35.22693; Collo G, 1997, NEUROPHARMACOLOGY, V36, P1277, DOI 10.1016/S0028-3908(97)00140-8; Collo G, 1996, J NEUROSCI, V16, P2495; Cook SP, 1997, NATURE, V387, P505, DOI 10.1038/387505a0; DEVILLERSTHIERY A, 1993, J MEMBRANE BIOL, V136, P97, DOI 10.1007/BF02505755; FREDHOLM BB, 1994, PHARMACOL REV, V46, P143; KHAKH BS, 1995, BRIT J PHARMACOL, V115, P177, DOI 10.1111/j.1476-5381.1995.tb16336.x; Le KT, 1998, J NEUROSCI, V18, P7152; LEWIS C, 1995, NATURE, V377, P432, DOI 10.1038/377432a0; Nori S, 1998, J VASC RES, V35, P179, DOI 10.1159/000025582; PRIBILLA I, 1992, EMBO J, V11, P4305, DOI 10.1002/j.1460-2075.1992.tb05529.x; Radford KM, 1997, J NEUROSCI, V17, P6529; Ralevic V, 1998, PHARMACOL REV, V50, P413; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; SEEBURG PH, 1993, TRENDS NEUROSCI, V16, P359, DOI 10.1016/0166-2236(93)90093-2; Soto M, 1996, BIOCHEM BIOPH RES CO, V223, P456, DOI 10.1006/bbrc.1996.0915; Tenneti L, 1998, J BIOL CHEM, V273, P26799, DOI 10.1074/jbc.273.41.26799; Torres GE, 1998, FEBS LETT, V425, P19, DOI 10.1016/S0014-5793(98)00179-3; Torres GE, 1998, MOL PHARMACOL, V54, P989, DOI 10.1124/mol.54.6.989; VALERA S, 1994, NATURE, V371, P516, DOI 10.1038/371516a0; Vulchanova L, 1997, NEUROPHARMACOLOGY, V36, P1229, DOI 10.1016/S0028-3908(97)00126-3; Wisden W, 1993, Curr Opin Neurobiol, V3, P291, DOI 10.1016/0959-4388(93)90120-N; Xiang ZH, 1998, NEUROSCI LETT, V256, P105, DOI 10.1016/S0304-3940(98)00774-5; Zhong Y, 1998, BRIT J PHARMACOL, V125, P771, DOI 10.1038/sj.bjp.0702118	30	348	354	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	1999	274	10					6653	6659		10.1074/jbc.274.10.6653	http://dx.doi.org/10.1074/jbc.274.10.6653			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172BQ	10037762	hybrid			2022-12-25	WOS:000078902800084
J	Yamazaki, M; Zhang, Y; Watanabe, H; Yokozeki, T; Ohno, S; Kaibuchi, K; Shibata, H; Mukai, H; Ono, Y; Frohman, MA; Kanaho, Y				Yamazaki, M; Zhang, Y; Watanabe, H; Yokozeki, T; Ohno, S; Kaibuchi, K; Shibata, H; Mukai, H; Ono, Y; Frohman, MA; Kanaho, Y			Interaction of the small G protein RhoA with the C terminus of human phospholipase D1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADP-RIBOSYLATION FACTOR; KINASE-C; RAT-BRAIN; POSTTRANSLATIONAL MODIFICATIONS; EXCHANGE PROTEINS; PHOSPHATIDIC-ACID; PUTATIVE TARGET; BINDING DOMAIN; SMALL GTPASE; D DEFINES	Mammalian phosphatidylcholine-specific phospholipase D1 (PLD1) is a signal transduction-activated enzyme thought to function in multiple cell biological settings including the regulation of membrane vesicular trafficking. PLD1 is activated by the small G proteins, ADP-ribosylation factor (ARF) and RhoA, and by protein kinase C-alpha (PKC-alpha). This stimulation has been proposed to involve direct interaction and to take place at a distinct site in PLD1 for each activator. In the present study, we employed the yeast two-hybrid system to attempt to identify these sites. Successful interaction of ARF and PKC-alpha with PLD1 was not achieved, but a C-terminal fragment of human PLD1 (denoted "D4") interacted with the active mutant of RhoA, RhoA(Val-14) Deletion of the CAAX box from RhoA(Val-14) decreased the strength of the interaction, suggesting that lipid modification of RhoA is important for efficient binding to PLD1. The specificity of the interaction was validated by showing that the PLD1 D4 fragment interacts with glutathione S-transferase-RhoA in vitro in a GTP-dependent manner and that it associates with RhoA(Val-14) in COS-7 cells, whereas the N-terminal two-thirds of PLD1 does not. Finally, we show that recombinant D4 peptide inhibits RhoA-stimulated PLD1 activation but not ARF- or PKC-alpha-stimulated PLD1 activation. These results conclusively demonstrate that the C-terminal region of PLD1 contains the RhoA-binding site and suggest that the ARF and PKC interactions occur elsewhere in the protein.	Tokyo Inst Technol, Dept Life Sci, Yokohama, Kanagawa 2268501, Japan; Yokohama City Univ, Sch Med, Dept Mol Biol, Yokohama, Kanagawa 2360004, Japan; Nara Inst Sci & Technol, Div Signal Transduct, Ikoma 6300101, Japan; Kobe Univ, Fac Sci, Dept Biol, Kobe, Hyogo 6578501, Japan; SUNY Stony Brook, Inst Cell & Dev Biol, Stony Brook, NY 11794 USA; SUNY Stony Brook, Program Mol & Cellular Biol, Stony Brook, NY 11794 USA; SUNY Stony Brook, Dept Pharmacol Sci, Stony Brook, NY 11794 USA	Tokyo Institute of Technology; Yokohama City University; Nara Institute of Science & Technology; Kobe University; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Kanaho, Y (corresponding author), Tokyo Inst Technol, Dept Life Sci, Yokohama, Kanagawa 2268501, Japan.		Watanabe, Hiroshi/GOP-0177-2022; Ohno, Shigeo/B-1768-2010	Watanabe, Hiroshi/0000-0001-8887-5407; Ohno, Shigeo/0000-0002-1294-5269; Mukai, Hideyuki/0000-0002-0167-8695				ADAMSON P, 1992, J BIOL CHEM, V267, P20033; Aelst L, 1997, GENE DEV, V11, P2295; ANDO S, 1992, J BIOL CHEM, V267, P25709; Bae CD, 1998, J BIOL CHEM, V273, P11596, DOI 10.1074/jbc.273.19.11596; Bartel P. L., 1993, CELLULAR INTERACTION, P153; BILLAH MM, 1993, CURR OPIN IMMUNOL, V5, P114; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN HA, 1993, CELL, V75, P1137, DOI 10.1016/0092-8674(93)90323-I; COCKCROFT S, 1994, SCIENCE, V263, P523, DOI 10.1126/science.8290961; Colley WC, 1997, CURR BIOL, V7, P191, DOI 10.1016/S0960-9822(97)70090-3; Cross MJ, 1996, CURR BIOL, V6, P588, DOI 10.1016/S0960-9822(02)00545-6; Exton JH, 1997, J BIOL CHEM, V272, P15579, DOI 10.1074/jbc.272.25.15579; Fujisawa K, 1996, J BIOL CHEM, V271, P23022, DOI 10.1074/jbc.271.38.23022; FUJISE A, 1994, J BIOL CHEM, V269, P31642; HAMMOND SM, 1995, J BIOL CHEM, V270, P29640; Hammond SM, 1997, J BIOL CHEM, V272, P3860, DOI 10.1074/jbc.272.6.3860; Hayes F, 1997, J BIOL CHEM, V272, P28833, DOI 10.1074/jbc.272.46.28833; HORI Y, 1991, ONCOGENE, V6, P515; Ishizaki T, 1996, EMBO J, V15, P1885, DOI 10.1002/j.1460-2075.1996.tb00539.x; KATAYAMA M, 1991, J BIOL CHEM, V266, P12639; Kodaki T, 1997, J BIOL CHEM, V272, P11408; Ktistakis NT, 1996, J CELL BIOL, V134, P295, DOI 10.1083/jcb.134.2.295; KURIBARA H, 1995, J BIOL CHEM, V270, P25667, DOI 10.1074/jbc.270.43.25667; Kuroda S, 1996, J BIOL CHEM, V271, P31029, DOI 10.1074/jbc.271.49.31029; Kuroda S, 1996, J BIOL CHEM, V271, P23363, DOI 10.1074/jbc.271.38.23363; Madaule P, 1995, FEBS LETT, V377, P243, DOI 10.1016/0014-5793(95)01351-2; MALCOLM KC, 1994, J BIOL CHEM, V269, P25951; MIZUNO T, 1991, P NATL ACAD SCI USA, V88, P6442, DOI 10.1073/pnas.88.15.6442; MOOLENAAR WH, 1995, CURR OPIN CELL BIOL, V7, P203, DOI 10.1016/0955-0674(95)80029-8; MORITZ A, 1992, J BIOL CHEM, V267, P7207; Morris AJ, 1996, TRENDS PHARMACOL SCI, V17, P182, DOI 10.1016/0165-6147(96)10016-X; NAKANISHI H, 1992, J BIOL CHEM, V267, P16347; Park SK, 1997, J BIOL CHEM, V272, P29263, DOI 10.1074/jbc.272.46.29263; Reid T, 1996, J BIOL CHEM, V271, P13556, DOI 10.1074/jbc.271.23.13556; Shibata H, 1996, FEBS LETT, V385, P221, DOI 10.1016/0014-5793(96)00385-7; Singer WD, 1996, J BIOL CHEM, V271, P4504; Sung TC, 1997, EMBO J, V16, P4519, DOI 10.1093/emboj/16.15.4519; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TOMIC S, 1995, J BIOL CHEM, V270, P21277, DOI 10.1074/jbc.270.36.21277; Vincent S, 1997, MOL CELL BIOL, V17, P2247, DOI 10.1128/MCB.17.4.2247; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; Watanabe G, 1996, SCIENCE, V271, P645, DOI 10.1126/science.271.5249.645; Watanabe N, 1997, EMBO J, V16, P3044, DOI 10.1093/emboj/16.11.3044	43	90	93	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1999	274	10					6035	6038		10.1074/jbc.274.10.6035	http://dx.doi.org/10.1074/jbc.274.10.6035			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172BQ	10037681	hybrid			2022-12-25	WOS:000078902800003
J	Ranganathan, S; Knaak, C; Morales, CR; Argraves, WS				Ranganathan, S; Knaak, C; Morales, CR; Argraves, WS			Identification of low density lipoprotein receptor-related protein-2/megalin as an endocytic receptor for seminal vesicle secretory protein II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROSTATE SPECIFIC ANTIGEN; RAT EPIDIDYMAL FLUID; ALPHA-2-MACROGLOBULIN RECEPTOR; ALPHA(2)-MACROGLOBULIN RECEPTOR; APOLIPOPROTEIN-J/CLUSTERIN; MEDIATES ENDOCYTOSIS; ORGAN DISTRIBUTION; GENE FAMILY; 2 MEMBERS; SVS-II	The low density lipoprotein receptor-related protein-2/megalin (LRP-2) is an endocytic receptor that is expressed on the apical surfaces of epithelial cells lining specific regions of the male and female reproductive tracts. In the present study, immunohistochemical staining revealed that LRP-2 is also expressed by epithelial cells lining the ductal region and the ampulla of the rat seminal vesicle. To identify LRP-2 ligands in the seminal vesicle, we probed seminal vesicle fluid with I-125-labeled LRP-2 in a gel-blot overlay assay. A 100-kDa protein (under non-reducing conditions) was found to bind the radiolabeled receptor. The protein was isolated and subjected to protease digestion, and the proteolytic fragments were subjected to mass spectroscopic sequence analysis. As a result, the 100-kDa protein was identified as the seminal vesicle secretory protein II (SVS-II), a major constituent of the seminal coagulum. Using purified preparations of SVS-II and LRP-2, solid-phase binding assays were used to show that the SVS-II bound to the receptor with high affinity (K-d = 5.6 nM). The binding of SVS-II to LRP-2 was inhibited using a known antagonist of LRP-2 function, the 39-kDa receptor-associated protein RAP. Using a series of recombinant subfragments of SVS-II, the LRP-2 binding site was mapped to a stretch of repeated 13-residue modules located in the central portion of the SVS-II polypeptide. To evaluate the ability of LRP-2 to mediate I-125-SVS-II endocytosis and lysosomal degradation, ligand clearance assays were performed using differentiated mouse F9 cells, which express high levels of LRP-2, Radiolabeled SVS-II was internalized and degraded by the cells, and both processes were inhibited by antibodies to LRP-2 or by RAP. The results indicate that LRP-2 binds SVS-II and can mediate its endocytosis leading to lysosomal degradation.	Med Univ S Carolina, Dept Cell Biol & Anat, Charleston, SC 29425 USA; McGill Univ, Dept Anat & Cell Biol, Montreal, PQ H3A 2B2, Canada	Medical University of South Carolina; McGill University	Argraves, WS (corresponding author), Med Univ S Carolina, Dept Cell Biol & Anat, 171 Ashley Ave, Charleston, SC 29425 USA.	argraves@musc.edu	Morales, Carlos R./H-1055-2011		NIDDK NIH HHS [DK45598] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045598] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AGRAWAL Y, 1987, J REPROD FERTIL, V79, P409, DOI 10.1530/jrf.0.0790409; AGRAWAL Y, 1988, J ANDROL, V9, P307; ARGRAVES WS, 1990, J CELL BIOL, V111, P3155, DOI 10.1083/jcb.111.6.3155; ASSMANN KJM, 1986, VIRCHOWS ARCH A, V408, P541, DOI 10.1007/BF00705307; BALASUBRAMANIAN K, 1991, INDIAN J EXP BIOL, P907; BROOKS DE, 1983, AUST J BIOL SCI, V36, P205, DOI 10.1071/BI9830205; Carballada R, 1997, J REPROD FERTIL, V109, P325, DOI 10.1530/jrf.0.1090325; CHAPMAN DA, 1984, BIOL REPROD, V31, P627, DOI 10.1095/biolreprod31.4.627; CHRISTENSEN EI, 1992, J HISTOCHEM CYTOCHEM, V40, P1481, DOI 10.1177/40.10.1382088; FORNES MW, 1991, ANDROLOGIA, V23, P347; FORNES WM, 1995, ANDROLOGIA, V27, P233; GOLDSTEIN JL, 1974, J BIOL CHEM, V249, P5153; HARRIS SE, 1990, J BIOL CHEM, V265, P9896; HERZ J, 1991, J BIOL CHEM, V266, P21232; Huang LS, 1996, P NATL ACAD SCI USA, V93, P10903, DOI 10.1073/pnas.93.20.10903; JONES R, 1981, BIOCHEM J, V200, P457, DOI 10.1042/bj2000457; Kounnas M Z, 1994, In Vivo, V8, P343; KOUNNAS MZ, 1995, J BIOL CHEM, V270, P13070, DOI 10.1074/jbc.270.22.13070; KOUNNAS MZ, 1992, J BIOL CHEM, V267, P21162; KOUNNAS MZ, 1993, J BIOL CHEM, V268, P14176; KOUNNAS MZ, 1994, ANN NY ACAD SCI, V737, P114, DOI 10.1111/j.1749-6632.1994.tb44305.x; KUNSTYR I, 1982, LAB ANIM, V16, P151, DOI 10.1258/002367782781110205; Law GL, 1997, J ANDROL, V18, P32; LEE KP, 1986, LAB ANIM SCI, V36, P671; Liu K, 1996, MOL HUM REPROD, V2, P99, DOI 10.1093/molehr/2.2.99; Lundgren S, 1997, J HISTOCHEM CYTOCHEM, V45, P383, DOI 10.1177/002215549704500306; Lundwall A, 1996, EUR J BIOCHEM, V235, P424, DOI 10.1111/j.1432-1033.1996.00424.x; LUNDWALL A, 1995, FEBS LETT, V374, P53, DOI 10.1016/0014-5793(95)01076-Q; Morales CR, 1996, BIOL REPROD, V55, P676, DOI 10.1095/biolreprod55.3.676; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; OESTERLING JE, 1991, J UROLOGY, V145, P907, DOI 10.1016/S0022-5347(17)38491-4; ORLANDO RA, 1992, P NATL ACAD SCI USA, V89, P6698, DOI 10.1073/pnas.89.15.6698; Renneberg H, 1995, ACTA ANAT, V153, P273; ROBERTS KP, 1995, HDB ANDROLOGY; RONQUIST G, 1978, ANDROLOGIA, V10, P261; RONQUIST G, 1978, ANDROLOGIA, V10, P427; SAYEGH RA, 1995, J SOC GYNECOL INVESD, V6, P748; SEITZ J, 1992, EUR J CELL BIOL, V57, P308; SETTY BS, 1979, ENDOKRINOLOGIE, V74, P100; SIDHU KS, 1991, INT REV CYTOL, V127, P253; STEFANSSON S, 1995, J BIOL CHEM, V270, P19417, DOI 10.1074/jbc.270.33.19417; STEFANSSON S, 1995, J CELL SCI, V108, P2361; WAGNER CL, 1987, BIOL REPROD, V36, P501, DOI 10.1095/biolreprod36.2.501; WANG MC, 1979, INVEST UROL, V17, P159; WILLIAMS SE, 1992, J BIOL CHEM, V267, P9035; WILLIAMS SE, 1994, ANN NY ACAD SCI, V737, P1, DOI 10.1111/j.1749-6632.1994.tb44297.x; ZHENG G, 1994, J HISTOCHEM CYTOCHEM, V42, P531, DOI 10.1177/42.4.7510321	48	16	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 26	1999	274	9					5557	5563		10.1074/jbc.274.9.5557	http://dx.doi.org/10.1074/jbc.274.9.5557			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	170KG	10026171	hybrid			2022-12-25	WOS:000078804400042
J	Latres, E; Chiaur, DS; Pagano, M				Latres, E; Chiaur, DS; Pagano, M			The human F box protein beta-Trcp associates with the Cul1/Skp1 complex and regulates the stability of beta-catenin	ONCOGENE			English	Article						ubiquitin; F-box; SCF; beta-catenin; cancer	CELL-CYCLE; SACCHAROMYCES-CEREVISIAE; HUMAN FIBROBLASTS; PATHWAY; KINASE	Ubiquitin-conjugation targets numerous cellular regulators for proteasome-mediated degradation. Thus, the identification of ubiquitin ligases and their physiological substrates is crucially important, especially for those cases in which aberrant levels of regulatory proteins (e.g., beta-catenin, p27) result from a deregulated ubiquitination pathway. In yeast, the proteolysis of several G1 regulators is controlled by ubiquitin ligases (or SCFs) formed by three subunits: (S) under bar kp1, (C) under bar ul A (Cdc53), and one of many (F) under bar-box proteins. Specific F-box proteins (Fbps) recruit different substrates to the SCF, Although many Fbps have been identified in mammals, their specific substrates and the existence of multiple SCFs have not yet been reported. We have found that one human Fbp, beta-Trcp (beta-Transducin repeat containing protein), does indeed form a novel SCF with human Skp1 and Cul1. Consistent with recent reports indicating that Xenopus and Drosophila beta-Trcp homologs act as negative regulators of the wnt/beta-catenin signaling pathway, we report here that human beta-Trcp interacts with beta-catenin in vivo, Furthermore, beta-catenin is specifically stabilized in vivo by the expression of a dominant negative beta-Trcp, These results indicate that the Cul1/Skp1/beta-Trcp complex forms a ubiquitin ligase that mediates the degradation of beta-catenin.	NYU Med Ctr, Dept Pathol, New York, NY 10016 USA; NYU Med Ctr, Kaplan Comprehens Canc Ctr, New York, NY 10016 USA	New York University; New York University	Pagano, M (corresponding author), NYU Med Ctr, Dept Pathol, MSB 548,550 1st Ave, New York, NY 10016 USA.		高, 雨莉/HGU-8187-2022	pagano, michele/0000-0003-3210-2442	NATIONAL CANCER INSTITUTE [R01CA076584, T32CA009161] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057587] Funding Source: NIH RePORTER; NCI NIH HHS [5T32-CA09161, R01-CA76584] Funding Source: Medline; NIGMS NIH HHS [R01-GM57587] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bai C, 1996, CELL, V86, P263, DOI 10.1016/S0092-8674(00)80098-7; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; GONEN H, 1999, UNPUB; HANNON GJ, 1995, CELL CYCLE MAT METHO, P231; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Jiang J, 1998, NATURE, V391, P493, DOI 10.1038/35154; KIPREOS ET, 1999, UNPUB; Lisztwan J, 1998, EMBO J, V17, P368, DOI 10.1093/emboj/17.2.368; Lyapina SA, 1998, P NATL ACAD SCI USA, V95, P7451, DOI 10.1073/pnas.95.13.7451; Margottin F, 1998, MOL CELL, V1, P565, DOI 10.1016/S1097-2765(00)80056-8; Marikawa Y, 1998, MECH DEVELOP, V77, P75, DOI 10.1016/S0925-4773(98)00134-8; Michel JJ, 1998, CELL GROWTH DIFFER, V9, P435; Miller JR, 1996, GENE DEV, V10, P2527, DOI 10.1101/gad.10.20.2527; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; MOUNTAIN HA, 1993, MOL MICROBIOL, V7, P215, DOI 10.1111/j.1365-2958.1993.tb01113.x; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; PAGANO M, 1993, J CELL BIOL, V121, P101, DOI 10.1083/jcb.121.1.101; Pagano M, 1997, FASEB J, V11, P1067, DOI 10.1096/fasebj.11.13.9367342; PAGANO M, 1994, GENE DEV, V8, P1627, DOI 10.1101/gad.8.14.1627; Peifer M, 1997, SCIENCE, V275, P1752, DOI 10.1126/science.275.5307.1752; Pennisi E, 1998, SCIENCE, V281, P1438, DOI 10.1126/science.281.5382.1438; RUBINFELD B, 1993, SCIENCE, V262, P1731, DOI 10.1126/science.8259518; Skowyra D, 1997, CELL, V91, P209, DOI 10.1016/S0092-8674(00)80403-1; SPEVAK W, 1993, MOL CELL BIOL, V13, P4953, DOI 10.1128/MCB.13.8.4953; SU LK, 1993, SCIENCE, V262, P1734, DOI 10.1126/science.8259519; Yu ZK, 1998, P NATL ACAD SCI USA, V95, P11324, DOI 10.1073/pnas.95.19.11324	26	354	367	2	14	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 28	1999	18	4					849	854		10.1038/sj.onc.1202653	http://dx.doi.org/10.1038/sj.onc.1202653			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	165FT	10023660				2022-12-25	WOS:000078510600001
J	Stahler, F; Roemer, K				Stahler, F; Roemer, K			Mutant p53 can provoke apoptosis in p53-deficient Hep3B cells with delayed kinetics relative to wild-type p53	ONCOGENE			English	Article						cell death; p53; c-Myc; serine protease	KAPPA-B ACTIVATION; DNA-DAMAGE; INDUCE APOPTOSIS; HEPATOMA-CELLS; GROWTH ARREST; DOMAIN; CHECKPOINT; PROMOTERS; PROTEIN; DEATH	Wild-type (wt) p53 frequently induces apoptosis when expressed in tumor cells whereas mutant p53 acts as an oncoprotein and consequently, stimulates cell proliferation. We report here exceptions to that rule, p53 conformational mutant 175H and DNA contact mutant 273H provoke apoptosis in human p53-deficient Hep3B hepatoma cells with delayed kinetics relative to wt p53. Similarly, c-Myc strongly stimulates apoptosis in these cells. In contrast,, viral oncoproteins EIA and E7, and the cellular oncoprotein MDM-2, fail to elicit cytocidal responses. Efficient apoptotic cell death by mutant p53 requires oligomerization as 175H and 273H with deletions between amino acid residues 326 and 347 of the oligomerization domain are nontoxic. Apoptosis by mutant or wt p53 was significantly inhibited by the serine protease inhibitor AEBSF but not by the inactive analog AEBSA, Together, these results suggest that a nit p53-independent control mechanism is operational in Hep3B cells that eliminates cells upon sensing illegitimate proliferation signals originating from certain oncoproteins, including mutant p53 and Myc. We suggest that some tumor cell types lack p53 altogether because they tolerate neither wild-type nor mutant forms of the protein.	Univ Saarlandes, Sch Med, Dept Virol, D-66421 Homburg, Germany	Saarland University	Roemer, K (corresponding author), Univ Saarlandes, Sch Med, Dept Virol, D-66421 Homburg, Germany.							ALLDAY MJ, 1995, EMBO J, V14, P4994, DOI 10.1002/j.1460-2075.1995.tb00182.x; Barlow C, 1997, NAT GENET, V17, P453, DOI 10.1038/ng1297-453; Bates S, 1996, CURR OPIN GENET DEV, V6, P12, DOI 10.1016/S0959-437X(96)90004-0; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; Chandler JM, 1997, BIOCHEM J, V322, P19, DOI 10.1042/bj3220019; Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; Friedlander P, 1996, MOL CELL BIOL, V16, P4961; Friedman SL, 1997, ONCOGENE, V15, P63, DOI 10.1038/sj.onc.1201149; Fuchs EJ, 1997, CANCER RES, V57, P2550; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; Israeli D, 1997, EMBO J, V16, P4384, DOI 10.1093/emboj/16.14.4384; Kagaya S, 1997, MOL CELL BIOL, V17, P6736, DOI 10.1128/MCB.17.11.6736; Klefstrom J, 1997, EMBO J, V16, P7382, DOI 10.1093/emboj/16.24.7382; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Ludwig RL, 1996, MOL CELL BIOL, V16, P4952; Mayo MW, 1997, SCIENCE, V278, P1812, DOI 10.1126/science.278.5344.1812; MIYASHITA T, 1995, CELL, V80, P293; Muller M, 1997, J CLIN INVEST, V99, P403, DOI 10.1172/JCI119174; Murphy M, 1996, GENE DEV, V10, P2971, DOI 10.1101/gad.10.23.2971; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Roemer K, 1996, ONCOGENE, V12, P2069; SABBATINI P, 1995, GENE DEV, V9, P2184, DOI 10.1101/gad.9.17.2184; Sakamuro D, 1997, ONCOGENE, V15, P887, DOI 10.1038/sj.onc.1201263; Theis S, 1997, INT J CANCER, V71, P858; Walker KK, 1996, P NATL ACAD SCI USA, V93, P15335, DOI 10.1073/pnas.93.26.15335; YEE JK, 1994, METHOD CELL BIOL, V43, P99; YonishRouach E, 1995, ONCOGENE, V11, P2197	29	29	32	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 31	1998	17	26					3507	3512		10.1038/sj.onc.1202245	http://dx.doi.org/10.1038/sj.onc.1202245			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	157XD	10030675				2022-12-25	WOS:000078086200012
J	McClure, RF; Heppelmann, CJ; Paya, CV				McClure, RF; Heppelmann, CJ; Paya, CV			Constitutive Fas ligand gene transcription in Sertoli cells is regulated by Sp1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KAPPA-B-ALPHA; IMMUNE PRIVILEGE; SP1-MEDIATED TRANSCRIPTION; NEGATIVE REGULATOR; MEDIATED APOPTOSIS; DEATH FACTOR; IN-VIVO; EXPRESSION; ACTIVATION; PROMOTER	The transcriptional regulation of the Fas ligand (FasL) gene in Sertoli cells was investigated, as these cells are known to have constitutive expression of FasL and hence maintain an "immune privileged" environment within the testicle, Using the Sertoli cell line TM4, it was demonstrated that a gene segment of the 5'-untranslated region located between -318 and -237 relative to the translation start site is required for constitutive Fast transcription. Deletion and mutation analysis demonstrate that an Sp1 rather than an NFAT or NFKB-like DNA binding motif present within this region is necessary and sufficient for constitutive Fast gene transcription. Nuclear extracts of Sertoli cells contain Sp1 and Sp3 that specifically binds to the Sp1 motif present in the Fast gene, and overexpression of Sp1 but not Sp3 leads to a further increase of transcription from the Fast promoter-enhancer region. The data presented demonstrates that constitutive Fast gene transcription in Sertoli cells is regulated by Sp1. In addition, it is shown that basal Fast expression in Jurkat T cells is also controlled by Sp1 and this is in contrast to induced Fast expression, which is NFAT-dependent.	Mayo Clin & Mayo Fdn, Dept Immunol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Pathol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Lab Med, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic; Mayo Clinic	Paya, CV (corresponding author), Mayo Clin & Mayo Fdn, Dept Immunol, 200 1st St SW,Guggenheim 501, Rochester, MN 55905 USA.	paya@mayo.edu						BELLGRAU D, 1995, NATURE, V377, P630, DOI 10.1038/377630a0; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; CHEN LI, 1994, MOL CELL BIOL, V14, P4380, DOI 10.1128/MCB.14.7.4380; Chinnaiyan A M, 1997, Semin Immunol, V9, P69, DOI 10.1006/smim.1996.0055; Clark SJ, 1997, GENE, V195, P67, DOI 10.1016/S0378-1119(97)00164-9; Conn KJ, 1996, J BIOL CHEM, V271, P28853, DOI 10.1074/jbc.271.46.28853; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; COUREY AJ, 1993, TRANSCRIPTIONAL REGU, V2, P743; DATTA PK, 1995, MOL CELL BIOL, V15, P5444; GALLE PR, 1995, J EXP MED, V182, P1223, DOI 10.1084/jem.182.5.1223; GRIFFITH TS, 1995, SCIENCE, V270, P1189, DOI 10.1126/science.270.5239.1189; Guller S, 1997, ANN NY ACAD SCI, V828, P268, DOI 10.1111/j.1749-6632.1997.tb48547.x; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; Hahne M, 1996, SCIENCE, V274, P1363, DOI 10.1126/science.274.5291.1363; Hirano F, 1998, MOL CELL BIOL, V18, P1266, DOI 10.1128/MCB.18.3.1266; Holtz-Heppelmann CJ, 1998, J BIOL CHEM, V273, P4416, DOI 10.1074/jbc.273.8.4416; Ihn H, 1997, NUCLEIC ACIDS RES, V25, P3712, DOI 10.1093/nar/25.18.3712; Ivanov VN, 1997, ONCOGENE, V14, P2455, DOI 10.1038/sj.onc.1201088; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KAGI D, 1994, SCIENCE, V265, P528, DOI 10.1126/science.7518614; Karlseder J, 1996, MOL CELL BIOL, V16, P1659; KHACHIGIAN LM, 1995, J BIOL CHEM, V270, P27679, DOI 10.1074/jbc.270.46.27679; KIM SJ, 1992, MOL CELL BIOL, V12, P2455, DOI 10.1128/MCB.12.6.2455; Korbutt GS, 1997, DIABETES, V46, P317, DOI 10.2337/diabetes.46.2.317; Lania L, 1997, INT J BIOCHEM CELL B, V29, P1313, DOI 10.1016/S1357-2725(97)00094-0; Latinis KM, 1997, J IMMUNOL, V158, P4602; Latinis KM, 1997, J BIOL CHEM, V272, P31427, DOI 10.1074/jbc.272.50.31427; Lau HT, 1996, SCIENCE, V273, P109, DOI 10.1126/science.273.5271.109; Lee JW, 1997, ENDOCRINOLOGY, V138, P2081, DOI 10.1210/en.138.5.2081; Lin SY, 1996, MOL CELL BIOL, V16, P1668; Look DC, 1995, J BIOL CHEM, V270, P30264, DOI 10.1074/jbc.270.51.30264; LOWIN B, 1994, NATURE, V370, P650, DOI 10.1038/370650a0; LUI MZ, 1996, J BIOL CHEM, V271, P2731; LYNCH DH, 1995, IMMUNOL TODAY, V16, P569, DOI 10.1016/0167-5699(95)80079-4; Majello B, 1997, J BIOL CHEM, V272, P4021, DOI 10.1074/jbc.272.7.4021; Matiba B, 1997, Semin Immunol, V9, P59, DOI 10.1006/smim.1996.0054; MCELHINNY JA, 1995, J VIROL, V69, P1500, DOI 10.1128/JVI.69.3.1500-1509.1995; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; NAGATA S, 1994, ADV IMMUNOL, V57, P129, DOI 10.1016/S0065-2776(08)60672-0; Noti JD, 1996, MOL CELL BIOL, V16, P2940; OConnell J, 1996, J EXP MED, V184, P1075, DOI 10.1084/jem.184.3.1075; OYAIZU N, 1995, BIOCHEM BIOPH RES CO, V213, P994, DOI 10.1006/bbrc.1995.2227; Perzova R, 1997, BRIT J HAEMATOL, V97, P123, DOI 10.1046/j.1365-2141.1997.d01-2113.x; RAO A, 1994, IMMUNOL TODAY, V15, P274, DOI 10.1016/0167-5699(94)90007-8; Saas P, 1997, J CLIN INVEST, V99, P1173, DOI 10.1172/JCI119273; SAFFER JD, 1991, MOL CELL BIOL, V11, P2189, DOI 10.1128/MCB.11.4.2189; Strand S, 1996, NAT MED, V2, P1361, DOI 10.1038/nm1296-1361; SUDA T, 1993, CELL, V75, P1169, DOI 10.1016/0092-8674(93)90326-L; Sugihara A, 1997, ANTICANCER RES, V17, P3861; Suzuki M, 1998, MOL CELL BIOL, V18, P3010, DOI 10.1128/MCB.18.5.3010; SUZUKI M, 1995, MOL CELL BIOL, V15, P5423; Tanaka M, 1996, NAT MED, V2, P317, DOI 10.1038/nm0396-317; UCKMAN D, 1997, MOL HUM REPROD, V3, P655; UDVADIA AJ, 1995, P NATL ACAD SCI USA, V92, P3953, DOI 10.1073/pnas.92.9.3953; Walker PR, 1997, J IMMUNOL, V158, P4521; Xerri L, 1997, LEUKEMIA, V11, P1868, DOI 10.1038/sj.leu.2400815; Xerri L, 1997, J CLIN PATHOL-MOL PA, V50, P87, DOI 10.1136/mp.50.2.87; Yano H, 1996, J HEPATOL, V25, P454, DOI 10.1016/S0168-8278(96)80204-2	59	65	67	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	1999	274	12					7756	7762		10.1074/jbc.274.12.7756	http://dx.doi.org/10.1074/jbc.274.12.7756			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	178LU	10075666	hybrid			2022-12-25	WOS:000079268100025
J	Portois, L; Maget, B; Tastenoy, M; Perret, J; Svoboda, M				Portois, L; Maget, B; Tastenoy, M; Perret, J; Svoboda, M			Identification of a glucose response element in the promoter of the rat glucagon receptor gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HORMONE-RELATED PEPTIDE; PYRUVATE-KINASE GENE; MESSENGER-RNA; CHROMOSOMAL LOCALIZATION; PARATHYROID-HORMONE; PANCREATIC-ISLETS; ENCODING GENE; EXPRESSION; CLONING; TRANSCRIPTION	We cloned the 5' upstream region of the rat glucagon receptor gene, demonstrating that the 5' noncoding domain of the glucagon receptor mRNA contained two untranslated exons of 131 and 166 nucleotides (nt), respectively, separated by two introns of 0.6 and 3.2 kilobase pairs. We also observed an alternative splicing involving the 166-base pair exon, Cloning of up to 2 kilobase pairs of the newly identified genomic domain and transfection of various constructs driving a reporter gene, in pancreatic islet cell line INS-I, uncovered a strong glucose regulation of the promoter activity of plasmids containing up to nucleotide -868, or more, upstream from the transcriptional start point. This promoter activity displayed threshold-like behavior, with low activity of the promoter below 5 mM glucose, and maximal activation as of 10 mM glucose. This glucose regulation was mapped to a highly palindromic 19-nucleotide region between nt -545 and -527, Indeed, deletion or mutation of this sequence abolished the glucose regulation. This domain contained two palindromic "E-boxes" CACGTG and CAGCTG separated by 3 nt, a feature similar to the "L4 box" found in the pyruvate kinase L gene promoter. This is the first description of a G protein-coupled receptor gene promoter regulated by glucose.	Free Univ Brussels, Dept Biochem & Nutr, Sch Med, B-1070 Brussels, Belgium	Universite Libre de Bruxelles; Vrije Universiteit Brussel	Svoboda, M (corresponding author), Free Univ Brussels, Dept Biochem & Nutr, Sch Med, 808 Route Lennik,Bldg G-E CP 611, B-1070 Brussels, Belgium.							ABRAHAMSEN N, 1995, J BIOL CHEM, V270, P15853, DOI 10.1074/jbc.270.26.15853; ABRAHAMSEN N, 1995, ENDOCRINOLOGY, V136, P1572, DOI 10.1210/en.136.4.1572; ASFARI M, 1992, ENDOCRINOLOGY, V130, P167, DOI 10.1210/en.130.1.167; BERGOT MO, 1992, NUCLEIC ACIDS RES, V20, P1871, DOI 10.1093/nar/20.8.1871; BUGGY J, 1995, BIOCHEM BIOPH RES CO, V208, P339, DOI 10.1006/bbrc.1995.1343; BURCELIN R, 1995, GENE, V164, P305, DOI 10.1016/0378-1119(95)00472-I; Burcelin R, 1998, J BIOL CHEM, V273, P8088, DOI 10.1074/jbc.273.14.8088; CAMPOS RV, 1994, ENDOCRINOLOGY, V134, P2156, DOI 10.1210/en.134.5.2156; Chatterjee TK, 1997, J BIOL CHEM, V272, P12122, DOI 10.1074/jbc.272.18.12122; Doiron B, 1996, J BIOL CHEM, V271, P5321, DOI 10.1074/jbc.271.10.5321; Dupriez VJ, 1997, DNA CELL BIOL, V16, P1075, DOI 10.1089/dna.1997.16.1075; FOUFELLE F, 1995, BIOCHEM J, V308, P521, DOI 10.1042/bj3080521; GUIGO R, 1992, J MOL BIOL, V226, P141, DOI 10.1016/0022-2836(92)90130-C; HANSEN LH, 1995, PEPTIDES, V16, P1163, DOI 10.1016/0196-9781(95)00078-X; Horn F, 1998, NUCLEIC ACIDS RES, V26, P275, DOI 10.1093/nar/26.1.275; JELINEK LJ, 1993, SCIENCE, V259, P1614, DOI 10.1126/science.8384375; Kahn A, 1997, BIOCHIMIE, V79, P113, DOI 10.1016/S0300-9084(97)81501-5; Kennedy HJ, 1997, J BIOL CHEM, V272, P20636, DOI 10.1074/jbc.272.33.20636; Kieffer TJ, 1996, ENDOCRINOLOGY, V137, P5119, DOI 10.1210/en.137.11.5119; KONG XF, 1994, BIOCHEM BIOPH RES CO, V200, P1290, DOI 10.1006/bbrc.1994.1591; LankatButtgereit B, 1997, PEPTIDES, V18, P617, DOI 10.1016/S0196-9781(97)00001-6; Leclerc I, 1998, FEBS LETT, V431, P180, DOI 10.1016/S0014-5793(98)00745-5; LEMAIGRE FP, 1994, BIOCHEM J, V303, P1; LOK S, 1994, GENE, V140, P203, DOI 10.1016/0378-1119(94)90545-2; MACNEIL DJ, 1994, BIOCHEM BIOPH RES CO, V198, P328, DOI 10.1006/bbrc.1994.1046; MAGET B, 1994, FEBS LETT, V351, P271, DOI 10.1016/0014-5793(94)00875-2; MARIE S, 1993, J BIOL CHEM, V268, P23881; Marine JC, 1996, ENDOCRINOLOGY, V137, P4108, DOI 10.1210/en.137.10.4108; MCCUAIG KA, 1995, NUCLEIC ACIDS RES, V23, P1948, DOI 10.1093/nar/23.11.1948; MCCUAIG KA, 1994, P NATL ACAD SCI USA, V91, P5051, DOI 10.1073/pnas.91.11.5051; Moens K, 1996, DIABETES, V45, P257, DOI 10.2337/diabetes.45.2.257; PEI L, 1995, BIOCHEM J, V308, P716; Qvist H, 1998, BIOL CHEM, V379, P75; Sambrook J., 2002, MOL CLONING LAB MANU; Schafer D, 1997, FEBS LETT, V417, P325, DOI 10.1016/S0014-5793(97)01314-8; SHIH HM, 1995, J BIOL CHEM, V270, P21991, DOI 10.1074/jbc.270.37.21991; SREEDHARAN SP, 1995, P NATL ACAD SCI USA, V92, P2939, DOI 10.1073/pnas.92.7.2939; SUDO Y, 1994, ENDOCRINOLOGY, V134, P2532, DOI 10.1210/en.134.6.2532; SVOBODA M, 1993, BIOCHEM BIOPH RES CO, V192, P135, DOI 10.1006/bbrc.1993.1392; SVOBODA M, 1993, BIOCHEM BIOPH RES CO, V191, P479, DOI 10.1006/bbrc.1993.1243; SVOBODA M, 1994, MOL CELL ENDOCRINOL, V105, P131, DOI 10.1016/0303-7207(94)90162-7; TOWLE HC, 1995, J BIOL CHEM, V270, P23235, DOI 10.1074/jbc.270.40.23235; Vallet VS, 1998, J BIOL CHEM, V273, P20175, DOI 10.1074/jbc.273.32.20175; ZOLNIEROWICZ S, 1994, J BIOL CHEM, V269, P19530	44	34	34	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 19	1999	274	12					8181	8190		10.1074/jbc.274.12.8181	http://dx.doi.org/10.1074/jbc.274.12.8181			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	178LU	10075722	hybrid			2022-12-25	WOS:000079268100081
J	Dell'Angelica, EC; Mullins, C; Bonifacino, JS				Dell'Angelica, EC; Mullins, C; Bonifacino, JS			AP-4, a novel protein complex related to clathrin adaptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VESICLE FORMATION; GOLGI MEMBRANES; SORTING SIGNALS; COAT PROTEINS; CELL-SURFACE; BINDING; RECEPTOR; SUBUNIT; IDENTIFICATION; RECRUITMENT	Here we report the identification and characterization of AP-4, a novel protein complex related to the heterotetrameric AP-1, AP-2, and AP-3 adaptors that mediate protein sorting in the endocytic and late secretory pathways. The key to the identification of this complex was the cloning and sequencing of two widely expressed, mammalian cDNAs encoding new homologs of the adaptor beta and a subunits named beta 4 and sigma 4, respectively. An antibody to beta 4 recognized in human cells an similar to 83-kDa polypeptide that exists in both soluble and membrane-associated forms. Golgi filtration, sedimentation velocity, and immunoprecipitation experiments revealed that beta 4 is a component of a multisubunit complex (AP-4) that also contains the sigma 4 polypeptide and two additional adaptor subunit homologs named mu 4 (mu-ARP2) and epsilon. Immunofluorescence analyses showed that AP-4 is associated with the trans-Golgis network or an adjacent structure and that this association is sensitive to the drug brefeldin A. We propose that, like the related AP-1, AP-2, and AP-3 complexes, AP-4 plays a role in signal-mediated trafficking of integral membrane proteins in mammalian cells.	NICHD, Cell Biol & Metab Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Bonifacino, JS (corresponding author), NICHD, Cell Biol & Metab Branch, NIH, Bldg 18T,Rm 101, Bethesda, MD 20892 USA.			Bonifacino, Juan S./0000-0002-5673-6370				AHLE S, 1989, J BIOL CHEM, V264, P20089; BNIFACINO JS, 1998, CURRENT PROTOCOLS CE; BOSSHART H, 1994, J CELL BIOL, V126, P1157, DOI 10.1083/jcb.126.5.1157; Chen H, 1998, NATURE, V394, P793, DOI 10.1038/29555; Cremona O, 1997, CURR OPIN NEUROBIOL, V7, P323, DOI 10.1016/S0959-4388(97)80059-1; Dell'Angelica EC, 1999, MOL CELL, V3, P11, DOI 10.1016/S1097-2765(00)80170-7; Dell'Angelica EC, 1998, SCIENCE, V280, P431, DOI 10.1126/science.280.5362.431; DellAngelica EC, 1997, J BIOL CHEM, V272, P15078, DOI 10.1074/jbc.272.24.15078; DellAngelica EC, 1997, EMBO J, V16, P917, DOI 10.1093/emboj/16.5.917; DONALDSON JG, 1994, CURR OPIN CELL BIOL, V6, P527, DOI 10.1016/0955-0674(94)90072-8; DONALDSON JG, 1992, P NATL ACAD SCI USA, V89, P6408, DOI 10.1073/pnas.89.14.6408; FUTTER CE, 1995, J BIOL CHEM, V270, P10999, DOI 10.1074/jbc.270.18.10999; Futter CE, 1998, J CELL BIOL, V141, P611, DOI 10.1083/jcb.141.3.611; GALLUSSER A, 1993, EMBO J, V12, P5237, DOI 10.1002/j.1460-2075.1993.tb06219.x; GRIFFITHS G, 1988, CELL, V52, P329, DOI 10.1016/S0092-8674(88)80026-6; Honing S, 1996, EMBO J, V15, P5230, DOI 10.1002/j.1460-2075.1996.tb00908.x; Keller P, 1997, J CELL SCI, V110, P3001; KIRCHHAUSEN T, 1989, P NATL ACAD SCI USA, V86, P2612, DOI 10.1073/pnas.86.8.2612; Kirchhausen T, 1997, CURR OPIN CELL BIOL, V9, P488, DOI 10.1016/S0955-0674(97)80024-5; Le Borgne R, 1998, J BIOL CHEM, V273, P29451, DOI 10.1074/jbc.273.45.29451; Le Borgne R, 1998, CURR OPIN CELL BIOL, V10, P499; LeBorgne R, 1996, J BIOL CHEM, V271, P2162; LEITINGER B, 1995, P NATL ACAD SCI USA, V92, P10109, DOI 10.1073/pnas.92.22.10109; Lewin DA, 1998, BBA-MOL CELL RES, V1401, P129, DOI 10.1016/S0167-4889(97)00130-4; Marks MS, 1997, TRENDS CELL BIOL, V7, P124, DOI 10.1016/S0962-8924(96)10057-X; MARKS MS, 1998, CURRENT PROTOCOLS CE; MATSUI W, 1990, BIOCHEMISTRY-US, V29, P10791, DOI 10.1021/bi00500a011; Ohno H, 1996, J BIOL CHEM, V271, P29009, DOI 10.1074/jbc.271.46.29009; OHNO H, 1995, SCIENCE, V269, P1872, DOI 10.1126/science.7569928; Ooi CE, 1998, J CELL BIOL, V142, P391, DOI 10.1083/jcb.142.2.391; PETERS PJ, 1991, NATURE, V349, P669, DOI 10.1038/349669a0; REST B, 1994, PROTEINS, V20, P216; ROBINSON MS, 1992, CELL, V69, P129, DOI 10.1016/0092-8674(92)90124-U; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; Schmid SL, 1997, ANNU REV BIOCHEM, V66, P511, DOI 10.1146/annurev.biochem.66.1.511; SCHRODER S, 1991, J BIOL CHEM, V266, P7910; Shih W, 1995, J BIOL CHEM, V270, P31083, DOI 10.1074/jbc.270.52.31083; Simpson F, 1996, J CELL BIOL, V133, P749, DOI 10.1083/jcb.133.4.749; Simpson F, 1997, J CELL BIOL, V137, P835, DOI 10.1083/jcb.137.4.835; TRAUB LM, 1995, J BIOL CHEM, V270, P4933, DOI 10.1074/jbc.270.9.4933; Wang XL, 1997, FEBS LETT, V402, P57, DOI 10.1016/S0014-5793(96)01500-1	41	209	218	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 12	1999	274	11					7278	7285		10.1074/jbc.274.11.7278	http://dx.doi.org/10.1074/jbc.274.11.7278			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	175DV	10066790	hybrid			2022-12-25	WOS:000079078400062
J	Kovoor, A; Celver, J; Abdryashitov, RI; Chavkin, C; Gurevich, VV				Kovoor, A; Celver, J; Abdryashitov, RI; Chavkin, C; Gurevich, VV			Targeted construction of phosphorylation-independent beta-arrestin mutants with constitutive activity in cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; THYROTROPIN RECEPTOR; RHODOPSIN; BINDING; MUTATIONS	Arrestin proteins play a key role in the desensitization of G protein-coupled receptors (GPCRs), Recently we proposed a molecular mechanism whereby arrestin preferentially binds to the activated and phosphorylated form of its cognate GPCR. To test the model, we introduced two different types of mutations into beta-arrestin that were expected to disrupt two crucial elements that make beta-arrestin binding to receptors phosphorylation-dependent. We found that two beta-arrestin mutants (Arg(169) --> Glu and Asp(383) --> Ter) (Ter, stop codon) are indeed "constitutively active." In vitro these mutants bind to the agonist-activated beta(2)-adrenergic receptor (beta(2)AR) regardless of its phosphorylation status. When expressed in Xenopus oocytes these beta-arrestin mutants effectively desensitize beta(2)AR in a phosphorylation-independent manner. Constitutively active beta-arrestin mutants also effectively desensitize delta opioid receptor (DOR) and restore the agonist-induced desensitization of a truncated DOR lacking the critical G protein-coupled receptor kinase (GRK) phosphorylation sites. The kinetics of the desensitization induced by phosphorylation-independent mutants in the absence of receptor phosphorylation appears identical to that induced by wild type beta-arrestin + GRK3. Either of the mutations could have occurred naturally and made receptor kinases redundant, raising the question of why a more complex two-step mechanism (receptor phosphorylation followed by arrestin binding) is universally used.	Sun Hlth Res Inst, Ralph & Muriel Roberts Lab Vis Sci, Sun City, AZ 85372 USA; Univ Washington, Dept Pharmacol, Seattle, WA 98195 USA	Banner Research; Banner Health; Banner Sun Health Research Institute; University of Washington; University of Washington Seattle	Gurevich, VV (corresponding author), Sun Hlth Res Inst, Ralph & Muriel Roberts Lab Vis Sci, Sun City, AZ 85372 USA.		Gurevich, Vsevolod/A-3236-2008; Chavkin, Charles/G-2797-2010	Gurevich, Vsevolod/0000-0002-3950-5351; 	NEI NIH HHS [EY 11500] Funding Source: Medline; NIDA NIH HHS [DA 04123, R37 DA011672] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY011500] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA004123, R37DA011672] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Bai M, 1996, J BIOL CHEM, V271, P19537, DOI 10.1074/jbc.271.32.19537; Barak LS, 1997, J BIOL CHEM, V272, P27497, DOI 10.1074/jbc.272.44.27497; CHEN J, 1995, SCIENCE, V267, P374, DOI 10.1126/science.7824934; DONOSO LA, 1990, CURR EYE RES, V9, P343, DOI 10.3109/02713689008999622; DUPREZ L, 1994, NAT GENET, V7, P396, DOI 10.1038/ng0794-396; Ferguson SSG, 1996, SCIENCE, V271, P363, DOI 10.1126/science.271.5247.363; Freedman NJ, 1996, RECENT PROG HORM RES, V51, P319; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; Granzin J, 1998, NATURE, V391, P918, DOI 10.1038/36147; GrayKeller MP, 1997, BIOCHEMISTRY-US, V36, P7058, DOI 10.1021/bi963110k; GUREVICH VV, 1993, J BIOL CHEM, V268, P11628; Gurevich VV, 1997, J BIOL CHEM, V272, P28849, DOI 10.1074/jbc.272.46.28849; GUREVICH VV, 1995, J BIOL CHEM, V270, P720, DOI 10.1074/jbc.270.2.720; Gurevich VV, 1998, J BIOL CHEM, V273, P15501, DOI 10.1074/jbc.273.25.15501; GUREVICH VV, 1995, J BIOL CHEM, V270, P6010, DOI 10.1074/jbc.270.11.6010; Gutkind JS, 1998, J BIOL CHEM, V273, P1839, DOI 10.1074/jbc.273.4.1839; Kovoor A, 1998, MOL PHARMACOL, V54, P704; Kovoor A, 1997, J BIOL CHEM, V272, P27605, DOI 10.1074/jbc.272.44.27605; Paschke R, 1997, NEW ENGL J MED, V337, P1675, DOI 10.1056/NEJM199712043372307; PEARCE S, 1995, J CLIN INVEST, V52, P736; RAO VR, 1994, NATURE, V367, P639, DOI 10.1038/367639a0; SCHIPANI E, 1995, SCIENCE, V268, P98, DOI 10.1126/science.7701349	22	150	161	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 12	1999	274	11					6831	6834		10.1074/jbc.274.11.6831	http://dx.doi.org/10.1074/jbc.274.11.6831			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	175DV	10066734	hybrid			2022-12-25	WOS:000079078400006
J	Langenbach, KJ; Sottile, J				Langenbach, KJ; Sottile, J			Identification of protein-disulfide isomerase activity in fibronectin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLD-INSOLUBLE GLOBULIN; MATRIX ASSEMBLY SITES; CROSS-LINKING; LYSOPHOSPHATIDIC ACID; PLASMA FIBRONECTIN; HUMAN-FIBROBLASTS; SELF-ASSOCIATION; COLLAGEN-BINDING; RIBONUCLEASE-A; IONIC-STRENGTH	Assembly and degradation of fibronectin-containing extracellular matrices are dynamic processes that are up-regulated during wound healing, embryogenesis, and metastasis. Although several of the early steps leading to fibronectin deposition have been identified, the mechanisms leading to the accumulation of fibronectin in disulfide-stabilized multimers are largely unknown, Disulfide-stabilized fibronectin multimers are thought to arise through intra- or intermolecular disulfide exchange. Several proteins involved in disulfide exchange reactions contain the sequence Cys-X-X-Cys in their active sites, including thioredoxin and protein-disulfide isomerase, The twelfth type I module of fibronectin (I-12) contains a Cys-X-X-Cys motif, suggesting that fibronectin may have the intrinsic ability to catalyze disulfide bond rearrangement. Using an established protein refolding assay, we demonstrate here that fibronectin has protein-disulfide isomerase activity and that this activity is localized to the carboxyl-terminal type I module I-12. I-12 was as active on an equal molar basis as intact fibronectin, indicating that most of the protein-disulfide isomerase activity of fibronectin is localized to I-12. Moreover, the protein-disulfide isomerase activity of fibronectin appears to be partially cryptic since limited proteolysis of I-10-I-12 increased its isomerase activity and dramatically enhanced the rate of RNase refolding, This is the first demonstration that fibronectin contains protein disulfide isomerase activity and suggests that cross-linking of fibronectin in the extracellular matrix may be catalyzed by a disulfide isomerase activity contained within the fibronectin molecule.	Albany Med Coll, Dept Physiol & Cell Biol A134, Albany, NY 12208 USA	Albany Medical College	Sottile, J (corresponding author), Albany Med Coll, Dept Physiol & Cell Biol A134, Neil Hellman Med Res Bldg,47 New Scotland Ave, Albany, NY 12208 USA.	jsottile@ccgateway.amc.edu			NHLBI NIH HHS [HL50549, T732-HL07194] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL050549] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AGUIRRE KM, 1994, J BIOL CHEM, V269, P27863; ALI IU, 1978, BIOCHIM BIOPHYS ACTA, V510, P140, DOI 10.1016/0005-2736(78)90136-0; ALLENHOFFMANN BL, 1987, J BIOL CHEM, V262, P14361; ANFINSEN CB, 1961, P NATL ACAD SCI USA, V47, P1309, DOI 10.1073/pnas.47.9.1309; BALIAN G, 1979, J BIOL CHEM, V254, P1429; BONIFACE JJ, 1990, SCIENCE, V247, P61, DOI 10.1126/science.2104678; BORSI L, 1986, ANAL BIOCHEM, V155, P335, DOI 10.1016/0003-2697(86)90443-4; Bourdoulous S, 1998, J CELL BIOL, V143, P267, DOI 10.1083/jcb.143.1.267; Chen F, 1996, J BIOL CHEM, V271, P9084, DOI 10.1074/jbc.271.15.9084; CHERNOUSOV MA, 1991, J BIOL CHEM, V266, P10851; Chivers PT, 1997, BIOCHEMISTRY-US, V36, P4061, DOI 10.1021/bi9628580; CHIVERS PT, 1996, PROLYL 4 HYDROXYLASE, P487; CHOI MG, 1979, J BIOL CHEM, V254, P2050; Clark RA., 1995, MOL CELLULAR BIOL WO, P3; COLVIN RB, 1989, FIBRONECTIN, P213; CREIGHTON TE, 1979, J MOL BIOL, V129, P411, DOI 10.1016/0022-2836(79)90504-7; CROOK EM, 1960, BIOCHEM J, V74, P234, DOI 10.1042/bj0740234; DARRIBERE R, 1993, DEV DYNAM, V194, P63; FOGERTY FJ, 1990, J CELL BIOL, V111, P699, DOI 10.1083/jcb.111.2.699; FREEDMAN RB, 1995, METHOD ENZYMOL, V251, P397, DOI 10.1016/0076-6879(95)51143-1; FUKAI F, 1995, BIOCHEMISTRY-US, V34, P11453, DOI 10.1021/bi00036a018; HANTGAN RR, 1974, BIOCHEMISTRY-US, V13, P3421, DOI 10.1021/bi00714a001; HAWKINS HC, 1991, BIOCHEM J, V275, P349, DOI 10.1042/bj2750349; HEDMAN D, 1989, FIBRONECTIN, P123; Hocking DC, 1996, J CELL BIOL, V133, P431, DOI 10.1083/jcb.133.2.431; HOCKING DC, 1994, J BIOL CHEM, V269, P19183; Hynes RO, 1990, FIBRONECTINS; Ingham KC, 1997, J BIOL CHEM, V272, P1718, DOI 10.1074/jbc.272.3.1718; KESKIOJA J, 1976, CELL, V9, P29, DOI 10.1016/0092-8674(76)90049-0; KOEDAM JA, 1994, BIOCHEM BIOPH RES CO, V198, P1225, DOI 10.1006/bbrc.1994.1173; LU XJ, 1992, BIOCHEMISTRY-US, V31, P4205, DOI 10.1021/bi00132a008; LUNDSTROM J, 1992, J BIOL CHEM, V267, P9047; LYLES MM, 1991, BIOCHEMISTRY-US, V30, P613, DOI 10.1021/bi00217a004; LYLES MM, 1994, J BIOL CHEM, V269, P30946; MARKOVIC Z, 1983, H-S Z PHYSIOL CHEM, V364, P1795, DOI 10.1515/bchm2.1983.364.2.1795; MAYADAS TN, 1992, P NATL ACAD SCI USA, V89, P3531, DOI 10.1073/pnas.89.8.3531; MCKEOWNLONGO PJ, 1983, J CELL BIOL, V97, P466, DOI 10.1083/jcb.97.2.466; MCKEOWNLONGO PJ, 1984, J BIOL CHEM, V259, P2210; MCKEOWNLONGO PJ, 1985, J CELL BIOL, V100, P364, DOI 10.1083/jcb.100.2.364; Mercurius KO, 1998, CIRC RES, V82, P548, DOI 10.1161/01.RES.82.5.548; MILLER DW, 1986, GENETIC ENG PRINCIPL, V8, P277; MORLA A, 1992, J CELL BIOL, V118, P421, DOI 10.1083/jcb.118.2.421; MORLA A, 1994, NATURE, V367, P193, DOI 10.1038/367193a0; Mosher, 1989, FIBRONECTIN, P1; MOSHER DF, 1975, J BIOL CHEM, V250, P6614; MOSHER DF, 1983, ANN NY ACAD SCI, V408, P583, DOI 10.1111/j.1749-6632.1983.tb23275.x; NOVOKHATNY VV, 1994, J MOL BIOL, V238, P833, DOI 10.1006/jmbi.1994.1337; Okada N, 1997, J BIOL CHEM, V272, P26978, DOI 10.1074/jbc.272.43.26978; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; Pasqualini R, 1996, NAT MED, V2, P1197, DOI 10.1038/nm1196-1197; PIGIET VP, 1986, P NATL ACAD SCI USA, V83, P7643, DOI 10.1073/pnas.83.20.7643; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Schor SL, 1996, J CELL SCI, V109, P2581; SCHWARZBAUER JE, 1991, J CELL BIOL, V113, P1463, DOI 10.1083/jcb.113.6.1463; Sechler JL, 1996, J CELL BIOL, V134, P573, DOI 10.1083/jcb.134.2.573; Sechler JL, 1998, J BIOL CHEM, V273, P25533, DOI 10.1074/jbc.273.40.25533; SOMMERS CE, 1993, J BIOL CHEM, V268, P22277; SOTTILE J, 1993, BIOCHEMISTRY-US, V32, P1641, DOI 10.1021/bi00057a031; Sottile J, 1998, J CELL SCI, V111, P2933; SOTTILE J, 1994, J BIOL CHEM, V269, P17192; SUMMERS MD, 1987, TEXAS AGR EXPT STATI, V1555, P1; UGAROVA TP, 1995, BIOCHEMISTRY-US, V34, P4457, DOI 10.1021/bi00013a039; VUORI K, 1992, J BIOL CHEM, V267, P7211; Walker KW, 1996, BIOCHEMISTRY-US, V35, P1972, DOI 10.1021/bi952157n; WILLIAMS EC, 1982, J BIOL CHEM, V257, P4973; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2; Wu CY, 1998, J BIOL CHEM, V273, P528, DOI 10.1074/jbc.273.1.528; Zhang QH, 1997, MOL BIOL CELL, V8, P1415, DOI 10.1091/mbc.8.8.1415; ZHANG QH, 1994, J CELL BIOL, V127, P1447, DOI 10.1083/jcb.127.5.1447; Zhong CL, 1998, J CELL BIOL, V141, P539, DOI 10.1083/jcb.141.2.539	72	82	84	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 12	1999	274	11					7032	7038		10.1074/jbc.274.11.7032	http://dx.doi.org/10.1074/jbc.274.11.7032			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	175DV	10066758	hybrid			2022-12-25	WOS:000079078400030
J	McLaughlin, SH; Conn, SN; Bulleid, NJ				McLaughlin, SH; Conn, SN; Bulleid, NJ			Folding and assembly of type X collagen mutants that cause metaphyseal chondrodysplasia-type Schmid - Evidence for co-assembly of the mutant and wild-type chains and binding to molecular chaperones	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM; DISULFIDE BONDS; ALPHA-1(X) NC1; IN-VITRO; DOMAIN; MUTATIONS; CELLS; PROCOLLAGEN; INVITRO; MATRIX	Schmid metaphyseal chondrodysplasia results from mutations within the COOH-terminal globular domain (NC1) of type X collagen, a short chain collagen expressed in the hypertrophic region of the growth plate cartilage. Previous in vitro studies have proposed that mutations prevent the association of the NC1 domain of constituent chains of the trimer based upon a lack of formation of a trimeric structure that is resistant to dissociation with sodium dodecyl sulfate. To examine the effect of mutations on folding and assembly within a cellular context, bovine type X cDNAs containing analogous disease causing mutations Y598D, N617K, W651R, and wild-type were expressed in semi-permeabilized cells, We assessed trimerization of the mutant chains by their ability to form a collagen triple helix. Using this approach, we demonstrate that although there is an apparent lower efficiency of association of the mutant NC1 domains, they can drive the formation of correctly aligned triple helices with the same thermal stability as the wild-type collagen. When epitope-tagged mutant and wild-type collagen were co-expressed, heterotrimers could be detected by sequential immunoprecipitation. Both wild-type and mutant type X chains were found in association with the molecular chaperones protein disulfide isomerase and Hsp 47, The implications of these findings on the likely mechanism of Schmid metaphyseal chondrodysplasia will be discussed.	Univ Manchester, Sch Biol Sci, Manchester M13 9PT, Lancs, England	University of Manchester	Bulleid, NJ (corresponding author), Univ Manchester, Sch Biol Sci, 2-205 Stopford Bldg, Manchester M13 9PT, Lancs, England.			McLaughlin, Stephen/0000-0001-9135-6253; Bulleid, Neil/0000-0002-9839-5279				ALLEN S, 1995, J BIOL CHEM, V270, P4797, DOI 10.1074/jbc.270.9.4797; BONAVENTURE J, 1995, HUM GENET, V96, P58, DOI 10.1007/BF00214187; BRASS A, 1992, FEBS LETT, V303, P126, DOI 10.1016/0014-5793(92)80503-9; Bulleid NJ, 1997, EMBO J, V16, P6694, DOI 10.1093/emboj/16.22.6694; Bulleid NJ, 1996, BIOCHEM J, V317, P195, DOI 10.1042/bj3170195; BULLEID NJ, 1988, BIOCHEM J, V254, P805, DOI 10.1042/bj2540805; CHAN D, 1995, J BIOL CHEM, V270, P4558, DOI 10.1074/jbc.270.9.4558; Chan D, 1996, J BIOL CHEM, V271, P13566, DOI 10.1074/jbc.271.23.13566; Chan D, 1998, J CLIN INVEST, V101, P1490, DOI 10.1172/JCI1976; CHESSLER SD, 1992, J BIOL CHEM, V267, P7751; ENGEL J, 1991, ANNU REV BIOPHYS BIO, V20, P137, DOI 10.1146/annurev.biophys.20.1.137; FOURIE AM, 1994, J BIOL CHEM, V269, P30470; GUREVICH VV, 1991, ANAL BIOCHEM, V195, P207, DOI 10.1016/0003-2697(91)90318-N; Horton R M, 1993, Methods Mol Biol, V15, P251, DOI 10.1385/0-89603-244-2:251; Ikegawa S, 1997, HUM MUTAT, V9, P131, DOI 10.1002/(SICI)1098-1004(1997)9:2<131::AID-HUMU5>3.3.CO;2-U; JACENKO O, 1993, NATURE, V365, P56, DOI 10.1038/365056a0; JOHN DCA, 1993, EMBO J, V12, P1587, DOI 10.1002/j.1460-2075.1993.tb05803.x; KWAN APL, 1991, J CELL BIOL, V114, P597, DOI 10.1083/jcb.114.3.597; Kwan KM, 1997, J CELL BIOL, V136, P459, DOI 10.1083/jcb.136.2.459; McLaughlin SH, 1998, BIOCHEM J, V331, P793, DOI 10.1042/bj3310793; McLaughlin SH, 1998, MATRIX BIOL, V16, P369, DOI 10.1016/S0945-053X(98)90010-5; Mellquist JL, 1998, BIOCHEMISTRY-US, V37, P6833, DOI 10.1021/bi972217k; PLUTNER H, 1992, J CELL BIOL, V119, P1097, DOI 10.1083/jcb.119.5.1097; Pokharel RK, 1995, BIOCHEM BIOPH RES CO, V217, P1157, DOI 10.1006/bbrc.1995.2890; Reddy P, 1996, EMBO J, V15, P2077, DOI 10.1002/j.1460-2075.1996.tb00561.x; ROSATI R, 1994, NAT GENET, V8, P129, DOI 10.1038/ng1094-129; SCHMID TM, 1983, J BIOL CHEM, V258, P9504; Tatu U, 1997, J CELL BIOL, V136, P555, DOI 10.1083/jcb.136.3.555; THOMAS JT, 1991, BIOCHEM J, V273, P141, DOI 10.1042/bj2730141; WALLIS GA, 1994, AM J HUM GENET, V54, P169; Wallis GA, 1996, J MED GENET, V33, P450, DOI 10.1136/jmg.33.6.450; WILSON R, 1995, BIOCHEM J, V307, P679, DOI 10.1042/bj3070679; Wilson R, 1998, J BIOL CHEM, V273, P9637, DOI 10.1074/jbc.273.16.9637	33	23	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 12	1999	274	11					7570	7575		10.1074/jbc.274.11.7570	http://dx.doi.org/10.1074/jbc.274.11.7570			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	175DV	10066825	hybrid			2022-12-25	WOS:000079078400097
J	Mo, XM; Bailin, T; Sadofsky, MJ				Mo, XM; Bailin, T; Sadofsky, MJ			RAG1 and RAG2 cooperate in specific binding to the recombination signal sequence in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOTO-CROSS-LINKING; V(D)J RECOMBINATION; SUBSTITUTED RNA; PROTEINS; CLEAVAGE; DEFINITION; COMPLEX; REGION; DNA; RECOGNITION	An essential step in the development of the vertebrate immune system is the DNA level rearrangement of the antigen receptor genes. This process, termed "V(D)J recombination," beans with DNA cleavage at the appropriate sites mediated by the two proteins RAG1 and RAG2. We report here that the two proteins cooperate to bind DNA with significantly higher specificity than either protein alone. Gel purification of the triple complex is performed in the absence of any cross-linking agents. Both proteins remain present in the complex, and UV cross-linking using iodouridine-containing probes shows that RAG1 makes close contacts in both the heptamer and nonamer motifs, The two proteins are also shown to associate with each other in the absence of any DNA. These findings refine our understanding of the protein-DNA interactions that accompany cleavage at the recombination signals.	Med Coll Georgia, Inst Mol Med & Genet, Augusta, GA 30912 USA	University System of Georgia; Augusta University	Sadofsky, MJ (corresponding author), Med Coll Georgia, Inst Mol Med & Genet, CB-2803, Augusta, GA 30912 USA.			Sadofsky, Moshe/0000-0002-6893-629X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI041711, R29AI041711] Funding Source: NIH RePORTER; NIAID NIH HHS [AI41711] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Agrawal A, 1997, CELL, V89, P43, DOI 10.1016/S0092-8674(00)80181-6; Akamatsu Y, 1998, MOL CELL BIOL, V18, P4670, DOI 10.1128/MCB.18.8.4670; CUOMO CA, 1994, NUCLEIC ACIDS RES, V22, P1810, DOI 10.1093/nar/22.10.1810; Difilippantonio MJ, 1996, CELL, V87, P253, DOI 10.1016/S0092-8674(00)81343-4; Eastman QM, 1996, NATURE, V380, P85, DOI 10.1038/380085a0; Gellert M, 1997, ADV IMMUNOL, V64, P39, DOI 10.1016/S0065-2776(08)60886-X; Grawunder U, 1997, NUCLEIC ACIDS RES, V25, P1375, DOI 10.1093/nar/25.7.1375; HESSE JE, 1989, GENE DEV, V3, P1053, DOI 10.1101/gad.3.7.1053; Hiom K, 1997, CELL, V88, P65, DOI 10.1016/S0092-8674(00)81859-0; Hiom K, 1998, MOL CELL, V1, P1011, DOI 10.1016/S1097-2765(00)80101-X; LEWIS SM, 1994, ADV IMMUNOL, V56, P27, DOI 10.1016/S0065-2776(08)60450-2; MCBLANE JF, 1995, CELL, V83, P387, DOI 10.1016/0092-8674(95)90116-7; McMahan CJ, 1997, J IMMUNOL, V158, P2202; Meisenheimer KM, 1996, NUCLEIC ACIDS RES, V24, P981, DOI 10.1093/nar/24.5.981; OETTINGER MA, 1990, SCIENCE, V248, P1517, DOI 10.1126/science.2360047; Ramsden DA, 1997, NATURE, V388, P488, DOI 10.1038/41351; SADOFSKY MJ, 1995, GENE DEV, V9, P2193, DOI 10.1101/gad.9.17.2193; SADOFSKY MJ, 1994, NUCLEIC ACIDS RES, V22, P1805, DOI 10.1093/nar/22.10.1805; SADOFSKY MJ, 1993, NUCLEIC ACIDS RES, V21, P5644, DOI 10.1093/nar/21.24.5644; SCHATZ DG, 1989, CELL, V59, P1035, DOI 10.1016/0092-8674(89)90760-5; Spanopoulou E, 1996, CELL, V87, P263, DOI 10.1016/S0092-8674(00)81344-6; TONEGAWA S, 1983, NATURE, V302, P575, DOI 10.1038/302575a0; vanGent DC, 1997, EMBO J, V16, P2665, DOI 10.1093/emboj/16.10.2665; vanGent DC, 1996, CELL, V85, P107, DOI 10.1016/S0092-8674(00)81086-7; VANGENT DC, 1995, CELL, V81, P925, DOI 10.1016/0092-8674(95)90012-8; WILLIS MC, 1993, SCIENCE, V262, P1255, DOI 10.1126/science.7694369	26	49	51	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 12	1999	274	11					7025	7031		10.1074/jbc.274.11.7025	http://dx.doi.org/10.1074/jbc.274.11.7025			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	175DV	10066757	hybrid			2022-12-25	WOS:000079078400029
J	Tang, DM; Lahti, JM; Grenet, J; Kidd, VJ				Tang, DM; Lahti, JM; Grenet, J; Kidd, VJ			Cycloheximide-induced T-cell death is mediated by a Fas-associated death domain-dependent mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED APOPTOSIS; CONTAINING RECEPTOR; SIGNALING COMPLEX; PROTEIN-SYNTHESIS; CD95 FAS/APO-1; CYTOCHROME-C; ACTIVATION; LIGAND; FLICE; FADD	Cycloheximide (CHX) can contribute to apoptotic processes, either in conjunction with another agent (e.g. tumor necrosis factor-alpha) or on its own. However, the basis of this CHX-induced apoptosis has not been clearly established. In this study, the molecular mechanisms of CHX-induced cell death were examined in two different human T-cell lines. In T-cells undergoing CHX-induced apoptosis (Jurkat), but not in T-cells resistant to the effects of CHX (CEM C7), caspase-8 and caspase-3 were activated. However, the Fas ligand was not expressed in Jurkat cells either before or after treatment with CHX suggesting that the activation of these caspases does not involve the Fas receptor. To determine whether CHX-induced apoptosis was mediated by a Fas-associated death domain (FADD)-dependent mechanism, a FADD-DN protein was expressed in cells prior to CHX treatment. Its expression effectively inhibited CHX-induced cell death, suggesting that CHX-mediated apoptosis primarily involves a FADD-dependent mechanism. Since CHX treatment did not result in the induction of Fas or Fast, and neutralizing anti-Fas and anti-tumor necrosis factor receptor-1 antibodies did not block CHX-mediated apoptosis, these results may also indicate that FADD functions in a receptor-independent manner. Surprisingly, death effector filaments containing FADD and caspase-8 were observed during CHX treatment of Jurkat, Jurkat-FADD-DN, and CEM C7 cells, suggesting that their formation may be necessary, but not sufficient, for cell death.	St Jude Childrens Res Hosp, Dept Tumor Cell Biol, Memphis, TN 38101 USA	St Jude Children's Research Hospital	Kidd, VJ (corresponding author), St Jude Childrens Res Hosp, Dept Tumor Cell Biol, 332 N Lauderdale, Memphis, TN 38101 USA.	vincent.kidd@stjude.org	Tang, Damu/AAQ-1786-2021	Tang, Damu/0000-0002-3282-9521	NCI NIH HHS [CA 21765] Funding Source: Medline; NIGMS NIH HHS [GM 44088] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044088] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alam A, 1997, J EXP MED, V186, P1503, DOI 10.1084/jem.186.9.1503; Armstrong RC, 1997, J NEUROSCI, V17, P553; BERTRAND R, 1994, EXP CELL RES, V211, P314, DOI 10.1006/excr.1994.1093; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Bossy-Wetzel E, 1998, EMBO J, V17, P37, DOI 10.1093/emboj/17.1.37; Brimmell M, 1998, ONCOGENE, V16, P1803, DOI 10.1038/sj.onc.1201704; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Chinnaiyan AM, 1996, SCIENCE, V274, P990, DOI 10.1126/science.274.5289.990; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4961; Cryns V, 1998, GENE DEV, V12, P1551, DOI 10.1101/gad.12.11.1551; Fulda S, 1997, CANCER RES, V57, P3823; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Geley S, 1997, ONCOGENE, V15, P2429, DOI 10.1038/sj.onc.1201399; Golstein P, 1997, CURR BIOL, V7, pR750, DOI 10.1016/S0960-9822(06)90000-1; Gottlieb RA, 1996, P NATL ACAD SCI USA, V93, P654, DOI 10.1073/pnas.93.2.654; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Hueber AO, 1997, SCIENCE, V278, P1305, DOI 10.1126/science.278.5341.1305; Jacobson MD, 1996, J CELL BIOL, V133, P1041, DOI 10.1083/jcb.133.5.1041; Kasibhatla S, 1998, MOL CELL, V1, P543, DOI 10.1016/S1097-2765(00)80054-4; Kitson J, 1996, NATURE, V384, P372, DOI 10.1038/384372a0; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Leverkus M, 1997, EXP CELL RES, V232, P255, DOI 10.1006/excr.1997.3514; Loyer P, 1998, J CELL SCI, V111, P1495; Marsters SA, 1996, CURR BIOL, V6, P750, DOI 10.1016/S0960-9822(09)00456-4; MARTIN DP, 1988, J CELL BIOL, V106, P829, DOI 10.1083/jcb.106.3.829; MARTIN SJ, 1990, J IMMUNOL, V145, P1859; Medema JP, 1997, EMBO J, V16, P2794, DOI 10.1093/emboj/16.10.2794; Muzio M, 1998, J BIOL CHEM, V273, P2926, DOI 10.1074/jbc.273.5.2926; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Perez D, 1998, J CELL BIOL, V141, P1255, DOI 10.1083/jcb.141.5.1255; Peter ME, 1996, CELL DEATH DIFFER, V3, P161; Reed JC, 1997, CELL, V91, P559, DOI 10.1016/S0092-8674(00)80442-0; Reed JC, 1997, NATURE, V387, P773, DOI 10.1038/42867; Rehemtulla A, 1997, J BIOL CHEM, V272, P25783, DOI 10.1074/jbc.272.41.25783; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Scaffidi C, 1997, J BIOL CHEM, V272, P26953, DOI 10.1074/jbc.272.43.26953; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Siegel RM, 1998, J CELL BIOL, V141, P1243, DOI 10.1083/jcb.141.5.1243; Stennicke HR, 1998, J BIOL CHEM, V273, P27084, DOI 10.1074/jbc.273.42.27084; Tang DM, 1998, J BIOL CHEM, V273, P16601, DOI 10.1074/jbc.273.26.16601; TSUCHIDA H, 1995, J IMMUNOL, V154, P2403; vanEngeland M, 1996, CYTOMETRY, V24, P131, DOI 10.1002/(SICI)1097-0320(19960601)24:2<131::AID-CYTO5>3.0.CO;2-M; WALLACH D, 1984, J IMMUNOL, V132, P2464; Walsh CM, 1998, IMMUNITY, V8, P439, DOI 10.1016/S1074-7613(00)80549-X; Woo M, 1998, GENE DEV, V12, P806, DOI 10.1101/gad.12.6.806; Yang XL, 1998, MOL CELL, V1, P319, DOI 10.1016/S1097-2765(00)80032-5; Yeh WC, 1998, SCIENCE, V279, P1954, DOI 10.1126/science.279.5358.1954	49	119	121	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	1999	274	11					7245	7252		10.1074/jbc.274.11.7245	http://dx.doi.org/10.1074/jbc.274.11.7245			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	175DV	10066786	hybrid			2022-12-25	WOS:000079078400058
J	Tian, H; White, S; Yu, L; Yu, CA				Tian, H; White, S; Yu, L; Yu, CA			Evidence for the head domain movement of the Rieske iron-sulfur protein in electron transfer reaction of the cytochrome bc(1) complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WATER-SOLUBLE FRAGMENT; MITOCHONDRIAL	The three-dimensional structure of the mitochondrial cytochrome bc(1) complex suggests that movement of the extramembrane domain (head) of the Rieske iron-sulfur protein (ISP) may play an important role in electron transfer. Such movement requires flexibility in the neck region of ISP, since the head and transmembrane domains of the protein are rather rigid. To test this hypothesis, Rhodobacter sphaeroides mutants expressing His-tagged cytochrome bc(1) complexes with cysteine substitution at various positions in the ISP neck (residues 39-48) were generated and characterized. The mutants with a single cysteine substitution at Ala(42) or Val(44) and a double cysteine substitution at Val(44) and Ala(46) (VQA-CQC) or at Ala(42) and Ala(46) (ADVQA-CDVQC) have photosynthetic growth rates comparable with that of complement cells, Chromatophore membrane and intracytoplasmic membrane (ICM) prepared from these mutants have cytochrome bc(1) complex activity similar to that in the complement membranes, indicating that flexibility of the neck region of ISP was not affected by these cysteine substitutions. Mutants with a double cysteine substitution at Ala(42) and Val(44) (ADV-CDC) or at Pro(40) and Ala(42) (PSA-CSC) have a retarded (50%) or no photosynthetic growth rate, respectively. The ADV-CDC or PSA-CSC mutant ICM contains 20 or 0% of the cytochrome bc(1) complex activity found in the complement ICM, However, activity can be restored by the treatment with beta-mercaptoethanol (beta-ME), The restored activity is diminished upon removal of beta-ME but is retained if the beta-ME-treated membrane is treated with the sulfhydryl reagent N-ethylmaleimide or p-chloromercuribenzoic acid, These results indicate that the loss of bc(1) complex activity in the ADV-CDC or PSA-CSC mutant membranes is due to disulfide bond formation, which increases the rigidity of ISP neck and, in turn, decreases the mobility of the head domain, Using the conditions developed for the isolation of His-tagged complement cytochrome bc(1) complex, a two-subunit complex (cytochromes b and c(1)) is obtained from all of the double cysteine-substituted mutants. This suggests that introduction of two cysteines in the neck region of ISP weakens the interactions between cytochromes b, ISP, and subunit TV.	Oklahoma State Univ, Dept Biochem & Mol Biol, Stillwater, OK 74078 USA	Oklahoma State University System; Oklahoma State University - Stillwater	Yu, CA (corresponding author), Oklahoma State Univ, Dept Biochem & Mol Biol, Stillwater, OK 74078 USA.	cayuq@okway.okstate.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM030721, R01GM030721] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 30721] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERDEN JA, 1970, BIOCHIM BIOPHYS ACTA, V216, P237, DOI 10.1016/0005-2728(70)90215-X; CROFTS AR, 1982, BIOCHEM SOC T, V10, P201, DOI 10.1042/bst0100201; GONZALEZHALPHEN D, 1991, J BIOL CHEM, V266, P3870; Iwata S, 1998, SCIENCE, V281, P64, DOI 10.1126/science.281.5373.64; Iwata S, 1996, STRUCTURE, V4, P567, DOI 10.1016/S0969-2126(96)00062-7; KHOSRAVI M, 1990, PLASMID, V23, P138, DOI 10.1016/0147-619X(90)90032-8; Kim H, 1998, P NATL ACAD SCI USA, V95, P8026, DOI 10.1073/pnas.95.14.8026; Kim H, 1997, FASEB J, V11, pA1084; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Link TA, 1996, EUR J BIOCHEM, V237, P71, DOI 10.1111/j.1432-1033.1996.0071n.x; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MITCHELL P, 1976, J THEOR BIOL, V62, P327, DOI 10.1016/0022-5193(76)90124-7; PEMBERTON JM, 1981, J BACTERIOL, V147, P110, DOI 10.1128/JB.147.1.110-117.1981; SISTROM WR, 1960, J GEN MICROBIOL, V22, P778, DOI 10.1099/00221287-22-3-778; Tian H, 1998, J BIOL CHEM, V273, P27953, DOI 10.1074/jbc.273.43.27953; TRUMPOWER BL, 1994, ANNU REV BIOCHEM, V63, P675, DOI 10.1146/annurev.bi.63.070194.003331; TSAI AL, 1987, J BIOL CHEM, V262, P8677; Xia D, 1997, SCIENCE, V277, P60, DOI 10.1126/science.277.5322.60; Yu CA, 1998, BBA-BIOENERGETICS, V1365, P151, DOI 10.1016/S0005-2728(98)00055-3; Yu CA, 1996, BBA-BIOENERGETICS, V1275, P47, DOI 10.1016/0005-2728(96)00049-7; YU L, 1991, BIOCHEMISTRY-US, V30, P4934, DOI 10.1021/bi00234a014; YU L, 1986, BIOCHIM BIOPHYS ACTA, V852, P203, DOI 10.1016/0005-2728(86)90225-2; Zhang ZL, 1998, NATURE, V392, P677, DOI 10.1038/33612	23	75	78	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	1999	274	11					7146	7152		10.1074/jbc.274.11.7146	http://dx.doi.org/10.1074/jbc.274.11.7146			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	175DV	10066773	hybrid			2022-12-25	WOS:000079078400045
J	Hall, JA; Fann, MC; Maloney, PC				Hall, JA; Fann, MC; Maloney, PC			Altered substrate selectivity in a mutant of an intrahelical salt bridge in UhpT, the sugar phosphate carrier of Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSPORT-SYSTEM; LACTOSE CARRIER; SALMONELLA-TYPHIMURIUM; TRANSLOCATION PATHWAY; STREPTOCOCCUS-LACTIS; MELIBIOSE CARRIER; ANION-EXCHANGE; IDENTIFICATION; PERMEASE; PROTEINS	Site-directed and second site suppressor mutagenesis identify an intrahelical salt bridge in the eleventh transmembrane segment of UhpT, the sugar phosphate carrier of Escherichia coli. Glucose 6-phosphate (G6P) transport by UhpT is inactivated if cysteine replaces either Asp(388) or Lys(391) but not if both are replaced. This suggests that Asp(388) and Lys(391) are involved in an intrahelical salt bridge and that neither is required for normal UhpT function. This interpretation is strengthened by the finding that mutations at Lys391 (K391N, K391Q, and K391T) are recovered as revertants of the inactive D388C variant. Further work shows that although the D388C variant is null for G6P transport, movement of P-32(i) by homologous P-i/P-i exchange is unaffected. This raises the possibility that this derivative may have latent function, a possibility confirmed by showing that D388C is a gain-of-function mutation in which phosphoenolpyruvate (PEP) is the preferred substrate. Added study of the P-i/P-i exchange shows that in wild type UhpT this partial reaction is readily blocked by G6P but not PEP. By contrast, in the D388C variant, Pi/Pi exchange is unaffected by G6P but is inhibited by both PEP and 3-phosphoglycerate. These latter substrates are used by PgtP, a related P-i-linked antiporter, which lacks the Asp(388)-Lys(391) Salt bridge but has instead an uncompensated arginine at position 391. For this reason, we conclude that in both UhpT and PgtP position 391 can serve as a determinant of substrate selectivity by acting as a receptor for the anionic carboxyl brought into the translocation pathway by PEP.	Johns Hopkins Univ, Sch Med, Dept Physiol, Baltimore, MD 21205 USA	Johns Hopkins University	Maloney, PC (corresponding author), Johns Hopkins Univ, Sch Med, Dept Physiol, 725 N Wolfe St, Baltimore, MD 21205 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R56GM024195, F32GM019421, R01GM024195] Funding Source: NIH RePORTER; NIGMS NIH HHS [F32GM19421, GM24195] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMBUDKAR SV, 1986, J BIOL CHEM, V261, P9083; AMBUDKAR SV, 1986, P NATL ACAD SCI USA, V83, P280, DOI 10.1073/pnas.83.2.280; Andersson SGE, 1998, NATURE, V396, P133, DOI 10.1038/24094; BOTFIELD MC, 1988, J BIOL CHEM, V263, P12909; BROOKER RJ, 1985, P NATL ACAD SCI USA, V82, P3959, DOI 10.1073/pnas.82.12.3959; CAIN BD, 1988, J BIOL CHEM, V263, P6606; CAIRNS J, 1988, NATURE, V335, P142, DOI 10.1038/335142a0; DIXON M, 1953, BIOCHEM J, V55, P170, DOI 10.1042/bj0550170; ELVIN CM, 1985, J BACTERIOL, V161, P1054, DOI 10.1128/JB.161.3.1054-1058.1985; Fann MC, 1998, J MEMBRANE BIOL, V164, P187, DOI 10.1007/s002329900404; FOSTER PL, 1993, ANNU REV MICROBIOL, V47, P467; FRIEDRICH MJ, 1987, J BACTERIOL, V169, P3556, DOI 10.1128/jb.169.8.3556-3563.1987; GOSWITZ VC, 1995, PROTEIN SCI, V4, P534; GOTT P, 1988, MOL MICROBIOL, V2, P655, DOI 10.1111/j.1365-2958.1988.tb00074.x; HARLOW E, 1988, ANTIBODIES LAB MANUA, P486; Henderson PJF, 1993, CURR OPIN CELL BIOL, V5, P708, DOI 10.1016/0955-0674(93)90144-F; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOFSTEE BHJ, 1959, NATURE, V184, P1296, DOI 10.1038/1841296b0; HONIG BH, 1984, P NATL ACAD SCI-BIOL, V81, P5412, DOI 10.1073/pnas.81.17.5412; ISLAND MD, 1992, J BACTERIOL, V174, P2754, DOI 10.1128/JB.174.9.2754-2762.1992; KABACK HR, 1994, J EXP BIOL, V196, P183; KING SC, 1991, BIOCHIM BIOPHYS ACTA, V1062, P177, DOI 10.1016/0005-2736(91)90390-T; KING SC, 1990, J BIOL CHEM, V265, P9638; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee JI, 1996, BBA-BIOMEMBRANES, V1278, P111, DOI 10.1016/0005-2736(95)00209-X; Lounnas V, 1997, BIOCHEMISTRY-US, V36, P5402, DOI 10.1021/bi9622940; MALONEY PC, 1990, MICROBIOL REV, V54, P1; MALONEY PC, 1984, J BACTERIOL, V158, P238, DOI 10.1128/JB.158.1.238-245.1984; MALONEY PC, 1996, ESCHERICHIA COLI SAL, P1130; MARGER MD, 1993, TRENDS BIOCHEM SCI, V18, P13, DOI 10.1016/0968-0004(93)90081-W; MARQUSEE S, 1994, PROTEIN SCI, V3, P2217, DOI 10.1002/pro.5560031207; Matos M, 1996, J BIOL CHEM, V271, P18571, DOI 10.1074/jbc.271.31.18571; Merino G, 1997, J BACTERIOL, V179, P7687, DOI 10.1128/jb.179.24.7687-7694.1997; Miller J. H., 1972, EXPT MOL GENETICS, P431; NIIYA S, 1982, J BIOL CHEM, V257, P8902; OLSEN SG, 1993, J BACTERIOL, V175, P6269, DOI 10.1128/JB.175.19.6269-6275.1993; Panayotova-Heiermann M, 1998, BIOCHEMISTRY-US, V37, P10522, DOI 10.1021/bi9800395; Pao SS, 1998, MICROBIOL MOL BIOL R, V62, P1; RASHIN AA, 1984, J MOL BIOL, V173, P515, DOI 10.1016/0022-2836(84)90394-2; SAIER MH, 1975, J BIOL CHEM, V250, P5089; SCHOLTZ JM, 1993, BIOCHEMISTRY-US, V32, P9668, DOI 10.1021/bi00088a019; SONNA LA, 1988, J BIOL CHEM, V263, P6625; STERN LJ, 1989, J BIOL CHEM, V264, P14202; Tamai E, 1997, PROTEIN EXPRES PURIF, V10, P275, DOI 10.1006/prep.1997.0754; VARADHACHARY A, 1991, J BIOL CHEM, V266, P130; Varela MF, 1996, BBA-BIOENERGETICS, V1276, P21, DOI 10.1016/0005-2728(96)00030-8; Venkatesan P, 1998, P NATL ACAD SCI USA, V95, P9802, DOI 10.1073/pnas.95.17.9802; WESTON LA, 1987, J BACTERIOL, V169, P3546, DOI 10.1128/jb.169.8.3546-3555.1987; WILSON DM, 1992, J BACTERIOL, V174, P3083, DOI 10.1128/JB.174.9.3083-3086.1992; YAN RT, 1993, CELL, V75, P37, DOI 10.1016/S0092-8674(05)80082-0; YAN RT, 1995, P NATL ACAD SCI USA, V92, P5973, DOI 10.1073/pnas.92.13.5973	52	24	24	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1999	274	10					6148	6153		10.1074/jbc.274.10.6148	http://dx.doi.org/10.1074/jbc.274.10.6148			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172BQ	10037698	hybrid			2022-12-25	WOS:000078902800020
J	Moechars, D; Dewachter, I; Lorent, K; Reverse, D; Baekelandt, V; Naidu, A; Tesseur, I; Spittaels, K; Van Den Haute, C; Checler, F; Godaux, E; Cordell, B; Van Leuven, F				Moechars, D; Dewachter, I; Lorent, K; Reverse, D; Baekelandt, V; Naidu, A; Tesseur, I; Spittaels, K; Van Den Haute, C; Checler, F; Godaux, E; Cordell, B; Van Leuven, F			Early phenotypic changes in transgenic mice that overexpress different mutants of amyloid precursor protein in brain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAMILIAL ALZHEIMERS-DISEASE; BETA-PROTEIN; NEUROFIBRILLARY TANGLES; SENILE PLAQUES; NEURONAL LOSS; IN-VIVO; MOUSE; DEFICITS; TERMINUS; DEATH	Transgenic mice overexpressing different forms of amyloid precursor protein (APP), i.e. wild type or clinical mutants, displayed an essentially comparable early phenotype in terms of behavior, differential glutamatergic responses, deficits in maintenance of long term potentiation, and premature death. The cognitive impairment, demonstrated in F1 hybrids of the different APP transgenic lines, was significantly different from nontransgenic littermates as early as 3 months of age. Biochemical analysis of secreted and membrane-bound APP, C-terminal "stubs," and A beta(40) and A beta(42) peptides in brain indicated that no single intermediate can be responsible for the complex of phenotypic dysfunctions. As expected, the A beta(42) levels were most prominent in APP/London transgenic mice and correlated directly with the formation of amyloid plaques in older mice of this line, Plaques were associated with immunoreactivity for hyperphosphorylated tau, eventually signaling some form of tau pathology. In conclusion, the different APP transgenic mouse lines studied display cognitive deficits and phenotypic traits early in life that dissociated in time from the formation of amyloid plaques and will be good models for both early and late neuropathological and clinical aspects of Alzheimer's disease.	Katholieke Univ Leuven VIB, Ctr Human Genet, Expt Genet Grp, B-3000 Leuven, Belgium; Scios Inc, Sunnyvale, CA 94086 USA; CNRS, Inst Pharmacol Mol & Cellulaire, UPR411, F-06560 Valbonne, France; Univ Mons, Neurosci Lab, B-7000 Mons, Belgium	Flanders Institute for Biotechnology (VIB); KU Leuven; Scios; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur; University of Mons	Van Leuven, F (corresponding author), Katholieke Univ Leuven VIB, Ctr Human Genet, Expt Genet Grp, Campus Gasthuisberg ON 06, B-3000 Leuven, Belgium.	fredvl@med.kuleuven.ac.be	Checler, Frederic/C-1241-2009; Wyss-Coray, Tony/AAF-3380-2019	Checler, Frederic/0000-0003-2098-1750; Wyss-Coray, Tony/0000-0001-5893-0831; , Ilse Dewachter/0000-0001-7202-515X				ABELIOVICH A, 1993, CELL, V75, P1263, DOI 10.1016/0092-8674(93)90614-V; ALBIN RL, 1992, NEUROLOGY, V42, P733, DOI 10.1212/WNL.42.4.733; Barelli HL, 1997, MOL MED, V3, P695, DOI 10.1007/BF03401708; Borchelt DR, 1996, NEURON, V17, P1005, DOI 10.1016/S0896-6273(00)80230-5; BRAAK E, 1994, ACTA NEUROPATHOL, V87, P554, DOI 10.1007/s004010050124; Carlson GA, 1997, HUM MOL GENET, V6, P1951, DOI 10.1093/hmg/6.11.1951; Citron M, 1996, P NATL ACAD SCI USA, V93, P13170, DOI 10.1073/pnas.93.23.13170; COLLINGRIDGE GL, 1995, TRENDS NEUROSCI, V18, P54, DOI 10.1016/0166-2236(95)93868-X; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; DESTROOPER B, 1995, EMBO J, V14, P4932, DOI 10.1002/j.1460-2075.1995.tb00176.x; GAMES D, 1995, NATURE, V373, P523, DOI 10.1038/373523a0; GARVEY W, 1991, J HISTOTECHNOL, V14, P39, DOI 10.1179/his.1991.14.1.39; GOATE A, 1991, NATURE, V349, P704, DOI 10.1038/349704a0; GREENAMYRE JT, 1989, NEUROBIOL AGING, V10, P593, DOI 10.1016/0197-4580(89)90143-7; HIGGINS LS, 1994, ANN NEUROL, V35, P598, DOI 10.1002/ana.410350514; Holcomb L, 1998, NAT MED, V4, P97, DOI 10.1038/nm0198-097; Hsiao K, 1996, SCIENCE, V274, P99, DOI 10.1126/science.274.5284.99; HSIAO KK, 1995, NEURON, V15, P1203, DOI 10.1016/0896-6273(95)90107-8; Irizarry MC, 1997, J NEUROPATH EXP NEUR, V56, P965, DOI 10.1097/00005072-199709000-00002; Irizarry MC, 1997, J NEUROSCI, V17, P7053; JohnsonWood K, 1997, P NATL ACAD SCI USA, V94, P1550, DOI 10.1073/pnas.94.4.1550; LAFERLA FM, 1995, NAT GENET, V9, P21, DOI 10.1038/ng0195-21; Moechars D, 1998, BEHAV BRAIN RES, V95, P55, DOI 10.1016/S0166-4328(97)00210-6; Moechars D, 1996, EMBO J, V15, P1265, DOI 10.1002/j.1460-2075.1996.tb00468.x; MOECHARS D, 1998, IN PRESS NEUROSCIENC; MORAN PM, 1995, P NATL ACAD SCI USA, V92, P5341, DOI 10.1073/pnas.92.12.5341; MUCKE L, 1994, BRAIN RES, V666, P151, DOI 10.1016/0006-8993(94)90767-6; MULLAN M, 1992, NAT GENET, V1, P345, DOI 10.1038/ng0892-345; Nalbantoglu J, 1997, NATURE, V387, P500, DOI 10.1038/387500a0; OsterGranite ML, 1996, J NEUROSCI, V16, P6732; QUON D, 1991, NATURE, V352, P239, DOI 10.1038/352239a0; Scheuner D, 1996, NAT MED, V2, P864, DOI 10.1038/nm0896-864; Selkoe DJ, 1996, J BIOL CHEM, V271, P18295, DOI 10.1074/jbc.271.31.18295; Smith DJ, 1997, NAT GENET, V16, P28, DOI 10.1038/ng0597-28; SturchlerPierrat C, 1997, P NATL ACAD SCI USA, V94, P13287, DOI 10.1073/pnas.94.24.13287; Suh YH, 1997, J NEUROCHEM, V68, P1781; Yankner BA, 1998, NAT MED, V4, P394, DOI 10.1038/nm0498-394; YOUNKIN SG, 1995, ANN NEUROL, V37, P287, DOI 10.1002/ana.410370303	38	577	636	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	1999	274	10					6483	6492		10.1074/jbc.274.10.6483	http://dx.doi.org/10.1074/jbc.274.10.6483			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172BQ	10037741	hybrid			2022-12-25	WOS:000078902800063
J	Janosi, JBM; Firth, SM; Bond, JJ; Baxter, RC; Delhanty, PJD				Janosi, JBM; Firth, SM; Bond, JJ; Baxter, RC; Delhanty, PJD			N-linked glycosylation and sialylation of the acid-labile subunit - Role in complex formation with insulin-like growth factor (IGF)-binding protein-3 and the IGFs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-BINDING PROTEIN-3; LEUCINE-RICH REPEATS; TERNARY COMPLEX; MOLECULAR-DISTRIBUTION; FACTOR-I; SERUM; PURIFICATION; EXPRESSION; CLONING; BINARY	Over 75% of the circulating insulin-like growth factors (IGF-I and -II) are bound in 140-kDa ternary complexes with IGF-binding protein-3 (IGFBP-3) and the 84-86-kDa acid-labile subunit (ALS), a glycoprotein containing 20 kDa of carbohydrate. The ternary complexes regulate IGF availability to the tissues. Since interactions of glycoproteins can be influenced by their glycan moieties, this study aimed to determine the role of ALS glycosylation in ternary complex formation. Complete deglycosylation abolished the ability of ALS to associate with IGFBP-3. To examine this further, seven recombinant ALS mutants each lacking one of the seven glycan attachment sites were expressed in CRO cells. All the mutants bound IGFBP-3, demonstrating that this interaction is not dependent on any single glycan chain. Enzymatic desialylation of ALS caused a shift in isoelectric point from 4.5 toward 7, demonstrating a substantial contribution of anionic charge by sialic acid. Ionic interactions are known to be involved in the association between ALS and IGFBP-3. Desialylation reduced the affinity of ALS for IGFBP-3 IGF complexes by 50-80%. Since serum protein glycosylation is often modified in disease states, the dependence of IGF ternary complex formation on the glycosylation state of ALS suggests a novel mechanism for regulation of IGF bioavailability.	Univ Sydney, Royal N Shore Hosp, Kolling Inst Med Res, St Leonards, NSW 2065, Australia	Royal North Shore Hospital; University of Sydney; Kolling Institute of Medical Research	Delhanty, PJD (corresponding author), Univ Sydney, Royal N Shore Hosp, Kolling Inst Med Res, St Leonards, NSW 2065, Australia.		Baxter, Robert C/F-3927-2012; Bond, Jude j/E-5246-2017	Baxter, Robert C/0000-0001-5061-2142; Bond, Jude j/0000-0002-2913-9335				ABIDI FE, 1987, ANAL BIOCHEM, V166, P257, DOI 10.1016/0003-2697(87)90573-2; AVVAKUMOV GV, 1993, J BIOL CHEM, V268, P862; BANG P, 1994, J CLIN ENDOCR METAB, V78, P1119, DOI 10.1210/jc.78.5.1119; BAXTER RC, 1993, BIOCHEM J, V294, P847, DOI 10.1042/bj2940847; BAXTER RC, 1988, J CLIN ENDOCR METAB, V67, P265, DOI 10.1210/jcem-67-2-265; BAXTER RC, 1993, BIOCHEM BIOPH RES CO, V196, P1267, DOI 10.1006/bbrc.1993.2389; BAXTER RC, 1990, BIOCHEM J, V271, P773, DOI 10.1042/bj2710773; BAXTER RC, 1989, J BIOL CHEM, V264, P11843; Baxter RC, 1997, GROWTH REGULAT, V7, P1; BAXTER RC, 1992, J BIOL CHEM, V267, P60; BAXTER RC, 1990, J CLIN ENDOCR METAB, V70, P1347, DOI 10.1210/jcem-70-5-1347; Boisclair YR, 1996, P NATL ACAD SCI USA, V93, P10028, DOI 10.1073/pnas.93.19.10028; CHANEY WG, 1986, SOMAT CELL MOLEC GEN, V12, P237, DOI 10.1007/BF01570782; DAI J, 1992, BIOCHEM BIOPH RES CO, V188, P304, DOI 10.1016/0006-291X(92)92385-B; Delhanty P, 1996, BIOCHEM BIOPH RES CO, V227, P897, DOI 10.1006/bbrc.1996.1602; Delhanty PJD, 1998, BIOCHEM BIOPH RES CO, V243, P269, DOI 10.1006/bbrc.1998.8089; DELHANTY PJD, 1998, REGULATION ACTIONS A, P135; Donaghy AJ, 1996, BAILLIERE CLIN ENDOC, V10, P421, DOI 10.1016/S0950-351X(96)80560-X; DORAI DT, 1981, ANAL BIOCHEM, V115, P130, DOI 10.1016/0003-2697(81)90535-2; Firth SM, 1998, J BIOL CHEM, V273, P2631, DOI 10.1074/jbc.273.5.2631; GULER HP, 1989, ACTA ENDOCRINOL-COP, V121, P753, DOI 10.1530/acta.0.1210753; Hansen JE, 1998, GLYCOCONJUGATE J, V15, P115, DOI 10.1023/A:1006960004440; Holman SR, 1996, GROWTH REGULAT, V6, P42; JONES JI, 1995, ENDOCR REV, V16, P3, DOI 10.1210/er.16.1.3; KOBE B, 1993, NATURE, V366, P751, DOI 10.1038/366751a0; KOBE B, 1995, CURR OPIN STRUC BIOL, V5, P409, DOI 10.1016/0959-440X(95)80105-7; LEONG SR, 1992, MOL ENDOCRINOL, V6, P870, DOI 10.1210/me.6.6.870; LEWITT MS, 1993, ENDOCRINOLOGY, V133, P1797, DOI 10.1210/en.133.4.1797; LIU F, 1994, J CLIN ENDOCR METAB, V79, P1883, DOI 10.1210/jc.79.6.1883; MALEY F, 1989, ANAL BIOCHEM, V180, P195, DOI 10.1016/0003-2697(89)90115-2; Rajaram S, 1997, ENDOCR REV, V18, P801, DOI 10.1210/er.18.6.801; TARENTINO AL, 1985, BIOCHEMISTRY-US, V24, P4665, DOI 10.1021/bi00338a028; Twigg SM, 1998, J BIOL CHEM, V273, P6074, DOI 10.1074/jbc.273.11.6074; UMEMOTO J, 1977, J BIOL CHEM, V252, P8609; VANDIJK W, 1995, GLYCOCONJUGATE J, V12, P227, DOI 10.1007/BF00731324; Yoshida A, 1997, J BIOL CHEM, V272, P16884, DOI 10.1074/jbc.272.27.16884	36	31	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 26	1999	274	9					5292	5298		10.1074/jbc.274.9.5292	http://dx.doi.org/10.1074/jbc.274.9.5292			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	170KG	10026136	hybrid			2022-12-25	WOS:000078804400007
J	Satake, H; Takuwa, K; Minakata, H; Matsushima, O				Satake, H; Takuwa, K; Minakata, H; Matsushima, O			Evidence for conservation of the vasopressin/oxytocin superfamily in annelida	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXYTOCIN-RELATED PEPTIDE; CATOSTOMUS-COMMERSONI; ARGININE VASOPRESSIN; MOLECULAR EVOLUTION; CRYSTAL-STRUCTURE; EISENIA-FOETIDA; VASOTOCIN GENE; CELL-LINE; HORMONE; RAT	Annetocin is a structurally and functionally oxytocin-related peptide isolated from the earthworm Eisenia foetida. We present the characterization of the annetocin cDNA. Sequence analyses of the deduced precursor polypeptide revealed that the annetocin precursor is composed of three segments: a signal peptide, an annetocin sequence flanked by a Gly C-terminal amidation signal and a Lys-Arg dibasic processing site, and a neurophysin domain, similar to other oxytocin family precursors. The proannetocin showed 37.4-45.8% amino acid homology to other prohormones. In the neurophysin domain, 14 cysteines and amino acid residues essential for association of a neurophysin with a vasopressin/oxytocin superfamily peptide were conserved, suggesting that the Eisenia neurophysin can bind to annetocin. Furthermore, in situ hybridization experiments demonstrated that the annetocin gene is expressed exclusively in neurons of the central nervous system predicted to be involved in regulation of reproductive behavior. These findings confirm that annetocin is a member of the vasopressin/oxytocin superfamily. This is the first identification of the cDNA encoding the precursor of an invertebrate oxytocin-related peptide and also the first report of the identification of an annelid vasopressin/oxytocin-related precursor.	Suntory Inst Bioorgan Res, Shimamoto, Osaka 6188503, Japan; Hiroshima Univ, Fac Sci, Dept Biol Sci, Higashihiroshima, Hiroshima 7398526, Japan	Suntory Holdings Ltd; Hiroshima University	Minakata, H (corresponding author), Suntory Inst Bioorgan Res, Wakayamadai 1-1-1, Shimamoto, Osaka 6188503, Japan.	Hiroyuki_Minakata@suntory.co.jp						Acher R., 1985, P11; Acher R, 1996, GEN COMP ENDOCR, V102, P157, DOI 10.1006/gcen.1996.0057; ACHER R, 1993, REGUL PEPTIDES, V45, P1, DOI 10.1016/0167-0115(93)90174-7; ACHER R, 1980, PROC R SOC SER B-BIO, V210, P21, DOI 10.1098/rspb.1980.0116; ADAN RAH, 1993, MOL ENDOCRINOL, V7, P47, DOI 10.1210/me.7.1.47; ADAN RAH, 1991, BIOCHEM BIOPH RES CO, V175, P117, DOI 10.1016/S0006-291X(05)81208-2; ADAN RAH, 1992, J BIOL CHEM, V267, P3771; BARNES RD, 1987, INVERTEBRATE ZOOLOGY, P312; BRESLOW E, 1990, ADV ENZYMOL RAMB, V63, P1; BURBACH JPH, 1994, J BIOL CHEM, V269, P15046; BURMAN S, 1989, P NATL ACAD SCI USA, V86, P429, DOI 10.1073/pnas.86.2.429; CHEN LQ, 1991, P NATL ACAD SCI USA, V88, P4240, DOI 10.1073/pnas.88.10.4240; CRUZ LJ, 1987, J BIOL CHEM, V262, P15821; de Bree FM, 1998, CELL MOL NEUROBIOL, V18, P173, DOI 10.1023/A:1022564803093; FIGUEROA J, 1989, EMBO J, V8, P2873, DOI 10.1002/j.1460-2075.1989.tb08435.x; HAMANN D, 1992, J NEUROENDOCRINOL, V4, P505, DOI 10.1111/j.1365-2826.1992.tb00198.x; HEIERHORST J, 1992, P NATL ACAD SCI USA, V89, P6798, DOI 10.1073/pnas.89.15.6798; Hoyle CHV, 1998, REGUL PEPTIDES, V73, P1, DOI 10.1016/S0167-0115(97)01073-2; Hyodo S, 1997, P NATL ACAD SCI USA, V94, P13339, DOI 10.1073/pnas.94.24.13339; IVELL R, 1984, P NATL ACAD SCI-BIOL, V81, P2006, DOI 10.1073/pnas.81.7.2006; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAND H, 1982, NATURE, V295, P299, DOI 10.1038/295299a0; LAND H, 1983, NATURE, V302, P342, DOI 10.1038/302342a0; MCMASTER D, 1992, PEPTIDES, V13, P413, DOI 10.1016/0196-9781(92)90069-F; MOHR E, 1991, MOL BRAIN RES, V9, P293, DOI 10.1016/0169-328X(91)90075-9; MOHR E, 1990, FEBS LETT, V260, P305, DOI 10.1016/0014-5793(90)80130-B; MORLEY SD, 1990, BIOCHEMISTRY-US, V29, P2506, DOI 10.1021/bi00462a011; OEDING P, 1990, J NEUROENDOCRINOL, V2, P859, DOI 10.1111/j.1365-2826.1990.tb00652.x; OUMI T, 1994, BIOCHEM BIOPH RES CO, V198, P393, DOI 10.1006/bbrc.1994.1055; Oumi T, 1996, J EXP ZOOL, V276, P151, DOI 10.1002/(SICI)1097-010X(19961001)276:2&lt;151::AID-JEZ8&gt;3.0.CO;2-N; PARDY K, 1992, J BIOL CHEM, V267, P21746; PROUX JP, 1987, BIOCHEM BIOPH RES CO, V149, P180, DOI 10.1016/0006-291X(87)91621-4; REICH G, 1992, NEUROSCI LETT, V134, P191, DOI 10.1016/0304-3940(92)90514-8; RICHARD S, 1990, J BIOL CHEM, V265, P6098; Rose JP, 1996, NAT STRUCT BIOL, V3, P163, DOI 10.1038/nsb0296-163; SALZET M, 1993, EUR J BIOCHEM, V217, P897, DOI 10.1111/j.1432-1033.1993.tb18319.x; SAUSVILLE E, 1985, J BIOL CHEM, V260, P236; Takahama H, 1998, ZOOL SCI, V15, P381, DOI 10.2108/zsj.15.381; VANKESTEREN RE, 1995, J NEUROSCI, V15, P5989; VANKESTEREN RE, 1992, P NATL ACAD SCI USA, V89, P4593, DOI 10.1073/pnas.89.10.4593; VERBEECK MAE, 1991, MOL ENDOCRINOL, V5, P795, DOI 10.1210/mend-5-6-795; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WEHRENBERG U, 1994, P NATL ACAD SCI USA, V91, P1440, DOI 10.1073/pnas.91.4.1440	44	69	69	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 26	1999	274	9					5605	5611		10.1074/jbc.274.9.5605	http://dx.doi.org/10.1074/jbc.274.9.5605			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	170KG	10026177	hybrid			2022-12-25	WOS:000078804400048
J	Marsh, SK; Bansal, GS; Zammit, C; Barnard, R; Coope, R; Roberts-Clarke, D; Gomm, JJ; Coombes, RC; Johnston, CL				Marsh, SK; Bansal, GS; Zammit, C; Barnard, R; Coope, R; Roberts-Clarke, D; Gomm, JJ; Coombes, RC; Johnston, CL			Increased expression of fibroblast growth factor 8 in human breast cancer	ONCOGENE			English	Article						fibroblast growth factor 8; human breast cancer; fibroblast growth factor receptor 4	HIGH-AFFINITY RECEPTOR; FACTOR FGF RECEPTORS; HUMAN MAMMARY-GLAND; CARCINOMA-CELLS; MOLECULAR-CLONING; FACTOR FAMILY; FACTOR-VIII; SIGNAL-TRANSDUCTION; GENE; ANDROGEN	Fibroblast growth factor 8 (FGF8) is an important developmental protein which is oncogenic and able to cooperate with wnt-1 to produce mouse mammary carcinoma. The level of expression of FGF8 mRNA was measured in 68 breast cancers and 24 non-malignant breast tissues. Elevated levels of FGF8 mRNA were found in malignant compared to non-malignant breast tissues with significantly more malignant tissues expressing FGF8 (P = 0.019) at significantly higher levels (P = 0.031), In situ hybridization of breast cancer tissues and analysis of purified populations of normal epithelial cells and breast cancer cell lines showed that malignant epithelial cells expressed FGF8 mRNA at high levels compared to non-malignant epithelial and myoepithelial cells and fibroblasts. Although two of the receptors which FGF8 binds to (FGFR2-IIIc, FGFR3-IIIc) are not expressed in breast cancer cells, an autocrine activation loop is possible since expression of fibroblast growth factor receptor (FGFR) 4 and FGFR1 are retained in malignant epithelial cells. This is the first member of the FGF family to have increased expression in breast cancer and a potential autocrine role in its progression.	Univ London Imperial Coll Sci Technol & Med, Sch Med, Dept Med Oncol, London W6 8RP, England	Imperial College London	Johnston, CL (corresponding author), Univ London Imperial Coll Sci Technol & Med, Sch Med, Dept Med Oncol, Charing Cross Campus,St Dunstans Rd, London W6 8RP, England.			Coombes, Raoul Charles/0000-0002-4811-1100				ANANDAPPA SY, 1994, BRIT J CANCER, V69, P772, DOI 10.1038/bjc.1994.146; Bansal GS, 1997, BRIT J CANCER, V75, P1567, DOI 10.1038/bjc.1997.269; BANSAL GS, 1995, BRIT J CANCER, V72, P1420, DOI 10.1038/bjc.1995.524; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; Blunt AG, 1997, J BIOL CHEM, V272, P3733, DOI 10.1074/jbc.272.6.3733; CHELLAIAH AT, 1994, J BIOL CHEM, V269, P11620; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Coope RC, 1997, BRIT J CANCER, V75, P1621, DOI 10.1038/bjc.1997.277; Crossley PH, 1996, NATURE, V380, P66, DOI 10.1038/380066a0; Crossley PH, 1996, CELL, V84, P127, DOI 10.1016/S0092-8674(00)80999-X; CROSSLEY PH, 1995, DEVELOPMENT, V121, P439; Gemel J, 1996, GENOMICS, V35, P253, DOI 10.1006/geno.1996.0349; Ghosh AK, 1996, CELL GROWTH DIFFER, V7, P1425; Gomm JJ, 1997, EXP CELL RES, V234, P165, DOI 10.1006/excr.1997.3593; GOMM JJ, 1991, CANCER RES, V51, P4685; GOMM JJ, 1995, ANAL BIOCHEM, V226, P91, DOI 10.1006/abio.1995.1196; HOU JZ, 1991, SCIENCE, V251, P665, DOI 10.1126/science.1846977; JAAKKOLA S, 1993, INT J CANCER, V54, P378, DOI 10.1002/ijc.2910540305; JAYE M, 1992, BIOCHIM BIOPHYS ACTA, V1135, P185, DOI 10.1016/0167-4889(92)90136-Y; Johnston CL, 1995, J BIOL CHEM, V270, P30643, DOI 10.1074/jbc.270.51.30643; JOHNSTON CL, 1995, BIOCHEM J, V306, P609, DOI 10.1042/bj3060609; KAN MK, 1993, SCIENCE, V259, P1918, DOI 10.1126/science.8456318; KLAGSBRUN M, 1991, CELL, V67, P229, DOI 10.1016/0092-8674(91)90173-V; KOUHARA H, 1994, ONCOGENE, V9, P455; Leung HY, 1996, ONCOGENE, V12, P1833; LORENZI MV, 1995, ONCOGENE, V10, P2051; LUQMANI YA, 1992, BRIT J CANCER, V66, P273, DOI 10.1038/bjc.1992.256; MACARTHUR CA, 1995, DEVELOPMENT, V121, P3603; MACARTHUR CA, 1995, CELL GROWTH DIFFER, V6, P817; MACARTHUR CA, 1995, J VIROL, V69, P2501, DOI 10.1128/JVI.69.4.2501-2507.1995; MCLESKEY SW, 1994, CANCER RES, V54, P523; MIKI T, 1992, P NATL ACAD SCI USA, V89, P246, DOI 10.1073/pnas.89.1.246; MIYAMOTO M, 1993, MOL CELL BIOL, V13, P4251, DOI 10.1128/MCB.13.7.4251; Ornitz DM, 1996, J BIOL CHEM, V271, P15292, DOI 10.1074/jbc.271.25.15292; Payson RA, 1996, ONCOGENE, V13, P47; PEKONEN F, 1993, MOL CELL ENDOCRINOL, V95, P43, DOI 10.1016/0303-7207(93)90027-H; PENAULTLLORCA F, 1995, INT J CANCER, V61, P170, DOI 10.1002/ijc.2910610205; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; RON D, 1993, J BIOL CHEM, V268, P5388; SAVAGNER P, 1994, MOL BIOL CELL, V5, P851, DOI 10.1091/mbc.5.8.851; Schmitt JF, 1996, J STEROID BIOCHEM, V57, P173, DOI 10.1016/0960-0760(95)00259-6; SMITH J, 1994, EUR J CANCER, V30A, P496, DOI 10.1016/0959-8049(94)90426-X; STOSSEL TP, 1993, SCIENCE, V260, P1086, DOI 10.1126/science.8493552; TANAKA A, 1995, FEBS LETT, V363, P226, DOI 10.1016/0014-5793(95)00324-3; TANAKA A, 1992, P NATL ACAD SCI USA, V89, P8928, DOI 10.1073/pnas.89.19.8928; VAINIKKA S, 1994, J BIOL CHEM, V269, P18320; Vainikka S, 1996, J BIOL CHEM, V271, P1270, DOI 10.1074/jbc.271.3.1270; WERNER S, 1992, MOL CELL BIOL, V12, P82, DOI 10.1128/MCB.12.1.82; Yamasaki M, 1996, J BIOL CHEM, V271, P15918, DOI 10.1074/jbc.271.27.15918; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W; Yiangou C, 1997, BRIT J CANCER, V75, P28, DOI 10.1038/bjc.1997.5; Yiangou C, 1997, BRIT J CANCER, V76, P1419, DOI 10.1038/bjc.1997.573	53	71	75	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 28	1999	18	4					1053	1060		10.1038/sj.onc.1202392	http://dx.doi.org/10.1038/sj.onc.1202392			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	165FT	10023681				2022-12-25	WOS:000078510600022
J	Vermeulen, SJ; Nollet, F; Teugels, E; Vennekens, KM; Malfait, F; Philippe, J; Speleman, F; Bracke, ME; van Roy, FM; Mareel, MM				Vermeulen, SJ; Nollet, F; Teugels, E; Vennekens, KM; Malfait, F; Philippe, J; Speleman, F; Bracke, ME; van Roy, FM; Mareel, MM			The alpha E-catenin gene (CTNNA1) acts as an invasion-suppressor gene in human colon cancer cells	ONCOGENE			English	Article						colon cancer; invasion; alpha E-catenin; genetic instability	NONPOLYPOSIS COLORECTAL-CARCINOMA; II RECEPTOR GENE; E-CADHERIN; MICROSATELLITE INSTABILITY; GROWTH-FACTOR; LYNCH SYNDROME; RETINOIC ACID; BETA-CATENIN; TUMOR-CELLS; MUTATIONS	The acquisition of invasiveness is a crucial step in the malignant progression of cancer. In cancers of the colon and of other organs the E-cadherin/catenin complex, which is implicated in homotypic cell-cell adhesion as well as in signal transduction, serves as a powerful inhibitor of invasion. We show here that one allele of the alpha E-catenin (CTNNA1) gene is mutated in the human colon cancer cell family HCT-8, which is identical to HCT-15, DLD-1 and HRT-18. Genetic instability, due to mutations in the HMSH6 (also called GTBP) mismatch repair gene, results in the spontaneous occurrence of invasive variants, all carrying either a mutation or exon skipping in the second alpha E-catenin allele, The alpha E-catenin gene is therefore, an invasion-suppressor gene in accordance with the two-hit model of Knudsen for tumour-suppressor genes.	State Univ Ghent Hosp, Dept Radiotherapy & Nucl Med, Expt Cancerol Lab, B-9000 Ghent, Belgium; State Univ Ghent, Dept Mol Biol, Mol Cell Biol Lab, B-9000 Ghent, Belgium; VIB, B-9000 Ghent, Belgium; Univ Hosp Brussels, Lab Med Oncol, B-1010 Jette, Belgium; State Univ Ghent Hosp, Dept Clin Chem Microbiol & Immunol, B-9000 Ghent, Belgium; State Univ Ghent Hosp, Dept Med Genet, B-9000 Ghent, Belgium	Ghent University; Ghent University Hospital; Ghent University; Flanders Institute for Biotechnology (VIB); University Hospital Brussels; Ghent University; Ghent University Hospital; Ghent University; Ghent University Hospital	Mareel, MM (corresponding author), State Univ Ghent Hosp, Dept Radiotherapy & Nucl Med, Expt Cancerol Lab, Pintelaan 185, B-9000 Ghent, Belgium.		van Roy, Frans M/C-6123-2009; philippé, jan/AAG-8964-2019; speleman, frank/AAR-5184-2020; Malfait, Fransiska/K-7897-2014; Philippé, Jan/A-1027-2008	van Roy, Frans M/0000-0003-4358-1039; philippé, jan/0000-0003-4857-5746; speleman, frank/0000-0002-6628-8559; Philippé, Jan/0000-0003-4857-5746; Malfait, Fransiska/0000-0002-5010-0304; Vermeulen, Stefan/0000-0003-3710-800X				BEHRENS J, 1989, J CELL BIOL, V108, P2435, DOI 10.1083/jcb.108.6.2435; Berx G, 1995, EMBO J, V14, P6107, DOI 10.1002/j.1460-2075.1995.tb00301.x; BHATTACHARYYA NP, 1995, HUM MOL GENET, V4, P2057, DOI 10.1093/hmg/4.11.2057; BHATTACHARYYA NP, 1994, P NATL ACAD SCI USA, V91, P6319, DOI 10.1073/pnas.91.14.6319; Bracke ME, 1996, CURR TOP MICROBIOL, V213, P123; BRACKE ME, 1993, BRIT J CANCER, V68, P282, DOI 10.1038/bjc.1993.329; BRACKE ME, 1991, BRIT J CANCER, V63, P867, DOI 10.1038/bjc.1991.191; BREEN E, 1993, CELL ADHES COMMUN, V1, P239, DOI 10.3109/15419069309097257; BRUSSEMAKERS MJG, 1996, CLIN EXP METASTAS S1, V14, P15; CAPIZZI RL, 1973, MUTAT RES, V17, P147, DOI 10.1016/0027-5107(73)90265-0; Casares S, 1995, ONCOGENE, V11, P2303; CHEN TR, 1995, CANCER GENET CYTOGEN, V81, P103, DOI 10.1016/0165-4608(94)00225-Z; DACOSTA LT, 1995, NAT GENET, V9, P10, DOI 10.1038/ng0195-10; Eshleman JR, 1996, ONCOGENE, V12, P1425; EWING CM, 1995, CANCER RES, V55, P4813; FREI JV, 1992, CANCER, V69, P1108; HIRANO S, 1992, CELL, V70, P293, DOI 10.1016/0092-8674(92)90103-J; KEMLER R, 1993, TRENDS GENET, V9, P317, DOI 10.1016/0168-9525(93)90250-L; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; KNUDSON AG, 1985, CANCER RES, V45, P1437; KOI M, 1994, CANCER RES, V54, P4308; KOURI M, 1990, CANCER, V65, P1825, DOI 10.1002/1097-0142(19900415)65:8<1825::AID-CNCR2820650827>3.0.CO;2-H; LAZAR V, 1994, HUM MOL GENET, V3, P2257, DOI 10.1093/hmg/3.12.2257; Luria SE, 1943, GENETICS, V28, P491; Lynch HT, 1996, CANCER, V78, P1149, DOI 10.1002/(SICI)1097-0142(19960915)78:6<1149::AID-CNCR1>3.3.CO;2-Q; Mareel M, 1996, J CELL BIOCHEM, V61, P524; MAREEL M, 1997, HDB CLIN NEUROLOGY 3, V25, P105; Mareel M. M., 1991, MECH INVASION METAST; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; MORTON RA, 1993, CANCER RES, V53, P3585; NOLLET F, 1995, GENOMICS, V26, P410, DOI 10.1016/0888-7543(95)80231-A; ODA T, 1993, BIOCHEM BIOPH RES CO, V193, P897, DOI 10.1006/bbrc.1993.1710; PAPADOPOULOS N, 1995, SCIENCE, V268, P1915, DOI 10.1126/science.7604266; PARSONS R, 1995, CANCER RES, V55, P5548; Rhyu MS, 1996, J NATL CANCER I, V88, P240, DOI 10.1093/jnci/88.5.240; ROEST PAM, 1993, HUM MOL GENET, V2, P1719, DOI 10.1093/hmg/2.10.1719; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; SHIBATA D, 1994, NAT GENET, V6, P273, DOI 10.1038/ng0394-273; SHIMOYAMA Y, 1992, CANCER RES, V52, P5770; SHIOZAKI H, 1994, AM J PATHOL, V144, P667; SHIOZAKI H, 1995, BRIT J CANCER, V71, P250, DOI 10.1038/bjc.1995.52; Souza RF, 1996, NAT GENET, V14, P255, DOI 10.1038/ng1196-255; SPELEMAN F, 1992, CANCER GENET CYTOGEN, V58, P176; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; TOMPKINS WA, 1974, J NATL CANCER I, V52, P1101, DOI 10.1093/jnci/52.4.1101; Vermeulen S, 1996, PATHOL RES PRACT, V192, P694, DOI 10.1016/S0344-0338(96)80091-4; VERMEULEN SJ, 1995, CANCER RES, V55, P4722; VERMEULEN SJ, 1995, BRIT J CANCER, V72, P1447, DOI 10.1038/bjc.1995.528; VERMEULEN SJ, 1998, IN PRESS CANC GENET; VLEMINCKX K, 1991, CELL, V66, P107, DOI 10.1016/0092-8674(91)90143-M	51	65	67	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 28	1999	18	4					905	915		10.1038/sj.onc.1202348	http://dx.doi.org/10.1038/sj.onc.1202348			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	165FT	10023666				2022-12-25	WOS:000078510600007
J	Russo, I; Silver, ARJ; Cuthbert, AP; Griffin, DK; Trott, DA; Newbold, RF				Russo, I; Silver, ARJ; Cuthbert, AP; Griffin, DK; Trott, DA; Newbold, RF			A telomere-independent senescence mechanism is the sole barrier to Syrian hamster cell immortalization	ONCOGENE			English	Article						telomere; telomerase; senescence; immortalization; hamster; carcinogenesis	MALIGNANT TRANSFORMATION; HUMAN FIBROBLASTS; MAMMALIAN-CELLS; HUMAN CANCER; MOUSE CELLS; IN-VITRO; LENGTH; DNA; CARCINOMA; EXPRESSION	Reactivation of telomerase and stabilization of telomeres occur simultaneously during human cell immortalization in, vitro and the vast majority of human cancers possess high le, els of telomerase activity, Telomerase repression in human somatic cells may therefore have evolved as a powerful resistance mechanism against immortalization, clonal evolution and malignant progression. The comparative ease with, which rodent cells immortalize in vitro suggests that they have less stringent controls over replicative senescence than human cells. Here, we report that Syrian hamster dermal fibroblasts possess substantial levels of telomerase activity throughout their culture life-span, even after growth arrest in senescence. In our studies, telomerase,vas also detected in uncultured new-horn hamster skin, in several adult tissues, and in cultured fibroblasts induced to enter the post-mitotic state irreversibly by serum withdrawal. Transfection of near-senescent dermal fibroblasts with a selectable plasmid vector expressing the SV40 T-antigen gene resulted in high-frequency single-step immortalization without the crisis typically observed during the immortalization of human cells, Collectively, these data provide an explanation for the increased susceptibility of rodent cells to immortalization (and malignant transformation) compared with their human equivalents, and provide evidence for a novel, growth factor-sensitive, mammalian senescence mechanism unrelated to telomere maintenance.	Brunel Univ, Dept Biol & Biochem, Human Canc Genet Unit, Uxbridge UB8 3PH, Middx, England; Natl Radiol Protect Board, Biomed Effects Dept, Chilton OX11 0RQ, Oxon, England	Brunel University	Newbold, RF (corresponding author), Brunel Univ, Dept Biol & Biochem, Human Canc Genet Unit, Uxbridge UB8 3PH, Middx, England.							ALLSOPP RC, 1995, EXP CELL RES, V220, P194, DOI 10.1006/excr.1995.1306; ALLSOPP RC, 1992, P NATL ACAD SCI USA, V89, P10114, DOI 10.1073/pnas.89.21.10114; ANNAND R, 1986, TRENDS GENET, V2, P278; BLACKBURN EH, 1991, NATURE, V350, P569, DOI 10.1038/350569a0; Blasco MA, 1997, CELL, V91, P25, DOI 10.1016/S0092-8674(01)80006-4; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Broccoli D, 1996, MOL CELL BIOL, V16, P3765; Bryan TM, 1997, EUR J CANCER, V33, P767, DOI 10.1016/S0959-8049(97)00065-8; BRYAN TM, 1995, EMBO J, V14, P4240, DOI 10.1002/j.1460-2075.1995.tb00098.x; Bryan TM, 1997, NAT MED, V3, P1271, DOI 10.1038/nm1197-1271; CHADENEAU C, 1995, ONCOGENE, V11, P893; COSTA M, 1995, AM J CLIN NUTR, V61, p666S, DOI 10.1093/ajcn/61.3.666S; COUNTER CM, 1994, P NATL ACAD SCI USA, V91, P2900, DOI 10.1073/pnas.91.8.2900; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; GONOS ES, 1992, INT J ONCOL, V1, P209; Greider CW, 1996, ANNU REV BIOCHEM, V65, P337, DOI 10.1146/annurev.bi.65.070196.002005; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; Hall M, 1996, ADV CANCER RES, V68, P67, DOI 10.1016/S0065-230X(08)60352-8; Hara E, 1996, MOL CELL BIOL, V16, P859; HarleBachor C, 1996, P NATL ACAD SCI USA, V93, P6476, DOI 10.1073/pnas.93.13.6476; HARLEY CB, 1994, COLD SPRING HARB SYM, V59, P307, DOI 10.1101/SQB.1994.059.01.035; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HARLEY CB, 1992, EXP GERONTOL, V27, P375, DOI 10.1016/0531-5565(92)90068-B; HASTIE ND, 1990, NATURE, V346, P866, DOI 10.1038/346866a0; HAYFLICK L, 1965, EXP CELL RES, V37, P614, DOI 10.1016/0014-4827(65)90211-9; Holliday R, 1996, BIOESSAYS, V18, P3, DOI 10.1002/bies.950180103; Holt SE, 1996, MOL CELL BIOL, V16, P2932; Holt SE, 1997, EUR J CANCER, V33, P761, DOI 10.1016/S0959-8049(97)00066-X; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; KIPLING D, 1990, NATURE, V347, P400, DOI 10.1038/347400a0; Kipling D., 1995, TELOMERE; KRAEMER PM, 1986, J NATL CANCER I, V76, P703, DOI 10.1093/jnci/76.4.703; Mazars GR, 1997, P NATL ACAD SCI USA, V94, P151, DOI 10.1073/pnas.94.1.151; Meijne EIM, 1996, GENE CHROMOSOME CANC, V16, P230, DOI 10.1002/(SICI)1098-2264(199608)16:4<230::AID-GCC2>3.0.CO;2-Z; MOYZIS RK, 1988, P NATL ACAD SCI USA, V85, P6622, DOI 10.1073/pnas.85.18.6622; MURNANE JP, 1994, EMBO J, V13, P4953, DOI 10.1002/j.1460-2075.1994.tb06822.x; Newbold R F, 1985, Carcinog Compr Surv, V9, P17; NEWBOLD RF, 1982, NATURE, V299, P633, DOI 10.1038/299633a0; NEWBOLD RF, 1993, TOXICOL LETT, V67, P211, DOI 10.1016/0378-4274(93)90057-5; NEWBOLD RF, 1983, NATURE, V304, P648, DOI 10.1038/304648a0; OLOVNIKOV AM, 1973, J THEOR BIOL, V41, P181, DOI 10.1016/0022-5193(73)90198-7; Piatyszek Mieczyslaw A., 1995, Methods in Cell Science, V17, P1, DOI 10.1007/BF00981880; PROWSE KR, 1993, P NATL ACAD SCI USA, V90, P1493, DOI 10.1073/pnas.90.4.1493; PROWSE KR, 1995, P NATL ACAD SCI USA, V92, P4818, DOI 10.1073/pnas.92.11.4818; Ramirez RD, 1997, J INVEST DERMATOL, V108, P113, DOI 10.1111/1523-1747.ep12285654; ROGAN EM, 1995, MOL CELL BIOL, V15, P4745; SCHWARZ E, 1985, NATURE, V314, P111, DOI 10.1038/314111a0; Sharma HW, 1995, P NATL ACAD SCI USA, V92, P12343, DOI 10.1073/pnas.92.26.12343; Shay JW, 1997, EUR J CANCER, V33, P787, DOI 10.1016/S0959-8049(97)00062-2; SHAY JW, 1991, EXP CELL RES, V196, P33, DOI 10.1016/0014-4827(91)90453-2; SILVER A, 1991, GENE CHROMOSOME CANC, V3, P376, DOI 10.1002/gcc.2870030508; SLIJEPCEVIC P, 1995, CYTOGENET CELL GENET, V69, P87, DOI 10.1159/000133944; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; STARLING JA, 1990, NUCLEIC ACIDS RES, V18, P6881, DOI 10.1093/nar/18.23.6881; TROTT DA, 1995, CARCINOGENESIS, V16, P193, DOI 10.1093/carcin/16.2.193; VAZIRI H, 1993, AM J HUM GENET, V52, P661; VAZIRI H, 1994, P NATL ACAD SCI USA, V91, P9857, DOI 10.1073/pnas.91.21.9857; WATSON JD, 1972, NATURE-NEW BIOL, V239, P197, DOI 10.1038/newbio239197a0; WynfordThomas D, 1997, EUR J CANCER, V33, P716, DOI 10.1016/S0959-8049(97)00064-6; Yamasaki H, 1996, MUTAT RES-FUND MOL M, V356, P1, DOI 10.1016/0027-5107(96)90031-7; Zijlmans JMJM, 1997, P NATL ACAD SCI USA, V94, P7423, DOI 10.1073/pnas.94.14.7423	62	46	47	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 31	1998	17	26					3417	3426		10.1038/sj.onc.1202261	http://dx.doi.org/10.1038/sj.onc.1202261			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	157XD	10030665				2022-12-25	WOS:000078086200002
J	Serfas, MS; Tyner, AL				Serfas, MS; Tyner, AL			Ryk is expressed in a differentiation-specific manner in epithelial tissues and is strongly induced in decidualizing uterine stroma	ONCOGENE			English	Article						Ryk; tyrosine kinase; differentiation; epithelia	PROTEIN-TYROSINE KINASES; GROWTH-FACTOR RECEPTOR; MOUSE SMALL-INTESTINE; VULVAL CELL LINEAGES; MOLECULAR-CLONING; CAENORHABDITIS-ELEGANS; STEM-CELLS; GENE; FAMILY; IDENTIFICATION	Ryk is a ubiquitously expressed tyrosine kinase-like receptor of unknown activity and associations, We examined ryk expression in adult mouse epithelial tissues and during embryonic development at the histological level. Ryk RNA is present at greatly increased le, els in cells at particular stages of epithelial differentiation: the basal layer of skin and tongue epithelia, the intervillous layer and some crypt bases of the intestine and the lower matrix region of the hair follicle, Although ryk RNA is expressed at similar levels in a variety of tissues from embryonic day 10.5 to 18.5, specific induction of ryk RNA can be seen by ill situ hybridization in the basal layer of skin and hair follicle at day 15.5-16.5, and protein staining localizes to the hair follicle by immunohistochemistry. At day 4.5 and 6.5, little if any ryk is present in the blastocyst, but it is transiently induced at a high le, el in mature decidual cells of the uterine stroma, We review a number of independent isolations of ryk, including fruit fly and nematode members of the ryk family, Because ryk is induced in epithelial cells seeking a final place in a differentiated tissue, or during remodeling of the endometrium, and a homologous gene, derailed, is known to regulate muscle and nerve target seeking in Drosophila, ryk mag also be involved in cellular recognition of appropriate contest.	Univ Illinois, Dept Mol Genet, Chicago, IL 60607 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Tyner, AL (corresponding author), Univ Illinois, Dept Mol Genet, M-C 669,Mol Biol Res Bldg, Chicago, IL 60607 USA.			Tyner, Angela/0000-0001-7448-8625	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R55DK044525, R01DK044525] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK44525, R01 DK044525-06, R01 DK044525] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABRAHAMSOHN PA, 1993, J EXP ZOOL, V266, P603, DOI 10.1002/jez.1402660610; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; CALLAHAN CA, 1995, NATURE, V376, P171, DOI 10.1038/376171a0; Callahan CA, 1996, DEVELOPMENT, V122, P2761; CHENG H, 1974, AM J ANAT, V141, P537, DOI 10.1002/aja.1001410407; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOU YH, 1991, P NATL ACAD SCI USA, V88, P4897, DOI 10.1073/pnas.88.11.4897; Dey SK, 1996, REPROD ENDOCRINOLOGY, V1, P421; FERGUSON EL, 1987, NATURE, V326, P259, DOI 10.1038/326259a0; FERGUSON EL, 1985, GENETICS, V110, P17; GOUGH NM, 1995, MAMM GENOME, V6, P255, DOI 10.1007/BF00352411; HOVENS CM, 1992, P NATL ACAD SCI USA, V89, P11818, DOI 10.1073/pnas.89.24.11818; HUME WJ, 1976, J CELL SCI, V22, P149; IWAMA A, 1994, BLOOD, V83, P3160, DOI 10.1182/blood.V83.11.3160.bloodjournal83113160; Kee NJ, 1997, KIDNEY INT, V52, P309, DOI 10.1038/ki.1997.336; KELMAN Z, 1993, ONCOGENE, V8, P37; LARSSONBLOMBERG L, 1994, FEBS LETT, V348, P119, DOI 10.1016/0014-5793(94)00577-X; LEE JJ, 1992, DEVELOPMENT, V115, P277; Lim H, 1997, ENDOCRINOLOGY, V138, P1328, DOI 10.1210/en.138.3.1328; MAMINTA MLD, 1992, BIOCHEM BIOPH RES CO, V189, P1077; MOSSIE K, 1995, ONCOGENE, V11, P2179; PARTANEN J, 1990, P NATL ACAD SCI USA, V87, P8913, DOI 10.1073/pnas.87.22.8913; PAUL SR, 1992, INT J CELL CLONING, V10, P309, DOI 10.1002/stem.5530100509; Potworowski EF, 1996, IMMUNOL LETT, V50, P65, DOI 10.1016/0165-2478(96)02520-5; ROCHAT A, 1994, CELL, V76, P1063, DOI 10.1016/0092-8674(94)90383-2; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; SIMONEAUX DK, 1995, J IMMUNOL, V154, P1157; SIYANOVA EY, 1994, ONCOGENE, V9, P2053; STACKER SA, 1993, ONCOGENE, V8, P1347; STARK KL, 1991, DEVELOPMENT, V113, P641; TAMAGNONE L, 1993, ONCOGENE, V8, P2009; Wang XC, 1996, MOL MED, V2, P189, DOI 10.1007/BF03401616; Weiner HL, 1996, PEDIATR NEUROSURG, V25, P64, DOI 10.1159/000121099; WELSH AO, 1985, AM J ANAT, V172, P1, DOI 10.1002/aja.1001720102; WILKS AF, 1989, P NATL ACAD SCI USA, V86, P1603, DOI 10.1073/pnas.86.5.1603; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; YEE K, 1993, BLOOD, V82, P1335	37	14	14	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 31	1998	17	26					3435	3444		10.1038/sj.onc.1202266	http://dx.doi.org/10.1038/sj.onc.1202266			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	157XD	10030667				2022-12-25	WOS:000078086200004
J	Betto, R; Senter, L; Ceoldo, S; Tarricone, E; Biral, D; Salviati, G				Betto, R; Senter, L; Ceoldo, S; Tarricone, E; Biral, D; Salviati, G			Ecto-ATPase activity of alpha-sarcoglycan (adhalin)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DYSTROPHIN-ASSOCIATED PROTEINS; RECESSIVE MUSCULAR-DYSTROPHY; SKELETAL-MUSCLE; GLYCOPROTEIN-COMPLEX; TRANSVERSE TUBULES; PLASMA-MEMBRANE; BINDING SITE; RECEPTOR; GENE; SARCOLEMMA	alpha-Sarcoglycan is a component of the sarcoglycan complex of dystrophin-associated proteins. Mutations of any of the sarcoglycan genes cause specific forms of muscular dystrophies, collectively termed sarcoglycanopathies. Importantly, a deficiency of any specific sarcoglycan affects the expression of the others. Thus, it appears that the lack of sarcoglycans deprives the muscle cell of an essential, yet unknown function. In the present study, we provide evidence for an ecto-ATPase activity of alpha-sarcoglycan. alpha-Sarcoglycan binds ATP in a Mg2+-dependent and Ca2+-independent manner. The binding is inhibited by 3'-O-(4-benzoyl)benzoyl ATP and ADP, Sequence analysis reveals the existence of a consensus site for nucleotide binding in the extracellular domain of the protein, An antibody against this sequence inhibits the binding of ATP, A dystrophin dystrophin-associated protein preparation demonstrates a Mg-ATPase activity that is inhibited by the antibody but not by inhibitors of endo-ATPases. In addition, we demonstrate the presence in the sarcolemmal membrane of a P2X-type purinergic receptor. These data suggest that alpha-sarcoglycan may modulate the activity of P2X receptors by buffering the extracellular ATP concentration. The absence of a-sarcoglycan in sarcoglycanopathies leaves elevated the concentration of extracellular ATP and the persistent activation of P2X receptors, leading to intracellular Ca2+ overload and muscle fiber death.	Univ Padua, Sch Med, CNR, Unit Muscle Biol & Physiopathol, I-35121 Padua, Italy; Univ Padua, Sch Med, Dept Biomed Sci, I-35121 Padua, Italy	Consiglio Nazionale delle Ricerche (CNR); University of Padua; University of Padua	Betto, R (corresponding author), Univ Padua, Sch Med, CNR, Unit Muscle Biol & Physiopathol, Viale Giuseppe Colombo 3, I-35121 Padua, Italy.	betto@civ.bio.unipd.it	Salviati, Giancarlo/F-4947-2016	Salviati, Giancarlo/0000-0002-9828-6371	Telethon [692] Funding Source: Medline	Telethon(Fondazione Telethon)		Ahn AH, 1996, J BIOL CHEM, V271, P2724, DOI 10.1074/jbc.271.5.2724; BAR-ZVI D, 1992, Journal of Biological Chemistry, V267, P11029; Barbacci E, 1996, BIOCHEM BIOPH RES CO, V222, P273, DOI 10.1006/bbrc.1996.0734; Beckmann JS, 1996, CURR OPIN NEUROL, V9, P389, DOI 10.1097/00019052-199610000-00013; Brake AJ, 1996, ANNU REV CELL DEV BI, V12, P519, DOI 10.1146/annurev.cellbio.12.1.519; BRENMAN JE, 1995, CELL, V82, P743, DOI 10.1016/0092-8674(95)90471-9; Burnstock G, 1996, CIBA F SYMP, V198, P1; Carlson CG, 1998, NEUROBIOL DIS, V5, P3, DOI 10.1006/nbdi.1998.0188; CUSACK NJ, 1993, DRUG DEVELOP RES, V28, P244, DOI 10.1002/ddr.430280310; ERVASTI JM, 1991, J BIOL CHEM, V266, P9161; Ettinger AJ, 1997, J BIOL CHEM, V272, P32534, DOI 10.1074/jbc.272.51.32534; FABIATO A, 1988, METHOD ENZYMOL, V157, P378; Henry MD, 1996, CURR OPIN CELL BIOL, V8, P625, DOI 10.1016/S0955-0674(96)80103-7; KAWAI H, 1995, J CLIN INVEST, V96, P1202, DOI 10.1172/JCI118152; Kennedy C, 1996, SEMIN NEUROSCI, V8, P195, DOI 10.1006/smns.1996.0025; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; LIM LE, 1995, NAT GENET, V11, P257, DOI 10.1038/ng1195-257; LIN SH, 1988, J BIOL CHEM, V263, P12253; LU Z, 1991, J PHYSIOL-LONDON, V436, P45, DOI 10.1113/jphysiol.1991.sp018538; LUISE M, 1993, BIOCHEM J, V293, P243, DOI 10.1042/bj2930243; MATSUMURA K, 1992, NATURE, V360, P588, DOI 10.1038/360588a0; MCNALLY EM, 1994, P NATL ACAD SCI USA, V91, P9690, DOI 10.1073/pnas.91.21.9690; McNally EM, 1998, FEBS LETT, V422, P27, DOI 10.1016/S0014-5793(97)01593-7; Michalak M, 1997, CURR OPIN NEUROL, V10, P436, DOI 10.1097/00019052-199710000-00014; MURGIA M, 1993, J BIOL CHEM, V268, P8199; Nigro V, 1996, NAT GENET, V14, P195, DOI 10.1038/ng1096-195; NOGUCHI S, 1995, SCIENCE, V270, P819, DOI 10.1126/science.270.5237.819; OHLENDIECK K, 1993, NEUROLOGY, V43, P795, DOI 10.1212/WNL.43.4.795; OHLENDIECK K, 1991, J CELL BIOL, V115, P1685, DOI 10.1083/jcb.115.6.1685; Ozawa E, 1998, MUSCLE NERVE, V21, P421, DOI 10.1002/(SICI)1097-4598(199804)21:4<421::AID-MUS1>3.3.CO;2-W; PAL PK, 1992, J BIOL CHEM, V267, P25003; PASTERNAK C, 1995, J CELL BIOL, V128, P355, DOI 10.1083/jcb.128.3.355; PETROF BJ, 1993, P NATL ACAD SCI USA, V90, P3710, DOI 10.1073/pnas.90.8.3710; PICCOLO F, 1995, NAT GENET, V10, P243, DOI 10.1038/ng0695-243; PIZZO P, 1991, BIOCHEM J, V274, P139, DOI 10.1042/bj2740139; PIZZO P, 1992, J IMMUNOL, V149, P3372; PLESNER L, 1991, BIOCHIM BIOPHYS ACTA, V1067, P191, DOI 10.1016/0005-2736(91)90043-8; PLESNER L, 1995, INT REV CYTOL, V158, P141; ROBERDS SL, 1993, J BIOL CHEM, V268, P11496; ROBERDS SL, 1994, CELL, V78, P625, DOI 10.1016/0092-8674(94)90527-4; SABBADINI RA, 1989, J BIOENERG BIOMEMBR, V21, P163, DOI 10.1007/BF00812068; SALVATORI S, 1990, BIOCHEM J, V267, P679, DOI 10.1042/bj2670679; SALVIATI G, 1982, BIOCHEM J, V202, P289, DOI 10.1042/bj2020289; SENTER L, 1995, BIOCHEM BIOPH RES CO, V206, P57, DOI 10.1006/bbrc.1995.1009; Straub V, 1997, CURR OPIN NEUROL, V10, P168, DOI 10.1097/00019052-199704000-00016; SUZUKI A, 1992, FEBS LETT, V308, P154, DOI 10.1016/0014-5793(92)81265-N; SUZUKI A, 1994, EUR J BIOCHEM, V220, P283, DOI 10.1111/j.1432-1033.1994.tb18624.x; TREUHEIT MJ, 1992, J BIOL CHEM, V267, P11777; TURNER PR, 1988, NATURE, V335, P535; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WARREN GB, 1974, P NATL ACAD SCI USA, V71, P622, DOI 10.1073/pnas.71.3.622; Winder SJ, 1997, J MUSCLE RES CELL M, V18, P617, DOI 10.1023/A:1018627705273; YOSHIDA M, 1994, EUR J BIOCHEM, V222, P1055, DOI 10.1111/j.1432-1033.1994.tb18958.x; Zimmermann H, 1996, DRUG DEVELOP RES, V39, P337, DOI 10.1002/(SICI)1098-2299(199611/12)39:3/4<337::AID-DDR15>3.0.CO;2-Z; [No title captured]	56	66	70	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	1999	274	12					7907	7912		10.1074/jbc.274.12.7907	http://dx.doi.org/10.1074/jbc.274.12.7907			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	178LU	10075685	hybrid			2022-12-25	WOS:000079268100044
J	Dai, P; Akimaru, H; Tanaka, Y; Maekawa, T; Nakafuku, M; Ishii, S				Dai, P; Akimaru, H; Tanaka, Y; Maekawa, T; Nakafuku, M; Ishii, S			Sonic hedgehog-induced activation of the Gli1 promoter is mediated by GLI3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-A; CUBITUS-INTERRUPTUS PROTEIN; RUBINSTEIN-TAYBI SYNDROME; SAETHRE-CHOTZEN SYNDROME; KINESIN-RELATED PROTEIN; ZINC-FINGER PROTEINS; LONG TERMINAL REPEAT; SIGNAL-TRANSDUCTION; TRANSCRIPTION FACTOR; LIMB DEVELOPMENT	Drosophila transcription factor cubitus interruptus (Ci) and its co-activator CRE (cAMP response element)binding protein (CBP) activate a group of target genes on the anterior-posterior border in response to hedgehog protein (Hh) signaling. In the anterior region, in contrast, the carboxyl-truncated form of Ci generated by protein processing represses Hh expression. In vertebrates, three Ci-related transcription factors (glioblastoma gene products (GLIs) 1, 2, and 3) were identified, but their functional difference in Hh signal transduction is unknown. Here, we report distinct roles for GLI1 and GLIB in Sonic hedgehog (Shh) signaling. GLIB containing both repression and activation domains acts both as an activator and a repressor, as does Ci, whereas GLI1 contains only the activation domain. Consistent with this, GLIB, but not GLI1, is processed to generate the repressor form. Transcriptional co-activator CBP binds to GLIB, but not to GLI1. The trans-activating capacity of GLIB is positively and negatively regulated by Shh and cAMP-dependent protein kinase, respectively, through a specific region of GLI3, which contains the CBP-binding domain and the phosphorylation sites of cAMP-dependent protein kinase. GLI3 directly binds to the Gli1 promoter and induces Gli1 transcription in response to Shh. Thus, GLI3 may act as a mediator of Shh signaling in the activation of the target gene Gli1.	RIKEN, Tsukuba Life Sci Ctr, Genet Mol Lab, Tsukuba, Ibaraki 3050074, Japan; Univ Tokyo, Grad Sch Med, Div Neurobiol, Dept Neurosci,Bunkyo Ku, Tokyo 1130033, Japan	RIKEN; University of Tokyo	Ishii, S (corresponding author), RIKEN, Tsukuba Life Sci Ctr, Genet Mol Lab, 3-1-1 Koyadai, Tsukuba, Ibaraki 3050074, Japan.	sishii@rtc.riken.go.jp	Ishii, Shunsuke/A-5271-2016; Nakafuku, Masato/J-3068-2013	Ishii, Shunsuke/0000-0002-6530-2478; Nakafuku, Masato/0000-0001-7783-9005				Akimaru H, 1997, NATURE, V386, P735, DOI 10.1038/386735a0; Akimaru H, 1997, NAT GENET, V17, P211, DOI 10.1038/ng1097-211; Alcedo J, 1996, CELL, V86, P221, DOI 10.1016/S0092-8674(00)80094-X; Alexandre C, 1996, GENE DEV, V10, P2003, DOI 10.1101/gad.10.16.2003; Altaba ARI, 1997, CELL, V90, P193, DOI 10.1016/S0092-8674(00)80325-6; Altaba ARI, 1998, DEVELOPMENT, V125, P2203; AzaBlanc P, 1997, CELL, V89, P1043, DOI 10.1016/S0092-8674(00)80292-5; Bannister AJ, 1995, ONCOGENE, V11, P2509; BASLER K, 1994, NATURE, V368, P208, DOI 10.1038/368208a0; Buscher D, 1997, MECH DEVELOP, V62, P175, DOI 10.1016/S0925-4773(97)00656-4; Chen Y, 1996, CELL, V87, P553, DOI 10.1016/S0092-8674(00)81374-4; Chen Y, 1998, P NATL ACAD SCI USA, V95, P2349, DOI 10.1073/pnas.95.5.2349; Chiang C, 1996, NATURE, V383, P407, DOI 10.1038/383407a0; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; Dai P, 1996, GENE DEV, V10, P528, DOI 10.1101/gad.10.5.528; Dominguez M, 1996, SCIENCE, V272, P1621, DOI 10.1126/science.272.5268.1621; ElGhouzzi V, 1997, NAT GENET, V15, P42; Epstein DJ, 1996, DEVELOPMENT, V122, P2885; Giles RH, 1998, TRENDS GENET, V14, P178, DOI 10.1016/S0168-9525(98)01438-3; Hammerschmidt M, 1996, GENE DEV, V10, P647, DOI 10.1101/gad.10.6.647; HENNEKAM RCM, 1990, AM J MED GENET, P17; Howard TD, 1997, NAT GENET, V15, P36, DOI 10.1038/ng0197-36; HUI CC, 1994, DEV BIOL, V162, P402, DOI 10.1006/dbio.1994.1097; HUI CC, 1993, NAT GENET, V3, P241, DOI 10.1038/ng0393-241; Hynes M, 1997, NEURON, V19, P15, DOI 10.1016/S0896-6273(00)80344-X; Ingham PW, 1998, EMBO J, V17, P3505, DOI 10.1093/emboj/17.13.3505; JIANG J, 1995, CELL, V80, P563, DOI 10.1016/0092-8674(95)90510-3; Kang S, 1997, NAT GENET, V15, P266, DOI 10.1038/ng0397-266; KINZLER KW, 1990, MOL CELL BIOL, V10, P634, DOI 10.1128/MCB.10.2.634; KINZLER KW, 1988, NATURE, V332, P371, DOI 10.1038/332371a0; KINZLER KW, 1987, SCIENCE, V236, P70, DOI 10.1126/science.3563490; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LAIMINS LA, 1984, J VIROL, V49, P183, DOI 10.1128/JVI.49.1.183-189.1984; Lee J, 1997, DEVELOPMENT, V124, P2537; LEE JJ, 1992, CELL, V71, P33, DOI 10.1016/0092-8674(92)90264-D; LEPAGE T, 1995, NATURE, V373, P711, DOI 10.1038/373711a0; LI W, 1995, CELL, V80, P553, DOI 10.1016/0092-8674(95)90509-X; Marigo V, 1996, NATURE, V384, P176, DOI 10.1038/384176a0; Marigo V, 1996, DEV BIOL, V180, P273, DOI 10.1006/dbio.1996.0300; Marine JC, 1997, MECH DEVELOP, V63, P211, DOI 10.1016/S0925-4773(97)00050-6; MASUYA H, 1995, GENE DEV, V9, P1645, DOI 10.1101/gad.9.13.1645; Matise MP, 1998, DEVELOPMENT, V125, P2759; Mo R, 1997, DEVELOPMENT, V124, P113; MOTZNY CK, 1995, MECH DEVELOP, V52, P137, DOI 10.1016/0925-4773(95)00397-J; Nakagawa Y, 1996, DEVELOPMENT, V122, P2449; Ohlmeyer JT, 1997, GENE DEV, V11, P2250, DOI 10.1101/gad.11.17.2250; ORENIC TV, 1990, GENE DEV, V4, P1053, DOI 10.1101/gad.4.6.1053; PETRIJ F, 1995, NATURE, V376, P348, DOI 10.1038/376348a0; Platt KA, 1997, MECH DEVELOP, V62, P121, DOI 10.1016/S0925-4773(96)00648-X; PREAT T, 1990, NATURE, V347, P87, DOI 10.1038/347087a0; Robbins DJ, 1997, CELL, V90, P225, DOI 10.1016/S0092-8674(00)80331-1; RUPPERT JM, 1988, MOL CELL BIOL, V8, P3104, DOI 10.1128/MCB.8.8.3104; Sasaki H, 1997, DEVELOPMENT, V124, P1313; Sisson JC, 1997, CELL, V90, P235, DOI 10.1016/S0092-8674(00)80332-3; Stone DM, 1996, NATURE, V384, P129, DOI 10.1038/384129a0; STRUTT DI, 1995, NATURE, V373, P705, DOI 10.1038/373705a0; TABATA T, 1994, CELL, V76, P89, DOI 10.1016/0092-8674(94)90175-9; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; Tanaka Y, 1997, P NATL ACAD SCI USA, V94, P10215, DOI 10.1073/pnas.94.19.10215; VonOhlen T, 1997, P NATL ACAD SCI USA, V94, P2404, DOI 10.1073/pnas.94.6.2404; VORTKAMP A, 1995, HUM GENET, V95, P82; VORTKAMP A, 1991, NATURE, V352, P539, DOI 10.1038/352539a0	62	429	436	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	1999	274	12					8143	8152		10.1074/jbc.274.12.8143	http://dx.doi.org/10.1074/jbc.274.12.8143			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	178LU	10075717	hybrid			2022-12-25	WOS:000079268100076
J	Tillotson, LG				Tillotson, LG			RIN ZF, a novel zinc finger gene, encodes proteins that bind to the CACC element of the gastrin promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; TRANSCRIPTIONAL ACTIVATION; MOLECULAR-CLONING; INSULINOMA CELLS; LEUCINE-ZIPPER; DNA; SP1; EXPRESSION; SEQUENCES; KRUPPEL	Expression of gastrin, a gut hormone and growth factor, has tissue-specific transcriptional regulation and can be induced in some tumors. Previous studies have shown that a CACC cis-regulatory element is important for transcriptional activation in pancreatic insulinoma cells, To identify CACC-binding proteins, a lambda phage cDNA library derived from a rat insulinoma cell line, RIN 38A, was screened by a Southwestern method. A novel member of the Cys(2)-His(2) zinc finger gene family was cloned and designated RIN ZF, having a cDNA sequence of 3.8 kilobases, One full-length and a shorter splice variant were sequenced and had predicted protein masses of 91.6 and 88.7 kDa, Expression of both splice forms were ubiquitous in fetal and adult rat tissues. Recombinant RIN ZF protein exhibited sequence specific binding to the gastrin CACC element in a gel mobility shift assay. In transient transfections, both splice variants appeared to have only weak activating effects on gastrin-luciferase reporter gene transcription, Furthermore, RIN ZF coexpression with Spl appeared to block the strongly activating effects of Spl mediated through the CACC element. These findings suggest that a novel set of zinc finger proteins may help regulate gastrin gene expression by interfering with Spl transactivation.	Univ N Carolina, Div Digest Dis & Nutr, Dept Med, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill	Tillotson, LG (corresponding author), Univ N Carolina, Div Digest Dis & Nutr, Dept Med, Rm 148,Glaxo Bldg,CB7038, Chapel Hill, NC 27599 USA.				NIDDK NIH HHS [R29 DK49860] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK049860] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Affolter M, 1990, CURR OPIN CELL BIOL, V2, P485, DOI 10.1016/0955-0674(90)90132-X; Akiri G, 1998, ONCOGENE, V17, P227, DOI 10.1038/sj.onc.1202019; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BELLEFROID EJ, 1989, DNA-J MOLEC CELL BIO, V8, P377, DOI 10.1089/dna.1.1989.8.377; Cabanillas AM, 1996, DNA CELL BIOL, V15, P643, DOI 10.1089/dna.1996.15.643; CHAPLIN T, 1995, BLOOD, V85, P1435, DOI 10.1182/blood.V85.6.1435.bloodjournal8561435; CHUNG DC, 1995, J BIOL CHEM, V270, P8829, DOI 10.1074/jbc.270.15.8829; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; Crossley M, 1996, MOL CELL BIOL, V16, P1695; DEMEDIUK BH, 1992, GASTROENTEROLOGY, V102, P728; FOULKES NS, 1992, CELL, V68, P411, DOI 10.1016/0092-8674(92)90178-F; GERBER HP, 1994, SCIENCE, V263, P808, DOI 10.1126/science.8303297; HAGEN G, 1992, NUCLEIC ACIDS RES, V20, P5519, DOI 10.1093/nar/20.21.5519; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; HARADA R, 1994, J BIOL CHEM, V269, P2062; HSU T, 1992, SCIENCE, V257, P1946, DOI 10.1126/science.1411512; IMATAKA H, 1992, EMBO J, V11, P3663, DOI 10.1002/j.1460-2075.1992.tb05451.x; JAN YN, 1993, CELL, V75, P827, DOI 10.1016/0092-8674(93)90525-U; KADONAGA JT, 1986, P NATL ACAD SCI USA, V83, P5889, DOI 10.1073/pnas.83.16.5889; KENNEDY GC, 1992, P NATL ACAD SCI USA, V89, P11498, DOI 10.1073/pnas.89.23.11498; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; Kozak M, 1996, MAMM GENOME, V7, P563, DOI 10.1007/s003359900171; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LARSSON LI, 1976, NATURE, V262, P609, DOI 10.1038/262609a0; LEGGETT RW, 1995, J BIOL CHEM, V270, P25879, DOI 10.1074/jbc.270.43.25879; Lin SY, 1996, MOL CELL BIOL, V16, P1668; LUTTICHAU HR, 1993, GASTROENTEROLOGY, V104, P1092; Merchant JL, 1996, MOL CELL BIOL, V16, P6644; MERCHANT JL, 1991, MOL CELL BIOL, V11, P2686, DOI 10.1128/MCB.11.5.2686; MERCHANT JL, 1993, GASTROENTEROLOGY, V104, P283; Mortensen ER, 1997, J BIOL CHEM, V272, P16540, DOI 10.1074/jbc.272.26.16540; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; PABO CO, 1992, ANNU REV BIOCHEM, V61, P1053, DOI 10.1146/annurev.bi.61.070192.005201; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; SAHA S, 1993, NATURE, V363, P648, DOI 10.1038/363648a0; Sambrook J., 2002, MOL CLONING LAB MANU; SAUER F, 1993, NATURE, V364, P454, DOI 10.1038/364454a0; SINGH H, 1989, BIOTECHNIQUES, V7, P252; SINGH H, 1988, CELL, V52, P415, DOI 10.1016/S0092-8674(88)80034-5; SMITH DB, 1997, CURRENT PROTOCOLS MO; SMITH JP, 1995, AM J PHYSIOL-REG I, V268, pR135, DOI 10.1152/ajpregu.1995.268.1.R135; Stuempfle KJ, 1997, BIOTECHNIQUES, V22, P260, DOI 10.2144/97222bm13; SUTERCRAZZOLARA C, 1995, BIOTECHNIQUES, V19, P202; TILLOTSON L, 1993, GASTROENTEROLOGY, V104, P456; TILLOTSON LG, 1994, J BIOL CHEM, V269, P2234; VAGNER S, 1995, MOL CELL BIOL, V15, P35, DOI 10.1128/MCB.15.1.35; VONSOLINGE WW, 1993, GASTROENTEROLOGY, V104, P1099; WANG TC, 1990, J BIOL CHEM, V265, P8908; WANG TC, 1995, AM J PHYSIOL-GASTR L, V268, pG1025, DOI 10.1152/ajpgi.1995.268.6.G1025; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; Yet SF, 1998, J BIOL CHEM, V273, P1026, DOI 10.1074/jbc.273.2.1026; ZOLLMAN S, 1994, P NATL ACAD SCI USA, V91, P10717, DOI 10.1073/pnas.91.22.10717	52	41	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 19	1999	274	12					8123	8128		10.1074/jbc.274.12.8123	http://dx.doi.org/10.1074/jbc.274.12.8123			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	178LU	10075714	Green Published, hybrid			2022-12-25	WOS:000079268100073
J	Kaplan, DL; Steitz, TA				Kaplan, DL; Steitz, TA			DnaB from Thermus aquaticus unwinds forked duplex DNA with an asymmetric tail length dependence	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-STRANDED-DNA; ESCHERICHIA-COLI CHROMOSOME; PROTEIN ACTION; BINDING-PROTEINS; REPLICATION FORK; RNA-POLYMERASE; HELICASE; PRIMASE; MECHANISM; BACTERIOPHAGE-T4	DnaB helicase is a ring-shaped hexamer of 300 kDa that is essential for replication of the bacterial chromo some. The dnaB gene from Thermus aquaticus was isolated and cloned, and its gene product was expressed and purified to homogeneity, A helicase assay was developed, and optimal conditions for T, aquaticus DnaB activity were determined using a forked duplex DNA substrate. The activity required a hydrolyzable nucleoside triphosphate and both 5'- and 3'-single-stranded DNA tail regions, Under conditions of single enzymatic turnover, the lengths of the 5'- and S'-single-stranded regions were varied, and 6-10 nucleotides of the 5'-single-stranded tail and 21-30 nucleotides of the 3'-single-stranded tail markedly stimulated the unwinding rate. These data suggest that DnaB from T, aquaticus interacts with both DNA single-stranded tails during unwinding and that a greater portion of the 3'-tail is in contact with the protein. Two models are consistent with these data. In one model, the 5'-single stranded region passes through the central hole of the DnaB ring, and the 3'-tail makes extensive contact with the outside of the protein. In the other model, the 3'-single-stranded region passes through the DnaB ring, and the outside of the protein contacts the 5'-tail.	Yale Univ, Dept Mol Biophys & Biochem, New Haven, CT 06520 USA; Yale Univ, Dept Chem, New Haven, CT 06520 USA; Howard Hughes Med Inst, New Haven, CT 06520 USA	Yale University; Yale University; Howard Hughes Medical Institute	Steitz, TA (corresponding author), Yale Univ, Dept Mol Biophys & Biochem, 266 Whitney Ave, New Haven, CT 06520 USA.		Steitz, Thomas A./C-6559-2009	Kaplan, Daniel/0000-0003-2760-7745				Ahnert P, 1997, J BIOL CHEM, V272, P32267, DOI 10.1074/jbc.272.51.32267; ARAI K, 1981, J BIOL CHEM, V256, P5260; ARAI K, 1979, P NATL ACAD SCI USA, V76, P4308, DOI 10.1073/pnas.76.9.4308; ARAI K, 1981, J BIOL CHEM, V256, P5267; ARAI K, 1981, J BIOL CHEM, V256, P5253; BAKER TA, 1986, CELL, V45, P53, DOI 10.1016/0092-8674(86)90537-4; BAKER TA, 1987, J BIOL CHEM, V262, P6877; BUJALOWSKI W, 1995, BIOCHEMISTRY-US, V34, P8513, DOI 10.1021/bi00027a001; BUJALOWSKI W, 1994, J BIOL CHEM, V269, P31350; CHASE JW, 1986, ANNU REV BIOCHEM, V55, P103, DOI 10.1146/annurev.biochem.55.1.103; Dalphin ME, 1996, NUCLEIC ACIDS RES, V24, P216, DOI 10.1093/nar/24.1.216; EGELMAN EH, 1995, P NATL ACAD SCI USA, V92, P3869, DOI 10.1073/pnas.92.9.3869; GORBALENYA AE, 1993, CURR OPIN STRUC BIOL, V3, P419, DOI 10.1016/S0959-440X(05)80116-2; Hacker KJ, 1997, BIOCHEMISTRY-US, V36, P14080, DOI 10.1021/bi971644v; ILYINA TV, 1992, J MOL EVOL, V34, P351, DOI 10.1007/BF00160243; Jezewska MJ, 1997, BIOCHEMISTRY-US, V36, P10320, DOI 10.1021/bi970712a; Jezewska MJ, 1998, BIOCHEMISTRY-US, V37, P3116, DOI 10.1021/bi972564u; Jezewska MJ, 1998, J BIOL CHEM, V273, P10515, DOI 10.1074/jbc.273.17.10515; KAGUNI JM, 1984, CELL, V38, P183, DOI 10.1016/0092-8674(84)90539-7; Kusakabe T, 1998, EMBO J, V17, P1542, DOI 10.1093/emboj/17.5.1542; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAWER FC, 1989, J BIOL CHEM, V264, P6427; LEBOWITZ JH, 1986, J BIOL CHEM, V261, P4738; LEE EH, 1989, P NATL ACAD SCI USA, V86, P9104, DOI 10.1073/pnas.86.23.9104; Lu YB, 1996, P NATL ACAD SCI USA, V93, P12902, DOI 10.1073/pnas.93.23.12902; Manna AC, 1996, CELL, V87, P881, DOI 10.1016/S0092-8674(00)81995-9; MARTIN MCS, 1995, J STRUCT BIOL, V114, P167; MATSON SW, 1983, J BIOL CHEM, V258, P4017; MOK M, 1987, J BIOL CHEM, V262, P16644; PETERSON MG, 1993, METHOD ENZYMOL, V218, P493; RICHARDSON RW, 1989, J BIOL CHEM, V264, P4725; Sambrook J., 2002, MOL CLONING LAB MANU; Silver J., 1991, PCR PRACTICAL APPROA, P137; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; VENKATESAN M, 1982, J BIOL CHEM, V257, P2426; WECHSLER JA, 1971, MOL GEN GENET, V113, P273, DOI 10.1007/BF00339547; WU CA, 1992, J BIOL CHEM, V267, P4030; Yu X, 1996, NAT STRUCT BIOL, V3, P740, DOI 10.1038/nsb0996-740; Yu X, 1996, J MOL BIOL, V259, P7, DOI 10.1006/jmbi.1996.0297	39	33	47	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 12	1999	274	11					6889	6897		10.1074/jbc.274.11.6889	http://dx.doi.org/10.1074/jbc.274.11.6889			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	175DV	10066742	hybrid			2022-12-25	WOS:000079078400014
J	Kimura, M; Matsuda, Y; Yoshioka, T; Okano, Y				Kimura, M; Matsuda, Y; Yoshioka, T; Okano, Y			Cell cycle-dependent expression and centrosome localization of a third human Aurora/Ip11-related protein kinase, AIK3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPARATIVE GENOMIC HYBRIDIZATION; COLLAGEN GENE COL2A1; POLO-LIKE KINASE; BREAST-CANCER; DNA CONTENT; CHROMOSOME SEGREGATION; INSITU HYBRIDIZATION; YEAST; CARCINOMA; TUMORS	We earlier isolated cDNAs encoding novel human protein kinases AIK and AIK2 sharing high amino acid sequence identities with Drosophila Aurora and Saccharomyces cerevisiae Ipl1 kinases whose mutations cause abnormal chromosome segregation. In the present study, a third human cDNA (AIK3) highly homologous to artrora/IPL1 was isolated, and the nucleotide sequence was determined. This cDNA encodes 309 amino acids with a predicted molecular mass of 35.9 kDa, C-terminal kinase domain of AIK3 protein shares high amino acid sequence identities with those of Aurora/Ipl1 family protein kinases including human AIK, human AIK2, Xenopus pEg2, Drosophila Aurora, and yeast Ipl1, whereas the N-terminal domain of AIK3 protein shares little homology with any other Aurora/Ipl1 family members. AIK3 gene was assigned to human chromosome 19q13.43, which is a frequently deleted or rearranged region in several tumor tissues, by fluorescence in situ hybridization, somatic cell hybrid panel, and radiation hybrid cell panel. Northern blot analyses revealed that AIK3 expression was limited to testis, The expression levels of AIK3 in several cancer cell lines were elevated severalfold compared with normal fibroblasts. In HeLa cells, the endogenous AIK3 protein level is low in G(1)/S, accumulates during G(2)/M, and reduces after mitosis, Immunofluorescence studies using a specific antibody have shown that AIK3 is localized to centrosome during mitosis from anaphase to cytokinesis, These results suggest that AIK3 may play a role(s) in centrosome function at later stages of mitosis.	Gifu Univ, Sch Med, Dept Mol Pathobiochem, Gifu 5008705, Japan; Nagoya Univ, Sch Agr Sci, Lab Anim Genet, Chikusa Ku, Nagoya, Aichi 4640814, Japan	Gifu University; Nagoya University	Okano, Y (corresponding author), Gifu Univ, Sch Med, Dept Mol Pathobiochem, Tsukasamachi 40, Gifu 5008705, Japan.	bunbyo@cc.gifu-u.ac.jp						Bicher A, 1997, GYNECOL ONCOL, V66, P36, DOI 10.1006/gyno.1997.4709; Bischoff JR, 1998, EMBO J, V17, P3052, DOI 10.1093/emboj/17.11.3052; BRINGUIER PP, 1993, CYTOMETRY, V14, P559, DOI 10.1002/cyto.990140516; BUNN PA, 1982, BLOOD, V59, P528; Cahill DP, 1998, NATURE, V392, P300, DOI 10.1038/32688; CHAN CSM, 1993, GENETICS, V135, P677; FRANCISCO L, 1994, MOL CELL BIOL, V14, P4731, DOI 10.1128/MCB.14.7.4731; GLOVER DM, 1995, CELL, V81, P95, DOI 10.1016/0092-8674(95)90374-7; Gopalan G, 1997, J CELL BIOL, V138, P643, DOI 10.1083/jcb.138.3.643; Gopalan G, 1998, MAMM GENOME, V9, P86, DOI 10.1007/s003359900688; Hoglund M, 1998, GENE CHROMOSOME CANC, V21, P8; ISOLA JJ, 1995, AM J PATHOL, V147, P905; IWABUCHI H, 1995, CANCER RES, V55, P6172; KALLIONIEMI A, 1994, P NATL ACAD SCI USA, V91, P2156, DOI 10.1073/pnas.91.6.2156; Kimura M, 1997, CYTOGENET CELL GENET, V78, P107, DOI 10.1159/000134639; Kimura M, 1997, CYTOGENET CELL GENET, V79, P201, DOI 10.1159/000134721; Kimura M, 1998, CYTOGENET CELL GENET, V82, P147, DOI 10.1159/000015089; Kimura M, 1997, J BIOL CHEM, V272, P13766, DOI 10.1074/jbc.272.21.13766; KIMURA M, 1991, J BIOCHEM, V109, P399, DOI 10.1093/oxfordjournals.jbchem.a123393; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MATSUDA Y, 1995, ELECTROPHORESIS, V16, P261, DOI 10.1002/elps.1150160142; McDonald JM, 1998, CANCER RES, V58, P1387; McManus DT, 1996, J PATHOL, V179, P177, DOI 10.1002/(SICI)1096-9896(199606)179:2<177::AID-PATH561>3.0.CO;2-2; MELCHIORRI C, 1993, CANCER, V72, P165, DOI 10.1002/1097-0142(19930701)72:1<165::AID-CNCR2820720131>3.0.CO;2-V; MERTENS F, 1994, CANCER GENET CYTOGEN, V73, P147, DOI 10.1016/0165-4608(94)90199-6; MOLENAAR WM, 1994, GENE CHROMOSOME CANC, V10, P66, DOI 10.1002/gcc.2870100111; Niwa H, 1996, GENE, V169, P197, DOI 10.1016/0378-1119(95)00809-8; Roghi C, 1998, J CELL SCI, V111, P557; Sakamoto T, 1996, GYNECOL ONCOL, V63, P173, DOI 10.1006/gyno.1996.0302; SAXENA A, 1992, CANCER RES, V52, P6716; Sen S, 1997, ONCOGENE, V14, P2195, DOI 10.1038/sj.onc.1201065; SHACKNEY SE, 1989, CANCER RES, V49, P3344; Shindo M, 1998, BIOCHEM BIOPH RES CO, V244, P285, DOI 10.1006/bbrc.1998.8250; SREEKANTAIAH C, 1993, AM J PATHOL, V142, P293; STEIN GS, 1972, J CELL BIOL, V52, P292, DOI 10.1083/jcb.52.2.292; TAKAHASHI E, 1989, JPN J HUM GENET, V34, P307, DOI 10.1007/BF01929213; TAKAHASHI E, 1990, HUM GENET, V86, P14; Terada Y, 1998, EMBO J, V17, P667, DOI 10.1093/emboj/17.3.667; Wolf G, 1997, ONCOGENE, V14, P543, DOI 10.1038/sj.onc.1200862; Yanai A, 1997, ONCOGENE, V14, P2943, DOI 10.1038/sj.onc.1201144; Yuan JP, 1997, AM J PATHOL, V150, P1165; Zhou HY, 1998, NAT GENET, V20, P189, DOI 10.1038/2496	42	221	237	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	1999	274	11					7334	7340		10.1074/jbc.274.11.7334	http://dx.doi.org/10.1074/jbc.274.11.7334			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	175DV	10066797	hybrid			2022-12-25	WOS:000079078400069
J	Walowsky, C; Fitzhugh, DJ; Castano, IB; Ju, JY; Levin, NA; Christman, MF				Walowsky, C; Fitzhugh, DJ; Castano, IB; Ju, JY; Levin, NA; Christman, MF			The topoisomerase-related function gene TRF4 affects cellular sensitivity to the antitumor agent camptothecin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOTIC CHROMOSOME CONDENSATION; SACCHAROMYCES-CEREVISIAE; DNA TOPOISOMERASES; ESCHERICHIA-COLI; YEAST-CELLS; TRANSFORMATION; RESISTANCE; MUTANTS; COMPLEX; DRUGS	Camptothecin is an antitumor agent that kills cells by converting DNA topoisomerase I into a DNA-damaging poison. Although camptothecin derivatives are now being used to treat tumors in a variety of clinical protocols, the cellular factors that influence sensitivity to the drug are only beginning to be understood. We report here that two genes required for sister chromatid cohesion, TRF4 and MCD1/SCC1, are also required to repair camptothecin-mediated damage to DNA. The hypersensitivity to camptothecin in the trf4 mutant does not result from elevated expression of DNA topoisomerase I. We show that Trf4 is a nuclear protein whose expression is cell cycle-regulated at a post-transcriptional level. Suppression of camptothecin hypersensitivity in the trf4 mutant by gene overexpression resulted in the isolation of three genes: another member of the TRF4 gene family, TRF5, and two genes that may influence higher order chromosome structure, ZDS1 and ZDS2, We have isolated and sequenced two human TRF4 family members, hTRF4-1 and hTRF4-2. The hTRF4-1 gene maps to chromosome 5p15, a region of frequent copy number alteration in several tumor types. The evolutionary conservation of TRF4 suggests that it may also influence mammalian cell sensitivity to camptothecin.	Univ Virginia, Dept Microbiol, Charlottesville, VA 22908 USA	University of Virginia	Christman, MF (corresponding author), Univ Virginia, Dept Microbiol, Box 441,Jordan Hall,1300 Jefferson Pk Ave, Charlottesville, VA 22908 USA.	mfc3f@virginia.edu	Levin, Nikki/AAE-7397-2022	Castano, Irene/0000-0002-5968-2101				Bi EF, 1996, MOL CELL BIOL, V16, P5264; BOEKE JD, 1984, MOL GEN GENET, V197, P345, DOI 10.1007/BF00330984; Castano IB, 1996, NUCLEIC ACIDS RES, V24, P2404, DOI 10.1093/nar/24.12.2404; Castano IB, 1996, GENE DEV, V10, P2564, DOI 10.1101/gad.10.20.2564; CHEN AY, 1994, ANNU REV PHARMACOL, V34, P191, DOI 10.1146/annurev.pa.34.040194.001203; DOWER WJ, 1988, NUCLEIC ACIDS RES, V16, P6127, DOI 10.1093/nar/16.13.6127; ENG WK, 1988, MOL PHARMACOL, V34, P755; GIETZ RD, 1995, YEAST, V11, P355, DOI 10.1002/yea.320110408; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; Guacci V, 1997, CELL, V91, P47, DOI 10.1016/S0092-8674(01)80008-8; Hartwell LH, 1997, SCIENCE, V278, P1064, DOI 10.1126/science.278.5340.1064; HERTZBERG RP, 1989, BIOCHEMISTRY-US, V28, P4629, DOI 10.1021/bi00437a018; HIRANO T, 1995, TRENDS BIOCHEM SCI, V20, P357, DOI 10.1016/S0968-0004(00)89076-3; HOFFMAN CS, 1987, GENE, V57, P267, DOI 10.1016/0378-1119(87)90131-4; HSIANG YH, 1989, CANCER RES, V49, P5077; HSIANG YH, 1985, J BIOL CHEM, V260, P4873; IWABUCHI H, 1995, CANCER RES, V55, P6172; KAUH EA, 1995, P NATL ACAD SCI USA, V92, P6299, DOI 10.1073/pnas.92.14.6299; Kimura K, 1997, CELL, V90, P625, DOI 10.1016/S0092-8674(00)80524-3; KING RW, 1995, CELL, V81, P279, DOI 10.1016/0092-8674(95)90338-0; LEVIN NA, 1993, GENETICS, V133, P799; LEVIN NA, 1995, GENE CHROMOSOME CANC, V13, P175, DOI 10.1002/gcc.2870130307; LEVIN NA, 1994, CANCER RES, V54, P5086; Ma XJ, 1996, GENE DEV, V10, P1327, DOI 10.1101/gad.10.11.1327; Michaelis C, 1997, CELL, V91, P35, DOI 10.1016/S0092-8674(01)80007-6; NITISS J, 1988, P NATL ACAD SCI USA, V85, P7501, DOI 10.1073/pnas.85.20.7501; Nitiss J L, 1994, Adv Pharmacol, V29B, P201; Nitiss JL, 1996, MOL PHARMACOL, V50, P1095; Pommier Y, 1996, ANN NY ACAD SCI, V803, P60, DOI 10.1111/j.1749-6632.1996.tb26377.x; Reid RJD, 1997, J BIOL CHEM, V272, P12091, DOI 10.1074/jbc.272.18.12091; RINE J, 1991, METHOD ENZYMOL, V194, P239; ROTHSTEIN R, 1991, METHOD ENZYMOL, V194, P281; SADOFF BU, 1995, GENETICS, V141, P465; SINGH J, 1992, GENE DEV, V6, P186, DOI 10.1101/gad.6.2.186; Sutani T, 1997, NATURE, V388, P798, DOI 10.1038/42062; Tlsty TD, 1997, CURR TOP MICROBIOL, V221, P37; WALL ME, 1966, J AM CHEM SOC, V88, P3888, DOI 10.1021/ja00968a057; Yu YX, 1996, MOL CELL BIOL, V16, P5254	38	60	65	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	1999	274	11					7302	7308		10.1074/jbc.274.11.7302	http://dx.doi.org/10.1074/jbc.274.11.7302			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	175DV	10066793	hybrid			2022-12-25	WOS:000079078400065
J	Watanabe, A; Takio, K; Ihara, Y				Watanabe, A; Takio, K; Ihara, Y			Deamidation and isoaspartate formation in smeared tan in paired helical filaments - Unusual properties of the microtubule-binding domain of tau	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALZHEIMER-LIKE FILAMENTS; D-ASPARTYL RESIDUES; NEUROFIBRILLARY TANGLES; PROTEIN-TAU; AMINO-ACID; GROWTH-HORMONE; DISEASE; SEQUENCE; BRAIN; PHOSPHORYLATION	An extensive loss of a selected population of neurons in Alzheimer's disease is closely related to the formation of paired helical filaments (PHFs), The most striking characteristic of PHFs upon Western blotting is their smearing. According to a previously described protocol (Morishima-Kawashima, M., Hasegawa, M., Takio, K., Suzuki, M,, Titani, K,, and Ihara, Y, (1993) Neuron 10, 1151-1160), smeared tau was purified, and its peptide map was compared with that of soluble (normal) tau, A CNBr fragment from soluble tau (CN5; residues 251-419 according to the 441-residue isoform) containing the microtubule-binding domain migrated at 15 and 18 kDa on SDS-polyacrylamide gel electrophoresis, whereas that from smeared tau exhibited two larger, unusually broad bands at similar to 30 and similar to 45 kDa, presumably representing dimers and trimers of CN5, In the peptide map of smeared tau-derived CN5, distinct peaks eluting at unusual locations were noted, Amino acid sequence and mass spectrometric analyses revealed that these distinct peptides bear isoaspartate at Asn-381 and Asp-387, Because no unusual peptides other than aspartyl or isoaspartyl peptide were found in the digests of smeared tau-derived CN5, it is likely that site-specific deamidation and isoaspartate formation are involved in its dimerization and trimerization and thus in PHF formation in vivo.	Univ Tokyo, Fac Med, Dept Neuropathol, Bunkyo Ku, Tokyo 1130033, Japan; RIKEN, Inst Phys & Chem Res, Div Biomol Characterizat, Wako, Saitama 3510198, Japan; Japan Sci & Technol Corp, CREST, Kawaguchi, Saitama 3320012, Japan	University of Tokyo; RIKEN; Japan Science & Technology Agency (JST)	Ihara, Y (corresponding author), Univ Tokyo, Fac Med, Dept Neuropathol, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan.							Alzheimer A., 1907, ALLGEMEINE Z PSYCHIA, V64, P146, DOI DOI 10.1002/CA.980080612; Aswad D.W., 1995, DEAMIDATION ISOASPAR, P1; ASWAD DW, 1995, DEAMIDATION ISOASPAR, P7; Bornstein P, 1977, Methods Enzymol, V47, P132; BRAAK H, 1986, NEUROSCI LETT, V65, P351, DOI 10.1016/0304-3940(86)90288-0; BRENNAN TV, 1995, DEAMIDATION ISOASPAR, P65; BRUNAUER LS, 1986, J BIOL CHEM, V261, P2538; Clark LN, 1998, P NATL ACAD SCI USA, V95, P13103, DOI 10.1073/pnas.95.22.13103; CROWTHER RA, 1994, FEBS LETT, V337, P135, DOI 10.1016/0014-5793(94)80260-2; EINARSSON S, 1987, ANAL CHEM, V59, P1191, DOI 10.1021/ac00135a025; FERNANDEZ J, 1992, ANAL BIOCHEM, V201, P255, DOI 10.1016/0003-2697(92)90336-6; Fisher GH, 1991, BRAIN RES B, V28, P127; FLATMARK T, 1966, ACTA CHEM SCAND, V20, P1487, DOI 10.3891/acta.chem.scand.20-1487; GEIGER T, 1987, J BIOL CHEM, V262, P785; Goedert M, 1996, NATURE, V383, P550, DOI 10.1038/383550a0; GOEDERT M, 1989, NEURON, V3, P519, DOI 10.1016/0896-6273(89)90210-9; GomezIsla T, 1997, ANN NEUROL, V41, P17, DOI 10.1002/ana.410410106; GRAYSON S, 1990, ANAL BIOCHEM, V189, P192, DOI 10.1016/0003-2697(90)90106-J; HASEGAWA M, 1993, J NEUROCHEM, V60, P2068, DOI 10.1111/j.1471-4159.1993.tb03491.x; HASEGAWA M, 1992, J BIOL CHEM, V267, P17047; HAYASHI T, 1993, ANAL BIOCHEM, V209, P163, DOI 10.1006/abio.1993.1097; Hutton M, 1998, NATURE, V393, P702, DOI 10.1038/31508; IHARA Y, 1983, NATURE, V304, P727, DOI 10.1038/304727a0; IHARA Y, 1990, GERONTOLOGY, V36, P15; IHARA Y, 1988, BRAIN RES, V459, P138, DOI 10.1016/0006-8993(88)90293-4; JAKES R, 1991, EMBO J, V10, P2725, DOI 10.1002/j.1460-2075.1991.tb07820.x; JOHNSON BA, 1995, DEAMIDATION ISOASPAR, P91; Kampers T, 1996, FEBS LETT, V399, P344, DOI 10.1016/S0014-5793(96)01386-5; KENESSEY A, 1995, BRAIN RES, V675, P183, DOI 10.1016/0006-8993(95)00061-T; KONDO J, 1988, NEURON, V1, P827, DOI 10.1016/0896-6273(88)90130-4; KOSIK KS, 1988, NEURON, V1, P817, DOI 10.1016/0896-6273(88)90129-8; LEWIS UJ, 1981, J BIOL CHEM, V256, P1645; LOWENSON JD, 1992, J BIOL CHEM, V267, P5985; MASTERS CL, 1985, P NATL ACAD SCI USA, V82, P4245, DOI 10.1073/pnas.82.12.4245; MCFADDEN PN, 1982, P NATL ACAD SCI-BIOL, V79, P2460, DOI 10.1073/pnas.79.8.2460; MIDELFORT CF, 1972, J BIOL CHEM, V247, P3618; MORI H, 1987, SCIENCE, V235, P1641, DOI 10.1126/science.3029875; MORISHIMAKAWASHIMA M, 1993, NEURON, V10, P1151, DOI 10.1016/0896-6273(93)90063-W; MORISHIMAKAWASHIMA M, 1995, J BIOL CHEM, V270, P823, DOI 10.1074/jbc.270.2.823; Najbauer J, 1996, BIOCHEMISTRY-US, V35, P5183, DOI 10.1021/bi953063g; NAKIHARA K, 1992, PEPTIDE CHEM, P203; NOVAK M, 1993, EMBO J, V12, P365, DOI 10.1002/j.1460-2075.1993.tb05665.x; PAYAN IL, 1992, NEUROCHEM RES, V17, P187, DOI 10.1007/BF00966798; Poorkaj P, 1998, ANN NEUROL, V43, P815, DOI 10.1002/ana.410430617; SECCHI C, 1986, INT J PEPT PROT RES, V28, P298; SVASTI J, 1972, BIOCHEM J, V128, P427, DOI 10.1042/bj1280427; TAM JP, 1988, P NATL ACAD SCI USA, V85, P5409, DOI 10.1073/pnas.85.15.5409; VOORTER CEM, 1987, FEBS LETT, V221, P249, DOI 10.1016/0014-5793(87)80935-3; WILLE H, 1992, J CELL BIOL, V118, P573, DOI 10.1083/jcb.118.3.573; WILSON JM, 1982, J BIOL CHEM, V257, P4830; WISCHIK CM, 1988, P NATL ACAD SCI USA, V85, P4506, DOI 10.1073/pnas.85.12.4506; WRIGHT HT, 1995, DEAMIDATION ISOASPAR, P229	52	101	104	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 12	1999	274	11					7368	7378		10.1074/jbc.274.11.7368	http://dx.doi.org/10.1074/jbc.274.11.7368			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	175DV	10066801	hybrid			2022-12-25	WOS:000079078400073
J	Lin, PJ; Luby-Phelps, K; Stull, JT				Lin, PJ; Luby-Phelps, K; Stull, JT			Properties of filament-bound myosin light chain kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE MYOSIN; RHO-ASSOCIATED KINASE; ENDOTHELIAL-CELL RETRACTION; PROTEIN-KINASE; OKADAIC ACID; PHOSPHORYLATION; CONTRACTION; ACTIN; BINDING; CALMODULIN	Myosin light chain kinase binds to actin-containing filaments from cells with a greater affinity than to F-actin, However, it is not known if this binding in cells is regulated by Ca2+/calmodulin as it is with F-actin. Therefore, the binding properties of the kinase to stress fibers were examined in smooth muscle-derived A7r5 cells, Full-length myosin light chain kinase or a truncation mutant lacking residues 2-142 was expressed as chimeras containing green fluorescent protein at the C terminus. In intact cells, the full-length kinase bound to stress fibers, whereas the truncated kinase showed diffuse fluorescence in the cytoplasm. After permeabilization with saponin, the fluorescence from the truncated kinase disappeared, whereas the fluorescence of the full-length kinase was retained on stress fibers. Measurements of fluorescence intensities and fluorescence recovery after photobleaching of the full-length myosin light chain kinase in saponin-permeable cells showed that Ca2+/calmodulin did not dissociate the kinase from these filaments. However, the filament-bound kinase was sufficient for Ca2+ dependent phosphorylation of myosin regulatory light chain and contraction of stress fibers. Thus, dissociation of myosin light chain kinase from actin-containing thin filaments is not necessary for phosphorylation of myosin light chain in thick filaments. We note that the distance between the N terminus and the catalytic core of the kinase is sufficient to span the distance between thin and thick filaments.	Univ Texas, SW Med Ctr, Dept Physiol, Dallas, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Stull, JT (corresponding author), Univ Texas, SW Med Ctr, Dept Physiol, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.			Luby-Phelps, Katherine/0000-0002-8378-1409	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL026043, R01HL026043] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL26043] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADELSTEIN RS, 1981, J BIOL CHEM, V256, P7501; BENGUR AR, 1987, J BIOL CHEM, V262, P7613; BLUMENTHAL DK, 1980, BIOCHEMISTRY-US, V19, P5608, DOI 10.1021/bi00565a023; BOWMAN BF, 1992, J BIOL CHEM, V267, P5346; COHEN DM, 1978, J GEN PHYSIOL, V72, P369, DOI 10.1085/jgp.72.3.369; COLBURN JC, 1988, J BIOL CHEM, V263, P19166; DELANEROLLE P, 1981, P NATL ACAD SCI-BIOL, V78, P4738; Gallagher PJ, 1997, MOL CELL BIOCHEM, V173, P51, DOI 10.1023/A:1006876318155; GOECKELER ZM, 1995, J CELL BIOL, V130, P613, DOI 10.1083/jcb.130.3.613; GUERRIERO V, 1981, CELL, V27, P449, DOI 10.1016/0092-8674(81)90386-X; Hartshorne D J, 1989, Adv Exp Med Biol, V255, P269; HASHIMOTO Y, 1994, BBA-MOL CELL RES, V1223, P163, DOI 10.1016/0167-4889(94)90222-4; HOLDEN HM, 1992, J MOL BIOL, V227, P840, DOI 10.1016/0022-2836(92)90226-A; HOLZAPFEL G, 1983, EXP CELL RES, V148, P117, DOI 10.1016/0014-4827(83)90192-1; HUBER AH, 1994, NEURON, V12, P717, DOI 10.1016/0896-6273(94)90326-3; IKEBE M, 1987, J BIOL CHEM, V262, P9569; IKEBE M, 1986, J BIOL CHEM, V261, P36; IKEBE M, 1985, J BIOL CHEM, V260, P27; Jian XY, 1996, J NEUROBIOL, V31, P379, DOI 10.1002/(SICI)1097-4695(199611)31:3<379::AID-NEU10>3.0.CO;2-B; KAMM KE, 1986, SCIENCE, V232, P80, DOI 10.1126/science.3754063; KAMM KE, 1985, ANNU REV PHARMACOL, V25, P593, DOI 10.1146/annurev.pharmtox.25.1.593; KANOH S, 1993, BIOCHEMISTRY-US, V32, P8902, DOI 10.1021/bi00085a023; KEMP BE, 1990, PEPTIDES PROTEIN PHO; KERRICK WGL, 1984, P NATL ACAD SCI-BIOL, V81, P165, DOI 10.1073/pnas.81.1.165; Kimura K, 1996, SCIENCE, V273, P245, DOI 10.1126/science.273.5272.245; KOLODNEY MS, 1993, J BIOL CHEM, V268, P23850; Krueger JK, 1997, BIOCHEMISTRY-US, V36, P6017, DOI 10.1021/bi9702703; Kureishi Y, 1997, J BIOL CHEM, V272, P12257, DOI 10.1074/jbc.272.19.12257; Lin PJ, 1997, J BIOL CHEM, V272, P7412, DOI 10.1074/jbc.272.11.7412; LUBYPHELPS K, 1995, J BIOL CHEM, V270, P21532, DOI 10.1074/jbc.270.37.21532; Mabuchi Y, 1998, BIOPHYS J, V74, pA38; MAMIYA S, 1989, J BIOL CHEM, V264, P8575; Matsui T, 1996, EMBO J, V15, P2208, DOI 10.1002/j.1460-2075.1996.tb00574.x; NAKANISHI S, 1992, J BIOL CHEM, V267, P2157; OBARA K, 1989, PFLUG ARCH EUR J PHY, V414, P134, DOI 10.1007/BF00580954; PEARSON RB, 1986, J BIOL CHEM, V261, P25; PERSECHINI A, 1986, J BIOL CHEM, V261, P6293; POWIS G, 1994, CANCER RES, V54, P2419; SELLERS JR, 1984, J BIOL CHEM, V259, P7740; SHIRINSKY VP, 1993, J BIOL CHEM, V268, P16578; SOMLYO AP, 1973, PHILOS T ROY SOC B, V265, P223, DOI 10.1098/rstb.1973.0027; Stull JT, 1997, ADV SEC MESS PHOSPH, V31, P141; Stull JT, 1998, ACTA PHYSIOL SCAND, V164, P471, DOI 10.1111/j.1365-201X.1998.tb10699.x; SWEENEY HL, 1993, AM J PHYSIOL, V264, pC1085, DOI 10.1152/ajpcell.1993.264.5.C1085; TANSEY MG, 1990, FEBS LETT, V270, P219, DOI 10.1016/0014-5793(90)81272-P; TANSEY MG, 1994, J BIOL CHEM, V269, P9912; TAYLOR DA, 1988, J BIOL CHEM, V263, P14456; UMEMOTO S, 1989, J BIOL CHEM, V264, P1431; Walsh MP, 1996, BIOCHEM CELL BIOL, V74, P485, DOI 10.1139/o96-053; WYSOLMERSKI RB, 1991, AM J PHYSIOL, V261, pC32, DOI 10.1152/ajpcell.1991.261.1.C32; WYSOLMERSKI RB, 1990, P NATL ACAD SCI USA, V87, P16, DOI 10.1073/pnas.87.1.16; Ye LH, 1997, J BIOL CHEM, V272, P32182, DOI 10.1074/jbc.272.51.32182; Zolotukhin S, 1996, J VIROL, V70, P4646, DOI 10.1128/JVI.70.7.4646-4654.1996	53	39	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 26	1999	274	9					5987	5994		10.1074/jbc.274.9.5987	http://dx.doi.org/10.1074/jbc.274.9.5987			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	170KG	10026225	hybrid			2022-12-25	WOS:000078804400096
J	Nishimura, JS; Narayanasami, R; Miller, RT; Roman, LJ; Panda, S; Masters, BSS				Nishimura, JS; Narayanasami, R; Miller, RT; Roman, LJ; Panda, S; Masters, BSS			The stimulatory effects of Hofmeister ions on the activities of neuronal nitric-oxide synthase - Apparent substrate inhibition by L-arginine is overcome in the presence of protein-destabilizing agents	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEME; BINDING; TETRAHYDROBIOPTERIN; CALMODULIN; OXIDATION; MECHANISM; EXPRESSION; REDUCTASE; COMPLEX	A variety of monovalent anions and cations were effective in stimulating both calcium ion/calmodulin (Ca2+/CaM)-independent NADPH-cytochrome c reductase activity of, and Ca2+/CaM-dependent nitric oxide (NO.) synthesis by, neuronal nitric oxide synthase (nNOS), The efficacy of the ions in stimulating both activities could be correlated, in general, with their efficacy in precipitating or stabilizing certain proteins, an order referred to as the Hofmeister ion series. In the hemoglobin capture assay, used for measurement of NO. production, apparent substrate inhibition by L-arginine was almost completely reversed by the addition of sodium perchlorate (NaClO4), one of the more effective protein-destabilizing agents tested. Examination of this phenomenon by the assay of L-arginine conversion to L-citrulline revealed that the stimulatory effect of NaClO4 on the reaction was observed only in the presence of oxyhemoglobin or superoxide anion (generated by xanthine and xanthine oxidase), both scavengers of NO.. Spectrophotometric examination of nNOS revealed that the addition of NaClO4 and a superoxide-generating system, but neither alone, prevented the increase of heme absorption at 436 nm, which has been attributed to the nitrosyl complex, The data are consistent with the release of autoinhibitory NO. coordinated to the prosthetic group of nNOS, which, in conjunction with an NO. scavenger, causes stimulation of the reaction.	Univ Texas, Hlth Sci Ctr, Dept Biochem, San Antonio, TX 78284 USA	University of Texas System; University of Texas Health San Antonio	Nishimura, JS (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Biochem, 7703 Floyd Curl Dr, San Antonio, TX 78284 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL030050, R01HL030050] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052419] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 30050] Funding Source: Medline; NIGMS NIH HHS [GM 52419] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abu-Soud HM, 1998, BIOCHEMISTRY-US, V37, P3777, DOI 10.1021/bi972398q; ABUSOUD HM, 1993, P NATL ACAD SCI USA, V90, P10769, DOI 10.1073/pnas.90.22.10769; ABUSOUD HM, 1995, J BIOL CHEM, V270, P22997, DOI 10.1074/jbc.270.39.22997; AbuSoud HM, 1996, J BIOL CHEM, V271, P32515, DOI 10.1074/jbc.271.51.32515; ASSREUY J, 1993, BRIT J PHARMACOL, V108, P833, DOI 10.1111/j.1476-5381.1993.tb12886.x; Baldwin RL, 1996, BIOPHYS J, V71, P2056, DOI 10.1016/S0006-3495(96)79404-3; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; BREDT DS, 1994, ANNU REV BIOCHEM, V63, P175, DOI 10.1146/annurev.bi.63.070194.001135; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; BUGA GM, 1993, CIRC RES, V73, P808, DOI 10.1161/01.RES.73.5.808; COLLINS KD, 1985, Q REV BIOPHYS, V18, P323, DOI 10.1017/S0033583500005369; DAVIS MD, 1993, ARCH BIOCHEM BIOPHYS, V304, P9, DOI 10.1006/abbi.1993.1315; DOYLE MP, 1981, J INORG BIOCHEM, V14, P351, DOI 10.1016/S0162-0134(00)80291-3; GREGOR HP, 1955, J AM CHEM SOC, V77, P2713, DOI 10.1021/ja01615a011; GRIFFITH OW, 1995, ANNU REV PHYSIOL, V57, P707, DOI 10.1146/annurev.ph.57.030195.003423; GRISCAVAGE JM, 1994, J BIOL CHEM, V269, P21644; GRISCAVAGE JM, 1993, J IMMUNOL, V151, P6329; HAMABATA A, 1973, BIOCHEMISTRY-US, V12, P1264, DOI 10.1021/bi00731a004; Hofmeister F., 1888, N-S ARCH EXP PATH PH, V24, P247; KELM M, 1988, BIOCHEM BIOPH RES CO, V154, P236, DOI 10.1016/0006-291X(88)90675-4; KLATT P, 1992, J BIOL CHEM, V267, P11374; MARLETTA MA, 1993, J BIOL CHEM, V268, P12231; Masters B, 1967, METHOD ENZYMOL, V10, P565; MASTERS BSS, 1994, ANNU REV NUTR, V14, P131, DOI 10.1146/annurev.nu.14.070194.001023; MATSUOKA A, 1994, J BIOL CHEM, V269, P20335; MAYER B, 1995, J BIOL CHEM, V270, P655, DOI 10.1074/jbc.270.2.655; MCCORD JM, 1969, J BIOL CHEM, V244, P6049; MCMILLAN K, 1995, BIOCHEMISTRY-US, V34, P3686, DOI 10.1021/bi00011a025; MELANDER W, 1977, ARCH BIOCHEM BIOPHYS, V183, P200, DOI 10.1016/0003-9861(77)90434-9; Migita CT, 1997, BIOCHEMISTRY-US, V36, P10987, DOI 10.1021/bi970823+; Narayanasami R, 1997, NITRIC OXIDE-BIOL CH, V1, P39, DOI 10.1006/niox.1996.0103; PENEFSKY HS, 1977, J BIOL CHEM, V252, P2891; RENGASAMY A, 1993, MOL PHARMACOL, V44, P124; ROGERS NE, 1992, BIOCHEM BIOPH RES CO, V189, P242, DOI 10.1016/0006-291X(92)91550-A; ROMAN LJ, 1995, P NATL ACAD SCI USA, V92, P8428, DOI 10.1073/pnas.92.18.8428; Salerno JC, 1997, J BIOL CHEM, V272, P29769, DOI 10.1074/jbc.272.47.29769; SCHMIDT HHHW, 1991, P NATL ACAD SCI USA, V88, P365, DOI 10.1073/pnas.88.2.365; Schrammel A, 1998, BBA-PROTEIN STRUCT M, V1387, P257, DOI 10.1016/S0167-4838(98)00138-1; SHETA EA, 1994, J BIOL CHEM, V269, P15147; Sorrentino R, 1997, LIFE SCI, V61, P1283, DOI 10.1016/S0024-3205(97)00673-5; STUEHR DJ, 1991, J BIOL CHEM, V266, P6259; Stuehr DJ, 1997, ANNU REV PHARMACOL, V37, P339, DOI 10.1146/annurev.pharmtox.37.1.339; VONHIPPE.PH, 1969, ACCOUNTS CHEM RES, V2, P257, DOI 10.1021/ar50021a001; VONHIPPEL PH, 1964, SCIENCE, V145, P577, DOI 10.1126/science.145.3632.577; WANG JL, 1994, P NATL ACAD SCI USA, V91, P10512, DOI 10.1073/pnas.91.22.10512	46	28	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 26	1999	274	9					5399	5406		10.1074/jbc.274.9.5399	http://dx.doi.org/10.1074/jbc.274.9.5399			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	170KG	10026150	hybrid			2022-12-25	WOS:000078804400021
J	Fulda, S; Lutz, W; Schwab, M; Debatin, KM				Fulda, S; Lutz, W; Schwab, M; Debatin, KM			MycN sensitizes neuroblastoma cells for drug-induced apoptosis	ONCOGENE			English	Article						MycN; apoptosis; CD95; drugs; neuroblastoma	APO-1/FAS RECEPTOR/LIGAND SYSTEM; CHEMOTHERAPY-INDUCED APOPTOSIS; SIGNALING COMPLEX DISC; C-MYC; TRANSGENIC MICE; CELLULAR-SUSCEPTIBILITY; CANCER-THERAPY; LEUKEMIA-CELLS; WILD-TYPE; DEATH	Amplification of the MYCN gene is found in a large proportion of neuroblastoma and considered as an adverse prognostic factor. To investigate the effect of ectopic MycN expression on the susceptibility of neuroblastoma cells to cytotoxic drugs we used a human neuroblastoma cell line harboring tetracycline-controlled expression of MycN, Neither conditional expression of MycN alone nor low drug concentrations triggered apoptosis. However, when acting in concert, MycN and cytotoxic drugs efficiently induced cell death. Apoptosis depended on mitochondrial permeability transition and activation of caspases, since the mitochondrion-specific inhibitor bongkrekic acid and the caspase inhibitor zVAD-fmk almost completely abrogated apoptosis, Loss of mitochondrial transmembrane potential and release of cytochrome c from mitochondria preceded activation of caspase-8 and caspase-3 and cleavage of PARP. CD95 expression was upregulated by treatment with cytotoxic drugs, while MycN cooperated with cytotoxic drugs to increase sensitivity to CD95-induced apoptosis and enhancing CD95-L expression. MycN overexpression and cytotoxic drugs also synergized to induce p53 and Bar protein expression, while Bcl-2 and Bcl-X-L protein levels remained unchanged. Since amplification of MYCN is usually associated with a poor prognosis, these findings suggest that dysfunctions in apoptosis pathways may be a mechanism by which MycN-induced apoptosis of neuroblastoma cells is inhibited.	Univ Ulm, Childrens Hosp, D-89075 Ulm, Germany; German Canc Res Ctr, Dept Cytogenet, D-69120 Heidelberg, Germany	Ulm University; Helmholtz Association; German Cancer Research Center (DKFZ)	Debatin, KM (corresponding author), Univ Ulm, Childrens Hosp, Prittwitzstr 43, D-89075 Ulm, Germany.		Fulda, Simone/D-5864-2011; Debatin, Klaus-Michael/J-9704-2014	Debatin, Klaus-Michael/0000-0002-8397-1886; Fulda, Simone/0000-0002-0459-6417				Bargou RC, 1996, J CLIN INVEST, V97, P2651, DOI 10.1172/JCI118715; BERTHOLD F, 1990, OVERVIEW BIOL NEUROB, P1; BISSONNETTE RP, 1992, NATURE, V359, P552, DOI 10.1038/359552a0; Dong JA, 1997, ONCOGENE, V15, P639, DOI 10.1038/sj.onc.1201237; Eischen CM, 1997, BLOOD, V90, P935, DOI 10.1182/blood.V90.3.935.935_935_943; Faris M, 1998, J IMMUNOL, V160, P134; FISHER DE, 1994, CELL, V78, P539, DOI 10.1016/0092-8674(94)90518-5; Friesen C, 1996, NAT MED, V2, P574, DOI 10.1038/nm0596-574; Fulda S, 1997, CANCER RES, V57, P4956; Fulda S, 1997, CANCER RES, V57, P3823; Fulda S, 1998, INT J CANCER, V76, P105; FULDA S, 1998, IN PRESS CELL DEATH; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; Herr I, 1997, EMBO J, V16, P6200, DOI 10.1093/emboj/16.20.6200; Hueber AO, 1997, SCIENCE, V278, P1305, DOI 10.1126/science.278.5341.1305; JANICKE RU, 1994, MOL CELL BIOL, V14, P5661; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; Klefstrom J, 1997, EMBO J, V16, P7382, DOI 10.1093/emboj/16.24.7382; KLEFSTROM J, 1994, EMBO J, V13, P5442, DOI 10.1002/j.1460-2075.1994.tb06879.x; Kroemer G, 1997, IMMUNOL TODAY, V18, P44, DOI 10.1016/S0167-5699(97)80014-X; Kroemer G, 1997, NAT MED, V3, P614, DOI 10.1038/nm0697-614; LOS M, 1995, NATURE, V375, P81, DOI 10.1038/375081a0; Lutz W, 1998, ONCOGENE, V17, P339, DOI 10.1038/sj.onc.1200201; Lutz W, 1996, ONCOGENE, V13, P803; Medema JP, 1997, EMBO J, V16, P2794, DOI 10.1093/emboj/16.10.2794; MIYASHITA T, 1995, CELL, V80, P293; Muller M, 1997, J CLIN INVEST, V99, P403, DOI 10.1172/JCI119174; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; NIIMI S, 1991, BRIT J CANCER, V63, P237, DOI 10.1038/bjc.1991.56; OEHM A, 1992, J BIOL CHEM, V267, P10709; Packham G, 1996, ONCOGENE, V13, P461; Pastorino JG, 1998, J BIOL CHEM, V273, P7770, DOI 10.1074/jbc.273.13.7770; Peter ME, 1996, CELL DEATH DIFFER, V3, P161; Scaffidi C, 1997, J BIOL CHEM, V272, P26953, DOI 10.1074/jbc.272.43.26953; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Schwab M, 1995, NEUROSCIENTIST, V1, P277; SCHWEIGERER L, 1990, CANCER RES, V50, P4411; Susin SA, 1997, J EXP MED, V186, P25, DOI 10.1084/jem.186.1.25; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; Villunger A, 1997, CANCER RES, V57, P3331; Weiss WA, 1997, EMBO J, V16, P2985, DOI 10.1093/emboj/16.11.2985; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; Yeh WC, 1998, SCIENCE, V279, P1954, DOI 10.1126/science.279.5358.1954; Yu K, 1997, CELL GROWTH DIFFER, V8, P731; Zamzami N, 1996, J EXP MED, V183, P1533, DOI 10.1084/jem.183.4.1533; ZORNIG M, 1995, ONCOGENE, V11, P2165; ZORNIG M, 1995, ONCOGENE, V10, P2397	50	114	116	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 18	1999	18	7					1479	1486		10.1038/sj.onc.1202435	http://dx.doi.org/10.1038/sj.onc.1202435			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	167UK	10050884				2022-12-25	WOS:000078651600009
J	Bell, A; Chen, QY; DeFrances, MC; Michalopoulos, GK; Zarnegar, R				Bell, A; Chen, QY; DeFrances, MC; Michalopoulos, GK; Zarnegar, R			The five amino acid-deleted isoform of hepatocyte growth factor promotes carcinogenesis in transgenic mice	ONCOGENE			English	Article						dHGF; hepatocellular carcinoma; liver; Met	FACTOR SCATTER FACTOR; MET PROTOONCOGENE PRODUCT; IN-VIVO; C-MET; HEPATOCELLULAR-CARCINOMA; STRUCTURAL ORGANIZATION; NEOPLASTIC DEVELOPMENT; LIVER-REGENERATION; EPITHELIAL-CELLS; GENE-EXPRESSION	Hepatocyte growth factor (HGF) is a polypeptide with mitogenic, motogenic, and morphogenic effects on different cell types including hepatocytes. HGF is expressed as two biologically active isotypes resulting from alternative RNA splicing, The roles of each HGF isoform in development, liver regeneration and tumorigenesis have not yet been well characterized. We report the generation and analysis of transgenic mice overexpressing the five amino acid-deleted variant of HGF (dHGF) in the liver by virtue of an albumin expression vector. These ALB-dHGF transgenic mice develop normally, have an enhanced rate of liver regeneration after partial hepatectomy, and exhibit a threefold higher incidence of hepatocellular carcinoma (HCC) beyond 17 months of age. Moreover, overexpression of dHGF dramatically accelerates diethyl-nitrosamine induced HCC tumorigenesis, These tumors arise faster, are significantly larger, more numerous and more invasive than those appearing in non-transgenic littermates. Approximately 90% of female dHGF-transgenic mice had multiple macroscopic HCCs 40 weeks after injection of DEN; whereas the non-transgenic counterparts had only microscopic nodules, Liver tumors and cultured tumor cell lines from dHGF transgenics showed high levels of HGF and c-Met mRNA and protein, Together, these results reveal that in vivo dHGF plays an active role in liver regeneration and HCC tumorigenesis.	Univ Pittsburgh, Sch Med, Dept Pathol, Div Cellular & Mol Pathol, Pittsburgh, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Zarnegar, R (corresponding author), Univ Pittsburgh, Sch Med, Dept Pathol, Div Cellular & Mol Pathol, Pittsburgh, PA 15261 USA.				NIEHS NIH HHS [R01ES06109] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES006109] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Amicone L, 1997, EMBO J, V16, P495, DOI 10.1093/emboj/16.3.495; BLADT F, 1995, NATURE, V373, P702; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; BRINKMANN V, 1995, J CELL BIOL, V131, P1573, DOI 10.1083/jcb.131.6.1573; BUSSOLINO F, 1992, J CELL BIOL, V119, P629, DOI 10.1083/jcb.119.3.629; Chan A, 1993, EXS, V65, P67; Chen QY, 1996, CELL GROWTH DIFFER, V7, P821; Chen QY, 1997, HEPATOLOGY, V26, P59; GOHDA E, 1988, J CLIN INVEST, V81, P414, DOI 10.1172/JCI113334; HOGAN B, 1986, MANIPULATING MOUSE E, P174; JOHNSON M, 1995, CANCER LETT, V96, P37, DOI 10.1016/0304-3835(95)03915-J; Kawasaki E. S., 1990, PCR PROTOCOLS GUIDE, P146; LIU ML, 1995, CARCINOGENESIS, V16, P841, DOI 10.1093/carcin/16.4.841; LIU YH, 1994, GENE, V144, P179, DOI 10.1016/0378-1119(94)90376-X; LIU YH, 1994, MOL CELL ENDOCRINOL, V104, P173, DOI 10.1016/0303-7207(94)90120-1; Maina F, 1996, CELL, V87, P531, DOI 10.1016/S0092-8674(00)81372-0; MIYAZAWA K, 1991, BIOCHEMISTRY-US, V30, P9170, DOI 10.1021/bi00102a007; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; NAKAMURA T, 1986, P NATL ACAD SCI USA, V83, P6489, DOI 10.1073/pnas.83.17.6489; NAKANUMA Y, 1993, LIVER, V13, P1; NALDINI L, 1991, ONCOGENE, V6, P501; OKAJIMA A, 1990, EUR J BIOCHEM, V193, P375, DOI 10.1111/j.1432-1033.1990.tb19349.x; PUGH TD, 1983, CANCER RES, V43, P1261; RONG S, 1993, CANCER RES, V53, P5355; ROOS F, 1995, AM J PHYSIOL-GASTR L, V268, pG380, DOI 10.1152/ajpgi.1995.268.2.G380; RUBIN JS, 1991, P NATL ACAD SCI USA, V88, P415, DOI 10.1073/pnas.88.2.415; RUBIN JS, 1993, BIOCHIM BIOPHYS ACTA, V1155, P357, DOI 10.1016/0304-419X(93)90015-5; Sakata H, 1996, CELL GROWTH DIFFER, V7, P1513; SantoniRugiu E, 1996, AM J PATHOL, V149, P407; SantoniRugiu E, 1996, P NATL ACAD SCI USA, V93, P9577, DOI 10.1073/pnas.93.18.9577; SCHMIDT C, 1995, NATURE, V373, P699, DOI 10.1038/373699a0; SEKI T, 1990, BIOCHEM BIOPH RES CO, V172, P321, DOI 10.1016/S0006-291X(05)80212-8; SHIMA N, 1994, BIOCHEM BIOPH RES CO, V200, P808, DOI 10.1006/bbrc.1994.1523; SHIMA N, 1991, BIOCHEM BIOPH RES CO, V180, P1151, DOI 10.1016/S0006-291X(05)81187-8; SHIOTA G, 1994, HEPATOLOGY, V19, P962, DOI 10.1016/0270-9139(94)90297-6; Shiota G, 1996, RES COMMUN MOL PATH, V91, P33; STOKER M, 1987, NATURE, V327, P239, DOI 10.1038/327239a0; Takayama H, 1996, P NATL ACAD SCI USA, V93, P5866, DOI 10.1073/pnas.93.12.5866; Tamagnone Luca, 1997, Cytokine and Growth Factor Reviews, V8, P129, DOI 10.1016/S1359-6101(97)00007-5; TONJES RR, 1995, ONCOGENE, V10, P765; TSARFATY I, 1992, SCIENCE, V257, P1258, DOI 10.1126/science.1387731; TSARFATY I, 1994, SCIENCE, V263, P98, DOI 10.1126/science.7505952; UEHARA Y, 1995, NATURE, V373, P702, DOI 10.1038/373702a0; WANLESS IR, 1990, HEPATOLOGY, V11, P787, DOI 10.1002/hep.1840110512; WEBBER EM, 1994, HEPATOLOGY, V19, P489; WEIDNER KM, 1993, J CELL BIOL, V121, P145, DOI 10.1083/jcb.121.1.145; WOLF H, 1991, AM J PATHOL, V138, P1305; YAONO M, 1995, JPN J CANCER RES, V86, P718, DOI 10.1111/j.1349-7006.1995.tb02459.x; YEE CJ, 1993, BIOCHEMISTRY-US, V32, P7922, DOI 10.1021/bi00082a013; ZARNEGAR R, 1989, CANCER RES, V49, P3314	50	61	63	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 28	1999	18	4					887	895		10.1038/sj.onc.1202379	http://dx.doi.org/10.1038/sj.onc.1202379			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	165FT	10023664				2022-12-25	WOS:000078510600005
J	Plaza, S; Aumercier, M; Bailly, M; Dozier, C; Saule, S				Plaza, S; Aumercier, M; Bailly, M; Dozier, C; Saule, S			Involvement of poly(ADP-ribose)-polymerase in the Pax-6 gene regulation in neuroretina	ONCOGENE			English	Article						Pax-6; neuroretina; PARP; enhancer	HOMEOBOX-CONTAINING GENE; DNA-DAMAGE; ALVEOLAR RHABDOMYOSARCOMA; EYELESS GENE; P53 PROTEIN; IN-VITRO; POLYMERASE; QNR; TRANSCRIPTION; EXPRESSION	The quail Pax-6 gene is expressed from two promoters named P0 and P1. P0 promoter is under the control of a neuroretina-specific enhancer (EP), This enhancer activates the P0 promoter specifically in neuroretina cells and in a de developmental stage-dependent manner, The EP enhancer binds efficiently, as revealed by southwestern experiments, to a 110 kDa protein present in neuroretina cells but not in Quail Embryos Cells and Retinal Pigmented Epithelium which do not express the P0-initiated mRNAs, To study the role of p110 in Pax-6 regulation, we have purified the p110 from neuroretina cells extracts. Based on the peptide sequence of the purified protein, we have identified the p110 as the poly(ADP-ribose) polymerase (PARP). Using bandshift experiments and footprinting studies, we present evidence that PARP is a component of protein complexes bound to the EP enhancer that increases the on rate of the protein complex formation to DNA. Using PARP inhibitors (3AB and 6.5 Hphe), we show that these products are able to inhibit EP enhancer activity in neuroretina cells. Finally, we demonstrate that these inhibitors are able to decrease the expression of the P0-initiated mRNA in the MC29-infected RPE cells which, in contrast to the RPE cells, accumulated the PARP in response to v-myc expression, Our results suggest that PARP is involved in the Pax-6 regulation.	Inst Pasteur, Inst Biol, CNRS, F-59021 Lille, France	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille	Saule, S (corresponding author), Inst Pasteur, Inst Biol, CNRS, EP 560,BP 447,1 Rue Calmette, F-59021 Lille, France.		plaza, serge/F-5290-2015; DOZIER, Christine/P-1539-2014	Aumercier, Marc/0000-0002-0370-3452				BARBU V, 1989, NUCLEIC ACIDS RES, V17, P7115, DOI 10.1093/nar/17.17.7115; BERGER NA, 1985, RADIAT RES, V101, P4, DOI 10.2307/3576299; Bork P, 1997, FASEB J, V11, P68, DOI 10.1096/fasebj.11.1.9034168; Bruhn L, 1997, GENE DEV, V11, P640, DOI 10.1101/gad.11.5.640; Callaerts P, 1997, ANNU REV NEUROSCI, V20, P483, DOI 10.1146/annurev.neuro.20.1.483; Calligaro DO, 1997, BIOORG MED CHEM LETT, V7, P25, DOI 10.1016/S0960-894X(96)00567-7; CARRIERE C, 1993, MOL CELL BIOL, V13, P7257, DOI 10.1128/MCB.13.12.7257; CHATTERJEE S, 1994, MOL CELL BIOCHEM, V138, P61, DOI 10.1007/BF00928444; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Dahl E, 1997, BIOESSAYS, V19, P755, DOI 10.1002/bies.950190905; DAVIS RJ, 1994, CANCER RES, V54, P2869; Dear TN, 1997, ONCOGENE, V14, P891, DOI 10.1038/sj.onc.1200912; DEMURCIA G, 1991, BIOESSAYS, V13, P455, DOI 10.1002/bies.950130905; DEMURCIA G, 1994, TRENDS BIOCHEM SCI, V19, P172, DOI 10.1016/0968-0004(94)90280-1; DING RC, 1994, CANCER RES, V54, P4627; DOZIER C, 1993, CELL GROWTH DIFFER, V4, P281; FUJIWARA M, 1994, DIFFERENTIATION, V57, P31, DOI 10.1046/j.1432-0436.1994.5710031.x; GAILLARD C, 1994, SCIENCE, V264, P433, DOI 10.1126/science.8153633; GALILI N, 1993, NAT GENET, V5, P230, DOI 10.1038/ng1193-230; Glardon S, 1997, DEVELOPMENT, V124, P817; HALDER G, 1995, SCIENCE, V267, P1788, DOI 10.1126/science.7892602; HILL RE, 1991, NATURE, V354, P522, DOI 10.1038/354522a0; ITTEL ME, 1991, GENE, V102, P157, DOI 10.1016/0378-1119(91)90073-K; LARSON CJ, 1992, NUCLEIC ACIDS RES, V20, P3525, DOI 10.1093/nar/20.13.3525; LINDAHL T, 1995, TRENDS BIOCHEM SCI, V20, P405, DOI 10.1016/S0968-0004(00)89089-1; Malanga M, 1998, J BIOL CHEM, V273, P11839, DOI 10.1074/jbc.273.19.11839; MANSOURI A, 1996, CURR OPIN CELL BIOL, V8, P951; MAULBECKER CC, 1993, EMBO J, V12, P2361, DOI 10.1002/j.1460-2075.1993.tb05890.x; Meisterernst M, 1997, P NATL ACAD SCI USA, V94, P2261, DOI 10.1073/pnas.94.6.2261; MONCOLLIN V, 1990, NUCLEIC ACIDS RES, V18, P4817, DOI 10.1093/nar/18.16.4817; NESTERENKO MV, 1994, J BIOCHEM BIOPH METH, V28, P239, DOI 10.1016/0165-022X(94)90020-5; Nie J, 1998, FEBS LETT, V424, P27, DOI 10.1016/S0014-5793(98)00131-8; Oei S L, 1997, Rev Physiol Biochem Pharmacol, V131, P127; Oei SL, 1997, BIOCHEM BIOPH RES CO, V240, P108, DOI 10.1006/bbrc.1997.7621; PLAZA S, 1993, CELL GROWTH DIFFER, V4, P1041; PLAZA S, 1995, MOL CELL BIOL, V15, P3344; PLAZA S, 1995, MOL CELL BIOL, V15, P892; Prosser J, 1998, HUM MUTAT, V11, P93, DOI 10.1002/(SICI)1098-1004(1998)11:2<93::AID-HUMU1>3.0.CO;2-M; QUIRING R, 1994, SCIENCE, V265, P785, DOI 10.1126/science.7914031; SASTRY SS, 1990, BIOCHEM BIOPH RES CO, V167, P842, DOI 10.1016/0006-291X(90)92102-6; SimbulanRosenthal CM, 1996, BIOCHEMISTRY-US, V35, P11622, DOI 10.1021/bi953010z; SMULSON M, 1994, BIOCHEMISTRY-US, V33, P6186, DOI 10.1021/bi00186a018; STEVNSNER T, 1994, NUCLEIC ACIDS RES, V22, P4620, DOI 10.1093/nar/22.22.4620; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; Tomarev SI, 1997, P NATL ACAD SCI USA, V94, P2421, DOI 10.1073/pnas.94.6.2421; TURQUE N, 1994, MOL ENDOCRINOL, V8, P929, DOI 10.1210/me.8.7.929; Vaziri H, 1997, EMBO J, V16, P6018, DOI 10.1093/emboj/16.19.6018; Weltin D, 1997, INT J RADIAT BIOL, V72, P685, DOI 10.1080/095530097142843; WesierskaGadek J, 1996, BIOCHEM BIOPH RES CO, V224, P96, DOI 10.1006/bbrc.1996.0990	49	35	35	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 28	1999	18	4					1041	1051		10.1038/sj.onc.1202406	http://dx.doi.org/10.1038/sj.onc.1202406			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	165FT	10023680				2022-12-25	WOS:000078510600021
J	Callaghan, MJ; Russell, AJ; Woollatt, E; Sutherland, GR; Sutherland, RL; Watts, CKW				Callaghan, MJ; Russell, AJ; Woollatt, E; Sutherland, GR; Sutherland, RL; Watts, CKW			Identification of a human HECT family protein with homology to the Drosophila tumor suppressor gene hyperplastic discs	ONCOGENE			English	Article						ubiquitination; tumor suppressor; progestin; breast cancer	HUMAN-BREAST-CANCER; UBIQUITIN-DEPENDENT DEGRADATION; SQUAMOUS-CELL CARCINOMA; NF-KAPPA-B; PROTEASOME PATHWAY; CYCLE PROGRESSION; ANGELMAN SYNDROME; GROWTH-FACTOR; C-JUN; EXPRESSION	Use of the differential display technique to isolate progestin-regulated genes in T-47D human breast cancer cells led to identification of a novel gene, EDD, The cDNA sequence contains a 2799 amino acid open reading frame sharing 40% identity with the predicted 2894 amino acid product of the Drosophila melanogaster tumor suppressor gene hyperplastic discs, while the carboxy-terminal 889 amino acids show 96% identity to a rat 100 kDa HECT domain protein. EDD mRNA was progestin-induced in T-47D cells and was highly abundant in testes and expressed at moderately high le,els in other tissues, suggesting a broad role for EDD, Anti-EDD antibodies immunoprecipitated an approximately 300 kDa protein from T-47D cell lysates, HECT family proteins function as E3 ubiquitin-protein ligases, targeting specific proteins for ubiquitin-mediated proteolysis. EDD is likely to function as an E3 as irt vitro translated protein hound ubiquitin reversibly through a conserved HECT domain cysteine residue. EDD was localized by FISH to chromosome 8q22, a locus disrupted in a variety of cancers. Given the homology between EDD and the hyperplastic discs protein, which is required for control of imaginal disc growth in Drosophila, EDD potentially has a role in regulation of cell proliferation or differentiation.	St Vincents Hosp, Garvan Inst Med Res, Canc Res Program, Sydney, NSW 2010, Australia; Womens & Childrens Hosp, Dept Cytogenet & Mol Genet, Ctr Genet Med, Adelaide, SA 5006, Australia	Garvan Institute of Medical Research; St Vincents Hospital Sydney; Womens & Childrens Hospital Australia	Watts, CKW (corresponding author), St Vincents Hosp, Garvan Inst Med Res, Canc Res Program, Sydney, NSW 2010, Australia.		Sutherland, Grant Robert/D-2606-2012; henderson, Michelle/G-6657-2012; Sutherland, Robert L/A-8378-2008					ALEXANDER IE, 1989, MOL ENDOCRINOL, V3, P1377, DOI 10.1210/mend-3-9-1377; Benito J, 1998, EMBO J, V17, P482, DOI 10.1093/emboj/17.2.482; BUCKLEY MF, 1993, ONCOGENE, V8, P2127; CALLEN DF, 1990, ANN GENET-PARIS, V33, P219; CHAN YL, 1984, J BIOL CHEM, V259, P224; CLARKE CL, 1990, ENDOCR REV, V11, P266, DOI 10.1210/edrv-11-2-266; CLARKE RA, 1995, AM J HUM GENET, V57, P1364; DICKSON RB, 1995, ENDOCR REV, V16, P559, DOI 10.1210/er.16.5.559; Diehl JA, 1997, GENE DEV, V11, P957, DOI 10.1101/gad.11.8.957; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; ElRifai W, 1996, CANCER RES, V56, P3230; ERICKSON P, 1992, BLOOD, V80, P1825; Groshong SD, 1997, MOL ENDOCRINOL, V11, P1593, DOI 10.1210/me.11.11.1593; GU J, 1994, MOL BRAIN RES, V24, P77, DOI 10.1016/0169-328X(94)90120-1; HALL RE, 1990, INT J CANCER, V46, P1081, DOI 10.1002/ijc.2910460622; Hamilton JA, 1997, MOL ENDOCRINOL, V11, P490, DOI 10.1210/me.11.4.490; Hatakeyama S, 1997, J BIOL CHEM, V272, P15085, DOI 10.1074/jbc.272.24.15085; Huibregtse JM, 1997, P NATL ACAD SCI USA, V94, P3656, DOI 10.1073/pnas.94.8.3656; HUIBREGTSE JM, 1995, P NATL ACAD SCI USA, V92, P5249, DOI 10.1073/pnas.92.11.5249-a; HUIBREGTSE JM, 1993, MOL CELL BIOL, V13, P775, DOI 10.1128/MCB.13.2.775; Johnson RL, 1996, SCIENCE, V272, P1668, DOI 10.1126/science.272.5268.1668; King RW, 1996, SCIENCE, V274, P1652, DOI 10.1126/science.274.5293.1652; Kishino T, 1997, NAT GENET, V15, P70, DOI 10.1038/ng0197-70; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; Kumar S, 1997, J BIOL CHEM, V272, P13548, DOI 10.1074/jbc.272.21.13548; Kumar S, 1997, GENOMICS, V40, P435, DOI 10.1006/geno.1996.4582; LAIDLAW IJ, 1995, ENDOCRINOLOGY, V136, P164, DOI 10.1210/en.136.1.164; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; LYDON JP, 1995, GENE DEV, V9, P2266, DOI 10.1101/gad.9.18.2266; MANSFIELD E, 1994, DEV BIOL, V165, P507, DOI 10.1006/dbio.1994.1271; Matsuura T, 1997, NAT GENET, V15, P74, DOI 10.1038/ng0197-74; Mitelman F, 1997, NAT GENET, V15, P417, DOI 10.1038/ng0497supp-417; MULERIS M, 1994, GENE CHROMOSOME CANC, V10, P160, DOI 10.1002/gcc.2870100303; MULLER D, 1992, NUCLEIC ACIDS RES, V20, P1471, DOI 10.1093/nar/20.7.1471; MUSGROVE EA, 1993, MOL CELL BIOL, V13, P3577, DOI 10.1128/MCB.13.6.3577; Musgrove EA, 1998, MOL CELL BIOL, V18, P1812, DOI 10.1128/MCB.18.4.1812; MUSGROVE EA, 1991, MOL CELL BIOL, V11, P5032, DOI 10.1128/MCB.11.10.5032; Musti AM, 1996, BIOL CHEM, V377, P619, DOI 10.1515/bchm3.1996.377.10.619; Musti AM, 1997, SCIENCE, V275, P400, DOI 10.1126/science.275.5298.400; Nagase T, 1995, DNA Res, V2, P37, DOI 10.1093/dnares/2.1.37; NAWROZ H, 1994, CANCER RES, V54, P1152; Nefsky B, 1996, EMBO J, V15, P1301, DOI 10.1002/j.1460-2075.1996.tb00472.x; Orford K, 1997, J BIOL CHEM, V272, P24735, DOI 10.1074/jbc.272.40.24735; ORIAN A, 1995, J BIOL CHEM, V270, P21707, DOI 10.1074/jbc.270.37.21707; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; Perry WL, 1998, NAT GENET, V18, P143, DOI 10.1038/ng0298-143; Piao Z, 1998, INT J CANCER, V75, P29, DOI 10.1002/(SICI)1097-0215(19980105)75:1<29::AID-IJC5>3.3.CO;2-#; Prall OWJ, 1997, J BIOL CHEM, V272, P10882; SATO S, 1994, CANCER RES, V54, P5652; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; SCHEFFNER M, 1995, NATURE, V373, P81, DOI 10.1038/373081a0; Staub O, 1996, EMBO J, V15, P2371, DOI 10.1002/j.1460-2075.1996.tb00593.x; Sutherland RL, 1998, J MAMMARY GLAND BIOL, V3, P63, DOI 10.1023/A:1018774302092; VANGOOL AJ, 1994, EMBO J, V13, P5361, DOI 10.1002/j.1460-2075.1994.tb06871.x; Won KA, 1996, EMBO J, V15, P4182, DOI 10.1002/j.1460-2075.1996.tb00793.x	56	96	103	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 31	1998	17	26					3479	3491		10.1038/sj.onc.1202249	http://dx.doi.org/10.1038/sj.onc.1202249			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	157XD	10030672				2022-12-25	WOS:000078086200009
J	White, GRM; Varley, JM; Heighway, J				White, GRM; Varley, JM; Heighway, J			Isolation and characterization of a human homologue of the latrophilin gene from a region of 1p31.1 implicated in breast cancer	ONCOGENE			English	Article						latrophilin; breast cancer; chromosome 1; alternative splicing	ALPHA-LATROTOXIN; RECEPTOR; PROTEIN; HETEROZYGOSITY; CLONING	We have identified a region of chromosome 1p31.1 that shows high frequency loss of heterozygosity (LOH) in human breast cancer. This region forms part of a 7 Mb YAC/BAC contig, In order to identify candidate sequences, mutation of which might contribute to the development of disease, we have carried out mapping studies of ESTs localized to 1p31.1. This analysis, coupled with library screening and a modified 5' RACE-PCR strategy, resulted in the identification and characterization of a novel gene (LPHH1) which is located adjacent to the smallest region of overlapping loss (SRO) seen in tumours, The 4209 bp open reading frame of the 7 kb LPHH1 transcript encodes a peptide which shows approximately 65% identity to rat latrophilin, a G-coupled, seven span transmembrane protein, which binds alpha-latrotoxin. In the human sequence, whilst conservation of the transmembrane domain is high, the intra- and extracellular domains show two regions of variable structure, which are presumably generated by alternative splicing. Surprisingly, while expression of the rat gene is tightly restricted to neurological and perhaps some endocrine cells, the human sequence appears to be expressed very widely in all normal tissues tested. Northern and RT-PCR analysis of a panel of tumour cell lines showed that LPHH1 expression was variable, apparently elevated in some lines and absent or markedly reduced in others. Furthermore, characterization of the range of transcripts encoded in a breast tumour cell line, compared to normal breast, suggested that gene product variability was higher in the tumour.	Christie Hosp NHS Trust, Paterson Inst Canc Res, CRC, Mol Genet Sect, Manchester M20 4BX, Lancs, England	Christie NHS Foundation Trust; Christie Hospital; Paterson Institute for Cancer Research	Varley, JM (corresponding author), Christie Hosp NHS Trust, Paterson Inst Canc Res, CRC, Mol Genet Sect, Wilmslow Rd, Manchester M20 4BX, Lancs, England.							Bittner MA, 1998, J NEUROSCI, V18, P2914; Davletov BA, 1996, J BIOL CHEM, V271, P23239, DOI 10.1074/jbc.271.38.23239; EVA A, 1982, NATURE, V295, P116, DOI 10.1038/295116a0; Geppert M, 1998, J BIOL CHEM, V273, P1705, DOI 10.1074/jbc.273.3.1705; HOGGARD N, 1995, GENOMICS, V30, P233, DOI 10.1006/geno.1995.9882; HOGGARD N, 1995, GENE CHROMOSOME CANC, V12, P24, DOI 10.1002/gcc.2870120105; Krasnoperov VG, 1996, BIOCHEM BIOPH RES CO, V227, P868, DOI 10.1006/bbrc.1996.1598; Krasnoperov VG, 1997, NEURON, V18, P925, DOI 10.1016/S0896-6273(00)80332-3; Lang JC, 1998, EMBO J, V17, P648, DOI 10.1093/emboj/17.3.648; Lelianova VG, 1997, J BIOL CHEM, V272, P21504, DOI 10.1074/jbc.272.34.21504; NACHEVA E, 1990, BRIT J HAEMATOL, V74, P70, DOI 10.1111/j.1365-2141.1990.tb02540.x; NAGAI H, 1995, CANCER RES, V55, P1752; Rechsteiner M, 1996, TRENDS BIOCHEM SCI, V21, P267, DOI 10.1016/S0968-0004(96)10031-1; Yamamichi K, 1998, INT J CANCER, V79, P256, DOI 10.1002/(SICI)1097-0215(19980619)79:3<256::AID-IJC8>3.0.CO;2-O	14	23	26	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 31	1998	17	26					3513	3519		10.1038/sj.onc.1202487	http://dx.doi.org/10.1038/sj.onc.1202487			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	157XD	10030676				2022-12-25	WOS:000078086200013
J	Makino, R; Matsuda, H; Obayashi, E; Shiro, Y; Iizuka, T; Hori, H				Makino, R; Matsuda, H; Obayashi, E; Shiro, Y; Iizuka, T; Hori, H			EPR characterization of axial bond in metal center of native and cobalt-substituted guanylate cyclase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-PARAMAGNETIC-RESONANCE; RESOLUTION CRYSTAL-STRUCTURES; LIGAND-BINDING PROPERTIES; NITRIC-OXIDE; BOVINE LUNG; MOLECULAR STEREOCHEMISTRY; PROXIMAL HISTIDINE; CARBON-MONOXIDE; RAMAN-SPECTROSCOPY; HYBRID HEMOGLOBINS	The nature of the metal-proximal base bond of soluble guanylate cyclase from bovine lung was examined by EPR spectroscopy. When the ferrous enzyme was mixed with NO, a new species was transiently produced and rapidly converted to a five-coordinate ferrous NO complex. The new species exhibited the EPR signal of six-coordinate ferrous NO complex with a feature of histidine-ligated heme, The histidine ligation was further examined by using the cobalt protoporphyrin M-substituted enzyme. The Co2+-substituted enzyme exhibited EPR signals of a broad g(perpendicular to) component and a g(parallel to) component with a poorly resolved triplet of N-14 superhyperfine splittings, which was indicative of the histidine ligation. These EPR features were analogous to those of Lu-subunits of Co2+-hemoglobin in tense state, showing a tension on the iron-histidine bond of the enzyme. The binding of NO to the Co2+-enzyme markedly stimulated the cGMP production by forming the five-coordinate NO complex. We found that N-3(-) elicited the activation of the ferric enzyme by yielding five-coordinate high spin N-3(-) heme. These results indicated that the activation of the enzymes was initiated by NO binding to the metals and proceeded via breaking of the metal-histidine bonds, and suggested that the iron-histidine bond in the ferric enzyme heme was broken by N-3(-) binding.	Rikkyo Univ, Coll Sci, Dept Chem, Toshima Ku, Tokyo 1710021, Japan; Himeji Inst Technol, Fac Sci, Dept Life Sci, Kamigoori, Hyogo 6781201, Japan; Chuo Univ, Dept Appl Chem, Bunkyo Ku, Tokyo 1120003, Japan; RIKEN, Inst Phys & Chem Res, Wako, Saitama 3510100, Japan; Osaka Univ, Grad Sch Engn Sci, Div Biophys Engn, Toyonaka, Osaka 5608531, Japan	Rikkyo University; University of Hyogo; Chuo University; RIKEN; Osaka University	Makino, R (corresponding author), Rikkyo Univ, Coll Sci, Dept Chem, Toshima Ku, Nishi Ikebukuro 3-34-1, Tokyo 1710021, Japan.	rmakino@rikkyo.ac.jp	Shiro, Yoshitsugu Y/J-3757-2014	Shiro, Yoshitsugu Y/0000-0003-0695-8327				ADAMS KM, 1979, INORG CHEM, V18, P1892, DOI 10.1021/ic50197a034; ASCENZI P, 1989, BIOCHEM J, V258, P473, DOI 10.1042/bj2580473; Barker R, 1974, Methods Enzymol, V34, P479; BREAD DS, 1989, P NATL ACAD SCI USA, V86, P9030; Brucker EA, 1996, J BIOL CHEM, V271, P25419, DOI 10.1074/jbc.271.41.25419; BURSTYN JN, 1995, BIOCHEMISTRY-US, V34, P5896, DOI 10.1021/bi00017a019; Deinum G, 1996, BIOCHEMISTRY-US, V35, P1540; Dierks EA, 1997, J AM CHEM SOC, V119, P7316, DOI 10.1021/ja9603057; DUPRAT AF, 1995, BIOCHEMISTRY-US, V34, P2634, DOI 10.1021/bi00008a030; FERMI G, 1982, J MOL BIOL, V155, P495, DOI 10.1016/0022-2836(82)90483-1; FERMI G, 1984, J MOL BIOL, V175, P159, DOI 10.1016/0022-2836(84)90472-8; FURCHGOTT RF, 1980, NATURE, V288, P373, DOI 10.1038/288373a0; GARTHWAITE J, 1988, NATURE, V336, P385, DOI 10.1038/336385a0; GERZER R, 1981, EUR J BIOCHEM, V116, P479, DOI 10.1111/j.1432-1033.1981.tb05361.x; GERZER R, 1981, FEBS LETT, V132, P71, DOI 10.1016/0014-5793(81)80429-2; HENRY Y, 1973, J MOL BIOL, V73, P469, DOI 10.1016/0022-2836(73)90094-6; HOARD JL, 1971, SCIENCE, V174, P1295, DOI 10.1126/science.174.4016.1295; HORI H, 1983, J BIOL CHEM, V258, P2368; HU SZ, 1993, INORG CHEM, V32, P1081, DOI 10.1021/ic00059a010; HUMBERT P, 1990, EUR J BIOCHEM, V190, P273, DOI 10.1111/j.1432-1033.1990.tb15572.x; IGNARRO LJ, 1985, ANNU REV PHARMACOL, V25, P171, DOI 10.1146/annurev.pharmtox.25.1.171; IGNARRO LJ, 1984, J BIOL CHEM, V259, P6201; IGNARRO LJ, 1982, P NATL ACAD SCI-BIOL, V79, P2870, DOI 10.1073/pnas.79.9.2870; IGNARRO LJ, 1986, J BIOL CHEM, V261, P4997; IGNARRO LJ, 1984, J BIOL CHEM, V259, P5923; IIZUKA T, 1969, BIOCHIM BIOPHYS ACTA, V194, P351, DOI 10.1016/0005-2795(69)90096-8; IIZUKA T, 1969, BIOCHIM BIOPHYS ACTA, V181, P275, DOI 10.1016/0005-2795(69)90250-5; IKEDASAITO M, 1977, J BIOL CHEM, V252, P8639; IKEDASAITO M, 1977, J BIOL CHEM, V252, P620; INUBUSHI T, 1983, BIOCHEMISTRY-US, V22, P2904, DOI 10.1021/bi00281a019; JAMESON GB, 1980, J AM CHEM SOC, V102, P3224, DOI 10.1021/ja00529a055; KAMISAKI Y, 1986, J BIOL CHEM, V261, P7236; KEILIN D, 1951, BIOCHEM J, V49, P88, DOI 10.1042/bj0490088; KON H, 1969, BIOCHEMISTRY-US, V8, P4757, DOI 10.1021/bi00840a016; MASUYA F, 1994, J BIOCHEM, V116, P1146, DOI 10.1093/oxfordjournals.jbchem.a124641; MAXWELL JC, 1976, BIOCHEMISTRY-US, V15, P388, DOI 10.1021/bi00647a023; MCCOY S, 1970, BIOCHEMISTRY-US, V9, P2387, DOI 10.1021/bi00814a001; MESSANA C, 1978, BIOCHEMISTRY-US, V17, P3652, DOI 10.1021/bi00610a035; MONCADA S, 1991, EUR J CLIN INVEST, V21, P361, DOI 10.1111/j.1365-2362.1991.tb01383.x; MORIKIS D, 1990, J BIOL CHEM, V265, P12143; NAGAI K, 1980, P NATL ACAD SCI-BIOL, V77, P2033, DOI 10.1073/pnas.77.4.2033; Paoli M, 1997, J MOL BIOL, V271, P161, DOI 10.1006/jmbi.1997.1180; PAUL KG, 1953, ACTA CHEM SCAND, V7, P1284, DOI 10.3891/acta.chem.scand.07-1284; QUILLIN ML, 1993, J MOL BIOL, V234, P140, DOI 10.1006/jmbi.1993.1569; REISBERG P, 1976, J BIOL CHEM, V251, P4379; SCHEIDT WR, 1976, J AM CHEM SOC, V98, P1913, DOI 10.1021/ja00423a044; SCHEIDT WR, 1983, INORG CHEM, V22, P1516, DOI 10.1021/ic00152a019; SCHEIDT WR, 1974, J AM CHEM SOC, V96, P84, DOI 10.1021/ja00808a013; SCHEIDT WR, 1973, J AM CHEM SOC, V95, P8281, DOI 10.1021/ja00806a013; SCHEIDT WR, 1975, J AM CHEM SOC, V97, P17, DOI 10.1021/ja00834a005; STONE JR, 1994, BIOCHEMISTRY-US, V33, P5636, DOI 10.1021/bi00184a036; Stone JR, 1996, BIOCHEMISTRY-US, V35, P3258, DOI 10.1021/bi952386+; STONE JR, 1995, BIOCHEM BIOPH RES CO, V207, P572, DOI 10.1006/bbrc.1995.1226; STONE JR, 1995, BIOCHEMISTRY-US, V34, P14668, DOI 10.1021/bi00045a007; Stone JR, 1996, BIOCHEMISTRY-US, V35, P1093, DOI 10.1021/bi9519718; Tomita T, 1997, J BIOCHEM-TOKYO, V122, P531; TRAYLOR TG, 1992, BIOCHEMISTRY-US, V31, P2847, DOI 10.1021/bi00126a001; VERMA A, 1993, SCIENCE, V259, P381, DOI 10.1126/science.7678352; WAGNER GC, 1981, J BIOL CHEM, V256, P6266; WALDMAN SA, 1987, PHARMACOL REV, V39, P163; WANG MYR, 1977, J BIOL CHEM, V252, P6268; WEDEL B, 1994, P NATL ACAD SCI USA, V91, P2592, DOI 10.1073/pnas.91.7.2592; WOLIN MS, 1982, J BIOL CHEM, V257, P13312; WOODRUFF WH, 1974, P NATL ACAD SCI USA, V71, P1065, DOI 10.1073/pnas.71.4.1065; YONETANI T, 1974, J BIOL CHEM, V249, P682; YONETANI T, 1972, J BIOL CHEM, V247, P2447; YONETANI T, 1961, J BIOL CHEM, V236, P1680; YOSHIMURA T, 1979, ARCH BIOCHEM BIOPHYS, V193, P301, DOI 10.1016/0003-9861(79)90035-3; YU AE, 1994, J AM CHEM SOC, V116, P4117, DOI 10.1021/ja00088a073; Zhao Y, 1997, BIOCHEMISTRY-US, V36, P15959, DOI 10.1021/bi971825x; Zhao Y, 1998, BIOCHEMISTRY-US, V37, P4502, DOI 10.1021/bi972686m; [No title captured]	72	68	71	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 19	1999	274	12					7714	7723		10.1074/jbc.274.12.7714	http://dx.doi.org/10.1074/jbc.274.12.7714			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	178LU	10075661	hybrid			2022-12-25	WOS:000079268100020
J	Natochin, M; Granovsky, AE; Muradov, KG; Artemyev, NO				Natochin, M; Granovsky, AE; Muradov, KG; Artemyev, NO			Roles of the transducin alpha-subunit alpha 4-helix/alpha 4-beta 6 loop in the receptor and effector interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHODIESTERASE GAMMA-SUBUNIT; CYCLIC-GMP PHOSPHODIESTERASE; HETEROTRIMERIC G-PROTEIN; CGMP-PHOSPHODIESTERASE; INHIBITORY SUBUNIT; CATALYTIC SUBUNITS; NUCLEOTIDE-BINDING; CRYSTAL-STRUCTURE; ADP-RIBOSYLATION; RHODOPSIN	The visual GTP-binding protein, transducin, couples light-activated rhodopsin (R*) with the effector enzyme, cGMP phosphodiesterase in vertebrate photoreceptor cells. The region corresponding to the alpha 4-helix and alpha 4-beta 6 loop of the transducin alpha-subunit (G(t)alpha) has been implicated in interactions with the receptor and the effector. Ala-scanning mutagenesis of the alpha 4-beta 6 region has been carried out to elucidate residues critical for the functions of transducin. The mutational analysis supports the role of the alpha 4-beta 6 loop in the R*-G(t)alpha interface and suggests that the G(t)alpha residues Arg(310) and Asp(311) are involved in the interaction with R*. These residues are likely to contribute to the specificity of the R* recognition. Contrary to the evidence previously obtained with synthetic peptides of G(t)alpha, our data indicate that none of the (alpha 4-beta 6 residues directly or significantly participate in the interaction with and activation of phosphodiesterase. However, Ile(299), Phe(303), and Leu(306) form a network of interactions with the alpha 3-helix of G(t)alpha, which is critical for the ability of G(t)alpha to undergo an activational conformational change. Thereby, Ile(299), Phe303 and Leu(306) play only an indirect role in the effector function of G(t)alpha.	Univ Iowa, Coll Med, Dept Phys & Biophys, Iowa City, IA 52242 USA	University of Iowa	Artemyev, NO (corresponding author), Univ Iowa, Coll Med, Dept Phys & Biophys, Iowa City, IA 52242 USA.			Artemyev, Nikolai/0000-0002-5266-6854	NATIONAL EYE INSTITUTE [R01EY010843] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK025295] Funding Source: NIH RePORTER; NEI NIH HHS [EY-10843] Funding Source: Medline; NIDDK NIH HHS [DK-25295] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARTEMYEV NO, 1992, BIOCHEM J, V283, P273, DOI 10.1042/bj2830273; ARTEMYEV NO, 1992, J BIOL CHEM, V267, P25067; ARTEMYEV NO, 1993, J BIOL CHEM, V268, P23611; Artemyev NO, 1997, BIOCHEMISTRY-US, V36, P4188, DOI 10.1021/bi963002y; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN RL, 1992, BIOCHEMISTRY-US, V31, P5918, DOI 10.1021/bi00140a031; CHABRE M, 1989, EUR J BIOCHEM, V179, P255, DOI 10.1111/j.1432-1033.1989.tb14549.x; FAUROBERT E, 1993, EMBO J, V12, P4191, DOI 10.1002/j.1460-2075.1993.tb06103.x; GARCIA PD, 1995, EMBO J, V14, P4460, DOI 10.1002/j.1460-2075.1995.tb00125.x; HAMM HE, 1988, SCIENCE, V241, P832, DOI 10.1126/science.3136547; HIGASHIJIMA T, 1987, J BIOL CHEM, V262, P757; IIRI T, 1994, NATURE, V371, P164, DOI 10.1038/371164a0; Kisselev OG, 1998, P NATL ACAD SCI USA, V95, P4270, DOI 10.1073/pnas.95.8.4270; KLEUSS C, 1987, J CHROMATOGR, V407, P281, DOI 10.1016/S0021-9673(01)92625-1; LAMBRIGHT DG, 1994, NATURE, V369, P621, DOI 10.1038/369621a0; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; LIPKIN VM, 1988, FEBS LETT, V234, P287, DOI 10.1016/0014-5793(88)80100-5; Liu Y, 1996, J BIOL CHEM, V271, P26900, DOI 10.1074/jbc.271.43.26900; Martin EL, 1996, J BIOL CHEM, V271, P361, DOI 10.1074/jbc.271.1.361; Mazzoni MR, 1996, J BIOL CHEM, V271, P30034, DOI 10.1074/jbc.271.47.30034; Natochin M, 1998, J BIOL CHEM, V273, P21808, DOI 10.1074/jbc.273.34.21808; NOEL JP, 1993, NATURE, V366, P654, DOI 10.1038/366654a0; Onrust R, 1997, SCIENCE, V275, P381, DOI 10.1126/science.275.5298.381; Osawa S, 1995, J BIOL CHEM, V270, P31052, DOI 10.1074/jbc.270.52.31052; OTTOBRUC A, 1993, BIOCHEMISTRY-US, V32, P8636, DOI 10.1021/bi00084a035; PAPERMASTER DS, 1974, BIOCHEMISTRY-US, V13, P2438, DOI 10.1021/bi00708a031; Posner BA, 1998, J BIOL CHEM, V273, P21752, DOI 10.1074/jbc.273.34.21752; RARICK HM, 1992, SCIENCE, V256, P1031, DOI 10.1126/science.1317058; SKIBA NP, 1995, J BIOL CHEM, V270, P13210, DOI 10.1074/jbc.270.22.13210; Skiba NP, 1996, J BIOL CHEM, V271, P413, DOI 10.1074/jbc.271.1.413; SPICKOFSKY N, 1994, NAT STRUCT BIOL, V1, P771, DOI 10.1038/nsb1194-771; Stryer L, 1996, P NATL ACAD SCI USA, V93, P557, DOI 10.1073/pnas.93.2.557; THOMAS TC, 1993, P NATL ACAD SCI USA, V90, P10295, DOI 10.1073/pnas.90.21.10295; VANDOP C, 1984, J BIOL CHEM, V259, P23; WEST RE, 1985, J BIOL CHEM, V260, P4428; YAMANAKA G, 1985, BIOCHEMISTRY-US, V24, P8094, DOI 10.1021/bi00348a039; YARFITZ S, 1994, J BIOL CHEM, V269, P14329	37	30	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 19	1999	274	12					7865	7869		10.1074/jbc.274.12.7865	http://dx.doi.org/10.1074/jbc.274.12.7865			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	178LU	10075679	hybrid			2022-12-25	WOS:000079268100038
J	Yamaguchi, Y; Wada, T; Watanabe, D; Takagi, T; Hasegawa, J; Handa, H				Yamaguchi, Y; Wada, T; Watanabe, D; Takagi, T; Hasegawa, J; Handa, H			Structure and function of the human transcription elongation factor DSIF	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; RNA-POLYMERASE; P-TEFB; GENE IMPORTANT; MESSENGER-RNA; HUMAN HOMOLOG; IN-VITRO; PROTEIN; ACTIVATION; SPT5	5,6-Dichloro-1-beta-D-ribofuranosylbenzimidazole (DRB) is a classic inhibitor of transcription elongation by RNA polymerase II (pol II). We have previously identified and purified a novel transcription elongation factor, termed DSIF (for DRB sensitivity-inducing factor), that makes transcription sensitive to DRB. DSIF is composed of 160- and 14-kDa subunits, which are homologs of the Saccharomyces cerevisiae transcription factors Spt5 and Spt4. DSIF may either repress or stimulate transcription in vitro, depending on conditions, but its physiological function remains elusive. Here we characterize the structure and function of DSIF p160. p160 is shown to be a ubiquitous nuclear protein that forms a stable complex with p14 and interacts directly with the pol II largest subunit, Mutation analysis of p160 is used to identify structural features essential for its in vitro activity and to map the domains required for its interaction with p14 and pol II. Finally, a p160 mutant that represses DSIF activity in a dominant-negative manner is identified and used to demonstrate that DSIF represses transcription from various promoters in vivo.	Tokyo Inst Technol, Fac Biosci & Biotechnol, Yokohama, Kanagawa 2268501, Japan	Tokyo Institute of Technology	Handa, H (corresponding author), Tokyo Inst Technol, Fac Biosci & Biotechnol, 4259 Nagatsuta, Yokohama, Kanagawa 2268501, Japan.	hhanda@bio.titech.ac.jp	Yamaguchi, Yuki/B-9390-2015	Yamaguchi, Yuki/0000-0002-0197-614X				Chiang PW, 1996, GENOMICS, V38, P421, DOI 10.1006/geno.1996.0646; CHODOSH LA, 1989, J BIOL CHEM, V264, P2250; GLANVILLE N, 1981, NATURE, V292, P267, DOI 10.1038/292267a0; GREENBLATT J, 1993, NATURE, V364, P401, DOI 10.1038/364401a0; Hartzog GA, 1998, GENE DEV, V12, P357, DOI 10.1101/gad.12.3.357; Hartzog GA, 1996, MOL CELL BIOL, V16, P2848; HORTON RM, 1993, METHOD ENZYMOL, V217, P270; JONES KA, 1994, ANNU REV BIOCHEM, V63, P717, DOI 10.1146/annurev.bi.63.070194.003441; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; Kyrpides NC, 1996, TRENDS BIOCHEM SCI, V21, P425, DOI 10.1016/S0968-0004(96)30036-4; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LEE WS, 1991, CELL, V67, P365, DOI 10.1016/0092-8674(91)90188-5; MALONE EA, 1993, MOL GEN GENET, V237, P449, DOI 10.1007/BF00279450; Mancebo HSY, 1997, GENE DEV, V11, P2633, DOI 10.1101/gad.11.20.2633; MARSHALL NF, 1992, MOL CELL BIOL, V12, P2078, DOI 10.1128/MCB.12.5.2078; MARSHALL NF, 1995, J BIOL CHEM, V270, P12335, DOI 10.1074/jbc.270.21.12335; Marshall NF, 1996, J BIOL CHEM, V271, P27176, DOI 10.1074/jbc.271.43.27176; MOGRIDGE J, 1995, GENE DEV, V9, P2831, DOI 10.1101/gad.9.22.2831; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; Moore DD, 1995, GLOB MOB SURV; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; Peng JM, 1998, GENE DEV, V12, P755, DOI 10.1101/gad.12.5.755; Sawa C, 1996, NUCLEIC ACIDS RES, V24, P4954, DOI 10.1093/nar/24.24.4954; SEHGAL PB, 1976, CELL, V9, P473, DOI 10.1016/0092-8674(76)90092-1; Stachora AA, 1997, FEBS LETT, V409, P74, DOI 10.1016/S0014-5793(97)00486-9; SULLIVAN SL, 1992, CELL, V68, P989, DOI 10.1016/0092-8674(92)90041-A; SWANSON MS, 1991, MOL CELL BIOL, V11, P3009, DOI 10.1128/MCB.11.6.3009; SWANSON MS, 1992, GENETICS, V132, P325; USUDA Y, 1991, EMBO J, V10, P2305, DOI 10.1002/j.1460-2075.1991.tb07767.x; WADA T, 1991, J VIROL, V65, P557, DOI 10.1128/JVI.65.2.557-564.1991; Wada T, 1998, EMBO J, V17, P7395, DOI 10.1093/emboj/17.24.7395; Wada T, 1998, GENE DEV, V12, P343, DOI 10.1101/gad.12.3.343; Wei P, 1998, CELL, V92, P451, DOI 10.1016/S0092-8674(00)80939-3; Winston, 1992, TRANSCRIPTIONAL REGU, P1271; WINSTON F, 1984, GENETICS, V107, P179; Wu-Baer F, 1998, J MOL BIOL, V277, P179, DOI 10.1006/jmbi.1997.1601; Yamaguchi Y, 1998, GENES CELLS, V3, P9, DOI 10.1046/j.1365-2443.1998.00162.x; ZANDOMENI R, 1982, P NATL ACAD SCI-BIOL, V79, P3167, DOI 10.1073/pnas.79.10.3167; Zhu YR, 1997, GENE DEV, V11, P2622, DOI 10.1101/gad.11.20.2622	39	115	120	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	1999	274	12					8085	8092		10.1074/jbc.274.12.8085	http://dx.doi.org/10.1074/jbc.274.12.8085			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	178LU	10075709	hybrid			2022-12-25	WOS:000079268100068
J	Luker, GD; Nilsson, KR; Covey, DF; Piwnica-Worms, D				Luker, GD; Nilsson, KR; Covey, DF; Piwnica-Worms, D			Multidrug resistance (MDR1) P-glycoprotein enhances esterification of plasma membrane cholesterol	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLOOD-BRAIN-BARRIER; ACYL-COENZYME-A; ENDOPLASMIC-RETICULUM; IN-VIVO; SPHINGOMYELIN DEGRADATION; HUMAN-FIBROBLASTS; CYSTIC-FIBROSIS; CELLS; TRANSPORT; GENE	Class I P-glycoproteins (Pgp) confer multidrug resistance in tumors, but the physiologic function of Pgp in normal tissues remains uncertain. In cells derived from tissues that normally express Pgp, recent data suggest a possible role for Pgp in cholesterol trafficking from the plasma membrane to the endoplasmic reticulum, We investigated the esterification of plasma membrane cholesterol under basal conditions and in response to sphingomyelinase treatment in transfected and drug-selected cell lines expressing differing amounts of functional class I Pgp. Compared with parental NIH 3T3 fibroblasts, cells transfected with human multidrug resistance (MDR1) Pgp esterified more cholesterol both without and with sphingomyelinase. Esterification also was greater in drug-selected Dox 6 myeloma cells than parental 8226 cells, which express low and non-immunodetectable amounts of Pgp, respectively. However, no differences in total plasma membrane cholesterol were detected. Transfection of fibroblasts with the multidrug resistance-associated protein (MRP) did not alter esterification, showing that cholesterol trafficking was not generally affected by ATP-binding cassette transporters. Steroidal (progesterone, dehydroepiandrosterone) and non-steroidal antagonists (verapamil, PSC 833, LY335979, and GF120918) were evaluated for effects on both cholesterol trafficking and the net content of Tc-99m-Sestamibi, a reporter of drug transport activity mediated by Pgp, In Pgp-expressing cells treated with nonselective and selective inhibitors, both the kinetics and efficacy of inhibition of cholesterol esterification differed from the antagonism of drug transport mediated by Pgp, Thus, although the data show that greater expression of class I Pgp within a given cell type is associated with enhanced esterification of plasma membrane cholesterol in support of a physiologic function for Pgp in facilitating cholesterol trafficking, the molecular mechanism is dissociated from the conventional drug transport activity of Pgp.	Washington Univ, Sch Med, Mallinckrodt Inst Radiol, Lab Mol Radiopharmacol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)	Piwnica-Worms, D (corresponding author), Washington Univ, Sch Med, Mallinckrodt Inst Radiol, Lab Mol Radiopharmacol, 510 S Kingshighway Blvd, St Louis, MO 63110 USA.	piwnica-worms@mirlink-wustl.edu		luker, gary/0000-0001-6832-2581	NHLBI NIH HHS [K08 HL03683] Funding Source: Medline; NIGMS NIH HHS [GM47696] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL003683] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R15GM047696] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAILLY JD, 1995, LEUKEMIA, V9, P799; BARASCH J, 1991, NATURE, V352, P70, DOI 10.1038/352070a0; Barnes KM, 1996, BIOCHEMISTRY-US, V35, P4820, DOI 10.1021/bi952380k; Bezombes C, 1998, FASEB J, V12, P101, DOI 10.1096/fasebj.12.1.101; BITTMAN R, 1994, BIOCHEMISTRY-US, V33, P11776, DOI 10.1021/bi00205a013; Biwersi J, 1996, P NATL ACAD SCI USA, V93, P12484, DOI 10.1073/pnas.93.22.12484; Bosch I, 1997, LEUKEMIA, V11, P1131, DOI 10.1038/sj.leu.2400695; Bosch I, 1996, BBA-REV CANCER, V1288, pF37, DOI 10.1016/0304-419X(96)00022-4; Bosch I, 1997, BIOCHEMISTRY-US, V36, P5685, DOI 10.1021/bi962728r; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; CHANG CCY, 1995, J BIOL CHEM, V270, P29532; Chang TY, 1997, ANNU REV BIOCHEM, V66, P613, DOI 10.1146/annurev.biochem.66.1.613; CORDONCARDO C, 1990, J HISTOCHEM CYTOCHEM, V38, P1277, DOI 10.1177/38.9.1974900; Crankshaw C, 1996, J NUCL MED, V37, P1110; DALTON WS, 1986, CANCER RES, V46, P5125; Dantzig AH, 1996, CANCER RES, V56, P4171; Debry P, 1997, J BIOL CHEM, V272, P1026, DOI 10.1074/jbc.272.2.1026; Ehlhardt WJ, 1998, DRUG METAB DISPOS, V26, P42; ELYANDOUZI E, 1994, BIOCHEMISTRY-US, V33, P2329, DOI 10.1021/bi00174a046; FIELD FJ, 1995, J LIPID RES, V36, P1533; FIELDING PE, 1995, BIOCHEMISTRY-US, V34, P14288, DOI 10.1021/bi00044a004; FRA AM, 1994, J BIOL CHEM, V269, P30745; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; Hendrikse NH, 1998, BRIT J CANCER, V77, P353, DOI 10.1038/bjc.1998.57; HYAFIL F, 1993, CANCER RES, V53, P4595; Jacobs NL, 1997, J LIPID RES, V38, P1973; Khelef N, 1998, J BIOL CHEM, V273, P11218, DOI 10.1074/jbc.273.18.11218; Kim H, 1997, AM J PHYSIOL-CELL PH, V273, pC687, DOI 10.1152/ajpcell.1997.273.2.C687; LANGE Y, 1993, J BIOL CHEM, V268, P13838; LANGE Y, 1994, J BIOL CHEM, V269, P3411; Lange Y, 1997, J BIOL CHEM, V272, P13103, DOI 10.1074/jbc.272.20.13103; LANGE Y, 1994, J BIOL CHEM, V269, P29371; LANGE Y, 1989, J BIOL CHEM, V264, P3786; Lautier D, 1996, BIOCHEM PHARMACOL, V52, P967, DOI 10.1016/0006-2952(96)00450-9; Luker GD, 1997, BIOCHEMISTRY-US, V36, P14218, DOI 10.1021/bi971931z; Mayer U, 1997, J CLIN INVEST, V100, P2430, DOI 10.1172/JCI119784; Nilsson KR, 1998, J MED CHEM, V41, P2604, DOI 10.1021/jm980148h; PIWNICAWORMS D, 1993, CANCER RES, V53, P977; PIWNICAWORMS D, 1995, BIOCHEMISTRY-US, V34, P12210, DOI 10.1021/bi00038a015; PORN MI, 1990, BIOCHEM J, V271, P121, DOI 10.1042/bj2710121; RAO V, 1998, P AM ASSOC CANC RES, V38, P76; RUETZ S, 1994, CELL, V77, P1071, DOI 10.1016/0092-8674(94)90446-4; RUETZ S, 1994, J BIOL CHEM, V269, P12277; SARGIACOMO M, 1993, J CELL BIOL, V122, P789, DOI 10.1083/jcb.122.4.789; Scherer PE, 1997, J BIOL CHEM, V272, P29337, DOI 10.1074/jbc.272.46.29337; Schinkel AH, 1997, P NATL ACAD SCI USA, V94, P4028, DOI 10.1073/pnas.94.8.4028; SCHISSEL SL, 1995, BIOCHEMISTRY-US, V34, P10463, DOI 10.1021/bi00033a019; Sharom FJ, 1998, BIOCHEM J, V333, P621, DOI 10.1042/bj3330621; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Skiba PJ, 1996, J BIOL CHEM, V271, P13392, DOI 10.1074/jbc.271.23.13392; SLOTTE JP, 1989, BIOCHIM BIOPHYS ACTA, V985, P90, DOI 10.1016/0005-2736(89)90108-9; SMART EJ, 1994, J CELL BIOL, V127, P1185, DOI 10.1083/jcb.127.5.1185; Smart EJ, 1996, J BIOL CHEM, V271, P29427, DOI 10.1074/jbc.271.46.29427; SMIT JJM, 1993, CELL, V75, P451, DOI 10.1016/0092-8674(93)90380-9; Stein WD, 1997, PHYSIOL REV, V77, P545, DOI 10.1152/physrev.1997.77.2.545; THIEBAUT F, 1987, P NATL ACAD SCI USA, V84, P7735, DOI 10.1073/pnas.84.21.7735; TWENTYMAN PR, 1991, EUR J CANCER, V27, P1639, DOI 10.1016/0277-5379(91)90435-G; Underwood KW, 1998, J BIOL CHEM, V273, P4266, DOI 10.1074/jbc.273.7.4266; vanHelvoort A, 1996, CELL, V87, P507, DOI 10.1016/S0092-8674(00)81370-7; WATTENBERG BW, 1983, J BIOL CHEM, V258, P2284; Winegar DA, 1996, J LIPID RES, V37, P179; YANG CPH, 1989, J BIOL CHEM, V264, P782	63	104	112	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	1999	274	11					6979	6991		10.1074/jbc.274.11.6979	http://dx.doi.org/10.1074/jbc.274.11.6979			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	175DV	10066752	hybrid			2022-12-25	WOS:000079078400024
J	Nadanaciva, S; Weber, J; Senior, AE				Nadanaciva, S; Weber, J; Senior, AE			Binding of the transition state analog MgADP-fluoroaluminate to F-1-ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI F1-ATPASE; BETA-SUBUNIT; CATALYTIC SITES; ATP SYNTHASE; MITOCHONDRIAL F1-ATPASE; ACTIVE CONFORMATIONS; NUCLEOTIDE-BINDING; CRYSTAL-STRUCTURE; GTP HYDROLYSIS; COMPLEX	Escherichia coli F-1-ATPase from mutant beta Y331W was potently inhibited by fluoroaluminate plus MgADP but not by MgADP alone. beta-Trp-331 fluorescence was used to measure MgADP binding to catalytic sites. Fluoroaluminate induced a very large increase in MgADP binding affinity at catalytic site one, a smaller increase at site two, and no effect at site three. Mutation of either of the critical catalytic site residues beta-Lys-155 or beta-Glu-181 to Gin abolished the effects of fluoroaluminate on MgADP binding, The results indicate that the MgADP-fluoroaluminate complex is a transition state analog and independently demonstrate that residues beta-Lys-155 and (particularly) beta-Glu-181 are important for generation and stabilization of the catalytic transition state. Dicyclohexylcarbodiimide-inhibited enzyme, with 1% residual steady-state ATPase, showed normal transition state formation as judged by fluoroaluminate-induced MgADP binding affinity changes, consistent with a proposed mechanism by which dicyclohexylcarbodiimide prevents a conformational interaction between catalytic sites but does not affect the catalytic step per se. The fluorescence technique should prove valuable for future transition state studies of F-1-ATPase.	Univ Rochester, Med Ctr, Dept Biochem & Biophys, Rochester, NY 14642 USA	University of Rochester	Nadanaciva, S (corresponding author), Univ Rochester, Med Ctr, Dept Biochem & Biophys, Rochester, NY 14642 USA.				NIGMS NIH HHS [GM25349] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM025349, R01GM025349] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; ALSHAWI MK, 1988, J BIOL CHEM, V263, P19640; ALSHAWI MK, 1990, J BIOL CHEM, V265, P4402; AMANO T, 1994, FEBS LETT, V348, P93, DOI 10.1016/0014-5793(94)00588-5; Bianchet MA, 1998, P NATL ACAD SCI USA, V95, P11065, DOI 10.1073/pnas.95.19.11065; COLEMAN DE, 1994, SCIENCE, V265, P1405, DOI 10.1126/science.8073283; Dou C, 1997, BIOCHEMISTRY-US, V36, P3719, DOI 10.1021/bi962353+; DUPUIS A, 1989, FEBS LETT, V255, P47, DOI 10.1016/0014-5793(89)81058-0; FISHER AJ, 1995, BIOCHEMISTRY-US, V34, P8960, DOI 10.1021/bi00028a004; ISSARTEL JP, 1991, BIOCHEMISTRY-US, V30, P4726, DOI 10.1021/bi00233a013; Lobau S, 1997, J BIOL CHEM, V272, P3648, DOI 10.1074/jbc.272.6.3648; LUNARDI J, 1988, P NATL ACAD SCI USA, V85, P8958, DOI 10.1073/pnas.85.23.8958; Nakamoto RK, 1996, J MEMBRANE BIOL, V151, P101, DOI 10.1007/s002329900061; OMOTE H, 1992, J BIOL CHEM, V267, P20571; PARK MY, 1994, J BIOCHEM-TOKYO, V116, P1139, DOI 10.1093/oxfordjournals.jbchem.a124640; PECORARO VL, 1984, BIOCHEMISTRY-US, V23, P5262, DOI 10.1021/bi00317a026; RAO R, 1988, J BIOL CHEM, V263, P5569; Rittinger K, 1997, NATURE, V389, P758, DOI 10.1038/39651; Scheffzek K, 1997, SCIENCE, V277, P333, DOI 10.1126/science.277.5324.333; Schindelin N, 1997, NATURE, V387, P370, DOI 10.1038/387370a0; Schlichting I, 1997, BIOCHEMISTRY-US, V36, P9290, DOI 10.1021/bi970974c; SENIOR AE, 1993, J BIOL CHEM, V268, P6989; SENIOR AE, 1992, ARCH BIOCHEM BIOPHYS, V297, P340, DOI 10.1016/0003-9861(92)90682-M; Senior AE, 1995, FEBS LETT, V377, P285, DOI 10.1016/0014-5793(95)01345-8; SENIOR AE, 1992, J BIOL CHEM, V267, P21471; SONDEK J, 1994, NATURE, V372, P276, DOI 10.1038/372276a0; TAUSSKY HH, 1953, J BIOL CHEM, V202, P675; Tesmer JJG, 1997, CELL, V89, P251, DOI 10.1016/S0092-8674(00)80204-4; TOMMASINO M, 1985, BIOCHEMISTRY-US, V24, P3972; Weber J, 1997, BBA-BIOENERGETICS, V1319, P19, DOI 10.1016/S0005-2728(96)00121-1; WEBER J, 1994, J BIOL CHEM, V269, P20462; WEBER J, 1992, J BIOL CHEM, V267, P1712; WEBER J, 1993, J BIOL CHEM, V268, P20126; Weber J, 1996, J BIOL CHEM, V271, P18711, DOI 10.1074/jbc.271.31.18711; Weber J, 1998, BIOCHEMISTRY-US, V37, P608, DOI 10.1021/bi972370e; Weber J, 1998, J BIOL CHEM, V273, P33210, DOI 10.1074/jbc.273.50.33210; Xu YW, 1997, P NATL ACAD SCI USA, V94, P3579, DOI 10.1073/pnas.94.8.3579; Yasuda R, 1997, J BIOENERG BIOMEMBR, V29, P207, DOI 10.1023/A:1022449708449; [No title captured]	39	48	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	1999	274	11					7052	7058		10.1074/jbc.274.11.7052	http://dx.doi.org/10.1074/jbc.274.11.7052			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	175DV	10066761	hybrid			2022-12-25	WOS:000079078400033
J	Stierum, RH; Croteau, DL; Bohr, VA				Stierum, RH; Croteau, DL; Bohr, VA			Purification and characterization of a mitochondrial thymine glycol endonuclease from rat liver	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HAMSTER OVARY CELLS; OXIDATIVE DNA-DAMAGE; ESCHERICHIA-COLI; ULTRAVIOLET-RADIATION; SACCHAROMYCES-CEREVISIAE; HUMAN HOMOLOG; POLYMERASE-I; BASE DAMAGE; REPAIR; GLYCOSYLASE	Mitochondrial DNA is exposed to oxygen radicals produced during oxidative phosphorylation, Accumulation of several kinds of oxidative lesions in mitochondrial DNA may lead to structural genomic alterations, mitochondrial dysfunction, and associated degenerative diseases. The pyrimidine hydrate thymine glycol, one of many oxidative lesions, can block DNA and RNA polymerases and thereby exert negative biological effects. Mitochondrial DNA repair of this lesion is important to ensure normal mitochondrial DNA metabolism. Here, we report the purification of a novel rat liver mitochondrial thymine glycol endonuclease (mtTGendo), By using a radiolabeled oligonucleotide duplex containing a single thymine glycol lesion, damage-specific incision at the modified thymine was observed upon incubation with mitochondrial protein extracts. After purification using cation exchange, hydrophobic interaction, and size exclusion chromatography, the most pure active fractions contained a single band of similar to 37 kDa on a silver-stained gel. MtTGendo is active within a broad KCI concentration range and is EDTA-resistant. Furthermore, mtTGendo has an associated apurinic/apyrimidiniclyase activity. MtTGendo does not incise 8-oxodeoxyguanosine or uracil-containing duplexes or thymine glycol in single-stranded DNA. Based upon functional similarity, we conclude that mtTGendo may be a rat mitochondrial homolog of the Escherichia coli endonuclease III protein.	NIA, Genet Mol Lab, NIH, Baltimore, MD 21224 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)	Bohr, VA (corresponding author), NIA, Genet Mol Lab, NIH, Box 01,5600 Nathan Shock Dr, Baltimore, MD 21224 USA.		Bohr, Vilhelm/AAP-5931-2020; Croteau, Deb/AAP-5933-2020	Croteau, Deborah/0000-0002-6094-4084				ADELMAN R, 1988, P NATL ACAD SCI USA, V85, P2706, DOI 10.1073/pnas.85.8.2706; Anson RM, 1998, NUCLEIC ACIDS RES, V26, P662, DOI 10.1093/nar/26.2.662; Aspinwall R, 1997, P NATL ACAD SCI USA, V94, P109, DOI 10.1073/pnas.94.1.109; Augeri L, 1997, BIOCHEMISTRY-US, V36, P721, DOI 10.1021/bi9625511; Bozner P, 1997, J NEUROPATH EXP NEUR, V56, P1356, DOI 10.1097/00005072-199712000-00010; CLARK JM, 1986, NUCLEIC ACIDS RES, V14, P737, DOI 10.1093/nar/14.2.737; CLARK JM, 1989, BIOCHEMISTRY-US, V28, P775, DOI 10.1021/bi00428a054; CLAYTON DA, 1974, P NATL ACAD SCI USA, V71, P2777, DOI 10.1073/pnas.71.7.2777; Cooper PK, 1997, SCIENCE, V275, P990, DOI 10.1126/science.275.5302.990; Croteau DL, 1997, J BIOL CHEM, V272, P27338, DOI 10.1074/jbc.272.43.27338; CUMMINGS OW, 1987, J BIOL CHEM, V262, P2005; DOETSCH PW, 1995, BIOCHEMISTRY-US, V34, P737, DOI 10.1021/bi00003a005; DRIGGERS WJ, 1993, J BIOL CHEM, V268, P22042; Eide L, 1996, P NATL ACAD SCI USA, V93, P10735, DOI 10.1073/pnas.93.20.10735; GERSCHENSON M, 1995, NUCLEIC ACIDS RES, V23, P88, DOI 10.1093/nar/23.1.88; HATAHET Z, 1994, ANN NY ACAD SCI, V726, P346, DOI 10.1111/j.1749-6632.1994.tb52847.x; HAYES RC, 1986, NUCLEIC ACIDS RES, V14, P1045, DOI 10.1093/nar/14.2.1045; HIGGINS SA, 1987, BIOCHEMISTRY-US, V26, P1683, DOI 10.1021/bi00380a029; Hilbert TP, 1996, BIOCHEMISTRY-US, V35, P2505, DOI 10.1021/bi952516e; Hilbert TP, 1997, J BIOL CHEM, V272, P6733, DOI 10.1074/jbc.272.10.6733; HTUN H, 1992, METHOD ENZYMOL, V212, P272; IDE H, 1985, NUCLEIC ACIDS RES, V13, P8035, DOI 10.1093/nar/13.22.8035; Jen J, 1997, PHOTOCHEM PHOTOBIOL, V65, P323, DOI 10.1111/j.1751-1097.1997.tb08565.x; Kung HC, 1997, J BIOL CHEM, V272, P9227; Le XC, 1998, SCIENCE, V280, P1066, DOI 10.1126/science.280.5366.1066; LEDOUX SP, 1992, CARCINOGENESIS, V13, P1967, DOI 10.1093/carcin/13.11.1967; Lyras L, 1997, J NEUROCHEM, V68, P2061; Pinz KG, 1998, MOL CELL BIOL, V18, P1257, DOI 10.1128/MCB.18.3.1257; RAGAN CI, 1987, PRACTICAL APPROACH S, P80; Reardon JT, 1997, P NATL ACAD SCI USA, V94, P9463, DOI 10.1073/pnas.94.17.9463; RICHTER C, 1988, P NATL ACAD SCI USA, V85, P6465, DOI 10.1073/pnas.85.17.6465; RoldanArjona T, 1996, NUCLEIC ACIDS RES, V24, P3307, DOI 10.1093/nar/24.17.3307; SHIGENAGA MK, 1994, P NATL ACAD SCI USA, V91, P10771, DOI 10.1073/pnas.91.23.10771; SNYDERWINE EG, 1992, CANCER RES, V52, P4183; Taffe BG, 1996, MUTAT RES-DNA REPAIR, V364, P183, DOI 10.1016/S0921-8777(96)00031-6; Takao M, 1998, NUCLEIC ACIDS RES, V26, P2917, DOI 10.1093/nar/26.12.2917; TOMKINSON AE, 1988, J BIOL CHEM, V263, P12532; TOMKINSON AE, 1990, NUCLEIC ACIDS RES, V18, P929, DOI 10.1093/nar/18.4.929; WANG YJ, 1995, CHEM-BIOL INTERACT, V94, P135, DOI 10.1016/0009-2797(94)03327-5; Wei HC, 1997, FREE RADICAL BIO MED, V23, P148, DOI 10.1016/S0891-5849(96)00526-6; You HJ, 1998, BIOCHEMISTRY-US, V37, P6033, DOI 10.1021/bi973042h; Zastawny TH, 1998, FREE RADICAL BIO MED, V24, P722, DOI 10.1016/S0891-5849(97)00331-6; Zhang XS, 1997, PHOTOCHEM PHOTOBIOL, V65, P119, DOI 10.1111/j.1751-1097.1997.tb01886.x; Zhang XS, 1997, FREE RADICAL BIO MED, V23, P980, DOI 10.1016/S0891-5849(97)00126-3	44	29	29	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 12	1999	274	11					7128	7136		10.1074/jbc.274.11.7128	http://dx.doi.org/10.1074/jbc.274.11.7128			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	175DV	10066771	hybrid			2022-12-25	WOS:000079078400043
J	Chen, RW; Chuang, DM				Chen, RW; Chuang, DM			Long term lithium treatment suppresses p53 and Bax expression but increases Bcl-2 expression - A prominent role in neuroprotection against excitotoxicity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CEREBELLAR GRANULE CELLS; CYTOCHROME-C; APOPTOSIS; INHIBITION; RELEASE; MITOCHONDRIA; PROTEASE; NEURONS; AP-1	This study was undertaken to investigate the molecular mechanisms underlying the neuroprotective actions of lithium against glutamate excitotoxicity with a focus on the role of proapoptotic and antiapoptotic genes. Long term, but not acute, treatment of cultured cerebellar granule cells with LiCl induces a concentration-dependent decrease in mRNA and protein levels of proapoptotic p53 and Bax; conversely, mRNA and protein levels of cytoprotective Bcl-2 are remarkably increased. The ratios of Bcl-2/Bax protein levels increase by approximately 5-fold after lithium treatment for 5-7 days. Exposure of cerebellar granule cells to glutamate induces a rapid increase in p53 and Bax mRNA and protein levels with no apparent effect on Bcl-2 expression. Pretreatment with LiCl for 7 days prevents glutamate-induced increase in p53 and Bax expression and maintains Bcl-2 in an elevated state. Glutamate exposure also triggers the release of cytochrome c from the mitochondria into the cytosol. Lithium pretreatment blocks glutamate-induced cytochrome c release and cleavage of lamin B1, a nuclear substrate for caspase-3. These results strongly suggest that lithium-induced Bcl-2 up-regulation and p53 and Bax down-regulation play a prominent role in neuroprotection against excitotoxicity. Our results further suggest that lithium, in addition to its use in the treatment of bipolar depressive illness, may have an expanded use in the intervention of neurodegeneration.	NIMH, Mol Neurobiol Sect, BPB, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH)	Chuang, DM (corresponding author), NIMH, Mol Neurobiol Sect, BPB, NIH, Bldg 10,Rm 3N212,10 Ctr Dr,MSC 1272, Bethesda, MD 20892 USA.	chuang@helix.nih.gov			NATIONAL INSTITUTE OF MENTAL HEALTH [ZIAMH002468, Z01MH002468] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Allen RT, 1998, CELL MOL LIFE SCI, V54, P427, DOI 10.1007/s000180050171; Antonsson B, 1997, SCIENCE, V277, P370, DOI 10.1126/science.277.5324.370; BAFFY G, 1993, J BIOL CHEM, V268, P6511; CHUANG DM, 1992, MOL PHARMACOL, V42, P210; Du YS, 1997, P NATL ACAD SCI USA, V94, P11657, DOI 10.1073/pnas.94.21.11657; FUKAMAUCHI F, 1993, MOL PHARMACOL, V44, P940; Grimm S, 1996, J CELL BIOL, V134, P13, DOI 10.1083/jcb.134.1.13; Hu YM, 1998, P NATL ACAD SCI USA, V95, P4386, DOI 10.1073/pnas.95.8.4386; HUDSON CJ, 1993, SYNAPSE, V13, P278, DOI 10.1002/syn.890130311; Jope RS, 1997, MOL BRAIN RES, V50, P171, DOI 10.1016/S0169-328X(97)00183-6; Jurgensmeier JM, 1998, P NATL ACAD SCI USA, V95, P4997, DOI 10.1073/pnas.95.9.4997; Klein PS, 1996, P NATL ACAD SCI USA, V93, P8455, DOI 10.1073/pnas.93.16.8455; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; KORSMEYER SJ, 1993, SEMIN CANCER BIOL, V4, P327; Kuwana T, 1998, J BIOL CHEM, V273, P16589, DOI 10.1074/jbc.273.26.16589; LAM M, 1994, P NATL ACAD SCI USA, V91, P6569, DOI 10.1073/pnas.91.14.6569; LENOX RH, 1998, J CLIN PSYCHIAT, V570, P333; MANJI HK, 1992, AM J PSYCHIAT, V149, P746; MIYASHITA T, 1994, ONCOGENE, V9, P1799; Nonaka S, 1998, P NATL ACAD SCI USA, V95, P2642, DOI 10.1073/pnas.95.5.2642; Nonaka S, 1998, NEUROREPORT, V9, P2081, DOI 10.1097/00001756-199806220-00031; Nonaka S, 1998, J PHARMACOL EXP THER, V286, P539; Ozaki N, 1997, J NEUROCHEM, V69, P2336; Susin SA, 1996, J EXP MED, V184, P1331, DOI 10.1084/jem.184.4.1331; VARNEY MA, 1992, MOL PHARMACOL, V42, P671; WOODGETT JR, 1991, TRENDS BIOCHEM SCI, V16, P177, DOI 10.1016/0968-0004(91)90071-3; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0; Yuan PX, 1998, MOL BRAIN RES, V58, P225, DOI 10.1016/S0169-328X(98)00114-4	30	301	331	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1999	274	10					6039	6042		10.1074/jbc.274.10.6039	http://dx.doi.org/10.1074/jbc.274.10.6039			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172BQ	10037682	hybrid			2022-12-25	WOS:000078902800004
J	Leal, SM; Huang, SS; Huang, JS				Leal, SM; Huang, SS; Huang, JS			Interactions of high affinity insulin-like growth factor-binding proteins with the type V transforming growth factor-P receptor in mink lung epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-BETA-RECEPTOR; FACTOR (IGF)-BINDING PROTEIN-3; BREAST-CANCER CELLS; TGF-BETA; IGF-I; TARGETED DISRUPTION; OSTEOBLASTIC CELLS; FIBROBLASTS; GROWTH-FACTOR-BETA-1; IDENTIFICATION	High affinity insulin-like growth factor-binding proteins (IGFBP-1 to -6) are a family of structurally homologous proteins that induce cellular responses by insulin-libe growth factor (IGF)-dependent and -independent mechanisms. The IGFBP-3 receptor, which mediates the IGF-independent growth inhibitory response, has recently been identified as the type V transforming growth factor-beta receptor (T beta R-V) (Leal, S.M, Liu, Q,L,, Huang, S.S., and Huang, J, S, (1997) J, Biob Chem, 272, 20572-20576), To characterize the interactions of high affinity IGFBPs with T beta R-V, mink lung epithelial cells (Mv1Lu cells) were incubated with I-125-labeled recombinant human IGFBPs (I-125-IGFBP-1 to -6) in the presence of the cross-linking agent disuccinimidyl suberate and analyzed by 5% SDS-polyacrylamide gel electrophoresis and autoradiography. I-125-IGFBP-3, -4, and -5 but not I-125-IGFBP-1, -2, and -6 bound to T beta R-V as demonstrated by the detection of the similar to 400-kDa I-125-IGFBP T beta R-V cross-linked complex in the cell lysates and immunoprecipitates. The analyses of 125I-labeled Ligand binding competition and DNA synthesis inhibition revealed that IGFBP-3 was a more potent Ligand for TPR-V than IGFBP-4 or -5, Most of the high affinity I-125-IGFBPs formed dimers at the cell surface. The cell-surface dimer of I-125-IGFBP-3 preferentially bound to and was cross-linked to TPR-V in the presence of disuccinimidyl suberate, IGFBP-3 did not stimulate the cellular phosphorylation of Smad2 and Smad3, key transducers of the transforming growth factor-beta type I/type II receptor (T beta R-IT beta R-II) heterocomplex-mediated signaling. These results suggest that IGFBP-3, -4, and -5 are specific ligands for T beta R-V, which mediates the growth inhibitory response through a signaling pathway(s) distinct from that mediated by the T beta R-I and T beta R-II heterocomplex.	St Louis Univ, Sch Med, Dept Biochem & Mol Biol, St Louis, MO 63104 USA	Saint Louis University	Huang, JS (corresponding author), St Louis Univ, Sch Med, Dept Biochem & Mol Biol, 1402 S Grand Blvd, St Louis, MO 63104 USA.	huangjs@wpogate.slu.edu			NCI NIH HHS [CA38808] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA038808] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDRESS DL, 1993, BIOCHEM BIOPH RES CO, V195, P25, DOI 10.1006/bbrc.1993.2004; ANDRESS DL, 1995, J BIOL CHEM, V270, P28289; Andress DL, 1998, AM J PHYSIOL-ENDOC M, V274, pE744, DOI 10.1152/ajpendo.1998.274.4.E744; ATTISANO L, 1994, BBA-MOL CELL RES, V1222, P71, DOI 10.1016/0167-4889(94)90026-4; BACH LA, 1992, BIOCHEM BIOPH RES CO, V186, P301, DOI 10.1016/S0006-291X(05)80807-1; BACH LA, 1992, DIABETES METAB REV, V8, P229, DOI 10.1002/dmr.5610080304; BAKER JB, 1979, NATURE, V278, P743, DOI 10.1038/278743a0; CONOVER CA, 1993, J CLIN ENDOCR METAB, V76, P1153, DOI 10.1210/jc.76.5.1153; DELBE J, 1991, BIOCHEM BIOPH RES CO, V179, P495, DOI 10.1016/0006-291X(91)91398-V; Fowlkes JL, 1997, ENDOCRINOLOGY, V138, P2280, DOI 10.1210/en.138.6.2280; Gill ZP, 1997, J BIOL CHEM, V272, P25602, DOI 10.1074/jbc.272.41.25602; Hinck AP, 1996, BIOCHEMISTRY-US, V35, P8517, DOI 10.1021/bi9604946; HODGKINSON S, 1995, J ENDOCRINOL, V145, pR2; Huang SS, 1997, J BIOL CHEM, V272, P27155, DOI 10.1074/jbc.272.43.27155; Huang SS, 1998, J BIOL CHEM, V273, P26036, DOI 10.1074/jbc.273.40.26036; JONES JI, 1993, J CELL BIOL, V121, P679, DOI 10.1083/jcb.121.3.679; JONES JI, 1993, P NATL ACAD SCI USA, V90, P10553, DOI 10.1073/pnas.90.22.10553; JONES JI, 1995, ENDOCR REV, V16, P3, DOI 10.1210/er.16.1.3; Kim HS, 1997, P NATL ACAD SCI USA, V94, P12981, DOI 10.1073/pnas.94.24.12981; Leal SM, 1997, J BIOL CHEM, V272, P20572, DOI 10.1074/jbc.272.33.20572; LINSLEY PS, 1979, NATURE, V278, P743; LIU QJ, 1994, J BIOL CHEM, V269, P9221; Liu QJ, 1997, J BIOL CHEM, V272, P18891, DOI 10.1074/jbc.272.30.18891; LOKESHWAR VB, 1989, J BIOL CHEM, V264, P19318; MOHAN S, 1995, J BIOL CHEM, V270, P20424, DOI 10.1074/jbc.270.35.20424; Nakao A, 1997, EMBO J, V16, P5353, DOI 10.1093/emboj/16.17.5353; Neumann GM, 1998, BIOCHEMISTRY-US, V37, P6572, DOI 10.1021/bi972894e; OGRADY P, 1992, J BIOL CHEM, V267, P21033; OGRADY P, 1991, J BIOL CHEM, V266, P8583; OGRADY P, 1991, BIOCHEM BIOPH RES CO, V179, P378, DOI 10.1016/0006-291X(91)91381-L; OH Y, 1993, J BIOL CHEM, V268, P26045; RAINES EW, 1991, PEPTIDE GROWTH FACTO, V1, P173; Rajah R, 1997, J BIOL CHEM, V272, P12181, DOI 10.1074/jbc.272.18.12181; SHIMASAKI S, 1991, Progress in Growth Factor Research, V3, P243, DOI 10.1016/0955-2235(91)90003-M; SINGH P, 1994, CANCER RES, V54, P6563; VALENTINIS B, 1995, MOL ENDOCRINOL, V9, P361, DOI 10.1210/me.9.3.361; VIVIEN D, 1995, J BIOL CHEM, V270, P7134, DOI 10.1074/jbc.270.13.7134; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; Weiss A, 1998, CELL, V94, P277, DOI 10.1016/S0092-8674(00)81469-5; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; Zadeh SM, 1997, ENDOCRINOLOGY, V138, P3069, DOI 10.1210/en.138.7.3069; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0	42	88	89	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1999	274	10					6711	6717		10.1074/jbc.274.10.6711	http://dx.doi.org/10.1074/jbc.274.10.6711			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172BQ	10037769	hybrid			2022-12-25	WOS:000078902800091
J	Schrem, A; Lange, C; Beyermann, M; Koch, KW				Schrem, A; Lange, C; Beyermann, M; Koch, KW			Identification of a domain in guanylyl cyclase-activating protein 1 that interacts with a complex of guanylyl cyclase and tubulin in photoreceptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTIONAL-CHARACTERIZATION; MOLECULAR-CLONING; RETINAL RODS; CALMODULIN; EXPRESSION; PHOTOTRANSDUCTION; LOCALIZATION; PURIFICATION; RECOGNITION; MODULATION	The membrane-bound guanylyl cyclase in rod photoreceptors is activated by guanylyl cyclase-activating protein 1 (GCAP-1) at low free [Ca(2+)]. GCAP-1 is a Ca(2+)- binding protein and belongs to the superfamily of EF-hand proteins. We created an oligopeptide library of overlapping peptides that encompass the entire amino acid sequence of GCAP-1, Peptides were used in competitive screening assays to identify interaction regions in GCAP-1 that directly bind the guanylyl cyclase in bovine photoreceptor cells. We found four regions in GCAP-1 that participate in regulating guanylyl cyclase. A 15-amino acid peptide located adjacent to the second EF-hand motif (Phe(73)-Lys(87)) was identified as the main interaction domain. Inhibition of GCAP-1-stimulated guanylyl cyclase activity by the peptide Phe(73)-Lys(87) was completely relieved when an excess amount of GCAP-1 was added. An affinity column made from this peptide was able to bind a complex of photoreceptor guanylyl cyclase and tubulin. Using an anti-GCAP-1 antibody, we coimmunoprecipitated GCAP-1 with guanylyl cyclase and tubulin. Complex formation between GCAP-1 and guanylyl cyclase was observed independent of [Ca(2+)]. Our experiments suggest that there exists a tight association of guanylyl cyclase and tubulin in rod outer segments.	Forschungszentrum Julich, Inst Biol Informat Verarbeitung, D-52425 Julich, Germany; Forschungsinst Mol Pharmakol, D-10315 Berlin, Germany	Helmholtz Association; Research Center Julich	Koch, KW (corresponding author), Forschungszentrum Julich, Inst Biol Informat Verarbeitung, Postfach 1913, D-52425 Julich, Germany.	k.w.koch@fz-juelich.de	Koch, Karl-Wilhelm/C-9551-2015	Koch, Karl-Wilhelm/0000-0003-1501-0044				DIZHOOR AM, 1995, J BIOL CHEM, V270, P25200, DOI 10.1074/jbc.270.42.25200; DIZHOOR AM, 1991, SCIENCE, V251, P915, DOI 10.1126/science.1672047; Duda T, 1996, BIOCHEMISTRY-US, V35, P8478, DOI 10.1021/bi960752z; Duda T, 1998, BIOCHEM BIOPH RES CO, V242, P118, DOI 10.1006/bbrc.1997.7921; FLEISCHMAN D, 1979, BIOCHEMISTRY-US, V18, P5060, DOI 10.1021/bi00590a006; Frins S, 1996, J BIOL CHEM, V271, P8022, DOI 10.1074/jbc.271.14.8022; Goraczniak R, 1997, BIOCHEM BIOPH RES CO, V234, P666, DOI 10.1006/bbrc.1997.6579; GORACZNIAK RM, 1994, BIOCHEM J, V302, P455, DOI 10.1042/bj3020455; GORCZYCA WA, 1995, J BIOL CHEM, V270, P22029, DOI 10.1074/jbc.270.37.22029; GORCZYCA WA, 1994, P NATL ACAD SCI USA, V91, P4014, DOI 10.1073/pnas.91.9.4014; Hallett MA, 1996, J CELL SCI, V109, P1803; HSU YT, 1993, NATURE, V361, P76, DOI 10.1038/361076a0; KLEE CB, 1980, ANNU REV BIOCHEM, V49, P489, DOI 10.1146/annurev.bi.49.070180.002421; KOCH KW, 1995, CELL CALCIUM, V18, P314, DOI 10.1016/0143-4160(95)90027-6; KOCH KW, 1994, EUR J BIOCHEM, V222, P589, DOI 10.1111/j.1432-1033.1994.tb18901.x; KOCH KW, 1991, J BIOL CHEM, V266, P8634; Laura RP, 1996, J BIOL CHEM, V271, P11646, DOI 10.1074/jbc.271.20.11646; LOWE DG, 1995, P NATL ACAD SCI USA, V92, P5535, DOI 10.1073/pnas.92.12.5535; Olshevskaya EV, 1997, J BIOL CHEM, V272, P14327, DOI 10.1074/jbc.272.22.14327; OttoBruc A, 1997, BIOCHEMISTRY-US, V36, P4295, DOI 10.1021/bi963000d; OttoBruc A, 1997, P NATL ACAD SCI USA, V94, P4727, DOI 10.1073/pnas.94.9.4727; PALCZEWSKI K, 1994, NEURON, V13, P395, DOI 10.1016/0896-6273(94)90355-7; PODZDNYAKOV N, 1997, BIOCHEMISTRY-US, V36, P14327; Polans A, 1996, TRENDS NEUROSCI, V19, P547, DOI 10.1016/S0166-2236(96)10059-X; Pugh EN, 1997, BIOSCIENCE REP, V17, P429; Rhoads AR, 1997, FASEB J, V11, P331, DOI 10.1096/fasebj.11.5.9141499; Rudnicka-Nawrot M, 1998, BIOCHEMISTRY-US, V37, P248, DOI 10.1021/bi972306x; SHYJAN AW, 1992, NEURON, V9, P727, DOI 10.1016/0896-6273(92)90035-C; Yang RB, 1997, J BIOL CHEM, V272, P13738, DOI 10.1074/jbc.272.21.13738; YANG RB, 1995, P NATL ACAD SCI USA, V92, P602, DOI 10.1073/pnas.92.2.602; YAU KW, 1994, INVEST OPHTH VIS SCI, V35, P9; YUEN PST, 1992, ANNU REV NEUROSCI, V15, P193; Zoche M, 1996, BIOCHEMISTRY-US, V35, P8742, DOI 10.1021/bi960445t	33	41	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1999	274	10					6244	6249		10.1074/jbc.274.10.6244	http://dx.doi.org/10.1074/jbc.274.10.6244			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172BQ	10037711	hybrid			2022-12-25	WOS:000078902800033
J	Torigoe, H; Ferdous, A; Watanabe, H; Akaike, T; Maruyama, A				Torigoe, H; Ferdous, A; Watanabe, H; Akaike, T; Maruyama, A			Poly(L-lysine)-graft-dextran copolymer promotes pyrimidine motif triplex DNA formation at physiological pH - Thermodynamic and kinetic studies	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EQUILIBRIUM ASSOCIATION CONSTANTS; HELIX FORMATION; OPTICAL BIOSENSOR; NUCLEIC-ACIDS; NEUTRAL PH; BINDING; SEQUENCE; OLIGODEOXYNUCLEOTIDES; 5-METHYLCYTOSINE; OLIGONUCLEOTIDES	Extreme instability of pyrimidine motif tripler DNA at physiological pH severely limits its use for artificial control of gene expression in vivo. Stabilization of the pyrimidine motif tripler at physiological pH is therefore of great importance in improving its therapeutic potential. To this end, isothermal titration calorimetry interaction analysis system and electrophoretic mobility shift assay have been used to explore the thermodynamic and kinetic effects of our previously reported tripler stabilizer, poly (L-lysine)-graft-dextran (PLL-g-Dex) copolymer, on pyrimidine motif tripler formation at physiological pH. Both the thermodynamic and kinetic analyses have clearly indicated that in the presence of the PLL-g-Dex copolymer, the binding constant of the pyrimidine motif tripler formation at physiological pH was about 100 times higher than that observed without any tripler stabilizer. Of importance, the tripler-promoting efficiency of the copolymer was more than 20 times higher than that of physiological concentrations of spermine, a putative intracellular tripler stabilizer. Kinetic data have also demonstrated that the observed copolymer-mediated promotion of the tripler formation at physiological pH resulted from the considerable increase in the association rate constant rather than the decrease in the dissociation rate constant. Our results certainly support the idea that the PLL g-Dex copolymer could be a key material and may eventually lead to progress in therapeutic applications of the antigene strategy in vivo.	Inst Phys & Chem Res, RIKEN, Tsukuba Life Sci Ctr, Gene Bank, Tsukuba, Ibaraki 3050074, Japan; Tokyo Inst Technol, Dept Biomol Engn, Yokohama, Kanagawa 2268501, Japan	RIKEN; Tokyo Institute of Technology	Maruyama, A (corresponding author), Inst Phys & Chem Res, RIKEN, Tsukuba Life Sci Ctr, Gene Bank, 3-1-1 Koyadai, Tsukuba, Ibaraki 3050074, Japan.		Maruyama, Atsushi/C-9186-2015	Maruyama, Atsushi/0000-0002-7495-2974				BATES PJ, 1995, NUCLEIC ACIDS RES, V23, P3627, DOI 10.1093/nar/23.18.3627; BOND JP, 1994, BIOPHYS J, V67, P825, DOI 10.1016/S0006-3495(94)80542-9; CUSH R, 1993, BIOSENS BIOELECTRON, V8, P347, DOI 10.1016/0956-5663(93)80073-X; EDWARDS PR, 1995, ANAL BIOCHEM, V231, P210, DOI 10.1006/abio.1995.1522; Ferdous A, 1998, J PHARM SCI-US, V87, P1400, DOI 10.1021/js980066g; Ferdous A, 1998, NUCLEIC ACIDS RES, V26, P3949, DOI 10.1093/nar/26.17.3949; FRANKKAMENETSKII MD, 1995, ANNU REV BIOCHEM, V64, P65, DOI 10.1146/annurev.bi.64.070195.000433; FRANKKAMENETSKII MD, 1992, METHOD ENZYMOL, V211, P180; HAMPEL KJ, 1991, BIOCHEMISTRY-US, V30, P4455, DOI 10.1021/bi00232a012; HAYNES M, 1970, BIOCHEMISTRY-US, V9, P4410, DOI 10.1021/bi00824a600; JETTER MC, 1993, BIOCHEMISTRY-US, V32, P3249, DOI 10.1021/bi00064a006; Kamiya M, 1996, J AM CHEM SOC, V118, P4532, DOI 10.1021/ja952287j; KOH JS, 1992, J AM CHEM SOC, V114, P1470, DOI 10.1021/ja00030a050; KRAWCZYK SH, 1992, P NATL ACAD SCI USA, V89, P3761, DOI 10.1073/pnas.89.9.3761; LEE JS, 1979, NUCLEIC ACIDS RES, V6, P3073, DOI 10.1093/nar/6.9.3073; LEE JS, 1984, NUCLEIC ACIDS RES, V12, P6603, DOI 10.1093/nar/12.16.6603; LYAMICHEV VI, 1985, J BIOMOL STRUCT DYN, V3, P327, DOI 10.1080/07391102.1985.10508420; MANNING GS, 1978, Q REV BIOPHYS, V11, P179, DOI 10.1017/S0033583500002031; MANZINI G, 1990, J MOL BIOL, V213, P833, DOI 10.1016/S0022-2836(05)80267-0; Maruyama A, 1997, BIOCONJUGATE CHEM, V8, P3, DOI 10.1021/bc960071g; Maruyama A, 1998, BIOCONJUGATE CHEM, V9, P292, DOI 10.1021/bc9701510; MASCOTTI DP, 1990, P NATL ACAD SCI USA, V87, P3142, DOI 10.1073/pnas.87.8.3142; MIRKIN SM, 1994, ANNU REV BIOPH BIOM, V23, P541, DOI 10.1146/annurev.bb.23.060194.002545; MOSER HE, 1987, SCIENCE, V238, P645, DOI 10.1126/science.3118463; MOUSCADET JF, 1994, BIOCHEMISTRY-US, V33, P4187, DOI 10.1021/bi00180a011; OLINS DE, 1967, J MOL BIOL, V24, P157, DOI 10.1016/0022-2836(67)90324-5; ONO A, 1991, J AM CHEM SOC, V113, P4032, DOI 10.1021/ja00010a077; POVSIC TJ, 1989, J AM CHEM SOC, V111, P3059, DOI 10.1021/ja00190a047; RECORD MT, 1978, Q REV BIOPHYS, V11, P103, DOI 10.1017/S003358350000202X; RECORD MT, 1976, J MOL BIOL, V107, P145, DOI 10.1016/S0022-2836(76)80023-X; ROUGEE M, 1992, BIOCHEMISTRY-US, V31, P9269, DOI 10.1021/bi00153a021; SHINDO H, 1993, BIOCHEMISTRY-US, V32, P8963, DOI 10.1021/bi00085a030; SINGLETON SF, 1993, BIOCHEMISTRY-US, V32, P13171, DOI 10.1021/bi00211a028; SINGLETON SF, 1992, BIOCHEMISTRY-US, V31, P10995, DOI 10.1021/bi00160a008; SOYFER VN, 1996, TROPLE HELICAL NUCL; SUN JS, 1991, P NATL ACAD SCI USA, V88, P6023, DOI 10.1073/pnas.88.14.6023; SUN JS, 1993, CURR OPIN STRUC BIOL, V3, P345, DOI 10.1016/S0959-440X(05)80105-8; Sun JS, 1996, CURR OPIN STRUC BIOL, V6, P327, DOI 10.1016/S0959-440X(96)80051-0; THOMAS T, 1993, BIOCHEMISTRY-US, V32, P14068, DOI 10.1021/bi00213a041; TSUBOI M, 1967, CONFORM BIOPOLYM, V2, P689; Ueno Y, 1998, BIOCONJUGATE CHEM, V9, P33, DOI 10.1021/bc9701508; WISEMAN T, 1989, ANAL BIOCHEM, V179, P131, DOI 10.1016/0003-2697(89)90213-3; XODO LE, 1991, NUCLEIC ACIDS RES, V19, P5625, DOI 10.1093/nar/19.20.5625	43	57	57	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1999	274	10					6161	6167		10.1074/jbc.274.10.6161	http://dx.doi.org/10.1074/jbc.274.10.6161			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172BQ	10037700	hybrid			2022-12-25	WOS:000078902800022
J	Yamamoto, H; Kihara-Negishi, F; Yamada, T; Hashimoto, Y; Oikawa, T				Yamamoto, H; Kihara-Negishi, F; Yamada, T; Hashimoto, Y; Oikawa, T			Physical and functional interactions between the transcription factor PU.1 and the coactivator CBP	ONCOGENE			English	Article						PU.1; CBP; transcription factor	NUCLEAR-PROTEIN CBP; C-MYB; ACTIVATION; P300; DIFFERENTIATION; ERYTHROLEUKEMIA; FAMILY; CREB; ONCOPROTEIN; SIMILARITY	Yeast two-hybrid system was employed to isolate novel proteins that physically interact with PU.1, a member of Ets family transcription factors. Sequence analyses of several isolated clones positive for beta-galactosidase activity revealed that one of these clones was confirmed to encode a transcriptional coactivator, CREB binding protein (CBP), GST binding assay showed that the interacting sites were located at the transcriptional activation domain of PU,1 through 74-122 and the region spanning residues 1283-1915 of CBP. CBP potentiated PU.1-mediated transcription of the reporter gene driven by the multimerized PU.1-binding sites, suggesting that CBP functions as a coactivator for PU.1. Considering that CBP is a limited cellular component to function as a coactivator for several transcription factors, CBP may mediate synergistic and antagonistic interactions between PU.1 and other transcription factors during the process of hematopoietic cell differentiation.	Sasaki Inst, Dept Cell Genet, Chiyoda Ku, Tokyo 1010062, Japan		Oikawa, T (corresponding author), Sasaki Inst, Dept Cell Genet, Chiyoda Ku, 2-2 Kanda Surugadai, Tokyo 1010062, Japan.							ARANY Z, 1995, NATURE, V374, P81, DOI 10.1038/374081a0; ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; BANNISTER AJ, 1995, EMBO J, V14, P4758, DOI 10.1002/j.1460-2075.1995.tb00157.x; Bellon T, 1997, BLOOD, V90, P1828, DOI 10.1182/blood.V90.5.1828; Beug H, 1996, BBA-REV CANCER, V1288, pM35, DOI 10.1016/S0304-419X(96)00032-7; Bhattacharya S, 1996, NATURE, V383, P344, DOI 10.1038/383344a0; Blobel GA, 1998, P NATL ACAD SCI USA, V95, P2061, DOI 10.1073/pnas.95.5.2061; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; CHEN HM, 1995, BLOOD, V85, P2918, DOI 10.1182/blood.V85.10.2918.bloodjournal85102918; Cheng XB, 1997, MOL CELL BIOL, V17, P1407, DOI 10.1128/MCB.17.3.1407; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; Dai P, 1996, GENE DEV, V10, P528, DOI 10.1101/gad.10.5.528; EISENBEIS CF, 1995, GENE DEV, V9, P1377, DOI 10.1101/gad.9.11.1377; GAUTHIER JM, 1993, EMBO J, V12, P5089, DOI 10.1002/j.1460-2075.1993.tb06203.x; Gerritsen ME, 1997, P NATL ACAD SCI USA, V94, P2927, DOI 10.1073/pnas.94.7.2927; Giles RH, 1998, TRENDS GENET, V14, P178, DOI 10.1016/S0168-9525(98)01438-3; Gong QH, 1996, MOL CELL BIOL, V16, P6055; Gu W, 1997, NATURE, V387, P819, DOI 10.1038/42972; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; HAGEMEIER C, 1993, P NATL ACAD SCI USA, V90, P1580, DOI 10.1073/pnas.90.4.1580; Janknecht R, 1996, NATURE, V383, P22, DOI 10.1038/383022a0; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Kihara-Negishi F, 1998, INT J CANCER, V76, P523, DOI 10.1002/(SICI)1097-0215(19980518)76:4<523::AID-IJC14>3.0.CO;2-8; Kitabayashi I, 1998, EMBO J, V17, P2994, DOI 10.1093/emboj/17.11.2994; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LUNDBLAD JR, 1995, NATURE, V374, P85, DOI 10.1038/374085a0; McKercher SR, 1996, EMBO J, V15, P5647, DOI 10.1002/j.1460-2075.1996.tb00949.x; MoreauGachelin F, 1996, MOL CELL BIOL, V16, P2453; MOREAUGACHELIN F, 1994, BBA-REV CANCER, V1198, P149, DOI 10.1016/0304-419X(94)90011-6; NAGULAPALLI S, 1995, J IMMUNOL, V155, P4330; Oelgeschlager M, 1996, EMBO J, V15, P2771, DOI 10.1002/j.1460-2075.1996.tb00637.x; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Perkins ND, 1997, SCIENCE, V275, P523, DOI 10.1126/science.275.5299.523; PONGUBALA JMR, 1993, SCIENCE, V259, P1622, DOI 10.1126/science.8456286; Rao G, 1997, ONCOGENE, V14, P123, DOI 10.1038/sj.onc.1200807; SCHUETZE S, 1993, MOL CELL BIOL, V13, P5670, DOI 10.1128/MCB.13.9.5670; SCOTT EW, 1994, SCIENCE, V265, P1573, DOI 10.1126/science.8079170; SHIVDASANI RA, 1995, CELL, V81, P695, DOI 10.1016/0092-8674(95)90531-6; Shivdasani RA, 1996, BLOOD, V87, P4025, DOI 10.1182/blood.V87.10.4025.bloodjournal87104025; Tanaka Y, 1997, P NATL ACAD SCI USA, V94, P10215, DOI 10.1073/pnas.94.19.10215; TENEN DG, 1997, BLOOD, V90, P498; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; Yamada T, 1997, BLOOD, V89, P1383, DOI 10.1182/blood.V89.4.1383; Yang C, 1998, MOL CELL BIOL, V18, P2218, DOI 10.1128/MCB.18.4.2218; Zhang DE, 1996, CURR TOP MICROBIOL, V211, P137; Zhang JJ, 1996, P NATL ACAD SCI USA, V93, P15092, DOI 10.1073/pnas.93.26.15092	47	100	100	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 18	1999	18	7					1495	1501		10.1038/sj.onc.1202427	http://dx.doi.org/10.1038/sj.onc.1202427			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	167UK	10050886				2022-12-25	WOS:000078651600011
J	Gimm, O; Neuberg, DS; Marsh, DJ; Dahia, PLM; Cuong, HV; Raue, F; Hinze, R; Dralle, H; Eng, C				Gimm, O; Neuberg, DS; Marsh, DJ; Dahia, PLM; Cuong, HV; Raue, F; Hinze, R; Dralle, H; Eng, C			Over-representation of a germline RET sequence variant in patients with sporadic medullary thyroid carcinoma and somatic RET codon 918 mutation	ONCOGENE			English	Article						tyrosine kinase; polymorphism; germline mutation; somatic mutation; medullary thyroid cancer	MULTIPLE-ENDOCRINE-NEOPLASIA; TYROSINE KINASE DOMAIN; POINT MUTATION; MESSENGER-RNA; PROTOONCOGENE; POLYMORPHISM; FMTC; GENE; ACTIVATION; DISEASE	The aetiology of sporadic medullary thyroid carcinoma is unknown, About 50% harbour a somatic mutation at codon 918 of RET (M918T). To investigate whether other RET sequence variants may be associated with or predispose to the development of sporadic medullary thyroid carcinoma, we analysed genomic DNA from the germline and corresponding tumour from 50 patients to identify RET sequence variants. In one patient, tumour DNA showed a novel somatic 12 bp in-frame deletion in exon 15. More interestingly, we found that the rare polymorphism at codon 836 (c.2439C > T; S836S) occurred at a significantly higher frequency than that in control individuals without sporadic medullary thyroid carcinoma (Fisher's exact test, P = 0.03), Further, among the nine evaluable cases with germline c.2439C/T, eight also had the somatic M918T mutation in MTC DNA which was more frequent than in patients with the more common c.2439C/C (89% vs 40%, respectively; Fisher's exact test, P = 0.01), These findings suggest that the rare sequence variant at codon 836 may somehow play a role in the genesis of sporadic medullary thyroid carcinoma.	Ohio State Univ, Ctr Comprehens Canc, Human Canc Genet Program, Columbus, OH 43210 USA; Harvard Univ, Dana Farber Canc Inst, Boston, MA 02115 USA; Univ Halle Wittenberg, Klin Allgemeinchirurg, D-06097 Halle, Germany; Endokrinol Gemeinschaftspraxis, D-69120 Heidelberg, Germany; Univ Halle Wittenberg, Inst Pathol, D-06097 Halle, Germany; Univ Cambridge, Canc Res Campaign, Human Canc Genet Res Grp, Cambridge CB2 2QQ, England	James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; Harvard University; Dana-Farber Cancer Institute; Martin Luther University Halle Wittenberg; Martin Luther University Halle Wittenberg; CRUK Cambridge Institute; University of Cambridge	Eng, C (corresponding author), Ohio State Univ, Ctr Comprehens Canc, Human Canc Genet Program, 420 W 12th Ave,690 MRF, Columbus, OH 43210 USA.		Marsh, Deborah J/I-1491-2014; Raue, Friedhelm/ABD-6150-2021; Dralle, Henning/ABD-4454-2020	Marsh, Deborah J/0000-0001-5899-4931; Raue, Friedhelm/0000-0002-7700-1648; Eng, Charis/0000-0002-3693-5145				BERGHOLM U, 1990, ACTA ONCOL, V29, P9, DOI 10.3109/02841869009089985; BOLINO A, 1995, ONCOGENE, V10, P2415; Borrello MG, 1995, ONCOGENE, V11, P2419; CARLSON KM, 1994, AM J HUM GENET, V55, P1076; CECCHERINI I, 1994, ONCOGENE, V9, P3025; Ceccherini I, 1997, ONCOGENE, V14, P2609, DOI 10.1038/sj.onc.1201079; DONISKELLER H, 1993, HUM MOL GENET, V2, P851, DOI 10.1093/hmg/2.7.851; ENG C, 1994, HUM MOL GENET, V3, P237, DOI 10.1093/hmg/3.2.237; ENG C, 1995, ONCOGENE, V10, P509; Eng C, 1997, HUM MUTAT, V9, P97, DOI 10.1002/(SICI)1098-1004(1997)9:2<97::AID-HUMU1>3.3.CO;2-Q; Eng C, 1996, JAMA-J AM MED ASSOC, V276, P1575, DOI 10.1001/jama.276.19.1575; FARNDON JR, 1986, BRIT J SURG, V73, P278, DOI 10.1002/bjs.1800730411; Gimm O, 1997, J CLIN ENDOCR METAB, V82, P3902, DOI 10.1210/jc.82.11.3902; HOFSTRA RMW, 1994, NATURE, V367, P375, DOI 10.1038/367375a0; Laken SJ, 1997, NAT GENET, V17, P79, DOI 10.1038/ng0997-79; Leviev I, 1997, ARTERIOSCL THROM VAS, V17, P2935, DOI 10.1161/01.ATV.17.11.2935; Liaw D, 1997, NAT GENET, V16, P64, DOI 10.1038/ng0597-64; LIGTENBERG MJL, 1991, NUCLEIC ACIDS RES, V19, P297, DOI 10.1093/nar/19.2.297; Marsh DJ, 1996, CLIN ENDOCRINOL, V44, P249, DOI 10.1046/j.1365-2265.1996.681503.x; Michiels FM, 1997, P NATL ACAD SCI USA, V94, P3330, DOI 10.1073/pnas.94.7.3330; MULLIGAN LM, 1993, NATURE, V363, P458, DOI 10.1038/363458a0; MULLIGAN LM, 1994, HUM MOL GENET, V3, P2163, DOI 10.1093/hmg/3.12.2163; Pasini A, 1997, ONCOGENE, V15, P393, DOI 10.1038/sj.onc.1201199; Platten M, 1997, J NEUROPATH EXP NEUR, V56, P806; RAUE F, 1993, CLIN INVESTIGATOR, V71, P7, DOI 10.1007/BF00210956; Rodien P, 1997, HORM RES, V47, P263, DOI 10.1159/000185474; SANTORO M, 1995, SCIENCE, V267, P381, DOI 10.1126/science.7824936; SCHIMKE RN, 1984, ANNU REV MED, V35, P25, DOI 10.1146/annurev.me.35.020184.000325; Smith DP, 1997, ONCOGENE, V15, P1213, DOI 10.1038/sj.onc.1201481; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; StallingsMann ML, 1996, P NATL ACAD SCI USA, V93, P12394, DOI 10.1073/pnas.93.22.12394	31	114	121	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 11	1999	18	6					1369	1373		10.1038/sj.onc.1202418	http://dx.doi.org/10.1038/sj.onc.1202418			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	165FW	10022819				2022-12-25	WOS:000078510900013
J	Micheau, O; Solary, E; Hammann, A; Dimanche-Boitrel, MT				Micheau, O; Solary, E; Hammann, A; Dimanche-Boitrel, MT			Fas ligand-independent, FADD-mediated activation of the Fas death pathway by anticancer drugs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; INDUCED APOPTOSIS; MONOCLONAL-ANTIBODY; CD95 FAS/APO-1; LEUKEMIA-CELLS; EXPRESSION; RECEPTOR; CERAMIDE; CHEMOTHERAPY; INVOLVEMENT	Trimerization of the Fas receptor (CD95, APO-1), a membrane bound protein, triggers cell death by apoptosis. The main death pathway activated by Fas receptor involves the adaptor protein FADD (for Fas-associated death domain) that connects Fas receptor to the caspase cascade. Anticancer drugs have been shown to enhance both Fas receptor and Fas ligand expression on tumor cells. The contribution of Fas ligand-Fas receptor interactions to the cytotoxic activity of these drugs remains controversial. Here, we show that neither the antagonistic anti-Fas antibody ZB4 nor the Fas-IgG molecule inhibit drug-induced apoptosis in three different cell lines. The expression of Fas ligand on the plasma membrane, which is identified in untreated U937 human leukemic cells but remains undetectable in untreated HT29 and HCT116 human colon cancer cell lines, is not modified by exposure to various cytotoxic agents. These drugs induce the clustering of Fas receptor, as observed by confocal laser scanning microscopy, and its interaction with FADD, as demonstrated by co-immunoprecipitation, Overexpression of FADD by stable transfection sensitizes tumor cells to drug-induced cell death and cytotoxicity, whereas down-regulation of FADD by transient transfection of an antisense construct decreases tumor cell sensitivity to drug-induced apoptosis, These results were confirmed by transient transfection of constructs encoding either a FADD dominant negative mutant or MC159 or E8 viral proteins that inhibit the FADD/caspase-8 pathway. These results suggest that drug-induced cell death involves the Fas/FADD pathway in a Fas ligand-independent fashion.	Fac Med & Pharm, U517, Pole Biol & Therapie Canc, JE515,INSERM, F-21033 Dijon, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Bourgogne	Dimanche-Boitrel, MT (corresponding author), Fac Med & Pharm, U517, Pole Biol & Therapie Canc, JE515,INSERM, 7 Blvd Jeanne dArc, F-21033 Dijon, France.	mtboitre@u-bourgogne.fr	micheau, olivier/C-3574-2011; Dimanche-Boitrel, Marie-Therese M/I-4642-2015	micheau, olivier/0000-0001-8499-7984; Solary, Eric/0000-0002-8629-1341; Dimanche-Boitrel, Marie-Therese/0000-0002-8038-7780				Aragane Y, 1998, J CELL BIOL, V140, P171, DOI 10.1083/jcb.140.1.171; BARRY MA, 1990, BIOCHEM PHARMACOL, V40, P2353, DOI 10.1016/0006-2952(90)90733-2; Belka C, 1998, RADIAT RES, V149, P588, DOI 10.2307/3579905; Bertin J, 1997, P NATL ACAD SCI USA, V94, P1172, DOI 10.1073/pnas.94.4.1172; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; BOSE R, 1995, CELL, V82, P405, DOI 10.1016/0092-8674(95)90429-8; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4961; Cock JGRBD, 1998, APOPTOSIS, V3, P17, DOI 10.1023/A:1009603001888; Eischen CM, 1997, BLOOD, V90, P935, DOI 10.1182/blood.V90.3.935.935_935_943; Friesen C, 1996, NAT MED, V2, P574, DOI 10.1038/nm0596-574; Hannun YA, 1997, BLOOD, V89, P1845, DOI 10.1182/blood.V89.6.1845; Herr I, 1997, EMBO J, V16, P6200, DOI 10.1093/emboj/16.20.6200; Hirata H, 1998, J EXP MED, V187, P587, DOI 10.1084/jem.187.4.587; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; McGahon AJ, 1998, BRIT J HAEMATOL, V101, P539, DOI 10.1046/j.1365-2141.1998.00745.x; Memon SA, 1998, J IMMUNOL, V160, P2046; Micheau O, 1997, J NATL CANCER I, V89, P783, DOI 10.1093/jnci/89.11.783; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Newton K, 1998, EMBO J, V17, P706, DOI 10.1093/emboj/17.3.706; Rehemtulla A, 1997, J BIOL CHEM, V272, P25783, DOI 10.1074/jbc.272.41.25783; RENSINGEHL A, 1995, EUR J IMMUNOL, V25, P2253, DOI 10.1002/eji.1830250821; Sillence DJ, 1997, BIOCHEM J, V324, P29, DOI 10.1042/bj3240029; Smith D, 1998, J IMMUNOL, V160, P4159; SUDA T, 1993, CELL, V75, P1169, DOI 10.1016/0092-8674(93)90326-L; TANAKA M, 1995, EMBO J, V14, P1129, DOI 10.1002/j.1460-2075.1995.tb07096.x; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; Villunger A, 1997, CANCER RES, V57, P3331; Yang XL, 1997, CELL, V89, P1067, DOI 10.1016/S0092-8674(00)80294-9; YONEHARA S, 1989, J EXP MED, V169, P1747, DOI 10.1084/jem.169.5.1747; Zhang JK, 1998, NATURE, V392, P296, DOI 10.1038/32681	31	288	302	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	1999	274	12					7987	7992		10.1074/jbc.274.12.7987	http://dx.doi.org/10.1074/jbc.274.12.7987			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	178LU	10075697	hybrid			2022-12-25	WOS:000079268100056
J	Pagano, A; Letourneur, F; Garcia-Estefania, D; Carpentier, JL; Orci, L; Paccaud, JP				Pagano, A; Letourneur, F; Garcia-Estefania, D; Carpentier, JL; Orci, L; Paccaud, JP			Sec24 proteins and sorting at the endoplasmic reticulum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GOLGI INTERMEDIATE COMPARTMENT; TRANSPORT VESICLES; SECRETORY PATHWAY; TRANSMEMBRANE PROTEIN; MEMBRANE-PROTEIN; COATED VESICLES; NEW-GENERATION; COPII; ER; YEAST	COPII proteins are necessary to generate secretory vesicles at the endoplasmic reticulum, In yeast, the Sec24p protein is the only COPII component in which two close orthologues have been identified. By using gene knock-out in yeast, we found that the absence of one of these Sec24 orthologues resulted in a selective secretion defect for a subset of proteins released into the medium. Data base searches revealed the existence of an entire family of Sec24-related proteins in humans, worms, flies, and plants. We identified and cloned two new human cDNAs encoding proteins homologous to yeast Sec24p, in addition to two human cDNAs already present within the data bases. The entire Sec24 family identified to date is characterized by clusters of highly conserved residues within the 2/3 carboxyl-terminal domain of all the proteins and a divergent amino terminus domain. Human (h) Sec24 orthologues co-immunoprecipitate with hSec23Ap and migrate as a complex by size exclusion chromatography. Immunofluorescence microscopy confirmed that these proteins co-localize with hSec23p and hSec13p. Together, our data suggest that in addition to its role in the shaping up of the vesicle, the Sec23-24p complex may be implicated in cargo selection and concentration.	Univ Geneva, Med Ctr, Dept Morphol, CH-1211 Geneva, Switzerland; Univ Geneva, Dept Zool, CH-1211 Geneva, Switzerland; CNRS, Inst Biol & Chem Prot, F-69367 Lyon, France	University of Geneva; University of Geneva; Centre National de la Recherche Scientifique (CNRS)	Paccaud, JP (corresponding author), Univ Geneva, Med Ctr, Dept Morphol, CH-1211 Geneva, Switzerland.			Letourneur, Francois/0000-0003-2232-6127				ALTSCHUL SF, 1990, P NATL ACAD SCI USA, V87, P5509, DOI 10.1073/pnas.87.14.5509; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; APPEL RD, 1994, TRENDS BIOCHEM SCI, V19, P258, DOI 10.1016/0968-0004(94)90153-8; Aridor M, 1998, J CELL BIOL, V141, P61, DOI 10.1083/jcb.141.1.61; Ausubel FM, 1992, CURRENT PROTOCOLS MO; Bairoch A, 1997, NUCLEIC ACIDS RES, V25, P217, DOI 10.1093/nar/25.1.217; BALCH WE, 1994, CELL, V76, P841, DOI 10.1016/0092-8674(94)90359-X; BARLOWE C, 1994, CELL, V77, P895, DOI 10.1016/0092-8674(94)90138-4; BAUDIN A, 1993, NUCLEIC ACIDS RES, V21, P3329, DOI 10.1093/nar/21.14.3329; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Dominguez M, 1998, J CELL BIOL, V140, P751, DOI 10.1083/jcb.140.4.751; ElrodErickson MJ, 1996, MOL BIOL CELL, V7, P1043, DOI 10.1091/mbc.7.7.1043; Fiedler K, 1997, J BIOL CHEM, V272, P24739, DOI 10.1074/jbc.272.40.24739; Fiedler K, 1996, SCIENCE, V273, P1396, DOI 10.1126/science.273.5280.1396; Gaynor EC, 1997, J CELL BIOL, V136, P789, DOI 10.1083/jcb.136.4.789; Gimeno RE, 1996, MOL BIOL CELL, V7, P1815, DOI 10.1091/mbc.7.11.1815; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; Guthrie C, 1991, METHODS ENZYMOL, V194; ITIN C, 1995, BIOCHEM SOC T, V23, P541, DOI 10.1042/bst0230541; James P, 1996, GENETICS, V144, P1425; KAISER CA, 1990, CELL, V61, P723, DOI 10.1016/0092-8674(90)90483-U; Kappeler F, 1997, J BIOL CHEM, V272, P31801, DOI 10.1074/jbc.272.50.31801; Kuehn MJ, 1996, J CELL BIOL, V135, P585, DOI 10.1083/jcb.135.3.585; Kuehn MJ, 1997, CURR OPIN CELL BIOL, V9, P477, DOI 10.1016/S0955-0674(97)80022-1; KUGE O, 1994, J CELL BIOL, V125, P51, DOI 10.1083/jcb.125.1.51; MIZUNO M, 1994, J CELL SCI, V107, P1321; MIZUNO M, 1993, P NATL ACAD SCI USA, V90, P5732, DOI 10.1073/pnas.90.12.5732; Nichols WC, 1998, CELL, V93, P61, DOI 10.1016/S0092-8674(00)81146-0; ORCI L, 1991, P NATL ACAD SCI USA, V88, P8611, DOI 10.1073/pnas.88.19.8611; Paccaud JP, 1996, MOL BIOL CELL, V7, P1535, DOI 10.1091/mbc.7.10.1535; PRYER NK, 1992, ANNU REV BIOCHEM, V61, P471; Rojo M, 1997, J CELL BIOL, V139, P1119, DOI 10.1083/jcb.139.5.1119; ROTHMAN JE, 1992, NATURE, V355, P409, DOI 10.1038/355409a0; SALAMA NR, 1993, EMBO J, V12, P4073, DOI 10.1002/j.1460-2075.1993.tb06091.x; SCHEKMAN R, 1992, Current Opinion in Cell Biology, V4, P587, DOI 10.1016/0955-0674(92)90076-O; Schekman R, 1996, SCIENCE, V271, P1526, DOI 10.1126/science.271.5255.1526; Schekman R, 1995, COLD SPRING HARB SYM, V60, P11, DOI 10.1101/SQB.1995.060.01.004; SCHIMMOLLER F, 1995, EMBO J, V14, P1329, DOI 10.1002/j.1460-2075.1995.tb07119.x; SCHINDLER R, 1993, EUR J CELL BIOL, V61, P1; SHAYWITZ DA, 1995, J CELL BIOL, V128, P769, DOI 10.1083/jcb.128.5.769; Sohn K, 1996, J CELL BIOL, V135, P1239, DOI 10.1083/jcb.135.5.1239; STAMNES MA, 1995, P NATL ACAD SCI USA, V92, P8011, DOI 10.1073/pnas.92.17.8011; Tang BL, 1997, MOL CELL BIOL, V17, P256, DOI 10.1128/MCB.17.1.256; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TRAINOR CD, 1990, NATURE, V343, P92, DOI 10.1038/343092a0; Vollenweider F, 1998, J CELL BIOL, V142, P377, DOI 10.1083/jcb.142.2.377	46	100	107	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 19	1999	274	12					7833	7840		10.1074/jbc.274.12.7833	http://dx.doi.org/10.1074/jbc.274.12.7833			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	178LU	10075675	hybrid			2022-12-25	WOS:000079268100034
J	Saucedo, LJ; Myers, CD; Perry, ME				Saucedo, LJ; Myers, CD; Perry, ME			Multiple murine double minute gene 2 (MDM2) proteins are induced by ultraviolet light	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P53-ASSOCIATED PROTEIN; EMBRYONIC LETHALITY; MDM2-DEFICIENT MICE; BINDING DOMAIN; P53; TRANSLATION; EXPRESSION; CELLS; AMPLIFICATION; TRANSCRIPTS	The mdm2 (murine double minute 2) oncogene encodes several proteins, the largest of which (p90) binds to and inactivates the p53 tumor suppressor protein. Multiple MDM2 proteins have been detected in tumors and in cell lines expressing high levels of mdm2 mRNAs, Here we show that one of these proteins (p76) is expressed, along with p90, in wild-type and p53-null mouse embryo fibroblasts, indicating that it may have an important physiological role in normal cells. Expression of this protein is induced, as is that of p90, by UV light in a p53-dependent manner. The p76 protein is synthesized via translational initiation at AUG codon 50 and thus lacks the N terminus of p90 and does not bind p53, In cells, p90 and p76 can be synthesized from mdm2 mRNAs transcribed from both the P1 (constitutive) and P2 (p53-responsive) promoters. Site-directed mutagenesis reveals that these RNAs give rise to p76 via internal initiation of translation. In addition, mdm2 mRNAs lacking exon 3 give rise to p76 exclusively, and such mRNAs are induced by p53 in response to UV light. These data indicate that p76 may be an important product of the mdm2 gene and a downstream effector of p53.	Univ Wisconsin, Mcardle Lab Canc Res 207A, Sch Med, Cell & Mol Biol Program, Madison, WI 53706 USA; Univ Wisconsin, Mcardle Lab Canc Res, Dept Oncol, Sch Med, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Perry, ME (corresponding author), Univ Wisconsin, Mcardle Lab Canc Res 207A, Sch Med, Cell & Mol Biol Program, 1400 Univ Ave, Madison, WI 53706 USA.	perry@oncology.wisc.edu			NATIONAL CANCER INSTITUTE [P30CA007175, T32CA009135] Funding Source: NIH RePORTER; NCI NIH HHS [CA-09135, CA-70718, CA-07175] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARAK Y, 1994, GENE DEV, V8, P1739, DOI 10.1101/gad.8.15.1739; BODDY MN, 1994, TRENDS BIOCHEM SCI, V19, P198, DOI 10.1016/0968-0004(94)90020-5; Bottger A, 1997, J MOL BIOL, V269, P744, DOI 10.1006/jmbi.1997.1078; CAHILLYSNYDER L, 1987, SOMAT CELL MOLEC GEN, V13, P235, DOI 10.1007/BF01535205; CHEN CY, 1994, P NATL ACAD SCI USA, V91, P2684, DOI 10.1073/pnas.91.7.2684; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; CHU G, 1981, GENE, V13, P197, DOI 10.1016/0378-1119(81)90008-1; DubsPoterszman MC, 1995, ONCOGENE, V11, P2445; FAKHARZADEH SS, 1991, EMBO J, V10, P1565, DOI 10.1002/j.1460-2075.1991.tb07676.x; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; HAINES DS, 1994, MOL CELL BIOL, V14, P1171, DOI 10.1128/MCB.14.2.1171; Harlow E., 1988, ANTIBODIES LAB MANUA; HARVEY DM, 1991, GENE DEV, V5, P2375, DOI 10.1101/gad.5.12b.2375; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Haupt Y, 1996, EMBO J, V15, P1596, DOI 10.1002/j.1460-2075.1996.tb00504.x; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; Kirchmaier AL, 1998, J VIROL, V72, P4657, DOI 10.1128/JVI.72.6.4657-4666.1998; KOZAK M, 1984, NATURE, V308, P241, DOI 10.1038/308241a0; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; LANDERS JE, 1994, ONCOGENE, V9, P2745; Lane DP, 1996, ONCOGENE, V12, P2461; LEACH FS, 1993, CANCER RES, V53, P2231; LUNA RMD, 1995, NATURE, V378, P203; Luna RMDO, 1996, GENOMICS, V33, P352, DOI 10.1006/geno.1996.0210; Lundgren K, 1997, GENE DEV, V11, P714, DOI 10.1101/gad.11.6.714; MARTIN K, 1995, NATURE, V375, P691, DOI 10.1038/375691a0; McMasters KM, 1996, ONCOGENE, V13, P1731; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; OLSON DC, 1993, ONCOGENE, V8, P2353; PAPWORTH C, 1995, STRATEGIES, V9, P3; PERRY ME, 1993, P NATL ACAD SCI USA, V90, P11623, DOI 10.1073/pnas.90.24.11623; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; Saucedo LJ, 1998, CELL GROWTH DIFFER, V9, P119; SHERLEY JL, 1991, J BIOL CHEM, V266, P24815; Sigalas I, 1996, NAT MED, V2, P912, DOI 10.1038/nm0896-912; XIAO ZX, 1995, NATURE, V375, P694, DOI 10.1038/375694a0; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; ZIEGLER A, 1994, NATURE, V372, P773, DOI 10.1038/372773a0	41	34	35	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	1999	274	12					8161	8168		10.1074/jbc.274.12.8161	http://dx.doi.org/10.1074/jbc.274.12.8161			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	178LU	10075719	hybrid			2022-12-25	WOS:000079268100078
J	Chapman, TL; You, I; Joseph, IM; Bjorkmann, PJ; Morrison, SL; Raghavan, M				Chapman, TL; You, I; Joseph, IM; Bjorkmann, PJ; Morrison, SL; Raghavan, M			Characterization of the interaction between the herpes simplex virus type I Fc receptor and immunoglobulin G	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STAPHYLOCOCCAL PROTEIN-A; C-GAMMA-2-C-GAMMA-3 INTERFACE REGION; RHEUMATOID-FACTOR BINDING; GLYCOPROTEIN-I; SUBCLASS SPECIFICITY; CRYSTAL-STRUCTURE; GENETIC CONTENT; INFECTED-CELLS; CHIMERIC IGG; COMPLEX	Herpes simplex virus type I (HSV-1) virions and HSV-1-infected cells bind to human immunoglobulin G (hIgG) via its Fc region. A complex of two surface glycoproteins encoded by HSV-1, gE and gI, is responsible for Fc binding. We have co-expressed soluble truncated forms of gE and gf in Chinese hamster ovary cells. Soluble gE-gI complexes can be purified from transfected cell supernatants using a purification scheme that is based upon the Fc receptor function of gE-gI. Using gel filtration and analytical ultracentrifugation, we determined that soluble gE-gI is a heterodimer composed of one molecule of gE and one molecule of gI and that gE-gI heterodimers bind hIgG with a 1:1 stoichiometry. Biosensor-based studies of the binding of wild type or mutant IgG proteins to soluble gE-gI indicate that histidine 435 at the C(H)2-C(H)3 domain interface of IgG is a critical residue for IgG binding to gE-gI, We observe many similarities between the characteristics of IgG binding by gE-gI and by rheumatoid factors and bacterial Fc receptors such as Staphylococcus aureus protein A. These observations support a model for the origin of some rheumatoid factors, in which they represent anti-idiotypic antibodies directed against antibodies to bacterial and viral Fc receptors.	Univ Michigan, Sch Med, Dept Microbiol & Immunol, Ann Arbor, MI 48109 USA; CALTECH, Howard Hughes Med Inst, Pasadena, CA 91125 USA; CALTECH, Div Biol 15629, Pasadena, CA 91125 USA; Univ Calif Los Angeles, Dept Microbiol Immunol & Mol Genet, Los Angeles, CA 90095 USA	University of Michigan System; University of Michigan; California Institute of Technology; Howard Hughes Medical Institute; California Institute of Technology; University of California System; University of California Los Angeles	Raghavan, M (corresponding author), Univ Michigan, Sch Med, Dept Microbiol & Immunol, Ann Arbor, MI 48109 USA.	malinir@umich.edu						ADLER R, 1978, INFECT IMMUN, V21, P442, DOI 10.1128/IAI.21.2.442-447.1978; ALLEN JC, 1966, ARTHRITIS RHEUM, V9, P758, DOI 10.1002/art.1780090603; ARTANDI SE, 1991, J IMMUNOL, V146, P603; BALAN P, 1994, J GEN VIROL, V75, P1245, DOI 10.1099/0022-1317-75-6-1245; BANKS TA, 1992, CLIN INFECT DIS, V14, P933, DOI 10.1093/clinids/14.4.933; BAUCKE RB, 1979, J VIROL, V32, P779, DOI 10.1128/JVI.32.3.779-789.1979; Bebbington CR, 1987, DNA CLONING PRACTICA, VIII, P163; BELL S, 1990, J VIROL, V64, P2181, DOI 10.1128/JVI.64.5.2181-2186.1990; BONAGURA VR, 1993, J IMMUNOL, V151, P3840; BONAGURA VR, 1992, DNA CELL BIOL, V11, P245, DOI 10.1089/dna.1992.11.245; Brown ZA, 1997, NEW ENGL J MED, V337, P509, DOI 10.1056/NEJM199708213370801; BURMEISTER WP, 1994, NATURE, V372, P379, DOI 10.1038/372379a0; CAMBIER JC, 1992, CURR OPIN IMMUNOL, V4, P257, DOI 10.1016/0952-7915(92)90074-O; COOKE A, 1984, LANCET, V2, P723; Corper AL, 1997, NAT STRUCT BIOL, V4, P374, DOI 10.1038/nsb0597-374; COSTA JC, 1975, LANCET, V1, P77; DEISENHOFER J, 1981, BIOCHEMISTRY-US, V20, P2361, DOI 10.1021/bi00512a001; DINGWELL KS, 1994, J VIROL, V68, P834, DOI 10.1128/JVI.68.2.834-845.1994; DINGWELL KS, 1995, J VIROL, V69, P7087, DOI 10.1128/JVI.69.11.7087-7098.1995; DOWLER KW, 1984, J MED VIROL, V13, P251, DOI 10.1002/jmv.1890130307; DUBIN G, 1991, J VIROL, V65, P7046, DOI 10.1128/JVI.65.12.7046-7050.1991; DUBIN G, 1990, J VIROL, V64, P2725, DOI 10.1128/JVI.64.6.2725-2731.1990; DUBIN G, 1992, CURR TOP MICROBIOL, V179, P111; Favoreel HW, 1997, J VIROL, V71, P8254, DOI 10.1128/JVI.71.11.8254-8261.1997; FRANK I, 1989, J VIROL, V63, P4479, DOI 10.1128/JVI.63.11.4479-4488.1989; GASTINEL LN, 1992, P NATL ACAD SCI USA, V89, P638, DOI 10.1073/pnas.89.2.638; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GOODING LR, 1992, CELL, V71, P5; Harlow E., 1988, ANTIBODIES LABORATOR, P310; Hashido M, 1997, MICROBIOL IMMUNOL, V41, P415, DOI 10.1111/j.1348-0421.1997.tb01872.x; HULETT MD, 1994, ADV IMMUNOL, V57, P1, DOI 10.1016/S0065-2776(08)60671-9; HUMMEL JP, 1962, BIOCHIM BIOPHYS ACTA, V63, P530, DOI 10.1016/0006-3002(62)90124-5; JERNE NK, 1974, ANN INST PASTEUR IMM, VC125, P373; JOHANSSON PJH, 1994, IMMUNOLOGY, V83, P631; JOHANSSON PJH, 1984, J VIROL, V50, P796, DOI 10.1128/JVI.50.3.796-804.1984; JOHANSSON PJH, 1989, IMMUNOLOGY, V66, P8; JOHANSSON PJH, 1985, J VIROL, V56, P489, DOI 10.1128/JVI.56.2.489-494.1985; JOHANSSON PJH, 1990, APMIS, V98, P685, DOI 10.1111/j.1699-0463.1990.tb04989.x; JOHNSON DC, 1987, J VIROL, V61, P2208, DOI 10.1128/JVI.61.7.2208-2216.1987; JOHNSON DC, 1988, J VIROL, V62, P1347, DOI 10.1128/JVI.62.4.1347-1354.1988; Karlsson R, 1997, J IMMUNOL METHODS, V200, P121, DOI 10.1016/S0022-1759(96)00195-0; Kimura H, 1997, VIROLOGY, V233, P382, DOI 10.1006/viro.1997.8625; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KRONVALL G, 1969, J IMMUNOL, V103, P828; Lange H, 1996, EUR J IMMUNOL, V26, P2234, DOI 10.1002/eji.1830260940; LANGONE JJ, 1982, ADV IMMUNOL, V32, P157; LEHNER T, 1975, LANCET, V2, P60; LEISBON PJ, 1997, IMMUNITY, V6, P655; LITWIN V, 1992, J VIROL, V66, P3643, DOI 10.1128/JVI.66.6.3643-3651.1992; LONGNECKER R, 1987, P NATL ACAD SCI USA, V84, P4303, DOI 10.1073/pnas.84.12.4303; MCGEOCH DJ, 1985, J MOL BIOL, V181, P1, DOI 10.1016/0022-2836(85)90320-1; MCGEOCH DJ, 1987, J GEN VIROL, V68, P19, DOI 10.1099/0022-1317-68-1-19; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; METCALF JF, 1988, INTERVIROLOGY, V29, P39, DOI 10.1159/000150027; Nagashunmugam T, 1998, J VIROL, V72, P5351, DOI 10.1128/JVI.72.7.5351-5359.1998; NARDELLA FA, 1985, J EXP MED, V162, P1811, DOI 10.1084/jem.162.6.1811; PARA MF, 1980, J VIROL, V34, P512, DOI 10.1128/JVI.34.2.512-520.1980; PETROVSKIS EA, 1986, J VIROL, V60, P185, DOI 10.1128/JVI.60.1.185-193.1986; Ploegh HL, 1998, SCIENCE, V280, P248, DOI 10.1126/science.280.5361.248; PLOTZ PH, 1983, LANCET, V2, P824; RAGHAVAN M, 1994, IMMUNITY, V1, P303, DOI 10.1016/1074-7613(94)90082-5; Raghavan M, 1996, ANNU REV CELL DEV BI, V12, P181, DOI 10.1146/annurev.cellbio.12.1.181; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SAUERERIKSSON AE, 1995, STRUCTURE, V3, P265, DOI 10.1016/S0969-2126(01)00157-5; STONE GC, 1989, J IMMUNOL, V143, P565; STORY CM, 1994, J EXP MED, V180, P2377, DOI 10.1084/jem.180.6.2377; Sutton BJ, 1998, ADV EXP MED BIOL, V435, P41; Tirabassi RS, 1997, J VIROL, V71, P6455, DOI 10.1128/JVI.71.9.6455-6464.1997; TROWBRIDGE IS, 1993, ANNU REV CELL BIOL, V9, P129, DOI 10.1146/annurev.cb.09.110193.001021; TSUCHIYA N, 1990, J IMMUNOL, V144, P4742; WESTMORELAND D, 1974, J GEN VIROL, V24, P167, DOI 10.1099/0022-1317-24-1-167; WHEALY ME, 1993, J VIROL, V67, P3786, DOI 10.1128/JVI.67.7.3786-3797.1993; WIGER D, 1985, IMMUNOLOGY, V54, P565; Zamyatnin A A, 1972, Prog Biophys Mol Biol, V24, P107, DOI 10.1016/0079-6107(72)90005-3; ZHENG Y, 1992, BIOCHEMISTRY-US, V31, P7446, DOI 10.1021/bi00148a004	75	41	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	1999	274	11					6911	6919		10.1074/jbc.274.11.6911	http://dx.doi.org/10.1074/jbc.274.11.6911			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	175DV	10066744	hybrid, Green Accepted			2022-12-25	WOS:000079078400016
J	Charles, AC; Piros, ET; Evans, CJ; Hales, TG				Charles, AC; Piros, ET; Evans, CJ; Hales, TG			L-type Ca2+ channels and K+ channels specifically modulate the frequency and amplitude of spontaneous Ca2+ oscillations and have distinct roles in prolactin release in GH(3) cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTERIOR-PITUITARY-CELLS; ADRENAL CHROMAFFIN CELLS; INTRACELLULAR CALCIUM; NEUROENDOCRINE CELLS; ELECTRICAL-ACTIVITY; POTASSIUM CURRENT; OPIOID RECEPTORS; GH3 CELLS; RAT; HORMONE	GH(3) cells showed spontaneous rhythmic oscillations in intracellular calcium concentration ([Ca2+](i)) and spontaneous prolactin release. The L-type Ca2+ channel inhibitor nimodipine reduced the frequency of Ca2+ oscillations at lower concentrations (100nm-1 mu M), whereas at higher concentrations (10 mu M), it completely abolished them. Ca2+ oscillations persisted following exposure to thapsigarsn, indicating that inositol 1,4,5-trisphosphate-sensitive intracellular Ca2+ stores were not required for spontaneous activity. The K+ channel inhibitors Ba2+, Cs+, and tetraethylammonium (TEA) had distinct effects on different K+ currents, as well as on Ca2+ oscillations and prolactin release. Cs+ inhibited the inward rectifier K+ current (K-IR) and increased the frequency of Ca2+ oscillations. TEA inhibited outward K+ currents activated at voltages above -40 mV (grouped within the category of Ca2+ and voltage-activated currents, K-Ca,K-V) and increased the amplitude of Ca2+ oscillations. Ba2+ inhibited both K-IR and K-Ca,K-V and increased both the amplitude and the frequency of Ca2+ oscillations. Prolactin release was increased by Ba2+ and Cs+ but not by TEA. These results indicate that L-type Ca2+ channels and K-IR channels modulate the frequency of Ca2+ oscillations and prolactin release, whereas TEA-sensitive K-Ca,K-V channels modulate the amplitude of Ca2+ oscillations without altering prolactin release. Differential regulation of these channels can produce frequency or amplitude modulation of calcium signaling that stimulates specific pituitary cell functions.	Univ Calif Los Angeles, Sch Med, Dept Neurol, Los Angeles, CA 90095 USA; Cornell Univ, Dept Physiol, New York, NY 10021 USA; Univ Calif Los Angeles, Sch Med, Inst Neuropsychiat, Dept Psychiat, Los Angeles, CA 90095 USA; George Washington Univ, Dept Pharmacol, Washington, DC 20037 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Cornell University; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; George Washington University	Charles, AC (corresponding author), Univ Calif Los Angeles, Sch Med, Dept Neurol, 710 Westwood Plaza, Los Angeles, CA 90095 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS002808, R29NS032283] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [P50DA005010] Funding Source: NIH RePORTER; NIDA NIH HHS [DA05010, P50 DA005010] Funding Source: Medline; NINDS NIH HHS [P01-NS 02808, R29 NS32283] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Barros F, 1996, PFLUG ARCH EUR J PHY, V431, P443, DOI 10.1007/BF02207284; BARROS F, 1994, PFLUG ARCH EUR J PHY, V426, P221, DOI 10.1007/BF00374775; BARROS F, 1992, PFLUG ARCH EUR J PHY, V422, P31, DOI 10.1007/BF00381510; BAUER CK, 1994, PFLUG ARCH EUR J PHY, V428, P17, DOI 10.1007/BF00374747; Berridge MJ, 1997, NATURE, V386, P759, DOI 10.1038/386759a0; CHARLES AC, 1991, NEURON, V6, P983, DOI 10.1016/0896-6273(91)90238-U; Chow RH, 1996, NEURON, V16, P369, DOI 10.1016/S0896-6273(00)80054-9; De Koninck P, 1998, SCIENCE, V279, P227, DOI 10.1126/science.279.5348.227; Dolmetsch RE, 1997, NATURE, V386, P855, DOI 10.1038/386855a0; DUBINSKY JM, 1985, P NATL ACAD SCI USA, V82, P4282, DOI 10.1073/pnas.82.12.4282; Engisch KL, 1997, J NEUROSCI, V17, P9010; Giovannucci DR, 1997, J PHYSIOL-LONDON, V498, P735, DOI 10.1113/jphysiol.1997.sp021898; GOLLASCH M, 1991, P NATL ACAD SCI USA, V88, P10262, DOI 10.1073/pnas.88.22.10262; HEINEMANN C, 1993, PFLUG ARCH EUR J PHY, V424, P105, DOI 10.1007/BF00374600; HORRIGAN FT, 1994, NEURON, V13, P1119, DOI 10.1016/0896-6273(94)90050-7; KUKULJAN M, 1994, J BIOL CHEM, V269, P4860; Kukuljan M, 1997, BIOPHYS J, V72, P698, DOI 10.1016/S0006-3495(97)78706-X; LI YX, 1995, BIOPHYS J, V69, P785, DOI 10.1016/S0006-3495(95)79952-0; LI YX, 1995, AM J PHYSIOL-CELL PH, V269, pC1079, DOI 10.1152/ajpcell.1995.269.5.C1079; MALGAROLI A, 1991, FEBS LETT, V283, P169, DOI 10.1016/0014-5793(91)80580-V; Mansvelder HD, 1998, J NEUROSCI, V18, P81; MARUYAMA Y, 1993, EMBO J, V12, P3017, DOI 10.1002/j.1460-2075.1993.tb05970.x; MASUMOTO N, 1995, CELL CALCIUM, V18, P223, DOI 10.1016/0143-4160(95)90067-5; MATTESON DR, 1986, J GEN PHYSIOL, V87, P161, DOI 10.1085/jgp.87.1.161; MIKI H, 1995, ENDOCRINOLOGY, V136, P2954, DOI 10.1210/en.136.7.2954; NELSON EJ, 1994, ENDOCRINOLOGY, V135, P1084, DOI 10.1210/en.135.3.1084; OXFORD GS, 1989, J PHYSIOL-LONDON, V410, P587, DOI 10.1113/jphysiol.1989.sp017550; Piros ET, 1996, MOL PHARMACOL, V50, P947; PIROS ET, 1995, MOL PHARMACOL, V47, P1041; RITCHIE AK, 1987, J PHYSIOL-LONDON, V385, P611, DOI 10.1113/jphysiol.1987.sp016510; ROGAWSKI MA, 1989, MOL PHARMACOL, V35, P458; SCHERUBL H, 1994, ANN NY ACAD SCI, V733, P335, DOI 10.1111/j.1749-6632.1994.tb17283.x; SCHLEGEL W, 1987, NATURE, V329, P719, DOI 10.1038/329719a0; SHANGOLD GA, 1985, LIFE SCI, V36, P2209, DOI 10.1016/0024-3205(85)90331-5; SIMASKO SM, 1991, AM J PHYSIOL, V261, pE66, DOI 10.1152/ajpendo.1991.261.1.E66; SIMASKO SM, 1988, AM J PHYSIOL, V254, pE328, DOI 10.1152/ajpendo.1988.254.3.E328; STOJILKOVIC SS, 1994, MOL PHARMACOL, V45, P1013; Thomas P, 1997, J PHYSIOL-LONDON, V504, P705, DOI 10.1111/j.1469-7793.1997.705bd.x; TSE A, 1993, SCIENCE, V260, P82, DOI 10.1126/science.8385366; TSE A, 1994, J PHYSIOL-LONDON, V477, P511, DOI 10.1113/jphysiol.1994.sp020212; TSE FW, 1994, P NATL ACAD SCI USA, V91, P9750, DOI 10.1073/pnas.91.21.9750; Tse FW, 1997, NEURON, V18, P121, DOI 10.1016/S0896-6273(01)80051-9; VARNEY MA, 1994, BRIT J PHARMACOL, V112, P390, DOI 10.1111/j.1476-5381.1994.tb13084.x; Varro A, 1996, BBA-MOL CELL RES, V1313, P101, DOI 10.1016/0167-4889(96)00056-0; WAGNER KA, 1993, BIOCHEM J, V292, P175, DOI 10.1042/bj2920175	45	51	51	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 12	1999	274	11					7508	7515		10.1074/jbc.274.11.7508	http://dx.doi.org/10.1074/jbc.274.11.7508			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	175DV	10066818	hybrid			2022-12-25	WOS:000079078400090
J	Webb, DJ; Nguyen, DHD; Sankovic, M; Gonias, SL				Webb, DJ; Nguyen, DHD; Sankovic, M; Gonias, SL			The very low density lipoprotein receptor regulates urokinase receptor catabolism and breast cancer cell motility in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; PSEUDOMONAS EXOTOXIN-A; PLASMINOGEN-ACTIVATOR; ALPHA-2-MACROGLOBULIN RECEPTOR; MEDIATES ENDOCYTOSIS; PROTEIN BINDS; INHIBITOR COMPLEX; EPITHELIAL-CELLS; SERPIN COMPLEXES; 39-KDA PROTEIN	The very low density lipoprotein receptor (VLDLr) binds diverse ligands, including urokinase-type plasminogen activator (uPA) and uPA-plasminogen activator inhibitor-1 (PAI-1) complex. In this study, we characterized the effects of the VLDLr on the internalization, catabolism, and function of the uPA receptor (uPAR) in MCF-7 and MDA-MB-435 breast cancer cells. When challenged with uPA . PAI-1 complex, MDA-MB-435 cells internalized uPAR; this process was inhibited by 80% when the activity of the VLDLr was neutralized with receptor-associated protein (RAP), To determine whether internalized uPAR is degraded, we studied the catabolism of [S-35]methionine-labeled uPAR. In the absence of exogenous agents, the uPAR catabolism t(1/2) was 8.2 h. uPA . PAI-1 complex accelerated uPAR catabolism (t(1/2) to 1.8 h), while RAP inhibited uPAR catabolism in the presence (t(1/2) of 7.8 h) and absence (t(1/2) of 16.9 h) of uPA . PAI-1 complex, demonstrating a critical role for the VLDLr, When MCF-7 cells were cultured in RAP, cell surface uPAR levels increased gradually, reaching a new steady-state in 3 days, The amount of uPA which accumulated in the medium also increased. Culturing in RAP for 3 days increased MCF-7 cell motility by 2.2 +/- 0.1-fold and by 4.4 +/- 0.3-fold when 1.0 nm uPA was added. The effects of RAP on MCF-7 cell motility were entirely abrogated by an antibody which binds uPA and prevents uPA binding to uPAR. MCF-7 cells that were cultured in RAP demonstrated increased levels of activated mitogen-activated protein kinases, Furthermore, the MEK inhibitor, PD098059, decreased the motility of RAP-treated cells without affecting control cultures. These studies suggest a model in which the VLDLr regulates autocrine uPAR-initiated signaling and thereby regulates cellular motility.	Univ Virginia, Hlth Sci Ctr, Dept Pathol, Charlottesville, VA 22908 USA; Univ Virginia, Hlth Sci Ctr, Dept Biochem & Mol Genet, Charlottesville, VA 22908 USA	University of Virginia; University of Virginia	Gonias, SL (corresponding author), Univ Virginia, Hlth Sci Ctr, Dept Pathol, Box 214, Charlottesville, VA 22908 USA.	SLG2T@VIRGINIA.EDU			NATIONAL CANCER INSTITUTE [R01CA053462] Funding Source: NIH RePORTER; NCI NIH HHS [CA-53462] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Andreasen PA, 1997, INT J CANCER, V72, P1, DOI 10.1002/(SICI)1097-0215(19970703)72:1<1::AID-IJC1>3.0.CO;2-Z; APPELLA E, 1987, J BIOL CHEM, V262, P4437; ARGRAVES KM, 1995, J BIOL CHEM, V270, P26550, DOI 10.1074/jbc.270.44.26550; BATTEY FD, 1994, J BIOL CHEM, V269, P23268; BU GJ, 1995, EMBO J, V14, P2269, DOI 10.1002/j.1460-2075.1995.tb07221.x; BUSSO N, 1994, J CELL BIOL, V126, P259, DOI 10.1083/jcb.126.1.259; CHUCHOLOWSKI N, 1992, FIBRINOLYSIS, V6, P95; CONESE M, 1995, BAILLIERE CLIN HAEM, V8, P365, DOI 10.1016/S0950-3536(05)80273-2; CONESE M, 1995, J CELL BIOL, V131, P1609, DOI 10.1083/jcb.131.6.1609; CUBELLIS MV, 1990, EMBO J, V9, P1079, DOI 10.1002/j.1460-2075.1990.tb08213.x; ESTREICHER A, 1989, J BIOL CHEM, V264, P1180; Fichtner I, 1997, ANTICANCER RES, V17, P3633; FRYKMAN PK, 1995, P NATL ACAD SCI USA, V92, P8453, DOI 10.1073/pnas.92.18.8453; HAYMAN EG, 1983, P NATL ACAD SCI-BIOL, V80, P4003, DOI 10.1073/pnas.80.13.4003; HEEGAARD CW, 1995, J BIOL CHEM, V270, P20855, DOI 10.1074/jbc.270.35.20855; HERZ J, 1992, CELL, V71, P411, DOI 10.1016/0092-8674(92)90511-A; HERZ J, 1991, J BIOL CHEM, V266, P21232; Higazi AAR, 1996, BLOOD, V88, P542, DOI 10.1182/blood.V88.2.542.bloodjournal882542; HolstHansen C, 1996, CLIN EXP METASTAS, V14, P297; JENSEN PH, 1990, CELL REGUL, V1, P1043, DOI 10.1091/mbc.1.13.1043; Konakova M, 1998, EUR J BIOCHEM, V253, P421, DOI 10.1046/j.1432-1327.1998.2530421.x; KOUNNAS MZ, 1992, J BIOL CHEM, V267, P21162; KOUNNAS MZ, 1992, J BIOL CHEM, V267, P12420; KRIEGER M, 1994, ANNU REV BIOCHEM, V63, P601, DOI 10.1146/annurev.bi.63.070194.003125; Martensen PM, 1997, EUR J BIOCHEM, V248, P583, DOI 10.1111/j.1432-1033.1997.00583.x; Mikhailenko I, 1997, J BIOL CHEM, V272, P6784, DOI 10.1074/jbc.272.10.6784; MOESTRUP SK, 1993, J BIOL CHEM, V268, P16564; Nguyen DHD, 1998, J BIOL CHEM, V273, P8502, DOI 10.1074/jbc.273.14.8502; Nykjaer A, 1997, EMBO J, V16, P2610, DOI 10.1093/emboj/16.10.2610; Nykjaer A, 1998, J CELL BIOL, V141, P815, DOI 10.1083/jcb.141.3.815; NYKJAER A, 1994, J BIOL CHEM, V269, P25668; NYKJAER A, 1992, J BIOL CHEM, V267, P14543; Okada SS, 1996, ARTERIOSCL THROM VAS, V16, P1269, DOI 10.1161/01.ATV.16.10.1269; Resnati M, 1996, EMBO J, V15, P1572, DOI 10.1002/j.1460-2075.1996.tb00502.x; Silvy M, 1998, ENDOCRINOLOGY, V139, P2382, DOI 10.1210/en.139.5.2382; SIMONSEN ACW, 1994, FEBS LETT, V354, P279, DOI 10.1016/0014-5793(94)01138-9; STEFANSSON S, 1995, J CELL SCI, V108, P2361; STRICKLAND DK, 1995, FASEB J, V9, P890, DOI 10.1096/fasebj.9.10.7615159; STRICKLAND DK, 1990, J BIOL CHEM, V265, P17401; TAKAHASHI S, 1995, J BIOL CHEM, V270, P15747, DOI 10.1074/jbc.270.26.15747; TELEN MJ, 1984, BLOOD, V64, P599; Tolsma SS, 1997, MICROVASC RES, V54, P13, DOI 10.1006/mvre.1997.2015; VASSALLI JD, 1987, FEBS LETT, V214, P187, DOI 10.1016/0014-5793(87)80039-X; VASSILIOU G, 1994, J BIOL CHEM, V269, P15172; WARSHAWSKY I, 1993, J BIOL CHEM, V268, P22046; Weaver AM, 1997, J LIPID RES, V38, P1841; Weaver AM, 1997, J BIOL CHEM, V272, P14372, DOI 10.1074/jbc.272.22.14372; Webb DJ, 1995, EUR J BIOCHEM, V234, P714, DOI 10.1111/j.1432-1033.1995.714_a.x; Wijnberg MJ, 1997, THROMB HAEMOSTASIS, V78, P880; WILLIAMS SE, 1992, J BIOL CHEM, V267, P9035; Willnow TE, 1996, EMBO J, V15, P2632, DOI 10.1002/j.1460-2075.1996.tb00623.x; Willnow TE, 1996, P NATL ACAD SCI USA, V93, P8460, DOI 10.1073/pnas.93.16.8460; WILLNOW TE, 1994, J CELL SCI, V107, P719; WILLNOW TE, 1992, J BIOL CHEM, V267, P26172; YATOHGO T, 1988, CELL STRUCT FUNCT, V13, P281, DOI 10.1247/csf1975.13.281	55	98	101	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	1999	274	11					7412	7420		10.1074/jbc.274.11.7412	http://dx.doi.org/10.1074/jbc.274.11.7412			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	175DV	10066806	hybrid			2022-12-25	WOS:000079078400078
J	Edwards, AS; Faux, MC; Scott, JD; Newton, AC				Edwards, AS; Faux, MC; Scott, JD; Newton, AC			Carboxyl-terminal phosphorylation regulates the function and subcellular localization of protein kinase C beta II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATALYTIC SUBUNIT; CRYSTAL-STRUCTURE; PHORBOL ESTERS; IN-VIVO; PERMISSIVE ACTIVATION; NEGATIVE CHARGE; ALPHA; AUTOPHOSPHORYLATION; INACTIVATION; BINDING	Protein kinase C is processed by three phosphorylation events before it is competent to respond to second messengers. Specifically, the enzyme is first phosphorylated at the activation loop by another kinase, followed by two ordered autophosphorylations at the carboxyl terminus (Keranen, L, M,, Dutil, E, M,, and Newton, A. C, (1995) Curr, Biol, 5, 1394-1403). This study examines the role of negative charge at the first conserved carboxyl-terminal phosphorylation position, Thr-641, in regulating the function and subcellular localization of protein kinase C beta II Mutation of this residue to Ala results in compensating phosphorylations at adjacent sites, so that a triple Ala mutant was required to address the function of phosphate at Thr-641, Biochemical and immunolocalization analyses of phosphorylation site mutants reveal that negative charge at this position is required for the following: 1) to process catalytically competent protein kinase C; 2) to allow autophosphorylation of Ser-660; 3) for cytosolic localization of protein kinase C; and 4) to permit phorbol ester-dependent membrane translocation. Thus, phosphorylation of Thr-641 in protein kinase C beta II is essential for both the catalytic function and correct subcellular localization of protein kinase C, The conservation of this residue in every protein kinase C isozyme, as well as other members of the kinase superfamily such as protein kinase A, suggests that carboxyl-terminal phosphorylation serves as a key molecular switch for defining kinase function.	Univ Calif San Diego, Dept Chem & Biochem, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA; Oregon Hlth Sci Univ, Vollum Inst, Howard Hughes Med Inst, Portland, OR 97201 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; Howard Hughes Medical Institute; Oregon Health & Science University	Newton, AC (corresponding author), Univ Calif San Diego, Dept Chem & Biochem, La Jolla, CA 92093 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043154, R01GM048231, R37GM043154, R37GM048231] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 43154, GM 48231] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Bornancin F, 1996, CURR BIOL, V6, P1114, DOI 10.1016/S0960-9822(02)70678-7; Bornancin F, 1997, J BIOL CHEM, V272, P3544, DOI 10.1074/jbc.272.6.3544; BORNER C, 1989, J BIOL CHEM, V264, P13902; CAZAUBON S, 1994, BIOCHEM J, V301, P443, DOI 10.1042/bj3010443; CAZAUBON SM, 1993, J BIOL CHEM, V268, P17559; CHAKRAVARTHY BR, 1991, ANAL BIOCHEM, V196, P144, DOI 10.1016/0003-2697(91)90130-L; Chou MM, 1998, CURR BIOL, V8, P1069, DOI 10.1016/S0960-9822(98)70444-0; DANG CV, 1983, J CELL BIOL, V96, P1138, DOI 10.1083/jcb.96.4.1138; DUTIL EM, 1994, J BIOL CHEM, V269, P29359; Dutil EM, 1998, CURR BIOL, V8, P1366, DOI 10.1016/S0960-9822(98)00017-7; Edwards AS, 1997, J BIOL CHEM, V272, P18382, DOI 10.1074/jbc.272.29.18382; FLINT AJ, 1990, SCIENCE, V249, P408, DOI 10.1126/science.2377895; Hansra G, 1996, J BIOL CHEM, V271, P32785, DOI 10.1074/jbc.271.51.32785; Johnson LN, 1996, CELL, V85, P149, DOI 10.1016/S0092-8674(00)81092-2; Keranen LM, 1995, CURR BIOL, V5, P1394, DOI 10.1016/S0960-9822(95)00277-6; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KOZMA SC, 1990, P NATL ACAD SCI USA, V87, P7564; KRAFT AS, 1982, J BIOL CHEM, V257, P13193; KRAFT AS, 1983, NATURE, V301, P621, DOI 10.1038/301621a0; Le Good JA, 1998, SCIENCE, V281, P2042, DOI 10.1126/science.281.5385.2042; Moser BA, 1997, MOL CELL BIOL, V17, P5648, DOI 10.1128/MCB.17.9.5648; Mosior M, 1996, BIOCHEMISTRY-US, V35, P1612, DOI 10.1021/bi952031q; Newton AC, 1997, CURR OPIN CELL BIOL, V9, P161, DOI 10.1016/S0955-0674(97)80058-0; NEWTON AC, 1987, J BIOL CHEM, V262, P10185; Nishikawa K, 1997, J BIOL CHEM, V272, P952, DOI 10.1074/jbc.272.2.952; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; ONO Y, 1986, FEBS LETT, V206, P347, DOI 10.1016/0014-5793(86)81010-9; ORR JW, 1994, J BIOL CHEM, V269, P27715; ORR JW, 1994, J BIOL CHEM, V269, P8383; ORR JW, 1992, J BIOL CHEM, V267, P15263; ORR JW, 1992, BIOCHEMISTRY-US, V31, P4661, DOI 10.1021/bi00134a018; PARKER PJ, 1986, SCIENCE, V233, P853, DOI 10.1126/science.3755547; PEARSON RB, 1995, EMBO J, V14, P5279, DOI 10.1002/j.1460-2075.1995.tb00212.x; Pullen N, 1998, SCIENCE, V279, P707, DOI 10.1126/science.279.5351.707; Stephens L, 1998, SCIENCE, V279, P710, DOI 10.1126/science.279.5351.710; TAYLOR SS, 1994, STRUCTURE, V2, P345, DOI 10.1016/S0969-2126(00)00036-8; THORSNESS PE, 1987, J BIOL CHEM, V262, P10422; TSUTAKAWA SE, 1995, J BIOL CHEM, V270, P26807, DOI 10.1074/jbc.270.45.26807; UHLER MD, 1986, P NATL ACAD SCI USA, V83, P1300, DOI 10.1073/pnas.83.5.1300; WOLF M, 1985, NATURE, V317, P546, DOI 10.1038/317546a0; Yonemoto W, 1997, PROTEIN ENG, V10, P915, DOI 10.1093/protein/10.8.915; ZHANG GG, 1995, CELL, V81, P917, DOI 10.1016/0092-8674(95)90011-X; ZHANG J, 1994, J BIOL CHEM, V269, P19578; ZHENG JH, 1993, BIOCHEMISTRY-US, V32, P2154, DOI 10.1021/bi00060a005	46	105	108	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1999	274	10					6461	6468		10.1074/jbc.274.10.6461	http://dx.doi.org/10.1074/jbc.274.10.6461			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172BQ	10037738	hybrid			2022-12-25	WOS:000078902800060
J	Ghafourifar, P; Klein, SD; Schucht, O; Schenk, U; Pruschy, M; Rocha, S; Richter, C				Ghafourifar, P; Klein, SD; Schucht, O; Schenk, U; Pruschy, M; Rocha, S; Richter, C			Ceramide induces cytochrome c release from isolated mitochondria - Importance of mitochondrial redox state	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER MITOCHONDRIA; CELL-PERMEABLE CERAMIDE; INDUCED APOPTOSIS; TNF-ALPHA; KAPPA-B; MECHANISM; DEATH; REQUIREMENT; GENERATION; INHIBITION	In the present study we show that N-acetylsphingosine (C-2-ceramide), N-hexanoylsphingosine (C-6-ceramide), and, to a much lesser extent, C-2-dihydroceramide induce cytochrome c (cyto c) release from isolated rat liver mitochondria. Ceramide-induced cyto c release is prevented by preincubation of mitochondria with a low concentration (40 nM) of Bcl-2. The release takes place when cyto c is oxidized but not when it is reduced. Upon cyto c loss, mitochondrial oxygen consumption, mitochondrial transmembrane potential (Delta Psi), and Ca2+ retention are diminished. Incubation with Bcl-2 prevents, and addition of cyto c reverses the alteration of these mitochondrial functions. In ATP-energized mitochondria, ceramides do not alter Delta Psi, neither when cyto c is oxidized nor when it is reduced, ruling out a nonspecific disturbance by ceramides of mitochondrial membrane integrity. Furthermore, ceramides decrease the reducibility of cyto c. We conclude that the apoptogenic properties of ceramides are in part mediated via their interaction with mitochondrial cyto c followed by its release and that the redox state of cyto c influences its detachment by ceramide from the inner mitochondrial membrane.	Swiss Fed Inst Technol, Biochem Lab 1, CH-8092 Zurich, Switzerland; Univ Zurich Hosp, Dept Radiat Oncol, CH-8092 Zurich, Switzerland	Swiss Federal Institutes of Technology Domain; ETH Zurich; University of Zurich; University Zurich Hospital	Richter, C (corresponding author), Swiss Fed Inst Technol, Biochem Lab 1, Univ Str 16, CH-8092 Zurich, Switzerland.	richter@bc.biol.ethz.ch	Klein, Sabine D./T-2854-2019	Klein, Sabine D./0000-0001-6843-1454; Pruschy, Martin/0000-0002-3124-9015; Rocha, Sonia/0000-0002-2413-4981				Amarante-Mendes GP, 1998, BLOOD, V91, P1700, DOI 10.1182/blood.V91.5.1700.1700_1700_1705; Arora AS, 1997, HEPATOLOGY, V25, P958, DOI 10.1002/hep.510250428; Bezombes C, 1998, FASEB J, V12, P101, DOI 10.1096/fasebj.12.1.101; BOSE R, 1995, CELL, V82, P405, DOI 10.1016/0092-8674(95)90429-8; Cai JY, 1998, J BIOL CHEM, V273, P11401, DOI 10.1074/jbc.273.19.11401; Dbaibo GS, 1997, J EXP MED, V185, P481, DOI 10.1084/jem.185.3.481; DeMaria R, 1997, SCIENCE, V277, P1652, DOI 10.1126/science.277.5332.1652; DUTTON PL, 1975, BIOCHIM BIOPHYS ACTA, V387, P536, DOI 10.1016/0005-2728(75)90092-4; FranceLanord V, 1997, J NEUROCHEM, V69, P1612; FREI B, 1985, J BIOL CHEM, V260, P7394; GarciaRuiz C, 1997, J BIOL CHEM, V272, P11369; Gudz TI, 1997, J BIOL CHEM, V272, P24154, DOI 10.1074/jbc.272.39.24154; Hampton MB, 1998, BIOCHEM J, V329, P95; HANNUN YA, 1994, J BIOL CHEM, V269, P3125; HENNET T, 1993, CANCER RES, V53, P1456; HERMANN S, 1995, SCIENCE, V267, P1445; Higuchi M, 1996, J IMMUNOL, V157, P297; Hirsch T, 1997, BIOSCIENCE REP, V17, P67, DOI 10.1023/A:1027339418683; Inai Y, 1997, CELL STRUCT FUNCT, V22, P555, DOI 10.1247/csf.22.555; Kharbanda S, 1997, P NATL ACAD SCI USA, V94, P6939, DOI 10.1073/pnas.94.13.6939; Kitajima I, 1996, BONE, V19, P263, DOI 10.1016/8756-3282(96)00181-0; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Kruman I, 1998, J NEUROSCI RES, V51, P293, DOI 10.1002/(SICI)1097-4547(19980201)51:3<293::AID-JNR3>3.0.CO;2-B; Kuroki J, 1996, LEUKEMIA, V10, P1950; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; LITHGOW T, 1994, CELL GROWTH DIFFER, V5, P411; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; LOTSCHER HR, 1980, J BIOL CHEM, V255, P9325; Macho A, 1997, J IMMUNOL, V158, P4612; Mancini M, 1998, J CELL BIOL, V140, P1485, DOI 10.1083/jcb.140.6.1485; Mignotte B, 1998, EUR J BIOCHEM, V252, P1, DOI 10.1046/j.1432-1327.1998.2520001.x; QuilletMary A, 1997, J BIOL CHEM, V272, P21388, DOI 10.1074/jbc.272.34.21388; Rosse T, 1998, NATURE, V391, P496, DOI 10.1038/35160; Schweizer M, 1996, BIOCHEMISTRY-US, V35, P4524, DOI 10.1021/bi952708+; Shidoji Y, 1997, BIOCHEM BIOPH RES CO, V230, P58, DOI 10.1006/bbrc.1996.5883; Subramanian M, 1998, BIOCHEMISTRY-US, V37, P1394, DOI 10.1021/bi9716581; Tang DG, 1998, BIOCHEM BIOPH RES CO, V242, P380, DOI 10.1006/bbrc.1997.7969; Tepper AD, 1997, J BIOL CHEM, V272, P24308, DOI 10.1074/jbc.272.39.24308; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Wadia JS, 1998, J NEUROSCI, V18, P932; Yang JC, 1998, FREE RADICAL BIO MED, V24, P624, DOI 10.1016/S0891-5849(97)00367-5; Zhang P, 1997, J BIOL CHEM, V272, P30615, DOI 10.1074/jbc.272.49.30615; Zhivotovsky B, 1998, NATURE, V391, P449, DOI 10.1038/35060	43	224	232	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	1999	274	10					6080	6084		10.1074/jbc.274.10.6080	http://dx.doi.org/10.1074/jbc.274.10.6080			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172BQ	10037689	hybrid			2022-12-25	WOS:000078902800011
J	Kallio, PJ; Wilson, WJ; O'Brien, S; Makino, Y; Poellinger, L				Kallio, PJ; Wilson, WJ; O'Brien, S; Makino, Y; Poellinger, L			Regulation of the hypoxia-inducible transcription factor 1 alpha by the ubiquitin-proteasome pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRACELLULAR PROTEIN-DEGRADATION; FACTOR-I; ERYTHROPOIETIN GENE; ALPHA-SUBUNIT; C-JUN; ACTIVATION; DOMAIN; STABILIZATION; LACTACYSTIN; RECRUITMENT	HIF-1 alpha (hypoxia-inducible factor 1 alpha) is a basic-helix-loop-helix PAS (Per/Arnt/Sim) transcription factor that, under hypoxic conditions, dimerizes with a partner factor, the basic-helix-loop-helix/PAS protein Arnt, to recognize hypoxia-responsive elements of target genes. It has recently been demonstrated that HLF-1 alpha protein but not mRNA levels are dramatically up-regulated in response to hypoxia, Here we show that inhibitors of 26 S proteasome activity produced a dramatic accumulation of endogenous as well as transfected HIF-1 alpha protein under normoxic conditions, whereas the levels of Amt protein were not affected. HIF-1 alpha was polyubiquitinated in vivo under normoxic conditions, indicating rapid degradation via the ubiquitin-proteasome pathway. This degradation process appeared to target a region within the C terminus of HIF-1 alpha. Importantly, HIF-1 alpha ubiquitination was drastically decreased under hypoxic conditions. Up-regulation of HIF-1 alpha protein by proteasome inhibitors did not result in transcriptional activation of reporter genes, indicating either the requirement of additional regulatory steps to induce functional activity of HIF-1 alpha: or the inability of polyubiquitinated forms of HIF-1 alpha to mediate hypoxic signal transduction, In support of both these notions, we demonstrate that HIF-1 alpha showed hypoxia-dependent translocation from the cytoplasm to the nucleus and that this regulatory mechanism was severely impaired in the presence of proteasome inhibitors. Taken together, these data demonstrate that the mechanism of hypoda-dependent activation of HIF-1 alpha is a complex multistep process and that stabilization of HIF-1 alpha protein levels is not sufficient to generate a functional form.	Karolinska Inst, Med Nobel Inst, Dept Cell & Mol Biol, S-17177 Stockholm, Sweden	Karolinska Institutet	Poellinger, L (corresponding author), Karolinska Inst, Med Nobel Inst, Dept Cell & Mol Biol, S-17177 Stockholm, Sweden.		Wilson, William/A-3631-2009	Wilson, William/0000-0001-5658-0997				CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; Craiu A, 1997, J BIOL CHEM, V272, P13437, DOI 10.1074/jbc.272.20.13437; Ema M, 1997, P NATL ACAD SCI USA, V94, P4273, DOI 10.1073/pnas.94.9.4273; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; Flamme I, 1997, MECH DEVELOP, V63, P51, DOI 10.1016/S0925-4773(97)00674-6; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; GOLDBERG MA, 1988, SCIENCE, V242, P1412, DOI 10.1126/science.2849206; GOTTESMAN S, 1992, MICROBIOL REV, V56, P592, DOI 10.1128/MMBR.56.4.592-621.1992; Gradin K, 1996, MOL CELL BIOL, V16, P5221; HOCHSTRASSER M, 1995, CURR OPIN CELL BIOL, V7, P215, DOI 10.1016/0955-0674(95)80031-X; Hochstrasser Mark, 1992, Current Opinion in Cell Biology, V4, P1024, DOI 10.1016/0955-0674(92)90135-Y; Huang LE, 1996, J BIOL CHEM, V271, P32253, DOI 10.1074/jbc.271.50.32253; Huang LE, 1998, P NATL ACAD SCI USA, V95, P7987, DOI 10.1073/pnas.95.14.7987; Jiang BH, 1997, J BIOL CHEM, V272, P19253, DOI 10.1074/jbc.272.31.19253; Jiang BH, 1996, AM J PHYSIOL-CELL PH, V271, pC1172, DOI 10.1152/ajpcell.1996.271.4.C1172; Kallio PJ, 1997, P NATL ACAD SCI USA, V94, P5667, DOI 10.1073/pnas.94.11.5667; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; MURAKAMI Y, 1992, NATURE, V360, P587; Musti AM, 1997, SCIENCE, V275, P400, DOI 10.1126/science.275.5298.400; Pugh CW, 1997, J BIOL CHEM, V272, P11205; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; Salceda S, 1997, J BIOL CHEM, V272, P22642, DOI 10.1074/jbc.272.36.22642; SEMENZA GL, 1992, MOL CELL BIOL, V12, P5447, DOI 10.1128/MCB.12.12.5447; Tian H, 1997, GENE DEV, V11, P72, DOI 10.1101/gad.11.1.72; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; WANG GL, 1993, J BIOL CHEM, V268, P21513; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Wenger RH, 1997, BIOL CHEM, V378, P609	28	658	697	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1999	274	10					6519	6525		10.1074/jbc.274.10.6519	http://dx.doi.org/10.1074/jbc.274.10.6519			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172BQ	10037745	hybrid			2022-12-25	WOS:000078902800067
J	Kendall, RL; Rutledge, RZ; Mao, X; Tebben, AJ; Hungate, RW; Thomas, KA				Kendall, RL; Rutledge, RZ; Mao, X; Tebben, AJ; Hungate, RW; Thomas, KA			Vascular endothelial growth factor receptor KDR tyrosine kinase activity is increased by autophosphorylation of two activation loop tyrosine residues	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSULIN-RECEPTOR; KINETIC MECHANISM; SIGNAL-TRANSDUCTION; DOMAIN; PHOSPHORYLATION; ANGIOGENESIS; INHIBITION; EXPRESSION; BINDING; IDENTIFICATION	Vascular endothelial growth factor is an important physiological regulator of angiogenesis, The function of this endothelial cell selective growth factor is mediated by two homologous tyrosine kinase receptors, fms-like tyrosine kinase 1 (Flt-1) and kinase domain receptor (KDR). Although the functional consequence of vascular endothelial growth factor binding to the Flt-1 receptor is not fully understood, it is well established that mitogenic signaling is mediated by KDR, Upon sequencing several independent cDNA clones spanning the cytoplasmic region of human KDR, we identified and confirmed the identity of a functionally required valine at position 848 in the ATP binding site, rather than the previously reported glutamic acid residue, which corresponds to an inactive tyrosine kinase, The cytoplasmic domain of recombinant native KDR, expressed as a glutathione S-transferase fusion protein, can undergo autophosphorylation in the presence of ATP. In addition, the kinase activity can be substantially increased by autophosphorylation at physiologic ATP concentrations. Mutation analysis indicates that both tyrosine residues 1054 and 1059 are required for activation, which is a consequence of an increased affinity for both ATP and the peptide substrate and has no effect on k(cat), the intrinsic catalytic activity of the enzyme. KDR kinase catalyzes phosphotransfer by formation of a ternary complex with ATP and the peptide substrate. We demonstrate that tyrosine kinase antagonists can preferentially inhibit either the unactivated or activated form of the enzyme.	Merck Res Labs, Dept Canc Res, W Point, PA 19486 USA; Merck Res Labs, Dept Mol Design & Divers, W Point, PA 19486 USA; Merck Res Labs, Dept Med Chem, W Point, PA 19486 USA	Merck & Company; Merck & Company; Merck & Company	Kendall, RL (corresponding author), Merck Res Labs, Dept Canc Res, 16-101, W Point, PA 19486 USA.							AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203; APRELIKOVA O, 1992, CANCER RES, V52, P746; Baxter RM, 1998, J BIOL CHEM, V273, P17050, DOI 10.1074/jbc.273.27.17050; Boerner RJ, 1995, BIOCHEMISTRY-US, V34, P16419, DOI 10.1021/bi00050a024; COLE PA, 1994, J BIOL CHEM, V269, P30880; COOK PF, 1982, BIOCHEMISTRY-US, V21, P5794, DOI 10.1021/bi00266a011; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; DOUGHERVERMAZEN M, 1994, BIOCHEM BIOPH RES CO, V205, P728, DOI 10.1006/bbrc.1994.2726; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; Ganju RK, 1998, J VIROL, V72, P6131, DOI 10.1128/JVI.72.7.6131-6137.1998; Goldman CK, 1998, P NATL ACAD SCI USA, V95, P8795, DOI 10.1073/pnas.95.15.8795; HARDIE G, 1995, PROTEIN KINASE FACTS, P7; KENDALL RL, 1994, BIOCHEM BIOPH RES CO, V201, P326, DOI 10.1006/bbrc.1994.1705; KENDALL RL, 1993, P NATL ACAD SCI USA, V90, P10705, DOI 10.1073/pnas.90.22.10705; KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0; KNIGHT WB, 1989, BIOCHEMISTRY-US, V28, P5728, DOI 10.1021/bi00440a005; Korpelainen EI, 1998, CURR OPIN CELL BIOL, V10, P159, DOI 10.1016/S0955-0674(98)80137-3; Kovalenko M, 1997, BIOCHEMISTRY-US, V36, P6260, DOI 10.1021/bi962553l; Leatherbarrow R. J., 1992, GRAFIT VERSION 3 0; LoGrasso PV, 1997, BIOCHEMISTRY-US, V36, P10422, DOI 10.1021/bi9706778; LONGATI P, 1994, ONCOGENE, V9, P49; MATTHEWS W, 1991, P NATL ACAD SCI USA, V88, P9026, DOI 10.1073/pnas.88.20.9026; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; Mohammadi M, 1997, SCIENCE, V276, P955, DOI 10.1126/science.276.5314.955; Mohammadi M, 1996, CELL, V86, P577, DOI 10.1016/S0092-8674(00)80131-2; Mohammadi M, 1996, MOL CELL BIOL, V16, P977; *MOL APPL GROUP, 1995, LOOK VERS 2 0; *MOL SIM INC, 1997, QUANTA97; PARK JE, 1994, J BIOL CHEM, V269, P25646; POSNER I, 1992, J BIOL CHEM, V267, P20638; Prade L, 1997, STRUCTURE, V5, P1627, DOI 10.1016/S0969-2126(97)00310-9; RONNSTRAND L, 1990, BIOCHEM BIOPH RES CO, V167, P1333, DOI 10.1016/0006-291X(90)90669-E; Segel I. H., 1975, ENZYME KINETICS, P273; SHIBUYA M, 1990, ONCOGENE, V5, P519; Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6; Sun L, 1998, J MED CHEM, V41, P2588, DOI 10.1021/jm980123i; TAVARE JM, 1991, J BIOL CHEM, V266, P1390; TERMAN BI, 1992, BIOCHEM BIOPH RES CO, V187, P1579, DOI 10.1016/0006-291X(92)90483-2; Thomas KA, 1996, J BIOL CHEM, V271, P603, DOI 10.1074/jbc.271.2.603; WALKER DH, 1987, BIOCHEMISTRY-US, V26, P1428, DOI 10.1021/bi00379a033; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; WEI L, 1995, J BIOL CHEM, V270, P8122, DOI 10.1074/jbc.270.14.8122; WILDEN PA, 1992, J BIOL CHEM, V267, P16660	45	102	108	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1999	274	10					6453	6460		10.1074/jbc.274.10.6453	http://dx.doi.org/10.1074/jbc.274.10.6453			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172BQ	10037737	hybrid			2022-12-25	WOS:000078902800059
J	Treuter, E; Johansson, L; Thomsen, JS; Warnmark, A; Leers, J; Pelto-Huikko, M; Sjoberg, M; Wright, APH; Spyrou, G; Gustafsson, JA				Treuter, E; Johansson, L; Thomsen, JS; Warnmark, A; Leers, J; Pelto-Huikko, M; Sjoberg, M; Wright, APH; Spyrou, G; Gustafsson, JA			Competition between thyroid hormone receptor-associated protein (TRAP) 220 and transcriptional intermediary factor (TIF) 2 for binding to nuclear receptors - Implications for the recruitment of trap and P160 coactivator complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOID-X-RECEPTOR; ESTROGEN-RECEPTOR; HISTONE ACETYLTRANSFERASES; CBP; ACTIVATION; DOMAIN; ACID; TRANSACTIVATION; HETERODIMERS; COREPRESSORS	Transcriptional activation by nuclear receptors (NRs) involves the concerted action of coactivators, chromatin components, and the basal transcription machinery. Crucial NR coactivators, which target primarily the conserved ligand-regulated activation (AF-2) domain, include p160 family members, such as TIF2, as well as p160-associated coactivators, such as CBP/p300. Because these coactivators possess intrinsic histone acetyltransferase activity, they are believed to function mainly by regulating chromatin-dependent transcriptional activation. Recent evidence suggests the existence of an additional NR coactivator complex, referred to as the thyroid hormone receptor-associated protein (TRAP) complex, which may function more directly as a bridging complex to the basal transcription machinery. TRAP220, the 220-kDa NR-binding subunit of the complex, has been identified in independent studies using both biochemical and genetic approaches. In light of the functional differences identified between p160 and TRAP coactivator complexes in NR activation, we have attempted to compare interaction and functional characteristics of TIF 2 and TRAP220. Our findings imply that competition between the NR-binding subunits of distinct coactivator complexes may act as a putative regulatory step in establishing either a sequential activation cascade or the formation of independent coactivator complexes.	Karolinska Inst, Novum, Dept Biosci, S-14157 Huddinge, Sweden; Tampere Univ Hosp, Dept Pathol, FIN-33101 Tampere, Finland; Tampere Univ, Sch Med, Dept Dev Biol, FIN-33101 Tampere, Finland; Karolinska Inst, Med Nobel Inst, Dept Cell & Mol Biol, S-17177 Stockholm, Sweden	Karolinska Institutet; Tampere University; Tampere University Hospital; Tampere University; Karolinska Institutet	Treuter, E (corresponding author), Karolinska Inst, Novum, Dept Biosci, S-14157 Huddinge, Sweden.	eckardt.treuter@csb.ki.se	Wright, Anthony/J-8187-2015	Wright, Anthony/0000-0003-1029-9969; thomsen, jane/0000-0002-9336-5695; Treuter, Eckardt/0000-0002-4147-8989				Almlof T, 1998, BIOCHEMISTRY-US, V37, P9586, DOI 10.1021/bi973029x; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; BERKENSTAM A, 1992, CELL, V69, P401, DOI 10.1016/0092-8674(92)90443-G; Blanco JCG, 1998, GENE DEV, V12, P1638, DOI 10.1101/gad.12.11.1638; BOURGUET W, 1995, NATURE, V375, P377, DOI 10.1038/375377a0; Brzozowski AM, 1997, NATURE, V389, P753, DOI 10.1038/39645; CAVAILLES V, 1994, P NATL ACAD SCI USA, V91, P10009, DOI 10.1073/pnas.91.21.10009; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; Cheng K, 1997, J ROY SOC MED, V90, P6, DOI 10.1177/014107689709031S03; DiRenzo J, 1997, MOL CELL BIOL, V17, P2166, DOI 10.1128/MCB.17.4.2166; Drane P, 1997, ONCOGENE, V15, P3013, DOI 10.1038/sj.onc.1201492; Enmark E, 1996, MOL ENDOCRINOL, V10, P1293, DOI 10.1210/me.10.11.1293; Feng WJ, 1998, SCIENCE, V280, P1747, DOI 10.1126/science.280.5370.1747; Fondell JD, 1996, P NATL ACAD SCI USA, V93, P8329, DOI 10.1073/pnas.93.16.8329; FORMAN BM, 1995, CELL, V81, P541, DOI 10.1016/0092-8674(95)90075-6; Fraser RA, 1998, J BIOL CHEM, V273, P16199, DOI 10.1074/jbc.273.26.16199; Glass CK, 1997, CURR OPIN CELL BIOL, V9, P222, DOI 10.1016/S0955-0674(97)80066-X; Grant PA, 1997, GENE DEV, V11, P1640, DOI 10.1101/gad.11.13.1640; Grant PA, 1998, CELL, V94, P45, DOI 10.1016/S0092-8674(00)81220-9; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; HALACHMI S, 1994, SCIENCE, V264, P1455, DOI 10.1126/science.8197458; Hanstein B, 1996, P NATL ACAD SCI USA, V93, P11540, DOI 10.1073/pnas.93.21.11540; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Hong H, 1997, MOL CELL BIOL, V17, P2735, DOI 10.1128/MCB.17.5.2735; Horwitz KB, 1996, MOL ENDOCRINOL, V10, P1167, DOI 10.1210/me.10.10.1167; Imhof A, 1997, CURR BIOL, V7, P689, DOI 10.1016/S0960-9822(06)00296-X; Janknecht R, 1996, NATURE, V383, P22, DOI 10.1038/383022a0; Kalkhoven E, 1998, EMBO J, V17, P232, DOI 10.1093/emboj/17.1.232; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Kuiper GGJM, 1996, P NATL ACAD SCI USA, V93, P5925, DOI 10.1073/pnas.93.12.5925; Kurokawa R, 1998, SCIENCE, V279, P700, DOI 10.1126/science.279.5351.700; KUROKAWA R, 1995, NATURE, V377, P451, DOI 10.1038/377451a0; LEE JW, 1995, MOL ENDOCRINOL, V9, P243; Leers J, 1998, MOL CELL BIOL, V18, P6001, DOI 10.1128/MCB.18.10.6001; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; Misiti S, 1998, ENDOCRINOLOGY, V139, P2493, DOI 10.1210/en.139.5.2493; Nakajima T, 1997, CELL, V90, P1107, DOI 10.1016/S0092-8674(00)80376-1; Nolte RT, 1998, NATURE, V395, P137, DOI 10.1038/25931; Ogryzko VV, 1998, CELL, V94, P35, DOI 10.1016/S0092-8674(00)81219-2; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Rachez C, 1998, GENE DEV, V12, P1787, DOI 10.1101/gad.12.12.1787; Schulman IG, 1997, GENE DEV, V11, P299, DOI 10.1101/gad.11.3.299; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; Treuter E, 1998, MOL ENDOCRINOL, V12, P864, DOI 10.1210/me.12.6.864; Voegel JJ, 1998, EMBO J, V17, P507, DOI 10.1093/emboj/17.2.507; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; WAGNER RL, 1995, NATURE, V378, P690, DOI 10.1038/378690a0; Westin S, 1998, NATURE, V395, P199, DOI 10.1038/26040; Wiebel FF, 1997, MOL CELL BIOL, V17, P3977, DOI 10.1128/MCB.17.7.3977; Wolffe AP, 1996, CELL, V84, P817, DOI 10.1016/S0092-8674(00)81059-4; Wurtz JM, 1996, NAT STRUCT BIOL, V3, P87, DOI 10.1038/nsb0196-87; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Yuan CX, 1998, P NATL ACAD SCI USA, V95, P7939, DOI 10.1073/pnas.95.14.7939; Zhou GC, 1998, MOL ENDOCRINOL, V12, P1594, DOI 10.1210/me.12.10.1594; Zhu YJ, 1997, J BIOL CHEM, V272, P25500, DOI 10.1074/jbc.272.41.25500	56	72	74	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	1999	274	10					6667	6677		10.1074/jbc.274.10.6667	http://dx.doi.org/10.1074/jbc.274.10.6667			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172BQ	10037764	hybrid			2022-12-25	WOS:000078902800086
J	Hedlund, H; Hedbom, E; Heinegard, D; Mengarelli-Widholm, S; Reinholt, FP; Svensson, O				Hedlund, H; Hedbom, E; Heinegard, D; Mengarelli-Widholm, S; Reinholt, FP; Svensson, O			Association of the aggrecan keratan sulfate-rich region with collagen in bovine articular cartilage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOCLONAL-ANTIBODIES; PROTEOGLYCAN; DECORIN; PROTEIN; FIBRILS; FIBROMODULIN; MATRIX; IX	Aggrecan, the predominant large proteoglycan of cartilage, is a multidomain macromolecule with each domain contributing specific functional properties. One of the domains contains the majority of the keratan sulfate (KS) chain substituents and a protein segment with a proline-rich hexapeptide repeat sequence. The function of this domain is unknown but the primary structure suggests a potential for binding to collagen fibrils. We have examined binding of aggrecan fragments encompassing the KS-rich region in a solid-phase assay, A moderate affinity (apparent K-d = 1.1 mu M) for isolated collagen II, as well as collagen I, was demonstrated. Enzymatic digestion of the RS chains did not alter the capacity of the peptide to bind to collagen, whereas cleavage of the protein core abolished the interaction. The distribution of the aggrecan KS-rich region in bovine tarsometatarsal joint cartilage was investigated using immunoelectron microscopy. Immunoreactivity was relatively low in the superficial zone and higher in the intermediate and deep zones of the uncalcified cartilage. Within the pericellular and territorial matrix compartments the epitopes representing the aggrecan KS-rich region were detected preferentially near or at collagen fibrils. Along the fibrils, epitope reactivity was non-randomly distributed, showing preference for the gap region within the D-period. Our data suggest that collagen fibrils interact with the KS-rich regions of several aggrecan monomers aligned within a proteoglycan aggregate. The fibril could therefore serve as a backbone in at least some of the aggrecan complexes.	Huddinge Univ Hosp, Karolinska Inst, Dept Orthoped, SE-14186 Huddinge, Sweden; Huddinge Univ Hosp, Karolinska Inst, Dept Pathol, SE-14186 Huddinge, Sweden; Univ Oslo, Natl Hosp, Dept Pathol, NO-0027 Oslo, Norway; Univ Zurich Hosp, Dept Rheumatol, CH-8091 Zurich, Switzerland; Univ Lund, Dept Cell & Mol Biol, SE-22100 Lund, Sweden	Karolinska Institutet; Karolinska Institutet; University of Oslo; National Hospital Norway; University of Zurich; University Zurich Hospital; Lund University	Hedlund, H (corresponding author), Huddinge Univ Hosp, Karolinska Inst, Dept Orthoped, SE-14186 Huddinge, Sweden.	Hakan.Hedlund@karo.ki.se						ANTONSSON P, 1989, J BIOL CHEM, V264, P16170; AYAD S, 1991, BIOCHEM J, V278, P441, DOI 10.1042/bj2780441; CATERSON B, 1983, J BIOL CHEM, V258, P8848; FLEISCHMAJER R, 1991, J STRUCT BIOL, V106, P82, DOI 10.1016/1047-8477(91)90065-5; FRANZEN A, 1981, BIOCHEM J, V195, P535, DOI 10.1042/bj1950535; Griffiths G., 1993, FINE STRUCTURE IMMUN, P237; HAGG R, 1998, IN PRESS J CELL BIOL; HASCALL VC, 1974, J BIOL CHEM, V249, P4242; HEDBOM E, 1989, J BIOL CHEM, V264, P6898; HEDBOM E, 1993, J BIOL CHEM, V268, P27307; HEDLUND H, 1993, APMIS, V101, P133, DOI 10.1111/j.1699-0463.1993.tb00092.x; HEDLUND H, 1994, MATRIX BIOL, V14, P227, DOI 10.1016/0945-053X(94)90186-4; HEINEGARD D, 1987, METHOD ENZYMOL, V144, P305; HEINEGARD D, 1978, BIOCHEM J, V175, P913, DOI 10.1042/bj1750913; HEINEGARD D, 1977, J BIOL CHEM, V252, P1971; Heinegard Dick, 1993, P189; HUKINS DWL, 1985, TRENDS BIOCHEM SCI, V10, P260, DOI 10.1016/0968-0004(85)90077-5; HULTENBY K, 1991, MATRIX, V11, P206, DOI 10.1016/S0934-8832(11)80160-5; LEMPERG R, 1974, CALC TISS RES, V15, P237, DOI 10.1007/BF02059060; MAROUDAS A, 1976, NATURE, V260, P808, DOI 10.1038/260808a0; OEGEMA TR, 1975, ARCH BIOCHEM BIOPHYS, V170, P698, DOI 10.1016/0003-9861(75)90167-8; ORFORD CR, 1984, CONNECT TISSUE RES, V12, P345, DOI 10.3109/03008208409013696; POOLE AR, 1982, J CELL BIOL, V93, P921, DOI 10.1083/jcb.93.3.921; PRINGLE GA, 1990, J HISTOCHEM CYTOCHEM, V38, P1405, DOI 10.1177/38.10.1698203; SCOTT JE, 1991, INT J BIOL MACROMOL, V13, P157, DOI 10.1016/0141-8130(91)90041-R; STOCKWELL RA, 1967, NATURE, V215, P1376, DOI 10.1038/2151376a0; TOOLE BP, 1976, J BIOL CHEM, V251, P895; VAUGHAN L, 1988, J CELL BIOL, V106, P991, DOI 10.1083/jcb.106.3.991; WIEDEMANN H, 1984, BIOCHEM J, V224, P331, DOI 10.1042/bj2240331; WIESLANDER J, 1979, BIOCHEM J, V179, P35, DOI 10.1042/bj1790035	31	47	48	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 26	1999	274	9					5777	5781		10.1074/jbc.274.9.5777	http://dx.doi.org/10.1074/jbc.274.9.5777			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	170KG	10026199	hybrid			2022-12-25	WOS:000078804400070
J	Murphy, M; Godson, C; Cannon, S; Kato, S; Mackenzie, HS; Martin, F; Brady, HR				Murphy, M; Godson, C; Cannon, S; Kato, S; Mackenzie, HS; Martin, F; Brady, HR			Suppression subtractive hybridization identifies high glucose levels as a stimulus for expression of connective tissue growth factor and other genes in human mesangial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; POLYMERASE CHAIN-REACTION; MESSENGER-RNA; FACTOR-BETA; DIABETIC GLOMERULOPATHY; DIFFERENTIAL DISPLAY; CDNA; HYPERGLYCEMIA; PATHOGENESIS; ADHESION	Accumulation of mesangial matrix is a pivotal event in the pathophysiology of diabetic nephropathy. The molecular triggers for matrix production are still being defined. Here, suppression subtractive hybridization identified 15 genes differentially induced when primary human mesangial cells are exposed to high glucose (30 mM versus 5 mM) in vitro. These genes included (a) known regulators of mesangial cell activation in diabetic nephropathy (fibronectin, caldesmon, thrombospondin, and plasminogen activator inhibitor-1), (b) novel genes, and (c) known genes whose induction by high glucose has not been reported. Prominent among the latter were genes encoding cytoskeleton-associated proteins and connective tissue growth factor (CTGF), a modulator of fibroblast matrix production. In parallel experiments, elevated CTGF mRNA levels were demonstrated in glomeruli of rats with streptozotocin-induced diabetic nephropathy. Mannitol provoked less mesangial cell CTGF expression in vitro than high glucose, excluding hyperosmolality as the key stimulus. The addition of recombinant CTGF to cultured mesangial cells enhanced expression of extracellular matrix proteins. High glucose stimulated expression of transforming growth factor beta 1 (TGF-beta 1), and addition of TGF-beta 1 to mesangial cells triggered CTGF expression. CTGF expression induced by high glucose was partially suppressed by anti-TGF-pl antibody and by the protein kinase C inhibitor GF 109203X. Together, these data suggest that 1) high glucose stimulates mesangial CTGF expression by TGF beta 1-dependent and protein kinase C dependent pathways, and 2) CTGF may be a mediator of TGF beta 1-driven matrix production within a diabetic milieu.	Univ Coll Dublin, Mater Misericordiae Hosp, Dept Med & Therapeut, Ctr Mol Inflammat & Vasc Res, Dublin 7, Ireland; Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Renal, Boston, MA 02115 USA; Natl Univ Ireland Univ Coll Dublin, Dept Pharmacol, Dublin 4, Ireland	Mater Misericordiae University Hospital; University College Dublin; Harvard University; Brigham & Women's Hospital; Harvard Medical School; University College Dublin	Brady, HR (corresponding author), Univ Coll Dublin, Mater Misericordiae Hosp, Dept Med & Therapeut, Ctr Mol Inflammat & Vasc Res, Dublin 7, Ireland.	hrbrady@mater.ie		Godson, Catherine/0000-0003-0655-1041				AYO SH, 1991, AM J PHYSIOL, V260, pF185, DOI 10.1152/ajprenal.1991.260.2.F185; AYO SH, 1990, AM J PATHOL, V136, P1339; BORK P, 1993, FEBS LETT, V327, P125, DOI 10.1016/0014-5793(93)80155-N; BRADHAM DM, 1991, J CELL BIOL, V114, P1285, DOI 10.1083/jcb.114.6.1285; BRADY HR, 1992, KIDNEY INT, V42, P480, DOI 10.1038/ki.1992.312; DENTON MD, 1991, AM J PHYSIOL, V261, pF1071, DOI 10.1152/ajprenal.1991.261.6.F1071; DERUBERTIS FR, 1994, DIABETES, V43, P1, DOI 10.2337/diabetes.43.1.1; Diatchenko L, 1996, P NATL ACAD SCI USA, V93, P6025, DOI 10.1073/pnas.93.12.6025; Frazier K, 1996, J INVEST DERMATOL, V107, P404, DOI 10.1111/1523-1747.ep12363389; FUMO P, 1994, AM J PHYSIOL-RENAL, V267, pF632, DOI 10.1152/ajprenal.1994.267.4.F632; Grotendorst Gary R., 1997, Cytokine and Growth Factor Reviews, V8, P171, DOI 10.1016/S1359-6101(97)00010-5; Gurskaya NG, 1996, ANAL BIOCHEM, V240, P90, DOI 10.1006/abio.1996.0334; Holmes DIR, 1997, BIOCHEM BIOPH RES CO, V238, P179, DOI 10.1006/bbrc.1997.7265; Hong CY, 1998, J DIABETES COMPLICAT, V12, P43, DOI 10.1016/S1056-8727(97)00045-7; HUBANK M, 1994, NUCLEIC ACIDS RES, V22, P5640, DOI 10.1093/nar/22.25.5640; Ishii H, 1996, SCIENCE, V272, P728, DOI 10.1126/science.272.5262.728; Ito Y, 1998, KIDNEY INT, V53, P853, DOI 10.1046/j.1523-1755.1998.00820.x; Kothapalli D, 1998, FASEB J, V12, P1151, DOI 10.1096/fasebj.12.12.1151; Kothapalli D, 1997, CELL GROWTH DIFFER, V8, P61; KREISBERG JI, 1993, KIDNEY INT, V43, P109, DOI 10.1038/ki.1993.18; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; Makino H, 1996, DIABETES, V45, P488, DOI 10.2337/diabetes.45.4.488; Murphy M, 1998, CURR OPIN NEPHROL HY, V7, P563, DOI 10.1097/00041552-199809000-00013; Park IS, 1997, DIABETES, V46, P473, DOI 10.2337/diabetes.46.3.473; PARRING HH, 1996, BRENNER RECTORS KIDN, P1864; Poncelet AC, 1998, AM J PHYSIOL-RENAL, V275, pF458; RYSECK RP, 1991, CELL GROWTH DIFFER, V2, P225; Sharma K, 1996, DIABETES, V45, P522, DOI 10.2337/diabetes.45.4.522; SHARMA K, 1995, DIABETES, V44, P1139, DOI 10.2337/diabetes.44.10.1139; SOHN RH, 1994, BIOESSAYS, V16, P465, DOI 10.1002/bies.950160705; Tada H, 1998, NEPHRON, V79, P38, DOI 10.1159/000044989; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; VELCULESCU VE, 1995, SCIENCE, V270, P484, DOI 10.1126/science.270.5235.484; Wahab NA, 1996, BIOCHEM J, V316, P985, DOI 10.1042/bj3160985; YAMAMOTO T, 1993, P NATL ACAD SCI USA, V90, P1814, DOI 10.1073/pnas.90.5.1814; ZATZ R, 1985, P NATL ACAD SCI USA, V82, P5963, DOI 10.1073/pnas.82.17.5963; ZHOU XP, 1995, LAB INVEST, V73, P372; Zhou XP, 1997, KIDNEY INT, V51, P1797, DOI 10.1038/ki.1997.247	38	325	388	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 26	1999	274	9					5830	5834		10.1074/jbc.274.9.5830	http://dx.doi.org/10.1074/jbc.274.9.5830			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	170KG	10026205	hybrid			2022-12-25	WOS:000078804400076
J	Petersen, C				Petersen, C			Inhibition of cellular growth by increased guanine nucleotide pools - Characterization of an Escherichia coli mutant with a guanosine kinase that is insensitive to feedback inhibition by GTP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHORIBOSYLPYROPHOSPHATE SYNTHETASE; SALMONELLA-TYPHIMURIUM; PHOSPHORIBOSYLTRANSFERASE; HYPOXANTHINE; OPERON; GSK	In Escherichia coli the enzyme guanosine kinase phosphorylates guanosine to GMP, which is further phosphorylated to GDP and GTP by other enzymes. Here I report that guanosine kinase is subject to efficient feedback inhibition by the end product of the pathway, GTP, and that this regulation is abolished by a previously described mutation, gsk-3, in the structural gene for guanosine kinase (Hove-Jensen, B., and Nygaard, P. (1989) J. Gen. Microbiol. 135, 1263-1273). Consequently, the gsk-3 mutant strain was extremely sensitive to guanosine, which caused the guanine nucleotide pools to increase dramatically, thereby initiating a cascade of metabolic changes that eventually led to growth arrest. By isolation and characterization of guanosine-resistant derivatives of the gsk-3 mutant, some of the crucial steps in this deleterious cascade of events were found to include the following: first, conversion of GMP to adenine nucleotides via GMP reductase, encoded by the guaC gene; second, inhibition of phosphoribosylpyrophosphate synthetase by an adenine nucleotide, presumably ADP, causing starvation for histidine, tryptophan, and pyrimidines, all of which require PRPP for their synthesis; third, accumulation of the regulatory nucleotide guanosine 5',3'-bispyrophosphate (ppGpp), a general transcriptional inhibitor synthesized by the relA gene product in response to amino acid starvation.	Univ Copenhagen, Inst Mol Biol, Dept Biol Chem, DK-1307 Copenhagen K, Denmark	University of Copenhagen	Petersen, C (corresponding author), Univ Copenhagen, Inst Mol Biol, Dept Biol Chem, Solvgade 83H, DK-1307 Copenhagen K, Denmark.							ANDREWS SC, 1988, BIOCHEM J, V255, P35, DOI 10.1042/bj2550035; BOUVIER J, 1984, P NATL ACAD SCI-BIOL, V81, P4139, DOI 10.1073/pnas.81.13.4139; CASHEL M, 1996, ESCHERICHIA COLI SAL, V1, P1458; CLARK DJ, 1967, J MOL BIOL, V23, P99, DOI 10.1016/S0022-2836(67)80070-6; DEHAAN PG, 1969, MUTAT RES, V8, P505, DOI 10.1016/0027-5107(69)90067-0; DEO SS, 1985, BIOCHIM BIOPHYS ACTA, V839, P233, DOI 10.1016/0304-4165(85)90003-0; DONAHUE JP, 1990, J BIOL CHEM, V265, P19091; EDLIN G, 1966, J MOL BIOL, V15, P428, DOI 10.1016/S0022-2836(66)80118-3; GIBSON KJ, 1982, J BIOL CHEM, V257, P2391; HARLOW KW, 1995, J BACTERIOL, V177, P2236, DOI 10.1128/jb.177.8.2236-2240.1995; Hochstadt J, 1978, Methods Enzymol, V51, P558; Hochstadt J, 1978, Methods Enzymol, V51, P549; HOULBERG U, 1983, J BACTERIOL, V153, P837, DOI 10.1128/JB.153.2.837-845.1983; HOVEJENSEN B, 1989, MOL MICROBIOL, V3, P1487, DOI 10.1111/j.1365-2958.1989.tb00134.x; HOVEJENSEN B, 1989, J GEN MICROBIOL, V135, P1263; HOVEJENSEN B, 1982, EUR J BIOCHEM, V126, P327; Jensen KF, 1996, EUR J BIOCHEM, V240, P637, DOI 10.1111/j.1432-1033.1996.0637h.x; JENSEN KF, 1979, ANAL BIOCHEM, V98, P254, DOI 10.1016/0003-2697(79)90138-6; Jensen KF, 1983, METABOLISM NUCLEOTID, P1; JOCHIMSEN B, 1975, MOL GEN GENET, V143, P85, DOI 10.1007/BF00269424; MESSENGER LJ, 1979, J BIOL CHEM, V254, P3382; Miller J.H., 1972, EXPT MOL GENETICS; NEUHARD J, 1987, ESCHERICHIA COLI SAL, V1, P445; NEUHARD J, 1996, ESCHERICHIA COLI SAL, V1, P580; SADLER WC, 1977, J BIOL CHEM, V252, P8504; SWITZER RL, 1973, J BIOL CHEM, V248, P1063; THELANDER L, 1979, ANNU REV BIOCHEM, V48, P133, DOI 10.1146/annurev.bi.48.070179.001025; TURNBOUGH CL, 1983, J BACTERIOL, V153, P998, DOI 10.1128/JB.153.2.998-1007.1983; XIAO H, 1991, J BIOL CHEM, V266, P5980; ZALKIN H, 1996, ESCHERICHIA COLI SAL, V1, P561	30	25	25	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 26	1999	274	9					5348	5356		10.1074/jbc.274.9.5348	http://dx.doi.org/10.1074/jbc.274.9.5348			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	170KG	10026143	hybrid			2022-12-25	WOS:000078804400014
J	Alkhalaf, M; Ganguli, G; Messaddeq, N; Le Meur, M; Wasylyk, B				Alkhalaf, M; Ganguli, G; Messaddeq, N; Le Meur, M; Wasylyk, B			MDM2 overexpression generates a skin phenotype in both wild type and p53 null mice	ONCOGENE			English	Article						cytokeratins; desquamation; differentiation; epidermis; proliferation ichthyosis vulgaris	HUMAN PAPILLOMAVIRUS TYPE-16; TRANSGENIC MICE; TARGETED EXPRESSION; TRANSCRIPTIONAL ACTIVITY; MALIGNANT PROGRESSION; CELL-DIFFERENTIATION; EMBRYONIC LETHALITY; MDM2-DEFICIENT MICE; ENHANCER PROMOTER; TUMOR-DEVELOPMENT	The MDM2 proto-oncogene is overexpressed in human tumours and regulates the activities of the tumour suppressors p53 and pRB We created mice that overexpress MDM2 under the control of the CMV promoter. These mice did not display an increased tumour incidence, but rather a specific skin phenotype, characterized by desquamation and hyperkeratosis. Transgenic MDM2 was found to be overexpressed in the epidermis, a tissue that normally expresses high levels of MDM2. The phenotype appeared during the first week after birth and then lessened with age, closely following the level of expression of the transgene. MDM2 overexpression was associated with an increase in proliferation in the basal layer, thickening of the epidermis, altered expression of the differentiation markers cytokeratin CK14, CK10 and CK1, and a decrease in the size and the number of granules that contain products of differentiation. Transgenic mice on a p53 null background displayed similar although not identical changes, showing that the effects of MDM2 are to a certain degree p53 independent. The skin is a major site of MDM2 expression in mice, raising the possibility that MDM2 overexpression perturbs the normal pattern of MDM2 expression and inhibits differentiation of the epidermis.	ULP, INSERM, CNRS, Inst Genet & Biol Mol & Cellulaire, F-67404 Illkirch Graffenstaden, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Wasylyk, B (corresponding author), ULP, INSERM, CNRS, Inst Genet & Biol Mol & Cellulaire, 1 Rue Laurent Fries,BP 163, F-67404 Illkirch Graffenstaden, France.		Indra, Gitali/G-2963-2016; Wasylyk, Bohdan/ABG-6778-2020	Wasylyk, Bohdan/0000-0002-1718-1237				Almog N, 1997, BBA-REV CANCER, V1333, pF1, DOI 10.1016/S0304-419X(97)00012-7; Arbeit JM, 1996, CANCER SURV, V26, P7; ARBEIT JM, 1994, J VIROL, V68, P4358, DOI 10.1128/JVI.68.7.4358-4368.1994; AUEWARAKUL P, 1994, MOL CELL BIOL, V14, P8250, DOI 10.1128/MCB.14.12.8250; BALE SJ, 1994, J INVEST DERMATOL, V102, pS49, DOI 10.1111/1523-1747.ep12388591; BARAK Y, 1994, GENE DEV, V8, P1739, DOI 10.1101/gad.8.15.1739; Bol D, 1998, MOL CARCINOGEN, V21, P2, DOI 10.1002/(SICI)1098-2744(199801)21:1<2::AID-MC2>3.3.CO;2-7; Bol DK, 1997, ONCOGENE, V14, P1725, DOI 10.1038/sj.onc.1201011; Bottger A, 1997, CURR BIOL, V7, P860, DOI 10.1016/S0960-9822(06)00374-5; Brown K, 1998, CURR BIOL, V8, P516, DOI 10.1016/S0960-9822(98)70203-9; BROWN K, 1995, CANCER METAST REV, V14, P113, DOI 10.1007/BF00665795; BuesoRamos CE, 1996, BREAST CANCER RES TR, V37, P179, DOI 10.1007/BF01806499; BUESORAMOS CE, 1995, LEUKEMIA LYMPHOMA, V17, P13, DOI 10.3109/10428199509051698; Byrne C, 1997, BIOESSAYS, V19, P691, DOI 10.1002/bies.950190809; CAHILLYSNYDER L, 1987, SOMAT CELL MOLEC GEN, V13, P235, DOI 10.1007/BF01535205; CARROLL JM, 1993, P NATL ACAD SCI USA, V90, P10270, DOI 10.1073/pnas.90.21.10270; Carroll JM, 1997, J INVEST DERMATOL, V108, P412, DOI 10.1111/1523-1747.ep12289702; CARROLL JM, 1995, CELL, V83, P957, DOI 10.1016/0092-8674(95)90211-2; Chen JD, 1996, MOL CELL BIOL, V16, P2445; CORDONCARDO C, 1994, CANCER RES, V54, P794; Coussens LM, 1996, AM J PATHOL, V149, P1899; CRISH JF, 1993, DIFFERENTIATION, V53, P191, DOI 10.1111/j.1432-0436.1993.tb00708.x; Cui W, 1996, CELL, V86, P531, DOI 10.1016/S0092-8674(00)80127-0; Dazard JE, 1997, ONCOGENE, V14, P1123, DOI 10.1038/sj.onc.1200922; DubsPoterszman MC, 1995, ONCOGENE, V11, P2445; Eckert RL, 1997, PHYSIOL REV, V77, P397, DOI 10.1152/physrev.1997.77.2.397; Epstein EH, 1996, CURR OPIN GENET DEV, V6, P295, DOI 10.1016/S0959-437X(96)80005-0; FAKHARZADEH SS, 1991, EMBO J, V10, P1565, DOI 10.1002/j.1460-2075.1991.tb07676.x; Fiddler TA, 1996, MOL CELL BIOL, V16, P5048; FINLAY CA, 1993, MOL CELL BIOL, V13, P301, DOI 10.1128/MCB.13.1.301; FLORENES VA, 1994, J NATL CANCER I, V86, P1297, DOI 10.1093/jnci/86.17.1297; Francis Julie S., 1994, Current Opinion in Pediatrics, V6, P447, DOI 10.1097/00008480-199408000-00016; FUCHS E, 1992, P NATL ACAD SCI USA, V89, P6906, DOI 10.1073/pnas.89.15.6906; FURTH PA, 1991, NUCLEIC ACIDS RES, V19, P6205, DOI 10.1093/nar/19.22.6205; GREENHALGH DA, 1994, CELL GROWTH DIFFER, V5, P667; Haines DS, 1997, LEUKEMIA LYMPHOMA, V26, P227, DOI 10.3109/10428199709051772; HAINES DS, 1994, MOL CELL BIOL, V14, P1171, DOI 10.1128/MCB.14.2.1171; Hall PA, 1997, CURR BIOL, V7, pR144, DOI 10.1016/S0960-9822(97)70074-5; Hansen R, 1997, CURR OPIN GENET DEV, V7, P46, DOI 10.1016/S0959-437X(97)80108-6; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Haupt Y, 1996, EMBO J, V15, P1596, DOI 10.1002/j.1460-2075.1996.tb00504.x; Herber R, 1996, J VIROL, V70, P1873, DOI 10.1128/JVI.70.3.1873-1881.1996; HOLBROOK KA, 1989, J INVEST DERMATOL, V92, pS84, DOI 10.1111/1523-1747.ep13075079; Hollstein M, 1997, Recent Results Cancer Res, V143, P369; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Jones SJ, 1997, J INVEST DERMATOL, V109, P187, DOI 10.1111/1523-1747.ep12319308; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; KEMP CJ, 1993, CELL, V74, P813, DOI 10.1016/0092-8674(93)90461-X; KOEDOOD M, 1995, J VIROL, V69, P2194, DOI 10.1128/JVI.69.4.2194-2207.1995; Kondo S, 1996, ONCOGENE, V13, P1773; KONDO S, 1995, ONCOGENE, V10, P2001; KOTHARY R, 1991, MECH DEVELOP, V35, P25, DOI 10.1016/0925-4773(91)90038-8; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Kussie PH, 1996, SCIENCE, V274, P948, DOI 10.1126/science.274.5289.948; Lane DP, 1997, TRENDS BIOCHEM SCI, V22, P372, DOI 10.1016/S0968-0004(97)01119-5; Leveillard T, 1997, J BIOL CHEM, V272, P30651, DOI 10.1074/jbc.272.49.30651; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LUNA RMD, 1995, NATURE, V378, P203; Luna RMDO, 1996, GENOMICS, V33, P352, DOI 10.1006/geno.1996.0210; Lundgren K, 1997, GENE DEV, V11, P714, DOI 10.1101/gad.11.6.714; Marks DI, 1996, BRIT J HAEMATOL, V92, P890, DOI 10.1046/j.1365-2141.1996.439978.x; MARTIN K, 1995, NATURE, V375, P691, DOI 10.1038/375691a0; MAXWELL SA, 1994, ANTICANCER RES, V14, P2541; Midgley CA, 1997, ONCOGENE, V15, P1179, DOI 10.1038/sj.onc.1201459; Momand J, 1997, J CELL BIOCHEM, V64, P343; Morgan SE, 1997, ADV CANCER RES, V71, P1, DOI 10.1016/S0065-230X(08)60095-0; Neil JC, 1997, TRENDS MICROBIOL, V5, P115, DOI 10.1016/S0966-842X(96)10083-4; OLSON DC, 1993, ONCOGENE, V8, P2353; Pierce AM, 1998, ONCOGENE, V16, P1267, DOI 10.1038/sj.onc.1201666; Pierce AM, 1998, P NATL ACAD SCI USA, V95, P8858, DOI 10.1073/pnas.95.15.8858; Piette J, 1997, ONCOGENE, V15, P1001, DOI 10.1038/sj.onc.1201432; Raskin CA, 1997, J AM ACAD DERMATOL, V36, P885, DOI 10.1016/S0190-9622(97)80266-6; Robles AI, 1996, P NATL ACAD SCI USA, V93, P7634, DOI 10.1073/pnas.93.15.7634; Santos M, 1997, MOL CARCINOGEN, V20, P3, DOI 10.1002/(SICI)1098-2744(199709)20:1<3::AID-MC2>3.0.CO;2-R; Schlott T, 1997, J PATHOL, V182, P54; SCHMIDT EV, 1990, MOL CELL BIOL, V10, P4406, DOI 10.1128/MCB.10.8.4406; Sigalas I, 1996, NAT MED, V2, P912, DOI 10.1038/nm0896-912; Song SY, 1998, P NATL ACAD SCI USA, V95, P2290, DOI 10.1073/pnas.95.5.2290; Thut CJ, 1997, GENE DEV, V11, P1974, DOI 10.1101/gad.11.15.1974; Wang XJ, 1998, ONCOGENE, V17, P35, DOI 10.1038/sj.onc.1201890; Wang XW, 1997, J CELL PHYSIOL, V173, P247, DOI 10.1002/(SICI)1097-4652(199711)173:2<247::AID-JCP30>3.0.CO;2-A; WEINBERG WC, 1995, ONCOGENE, V10, P2271; WERNER S, 1993, EMBO J, V12, P2635, DOI 10.1002/j.1460-2075.1993.tb05924.x; WILLIAMS ML, 1992, PEDIATR DERMATOL, V9, P365, DOI 10.1111/j.1525-1470.1992.tb00632.x; XIAO JH, 1991, CELL, V65, P551, DOI 10.1016/0092-8674(91)90088-G; XIAO ZX, 1995, NATURE, V375, P694, DOI 10.1038/375694a0; Xie W, 1998, CELL GROWTH DIFFER, V9, P313; zurHausen H, 1996, BBA-REV CANCER, V1288, pF55	88	34	34	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 18	1999	18	7					1419	1434		10.1038/sj.onc.1202448	http://dx.doi.org/10.1038/sj.onc.1202448			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	167UK	10050879	Bronze			2022-12-25	WOS:000078651600004
J	Arriola, EL; Rodriguez-Lopez, AM; Hickman, JA; Chresta, CM				Arriola, EL; Rodriguez-Lopez, AM; Hickman, JA; Chresta, CM			Bcl-2 overexpression results in reciprocal downregulation of Bcl-X-L and sensitizes human testicular germ cell tumours to chemotherapy-induced apoptosis	ONCOGENE			English	Article						testicular tumours; apoptosis; Bcl-2; Bcl-X-L	CISPLATIN-INDUCED APOPTOSIS; ETOPOSIDE-INDUCED APOPTOSIS; CYTOCHROME-C; IN-VIVO; IMMUNOHISTOCHEMICAL ANALYSIS; CLONOGENIC SURVIVAL; UP-REGULATION; DEATH; EXPRESSION; PROTEIN	Testicular germ cell tumours are hypersentive to chemotherapy and cell lines derived from these tumours are chemosensitive in vitro. We have previously shown that these cell lines express undetectable levels of the suppressor of apoptosis Bcl-2 and relatively high levels of the apoptosis inducer Bar (Chresta et al., 1996). To determine whether the absence of Bcl-2 in these cell lines makes them highly susceptible to drug-induced apoptosis, Bcl-2 was expressed ectopically in the 833K testicular germ cell tumour cell line. Stable overexpressing clones were isolated and three clones were studied further. Surprisingly, Eel-2 overexpressing cells were sensitized to chemotherapy-induced apoptosis compared to the parental and vector control cells. Analysis of potential mechanisms of sensitization revealed there was reciprocal downregulation of the endogenously expressed Bcl-X-L in the Eel-2 overexpressing clones. Downregulation of Bcl-X-L to the same extent using antisense oligonucleotides enhanced etoposide-induced apoptosis by twofold. Our results indicate that Eel-2 and Bcl-X-L have different abilities to protect against chemotherapy-induced apoptosis in testicular germ cell tumours. In contrast to findings in some tumour cell types, Eel-2 did not act as a gatekeeper to prevent entry of p53 to the nucleus.	Univ Manchester, Sch Biol Sci, CRC, Mol & Cellular Pharmacol Res Grp, Manchester M13 9PT, Lancs, England	University of Manchester	Chresta, CM (corresponding author), Univ Manchester, Sch Biol Sci, CRC, Mol & Cellular Pharmacol Res Grp, G38 Stopford Bldg,Oxford Rd, Manchester M13 9PT, Lancs, England.							Beham A, 1997, ONCOGENE, V15, P2767, DOI 10.1038/sj.onc.1201464; BERTRAND R, 1991, CANCER RES, V51, P6280; Boersma AWM, 1997, CYTOMETRY, V27, P275, DOI 10.1002/(SICI)1097-0320(19970301)27:3<275::AID-CYTO10>3.0.CO;2-Q; Burger H, 1997, INT J CANCER, V73, P592, DOI 10.1002/(SICI)1097-0215(19971114)73:4<592::AID-IJC22>3.0.CO;2-A; CHAO DT, 1995, J EXP MED, V182, P821, DOI 10.1084/jem.182.3.821; Cheng EHY, 1997, SCIENCE, V278, P1966, DOI 10.1126/science.278.5345.1966; Chresta CM, 1996, CANCER RES, V56, P1834; Cosulich SC, 1996, CURR BIOL, V6, P997, DOI 10.1016/S0960-9822(02)00644-9; Dibbert B, 1998, BLOOD, V92, P778, DOI 10.1182/blood.V92.3.778.415k38_778_783; DIVE C, 1991, BRIT J CANCER, V64, P192, DOI 10.1038/bjc.1991.269; EINHORN LH, 1990, J CLIN ONCOL, V8, P1777, DOI 10.1200/JCO.1990.8.11.1777; Farrow SN, 1996, CURR OPIN GENET DEV, V6, P45, DOI 10.1016/S0959-437X(96)90009-X; FISHER TC, 1993, CANCER RES, V53, P3321; GOTTSCHALK AR, 1994, P NATL ACAD SCI USA, V91, P7350, DOI 10.1073/pnas.91.15.7350; HALDAR S, 1995, P NATL ACAD SCI USA, V92, P4507, DOI 10.1073/pnas.92.10.4507; Haldar S, 1996, CANCER RES, V56, P1253; Han ZY, 1996, CANCER RES, V56, P1621; HASHIMOTO H, 1995, CANCER RES, V55, P4029; HOCKENBERY DM, 1991, P NATL ACAD SCI USA, V88, P6961, DOI 10.1073/pnas.88.16.6961; Hsu YT, 1997, P NATL ACAD SCI USA, V94, P3668, DOI 10.1073/pnas.94.8.3668; KAMESAKI S, 1993, CANCER RES, V53, P4251; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Knudson CM, 1997, NAT GENET, V16, P358, DOI 10.1038/ng0897-358; KORSMEYER SJ, 1995, TRENDS GENET, V11, P101, DOI 10.1016/S0168-9525(00)89010-1; KRAJEWSKI S, 1995, AM J PATHOL, V146, P1309; KRAJEWSKI S, 1994, CANCER RES, V54, P5501; Kroemer G, 1997, IMMUNOL TODAY, V18, P44, DOI 10.1016/S0167-5699(97)80014-X; Kroemer G, 1997, NAT MED, V3, P614, DOI 10.1038/nm0697-614; Lock RB, 1996, CANCER RES, V56, P4006; LU QL, 1993, J PATHOL, V169, P431, DOI 10.1002/path.1711690408; Naumovski L, 1996, MOL CELL BIOL, V16, P3884; OLTVAI ZN, 1994, CELL, V79, P189, DOI 10.1016/0092-8674(94)90188-0; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; OReilly LA, 1996, EMBO J, V15, P6979, DOI 10.1002/j.1460-2075.1996.tb01090.x; PIETENPOL JA, 1994, CANCER RES, V54, P3714; Reed JC, 1997, NATURE, V387, P773, DOI 10.1038/42867; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; SCHWARZE MMK, 1995, CANCER RES, V55, P2262; Simonian PL, 1997, BLOOD, V90, P1208, DOI 10.1182/blood.V90.3.1208.1208_1208_1216; Simonian PL, 1996, J BIOL CHEM, V271, P22764, DOI 10.1074/jbc.271.37.22764; Simonian PL, 1997, ONCOGENE, V15, P1871, DOI 10.1038/sj.onc.1201350; Uhlmann EJ, 1998, J BIOL CHEM, V273, P17926, DOI 10.1074/jbc.273.28.17926; Walker A, 1997, CANCER RES, V57, P1939; Wang HG, 1996, CELL, V87, P629, DOI 10.1016/S0092-8674(00)81383-5; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; YIN DX, 1995, CANCER RES, V55, P4922; Zhu WJ, 1996, EMBO J, V15, P4130, DOI 10.1002/j.1460-2075.1996.tb00788.x; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	50	63	65	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 18	1999	18	7					1457	1464		10.1038/sj.onc.1202420	http://dx.doi.org/10.1038/sj.onc.1202420			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	167UK	10050882				2022-12-25	WOS:000078651600007
J	Galloway, AM; Spencer, CA; Anderson, CW; Allalunis-Turner, MJ				Galloway, AM; Spencer, CA; Anderson, CW; Allalunis-Turner, MJ			Differential stability of the DNA-activated protein kinase catalytic subunit mRNA in human glioma cells	ONCOGENE			English	Article						DNA-PKcs; radiation sensitivity; M059J cell line; mRNA stability; transcription rates	STRAND BREAK REPAIR; MESSENGER-RNA DECAY; NONSENSE CODONS; TRANSLATION; RADIATION; REGION; GENE; TRANSCRIPTION; SITE; KU	DNA-dependent protein kinase (DNA-PK) functions in double-strand break repair and immunoglobulin [V(D)J] recombination. We previously established a radiation-sensitive human cell line, M059J, derived from malignant glioma, which lacks the catalytic subunit (DNA-PKcs) of the DNA-PK multiprotein complex, Although previous Northern blot analysis failed to detect the DNA-PKcs transcript in these cells, we show here through quantitative studies that the transcript is present, albeit at greatly reduced ( similar to 20x) levels. Sequencing revealed no genetic alteration in either the promoter region, the kinase domain, or the 3' untranslated region of the DNA-PKcs gene to account for the reduced transcript levels. Nuclear run-on transcription assays indicated that the rate of DNA-PKcs transcription in M059J and DNA-PKcs proficient cell lines was similar, but the stability of the DNA-PKcs message in the M059J cell line was drastically ( similar to 20x) reduced. Furthermore, M059J cells lack an alternately spliced DNA-PKcs transcript that accounts for a minor (5 - 20%) proportion of the DNA-PKcs message in all other cell lines tested. Thus, alterations in DNA-PKcs mRNA stability and/or the lack of the alternate mRNA may result in the loss of DNA-PKcs activity, This finding has important implications as DNA-PKcs activity is essential to cells repairing damage induced by radiation or radiomimetric agents.	Univ Alberta, Cross Canc Inst, Edmonton, AB T6G 1Z2, Canada; Univ Alberta, Dept Oncol, Edmonton, AB T6G 1Z2, Canada; Brookhaven Natl Lab, Dept Biol, Upton, NY 11973 USA	University of Alberta; University of Alberta; United States Department of Energy (DOE); Brookhaven National Laboratory	Allalunis-Turner, MJ (corresponding author), Univ Alberta, Cross Canc Inst, Edmonton, AB T6G 1Z2, Canada.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052825] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM52825] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLALUNISTURNER MJ, 1995, RADIAT RES, V144, P288, DOI 10.2307/3578948; ALLALUNISTURNER MJ, 1993, RADIAT RES, V134, P349, DOI 10.2307/3578196; Anderson Carl W., 1992, Critical Reviews in Eukaryotic Gene Expression, V2, P283; Anderson Carl W., 1994, Seminars in Cell Biology, V5, P427, DOI 10.1006/scel.1994.1050; ANDERSON CW, 1993, TRENDS BIOCHEM SCI, V18, P433, DOI 10.1016/0968-0004(93)90144-C; Anderson CW, 1996, CURR TOP MICROBIOL, V217, P91; Belasco J.G., 2012, CONTROL MESSENGER RN; BELGRADER P, 1993, P NATL ACAD SCI USA, V90, P482, DOI 10.1073/pnas.90.2.482; BLIER PR, 1993, J BIOL CHEM, V268, P7594; Blunt T, 1996, P NATL ACAD SCI USA, V93, P10285, DOI 10.1073/pnas.93.19.10285; Chen P, 1996, INT J RADIAT BIOL, V69, P385, DOI 10.1080/095530096145940; Chu G, 1997, J BIOL CHEM, V272, P24097, DOI 10.1074/jbc.272.39.24097; Connelly MA, 1998, GENOMICS, V47, P71, DOI 10.1006/geno.1997.5076; Connelly MA, 1996, GENE, V175, P271, DOI 10.1016/0378-1119(96)00135-7; CURATOLA AM, 1995, MOL CELL BIOL, V15, P6331; EdwaldsGilbert G, 1997, NUCLEIC ACIDS RES, V25, P2547, DOI 10.1093/nar/25.13.2547; FALZON M, 1993, J BIOL CHEM, V268, P10546; HAGAN KW, 1995, MOL CELL BIOL, V15, P809; HARTLEY KO, 1995, CELL, V82, P849, DOI 10.1016/0092-8674(95)90482-4; HORIKOSHI T, 1992, CANCER RES, V52, P108; JACKSON SP, 1995, TRENDS BIOCHEM SCI, V20, P412, DOI 10.1016/S0968-0004(00)89090-8; Jacobson A, 1996, ANNU REV BIOCHEM, V65, P693, DOI 10.1146/annurev.bi.65.070196.003401; Jin SF, 1997, CANCER SURV, V29, P221; LEESMILLER SP, 1995, SCIENCE, V267, P1183, DOI 10.1126/science.7855602; LIM SK, 1992, MOL CELL BIOL, V12, P1149, DOI 10.1128/MCB.12.3.1149; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; NANBU R, 1994, MOL CELL BIOL, V14, P4920, DOI 10.1128/MCB.14.7.4920; ROTH DB, 1995, CURR BIOL, V5, P496, DOI 10.1016/S0960-9822(95)00101-1; SCHIAVI SC, 1994, J BIOL CHEM, V269, P3441; SIPLEY JD, 1995, P NATL ACAD SCI USA, V92, P7515, DOI 10.1073/pnas.92.16.7515; Spencer CA, 1997, J VIROL, V71, P2031, DOI 10.1128/JVI.71.3.2031-2040.1997; SUWA A, 1994, P NATL ACAD SCI USA, V91, P6904, DOI 10.1073/pnas.91.15.6904; THOMPSON LH, 1995, MUTAT RES-DNA REPAIR, V337, P131, DOI 10.1016/0921-8777(95)00018-F; YUN DF, 1995, MOL CELL BIOL, V15, P1021; ZHANG SA, 1995, MOL CELL BIOL, V15, P2231	35	15	15	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 11	1999	18	6					1361	1368		10.1038/sj.onc.1202433	http://dx.doi.org/10.1038/sj.onc.1202433			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	165FW	10022818				2022-12-25	WOS:000078510900012
J	Lee, AC; Fenster, BE; Ito, H; Takeda, K; Bae, NS; Hirai, T; Yu, ZX; Ferrans, VJ; Howard, BH; Finkel, T				Lee, AC; Fenster, BE; Ito, H; Takeda, K; Bae, NS; Hirai, T; Yu, ZX; Ferrans, VJ; Howard, BH; Finkel, T			Ras proteins induce senescence by altering the intracellular levels of reactive oxygen species	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-FIBROBLASTS; HYDROGEN-PEROXIDE; OXIDATIVE STRESS; GROWTH ARREST; IN-VIVO; CELLS; GENERATION; TRANSFORMATION; INVOLVEMENT; APOPTOSIS	Human diploid fibroblasts eventually lose the capacity to replicate in culture and enter a viable but nonproliferative state of senescence. Recently, it has been demonstrated that retroviral-mediated gene transfer into primary fibroblasts of an activated ras gene (V12ras) rapidly accelerates development of the senescent phenotype, Using this in vitro system, we have sought to define the mediators of Res-induced senescence. We demonstrate that expression of V12Ras results in an increase in intracellular and in particular, mitochondrial reactive oxygen species, The ability of V12Ras to induce growth arrest and senescence is shown to be partially inhibited by coexpression of an activated rad gene. A more dramatic rescue of V12Ras-expressing cells is demonstrated when the cells are placed in a low oxygen environment, a condition in which reactive oxygen species production is inhibited. In addition, in a 1% oxygen environment, Res is unable to trigger an increase in the level of the cyclin-dependent kinase inhibitor p21 or to activate the senescent program. Under normoxic (20% O-2) conditions, the V12Ras senescent phenotype is demonstrated to be unaffected by scavengers of superoxide but rescued by scavengers of hydrogen peroxide. These results suggest that in normal diploid cells, Ras proteins regulate oxidant production and that a rise in intracellular H2O2 represents a critical signal mediating replicative senescence.	NHLBI, Cardiol Branch, NIH, Bethesda, MD 20892 USA; NHLBI, Pathol Sect, NIH, Bethesda, MD 20892 USA; NICHD, Lab Mol Growth Regulat, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Finkel, T (corresponding author), NHLBI, Cardiol Branch, NIH, 10 Ctr Dr, Bethesda, MD 20892 USA.	finkelt@gwgate.nhlbi.nih.gov						Alcorta DA, 1996, P NATL ACAD SCI USA, V93, P13742, DOI 10.1073/pnas.93.24.13742; Bae YS, 1997, J BIOL CHEM, V272, P217, DOI 10.1074/jbc.272.1.217; Beckman KB, 1998, PHYSIOL REV, V78, P547, DOI 10.1152/physrev.1998.78.2.547; Bladier C, 1997, CELL GROWTH DIFFER, V8, P589; Brown JP, 1997, SCIENCE, V277, P831, DOI 10.1126/science.277.5327.831; Cai JY, 1998, J BIOL CHEM, V273, P11401, DOI 10.1074/jbc.273.19.11401; CHANCE B, 1979, PHYSIOL REV, V59, P527, DOI 10.1152/physrev.1979.59.3.527; CHEN Q, 1995, P NATL ACAD SCI USA, V92, P4337, DOI 10.1073/pnas.92.10.4337; CHEN Q, 1994, P NATL ACAD SCI USA, V91, P4130, DOI 10.1073/pnas.91.10.4130; Chen QM, 1998, BIOCHEM J, V332, P43, DOI 10.1042/bj3320043; Crawford LE, 1996, J BIOL CHEM, V271, P26863, DOI 10.1074/jbc.271.43.26863; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Finkel T, 1998, CURR OPIN CELL BIOL, V10, P248, DOI 10.1016/S0955-0674(98)80147-6; GarciaRuiz C, 1997, J BIOL CHEM, V272, P11369; GRIENDLING KK, 1994, CIRC RES, V74, P1141, DOI 10.1161/01.RES.74.6.1141; GUZMAN RJ, 1994, P NATL ACAD SCI USA, V91, P10732, DOI 10.1073/pnas.91.22.10732; Hagen TM, 1997, P NATL ACAD SCI USA, V94, P3064, DOI 10.1073/pnas.94.7.3064; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; HARMAN D, 1956, J GERONTOL, V11, P298, DOI 10.1093/geronj/11.3.298; Irani K, 1997, SCIENCE, V275, P1649, DOI 10.1126/science.275.5306.1649; Johnson TM, 1996, P NATL ACAD SCI USA, V93, P11848, DOI 10.1073/pnas.93.21.11848; JONES N, 1979, CELL, V17, P683, DOI 10.1016/0092-8674(79)90275-7; Joneson T, 1998, J BIOL CHEM, V273, P17991, DOI 10.1074/jbc.273.29.17991; Kheradmand F, 1998, SCIENCE, V280, P898, DOI 10.1126/science.280.5365.898; KOHL NE, 1987, ONCOGENE, V2, P41; KRIEGERBRAUER HI, 1992, J CLIN INVEST, V89, P1006, DOI 10.1172/JCI115641; LO YYC, 1995, J BIOL CHEM, V270, P11727, DOI 10.1074/jbc.270.20.11727; Martin GM, 1996, NAT GENET, V13, P25, DOI 10.1038/ng0596-25; MEIER B, 1989, BIOCHEM J, V263, P539, DOI 10.1042/bj2630539; Melov S, 1998, NAT GENET, V18, P159, DOI 10.1038/ng0298-159; Ogryzko VV, 1997, MOL CELL BIOL, V17, P4877, DOI 10.1128/MCB.17.8.4877; OHBA M, 1994, J CELL BIOL, V126, P1079, DOI 10.1083/jcb.126.4.1079; Olson MF, 1998, NATURE, V394, P295, DOI 10.1038/28425; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Pracyk JB, 1998, J CLIN INVEST, V102, P929, DOI 10.1172/JCI2552; RIDLEY AJ, 1988, EMBO J, V7, P1635, DOI 10.1002/j.1460-2075.1988.tb02990.x; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Sohal RS, 1996, SCIENCE, V273, P59, DOI 10.1126/science.273.5271.59; STEIN GH, 1995, BIOESSAYS, V17, P537, DOI 10.1002/bies.950170610; Sugrue MM, 1997, P NATL ACAD SCI USA, V94, P9648, DOI 10.1073/pnas.94.18.9648; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; Sundaresan M, 1996, BIOCHEM J, V318, P379, DOI 10.1042/bj3180379; Venable ME, 1995, J BIOL CHEM, V270, P30701, DOI 10.1074/jbc.270.51.30701; YUAN HT, 1995, MECH AGEING DEV, V81, P159, DOI 10.1016/0047-6374(95)01584-M	44	510	521	1	25	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 19	1999	274	12					7936	7940		10.1074/jbc.274.12.7936	http://dx.doi.org/10.1074/jbc.274.12.7936			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	178LU	10075689	hybrid			2022-12-25	WOS:000079268100048
J	Lillig, CH; Prior, A; Schwenn, JD; Aslund, F; Ritz, D; Vlamis-Gardikas, A; Holmgren, A				Lillig, CH; Prior, A; Schwenn, JD; Aslund, F; Ritz, D; Vlamis-Gardikas, A; Holmgren, A			New thioredoxins and glutaredoxins as electron donors of 3 '-phosphoadenylylsulfate reductase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUTATHIONE-DEPENDENT SYNTHESIS; ESCHERICHIA-COLI; RIBONUCLEOTIDE REDUCTASE; SULFATE REDUCTION; MIXED DISULFIDE; PAPS-REDUCTASE; PROTEINS; DEOXYRIBONUCLEOTIDES; MECHANISM; MUTANT	Reduction of inorganic sulfate to sulfite in prototrophic bacteria occurs with 3'-phosphoadenylylsulfate (PAPS) as substrate for PAPS reductase and is the first step leading to reduced sulfur for cellular biosynthetic reactions. The relative efficiency as reductants of homogeneous highly active PAPS reductase of the newly identified second thioredoxin (Trx2) and glutaredoxins (Grx1, Grx2, Grx3, and a mutant Grx1C14S) was compared with the well known thioredoxin (Trx1) from Escherichia coli, Trx1, Trx2, and Grx1 supported virtually identical rates of sulfite formation with a V-max, ranging from 6.6 units mg(-1) (Trx1) to 5.1 units mg(-1) (Grx1), whereas Grx1C14S was only marginally active, and Grx2 and Grx3 had no activity. The structural difference between active reductants had no effect upon K-m (PAPS) (22.5 mu m) Grx1 effectively replaced Trx1 with essentially identical K-m-values: K-m (trx1) (13.7 mu M), K-m (grx1) (14.9 mu M), whereas the K-m (trx2) was considerably higher (34.2 mu M). The results agree with previous in vivo data suggesting that Trx1 or Grx1 is essential for sulfate reduction but not for ribonucleotide reduction in E, coli.	Ruhr Univ Bochum, Fac Biol, D-44780 Bochum, Germany; Harvard Med Sch, Dept Microbiol & Mol Genet, Boston, MA USA; Karolinska Inst, Med Nobel Inst Biochem, Dept Med Biochem & Biophys, Stockholm, Sweden	Ruhr University Bochum; Harvard University; Harvard Medical School; Karolinska Institutet	Schwenn, JD (corresponding author), Ruhr Univ Bochum, Fac Biol, POB 10 21 48, D-44780 Bochum, Germany.	jens-dirk.schwenn@ruhr-uni-bochum.de	Vlamis, Alexios/AAF-5152-2020; Lillig, Christopher Horst/AAD-7098-2019	Vlamis, Alexios/0000-0001-5068-6459; Lillig, Christopher Horst/0000-0003-2509-5117				Aslund F, 1996, J BIOL CHEM, V271, P6736, DOI 10.1074/jbc.271.12.6736; ASLUND F, 1994, P NATL ACAD SCI USA, V91, P9813, DOI 10.1073/pnas.91.21.9813; BEAVIS RC, 1990, ANAL CHEM, V62, P1836, DOI 10.1021/ac00216a020; Berardi MJ, 1998, BIOCHEMISTRY-US, V37, P5849, DOI 10.1021/bi972924d; BERENDT U, 1995, EUR J BIOCHEM, V233, P347, DOI 10.1111/j.1432-1033.1995.347_1.x; Bjornberg O, 1991, Protein Expr Purif, V2, P287, DOI 10.1016/1046-5928(91)90085-W; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUSHWELLER JH, 1994, J MOL BIOL, V235, P1585, DOI 10.1006/jmbi.1994.1108; BUSHWELLER JH, 1992, BIOCHEMISTRY-US, V31, P9288, DOI 10.1021/bi00153a023; GONZALEZ.P, 1970, J BIOL CHEM, V245, P2371; Hanahan D., 1985, DNA CLONING PRACTICA, V1, P109; HOLMGREN A, 1979, J BIOL CHEM, V254, P3672; HOLMGREN A, 1979, J BIOL CHEM, V254, P3664; Jordan A, 1997, J BIOL CHEM, V272, P18044, DOI 10.1074/jbc.272.29.18044; KRONE FA, 1991, MOL GEN GENET, V225, P314, DOI 10.1007/BF00269864; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Miranda-Vizuete A, 1997, J BIOL CHEM, V272, P30841, DOI 10.1074/jbc.272.49.30841; MirandaVizuete A, 1996, J BIOL CHEM, V271, P19099, DOI 10.1074/jbc.271.32.19099; Prinz WA, 1997, J BIOL CHEM, V272, P15661, DOI 10.1074/jbc.272.25.15661; RUSSEL M, 1990, J BACTERIOL, V172, P1923, DOI 10.1128/jb.172.4.1923-1929.1990; Sambrook J., 2002, MOL CLONING LAB MANU; Savage H, 1997, STRUCTURE, V5, P895, DOI 10.1016/S0969-2126(97)00244-X; SCHIFFMANN S, 1998, THESIS FACULTY BIOLO; SCHRIEK U, 1986, ARCH MICROBIOL, V145, P32, DOI 10.1007/BF00413024; SCHWENN JD, 1987, Z NATURFORSCH C, V42, P93; SCHWENN JD, 1980, J CHROMATOGR, V139, P285; Stewart EJ, 1998, EMBO J, V17, P5543, DOI 10.1093/emboj/17.19.5543; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TSANG MLS, 1978, J BACTERIOL, V134, P131, DOI 10.1128/JB.134.1.131-138.1978; TSANG MLS, 1981, J BACTERIOL, V146, P1059, DOI 10.1128/JB.146.3.1059-1066.1981; VlamisGardikas A, 1997, J BIOL CHEM, V272, P11236; WAGNER W, 1978, Z NATURFORSCH C, V33, P517; Warburg O., 1942, BIOCHEM Z, V310, P384; WILSON LG, 1961, J BIOL CHEM, V236, P1822; Zheng M, 1998, SCIENCE, V279, P1718, DOI 10.1126/science.279.5357.1718	35	119	123	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	1999	274	12					7695	7698		10.1074/jbc.274.12.7695	http://dx.doi.org/10.1074/jbc.274.12.7695			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	178LU	10075658	hybrid			2022-12-25	WOS:000079268100017
J	Miele, RG; Prorok, M; Costa, VA; Castellino, FJ				Miele, RG; Prorok, M; Costa, VA; Castellino, FJ			Glycosylation of asparagine-28 of recombinant staphylokinase with high-mannose-type oligosaccharides results in a protein with highly attenuated plasminogen activator activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; KRINGLE-2 DOMAIN; PICHIA-PASTORIS; GENE; EXPRESSION; CLONING	The properties of recombinant staphylokinase (SakSTAR) expressed in Pichia pastoris cells have been determined. The single consensus N-linked oligosaccharide linkage site in SakSTAR (at Asn(28) of the mature protein) was occupied in approximately 50% of the expressed protein with high-mannose-type oligosaccharides. The majority of these glycans ranged in polymerization state from Man(8)GlcNAc(2) to Man(14)GlcNAc(2), with the predominant species being Man(10)GlcNAc(2) and Man(11)GlcNAc(2). Glycosylated SakSTAR (SakSTAR(g)) did not differ from its aglycosyl form in its aggregation state in solution, its thermal denaturation properties, its ability to form a complex with human plasmin (hPm), the amidolytic properties of the respective SakSTAR-hPm complexes, or its ability to liberate the amino-terminal decapeptide required for formation of a functional SakSTAR-hPm plasminogen activator complex. However, this latter complex with SakSTAR(g) showed a greatly reduced ability to activate human plasminogen (hPg) as compared with the same complex with the aglycosyl form of SakSTAR, We conclude that glycosylation at Asn28 does not affect the structural properties of SakSTAR or its ability to participate in the formation of an active enzymatic complex with hPm, but it is detrimental to the ability of the SakSTAR-hPm complex to serve as a hPg activator. This is likely due to restricted access of hPg to the active site of the SakSTAR(g)-hPm complex.	Univ Notre Dame, Dept Chem & Biochem, Notre Dame, IN 46556 USA	University of Notre Dame	Castellino, FJ (corresponding author), Univ Notre Dame, Dept Chem & Biochem, Notre Dame, IN 46556 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL013423, R01HL013423] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-13423] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BEHNKE D, 1987, MOL GEN GENET, V210, P528, DOI 10.1007/BF00327208; CASTELLINO F J, 1988, Haemostasis, V18, P15; COLLEN D, 1992, FIBRINOLYSIS, V6, P226, DOI 10.1016/0268-9499(92)90075-S; COLLEN D, 1994, BLOOD, V84, P680, DOI 10.1182/blood.V84.3.680.680; COLLEN D, 1993, CIRCULATION, V87, P1850, DOI 10.1161/01.CIR.87.6.1850; COLLEN D, 1992, FIBRINOLYSIS, V6, P203, DOI 10.1016/0268-9499(92)90073-Q; Duman JG, 1998, BIOTECHNOL APPL BIOC, V28, P39; GASE A, 1994, EUR J BIOCHEM, V223, P303, DOI 10.1111/j.1432-1033.1994.tb18995.x; GERLACH D, 1988, ZBL BAKT-INT J MED M, V269, P314; Grella DK, 1997, BLOOD, V89, P1585, DOI 10.1182/blood.V89.5.1585.1585_1585_1589; KOWALSKALOTH B, 1975, ACTA BIOCHIM POL, V22, P327; LIJNEN HR, 1994, EUR J BIOCHEM, V224, P143, DOI 10.1111/j.1432-1033.1994.tb20005.x; Miele RG, 1997, BIOTECHNOL APPL BIOC, V25, P151; Miele RG, 1997, BIOTECHNOL APPL BIOC, V26, P79; Nilsen SL, 1997, BIOTECHNOL APPL BIOC, V25, P63, DOI 10.1111/j.1470-8744.1997.tb00415.x; Parry MAA, 1998, NAT STRUCT BIOL, V5, P917, DOI 10.1038/2359; Rabijns A, 1997, NAT STRUCT BIOL, V4, P357, DOI 10.1038/nsb0597-357; ROBBINS KC, 1967, J BIOL CHEM, V242, P2333; SAKO T, 1985, EUR J BIOCHEM, V149, P557, DOI 10.1111/j.1432-1033.1985.tb08961.x; SAKO T, 1983, MOL GEN GENET, V190, P271, DOI 10.1007/BF00330650; SANGER F, 1977, P NATL ACAD SCI USA, V74, P6463; SCHLOTT B, 1994, BBA-PROTEIN STRUCT M, V1204, P235, DOI 10.1016/0167-4838(94)90013-2; SCHLOTT B, 1994, BIO-TECHNOL, V12, P185, DOI 10.1038/nbt0294-185; Schlott B, 1997, J BIOL CHEM, V272, P6067, DOI 10.1074/jbc.272.9.6067; Ueshima S, 1996, BLOOD COAGUL FIBRIN, V7, P522, DOI 10.1097/00001721-199607000-00003	25	21	27	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 19	1999	274	12					7769	7776		10.1074/jbc.274.12.7769	http://dx.doi.org/10.1074/jbc.274.12.7769			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	178LU	10075668	hybrid			2022-12-25	WOS:000079268100027
J	Steiner, H; Romig, H; Grim, MG; Philipp, U; Pesold, B; Citron, M; Baumeister, R; Haass, C				Steiner, H; Romig, H; Grim, MG; Philipp, U; Pesold, B; Citron, M; Baumeister, R; Haass, C			The biological and pathological function of the presenilin-1 Delta exon 9 mutation is independent of its defect to undergo proteolytic processing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAMILIAL ALZHEIMERS-DISEASE; AMYLOID BETA-PROTEIN; IN-VIVO; CAENORHABDITIS-ELEGANS; MISSENSE MUTATIONS; GENE; ENDOPROTEOLYSIS; CELLS	The two homologous presenilins are key factors for the generation of amyloid beta-peptide (A beta), since Alzheimer's disease (AD)-associated mutations enhance the production of the pathologically relevant 42-amino acid A beta (A beta 42), and a gene knockout of presenilin-1 (PS1) significantly inhibits total A beta production. Presenilins undergo proteolytic processing within the domain encoded by exon 9, a process that may be closely related to their biological and pathological activity. An AD-associated mutation within the PS1 gene deletes exon 9 (PS1 Delta exon9) due to a splicing error and results in the accumulation of the uncleaved full-length protein. We now demonstrate the unexpected finding that the pathological activity of PS1 Delta exon9 is independent of its lack to undergo proteolytic processing, but is rather due to a point mutation (S290C) occurring at the aberrant exon 8/10 splice junction. Mutagenizing the cysteine residue at position 290 to the original serine residue completely inhibits the pathological activity in regard to the elevated production of A beta 42. Like PS1 Delta exon9, the resulting presenilin variant (PS1 Delta exon9 C290S) accumulates as an uncleaved protein and fully replaces endogenous presenilin fragments. Moreover, PS1 Delta exon9 C290S exhibits a significantly increased biological activity in a highly sensitive in vivo assay as compared with the AD-associated mutation. Therefore not only the increased A beta 42 production but also the decreased biological function of PS1 Delta exon9 is due to a point mutation and independent of the lack of proteolytic processing.	Cent Inst Mental Hlth, Dept Biol Mol, D-68159 Mannheim, Germany; Boehringer Ingelheim KG, CNS Res, D-55216 Ingelheim, Germany; Genzentrum, D-81377 Munich, Germany; Amgen Inc, Thousand Oaks, CA 91320 USA	Central Institute of Mental Health; Boehringer Ingelheim; University of Munich; Amgen	Baumeister, R (corresponding author), Cent Inst Mental Hlth, Dept Biol Mol, J5, D-68159 Mannheim, Germany.							Baumeister R, 1997, Genes Funct, V1, P149; Borchelt DR, 1996, NEURON, V17, P1005, DOI 10.1016/S0896-6273(00)80230-5; Capell A, 1998, J BIOL CHEM, V273, P3205, DOI 10.1074/jbc.273.6.3205; Citron M, 1997, NAT MED, V3, P67, DOI 10.1038/nm0197-67; CITRON M, 1992, NATURE, V360, P672, DOI 10.1038/360672a0; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; GRUNBERG J, 1997, ALZHEIMERS RES, V3, P253; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; JARRETT JT, 1993, CELL, V73, P1055, DOI 10.1016/0092-8674(93)90635-4; Klafki HW, 1996, ANAL BIOCHEM, V237, P24, DOI 10.1006/abio.1996.0195; Lee MK, 1997, NAT MED, V3, P756, DOI 10.1038/nm0797-756; Levitan D, 1996, P NATL ACAD SCI USA, V93, P14940, DOI 10.1073/pnas.93.25.14940; LEVITAN D, 1995, NATURE, V377, P351, DOI 10.1038/377351a0; LEVYLAHAD E, 1995, SCIENCE, V269, P973, DOI 10.1126/science.7638622; Mercken M, 1996, FEBS LETT, V389, P297, DOI 10.1016/0014-5793(96)00608-4; Murayama O, 1997, NEUROSCI LETT, V229, P61, DOI 10.1016/S0304-3940(97)00417-5; PerezTur J, 1995, NEUROREPORT, V7, P297; Podlisny MB, 1997, NEUROBIOL DIS, V3, P325, DOI 10.1006/nbdi.1997.0129; Price DL, 1998, ANNU REV NEUROSCI, V21, P479, DOI 10.1146/annurev.neuro.21.1.479; ROGAEV EI, 1995, NATURE, V376, P775, DOI 10.1038/376775a0; Selkoe DJ, 1996, J BIOL CHEM, V271, P18295, DOI 10.1074/jbc.271.31.18295; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; Steiner H, 1998, J BIOL CHEM, V273, P32322, DOI 10.1074/jbc.273.48.32322; Thinakaran G, 1997, J BIOL CHEM, V272, P28415, DOI 10.1074/jbc.272.45.28415; Thinakaran G, 1996, NEURON, V17, P181, DOI 10.1016/S0896-6273(00)80291-3; Walter J, 1998, BIOCHEMISTRY-US, V37, P5961, DOI 10.1021/bi971763a; Walter J, 1997, P NATL ACAD SCI USA, V94, P5349, DOI 10.1073/pnas.94.10.5349	27	111	112	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 19	1999	274	12					7615	7618		10.1074/jbc.274.12.7615	http://dx.doi.org/10.1074/jbc.274.12.7615			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	178LU	10075646	hybrid			2022-12-25	WOS:000079268100005
J	Klukas, O; Schubert, WD; Jordan, P; Krauss, N; Fromme, P; Witt, HT; Saenger, W				Klukas, O; Schubert, WD; Jordan, P; Krauss, N; Fromme, P; Witt, HT; Saenger, W			Photosystem I, an improved model of the stromal subunits PsaC, PsaD, and PsaE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYANOBACTERIUM SYNECHOCOCCUS SP; SYNECHOCYSTIS SP PCC-6803; CROSS-LINKED COMPLEX; STRUCTURAL ORGANIZATION; ANGSTROM RESOLUTION; PSI-C; PROTEIN; FERREDOXIN; REFINEMENT; POLYPEPTIDES	An improved electron density map of photosystem I (PSI) calculated at 4-Angstrom resolution yields a more detailed structural model of the stromal subunits PsaC, PsaD, and PsaE than previously reported. The NMR structure of the subunit PsaE of PSI from Synechococcus sp, PCC7002 (Falzone, C, J., Kao, Y.-H., Zhao, J., Bryant, D. A, and Lecomte, J, T, J, (1994) Biochemistry 33, 6052-6062) has been used as a model to interpret the region of the electron density map corresponding to this subunit, The spatial orientation with respect to other subunits is described as well as the possible interactions between the stromal subunits. A first model of PsaD consisting of a four-stranded beta-sheet and an alpha-helix is suggested, indicating that this subunit partly shields PsaC from the stromal side. In addition to the improvements on the stromal subunits, the structural model of the membrane-integral region of PSI is also extended. The current electron density map allows the identification of the N and C termini of the subunits PsaA and PsaB, The 11-transmembrane alpha-helices of these subunits can now be assigned uniquely to the hydrophobic segments identified by hydrophobicity analyses.	Free Univ Berlin, Inst Kristallog, D-14195 Berlin, Germany; Tech Univ Berlin, Max Volmer Inst Biophys Chem & Biochim, D-10623 Berlin, Germany	Free University of Berlin; Technical University of Berlin	Krauss, N (corresponding author), Free Univ Berlin, Inst Kristallog, Takustr 6, D-14195 Berlin, Germany.	nkrauss@chemie.fu-berlin.de	Schubert, Wolf-Dieter/A-5617-2009	Schubert, Wolf-Dieter/0000-0003-4998-519X; Krauss, Norbert/0000-0002-7128-4632				Abrahams JP, 1996, ACTA CRYSTALLOGR D, V52, P30, DOI 10.1107/S0907444995008754; ADMAN ET, 1976, J BIOL CHEM, V251, P3801; Armbrust TS, 1996, PLANT PHYSIOL, V111, P1307, DOI 10.1104/pp.111.4.1307; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BOTTCHER B, 1992, BIOCHIM BIOPHYS ACTA, V1100, P125, DOI 10.1016/0167-4838(92)90544-N; CANTRELL A, 1987, PLANT MOL BIOL, V9, P453, DOI 10.1007/BF00015877; CHITNIS PR, 1995, PHOTOSYNTH RES, V44, P23, DOI 10.1007/BF00018294; Chitnis VP, 1996, J BIOL CHEM, V271, P11772, DOI 10.1074/jbc.271.20.11772; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; Diaz-Quintana A, 1998, BIOCHEMISTRY-US, V37, P3429, DOI 10.1021/bi972469l; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; FALZONE CJ, 1994, BIOCHEMISTRY-US, V33, P6052, DOI 10.1021/bi00186a004; FROMME P, 1994, BBA-BIOENERGETICS, V1187, P99, DOI 10.1016/0005-2728(94)90092-2; Fromme P, 1998, BBA-BIOENERGETICS, V1365, P175, DOI 10.1016/S0005-2728(98)00059-0; FROMME P, 1998, THESIS TU BERLIN GER; Golbeck JH, 1994, MOL BIOL CYANOBACTER, P319; Hanley J, 1996, BIOCHEMISTRY-US, V35, P8563, DOI 10.1021/bi960399x; Jansson S, 1996, PLANT PHYSIOL, V112, P409, DOI 10.1104/pp.112.1.409; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kamlowski A, 1997, BBA-BIOENERGETICS, V1319, P199, DOI 10.1016/S0005-2728(96)00162-4; KRAUSS N, 1993, NATURE, V361, P326, DOI 10.1038/361326a0; Krauss N, 1996, NAT STRUCT BIOL, V3, P965, DOI 10.1038/nsb1196-965; Kruip J, 1997, J BIOL CHEM, V272, P17061, DOI 10.1074/jbc.272.27.17061; Lelong C, 1996, EMBO J, V15, P2160, DOI 10.1002/j.1460-2075.1996.tb00569.x; LI N, 1991, BIOCHEMISTRY-US, V30, P7863, DOI 10.1021/bi00245a028; Muhlenhoff U, 1996, EMBO J, V15, P488, DOI 10.1002/j.1460-2075.1996.tb00381.x; MUHLENHOFF U, 1993, GENE, V127, P71, DOI 10.1016/0378-1119(93)90618-D; Naver H, 1996, J BIOL CHEM, V271, P8996, DOI 10.1074/jbc.271.15.8996; NAVER H, 1995, PHYSIOL PLANTARUM, V95, P19, DOI 10.1111/j.1399-3054.1995.tb00802.x; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; OTWINOWSKI Z, 1996, P CCP4 STUD WEEK IS, P80; RODDAY SM, 1994, PHOTOSYNTH RES, V42, P185, DOI 10.1007/BF00018261; Rodday SM, 1996, BIOCHEMISTRY-US, V35, P11832, DOI 10.1021/bi9612834; RODDAY SM, 1995, BIOCHEMISTRY-US, V34, P6328, DOI 10.1021/bi00019a010; ROUSSEAU F, 1993, EMBO J, V12, P1755, DOI 10.1002/j.1460-2075.1993.tb05823.x; Schubert WD, 1997, J MOL BIOL, V272, P741, DOI 10.1006/jmbi.1997.1269; Schubert WD, 1995, PHOTOSYNTHESIS: FROM LIGHT TO BIOSPHERE, VOL II, P3; Setif P, 1995, PHOTOSYNTHESIS: FROM LIGHT TO BIOSPHERE, VOL II, P23; Sun J, 1997, J BIOL CHEM, V272, P21793, DOI 10.1074/jbc.272.35.21793; Terwilliger TC, 1996, ACTA CRYSTALLOGR D, V52, P743, DOI 10.1107/S0907444996001473; TERWILLIGER TC, 1983, ACTA CRYSTALLOGR A, V39, P813, DOI 10.1107/S0108767383001592; Vassiliev IR, 1998, BIOPHYS J, V74, P2029, DOI 10.1016/S0006-3495(98)77909-3; WEBER N, 1993, BIOCHIM BIOPHYS ACTA, V1143, P204, DOI 10.1016/0005-2728(93)90144-5; Xia ZC, 1998, EUR J BIOCHEM, V255, P309, DOI 10.1046/j.1432-1327.1998.2550309.x; XU G, 1994, PLANT PHYSIOL, V106, P617; YU L, 1993, PLANT PHYSIOL, V103, P171, DOI 10.1104/pp.103.1.171; ZHAO J, 1993, MOL MICROBIOL, V9, P183, DOI 10.1111/j.1365-2958.1993.tb01680.x	49	85	98	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	1999	274	11					7351	7360		10.1074/jbc.274.11.7351	http://dx.doi.org/10.1074/jbc.274.11.7351			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	175DV	10066799	hybrid			2022-12-25	WOS:000079078400071
J	Park, SH; Liu, XW; Hennighausen, L; Davey, HW; Waxman, DJ				Park, SH; Liu, XW; Hennighausen, L; Davey, HW; Waxman, DJ			Distinctive roles of STAT5a and STAT5b in sexual dimorphism of hepatic P450 gene expression - Impact of Stat5a gene disruption	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TESTOSTERONE 16-ALPHA-HYDROXYLASE I-P-45016-ALPHA; GROWTH-HORMONE STIMULATION; DNA-BINDING; TYROSINE PHOSPHORYLATION; MAMMARY-GLAND; MOUSE-LIVER; RAT HEPATOCYTES; PROLACTIN; CYTOCHROME-P450; TRANSCRIPTION	Stat5b gene disruption leads to an apparent growth hormone (GH) pulse insensitivity associated with loss of male-characteristic body growth rates and male-specific liver gene expression (Udy, G, B,, Towers, R. P,, Snell, R. G,, Wilkins, R, J,, Park, S, H,, Ram, P, A., Waxman, D, J,, and Davey, H, W, (1997) Proc. Natl. Acad. Sci. U.S.A. 94, 7239-7244). In the present study, disruption of the mouse Stat5a gene, whose coding sequence is similar to 90% identical to the Stat5b gene, resulted in no loss of expression in male mice of several sex-dependent, GH-regulated liver cytochrome P450 (CYP) enzymes. By contrast, the loss of STAT5b feminized the livers of males by decreasing expression of male-specific CYPs (CYP2D9 and testosterone 16 alpha-hydroxylase) while increasing to female levels several female-predominant liver CYPs (CYP3A, CYP2B, and testosterone 6 beta-droxylase). Since STAT5a is thus nonessential for these male GH responses, STAT5b homodimers, but not STAT5a-STAT5b heterodimers, probably mediate the sexually dimorphic effects of male GH pulses on liver CYP expression. In female mice, however, disruption of either Stat5a or Stat5b led to striking decreases in several liver CYP-catalyzed testosterone hydroxylase activities. Stat5a or Stat5b gene disruption also led to the loss of a female-specific, GH-regulated hepatic CYP2B enzyme. STAT5a, which is much less abundant in liver than STAT5b, and STAT5b are therefore both required for constitutive expression in female but not male mouse liver of certain GH-regulated CYP steroid hydroxylases, suggesting that STAT5 protein heterodimerization is an important determinant of the sex-dependent and gene-specific effects that GH has on the liver.	Boston Univ, Dept Biol, Div Cell & Mol Biol, Boston, MA 02215 USA; NIDDK, NIH, Bethesda, MD 20892 USA; AgResearch, Hamilton, New Zealand	Boston University; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); AgResearch - New Zealand	Waxman, DJ (corresponding author), Boston Univ, Dept Biol, Div Cell & Mol Biol, 5 Cummington St, Boston, MA 02215 USA.	djw@bio.bu.edu		Hennighausen, Lothar/0000-0001-8319-9841; Waxman, David/0000-0001-7982-9206	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK061000, R01DK033765] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK033765] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABDELRAZZAK Z, 1995, FEBS LETT, V366, P159, DOI 10.1016/0014-5793(95)00513-9; AZAM M, 1995, EMBO J, V14, P1402, DOI 10.1002/j.1460-2075.1995.tb07126.x; DEVORE K, 1985, BIOCHEMISTRY-US, V24, P5632, DOI 10.1021/bi00341a052; FINBLOOM DS, 1994, MOL CELL BIOL, V14, P2113, DOI 10.1128/MCB.14.3.2113; FORD HC, 1979, ENDOCRINOLOGY, V104, P857, DOI 10.1210/endo-104-4-857; Gebert CA, 1999, MOL ENDOCRINOL, V13, P213, DOI 10.1210/me.13.2.213; Gebert CA, 1997, MOL ENDOCRINOL, V11, P400, DOI 10.1210/me.11.4.400; GOUILLEUX F, 1994, EMBO J, V13, P4361, DOI 10.1002/j.1460-2075.1994.tb06756.x; GOUILLEUX F, 1995, EMBO J, V14, P2005, DOI 10.1002/j.1460-2075.1995.tb07192.x; HARADA N, 1984, J BIOL CHEM, V259, P2285; Hennighausen L, 1997, J BIOL CHEM, V272, P7567, DOI 10.1074/jbc.272.12.7567; HONKAKOSKI P, 1992, BIOCHEM J, V285, P979, DOI 10.1042/bj2850979; Jahn GA, 1997, BIOL REPROD, V57, P894, DOI 10.1095/biolreprod57.4.894; LAKSO M, 1991, EUR J BIOCHEM, V195, P477, DOI 10.1111/j.1432-1033.1991.tb15728.x; Liu XW, 1996, MOL ENDOCRINOL, V10, P1496, DOI 10.1210/me.10.12.1496; Liu XW, 1997, GENE DEV, V11, P179, DOI 10.1101/gad.11.2.179; LIU XW, 1995, P NATL ACAD SCI USA, V92, P8831, DOI 10.1073/pnas.92.19.8831; Liu XW, 1998, CELL GROWTH DIFFER, V9, P795; Luo GY, 1997, J BIOL CHEM, V272, P26841, DOI 10.1074/jbc.272.43.26841; MACLEOD JN, 1991, J ENDOCRINOL, V131, P395, DOI 10.1677/joe.0.1310395; MODE A, 1992, ADV ENZYME REGUL, V32, P255; Moriggl R, 1996, MOL CELL BIOL, V16, P5691; MUI ALF, 1995, EMBO J, V14, P1166, DOI 10.1002/j.1460-2075.1995.tb07100.x; NAGANO M, 1994, J BIOL CHEM, V269, P13337; NEGISHI M, 1991, METHOD ENZYMOL, V206, P267; Nelson DR, 1996, PHARMACOGENETICS, V6, P1, DOI 10.1097/00008571-199602000-00002; NOSHIRO M, 1986, J BIOL CHEM, V261, P5923; NOSHIRO M, 1986, ARCH BIOCHEM BIOPHYS, V244, P857, DOI 10.1016/0003-9861(86)90655-7; Ormandy CJ, 1997, GENE DEV, V11, P167, DOI 10.1101/gad.11.2.167; PALLARD C, 1995, J BIOL CHEM, V270, P15942, DOI 10.1074/jbc.270.27.15942; Paolini M, 1996, ARCH TOXICOL, V70, P451, DOI 10.1007/s002040050298; Ram PA, 1996, J BIOL CHEM, V271, P5929, DOI 10.1074/jbc.271.10.5929; RIPPERGER JA, 1995, J BIOL CHEM, V270, P29998, DOI 10.1074/jbc.270.50.29998; SHAPIRO BH, 1995, INT J BIOCHEM CELL B, V27, P9, DOI 10.1016/1357-2725(94)00056-5; Sharma MC, 1998, BIOCHEM PHARMACOL, V56, P1251, DOI 10.1016/S0006-2952(98)00247-0; Silva CM, 1996, MOL ENDOCRINOL, V10, P508, DOI 10.1210/me.10.5.508; Smit LS, 1997, ENDOCRINOLOGY, V138, P3426, DOI 10.1210/en.138.8.3426; STANLEY LA, 1991, BIOCHEM PHARMACOL, V42, P311, DOI 10.1016/0006-2952(91)90718-K; Subramanian A, 1998, NUCLEIC ACIDS RES, V26, P2173, DOI 10.1093/nar/26.9.2173; Tapner M, 1996, HEPATOLOGY, V24, P367; Teglund S, 1998, CELL, V93, P841, DOI 10.1016/S0092-8674(00)81444-0; TOLLET P, 1995, J BIOL CHEM, V270, P12569, DOI 10.1074/jbc.270.21.12569; Udy GB, 1997, P NATL ACAD SCI USA, V94, P7239, DOI 10.1073/pnas.94.14.7239; Verdier F, 1998, MOL CELL BIOL, V18, P5852, DOI 10.1128/MCB.18.10.5852; WAKAO H, 1994, EMBO J, V13, P2182, DOI 10.1002/j.1460-2075.1994.tb06495.x; Waxman David J., 1995, P391; Waxman DJ, 1996, J BIOL CHEM, V271, P29978, DOI 10.1074/jbc.271.47.29978; WAXMAN DJ, 1991, METHOD ENZYMOL, V206, P462; WAXMAN DJ, 1982, J BIOL CHEM, V257, P446; WAXMAN DJ, 1992, J STEROID BIOCHEM, V43, P1055, DOI 10.1016/0960-0760(92)90333-E; WAXMAN DJ, 1995, J BIOL CHEM, V270, P13262, DOI 10.1074/jbc.270.22.13262; WAXMAN DJ, 1991, P NATL ACAD SCI USA, V88, P6868, DOI 10.1073/pnas.88.15.6868; WAXMAN DJ, 1987, MOL PHARMACOL, V32, P615; WONG G, 1987, BIOCHEMISTRY-US, V26, P8683, DOI 10.1021/bi00400a029; Zhou YC, 1999, J BIOL CHEM, V274, P2672, DOI 10.1074/jbc.274.5.2672	55	96	98	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	1999	274	11					7421	7430		10.1074/jbc.274.11.7421	http://dx.doi.org/10.1074/jbc.274.11.7421			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	175DV	10066807	hybrid			2022-12-25	WOS:000079078400079
J	Schuenemann, TA; Delgado-Nixon, VM; Dalbey, RE				Schuenemann, TA; Delgado-Nixon, VM; Dalbey, RE			Direct evidence that the proton motive force inhibits membrane translocation of positively charged residues within membrane proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							M13 COAT PROTEIN; ESCHERICHIA-COLI; INNER MEMBRANE; ELECTROCHEMICAL GRADIENT; CYTOPLASMIC MEMBRANE; LEADER PEPTIDASE; PLASMA-MEMBRANE; INSERTION; TOPOLOGY; PROCOAT	The M13 phage procoat protein requires both its signal sequence and its membrane anchor sequence in the mature part of the protein for membrane insertion. Translocation of its short acidic periplasmic loop is stimulated by the proton motive force (pmf) and does not require the Sec components. We now find that the pmf becomes increasingly important for the translocation of negatively charged residues within procoat when the hydrophobicity of the signal or membrane anchor is incrementally reduced. In contrast, we find that the pmf inhibits translocation of the periplasmic loop when it contains one or two positively charged residues. This inhibitory effect of the pmf is stronger when the hydrophobicity of the inserting procoat protein is compromised. No pmf effect is observed for translocation of an uncharged periplasmic loop even when the hydrophobicity is reduced. We also show that the Delta Psi component of the pmf is necessary and sufficient for insertion of representative constructs and that the translocation effects of charged residues are primarily due to the Delta Psi component of the pmf and not the pH component.	Ohio State Univ, Dept Chem, Columbus, OH 43210 USA	Ohio State University	Dalbey, RE (corresponding author), Ohio State Univ, Dept Chem, 120 W 18Th Ave, Columbus, OH 43210 USA.	dalbey@chemistry.ohio-state.edu						ANDERSSON H, 1994, EMBO J, V13, P2267, DOI 10.1002/j.1460-2075.1994.tb06508.x; BAKKER EP, 1984, EMBO J, V3, P895, DOI 10.1002/j.1460-2075.1984.tb01902.x; Bassilana M, 1996, EMBO J, V15, P5202, DOI 10.1002/j.1460-2075.1996.tb00905.x; BOYD D, 1990, CELL, V62, P1031, DOI 10.1016/0092-8674(90)90378-R; CALAMIA J, 1990, P NATL ACAD SCI USA, V87, P4937, DOI 10.1073/pnas.87.13.4937; CAO GQ, 1994, EMBO J, V13, P4662, DOI 10.1002/j.1460-2075.1994.tb06789.x; CAO GQ, 1995, EMBO J, V14, P866, DOI 10.1002/j.1460-2075.1995.tb07068.x; COHEN SN, 1973, P NATL ACAD SCI USA, V70, P3240, DOI 10.1073/pnas.70.11.3240; DALBEY RE, 1995, TRENDS CELL BIOL, V5, P380, DOI 10.1016/S0962-8924(00)89079-0; DALBEY RE, 1990, TRENDS BIOCHEM SCI, V15, P253, DOI 10.1016/0968-0004(90)90047-F; DANIELS CJ, 1981, P NATL ACAD SCI-BIOL, V78, P5396, DOI 10.1073/pnas.78.9.5396; DATE T, 1980, P NATL ACAD SCI-BIOL, V77, P4669, DOI 10.1073/pnas.77.8.4669; Delgado-Partin VM, 1998, J BIOL CHEM, V273, P9927, DOI 10.1074/jbc.273.16.9927; ENEQUIST HG, 1981, EUR J BIOCHEM, V116, P227, DOI 10.1111/j.1432-1033.1981.tb05323.x; ENGELMAN DM, 1986, ANNU REV BIOPHYS BIO, V15, P321, DOI 10.1146/annurev.bb.15.060186.001541; FLEWELLING RF, 1986, BIOPHYS J, V49, P541, DOI 10.1016/S0006-3495(86)83664-5; GELLER B, 1993, J BIOL CHEM, V268, P9442; GELLER BL, 1990, J BACTERIOL, V172, P4870, DOI 10.1128/jb.172.9.4870-4876.1990; GELLER BL, 1985, J BIOL CHEM, V260, P3281; HONIG BH, 1986, ANNU REV BIOPHYS BIO, V15, P163; INADA T, 1989, J BACTERIOL, V171, P585, DOI 10.1128/jb.171.1.585-587.1989; ITO K, 1980, J BIOL CHEM, V255, P2123; JOHNSTON S, 1985, GENE, V34, P137, DOI 10.1016/0378-1119(85)90121-0; KATO M, 1992, J BIOL CHEM, V267, P413; Kiefer D, 1997, EMBO J, V16, P2197, DOI 10.1093/emboj/16.9.2197; KORONAKIS V, 1991, EMBO J, V10, P3263, DOI 10.1002/j.1460-2075.1991.tb04890.x; KUHN A, 1986, EMBO J, V5, P3681, DOI 10.1002/j.1460-2075.1986.tb04699.x; KUHN A, 1990, J STRUCT BIOL, V104, P38, DOI 10.1016/1047-8477(90)90055-H; KUHN A, 1986, NATURE, V322, P335, DOI 10.1038/322335a0; KUHN A, 1995, FEMS MICROBIOL REV, V17, P185; LEE E, 1994, J BIOL CHEM, V269, P28822; Nouwen N, 1996, P NATL ACAD SCI USA, V93, P5953, DOI 10.1073/pnas.93.12.5953; PADAN E, 1976, EUR J BIOCHEM, V63, P533, DOI 10.1111/j.1432-1033.1976.tb10257.x; ROHRER J, 1990, SCIENCE, V250, P1418, DOI 10.1126/science.2124001; ROJO EE, 1995, EMBO J, V14, P3445, DOI 10.1002/j.1460-2075.1995.tb07350.x; SCHIEBEL E, 1991, CELL, V64, P927, DOI 10.1016/0092-8674(91)90317-R; Soekarjo M, 1996, BIOCHEMISTRY-US, V35, P1232, DOI 10.1021/bi951087h; SPIESS M, 1987, EMBO J, V6, P2683, DOI 10.1002/j.1460-2075.1987.tb02560.x; Stuart RA, 1996, TRENDS BIOCHEM SCI, V21, P261, DOI 10.1016/S0968-0004(96)10035-9; TANI K, 1989, J BIOL CHEM, V264, P18582; vanKlompenburg W, 1997, EMBO J, V16, P4261, DOI 10.1093/emboj/16.14.4261; VONHEIJNE G, 1988, EUR J BIOCHEM, V174, P671; VONHEIJNE G, 1994, ANNU REV BIOPH BIOM, V23, P167; VONHEIJNE G, 1990, PROTEIN ENG, V4, P109, DOI 10.1093/protein/4.2.109; VONHEIJNE G, 1986, EMBO J, V5, P3021, DOI 10.1002/j.1460-2075.1986.tb04601.x; WOLFE PB, 1985, J BIOL CHEM, V260, P1836; WOLFE PB, 1982, J BIOL CHEM, V257, P7898; ZIMMERMANN R, 1982, J BIOL CHEM, V257, P6529; ZIMMERMANN R, 1983, J BIOL CHEM, V258, P3920	49	32	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 12	1999	274	11					6855	6864		10.1074/jbc.274.11.6855	http://dx.doi.org/10.1074/jbc.274.11.6855			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	175DV	10066738	hybrid			2022-12-25	WOS:000079078400010
J	Berjukow, S; Gapp, F; Aczel, S; Sinnegger, J; Mitterdorfer, J; Glossmann, H; Hering, S				Berjukow, S; Gapp, F; Aczel, S; Sinnegger, J; Mitterdorfer, J; Glossmann, H; Hering, S			Sequence differences between alpha(1C) and alpha(1S) Ca2+ channel subunits reveal structural determinants of a guarded and modulated benzothiazepine receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BI CALCIUM CHANNELS; AMINO-ACID-RESIDUES; MOLECULAR DETERMINANTS; 1,4-DIHYDROPYRIDINE SENSITIVITY; FUNCTIONAL EXPRESSION; SKELETAL-MUSCLE; IVS6 SEGMENT; PHENYLALKYLAMINES; BINDING; BLOCK	The molecular basis of the Ca2+ channel block by (+)cis-diltiazem was studied in class A/L-type chimeras and mutant ore. Ca2+ channels. Chimeras consisted of either rabbit heart (alpha(1C-a)) or carp skeletal muscle (alpha(1S)) sequence in transmembrane segments IILS6, IVS6, and adjacent S5-S6 linkers. Only chimeras containing sequences from alpha(1C-a) were efficiently blocked by (+)-cis-diltiazem, whereas the phenylalkylamine (-)-gallopamil efficiently blocked both constructs. Carp skeletal muscle and rabbit heart Ca2+ channel alpha(1) subunits differ with respect to two nonconserved amino acids in segments IVS6. Transfer of a single leucine (Leu(1383), located at the extracellular mouth of the pore) from IVS6 alpha(1C-a) to IVS6 of alpha(1S) Significantly increased the (+)-cis-diltiazem sensitivity of the corresponding mutant L1383I. An analysis of the role of the two heterologous amino acids in a L-type alpha(1) subunit revealed that corresponding amino acids in position 1487 (outer channel mouth) determine recovery of resting Ca2+ channels from block by (+)-cis-diltiazem. The second heterologous amino acid in position 1504 of segment IVS6 (inner channel mouth) was identified as crucial inactivation determinant of L-type Ca2+ channels. This residue simultaneously modulates drug binding during membrane depolarization. Our study provides the first evidence for a guarded and modulated benzothiazepine receptor on L-type channels.	Inst Biochem Pharmacol, A-6020 Innsbruck, Austria		Hering, S (corresponding author), Inst Biochem Pharmacol, Peter Mayr Str 1, A-6020 Innsbruck, Austria.	Steffen.Hering@uibk.ac.at	Glossmann, Hartmut/AAL-9790-2020	Brauns, Martina/0000-0002-0547-2731; glossmann, hartmut h./0000-0002-7392-3266				Barrish J C, 1993, Bioorg Med Chem, V1, P309, DOI 10.1016/S0968-0896(00)82135-5; Berjukov S, 1996, BRIT J PHARMACOL, V119, P1197, DOI 10.1111/j.1476-5381.1996.tb16022.x; BIRNBAUMER L, 1994, NEURON, V13, P505, DOI 10.1016/0896-6273(94)90021-3; Bodi I, 1997, J BIOL CHEM, V272, P24952, DOI 10.1074/jbc.272.40.24952; Cai DM, 1997, MOL PHARMACOL, V51, P872, DOI 10.1124/mol.51.5.872; Degtiar VE, 1997, BIOPHYS J, V73, P157, DOI 10.1016/S0006-3495(97)78056-1; Doring F, 1996, J BIOL CHEM, V271, P11745, DOI 10.1074/jbc.271.20.11745; Grabner M, 1996, NEURON, V16, P207, DOI 10.1016/S0896-6273(00)80037-9; GRABNER M, 1991, P NATL ACAD SCI USA, V88, P727, DOI 10.1073/pnas.88.3.727; HERING S, 1993, MOL PHARMACOL, V43, P820; Hering S, 1997, P NATL ACAD SCI USA, V94, P13323, DOI 10.1073/pnas.94.24.13323; Hering S, 1996, J BIOL CHEM, V271, P24471, DOI 10.1074/jbc.271.40.24471; Hering S, 1998, TRENDS PHARMACOL SCI, V19, P439, DOI 10.1016/S0165-6147(98)01258-9; HESCHELER J, 1982, PFLUG ARCH EUR J PHY, V393, P287, DOI 10.1007/BF00581411; HILLE B, 1977, J GEN PHYSIOL, V69, P497, DOI 10.1085/jgp.69.4.497; HOCKERMAN GH, 1995, J BIOL CHEM, V270, P22119, DOI 10.1074/jbc.270.38.22119; Hockerman GH, 1997, ANNU REV PHARMACOL, V37, P361, DOI 10.1146/annurev.pharmtox.37.1.361; Holmgren M, 1996, J GEN PHYSIOL, V108, P195, DOI 10.1085/jgp.108.3.195; Ito H, 1997, MOL PHARMACOL, V52, P735, DOI 10.1124/mol.52.4.735; Kraus R, 1996, J BIOL CHEM, V271, P20113, DOI 10.1074/jbc.271.33.20113; Kraus RL, 1998, BIOPHYS J, V74, pA107; LEE KS, 1983, NATURE, V302, P790, DOI 10.1038/302790a0; MIKAMI A, 1989, NATURE, V340, P230, DOI 10.1038/340230a0; Mitterdorfer J, 1996, J BIOL CHEM, V271, P30330, DOI 10.1074/jbc.271.48.30330; MORI Y, 1991, NATURE, V350, P398, DOI 10.1038/350398a0; Peterson BZ, 1997, J BIOL CHEM, V272, P18752, DOI 10.1074/jbc.272.30.18752; Peterson BZ, 1996, J BIOL CHEM, V271, P5293, DOI 10.1074/jbc.271.10.5293; Schuster A, 1996, EMBO J, V15, P2365, DOI 10.1002/j.1460-2075.1996.tb00592.x; Sinnegger MJ, 1997, J BIOL CHEM, V272, P27686, DOI 10.1074/jbc.272.44.27686; STARMER CF, 1985, MOL PHARMACOL, V28, P348; Striessnig J, 1998, TRENDS PHARMACOL SCI, V19, P108, DOI 10.1016/S0165-6147(98)01171-7; TANABE T, 1987, NATURE, V328, P313, DOI 10.1038/328313a0	32	25	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	1999	274	10					6154	6160		10.1074/jbc.274.10.6154	http://dx.doi.org/10.1074/jbc.274.10.6154			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172BQ	10037699	hybrid			2022-12-25	WOS:000078902800021
J	Kwon, BS; Yu, KY; Ni, J; Yu, GL; Jang, IK; Kim, YJ; Xing, L; Liu, D; Wang, SX; Kwon, BS				Kwon, BS; Yu, KY; Ni, J; Yu, GL; Jang, IK; Kim, YJ; Xing, L; Liu, D; Wang, SX; Kwon, BS			Identification of a novel activation-inducible protein of the tumor necrosis factor receptor superfamily and its ligand	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOMAIN-CONTAINING RECEPTOR; FACTOR-KAPPA-B; APOPTOSIS-MEDIATING RECEPTOR; CELL-SURFACE ANTIGEN; DEATH-DOMAIN; MOLECULAR-CLONING; MONOCLONAL-ANTIBODY; MEMBER; FAMILY; TRAIL	Among members of the tumor necrosis factor receptor (TNFR) superfamily, 4-1BB, CD27, and glucocorticoid-induced tumor necrosis factor receptor family-related gene (GITR) share a striking homology in the cytoplasmic domain. Here we report the identification of a new member, activation-inducible TNFR family member (AITR), which belongs to this subfamily, and its ligand. The receptor is expressed in lymph node and peripheral blood leukocytes, and its expression is up-regulated in human peripheral mononuclear cells mainly after stimulation with anti-CD3/CD28 monoclonal antibodies or phorbol 12-myristate 13-acetate/ionomycin. AITR associates with TRAF1 (TNF receptor-associated factor 1), TRAF2, and TRAF3, and induces nuclear factor (NF)-kappa B activation via TRAF2. The ligand for AITR (AITRL) was found to be an undescribed member of the TNF family, which is expressed in endothelial cells. Thus, AITR and AITRL seem to be important for interactions between activated T lymphocytes and endothelial cells.	Indiana Univ, Sch Med, Dept Microbiol & Immunol, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Walther Oncol Ctr, Indianapolis, IN 46202 USA; Walther Canc Inst, Indianapolis, IN 46202 USA; Human Genome Sci, Rockville, MD 20850 USA; Univ Ulsan, Immunomodulat Res Ctr, Ulsan 680749, South Korea; Univ Ulsan, Dept Sci Biol, Ulsan 680749, South Korea	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute; Walther Cancer Institute; GlaxoSmithKline; Human Genome Sciences Inc; University of Ulsan; University of Ulsan	Kwon, BS (corresponding author), Indiana Univ, Sch Med, Dept Microbiol & Immunol, 635 Barnhill Dr, Indianapolis, IN 46202 USA.	kkwon@sunflower.bio.indiana.edu			NIAID NIH HHS [AI28125] Funding Source: Medline; NIDCR NIH HHS [DE12156] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R43AI028125, R44AI028125] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE012156] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Akiba H, 1998, J BIOL CHEM, V273, P13353, DOI 10.1074/jbc.273.21.13353; Arch RH, 1998, MOL CELL BIOL, V18, P558, DOI 10.1128/MCB.18.1.558; Bodmer JL, 1997, IMMUNITY, V6, P79, DOI 10.1016/S1074-7613(00)80244-7; CAMERINI D, 1991, J IMMUNOL, V147, P3165; Cao ZD, 1996, NATURE, V383, P443, DOI 10.1038/383443a0; Chaudhary PM, 1997, IMMUNITY, V7, P821, DOI 10.1016/S1074-7613(00)80400-8; CHENG GH, 1995, SCIENCE, V267, P1494, DOI 10.1126/science.7533327; Chinnaiyan AM, 1996, SCIENCE, V274, P990, DOI 10.1126/science.274.5289.990; Degli-Esposti MA, 1997, IMMUNITY, V7, P813, DOI 10.1016/S1074-7613(00)80399-4; DegliEsposti MA, 1997, J EXP MED, V186, P1165, DOI 10.1084/jem.186.7.1165; Duckett CS, 1997, MOL CELL BIOL, V17, P1535, DOI 10.1128/MCB.17.3.1535; HU HM, 1994, J BIOL CHEM, V269, P30069; Jang IK, 1998, BIOCHEM BIOPH RES CO, V242, P613, DOI 10.1006/bbrc.1997.8016; Kitson J, 1996, NATURE, V384, P372, DOI 10.1038/384372a0; KWON BS, 1989, P NATL ACAD SCI USA, V86, P1963, DOI 10.1073/pnas.86.6.1963; MacFarlane M, 1997, J BIOL CHEM, V272, P25417, DOI 10.1074/jbc.272.41.25417; Marsters SA, 1997, CURR BIOL, V7, P1003, DOI 10.1016/S0960-9822(06)00422-2; Mauri DN, 1998, IMMUNITY, V8, P21, DOI 10.1016/S1074-7613(00)80455-0; Nakano H, 1996, J BIOL CHEM, V271, P14661, DOI 10.1074/jbc.271.25.14661; Nocentini G, 1997, P NATL ACAD SCI USA, V94, P6216, DOI 10.1073/pnas.94.12.6216; OEHM A, 1992, J BIOL CHEM, V267, P10709; Pan GH, 1997, SCIENCE, V277, P815, DOI 10.1126/science.277.5327.815; Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111; Pitt RM, 1996, J BIOL CHEM, V271, P12687, DOI 10.1074/jbc.271.22.12687; POLLOK KE, 1993, J IMMUNOL, V150, P771; Prasad KVS, 1997, P NATL ACAD SCI USA, V94, P6346, DOI 10.1073/pnas.94.12.6346; ROTHE M, 1995, SCIENCE, V269, P1421; Saoulli K, 1998, J EXP MED, V187, P1849, DOI 10.1084/jem.187.11.1849; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; SCHINDLER U, 1994, MOL CELL BIOL, V14, P5820, DOI 10.1128/MCB.14.9.5820; Schneider P, 1997, IMMUNITY, V7, P831, DOI 10.1016/S1074-7613(00)80401-X; Screaton GR, 1997, P NATL ACAD SCI USA, V94, P4615, DOI 10.1073/pnas.94.9.4615; Sheridan JP, 1997, SCIENCE, V277, P818, DOI 10.1126/science.277.5327.818; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; Song HY, 1997, P NATL ACAD SCI USA, V94, P9792, DOI 10.1073/pnas.94.18.9792; Takeuchi M, 1996, J BIOL CHEM, V271, P19935, DOI 10.1074/jbc.271.33.19935; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; VanArsdale TL, 1997, P NATL ACAD SCI USA, V94, P2460, DOI 10.1073/pnas.94.6.2460; Walczak H, 1997, EMBO J, V16, P5386, DOI 10.1093/emboj/16.17.5386; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; YONEHARA S, 1989, J EXP MED, V169, P1747, DOI 10.1084/jem.169.5.1747	41	159	204	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1999	274	10					6056	6061		10.1074/jbc.274.10.6056	http://dx.doi.org/10.1074/jbc.274.10.6056			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172BQ	10037686	hybrid			2022-12-25	WOS:000078902800008
J	Lamontagne, J; Papadopoulou, B				Lamontagne, J; Papadopoulou, B			Developmental regulation of spliced leader RNA gene in Leishmania donovani amastigotes is mediated by specific polyadenylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MINI-EXON GENE; PROCYCLIN MESSENGER-RNAS; TRYPANOSOMA-BRUCEI; HEAT-SHOCK; 3'-UNTRANSLATED REGION; INTERGENIC REGIONS; DISCONTINUOUS TRANSCRIPTION; DIFFERENTIAL EXPRESSION; CHAGASI PROMASTIGOTES; STABILITY	Leishmania cycles between the insect vector and its mammalian host undergoing several important changes mediated by the stage-specific expression of a number of genes. Using a genomic differential screening approach, we isolated differentially expressed cosmid clones carrying several copies of the mini-exon gene. We report that the spliced leader (SL) RNA essential for the maturation of all pre-mRNAs by trans-splicing, is developmentally regulated in Leishmania donovani amastigotes and that this regulation is rapidly induced upon parasite growth under acidic conditions. Stage-specific regulation of the SL RNA is associated with the expression of a larger similar to 170-nucleotide transcript that bears an additional 15-nucleotide sequence at its 3'-end and is polyadenylated in contrast to the mature SL RNA. The poly(A)(+) SL RNA represents 12-16% of the total SL transcript synthesized in amastigotes and is 2.5-3-fold more stable than the poly(A)(-) transcript. The poly(A)(+) SL transcript is synthesized specifically from one class of the genomic mini-exon copies. Polyadenylation of the SL RNA may control the levels of the SL mature transcript under amastigote growth and may represent an additional step in the gene regulation process during parasite differentiation.	Univ Laval, Ctr Hosp, CHUQ, Ctr Rech Infectiol, Quebec City, PQ G1V 4G2, Canada; Univ Laval, Fac Med, Quebec City, PQ G1V 4G2, Canada	Laval University; Laval University	Papadopoulou, B (corresponding author), Univ Laval, Ctr Hosp, CHUQ, Ctr Rech Infectiol, Pavillon CHUL,2705 Boul Laurier, Quebec City, PQ G1V 4G2, Canada.	Barbara.Papadopoulou@crchul.ulaval.ca						AGABIAN N, 1990, CELL, V61, P1157, DOI 10.1016/0092-8674(90)90674-4; ALY R, 1994, NUCLEIC ACIDS RES, V22, P2922, DOI 10.1093/nar/22.15.2922; ARGAMAN M, 1994, MOL BIOCHEM PARASIT, V64, P95, DOI 10.1016/0166-6851(94)90138-4; Baker EJ, 1993, CONTROL MESSENGER RN, P367; Beetham JK, 1997, J BIOL CHEM, V272, P17360, DOI 10.1074/jbc.272.28.17360; BELLOFATTO V, 1988, NUCLEIC ACIDS RES, V16, P7437, DOI 10.1093/nar/16.15.7437; BERSTEIN P, 1989, TRENDS BIOCHEM SCI, V14, P373; BORST P, 1986, ANNU REV BIOCHEM, V55, P701, DOI 10.1146/annurev.bi.55.070186.003413; Charest H, 1996, J BIOL CHEM, V271, P17081, DOI 10.1074/jbc.271.29.17081; CHAREST H, 1994, MOL CELL BIOL, V14, P2975, DOI 10.1128/MCB.14.5.2975; FERNANDES O, 1994, MOL BIOCHEM PARASIT, V66, P261, DOI 10.1016/0166-6851(94)90153-8; FLEISCHMANN J, 1994, GENE, V144, P45, DOI 10.1016/0378-1119(94)90201-1; FLINN HM, 1992, NUCLEIC ACIDS RES, V20, P755, DOI 10.1093/nar/20.4.755; Ford LP, 1997, MOL CELL BIOL, V17, P398, DOI 10.1128/MCB.17.1.398; Furger A, 1997, MOL CELL BIOL, V17, P4372, DOI 10.1128/MCB.17.8.4372; GRONDAL EJM, 1989, EMBO J, V8, P3383, DOI 10.1002/j.1460-2075.1989.tb08502.x; Hausler T, 1996, MOL BIOCHEM PARASIT, V76, P57, DOI 10.1016/0166-6851(95)02538-3; HEHL A, 1994, P NATL ACAD SCI USA, V91, P370, DOI 10.1073/pnas.91.1.370; Hotz HR, 1997, NUCLEIC ACIDS RES, V25, P3017, DOI 10.1093/nar/25.15.3017; HUBEL A, 1995, MOL BIOCHEM PARASIT, V70, P107, DOI 10.1016/0166-6851(95)00012-P; JOHNSON PJ, 1987, CELL, V51, P273, DOI 10.1016/0092-8674(87)90154-1; JOSHI M, 1993, MOL BIOCHEM PARASIT, V58, P345, DOI 10.1016/0166-6851(93)90057-5; KOOTER JM, 1984, EMBO J, V3, P2387, DOI 10.1002/j.1460-2075.1984.tb02144.x; Krobitsch S, 1998, J BIOL CHEM, V273, P6488, DOI 10.1074/jbc.273.11.6488; Kudla J, 1996, EMBO J, V15, P7137, DOI 10.1002/j.1460-2075.1996.tb01105.x; LABAN A, 1990, NATURE, V343, P572, DOI 10.1038/343572a0; LAIRD PW, 1985, NUCLEIC ACIDS RES, V13, P4253, DOI 10.1093/nar/13.12.4253; LEBOWITZ JH, 1993, GENE DEV, V7, P996, DOI 10.1101/gad.7.6.996; Lou H, 1996, GENE DEV, V10, P208, DOI 10.1101/gad.10.2.208; MATTHEWS KR, 1994, GENE DEV, V8, P491, DOI 10.1101/gad.8.4.491; MILHAUSEN M, 1984, CELL, V38, P721, DOI 10.1016/0092-8674(84)90267-8; MILLER SI, 1986, NUCLEIC ACIDS RES, V14, P7341, DOI 10.1093/nar/14.18.7341; Mottram JC, 1996, P NATL ACAD SCI USA, V93, P6008, DOI 10.1073/pnas.93.12.6008; MUHICH ML, 1989, J BIOL CHEM, V264, P7107; MUHICH ML, 1988, MOL CELL BIOL, V8, P3837, DOI 10.1128/MCB.8.9.3837; MURPHY WJ, 1986, CELL, V47, P517, DOI 10.1016/0092-8674(86)90616-1; Noll TM, 1997, MOL BIOCHEM PARASIT, V84, P215, DOI 10.1016/S0166-6851(96)02801-0; Nozaki T, 1995, MOL BIOCHEM PARASIT, V75, P55, DOI 10.1016/0166-6851(95)02512-X; OHARA EB, 1995, P NATL ACAD SCI USA, V92, P1807, DOI 10.1073/pnas.92.6.1807; PAPADOPOULOU B, 1992, EMBO J, V11, P3601, DOI 10.1002/j.1460-2075.1992.tb05444.x; PELLE R, 1993, MOL BIOCHEM PARASIT, V59, P277, DOI 10.1016/0166-6851(93)90225-M; Quijada L, 1997, J BIOL CHEM, V272, P4493, DOI 10.1074/jbc.272.7.4493; RAMAMOORTHY R, 1995, J BIOL CHEM, V270, P12133, DOI 10.1074/jbc.270.20.12133; REDDY R, 1985, J BIOL CHEM, V260, P930; Ross J, 1996, TRENDS GENET, V12, P171, DOI 10.1016/0168-9525(96)10016-0; ROSS J, 1995, MICROBIOL REV, V59, P423, DOI 10.1128/MMBR.59.3.423-450.1995; RUDENKO G, 1990, MOL CELL BIOL, V10, P3492, DOI 10.1128/MCB.10.7.3492; RYAN KA, 1993, GENE, V131, P145, DOI 10.1016/0378-1119(93)90684-U; SACHS AB, 1993, CELL, V74, P413, DOI 10.1016/0092-8674(93)80043-E; SAITO RM, 1994, EMBO J, V13, P5460, DOI 10.1002/j.1460-2075.1994.tb06881.x; Sambrook J., 2002, MOL CLONING LAB MANU; SCHOLLER JK, 1989, NUCLEIC ACIDS RES, V17, P7999, DOI 10.1093/nar/17.19.7999; SCHURCH N, 1994, MOL CELL BIOL, V14, P3668, DOI 10.1128/MCB.14.6.3668; STURM NR, 1998, WOODS HOL MOL PAR 9, P60; TSCHUDI C, 1988, EMBO J, V7, P455, DOI 10.1002/j.1460-2075.1988.tb02833.x; VANHAMME L, 1995, MICROBIOL REV, V59, P223, DOI 10.1128/MMBR.59.2.223-240.1995; VASSELLA E, 1994, NUCLEIC ACIDS RES, V22, P1359, DOI 10.1093/nar/22.8.1359; WAHLE E, 1992, ANNU REV BIOCHEM, V61, P419; Wormington M, 1993, CURR OPIN CELL BIOL, V5, P950, DOI 10.1016/0955-0674(93)90075-2; ZILBERSTEIN D, 1994, ANNU REV MICROBIOL, V48, P449, DOI 10.1146/annurev.mi.48.100194.002313	60	47	50	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	1999	274	10					6602	6609		10.1074/jbc.274.10.6602	http://dx.doi.org/10.1074/jbc.274.10.6602			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172BQ	10037755	hybrid			2022-12-25	WOS:000078902800077
J	Sueyoshi, T; Kawamoto, T; Zelko, I; Honkakoski, P; Negishi, M				Sueyoshi, T; Kawamoto, T; Zelko, I; Honkakoski, P; Negishi, M			The repressed nuclear receptor CAR responds to phenobarbital in activating the human CYP2B6 gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCTION; DEXAMETHASONE; EXPRESSION; ELEMENTS; BINDING; P450	The endogenous CYP2B6 gene becomes phenobarbital (PB) inducible in androstenol-treated HepG2 cells either transiently or stably transfected with a nuclear receptor CAR expression vector. The PB induction mediated by CAR is regulated by a conserved 51-base pair element called PR-responsive enhancer module (PBREM) that has now been located between -1733 and -1683 bp in the gene's 5'-flanking region. An in vitro translated CAR acting as a retinoid X receptor alpha heterodimer binds directly to the two nuclear receptor sites NR1 and NR2 within PBREM, In a stably transfected HepG2 cell line, both PBREM and NR1 are activated by PB and PR-type compounds such as chlorinated pesticides, polychlorinated biphenyls and chlorpromazine, In addition to PBREM, CAR also transactivates the steroid/rifampicin-response element of the human CYP3A4 gene in HepG2 cells. Thus, activation of the repressed nuclear receptor CAR appears to be a versatile mediator that regulates PB induction of the CYP2B and other genes.	NIEHS, Pharmacogenet Sect, Reprod & Dev Toxicol Lab, NIH, Res Triangle Pk, NC 27709 USA; Univ Kuopio, Dept Pharmaceut, FIN-70211 Kuopio, Finland	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); University of Eastern Finland	Negishi, M (corresponding author), NIEHS, Pharmacogenet Sect, Reprod & Dev Toxicol Lab, NIH, POB 12233, Res Triangle Pk, NC 27709 USA.		, 河本健/D-7938-2015; Negishi, Masahiko/F-7805-2019; Zelko, Igor N/L-2673-2013; Honkakoski, Paavo/AAJ-1278-2020	, 河本健/0000-0003-3337-1775; Negishi, Masahiko/0000-0002-2076-8928; Zelko, Igor N/0000-0003-3976-3884; Honkakoski, Paavo/0000-0002-4332-3577				BAES M, 1994, MOL CELL BIOL, V14, P1544, DOI 10.1128/MCB.14.3.1544; BULGER WH, 1985, MOL PHARMACOL, V27, P115; CONNEY AH, 1982, CANCER RES, V42, P4875; DEWAZIERS I, 1992, PHARMACOGENETICS, V2, P12, DOI 10.1097/00008571-199202000-00003; Forman BM, 1998, NATURE, V395, P612, DOI 10.1038/26996; GOWER DB, 1993, J ENDOCRINOL, V137, P167, DOI 10.1677/joe.0.1370167; Hoffman SMG, 1995, J MOL EVOL, V41, P894; Honkakoski P, 1997, J BIOL CHEM, V272, P14943, DOI 10.1074/jbc.272.23.14943; Honkakoski P, 1998, MOL PHARMACOL, V53, P597, DOI 10.1124/mol.53.4.597; Honkakoski P, 1996, J BIOL CHEM, V271, P9746, DOI 10.1074/jbc.271.16.9746; Honkakoski P, 1998, MOL CELL BIOL, V18, P5652, DOI 10.1128/MCB.18.10.5652; Honkakoski P, 1998, J BIOCHEM MOL TOXIC, V12, P3; Huss JM, 1996, P NATL ACAD SCI USA, V93, P4666, DOI 10.1073/pnas.93.10.4666; Johnson EF, 1996, FASEB J, V10, P1241, DOI 10.1096/fasebj.10.11.8836037; KENDE AS, 1985, MOL PHARMACOL, V28, P445; Kim J, 1997, J BIOL CHEM, V272, P29423, DOI 10.1074/jbc.272.47.29423; Kliewer SA, 1998, CELL, V92, P73, DOI 10.1016/S0092-8674(00)80900-9; LEE SST, 1995, MOL CELL BIOL, V15, P3012; Lehmann JM, 1998, J CLIN INVEST, V102, P1016, DOI 10.1172/JCI3703; Park YK, 1996, J BIOL CHEM, V271, P23725, DOI 10.1074/jbc.271.39.23725; REMMER H, 1963, SCIENCE, V142, P1657, DOI 10.1126/science.142.3600.1657; Stoltz C, 1998, J BIOL CHEM, V273, P8528, DOI 10.1074/jbc.273.14.8528; TROTTIER E, 1995, GENE, V158, P263, DOI 10.1016/0378-1119(94)00916-G; WAXMAN DJ, 1992, BIOCHEM J, V281, P577, DOI 10.1042/bj2810577	24	579	601	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1999	274	10					6043	6046		10.1074/jbc.274.10.6043	http://dx.doi.org/10.1074/jbc.274.10.6043			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172BQ	10037683	hybrid			2022-12-25	WOS:000078902800005
J	Tsuchida, M; Knechtle, SJ; Hamawy, MM				Tsuchida, M; Knechtle, SJ; Hamawy, MM			CD28 ligation induces tyrosine phosphorylation of Pyk2 but not Fak in Jurkat T cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; RECEPTOR SIGNAL-TRANSDUCTION; PHOSPHATIDYLINOSITOL 3-KINASE; DEPENDENT PHOSPHORYLATION; COSTIMULATORY RECEPTOR; CD28-DEFICIENT MICE; GENE-EXPRESSION; MAST-CELLS; PROTEIN; ACTIVATION	Protein tyrosine kinases are critical for the function of CD28 in T cells. We examined whether the tyrosine kinases Pyk2 and Fak (members of the focal adhesion kinase family) are involved in CD28 signaling. We found that ligating CD28 in Jurkat T cells rapidly increases the tyrosine phosphorylation of Pyk2 but not of Fak. Paxillin, a substrate for Pyk2 and Fak, was not tyrosine-phosphorylated after CD28 ligation. CD28-induced tyrosine phosphorylation of Pyk2 was markedly reduced in the absence of external Ca2+. Previous studies have shown that the T cell antigen receptor (TCR) induces tyrosine phosphorylation of Pyk2. In this report, the concurrent ligation of CD28 and TCR increased tyrosine phosphorylation of Pyk2; however, the extent of phosphorylation by both receptors was equivalent to the sum of that induced by each receptor alone. The Syk/Zap inhibitor piceatannol blocked CD28, and TCR induced tyrosine phosphorylation of Pyk2, suggesting that Syk/ Zap is involved in Pyk2 phosphorylation. In contrast, the phosphatidylinositol 3-kinase inhibitor wortmannin blocked TCR- but not CD28-induced phosphorylation of Pyk2, suggesting that CD28 and TCR activate distinct pathways to induce tyrosine phosphorylation of Pyk2. Notably, depleting phorbol 12-myristate 13-acetate-sensitive protein kinase C did not block CD28- and CD3-induced tyrosine phosphorylation of Pyk2. These data provide evidence for the involvement of Pyk2 in the CD28 signaling cascade and suggest that neither Fak nor paxillin is involved in the signaling pathways of CD28.	Univ Wisconsin, Dept Surg, Madison, WI 53792 USA	University of Wisconsin System; University of Wisconsin Madison	Hamawy, MM (corresponding author), Univ Wisconsin, Dept Surg, 600 Highland Ave,H4-749, Madison, WI 53792 USA.	hamawy@surgery.wisc.edu		Knechtle, Stuart/0000-0002-1625-385X				ARUFFO A, 1987, P NATL ACAD SCI USA, V84, P8573, DOI 10.1073/pnas.84.23.8573; Astier A, 1997, J BIOL CHEM, V272, P228; AUGUST A, 1994, INT IMMUNOL, V6, P769, DOI 10.1093/intimm/6.5.769; AUGUST A, 1994, BIOCHEM BIOPH RES CO, V199, P1466, DOI 10.1006/bbrc.1994.1396; AUGUST A, 1994, P NATL ACAD SCI USA, V91, P9347, DOI 10.1073/pnas.91.20.9347; AVRAHAM S, 1995, J BIOL CHEM, V270, P27742, DOI 10.1074/jbc.270.46.27742; BLOEMENA E, 1994, EUR J IMMUNOL, V5, P943; Cantrell D, 1996, ANNU REV IMMUNOL, V14, P259, DOI 10.1146/annurev.immunol.14.1.259; Carpino N, 1997, CELL, V88, P197, DOI 10.1016/S0092-8674(00)81840-1; Cefai D, 1996, INT IMMUNOL, V8, P1609, DOI 10.1093/intimm/8.10.1609; Chan AC, 1996, CURR OPIN IMMUNOL, V8, P394, DOI 10.1016/S0952-7915(96)80130-0; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; DEKKER LV, 1995, CURR OPIN STRUC BIOL, V5, P396, DOI 10.1016/0959-440X(95)80103-0; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; Felsch JS, 1998, P NATL ACAD SCI USA, V95, P5051, DOI 10.1073/pnas.95.9.5051; FUJIHARA M, 1994, J IMMUNOL, V152, P1898; Ganju RK, 1997, J EXP MED, V185, P1055, DOI 10.1084/jem.185.6.1055; Ganju RK, 1998, BLOOD, V91, P791, DOI 10.1182/blood.V91.3.791.791_791_797; GREEN JM, 1994, IMMUNITY, V1, P501, DOI 10.1016/1074-7613(94)90092-2; Guan JL, 1997, INT J BIOCHEM CELL B, V29, P1085, DOI 10.1016/S1357-2725(97)00051-4; HAMAWY MM, 1995, J BIOL CHEM, V270, P12305, DOI 10.1074/jbc.270.20.12305; HAMAWY MM, 1994, J IMMUNOL, V153, P4655; HAMAWY MM, 1995, CELL SIGNAL, V7, P535, DOI 10.1016/0898-6568(95)00024-J; HAMAWY MM, 1993, J BIOL CHEM, V268, P6851; Hamawy MM, 1997, J BIOL CHEM, V272, P30498, DOI 10.1074/jbc.272.48.30498; HAMAWY MM, 1993, J BIOL CHEM, V268, P5227; HANKS SK, 1992, P NATL ACAD SCI USA, V89, P8487, DOI 10.1073/pnas.89.18.8487; Hanks SK, 1997, BIOESSAYS, V19, P137, DOI 10.1002/bies.950190208; Hiregowdara D, 1997, J BIOL CHEM, V272, P10804; HUTCHCROFT JE, 1994, P NATL ACAD SCI USA, V91, P3260, DOI 10.1073/pnas.91.8.3260; Ilic D, 1997, J CELL SCI, V110, P401; JUNE CH, 1990, IMMUNOL TODAY, V11, P211, DOI 10.1016/0167-5699(90)90085-N; JUNE CH, 1987, MOL CELL BIOL, V7, P4472, DOI 10.1128/MCB.7.12.4472; Kaga S, 1998, J IMMUNOL, V160, P24; Kaga S, 1998, J IMMUNOL, V160, P4182; Kim HH, 1998, J BIOL CHEM, V273, P296, DOI 10.1074/jbc.273.1.296; Klasen S, 1998, INT IMMUNOL, V10, P481, DOI 10.1093/intimm/10.4.481; LEDBETTER JA, 1992, ADV EXP MED BIOL, V323, P23; LEDBETTER JA, 1987, P NATL ACAD SCI USA, V84, P1384, DOI 10.1073/pnas.84.5.1384; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; Li JZ, 1996, BLOOD, V88, P417, DOI 10.1182/blood.V88.2.417.bloodjournal882417; Liao XC, 1997, J EXP MED, V186, P221, DOI 10.1084/jem.186.2.221; LINSLEY PS, 1993, ANNU REV IMMUNOL, V11, P191, DOI 10.1146/annurev.iy.11.040193.001203; LU YL, 1992, J IMMUNOL, V149, P24; MAGUIRE JE, 1995, J EXP MED, V182, P2079, DOI 10.1084/jem.182.6.2079; Marengere LEM, 1997, J IMMUNOL, V159, P3220; Newton AC, 1997, CURR OPIN CELL BIOL, V9, P161, DOI 10.1016/S0955-0674(97)80058-0; Nunes JA, 1996, J BIOL CHEM, V271, P1591, DOI 10.1074/jbc.271.3.1591; NUNES JA, 1994, J EXP MED, V180, P1067, DOI 10.1084/jem.180.3.1067; Okazaki H, 1997, J BIOL CHEM, V272, P32443, DOI 10.1074/jbc.272.51.32443; OLIVER JM, 1994, J BIOL CHEM, V269, P29697; Ostergaard HL, 1998, J BIOL CHEM, V273, P5692, DOI 10.1074/jbc.273.10.5692; Pages F, 1996, J BIOL CHEM, V271, P9403, DOI 10.1074/jbc.271.16.9403; Parsons JT, 1996, CURR OPIN CELL BIOL, V8, P146, DOI 10.1016/S0955-0674(96)80059-7; PERI KG, 1994, CHEM IMMUNOL, V59, P19; PRASAD KVS, 1994, P NATL ACAD SCI USA, V91, P2834, DOI 10.1073/pnas.91.7.2834; Qian DP, 1997, J EXP MED, V185, P1253, DOI 10.1084/jem.185.7.1253; Qian DP, 1997, CURR OPIN CELL BIOL, V9, P205, DOI 10.1016/S0955-0674(97)80064-6; RAAB M, 1995, P NATL ACAD SCI USA, V92, P8891, DOI 10.1073/pnas.92.19.8891; Reif K, 1998, IMMUNITY, V8, P395, DOI 10.1016/S1074-7613(00)80545-2; SASAKI H, 1995, J BIOL CHEM, V270, P21206, DOI 10.1074/jbc.270.36.21206; Schaller MD, 1997, J BIOL CHEM, V272, P25319, DOI 10.1074/jbc.272.40.25319; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SCHNEIDER H, 1995, EUR J IMMUNOL, V25, P1044, DOI 10.1002/eji.1830250428; SHAHINIAN A, 1993, SCIENCE, V261, P609, DOI 10.1126/science.7688139; SU B, 1994, CELL, V77, P727, DOI 10.1016/0092-8674(94)90056-6; Su B, 1996, CURR OPIN IMMUNOL, V8, P402, DOI 10.1016/S0952-7915(96)80131-2; SUNG CK, 1994, J BIOL CHEM, V269, P12503; Tokiwa G, 1996, SCIENCE, V273, P792, DOI 10.1126/science.273.5276.792; TURNER CE, 1994, BIOESSAYS, V16, P47, DOI 10.1002/bies.950160107; VANDENBERGHE P, 1992, J EXP MED, V175, P951, DOI 10.1084/jem.175.4.951; VOJTEK AB, 1995, CELL, V82, P527, DOI 10.1016/0092-8674(95)90023-3; Wange RL, 1996, IMMUNITY, V5, P197, DOI 10.1016/S1074-7613(00)80315-5; Ward SG, 1996, IMMUNOL TODAY, V17, P187, DOI 10.1016/0167-5699(96)80618-9; Yamanashi Y, 1997, CELL, V88, P205, DOI 10.1016/S0092-8674(00)81841-3; Yu H, 1996, J BIOL CHEM, V271, P29993, DOI 10.1074/jbc.271.47.29993; Zheng CH, 1998, J BIOL CHEM, V273, P2384, DOI 10.1074/jbc.273.4.2384	77	32	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1999	274	10					6735	6740		10.1074/jbc.274.10.6735	http://dx.doi.org/10.1074/jbc.274.10.6735			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172BQ	10037772	hybrid			2022-12-25	WOS:000078902800094
J	Friedmann, I; Faber-Elman, A; Yoles, E; Schwartz, M				Friedmann, I; Faber-Elman, A; Yoles, E; Schwartz, M			Injury-induced gelatinase and thrombin-like activities in regenerating and nonregenerating nervous systems	FASEB JOURNAL			English	Article						thrombin; matrix metalloproteases; CNS; PNS	FIBROBLAST GROWTH-FACTOR; GLIA-DERIVED NEXIN; MATRIX METALLOPROTEINASE EXPRESSION; NEURITE OUTGROWTH; PERIPHERAL-NERVE; EXTRACELLULAR-MATRIX; CEREBROSPINAL-FLUID; RAT ASTROBLASTS; PRIMARY CULTURE; CELL-CULTURES	It is now widely accepted that injured nerves, like any other injured tissue, need assistance from their extracellular milieu in order to heal. We compared the postinjury activities of thrombin and gelatinases, two types of proteolytic activities known to be critically involved in tissue healing, in nonregenerative (rat optic nerve) and regenerative (fish optic nerve and rat sciatic nerve) neural tissue. Unlike gelatinases, whose induction pattern was comparable in all three nerves, thrombin-like activity differed clearly between regenerating and nonregenerating nervous systems. Postinjury levels of this latter activity seem to dictate whether it will display beneficial or detrimental effects on the capacity of the tissue for repair. The results of this study further highlight the fact that tissue repair and nerve regeneration are closely linked and that substances that are not unique to the nervous system, but participate in wound healing in general, are also crucial for regeneration or its failure in the nervous system.	Weizmann Inst Sci, Dept Neurobiol, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Schwartz, M (corresponding author), Weizmann Inst Sci, Dept Neurobiol, IL-76100 Rehovot, Israel.							APODACA G, 1990, CANCER RES, V50, P2322; BARSHAVIT R, 1983, SCIENCE, V220, P728, DOI 10.1126/science.6836310; CAVANAUGH KP, 1990, J NEUROCHEM, V54, P1735, DOI 10.1111/j.1471-4159.1990.tb01228.x; COUGHLIN SR, 1992, J CLIN INVEST, V89, P351, DOI 10.1172/JCI115592; Debeir T, 1996, BRAIN RES, V708, P159, DOI 10.1016/0006-8993(95)01237-0; DESCHEPPER CF, 1991, MOL BRAIN RES, V11, P355, DOI 10.1016/0169-328X(91)90045-Y; DIHANICH M, 1991, NEURON, V6, P575, DOI 10.1016/0896-6273(91)90060-D; Donovan FM, 1998, J BIOL CHEM, V273, P12746, DOI 10.1074/jbc.273.21.12746; Donovan FM, 1997, J NEUROSCI, V17, P5316; DUVDEVANI R, 1990, RESTOR NEUROL NEUROS, V2, P31, DOI 10.3233/RNN-1990-2104; ELMAN AF, 1995, J NEUROCHEM, V65, P1524; ELMAN AF, 1996, J CLIN INVEST, V97, P162; Gallagher S, 1997, CURRENT PROTOCOLS MO, P1081, DOI DOI 10.8.110.8.21; GIJBELS K, 1993, J NEUROSCI RES, V36, P432, DOI 10.1002/jnr.490360409; GIJBELS K, 1992, J NEUROIMMUNOL, V41, P29, DOI 10.1016/0165-5728(92)90192-N; GLOOR S, 1986, CELL, V47, P687; GOTTSCHALL PE, 1995, J NEUROSCI RES, V42, P335, DOI 10.1002/jnr.490420307; Gottschall PE, 1996, NEUROIMMUNOMODULAT, V3, P69, DOI 10.1159/000097229; GRABHAM PW, 1991, EUR J NEUROSCI, V3, P663, DOI 10.1111/j.1460-9568.1991.tb00852.x; GRANDALIANO G, 1994, J EXP MED, V179, P1737, DOI 10.1084/jem.179.5.1737; GURWITZ D, 1988, P NATL ACAD SCI USA, V85, P3440, DOI 10.1073/pnas.85.10.3440; Halkier T., 1991, MECH BLOOD COAGULATI; HIRSCHBERG DL, 1995, J NEUROIMMUNOL, V61, P89, DOI 10.1016/0165-5728(95)00087-I; KNOOPS B, 1991, BRAIN RES, V540, P183, DOI 10.1016/0006-8993(91)90506-Q; KRANE SM, 1994, ANN NY ACAD SCI, V732, P1, DOI 10.1111/j.1749-6632.1994.tb24719.x; LaFleur M, 1996, J EXP MED, V184, P2311; LazarovSpiegler O, 1996, FASEB J, V10, P1296, DOI 10.1096/fasebj.10.11.8836043; LIPTON SA, 1988, P NATL ACAD SCI USA, V85, P2388, DOI 10.1073/pnas.85.7.2388; LOBB RR, 1988, BIOCHEMISTRY-US, V27, P2572, DOI 10.1021/bi00407a045; LORET C, 1989, J BIOL CHEM, V264, P8319; LOTAN M, 1994, FASEB J, V8, P1026, DOI 10.1096/fasebj.8.13.7926367; LOTTENBERG R, 1983, BIOCHIM BIOPHYS ACTA, V742, P539, DOI 10.1016/0167-4838(83)90272-8; MEIER R, 1989, NATURE, V342, P548, DOI 10.1038/342548a0; MONARD D, 1988, TRENDS NEUROSCI, V11, P541, DOI 10.1016/0166-2236(88)90182-8; MONARD D, 1983, PROG BRAIN RES, V58, P359, DOI 10.1016/S0079-6123(08)60037-0; Monsonego A, 1998, FASEB J, V12, P1163, DOI 10.1096/fasebj.12.12.1163; MUIR D, 1995, CLIN EXP METASTAS, V13, P303, DOI 10.1007/BF00133486; MUIR D, 1994, EXP CELL RES, V210, P243, DOI 10.1006/excr.1994.1036; NEVEU I, 1993, J NEUROCHEM, V60, P858, DOI 10.1111/j.1471-4159.1993.tb03230.x; PERRAUD F, 1987, INT J DEV NEUROSCI, V5, P181, DOI 10.1016/0736-5748(87)90028-1; PERRY VH, 1987, J EXP MED, V165, P1218, DOI 10.1084/jem.165.4.1218; PITTMAN RN, 1989, DEV NEUROSCI-BASEL, V11, P361, DOI 10.1159/000111912; RAGHOW R, 1994, FASEB J, V8, P823, DOI 10.1096/fasebj.8.11.8070631; Rapalino O, 1998, NAT MED, V4, P814, DOI 10.1038/nm0798-814; RICHMOND G, 1980, PROG SURF SCI, V28, P1; ROSENBERG GA, 1994, LAB INVEST, V71, P417; Rosenberg GA, 1995, BRAIN RES, V703, P151, DOI 10.1016/0006-8993(95)01089-0; SEKIYA F, 1994, J BIOL CHEM, V269, P32441; SHANKAR R, 1992, AM J PHYSIOL, V262, pC199, DOI 10.1152/ajpcell.1992.262.1.C199; Shikamoto Y, 1997, FEBS LETT, V412, P526, DOI 10.1016/S0014-5793(97)00852-1; Smirnova IV, 1998, J NEUROBIOL, V36, P64, DOI 10.1002/(SICI)1097-4695(199807)36:1<64::AID-NEU6>3.0.CO;2-8; Smirnova IV, 1996, J NEUROCHEM, V67, P2188; SOWER LE, 1995, J IMMUNOL, V155, P895; STAMATOGLOU SC, 1987, J CELL BIOL, V105, P2417, DOI 10.1083/jcb.105.5.2417; SUIDAN HS, 1992, NEURON, V8, P363, DOI 10.1016/0896-6273(92)90302-T; VAUGHAN PJ, 1995, J NEUROSCI, V15, P5389; WEINBERG EL, 1979, BRAIN RES, V162, P273, DOI 10.1016/0006-8993(79)90289-0; WILLIAMS LR, 1983, J COMP NEUROL, V218, P460, DOI 10.1002/cne.902180409; WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705; ZURN AD, 1988, DEV NEUROSCI-BASEL, V10, P17, DOI 10.1159/000111951	60	32	33	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	1999	13	3					533	543		10.1096/fasebj.13.3.533	http://dx.doi.org/10.1096/fasebj.13.3.533			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	174CF	10064620				2022-12-25	WOS:000079016000013
J	Raisanen, SR; Lehenkari, P; Tasanen, M; Rahkila, P; Harkonen, PL; Vaananen, HK				Raisanen, SR; Lehenkari, P; Tasanen, M; Rahkila, P; Harkonen, PL; Vaananen, HK			Carbonic anhydrase III protects cells from hydrogen peroxide-induced apoptosis	FASEB JOURNAL			English	Article						oxidative stress; skeleton muscle; overexpression	S-THIOLATION; OXIDATIVE STRESS; PHOSPHATASE-ACTIVITY; RAT-LIVER; RESPIRATORY BURST; ACTIVATION; GENE; SUPEROXIDE; EXPRESSION; PROTEINS	Carbonic anhydrase III (CA III; EC 4.2.1.1) is a cytoplasmic enzyme that exhibits a relatively low carbon dioxide hydratase activity. It is expressed at a very high level in skeletal muscle, where physical exercise has been shown to increase free radical production. In this work we show the effect of overexpression of CA III on cellular response to oxidative stress. Rat CA III cDNA was transfected to NIH/3T3 cells, which have no endogenous CA III expression. The isolated clones expressed CA III mRNA and protein. The protein was localized to cytoplasm and nuclei, Compared to parental cells, transfected cells showed lower basal oxidized state as judged by measurement of intracellular reactive oxygen species (ROS) using fluorescent dye and an image analysis system. Addition of exogenous H2O2 to cells induced a rapid increase of ROS in control but not in CA III overexpressing cells, Association of this phenomenon with CA III expression was further confirmed by showing that overexpression of CA II could not prevent H2O2-stimulated increase of ROS, In proliferation assays, CA III overexpressing cells grew faster and were more resistant to cytotoxic concentrations of H2O2 than control cells. After a 16 h exposure to oxidative stress, the number of apoptotic cells was also reduced in transfectants, Our results suggest that CA III functions as an oxyradical scavenger and thus protects cells from oxidative damage. A lower level of free radicals in CA III overexpressing cells may also affect growth signaling pathways.	Univ Turku, Inst Biomed, Dept Anat, FIN-20520 Turku, Finland; Univ Turku, Medcity Res Lab, FIN-20520 Turku, Finland	University of Turku; University of Turku	Vaananen, HK (corresponding author), Univ Turku, Inst Biomed, Dept Anat, Kiinamyllynkatu 10, FIN-20520 Turku, Finland.	kalervo.vaananen@utu.fi	Lehenkari, Petri/O-3009-2016	Lehenkari, Petri/0000-0002-0055-5183				BASS DA, 1983, J IMMUNOL, V133, P3303; BURDON RH, 1995, FREE RADICAL BIO MED, V18, P775, DOI 10.1016/0891-5849(94)00198-S; Cabiscol E, 1996, P NATL ACAD SCI USA, V93, P4170, DOI 10.1073/pnas.93.9.4170; CABISCOL E, 1995, J BIOL CHEM, V270, P14742, DOI 10.1074/jbc.270.24.14742; CARTER WO, 1994, J LEUKOCYTE BIOL, V55, P253; CHAI YC, 1994, ARCH BIOCHEM BIOPHYS, V310, P264, DOI 10.1006/abbi.1994.1166; CHAI YC, 1991, ARCH BIOCHEM BIOPHYS, V284, P270, DOI 10.1016/0003-9861(91)90295-T; CHAI YC, 1994, ARCH BIOCHEM BIOPHYS, V310, P364; CHATTERJEE B, 1981, J BIOL CHEM, V256, P5939; Cote CH, 1997, AM J PHYSIOL-REG I, V273, pR1211, DOI 10.1152/ajpregu.1997.273.4.R1211; Cotgreave IA, 1998, BIOCHEM BIOPH RES CO, V242, P1, DOI 10.1006/bbrc.1997.7812; DARBRE PD, 1930, BREAST CANC CELLULAR, P307; DAVIES KJA, 1982, BIOCHEM BIOPH RES CO, V107, P1198, DOI 10.1016/S0006-291X(82)80124-1; DEHAAN J, 1996, HUM MOL GENET, V2, P283; DEVARY Y, 1991, MOL CELL BIOL, V11, P2804, DOI 10.1128/MCB.11.5.2804; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DODGSON SJ, 1993, J APPL PHYSIOL, V75, P1186, DOI 10.1152/jappl.1993.75.3.1186; Gansauge S, 1997, FEBS LETT, V404, P6, DOI 10.1016/S0014-5793(97)00059-8; HewettEmmett D, 1996, MOL PHYLOGENET EVOL, V5, P50, DOI 10.1006/mpev.1996.0006; JENKINS RR, 1988, SPORTS MED, V5, P156, DOI 10.2165/00007256-198805030-00003; JENKINS RR, 1993, INT J SPORT NUTR, V3, P356, DOI 10.1123/ijsn.3.4.356; KANE DJ, 1993, SCIENCE, V262, P1274, DOI 10.1126/science.8235659; KOESTER MK, 1981, ARCH BIOCHEM BIOPHYS, V211, P632, DOI 10.1016/0003-9861(81)90499-9; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LII CK, 1994, ARCH BIOCHEM BIOPHYS, V308, P231, DOI 10.1006/abbi.1994.1033; MACLIN LJ, 1987, FASEB J, V1, P441; MAKELA TP, 1992, GENE, V118, P293, DOI 10.1016/0378-1119(92)90203-2; MAREN TH, 1967, PHYSIOL REV, V47, P595, DOI 10.1152/physrev.1967.47.4.595; MIRAULT ME, 1991, J BIOL CHEM, V266, P20752; Miyamoto T, 1996, J BIOCHEM, V120, P725; NOSE K, 1991, EUR J BIOCHEM, V201, P99, DOI 10.1111/j.1432-1033.1991.tb16261.x; PASTOREK J, 1994, ONCOGENE, V9, P2877; ROKUTAN K, 1991, J IMMUNOL, V147, P260; ROTHE G, 1990, J LEUKOCYTE BIOL, V47, P440, DOI 10.1002/jlb.47.5.440; Sambrook J., 2002, MOL CLONING LAB MANU; SANDSTROM PA, 1994, J LEUKOCYTE BIOL, V55, P221, DOI 10.1002/jlb.55.2.221; SANDSTROM PA, 1993, P NATL ACAD SCI USA, V90, P4708, DOI 10.1073/pnas.90.10.4708; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SHIBANUMA M, 1995, EXP CELL RES, V218, P132, DOI 10.1006/excr.1995.1139; Sly WS, 1995, ANNU REV BIOCHEM, V64, P365; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; SPICER SS, 1990, AM J ANAT, V187, P55, DOI 10.1002/aja.1001870107; Stangel M, 1996, J NEUROPATH EXP NEUR, V55, P36, DOI 10.1097/00005072-199601000-00004; STARKE PE, 1985, J BIOL CHEM, V260, P99; TASHIAN RE, 1989, BIOESSAYS, V10, P186, DOI 10.1002/bies.950100603; Tashian RE, 1991, CARBONIC ANHYDRASES, P247, DOI DOI 10.1007/978-1-4899-0750-9_21; THOMAS JA, 1995, ARCH BIOCHEM BIOPHYS, V319, P1, DOI 10.1006/abbi.1995.1261; Tureci O, 1998, P NATL ACAD SCI USA, V95, P7608, DOI 10.1073/pnas.95.13.7608; VAANANEN HK, 1985, HISTOCHEMISTRY, V83, P231, DOI 10.1007/BF00953989	49	179	185	1	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	1999	13	3					513	522		10.1096/fasebj.13.3.513	http://dx.doi.org/10.1096/fasebj.13.3.513			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	174CF	10064618				2022-12-25	WOS:000079016000011
J	Froy, O; Zilberberg, N; Gordon, D; Turkov, M; Gilles, N; Stankiewicz, N; Pelhate, M; Loret, E; Oren, DA; Shaanan, B; Gurevitz, M				Froy, O; Zilberberg, N; Gordon, D; Turkov, M; Gilles, N; Stankiewicz, N; Pelhate, M; Loret, E; Oren, DA; Shaanan, B; Gurevitz, M			The putative bioactive surface of insect-selective scorpion excitatory neurotoxins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANDROCTONUS-AUSTRALIS HECTOR; IMPROVED BACULOVIRUS INSECTICIDE; SITE-DIRECTED ANTIBODIES; SODIUM-CHANNELS; SECONDARY STRUCTURE; CIRCULAR-DICHROISM; BUTHOTUS-JUDAICUS; TOXIN-II; VENOM; EXPRESSION	Scorpion neurotoxins of the excitatory group show total specificity for insects and serve as invaluable probes for insect sodium channels. However, despite their significance and potential for application in insect-pest control, the structural basis for their bioactivity is still unknown. We isolated, characterized, and expressed an atypically long excitatory toxin, Bj-xtrIT, whose bioactive features resembled those of classical excitatory toxins, despite only 49% sequence identity. With the objective of clarifying the toxic site of this unique pharmacological group, Bj-xtrIT was employed in a genetic approach using point mutagenesis and biological and structural assays of the mutant products. A primary target for modification was the structurally unique C-terminal region, Sequential deletions of C-terminal residues suggested an inevitable significance of Ile(73) and Ile(74) for toxicity. Based on the bioactive role of the C-terminal region and a comparison of Bj-xtrIT with a Bj-xtrIT-based model of a classical excitatory toxin, AaHIT, a conserved surface comprising the C terminus is suggested to form the site of recognition with the sodium channel receptor.	Tel Aviv Univ, Dept Plant Sci, George S Wise Fac Life Sci, IL-69978 Tel Aviv, Israel; CE Saclay, Dept Ingn & Etudes Proteines, Commissariat Energie Atom, F-91191 Gif Sur Yvette, France; Univ Angers, Fac Med, Neurophysiol Lab, F-49045 Angers, France; CNRS, LIDSM, IBSM, UPR 9027, F-13402 Marseille, France; Hebrew Univ Jerusalem, Inst Life Sci, Wolfson Ctr Appl Struct Biol, IL-91904 Jerusalem, Israel; Hebrew Univ Jerusalem, Inst Life Sci, Dept Biol Chem, IL-91904 Jerusalem, Israel	Tel Aviv University; CEA; UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); Universite Paris Saclay; Universite d'Angers; Centre National de la Recherche Scientifique (CNRS); Hebrew University of Jerusalem; Hebrew University of Jerusalem	Shaanan, B (corresponding author), Tel Aviv Univ, Dept Plant Sci, George S Wise Fac Life Sci, IL-69978 Tel Aviv, Israel.	boazsh@vms.huji.ac.il; mamgur@ccsg.tau.ac.il	Stankiewicz, Maria/H-6780-2014; Froy, Oren/C-3550-2009; Shaanan, Boaz/F-1202-2012; Zilberberg, Noam/F-2005-2012	Shaanan, Boaz/0000-0001-8925-4362; Zilberberg, Noam/0000-0002-7848-2391; Maria, Stankiewicz/0000-0001-7038-0959				ALMASSY RJ, 1983, J MOL BIOL, V170, P497, DOI 10.1016/S0022-2836(83)80159-4; BOUGIS PE, 1989, J BIOL CHEM, V264, P19259; BRUNGER AT, 1992, X PLOR MANUAL VERSIO; CESTELE S, 1995, J BIOL CHEM, V270, P15153, DOI 10.1074/jbc.270.25.15153; CORY JS, 1994, NATURE, V370, P138, DOI 10.1038/370138a0; DARBON H, 1991, BIOCHEMISTRY-US, V30, P1836, DOI 10.1021/bi00221a016; DARBON H, 1982, INT J PEPT PROT RES, V20, P320; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; FONTECILLACAMPS JC, 1988, P NATL ACAD SCI USA, V85, P7443, DOI 10.1073/pnas.85.20.7443; FONTECILLACAMPS JC, 1989, J MOL EVOL, V29, P63, DOI 10.1007/BF02106182; FROY O, 1999, IN PRESS J MOL EVOL; Gershburg E, 1998, FEBS LETT, V422, P132, DOI 10.1016/S0014-5793(97)01614-1; GORDON D, 1992, BIOCHEMISTRY-US, V31, P7622, DOI 10.1021/bi00148a025; GORDON D, 1990, BIOCHIM BIOPHYS ACTA, V1026, P80, DOI 10.1016/0005-2736(90)90335-L; GORDON D, 1984, BIOCHIM BIOPHYS ACTA, V778, P349, DOI 10.1016/0005-2736(84)90379-1; GRANIER C, 1989, MOL IMMUNOL, V26, P503, DOI 10.1016/0161-5890(89)90001-1; HERRMANN R, 1995, TOXICON, V33, P1099, DOI 10.1016/0041-0101(95)98053-X; Jarvis DL, 1996, BIOL CONTROL, V7, P228, DOI 10.1006/bcon.1996.0088; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KOPEYAN C, 1990, FEBS LETT, V261, P423, DOI 10.1016/0014-5793(90)80607-K; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LESTER D, 1982, BIOCHIM BIOPHYS ACTA, V701, P370, DOI 10.1016/0167-4838(82)90240-0; LORET EP, 1990, BIOCHEMISTRY-US, V29, P1492, DOI 10.1021/bi00458a021; MAEDA S, 1991, VIROLOGY, V184, P777, DOI 10.1016/0042-6822(91)90451-G; MANAVALAN P, 1987, ANAL BIOCHEM, V167, P76, DOI 10.1016/0003-2697(87)90135-7; MARTINEAUCLAIRE MF, 1994, EUR J BIOCHEM, V223, P637, DOI 10.1111/j.1432-1033.1994.tb19036.x; MCCUTCHEN BF, 1991, BIO-TECHNOL, V9, P848, DOI 10.1038/nbt0991-848; MOSKOWITZ H, 1994, INSECT BIOCHEM MOLEC, V24, P13, DOI 10.1016/0965-1748(94)90118-X; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Oren DA, 1998, STRUCTURE, V6, P1095, DOI 10.1016/S0969-2126(98)00111-7; PANG SZ, 1992, GENE, V116, P165, DOI 10.1016/0378-1119(92)90512-N; PELHATE M, 1982, J INSECT PHYSIOL, V28, P889, DOI 10.1016/0022-1910(82)90104-4; PELHATE M, 1982, J EXP BIOL, V97, P67; PICHON Y, 1967, J EXP BIOL, V47, P343; REED L. J., 1938, AMER JOUR HYG, V27, P493; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; STEWART LMD, 1991, NATURE, V352, P85, DOI 10.1038/352085a0; Turkov M, 1997, PROTEIN EXPRES PURIF, V10, P123, DOI 10.1006/prep.1997.0724; ZILBERBERG N, 1991, TOXICON, V29, P1155, DOI 10.1016/0041-0101(91)90213-B; Zilberberg N, 1996, BIOCHEMISTRY-US, V35, P10215, DOI 10.1021/bi9528309; ZLOTKIN E, 1985, ARCH BIOCHEM BIOPHYS, V240, P877, DOI 10.1016/0003-9861(85)90098-0; ZLOTKIN E, 1971, BIOCHIMIE, V53, P1073, DOI 10.1016/S0300-9084(71)80195-5; ZLOTKIN E, 1987, ENDEAVOUR, V11, P168, DOI 10.1016/0160-9327(87)90280-8; ZLOTKIN E, 1979, INSECT BIOCHEM, V9, P347, DOI 10.1016/0020-1790(79)90081-7; Zlotkin E., 1985, P243	46	90	95	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 26	1999	274	9					5769	5776		10.1074/jbc.274.9.5769	http://dx.doi.org/10.1074/jbc.274.9.5769			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	170KG	10026198	hybrid			2022-12-25	WOS:000078804400069
J	Wells, RG; Gilboa, L; Sun, Y; Liu, XD; Henis, YI; Lodish, HF				Wells, RG; Gilboa, L; Sun, Y; Liu, XD; Henis, YI; Lodish, HF			Transforming growth factor-beta induces formation of a dithiothreitol-resistant type I type II receptor complex in live cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERINE THREONINE KINASE; TGF-BETA; HETEROOLIGOMERIC COMPLEXES; SIGNAL-TRANSDUCTION; PROTEINS; FORM; TRANSPHOSPHORYLATION; COMPLEMENTATION; PHOSPHORYLATION; EXPRESSION	Transforming growth factor-beta (TGF-beta) binds to and signals via two serine-threonine kinase receptors, the type I (T beta RI) and type II (T beta RII) receptors. We ha ve used different and complementary techniques to study the physical nature and Ligand dependence of the complex formed by T beta RI and T beta RII. Velocity centrifugation of endogenous receptors suggests that ligand-bound T beta RI and T beta RII form a heteromeric complex that is most likely a heterotetramer. Antibody-mediated immunofluorescence co-patching of epitope-tagged receptors provides the first evidence in live cells that T beta RI.T beta RII complex formation occurs at a low but measurable degree in the absence of ligand, increasing significantly after TGF-beta binding. In addition, we demonstrate that pretreatment of cells with dithiothreitol, which inhibits the binding of TGF-beta to T beta RI, does not prevent formation of the T beta RI.T beta RII complex, but increases its sensitivity to detergent and prevents TGF-beta-activated T beta RI from phosphorylating Smad3 in vitro. This indicates that either a specific conformation of the T beta RI.T beta RII complex, disrupted by dithiothreitol, or direct binding of TGF-beta to T beta RI is required for signaling.	Whitehead Inst Biomed Res, Cambridge, MA 02142 USA; Tel Aviv Univ, George S Wise Fac Life Sci, Dept Neurobiochem, IL-69978 Tel Aviv, Israel; Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; MIT, Dept Biol, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT); Whitehead Institute; Tel Aviv University; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Massachusetts Institute of Technology (MIT)	Lodish, HF (corresponding author), Whitehead Inst Biomed Res, 9 Cambridge Ctr, Cambridge, MA 02142 USA.			Henis, Yoav/0000-0002-1408-3877; LIU, XUEDONG/0000-0001-7209-4964	NATIONAL CANCER INSTITUTE [R01CA063260] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K08DK002290] Funding Source: NIH RePORTER; NCI NIH HHS [CA63260] Funding Source: Medline; NIDDK NIH HHS [DK02290] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Anders RA, 1996, J BIOL CHEM, V271, P21758, DOI 10.1074/jbc.271.36.21758; ATTISANO L, 1994, BBA-MOL CELL RES, V1222, P71, DOI 10.1016/0167-4889(94)90026-4; CENTRELLA M, 1995, MOL CELL BIOL, V15, P3273; CHEIFETZ S, 1991, J BIOL CHEM, V266, P20767; CHEN F, 1995, P NATL ACAD SCI USA, V92, P1565, DOI 10.1073/pnas.92.5.1565; FRANZEN P, 1993, CELL, V75, P681, DOI 10.1016/0092-8674(93)90489-D; GARAVITO RM, 1986, METHOD ENZYMOL, V125, P309; Gilboa L, 1998, J CELL BIOL, V140, P767, DOI 10.1083/jcb.140.4.767; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; HENIS YI, 1985, EXP CELL RES, V160, P514, DOI 10.1016/0014-4827(85)90198-3; HENIS YI, 1994, J CELL BIOL, V126, P139, DOI 10.1083/jcb.126.1.139; JOKIRANTA TS, 1995, FEBS LETT, V376, P31, DOI 10.1016/0014-5793(95)01239-7; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; KURKELA R, 1988, J IMMUNOL METHODS, V110, P229, DOI 10.1016/0022-1759(88)90108-1; LAIHO M, 1991, J BIOL CHEM, V266, P9108; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; Liu XD, 1997, P NATL ACAD SCI USA, V94, P10669, DOI 10.1073/pnas.94.20.10669; Luo KX, 1996, EMBO J, V15, P4485, DOI 10.1002/j.1460-2075.1996.tb00826.x; Massague J, 1996, CANCER SURV, V27, P41; McCaffrey TA, 1995, J CLIN INVEST, V96, P2667, DOI 10.1172/JCI118333; MOUSTAKAS A, 1993, J BIOL CHEM, V268, P22215; MULDER KM, 1993, J CELL PHYSIOL, V154, P162, DOI 10.1002/jcp.1041540120; Muramatsu M, 1997, MOL BIOL CELL, V8, P469, DOI 10.1091/mbc.8.3.469; OKADOME T, 1994, J BIOL CHEM, V269, P30753; Roberts AB, 1990, HDB EXPT PHARM, V95, P419; RODRIGUEZ C, 1995, J BIOL CHEM, V270, P15919, DOI 10.1074/jbc.270.27.15919; Sankar S, 1996, J CLIN INVEST, V97, P1436, DOI 10.1172/JCI118565; TENDIJKE P, 1993, ONCOGENE, V8, P2879; VENTURA F, 1994, EMBO J, V13, P5581, DOI 10.1002/j.1460-2075.1994.tb06895.x; VIVIEN D, 1995, EXP CELL RES, V221, P60, DOI 10.1006/excr.1995.1352; VIVIEN D, 1995, J BIOL CHEM, V270, P7134, DOI 10.1074/jbc.270.13.7134; WeisGarcia F, 1996, EMBO J, V15, P276, DOI 10.1002/j.1460-2075.1996.tb00358.x; Wells RG, 1997, J BIOL CHEM, V272, P11444; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; YAMASHITA H, 1994, J BIOL CHEM, V269, P20172; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0	38	51	53	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 26	1999	274	9					5716	5722		10.1074/jbc.274.9.5716	http://dx.doi.org/10.1074/jbc.274.9.5716			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	170KG	10026191	hybrid			2022-12-25	WOS:000078804400062
J	Bell, B; Xing, HM; Yan, K; Gautam, N; Muslin, AJ				Bell, B; Xing, HM; Yan, K; Gautam, N; Muslin, AJ			KSR-1 binds to G-protein beta gamma subunits and inhibits beta gamma-induced mitogen-activated protein kinase activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA-MEMBRANE; SIGNAL-TRANSDUCTION; COUPLED RECEPTORS; CRYSTAL-STRUCTURE; GENE ENCODES; C-ELEGANS; RAS; RAF-1; INTERACTS; PATHWAY	The protein kinase KSR-1 is a recently identified participant in the Res signaling pathway. The subcellular localization of KSR-1 is variable. In serum-deprived cultured cells, KSR-1 is primarily found in the cytoplasm; in serum-stimulated cells, a significant portion of KSR-1 is found at the plasma membrane. To identify the mechanism that mediates KSR-1 translocation, we performed a yeast two-hybrid screen. Three clones that interacted with KSR-1 were found to encode the full-length gamma(10) subunit of heterotrimeric G-proteins. KSR-1 also interacted with gamma(2) and gamma(3) in a two-hybrid assay. Deletion analysis demonstrated that the isolated CA3 domain of KSR-1, which contains a cysteine-rich zinc finger-like domain, interacted with gamma subunits. Coimmunoprecipitation experiments demonstrated that KSR-1 bound to beta(1)gamma(3) subunits when all three were transfected into cultured cells. Lysophosphatidic acid treatment of cells induced KSR-1 translocation to the plasma membrane from the cytoplasm that was blocked by administration of pertussis toxin but not by dominant-negative Ras. Finally, transfection of wild-type KSR-1 inhibited beta(1)gamma(3)-induced mitogen-activated protein kinase activation in cultured cells. These results demonstrate that KSR-1 translocation to the plasma membrane is mediated, at least in part, by an interaction with beta(gamma) and that this interaction may modulate mitogen-activated protein kinase signaling.	Washington Univ, Cardiovasc Res Ctr, Sch Med, Dept Med, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Anesthesiol, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)	Muslin, AJ (corresponding author), Washington Univ, Cardiovasc Res Ctr, Sch Med, Dept Med, Box 8086,660 S Euclid Ave, St Louis, MO 63110 USA.	amuslin@imgate.wustl.edu						Coso OA, 1996, J BIOL CHEM, V271, P3963; Denouel-Galy A, 1998, CURR BIOL, V8, P46, DOI 10.1016/S0960-9822(98)70019-3; FANTL WJ, 1994, NATURE, V371, P612, DOI 10.1038/371612a0; Feng YY, 1998, CURR BIOL, V8, P267, DOI 10.1016/S0960-9822(98)70108-3; Ford CE, 1998, SCIENCE, V280, P1271, DOI 10.1126/science.280.5367.1271; GALLAGHER C, 1994, METHOD ENZYMOL, V237, P471; Gautam N, 1998, CELL SIGNAL, V10, P447, DOI 10.1016/S0898-6568(98)00006-0; GRISHIN AV, 1994, MOL CELL BIOL, V14, P4571, DOI 10.1128/MCB.14.7.4571; Inouye C, 1997, SCIENCE, V278, P103, DOI 10.1126/science.278.5335.103; IZQUIERDO M, 1993, J EXP MED, V178, P1199, DOI 10.1084/jem.178.4.1199; Jacobs D, 1999, GENE DEV, V13, P163, DOI 10.1101/gad.13.2.163; Joneson T, 1998, J BIOL CHEM, V273, P7743, DOI 10.1074/jbc.273.13.7743; KORNFELD K, 1995, CELL, V83, P903, DOI 10.1016/0092-8674(95)90206-6; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; LEBERER E, 1992, EMBO J, V11, P4805, DOI 10.1002/j.1460-2075.1992.tb05586.x; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LopezIlasaca M, 1997, SCIENCE, V275, P394, DOI 10.1126/science.275.5298.394; MARAIS R, 1995, EMBO J, V14, P3136, DOI 10.1002/j.1460-2075.1995.tb07316.x; Michaud NR, 1997, P NATL ACAD SCI USA, V94, P12792, DOI 10.1073/pnas.94.24.12792; Moolenaar WH, 1997, CURR OPIN CELL BIOL, V9, P168, DOI 10.1016/S0955-0674(97)80059-2; Morishita R, 1998, FEBS LETT, V428, P85, DOI 10.1016/S0014-5793(98)00498-0; Pellegrino S, 1997, J BIOL CHEM, V272, P25360, DOI 10.1074/jbc.272.40.25360; PRONIN AN, 1994, METHOD ENZYMOL, V237, P482; PUMIGLIA KM, 1995, J BIOL CHEM, V270, P14251, DOI 10.1074/jbc.270.24.14251; Sondek J, 1996, NATURE, V379, P369, DOI 10.1038/379369a0; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; Sugimoto T, 1998, EMBO J, V17, P1717, DOI 10.1093/emboj/17.6.1717; SUNDARAM M, 1995, CELL, V83, P889, DOI 10.1016/0092-8674(95)90205-8; THERRIEN M, 1995, CELL, V83, P879, DOI 10.1016/0092-8674(95)90204-X; Therrien M, 1996, GENE DEV, V10, P2684, DOI 10.1101/gad.10.21.2684; Vojtek AB, 1998, J BIOL CHEM, V273, P19925, DOI 10.1074/jbc.273.32.19925; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; Xing HM, 1997, CURR BIOL, V7, P294, DOI 10.1016/S0960-9822(06)00152-7; Yan K, 1997, J BIOL CHEM, V272, P2056; Yan K, 1996, J BIOL CHEM, V271, P17597, DOI 10.1074/jbc.271.30.17597; Yu W, 1998, CURR BIOL, V8, P56, DOI 10.1016/S0960-9822(98)70020-X	36	45	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	1999	274	12					7982	7986		10.1074/jbc.274.12.7982	http://dx.doi.org/10.1074/jbc.274.12.7982			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	178LU	10075696	hybrid			2022-12-25	WOS:000079268100055
J	Biswas, N; Weller, SK				Biswas, N; Weller, SK			A mutation in the C-terminal putative Zn2+ finger motif of UL52 severely affects the biochemical activities of the HSV-1 helicase-primase subcomplex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIMPLEX VIRUS TYPE-1; ORIGIN-BINDING PROTEIN; PHOTO-CROSS-LINKING; SINGLE-STRANDED-DNA; COLI REP HELICASE; ZINC FINGERS; UL8 SUBUNIT; CRYSTAL-STRUCTURE; DEPENDENT ATPASE; GENE-PRODUCTS	Herpes simplex virus type 1 encodes a heterotrimeric helicase-primase complex that is composed of the products of the UL5, UL52, and UL8 genes. A subcomplex consisting of the UL5 and UL52 proteins retains all the enzymatic activities exhibited by the holoenzyme in vitro. The UL52 protein contains a putative zinc finger at its C terminus which is highly conserved among both prokaryotic and eukaryotic primases. We constructed a mutation in which two highly conserved cysteine residues in the zinc finger motif were replaced with alanine residues. A UL52 expression plasmid containing the mutation in the zinc finger region is unable to support the growth of a UL52 mutant virus in a transient complementation assay. Wild type and mutant UL5.UL52 subcomplexes were purified from insect cells infected with recombinant baculoviruses. Surprisingly, the mutant protein was severely affected in all biochemical activities tested; no helicase or primase activities could be detected, and the mutant protein retains only about 9% of wild type levels of single-stranded DNA-dependent ATPase activity. Gel mobility shift assays showed that DNA binding is severely affected as well; the mutant subcomplex only retains approximately 8% of wild type levels of binding to a forked substrate. On the other hand, the mutant protein retains its ability to interact with UL5 as indicated by copurification and with UL8 as indicated by a supershifted band in the gel mobility shift assay. In addition, the ability of individual subunits to bind single-stranded DNA was examined by photo crosslinking. In the wild type UL5 UL52 subcomplex, both subunits are able to bind an 18-mer of oligo(dT), The mutant subcomplex was severely compromised in the ability of both UL5 and UL52 to bind the oligonucleotide; total cross-linking was only 2% of wild type levels. These results are consistent with the proposal that the putative zinc binding motif of UL52 is required not only for binding of the UL52 subunit to DNA and for primase activity but also for optimal binding of UL5 to DNA and for the subsequent ATPase and helicase activities.	Univ Connecticut, Ctr Hlth, Dept Microbiol, Farmington, CT 06030 USA	University of Connecticut	Weller, SK (corresponding author), Univ Connecticut, Ctr Hlth, Dept Microbiol, Farmington, CT 06030 USA.		Weller, Sandra/N-3979-2013	Weller, Sandra/0000-0002-4519-6276	PHS HHS [A121747] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AGARWAL K, 1991, BIOCHEMISTRY-US, V30, P7842, DOI 10.1021/bi00245a026; AUSUBEL FM, 1990, CURRENT PROTOCOLS MO; BLATTER EE, 1992, NATURE, V359, P650, DOI 10.1038/359650a0; CALDER JM, 1990, NUCLEIC ACIDS RES, V18, P3573, DOI 10.1093/nar/18.12.3573; CALDER JM, 1992, J GEN VIROL, V73, P531, DOI 10.1099/0022-1317-73-3-531; CARMICHAEL EP, 1989, J VIROL, V63, P591, DOI 10.1128/JVI.63.2.591-599.1989; CATALANO CE, 1990, BIOCHEMISTRY-US, V29, P3612, DOI 10.1021/bi00467a004; CRUTE JJ, 1991, J BIOL CHEM, V266, P4484; CRUTE JJ, 1991, J BIOL CHEM, V266, P21252; CRUTE JJ, 1988, NUCLEIC ACIDS RES, V16, P6585, DOI 10.1093/nar/16.14.6585; CRUTE JJ, 1989, P NATL ACAD SCI USA, V86, P2186, DOI 10.1073/pnas.86.7.2186; DODSON MS, 1989, J BIOL CHEM, V264, P20835; DODSON MS, 1991, P NATL ACAD SCI USA, V88, P1105, DOI 10.1073/pnas.88.4.1105; Dong F, 1996, J BIOL CHEM, V271, P19625, DOI 10.1074/jbc.271.32.19625; DRACHEVA S, 1995, J BIOL CHEM, V270, P14148, DOI 10.1074/jbc.270.23.14148; EARNSHAW DL, 1994, BIOCHEM BIOPH RES CO, V199, P1333, DOI 10.1006/bbrc.1994.1377; Falkenberg M, 1997, J BIOL CHEM, V272, P22766, DOI 10.1074/jbc.272.36.22766; GAC NTL, 1996, J BIOL CHEM, V271, P21645; GOLDSTEIN DJ, 1988, J VIROL, V62, P2970, DOI 10.1128/JVI.62.8.2970-2977.1988; GORBALENYA AE, 1993, CURR OPIN STRUC BIOL, V3, P419, DOI 10.1016/S0959-440X(05)80116-2; GravesWoodward KL, 1997, J BIOL CHEM, V272, P4623, DOI 10.1074/jbc.272.7.4623; GravesWoodward KL, 1996, J BIOL CHEM, V271, P13629, DOI 10.1074/jbc.271.23.13629; Hamatake RK, 1997, J GEN VIROL, V78, P857, DOI 10.1099/0022-1317-78-4-857; Healy S, 1997, J BIOL CHEM, V272, P3411, DOI 10.1074/jbc.272.6.3411; Hong Z, 1996, J VIROL, V70, P4261, DOI 10.1128/JVI.70.7.4261-4268.1996; ILYINA TV, 1992, J MOL EVOL, V34, P351, DOI 10.1007/BF00160243; Joo WS, 1998, MOL CELL BIOL, V18, P2677, DOI 10.1128/MCB.18.5.2677; KLINEDINST DK, 1994, J VIROL, V68, P3693, DOI 10.1128/JVI.68.6.3693-3701.1994; KLUG A, 1987, COLD SPRING HARB SYM, V52, P473, DOI 10.1101/SQB.1987.052.01.054; Korolev S, 1997, CELL, V90, P635, DOI 10.1016/S0092-8674(00)80525-5; LOHMAN TM, 1993, J BIOL CHEM, V268, P2269; Lukonis CJ, 1997, J VIROL, V71, P2390, DOI 10.1128/JVI.71.3.2390-2399.1997; Marsden HS, 1997, J VIROL, V71, P6390, DOI 10.1128/JVI.71.9.6390-6397.1997; MARTINEZ R, 1992, J VIROL, V66, P6735, DOI 10.1128/JVI.66.11.6735-6746.1992; Meisenheimer KM, 1996, NUCLEIC ACIDS RES, V24, P981, DOI 10.1093/nar/24.5.981; MENDELMAN LV, 1994, EMBO J, V13, P3909, DOI 10.1002/j.1460-2075.1994.tb06702.x; OGATA R, 1977, P NATL ACAD SCI USA, V74, P4973, DOI 10.1073/pnas.74.11.4973; OLIVO PD, 1990, HERPESVIRUS TRANSCRI; PATEL SS, 1993, J BIOL CHEM, V268, P10668; PAVLETICH NP, 1993, SCIENCE, V261, P1701, DOI 10.1126/science.8378770; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; QIAN XQ, 1993, BIOCHEMISTRY-US, V32, P9944, DOI 10.1021/bi00089a010; RHODES D, 1993, SCI AM, V268, P56, DOI 10.1038/scientificamerican0293-56; Sambrook J., 2002, MOL CLONING LAB MANU; SCHWABE JWR, 1990, NATURE, V348, P458, DOI 10.1038/348458a0; SCHWABE JWR, 1991, TRENDS BIOCHEM SCI, V16, P291, DOI 10.1016/0968-0004(91)90121-B; SHERMAN G, 1992, J VIROL, V66, P4884, DOI 10.1128/JVI.66.8.4884-4892.1992; Smelkova NV, 1997, J VIROL, V71, P8766, DOI 10.1128/JVI.71.11.8766-8773.1997; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WELLER SK, 1983, J VIROL, V45, P354, DOI 10.1128/JVI.45.1.354-366.1983; WELLER SK, 1990, HERPESVIRUS TRANSCRI, P105; WILLIS MC, 1994, NUCLEIC ACIDS RES, V22, P4947, DOI 10.1093/nar/22.23.4947; WITTE MM, 1988, MOL CELL BIOL, V8, P3726, DOI 10.1128/MCB.8.9.3726; WONG I, 1992, J BIOL CHEM, V267, P7596; WONG I, 1992, SCIENCE, V256, P350, DOI 10.1126/science.256.5055.350; ZHU L, 1992, J VIROL, V66, P458, DOI 10.1128/JVI.66.1.458-468.1992; ZHU L, 1992, J VIROL, V66, P469, DOI 10.1128/JVI.66.1.469-479.1992	57	44	44	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 19	1999	274	12					8068	8076		10.1074/jbc.274.12.8068	http://dx.doi.org/10.1074/jbc.274.12.8068			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	178LU	10075707	hybrid			2022-12-25	WOS:000079268100066
J	Gelman, L; Zhou, GC; Fajas, L; Raspe, E; Fruchart, JC; Auwerx, J				Gelman, L; Zhou, GC; Fajas, L; Raspe, E; Fruchart, JC; Auwerx, J			p300 interacts with the N- and C-terminal part of PPAR gamma 2 in a ligand-independent and -dependent manner, respectively	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROLIFERATOR-ACTIVATED RECEPTOR; KINASE-MEDIATED PHOSPHORYLATION; PROTEIN-KINASE; PPAR-GAMMA; TRANSCRIPTIONAL COACTIVATOR; RETINOIC ACID; FATTY-ACIDS; CBP; EXPRESSION; THIAZOLIDINEDIONE	The nuclear peroxisome proliferator-activated receptor gamma (PPAR gamma) activates the transcription of multiple genes involved in intra- and extracellular lipid metabolism. Several cofactors are crucial for the stimulation or the silencing of nuclear receptor transcriptional activities. The two homologous cofactors p300 and CREB-binding protein (CBP) have been shown to co-activate the ligand-dependent transcriptional activities of several nuclear receptors as well as the ligand-independent transcriptional activity of the androgen receptor. We show here that the interaction between p300/CBP and PPAR gamma is complex and involves multiple domains in each protein, p300/CBP not only bind in a ligand-dependent manner to the DEF region of PPAR gamma but also bind directly in a ligand-independent manner to a region in the AB domain localized between residue 31 to 99, In transfection experiments, p300/CBP could thereby enhance the transcriptional activities of both the activating function (AF)-1 and AF-2 domains. p300/CBP displays itself at least two docking sites for PPAR gamma located in its N terminus (between residues 1 and 113 for CBP) and in the middle of the protein (between residues 1099 and 1460).	Inst Pasteur, LBRE, Unite 325,INSERM, Dept Atherosclerose, F-59019 Lille, France; Merck & Co Inc, Merck Sharp & Dohme Res Labs, Rahway, NJ 07065 USA	Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Merck & Company	Auwerx, J (corresponding author), Inst Pasteur, LBRE, Unite 325,INSERM, Dept Atherosclerose, 1 Rue Prof Calmette, F-59019 Lille, France.		Coll, Lluis Fajas/C-8567-2014	Auwerx, Johan/0000-0002-5065-5393; Fajas, Lluis/0000-0002-1283-9503; Gelman, Laurent/0000-0003-3277-3115				ABRAHAM SE, 1993, ONCOGENE, V8, P1639; Adams M, 1997, J BIOL CHEM, V272, P5128, DOI 10.1074/jbc.272.8.5128; ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; Avantaggiati ML, 1996, EMBO J, V15, P2236, DOI 10.1002/j.1460-2075.1996.tb00577.x; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; Bannister AJ, 1995, ONCOGENE, V11, P2509; Bender M, 1997, CELL, V91, P777, DOI 10.1016/S0092-8674(00)80466-3; Camp HS, 1997, J BIOL CHEM, V272, P10811; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DiRenzo J, 1997, MOL CELL BIOL, V17, P2166, DOI 10.1128/MCB.17.4.2166; Dowell P, 1997, J BIOL CHEM, V272, P33435, DOI 10.1074/jbc.272.52.33435; Eckner R, 1996, BIOL CHEM, V377, P685; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; Fajas L, 1997, J BIOL CHEM, V272, P18779, DOI 10.1074/jbc.272.30.18779; Glass CK, 1997, CURR OPIN CELL BIOL, V9, P222, DOI 10.1016/S0955-0674(97)80066-X; Hanstein B, 1996, P NATL ACAD SCI USA, V93, P11540, DOI 10.1073/pnas.93.21.11540; Hu ED, 1996, SCIENCE, V274, P2100, DOI 10.1126/science.274.5295.2100; Ikonen T, 1997, J BIOL CHEM, V272, P29821, DOI 10.1074/jbc.272.47.29821; Janknecht R, 1996, CURR BIOL, V6, P951, DOI 10.1016/S0960-9822(02)00636-X; Kalkhoven E, 1998, EMBO J, V17, P232, DOI 10.1093/emboj/17.1.232; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; KITABAYASHI I, 1995, EMBO J, V14, P3496, DOI 10.1002/j.1460-2075.1995.tb07356.x; Krey G, 1997, MOL ENDOCRINOL, V11, P779, DOI 10.1210/me.11.6.779; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; Leong GM, 1998, J BIOL CHEM, V273, P2296, DOI 10.1074/jbc.273.4.2296; Li H, 1997, P NATL ACAD SCI USA, V94, P8479, DOI 10.1073/pnas.94.16.8479; LUNDBLAD JR, 1995, NATURE, V374, P85, DOI 10.1038/374085a0; McInerney EM, 1996, P NATL ACAD SCI USA, V93, P10069, DOI 10.1073/pnas.93.19.10069; Mizukami J, 1997, BIOCHEM BIOPH RES CO, V240, P61, DOI 10.1006/bbrc.1997.7602; Norris JD, 1998, J BIOL CHEM, V273, P6679, DOI 10.1074/jbc.273.12.6679; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Onate SA, 1998, J BIOL CHEM, V273, P12101, DOI 10.1074/jbc.273.20.12101; Puigserver P, 1998, CELL, V92, P829, DOI 10.1016/S0092-8674(00)81410-5; Schoonjans K, 1997, CURR OPIN LIPIDOL, V8, P159, DOI 10.1097/00041433-199706000-00006; Schoonjans K, 1996, J LIPID RES, V37, P907; Shalev A, 1996, ENDOCRINOLOGY, V137, P4499, DOI 10.1210/en.137.10.4499; Smith CL, 1996, P NATL ACAD SCI USA, V93, P8884, DOI 10.1073/pnas.93.17.8884; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; Treuter E, 1998, MOL ENDOCRINOL, V12, P864, DOI 10.1210/me.12.6.864; Voegel JJ, 1998, EMBO J, V17, P507, DOI 10.1093/emboj/17.2.507; VUDAC N, 1995, J CLIN INVEST, V96, P741, DOI 10.1172/JCI118118; Webb P, 1998, MOL ENDOCRINOL, V12, P1605, DOI 10.1210/me.12.10.1605; Yao TP, 1996, P NATL ACAD SCI USA, V93, P10626, DOI 10.1073/pnas.93.20.10626; Zamir I, 1997, GENE DEV, V11, P835, DOI 10.1101/gad.11.7.835; Zhang B, 1996, J BIOL CHEM, V271, P31771, DOI 10.1074/jbc.271.50.31771; Zhu YJ, 1996, GENE EXPRESSION, V6, P185; Zhu YJ, 1997, J BIOL CHEM, V272, P25500, DOI 10.1074/jbc.272.41.25500	48	191	194	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 19	1999	274	12					7681	7688		10.1074/jbc.274.12.7681	http://dx.doi.org/10.1074/jbc.274.12.7681			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	178LU	10075656	hybrid			2022-12-25	WOS:000079268100015
J	Na, SY; Kang, BY; Chung, SW; Han, SJ; Ma, XJ; Trinchieri, G; Im, SY; Lee, JW; Kim, TS				Na, SY; Kang, BY; Chung, SW; Han, SJ; Ma, XJ; Trinchieri, G; Im, SY; Lee, JW; Kim, TS			Retinoids inhibit interleukin-12 production in macrophages through physical associations of retinoid X receptor and NF kappa B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATION FUNCTION AF-2; ESTROGEN-RECEPTOR; P65 SUBUNIT; NUCLEAR RECEPTORS; DENDRITIC CELLS; IL-12; EXPRESSION; PROTEIN; COACTIVATOR; IDENTIFICATION	Lipopolysaccharide (LPS) increases the production of interleukin-12 (IL-12) from mouse macrophages via a kappa B site within the IL-12 p40 promoter. In this study, we found that retinoids inhibit this LPS-stimulated production of IL-12 in a dose-dependent manner. The NF kappa B components p50 and p65 bound retinoid X receptor (RXR) in a ligand-independent manner in vitro, and the interaction interfaces involved the p50 residues 1-245, the p65 residues 194-441, and the N-terminal A/B/C domains of RXR, Activation of macrophages by LPS resulted in markedly enhanced binding activities to the kappa B site, which significantly decreased upon addition of retinoids, as demonstrated by the electrophoretic mobility shift assays. In cotransfections of CV-1 and HeLa cells, RXR also inhibited the NF kappa B transactivation in a ligand-dependent manner, whereas a mutant RXR lacking the AF2 transactivation domain, which serves as ligand-dependent binding sites for transcription integrators SRC-1 and p300, was without any effect. In addition, coexpression of increasing amounts of SRC-1 or p300 relieved the retinoid-mediated inhibition of the NF kappa B transactivation, From these results, we propose that retinoid-mediated suppression of the IL-12 production from LPS-activated macrophages may involve both inhibition of the NF kappa B-DNA interactions and competitive recruitment of transcription integrators between NF kappa B and RXR.	Chonnam Natl Univ, Coll Pharm, Kwangju 500757, South Korea; Chonnam Natl Univ, Dept Biol, Kwangju 500757, South Korea; Chonnam Natl Univ, Dept Microbiol, Kwangju 500757, South Korea; Chonnam Natl Univ, Hormone Res Ctr, Kwangju 500757, South Korea; Chonnam Natl Univ, Ctr Ligand & Transcript, Kwangju 500757, South Korea; Wistar Inst Anat & Biol, Philadelphia, PA 19104 USA	Chonnam National University; Chonnam National University; Chonnam National University; Chonnam National University; Chonnam National University; The Wistar Institute	Kim, TS (corresponding author), Chonnam Natl Univ, Coll Pharm, Kwangju 500757, South Korea.	taekim@chonnam.chonnam.ac.kr	Trinchieri, Giorgio/F-9369-2015	Trinchieri, Giorgio/0000-0001-5892-7464				Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BEAUPARLANT P, 1994, ONCOGENE, V9, P3189; Benjamin D, 1996, J IMMUNOL, V156, P1626; BULL P, 1990, MOL CELL BIOL, V10, P5473, DOI 10.1128/MCB.10.10.5473; Caspi NR, 1998, CLIN IMMUNOL IMMUNOP, V88, P4, DOI 10.1006/clin.1998.4540; CAVAILLES V, 1995, EMBO J, V14, P3741, DOI 10.1002/j.1460-2075.1995.tb00044.x; Cella M, 1996, J EXP MED, V184, P747, DOI 10.1084/jem.184.2.747; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; Constantinescu CS, 1998, IMMUNOL LETT, V62, P25, DOI 10.1016/S0165-2478(98)00025-X; D'Ambrosio D, 1998, J CLIN INVEST, V101, P252, DOI 10.1172/JCI1050; DeKruyff R, 1998, J IMMUNOL, V160, P2231; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FORMAN BM, 1995, CELL, V81, P541, DOI 10.1016/0092-8674(95)90075-6; Gately MK, 1998, ANNU REV IMMUNOL, V16, P495, DOI 10.1146/annurev.immunol.16.1.495; Gerritsen ME, 1997, P NATL ACAD SCI USA, V94, P2927, DOI 10.1073/pnas.94.7.2927; GILMORE TD, 1993, TRENDS GENET, V9, P427, DOI 10.1016/0168-9525(93)90106-R; GOLDFELD AE, 1990, P NATL ACAD SCI USA, V87, P9769, DOI 10.1073/pnas.87.24.9769; Goldman PS, 1997, RECENT PROG HORM RES, V52, P103; Gri G, 1998, J BIOL CHEM, V273, P6431, DOI 10.1074/jbc.273.11.6431; HIGGINS KA, 1993, P NATL ACAD SCI USA, V90, P9901, DOI 10.1073/pnas.90.21.9901; Irving H, 1998, EUR J CANCER, V34, P111, DOI 10.1016/S0959-8049(97)10027-2; Kalkhoven E, 1996, J BIOL CHEM, V271, P6217, DOI 10.1074/jbc.271.11.6217; Kang KF, 1996, J IMMUNOL, V156, P1402; Kim CH, 1995, J INFLAMM, V45, P312; Kim HJ, 1998, J BIOL CHEM, V273, P28564, DOI 10.1074/jbc.273.44.28564; Kim TS, 1997, J IMMUNOL, V158, P4137; KOBAYASHI M, 1989, J EXP MED, V170, P827, DOI 10.1084/jem.170.3.827; Koch F, 1996, J EXP MED, V184, P741, DOI 10.1084/jem.184.2.741; LEDOUARIN B, 1995, EMBO J, V14, P2020, DOI 10.1002/j.1460-2075.1995.tb07194.x; Lee SK, 1998, J BIOL CHEM, V273, P16651, DOI 10.1074/jbc.273.27.16651; Ma XJ, 1996, J EXP MED, V183, P147, DOI 10.1084/jem.183.1.147; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; McDyer JF, 1998, J ALLERGY CLIN IMMUN, V102, P11; Moller DR, 1997, IMMUNOLOGY, V91, P197, DOI 10.1046/j.1365-2567.1997.00246.x; Moller DR, 1997, J IMMUNOL, V159, P5157; Moore DD, 1995, GLOB MOB SURV; MURPHY TL, 1995, MOL CELL BIOL, V15, P5258; Na SY, 1998, J BIOL CHEM, V273, P10831, DOI 10.1074/jbc.273.18.10831; NARAYANAN R, 1992, SCIENCE, V256, P367, DOI 10.1126/science.256.5055.367; ONATE SA, 1995, SCIENCE, V270, P1354; Palvimo JJ, 1996, J BIOL CHEM, V271, P24151, DOI 10.1074/jbc.271.39.24151; PaninaBordignon P, 1997, J CLIN INVEST, V100, P1513, DOI 10.1172/JCI119674; Perkins ND, 1997, SCIENCE, V275, P523, DOI 10.1126/science.275.5299.523; RAY A, 1994, J BIOL CHEM, V269, P12940; RAY A, 1994, P NATL ACAD SCI USA, V91, P752, DOI 10.1073/pnas.91.2.752; Rogers MB, 1997, CURR TOP DEV BIOL, V35, P1, DOI 10.1016/S0070-2153(08)60255-0; SCHEINMAN RI, 1995, MOL CELL BIOL, V15, P943; STEIN B, 1995, MOL CELL BIOL, V15, P4971; STERN AS, 1990, P NATL ACAD SCI USA, V87, P6808, DOI 10.1073/pnas.87.17.6808; Tone Y, 1996, EUR J IMMUNOL, V26, P1222, DOI 10.1002/eji.1830260606; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; Trinchieri G, 1998, Int Rev Immunol, V16, P365, DOI 10.3109/08830189809043002; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; Yoshimoto T, 1996, J IMMUNOL, V156, P1082; Zavacki AM, 1997, P NATL ACAD SCI USA, V94, P7909, DOI 10.1073/pnas.94.15.7909	55	211	214	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	1999	274	12					7674	7680		10.1074/jbc.274.12.7674	http://dx.doi.org/10.1074/jbc.274.12.7674			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	178LU	10075655	hybrid			2022-12-25	WOS:000079268100014
J	Vacherot, F; Delbe, J; Heroult, M; Barritault, D; Fernig, DG; Courty, J				Vacherot, F; Delbe, J; Heroult, M; Barritault, D; Fernig, DG; Courty, J			Glycosaminoglycans differentially bind HARP and modulate its biological activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST GROWTH-FACTOR; AFFIN REGULATORY PEPTIDE; MOLECULE HB-GAM; AMINO-ACID-SEQUENCE; HEPARAN-SULFATE; CELL-SURFACE; EXTRACELLULAR-MATRIX; ENDOTHELIAL-CELLS; NEURITE OUTGROWTH; DEVELOPING BRAIN	Heparin affin regulatory peptide (HARP) is a polypeptide belonging to a family of heparin binding growth/differentiation factors. The high affinity of HARP for heparin suggests that this secreted polypeptide should also bind to heparan sulfate proteoglycans derived from cell surface and extracellular matrix defined as extracellular compartments. Using Western blot analysis, we detected HARP bound to heparan sulfate proteoglycans in the extracellular compartments of MDA-MB 231 and MC 3T3-E1 as well as NIH3T3 cells overexpressing HARP protein. Heparitinase treatment of EEL cells inhibited HARP-induced cell proliferation, and the biological activity of HARP in this system was restored by the addition of heparin, We report that heparan sulfate, dermatan sulfate, and to a lesser extent, chondroitin sulfate A, displaced HARP bound to the extracellular compartment, Binding analyses with a biosensor showed that HARP bound heparin with fast association and dissociation kinetics (k(ass) = 1.6 x 10(6) M-1 s(-1); k(diss) = 0.02 s(-1)), yielding a K-d value of 13 nM; the interaction between HARP and dermatan sulfate was characterized by slower association kinetics (k(ass) = 0.68 x 10(6) M-1 s(-1)) and a lower affinity (K-d = 51 nM). Exogenous heparin, heparan sulfate, and dermatan sulfate potentiated the growth-stimulatory activity of HARP, suggesting that corresponding proteoglycans could be involved in the regulation of the mitogenic activity of HARP.	Univ Paris 12, CNRS 7053, UPRES A,Unite Propre Rec Enseignement Superieur A, CRRET,Lab Rech Croissance Cellulaire Reparat & Re, F-94010 Creteil, France; Univ Liverpool, Sch Biol Sci, Liverpool L69 7ZB, Merseyside, England	Universite Paris-Est-Creteil-Val-de-Marne (UPEC); University of Liverpool	Courty, J (corresponding author), Univ Paris 12, CNRS 7053, UPRES A,Unite Propre Rec Enseignement Superieur A, CRRET,Lab Rech Croissance Cellulaire Reparat & Re, Ave Gen de Gaulle, F-94010 Creteil, France.		Delbe, Jean/R-3680-2018; Courty, Jose/Q-3702-2018; Vacherot, Francis/R-6588-2018; Fernig, David G/A-3590-2008	Vacherot, Francis/0000-0002-3677-1267; Fernig, David G/0000-0003-4875-4293				BAIRD A, 1987, BIOCHEM BIOPH RES CO, V142, P428, DOI 10.1016/0006-291X(87)90292-0; BASHKIN P, 1992, J CELL PHYSIOL, V151, P126, DOI 10.1002/jcp.1041510117; Besner GE, 1992, GROWTH FACTORS, V7, P289, DOI 10.3109/08977199209046411; Bohlen P, 1991, GROWTH FACTORS, V4, P97, DOI 10.3109/08977199109000261; BRUNNER G, 1991, J CELL BIOL, V114, P1275, DOI 10.1083/jcb.114.6.1275; CHAUHAN AK, 1993, P NATL ACAD SCI USA, V90, P679, DOI 10.1073/pnas.90.2.679; COURTY J, 1991, BIOCHEM BIOPH RES CO, V180, P145, DOI 10.1016/S0006-291X(05)81267-7; CUSH R, 1993, BIOSENS BIOELECTRON, V8, P355; DELBE J, 1995, J CELL PHYSIOL, V164, P47, DOI 10.1002/jcp.1041640107; Fannon M, 1996, J BIOL CHEM, V271, P17949, DOI 10.1074/jbc.271.30.17949; FOLKMAN J, 1988, AM J PATHOL, V130, P393; GITAYGOREN H, 1992, J BIOL CHEM, V267, P6093; HUGHES RC, 1975, EUR J BIOCHEM, V52, P143, DOI 10.1111/j.1432-1033.1975.tb03982.x; ISHAIMICHAELI R, 1990, CELL REGUL, V1, P833, DOI 10.1091/mbc.1.11.833; KADOMATSU K, 1988, BIOCHEM BIOPH RES CO, V151, P1312, DOI 10.1016/S0006-291X(88)80505-9; Kinnunen T, 1996, J BIOL CHEM, V271, P2243, DOI 10.1074/jbc.271.4.2243; Kinsella L, 1998, GLYCOCONJUGATE J, V15, P419, DOI 10.1023/A:1006986104865; Kojima T, 1996, J BIOL CHEM, V271, P5914, DOI 10.1074/jbc.271.10.5914; Kretschmer P J, 1991, Growth Factors, V5, P99, DOI 10.3109/08977199109000275; KUO MD, 1990, J BIOL CHEM, V265, P18749; Kurtz A, 1995, CRIT REV ONCOGENESIS, V6, P151; LAAROUBI K, 1994, GROWTH FACTORS, V10, P89, DOI 10.3109/08977199409010982; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Ledoux D, 1997, J HISTOCHEM CYTOCHEM, V45, P1239, DOI 10.1177/002215549704500907; LI YS, 1990, SCIENCE, V250, P1690, DOI 10.1126/science.2270483; Lyon M, 1997, J BIOL CHEM, V272, P18000, DOI 10.1074/jbc.272.29.18000; LYON M, 1994, J BIOL CHEM, V269, P11216; Lyon M, 1998, J BIOL CHEM, V273, P271, DOI 10.1074/jbc.273.1.271; MERENMIES J, 1990, J BIOL CHEM, V265, P16721; MILNER PG, 1989, BIOCHEM BIOPH RES CO, V165, P1096, DOI 10.1016/0006-291X(89)92715-0; MITSIADIS TA, 1995, DEVELOPMENT, V121, P37; MURAMATSU H, 1991, BIOCHEM BIOPH RES CO, V177, P652, DOI 10.1016/0006-291X(91)91838-4; NURCOMBE V, 1992, DEVELOPMENT, V116, P1175; PENG HB, 1995, J NEUROSCI, V15, P3027; Rahmoune H, 1998, BIOCHEMISTRY-US, V37, P6003, DOI 10.1021/bi972468t; Rahmoune H, 1998, J BIOL CHEM, V273, P7303, DOI 10.1074/jbc.273.13.7303; RAINES EW, 1992, J CELL BIOL, V116, P533, DOI 10.1083/jcb.116.2.533; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; RAULO E, 1994, J BIOL CHEM, V269, P12999; RAUVALA H, 1989, EMBO J, V8, P2933, DOI 10.1002/j.1460-2075.1989.tb08443.x; SAKSELA O, 1990, J CELL BIOL, V110, P767, DOI 10.1083/jcb.110.3.767; TURNBULL JE, 1992, J BIOL CHEM, V267, P10337; VLODAVSKY I, 1987, P NATL ACAD SCI USA, V84, P2292, DOI 10.1073/pnas.84.8.2292; WANAKA A, 1993, DEV BRAIN RES, V72, P133, DOI 10.1016/0165-3806(93)90166-8; WELLSTEIN A, 1992, J BIOL CHEM, V267, P2582; YEUNG D, 1995, TRAC-TREND ANAL CHEM, V14, P49, DOI 10.1016/0165-9936(95)91472-5; ZHOU HY, 1992, BIOCHEM BIOPH RES CO, V186, P1288, DOI 10.1016/S0006-291X(05)81545-1	47	48	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 19	1999	274	12					7741	7747		10.1074/jbc.274.12.7741	http://dx.doi.org/10.1074/jbc.274.12.7741			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	178LU	10075664	hybrid			2022-12-25	WOS:000079268100023
J	Chen, W; LoBrutto, R; Frasch, WD				Chen, W; LoBrutto, R; Frasch, WD			EPR spectroscopy of VO2+-ATP bound to catalytic site 3 of chloroplast F-1-ATPase from Chlamydomonas reveals changes in metal ligation resulting from mutations to the phosphate-binding loop threonine (beta T168)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COUPLING FACTOR-I; MITOCHONDRIAL F1-ATPASE; ESCHERICHIA-COLI; ATP; ADP; SUBUNIT; DOMAIN; SUBSTITUTION; NUCLEOTIDES; RESOLUTION	Site-directed mutations were made to the phosphate-binding loop threonine in the P-subunit of the chloroplast F-1-ATPase in Chlamydomonas (beta T168), Rates of photophosphorylation and ATPase-driven proton translocation measured in coupled thylakoids purified from beta T168D, beta T168C, and beta T168L mutants had <10% of the wild type rates, as did rates of Mg2+-ATPase activity of purified chloroplast F-1-ATPase (CF1), The EPR spectra of VO2+-ATP bound to Site 3 of CF1 from wild type and mutants showed that EPR species C, formed exclusively upon activation, was altered in CF, from each mutant in both signal intensity and in V-51 hyperfine parameters that depend on the equatorial VO2+ ligands. These data provide the first direct evidence that Site 3 is a catalytic site, No significant differences between wild type and mutants were observed in EPR species B, the predominant form of the latent enzyme. Thus, the phosphate-binding loop threonine is an equatorial metal ligand in the activated conformation but not in the latent conformation of Site 3, The metal-nucleotide conformation that gives rise to species B is consistent with the Mg2+-ADP complex that becomes entrapped in a catalytic site in a manner that regulates enzymatic activity. The lack of catalytic function of CF1 with entrapped Mg2+-ADP may be explained in part by the absence of the phosphate-binding loop threonine as a metal ligand.	Arizona State Univ, Ctr Study Early Events Photosynth, Tempe, AZ 85287 USA	Arizona State University; Arizona State University-Tempe	Frasch, WD (corresponding author), Arizona State Univ, Ctr Study Early Events Photosynth, Tempe, AZ 85287 USA.	frasch@asu.edu			NIGMS NIH HHS [R01 GM050202, GM50202] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050202] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; BERCHTOLD H, 1993, NATURE, V365, P126, DOI 10.1038/365126a0; BRUIST MF, 1981, BIOCHEMISTRY-US, V20, P6298, DOI 10.1021/bi00525a003; Chasteen N.D., 1981, BIOL MAGN RESON, V3, P53; DUNHAM KR, 1981, J BIOL CHEM, V256, P212; FISHER AJ, 1995, BIOCHEMISTRY-US, V34, P8960, DOI 10.1021/bi00028a004; FRASCH WD, 1982, BIOCHEMISTRY-US, V21, P3636, DOI 10.1021/bi00258a017; Frasch WD, 1994, MOL BIOL CYANOBACTER, P361; Hamstra BJ, 1997, INORG CHEM, V36, P4866, DOI 10.1021/ic970284x; HOLYK N, 1979, THESIS U NEW HAMSPHI; HOUSEMAN ALP, 1995, BIOCHEMISTRY-US, V34, P3277, DOI 10.1021/bi00010a018; HOUSEMAN ALP, 1994, BIOCHEMISTRY-US, V33, P4910, DOI 10.1021/bi00182a020; HOUSEMAN ALP, 1994, BIOCHEMISTRY-US, V33, P10000, DOI 10.1021/bi00199a025; Hu CY, 1996, BIOCHEMISTRY-US, V35, P12201, DOI 10.1021/bi961105a; Hu DL, 1998, FEBS LETT, V421, P65, DOI 10.1016/S0014-5793(97)01531-7; Jault JM, 1996, J BIOL CHEM, V271, P28818, DOI 10.1074/jbc.271.46.28818; JAULT JM, 1993, J BIOL CHEM, V268, P1558; JAULT JM, 1994, J BIOL CHEM, V269, P319; JURNAK F, 1985, SCIENCE, V230, P32, DOI 10.1126/science.3898365; MARKHAM GD, 1984, BIOCHEMISTRY-US, V23, P470, DOI 10.1021/bi00298a011; MAURICE AM, 1981, THESIS U ILLINOIS; MCCARTY RE, 1987, TRENDS BIOCHEM SCI, V12, P234, DOI 10.1016/0968-0004(87)90116-2; MUELLER DM, 1994, EUR J BIOCHEM, V222, P991, DOI 10.1111/j.1432-1033.1994.tb18950.x; MUELLER DM, 1989, J BIOL CHEM, V264, P16552; MULLER CW, 1992, J MOL BIOL, V224, P159, DOI 10.1016/0022-2836(92)90582-5; Nilges M. J., 1979, THESIS U ILLINOIS UR; OMOTE H, 1992, J BIOL CHEM, V267, P20571; ONEAL CC, 1984, J BIOL CHEM, V259, P5761; Pal E.F., 1989, NATURE, V341, P209; Sambrook J., 1989, MOL CLONING LAB MANU, V1; SCHUMANN J, 1980, P 5 INT PHOT C BALB, V2, P881; SHAPIRO AB, 1991, J BIOL CHEM, V266, P4194; SMITH DJ, 1976, P NATL ACAD SCI USA, V73, P4314, DOI 10.1073/pnas.73.12.4314; STORY RM, 1992, NATURE, V355, P374, DOI 10.1038/355374a0; WALKER JE, 1985, J MOL BIOL, V184, P677, DOI 10.1016/0022-2836(85)90313-4; Weber J, 1997, BBA-BIOENERGETICS, V1319, P19, DOI 10.1016/S0005-2728(96)00121-1; Weber J, 1996, J BIOL CHEM, V271, P18711, DOI 10.1074/jbc.271.31.18711; Weber J, 1998, BIOCHEMISTRY-US, V37, P608, DOI 10.1021/bi972370e; XIAO JP, 1989, BIOCHIM BIOPHYS ACTA, V976, P203, DOI 10.1016/S0005-2728(89)80231-2; ZHOU JM, 1988, BIOCHEMISTRY-US, V27, P5129, DOI 10.1021/bi00414a027	40	13	14	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 12	1999	274	11					7089	7094		10.1074/jbc.274.11.7089	http://dx.doi.org/10.1074/jbc.274.11.7089			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	175DV	10066766	hybrid			2022-12-25	WOS:000079078400038
J	Jobbagy, Z; Olah, Z; Petrovics, G; Eiden, MV; Leverett, BD; Dean, NM; Anderson, WB				Jobbagy, Z; Olah, Z; Petrovics, G; Eiden, MV; Leverett, BD; Dean, NM; Anderson, WB			Up-regulation of the Pit-2 phosphate transporter retrovirus receptor by protein kinase C epsilon	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APE LEUKEMIA-VIRUS; OSTEOBLAST-LIKE CELLS; NIH 3T3 CELLS; ECOTROPIC MURINE RETROVIRUSES; AMINO-ACID TRANSPORTER; PARATHYROID-HORMONE; SURFACE RECEPTOR; GROWTH; INVOLVEMENT; STIMULATION	The membrane receptors for the gibbon ape leukemia retrovirus and the amphotropic murine retrovirus serve normal cellular functions as sodium-dependent phosphate transporters (Pit-1 and Pit-2, respectively). Our earlier studies established that activation of protein kinase C (PKC) by treatment of cells with phorbol 12-myristate 13-acetate (PMA) enhanced sodium-dependent phosphate (Na/P-i) uptake, Studies now have been carried out to determine which type of Na/P-i transporter (Pit-1 or Pit-2) is regulated by PKC and which PKC isotypes are involved in the up-regulation of Na/P-i uptake by the Na/P-i transporter/viral receptor. It was found that the activation of short term (2-min) Na/P-i uptake by PMA is abolished when cells are infected with amphotropic murine retrovirus (binds Pit-2 receptor) but not with gibbon ape leukemia retrovirus (binds Pit-1 receptor), indicating that Pit-2 is the form of Na/P-i, transporter/viral receptor regulated by PKC, The PKC-mediated activation of Pit-2 was blocked by pretreating cells with the pan-PKC inhibitor bisindolylmaleimide but not with the conventional PKC isotype inhibitor Go 6976, suggesting that a novel PKC isotype is required to regulate Pit-2. Overexpression of PKC epsilon, but not of PKC alpha, -delta, or -zeta was found to mimic the activation of Na/P-i uptake. To further establish that PKC epsilon is involved in the regulation of Pit-2, cells were treated with PKC epsilon-selective antisense oligonucleotides, Treatment with PKC epsilon antisense oligonucleotides decreased the PMA-induced activation of Na/P-i uptake. These results indicate that PMA-induced stimulation of Na/P-i uptake by Pit-2 is specifically mediated through activation of PKC epsilon.	NCI, Cellular Oncol Lab, NIH, Bethesda, MD 20892 USA; NIMH, Lab Cellular & Mol Regulat, NIH, Bethesda, MD 20892 USA; US FDA, Ctr Biol Evaluat & Res, Bethesda, MD 20892 USA; ISIS Pharmaceut, Carlsbad Res Ctr, Dept Pharmacol, Carlsbad, CA 92008 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH); US Food & Drug Administration (FDA); Isis Pharmaceuticals Inc	Anderson, WB (corresponding author), NCI, Cellular Oncol Lab, NIH, Bldg 37,Rm 1E-14,37 Convent Dr,MSC 4255, Bethesda, MD 20892 USA.			Petrovics, Gyorgy/0000-0003-3732-284X	NATIONAL INSTITUTE OF MENTAL HEALTH [ZIAMH002592, Z01MH002592] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ARAO M, 1994, EUR J ENDOCRINOL, V131, P646, DOI 10.1530/eje.0.1310646; BARQUINERO J, 1995, BLOOD, V85, P1195, DOI 10.1182/blood.V85.5.1195.bloodjournal8551195; Caverzasio J, 1996, KIDNEY INT, V49, P975, DOI 10.1038/ki.1996.138; COREY JL, 1994, J BIOL CHEM, V269, P14757; Enyedi A, 1996, J BIOL CHEM, V271, P32461, DOI 10.1074/jbc.271.50.32461; FranchiGazzola R, 1996, J BIOL CHEM, V271, P26124, DOI 10.1074/jbc.271.42.26124; HUDSON AW, 1992, J CELL BIOL, V116, P785, DOI 10.1083/jcb.116.3.785; KARIM Z, 1995, AM J PHYSIOL-CELL PH, V269, pC134, DOI 10.1152/ajpcell.1995.269.1.C134; Kavanaugh MP, 1996, KIDNEY INT, V49, P959, DOI 10.1038/ki.1996.135; KAVANAUGH MP, 1994, P NATL ACAD SCI USA, V91, P7071, DOI 10.1073/pnas.91.15.7071; LEHEL C, 1995, P NATL ACAD SCI USA, V92, P1406, DOI 10.1073/pnas.92.5.1406; LEHEL C, 1994, J BIOL CHEM, V269, P4761; Liedtke CM, 1997, AM J PHYSIOL-CELL PH, V273, pC1632, DOI 10.1152/ajpcell.1997.273.5.C1632; MISCHAK H, 1993, J BIOL CHEM, V268, P6090; MURER H, 1991, AM J PHYSIOL, V260, pC885, DOI 10.1152/ajpcell.1991.260.5.C885; Nishizuka Yasutomi, 1995, Clinical and Experimental Pharmacology and Physiology, V22, pS202, DOI 10.1111/j.1440-1681.1995.tb02883.x; OLAH Z, 1994, ANAL BIOCHEM, V221, P94, DOI 10.1006/abio.1994.1384; OLAH Z, 1994, J BIOL CHEM, V269, P25426; OLAH Z, 1993, BIOCHIM BIOPHYS ACTA, V1176, P333, DOI 10.1016/0167-4889(93)90063-U; Palmer G, 1997, ENDOCRINOLOGY, V138, P5202, DOI 10.1210/en.138.12.5202; QUAMME G, 1989, AM J PHYSIOL, V257, pF967, DOI 10.1152/ajprenal.1989.257.6.F967; QUAMME G, 1994, BBA-MOL CELL RES, V1223, P107, DOI 10.1016/0167-4889(94)90079-5; Ribeiro CMP, 1996, J BIOL CHEM, V271, P21522, DOI 10.1074/jbc.271.35.21522; Rokaw MD, 1996, J BIOL CHEM, V271, P32468, DOI 10.1074/jbc.271.50.32468; Schmid C, 1998, BIOCHEM BIOPH RES CO, V245, P220, DOI 10.1006/bbrc.1998.8403; VANZEIJL M, 1994, P NATL ACAD SCI USA, V91, P1168, DOI 10.1073/pnas.91.3.1168; Veldman CM, 1997, BONE, V21, P41, DOI 10.1016/S8756-3282(97)00077-X; Veldman CR, 1998, ENDOCRINOLOGY, V139, P89, DOI 10.1210/en.139.1.89; WANG H, 1992, J BIOL CHEM, V267, P23617; WANG H, 1991, NATURE, V352, P729, DOI 10.1038/352729a0; WEISS RA, 1995, CELL, V82, P531, DOI 10.1016/0092-8674(95)90024-1; WILSON CA, 1991, J VIROL, V65, P5975, DOI 10.1128/JVI.65.11.5975-5982.1991; WILSON CA, 1995, J VIROL, V69, P534, DOI 10.1128/JVI.69.1.534-537.1995; Zhen XC, 1997, J BONE MINER RES, V12, P36, DOI 10.1359/jbmr.1997.12.1.36	34	23	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 12	1999	274	11					7067	7071		10.1074/jbc.274.11.7067	http://dx.doi.org/10.1074/jbc.274.11.7067			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	175DV	10066763	hybrid			2022-12-25	WOS:000079078400035
J	Aspinwall, CA; Lakey, JRT; Kennedy, RT				Aspinwall, CA; Lakey, JRT; Kennedy, RT			Insulin-stimulated insulin secretion in single pancreatic beta cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FEEDBACK INHIBITION; B-CELLS; RECEPTOR SUBSTRATE-1; EXOGENOUS INSULIN; CANINE PANCREAS; GLUCOSE; ISLETS; RELEASE; RESISTANCE; CA2+	Functional insulin receptors are known to occur in pancreatic beta cells; however, except for a positive feedback on insulin synthesis, their physiological effects are unknown. Amperometric measurements at single, primary pancreatic beta cells reveal that application of exogenous insulin in the presence or absence of nonstimulatory concentrations of glucose evokes exocytosis mediated by the beta cell insulin receptor. Insulin also elicits increases in intracellular Ca2+ concentration in beta cells but has minimal effects on membrane potential. Conditions where the insulin receptor is blocked or cell surface concentration of free insulin is reduced during exocytosis diminishes secretion induced by other secretagogues, providing evidence for direct autocrine action of insulin upon secretion from the same cell. These results indicate that the beta cell insulin receptor can mediate positive feedback for insulin secretion. The presence of a positive feedback mechanism for insulin secretion mediated by the insulin receptor provides a potential Link between impaired insulin secretion and insulin resistance.	Univ Florida, Dept Chem, Gainesville, FL 32611 USA; Univ Alberta, Dept Surg, Comprehens Tissue Ctr, Edmonton, AB T6G 2N8, Canada	State University System of Florida; University of Florida; University of Alberta	Kennedy, RT (corresponding author), Univ Florida, Dept Chem, Gainesville, FL 32611 USA.	rtkenn@chem.ufl.edu	Kennedy, Robert/G-9095-2016	Kennedy, Robert/0000-0003-2447-7471; Aspinwall, Craig/0000-0002-4359-5812	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046960] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01-DK46960] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AMMON HPT, 1976, ENDOCRINOLOGY, V99, P1468, DOI 10.1210/endo-99-6-1469; ARGOUD GM, 1987, DIABETES, V36, P959, DOI 10.2337/diabetes.36.8.959; Aspinwall CA, 1997, J BIOL CHEM, V272, P31308, DOI 10.1074/jbc.272.50.31308; BEISCHER W, 1983, DIABETOLOGIA, V25, P139; BOSCO D, 1989, EXP CELL RES, V184, P72, DOI 10.1016/0014-4827(89)90365-0; Cunningham BA, 1996, AM J PHYSIOL-ENDOC M, V271, pE702, DOI 10.1152/ajpendo.1996.271.4.E702; DRAZNIN B, 1986, ENDOCRINOLOGY, V118, P1054, DOI 10.1210/endo-118-3-1054; GAZZANO H, 1985, BIOCHEM J, V226, P867, DOI 10.1042/bj2260867; Harbeck MC, 1996, DIABETES, V45, P711, DOI 10.2337/diabetes.45.6.711; HUANG L, 1995, P NATL ACAD SCI USA, V92, P9608, DOI 10.1073/pnas.92.21.9608; HURLEY LS, 1969, AM J CLIN NUTR, V22, P1332; IVERSEN J, 1971, DIABETES, V20, P1; Kennedy RT, 1996, J AM CHEM SOC, V118, P1795, DOI 10.1021/ja953271w; Komatsu M, 1997, DIABETES, V46, P1928, DOI 10.2337/diabetes.46.12.1928; Kulkarni RN, 1998, DIABETES, V47, pA57; Leibiger IB, 1998, MOL CELL, V1, P933, DOI 10.1016/S1097-2765(00)80093-3; LI GD, 1991, J BIOL CHEM, V266, P3449; LILJENQUIST JE, 1978, DIABETES, V27, P563, DOI 10.2337/diab.27.5.563; LORETI L, 1974, DIABETOLOGIA, V10, P309; LUZI L, 1992, DIABETES, V41, P1632, DOI 10.2337/diabetes.41.12.1632; MAES E, 1984, ENDOCRINOLOGY, V114, P2205, DOI 10.1210/endo-114-6-2205; MAKI LW, 1995, AM J PHYSIOL-CELL PH, V268, pC780, DOI 10.1152/ajpcell.1995.268.3.C780; MALAISSE WJ, 1967, P SOC EXP BIOL MED, V124, P497; MARINCOLA F, 1983, DIABETES, V32, P1162, DOI 10.2337/diabetes.32.12.1162; MARTIN BC, 1992, LANCET, V340, P925, DOI 10.1016/0140-6736(92)92814-V; Moens K, 1996, DIABETES, V45, P257, DOI 10.2337/diabetes.45.2.257; ORAHILLY S, 1988, NEW ENGL J MED, V318, P1225, DOI 10.1056/NEJM198805123181902; PACE CS, 1977, BIOCHIM BIOPHYS ACTA, V497, P408; PATEL YC, 1982, SCIENCE, V217, P1155, DOI 10.1126/science.6126003; POLONSKY KS, 1995, DIABETES, V44, P705, DOI 10.2337/diabetes.44.6.705; PRALONG WF, 1990, EMBO J, V9, P53, DOI 10.1002/j.1460-2075.1990.tb08079.x; Prentki M, 1997, DIABETOLOGIA, V40, pS32, DOI 10.1007/s001250051395; RICORDI C, 1988, DIABETES, V37, P413, DOI 10.2337/diabetes.37.4.413; ROTHENBERG PL, 1995, DIABETES, V44, P802, DOI 10.2337/diabetes.44.7.802; SCHATZ H, 1977, J ENDOCRINOL, V74, P243, DOI 10.1677/joe.0.0740243; SCHUIT FC, 1989, DIABETOLOGIA, V32, P207, DOI 10.1007/BF00265096; SMITH PA, 1995, PFLUG ARCH EUR J PHY, V430, P808, DOI 10.1007/BF00386180; SODOYEZ JC, 1969, P SOC EXP BIOL MED, V130, P568; STAGNER J, 1986, J CLIN INVEST, V78, P1193, DOI 10.1172/JCI112702; TAMEMOTO H, 1994, NATURE, V372, P182, DOI 10.1038/372182a0; TANAKA R, 1980, ENDOCRINOL JAPON, V27, P343; Tang JP, 1996, AM J PHYSIOL-ENDOC M, V270, pE504, DOI 10.1152/ajpendo.1996.270.3.E504; TAYLOR SI, 1994, DIABETES, V43, P735, DOI 10.2337/diab.43.6.735; VANSCHRAVENDIJK CFH, 1990, DIABETOLOGIA, V33, P649, DOI 10.1007/BF00400565; VERSPOHL EJ, 1980, J CLIN INVEST, V65, P1230, DOI 10.1172/JCI109778; WARNOCK GL, 1994, PANCREATIC ISLET TRA, V1, P81; WIGHTMAN RM, 1991, P NATL ACAD SCI USA, V88, P10754, DOI 10.1073/pnas.88.23.10754; Withers DJ, 1998, NATURE, V391, P900, DOI 10.1038/36116; Xu G, 1998, J BIOL CHEM, V273, P4485, DOI 10.1074/jbc.273.8.4485; Xu G, 1998, DIABETES, V47, pA57; Xu GG, 1998, DIABETES, V47, P1243, DOI 10.2337/diabetes.47.8.1243; ZHOU Z, 1995, J BIOL CHEM, V270, P3498, DOI 10.1074/jbc.270.8.3498	52	179	188	2	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	1999	274	10					6360	6365		10.1074/jbc.274.10.6360	http://dx.doi.org/10.1074/jbc.274.10.6360			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172BQ	10037726	hybrid			2022-12-25	WOS:000078902800048
J	Gilchrist, A; Bunemann, M; Li, A; Hosey, MM; Hamm, HE				Gilchrist, A; Bunemann, M; Li, A; Hosey, MM; Hamm, HE			A dominant-negative strategy for studying roles of G proteins in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCARINIC ACETYLCHOLINE-RECEPTORS; NUCLEOTIDE-BINDING PROTEIN; HETEROTRIMERIC G-PROTEIN; PIG ATRIAL MYOCYTES; ALPHA-SUBUNIT; K+-CHANNEL; CRYSTAL-STRUCTURE; CYTOPLASMIC DOMAINS; CELLULAR EXPRESSION; SYNTHETIC PEPTIDES	G proteins play a critical role in transducing a large variety of signals into intracellular responses, Increasingly, there is evidence that G proteins may play other roles as well. Dominant-negative constructs of the ct subunit of G proteins would be useful in studying the roles of G proteins in a variety of processes, but the currently available dominant-negative constructs, which target Mg2+-binding sites, are rather leaky. A variety of studies have implicated the carboxyl terminus of G protein alpha subunits in both mediating receptor-G protein interaction and in receptor selectivity. Thus we have made minigene plasmid constructs that encode oligonucleotide sequences corresponding to the carboxyl-terminal undecapeptide of G alpha(i), G alpha(q), Or G alpha(s) To determine whether overexpression of the carboxyl-terminal peptide would block cellular responses, we used as a test system the activation of the M-2 muscarinic receptor activated K+ channels in HEK 293 cells. The minigenes were transiently transfected along with G protein-regulated inwardly rectifying K+ channels (GIRK) into HER 293 cells that stably express the M-2 muscarinic receptor. The presence of the G alpha(i) carboxyl-terminal peptide results in specific inhibition of GIRK activity in response to agonist stimulation of the M-2 muscarinic receptor. The G alpha(i) minigene construct completely blocks agonist-mediated M-2 mAChR K+ channel response whereas the control minigene constructs (empty vector, pcDNA3,1, and the G alpha carboxyl peptide in random order, pcDNA-G alpha(i)R) had no effect on agonist-mediated M-2 muscarinic receptor GIRK response. The inhibitory effects of the G alpha i minigene construct were specific because overexpression of peptides corresponding to the carboxyl terminus of G alpha(q) Or G alpha(s) had no effect on M-2 muscarinic receptor stimulation of the K+ channel.	Northwestern Univ, Inst Neurosci, Chicago, IL 60611 USA; Northwestern Univ, Dept Mol Pharmacol & Biochem, Chicago, IL 60611 USA; Univ Illinois, Dept Pharmacol, Chicago, IL 60612 USA	Northwestern University; Northwestern University; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Hamm, HE (corresponding author), Northwestern Univ, Inst Neurosci, 320 E Super 5-555 Searle, Chicago, IL 60611 USA.		Gilchrist, Annette/I-4465-2014; Hamm, Heidi E/G-2374-2014	Gilchrist, Annette/0000-0003-2386-7646; 	NEI NIH HHS [EY06062, EY10291] Funding Source: Medline; NHLBI NIH HHS [HL50121] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY006062, R01EY010291] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL050121] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Akhter SA, 1998, SCIENCE, V280, P574, DOI 10.1126/science.280.5363.574; ARAGAY AM, 1995, J BIOL CHEM, V270, P20073, DOI 10.1074/jbc.270.34.20073; Bae H, 1997, J BIOL CHEM, V272, P32071, DOI 10.1074/jbc.272.51.32071; Blahos J, 1998, J BIOL CHEM, V273, P25765, DOI 10.1074/jbc.273.40.25765; Bourne HR, 1997, CURR OPIN CELL BIOL, V9, P134, DOI 10.1016/S0955-0674(97)80054-3; Breitwieser GE, 1996, J MEMBRANE BIOL, V152, P1, DOI 10.1007/s002329900080; Bunemann M, 1995, J PHYSIOL-LONDON, V489, P701; BUNEMANN M, 1995, J PHYSIOL-LONDON, V482, P81; Carlson SA, 1996, J BIOL CHEM, V271, P23146, DOI 10.1074/jbc.271.38.23146; CARREL F, 1994, MOL BIOL CELL, V5, P7, DOI 10.1091/mbc.5.1.7; COLEMAN DE, 1994, SCIENCE, V265, P1405, DOI 10.1126/science.8073283; CONKLIN BR, 1993, NATURE, V363, P274, DOI 10.1038/363274a0; Corey S, 1998, J BIOL CHEM, V273, P5271, DOI 10.1074/jbc.273.9.5271; DELLACQUA ML, 1993, J BIOL CHEM, V268, P5676; Dickenson JM, 1998, EUR J PHARMACOL, V355, P85, DOI 10.1016/S0014-2999(98)00468-3; Fedorov YV, 1998, MOL CELL BIOL, V18, P5780, DOI 10.1128/MCB.18.10.5780; Gilchrist A, 1998, J BIOL CHEM, V273, P14912, DOI 10.1074/jbc.273.24.14912; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HAMM HE, 1988, SCIENCE, V241, P832, DOI 10.1126/science.3136547; Hamm HE, 1998, J BIOL CHEM, V273, P669, DOI 10.1074/jbc.273.2.669; Hamm HE, 1996, CURR OPIN CELL BIOL, V8, P189, DOI 10.1016/S0955-0674(96)80065-2; HAMM HE, 1987, J BIOL CHEM, V262, P10831; HAWES BE, 1994, J BIOL CHEM, V269, P15776; HERMOUET S, 1991, P NATL ACAD SCI USA, V88, P10455, DOI 10.1073/pnas.88.23.10455; HIGASHIJIMA T, 1987, J BIOL CHEM, V262, P762; HIGASHIJIMA T, 1987, J BIOL CHEM, V262, P757; Jan LY, 1997, CURR OPIN CELL BIOL, V9, P155, DOI 10.1016/S0955-0674(97)80057-9; JOHN J, 1993, J BIOL CHEM, V268, P923; JONES S, 1995, NEURON, V14, P399, DOI 10.1016/0896-6273(95)90295-3; JURMAN ME, 1994, BIOTECHNIQUES, V17, P876; KOCH WJ, 1994, J BIOL CHEM, V269, P6193; Kostenis E, 1997, BIOCHEMISTRY-US, V36, P1487, DOI 10.1021/bi962554d; Krapivinsky G, 1998, J BIOL CHEM, V273, P16946, DOI 10.1074/jbc.273.27.16946; KRAPIVINSKY G, 1995, NATURE, V374, P135, DOI 10.1038/374135a0; KRAPIVINSKY G, 1995, J BIOL CHEM, V270, P29059, DOI 10.1074/jbc.270.49.29059; LAI J, 1991, J PHARMACOL EXP THER, V258, P938; LAMBRIGHT DG, 1994, NATURE, V369, P621, DOI 10.1038/369621a0; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; LEE E, 1992, J BIOL CHEM, V267, P1212; LIU J, 1995, P NATL ACAD SCI USA, V92, P11642, DOI 10.1073/pnas.92.25.11642; LUTTRELL LM, 1993, SCIENCE, V259, P1453, DOI 10.1126/science.8383880; LUTTRELL LM, 1995, J BIOL CHEM, V270, P12984, DOI 10.1074/jbc.270.22.12984; Martin EL, 1996, J BIOL CHEM, V271, P361, DOI 10.1074/jbc.271.1.361; MIXON MB, 1995, SCIENCE, V270, P954, DOI 10.1126/science.270.5238.954; OFFERMANNS S, 1994, MOL PHARMACOL, V45, P890; Onrust R, 1997, SCIENCE, V275, P381, DOI 10.1126/science.275.5298.381; Osawa S, 1995, J BIOL CHEM, V270, P31052, DOI 10.1074/jbc.270.52.31052; PALSRYLAARSDAM R, 1995, J BIOL CHEM, V270, P29004, DOI 10.1074/jbc.270.48.29004; QUILLIAM LA, 1994, MOL CELL BIOL, V14, P1113, DOI 10.1128/MCB.14.2.1113; RASENICK MM, 1994, J BIOL CHEM, V269, P21519; SLEPAK VZ, 1995, J BIOL CHEM, V270, P4037, DOI 10.1074/jbc.270.8.4037; SLEPAK VZ, 1993, J BIOL CHEM, V268, P21889; SONDEK J, 1994, NATURE, V372, P276, DOI 10.1038/372276a0; Sondek J, 1996, NATURE, V379, P369, DOI 10.1038/379369a0; Sowell MO, 1997, P NATL ACAD SCI USA, V94, P7921, DOI 10.1073/pnas.94.15.7921; Sprang SR, 1997, ANNU REV BIOCHEM, V66, P639, DOI 10.1146/annurev.biochem.66.1.639; Takano K, 1997, J PHYSIOL-LONDON, V502, P559, DOI 10.1111/j.1469-7793.1997.559bj.x; THOMAS EA, 1994, J PHARMACOL EXP THER, V271, P1042; Thompson JB, 1998, J PHARMACOL EXP THER, V285, P216; Ulloa-Aguirre A, 1998, ENDOCRINOLOGY, V139, P2472, DOI 10.1210/en.139.5.2472; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; WICKMAN KD, 1995, CURR OPIN NEUROBIOL, V5, P278, DOI 10.1016/0959-4388(95)80039-5; WINITZ S, 1994, J BIOL CHEM, V269, P1889	63	81	85	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1999	274	10					6610	6616		10.1074/jbc.274.10.6610	http://dx.doi.org/10.1074/jbc.274.10.6610			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172BQ	10037756	hybrid			2022-12-25	WOS:000078902800078
J	Guillen, E; Abeijon, C; Hirschberg, CB				Guillen, E; Abeijon, C; Hirschberg, CB			The genes for the Golgi apparatus N-acetylglucosaminyltransferase and the UDP-N-acetylglucosamine transporter are contiguous in Kluyveromyces lactis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-CLONING; YEAST; BIOSYNTHESIS	The mannan chains of Kluyveromyces lactis mannoproteins are similar to those of Saccharomyces cerevisiae except that they lack mannose phosphate and have terminal alpha(1-->2)-linked N-acetylglucosamine. Previously, Smith ct al, (Smith, W, L, Nakajima, T, and Ballou, C, E. (1975) J, Biol, Chem. 250, 3426-3435) characterized two mutants, mnn2-1 and mnn2-2, which lacked terminal N-acetylglucosamine in their mannoproteins. The former mutant lacks the Golgi N-acetylglucosaminyl-transferase activity, whereas the latter one was recently found to be deficient in the Golgi UDP-GlcNAc transporter activity. Analysis of extensive crossings between the two mutants led Ballou and co-workers (reference cited above) to conclude that these genes were allelic or tightly linked. We have now cloned the gene encoding the K. lactis Golgis membrane N-acetylglucosaminyltransferase by complementation of the mnn2-1 mutation and named it GNT1. The mnn2-1 mutant was transformed with a 9.5-kilobase (kb) genomic fragment previously shown to contain the gene encoding the UDP-GlcNAc transporter; transformants were isolated, and phenotypic correction was monitored after cell surface labeling with fluorescein isothiocyanate-conjugated Griffonia simplicifolia II lectin, which binds terminal N-acetylglucosamine, and a fluorescence-activated cell sorter. The above 9.5-kb DNA fragment restored the wild-type lectin binding phenotype of the transferase mutant; further subcloning of this fragment yielded a smaller one containing an opening reading frame of 1,383 bases encoding a protein of 460 amino acids with an estimated molecular mass of 53 kDa, which also restored the wild-type phenotype. Transformants had also regained the ability to transfer N-acetylglucosamine to 3-O-alpha-D-mannopyranosyl-D-mannopyranoside. The gene encoding the above transferase was found to be approximately 1 kb upstream from the previously characterized MNN2 gene encoding the UDP-GlcNAc Golgi transporter. Each gene can be transcribed independently by their own promoter. To our knowledge this is the first demonstration of two Golgis apparatus functionally related genes being contiguous in a genome.	Boston Univ, Goldman Sch Dent Med, Dept Mol & Cell Biol, Boston, MA 02118 USA	Boston University	Hirschberg, CB (corresponding author), Boston Univ, Goldman Sch Dent Med, Dept Mol & Cell Biol, 700 Albany St,W200, Boston, MA 02118 USA.	chirschb@bu.edu		Hirschberg, Carlos/0000-0003-2299-7721	NIGMS NIH HHS [GM 30365] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM030365, R01GM030365] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abeijon C, 1996, J BIOL CHEM, V271, P8851, DOI 10.1074/jbc.271.15.8851; Abeijon C, 1996, P NATL ACAD SCI USA, V93, P5963, DOI 10.1073/pnas.93.12.5963; Blumenthal T, 1998, BIOESSAYS, V20, P480, DOI 10.1002/(SICI)1521-1878(199806)20:6&lt;480::AID-BIES6&gt;3.0.CO;2-Q; Brown T., 1997, CURRENT PROTOCOLS MO; Busch C, 1998, J BIOL CHEM, V273, P19566, DOI 10.1074/jbc.273.31.19566; CHEN XJ, 1991, BIOCHIMIE, V73, P1195, DOI 10.1016/0300-9084(91)90004-K; COLLART M, 1993, CURRENT PROTOCOLS MO; DOUGLAS RH, 1982, BIOCHEMISTRY-US, V21, P1561, DOI 10.1021/bi00536a015; FIELD MC, 1995, GLYCOBIOLOGY, V5, P463, DOI 10.1093/glycob/5.5.463; FRITZ TA, 1994, J BIOL CHEM, V269, P28809; Guillen E, 1998, P NATL ACAD SCI USA, V95, P7888, DOI 10.1073/pnas.95.14.7888; HEIN J, 1990, METHOD ENZYMOL, V183, P626; HERMAN A, 1963, J BACTERIOL, V85, P895, DOI 10.1128/JB.85.4.895-900.1963; Kaiser C., 1994, METHODS YEAST GENETI, P209; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Lind T, 1998, J BIOL CHEM, V273, P26265, DOI 10.1074/jbc.273.41.26265; NATSUKA S, 1994, CURR OPIN STRUC BIOL, V4, P683, DOI 10.1016/S0959-440X(94)90166-X; NEEDLEMAN R, 1991, MOL MICROBIOL, V5, P2079, DOI 10.1111/j.1365-2958.1991.tb02136.x; NEEDLEMAN RB, 1984, P NATL ACAD SCI-BIOL, V81, P2811, DOI 10.1073/pnas.81.9.2811; RASHKE WC, 1972, BIOCHEMISTRY-US, V11, P3807; Roach PJ, 1997, PROG NUCLEIC ACID RE, V57, P289, DOI 10.1016/S0079-6603(08)60284-6; SMITH WL, 1975, J BIOL CHEM, V250, P3426; WESOLOWSKILOUVEL M, 1988, YEAST, V4, P71, DOI 10.1002/yea.320040108; Wiggins CAR, 1998, P NATL ACAD SCI USA, V95, P7945, DOI 10.1073/pnas.95.14.7945; Wolfe KH, 1997, NATURE, V387, P708, DOI 10.1038/42711	25	10	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	1999	274	10					6641	6646		10.1074/jbc.274.10.6641	http://dx.doi.org/10.1074/jbc.274.10.6641			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172BQ	10037760	hybrid			2022-12-25	WOS:000078902800082
J	Haeseleer, F; Sokal, I; Li, N; Pettenati, M; Rao, N; Bronson, D; Wechter, R; Baehr, W; Palczewski, K				Haeseleer, F; Sokal, I; Li, N; Pettenati, M; Rao, N; Bronson, D; Wechter, R; Baehr, W; Palczewski, K			Molecular characterization of a third member of the guanylyl cyclase-activating protein subfamily	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTIONAL-CHARACTERIZATION; CA2+-BINDING PROTEIN; VERTEBRATE RODS; MESSENGER-RNAS; CLONING; CALCIUM; LOCALIZATION; EXPRESSION; RETINA; GENES	The mammalian retina contains at least two guanylyl cyclases (GC1 and GC2) and two guanylyl cyclase-activating proteins (GCAP1 and GCAP2). Here we present evidence of the presence of a new photoreceptor-specific GCAP, termed GCAP3, which is closely related to GCAP1. The sequence similarity of GCAP3 with GCAP1 and GCAP2 is 57 and 49%, respectively. Recombinant GCAP3 and GCAP2 stimulate GC1 and GC2 in low [Ca2+](free) and inhibit GCs when [Ca2+](free) is elevated, unlike GCAP1, which only stimulates GC1. GCAP3 is encoded by a distinct gene present in other mammalian species but could not be detected by genomic Southern blotting in rodents, amphibians, and lower vertebrates. The intron/exon arrangement of the GCAP3 gene is identical to that of the other GCAP genes. While the GCAP1 and GCAP2 genes are arranged in a tail-to-tail array on chromosome 6p in human, the GCAP3 gene is located on 3q13.1, suggesting an ancestral gene duplication/translocation event. The identification of multiple Ca2+-binding proteins that interact with GC is suggestive of complex regulatory mechanisms for photoreceptor GC.	Univ Washington, Sch Med, Dept Ophthalmol, Seattle, WA 98195 USA; Univ Washington, Sch Med, Dept Pharmacol, Seattle, WA 98195 USA; Univ Washington, Sch Med, Dept Chem, Seattle, WA 98195 USA; Baylor Coll Med, Dept Biochem, Houston, TX 77030 USA; Wake Forest Univ, Bowman Gray Sch Med, Dept Pediat, Med Genet Sect, Winston Salem, NC 27157 USA; Univ Utah, Hlth Sci Ctr, Moran Eye Ctr, Salt Lake City, UT 84132 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Baylor College of Medicine; Wake Forest University; Wake Forest Baptist Medical Center; Utah System of Higher Education; University of Utah	Haeseleer, F (corresponding author), Univ Washington, Sch Med, Dept Ophthalmol, Box 356485, Seattle, WA 98195 USA.				NEI NIH HHS [EY08123, EY08061] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY008123, R29EY008061, R01EY008061] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Cuenca N, 1998, INVEST OPHTH VIS SCI, V39, P1243; Dizhoor A. M., 1998, IOVS, V39, pS443; Dizhoor AM, 1998, J BIOL CHEM, V273, P17311, DOI 10.1074/jbc.273.28.17311; DIZHOOR AM, 1992, J BIOL CHEM, V267, P16033; DIZHOOR AM, 1995, J BIOL CHEM, V270, P25200, DOI 10.1074/jbc.270.42.25200; Faurobert E, 1996, J BIOL CHEM, V271, P10256, DOI 10.1074/jbc.271.17.10256; FISCHER R, 1988, J BIOL CHEM, V263, P17055; Frins S, 1996, J BIOL CHEM, V271, P8022, DOI 10.1074/jbc.271.14.8022; GORACZNIAK RM, 1994, BIOCHEM J, V302, P455, DOI 10.1042/bj3020455; GORCZYCA WA, 1995, J BIOL CHEM, V270, P22029, DOI 10.1074/jbc.270.37.22029; GRAYKELLER MP, 1994, NEURON, V13, P849, DOI 10.1016/0896-6273(94)90251-8; HOWARD A, 1992, BIOCHEM BIOPH RES CO, V185, P663, DOI 10.1016/0006-291X(92)91676-H; Howes K, 1998, INVEST OPHTH VIS SCI, V39, P867; JEUNG EB, 1994, J MOL BIOL, V235, P1231, DOI 10.1006/jmbi.1994.1076; Koutalos Y, 1996, TRENDS NEUROSCI, V19, P73; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; Li N, 1998, EUR J BIOCHEM, V252, P591, DOI 10.1046/j.1432-1327.1998.2520591.x; LOWE DG, 1995, P NATL ACAD SCI USA, V92, P5535, DOI 10.1073/pnas.92.12.5535; MURAKAMI A, 1992, BIOCHEM BIOPH RES CO, V187, P234, DOI 10.1016/S0006-291X(05)81483-4; OttoBruc A, 1997, BIOCHEMISTRY-US, V36, P4295, DOI 10.1021/bi963000d; OttoBruc A, 1997, P NATL ACAD SCI USA, V94, P4727, DOI 10.1073/pnas.94.9.4727; PALCZEWSKI K, 1994, NEURON, V13, P395, DOI 10.1016/0896-6273(94)90355-7; Payne AM, 1998, HUM MOL GENET, V7, P273, DOI 10.1093/hmg/7.2.273; PETTENATI MJ, 1998, NUCL ACID HYBRIDIZAT, P81; Polans A, 1996, TRENDS NEUROSCI, V19, P547, DOI 10.1016/S0166-2236(96)10059-X; Pozdnyakov N, 1997, BIOCHEMISTRY-US, V36, P14159, DOI 10.1021/bi971792l; PROUDFOOT NJ, 1989, TRENDS BIOCHEM SCI, V14, P105, DOI 10.1016/0968-0004(89)90132-1; Rudnicka-Nawrot M, 1998, BIOCHEMISTRY-US, V37, P248, DOI 10.1021/bi972306x; SCHAFER BW, 1995, GENOMICS, V25, P638, DOI 10.1016/0888-7543(95)80005-7; SCHNETKAMP PPM, 1995, AM J PHYSIOL-CELL PH, V269, pC1153, DOI 10.1152/ajpcell.1995.269.5.C1153; Semple-Rowland S. L., 1998, IOVS, V39, pS952; SHYJAN AW, 1992, NEURON, V9, P727, DOI 10.1016/0896-6273(92)90035-C; Sokal I, 1998, MOL CELL, V2, P129, DOI 10.1016/S1097-2765(00)80121-5; STRYER L, 1991, J BIOL CHEM, V266, P10711; SUBBARAYA I, 1994, J BIOL CHEM, V269, P31080; Surgucheva I., 1997, Investigative Ophthalmology and Visual Science, V38, pS477; Surguchov A, 1997, GENOMICS, V39, P312, DOI 10.1006/geno.1996.4513	37	115	117	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1999	274	10					6526	6535		10.1074/jbc.274.10.6526	http://dx.doi.org/10.1074/jbc.274.10.6526			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172BQ	10037746	hybrid			2022-12-25	WOS:000078902800068
J	Jungmann, J; Rayner, JC; Munro, S				Jungmann, J; Rayner, JC; Munro, S			The Saccharomyces cerevisiae protein Mnn10p/Bed1p is a subunit of a Golgi mannosyltransferase complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-LINKED OLIGOSACCHARIDES; OUTER CHAIN ELONGATION; YEAST MANNAN STRUCTURE; CELL-WALL; SCHIZOSACCHAROMYCES-POMBE; CHEMICAL-STRUCTURE; GLYCOSYLATION DEFECTS; GENETIC-CONTROL; MUTANTS; GLYCOSYLTRANSFERASES	In the yeast Saccharomyces cerevisiae many of the N-linked glycans on cell wall and periplasmic proteins are modified by the addition of mannan, a large mannose-containing polysaccharide. Mannan comprises a backbone of approximately 50 alpha-1,6-linked mannoses to which are attached many branches consisting of alpha-1,2-linked and alpha-1,3-linked mannoses. The initiation and subsequent elongation of the mannan backbone is performed by two complexes of proteins in the cis Golgis. In this study we show that the product of the MNN10/BED1 gene is a component of one of these complexes, that which elongates the backbone. Analysis of interactions between the proteins in this complex shows that Mnn10p, and four previously characterized proteins (Anp1p, Mnn9p, Mnn11p, and Hoc1p) are indeed all components of the same large structure, Deletion of either Mnn10p, or its homologue Mnn11p, results in defects in mannan synthesis in vivo, and analysis of the enzymatic activity of the complexes isolated from mutant strains suggests that Mnn10p and Mnn11p are responsible for the majority of the alpha-1,6-polymerizing activity of the complex.	MRC, Mol Biol Lab, Cambridge CB2 2QH, England	MRC Laboratory Molecular Biology	Munro, S (corresponding author), MRC, Mol Biol Lab, Hills Rd, Cambridge CB2 2QH, England.			Munro, Sean/0000-0001-6160-5773; Rayner, Julian/0000-0002-9835-1014				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; BALLOU CE, 1990, METHOD ENZYMOL, V185, P440; BALLOU CE, 1973, J BIOL CHEM, V248, P4667; BALLOU L, 1995, P NATL ACAD SCI USA, V92, P2790, DOI 10.1073/pnas.92.7.2790; BALLOU L, 1990, P NATL ACAD SCI USA, V87, P3368, DOI 10.1073/pnas.87.9.3368; BALLOU L, 1991, P NATL ACAD SCI USA, V88, P3209, DOI 10.1073/pnas.88.8.3209; BALLOU L, 1980, J BIOL CHEM, V255, P5986; BALLOU L, 1989, J BIOL CHEM, V264, P11857; BARDALAYE PC, 1977, J BIOL CHEM, V252, P2584; BAUDIN A, 1993, NUCLEIC ACIDS RES, V21, P3329, DOI 10.1093/nar/21.14.3329; CHAPMAN RE, 1994, EMBO J, V13, P4896, DOI 10.1002/j.1460-2075.1994.tb06817.x; CHAPPELL TG, 1994, MOL BIOL CELL, V5, P519, DOI 10.1091/mbc.5.5.519; Colley KJ, 1997, GLYCOBIOLOGY, V7, P1, DOI 10.1093/glycob/7.1.1-b; Dallies N, 1998, YEAST, V14, P1297, DOI 10.1002/(SICI)1097-0061(1998100)14:14<1297::AID-YEA310>3.0.CO;2-L; Dean N, 1996, GLYCOBIOLOGY, V6, P73, DOI 10.1093/glycob/6.1.73; FIELD MC, 1995, GLYCOBIOLOGY, V5, P463, DOI 10.1093/glycob/5.5.463; Gemmill TR, 1996, J BIOL CHEM, V271, P25945, DOI 10.1074/jbc.271.42.25945; Hashimoto H, 1997, BIOCHEM BIOPH RES CO, V241, P682, DOI 10.1006/bbrc.1997.7888; HAUSLER A, 1992, GLYCOBIOLOGY, V2, P77, DOI 10.1093/glycob/2.1.77; HERNANDEZ LM, 1989, J BIOL CHEM, V264, P13648; HERSCOVICS A, 1993, FASEB J, V7, P540, DOI 10.1096/fasebj.7.6.8472892; Ikuta K, 1997, FEBS LETT, V414, P338, DOI 10.1016/S0014-5793(97)01028-4; JACKSON P, 1994, METHOD ENZYMOL, V230, P250; JIMENEZBARBERO J, 1995, CARBOHYD RES, V272, P121, DOI 10.1016/0008-6215(95)00023-M; Jungmann J, 1998, EMBO J, V17, P423, DOI 10.1093/emboj/17.2.423; KLIS FM, 1994, YEAST, V10, P851, DOI 10.1002/yea.320100702; LEWIS MS, 1991, J BIOL CHEM, V266, P8255; Mondesert G, 1996, J CELL BIOL, V132, P137, DOI 10.1083/jcb.132.1.137; Mondesert G, 1997, GENETICS, V147, P421; NAKAJIMA T, 1994, J FERMENT BIOENG, V78, P472, DOI 10.1016/0922-338X(94)90050-7; Nakamura T, 1997, MOL GEN GENET, V256, P481, DOI 10.1007/s004380050592; NAKAYAMA K, 1992, EMBO J, V11, P2511, DOI 10.1002/j.1460-2075.1992.tb05316.x; Neiman AM, 1997, GENETICS, V145, P637; NILSSON I, 1993, J BIOL CHEM, V268, P5798; Orlean P., 1997, MOL CELLULAR BIOL YE, V21, P229; PAULSON JC, 1989, J BIOL CHEM, V264, P17615; PEAT S, 1961, J CHEM SOC, P3918, DOI 10.1039/jr9610003918; RASCHKE WC, 1973, J BIOL CHEM, V248, P4660; Rayner JC, 1998, J BIOL CHEM, V273, P26836, DOI 10.1074/jbc.273.41.26836; ROBINSON JS, 1988, MOL CELL BIOL, V8, P4936, DOI 10.1128/MCB.8.11.4936; Roy SK, 1998, J BIOL CHEM, V273, P2583, DOI 10.1074/jbc.273.5.2583; Sekiya-Kawasaki M, 1998, GENETICS, V150, P43; SHIBATA N, 1995, J BIOL CHEM, V270, P1113, DOI 10.1074/jbc.270.3.1113; SMITH EL, 1940, P NATL ACAD SCI USA, V26, P23658; Wach A, 1997, YEAST, V13, P1065, DOI 10.1002/(SICI)1097-0061(19970915)13:11<1065::AID-YEA159>3.3.CO;2-B; Wang XH, 1997, J BIOL CHEM, V272, P18117, DOI 10.1074/jbc.272.29.18117; Wiggins CAR, 1998, P NATL ACAD SCI USA, V95, P7945, DOI 10.1073/pnas.95.14.7945	47	102	109	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1999	274	10					6579	6585		10.1074/jbc.274.10.6579	http://dx.doi.org/10.1074/jbc.274.10.6579			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172BQ	10037752	hybrid			2022-12-25	WOS:000078902800074
J	Louis, JM; Oroszlan, S; Tozser, J				Louis, JM; Oroszlan, S; Tozser, J			Stabilization from autoproteolysis and kinetic characterization of the human T-cell leukemia virus type 1 proteinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; I-ASSOCIATED MYELOPATHY; ESCHERICHIA-COLI; HIV-1 PROTEASE; RETROVIRAL PROTEINASES; BACTERIAL EXPRESSION; ASPARTIC PROTEINASE; RATIONAL DESIGN; ANEMIA VIRUS; SPECIFICITY	We have developed a system for expression and purification of wild-type human T-cell leukemia virus type 1 (HTLV-1) proteinase to attain sufficient quantities for structural, kinetic, and biophysical investigations. However, similar to the human immunodeficiency virus type 1 (HIV-1) proteinase, HTLV-1 proteinase also undergoes autoproteolysis rapidly upon renaturation to produce two products. The site of this autoproteolytic cleavage was mapped, and a resistant HTLV-1 proteinase construct (L40I) as well as another construct, wherein the two cysteine residues were exchanged to alanines, were expressed and purified. Oligopeptide substrates representing the naturally occurring cleavage sites in HTLV-1 were good substrates of the HTLV-1 proteinase. The kinetic parameters k(cat) and K-m were nearly identical for all the three enzymes. Although three of four peptides representing HTLV-1 proteinase cleavage sites were fairly good substrates of HIV-1 proteinase, only two of nine peptides representing HIV-1 proteinase cleavage sites were hydrolyzed by the HTLV-1 proteinase, suggesting substantial differences in the specificity of the two enzymes. The large difference in the specificity of the two enzymes was also demonstrated by inhibition studies. Of the several. inhibitors of HIV-1 or other retroviral proteinases that were tested on HTLV-1 proteinase, only two inhibit the enzyme with a K-i lower than 100 nM.	NIDDK, Chem Phys Lab, NIH, Bethesda, MD 20892 USA; Debrecen Univ Med, Sch Med, Dept Biochem & Mol Biol, H-4012 Debrecen, Hungary; NCI, Mol Virol & Carcinogenesis Lab, ABL, Basic Res Program,Frederick Canc Res & Dev Ctr, Frederick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); University of Debrecen; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	Louis, JM (corresponding author), NIDDK, Chem Phys Lab, NIH, Bethesda, MD 20892 USA.	jmlouis@helix.nih.gov; tozser@indi.biochem.dote.hu	Tozser, Jozsef/A-7840-2008	Tozser, Jozsef/0000-0003-0274-0056; Louis, John M/0000-0002-0052-1899; Tozser, Jozsef/0000-0001-5076-8729				BABOONIAN C, 1991, BIOCHEM BIOPH RES CO, V179, P17, DOI 10.1016/0006-291X(91)91327-9; CIMINALE V, 1992, J VIROL, V66, P1737, DOI 10.1128/JVI.66.3.1737-1745.1992; DAENKE S, 1994, J GEN VIROL, V75, P2233, DOI 10.1099/0022-1317-75-9-2233; Ding YS, 1998, J VIROL, V72, P3383, DOI 10.1128/JVI.72.4.3383-3386.1998; DIXON M, 1953, BIOCHEM J, V55, P170, DOI 10.1042/bj0550170; DUNN BM, 1994, METHOD ENZYMOL, V241, P254; Flexner C, 1998, NEW ENGL J MED, V338, P1281, DOI 10.1056/NEJM199804303381808; GESSAIN A, 1985, LANCET, V2, P407; GROBELNY D, 1990, BIOCHEM BIOPH RES CO, V169, P1111, DOI 10.1016/0006-291X(90)92010-W; GUSTCHINA A, 1995, PROTEIN SCI, V8, P1453; HATFIELD DL, 1992, ADV VIRUS RES, V41, P193, DOI 10.1016/S0065-3527(08)60037-8; HAYAKAWA T, 1991, BIOCHEM BIOPH RES CO, V181, P1281, DOI 10.1016/0006-291X(91)92077-W; HINUMA Y, 1981, P NATL ACAD SCI-BIOL, V78, P6476, DOI 10.1073/pnas.78.10.6476; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HRUSKOVAHEIDING.O, 1997, LEUKEMIA S, V3, P45; HRUSKOVAHEIDINGSFELDOVA O, 1995, J BIOL CHEM, V270, P15053, DOI 10.1074/jbc.270.25.15053; HUI KY, 1991, FASEB J, V5, P2606, DOI 10.1096/fasebj.5.11.1868985; KAPLAN JE, 1993, REV MED VIROL, V3, P137, DOI 10.1002/rmv.1980030304; KOBAYASHI M, 1991, FEBS LETT, V293, P106, DOI 10.1016/0014-5793(91)81162-2; Laco GS, 1997, J VIROL, V71, P5505, DOI 10.1128/JVI.71.7.5505-5511.1997; LAM PYS, 1994, SCIENCE, V263, P380, DOI 10.1126/science.8278812; LEIS J, 1988, J VIROL, V62, P1808, DOI 10.1128/JVI.62.5.1808-1809.1988; LOUIS JM, 1991, EUR J BIOCHEM, V199, P361, DOI 10.1111/j.1432-1033.1991.tb16132.x; LOUIS JM, 1994, P NATL ACAD SCI USA, V91, P7970, DOI 10.1073/pnas.91.17.7970; LUUKKONEN BGM, 1995, J GEN VIROL, V76, P2169, DOI 10.1099/0022-1317-76-9-2169; MENENDEZARIAS L, 1992, J BIOL CHEM, V267, P24134; MENENDEZARIAS L, 1993, VIROLOGY, V196, P557, DOI 10.1006/viro.1993.1511; MILDNER AM, 1994, BIOCHEMISTRY-US, V33, P9405, DOI 10.1021/bi00198a005; OROSZLAN S, 1990, CURR TOP MICROBIOL, V157, P153; OSAME M, 1986, LANCET, V1, P1031; Pettit SC, 1998, AIDS RES HUM RETROV, V14, P1007, DOI 10.1089/aid.1998.14.1007; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; Powell DJ, 1996, EUR J BIOCHEM, V241, P664, DOI 10.1111/j.1432-1033.1996.00664.x; ROBERTS NA, 1990, SCIENCE, V248, P358, DOI 10.1126/science.2183354; ROSE JR, 1993, J BIOL CHEM, V268, P11939; SAIGA A, 1993, ARCH VIROL, V128, P195, DOI 10.1007/BF01309434; SHEREMATA WA, 1993, NEUROLOGY, V43, P2125, DOI 10.1212/WNL.43.10.2125; STROP P, 1991, BIOCHEMISTRY-US, V30, P3437, DOI 10.1021/bi00228a013; Tessmer U, 1998, J VIROL, V72, P3459, DOI 10.1128/JVI.72.4.3459-3463.1998; TOMASSELLI AG, 1994, METHOD ENZYMOL, V241, P279; TOMASSELLI AG, 1990, J BIOL CHEM, V265, P14675; TOZSER J, 1991, FEBS LETT, V281, P77, DOI 10.1016/0014-5793(91)80362-7; TOZSER J, 1992, BIOCHEMISTRY-US, V31, P4793, DOI 10.1021/bi00135a008; TOZSER J, 1993, BIOCHEMISTRY-US, V32, P3347, DOI 10.1021/bi00064a018; WLODAWER A, 1995, NAT STRUCT BIOL, V2, P480, DOI 10.1038/nsb0695-480; WODAWER A, 1993, ANNU REV BIOCHEM, V62, P543; Wondrak EM, 1996, BIOCHEMISTRY-US, V35, P12957, DOI 10.1021/bi960984y; Wondrak EM, 1996, J BIOL CHEM, V271, P4477, DOI 10.1074/jbc.271.8.4477; Wu J, 1998, BIOCHEMISTRY-US, V37, P4518, DOI 10.1021/bi972183g; Yamazaki T, 1996, PROTEIN SCI, V5, P495	50	49	52	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	1999	274	10					6660	6666		10.1074/jbc.274.10.6660	http://dx.doi.org/10.1074/jbc.274.10.6660			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172BQ	10037763	hybrid			2022-12-25	WOS:000078902800085
J	Nixon, AB; O'Flaherty, JT; Salyer, JK; Wykle, RL				Nixon, AB; O'Flaherty, JT; Salyer, JK; Wykle, RL			Acetyl-CoA : 1-O-alkyl-2-lyso-sn-glycero-3-phosphocholine acetyltransferase is directly activated by p38 kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN POLYMORPHONUCLEAR LEUKOCYTES; CYTOSOLIC PHOSPHOLIPASE A(2); DEPENDENT PROTEIN-KINASE; HUMAN-NEUTROPHILS; FACTOR PAF; ARACHIDONIC-ACID; CALCIUM IONOPHORE; BIOSYNTHESIS; PHOSPHORYLATION; INHIBITOR	Acetyl-CoA:1-O-alkyl-2-lyso-sn-glycero-3-phosphocholine acetyltransferase, along with phospholipase A(2), is a key regulator of platelet-activating factor biosynthesis via the remodeling pathway. We have now obtained evidence in human neutrophils indicating that this enzyme is regulated by a specific member of the mitogen-activated protein kinases, namely the p38 kinase, We earlier demonstrated that tumor necrosis factor-alpha (TNF-alpha) as well as N-formyl-methionyl-leucyl-phenylalanine treatment leads to increased phosphorylation and activation of p38 kinase in human neutrophils, Strikingly, in the present study these stimuli increased the catalytic activity of acetyltransferase up to S-fold, whereas 4-phorbol 12-myristate 13-acetate, which activates the extracellular-regulated kinases (ERKs) but not p38 kinase, had no effect. Furthermore, a selective inhibitor of p38 kinase, SE 203580, was able to abolish the TNF-alpha- and N-formyl-methionyl-leucyl-phenylalanine-induced activation of acetyltransferase. The same effect was not observed in the presence of an inhibitor that blocked ERK activation (PD 98059), Complementing the findings in intact cells, we have shown that recombinant, activated p38 kinase added to microsomes in the presence of Mg2+ and ATP increased acetyltransferase activity to the same degree as in microsomes obtained from TNF-alpha-stimulated cells. No activation of acetyltransferase occurred upon treatment of microsomes with either recombinant, activated ERK-1 or ERK-2, Finally, the increases in acetyltransferase activity induced by TNF-alpha could be ablated by treating the microsomes with alkaline phosphatase. Thus acetyltransferase appears to be a downstream target for p38 kinase but not ERKs, These data from whole cells as well as cell-free systems fit a model wherein stimulus-induced acetyltransferase activation is mediated by a phosphorylation event catalyzed directly by p38 kinase.	Wake Forest Univ, Med Ctr, Dept Biochem, Winston Salem, NC 27157 USA; Wake Forest Univ, Med Ctr, Dept Med Infect Dis, Winston Salem, NC 27157 USA	Wake Forest University; Wake Forest University	Wykle, RL (corresponding author), Wake Forest Univ, Med Ctr, Dept Biochem, Winston Salem, NC 27157 USA.		Nixon, Andrew/AAJ-4712-2020	Nixon, Andrew/0000-0003-3971-2964	NHLBI NIH HHS [HL-50395, HL-56710] Funding Source: Medline; NIAID NIH HHS [AI-17287] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL056710, P01HL050395] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI017287] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALBERT DH, 1983, J BIOL CHEM, V258, P97; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; ALONSO F, 1982, J BIOL CHEM, V257, P3376; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BorschHaubold AG, 1996, BIOCHEM J, V318, P207; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHILTON FH, 1984, J BIOL CHEM, V259, P2014; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; DECHATELET LR, 1982, INFECT IMMUN, V35, P206, DOI 10.1128/IAI.35.1.206-212.1982; DOEBBER TW, 1987, P NATL ACAD SCI USA, V84, P7557, DOI 10.1073/pnas.84.21.7557; DOMENECH C, 1987, J BIOL CHEM, V262, P5671; GOMEZCAMBRONERO J, 1985, BIOCHIM BIOPHYS ACTA, V845, P516, DOI 10.1016/0167-4889(85)90219-8; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HELLER R, 1991, J BIOL CHEM, V266, P21358; Knall C, 1997, P NATL ACAD SCI USA, V94, P3052, DOI 10.1073/pnas.94.7.3052; Kramer RM, 1996, J BIOL CHEM, V271, P27723, DOI 10.1074/jbc.271.44.27723; Kuroki M, 1997, BIOCHEM BIOPH RES CO, V232, P474, DOI 10.1006/bbrc.1997.6296; Lee JC, 1996, J LEUKOCYTE BIOL, V59, P152, DOI 10.1002/jlb.59.2.152; LEE TC, 1982, BIOCHEM BIOPH RES CO, V105, P1303, DOI 10.1016/0006-291X(82)90928-7; LENIHAN DJ, 1984, BIOCHEM BIOPH RES CO, V120, P834, DOI 10.1016/S0006-291X(84)80182-5; LEYRAVAUD S, 1989, J IMMUNOL, V143, P245; MOLLINEDO F, 1988, BIOCHEM BIOPH RES CO, V154, P1232, DOI 10.1016/0006-291X(88)90271-9; MUELLER HW, 1983, J BIOL CHEM, V258, P6213; Nick JA, 1997, J CLIN INVEST, V99, P975, DOI 10.1172/JCI119263; NIETO ML, 1988, J BIOL CHEM, V263, P2217; NIETO ML, 1991, J BIOL CHEM, V266, P18699; OFLAHERTY JT, 1983, BIOCHEM BIOPH RES CO, V111, P1, DOI 10.1016/S0006-291X(83)80108-9; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; PEPLOW PV, 1990, PROSTAG LEUKOTR ESS, V41, P71, DOI 10.1016/0952-3278(90)90057-R; PRESCOTT SM, 1990, J BIOL CHEM, V265, P17381; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; RAMESHA CS, 1986, J BIOL CHEM, V261, P7592; RECORD M, 1989, J CELL BIOCHEM, V40, P353, DOI 10.1002/jcb.240400311; RIBBES G, 1985, FEBS LETT, V191, P195, DOI 10.1016/0014-5793(85)80007-7; SISSON JH, 1987, J IMMUNOL, V138, P3918; SNYDER F, 1989, P SOC EXP BIOL MED, V190, P125; SWENDSEN CL, 1983, BIOCHEM BIOPH RES CO, V113, P72, DOI 10.1016/0006-291X(83)90433-3; TESSNER TG, 1989, J BIOL CHEM, V264, P4794; Waterman WH, 1996, BIOCHEM J, V319, P17, DOI 10.1042/bj3190017; WYKLE RL, 1988, METHOD ENZYMOL, V163, P44; WYKLE RL, 1980, J BIOL CHEM, V255, P256; WYKLE RL, 1987, PLATELET ACTIVATING, P273; WYKLE RL, 1983, INSERM S, V23, P277; WYRICK SD, 1985, J LABELLED COMPD RAD, V22, P1169, DOI 10.1002/jlcr.2580221110	44	31	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 26	1999	274	9					5469	5473		10.1074/jbc.274.9.5469	http://dx.doi.org/10.1074/jbc.274.9.5469			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	170KG	10026159	hybrid			2022-12-25	WOS:000078804400030
J	Rao, GN; Katki, KA; Madamanchi, NR; Wu, YX; Birrer, MJ				Rao, GN; Katki, KA; Madamanchi, NR; Wu, YX; Birrer, MJ			JunB forms the majority of the AP-1 complex and is a target for redox regulation by receptor tyrosine kinase and G protein-coupled receptor agonists in smooth muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING ACTIVITY; C-FOS EXPRESSION; RAT MESANGIAL CELLS; HYDROGEN-PEROXIDE; REACTIVE-OXYGEN; ANGIOTENSIN-II; GROWTH-FACTOR; SIGNAL-TRANSDUCTION; OXIDATION-REDUCTION; ARACHIDONIC-ACID	To understand the role of redox-sensitive mechanisms in vascular smooth muscle cell (VSMC) growth, we have studied the effect of N-acetylcysteine (NAC), a thiol antioxidant, and diphenyleneiodonium (DPI), a potent NADH/NADPH oxidase inhibitor, on serum-, platelet-derived growth factor BB-, and thrombin-induced ERK2, JNK1, and p38 mitogen-activated protein (MAP) kinase activation; c-Fos, c-Jun, and JunB expression; and DNA synthesis. Both NAC and DPI completely inhibited agonist-induced AP-1 activity and DNA synthesis in VSMC. On the contrary, these compounds had differential effects on agonist-induced ERK2, JNK1, and p38 MAP kinase activation and c-Fos, c-Jun, and JunB expression. NAC inhibited agonist-induced ERK2, JNK1, and p38 MAP kinase activation and c-Fos, c-Jun, and JunB expression except for platelet-derived growth factor BB-induced ERK2 activation. In contrast, DPI only inhibited agonist-induced p38 MAP kinase activation and c-Fos and JunB expression. Antibody supershift assays indicated the presence of c-Fos and JunB in the AP-1 complex formed in response to all three agonists. In addition, cotransfection of VSMC with expression plasmids for c-Fos and members of the Jun family along with the AP-l-dependent reporter gene revealed that AP-1 with c-Fos and JunB composition exhibited a higher transactivating activity than AP-I with other compositions tested. All three agonists significantly stimulated reactive oxygen species production, and this effect was inhibited by both NAC and DPI. Together, these results strongly suggest a role for redox-sensitive mechanisms in agonist-induced ERK2, JNK1, and p38 MAP kinase activation; c-Fos, c-Jun, and JunB expression; AP-1 activity; and DNA synthesis in VSMC. These results also suggest a role for NADH/NADPH oxidase activity in some subset of early signaling events such as p38 MAP kinase activation and c-Fos and JunB induction, which appear to be important in agonist-induced AP-I activity and DNA synthesis in VSMC.	Univ Texas, Med Branch, Div Cardiol, Galveston, TX 77555 USA; NCI, NIH, Div Canc Prevent & Control, Rockville, MD 20850 USA	University of Texas System; University of Texas Medical Branch Galveston; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Rao, GN (corresponding author), Univ Texas, Med Branch, Old John Sealy Hosp 4 124B, 301 Univ Blvd,Route 0567, Galveston, TX 77555 USA.	grao@utmb.edu		Madamanchi, Nageswara/0000-0003-0590-0908				ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; AMES BN, 1993, P NATL ACAD SCI USA, V90, P7915, DOI 10.1073/pnas.90.17.7915; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BAAS AS, 1995, CIRC RES, V77, P29, DOI 10.1161/01.RES.77.1.29; BELLAVITE P, 1988, J BIOL CHEM, V263, P8210; BRIGHTMAN AO, 1992, BIOCHIM BIOPHYS ACTA, V1105, P109, DOI 10.1016/0005-2736(92)90168-L; BURDON RH, 1995, FREE RADICAL BIO MED, V18, P775, DOI 10.1016/0891-5849(94)00198-S; CAVIGELLI M, 1995, EMBO J, V14, P5957, DOI 10.1002/j.1460-2075.1995.tb00284.x; CERUTTI PA, 1991, CANCER CELL-MON REV, V3, P1; CRAVEN PA, 1986, J CLIN INVEST, V77, P850, DOI 10.1172/JCI112382; CRAWFORD D, 1988, ONCOGENE, V3, P27; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DENNIS EA, 1994, J BIOL CHEM, V269, P13057; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; DETHLEFSEN SM, 1994, EXP CELL RES, V212, P262, DOI 10.1006/excr.1994.1142; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DUQUE I, 1993, J PHARMACOL EXP THER, V267, P612; FRIDOVICH I, 1978, SCIENCE, V201, P875, DOI 10.1126/science.210504; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; Grass DS, 1996, J CLIN INVEST, V97, P2233, DOI 10.1172/JCI118664; GRIENDLING KK, 1994, CIRC RES, V74, P1141, DOI 10.1161/01.RES.74.6.1141; Guyton KZ, 1996, J BIOL CHEM, V271, P4138, DOI 10.1074/jbc.271.7.3604; HALLIWELL B, 1989, BRIT J EXP PATHOL, V70, P737; HARDWICK JS, 1995, P NATL ACAD SCI USA, V92, P4527, DOI 10.1073/pnas.92.10.4527; HENTZE MW, 1989, SCIENCE, V244, P357, DOI 10.1126/science.2711187; Irani K, 1997, SCIENCE, V275, P1649, DOI 10.1126/science.275.5306.1649; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KARIN M, 1994, CURR OPIN CELL BIOL, V6, P415, DOI 10.1016/0955-0674(94)90035-3; Knebel A, 1996, EMBO J, V15, P5314, DOI 10.1002/j.1460-2075.1996.tb00916.x; KONDO T, 1992, J BIOL CHEM, V267, P23609; KRIEGERBRAUER HI, 1992, J CLIN INVEST, V89, P1006, DOI 10.1172/JCI115641; KRIEGERBRAUER HI, 1995, BIOCHEM J, V307, P543, DOI 10.1042/bj3070543; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LANDER HM, 1995, J BIOL CHEM, V270, P21195, DOI 10.1074/jbc.270.36.21195; Lo YYC, 1996, J BIOL CHEM, V271, P15703, DOI 10.1074/jbc.271.26.15703; LO YYC, 1995, J BIOL CHEM, V270, P11727, DOI 10.1074/jbc.270.20.11727; MAKI A, 1992, FASEB J, V6, P919, DOI 10.1096/fasebj.6.3.1740241; MEIER B, 1989, BIOCHEM J, V263, P539, DOI 10.1042/bj2630539; MEISTER A, 1991, PHARMACOL THERAPEUT, V51, P155, DOI 10.1016/0163-7258(91)90076-X; MURRELL GAC, 1990, BIOCHEM J, V265, P659, DOI 10.1042/bj2650659; NAJITA L, 1990, P NATL ACAD SCI USA, V87, P5846, DOI 10.1073/pnas.87.15.5846; OHBA M, 1994, J CELL BIOL, V126, P1079, DOI 10.1083/jcb.126.4.1079; Price MA, 1996, EMBO J, V15, P6552, DOI 10.1002/j.1460-2075.1996.tb01046.x; PURI PL, 1995, J BIOL CHEM, V270, P22129, DOI 10.1074/jbc.270.38.22129; Rao GN, 1997, CELL SIGNAL, V9, P181, DOI 10.1016/S0898-6568(96)00139-8; RAO GN, 1992, CIRC RES, V70, P593, DOI 10.1161/01.RES.70.3.593; RAO GN, 1994, BIOCHEM J, V299, P197, DOI 10.1042/bj2990197; RAO GN, 1993, ONCOGENE, V8, P2759; RAO GN, 1993, NUCLEIC ACIDS RES, V21, P1259, DOI 10.1093/nar/21.5.1259; Rao GN, 1996, ONCOGENE, V13, P713; Rosette C, 1996, SCIENCE, V274, P1194, DOI 10.1126/science.274.5290.1194; RUPPERSBERG JP, 1991, NATURE, V352, P711, DOI 10.1038/352711a0; SEGER R, 1991, P NATL ACAD SCI USA, V88, P6142, DOI 10.1073/pnas.88.14.6142; SELLMAYER A, 1991, J BIOL CHEM, V266, P3800; SHIBANUMA M, 1988, ONCOGENE, V3, P17; SLUSS HK, 1994, MOL CELL BIOL, V14, P8376, DOI 10.1128/MCB.14.12.8376; STORZ G, 1990, SCIENCE, V248, P189, DOI 10.1126/science.2183352; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; Sundaresan M, 1996, BIOCHEM J, V318, P379, DOI 10.1042/bj3180379; Thannickal VJ, 1995, J BIOL CHEM, V270, P30334, DOI 10.1074/jbc.270.51.30334; TOLEDANO MB, 1991, P NATL ACAD SCI USA, V88, P4328, DOI 10.1073/pnas.88.10.4328; UshioFukai M, 1996, J BIOL CHEM, V271, P23317, DOI 10.1074/jbc.271.38.23317; WARNER GL, 1986, CELL IMMUNOL, V101, P425, DOI 10.1016/0008-8749(86)90155-3; Wilkie N, 1996, J BIOL CHEM, V271, P32447, DOI 10.1074/jbc.271.50.32447; XANTHOUDAKIS S, 1992, EMBO J, V11, P3323, DOI 10.1002/j.1460-2075.1992.tb05411.x; ZIEGLER DM, 1985, ANNU REV BIOCHEM, V54, P305, DOI 10.1146/annurev.bi.54.070185.001513	68	104	105	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 26	1999	274	9					6003	6010		10.1074/jbc.274.9.6003	http://dx.doi.org/10.1074/jbc.274.9.6003			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	170KG	10026227	hybrid			2022-12-25	WOS:000078804400098
J	Wong, V; Ching, DX; McCrea, PD; Firestone, GL				Wong, V; Ching, DX; McCrea, PD; Firestone, GL			Glucocorticoid down-regulation of fascin protein expression is required for the steroid-induced formation of tight junctions and cell-cell interactions in rat mammary epithelial tumor cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-ALPHA; ADHESION MOLECULE UVOMORULIN; TYROSINE KINASE SUBSTRATE; ACTIN-BUNDLING PROTEINS; BETA-CATENIN COMPLEX; E-CADHERIN; ADHERENS JUNCTIONS; SUPPRESSOR PROTEIN; HORMONE RECEPTORS; MEMBRANE-PROTEIN	Glucocorticoid hormones, which are physiological regulators of mammary epithelium development, induce the formation of tight junctions in rat Con8 mammary epithelial tumor cells. We have discovered that, as part of this process, the synthetic glucocorticoid dexamethasone strongly and reversibly down-regulated the expression of fascin, an actin-bundling protein that also interacts with the adherens junction component beta-catenin, Ectopic constitutive expression of full-length mouse fascin containing a Myc epitope tag (Myc-fascin) in Con8 cells inhibited the dexamethasone stimulation of transepithelial electrical resistance, disrupted the induced localization of the tight junction protein occludin and the adherens junction protein beta-catenin to the cell periphery, and prevented the rearrangement of the actin cytoskeleton, Ectopic expression of either the carboxyl-terminal 213 amino acids of fascin, which includes the actin and beta-catenin-binding sites, or the amino-terminal 313 amino acids of fascin failed to disrupt the glucocorticoid induction of tight junction formation. Mammary tumor cells expressing the full-length Myc-fascin remained generally glucocorticoid responsive and displayed no changes in the levels or protein-protein interactions of junctional proteins or the amount of cytoskeletal associated actin filaments, However, a cell aggregation assay demonstrated that the expression of Myc-fascin abrogated the dexamethasone induction of cell-cell adhesion. Our results implicate the down-regulation of fascin as a key intermediate step that directly links glucocorticoid receptor signaling to the coordinate control of junctional complex formation and cell-cell interactions in mammary tumor epithelial cells.	Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA; Univ Calif Berkeley, Canc Res Lab, Berkeley, CA 94720 USA; Univ Texas, MD Anderson Cancer Ctr, Dept Biochem & Mol Biol, Houston, TX 77030 USA	University of California System; University of California Berkeley; University of California System; University of California Berkeley; University of Texas System; UTMD Anderson Cancer Center	Firestone, GL (corresponding author), Univ Calif Berkeley, Dept Mol & Cell Biol, 591 LSA, Berkeley, CA 94720 USA.	glfire@uclink4.berkeley.edu			NIDDK NIH HHS [DK-42799] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042799, R56DK042799] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adams CL, 1996, J CELL BIOL, V135, P1899, DOI 10.1083/jcb.135.6.1899; Adams JC, 1997, MOL BIOL CELL, V8, P2345, DOI 10.1091/mbc.8.11.2345; AGHIB DF, 1995, EXP CELL RES, V218, P359, DOI 10.1006/excr.1995.1167; Angres B, 1996, J CELL BIOL, V134, P549, DOI 10.1083/jcb.134.2.549; BALDA MS, 1991, J MEMBRANE BIOL, V122, P193, DOI 10.1007/BF01871420; Balda MS, 1996, J CELL BIOL, V134, P1031, DOI 10.1083/jcb.134.4.1031; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; BEHRENS J, 1993, J CELL BIOL, V120, P757, DOI 10.1083/jcb.120.3.757; BEHRENS J, 1985, J CELL BIOL, V101, P1307, DOI 10.1083/jcb.101.4.1307; Braga VMM, 1997, J CELL BIOL, V137, P1421, DOI 10.1083/jcb.137.6.1421; BUSE P, 1995, J BIOL CHEM, V270, P6505, DOI 10.1074/jbc.270.12.6505; BUSE P, 1995, J BIOL CHEM, V270, P28223; CITI S, 1989, J CELL SCI, V93, P107; CITI S, 1988, NATURE, V333, P272, DOI 10.1038/333272a0; COWIN P, 1986, CELL, V46, P1063, DOI 10.1016/0092-8674(86)90706-3; DHARMAWARDHANE S, 1989, CELL MOTIL CYTOSKEL, V13, P57, DOI 10.1002/cm.970130107; DRENCKHAHN D, 1986, J CELL BIOL, V102, P1843, DOI 10.1083/jcb.102.5.1843; Drubin DG, 1996, CELL, V84, P335, DOI 10.1016/S0092-8674(00)81278-7; EATON S, 1995, CELL, V82, P5, DOI 10.1016/0092-8674(95)90045-4; EDWARDS RA, 1995, CELL MOTIL CYTOSKEL, V32, P1, DOI 10.1002/cm.970320102; EDWARDS RA, 1995, J BIOL CHEM, V270, P10764, DOI 10.1074/jbc.270.18.10764; FARQUHAR MG, 1963, J CELL BIOL, V17, P375, DOI 10.1083/jcb.17.2.375; Fialka I, 1996, J CELL BIOL, V132, P1115, DOI 10.1083/jcb.132.6.1115; FURUSE M, 1993, J CELL BIOL, V123, P1777, DOI 10.1083/jcb.123.6.1777; Gopalakrishnan S, 1998, AM J PHYSIOL-CELL PH, V275, pC798, DOI 10.1152/ajpcell.1998.275.3.C798; GOYA L, 1993, MOL ENDOCRINOL, V7, P1121, DOI 10.1210/me.7.9.1121; GUMBINER B, 1991, P NATL ACAD SCI USA, V88, P3460, DOI 10.1073/pnas.88.8.3460; GUMBINER B, 1988, J CELL BIOL, V107, P1575, DOI 10.1083/jcb.107.4.1575; Gumbiner B, 1990, CURR OPIN CELL BIOL, V2, P881, DOI 10.1016/0955-0674(90)90087-U; GUMBINER B, 1987, AM J PHYSIOL, V253, P749; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; HERRENKNECHT K, 1991, P NATL ACAD SCI USA, V88, P9156, DOI 10.1073/pnas.88.20.9156; Horwitz KB, 1996, MOL ENDOCRINOL, V10, P1167, DOI 10.1210/me.10.10.1167; JESAITIS LA, 1994, J CELL BIOL, V124, P949, DOI 10.1083/jcb.124.6.949; Jou TS, 1998, J CELL BIOL, V142, P85, DOI 10.1083/jcb.142.1.85; KEMLER R, 1993, TRENDS GENET, V9, P317, DOI 10.1016/0168-9525(93)90250-L; Keon BH, 1996, J CELL BIOL, V134, P1003, DOI 10.1083/jcb.134.4.1003; KINCH MS, 1995, J CELL BIOL, V130, P461, DOI 10.1083/jcb.130.2.461; KNUDSEN KA, 1992, J CELL BIOL, V118, P671, DOI 10.1083/jcb.118.3.671; KNUDSEN KA, 1995, J CELL BIOL, V130, P67, DOI 10.1083/jcb.130.1.67; MADARA JL, 1992, ANN NY ACAD SCI, V664, P47, DOI 10.1111/j.1749-6632.1992.tb39748.x; MADARA JL, 1987, AM J PHYSIOL, V253, P171; Maiyar AC, 1997, MOL ENDOCRINOL, V11, P312, DOI 10.1210/me.11.3.312; McCarthy KM, 1996, J CELL SCI, V109, P2287; MCCREA PD, 1991, SCIENCE, V254, P1359, DOI 10.1126/science.1962194; McEwan IJ, 1997, BIOESSAYS, V19, P153, DOI 10.1002/bies.950190210; MCNEILL H, 1990, CELL, V62, P309, DOI 10.1016/0092-8674(90)90368-O; NAGAFUCHI A, 1991, CELL, V65, P849, DOI 10.1016/0092-8674(91)90392-C; NAGAFUCHI A, 1988, EMBO J, V7, P3679, DOI 10.1002/j.1460-2075.1988.tb03249.x; NUSRAT A, 1995, P NATL ACAD SCI USA, V92, P10629, DOI 10.1073/pnas.92.23.10629; Ono S, 1997, J BIOL CHEM, V272, P2527; OTTO JJ, 1994, CURR OPIN CELL BIOL, V6, P105, DOI 10.1016/0955-0674(94)90123-6; OWARIBE K, 1981, J CELL BIOL, V90, P507, DOI 10.1083/jcb.90.2.507; OZAWA M, 1990, P NATL ACAD SCI USA, V87, P4246, DOI 10.1073/pnas.87.11.4246; PEIFER M, 1992, J CELL BIOL, V118, P681, DOI 10.1083/jcb.118.3.681; PITELKA DR, 1973, J CELL BIOL, V56, P797, DOI 10.1083/jcb.56.3.797; REYNOLDS AB, 1994, MOL CELL BIOL, V14, P8333, DOI 10.1128/MCB.14.12.8333; RODRIGUEZBOULAN E, 1989, SCIENCE, V245, P719; Rubinfeld B, 1996, SCIENCE, V272, P1023, DOI 10.1126/science.272.5264.1023; RUPP RAW, 1994, GENE DEV, V8, P1311, DOI 10.1101/gad.8.11.1311; SHIBAMOTO S, 1995, J CELL BIOL, V128, P949, DOI 10.1083/jcb.128.5.949; SINGER KL, 1994, J BIOL CHEM, V269, P16108; SNEDEKER SM, 1991, P NATL ACAD SCI USA, V88, P276, DOI 10.1073/pnas.88.1.276; Stevenson BR, 1989, CURR OPIN CELL BIOL, V1, P884, DOI 10.1016/0955-0674(89)90054-9; STEVENSON BR, 1986, J CELL BIOL, V103, P755, DOI 10.1083/jcb.103.3.755; STOKER AW, 1986, J VIROL, V58, P876, DOI 10.1128/JVI.58.3.876-883.1986; STUART RO, 1995, P NATL ACAD SCI USA, V92, P6072, DOI 10.1073/pnas.92.13.6072; Takaishi K, 1997, J CELL BIOL, V139, P1047, DOI 10.1083/jcb.139.4.1047; Tao YS, 1996, J CELL BIOL, V134, P1271, DOI 10.1083/jcb.134.5.1271; TOPPER YJ, 1980, PHYSIOL REV, V60, P1049, DOI 10.1152/physrev.1980.60.4.1049; TRUSS M, 1993, ENDOCR REV, V14, P459, DOI 10.1210/er.14.4.459; TSUKITA S, 1989, J CELL BIOL, V108, P2369, DOI 10.1083/jcb.108.6.2369; TSUKITA S, 1989, J CELL BIOL, V109, P2905, DOI 10.1083/jcb.109.6.2905; TURNER DL, 1994, GENE DEV, V8, P1434, DOI 10.1101/gad.8.12.1434; WAHLI W, 1991, FASEB J, V5, P2243, DOI 10.1096/fasebj.5.9.1860615; WEBSTER MK, 1993, MOL CELL BIOL, V13, P2031, DOI 10.1128/MCB.13.4.2031; WEBSTER MK, 1990, J BIOL CHEM, V265, P4831; Wong V, 1997, J CELL BIOL, V136, P399, DOI 10.1083/jcb.136.2.399; Woo PL, 1996, J BIOL CHEM, V271, P404, DOI 10.1074/jbc.271.1.404; Yamakita Y, 1996, J BIOL CHEM, V271, P12632, DOI 10.1074/jbc.271.21.12632; ZAHRAOUI A, 1994, J CELL BIOL, V124, P101, DOI 10.1083/jcb.124.1.101; ZETTL KS, 1992, P NATL ACAD SCI USA, V89, P9069, DOI 10.1073/pnas.89.19.9069; ZHONG Y, 1994, EXP CELL RES, V214, P614, DOI 10.1006/excr.1994.1299; ZHONG Y, 1993, J CELL BIOL, V120, P477, DOI 10.1083/jcb.120.2.477; ZILLIACUS J, 1995, MOL ENDOCRINOL, V9, P389, DOI 10.1210/me.9.4.389	86	57	57	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 26	1999	274	9					5443	5453		10.1074/jbc.274.9.5443	http://dx.doi.org/10.1074/jbc.274.9.5443			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	170KG	10026156	hybrid			2022-12-25	WOS:000078804400027
J	Yamada, K; Duong, DT; Scott, DK; Wang, JC; Granner, DK				Yamada, K; Duong, DT; Scott, DK; Wang, JC; Granner, DK			CCAAT/enhancer-binding protein beta is an accessory factor for the glucocorticoid response from the cAMP response element in the rat phosphoenolpyruvate carboxykinase gene promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; SYNERGISTICALLY ACTIVATE TRANSCRIPTION; C/EBP-BETA; DNA-BINDING; GTP GENE; REGULATORY ELEMENT; HEPATOMA-CELLS; NUCLEAR FACTOR; COUP-TF; EXPRESSION	The cyclic AMP response element (CRE) of the rat phosphoenolpyruvate carboxykinase (PEPCK) gene promoter is required for a complete glucocorticoid response. Proteins known to bind the PEPCK CRE include the CRE-binding protein (CREB) and members of the CCAAT/enhancer-binding protein (C/EBP) family We took two different approaches to determine which of these proteins provides the accessory factor activity for the glucocorticoid response from the PEPCK CRE. The first strategy involved replacing the CRE of the PEPCK promoter/chloramphenicol acetyltransferase reporter plasmid (pPL32) with a consensus C/EBP-binding sequence. This construct, termed p Delta CREC/EBP, binds C/EBP alpha and beta but not CREB, yet it confers a nearly complete glucocorticoid response when transiently transfected into H4IIE rat hepatoma cells. These results suggest that one of the C/EBP family members may be the accessory factor. The second strategy involved cotransfecting H4IIE cells with a pPL32 mutant, in which the CRE was replaced with a GAL4-binding sequence (p Delta CREGAL4), and various GAL4 DNA-binding domain (DBD) fusion protein expression vectors. Although chimeric proteins consisting of the GAL4 DBD fused to either CREB or C/EBPa: are able to confer an increase in basal transcription, they do not facilitate the glucocorticoid response. In contrast, a fusion protein consisting of the GAIA DBD and amino acids 1-118 of C/EBP beta provides a significant glucocorticoid response. Additional GAIA fusion studies were done to map the minimal domain of C/EBP beta needed for accessory factor activity to the glucocorticoid response. Chimeric proteins containing amino acid regions 1-84, 52-118, or 85-118 of C/EBP beta fused to the GAL4 DBD do not mediate a glucocorticoid response. We conclude that the amino terminus of C/EBP beta contains a multicomponent domain necessary to confer accessory factor activity to the glucocorticoid response from the CRE of the PEPCK gene promoter.	Vanderbilt Univ, Sch Med, Dept Mol Physiol & Biophys, Nashville, TN 37232 USA	Vanderbilt University	Granner, DK (corresponding author), Vanderbilt Univ, Sch Med, Dept Mol Physiol & Biophys, 221 Kirkland Hall, Nashville, TN 37232 USA.		Wang, Jen-Chywan/AAX-4445-2020	Wang, Jen-Chywan/0000-0001-6030-6886	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK035107, P60DK020593, R37DK035107, P30DK020593] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007347] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK35107, DK20593] Funding Source: Medline; NIGMS NIH HHS [GM07347] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALAM T, 1992, J BIOL CHEM, V267, P5021; ANGRAND PO, 1994, CELL GROWTH DIFFER, V5, P957; BARIK S, 1993, PCR PROTOCOLS CURREN; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Crosson SM, 1997, DIABETOLOGIA, V40, P1117, DOI 10.1007/s001250050796; DAY RN, 1989, J BIOL CHEM, V264, P431; FRIEDMAN JE, 1994, AM J PHYSIOL, V266, pE560, DOI 10.1152/ajpendo.1994.266.4.E560; GINIGER E, 1985, CELL, V40, P767, DOI 10.1016/0092-8674(85)90336-8; GONZALEZ GA, 1989, NATURE, V337, P749, DOI 10.1038/337749a0; GURNEY AL, 1992, J BIOL CHEM, V267, P18133; HALL RK, 1992, MOL CELL BIOL, V12, P5527, DOI 10.1128/MCB.12.12.5527; HALL RK, 1995, P NATL ACAD SCI USA, V92, P412, DOI 10.1073/pnas.92.2.412; Hanson RW, 1997, ANNU REV BIOCHEM, V66, P581, DOI 10.1146/annurev.biochem.66.1.581; IMAI E, 1993, J BIOL CHEM, V268, P5353; IMAI E, 1990, MOL CELL BIOL, V10, P4712, DOI 10.1128/MCB.10.9.4712; LECLAIR KP, 1992, P NATL ACAD SCI USA, V89, P8145, DOI 10.1073/pnas.89.17.8145; Lee YH, 1997, MOL CELL BIOL, V17, P2038, DOI 10.1128/MCB.17.4.2038; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; LIU JS, 1991, J BIOL CHEM, V266, P19095; LUCAS PC, 1992, ANNU REV BIOCHEM, V61, P1131; MATSUSAKA T, 1993, P NATL ACAD SCI USA, V90, P10193, DOI 10.1073/pnas.90.21.10193; Merika M, 1998, MOL CELL, V1, P277, DOI 10.1016/S1097-2765(00)80028-3; Mink S, 1997, MOL CELL BIOL, V17, P6609, DOI 10.1128/MCB.17.11.6609; MITCHELL J, 1994, MOL ENDOCRINOL, V8, P585, DOI 10.1210/me.8.5.585; NISHIO Y, 1993, MOL CELL BIOL, V13, P1854, DOI 10.1128/MCB.13.3.1854; Nizielski SE, 1996, AM J PHYSIOL-REG I, V270, pR1005, DOI 10.1152/ajpregu.1996.270.5.R1005; NORDEEN SK, 1987, DNA-J MOLEC CELL BIO, V6, P173, DOI 10.1089/dna.1987.6.173; OBRIEN RM, 1994, J BIOL CHEM, V269, P30419; OBRIEN RM, 1995, MOL CELL BIOL, V15, P1747; Osada S, 1996, J BIOL CHEM, V271, P3891; PARK EA, 1990, MOL CELL BIOL, V10, P6264, DOI 10.1128/MCB.10.12.6264; PARK EA, 1993, J BIOL CHEM, V268, P613; PETERSEN DD, 1988, MOL CELL BIOL, V8, P96, DOI 10.1128/MCB.8.1.96; QUINN PG, 1990, MOL CELL BIOL, V10, P3357, DOI 10.1128/MCB.10.7.3357; QUINN PG, 1988, MOL CELL BIOL, V8, P3467, DOI 10.1128/MCB.8.8.3467; ROESLER WJ, 1993, J BIOL CHEM, V268, P3791; Roesler WJ, 1996, J BIOL CHEM, V271, P8068, DOI 10.1074/jbc.271.14.8068; ROESLER WJ, 1992, J BIOL CHEM, V267, P21235; RYDEN TA, 1989, MOL CELL BIOL, V9, P1155, DOI 10.1128/MCB.9.3.1155; SADOWSKI I, 1989, NUCLEIC ACIDS RES, V17, P7539, DOI 10.1093/nar/17.18.7539; Savoldi G, 1997, DNA CELL BIOL, V16, P1467, DOI 10.1089/dna.1997.16.1467; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SCHULE R, 1988, SCIENCE, V242, P1418, DOI 10.1126/science.3201230; Scott DK, 1996, J BIOL CHEM, V271, P31909, DOI 10.1074/jbc.271.50.31909; STEIN B, 1995, MOL CELL BIOL, V15, P4971; STEIN B, 1993, MOL CELL BIOL, V13, P3964, DOI 10.1128/MCB.13.7.3964; Sugiyama T, 1998, MOL ENDOCRINOL, V12, P1487, DOI 10.1210/me.12.10.1487; SUN PQ, 1995, J BIOL CHEM, V270, P7041, DOI 10.1074/jbc.270.13.7041; TEBBEY PW, 1995, BIOCHEM BIOPH RES CO, V215, P1006, DOI 10.1006/bbrc.1995.2564; Wang JC, 1996, MOL ENDOCRINOL, V10, P794, DOI 10.1210/me.10.7.794; WILLIAMS SC, 1995, EMBO J, V14, P3170, DOI 10.1002/j.1460-2075.1995.tb07319.x	51	85	86	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 26	1999	274	9					5880	5887		10.1074/jbc.274.9.5880	http://dx.doi.org/10.1074/jbc.274.9.5880			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	170KG	10026211	hybrid			2022-12-25	WOS:000078804400082
J	Sheng, HM; Shao, JY; O'Mahony, CA; Lamps, L; Albo, D; Isakson, PC; Berger, DH; DuBois, RN; Beauchamp, RD				Sheng, HM; Shao, JY; O'Mahony, CA; Lamps, L; Albo, D; Isakson, PC; Berger, DH; DuBois, RN; Beauchamp, RD			Transformation of intestinal epithelial cells by chronic TGF-beta 1 treatment results in downregulation of the type II TGF-beta receptor and induction of cyclooxygenase-2	ONCOGENE			English	Article						intestinal epithelial cells; transforming growth factor beta; cyclooxygenase-2; carcinogenesis	GROWTH-FACTOR-BETA; APC(DELTA-716) KNOCKOUT MICE; BREAST-CANCER-CELLS; BENIGN SKIN TUMORS; CYCLIN D1; DIFFERENTIAL SENSITIVITY; SELECTIVE-INHIBITION; MALIGNANT CONVERSION; CARCINOMA-CELLS; FAMILY SIGNALS	The precise role of TGF-P in colorectal carcinogenesis is not clear, The purpose of this study was to determine the phenotypic alterations caused by chronic exposure to TGF-beta in non-transformed intestinal epithelial (RIE-1) cells. Growth of RIE-1 cells was inhibited by >75% following TGF-beta 1 treatment for 7 days, after which the cells resumed a normal growth despite the presence of TGF-beta 1, These 'TGF-beta-resistant' cells (RIE-Tr) were continuously exposed to TGF-beta for >50 days, Unlike the parental RIE cells, RIE-Tr cells lost contact inhibition, formed foci in culture, grew in soft agarose, RIE-Tr cells demonstrated TGF-beta-dependent invasive potential in an in vitro assay and were resistant to Matrigel and Na-butyrate-induced apoptosis, The RIE-Tr cells were also tumorigenic in nude mice. The transformed phenotype of RIE-Tr cells was associated with a 95% decrease in the level of the type II TGF-P receptor (T beta RII) protein, a 40-fold increase in cyclooxygenase-2 (COX-2) protein, and 5.9-fold increase in the production of prostacyclin, Most RIE-Tr subclones that expressed low levels of T beta RII and high levels of COX-2 were tumorigenic. Those subclones that express abundant T beta RII and low levels of COX-2 were not tumorigenic in nude mice. A selective COX-2 inhibitor inhibited RIE-Tr cell growth in culture and tumor growth in nude mice. The reduced expression of T beta RII, increased expression of COX-2, and the ability to form colonies in Matrigel mere all reversible upon withdrawal of exogenous TGF-beta 1 for the RIE-Tr cells.	Vanderbilt Univ, Med Ctr N, Vanderbilt Canc Ctr, Dept Surg, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Vanderbilt Canc Ctr, Dept Med, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Vanderbilt Canc Ctr, Dept Cell Biol, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Vanderbilt Canc Ctr, Dept Pathol, Nashville, TN 37232 USA; Vet Affairs Med Ctr, Nashville, TN 37232 USA; Searle Res & Dev, Dept Inflammatory Dis Res, St Louis, MO 63198 USA; Allegheny Univ Hlth Sci, Dept Surg, Philadelphia, PA 19102 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System; Pfizer; Drexel University	Beauchamp, RD (corresponding author), Vanderbilt Univ, Med Ctr N, Vanderbilt Canc Ctr, Dept Surg, CC2306, Nashville, TN 37232 USA.		DuBois, Raymond N./AAX-8869-2020	Beauchamp, Robert Daniel/0000-0002-8446-4114	NCI NIH HHS [CA68485, CA-69457] Funding Source: Medline; NIDDK NIH HHS [DK-52334] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA068485, R01CA069457] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052334] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Anderson GD, 1996, J CLIN INVEST, V97, P2672, DOI 10.1172/JCI118717; ARTEAGA CL, 1993, CELL GROWTH DIFFER, V4, P193; ARTEAGA CL, 1988, CANCER RES, V48, P3898; BARNARD JA, 1993, GASTROENTEROLOGY, V105, P67, DOI 10.1016/0016-5085(93)90011-Z; BARNARD JA, 1989, P NATL ACAD SCI USA, V86, P1578, DOI 10.1073/pnas.86.5.1578; BEAUCHAMP RD, 1990, PANCREAS, V5, P369, DOI 10.1097/00006676-199007000-00001; BIRCHENALLROBERTS MC, 1990, MOL CELL BIOL, V10, P4978, DOI 10.1128/MCB.10.9.4978; BLAY J, 1985, J CELL PHYSIOL, V124, P107, DOI 10.1002/jcp.1041240117; BLAY J, 1984, CELL BIOL INT REP, V8, P551, DOI 10.1016/0309-1651(84)90054-7; CAULIN C, 1995, CELL GROWTH DIFFER, V6, P1027; CHEN RH, 1993, SCIENCE, V260, P1335, DOI 10.1126/science.8388126; CHEN X, 1996, NATURE, V383, P791; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CUI W, 1994, CANCER RES, V54, P5831; Cui W, 1996, CELL, V86, P531, DOI 10.1016/S0092-8674(00)80127-0; DERYNCK R, 1994, TRENDS BIOCHEM SCI, V19, P548, DOI 10.1016/0968-0004(94)90059-0; DERYNCK R, 1987, CANCER RES, V47, P707; Derynck R, 1996, CELL, V87, P173, DOI 10.1016/S0092-8674(00)81335-5; DuBois RN, 1996, GASTROENTEROLOGY, V110, P1259, DOI 10.1053/gast.1996.v110.pm8613017; DUBOIS RN, 1994, J CLIN INVEST, V93, P493, DOI 10.1172/JCI116998; EBERHART CE, 1994, GASTROENTEROLOGY, V107, P1183, DOI 10.1016/0016-5085(94)90246-1; Eppert K, 1996, CELL, V86, P543, DOI 10.1016/S0092-8674(00)80128-2; FILMUS J, 1992, ONCOGENE, V7, P521; FILMUS J, 1994, ONCOGENE, V9, P3627; GEISER AG, 1992, J BIOL CHEM, V267, P2588; GILBERT RS, 1994, J CELL PHYSIOL, V159, P67, DOI 10.1002/jcp.1041590110; GILBERT RS, 1994, CELL MOL BIOL RES, V40, P653; GLICK AB, 1994, GENE DEV, V8, P2429, DOI 10.1101/gad.8.20.2429; GLICK AB, 1993, P NATL ACAD SCI USA, V90, P6076, DOI 10.1073/pnas.90.13.6076; HAFEZ MM, 1992, CELL GROWTH DIFFER, V3, P753; HAGUE A, 1993, INT J CANCER, V55, P498, DOI 10.1002/ijc.2910550329; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; HOOSEIN NM, 1989, EXP CELL RES, V181, P442, DOI 10.1016/0014-4827(89)90101-8; KIMCHI A, 1988, SCIENCE, V240, P196, DOI 10.1126/science.2895499; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Ko TC, 1998, ONCOGENE, V16, P3445, DOI 10.1038/sj.onc.1201902; KO TC, 1995, ONCOGENE, V10, P177; KUROKOWA M, 1987, BIOCHEM BIOPH RES CO, V142, P775, DOI 10.1016/0006-291X(87)91481-1; LAGNA G, 1996, NATURE, V383, P382; MANNING AM, 1991, ONCOGENE, V6, P1471; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; Masferrer JL, 1996, GASTROENTEROL CLIN N, V25, P363, DOI 10.1016/S0889-8553(05)70252-1; Massague J, 1996, CANCER SURV, V27, P41; MASSAGUE J, 1995, CURR OPIN GENET DEV, V5, P91, DOI 10.1016/S0959-437X(95)90059-4; MIETTINEN PJ, 1994, J CELL BIOL, V127, P2021, DOI 10.1083/jcb.127.6.2021; Oft M, 1996, GENE DEV, V10, P2462, DOI 10.1101/gad.10.19.2462; Oshima H, 1997, CANCER RES, V57, P1644; Oshima M, 1996, CELL, V87, P803, DOI 10.1016/S0092-8674(00)81988-1; PIERCE DF, 1995, P NATL ACAD SCI USA, V92, P4254, DOI 10.1073/pnas.92.10.4254; Prescott SM, 1996, CELL, V87, P783, DOI 10.1016/S0092-8674(00)81983-2; SCHROY P, 1990, CANCER RES, V50, P261; SEIBERT K, 1994, P NATL ACAD SCI USA, V91, P12013, DOI 10.1073/pnas.91.25.12013; Sheng GG, 1997, GASTROENTEROLOGY, V113, P1883, DOI 10.1016/S0016-5085(97)70007-6; Sheng HM, 1998, CANCER RES, V58, P362; Sheng HM, 1997, CELL GROWTH DIFFER, V8, P463; Sheng HM, 1997, J CLIN INVEST, V99, P2254, DOI 10.1172/JCI119400; SIEWEKE MH, 1990, SCIENCE, V248, P1656, DOI 10.1126/science.2163544; SIEWEKE MH, 1994, CRIT REV ONCOGENESIS, V5, P297, DOI 10.1615/CritRevOncog.v5.i2-3.90; SUN LZ, 1994, J BIOL CHEM, V269, P26449; Takagi Y, 1996, GASTROENTEROLOGY, V111, P1369, DOI 10.1053/gast.1996.v111.pm8898652; TORREAMIONE G, 1990, P NATL ACAD SCI USA, V87, P1486, DOI 10.1073/pnas.87.4.1486; Tsujii M, 1997, P NATL ACAD SCI USA, V94, P3336, DOI 10.1073/pnas.94.7.3336; TSUJII M, 1995, CELL, V83, P493, DOI 10.1016/0092-8674(95)90127-2; WANG DH, 1995, J BIOL CHEM, V270, P14154, DOI 10.1074/jbc.270.23.14154; WANG J, 1995, J BIOL CHEM, V270, P22044, DOI 10.1074/jbc.270.37.22044; WIESER R, 1993, MOL CELL BIOL, V13, P7239, DOI 10.1128/MCB.13.12.7239; Williams CS, 1996, AM J PHYSIOL-GASTR L, V270, pG393; Winesett MP, 1996, CARCINOGENESIS, V17, P989, DOI 10.1093/carcin/17.5.989; ZAMBRUNO G, 1995, J CELL BIOL, V129, P853, DOI 10.1083/jcb.129.3.853; Zhang T, 1997, CANCER RES, V57, P169; Zhang T, 1997, CANCER RES, V57, P1638; ZHANG XY, 1994, CANCER RES, V54, P6122; ZHAO J, 1995, CANCER RES, V55, P6181	73	57	59	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 28	1999	18	4					855	867		10.1038/sj.onc.1202397	http://dx.doi.org/10.1038/sj.onc.1202397			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	165FT	10023661				2022-12-25	WOS:000078510600002
J	Huang, ZQ; Philippin, B; O'Leary, E; Bonventre, JV; Kriz, W; Witzgall, R				Huang, ZQ; Philippin, B; O'Leary, E; Bonventre, JV; Kriz, W; Witzgall, R			Expression of the transcriptional repressor protein Kid-1 leads to the disintegration of the nucleolus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-I; ZINC-FINGER PROTEINS; DNA-BINDING; FACTOR UBF; MEDIATED REPRESSION; GENE-TRANSCRIPTION; MAMMALIAN-CELLS; NUCLEAR MATRIX; KRUPPEL-TYPE; FACTOR HUBF	The rat Kid-1 gene codes for a 66-kDa protein with KRAB domains at the NH2 terminus and two Cys(2)His(2)-zinc finger clusters of four and nine zinc fingers at the COOH terminus. It was the first KRAB-zinc finger protein for which a transcriptional repressor activity was demonstrated. Subsequently, the KRAB-A domain was identified as a widespread transcriptional repressor motif, We now present a biochemical and functional analysis of the Kid-1 protein in transfected cells. The full-length Kid-1 protein is targeted to the nucleolus and adheres tightly to as yet undefined nucleolar structures, leading eventually to the disintegration of the nucleolus. The tight adherence and nucleolar distribution can be attributed to the larger zinc finger cluster, whereas the KRAB-A domain is responsible for the nucleolar fragmentation, Upon disintegration of the nucleolus, the nucleolar transcription factor upstream binding factor disappears from the nucleolar fragments, In the absence of Kid-1, the KRIP-1 protein, which represents the natural interacting partner of zinc finger proteins with a KRAB-A domain, is homogeneously distributed in the nucleus, whereas coexpression of Kid-1 leads to a shift of KRIP-1 into the nucleolus. Nucleolar run-ons demonstrate that rDNA transcription is shut off in the nucleolar fragments. Our data demonstrate the functional diversity of the KRAB and zinc finger domains of Kid-1 and provide new functional insights into the regulation of the nucleolar structure.	Univ Heidelberg, Inst Anat & Cell Biol 1, D-69120 Heidelberg, Germany; Harvard Univ, Sch Med, Dept Med, Charlestown, MA 02129 USA; Massachusetts Gen Hosp, Renal Unit, Charlestown, MA 02129 USA	Ruprecht Karls University Heidelberg; Harvard University; Harvard University; Massachusetts General Hospital	Witzgall, R (corresponding author), Univ Heidelberg, Inst Anat & Cell Biol 1, Neuenheimer Feld 307, D-69120 Heidelberg, Germany.			Witzgall, Ralph/0000-0002-5283-4846	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK039773, R37DK039773] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK39773] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Arranz V, 1997, MOL CELL BIOL, V17, P2116, DOI 10.1128/MCB.17.4.2116; Ausubel FM., 1992, CURRENT PROTOCOLS MO, V3; BELL P, 1992, J CELL BIOL, V118, P1297, DOI 10.1083/jcb.118.6.1297; BELLEFROID EJ, 1991, P NATL ACAD SCI USA, V88, P3608, DOI 10.1073/pnas.88.9.3608; BELLEFROID EJ, 1989, DNA-J MOLEC CELL BIO, V8, P377, DOI 10.1089/dna.1.1989.8.377; BENAVENTE R, 1987, J CELL BIOL, V105, P1483, DOI 10.1083/jcb.105.4.1483; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brady JP, 1997, EXP EYE RES, V64, P287, DOI 10.1006/exer.1996.0206; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CLEVELAND DW, 1995, TRENDS CELL BIOL, V5, P60, DOI 10.1016/S0962-8924(00)88947-3; COPENHAVER GP, 1994, NUCLEIC ACIDS RES, V22, P2651, DOI 10.1093/nar/22.13.2651; Elser B, 1997, J BIOL CHEM, V272, P27908, DOI 10.1074/jbc.272.44.27908; Friedman JR, 1996, GENE DEV, V10, P2067, DOI 10.1101/gad.10.16.2067; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; GOESSENS G, 1984, INT REV CYTOL, V87, P107, DOI 10.1016/S0074-7696(08)62441-9; GRANICK D, 1975, J CELL BIOL, V65, P418, DOI 10.1083/jcb.65.2.418; Grondin B, 1996, J BIOL CHEM, V271, P15458, DOI 10.1074/jbc.271.26.15458; HannaRose W, 1996, TRENDS GENET, V12, P229, DOI 10.1016/0168-9525(96)10022-6; HE DC, 1990, J CELL BIOL, V110, P569, DOI 10.1083/jcb.110.3.569; HISATAKE K, 1991, NUCLEIC ACIDS RES, V19, P4631, DOI 10.1093/nar/19.17.4631; HOPPESEYLER F, 1991, NUCLEIC ACIDS RES, V19, P5080, DOI 10.1093/nar/19.18.5080; HOZAK P, 1995, J CELL SCI, V108, P635; HU CH, 1994, MOL CELL BIOL, V14, P2871, DOI 10.1128/MCB.14.5.2871; HULL RN, 1976, IN VITRO CELL DEV B, V12, P670, DOI 10.1007/BF02797469; IMAI H, 1994, MOL BIOL REP, V19, P115, DOI 10.1007/BF00997157; Israeli D, 1997, EMBO J, V16, P4384, DOI 10.1093/emboj/16.14.4384; JACKSON DA, 1993, EMBO J, V12, P1059, DOI 10.1002/j.1460-2075.1993.tb05747.x; JANTZEN HM, 1992, GENE DEV, V6, P1950, DOI 10.1101/gad.6.10.1950; JANTZEN HM, 1990, NATURE, V344, P830, DOI 10.1038/344830a0; JOHNSON PF, 1989, ANNU REV BIOCHEM, V58, P799, DOI 10.1146/annurev.biochem.58.1.799; Kamakaka RT, 1997, TRENDS BIOCHEM SCI, V22, P124, DOI 10.1016/S0968-0004(96)10074-8; KEMPF T, 1994, FEBS LETT, V354, P307, DOI 10.1016/0014-5793(94)01151-6; Kim SS, 1996, P NATL ACAD SCI USA, V93, P15299, DOI 10.1073/pnas.93.26.15299; KUHN A, 1993, NUCLEIC ACIDS RES, V21, P2057, DOI 10.1093/nar/21.9.2057; KUHN A, 1994, EMBO J, V13, P416, DOI 10.1002/j.1460-2075.1994.tb06276.x; LeDouarin B, 1996, EMBO J, V15, P6701, DOI 10.1002/j.1460-2075.1996.tb01060.x; MAEDA Y, 1992, EMBO J, V11, P3695, DOI 10.1002/j.1460-2075.1992.tb05454.x; MARGOLIN JF, 1994, P NATL ACAD SCI USA, V91, P4509, DOI 10.1073/pnas.91.10.4509; Masson C, 1996, EXP CELL RES, V226, P114, DOI 10.1006/excr.1996.0209; MATHENY C, 1994, J BIOL CHEM, V269, P8176; MCSTAY B, 1991, GENE DEV, V5, P1957, DOI 10.1101/gad.5.11.1957; Moosmann P, 1996, NUCLEIC ACIDS RES, V24, P4859, DOI 10.1093/nar/24.24.4859; Moosmann P, 1997, BIOL CHEM, V378, P669, DOI 10.1515/bchm.1997.378.7.669; Omori Y, 1997, CYTOGENET CELL GENET, V78, P285, DOI 10.1159/000134673; PASSANANTI C, 1995, CELL GROWTH DIFFER, V6, P1037; Payen E, 1998, J BIOL CHEM, V273, P9099, DOI 10.1074/jbc.273.15.9099; PENGUE G, 1994, NUCLEIC ACIDS RES, V22, P2908, DOI 10.1093/nar/22.15.2908; Pengue G, 1996, P NATL ACAD SCI USA, V93, P1015, DOI 10.1073/pnas.93.3.1015; Perrin L, 1998, J CELL SCI, V111, P2753; ROSATI M, 1991, NUCLEIC ACIDS RES, V19, P5661, DOI 10.1093/nar/19.20.5661; ROUSSEL P, 1993, J CELL SCI, V104, P327; Roussel P, 1996, J CELL BIOL, V133, P235, DOI 10.1083/jcb.133.2.235; Saurin AJ, 1996, TRENDS BIOCHEM SCI, V21, P208, DOI 10.1016/S0968-0004(96)80017-X; SCHEER U, 1984, J CELL BIOL, V99, P672, DOI 10.1083/jcb.99.2.672; SCHEER U, 1984, P NATL ACAD SCI-BIOL, V81, P1431, DOI 10.1073/pnas.81.5.1431; Scheer Ulrich, 1993, Trends in Cell Biology, V3, P236, DOI 10.1016/0962-8924(93)90123-I; Shaw PJ, 1995, ANNU REV CELL DEV BI, V11, P93, DOI 10.1146/annurev.cb.11.110195.000521; Shields JM, 1997, J BIOL CHEM, V272, P18504, DOI 10.1074/jbc.272.29.18504; SU LS, 1993, GENE DEV, V7, P735, DOI 10.1101/gad.7.5.735; VISSING H, 1995, FEBS LETT, V369, P153, DOI 10.1016/0014-5793(95)00728-R; WEISENBERGER D, 1993, EUR J CELL BIOL, V61, P189; WITZGALL R, 1993, MOL CELL BIOL, V13, P1933, DOI 10.1128/MCB.13.3.1933; WITZGALL R, 1994, P NATL ACAD SCI USA, V91, P4514, DOI 10.1073/pnas.91.10.4514; WYLLIE AH, 1981, HISTOCHEM J, V13, P681, DOI 10.1007/BF01002719	64	19	19	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 19	1999	274	12					7640	7648		10.1074/jbc.274.12.7640	http://dx.doi.org/10.1074/jbc.274.12.7640			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	178LU	10075651	hybrid			2022-12-25	WOS:000079268100010
J	Patel, R; Holt, M; Philipova, R; Moss, S; Schulman, H; Hidaka, H; Whitaker, M				Patel, R; Holt, M; Philipova, R; Moss, S; Schulman, H; Hidaka, H; Whitaker, M			Calcium/calmodulin-dependent phosphorylation and activation of human cdc25-c at the G(2)/M phase transition in HeLa cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN KINASE-II; SEA-URCHIN EMBRYOS; P80CDC25 MITOTIC INDUCER; FISSION YEAST; ASPERGILLUS-NIDULANS; CYCLIN-B; TYROSINE PHOSPHORYLATION; CALMODULIN ANTAGONIST; CATALYTIC SUBUNIT; CDK REGULATION	The human tyrosine phosphatase (p54(cdc25-c)) is activated by phosphorylation at mitosis entry. The phosphorylated p54(cdc25-c) in turn activates the p34-cyclin B protein kinase and triggers mitosis. Although the active p34-cyclin B protein kinase can itself phosphorylate and activate p54(cdc25-c), we have investigated the possibility that other kinases may initially trigger the phosphorylation and activation of p54(cdc25-c). We have examined the effects of the calcium/calmodulin-dependent protein kinase (CaM kinase II) on p54(cdc25-c). Our in vitro experiments show that CaM kinase II can phosphorylate p54(cdc25-c) and increase its phosphatase activity by 2.5-3-fold. Treatment of a synchronous population of HeLa cells with KN-93 (a water-soluble inhibitor of CaM kinase II) or the microinjection of AC3-I (a specific peptide inhibitor of CaM kinase II) results in a cell cycle block in G(2) phase. In the KN-93-arrested cells, p54(cdc25-c) is not phosphorylated, p34(cdc2) remains tyrosine phosphorylated, and there is no increase in histone H1 kinase activity. Our data suggest that a calcium-calmodulin-dependent step may be involved in the initial activation of p54(cdc25-c).	Univ Newcastle Upon Tyne, Sch Med, Dept Physiol Sci, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; Univ Leicester, Dept Biochem, Leicester LE1 7RH, Leics, England; UCL, MRC, Mol Cell Biol Lab, London WC1E 6BT, England; UCL, Dept Pharmacol, London WC1E 6BT, England; Stanford Univ, Sch Med, Dept Neurobiol, Stanford, CA 94305 USA; Nagoya Univ, Sch Med, Dept Pharmacol, Showa Ku, Nagoya, Aichi 466, Japan	Newcastle University - UK; University of Leicester; University of London; University College London; University of London; University College London; Stanford University; Nagoya University	Whitaker, M (corresponding author), Univ Newcastle Upon Tyne, Sch Med, Dept Physiol Sci, Framlington Pl, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.			Holt, Mark/0000-0001-7775-8539				BAITINGER C, 1990, J CELL BIOL, V111, P1763, DOI 10.1083/jcb.111.5.1763; BARTELT DC, 1988, P NATL ACAD SCI USA, V85, P3279, DOI 10.1073/pnas.85.10.3279; BRAUN AP, 1995, J PHYSIOL-LONDON, V488, P37, DOI 10.1113/jphysiol.1995.sp020944; CHAFOULEAS JG, 1982, CELL, V28, P41, DOI 10.1016/0092-8674(82)90373-7; COLBRAN RJ, 1989, BIOCHEM J, V258, P313, DOI 10.1042/bj2580313; Crenshaw DG, 1998, EMBO J, V17, P1315, DOI 10.1093/emboj/17.5.1315; EDGAR BA, 1989, CELL, V57, P177, DOI 10.1016/0092-8674(89)90183-9; EDGECOMBE M, 1991, EMBO J, V10, P3769, DOI 10.1002/j.1460-2075.1991.tb04946.x; FESQUET D, 1993, EMBO J, V12, P3111, DOI 10.1002/j.1460-2075.1993.tb05980.x; Furnari B, 1997, SCIENCE, V277, P1495, DOI 10.1126/science.277.5331.1495; GAUTIER J, 1990, CELL, V60, P487, DOI 10.1016/0092-8674(90)90599-A; GAUTIER J, 1991, CELL, V67, P197, DOI 10.1016/0092-8674(91)90583-K; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; GOULD KL, 1991, EMBO J, V10, P3297, DOI 10.1002/j.1460-2075.1991.tb04894.x; Graessmann A, 1980, Methods Enzymol, V65, P816; Groigno L, 1998, CELL, V92, P193, DOI 10.1016/S0092-8674(00)80914-9; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; HEINTZ N, 1983, MOL CELL BIOL, V3, P539, DOI 10.1128/MCB.3.4.539; HEPLER PK, 1994, CELL CALCIUM, V16, P322, DOI 10.1016/0143-4160(94)90096-5; HOFFMANN I, 1993, EMBO J, V12, P53, DOI 10.1002/j.1460-2075.1993.tb05631.x; HUNT T, 1989, CURR OPIN CELL BIOL, V1, P286; IZUMI T, 1995, MOL BIOL CELL, V6, P215, DOI 10.1091/mbc.6.2.215; IZUMI T, 1993, MOL BIOL CELL, V4, P1337, DOI 10.1091/mbc.4.12.1337; JESSUS C, 1992, CELL, V68, P323, DOI 10.1016/0092-8674(92)90473-P; KAO JPY, 1990, J CELL BIOL, V111, P183, DOI 10.1083/jcb.111.1.183; KEITH CH, 1985, NATURE, V316, P848, DOI 10.1038/316848a0; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; KREIS TE, 1982, INT REV CYTOL, V75, P209, DOI 10.1016/S0074-7696(08)61005-0; KUMAGAI A, 1991, CELL, V64, P903, DOI 10.1016/0092-8674(91)90315-P; KUMAGAI A, 1992, CELL, V70, P139, DOI 10.1016/0092-8674(92)90540-S; Kumagai A, 1996, SCIENCE, V273, P1377, DOI 10.1126/science.273.5280.1377; LABBE JC, 1989, EMBO J, V8, P3053, DOI 10.1002/j.1460-2075.1989.tb08456.x; LEE JC, 1994, P NATL ACAD SCI USA, V91, P6413, DOI 10.1073/pnas.91.14.6413; LEE TH, 1991, CELL, V64, P415, DOI 10.1016/0092-8674(91)90649-J; LINDSAY HD, 1995, J CELL SCI, V108, P3557; LONDESBOROUGH J, 1989, J GEN MICROBIOL, V135, P3373; LU KP, 1993, ENDOCR REV, V14, P40, DOI 10.1210/er.14.1.40; MEANS AR, 1991, PHARMACOL THERAPEUT, V50, P255, DOI 10.1016/0163-7258(91)90017-G; MEANS AR, 1994, FEBS LETT, V347, P1, DOI 10.1016/0014-5793(94)00492-7; MEIJER L, 1989, EMBO J, V8, P3053; MILLAR JBA, 1991, EMBO J, V10, P4301, DOI 10.1002/j.1460-2075.1991.tb05008.x; MORENO S, 1990, NATURE, V344, P549, DOI 10.1038/344549a0; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; MOSS SJ, 1992, J BIOL CHEM, V267, P14470; NGHIEM P, 1994, NATURE, V371, P347, DOI 10.1038/371347a0; NISHIMOTO T, 1985, EXP CELL RES, V156, P351, DOI 10.1016/0014-4827(85)90542-7; NORBURY C, 1991, EMBO J, V10, P3321, DOI 10.1002/j.1460-2075.1991.tb04896.x; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; OCORR KA, 1991, NEURON, V6, P907, DOI 10.1016/0896-6273(91)90231-N; OHTA Y, 1990, P NATL ACAD SCI USA, V87, P5341, DOI 10.1073/pnas.87.14.5341; OSMANI AH, 1991, CELL, V67, P283, DOI 10.1016/0092-8674(91)90180-7; PATEL R, 1991, CELL REGUL, V2, P391, DOI 10.1091/mbc.2.5.391; PAUSCH MH, 1991, EMBO J, V10, P1511, DOI 10.1002/j.1460-2075.1991.tb07671.x; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; PICCIOTTO MR, 1993, J BIOL CHEM, V268, P26512; PLANASSILVA MD, 1992, EMBO J, V11, P507, DOI 10.1002/j.1460-2075.1992.tb05081.x; POON RYC, 1993, EMBO J, V12, P3123, DOI 10.1002/j.1460-2075.1993.tb05981.x; RASMUSSEN CD, 1990, J BIOL CHEM, V265, P13767; RASMUSSEN CD, 1989, EMBO J, V8, P73, DOI 10.1002/j.1460-2075.1989.tb03350.x; SADHU K, 1990, P NATL ACAD SCI USA, V87, P5139, DOI 10.1073/pnas.87.13.5139; Sambrook J., 2002, MOL CLONING LAB MANU; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; SASAKI Y, 1982, BIOCHEM BIOPH RES CO, V104, P451, DOI 10.1016/0006-291X(82)90658-1; SCHATZMAN RC, 1983, BIOCHIM BIOPHYS ACTA, V755, P144, DOI 10.1016/0304-4165(83)90284-2; Schulman H, 1993, CURR OPIN CELL BIOL, V5, P247, DOI 10.1016/0955-0674(93)90111-3; SOLOMON MJ, 1993, EMBO J, V12, P3133, DOI 10.1002/j.1460-2075.1993.tb05982.x; SOLOMON MJ, 1992, MOL BIOL CELL, V3, P13, DOI 10.1091/mbc.3.1.13; SOLOMON MJ, 1990, CELL, V63, P1013, DOI 10.1016/0092-8674(90)90504-8; SRINIVASAN M, 1994, J CELL BIOL, V126, P839, DOI 10.1083/jcb.126.4.839; STRAUSFELD U, 1991, NATURE, V351, P242, DOI 10.1038/351242a0; SUMI M, 1991, BIOCHEM BIOPH RES CO, V181, P968, DOI 10.1016/0006-291X(91)92031-E; Torok K, 1998, CURR BIOL, V8, P692, DOI 10.1016/S0960-9822(98)70275-1; TWIGG J, 1988, NATURE, V332, P364; ULLOA RM, 1991, MOL CELL BIOCHEM, V102, P155; VALTORTA F, 1992, J BIOL CHEM, V267, P7195; WALDMANN R, 1990, BIOCHEMISTRY-US, V29, P1679, DOI 10.1021/bi00459a002; WELSH MJ, 1979, J CELL BIOL, V81, P624, DOI 10.1083/jcb.81.3.624; WELSH MJ, 1978, P NATL ACAD SCI USA, V78, P1867; WHITAKER M, 1990, DEVELOPMENT, V108, P525; WHITFIELD WGF, 1989, NATURE, V338, P337, DOI 10.1038/338337a0; Wilding M, 1996, J CELL BIOL, V135, P191, DOI 10.1083/jcb.135.1.191; WOLNIAK SM, 1980, J CELL BIOL, V87, P23, DOI 10.1083/jcb.87.1.23; YAMASHITA K, 1990, EMBO J, V9, P4331, DOI 10.1002/j.1460-2075.1990.tb07882.x	83	114	119	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 19	1999	274	12					7958	7968		10.1074/jbc.274.12.7958	http://dx.doi.org/10.1074/jbc.274.12.7958			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	178LU	10075693	hybrid			2022-12-25	WOS:000079268100052
J	Chaudhry, AZ; Vitullo, AD; Gronostajski, RM				Chaudhry, AZ; Vitullo, AD; Gronostajski, RM			Nuclear factor I-mediated repression of the mouse mammary tumor virus promoter is abrogated by the coactivators p300/CBP and SRC-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENOVIRUS DNA-REPLICATION; BINDING-SITES; MMTV PROMOTER; TRANSCRIPTIONAL ACTIVATION; HISTONE ACETYLTRANSFERASE; CHROMATIN STRUCTURE; GENE-TRANSCRIPTION; TERMINAL DOMAIN; PROTEIN GENE; GLOBIN GENE	To better understand the function of nuclear factor I (NFI) proteins in transcription, we have used transient transfection assays to assess transcriptional modulation by NFI proteins on the NFI-dependent mouse mammary tumor virus (MMTV) promoter. Expression of NFI-C or NFI-X, but not NFI-A or NFI-B proteins, represses glucocorticoid induction of the MMTV promoter in HeLa cells. Repression is DNA binding-independent as a deletion construct expressing the NH2-terminal 160 residues of NFI-C represses but does not bind DNA, Repression by NFI-C is cell type-dependent and occurs in HeLa and COS-1 cells but not 293 or JEG-3 cells. NFI-C does not repress progesterone induction of the MMTV promoter in HeLa cells, suggesting that progesterone induction of the promoter differs mechanistically from glucocorticoid induction. NFI-C-mediated repression is alleviated by overexpression of glucocorticoid receptor (GR), suggesting that NFI-C represses the MMTV promoter by preventing GR function. However, repression by NFI-C occurs with only a subset of glucocorticoid-responsive promoters, as the chimeric NFIGRE beta-gal promoter that is activated by GR is not repressed by NFI-C. Since the coactivator proteins p300/CBP, SRC-1A, and RAC3 had previously been shown to function at steroid hormone-responsive promoters, we asked whether they could influence NFI-C-mediated repression of MMTV expression, Expression of p300/CBP or SRC-1A alleviates repression by NFI-C, whereas RACE has no effect. This abrogation of NFI-C-mediated repression by p300/CBP and SRC-1A suggests that repression by NFI-C may occur by interference with coactivator function at the MMTV promoter.	Cleveland Clin Fdn, Lerner Res Inst, Dept Canc Biol NB40, Cleveland, OH 44195 USA; Case Western Reserve Univ, Dept Biochem, Cleveland, OH 44106 USA	Cleveland Clinic Foundation; Case Western Reserve University	Gronostajski, RM (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, Dept Canc Biol NB40, 9500 Euclid Ave, Cleveland, OH 44195 USA.		Vitullo, Alfredo/F-9744-2015	Vitullo, Alfredo/0000-0002-4833-5147; Gronostajski, Richard/0000-0003-4264-208X	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD034908] Funding Source: NIH RePORTER; NICHD NIH HHS [HD34908] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		AMEMIYA K, 1992, J BIOL CHEM, V267, P14204; AOYAMA A, 1990, BIOCHEM BIOPH RES CO, V167, P648, DOI 10.1016/0006-291X(90)92074-A; ARCHER TK, 1994, MOL ENDOCRINOL, V8, P568, DOI 10.1210/me.8.5.568; ARCHER TK, 1992, SCIENCE, V255, P1573, DOI 10.1126/science.1347958; Bandyopadhyay S, 1998, J BIOL CHEM, V273, P392, DOI 10.1074/jbc.273.1.392; BRUGGEMEIER U, 1991, CELL, V64, P565, DOI 10.1016/0092-8674(91)90240-Y; CEREGHINI S, 1987, CELL, V50, P627, DOI 10.1016/0092-8674(87)90036-5; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; Chaudhry AZ, 1998, J BIOL CHEM, V273, P18538, DOI 10.1074/jbc.273.29.18538; Chaudhry AZ, 1997, DEV DYNAM, V208, P313; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; CORDINGLEY MG, 1987, CELL, V48, P261, DOI 10.1016/0092-8674(87)90429-6; DARVILLE MI, 1992, NUCLEIC ACIDS RES, V20, P3575, DOI 10.1093/nar/20.14.3575; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; Fryer CJ, 1998, NATURE, V393, P88, DOI 10.1038/30032; GLOSS B, 1989, NUCLEIC ACIDS RES, V17, P3519, DOI 10.1093/nar/17.9.3519; Gorman C., 1985, DNA CLONING, V2; GOUNARI F, 1990, EMBO J, V9, P559, DOI 10.1002/j.1460-2075.1990.tb08143.x; GOWLAND PL, 1989, MOL CELL BIOL, V9, P3999, DOI 10.1128/MCB.9.9.3999; GOYAL N, 1990, MOL CELL BIOL, V10, P1041, DOI 10.1128/MCB.10.3.1041; GRAVES RA, 1991, GENE DEV, V5, P428, DOI 10.1101/gad.5.3.428; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Jenster G, 1997, P NATL ACAD SCI USA, V94, P7879, DOI 10.1073/pnas.94.15.7879; KALFF M, 1990, NATURE, V344, P360, DOI 10.1038/344360a0; KNEZETIC JA, 1993, MOL CELL BIOL, V13, P4632, DOI 10.1128/MCB.13.8.4632; KNOX JJ, 1991, MOL CELL BIOL, V11, P2946, DOI 10.1128/MCB.11.6.2946; KRUSE U, 1994, FEBS LETT, V348, P46, DOI 10.1016/0014-5793(94)00585-0; KRUSE U, 1994, J MOL BIOL, V238, P860, DOI 10.1006/jmbi.1994.1343; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Li H, 1997, P NATL ACAD SCI USA, V94, P8479, DOI 10.1073/pnas.94.16.8479; LI S, 1995, MOL CELL BIOL, V15, P2063; Liu YC, 1997, J BIOL CHEM, V272, P10739; LUNDBLAD JR, 1995, NATURE, V374, P85, DOI 10.1038/374085a0; MACLEOD K, 1991, MOL CELL BIOL, V11, P4324, DOI 10.1128/MCB.11.9.4324; MARTINEZ E, 1991, MOL CELL BIOL, V11, P2937, DOI 10.1128/MCB.11.6.2937; MEISTERERNST M, 1989, BIOCHEMISTRY-US, V28, P8191, DOI 10.1021/bi00446a034; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; MIKSICEK R, 1987, EMBO J, V6, P1355, DOI 10.1002/j.1460-2075.1987.tb02375.x; Misiti S, 1998, ENDOCRINOLOGY, V139, P2493, DOI 10.1210/en.139.5.2493; MYMRYK JS, 1995, MOL CELL BIOL, V15, P26, DOI 10.1128/MCB.15.1.26; NAGATA K, 1983, P NATL ACAD SCI-BIOL, V80, P4266, DOI 10.1073/pnas.80.14.4266; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Onate SA, 1998, J BIOL CHEM, V273, P12101, DOI 10.1074/jbc.273.20.12101; QUINN PG, 1988, MOL CELL BIOL, V8, P3467, DOI 10.1128/MCB.8.8.3467; RICHARDFOY H, 1987, EMBO J, V6, P2321, DOI 10.1002/j.1460-2075.1987.tb02507.x; RUPP RAW, 1990, NUCLEIC ACIDS RES, V18, P2607, DOI 10.1093/nar/18.9.2607; RUPP RAW, 1987, NUCLEIC ACIDS RES, V15, P9707, DOI 10.1093/nar/15.23.9707; SANTORO C, 1988, NATURE, V334, P218, DOI 10.1038/334218a0; Smith CL, 1997, J BIOL CHEM, V272, P14227, DOI 10.1074/jbc.272.22.14227; SMITH CL, 1993, P NATL ACAD SCI USA, V90, P11202, DOI 10.1073/pnas.90.23.11202; Soderstrom M, 1997, MOL ENDOCRINOL, V11, P682, DOI 10.1210/me.11.6.682; Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304; Tagami T, 1997, MOL CELL BIOL, V17, P2642, DOI 10.1128/MCB.17.5.2642; TOOHEY MG, 1990, J VIROL, V64, P4477, DOI 10.1128/JVI.64.9.4477-4488.1990; WADE PA, 1997, CURR BIOL, V7, P82; Wenzelides S, 1996, NUCLEIC ACIDS RES, V24, P2416, DOI 10.1093/nar/24.12.2416; XIAO H, 1994, NUCLEIC ACIDS RES, V22, P1966, DOI 10.1093/nar/22.11.1966; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Yao TP, 1996, P NATL ACAD SCI USA, V93, P10626, DOI 10.1073/pnas.93.20.10626; Zhang WJ, 1998, P NATL ACAD SCI USA, V95, P9855, DOI 10.1073/pnas.95.17.9855	62	36	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 12	1999	274	11					7072	7081		10.1074/jbc.274.11.7072	http://dx.doi.org/10.1074/jbc.274.11.7072			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	175DV	10066764	hybrid			2022-12-25	WOS:000079078400036
J	Klukas, O; Schubert, WD; Jordan, P; Krauss, N; Fromme, P; Witt, HT; Saenger, W				Klukas, O; Schubert, WD; Jordan, P; Krauss, N; Fromme, P; Witt, HT; Saenger, W			Localization of two phylloquinones, Q(K) and Q(K)', in an improved electron density map of photosystem I at 4-angstrom resolution	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRON-SULFUR CENTERS; PHOTOSYNTHETIC REACTION-CENTER; BACTERIAL REACTION CENTERS; SINGLE-CRYSTALS; STRUCTURAL ORGANIZATION; OXYGENIC PHOTOSYNTHESIS; ANGSTROM RESOLUTION; RADICAL PAIRS; CHLOROPHYLL-A; EPR	An improved electron density map of photosystem I from Synechococcus elongatus calculated at 4-Angstrom resolution for the first time reveals a second phylloquinone molecule and thereby completes the set of cofactors constituting the electron transfer system of this iron-sulfur type photosynthetic reaction center: six chlorophyll a, two phylloquinones, and three Fe4S4 clusters. The location of the newly identified phylloquinone pair, the individual plane orientations of these molecules, and the resulting distances to other cofactors of the electron transfer system are discussed and compared with those determined by magnetic resonance techniques.	Free Univ Berlin, Inst Kristallog, D-14195 Berlin, Germany; Tech Univ Berlin, Max Volmer Inst Biophys Chem & Biochem, D-10623 Berlin, Germany	Free University of Berlin; Technical University of Berlin	Krauss, N (corresponding author), Free Univ Berlin, Inst Kristallog, Takustr 6, D-14195 Berlin, Germany.	nkrauss@chemie.fu-berlin.de	Schubert, Wolf-Dieter/A-5617-2009	Schubert, Wolf-Dieter/0000-0003-4998-519X; Krauss, Norbert/0000-0002-7128-4632				ADMAN ET, 1976, J BIOL CHEM, V251, P3801; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bittl R, 1997, BIOCHEMISTRY-US, V36, P12001, DOI 10.1021/bi971645n; Brettel K, 1997, BBA-BIOENERGETICS, V1318, P322, DOI 10.1016/S0005-2728(96)00112-0; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; Diaz-Quintana A, 1998, BIOCHEMISTRY-US, V37, P3429, DOI 10.1021/bi972469l; Dzuba SA, 1997, CHEM PHYS LETT, V264, P238, DOI 10.1016/S0009-2614(96)01302-4; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; Fischer N, 1998, EMBO J, V17, P849, DOI 10.1093/emboj/17.4.849; GLOUX J, 1994, J AM CHEM SOC, V116, P1953, DOI 10.1021/ja00084a040; GUIGLIARELLI B, 1993, J BIOL CHEM, V268, P900; Iwaki M, 1996, J PHYS CHEM-US, V100, P10802, DOI 10.1021/jp960221k; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kamlowski A, 1998, J PHYS CHEM B, V102, P8266, DOI 10.1021/jp9817022; Kamlowski A, 1997, BBA-BIOENERGETICS, V1319, P199, DOI 10.1016/S0005-2728(96)00162-4; Kamlowski A, 1997, BBA-BIOENERGETICS, V1319, P185, DOI 10.1016/S0005-2728(96)00161-2; Kass H, 1996, CHEM PHYS LETT, V251, P193, DOI 10.1016/0009-2614(96)00129-7; Klukas O, 1999, J BIOL CHEM, V274, P7351, DOI 10.1074/jbc.274.11.7351; KRAUSS N, 1993, NATURE, V361, P326, DOI 10.1038/361326a0; Krauss N, 1996, NAT STRUCT BIOL, V3, P965, DOI 10.1038/nsb1196-965; LEIBL W, 1995, BIOCHEMISTRY-US, V34, P10237, DOI 10.1021/bi00032a018; MacMillan F, 1997, BIOCHEMISTRY-US, V36, P9297, DOI 10.1021/bi971097d; MARCUS RA, 1985, BIOCHIM BIOPHYS ACTA, V811, P265, DOI 10.1016/0304-4173(85)90014-X; MOSER CC, 1992, NATURE, V355, P796, DOI 10.1038/355796a0; Nugent JHA, 1996, EUR J BIOCHEM, V237, P519, DOI 10.1111/j.1432-1033.1996.00519.x; Otwinowski Z., 1991, ISOMORPHOUS REPLACEM, P80; RIUS G, 1989, J AM CHEM SOC, V111, P2464, DOI 10.1021/ja00189a015; Schubert WD, 1997, J MOL BIOL, V272, P741, DOI 10.1006/jmbi.1997.1269; Schubert WD, 1995, PHOTOSYNTHESIS: FROM LIGHT TO BIOSPHERE, VOL II, P3; SETIF P, 1989, BIOCHEMISTRY-US, V28, P2689, DOI 10.1021/bi00432a049; SETIF P, 1993, BIOCHEMISTRY-US, V32, P7846, DOI 10.1021/bi00082a002; SNYDER SW, 1991, P NATL ACAD SCI USA, V88, P9895, DOI 10.1073/pnas.88.21.9895; vanderEst A, 1997, J PHYS CHEM B, V101, P1437, DOI 10.1021/jp9622086; Vassiliev IR, 1998, BIOPHYS J, V74, P2029, DOI 10.1016/S0006-3495(98)77909-3; Witt HT, 1996, BER BUNSEN PHYS CHEM, V100, P1923, DOI 10.1002/bbpc.19961001202; Zech SG, 1996, BER BUNSEN PHYS CHEM, V100, P2041, DOI 10.1002/bbpc.19961001220	37	71	82	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	1999	274	11					7361	7367		10.1074/jbc.274.11.7361	http://dx.doi.org/10.1074/jbc.274.11.7361			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	175DV	10066800	hybrid			2022-12-25	WOS:000079078400072
J	Rudgers, GW; Palzkill, T				Rudgers, GW; Palzkill, T			Identification of residues in beta-lactamase critical for binding beta-lactamase inhibitory protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STREPTOMYCES-CLAVULIGERUS; ESCHERICHIA-COLI; RESISTANCE; CEPHALOSPORINS; DETERMINANTS; CEFTAZIDIME; EFFICIENCY; MUTANTS; GENES; ACID	beta-Lactamase inhibitory protein (BLIP) is a potent inhibitor of several beta-lactamases including TEM-1 beta-lactamase (K-i = 0.1 nM), The co-crystal structure of TEM-1 beta-lactamase and BLIP has been solved, revealing the contact residues involved in the interface between the enzyme and inhibitor. To determine which residues in TEM-1 beta-lactamase are critical for binding BLIP, the method of monovalent phage display was employed. Random mutants of TEM-1 beta-lactamase in the 99-114 loop-helix and 235-240 B3 beta-strand regions were displayed as fusion proteins on the surface of the M13 bacteriophage. Functional mutants were selected based on the ability to bind BLIP, After three rounds of enrichment, the sequences of a collection of functional beta-lactamase mutants revealed a consensus sequence for the binding of BLIP. Seven loop-helix residues including Asp-101, Leu-102, Val-103, Ser-106, Pro-107, Thr-109, and His-112 and three B3 beta-strand residues including Ser-235, Gly-236, and Gly-238 were found to be critical for tight binding of BLIP, In addition, the selected beta-lactamase mutants A113L/T114R and E240K were found to increase binding of BLIP by over 6- and 11-fold, respectively. Combining these substitutions resulted in 550-fold tighter binding between the enzyme and BLIP with a K-i of 0.40 pM. These results reveal that the binding between TEM-1 beta-lactamase and BLIP can be improved and that there are a large number of sequences consistent with tight binding between BLIP and beta-lactamase.	Baylor Coll Med, Dept Microbiol & Immunol, Houston, TX 77030 USA; Baylor Coll Med, Dept Biochem, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine	Palzkill, T (corresponding author), Baylor Coll Med, Dept Microbiol & Immunol, 1 Baylor Plaza, Houston, TX 77030 USA.	timothyp@bcm.tmc.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI032956, R01AI032956, R56AI032956] Funding Source: NIH RePORTER; NIAID NIH HHS [AI32956] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AMANN E, 1983, GENE, V25, P167, DOI 10.1016/0378-1119(83)90222-6; AMBLER RP, 1980, PHILOS T R SOC B, V289, P321, DOI 10.1098/rstb.1980.0049; AMBLER RP, 1991, BIOCHEM J, V276, P269, DOI 10.1042/bj2760269; BULLOCK WO, 1987, BIOTECHNIQUES, V5, P376; BUSH K, 1989, ANTIMICROB AGENTS CH, V33, P259, DOI 10.1128/AAC.33.3.259; Cantu C, 1997, J BIOL CHEM, V272, P29144, DOI 10.1074/jbc.272.46.29144; CLACKSON T, 1995, SCIENCE, V267, P383, DOI 10.1126/science.7529940; DAVIES J, 1994, SCIENCE, V264, P375, DOI 10.1126/science.8153624; DORAN JL, 1990, J BACTERIOL, V172, P4909, DOI 10.1128/jb.172.9.4909-4918.1990; Gibson T. J., 1984, THESIS CAMBRIDGE U C; HANKE M, 1994, BIOTECHNIQUES, V17, P858; HOOGENBOOM HR, 1991, NUCLEIC ACIDS RES, V19, P4133, DOI 10.1093/nar/19.15.4133; Huang WZ, 1998, ANTIMICROB AGENTS CH, V42, P2893, DOI 10.1128/AAC.42.11.2893; Huang WZ, 1996, J MOL BIOL, V258, P688, DOI 10.1006/jmbi.1996.0279; IMTIAZ U, 1994, ANTIMICROB AGENTS CH, V38, P1134, DOI 10.1128/AAC.38.5.1134; JORIS B, 1988, BIOCHEM J, V250, P313, DOI 10.1042/bj2500313; KNOTHE H, 1983, INFECTION, V11, P315, DOI 10.1007/BF01641355; Lowman HB., 1991, METHODS COMPANION ME, V3, P205; MATTHEW M, 1979, J ANTIMICROB CHEMOTH, V5, P349, DOI 10.1093/jac/5.4.349; MEDEIROS AA, 1984, BRIT MED BULL, V40, P18, DOI 10.1093/oxfordjournals.bmb.a071942; NEU HC, 1992, SCIENCE, V257, P1064, DOI 10.1126/science.257.5073.1064; PALZKILL T, 1992, PROTEINS, V14, P29, DOI 10.1002/prot.340140106; PALZKILL T, 1991, METHODS COMPANION ME, V3, P155; PARKER RH, 1987, INFECT CONT HOSP EP, V8, P36, DOI 10.1017/S0195941700066972; PerezLlarena F, 1997, J BACTERIOL, V179, P6035, DOI 10.1128/jb.179.19.6035-6040.1997; Petrosino J, 1998, TRENDS MICROBIOL, V6, P323, DOI 10.1016/S0966-842X(98)01317-1; Petrosino J, 1999, J BIOL CHEM, V274, P2394, DOI 10.1074/jbc.274.4.2394; RAQUET X, 1994, J MOL BIOL, V244, P625, DOI 10.1006/jmbi.1994.1756; READING C, 1977, ANTIMICROB AGENTS CH, V11, P852, DOI 10.1128/AAC.11.5.852; SOWEK JA, 1991, BIOCHEMISTRY-US, V30, P3179, DOI 10.1021/bi00227a004; STRYNADKA NCJ, 1994, NATURE, V368, P657, DOI 10.1038/368657a0; Strynadka NCJ, 1996, NAT STRUCT BIOL, V3, P290, DOI 10.1038/nsb0396-290; VENKATACHALAM KV, 1994, J BIOL CHEM, V269, P23444; WELLS JA, 1990, BIOCHEMISTRY-US, V29, P8509, DOI 10.1021/bi00489a001; WIEDEMANN B, 1989, J ANTIMICROB CHEMOTH, V24, P1	35	27	30	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	1999	274	11					6963	6971		10.1074/jbc.274.11.6963	http://dx.doi.org/10.1074/jbc.274.11.6963			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	175DV	10066750	hybrid			2022-12-25	WOS:000079078400022
J	Gehring, NH; Hentze, MW; Pantopoulos, K				Gehring, NH; Hentze, MW; Pantopoulos, K			Inactivation of both RNA binding and aconitase activities of iron regulatory protein-1 by quinone-induced oxidative stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-GLUTAMYLCYSTEINE SYNTHETASE; SULFUR CLUSTERS; MESSENGER-RNA; NITRIC-OXIDE; ESCHERICHIA-COLI; CELLS; MODULATION; METABOLISM; INDUCTION; OXYGEN	Iron regulatory protein-1 (IRP-1) controls the expression of several mRNAs by binding to iron-responsive elements (IREs) in their untranslated regions, In iron-replete cells, a 4Fe-4S cluster converts IRP-1 to cytoplasmic aconitase, IRE binding activity is restored by cluster loss in response to iron starvation, NO, or extracellular H2O2. Here, we study the effects of intracellular quinone-induced oxidative stress on IRP-1. Treatment of murine Be fibroblasts with menadione sodium bisulfite (MSB), a redox cycling drug, causes a modest activation of IRP-1 to bind to IREs within 15-30 min. However, IRE binding drops to basal levels within 60 min. Surprisingly, a remarkable loss of both IRE binding and aconitase activities of IRP-1 follows treatment with MSB for 1-2 h, These effects do not result from alterations in IRP-1 half-life, can be antagonized by the antioxidant N-acetylcysteine, and regulate IRE-containing mRNAs; the capacity of iron-starved MSB-treated cells to increase transferrin receptor mRNA levels is inhibited, and MSB increases the translation of a human growth hormone indicator mRNA bearing an IRE in its 5'-untranslated region, Nonetheless, MSB inhibits ferritin synthesis. Thus, menadione-induced oxidative stress leads to post-translational inactivation of both genetic and enzymatic functions of IRP-1 by a mechanism that lies beyond the "classical" Fe-S cluster switch and exerts multiple effects on cellular iron metabolism.	European Mol Biol Lab, D-69117 Heidelberg, Germany	European Molecular Biology Laboratory (EMBL)	Pantopoulos, K (corresponding author), Sir Mortimer B Davis Jewish Hosp, Lady Davis Inst Med Res, 3755 Chemin Cote Ste Catherine, Montreal, PQ H3T 1E2, Canada.	mbgl@musica.mcgill.ca	Pantopoulos, Kostas/A-9668-2008; Hentze, Matthias W/V-3980-2017	Pantopoulos, Kostas/0000-0002-2305-0057; Hentze, Matthias W/0000-0002-4023-7876				Beinert H, 1996, FEBS LETT, V382, P218, DOI 10.1016/0014-5793(96)00140-8; Beinert H, 1997, SCIENCE, V277, P653, DOI 10.1126/science.277.5326.653; Berlett BS, 1997, J BIOL CHEM, V272, P20313, DOI 10.1074/jbc.272.33.20313; CADENAS E, 1989, ANNU REV BIOCHEM, V58, P79, DOI 10.1146/annurev.bi.58.070189.000455; CAIRO G, 1995, J BIOL CHEM, V270, P700, DOI 10.1074/jbc.270.2.700; COCCIA EM, 1992, MOL CELL BIOL, V12, P3015, DOI 10.1128/MCB.12.7.3015; DASILVA JJR, 1991, BIOL CHEM ELEMENTS I, V21, P319; DRAPIER JC, 1993, EMBO J, V12, P3643, DOI 10.1002/j.1460-2075.1993.tb06038.x; GARDNER PR, 1995, J BIOL CHEM, V270, P13399, DOI 10.1074/jbc.270.22.13399; GARDNER PR, 1991, J BIOL CHEM, V266, P19328; Grune T, 1997, FASEB J, V11, P526, DOI 10.1096/fasebj.11.7.9212076; HALLIWELL B, 1990, METHOD ENZYMOL, V186, P1; Hentze MW, 1996, TRENDS BIOCHEM SCI, V21, P282, DOI 10.1016/S0968-0004(96)20019-2; HENTZE MW, 1989, SCIENCE, V244, P357, DOI 10.1126/science.2711187; Hentze MW, 1996, P NATL ACAD SCI USA, V93, P8175, DOI 10.1073/pnas.93.16.8175; HIRLING H, 1994, EMBO J, V13, P453, DOI 10.1002/j.1460-2075.1994.tb06280.x; Lazazzera BA, 1996, J BIOL CHEM, V271, P2762, DOI 10.1074/jbc.271.5.2762; Liu HD, 1996, GENE DEV, V10, P592; MALORNI W, 1993, J CELL SCI, V106, P309; MALORNI W, 1993, EXP CELL RES, V206, P195, DOI 10.1006/excr.1993.1138; MARTINS EAL, 1995, ARCH BIOCHEM BIOPHYS, V316, P128, DOI 10.1006/abbi.1995.1019; McDuffee AT, 1997, J CELL PHYSIOL, V171, P143, DOI 10.1002/(SICI)1097-4652(199705)171:2<143::AID-JCP4>3.0.CO;2-O; MEISTER A, 1983, ANNU REV BIOCHEM, V52, P711, DOI 10.1146/annurev.bi.52.070183.003431; Menotti E, 1998, J BIOL CHEM, V273, P1821, DOI 10.1074/jbc.273.3.1821; MULLNER EW, 1992, EUR J BIOCHEM, V208, P597, DOI 10.1111/j.1432-1033.1992.tb17224.x; Pantopoulos K, 1998, P NATL ACAD SCI USA, V95, P10559, DOI 10.1073/pnas.95.18.10559; PANTOPOULOS K, 1995, EMBO J, V14, P2917, DOI 10.1002/j.1460-2075.1995.tb07291.x; Pantopoulos K, 1996, MOL CELL BIOL, V16, P3781; Pantopoulos K, 1997, J BIOL CHEM, V272, P9802; PANTOPOULOS K, 1995, RNA, V1, P155; Paraskeva E, 1996, FEBS LETT, V389, P40, DOI 10.1016/0014-5793(96)00574-1; PHILPOTT CC, 1993, J BIOL CHEM, V268, P17655; Qiu XB, 1996, J BIOL CHEM, V271, P31915, DOI 10.1074/jbc.271.50.31915; Rouault TA, 1996, TRENDS BIOCHEM SCI, V21, P174, DOI 10.1016/0968-0004(96)10024-4; ROUAULT TA, 1996, TRANSLATIONAL CONTRO, P335; SHI MM, 1994, J BIOL CHEM, V269, P26512; Shi MM, 1996, J BIOL CHEM, V271, P5878, DOI 10.1074/jbc.271.10.5878; SHI MM, 1994, AM J PHYSIOL, V11, pL414; TANG CK, 1992, J BIOL CHEM, V267, P24466	39	59	61	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	1999	274	10					6219	6225		10.1074/jbc.274.10.6219	http://dx.doi.org/10.1074/jbc.274.10.6219			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172BQ	10037708	hybrid			2022-12-25	WOS:000078902800030
J	Luchin, S; Putzer, H; Hershey, JWB; Cenatiempo, Y; Grunberg-Manago, M; Laalami, S				Luchin, S; Putzer, H; Hershey, JWB; Cenatiempo, Y; Grunberg-Manago, M; Laalami, S			In vitro study of two dominant inhibitory GTPase mutants of Escherichia coli translation initiation factor IF2 - Direct evidence that GTP hydrolysis is necessary for factor recycling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELONGATION-FACTOR-TU; AMINOACYL-TRANSFER RNA; PROTEIN-SYNTHESIS; EF-TU; BINDING DOMAIN; RIBOSOMAL-RNA; SUBSTITUTION; HISTIDINE-84; MECHANISM; GROWTH	We have recently shown that the Escherichia coli initiation factor 2 (IF2) G-domain mutants V400G and H448E do not support cell survival and have a strong negative effect on growth even in the presence of wildtype IF2. We have isolated both mutant proteins and performed an in vitro study of their main functions. The affinity of both mutant proteins for GTP is almost unchanged compared with wild-type IF2. However, the uncoupled GTPase activity of the V400G and H448E mutants is severely impaired, the V-max values being 11- and 40-fold lower, respectively. Both mutant forms promoted fMet-tRNA(f)(Met) binding to 70 S ribosomes with similar efficiencies and were as sensitive to competitive inhibition by GDP as wild-type IF2. Formation of the first peptide bond, as measured by the puromycin reaction, was completely inhibited in the presence of the H448E mutant but still significant in the case of the V400G mutant. Sucrose density gradient centrifugation revealed that, in contrast to wild-type IF2, both mutant proteins stay blocked on the ribosome after formation of the 70 S initiation complex. This probably explains their dominant negative effect in vivo. Our results underline the importance of GTP hydrolysis for the recycling of IF2.	Univ Poitiers, Inst Biol Mol & Ingn Genet, CNRS, ESA 6031, F-86022 Poitiers, France; Inst Biol Physicochim, CNRS, UPR 9073, F-75005 Paris, France; Univ Calif Davis, Sch Med, Dept Biol Chem, Davis, CA 95616 USA	Centre National de la Recherche Scientifique (CNRS); Universite de Poitiers; Centre National de la Recherche Scientifique (CNRS); University of California System; University of California Davis	Laalami, S (corresponding author), Univ Poitiers, Inst Biol Mol & Ingn Genet, CNRS, ESA 6031, 40 Ave Recteur Pineau, F-86022 Poitiers, France.	Soumaya.Laalami@cri.univ-poitiers.fr	Putzer, Harald/GRY-6203-2022					BEAUDRY P, 1979, BIOCHEMISTRY-US, V18, P202, DOI 10.1021/bi00568a031; BENNE R, 1972, FEBS LETT, V20, P347, DOI 10.1016/0014-5793(72)80104-2; BERCHTOLD H, 1993, NATURE, V365, P126, DOI 10.1038/365126a0; BOLIVAR F, 1977, GENE, V2, P95, DOI 10.1016/0378-1119(77)90000-2; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; CAMMACK KA, 1965, BIOCHEM J, V96, P671, DOI 10.1042/bj0960671; CENATIEMPO Y, 1987, BIOCHEMISTRY-US, V26, P5070, DOI 10.1021/bi00390a028; COOL RH, 1991, BIOCHEMISTRY-US, V30, P362, DOI 10.1021/bi00216a008; DEVER TE, 1987, P NATL ACAD SCI USA, V84, P1814, DOI 10.1073/pnas.84.7.1814; DONDON J, 1985, BIOCHIMIE, V67, P643, DOI 10.1016/S0300-9084(85)80206-6; DUBNOFF JS, 1972, J BIOL CHEM, V247, P2884; EGEBJERG J, 1990, J MOL BIOL, V213, P275, DOI 10.1016/S0022-2836(05)80190-1; FAKUNDING JL, 1973, J BIOL CHEM, V248, P4206; FASANO O, 1978, EUR J BIOCHEM, V89, P557, DOI 10.1111/j.1432-1033.1978.tb12560.x; GIRSHOVICH AS, 1986, FEBS LETT, V197, P192, DOI 10.1016/0014-5793(86)80325-8; GODEFROYCOLBURN T, 1975, J MOL BIOL, V94, P461, DOI 10.1016/0022-2836(75)90215-6; Grunberg-Manago M., 1996, ESCHERICHIA COLI SAL, V1, P1432; GUALERZI CO, 1991, J BIOL CHEM, V266, P16356; HEIMARK RL, 1976, J BIOL CHEM, V251, P779; HERSHEY JWB, 1987, ESCHERICHIA COLI SAL, V1, P613; JACQUET E, 1989, EUR J BIOCHEM, V185, P341, DOI 10.1111/j.1432-1033.1989.tb15121.x; JACQUET E, 1988, EMBO J, V7, P2861, DOI 10.1002/j.1460-2075.1988.tb03142.x; JURNAK F, 1985, SCIENCE, V230, P32, DOI 10.1126/science.3898365; KAY A, 1973, BIOCHEM BIOPH RES CO, V51, P979, DOI 10.1016/0006-291X(73)90023-5; KJELDGAARD M, 1992, J MOL BIOL, V223, P721, DOI 10.1016/0022-2836(92)90986-T; KOLAKOFSKY D, 1968, P NATL ACAD SCI USA, V61, P1066, DOI 10.1073/pnas.61.3.1066; KOLAKOFSKY D, 1969, NATURE, V223, P694, DOI 10.1038/223694a0; Laalami S, 1996, BIOCHIMIE, V78, P577, DOI 10.1016/S0300-9084(96)80004-6; LAALAMI S, 1994, MOL MICROBIOL, V11, P293, DOI 10.1111/j.1365-2958.1994.tb00309.x; LAALAMI S, 1991, J MOL BIOL, V220, P335, DOI 10.1016/0022-2836(91)90017-Z; LACOUR TFM, 1985, EMBO J, V4, P2385, DOI 10.1002/j.1460-2075.1985.tb03943.x; LANGER JA, 1986, J MOL BIOL, V187, P617, DOI 10.1016/0022-2836(86)90339-6; LEDER P, 1966, BIOCHEM BIOPH RES CO, V25, P233, DOI 10.1016/0006-291X(66)90586-9; LELONG JC, 1970, NATURE, V226, P505, DOI 10.1038/226505a0; LERNER CG, 1990, NUCLEIC ACIDS RES, V18, P4631, DOI 10.1093/nar/18.15.4631; LOCKWOOD AH, 1972, P NATL ACAD SCI USA, V69, P3602, DOI 10.1073/pnas.69.12.3602; MAZUMDER R, 1972, P NATL ACAD SCI USA, V69, P2770, DOI 10.1073/pnas.69.10.2770; NIRENBERG MW, 1964, SCIENCE, V145, P1399, DOI 10.1126/science.145.3639.1399; PON CL, 1985, J BIOL CHEM, V260, P8918; ROSENDAHL G, 1993, J MOL BIOL, V234, P1013, DOI 10.1006/jmbi.1993.1655; SACERDOT C, 1992, J MOL BIOL, V225, P67, DOI 10.1016/0022-2836(92)91026-L; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCARANO G, 1995, FEBS LETT, V365, P214, DOI 10.1016/0014-5793(95)00469-P; SCHAUDER B, 1987, GENE, V52, P279, DOI 10.1016/0378-1119(87)90054-0; THACH SS, 1971, NATURE-NEW BIOL, V229, P219, DOI 10.1038/newbio229219a0; WEIEL J, 1981, BIOCHEMISTRY-US, V20, P5859, DOI 10.1021/bi00523a032	46	52	53	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1999	274	10					6074	6079		10.1074/jbc.274.10.6074	http://dx.doi.org/10.1074/jbc.274.10.6074			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172BQ	10037688	hybrid			2022-12-25	WOS:000078902800010
J	Ozawa, K; Kuwabara, K; Tamatani, M; Takatsuji, K; Tsukamoto, Y; Kaneda, S; Yanagi, H; Stern, DM; Eguchi, Y; Tsujimoto, Y; Ogawa, S; Tohyama, M				Ozawa, K; Kuwabara, K; Tamatani, M; Takatsuji, K; Tsukamoto, Y; Kaneda, S; Yanagi, H; Stern, DM; Eguchi, Y; Tsujimoto, Y; Ogawa, S; Tohyama, M			150-kDa oxygen-regulated protein (ORP150) suppresses hypoxia-induced apoptotic cell death	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; ENDOPLASMIC-RETICULUM; GENE-EXPRESSION; STRESS PROTEIN; ASTROCYTES; INDUCTION; INTERLEUKIN-6; REOXYGENATION; ACTIVATION; EXPOSURE	To determine the contribution of 180-kDa oxygen-regulated protein (ORP150) to cellular processes underlying adaptation to hypoxia, a cell line stably transfected to overexpress ORP150 antisense RNA was created. In human embryonic kidney (HEK) cells stably overexpressing ORP150 antisense RNA, ORP150 antigen and transcripts were suppressed to low levels in normoxia and hypoxia, whereas wild-type cells showed induction of ORP150 with oxygen deprivation. Inhibition of ORP150 in antisense transfectants was selective, as hypoxia-mediated enhancement of glucose-regulated protein (GRP) 78 and GRP94 was maintained. However, antisense ORP150 transfectants displayed reduced viability when subjected to hypoxia, compared with wildtype and sense-transfected HEK cells. In contrast, diminished levels of ORP150 had no effect on cytotoxicity induced by other stimuli, including oxygen-free radicals and sodium arsenate. Although cellular ATP content was similar in hypoxia, compared with ORP150 antisense transfectants and wild-type HEK cells, suppression of ORP150 expression was associated with accelerated apoptosis, Hypoxia-mediated cell death in antisense HEK transfectants did not cause an increase in caspase activity or in cytoplasmic cytochrome c antigen. A well recognized inducer of apoptosis in HEK cells, staurosporine, caused increased caspase activity and cytoplasmic cytochrome c levels in both wild-type and antisense cells. These data indicate that ORP150 has an important cytoprotective role in hypoxia-induced cellular perturbation and that ORP150-associated inhibition of apoptosis may involve mechanisms distinct from those triggered by other apoptotic stimuli.	Osaka Univ, Sch Med, Ctr Biomed Res, Dept Anat & Neurosci, Suita, Osaka 565, Japan; Osaka Univ, Sch Med, Ctr Biomed Res, Dept Pathol, Suita, Osaka 565, Japan; Osaka Univ, Sch Med, Ctr Biomed Res, Dept Med 1, Suita, Osaka 565, Japan; Osaka Univ, Sch Med, Ctr Biomed Res, Dept Med Genet, Suita, Osaka 565, Japan; HSP Res Inst, Kyoto 610, Japan; Columbia Univ Coll Phys & Surg, Dept Physiol & Cellular Biophys, New York, NY 10032 USA	Osaka University; Osaka University; Osaka University; Osaka University; Columbia University	Ozawa, K (corresponding author), Osaka Univ, Sch Med, Ctr Biomed Res, Dept Anat & Neurosci, 2-2 Yamadaoka, Suita, Osaka 565, Japan.	ozawa@anat2.med.osaka-u.ac.jp						BESSHO R, 1994, BIOCHEM PHARMACOL, V48, P1883, DOI 10.1016/0006-2952(94)90586-X; CasciolaRosen L, 1996, J EXP MED, V183, P1957, DOI 10.1084/jem.183.5.1957; Choi AMK, 1996, AM J RESP CELL MOL, V15, P9, DOI 10.1165/ajrcmb.15.1.8679227; COYLE JT, 1993, SCIENCE, V262, P689, DOI 10.1126/science.7901908; Craven RA, 1996, EMBO J, V15, P2640, DOI 10.1002/j.1460-2075.1996.tb00624.x; Despres P, 1996, J VIROL, V70, P4090; Du YS, 1997, J NEUROCHEM, V69, P1382; Duan HJ, 1996, J BIOL CHEM, V271, P1621, DOI 10.1074/jbc.271.3.1621; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FREI K, 1989, EUR J IMMUNOL, V19, P689, DOI 10.1002/eji.1830190418; Harkness RA, 1997, ACTA PAEDIATR, V86, P1, DOI 10.1111/j.1651-2227.1997.tb08820.x; Harvey NL, 1997, J BIOL CHEM, V272, P13134, DOI 10.1074/jbc.272.20.13134; HEACOCK CS, 1986, INT J RADIAT ONCOL, V12, P1287, DOI 10.1016/0360-3016(86)90155-0; HORI O, 1994, J NEUROCHEM, V62, P1489; Hori O, 1996, J NEUROCHEM, V66, P973; Hu YM, 1998, P NATL ACAD SCI USA, V95, P4386, DOI 10.1073/pnas.95.8.4386; Ikeda J, 1997, BIOCHEM BIOPH RES CO, V230, P94, DOI 10.1006/bbrc.1996.5890; Jacobson MD, 1996, J CELL BIOL, V133, P1041, DOI 10.1083/jcb.133.5.1041; KORSMEYER SJ, 1995, TRENDS GENET, V11, P101, DOI 10.1016/S0168-9525(00)89010-1; Kuwabara K, 1996, J BIOL CHEM, V271, P5025; LEE A S, 1992, Current Opinion in Cell Biology, V4, P267, DOI 10.1016/0955-0674(92)90042-B; LEIST M, 1994, J IMMUNOL, V153, P1778; LI LJ, 1992, J CELL PHYSIOL, V153, P575, DOI 10.1002/jcp.1041530319; LIN HY, 1993, MOL BIOL CELL, V4, P1109, DOI 10.1091/mbc.4.11.1109; LOWRY OH, 1951, J BIOL CHEM, V193, P265; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; OGAWA S, 1990, J CLIN INVEST, V85, P1090, DOI 10.1172/JCI114540; PAHL HL, 1995, EMBO J, V14, P2580, DOI 10.1002/j.1460-2075.1995.tb07256.x; Papa S, 1997, MOL CELL BIOCHEM, V174, P305, DOI 10.1023/A:1006873518427; PECHAN PA, 1992, NEUROREPORT, V3, P469, DOI 10.1097/00001756-199206000-00003; PELHAM HRB, 1986, CELL, V46, P959, DOI 10.1016/0092-8674(86)90693-8; Scaffidi C, 1997, J BIOL CHEM, V272, P26953, DOI 10.1074/jbc.272.43.26953; SHCREENIWAS R, 1991, J CELL PHYSL, V146, P8; SZAFLARSKI J, 1995, STROKE, V26, P1093, DOI 10.1161/01.STR.26.6.1093; Tamatani M, 1998, MOL BRAIN RES, V58, P27, DOI 10.1016/S0169-328X(98)00095-3; Tsukamoto Y, 1998, LAB INVEST, V78, P699; Tsukamoto Y, 1996, J CLIN INVEST, V98, P1930, DOI 10.1172/JCI118994; UEDA H, 1988, J BIOCHEM, V104, P81, DOI 10.1093/oxfordjournals.jbchem.a122427; vanEngeland M, 1997, EXP CELL RES, V235, P421, DOI 10.1006/excr.1997.3738; Villa P, 1997, TRENDS BIOCHEM SCI, V22, P388, DOI 10.1016/S0968-0004(97)01107-9	40	152	160	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	1999	274	10					6397	6404		10.1074/jbc.274.10.6397	http://dx.doi.org/10.1074/jbc.274.10.6397			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172BQ	10037731	hybrid			2022-12-25	WOS:000078902800053
J	Schnappinger, D; Schubert, P; Berens, C; Pfleiderer, K; Hillen, W				Schnappinger, D; Schubert, P; Berens, C; Pfleiderer, K; Hillen, W			Solvent-exposed residues in the Tet repressor (TetR) four-helix bundle contribute to subunit recognition and dimer stability	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTIBIOTIC-RESISTANCE; ESCHERICHIA-COLI; GENE-EXPRESSION; DNA-BINDING; TETRACYCLINE; MUTAGENESIS; SPECIFICITY; COMPLEX; MOTIF; DIMERIZATION	Dimerization specificity of Tet repressor (TetR) can be altered by changes in the core of the four-helix bundle that mediates protein-protein recognition. We demonstrate here that the affinity of subunit interaction depends also on the solvent-exposed residues at positions 128 and 179'-184', which interact across the dimerization surface. TetR(B) and (D), two naturally occurring sequence variants, differ at position 128 with respect to the monomer-monomer distances in the crystal structures and the charge of the amino acids, being glutamate in TetR(B) and arginine in TetR(D), In vivo analysis of chimeric TetR(B/D) variants revealed that the single E128R exchange does not alter the dimerization specificity of TetR(B) to the one of TetR(D), When combined with specificity mutations in (alpha 10, it is, however, able to increase dimerization efficiency of the TetR(B/D) chimera with TetR(D), A loss of contact analysis revealed a positive interaction between Arg-128 and residues located at positions 179'-184' of the second monomer, We constructed a hyperstable TetR(B) variant by replacing residues 128 and 179-184 by the respective TetR(D) sequence. These results establish that in addition to a region in the hydrophobic core residues at the solvent-exposed periphery of the dimerization surface participate in protein-protein recognition in the TetR four-helix bundle.	Univ Erlangen Nurnberg, Inst Mikrobiol Biochem & Genet, Lehrstuhl Mikrobiol, D-91058 Erlangen, Germany	University of Erlangen Nuremberg	Hillen, W (corresponding author), Univ Erlangen Nurnberg, Inst Mikrobiol Biochem & Genet, Lehrstuhl Mikrobiol, Staudtstr 5, D-91058 Erlangen, Germany.	whillen@biologie.uni-erlangen.de						ALTSCHMIED L, 1988, EMBO J, V7, P4011, DOI 10.1002/j.1460-2075.1988.tb03290.x; Backes H, 1997, BIOCHEMISTRY-US, V36, P5311, DOI 10.1021/bi961527k; Berens C, 1997, J BIOL CHEM, V272, P6936, DOI 10.1074/jbc.272.11.6936; BERENS C, 1995, MOL MICROBIOL, V18, P437, DOI 10.1111/j.1365-2958.1995.mmi_18030437.x; CLACKSON T, 1995, SCIENCE, V267, P383, DOI 10.1126/science.7529940; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; Davies DR, 1996, P NATL ACAD SCI USA, V93, P7, DOI 10.1073/pnas.93.1.7; Ettner N, 1996, J CHROMATOGR A, V742, P95, DOI 10.1016/0021-9673(96)00232-4; Gatz C, 1997, ANNU REV PLANT PHYS, V48, P89, DOI 10.1146/annurev.arplant.48.1.89; GREENBLATT J, 1992, TRANSCRIPTIONAL REGU, P203; HILLEN W, 1994, ANNU REV MICROBIOL, V48, P345, DOI 10.1146/annurev.mi.48.100194.002021; HINRICHS W, 1994, SCIENCE, V264, P418, DOI 10.1126/science.8153629; KISKER C, 1995, J MOL BIOL, V247, P260, DOI 10.1006/jmbi.1994.0138; Kohn WD, 1997, J BIOL CHEM, V272, P2583, DOI 10.1074/jbc.272.5.2583; LANDT O, 1990, GENE, V96, P125, DOI 10.1016/0378-1119(90)90351-Q; LIN M, 1995, IMMUNOTECHNOLOGY, V1, P151, DOI 10.1016/1380-2933(95)00016-X; Lupas A, 1996, TRENDS BIOCHEM SCI, V21, P375, DOI 10.1016/0968-0004(96)10052-9; Miller JH., 1992, SHORT COURSE BACTERI, P72; NICOLLS A, 1991, PROTEINS, V11, P281; NOSSAL NG, 1992, FASEB J, V6, P871, DOI 10.1096/fasebj.6.3.1310946; OSHEA EK, 1992, CELL, V68, P699, DOI 10.1016/0092-8674(92)90145-3; Ptashne M, 1997, NATURE, V386, P569, DOI 10.1038/386569a0; Saez E, 1997, CURR OPIN BIOTECH, V8, P608, DOI 10.1016/S0958-1669(97)80037-7; SANCAR A, 1994, SCIENCE, V266, P1954, DOI 10.1126/science.7801120; Schnappinger D, 1998, EMBO J, V17, P535, DOI 10.1093/emboj/17.2.535; SCHREIBER G, 1995, J MOL BIOL, V248, P478, DOI 10.1006/jmbi.1995.0235; VINSON CR, 1993, GENE DEV, V7, P1047, DOI 10.1101/gad.7.6.1047; Wells JA, 1996, P NATL ACAD SCI USA, V93, P1, DOI 10.1073/pnas.93.1.1; WISSMANN A, 1991, GENETICS, V128, P225; Zeng XG, 1997, PROTEIN SCI, V6, P2218; ZHOU SY, 1995, TRENDS BIOCHEM SCI, V20, P470	31	12	13	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1999	274	10					6405	6410		10.1074/jbc.274.10.6405	http://dx.doi.org/10.1074/jbc.274.10.6405			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172BQ	10037732	hybrid			2022-12-25	WOS:000078902800054
J	Braverman, LE; Quilliam, LA				Braverman, LE; Quilliam, LA			Identification of Grb4/Nck beta, a Src homology 2 and 3 domain-containing adapter protein having similar binding and biological properties to Nck	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; ALDRICH SYNDROME PROTEIN; C-CBL PROTOONCOGENE; EXCHANGE FACTOR SOS; SH2 DOMAIN; RAS TRANSFORMATION; SIGNALING PATHWAYS; TYROSINE KINASE; FACTOR RECEPTOR; K-RAS	Adapter proteins made up of Src homology (SH) domains mediate multiple cellular signaling events initiated by receptor protein tyrosine kinases. Here we report that Grb4 is an adapter protein closely related to but distinct from Nck that is made up of three SH3 domains and one SH2 domain. Northern analysis indicated that both genes are expressed in multiple tissues. Both Nck and Grb4 proteins could associate with receptor tyrosine kinases and the SH3-binding proteins PAH, Sos1, and PRK2, and they synergized with v-Abl and Sos to induce gene expression via the transcription factor Elk-1. Although neither protein was transforming on its own, both Nck and Grb4 cooperated with v-Abl to transform NIR 3T3 cells and influenced the morphology and anchorage-dependent growth of wild type Ras-transformed cells. Nck and Grb4 therefore appear to be functionally redundant.	Indiana Univ, Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Walther Oncol Ctr, Indianapolis, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute	Quilliam, LA (corresponding author), Indiana Univ, Sch Med, Dept Biochem & Mol Biol, 635 Barnhill Dr,MS-4053, Indianapolis, IN 46202 USA.		Quilliam, Lawrence/B-6447-2015; Quilliam, Lawrence/Q-4987-2019	Braverman, Lewis/0000-0003-1263-1099	NCI NIH HHS [CA63139] Funding Source: Medline; NIDDK NIH HHS [P60 DK20542-16] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA063139] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P60DK020542] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; BAGRODIA S, 1995, J BIOL CHEM, V270, P22731, DOI 10.1074/jbc.270.39.22731; Bokoch GM, 1996, J BIOL CHEM, V271, P25746, DOI 10.1074/jbc.271.42.25746; Byrne JL, 1996, ONCOGENE, V13, P2055; CEPKO CL, 1984, CELL, V37, P1053, DOI 10.1016/0092-8674(84)90440-9; Chen M, 1998, J BIOL CHEM, V273, P25171, DOI 10.1074/jbc.273.39.25171; CHOU MM, 1992, MOL CELL BIOL, V12, P5834, DOI 10.1128/MCB.12.12.5834; CHOU MM, 1995, J BIOL CHEM, V270, P7359, DOI 10.1074/jbc.270.13.7359; CLARK GJ, 1995, METHOD ENZYMOL, V255, P395; Clemens JC, 1996, J BIOL CHEM, V271, P17002, DOI 10.1074/jbc.271.29.17002; EGAN SE, 1993, NATURE, V365, P781, DOI 10.1038/365781a0; FATH I, 1994, SCIENCE, V264, P971, DOI 10.1126/science.8178156; Feng GS, 1996, J BIOL CHEM, V271, P12129, DOI 10.1074/jbc.271.21.12129; Frost JA, 1997, EMBO J, V16, P6426, DOI 10.1093/emboj/16.21.6426; GALISTEO ML, 1995, J BIOL CHEM, V270, P20242, DOI 10.1074/jbc.270.35.20242; Garrity PA, 1996, CELL, V85, P639, DOI 10.1016/S0092-8674(00)81231-3; GIBBS JB, 1990, J BIOL CHEM, V265, P20437; GUO DQ, 1995, J BIOL CHEM, V270, P6729, DOI 10.1074/jbc.270.12.6729; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HAUSER CA, 1995, METHOD ENZYMOL, V255, P412; Holland SJ, 1997, EMBO J, V16, P3877, DOI 10.1093/emboj/16.13.3877; HU QJ, 1995, MOL CELL BIOL, V15, P1169; HUEBNER K, 1994, GENOMICS, V22, P281, DOI 10.1006/geno.1994.1385; Johnson L, 1997, GENE DEV, V11, P2468, DOI 10.1101/gad.11.19.2468; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; Kochhar KS, 1996, CANCER LETT, V104, P163, DOI 10.1016/0304-3835(96)04244-9; Koera K, 1997, ONCOGENE, V15, P1151, DOI 10.1038/sj.onc.1201284; Lawe DC, 1997, ONCOGENE, V14, P223, DOI 10.1038/sj.onc.1200821; LEE CH, 1993, P NATL ACAD SCI USA, V90, P11713, DOI 10.1073/pnas.90.24.11713; LEHMANN JM, 1990, NUCLEIC ACIDS RES, V18, P1048, DOI 10.1093/nar/18.4.1048; LI W, 1992, MOL CELL BIOL, V12, P5824, DOI 10.1128/MCB.12.12.5824; Lim L, 1996, EUR J BIOCHEM, V242, P171, DOI 10.1111/j.1432-1033.1996.0171r.x; Lu WG, 1997, CURR BIOL, V7, P85, DOI 10.1016/S0960-9822(06)00052-2; Lussier G, 1997, J BIOL CHEM, V272, P2688, DOI 10.1074/jbc.272.5.2688; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MARGOLIS B, 1992, P NATL ACAD SCI USA, V89, P8894, DOI 10.1073/pnas.89.19.8894; Matsuda M, 1996, CELL SIGNAL, V8, P335, DOI 10.1016/0898-6568(96)00067-8; MEISENHELDER J, 1992, MOL CELL BIOL, V12, P5843, DOI 10.1128/MCB.12.12.5843; NISHIMURA R, 1993, MOL CELL BIOL, V13, P6889, DOI 10.1128/MCB.13.11.6889; PARK D, 1992, MOL CELL BIOL, V12, P5816, DOI 10.1128/MCB.12.12.5816; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/S0092-8674(05)80094-7; Quilliam LA, 1996, J BIOL CHEM, V271, P28772, DOI 10.1074/jbc.271.46.28772; REN RB, 1994, GENE DEV, V8, P783, DOI 10.1101/gad.8.7.783; RENSHAW MW, 1992, EMBO J, V11, P3941, DOI 10.1002/j.1460-2075.1992.tb05488.x; RIVEROLEZCANO OM, 1995, MOL CELL BIOL, V15, P5725; RIVEROLEZCANO OM, 1994, J BIOL CHEM, V269, P17363; SCHLAEFER M, 1993, SPRACHWISSENSCHAFT, V18, P213; Schlaepfer DD, 1997, MOL CELL BIOL, V17, P1702, DOI 10.1128/MCB.17.3.1702; Shi ZQ, 1998, J BIOL CHEM, V273, P4904, DOI 10.1074/jbc.273.9.4904; STEIN D, 1994, EMBO J, V13, P1331, DOI 10.1002/j.1460-2075.1994.tb06386.x; Stein E, 1998, J BIOL CHEM, V273, P1303, DOI 10.1074/jbc.273.3.1303; Su YC, 1997, EMBO J, V16, P1279, DOI 10.1093/emboj/16.6.1279; SUEN KL, 1993, MOL CELL BIOL, V13, P5500, DOI 10.1128/MCB.13.9.5500; Symons M, 1996, CELL, V84, P723, DOI 10.1016/S0092-8674(00)81050-8; Tanaka M, 1997, P NATL ACAD SCI USA, V94, P4493, DOI 10.1073/pnas.94.9.4493; TANAKA M, 1995, MOL CELL BIOL, V15, P6829; Tang JP, 1997, ONCOGENE, V15, P1823, DOI 10.1038/sj.onc.1201351; Tu YZ, 1998, MOL BIOL CELL, V9, P3367, DOI 10.1091/mbc.9.12.3367	59	65	73	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 26	1999	274	9					5542	5549		10.1074/jbc.274.9.5542	http://dx.doi.org/10.1074/jbc.274.9.5542			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	170KG	10026169	hybrid			2022-12-25	WOS:000078804400040
J	Grand, RJA; Parkhill, J; Szestak, T; Rookes, SM; Roberts, S; Gallimore, PH				Grand, RJA; Parkhill, J; Szestak, T; Rookes, SM; Roberts, S; Gallimore, PH			Definition of a major p53 binding site on Ad2E1B58K protein and a possible nuclear localization signal on the Ad12E1B54K protein	ONCOGENE			English	Article						p53; nuclear localization signal; Ad2E1B; Ad12E1B; p53-binding proteins	REGION-4 34-KILODALTON PROTEIN; ADENOVIRUS E1A PROTEINS; WILD-TYPE P53; TRANSFORMED-CELLS; 55-KILODALTON PROTEIN; MESSENGER-RNA; GENE-PRODUCTS; TUMOR-ANTIGEN; CELLULAR P53; RAT-CELLS	Previous studies have established that adenovirus 2/5 early region 1B (Ad E1B) 58K protein binds p53 strongly and co-localizes with it to cytoplasmic dense bodies whilst the homologous Ad12E1B54K protein binds only weakly and co-localizes primarily to the nucleus in Ad12E1 transformed cells. We have used these properties of the E1B proteins from different viral serotypes to map the p53 binding site on the Ad2/5 protein. A set of chimaeric genes was constructed containing different proportions of the Ad12 and Ad2E1B DNA, These, together with Ad12E1A and E1B19K DNA, were transfected into baby rat kidney cells and transformed lines isolated, From an examination of the properties of these Ad12/Ad2E1B fusion proteins in co-immunoprecipitation and subcellular localization experiments it has been concluded that the p53 binding site on Ad2E1B58K protein lies between amino acids 216 and 235 and that the homologous region on Ad12E1B54K protein also binds p53. In addition, a unique nuclear localization signal is located on Ad12E1B54K between residues 228 and 239, We suggest that primary structure differences in these regions of the Ad2 and Ad12E1B proteins are responsible for the different subcellular localizations in AdE1 transformants.	Univ Birmingham, CRC, Inst Canc Studies, Birmingham B15 2TA, W Midlands, England	University of Birmingham	Grand, RJA (corresponding author), Univ Birmingham, CRC, Inst Canc Studies, Birmingham B15 2TA, W Midlands, England.		Parkhill, Julian/G-4703-2011; Roberts, Sally/N-6143-2014	Parkhill, Julian/0000-0002-7069-5958; Roberts, Sally/0000-0003-4653-9442				BABISS LE, 1984, J VIROL, V50, P202, DOI 10.1128/JVI.50.1.202-212.1984; BABISS LE, 1985, MOL CELL BIOL, V5, P2552, DOI 10.1128/MCB.5.10.2552; BAYLEY ST, 1994, INT J ONCOL, V5, P425; BERNARDS R, 1982, VIROLOGY, V120, P422, DOI 10.1016/0042-6822(82)90042-3; BERNARDS R, 1984, BIOCHIM BIOPHYS ACTA, V783, P187, DOI 10.1016/0167-4781(84)90029-0; BOULANGER PA, 1991, BIOCHEM J, V275, P281, DOI 10.1042/bj2750281; BOYD JM, 1995, ONCOGENE, V11, P1921; BREIDING DE, 1988, VIROLOGY, V164, P390, DOI 10.1016/0042-6822(88)90552-1; BYRD PJ, 1988, VIROLOGY, V163, P156; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; Dobbelstein M, 1997, EMBO J, V16, P4276, DOI 10.1093/emboj/16.14.4276; Gallimore PH, 1997, J VIROL, V71, P6629, DOI 10.1128/JVI.71.9.6629-6640.1997; GALLIMORE PH, 1985, CANCER RES, V45, P2670; GALLIMORE PH, 1985, VIRUSES CANCER, P125; Goodrum FD, 1996, J VIROL, V70, P6323, DOI 10.1128/JVI.70.9.6323-6335.1996; GRAND RJA, 1994, VIROLOGY, V203, P229, DOI 10.1006/viro.1994.1480; Grand RJA, 1996, VIROLOGY, V218, P23, DOI 10.1006/viro.1996.0162; GRAND RJA, 1993, VIROLOGY, V193, P579, DOI 10.1006/viro.1993.1166; HALBERT DN, 1985, J VIROL, V56, P250, DOI 10.1128/JVI.56.1.250-257.1985; Han JH, 1996, GENE DEV, V10, P461, DOI 10.1101/gad.10.4.461; HENDERSON S, 1993, P NATL ACAD SCI USA, V90, P8479, DOI 10.1073/pnas.90.18.8479; HOUWELING A, 1980, VIROLOGY, V105, P537, DOI 10.1016/0042-6822(80)90054-9; KAO CC, 1990, VIROLOGY, V179, P806, DOI 10.1016/0042-6822(90)90148-K; LEPPARD KN, 1989, EMBO J, V8, P2329, DOI 10.1002/j.1460-2075.1989.tb08360.x; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; MAK I, 1988, VIROLOGY, V163, P201, DOI 10.1016/0042-6822(88)90248-6; MERRICK RM, 1991, J GEN VIROL, V72, P955, DOI 10.1099/0022-1317-72-4-955; MONTELL C, 1984, CELL, V36, P951, DOI 10.1016/0092-8674(84)90045-X; MORAN E, 1994, SEMIN VIROL, V5, P327, DOI 10.1006/smvy.1994.1037; ORNELLES DA, 1991, J VIROL, V65, P424, DOI 10.1128/JVI.65.1.424-429.1991; PARASKEVA C, 1982, J GEN VIROL, V58, P73, DOI 10.1099/0022-1317-58-1-73; PILDER S, 1986, MOL CELL BIOL, V6, P470, DOI 10.1128/MCB.6.2.470; Prochiantz A, 1996, CURR OPIN NEUROBIOL, V6, P629, DOI 10.1016/S0959-4388(96)80095-X; RAO L, 1992, P NATL ACAD SCI USA, V89, P7742, DOI 10.1073/pnas.89.16.7742; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SARNOW P, 1984, J VIROL, V49, P592; SPRENGEL J, 1995, CURR TOP MICROBIOL, V199, P11; VANDENELSEN P, 1983, VIROLOGY, V131, P242, DOI 10.1016/0042-6822(83)90549-4; YEW PR, 1994, GENE DEV, V8, P190, DOI 10.1101/gad.8.2.190; YEW PR, 1992, NATURE, V357, P82, DOI 10.1038/357082a0; ZAJDEL MEB, 1988, ONCOGENE, V2, P579; ZANTEMA A, 1985, VIROLOGY, V142, P44, DOI 10.1016/0042-6822(85)90421-0; ZANTEMA A, 1985, MOL CELL BIOL, V5, P3084, DOI 10.1128/MCB.5.11.3084	43	25	25	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 28	1999	18	4					955	965		10.1038/sj.onc.1202358	http://dx.doi.org/10.1038/sj.onc.1202358			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	165FT	10023671				2022-12-25	WOS:000078510600012
J	Ichimiya, S; Nimura, Y; Kageyama, H; Takada, N; Sunahara, M; Shishikura, T; Nakamura, Y; Sakiyama, S; Seki, N; Ohira, M; Kaneko, Y; McKeon, F; Caput, D; Nakagawara, A				Ichimiya, S; Nimura, Y; Kageyama, H; Takada, N; Sunahara, M; Shishikura, T; Nakamura, Y; Sakiyama, S; Seki, N; Ohira, M; Kaneko, Y; McKeon, F; Caput, D; Nakagawara, A			p73 at chromosome 1p36.3 is lost in advanced stage neuroblastoma but its mutation is infrequent	ONCOGENE			English	Article						p73; neuroblastoma; loss of heterozygosity; 1p36; mutation; p53	N-MYC AMPLIFICATION; P53 GENE-MUTATIONS; SHORT ARM; EXPRESSION; DELETION; PROTEIN; REGION; INSTABILITY; TUMORS; LOCI	p73, a novel p53 family member, is a recently identified candidate neuroblastoma (NBL) suppressor gene mapped at chromosome 1p36.33 and was found to inhibit growth and induce apoptosis in cell lines. To test the hypothesis that p73 is a NBL suppressor gene, we analysed the p73 gene in primary human NBLs, Loss of heterozygosity (LOH) for p73 was observed in 19% (28/151) of informative cases which included 92 mass-screening (MS) tumors. The high frequency of p73 LOH was significantly associated with sporadic NBLs (9% vs 34%, P < 0.001), N-myc amplification (10% vs 71%, P < 0.001), and advanced stage (14% vs 28%, P < 0.05), Both p73 alpha and p73 beta transcripts were detectable in only 46 of 134 (34%) NBLs at low levels by RT-PCR methods, while they were easily detectable in most breast cancers and colorectal cancers under the same conditions. They found no correlation between p73 LOH and its expression levels (P > 0.1), We found two mutations out of 140 NBLs, one somatic and one germline, which result in amino acid substitutions in the C-terminal region of p73 which may affect transactivation functions, though, in the same tumor samples, no mutation of the p53 gene was observed as reported previously. These results suggest that allelic loss of the p73 gene may be a later event in NBL tumorigenesis. However, p73 is infrequently mutated in primary NBLs and may hardly function as a tumor suppressor in a classic Knudson's manner.	Chiba Canc Ctr, Res Inst, Div Biochem, Chiba 2608717, Japan; Kazusa DNA Res Inst, Lab Gene Struct 1, Chiba 2920812, Japan; Saitama Canc Ctr Hosp, Dept Canc Chemotherapy, Ina, Saitama 362, Japan; Sanofi Rech, F-31676 Labege, France; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA	Chiba Cancer Center; Kazusa DNA Research Institute; Sanofi-Aventis; Sanofi France; Harvard University; Harvard Medical School	Nakagawara, A (corresponding author), Chiba Canc Ctr, Res Inst, Div Biochem, 666-2 Nitona, Chiba 2608717, Japan.							AMLER LC, 1995, ONCOGENE, V10, P1095; BRODEUR GM, 1993, J CLIN ONCOL, V11, P1466, DOI 10.1200/JCO.1993.11.8.1466; CARON H, 1995, HUM MOL GENET, V4, P535, DOI 10.1093/hmg/4.4.535; CHENG JM, 1993, NAT GENET, V4, P191, DOI 10.1038/ng0693-191; CHRISTIANSEN H, 1992, GENE CHROMOSOME CANC, V5, P141, DOI 10.1002/gcc.2870050208; FONG CT, 1992, CANCER RES, V52, P1780; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Kobayashi H, 1996, BRIT J HAEMATOL, V94, P105, DOI 10.1046/j.1365-2141.1996.d01-1762.x; KOMURO H, 1993, CANCER RES, V53, P5284; Mai M, 1998, CANCER RES, V58, P2347; MARTINSSON T, 1995, CANCER RES, V55, P5681; MASHIYAMA S, 1991, ONCOGENE, V6, P1313; MIHARA M, 1998, IN PRESS BR J CANC; MOLL UM, 1995, P NATL ACAD SCI USA, V92, P4407, DOI 10.1073/pnas.92.10.4407; NAKAGAWARA A, 1992, CANCER RES, V52, P1364; NAKAGAWARA A, 1994, MOL CELL BIOL, V14, P759, DOI 10.1128/MCB.14.1.759; NAKAGAWARA A, 1993, NEW ENGL J MED, V328, P847, DOI 10.1056/NEJM199303253281205; NIMURA Y, 1998, IN PRESS INT J CANC; Nomoto S, 1998, CANCER RES, V58, P1380; Ohira M, 1996, GENOMICS, V33, P65, DOI 10.1006/geno.1996.0160; Ohtsu K, 1997, CLIN CANCER RES, V3, P1221; Ostermeyer AG, 1996, P NATL ACAD SCI USA, V93, P15190, DOI 10.1073/pnas.93.26.15190; SCHLEIERMACHER G, 1994, GENE CHROMOSOME CANC, V10, P275, DOI 10.1002/gcc.2870100409; Schwab M, 1996, GENE CHROMOSOME CANC, V16, P211, DOI 10.1002/(SICI)1098-2264(199608)16:4<211::AID-GCC1>3.0.CO;2-0; SHEPHERD NS, 1994, P NATL ACAD SCI USA, V91, P2629, DOI 10.1073/pnas.91.7.2629; Sunahara M, 1998, INT J ONCOL, V13, P319; Takahashi H, 1998, CANCER RES, V58, P2076; TAKEDA O, 1994, GENE CHROMOSOME CANC, V10, P30, DOI 10.1002/gcc.2870100106; VOGAN K, 1993, CANCER RES, V53, P5269; WHITE PS, 1995, P NATL ACAD SCI USA, V92, P5520, DOI 10.1073/pnas.92.12.5520	31	120	127	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 28	1999	18	4					1061	1066		10.1038/sj.onc.1202390	http://dx.doi.org/10.1038/sj.onc.1202390			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	165FT	10023682				2022-12-25	WOS:000078510600023
J	Zhang, FX; Kirschning, CJ; Mancinelli, R; Xu, XP; Jin, YP; Faure, E; Mantovani, A; Rothe, M; Muzio, M; Arditi, M				Zhang, FX; Kirschning, CJ; Mancinelli, R; Xu, XP; Jin, YP; Faure, E; Mantovani, A; Rothe, M; Muzio, M; Arditi, M			Bacterial lipopolysaccharide activates nuclear factor-kappa B through interleukin-1 signaling mediators in cultured human dermal endothelial cells and mononuclear phagocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE PHOSPHORYLATION; DROSOPHILA TOLL PROTEIN; SOLUBLE CD14; KINASE; ENDOTOXIN; MACROPHAGES; REQUIRES; PATHWAY; IRAK	Bacterial lipopolysaccharide (LPS)-mediated immune responses, including activation of monocytes, macrophages, and endothelial cells, play an important role in the pathogenesis of Gram-negative bacteria-induced sepsis syndrome. Activation of NF-kappa B is thought to be required for cytokine release from LPS-responsive cells, a critical step for endotoxic effects. Here we investigated the role and involvement of interleukin-l (IL-1) and tumor necrosis factor (TNF-alpha) signal transducer molecules in LPS signaling in human dermal microvessel endothelial cells (HDMEC) and THP-1 monocytic cells. LPS stimulation of HDMEC and THP-1 cells initiated an IL-l receptor-like NF-kappa B signaling cascade, In transient cotransfection experiments, dominant negative mutants of the IL-1 signaling pathway, including MyD88, IRAK, IRAK2, and TRAF6 inhibited both IL-1- and LPS-induced NF-kappa B-luciferase activity. LPS-induced NF-kappa B activation was not inhibited by a dominant negative mutant of TRAF2 that is involved in TNF signaling. LPS-induced activation of NF-kappa B-responsive reporter gene was not inhibited by IL-1 receptor antagonist. TLR2 and TLR4 were expressed on the cell surface of HDMEC and THP-1 cells. These findings suggest that a signal transduction molecule in the LPS receptor complex may belong to the IL-1 receptor/toll-like receptor (TLR) super family, and the LPS signaling cascade uses an analogous molecular framework for signaling as IL-I in mononuclear phagocytes and endothelial cells.	Steven Spielberg Pediat Res Ctr, Div Pediat Infect Dis, Ahmanson Dept Pediat, Los Angeles, CA 90048 USA; Cedars Sinai Med Ctr, Div Cardiol, Los Angeles, CA 90048 USA; Cedars Sinai Med Ctr, Burns & Allen Res Inst, Los Angeles, CA 90048 USA; Univ Calif Los Angeles, Sch Med, Los Angeles, CA 90048 USA; Tularik Inc, San Francisco, CA USA; Mario Negri Inst Pharmacol Res, Dept Immunol & Cell Biol, I-20157 Milan, Italy	Cedars Sinai Medical Center; Cedars Sinai Medical Center; Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Istituto di Ricerche Farmacologiche Mario Negri IRCCS	Arditi, M (corresponding author), Cedars Sinai Med Ctr, Dept Pediat, 8700 Beverly Blvd,Rm 4310, Los Angeles, CA 90048 USA.	moshe.arditi@cshs.org	Mantovani, Alberto/HCI-7449-2022; Muzio, Marta/J-9360-2018	Mantovani, Alberto/0000-0001-5578-236X; Muzio, Marta/0000-0002-7761-759X	NIAID NIH HHS [AI40275] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI040275] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARDITI M, 1995, J IMMUNOL, V155, P3994; ARDITI M, 1993, INFECT IMMUN, V61, P3149, DOI 10.1128/IAI.61.8.3149-3156.1993; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Baeuerle PA, 1998, CURR BIOL, V8, pR19, DOI 10.1016/S0960-9822(98)70010-7; Belvin MP, 1996, ANNU REV CELL DEV BI, V12, P393, DOI 10.1146/annurev.cellbio.12.1.393; Burns K, 1998, J BIOL CHEM, V273, P12203, DOI 10.1074/jbc.273.20.12203; CAO Z, 1996, SCIENCE, V383, P443; Chaudhary PM, 1998, BLOOD, V91, P4020, DOI 10.1182/blood.V91.11.4020.411a44_4020_4027; CORDLE SR, 1993, J BIOL CHEM, V268, P11803; CROSTON GE, 1995, J BIOL CHEM, V270, P16514, DOI 10.1074/jbc.270.28.16514; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; FREY EA, 1992, J EXP MED, V176, P1665, DOI 10.1084/jem.176.6.1665; Haeffner A, 1997, J IMMUNOL, V158, P1310; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HEGUY A, 1992, J BIOL CHEM, V267, P2605; Huang JN, 1997, P NATL ACAD SCI USA, V94, P12829, DOI 10.1073/pnas.94.24.12829; Kirschning CJ, 1998, J EXP MED, V188, P2091, DOI 10.1084/jem.188.11.2091; Kuhns DB, 1997, J IMMUNOL, V158, P3959; Medzhitov R, 1997, NATURE, V388, P394, DOI 10.1038/41131; Muzio M, 1998, J EXP MED, V187, P2097, DOI 10.1084/jem.187.12.2097; Muzio M, 1997, SCIENCE, V278, P1612, DOI 10.1126/science.278.5343.1612; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; PUGIN J, 1993, P NATL ACAD SCI USA, V90, P2744, DOI 10.1073/pnas.90.7.2744; READ MA, 1993, P NATL ACAD SCI USA, V90, P9887, DOI 10.1073/pnas.90.21.9887; REIMANN T, 1994, J IMMUNOL, V153, P5740; RIETSCHEL ET, 1996, CURR TOP MICROBIOL I, V216, P40; Rock FL, 1998, P NATL ACAD SCI USA, V95, P588, DOI 10.1073/pnas.95.2.588; ROTHE M, 1995, SCIENCE, V269, P1424, DOI 10.1126/science.7544915; Scheidereit C, 1998, NATURE, V395, P225, DOI 10.1038/26121; Schumann RR, 1996, BLOOD, V87, P2805, DOI 10.1182/blood.V87.7.2805.bloodjournal8772805; Song HY, 1997, P NATL ACAD SCI USA, V94, P9792, DOI 10.1073/pnas.94.18.9792; Stancovski I, 1997, CELL, V91, P299, DOI 10.1016/S0092-8674(00)80413-4; Takeuchi M, 1996, J BIOL CHEM, V271, P19935, DOI 10.1074/jbc.271.33.19935; ULEVITCH RJ, 1994, CURR OPIN IMMUNOL, V6, P125, DOI 10.1016/0952-7915(94)90043-4; WEINSTEIN SL, 1992, J BIOL CHEM, V267, P14955; WEINSTEIN SL, 1991, P NATL ACAD SCI USA, V88, P4148, DOI 10.1073/pnas.88.10.4148; Wenzel RP, 1996, CLIN INFECT DIS, V22, P407, DOI 10.1093/clinids/22.3.407; Wesche H, 1997, IMMUNITY, V7, P837, DOI 10.1016/S1074-7613(00)80402-1; Yang RB, 1998, NATURE, V395, P284, DOI 10.1038/26239	39	529	552	2	44	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	1999	274	12					7611	7614		10.1074/jbc.274.12.7611	http://dx.doi.org/10.1074/jbc.274.12.7611			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	178LU	10075645	hybrid			2022-12-25	WOS:000079268100004
J	Brunati, AM; Donella-Deana, A; James, P; Quadroni, M; Contri, A; Marin, O; Pinna, LA				Brunati, AM; Donella-Deana, A; James, P; Quadroni, M; Contri, A; Marin, O; Pinna, LA			Molecular features underlying the sequential phosphorylation of HS1 protein and its association with c-Fgr protein-tyrosine kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEMATOPOIETIC-LINEAGE; SRC FAMILY; MEDIATED APOPTOSIS; LYMPHOMA-CELLS; SH2 DOMAINS; TPK-IIB; RECEPTOR; SUBSTRATE; SYK; IDENTIFICATION	The hematopoietic lineage cell-specific protein HS1 was shown to undergo a process of sequential phosphorylation both in vitro and in vitro, which is synergistically mediated by Syk and Src family protein-tyrosine kinases and essential for B cell antigen receptor-mediated apoptosis, We have now identified tyrosine 222 as the HS1 residue phosphorylated by the Src family protein kinases c-Fgr and Lyn, and we show that a truncated form of HS1 (HS1-208-401) lacking the N-terminal putative DNA binding region and the C-terminal Src homology 3 (SH3) domain is still able to undergo all the steps of sequential phosphorylation as efficiently as full-length HS1. We also show that a stable association of phospho-HS1 with c-Fgr through its SH2 domain requires previous autophosphorylation of the kinase and is prevented by subsequent phosphorylation of Tyr-222. Kinetic studies with HS1 and its truncated forms previously phosphorylated by Syk and with a peptide substrate reproducing the sequence around tyrosine 222 support the view that efficient phosphorylation of HS1 by Src family protein kinases entirely relies on TyrP SH2 domain interaction with negligible, if any, contribution of local specificity determinants. Our data indicate that the proline-rich region of HS1 bordered by tyrosyl residues affected by Syk and Src family kinases represents a functional domain designed to undergo a process of sequential phosphorylation.	Univ Padua, Dipartimento Chim Biol, CNR, Ctr Studio Biomembrane, I-35121 Padua, Italy; Univ Padua, Ctr Ric Interdipartimentale Biotechnol Innovat, I-35121 Padua, Italy; Swiss Fed Inst Technol Zentrum, Prot Chem Lab, CH-8090 Zurich, Switzerland; Univ British Columbia, Biomed Res Ctr, Vancouver, BC V6T 1Z3, Canada	Consiglio Nazionale delle Ricerche (CNR); University of Padua; University of Padua; Swiss Federal Institutes of Technology Domain; ETH Zurich; University of British Columbia	Pinna, LA (corresponding author), Univ Padua, Dipartimento Chim Biol, CNR, Ctr Studio Biomembrane, Via Colombo 3, I-35121 Padua, Italy.		Brunati, Anna Maria/I-8136-2018	Brunati, Anna Maria/0000-0002-3481-9503; Quadroni, Manfredo/0000-0002-2720-4084				BENHAMOU LE, 1994, EUR J IMMUNOL, V24, P1993, DOI 10.1002/eji.1830240909; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P111; Brunati AM, 1998, BIOCHEM BIOPH RES CO, V243, P700, DOI 10.1006/bbrc.1998.8153; Brunati AM, 1996, EUR J BIOCHEM, V240, P400, DOI 10.1111/j.1432-1033.1996.0400h.x; BRUNATI AM, 1995, EUR J BIOCHEM, V229, P164, DOI 10.1111/j.1432-1033.1995.0164l.x; BRUNATI AM, 1995, FEBS LETT, V367, P149, DOI 10.1016/0014-5793(95)00555-N; BRUNATI AM, 1993, EUR J BIOCHEM, V216, P323, DOI 10.1111/j.1432-1033.1993.tb18149.x; Chu DH, 1996, EMBO J, V15, P6251, DOI 10.1002/j.1460-2075.1996.tb01015.x; DonellaDeana A, 1996, EUR J BIOCHEM, V235, P18, DOI 10.1111/j.1432-1033.1996.00018.x; FUKUDA T, 1995, P NATL ACAD SCI USA, V92, P7302, DOI 10.1073/pnas.92.16.7302; HATA D, 1993, IMMUNOL LETT, V40, P65; He H, 1998, MOL CELL BIOL, V18, P3829, DOI 10.1128/MCB.18.7.3829; KITAMURA D, 1989, NUCLEIC ACIDS RES, V17, P9367; Kurosaki T, 1997, CURR OPIN IMMUNOL, V9, P309, DOI 10.1016/S0952-7915(97)80075-1; Marin O, 1997, BIOCHEMISTRY-US, V36, P7192, DOI 10.1021/bi962885q; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; ROWLEY RB, 1995, J BIOL CHEM, V270, P11590, DOI 10.1074/jbc.270.19.11590; Ruzzene M, 1997, EUR J BIOCHEM, V246, P433, DOI 10.1111/j.1432-1033.1997.t01-1-00433.x; Ruzzene M, 1996, BIOCHEMISTRY-US, V35, P5327, DOI 10.1021/bi9528614; SHIUE L, 1995, J BIOL CHEM, V270, P10498, DOI 10.1074/jbc.270.18.10498; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; Songyang Zhou, 1995, Trends in Biochemical Sciences, V20, P470, DOI 10.1016/S0968-0004(00)89103-3; Suzuki Y, 1997, J IMMUNOL, V158, P2736; TAKEMOTO Y, 1995, EMBO J, V14, P3403, DOI 10.1002/j.1460-2075.1995.tb07346.x; TANIUCHI I, 1995, EMBO J, V14, P3664, DOI 10.1002/j.1460-2075.1995.tb00036.x; WENG ZG, 1994, MOL CELL BIOL, V14, P4509, DOI 10.1128/MCB.14.7.4509; Williams S, 1997, EUR J BIOCHEM, V245, P84, DOI 10.1111/j.1432-1033.1997.00084.x; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; YAMANASHI Y, 1993, P NATL ACAD SCI USA, V90, P3631, DOI 10.1073/pnas.90.8.3631; Yamanashi Y, 1997, J EXP MED, V185, P1387, DOI 10.1084/jem.185.7.1387	31	39	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 12	1999	274	11					7557	7564		10.1074/jbc.274.11.7557	http://dx.doi.org/10.1074/jbc.274.11.7557			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	175DV	10066823	hybrid			2022-12-25	WOS:000079078400095
J	Littman, SJ; Fang, WH; Modrich, P				Littman, SJ; Fang, WH; Modrich, P			Repair of large insertion/deletion heterologies in human nuclear extracts is directed by a 5 ' single-strand break and is independent of the mismatch repair system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HETERODUPLEX DNA-MOLECULES; ESCHERICHIA-COLI; MAMMALIAN-CELLS; TUMOR-CELLS; LOOPS; REPLICATION; SEQUENCES; CANCER; HETERODIMER; SPECIFICITY	The repair of 12-, 27-, 62-, and 216-nucleotide unpaired insertion/deletion heterologies has been demonstrated in nuclear extracts of human cells. When present in covalently closed circular heteroduplexes or heteroduplexes containing a single-strand break 3' to the heterology, such structures are subject to a low level repair reaction that occurs with little strand bias. However, the presence of a single-strand break 5' to the insertion/deletion heterology greatly increases the efficiency of rectification and directs repair to the incised DNA strand. Because nick direction of repair is independent of the strand in which a particular heterology is placed, the observed strand bias is not due to asymmetry imposed on the heteroduplex by the extrahelical DNA segment. Strand-specific repair by this system requires ATP and the four dNTPs and is inhibited by aphidicolin, Repair is independent of the mismatch repair proteins MSH2, MSH6, MLH1, and PMS2 and occurs by a mechanism that is distinct from that of the conventional mismatch repair system. Large heterology repair in nuclear extracts of human cells is also independent of the XPF gene product, and extracts of Chinese hamster ovary cells deficient in the ERCC1 and ERCC4 gene products also support the reaction.	Duke Univ, Med Ctr, Dept Biochem, Howard Hughes Med Inst, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Med Med Oncol, Durham, NC 27710 USA; Natl Taiwan Univ, Coll Med, Sch Med Technol, Taipei 10002, Taiwan	Duke University; Howard Hughes Medical Institute; Duke University; National Taiwan University	Modrich, P (corresponding author), Duke Univ, Med Ctr, Dept Biochem, Howard Hughes Med Inst, Rm 150,POB 3711, Durham, NC 27710 USA.			FANG, WOEI-HORNG/0000-0003-4728-5931; Modrich, Paul/0000-0001-8708-9885	NATIONAL CANCER INSTITUTE [K08CA071554] Funding Source: NIH RePORTER; NCI NIH HHS [K08 CA71554] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AYARES D, 1987, MOL CELL BIOL, V7, P1656, DOI 10.1128/MCB.7.5.1656; CARRAWAY M, 1993, J BACTERIOL, V175, P3972, DOI 10.1128/JB.175.13.3972-3980.1993; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CLAVERYS JP, 1986, MICROBIOL REV, V50, P133, DOI 10.1128/MMBR.50.2.133-165.1986; DEPAMPHILIS ML, 1980, ANNU REV BIOCHEM, V49, P627, DOI 10.1146/annurev.bi.49.070180.003211; DOHET C, 1987, MOL GEN GENET, V206, P181, DOI 10.1007/BF00326556; DRUMMOND JT, 1995, SCIENCE, V268, P1909, DOI 10.1126/science.7604264; EDENBERG HJ, 1978, J BIOL CHEM, V253, P3273; FANG WH, 1993, J BIOL CHEM, V268, P11838; Fang WH, 1997, J BIOL CHEM, V272, P22714, DOI 10.1074/jbc.272.36.22714; Genschel J, 1998, J BIOL CHEM, V273, P19895, DOI 10.1074/jbc.273.31.19895; HOLMES J, 1990, P NATL ACAD SCI USA, V87, P5837, DOI 10.1073/pnas.87.15.5837; Kirkpatrick DT, 1997, NATURE, V387, P929, DOI 10.1038/43225; Kolodner R, 1996, GENE DEV, V10, P1433, DOI 10.1101/gad.10.12.1433; LAHUE RS, 1989, SCIENCE, V245, P160, DOI 10.1126/science.2665076; LAHUE RS, 1987, P NATL ACAD SCI USA, V84, P1482, DOI 10.1073/pnas.84.6.1482; LI GM, 1995, P NATL ACAD SCI USA, V92, P1950, DOI 10.1073/pnas.92.6.1950; LICHTEN M, 1990, P NATL ACAD SCI USA, V87, P7653, DOI 10.1073/pnas.87.19.7653; Longley MJ, 1997, J BIOL CHEM, V272, P10917; MESELSON M, 1988, RECOMBINATION GENETI, P91; MODRICH P, 1991, ANNU REV GENET, V25, P229, DOI 10.1146/annurev.ge.25.120191.001305; Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533; Nicolaides NC, 1998, MOL CELL BIOL, V18, P1635, DOI 10.1128/MCB.18.3.1635; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; PAPADOPOULOS N, 1995, SCIENCE, V268, P1915, DOI 10.1126/science.7604266; PARKER BO, 1992, P NATL ACAD SCI USA, V89, P1730, DOI 10.1073/pnas.89.5.1730; PARSONS R, 1993, CELL, V75, P1227, DOI 10.1016/0092-8674(93)90331-J; Petes T. D., 1991, MOL CELLULAR BIOL YE, P407; PUKKILA PJ, 1983, GENETICS, V104, P571; REENAN RAG, 1992, GENETICS, V132, P975; RIPLEY LS, 1990, ANNU REV GENET, V24, P189, DOI 10.1146/annurev.ge.24.120190.001201; RISINGER JI, 1995, J BIOL CHEM, V270, P18183, DOI 10.1074/jbc.270.31.18183; Risinger JI, 1998, CANCER RES, V58, P2978; STREISINGER G, 1966, COLD SPRING HARB SYM, V31, P77, DOI 10.1101/SQB.1966.031.01.014; SU SS, 1988, J BIOL CHEM, V263, P6829; THOMAS DC, 1991, J BIOL CHEM, V266, P3744; UMAR A, 1994, J BIOL CHEM, V269, P14367; UMAR A, 1994, SCIENCE, V266, P814, DOI 10.1126/science.7973637; VANDERVLIET PC, 1978, NATURE, V276, P532, DOI 10.1038/276532a0; WEISS U, 1988, NUCLEIC ACIDS RES, V16, P2313, DOI 10.1093/nar/16.5.2313; WEISS U, 1989, SOMAT CELL MOLEC GEN, V15, P13, DOI 10.1007/BF01534665; WEISS U, 1987, P NATL ACAD SCI USA, V84, P1619, DOI 10.1073/pnas.84.6.1619	42	34	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 12	1999	274	11					7474	7481		10.1074/jbc.274.11.7474	http://dx.doi.org/10.1074/jbc.274.11.7474			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	175DV	10066813	hybrid			2022-12-25	WOS:000079078400085
J	Persechini, A; Cronk, B				Persechini, A; Cronk, B			The relationship between the free concentrations of Ca2+ and Ca2+-calmodulin in intact cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT-CHAIN KINASE; CALMODULIN-BINDING DOMAIN; ADENYLYL-CYCLASE; FLUORESCENT INDICATORS; CALCIUM; PROTEINS; LOCALIZATION; ACTIVATION; SITES; CA2+/CALMODULIN	Using stably expressed fluorescent indicator proteins, we have determined for the first time the relationship between the free Ca2+ and Ca2+-calmodulin concentrations in intact cells. A similar relationship is obtained when the free Ca2+ concentration is externally buffered or when it is transiently increased in response to a Ca2+-mobilizing agonist, Below a free Ca2+ concentration of 0.2 mu M, no Ca2+-calmodulin is detectable. A global maximum free Ca2+-calmodulin concentration of similar to 45 nM is produced when the free Ca2+ concentration exceeds 3 mu M, and a half-maximal concentration is produced at a free Ca2+ concentration of 1 mu M. Data for fractional saturation of the indicators suggest that the total concentration of calmodulin-binding proteins is similar to 2-fold higher than the total calmodulin concentration. We conclude that high-affinity calmodulin targets (K-d less than or equal to 10 nM) are efficiently activated throughout the cell, but efficient activation of low-affinity targets (K-d greater than or equal to 100 nM) occurs only where free Ca2+-calmodulin concentrations can be locally enhanced.	Univ Rochester, Med Ctr, Dept Pharmacol & Physiol, Rochester, NY 14642 USA	University of Rochester	Persechini, A (corresponding author), Univ Rochester, Med Ctr, Dept Pharmacol & Physiol, 601 Elmwood Ave,Box 711, Rochester, NY 14642 USA.				NIDDK NIH HHS [DK44322] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK044322] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bauer PJ, 1996, J PHYSIOL-LONDON, V494, P675, DOI 10.1113/jphysiol.1996.sp021523; BERS DM, 1994, METHOD CELL BIOL, V40, P3; BJORK J, 1995, EUR J CELL BIOL, V66, P200; BLUMENTHAL DK, 1987, METHOD ENZYMOL, V139, P115; BLUMENTHAL DK, 1980, BIOCHEMISTRY-US, V19, P5608, DOI 10.1021/bi00565a023; Cali JJ, 1996, J BIOL CHEM, V271, P1089, DOI 10.1074/jbc.271.2.1089; CHAFOULEAS JG, 1982, CELL, V28, P41, DOI 10.1016/0092-8674(82)90373-7; CHOI EJ, 1992, BIOCHEMISTRY-US, V31, P6492, DOI 10.1021/bi00143a019; CHOI EJ, 1992, J BIOL CHEM, V267, P12440; Cooper Dermot M.F., 1998, Advances in Second Messenger and Phosphoprotein Research, V32, P23; CRUZALEGUI FH, 1993, J BIOL CHEM, V268, P26171; Deisseroth K, 1998, NATURE, V392, P198, DOI 10.1038/32448; Fagan KA, 1996, J BIOL CHEM, V271, P12438, DOI 10.1074/jbc.271.21.12438; Faux MC, 1997, J BIOL CHEM, V272, P17038, DOI 10.1074/jbc.272.27.17038; Gamby C, 1996, J BIOL CHEM, V271, P26698, DOI 10.1074/jbc.271.43.26698; GERENDASY DD, 1994, J BIOL CHEM, V269, P22420; GOUGH AH, 1993, J CELL BIOL, V121, P1095, DOI 10.1083/jcb.121.5.1095; GUERRIERO V, 1986, BIOCHEMISTRY-US, V25, P8372, DOI 10.1021/bi00374a007; HUANG CY, 1981, P NATL ACAD SCI-BIOL, V78, P871, DOI 10.1073/pnas.78.2.871; Johnson JD, 1996, J BIOL CHEM, V271, P761, DOI 10.1074/jbc.271.2.761; KAKIUCHI S, 1982, J BIOCHEM-TOKYO, V92, P1041, DOI 10.1093/oxfordjournals.jbchem.a134019; KATADA T, 1987, J BIOL CHEM, V262, P11897; LIU YC, 1993, BIOCHEMISTRY-US, V32, P10714, DOI 10.1021/bi00091a023; MAMARBACHI A, 1987, CELL CALCIUM, V8, P473, DOI 10.1016/0143-4160(87)90030-3; Marsault R, 1997, EMBO J, V16, P1575, DOI 10.1093/emboj/16.7.1575; Medvedeva MV, 1996, BIOCHEM J, V315, P1021, DOI 10.1042/bj3151021; Miyawaki A, 1997, NATURE, V388, P882, DOI 10.1038/42264; MONS N, 1995, P NATL ACAD SCI USA, V92, P8473, DOI 10.1073/pnas.92.18.8473; Nakahashi Y, 1997, J BIOL CHEM, V272, P18093, DOI 10.1074/jbc.272.29.18093; Nicol S, 1997, BIOCHEMISTRY-US, V36, P11487, DOI 10.1021/bi970709r; OLWIN BB, 1985, BIOCHEMISTRY-US, V24, P8081, DOI 10.1021/bi00348a037; OLWIN BB, 1984, J BIOL CHEM, V259, P949; Persechini A, 1997, CELL CALCIUM, V22, P209, DOI 10.1016/S0143-4160(97)90014-2; PERSECHINI A, 1994, J BIOL CHEM, V269, P16148; Persechini A, 1996, J BIOL CHEM, V271, P32217, DOI 10.1074/jbc.271.50.32217; Pronin AN, 1997, J BIOL CHEM, V272, P18273, DOI 10.1074/jbc.272.29.18273; Romoser VA, 1997, J BIOL CHEM, V272, P13270, DOI 10.1074/jbc.272.20.13270; Shupnik MA, 1996, MOL ENDOCRINOL, V10, P90, DOI 10.1210/me.10.1.90; STEMMER PM, 1994, BIOCHEMISTRY-US, V33, P6859, DOI 10.1021/bi00188a015; TANSEY MG, 1994, J BIOL CHEM, V269, P9912; Xia ZG, 1997, CURR OPIN NEUROBIOL, V7, P391, DOI 10.1016/S0959-4388(97)80068-2	41	132	133	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 12	1999	274	11					6827	6830		10.1074/jbc.274.11.6827	http://dx.doi.org/10.1074/jbc.274.11.6827			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	175DV	10066733	hybrid			2022-12-25	WOS:000079078400005
J	Tsuji, Y; Moran, E; Torti, SV; Torti, FM				Tsuji, Y; Moran, E; Torti, SV; Torti, FM			Transcriptional regulation of the mouse ferritin H gene - Involvement of p300/CBP adaptor proteins in FER-1 enhancer activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; HEAVY-CHAIN; MOLECULAR-CLONING; ADENOVIRUS E1A; FUNCTIONAL COLLABORATION; CELLULAR PROTEINS; BREAST-CARCINOMA; IRON-METABOLISM; SERUM FERRITIN; MESSENGER-RNA	We previously identified a major enhancer of the mouse ferritin H gene (FER-1) that is central to repression of the ferritin H gene by the adenovirus E1A oncogene (Tsuji, Y,, Akebi, N,, Lam, T, K,, Nakabeppu, Y,, Torti, S. V,, and Torti, F, M, (1995) Mel. Cell. Biol, 15, 5152-5164), To dissect the molecular mechanism of transcriptional regulation of ferritin H, E1A mutants were tested for their ability to repress FER-1 enhancer activity using cotransfection with ferritin H-chloramphenicol acetyltransferase (CAT) reporter constructs. Here we report that p300/CBP transcriptional adaptor proteins are involved in the regulation of ferritin H transcription through the FER-1 enhancer element. Thus, ELA mutants that failed to bind p300/CBP lost the ability to repress FER-1, whereas mutants of E1A that abrogated its interaction with Rb, p107, or p130 were fully functional in transcriptional repression. Transfection with EIA did not affect endogenous p300/CBP levels, suggesting that repression of FER-1 by E1A is not due to repression of p300/CBP synthesis, but to E1A and p300/CBP interaction. In addition, we have demonstrated that transfection of a p300 expression plasmid significantly activated ferritin H-CAT containing the FER-1 enhancer, but had a marginal effect on ferritin H-CAT with FER-1 deleted, Furthermore, both wild-type p300 and a p300 mutant that failed to bind E1A but retained an adaptor function restored FER-1 enhancer activity repressed by E1A. Sodium butyrate, an inhibitor of histone deacetylase, mimicked p300/CBP function in activation of ferritin H-CAT and elevation of endogenous ferritin H mRNA, suggesting that the histone acetyltransferase activity of p300/CBP or its associated proteins may contribute to the activation of ferritin H transcription, Recruitment of these broadly active transcriptional adaptor proteins for ferritin H synthesis may represent an important mechanism by which changes in iron metabolism are coordinated with other cellular responses mediated by p300/CBP.	Wake Forest Univ, Bowman Gray Sch Med, Dept Canc Biol, Winston Salem, NC 27157 USA; Wake Forest Univ, Bowman Gray Sch Med, Dept Biochem, Winston Salem, NC 27157 USA; Wake Forest Univ, Bowman Gray Sch Med, Dept Med, Winston Salem, NC 27157 USA; Wake Forest Univ, Bowman Gray Sch Med, Ctr Comprehens Canc, Winston Salem, NC 27157 USA; Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, Philadelphia, PA 19140 USA	Wake Forest University; Wake Forest Baptist Medical Center; Wake Forest University; Wake Forest Baptist Medical Center; Wake Forest University; Wake Forest Baptist Medical Center; Wake Forest University; Wake Forest Baptist Medical Center; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Tsuji, Y (corresponding author), Wake Forest Univ, Bowman Gray Sch Med, Dept Canc Biol, 300 S Hawthorne Rd, Winston Salem, NC 27157 USA.				NATIONAL CANCER INSTITUTE [P30CA012197] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042412, R37DK042412] Funding Source: NIH RePORTER; NCI NIH HHS [CA12197] Funding Source: Medline; NIDDK NIH HHS [DK-42412] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARANY Z, 1995, NATURE, V374, P81, DOI 10.1038/374081a0; ARANY Z, 1994, CELL, V77, P799, DOI 10.1016/0092-8674(94)90127-9; ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; Avantaggiati ML, 1997, CELL, V89, P1175, DOI 10.1016/S0092-8674(00)80304-9; BANNISTER AJ, 1995, EMBO J, V14, P4758, DOI 10.1002/j.1460-2075.1995.tb00157.x; BEAUMONT C, 1994, J BIOL CHEM, V269, P20281; BECK GR, 1997, J CELL BIOCHEM, V68, P1; Bevilacqua MA, 1997, J BIOL CHEM, V272, P20736, DOI 10.1074/jbc.272.33.20736; BLATT J, 1992, J LAB CLIN MED, V119, P139; CAIRO G, 1995, J BIOL CHEM, V270, P700, DOI 10.1074/jbc.270.2.700; CAIRO G, 1986, BIOCHEM BIOPH RES CO, V139, P652, DOI 10.1016/S0006-291X(86)80040-7; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; COX F, 1988, J BIOL CHEM, V263, P7060; Dallas PB, 1997, J VIROL, V71, P1726, DOI 10.1128/JVI.71.2.1726-1731.1997; Eckner R, 1996, BIOL CHEM, V377, P685; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; Eckner R, 1996, GENE DEV, V10, P2478, DOI 10.1101/gad.10.19.2478; ELLIOTT RL, 1993, ANN NY ACAD SCI, V698, P159, DOI 10.1111/j.1749-6632.1993.tb17204.x; GUNER G, 1992, CANCER LETT, V67, P103, DOI 10.1016/0304-3835(92)90132-F; HAGMEYER BM, 1993, EMBO J, V12, P3559, DOI 10.1002/j.1460-2075.1993.tb06030.x; HARLOW E, 1986, MOL CELL BIOL, V6, P1579, DOI 10.1128/MCB.6.5.1579; Harrison PM, 1996, BBA-BIOENERGETICS, V1275, P161, DOI 10.1016/0005-2728(96)00022-9; Horvai AE, 1997, P NATL ACAD SCI USA, V94, P1074, DOI 10.1073/pnas.94.4.1074; IMLER JL, 1988, NUCLEIC ACIDS RES, V16, P3005, DOI 10.1093/nar/16.7.3005; Kawasaki H, 1998, GENE DEV, V12, P233, DOI 10.1101/gad.12.2.233; KIKYO N, 1994, CANCER RES, V54, P268; KITABAYASHI I, 1995, EMBO J, V14, P3496, DOI 10.1002/j.1460-2075.1995.tb07356.x; KLAUSNER RD, 1993, CELL, V72, P19, DOI 10.1016/0092-8674(93)90046-S; KWAK EL, 1990, GENE, V94, P255, DOI 10.1016/0378-1119(90)90396-9; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; Lee JS, 1996, MOL CELL BIOL, V16, P4312; LUNDBLAD JR, 1995, NATURE, V374, P85, DOI 10.1038/374085a0; Marziali G, 1997, MOL CELL BIOL, V17, P1387, DOI 10.1128/MCB.17.3.1387; Mink S, 1997, MOL CELL BIOL, V17, P6609, DOI 10.1128/MCB.17.11.6609; MODJTAHEDI N, 1992, EXP CELL RES, V201, P74, DOI 10.1016/0014-4827(92)90349-D; Mymryk JS, 1996, ONCOGENE, V13, P1581; MYMRYK JS, 1992, MOL BIOL CELL, V3, P1107, DOI 10.1091/mbc.3.10.1107; Noti JD, 1996, MOL CELL BIOL, V16, P2940; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; ROUAULT TA, 1987, P NATL ACAD SCI USA, V84, P6335, DOI 10.1073/pnas.84.18.6335; STEIN RW, 1990, J VIROL, V64, P4421, DOI 10.1128/JVI.64.9.4421-4427.1990; THEIL EC, 1987, ANNU REV BIOCHEM, V56, P289, DOI 10.1146/annurev.biochem.56.1.289; TORTI SV, 1988, J BIOL CHEM, V263, P12638; TSUJI Y, 1993, EXP CELL RES, V209, P175, DOI 10.1006/excr.1993.1299; TSUJI Y, 1993, J IMMUNOL, V150, P1897; TSUJI Y, 1993, J BIOL CHEM, V268, P7270; TSUJI Y, 1995, MOL CELL BIOL, V15, P5152; Tsuji Y, 1998, J BIOL CHEM, V273, P2984, DOI 10.1074/jbc.273.5.2984; VAUGHN CB, 1987, CANCER INVEST, V5, P7, DOI 10.3109/07357908709020300; WAGSTAFF M, 1978, BIOCHEM J, V173, P969, DOI 10.1042/bj1730969; WANG HGH, 1995, J VIROL, V69, P7917, DOI 10.1128/JVI.69.12.7917-7924.1995; WANG HGH, 1993, J VIROL, V67, P476, DOI 10.1128/JVI.67.1.476-488.1993; WEI Y, 1990, BIOCHEM BIOPH RES CO, V169, P289, DOI 10.1016/0006-291X(90)91466-6; WILLIAMS MR, 1990, EUR J SURG ONCOL, V16, P22; Wolffe AP, 1996, CELL, V84, P817, DOI 10.1016/S0092-8674(00)81059-4; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; YEE SP, 1985, VIROLOGY, V147, P142, DOI 10.1016/0042-6822(85)90234-X	57	35	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 12	1999	274	11					7501	7507		10.1074/jbc.274.11.7501	http://dx.doi.org/10.1074/jbc.274.11.7501			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	175DV	10066817	hybrid			2022-12-25	WOS:000079078400089
J	Zhang, YL; Hervio, L; Strandberg, L; Madison, EL				Zhang, YL; Hervio, L; Strandberg, L; Madison, EL			Distinct contributions of residue 192 to the specificity of coagulation and fibrinolytic serine proteases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE PLASMINOGEN-ACTIVATOR; SITE-DIRECTED MUTAGENESIS; SUBSTRATE-SPECIFICITY; CORONARY THROMBOLYSIS; MYOCARDIAL-INFARCTION; INHIBITOR; ENZYME; DETERMINANTS; SUBSTITUTION; EFFICIENT	Archetypal members of the chymotrypsin family of serine proteases, such as trypsin, chymotrypsin, and elastase, exhibit relatively broad substrate specificity. However, the successful development of efficient proteolytic cascades, such as the blood coagulation and fibrinolytic systems, required the evolution of proteases that displayed restricted specificity. Tissue-type plasminogen activator (t-PA), for example, possesses exquisitely stringent substrate specificity, and the molecular basis of this important biochemical property of t-PA remains obscure. Previous investigations of related serine proteases, which participate in the blood coagulation cascade, have focused attention on the residue that occupies position 192 (chymotrypsin numbering system), which plays a pivotal role in determining both the inhibitor and substrate specificity of these enzymes, Consequently, we created and characterized the kinetic properties of new variants of t-PA that contained point mutations at position 192. These studies demonstrated that, unlike in coagulation serine proteases, Gln-192 does not contribute significantly to the substrate or inhibitor specificity of t-PA in physiologically relevant reactions. Replacement of Gln-192 with a glutamic acid residue did, however, decrease the catalytic efficiency of mature, two-chain t-PA toward plasminogen in the absence of a fibrin co-factor.	Corvas Int, Dept Mol Biol, San Diego, CA 92121 USA; Scripps Res Inst, Dept Vasc Biol, La Jolla, CA 92037 USA	Scripps Research Institute	Madison, EL (corresponding author), Corvas Int, Dept Mol Biol, 3030 Sci Pk Rd, San Diego, CA 92121 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL052475, P01HL031950] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01 HL31950, R01 HL52475] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BEATTY K, 1982, BIOCHIM BIOPHYS ACTA, V704, P221, DOI 10.1016/0167-4838(82)90149-2; BELL LD, 1988, GENE, V63, P155, DOI 10.1016/0378-1119(88)90521-5; BENNETT WF, 1991, J BIOL CHEM, V266, P5191; BERGMANN SR, 1983, SCIENCE, V220, P1181; BOOSE JA, 1989, BIOCHEMISTRY-US, V28, P635, DOI 10.1021/bi00428a033; Cannon CP, 1997, CIRCULATION, V95, P351; Castellino F. J, 1995, MOL BASIS THROMBOSIS, P495; COLLEN D, 1988, SEMIN THROMB HEMOST, V14, P95, DOI 10.1055/s-2007-1002761; COLLEN D, 1989, DRUGS, V38, P346, DOI 10.2165/00003495-198938030-00003; COLLEN D, 1991, BLOOD, V78, P3114; COLLEN D, 1980, THROMB HAEMOSTASIS, V43, P77; COLLEN D, 1992, HEART CARDIOVASCULAR, V1, P275; COLLEN DC, 1990, THROMB RES, P105; GUINTO ER, 1994, J BIOL CHEM, V269, P18395; HOLMES WE, 1987, BIOCHEMISTRY-US, V26, P5133, DOI 10.1021/bi00390a036; Ke SH, 1997, J BIOL CHEM, V272, P1811, DOI 10.1074/jbc.272.3.1811; Keyt Bruce A., 1996, P435; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; Lamba D, 1996, J MOL BIOL, V258, P117, DOI 10.1006/jmbi.1996.0238; LEBONNIEC BF, 1991, P NATL ACAD SCI USA, V88, P7371, DOI 10.1073/pnas.88.16.7371; LIJNEN HR, 1991, THROMB HAEMOSTASIS, V66, P88; LUCAS MA, 1983, J BIOL CHEM, V258, P4249; MADISON EL, 1989, NATURE, V339, P721, DOI 10.1038/339721a0; MADISON EL, 1994, FIBRINOLYSIS, V8, P221, DOI 10.1016/0268-9499(94)90720-X; MADISON EL, 1995, J BIOL CHEM, V270, P7558, DOI 10.1074/jbc.270.13.7558; MCCLUSKEY ER, 1997, NEW THERAPEUTIC AGEN, P475; NEUENSCHWANDER PF, 1995, BIOCHEMISTRY-US, V34, P8701, DOI 10.1021/bi00027a020; PERONA JJ, 1995, PROTEIN SCI, V4, P337; RANBY M, 1982, BIOCHIM BIOPHYS ACTA, V704, P461, DOI 10.1016/0167-4838(82)90068-1; Renatus M, 1997, J BIOL CHEM, V272, P21713, DOI 10.1074/jbc.272.35.21713; Rezaie AR, 1996, EUR J BIOCHEM, V242, P477, DOI 10.1111/j.1432-1033.1996.477rr.x; REZAIE AR, 1993, J BIOL CHEM, V268, P19943; REZAIE AR, 1995, J BIOL CHEM, V270, P16176, DOI 10.1074/jbc.270.27.16176; ROSS AM, 1993, NEW ENGL J MED, V329, P1615; STRANDBERG L, 1995, J BIOL CHEM, V270, P23444, DOI 10.1074/jbc.270.40.23444; SUENSON E, 1981, BIOCHEM J, V197, P619, DOI 10.1042/bj1970619; Tachias K, 1997, J BIOL CHEM, V272, P28; Tachias K, 1997, J BIOL CHEM, V272, P14580, DOI 10.1074/jbc.272.23.14580; Tachias K, 1996, J BIOL CHEM, V271, P28749, DOI 10.1074/jbc.271.46.28749; TATE KM, 1987, BIOCHEMISTRY-US, V26, P338, DOI 10.1021/bi00376a002; THORSEN S, 1981, BIOCHIM BIOPHYS ACTA, V668, P377, DOI 10.1016/0005-2795(81)90171-9; TOPOL E, 1993, NEW ENGL J MED, V329, P673, DOI 10.1056/nejm199309023291001; VANDEWERF F, 1984, NEW ENGL J MED, V310, P609; WEENINGVERHOEFF EJD, 1990, PROTEIN ENG, V4, P191, DOI 10.1093/protein/4.2.191; ZOLLER MJ, 1982, NUCLEIC ACIDS RES, V10, P6487, DOI 10.1093/nar/10.20.6487	45	8	12	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	1999	274	11					7153	7156		10.1074/jbc.274.11.7153	http://dx.doi.org/10.1074/jbc.274.11.7153			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	175DV	10066774	hybrid			2022-12-25	WOS:000079078400046
J	Corbett, EF; Oikawa, K; Francois, P; Tessier, DC; Kay, C; Bergeron, JJM; Thomas, DY; Krause, KH; Michalak, M				Corbett, EF; Oikawa, K; Francois, P; Tessier, DC; Kay, C; Bergeron, JJM; Thomas, DY; Krause, KH; Michalak, M			Ca2+ regulation of interactions between endoplasmic reticulum chaperones	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN DISULFIDE-ISOMERASE; THIOL-DEPENDENT REDUCTASE; TRIGLYCERIDE-TRANSFER PROTEIN; GENE-EXPRESSION; CALRETICULIN INCREASES; STRUCTURAL-PROPERTIES; INTRACELLULAR STORES; BINDING-PROTEIN; CALCIUM; INHIBITION	Casade Blue (CB), a fluorescent dye, was used to investigate the dynamics of interactions between endoplasmic reticulum (ER) lumenal chaperones including calreticulin, protein disulfide isomerase (PDI), and ERp57. PDI and ERp57 were labeled with CB, and subsequently, we show that the fluorescence intensity of the CB-conjugated proteins changes upon exposure to microenvironments of a different polarity. CD analysis of the purified proteins revealed that changes in the fluorescence intensity of CB-ERp57 and CB-PDI correspond to conformational changes in the proteins. Using this technique we demonstrate that PDI interacts with calreticulin at low Ca2+ concentration (below 100 mu M), whereas the protein complex dissociates at >400 mu M Ca2+. These are the Ca2+ concentrations reminiscent of Ca2+ levels found in empty or full ER Ca2+ stores. The N-domain of calreticulin interacts with PDI, but Ca2+ binding to the C-domain of the protein is responsible for Ca2+ sensitivity of the interaction. ERp57 also interacts with calreticulin through the N-domain of the protein. Initial interaction between these proteins is Ca2+-independent, but it is modulated by Ca2+ binding to the C-domain of calreticulin. We conclude that changes in ER lumenal Ca2+ concentration may be responsible for the regulation of protein-protein interactions. Calreticulin may play a role of Ca2+ "sensor" for ER chaperones via regulation of Ca2+-dependent formation and maintenance of structural and functional complexes between different proteins involved in a variety of steps during protein synthesis, folding, and post-translational modification.	Univ Alberta, Dept Biochem, Edmonton, AB T6G 2H7, Canada; Univ Alberta, MRC Canada, Grp Mol Biol Membranes, Edmonton, AB T6G 2H7, Canada; Univ Alberta, MRC Canada, Grp Prot Struct & Funct, Prot Engn Network Ctr Excellence, Edmonton, AB T6G 2H7, Canada; Univ Hosp Geneva, Div Infect Dis, CH-1216 Geneva, Switzerland; Natl Res Council Canada, Biotechnol Res Inst, Genet Grp, Montreal, PQ H4P 2R2, Canada; McGill Univ, Dept Anat & Cell Biol, Montreal, PQ H3A 2B2, Canada	University of Alberta; University of Alberta; University of Alberta; University of Geneva; National Research Council Canada; McGill University	Michalak, M (corresponding author), Univ Alberta, Dept Biochem, Edmonton, AB T6G 2H7, Canada.	marek.michalak@ualberta.ca	Bergeron, John/AAW-1893-2021; francois, patrice/AAL-5583-2020; Krause, Karl-Heinz/E-8030-2011; Thomas, David/M-7661-2017	Krause, Karl-Heinz/0000-0002-9033-6768; Thomas, David/0000-0002-8854-762X; francois, patrice/0000-0002-0540-750X				Ausubel F. M., 1988, CURRENT PROTOCOLS MO; Baksh S, 1995, J BIOL CHEM, V270, P31338, DOI 10.1074/jbc.270.52.31338; BAKSH S, 1995, FEBS LETT, V376, P53, DOI 10.1016/0014-5793(95)01246-4; BAKSH S, 1992, PROTEIN EXPRES PURIF, V3, P322, DOI 10.1016/1046-5928(92)90008-K; BAKSH S, 1991, J BIOL CHEM, V266, P21458; BAKSH S, 1995, BIOCHEM BIOPH RES CO, V209, P310, DOI 10.1006/bbrc.1995.1504; BASTIANUTTO C, 1995, J CELL BIOL, V130, P847, DOI 10.1083/jcb.130.4.847; BERGERON JJM, 1994, TRENDS BIOCHEM SCI, V19, P124, DOI 10.1016/0968-0004(94)90205-4; Brostrom CO, 1998, PROG NUCLEIC ACID RE, V58, P79; BURNS K, 1994, NATURE, V367, P476, DOI 10.1038/367476a0; CAMACHO P, 1995, CELL, V82, P765, DOI 10.1016/0092-8674(95)90473-5; Coppolino MG, 1997, NATURE, V386, P843, DOI 10.1038/386843a0; DEDHAR S, 1994, NATURE, V367, P480, DOI 10.1038/367480a0; Elliott JG, 1997, J BIOL CHEM, V272, P13849, DOI 10.1074/jbc.272.21.13849; Favre CJ, 1996, J BIOL CHEM, V271, P14925, DOI 10.1074/jbc.271.25.14925; FREEDMAN RB, 1994, TRENDS BIOCHEM SCI, V19, P331, DOI 10.1016/0968-0004(94)90072-8; Helenius A, 1997, TRENDS CELL BIOL, V7, P193; HIRANO N, 1995, EUR J BIOCHEM, V234, P336, DOI 10.1111/j.1432-1033.1995.336_c.x; IVESSA NE, 1995, J BIOL CHEM, V270, P25960, DOI 10.1074/jbc.270.43.25960; John LM, 1998, J CELL BIOL, V142, P963, DOI 10.1083/jcb.142.4.963; KHANNA NC, 1986, J BIOL CHEM, V261, P8883; Krause KH, 1997, CELL, V88, P439, DOI 10.1016/S0092-8674(00)81884-X; LAMBERT N, 1983, BIOCHEM J, V213, P225, DOI 10.1042/bj2130225; LI WWF, 1993, J BIOL CHEM, V268, P12003; Lievremont JP, 1997, J BIOL CHEM, V272, P30873, DOI 10.1074/jbc.272.49.30873; Llewellyn DH, 1996, BIOCHEM J, V318, P555, DOI 10.1042/bj3180555; Lucero HA, 1998, J BIOL CHEM, V273, P9857, DOI 10.1074/jbc.273.16.9857; Meldolesi J, 1998, TRENDS BIOCHEM SCI, V23, P10, DOI 10.1016/S0968-0004(97)01143-2; Mery L, 1996, J BIOL CHEM, V271, P9332, DOI 10.1074/jbc.271.16.9332; Michalak M, 1996, J BIOL CHEM, V271, P29436, DOI 10.1074/jbc.271.46.29436; MICHALAK M, 1992, BIOCHEM J, V285, P681, DOI 10.1042/bj2850681; MICHALAK M, 1995, CALRETICULIN; MILNER RE, 1992, MOL CELL BIOCHEM, V112, P1; MILNER RE, 1991, J BIOL CHEM, V266, P7155; Miyawaki A, 1997, NATURE, V388, P882, DOI 10.1038/42264; MONTERO M, 1995, EMBO J, V14, P5467, DOI 10.1002/j.1460-2075.1995.tb00233.x; MORI K, 1993, CELL, V74, P743; Nguyen TQ, 1996, MOL IMMUNOL, V33, P379, DOI 10.1016/0161-5890(95)00149-2; NOIVA R, 1992, J BIOL CHEM, V267, P3553; Oliver JD, 1997, SCIENCE, V275, P86, DOI 10.1126/science.275.5296.86; Opas M, 1996, J CELL BIOL, V135, P1913, DOI 10.1083/jcb.135.6.1913; Pahl HL, 1997, TRENDS CELL BIOL, V7, P50, DOI 10.1016/S0962-8924(96)10050-7; POZZAN T, 1994, PHYSIOL REV, V74, P595, DOI 10.1152/physrev.1994.74.3.595; PROVENCHER SW, 1981, BIOCHEMISTRY-US, V20, P33, DOI 10.1021/bi00504a006; RACCHETTI G, 1994, BIOCHEM BIOPH RES CO, V203, P828, DOI 10.1006/bbrc.1994.2257; Reilly BA, 1998, J BIOL CHEM, V273, P3747, DOI 10.1074/jbc.273.6.3747; SONTHEIMER RD, 1995, J INVEST MED, V43, P362; SRIVASTAVA SP, 1995, J BIOL CHEM, V270, P16619, DOI 10.1074/jbc.270.28.16619; Urade R, 1997, J BIOCHEM-TOKYO, V122, P834; Vassilakos A, 1998, BIOCHEMISTRY-US, V37, P3480, DOI 10.1021/bi972465g; Waser M, 1997, J CELL BIOL, V138, P547, DOI 10.1083/jcb.138.3.547; WETTERAU JR, 1991, BIOCHEMISTRY-US, V30, P9728, DOI 10.1021/bi00104a023; WETTERAU JR, 1991, BIOCHEMISTRY-US, V30, P4406, DOI 10.1021/bi00232a006; WHITAKER JE, 1991, ANAL BIOCHEM, V198, P119, DOI 10.1016/0003-2697(91)90515-U; Zapun A, 1998, J BIOL CHEM, V273, P6009, DOI 10.1074/jbc.273.11.6009	55	163	166	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	1999	274	10					6203	6211		10.1074/jbc.274.10.6203	http://dx.doi.org/10.1074/jbc.274.10.6203			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172BQ	10037706	hybrid			2022-12-25	WOS:000078902800028
J	Holzfeind, PJ; Ambrose, HJ; Newey, SE; Nawrotzki, RA; Blake, DJ; Davies, KE				Holzfeind, PJ; Ambrose, HJ; Newey, SE; Nawrotzki, RA; Blake, DJ; Davies, KE			Tissue-selective expression of alpha-dystrobrevin is determined by multiple promoters	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TORPEDO ELECTRIC ORGAN; OPEN READING FRAMES; MUSCULAR-DYSTROPHY; TRANSLATIONAL CONTROL; GENE-EXPRESSION; TRANSGENIC MICE; PROTEIN; MUSCLE; BRAIN; TRANSCRIPT	alpha-Dystrobrevin, the mammalian orthologue of the Torpedo 87-kDa postsynaptic protein, is a dystrophin-associated and dystrophin-related protein. Knockout of the gene in the mouse results in muscular dystrophy. The control of the alpha-dystrobrevin gene in the various tissues is therefore of interest. Multiple dystrobrevin isoforms differing in their domain content are generated by alternative splicing of a single gene. The data presented here demonstrate that expression of alpha-dystrobrevin from three promoters, that are active in a tissue-selective manner, also plays a role in the function of the protein in different tissues. The most proximal promoter A is active in brain and to a lesser extent in lung, whereas the most distal promoter B, which possesses several Sp1 binding sites, is restricted to brain. Promoter C, which contains multiple consensus myogenic binding sites, is up-regulated during in vitro myoblast differentiation. interestingly, the organization and the activity of the alpha-dystrobrevin promoters is reminiscent of those in the dystrophin gene. Taken together we suggest that the multipromoter system, distributed over a region of 270 kilobases at the 5'-end of the alpha-dystrobrevin gene, has been developed to allow the regulation of this gene in different cell types and/or different developmental stages.	Univ Oxford, Dept Biochem, Genet Unit, Oxford OX1 3QX, England	University of Oxford	Davies, KE (corresponding author), Univ Oxford, Dept Human Anat & Genet, S Parks Rd, Oxford OX1 3QX, England.							Ambrose HJ, 1997, GENOMICS, V39, P359, DOI 10.1006/geno.1996.4515; BALDWIN TJ, 1989, NATURE, V341, P716, DOI 10.1038/341716a0; Blake Derek J., 1992, Human Molecular Genetics, V1, P103, DOI 10.1093/hmg/1.2.103; Blake DJ, 1998, P NATL ACAD SCI USA, V95, P241, DOI 10.1073/pnas.95.1.241; BLAKE DJ, 1995, TRENDS BIOCHEM SCI, V20, P133, DOI 10.1016/S0968-0004(00)88986-0; BLAKE DJ, 1995, P NATL ACAD SCI USA, V92, P3697, DOI 10.1073/pnas.92.9.3697; Blake DJ, 1996, J BIOL CHEM, V271, P7802, DOI 10.1074/jbc.271.13.7802; BOYCE FM, 1991, P NATL ACAD SCI USA, V88, P1276, DOI 10.1073/pnas.88.4.1276; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; BUSKIN JN, 1989, MOL CELL BIOL, V9, P2627, DOI 10.1128/MCB.9.6.2627; BYERS TJ, 1993, NAT GENET, V4, P77, DOI 10.1038/ng0593-77; CARR C, 1989, J CELL BIOL, V109, P1753, DOI 10.1083/jcb.109.4.1753; CHELLY J, 1990, NATURE, V344, P64, DOI 10.1038/344064a0; DWYER TM, 1995, FEBS LETT, V375, P91, DOI 10.1016/0014-5793(95)01176-F; GORECKI DC, 1992, HUM MOL GENET, V1, P505, DOI 10.1093/hmg/1.7.505; Ince TA, 1995, J BIOL CHEM, V270, P30249, DOI 10.1074/jbc.270.51.30249; KESSEL M, 1988, NATURE, V332, P117, DOI 10.1038/332117c0; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; KRAMARCY NR, 1994, J BIOL CHEM, V269, P2870; LASSAR AB, 1989, CELL, V58, P823, DOI 10.1016/0092-8674(89)90935-5; LIDOV HGW, 1995, HUM MOL GENET, V4, P329, DOI 10.1093/hmg/4.3.329; MAR JH, 1990, MOL CELL BIOL, V10, P4271, DOI 10.1128/MCB.10.8.4271; Metzinger L, 1997, HUM MOL GENET, V6, P1185, DOI 10.1093/hmg/6.7.1185; MORGAN JE, 1994, DEV BIOL, V162, P486, DOI 10.1006/dbio.1994.1103; Nawrotzki R, 1998, J CELL SCI, V111, P2595; NUDEL U, 1989, NATURE, V337, P76, DOI 10.1038/337076a0; Ponting CP, 1996, TRENDS BIOCHEM SCI, V21, P11, DOI 10.1016/0968-0004(96)80878-4; Roberts RG, 1998, HUM MOL GENET, V7, P589, DOI 10.1093/hmg/7.4.589; SadouletPuccio HM, 1997, P NATL ACAD SCI USA, V94, P12413, DOI 10.1073/pnas.94.23.12413; SadouletPuccio HM, 1996, HUM MOL GENET, V5, P489, DOI 10.1093/hmg/5.4.489; SHAPIRO MB, 1987, NUCLEIC ACIDS RES, V15, P7155, DOI 10.1093/nar/15.17.7155; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; TIMMUSK T, 1995, J CELL BIOL, V128, P185, DOI 10.1083/jcb.128.1.185; TIMMUSK T, 1993, NEURON, V10, P475, DOI 10.1016/0896-6273(93)90335-O; TINSLEY JM, 1993, HUM MOL GENET, V2, P521, DOI 10.1093/hmg/2.5.521; WAGNER KR, 1993, NEURON, V10, P511, DOI 10.1016/0896-6273(93)90338-R; Zhou H., 1998, Society for Neuroscience Abstracts, V24, P1534; ZIMMER A, 1994, J CELL BIOL, V127, P1111, DOI 10.1083/jcb.127.4.1111	38	26	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1999	274	10					6250	6258		10.1074/jbc.274.10.6250	http://dx.doi.org/10.1074/jbc.274.10.6250			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172BQ	10037712	hybrid			2022-12-25	WOS:000078902800034
J	Kennedy, KA; Traxler, B				Kennedy, KA; Traxler, B			MalK forms a dimer independent of its assembly into the MalFGK(2) ATP-binding cassette transporter of Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SALMONELLA-TYPHIMURIUM; NUCLEOTIDE-BINDING; PROTEIN; SYSTEM; PURIFICATION; SUBUNIT; COMPLEX; DIMERIZATION; REQUIREMENTS; EXPRESSION	The maltose transport complex (MTC) is a member of the ATP-binding cassette superfamily of membrane transport proteins and is a model for understanding the folding and assembly of hetero oligomeric membrane protein complexes. The MTC is made up of two integral membrane proteins, MalF and MalG, and a peripheral membrane protein, MalK, These proteins associate with a stoichiometry of 1:1:2 to form the complex MalFGK(2). In our studies of the oligomerization of this complex, we have shown that the ATP-binding component, MalK, forms a dimer in the absence of MalF and MalG, Epitope-tagged MalK coimmunoprecipitated with wild-type MalK, indicating that the MalK protein forms an oligomer, The relative amounts of tagged and wild-type MalK that were present in the whole cell extracts and in the immunoprecipitated complexes show that the MalK oligomer is a dimer, These hetero-oligomers can also be formed in vitro by mixing two extracts, each containing either tagged or wild-type MalK. The dimerization of MalK was also demonstrated in vivo using the bacteriophage lambda repressor fusion assay. The formation of a MalK dimer in the absence of MalF and MalG may represent an initial step in the assembly pathway of the MTC.	Univ Washington, Dept Microbiol, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Traxler, B (corresponding author), Univ Washington, Dept Microbiol, Box 357242, Seattle, WA 98195 USA.							AMANN E, 1988, GENE, V69, P301, DOI 10.1016/0378-1119(88)90440-4; AMSTERCHODER O, 1992, SCIENCE, V257, P1395, DOI 10.1126/science.1382312; BALBAS P, 1986, VECTORS, P5; Boos W, 1998, MICROBIOL MOL BIOL R, V62, P204, DOI 10.1128/MMBR.62.1.204-229.1998; BOOS W, 1996, ESCHERICHIA COLI SAL, P1175; BOYD D, 1987, P NATL ACAD SCI USA, V84, P8525, DOI 10.1073/pnas.84.23.8525; CHANG ACY, 1978, J BACTERIOL, V134, P1141, DOI 10.1128/JB.134.3.1141-1156.1978; DAVIDSON AL, 1991, J BIOL CHEM, V266, P8946; Davidson AL, 1997, J BACTERIOL, V179, P5458, DOI 10.1128/jb.179.17.5458-5464.1997; Davidson AL, 1996, J BIOL CHEM, V271, P4858; DEAN DA, 1990, J BIOL CHEM, V265, P21005; HU JC, 1990, SCIENCE, V250, P1400, DOI 10.1126/science.2147779; Lippincott J, 1997, J BACTERIOL, V179, P1337, DOI 10.1128/jb.179.4.1337-1343.1997; Liu PQ, 1998, P NATL ACAD SCI USA, V95, P3495, DOI 10.1073/pnas.95.7.3495; Manoil C, 1997, J MOL BIOL, V267, P250, DOI 10.1006/jmbi.1996.0881; Miller J.H., 1972, EXPT MOL GENETICS; Nikaido K, 1997, J BIOL CHEM, V272, P27745, DOI 10.1074/jbc.272.44.27745; PANAGIOTIDIS CH, 1993, J BIOL CHEM, V268, P23685; REYES M, 1988, J BACTERIOL, V170, P4598, DOI 10.1128/jb.170.10.4598-4602.1988; Sambrook J., 2002, MOL CLONING LAB MANU; TRAXLER B, 1992, P NATL ACAD SCI USA, V89, P10852, DOI 10.1073/pnas.89.22.10852; WALTER C, 1992, J BIOL CHEM, V267, P8863	22	27	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1999	274	10					6259	6264		10.1074/jbc.274.10.6259	http://dx.doi.org/10.1074/jbc.274.10.6259			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172BQ	10037713	hybrid			2022-12-25	WOS:000078902800035
J	Wiley, JC; Wailes, LA; Idzerda, RL; McKnight, GS				Wiley, JC; Wailes, LA; Idzerda, RL; McKnight, GS			Role of regulatory subunits and protein kinase inhibitor (PKI) in determining nuclear localization and activity of the catalytic subunit of protein kinase A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							A ANCHORING PROTEIN; SIGNAL-TRANSDUCTION; GOLGI-COMPLEX; EXPORT; EXPRESSION; MUTATIONS; GENE; PHOSPHORYLATION; IDENTIFICATION; TRANSCRIPTION	Regulation of protein kinase A by subcellular localization may be critical to target catalytic subunits to specific substrates. We employed epitope-tagged catalytic subunit to correlate subcellular localization and gene-inducing activity in the presence of regulatory subunit or protein kinase inhibitor (PKI). Transiently expressed catalytic subunit distributed throughout the cell and induced gene expression. Go-expression of regulatory subunit or PKI blocked gene induction and prevented nuclear accumulation. A mutant PKI lacking the nuclear export signal blocked gene induction but not nuclear accumulation, demonstrating that nuclear export is not essential to inhibit gene induction. When the catalytic subunit was targeted to the nucleus with a nuclear localization signal, it was not sequestered in the cytoplasm by regulatory subunit, although its activity was completely inhibited. PKI redistributed the nuclear catalytic subunit to the cytoplasm and blocked gene induction, demonstrating that the nuclear export signal of PKI can override a strong nuclear localization signal. With increasing PKI, the export process appeared to saturate, resulting in the return of catalytic subunit to the nucleus. These results demonstrate that both the regulatory subunit and PKI are able to completely inhibit the gene-inducing activity of the catalytic subunit even when the catalytic subunit is forced to concentrate in the nuclear compartment.	Univ Washington, Dept Pharmacol, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	McKnight, GS (corresponding author), Univ Washington, Dept Pharmacol, Box 357750, Seattle, WA 98195 USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R29HD033057] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007270, R01GM032875] Funding Source: NIH RePORTER; NICHD NIH HHS [HD33057] Funding Source: Medline; NIGMS NIH HHS [GM32875, 2T32-GM07270] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Chen Q, 1997, J BIOL CHEM, V272, P15247, DOI 10.1074/jbc.272.24.15247; COGHLAN VM, 1993, MOL CELL BIOCHEM, V128, P309, DOI 10.1007/BF01076780; Collins SP, 1997, J BIOL CHEM, V272, P18169, DOI 10.1074/jbc.272.29.18169; CORRELL LA, 1989, J BIOL CHEM, V264, P16672; DAVIS LI, 1995, ANNU REV BIOCHEM, V64, P865, DOI 10.1146/annurev.bi.64.070195.004245; DellAcqua ML, 1997, J BIOL CHEM, V272, P12881, DOI 10.1074/jbc.272.20.12881; FANTOZZI DA, 1992, J BIOL CHEM, V267, P16824; FANTOZZI DA, 1994, J BIOL CHEM, V269, P2676; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; Guthrie CR, 1997, J BIOL CHEM, V272, P29560, DOI 10.1074/jbc.272.47.29560; HAROOTUNIAN AT, 1993, MOL BIOL CELL, V4, P993, DOI 10.1091/mbc.4.10.993; Huang LJS, 1997, J BIOL CHEM, V272, P8057, DOI 10.1074/jbc.272.12.8057; Huang LJS, 1997, P NATL ACAD SCI USA, V94, P11184, DOI 10.1073/pnas.94.21.11184; MATTHEWS RP, 1994, MOL CELL BIOL, V14, P6107, DOI 10.1128/MCB.14.9.6107; MEINKOTH JL, 1993, MOL CELL BIOCHEM, V128, P179, DOI 10.1007/BF01076769; MELLON PL, 1989, P NATL ACAD SCI USA, V86, P4887, DOI 10.1073/pnas.86.13.4887; MOCHLYROSEN D, 1995, SCIENCE, V268, P247, DOI 10.1126/science.7716516; Newmeyer DD, 1993, CURR OPIN CELL BIOL, V5, P395, DOI 10.1016/0955-0674(93)90003-9; NIGG EA, 1985, CELL, V41, P1039, DOI 10.1016/S0092-8674(85)80084-2; NIGG EA, 1985, EMBO J, V4, P2801, DOI 10.1002/j.1460-2075.1985.tb04006.x; Ohno M, 1998, CELL, V92, P327, DOI 10.1016/S0092-8674(00)80926-5; ORELLANA SA, 1993, J BIOL CHEM, V268, P6843; ORELLANA SA, 1992, P NATL ACAD SCI USA, V89, P4726, DOI 10.1073/pnas.89.10.4726; SCARPETTA MA, 1993, J BIOL CHEM, V268, P10927; SUN PQ, 1992, MOL ENDOCRINOL, V6, P1858, DOI 10.1210/me.6.11.1858; TAYLOR SS, 1993, RECEPTOR, V3, P165; THOMAS J, 1991, J BIOL CHEM, V266, P10906; WEN W, 1995, J BIOL CHEM, V270, P2041, DOI 10.1074/jbc.270.5.2041; WEN W, 1994, J BIOL CHEM, V269, P32214; WEN W, 1995, CELL, V82, P463, DOI 10.1016/0092-8674(95)90435-2	31	36	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1999	274	10					6381	6387		10.1074/jbc.274.10.6381	http://dx.doi.org/10.1074/jbc.274.10.6381			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172BQ	10037729	hybrid			2022-12-25	WOS:000078902800051
J	Chang, DK; Cheng, SF; Trivedi, VD				Chang, DK; Cheng, SF; Trivedi, VD			Biophysical characterization of the structure of the amino-terminal region of gp41 of HIV-1 - Implications on viral fusion mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; CELL-CELL FUSION; ENVELOPE GLYCOPROTEIN; MEMBRANE-FUSION; INFLUENZA HEMAGGLUTININ; ATOMIC-STRUCTURE; LEUCINE ZIPPER; PEPTIDE; DOMAIN; INFECTIVITY	A peptide of 51 amino acids corresponding to the NH2-terminal region (5-55) of the glycoprotein gp41 of human immunodeficiency virus type 1 was synthesized to study its conformation and assembly. Nuclear magnetic resonance experiments indicated the sequence NH2-terminal to the leucine zipper-like domain of gp41 was induced into helix in the micellar solution, in agreement with circular dichroism data. Light scattering experiment showed that the peptide molecules self-assembled in water into trimeric structure on average. That the peptide molecules oligomerize in aqueous solution was supported by gel filtration and diffusion coefficient experiments. Molecular dynamics simulation based on the NMR data revealed a flexible region adjacent to the hydrophobic NH2, terminus of gp41. The biological significance of the present findings on the conformational flexibility and the propensity of oligomerization of the peptide may be envisioned by a proposed model for the interaction of gp41 with membranes during fusion process.	Acad Sinica, Inst Chem, Taipei 11529, Taiwan	Academia Sinica - Taiwan	Chang, DK (corresponding author), Acad Sinica, Inst Chem, Taipei 11529, Taiwan.	dkc@chem.sinica.edu.tw	Cheng, Shu-Fang/ABE-1287-2020; Chang, Ding-Kwo/E-7079-2015	Cheng, Shu-Fang/0000-0003-0536-4404; 				AROETI B, 1991, J BIOL CHEM, V266, P15845; BERNSTEIN HB, 1995, J VIROL, V69, P2745, DOI 10.1128/JVI.69.5.2745-2750.1995; BULLOUGH PA, 1994, NATURE, V371, P37, DOI 10.1038/371037a0; Caffrey M, 1998, EMBO J, V17, P4572, DOI 10.1093/emboj/17.16.4572; CAO J, 1993, J VIROL, V67, P2747, DOI 10.1128/JVI.67.5.2747-2755.1993; CARR CI, 1950, J CHEM PHYS, V18, P1616, DOI 10.1063/1.1747550; Chan DC, 1997, CELL, V89, P263, DOI 10.1016/S0092-8674(00)80205-6; Chan DC, 1998, CELL, V93, P681, DOI 10.1016/S0092-8674(00)81430-0; Chang DK, 1997, J VIROL, V71, P6593, DOI 10.1128/JVI.71.9.6593-6602.1997; Chang DK, 1997, EUR J BIOCHEM, V247, P896, DOI 10.1111/j.1432-1033.1997.00896.x; ELLENS H, 1990, BIOCHEMISTRY-US, V29, P9697, DOI 10.1021/bi00493a027; FREED EO, 1990, P NATL ACAD SCI USA, V87, P4650, DOI 10.1073/pnas.87.12.4650; FREED EO, 1992, P NATL ACAD SCI USA, V89, P70, DOI 10.1073/pnas.89.1.70; Furuta RA, 1998, NAT STRUCT BIOL, V5, P276, DOI 10.1038/nsb0498-276; HENNESSEY JP, 1981, BIOCHEMISTRY-US, V20, P1085, DOI 10.1021/bi00508a007; Hernandez LD, 1996, ANNU REV CELL DEV BI, V12, P627, DOI 10.1146/annurev.cellbio.12.1.627; KEMBLE GW, 1994, CELL, V76, P383, DOI 10.1016/0092-8674(94)90344-1; Kliger Y, 1997, J BIOL CHEM, V272, P13496, DOI 10.1074/jbc.272.21.13496; KOWALSKI M, 1987, SCIENCE, V237, P1351, DOI 10.1126/science.3629244; MARSH M, 1989, ADV VIRUS RES, V36, P107, DOI 10.1016/S0065-3527(08)60583-7; Myers GK, 1995, HUMAN RETROVIRUSES A; NIEVA JL, 1994, BIOCHEMISTRY-US, V33, P3201, DOI 10.1021/bi00177a009; OSHEA EK, 1989, SCIENCE, V243, P538, DOI 10.1126/science.2911757; Pritsker M, 1998, P NATL ACAD SCI USA, V95, P7287, DOI 10.1073/pnas.95.13.7287; RAFALSKI M, 1990, BIOCHEMISTRY-US, V29, P7917, DOI 10.1021/bi00486a020; RAND RP, 1981, ANNU REV BIOPHYS BIO, V10, P277, DOI 10.1146/annurev.bb.10.060181.001425; SATTENTAU QJ, 1990, J EXP BIOL, V174, P407; SCHAAL H, 1995, J VIROL, V69, P3308, DOI 10.1128/JVI.69.6.3308-3314.1995; Shugars DC, 1996, J VIROL, V70, P2982, DOI 10.1128/JVI.70.5.2982-2991.1996; SLEPUSHKIN VA, 1992, AIDS RES HUM RETROV, V8, P9, DOI 10.1089/aid.1992.8.9; SPRUCE AE, 1991, P NATL ACAD SCI USA, V88, P3623, DOI 10.1073/pnas.88.9.3623; STEFFY KR, 1992, J VIROL, V66, P4532, DOI 10.1128/JVI.66.7.4532-4535.1992; Tan KM, 1997, P NATL ACAD SCI USA, V94, P12303, DOI 10.1073/pnas.94.23.12303; Weissenhorn W, 1997, NATURE, V387, P426, DOI 10.1038/387426a0; WHARTON SA, 1988, J GEN VIROL, V69, P1847, DOI 10.1099/0022-1317-69-8-1847; WHITE J, 1981, J CELL BIOL, V89, P674, DOI 10.1083/jcb.89.3.674; WHITE JM, 1992, SCIENCE, V258, P917, DOI 10.1126/science.1439803; WHITE JM, 1990, ANNU REV PHYSIOL, V52, P675, DOI 10.1146/annurev.ph.52.030190.003331; WILD C, 1994, P NATL ACAD SCI USA, V91, P12676, DOI 10.1073/pnas.91.26.12676; WISHART DS, 1994, METHOD ENZYMOL, V239, P363; WYATT PJ, 1993, ANAL CHIM ACTA, V272, P1, DOI 10.1016/0003-2670(93)80373-S	41	44	44	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 26	1999	274	9					5299	5309		10.1074/jbc.274.9.5299	http://dx.doi.org/10.1074/jbc.274.9.5299			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	170KG	10026137	hybrid			2022-12-25	WOS:000078804400008
J	Chelbi-Alix, MK; de The, H				Chelbi-Alix, MK; de The, H			Herpes virus induced proteasome-dependent degradation of the nuclear bodies-associated PML and Sp100 proteins	ONCOGENE			English	Article						nuclear bodies; PML; Sp100; ubiquitin; SUMO-1; HSV-1	ACUTE PROMYELOCYTIC LEUKEMIA; PRIMARY BILIARY-CIRRHOSIS; RETINOIC ACID; GROWTH-SUPPRESSOR; DOMAIN-10 ND10; PORE COMPLEX; RAR-ALPHA; CELLS; GENE; INTERFERON	The PML protein is associated to nuclear bodies (NBs) whose functions are as yet unknown. PML and two other NBs-associated proteins, Sp100 And ISG20 are directly induced by interferons (IFN). PML and Sp100 proteins are covalently linked to SUMO-1, and ubiquitin-like peptide. PML NBs are disorganized in acute promyelocytic leukemia and during several DNA virus infections. In particular, the HSV-1 ICP0 protein is known to delocalize PML from NBs. Thus, NBs could play an important role in oncogenesis, IFN response and viral infections. Here, we show that HSV-1 induced PML protein degradation without altering its mRNA level. This degradation was time- and multiplicity of infection-dependent. Sp100 protein was also degraded, while another SUMO-1 conjugated protein, RanGAP1 and the IFN-induced protein kinase PKR were not. The proteasome inhibitor MG132 abrogated the HSV-1-induced PML and Sp100 degradation and partially restored their NB-localization. HSV-1 induced PML and Sp100 degradation constitutes a new example of viral inactivation of IFN target gene products.	Univ Paris 07, Inst Univ Hematol, Com Paris Ligue Contre Canc, Lab Associe,CNRS,Unite Propre Rech 9051, Paris, France; Hop St Louis, Serv Biochim B, Paris, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite	Chelbi-Alix, MK (corresponding author), Hop St Louis, CNRS, UPR 9051, 1 Ave Vellefaux, F-75475 Paris 10, France.							Boddy MN, 1996, ONCOGENE, V13, P971; Borden KLB, 1998, J VIROL, V72, P758, DOI 10.1128/JVI.72.1.758-766.1998; CAMPBELL IG, 1994, HUM MOL GENET, V3, P589, DOI 10.1093/hmg/3.4.589; CARVALHO T, 1995, J CELL BIOL, V131, P45, DOI 10.1083/jcb.131.1.45; CAYLEY PJ, 1984, EUR J BIOCHEM, V143, P165, DOI 10.1111/j.1432-1033.1984.tb08355.x; CHEBIALIX MK, 1996, PML PRIMARY TARGET G; Chelbi-Alix MK, 1998, J VIROL, V72, P1043, DOI 10.1128/JVI.72.2.1043-1051.1998; ChelbiAlix MK, 1995, LEUKEMIA, V9, P2027; CHOU J, 1995, P NATL ACAD SCI USA, V92, P10516, DOI 10.1073/pnas.92.23.10516; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; DANIEL MT, 1993, BLOOD, V82, P1858; DEBOIS C, 1996, SCIENCE, V273, P951; DETHE H, 1990, NATURE, V347, P558, DOI 10.1038/347558a0; DYCK JA, 1994, CELL, V76, P333, DOI 10.1016/0092-8674(94)90340-9; EVERETT RD, 1994, EMBO J, V13, P5062, DOI 10.1002/j.1460-2075.1994.tb06835.x; Everett RD, 1997, EMBO J, V16, P566, DOI 10.1093/emboj/16.3.566; Everett RD, 1998, J VIROL, V72, P6581, DOI 10.1128/JVI.72.8.6581-6591.1998; FAGIOLI M, 1992, ONCOGENE, V7, P1083; FREEMONT PS, 1991, CELL, V64, P483, DOI 10.1016/0092-8674(91)90229-R; Gale M, 1998, PHARMACOL THERAPEUT, V78, P29, DOI 10.1016/S0163-7258(97)00165-4; GODDARD AD, 1991, SCIENCE, V254, P1371, DOI 10.1126/science.1720570; Gongora C, 1997, J BIOL CHEM, V272, P19457, DOI 10.1074/jbc.272.31.19457; Grotzinger T, 1996, J BIOL CHEM, V271, P25253, DOI 10.1074/jbc.271.41.25253; Grotzinger T, 1996, EUR J BIOCHEM, V238, P554, DOI 10.1111/j.1432-1033.1996.0554z.x; GULDNER HH, 1992, J IMMUNOL, V149, P4067; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; KASTNER P, 1992, EMBO J, V11, P629, DOI 10.1002/j.1460-2075.1992.tb05095.x; KOKEN MHM, 1995, ONCOGENE, V10, P1315; KOKEN MHM, 1994, EMBO J, V13, P1073, DOI 10.1002/j.1460-2075.1994.tb06356.x; Korioth F, 1996, EXP CELL RES, V229, P155, DOI 10.1006/excr.1996.0353; LAVAU C, 1995, ONCOGENE, V11, P871; Le XF, 1998, ONCOGENE, V16, P1839, DOI 10.1038/sj.onc.1201705; LIU JH, 1995, J EXP MED, V181, P1965, DOI 10.1084/jem.181.6.1965; Mahajan R, 1997, CELL, V88, P97, DOI 10.1016/S0092-8674(00)81862-0; Matunis MJ, 1996, J CELL BIOL, V135, P1457, DOI 10.1083/jcb.135.6.1457; MAUL GG, 1994, J GEN VIROL, V75, P1223, DOI 10.1099/0022-1317-75-6-1223; Maul GG, 1996, VIROLOGY, V217, P67, DOI 10.1006/viro.1996.0094; Maul GG, 1995, J CELL BIOCHEM, V59, P498, DOI 10.1002/jcb.240590410; MEREDITH M, 1995, VIROLOGY, V209, P174, DOI 10.1006/viro.1995.1241; Mu ZM, 1996, LEUKEMIA LYMPHOMA, V23, P277, DOI 10.3109/10428199609054830; Mu ZM, 1997, CARCINOGENESIS, V18, P2063, DOI 10.1093/carcin/18.11.2063; MU ZM, 1994, MOL CELL BIOL, V14, P6858, DOI 10.1128/MCB.14.10.6858; Muller S, 1998, EMBO J, V17, P61, DOI 10.1093/emboj/17.1.61; PANDOLFI PP, 1992, EMBO J, V11, P1397, DOI 10.1002/j.1460-2075.1992.tb05185.x; PEREZ A, 1993, EMBO J, V12, P3171, DOI 10.1002/j.1460-2075.1993.tb05986.x; PUVIONDUTILLEUL F, 1995, EXP CELL RES, V221, P448, DOI 10.1006/excr.1995.1396; REDDY BA, 1992, TRENDS BIOCHEM SCI, V17, P344, DOI 10.1016/0968-0004(92)90308-V; Rees S, 1996, BIOTECHNIQUES, V20, P102; SEN GC, 1993, ADV VIRUS RES, V42, P57, DOI 10.1016/S0065-3527(08)60083-4; Stadler M, 1995, ONCOGENE, V11, P2565; Sternsdorf T, 1997, IMMUNOBIOLOGY, V198, P307, DOI 10.1016/S0171-2985(97)80051-4; Sternsdorf T, 1997, J CELL BIOL, V139, P1621, DOI 10.1083/jcb.139.7.1621; Szekely L, 1996, J VIROL, V70, P2562, DOI 10.1128/JVI.70.4.2562-2568.1996; SZOSTECKI C, 1990, J IMMUNOL, V145, P4338; WEIS K, 1994, CELL, V76, P345, DOI 10.1016/0092-8674(94)90341-7; Yoshida H, 1996, CANCER RES, V56, P2945; Zhu J, 1997, P NATL ACAD SCI USA, V94, P3978, DOI 10.1073/pnas.94.8.3978	57	271	276	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 28	1999	18	4					935	941		10.1038/sj.onc.1202366	http://dx.doi.org/10.1038/sj.onc.1202366			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	165FT	10023669				2022-12-25	WOS:000078510600010
J	Fritz, G; Kaina, B				Fritz, G; Kaina, B			Phosphorylation of the DNA repair protein APE/REF-1 by CKII affects redox regulation of AP-1	ONCOGENE			English	Article						apurinic endonuclease; phosphorylation; casein kinase; DNA repair; AP-1; stress response	CASEIN KINASE-II; C-FOS; TOPOISOMERASE-II; ENZYME HAP1; TRANSCRIPTIONAL ACTIVITY; ATAXIA-TELANGIECTASIA; XERODERMA-PIGMENTOSUM; CELLULAR-PROTECTION; BINDING ACTIVITY; ACTIVITY INVITRO	The DNA repair protein apurinic endonuclease (APE/Ref-1) exerts several physiological functions such as cleavage of apurinic/apyrimidinic sites and redox regulation of the transcription factor AP-1, whose activation is part of the cellular response to DNA damaging treatments. Here we demonstrate that APE/Ref-1 is phosphorylated by casein kinase II (CKII), This was shown for both the recombinant APE/Ref-1 protein (Km = 0.55 mM) and for APE/Ref-1 expressed in COS cells. Phosphorylation of APE/Ref-1 did not alter the repair activity of the enzyme, whereas it stimulated its redox capability towards AP-1, thus promoting DNA binding activity of AP-1, Inhibition of CKII mediated phosphorylation of APE/Ref-1 blocked mutagen-stimulated increase in AP-1 binding. It also abrogated the induction of c-Jun protein and rendered cells more sensitive to induced DNA damage. Thus, phosphorylation of APE/Ref-1 appears to be involved in regulating the different physiological activities of the enzyme, CKII mediated phosphorylation of APE/Ref-1 and concomitant increase in AP-1 binding activity appears to be a novel mechanism of cellular stress response, forcing transcription of AP-1 target gene(s) the product(s) of which may exert protective function.	Univ Mainz, Inst Toxicol, Div Appl Toxicol, D-55131 Mainz, Germany	Johannes Gutenberg University of Mainz	Fritz, G (corresponding author), Univ Mainz, Inst Toxicol, Div Appl Toxicol, Obere Zahlbacher Str 67, D-55131 Mainz, Germany.							ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; ACKERMAN P, 1990, P NATL ACAD SCI USA, V87, P821, DOI 10.1073/pnas.87.2.821; ACKERMAN P, 1985, P NATL ACAD SCI USA, V82, P3164, DOI 10.1073/pnas.82.10.3164; AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; BARNES DE, 1992, CELL, V69, P495, DOI 10.1016/0092-8674(92)90450-Q; BARZILAY G, 1995, NUCLEIC ACIDS RES, V23, P1544, DOI 10.1093/nar/23.9.1544; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAIZERGUESFERRER M, 1987, BIOCHEMISTRY-US, V26, P7876, DOI 10.1021/bi00398a051; CAVIGELLI M, 1995, EMBO J, V14, P5957, DOI 10.1002/j.1460-2075.1995.tb00284.x; CHEN DS, 1991, NUCLEIC ACIDS RES, V19, P5907, DOI 10.1093/nar/19.21.5907; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; COCHET C, 1982, BIOCHEM PHARMACOL, V31, P1357, DOI 10.1016/0006-2952(82)90028-4; DENG TL, 1994, NATURE, V371, P171, DOI 10.1038/371171a0; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; Dosch J, 1996, ONCOGENE, V13, P1927; DUCEMAN BW, 1981, J BIOL CHEM, V256, P755; DURBAN E, 1985, EMBO J, V4, P2921, DOI 10.1002/j.1460-2075.1985.tb04024.x; Ford JM, 1997, J BIOL CHEM, V272, P28073, DOI 10.1074/jbc.272.44.28073; FRIEDBERG EC, 1995, DNA REPAIR MUTAGNESI; GRUNICKE H, 1994, ANN HEMATOL, V69, P1; GZUDER SN, 1994, NATURE, V369, P578; HAAS S, 1995, CARCINOGENESIS, V16, P985, DOI 10.1093/carcin/16.5.985; HAGIWARA M, 1988, BIOCHEM PHARMACOL, V37, P2987; HATHAWAY GM, 1982, CURR TOP CELL REGUL, V21, P101; ISSINGER OG, 1988, EMBO J, V7, P1621, DOI 10.1002/j.1460-2075.1988.tb02988.x; Jayaraman L, 1997, GENE DEV, V11, P558, DOI 10.1101/gad.11.5.558; JONES NJ, 1993, CARCINOGENESIS, V14, P2487, DOI 10.1093/carcin/14.12.2487; Kaina B, 1997, CANCER RES, V57, P2721; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LEE SK, 1984, J BIOL CHEM, V259, P4695; LEVIN JD, 1990, NUCLEIC ACIDS RES, V18, P5069, DOI 10.1093/nar/18.17.5069; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LIEBERMANN DA, 1995, ONCOGENE, V11, P199; LUSCHER B, 1990, NATURE, V344, P517, DOI 10.1038/344517a0; MATTER WF, 1992, BIOCHEM BIOPH RES CO, V186, P624, DOI 10.1016/0006-291X(92)90792-J; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; OKAZAKI T, 1994, J BIOL CHEM, V269, P27855; PRIGENT C, 1992, EMBO J, V11, P2925, DOI 10.1002/j.1460-2075.1992.tb05362.x; RITKE MK, 1995, MOL PHARMACOL, V48, P798; SACHSENMAIER C, 1994, CELL, V78, P963, DOI 10.1016/0092-8674(94)90272-0; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SCHNEIDER HR, 1986, EUR J BIOCHEM, V161, P733, DOI 10.1111/j.1432-1033.1986.tb10501.x; SCHREIBER M, 1995, EMBO J, V14, P5338, DOI 10.1002/j.1460-2075.1995.tb00218.x; SMITH PJ, 1989, CANCER RES, V49, P1118; SOMMERCORN J, 1987, J BIOL CHEM, V262, P3839; SRIVASTAVA AK, 1985, BIOCHEM BIOPH RES CO, V131, P1, DOI 10.1016/0006-291X(85)91761-9; STRYER L, 1998, BIOCHEMISTRY; TEITZ T, 1990, MUTAT RES, V236, P85, DOI 10.1016/0921-8777(90)90036-5; TUTEJA N, 1995, GENE, V160, P143, DOI 10.1016/0378-1119(95)00207-M; VANDAM H, 1993, EMBO J, V12, P479, DOI 10.1002/j.1460-2075.1993.tb05680.x; VANDAM H, 1995, EMBO J, V14, P1798, DOI 10.1002/j.1460-2075.1995.tb07168.x; Vassetzky YS, 1996, BRIT J CANCER, V73, P1201, DOI 10.1038/bjc.1996.231; Wada T, 1996, NUCLEIC ACIDS RES, V24, P876, DOI 10.1093/nar/24.5.876; WALKER LJ, 1993, MOL CELL BIOL, V13, P5370, DOI 10.1128/MCB.13.9.5370; WALKER LJ, 1994, NUCLEIC ACIDS RES, V22, P4884, DOI 10.1093/nar/22.23.4884; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang XZ, 1996, SCIENCE, V272, P1347, DOI 10.1126/science.272.5266.1347; WEEDA G, 1990, CELL, V62, P777, DOI 10.1016/0092-8674(90)90122-U; XANTHOUDAKIS S, 1992, EMBO J, V11, P3323, DOI 10.1002/j.1460-2075.1992.tb05411.x; YAO KS, 1994, MOL CELL BIOL, V14, P5997, DOI 10.1128/MCB.14.9.5997	60	97	101	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 28	1999	18	4					1033	1040		10.1038/sj.onc.1202394	http://dx.doi.org/10.1038/sj.onc.1202394			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	165FT	10023679				2022-12-25	WOS:000078510600020
J	Ma, JY; Simonovic, M; Qian, R; Colley, KJ				Ma, JY; Simonovic, M; Qian, R; Colley, KJ			Sialyltransferase isoforms are phosphorylated in the cis-medial Golgi on serine and threonine residues in their luminal sequences	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GALACTOSIDE ALPHA-2,6-SIALYLTRANSFERASE; RAT MAMMARY-GLAND; ENDOPLASMIC-RETICULUM; CASEIN KINASE; BREFELDIN-A; MEMBRANE-PROTEINS; N-ACETYLGALACTOSAMINYLTRANSFERASE; DETERMINES EXPRESSION; BINDING PROTEIN; SIGNAL ANCHOR	ST6Gal-I (alpha 2,6-sialyltransferase) is expressed as two isoforms, STTyr and STCys, which exhibit differences in catalytic activity, trafficking through the secretory pathway, and proteolytic processing and secretion. We have found that the ST6Gal-I isoforms are phosphorylated on luminal Ser and Thr residues. Immunoprecipitation of S-35- and P-32-labeled proteins expressed in COS-1 cells suggests that the STTyr isoform is phosphorylated to a greater extent than the STTyr isoform. Analysis of domain deletion mutants revealed that STTyr is phosphorylated on stem and catalytic domain amino acids, whereas STTyr is phosphorylated on catalytic domain amino acids. An endoplasmic reticulum retained/retrieved chimeric Iip33-ST protein demonstrates drastically lower phosphorylation than does the wild type STTyr isoform. This suggests that the bulk of the ST6Gal-I phosphorylation is occurring in the Golgi. Treatment of cells with the ionophore monensin does not significantly block phosphorylation of the STTyr isoform, suggesting that phosphorylation is occurring in the cis-medial Golgi prior to the monensin block. This study demonstrates the presence of kinase activities in the cia-medial Golgi and the substantial phosphorylation of the luminal sequences of a glycosyltransferase.	Univ Illinois, Coll Med, Dept Biochem & Mol Biol, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Colley, KJ (corresponding author), Univ Illinois, Coll Med, Dept Biochem & Mol Biol, 1819 W Polk St,M-C 536, Chicago, IL 60612 USA.	karenc@uic.edu		Simonovic, Miljan/0000-0002-1576-2222	NIGMS NIH HHS [GM48134] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048134, R29GM048134] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASHKAR S, 1995, ANN NY ACAD SCI, V760, P296, DOI 10.1111/j.1749-6632.1995.tb44639.x; BARTHOLOMEW BA, 1973, J BIOL CHEM, V248, P5751; CAPASSO JM, 1989, J BIOL CHEM, V264, P5233; CAPASSO JM, 1985, J BIOL CHEM, V260, P4879; Cho SK, 1997, GLYCOCONJUGATE J, V14, P809, DOI 10.1023/A:1018533804015; Cho SK, 1997, J BIOL CHEM, V272, P13622, DOI 10.1074/jbc.272.21.13622; CLAESSON L, 1983, P NATL ACAD SCI-BIOL, V80, P7395, DOI 10.1073/pnas.80.24.7395; Colley KJ, 1997, GLYCOBIOLOGY, V7, P1, DOI 10.1093/glycob/7.1.1-b; COLLEY KJ, 1992, J BIOL CHEM, V267, P7784; CSERMELY P, 1995, J BIOL CHEM, V270, P6381, DOI 10.1074/jbc.270.11.6381; DAGOSTARO G, 1989, EUR J BIOCHEM, V183, P211, DOI 10.1111/j.1432-1033.1989.tb14915.x; EIPPER BA, 1982, J BIOL CHEM, V257, P4907; GAUT JR, 1993, J BIOL CHEM, V268, P12691; GU XB, 1995, J NEUROCHEM, V64, P2295; HATHAWAY H J, 1991, Glycobiology, V1, P211, DOI 10.1093/glycob/1.2.211; HENDERSHOT LM, 1988, MOL CELL BIOL, V8, P4250, DOI 10.1128/MCB.8.10.4250; HOMA FL, 1993, J BIOL CHEM, V268, P12609; HUDGIN RL, 1971, CAN J BIOCHEM CELL B, V49, P829, DOI 10.1139/o71-117; Jaskiewicz E, 1996, J BIOL CHEM, V271, P26395, DOI 10.1074/jbc.271.42.26395; KAMPS MP, 1989, ANAL BIOCHEM, V176, P22, DOI 10.1016/0003-2697(89)90266-2; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; KRESSE H, 1986, CIBA F SYMP, V124, P89; KUKOWSKALATALLO JF, 1990, GENE DEV, V4, P1288, DOI 10.1101/gad.4.8.1288; LARSEN RD, 1989, P NATL ACAD SCI USA, V86, P8227, DOI 10.1073/pnas.86.21.8227; Lasa M, 1997, EUR J BIOCHEM, V243, P719, DOI 10.1111/j.1432-1033.1997.00719.x; Lasa M, 1997, BIOCHEM BIOPH RES CO, V240, P602, DOI 10.1006/bbrc.1997.7702; LasaBenito M, 1996, FEBS LETT, V382, P149, DOI 10.1016/0014-5793(96)00136-6; LIBERTI JP, 1985, BIOCHEM BIOPH RES CO, V128, P713, DOI 10.1016/0006-291X(85)90105-6; Ma JY, 1997, J BIOL CHEM, V272, P672; NARA K, 1994, P NATL ACAD SCI USA, V91, P7952, DOI 10.1073/pnas.91.17.7952; OETTING WS, 1986, J BIOL CHEM, V261, P1649; Osman N, 1996, J BIOL CHEM, V271, P33105, DOI 10.1074/jbc.271.51.33105; PAUL JI, 1984, J BIOL CHEM, V259, P3477; PAULSON JC, 1977, J BIOL CHEM, V252, P2356; Ramakrishnan M, 1997, J CELL PHYSIOL, V170, P115, DOI 10.1002/(SICI)1097-4652(199702)170:2<115::AID-JCP3>3.3.CO;2-J; Ridgway ND, 1998, BBA-LIPID LIPID MET, V1390, P37, DOI 10.1016/S0005-2760(97)00167-7; ROSA P, 1992, J BIOL CHEM, V267, P12227; ROSEMAN S, 1970, CHEM PHYS LIPIDS, V5, P270, DOI 10.1016/0009-3084(70)90024-1; SCHEIDELER MA, 1986, J NEUROCHEM, V46, P1639, DOI 10.1111/j.1471-4159.1986.tb01787.x; SCHUTZE MP, 1994, EMBO J, V13, P1696, DOI 10.1002/j.1460-2075.1994.tb06434.x; Skrincosky D, 1997, J BIOL CHEM, V272, P22695, DOI 10.1074/jbc.272.36.22695; SMITH PL, 1994, J BIOL CHEM, V269, P15162; STROUS GJ, 1987, EUR J BIOCHEM, V169, P307, DOI 10.1111/j.1432-1033.1987.tb13613.x; STROUS GJ, 1986, CRC CR REV BIOCH MOL, V21, P119, DOI 10.3109/10409238609113610; Swift LL, 1996, J BIOL CHEM, V271, P31491; TARTAKOFF AM, 1983, CELL, V32, P1026, DOI 10.1016/0092-8674(83)90286-6; Teasdale RD, 1996, ANNU REV CELL DEV BI, V12, P27, DOI 10.1146/annurev.cellbio.12.1.27; VARKI A, 1993, GLYCOBIOLOGY, V3, P97, DOI 10.1093/glycob/3.2.97; VARRO A, 1994, J BIOL CHEM, V269, P20764; VARRO A, 1993, BIOCHEM J, V295, P813, DOI 10.1042/bj2950813; VEGH M, 1994, BBA-PROTEIN STRUCT M, V1205, P49, DOI 10.1016/0167-4838(94)90090-6; Walter J, 1997, J BIOL CHEM, V272, P1896, DOI 10.1074/jbc.272.3.1896; WANG SY, 1982, J BIOL CHEM, V257, P3837; WEINSTEIN J, 1987, J BIOL CHEM, V262, P17735; WEST DW, 1983, EUR J BIOCHEM, V137, P215, DOI 10.1111/j.1432-1033.1983.tb07817.x; WU CB, 1995, CALCIFIED TISSUE INT, V57, P285, DOI 10.1007/BF00298884; Zhu GF, 1997, GLYCOBIOLOGY, V7, P987, DOI 10.1093/glycob/7.7.987	57	26	26	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	1999	274	12					8046	8052		10.1074/jbc.274.12.8046	http://dx.doi.org/10.1074/jbc.274.12.8046			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	178LU	10075704	hybrid			2022-12-25	WOS:000079268100063
J	Ahmed, M; Taylor, W; Smith, PR; Becker, MA				Ahmed, M; Taylor, W; Smith, PR; Becker, MA			Accelerated transcription of PRPS1 in X-linked overactivity of normal human phosphoribosylpyrophosphate synthetase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DELTA-GLOBIN GENE; SUBUNIT-I; PYROPHOSPHATE SYNTHETASE; HUMAN-FIBROBLASTS; PURINE OVERPRODUCTION; SUPERACTIVITY; EXPRESSION; THALASSEMIA; MUTATION; PROMOTER	Phosphoribosylpyrophosphate (PRPP) synthetase (PRS) superactivity is an X-linked disorder characterized by gout with overproduction of purine nucleotides and uric acid. Study of the two X-linked PRS isoforms (PRS1 and PRS2) in cells from certain affected individuals has shown selectively increased concentrations of structurally normal PRS1 transcript and isoform, suggesting that this form of the disorder involves pretranslational dysregulation of PRPS1 expression and might be more appropriately termed overactivity of normal PRS. We applied Southern and Northern blot analyses and slot blotting of nuclear runoffs to delineate the process underlying aberrant PRPS1 expression in fibroblasts and lymphoblasts from patients with overactivity of normal PRS, Neither PRPS1 amplification nor altered stability or processing of PRS1 mRNA was identified, but PRPS1 transcription was increased relative to GAPDH (3- to 4-fold normal in fibroblasts; 1.9 to 2.4-fold in lymphoblasts) and PRPS2, Nearly coordinate relative increases in each process mediating transfer of genetic information from PRPS1 transcription to maximal PRS1 isoform expression in patient fibroblasts further supported the idea that accelerated PRPS1 transcription is the major aberration leading to PRS1 overexpression. In addition, modulated relative increases in PRS activities at suboptimal Pi concentration and in rates of PRPP and purine nucleotide synthesis in intact patient fibroblasts indicate that despite an intact allosteric mechanism of regulation of PRS activity, PRPS1 transcription is a major determinant of PRPP and purine synthesis. The genetic basis of disordered PRPS1 transcription remains unresolved; normal- and patient-derived PRPS1s share nucleotide sequence identity at least 850 base pairs 5' to the consensus transcription initiation site.	Univ Chicago, Dept Med, Rheumatol Sect, Chicago, IL 60637 USA	University of Chicago	Becker, MA (corresponding author), Univ Chicago, Med Ctr, 5841 S Maryland Ave,MC 0930, Chicago, IL 60637 USA.	mbecker@medicine.bsd.uchicago.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK028554] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK28554] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANTONARAKIS SE, 1984, P NATL ACAD SCI-BIOL, V81, P1154, DOI 10.1073/pnas.81.4.1154; ARANOW BJ, 1992, MOL CELL BIOL, V12, P4170; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; Becker M.A., 1990, GENOMICS, V8, P550; BECKER MA, 1995, J CLIN INVEST, V96, P2133, DOI 10.1172/JCI118267; BECKER MA, 1976, J CLIN INVEST, V57, P308, DOI 10.1172/JCI108282; BECKER MA, 1980, J CLIN INVEST, V65, P109, DOI 10.1172/JCI109640; BECKER MA, 1987, J BIOL CHEM, V262, P5596; BECKER MA, 1986, BIOCHIM BIOPHYS ACTA, V882, P168, DOI 10.1016/0304-4165(86)90151-0; BECKER MA, 1986, ARTHRITIS RHEUM, V29, P880, DOI 10.1002/art.1780290710; Becker MA, 1996, J BIOL CHEM, V271, P19894, DOI 10.1074/jbc.271.33.19894; BECKER MA, 1987, J BIOL CHEM, V262, P14531; Becker MA, 1998, ADV EXP MED BIOL, V431, P215; BECKER MA, 1988, AM J MED, V85, P383, DOI 10.1016/0002-9343(88)90591-8; BECKER MA, 1973, SCIENCE, V179, P1123, DOI 10.1126/science.179.4078.1123; BECKER MA, 1982, J LAB CLIN MED, V99, P485; BERG PE, 1991, AM J HEMATOL, V36, P42, DOI 10.1002/ajh.2830360109; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; COLLINS FS, 1984, P NATL ACAD SCI-BIOL, V81, P4894, DOI 10.1073/pnas.81.15.4894; ERICKSON JM, 1981, GENE, V16, P1, DOI 10.1016/0378-1119(81)90055-X; FOX IH, 1972, J BIOL CHEM, V247, P2126; FOX IH, 1971, J BIOL CHEM, V246, P5739; GROSVELD F, 1987, CELL, V51, P975, DOI 10.1016/0092-8674(87)90584-8; HOLMES EW, 1973, J BIOL CHEM, V248, P6035; HOLMES EW, 1973, J BIOL CHEM, V248, P144; ISHIJIMA S, 1991, J BIOL CHEM, V266, P15693; ISHIZUKA T, 1992, BIOCHIM BIOPHYS ACTA, V1130, P139, DOI 10.1016/0167-4781(92)90521-Z; KORNBERG A, 1955, J BIOL CHEM, V215, P389; LOSMAN MJ, 1985, J CLIN INVEST, V76, P1657, DOI 10.1172/JCI112151; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARTIN DIK, 1989, NATURE, V338, P435, DOI 10.1038/338435a0; MARZLUFF WF, 1988, TRANSCRIPTION TRANSL, P89; MATSUDA M, 1992, BLOOD, V80, P1347; MOI P, 1992, BLOOD, V79, P512; NOSAL JM, 1993, J BIOL CHEM, V268, P10168; ORKIN SH, 1984, J BIOL CHEM, V259, P8679; SIMMONDS HA, 1985, NEUROPEDIATRICS, V16, P106, DOI 10.1055/s-2008-1052552; SONODA T, 1991, J BIOCHEM-TOKYO, V109, P361; SPERLING O, 1972, EUR J CLIN BIOL RES, V17, P703; TAIRA M, 1990, J BIOL CHEM, V265, P16491; TAIRA M, 1989, BIOCHIM BIOPHYS ACTA, V1007, P203, DOI 10.1016/0167-4781(89)90040-7; TAIRA M, 1989, SOMAT CELL MOLEC GEN, V15, P29, DOI 10.1007/BF01534667; Tatibana M, 1972, Adv Enzyme Regul, V10, P249, DOI 10.1016/0065-2571(72)90017-9; YEN RCK, 1981, J BIOL CHEM, V256, P1839; YEN RCK, 1978, P NATL ACAD SCI USA, V75, P482, DOI 10.1073/pnas.75.1.482; ZOREF E, 1975, J CLIN INVEST, V56, P1093, DOI 10.1172/JCI108183	46	35	38	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 12	1999	274	11					7482	7488		10.1074/jbc.274.11.7482	http://dx.doi.org/10.1074/jbc.274.11.7482			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	175DV	10066814	hybrid			2022-12-25	WOS:000079078400086
J	Barry, OP; Kazanietz, MG; Pratico, D; FitzGerald, GA				Barry, OP; Kazanietz, MG; Pratico, D; FitzGerald, GA			Arachidonic acid in platelet microparticles up-regulates cyclooxygenase-2-dependent prostaglandin formation via a protein kinase C mitogen-activated protein kinase-dependent pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NONSTEROIDAL ANTIINFLAMMATORY DRUGS; RAT MESANGIAL CELLS; PHORBOL ESTER; MAP KINASE; GENE-EXPRESSION; H SYNTHASE-2; ENDOPEROXIDE SYNTHASE-2; DIFFERENTIAL INHIBITION; STIMULATED PLATELETS; TRANSCRIPTION FACTOR	Activation of platelets results in shedding of membrane microparticles (RIP) with potentially bioactive properties. Platelet MP modulate platelet, monocyte, and vascular endothelial cell function, both by direct effects of MP arachidonic acid (AA) and by its metabolism to bioactive prostanoids. We have previously reported that platelet MP induce expression of cyclooxygenase (COX)-2 and prostacyclin production in monocytes and endothelial cells. To elucidate further the molecular mechanisms that underlie RIP-induced upregulation of COX-2 expression, we investigated the response of a human monocytoid (U-937) cell line to platelet MP stimulation, In U-937 cells, RIP-induced COX-2 expression and eicosanoid formation is prevented by pharmacological inhibitors of protein kinase C (PKC), PI 3-kinase, mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase, and p38 kinase, Treatment with the PI 3-kinase inhibitors wortmannin and LY294002 also blocked RIP-induced p42/p44 MAPK, p38, and JNK1 phosphorylation. Conversely, platelet RIP stimulation of U-937 cells results in direct activation of PKC, p42/p44 MAPK, p38 kinase, and c-Jun N-terminal kinase (JNK) as well as activation of the transcription factors c-Jun and Elk-l, However, MP failed to activate the cAMP response element. Activation of U-937 cells by MP induces translocation of classical (PKC beta), novel (PKC delta) and atypical (PKC zeta and PKC lambda) isozymes of PKC from the cytosol to the membrane, with concomitant activation of downstream MAPK. While RIP-induced activation of p42/p44 MAPK and p38 kinase is transient, a sustained activation of JNK1 was observed. Although PKC activation is required for RIP-induced p42/p44 MAPK, activation of the stress kinases p38 and JNK1 was PKC-independent, The fatty acid fraction of the MP accounted for these effects, which were mimicked by MP Ak Rather than acting directly via nuclear receptors, MP AA activates COX-2-dependent prostaglandin production by a PKC/p42/p44 MAPK/p38 kinase-sensitive pathway in which PI 3-kinase plays a significant role. RIP AA also stimulates transcriptional activation of COX-2 as well as c-Jun and Elk-1.	Univ Penn, Sch Med, Ctr Expt Therapeut, Stellar Chance Labs 905, Philadelphia, PA 19104 USA	University of Pennsylvania	FitzGerald, GA (corresponding author), Univ Penn, Sch Med, Ctr Expt Therapeut, Stellar Chance Labs 905, Philadelphia, PA 19104 USA.	garret@spirit.gcrc.upenn.edu	Pratico, Domenico/ABA-9590-2020; FitzGerald, Garret A/A-4222-2010	Barry, Orla/0000-0001-6364-3642	NCI NIH HHS [CA74197] Funding Source: Medline; NHLBI NIH HHS [HL57847, HL50400] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA074197] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL057847] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABRAMS CS, 1990, BLOOD, V75, P128; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Barry OP, 1997, J CLIN INVEST, V99, P2118, DOI 10.1172/JCI119385; Barry OP, 1998, J CLIN INVEST, V102, P136, DOI 10.1172/JCI2592; BIZIOS R, 1988, J CELL PHYSIOL, V134, P275, DOI 10.1002/jcp.1041340214; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BLUMER KJ, 1994, TRENDS BIOCHEM SCI, V19, P236, DOI 10.1016/0968-0004(94)90147-3; BOGOYEVITCH MA, 1994, J BIOL CHEM, V269, P1110; Caloca MJ, 1997, J BIOL CHEM, V272, P26488, DOI 10.1074/jbc.272.42.26488; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; CREMINON C, 1995, BBA-LIPID LIPID MET, V1254, P333, DOI 10.1016/0005-2760(94)00196-6; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; DAHLBACK B, 1992, BIOCHEMISTRY-US, V31, P12769, DOI 10.1021/bi00166a009; DEVAUX PF, 1993, CURR OPIN STRUC BIOL, V3, P489, DOI 10.1016/0959-440X(93)90072-S; FLETCHER BS, 1992, J BIOL CHEM, V267, P4338; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; Franklin CC, 1995, ONCOGENE, V11, P2365; Franklin RA, 1996, CLIN IMMUNOL IMMUNOP, V80, P116, DOI 10.1006/clin.1996.0104; GEORGE JN, 1986, J CLIN INVEST, V78, P340, DOI 10.1172/JCI112582; Guan ZH, 1998, J BIOL CHEM, V273, P12901, DOI 10.1074/jbc.273.21.12901; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; Gupta S, 1996, EMBO J, V15, P2760, DOI 10.1002/j.1460-2075.1996.tb00636.x; HABIB A, 1993, J BIOL CHEM, V268, P23448; HERSCHMAN HR, 1994, CANCER METAST REV, V13, P241, DOI 10.1007/BF00666095; Herschman HR, 1996, BBA-LIPID LIPID MET, V1299, P125, DOI 10.1016/0005-2760(95)00194-8; Herschman HR, 1997, ADV EXP MED BIOL, V407, P61; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HIPSKIND RA, 1994, GENE DEV, V8, P1803, DOI 10.1101/gad.8.15.1803; Holme PA, 1997, ARTERIOSCL THROM VAS, V17, P646, DOI 10.1161/01.ATV.17.4.646; ISSEKUTZ TB, 1981, AM J PATHOL, V103, P47; KAZANIETZ MG, 1993, MOL PHARMACOL, V44, P298; KESTER M, 1994, J BIOL CHEM, V269, P22574; KILEY SC, 1995, J CELL SCI, V108, P1003; KLIEWER SA, 1995, CELL, V83, P813, DOI 10.1016/0092-8674(95)90194-9; Kramer RM, 1996, J BIOL CHEM, V271, P27723, DOI 10.1074/jbc.271.44.27723; Kutchera W, 1996, P NATL ACAD SCI USA, V93, P4816, DOI 10.1073/pnas.93.10.4816; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LANEUVILLE O, 1994, J PHARMACOL EXP THER, V271, P927; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; LEE YJ, 1993, THROMB RES, V72, P295, DOI 10.1016/0049-3848(93)90138-E; LI Q, 1994, J BIOL CHEM, V269, P17508; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; Long SD, 1996, J BIOL CHEM, V271, P1138, DOI 10.1074/jbc.271.2.1138; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MEADE EA, 1993, J BIOL CHEM, V268, P6610; Miyazaki Y, 1996, BLOOD, V88, P3456, DOI 10.1182/blood.V88.9.3456.bloodjournal8893456; NAOR Z, 1988, MOL ENDOCRINOL, V2, P1043, DOI 10.1210/mend-2-11-1043; OHKI S, 1979, J BIOL CHEM, V254, P829; OLIVIER AR, 1992, J CELL PHYSIOL, V152, P240, DOI 10.1002/jcp.1041520204; Pratico D, 1996, J BIOL CHEM, V271, P8919, DOI 10.1074/jbc.271.15.8919; RAO GN, 1994, J BIOL CHEM, V269, P32586; Ridley SH, 1997, J IMMUNOL, V158, P3165; RIZZO MT, 1995, BLOOD, V86, P2967, DOI 10.1182/blood.V86.8.2967.bloodjournal8682967; SHEARMAN MS, 1991, FEBS LETT, V279, P261, DOI 10.1016/0014-5793(91)80163-W; SHOJI M, 1986, BIOCHEM BIOPH RES CO, V135, P1144, DOI 10.1016/0006-291X(86)91047-8; Siljander P, 1996, BLOOD, V87, P4651, DOI 10.1182/blood.V87.11.4651.bloodjournal87114651; SIMS PJ, 1988, J BIOL CHEM, V263, P18205; Singh N, 1995, CAN J CARDIOL, V11, P1015; SMITH WL, 1991, BIOCHIM BIOPHYS ACTA, V1083, P1, DOI 10.1016/0005-2760(91)90119-3; STROEBEL M, 1994, J BIOL CHEM, V269, P22952; SZALLASI Z, 1994, J BIOL CHEM, V269, P2118; SZALLASI Z, 1994, MOL PHARMACOL, V46, P840; TANS G, 1991, BLOOD, V77, P2641; TAZAWA R, 1994, BIOCHEM BIOPH RES CO, V203, P190, DOI 10.1006/bbrc.1994.2167; Topper JN, 1996, P NATL ACAD SCI USA, V93, P10417, DOI 10.1073/pnas.93.19.10417; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; Watabe M, 1998, ONCOGENE, V16, P779, DOI 10.1038/sj.onc.1201592; WAYS DK, 1987, CANCER RES, V47, P3344; Wymann MP, 1996, MOL CELL BIOL, V16, P1722; XIE WL, 1995, J BIOL CHEM, V270, P27622, DOI 10.1074/jbc.270.46.27622; YANG ZH, 1994, CIRCULATION, V89, P2266, DOI 10.1161/01.CIR.89.5.2266; ZACHOWSKI A, 1993, BIOCHEM J, V294, P1	73	202	206	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	1999	274	11					7545	7556		10.1074/jbc.274.11.7545	http://dx.doi.org/10.1074/jbc.274.11.7545			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	175DV	10066822	hybrid			2022-12-25	WOS:000079078400094
J	Fu, WM; Begley, JG; Killen, MW; Mattson, MP				Fu, WM; Begley, JG; Killen, MW; Mattson, MP			Anti-apoptotic role of telomerase in pheochromocytoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REVERSE-TRANSCRIPTASE INHIBITORS; AMPLIFICATION PROTOCOL TRAP; OXIDATIVE STRESS; DOWN-REGULATION; IMMORTAL CELLS; BCL-2; PROTEASES; CANCER; DEATH; DIFFERENTIATION	Telomerase is a protein-RNA enzyme complex that adds a six-base DNA sequence (TTAGGG) to the ends of chromosomes and thereby prevents their shortening. Reduced telomerase activity is associated with cell differentiation and accelerated cellular senescence, whereas increased telomerase activity is associated with cell transformation and immortalization, Because many types of cancer have been associated with reduced apoptosis, whereas cell differentiation and senescence have been associated with increased apoptosis, we tested the hypothesis that telomerase activity is mechanistically involved in the regulation of apoptosis. Levels of telomerase activity in cultured pheochromocytoma cells decreased prior to cell death in cells undergoing apoptosis, Treatment of cells with the oligodeoxynucleotide TTAGGG or with 3,3'-diethyloxadicarbocyanine, agents that inhibit telomerase activity in a concentration-dependent manner, significantly enhanced mitochondrial dysfunction and apoptosis induced by staurosporine, Fe2+ (an oxidative insult), and amyloid beta-peptide (a cytotoxic peptide linked to neuronal apoptosis in Alzheimer's disease). Overexpression of Bcl-2 and the caspase inhibitor zVAD-fmk protected cells against apoptosis in the presence of telomerase inhibitors, suggesting a site of action of telomerase prior to caspase activation and mitochondrial dysfunction, Telomerase activity decreased in cells during the process of nerve growth factor-induced differentiation, and such differentiated cells exhibited increased sensitivity to apoptosis, Our data establish a role for telomerase in suppressing apoptotic signaling cascades and suggest a mechanism whereby telomerase may suppress cellular senescence and promote tumor formation.	Univ Kentucky, Sanders Brown Res Ctr Aging, Lexington, KY 40536 USA; Univ Kentucky, Dept Anat & Neurobiol, Lexington, KY 40536 USA	University of Kentucky; University of Kentucky	Mattson, MP (corresponding author), Univ Kentucky, Sanders Brown Res Ctr Aging, 211 Sanders Brown Bldg, Lexington, KY 40536 USA.	mmattson@aging.coa.uky.edu	Mattson, Mark P/F-6038-2012					Antoku K, 1997, LEUKEMIA, V11, P1665, DOI 10.1038/sj.leu.2400805; BARRETT JC, 1994, COLD SPRING HARB SYM, V59, P411, DOI 10.1101/SQB.1994.059.01.046; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Bredesen DE, 1995, ANN NEUROL, V38, P839, DOI 10.1002/ana.410380604; Burger AM, 1997, EUR J CANCER, V33, P638, DOI 10.1016/S0959-8049(96)00521-7; Chao DT, 1998, ANNU REV IMMUNOL, V16, P395, DOI 10.1146/annurev.immunol.16.1.395; Chen Q, 1996, P NATL ACAD SCI USA, V93, P2635, DOI 10.1073/pnas.93.7.2635; COOKE HJ, 1986, COLD SPRING HARB SYM, V51, P213, DOI 10.1101/SQB.1986.051.01.026; D'Mello SR, 1998, CURR TOP DEV BIOL, V39, P187, DOI 10.1016/S0070-2153(08)60456-1; FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491; GREIDER CW, 1989, NATURE, V337, P331, DOI 10.1038/337331a0; Greider CW, 1996, SCI AM, V274, P92, DOI 10.1038/scientificamerican0296-92; Guo Q, 1998, NAT MED, V4, P957, DOI 10.1038/nm0898-957; Guo Q, 1997, J NEUROSCI, V17, P4212; HARLEY CB, 1991, MUTAT RES, V256, P271, DOI 10.1016/0921-8734(91)90018-7; Hetts SW, 1998, JAMA-J AM MED ASSOC, V279, P300, DOI 10.1001/jama.279.4.300; Higuchi Y, 1997, FREE RADICAL BIO MED, V23, P90, DOI 10.1016/S0891-5849(96)00589-8; JOHNSON LV, 1981, J CELL BIOL, V88, P526, DOI 10.1083/jcb.88.3.526; KANE DJ, 1993, SCIENCE, V262, P1274, DOI 10.1126/science.8235659; Keller JN, 1998, J NEUROSCI, V18, P687; Kidd VJ, 1998, ANNU REV PHYSIOL, V60, P533, DOI 10.1146/annurev.physiol.60.1.533; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kim NW, 1997, NUCLEIC ACIDS RES, V25, P2595, DOI 10.1093/nar/25.13.2595; Kondo Y, 1998, ONCOGENE, V16, P2243, DOI 10.1038/sj.onc.1201754; Kroemer G, 1997, IMMUNOL TODAY, V18, P44, DOI 10.1016/S0167-5699(97)80014-X; Kruman I, 1997, J NEUROSCI, V17, P5089; Kruman I, 1998, J NEUROSCI RES, V51, P293, DOI 10.1002/(SICI)1097-4547(19980201)51:3<293::AID-JNR3>3.0.CO;2-B; Lingner J, 1997, SCIENCE, V276, P561, DOI 10.1126/science.276.5312.561; LINNIK MD, 1993, STROKE, V24, P2002, DOI 10.1161/01.STR.24.12.2002; MacManus J P, 1996, Hum Cell, V9, P197; Mandal M, 1997, J BIOL CHEM, V272, P14183, DOI 10.1074/jbc.272.22.14183; Martin DS, 1997, CANCER INVEST, V15, P372, DOI 10.3109/07357909709039742; Mata JE, 1997, TOXICOL APPL PHARM, V144, P189, DOI 10.1006/taap.1997.8103; MATTSON MP, 1993, EXP NEUROL, V121, P1, DOI 10.1006/exnr.1993.1066; Miller D K, 1997, Semin Immunol, V9, P35, DOI 10.1006/smim.1996.0058; Miyake H, 1998, ONCOGENE, V16, P933, DOI 10.1038/sj.onc.1201602; MORIN GB, 1989, CELL, V59, P521, DOI 10.1016/0092-8674(89)90035-4; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; Reichman TW, 1997, J CELL BIOCHEM, V67, P13, DOI 10.1002/(SICI)1097-4644(19971001)67:1<13::AID-JCB2>3.0.CO;2-Z; RHYU MS, 1995, J NATL CANCER I, V87, P884, DOI 10.1093/jnci/87.12.884; Sabbah HN, 1998, PROG CARDIOVASC DIS, V40, P549, DOI 10.1016/S0033-0620(98)80003-0; Savoysky E, 1996, BIOCHEM BIOPH RES CO, V226, P329, DOI 10.1006/bbrc.1996.1356; Sharma HW, 1995, P NATL ACAD SCI USA, V92, P12343, DOI 10.1073/pnas.92.26.12343; Sharma S, 1997, ANN ONCOL, V8, P1063, DOI 10.1023/A:1008206420505; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; Stern G, 1996, ADV NEUROL, V69, P101; Strahl C, 1996, MOL CELL BIOL, V16, P53; Susin SA, 1997, J EXP MED, V186, P25, DOI 10.1084/jem.186.1.25; Takeda M, 1997, ARCH TOXICOL, V71, P612, DOI 10.1007/s002040050434; Warner HR, 1997, CURR TOP CELL REGUL, V35, P107, DOI 10.1016/S0070-2137(97)80004-0; WELLER M, 1995, J CLIN INVEST, V95, P2633, DOI 10.1172/JCI117965; WRIGHT WE, 1995, NUCLEIC ACIDS RES, V23, P3794, DOI 10.1093/nar/23.18.3794; Wyllie A H, 1980, Int Rev Cytol, V68, P251; Yegorov YE, 1996, FEBS LETT, V389, P115, DOI 10.1016/0014-5793(96)00533-9; ZAHLER AM, 1991, NATURE, V350, P718, DOI 10.1038/350718a0	55	222	246	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 12	1999	274	11					7264	7271		10.1074/jbc.274.11.7264	http://dx.doi.org/10.1074/jbc.274.11.7264			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	175DV	10066788	hybrid			2022-12-25	WOS:000079078400060
J	Haug, LS; Jensen, V; Hvalby, O; Walaas, SI; Ostvold, AC				Haug, LS; Jensen, V; Hvalby, O; Walaas, SI; Ostvold, AC			Phosphorylation of the inositol 1,4,5-trisphosphate receptor by cyclic nucleotide-dependent kinases in vitro and in rat cerebellar slices in situ	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASCULAR SMOOTH-MUSCLE; RECONSTITUTED LIPID VESICLES; LONG-TERM DEPRESSION; PROTEIN-KINASE; TRISPHOSPHATE RECEPTOR; CA2+ RELEASE; MAMMALIAN BRAIN; CALCIUM; CELLS; PURIFICATION	We have examined cyclic nucleotide-regulated phosphorylation of the neuronal type I inositol 1,4,5-trisphosphate (IP3) receptor immunopurified from rat cerebellar membranes in vitro and in rat cerebellar slices in situ, The isolated IP(3)eceptor protein was phosphorylated by both cAMP- and cGMP-dependent protein kinases on two distinct sites as determined by thermolytic phosphopeptide mapping, phosphopeptide 1, representing Ser-1589, and phosphopeptide 2, representing Ser-1756 in the rat protein (Ferris, C, D,, Cameron, A M,, Bredt, D, S,, Huganir, R, L,, and Snyder, S, H. (1991) Biochem. Biophys, Res. Commun. 175, 192-198), Phosphopeptide maps show that cAMP-dependent protein kinase (PKA) labeled both sites with the same time course and same stoichiometry, whereas cGMP-dependent protein kinase (PKG) phosphorylated Ser-1756 with a higher velocity and a higher stoichiometry than Ser-1589, Synthetic decapeptides corresponding to the two phosphorylation sites (peptide 1, AARRD (S) under bar VLAA (Ser-1589), and peptide 2, SGRRE (S) under bar LTSF (Ser-1756)) were used to determine kinetic constants for the phosphorylation by PKG and PKA, and the catalytic efficiencies were in agreement with the results obtained by in vitro phosphorylation of the intact protein. In cerebellar slices prelabeled with [P-32]orthophosphate, activation of endogenous kinases by incubation in the presence of cAMP/cGMP analogues and specific inhibitors of PKG and PKA induced in both cases a 3-fold increase in phosphorylation of the IP(3)eceptor. Thermolytic phosphopeptide mapping of in situ labeled IP(3)eceptor by PKA showed labeling on the same sites (Ser-1589 and Ser-1756) as in vitro. In contrast to the findings in vitro, PKG preferentially phosphorylated Ser-1589 in situ, Because both PKG and the IP(3)eceptor are specifically enriched in cerebellar Purkinje cells, PKG may be an important IP(3)eceptor regulator irt vivo.	Univ Oslo, Neurochem Lab, N-0317 Oslo, Norway; Univ Oslo, Dept Neurophysiol, N-0317 Oslo, Norway; Univ Oslo, Dept Grp Basic Med Sci, N-0317 Oslo, Norway	University of Oslo; University of Oslo; University of Oslo	Ostvold, AC (corresponding author), Univ Oslo, Neurochem Lab, POB 1115 Blindern, N-0317 Oslo, Norway.							BALTENSPERGER K, 1990, BIOCHEMISTRY-US, V29, P9753, DOI 10.1021/bi00493a035; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BERRIDGE MJ, 1993, NATURE, V365, P388, DOI 10.1038/365388a0; BURGESS GM, 1991, J BIOL CHEM, V266, P4772; CAMERON AM, 1995, CELL, V83, P463, DOI 10.1016/0092-8674(95)90124-8; CARAFOLI E, 1992, CURR TOP CELL REGUL, V32, P209; CASNELLIE JE, 1980, J BIOL CHEM, V255, P3770; Cavallini L, 1996, J BIOL CHEM, V271, P5545, DOI 10.1074/jbc.271.10.5545; Chatton JY, 1998, BIOCHEM J, V330, P1411, DOI 10.1042/bj3301411; CORNWELL TL, 1991, MOL PHARMACOL, V40, P923; DANOFF SK, 1991, P NATL ACAD SCI USA, V88, P2951, DOI 10.1073/pnas.88.7.2951; FERRIS CD, 1991, BIOCHEM BIOPH RES CO, V175, P192, DOI 10.1016/S0006-291X(05)81219-7; FERRIS CD, 1992, J BIOL CHEM, V267, P7036; FERRIS CD, 1991, P NATL ACAD SCI USA, V88, P2232, DOI 10.1073/pnas.88.6.2232; FURUICHI T, 1989, NATURE, V342, P32, DOI 10.1038/342032a0; FURUICHI T, 1995, J NEUROCHEM, V64, P953, DOI 10.1046/j.1471-4159.1995.64030953.x; Guihard G, 1996, BIOCHEM J, V318, P849, DOI 10.1042/bj3180849; HAJNOCZKY G, 1993, BIOCHEM J, V293, P413, DOI 10.1042/bj2930413; Haug LS, 1998, NEUROCHEM INT, V33, P109, DOI 10.1016/S0197-0186(98)00021-7; Haug LS, 1996, NEURODEGENERATION, V5, P169, DOI 10.1006/neur.1996.0024; HAUG LS, 1994, J NEUROCHEM S1, V63; HAUG LS, 1998, J NEUROCHEM S, V71; HEMART N, 1995, EUR J NEUROSCI, V7, P45, DOI 10.1111/j.1460-9568.1995.tb01019.x; Inoue T, 1998, J NEUROSCI, V18, P5366, DOI 10.1523/JNEUROSCI.18-14-05366.1998; IVES HE, 1980, J BIOL CHEM, V255, P3777; Jayaraman T, 1996, SCIENCE, V272, P1492, DOI 10.1126/science.272.5267.1492; Joseph SK, 1996, CELL SIGNAL, V8, P1, DOI 10.1016/0898-6568(95)02012-8; KACZMAREK LK, 1980, P NATL ACAD SCI-BIOL, V77, P7487, DOI 10.1073/pnas.77.12.7487; Khodakhah K, 1997, P NATL ACAD SCI USA, V94, P14009, DOI 10.1073/pnas.94.25.14009; KOGA T, 1994, J BIOL CHEM, V269, P11640; KOMALAVILAS P, 1994, J BIOL CHEM, V269, P8701; Komalavilas P, 1996, J BIOL CHEM, V271, P21933, DOI 10.1074/jbc.271.36.21933; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOHMANN SM, 1981, P NATL ACAD SCI-BIOL, V78, P653, DOI 10.1073/pnas.78.1.653; MAGNUSSON A, 1993, FEBS LETT, V323, P229, DOI 10.1016/0014-5793(93)81345-Z; MATTER N, 1993, J BIOL CHEM, V268, P732; NAKADE S, 1994, J BIOL CHEM, V269, P6735; PARKS TP, 1987, ARCH BIOCHEM BIOPHYS, V255, P361, DOI 10.1016/0003-9861(87)90404-8; QUINTON TM, 1992, BIOCHEM BIOPH RES CO, V184, P893, DOI 10.1016/0006-291X(92)90675-B; Quinton TM, 1996, BIOCHEMISTRY-US, V35, P6865, DOI 10.1021/bi960128m; Rooney TA, 1996, J BIOL CHEM, V271, P19817, DOI 10.1074/jbc.271.33.19817; Sharma K, 1997, J BIOL CHEM, V272, P14617, DOI 10.1074/jbc.272.23.14617; SHIBUKI K, 1991, NATURE, V349, P326, DOI 10.1038/349326a0; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SUPATTAPONE S, 1988, P NATL ACAD SCI USA, V85, P8747, DOI 10.1073/pnas.85.22.8747; SUPATTAPONE S, 1988, J BIOL CHEM, V263, P1530; TSOU K, 1993, P NATL ACAD SCI USA, V90, P3462, DOI 10.1073/pnas.90.8.3462; WALAAS SI, 1983, J NEUROSCI, V3, P291; WALAAS SI, 1989, J MOL NEUROSCI, V1, P117, DOI 10.1007/BF02918897; WALAAS SI, 1996, NEUROMETHODS, V30, P1; WEEKS G, 1988, SYNAPSE, V2, P89, DOI 10.1002/syn.890020112; WITT JJ, 1975, ANAL BIOCHEM, V66, P253, DOI 10.1016/0003-2697(75)90743-5; Wojcikiewicz RJH, 1998, J BIOL CHEM, V273, P5670, DOI 10.1074/jbc.273.10.5670; YAMAMOTO H, 1989, J NEUROCHEM, V53, P917, DOI 10.1111/j.1471-4159.1989.tb11792.x; ZHANG BX, 1993, J BIOL CHEM, V268, P10997; Zhu DM, 1996, BIOCHEMISTRY-US, V35, P7214, DOI 10.1021/bi952471h	56	91	95	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 12	1999	274	11					7467	7473		10.1074/jbc.274.11.7467	http://dx.doi.org/10.1074/jbc.274.11.7467			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	175DV	10066812	hybrid			2022-12-25	WOS:000079078400084
J	Lagree, V; Froger, A; Deschamps, S; Hubert, JF; Delamarche, C; Bonnec, G; Thomas, D; Gouranton, J; Pellerin, I				Lagree, V; Froger, A; Deschamps, S; Hubert, JF; Delamarche, C; Bonnec, G; Thomas, D; Gouranton, J; Pellerin, I			Switch from an aquaporin to a glycerol channel by two amino acids substitution	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KIDNEY COLLECTING DUCT; WATER CHANNEL; MOLECULAR-CLONING; ESCHERICHIA-COLI; XENOPUS-OOCYTES; MIP FAMILY; EXPRESSION; PROTEINS; SEQUENCE; CELLS	The MIP (major intrinsic protein) proteins constitute a channel family of currently 150 members that have been identified in cell membranes of organisms ranging from bacteria to man. Among these proteins, two functionally distinct subgroups are characterized: aquaporins that allow specific water transfer and glycerol channels that are involved in glycerol and small neutral solutes transport. Since the flow of small molecules across cell membranes is vital for every living organism, the study of such proteins is of particular interest, For instance, aquaporins located in kidney cell membranes are responsible for reabsorption of 150 liters of water/ day in adult human. To understand the molecular mechanisms of solute transport specificity, we analyzed mutant aquaporins in which highly conserved residues have been substituted by amino acids located at the same positions in glycerol channels. Here, we show that substitution of a tyrosine and a tryptophan by a proline and a leucine, respectively, in the sixth transmembrane helix of an aquaporin leads to a switch in the selectivity of the channel, from water to glycerol.	Univ Rennes 1, CNRS, UPRES A 6026, Equipe Canaux & Recepteurs Membranaires, F-35042 Rennes, France	Centre National de la Recherche Scientifique (CNRS); Universite de Rennes	Pellerin, I (corresponding author), Univ Rennes 1, CNRS, UPRES A 6026, Equipe Canaux & Recepteurs Membranaires, Batiment 13,Campus Beaulieu, F-35042 Rennes, France.		THOMAS, Danniel/AAJ-5033-2020; DELAMARCHE, Christian/A-2138-2010	THOMAS, Danniel/0000-0002-9650-0434; DELAMARCHE, Christian/0000-0002-8963-0062				BEURON F, 1995, J BIOL CHEM, V270, P17414, DOI 10.1074/jbc.270.29.17414; Cheng AC, 1997, NATURE, V387, P627, DOI 10.1038/42517; ECHEVARRIA M, 1994, P NATL ACAD SCI USA, V91, P10997, DOI 10.1073/pnas.91.23.10997; Froger A, 1998, PROTEIN SCI, V7, P1458, DOI 10.1002/pro.5560070623; Horton MR, 1991, DIRECTED MUTAGENESIS, P217; Ishibashi K, 1997, J BIOL CHEM, V272, P20782, DOI 10.1074/jbc.272.33.20782; Ishibashi K, 1998, NEWS PHYSIOL SCI, V13, P137; ISHIBASHI K, 1994, P NATL ACAD SCI USA, V91, P6269, DOI 10.1073/pnas.91.14.6269; JUNG JS, 1994, J BIOL CHEM, V269, P14648; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lagree V, 1998, J BIOL CHEM, V273, P12422, DOI 10.1074/jbc.273.20.12422; Lagree V, 1998, J BIOL CHEM, V273, P33949, DOI 10.1074/jbc.273.51.33949; LeCaherec F, 1996, EUR J BIOCHEM, V241, P707, DOI 10.1111/j.1432-1033.1996.00707.x; Li HL, 1997, NAT STRUCT BIOL, V4, P263, DOI 10.1038/nsb0497-263; MA TH, 1994, J BIOL CHEM, V269, P21845; MACARTHUR MW, 1991, J MOL BIOL, V218, P397, DOI 10.1016/0022-2836(91)90721-H; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MAUREL C, 1994, J BIOL CHEM, V269, P11869; MURAMATSU S, 1989, NUCLEIC ACIDS RES, V17, P4378; Park JH, 1996, J MEMBRANE BIOL, V153, P171, DOI 10.1007/s002329900120; PRESTON GM, 1992, SCIENCE, V256, P385, DOI 10.1126/science.256.5055.385; PRESTON GM, 1993, J BIOL CHEM, V268, P17; Sasaki S, 1998, ANNU REV PHYSIOL, V60, P199, DOI 10.1146/annurev.physiol.60.1.199; Tsukaguchi H, 1998, J BIOL CHEM, V273, P24737, DOI 10.1074/jbc.273.38.24737; Walz T, 1997, NATURE, V387, P624, DOI 10.1038/42512	25	90	91	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 12	1999	274	11					6817	6819		10.1074/jbc.274.11.6817	http://dx.doi.org/10.1074/jbc.274.11.6817			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	175DV	10066730	hybrid			2022-12-25	WOS:000079078400002
J	Moriyama, H; Horiuchi, H; Koga, R; Fukuhara, T				Moriyama, H; Horiuchi, H; Koga, R; Fukuhara, T			Molecular characterization of two endogenous double-stranded RNAs in rice and their inheritance by interspecific hybrids	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOPLASMIC MALE-STERILITY; VICIA-FABA; SACCHAROMYCES-CEREVISIAE; RIBONUCLEIC-ACID; REPLICON; TRANSMISSION; CULTIVARS; BARLEY	We completely sequenced 13,936 nucleotides (nt) of a double-stranded RNA (dsRNA) of wild rice (W-dsRNA). A single long open reading frame (13,719 nt) containing the conserved motifs of RNA-dependent RNA polymerase and RNA helicase was located in the coding strand. The identity between entire nucleotide sequence of W-dsRNA and that of the dsRNA of temperate japonica rice (J-dsRNA, 13,952 nt) was 75.5%. A site-specific discontinuity (nick) was identified at nt 1,197 from the 5' end of the coding strand of W-dsRNA. This nick is also located at nt 1,211 from the 5' end in the coding strand of J-dsRNA. The dsRNA copy number was increased more than 10-fold in pollen grains of both rice plants. This remarkable increase may be responsible for the highly efficient transmission of J-dsRNA via pollen that we already reported. J-dsRNA and W-dsRNA were also efficiently transmitted to interspecific F1 hybrids. Seed-mediated dsRNA transmission to F2 plants was also highly efficient when the maternal parent was wild rice. The efficiency of dsRNA transmission to F2 plants was reduced when the maternal parent was temperate japonica rice; however, the reduced rates in F2 plants were returned to high levels in F3 plants.	Tokyo Univ Agr & Technol, Fac Agr, Mol & Cellular Biol Lab, Tokyo 1838509, Japan	Tokyo University of Agriculture & Technology	Fukuhara, T (corresponding author), Tokyo Univ Agr & Technol, Fac Agr, Mol & Cellular Biol Lab, 3-5-8 Fuchu, Tokyo 1838509, Japan.	fuku@cc.tuat.ac.jp	Fukuhara, T./C-3208-2013; Moriyama, Hiromitsu/F-9256-2013					BROWN GG, 1989, INT REV CYTOL, V117, P1; FAIRBANKS DJ, 1988, THEOR APPL GENET, V76, P619, DOI 10.1007/BF00260917; FROHMAN MA, 1990, PCR PROTOCOLS GUIDE, P25; FUKUHARA T, 1995, J BIOL CHEM, V270, P18147, DOI 10.1074/jbc.270.30.18147; FUKUHARA T, 1993, PLANT MOL BIOL, V21, P1121, DOI 10.1007/BF00023608; GABRIEL CJ, 1987, PHYTOPATHOLOGY, V77, P92, DOI 10.1094/Phyto-77-92; GRILL LK, 1981, P NATL ACAD SCI-BIOL, V78, P7043, DOI 10.1073/pnas.78.11.7043; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; KADOWAKI K, 1971, J BACTERIOL, V105, P826, DOI 10.1128/JB.105.3.826-830.1971; LEFEBVRE A, 1990, PLANT MOL BIOL, V14, P477, DOI 10.1007/BF00027494; MACKENZIE SA, 1988, THEOR APPL GENET, V76, P59, DOI 10.1007/BF00288832; MATSUMOTO Y, 1990, P NATL ACAD SCI USA, V87, P7628, DOI 10.1073/pnas.87.19.7628; Matsuo T., 1997, SCI RICE PLANT, V3; Matzura O, 1996, COMPUT APPL BIOSCI, V12, P247; MORIYAMA H, 1995, MOL GEN GENET, V248, P364, DOI 10.1007/BF02191603; Moriyama H, 1996, PLANT MOL BIOL, V31, P713, DOI 10.1007/BF00019459; MORIYAMA H, 1999, IN PRESS PLANT MOL B; MORRIS TJ, 1979, PHYTOPATHOLOGY, V69, P854, DOI 10.1094/Phyto-69-854; PFEIFFER P, 1993, J GEN VIROL, V74, P1167, DOI 10.1099/0022-1317-74-6-1167; Pfeiffer P, 1998, J GEN VIROL, V79, P2349, DOI 10.1099/0022-1317-79-10-2349; TURPEN T, 1988, PLANT MOL BIOL, V10, P489, DOI 10.1007/BF00033604; VALVERDE RA, 1990, PLANT SCI, V67, P195, DOI 10.1016/0168-9452(90)90243-H; VALVERDE RA, 1991, J AM SOC HORTIC SCI, V116, P903, DOI 10.21273/JASHS.116.5.903; WAKARCHUK DA, 1985, PLANT MOL BIOL, V5, P55, DOI 10.1007/BF00017873; WANG B, 1990, THEOR APPL GENET, V79, P556, DOI 10.1007/BF00226167; WANG ZY, 1989, PLANT SCI, V61, P227, DOI 10.1016/0168-9452(89)90229-X; Wickner RB, 1996, MICROBIOL REV, V60, P250, DOI 10.1128/MMBR.60.1.250-265.1996; ZABALGOGEAZCOA I, 1993, PLANT SCI, V91, P45, DOI 10.1016/0168-9452(93)90187-5; ZABALGOGEAZCOA IA, 1992, PLANT SCI, V83, P187, DOI 10.1016/0168-9452(92)90078-Z	29	21	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	1999	274	11					6882	6888		10.1074/jbc.274.11.6882	http://dx.doi.org/10.1074/jbc.274.11.6882			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	175DV	10066741	hybrid			2022-12-25	WOS:000079078400013
J	Pahan, K; Raymond, JR; Singh, I				Pahan, K; Raymond, JR; Singh, I			Inhibition of phosphatidylinositol 3-kinase induces nitric-oxide synthase in lipopolysaccharide- or cytokine-stimulated C-6 glial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KAPPA-B-ALPHA; C6 GLIOMA-CELLS; SELECTIVE INHIBITOR; MULTIPLE-SCLEROSIS; MOLECULAR-CLONING; GLUCOSE-TRANSPORT; MAMMALIAN-CELLS; IN-VITRO; EXPRESSION; INDUCTION	Nitric oxide (NO) produced by inducible nitric-oxide synthase (iNOS) in different cells including brain cells in response to proinflammatory cytokines plays an important role in the pathophysiology of demyelinating and neurodegenerative diseases, The present study underlines the importance of phosphatidylinositol 3-kinase (PI 3-kinase) in the expression of iNOS in C-6 glial cells and rat primary astrocytes. Bacterial lipopolysaccharide (LPS) or interleukin-1 beta (IL-1 beta) was unable to induce the expression of iNOS and the production of NO in rat C-6 glial cells. Similarly, wortmannin and LY294002, compounds that inhibit PI3-kinase, were also unable to induce the expression of NOS and the production of NO. However, a combination of wortmannin or LY294002 with LPS or IL-1 beta induced the expression of iNOS and the production of NO in C-6 glial cells. Consistent with the induction of iNOS, wortmannin also induced iNOS promoter-derived chloramphenicol acetyltransferase activity in LPS- or IL-1 beta-treated C-6 glial cells. The expression of iNOS by LPS in C-6 glial cells expressing a dominant-negative mutant of p85 alpha, the regulatory subunit of PI 3-kinase, further supports the conclusion that inhibition of PI 3-kinase provides a necessary signal for the induction of iNOS, Next we examined the effect of wortmannin on the activation of mitogen-activated protein (MAP) kinase and nuclear factor NF-kappa B in LPS- or IL-1 beta-stimulated C-6 glial cells. In contrast to the inability of LPS and IL-1 beta alone to induce the expression of iNOS, both LPS and IL-1 beta individually stimulated MAP kinase activity and induced DNA binding and transcriptional activity of NF-kappa B, Wortmannin alone was unable to activate MAP kinase and NF-kappa B. Moreover, wortmannin had no effect on LPS- or IL-1 beta-mediated activation of MAP kinase and NF-kappa B, suggesting that wortmannin induced the expression of iNOS in LPS- or IL-1 beta-stimulated C-6 glial cells without modulating the activation of MAP kinase and NF-kappa B, Similar to C-6 glial cells, wortmannin also stimulated LPS-mediated expression of iNOS and production of NO in astrocytes without affecting the LPS-mediated activation of NF-kappa B, Taken together, the results from specific chemical inhibitors and dominant-negative mutant expression studies demonstrate that apart from the activation of NF-kappa B, inhibition of PI 3-kinase is also necessary for the expression of iNOS and production of NO.	Med Univ S Carolina, Dept Pediat, Charleston, SC 29425 USA; Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA	Medical University of South Carolina; Medical University of South Carolina	Singh, I (corresponding author), Med Univ S Carolina, Dept Pediat, 171 Ashley Ave, Charleston, SC 29425 USA.				NINDS NIH HHS [NS-37766, NS-34741, NS-22576] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R37NS022576, R01NS037766, R01NS022576, R01NS034741] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BEG AA, 1992, GENE DEV, V6, P1899, DOI 10.1101/gad.6.10.1899; BO L, 1994, ANN NEUROL, V36, P778, DOI 10.1002/ana.410360515; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; CROSS AH, 1994, J CLIN INVEST, V93, P2684, DOI 10.1172/JCI117282; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Dobashi K, 1997, J NEUROCHEM, V68, P1896; Eberhardt W, 1996, BIOCHEM BIOPH RES CO, V223, P752, DOI 10.1006/bbrc.1996.0968; FEINSTEIN DL, 1994, J NEUROCHEM, V62, P811; FEINSTEIN DL, 1994, J NEUROCHEM, V62, P315; GALEA E, 1992, P NATL ACAD SCI USA, V89, P10945, DOI 10.1073/pnas.89.22.10945; GELLER DA, 1993, P NATL ACAD SCI USA, V90, P3491, DOI 10.1073/pnas.90.8.3491; Ghoda L, 1997, J BIOL CHEM, V272, P21281, DOI 10.1074/jbc.272.34.21281; HARA K, 1994, P NATL ACAD SCI USA, V91, P7415, DOI 10.1073/pnas.91.16.7415; Hooper DC, 1997, P NATL ACAD SCI USA, V94, P2528, DOI 10.1073/pnas.94.6.2528; Hu SX, 1995, GLIA, V15, P491, DOI 10.1002/glia.440150412; Jaffrey SR, 1995, ANNU REV CELL DEV BI, V11, P417; KOPROWSKI H, 1993, P NATL ACAD SCI USA, V90, P3024, DOI 10.1073/pnas.90.7.3024; KWON G, 1995, ENDOCRINOLOGY, V136, P4790, DOI 10.1210/en.136.11.4790; Leist M, 1997, EUR J NEUROSCI, V9, P1488, DOI 10.1111/j.1460-9568.1997.tb01503.x; Liu Q, 1997, J IMMUNOL, V159, P829; MCCARTHY KD, 1980, J CELL BIOL, V85, P890, DOI 10.1083/jcb.85.3.890; MERRILL JE, 1993, J IMMUNOL, V151, P2132; Minshall C, 1996, J IMMUNOL, V156, P939; MITROVIC B, 1994, NEUROSCIENCE, V61, P575, DOI 10.1016/0306-4522(94)90435-9; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; NGUYEN VT, 1988, ANAL BIOCHEM, V171, P404, DOI 10.1016/0003-2697(88)90505-2; NISHIYA T, 1995, FEBS LETT, V371, P333, DOI 10.1016/0014-5793(95)00933-Z; OKADA T, 1994, J BIOL CHEM, V269, P3568; Pahan K, 1997, J CLIN INVEST, V100, P2671, DOI 10.1172/JCI119812; Pahan K, 1997, J BIOL CHEM, V272, P7786, DOI 10.1074/jbc.272.12.7786; Pahan K, 1998, J BIOL CHEM, V273, P2591, DOI 10.1074/jbc.273.5.2591; Pahan K, 1998, FREE RADICAL BIO MED, V24, P39, DOI 10.1016/S0891-5849(97)00137-8; Pahan K, 1998, J BIOL CHEM, V273, P12219, DOI 10.1074/jbc.273.20.12219; POWIS G, 1994, CANCER RES, V54, P2419; Salkowski CA, 1997, J IMMUNOL, V158, P905; STEFANOVA I, 1993, J BIOL CHEM, V268, P20725; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; Teruel T, 1998, J CELL PHYSIOL, V176, P99, DOI 10.1002/(SICI)1097-4652(199807)176:1<99::AID-JCP12>3.3.CO;2-6; WARD SG, 1992, J BIOL CHEM, V267, P23862; Xie KP, 1997, ONCOGENE, V15, P771, DOI 10.1038/sj.onc.1201239; XIE QW, 1994, J BIOL CHEM, V269, P4705	41	101	103	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 12	1999	274	11					7528	7536		10.1074/jbc.274.11.7528	http://dx.doi.org/10.1074/jbc.274.11.7528			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	175DV	10066820	hybrid			2022-12-25	WOS:000079078400092
J	Fjellstrom, O; Axelsson, M; Bizouarn, T; Hu, X; Johansson, C; Meuller, J; Rydstrom, J				Fjellstrom, O; Axelsson, M; Bizouarn, T; Hu, X; Johansson, C; Meuller, J; Rydstrom, J			Mapping of residues in the NADP(H)-binding site of proton-translocating nicotinamide nucleotide transhydrogenase from Escherichia coli - A study of structure and function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RHODOSPIRILLUM-RUBRUM; ADENINE-DINUCLEOTIDE; BINDING DOMAINS; PUMPING TRANSHYDROGENASE; DIRECTED MUTAGENESIS; BETA-SUBUNIT; MOBILE LOOP; PROTEIN; PREDICTION; ACID	Conformational changes in proton pumping transhydrogenases have been suggested to be dependent on binding of NADP(H) and the redox state of this substrate. Based on a detailed amino acid sequence analysis, it is argued that a classical beta alpha beta alpha beta dinucleotide binding fold is responsible for binding NADP(H). A model defining beta A, alpha B, beta B, beta D, and beta E of this domain is presented. To test this model, four single cysteine mutants (cf beta A348C, cf beta A390C, cf beta K424C, and cf beta RA25C) were introduced into a functional cysteine-free transhydrogenase. Also, five cysteine mutants were constructed in the isolated domain III of Escherichia coli transhydrogenase (ecIIIH345C, ecIIIA348C, ecIIIR350C, ecIIID392C, and ecIIIK424C). In addition to kinetic characterizations, effects of sulfhydryl-specific labeling with N-ethylmaleimide, 2-(4'-maleimidylanilino)naphthalene-6-sulfonic acid, and diazotized 3-aminopyridine adenine dinucleotide (phosphate) were examined. The results are consistent with the view that, in agreement with the model, beta-Ala(348), beta-Arg(350), beta-Ala(390), beta-Asp(392), and beta-Lys(424) are located in or close to the NADP(H) site. More specifically, beta-Ala(348) succeeds beta B. The remarkable reactivity of beta R350C toward NNADP suggests that this residue is close to the nicotinamide moiety of NADP(H). beta-Ala(390) and beta-Asp(392) terminate or succeed beta D, and are thus, together with the region following PA, creating the switch point crevice where NADP(H) binds. beta-Asp(392) is particularly important for the substrate affinity,but it could also have a more complex role in the coupling mechanism for transhydrogenase.	Univ Gothenburg, Dept Biochem & Biophys, S-40530 Gothenburg, Sweden; Chalmers Univ Technol, S-40530 Gothenburg, Sweden	University of Gothenburg; Chalmers University of Technology	Rydstrom, J (corresponding author), Univ Gothenburg, Dept Biochem & Biophys, Box 462, S-40530 Gothenburg, Sweden.		bizouarn, tania/W-6782-2019; Rydström, Jan/A-7683-2010					ADAMS MJ, 1970, NATURE, V227, P1098, DOI 10.1038/2271098a0; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; AMY NK, 1977, BIOCHIM BIOPHYS ACTA, V480, P83; ANDERSON BM, 1978, ARCH BIOCHEM BIOPHYS, V188, P214, DOI 10.1016/0003-9861(78)90374-0; Baker PJ, 1998, NAT STRUCT BIOL, V5, P561, DOI 10.1038/817; Bellamacina CR, 1996, FASEB J, V10, P1257, DOI 10.1096/fasebj.10.11.8836039; Bizouarn T, 1996, EUR J BIOCHEM, V239, P737, DOI 10.1111/j.1432-1033.1996.0737u.x; Bizouarn T, 1997, BBA-BIOENERGETICS, V1320, P265, DOI 10.1016/S0005-2728(97)00030-3; Bizouarn T, 1996, BBA-BIOENERGETICS, V1273, P4, DOI 10.1016/0005-2728(95)00125-5; Bragg PD, 1997, ARCH BIOCHEM BIOPHYS, V338, P57, DOI 10.1006/abbi.1996.9797; Bragg PD, 1996, EUR J BIOCHEM, V241, P611, DOI 10.1111/j.1432-1033.1996.00611.x; CHAN JK, 1975, J BIOL CHEM, V250, P67; DIGGLE C, 1995, EUR J BIOCHEM, V232, P315, DOI 10.1111/j.1432-1033.1995.tb20814.x; DIGGLE C, 1995, EUR J BIOCHEM, V228, P719, DOI 10.1111/j.1432-1033.1995.0719m.x; Diggle C, 1996, EUR J BIOCHEM, V241, P162, DOI 10.1111/j.1432-1033.1996.0162t.x; EBEL RE, 1981, ARCH BIOCHEM BIOPHYS, V211, P227, DOI 10.1016/0003-9861(81)90448-3; FISHER TL, 1973, J BIOL CHEM, V248, P4298; Fjellstrom O, 1999, BIOCHEMISTRY-US, V38, P415, DOI 10.1021/bi9817111; FJELLSTROM O, 1995, PROTEINS, V21, P91, DOI 10.1002/prot.340210203; Fjellstrom O, 1997, BIOCHEMISTRY-US, V36, P11331, DOI 10.1021/bi970958f; *GEN COMP GROUP, 1996, GCG SEQ AN SOFTW PAC; GLAVAS N, 1993, J BIOL CHEM, V268, P14125; GLAVAS NA, 1995, BIOCHEMISTRY-US, V34, P7694, DOI 10.1021/bi00023a016; HAUGLAND RP, 1996, HDB FLUORESCENT PROB, P49; HOLMBERG E, 1994, BIOCHEMISTRY-US, V33, P7691, DOI 10.1021/bi00190a024; HU X, 1995, BBA-BIOENERGETICS, V1229, P64, DOI 10.1016/0005-2728(94)00187-A; HU X, 1999, IN PRESS BIOCHEMISTR; HUTTON M, 1994, EUR J BIOCHEM, V219, P1041, DOI 10.1111/j.1432-1033.1994.tb18587.x; JACKSON JB, 1991, J BIOENERG BIOMEMBR, V23, P715, DOI 10.1007/BF00785998; KARPLUS PA, 1989, J MOL BIOL, V210, P163, DOI 10.1016/0022-2836(89)90298-2; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUBISTA M, 1994, ANALYST, V119, P417, DOI 10.1039/an9941900417; LANDT O, 1990, GENE, V96, P125, DOI 10.1016/0378-1119(90)90351-Q; Lesk AM, 1995, CURR OPIN STRUC BIOL, V5, P775, DOI 10.1016/0959-440X(95)80010-7; Meuller J, 1996, BBA-BIOENERGETICS, V1273, P191, DOI 10.1016/0005-2728(95)00154-9; Meuller J, 1997, BIOCHEM J, V324, P681, DOI 10.1042/bj3240681; NIEFIND K, 1991, J MOL BIOL, V219, P481, DOI 10.1016/0022-2836(91)90188-C; OLAUSSON T, 1995, BBA-BIOENERGETICS, V1231, P1, DOI 10.1016/0005-2728(95)00058-Q; OLAUSSON T, 1993, BIOCHEMISTRY-US, V32, P13237, DOI 10.1021/bi00211a036; PALMER T, 1992, BIOCHIM BIOPHYS ACTA, V1099, P157, DOI 10.1016/0304-4173(92)90022-7; REST B, 1994, PROTEINS, V20, P216; Rossmann M. G., 1975, ENZYMES, V11, P62; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; TONG RCW, 1991, BIOCHIM BIOPHYS ACTA, V1080, P19, DOI 10.1016/0167-4838(91)90106-A; Venning JD, 1997, J BIOL CHEM, V272, P27535, DOI 10.1074/jbc.272.44.27535; WOOLF JH, 1977, MOL CELL BIOCHEM, V15, P19, DOI 10.1007/BF01731286; YAMAGUCHI M, 1995, J BIOL CHEM, V270, P28165; Yamaguchi M, 1997, BBA-BIOENERGETICS, V1318, P225, DOI 10.1016/S0005-2728(96)00139-9	49	23	23	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1999	274	10					6350	6359		10.1074/jbc.274.10.6350	http://dx.doi.org/10.1074/jbc.274.10.6350			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172BQ	10037725	hybrid			2022-12-25	WOS:000078902800047
J	Dooley, KA; Bennett, MK; Osborne, TF				Dooley, KA; Bennett, MK; Osborne, TF			A critical role for cAMP response element-binding protein (CREB) as a co-activator in sterol-regulated transcription of 3-hydroxy-3-methylglutaryl coenzyme A synthase promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; CYCLIC-AMP; SOMATOSTATIN GENE; REDUCTASE GENE; RECEPTOR GENE; A SYNTHASE; NF-Y; IDENTIFICATION; FAMILY; EXPRESSION	3-Hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) synthase, a key regulatory enzyme in the pathway for endogenous cholesterol synthesis, is a target for negative feedback regulation by cholesterol, When cellular sterol levels are low, the sterol regulatory element-binding proteins (SREBPs) are released from the endoplasmic reticulum membrane, allowing them to translocate to the nucleus and activate SREBP target genes. However, in all SREBP-regulated promoters studied to date, additional co-regulatory transcription factors are required for sterol-regulated activation of transcription. We have previously shown that, in addition to SREBPs, NF-Y/CBF is required for sterol-regulated transcription of HMG-CoA synthase, This heterotrimeric transcription factor has recently been shown to function as a co-regulator in several other SREBP-regulated promoters, as well. In addition to cis-acting sites for both SREBP and NF-Y/CBF, the sterol regulatory region of the synthase promoter also contains a consensus cAMP response element (CRE), an element that binds members of the CREB/ATF family of transcription factors. Here, we show that this consensus CRE is essential for sterol-regulated transcription of the synthase promoter. Using in vitro binding assays, we also demonstrate that CREB binds to this CRE, and mutations within the CRE that result in a loss of CREB binding also result in a loss of sterol-regulated transcription. We further show that efficient activation of the synthase promoter in Drosophila SL2 cells requires the simultaneous expression of all three factors: SREBPs, NF-Y/CBF, and CREB. To date this is the first promoter shown to require CREB for efficient sterol-regulated transcription, and to require two different co-regulatory factors in addition to SREBPs for maximal activation.	Univ Calif Irvine, Dept Mol Biol & Biochem, Irvine, CA 92697 USA	University of California System; University of California Irvine	Osborne, TF (corresponding author), Univ Calif Irvine, Dept Mol Biol & Biochem, 19172 Jamboree Rd, Irvine, CA 92697 USA.	tfosborn@uci.edu			NHLBI NIH HHS [HL48044] Funding Source: Medline; NIGMS NIH HHS [GM07311] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048044] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BENBROOK D, 1990, ONCOGENE, V5, P293; BENNETT MK, 1995, J BIOL CHEM, V270, P25578, DOI 10.1074/jbc.270.43.25578; Brindle PK, 1992, CURR OPIN GENET DEV, V2, P199, DOI 10.1016/S0959-437X(05)80274-6; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; COMB M, 1986, NATURE, V323, P353, DOI 10.1038/323353a0; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; Dooley KA, 1998, J BIOL CHEM, V273, P1349, DOI 10.1074/jbc.273.3.1349; Ericsson J, 1996, P NATL ACAD SCI USA, V93, P945, DOI 10.1073/pnas.93.2.945; Ericsson J, 1997, J BIOL CHEM, V272, P7298, DOI 10.1074/jbc.272.11.7298; Ericsson J, 1996, J BIOL CHEM, V271, P24359, DOI 10.1074/jbc.271.40.24359; GIL G, 1986, J BIOL CHEM, V261, P3710; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; Guan GM, 1997, J BIOL CHEM, V272, P10295; HABENER JF, 1990, MOL ENDOCRINOL, V4, P1087, DOI 10.1210/mend-4-8-1087; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; JACKSON SM, 1995, J BIOL CHEM, V270, P21445, DOI 10.1074/jbc.270.37.21445; Klemm DJ, 1998, J BIOL CHEM, V273, P917, DOI 10.1074/jbc.273.2.917; LEE KAW, 1993, BIOCHIM BIOPHYS ACTA, V1174, P221, DOI 10.1016/0167-4781(93)90191-F; LEONARD J, 1992, P NATL ACAD SCI USA, V89, P6247, DOI 10.1073/pnas.89.14.6247; LIU F, 1990, CELL, V61, P1217, DOI 10.1016/0092-8674(90)90686-9; Lopez JM, 1996, P NATL ACAD SCI USA, V93, P1049, DOI 10.1073/pnas.93.3.1049; MEYER TE, 1993, ENDOCR REV, V14, P269, DOI 10.1210/er.14.3.269; MONTMINY MR, 1987, NATURE, V328, P175, DOI 10.1038/328175a0; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; OSBORNE TF, 1985, CELL, V42, P203, DOI 10.1016/S0092-8674(85)80116-1; OSBORNE TF, 1987, P NATL ACAD SCI USA, V84, P3614, DOI 10.1073/pnas.84.11.3614; Pai JT, 1998, J BIOL CHEM, V273, P26138, DOI 10.1074/jbc.273.40.26138; REHFUSS RP, 1991, J BIOL CHEM, V266, P18431; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SANCHEZ HB, 1995, J BIOL CHEM, V270, P1161, DOI 10.1074/jbc.270.3.1161; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; SHORT JM, 1986, J BIOL CHEM, V261, P9721; SMITH JR, 1988, J BIOL CHEM, V263, P18480; SUDHOF TC, 1987, J BIOL CHEM, V262, P10773; VALLEJO M, 1992, J BIOL CHEM, V267, P12876; VALLETT SM, 1994, NUCLEIC ACIDS RES, V22, P5184, DOI 10.1093/nar/22.24.5184; WINOTO A, 1989, EMBO J, V8, P729, DOI 10.1002/j.1460-2075.1989.tb03432.x; Xing J, 1996, SCIENCE, V273, P959, DOI 10.1126/science.273.5277.959; YAMAMOTO KK, 1988, NATURE, V334, P494, DOI 10.1038/334494a0	41	67	67	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 26	1999	274	9					5285	5291		10.1074/jbc.274.9.5285	http://dx.doi.org/10.1074/jbc.274.9.5285			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	170KG	10026135	hybrid			2022-12-25	WOS:000078804400006
J	Miseta, A; Fu, LW; Kellermayer, R; Buckley, J; Bedwell, DM				Miseta, A; Fu, LW; Kellermayer, R; Buckley, J; Bedwell, DM			The Golgi apparatus plays a significant role in the maintenance of Ca2+ homeostasis in the vps33 Delta vacuolar biogenesis mutant of Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							H+-ATPASE; PLASMA-MEMBRANE; YEAST MUTANTS; CALCINEURIN; CALCIUM; TRANSPORT; PMR1; HOMOLOG; CELLS; CYCLOSPORINE	The vacuole is the major site of intracellular Ca2+ storage in yeast and functions to maintain cytosolic Ca2+ levels within a narrow physiological range, In this study, we examined how cellular Ca2+ homeostasis is maintained in a vps33 Delta vacuolar biogenesis mutant. We found that growth of the vps33 Delta strain was sensitive to high or low extracellular Ca2+ This strain could not properly regulate cytosolic Ca2+ levels and was able to retain only a small fraction of its total cellular Ca2+ in a nonexchangeable intracellular pool. Surprisingly, the vps33 Delta strain contained more total cellular Ca2+ than the wild type strain. Because most cellular Ca2+ is normally found within the vacuole, this suggested that other intracellular compartments compensated for the reduced capacity to store Ca2+ within the vacuole of this strain. To test this hypothesis, we examined the contribution of the Golgi-localized Ca2+ ATPase Pmr1p in the maintenance of cellular Ca2+ homeostasis, We found that a vps33 Delta/pmr1 Delta strain was hypersensitive to high extracellular Ca2+. In addition, certain combinations of mutations effecting both vacuolar and Golgi Ca2+ transport resulted in synthetic lethality. These results indicate that the Golgi apparatus plays a significant role in maintaining Ca2+ homeostasis when vacuolar biogenesis is compromised.	Univ Alabama, Dept Microbiol, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham	Bedwell, DM (corresponding author), Univ Alabama, Dept Microbiol, Bevill Biomed Res Bldg,Rm 432, Birmingham, AL 35294 USA.	dbedwell@uab.edu		Miseta, Attila/0000-0002-7984-3347; Fu, Karl/0000-0001-5386-9429; Bedwell, David/0000-0002-6605-818X				ALLEN DG, 1977, SCIENCE, V195, P996, DOI 10.1126/science.841325; ANTEBI A, 1992, MOL BIOL CELL, V3, P633, DOI 10.1091/mbc.3.6.633; BANTA LM, 1990, MOL CELL BIOL, V10, P4638, DOI 10.1128/MCB.10.9.4638; BANTA LM, 1988, J CELL BIOL, V107, P1369, DOI 10.1083/jcb.107.4.1369; Batiza AF, 1996, J BIOL CHEM, V271, P23357, DOI 10.1074/jbc.271.38.23357; BONETTI B, 1995, J MOL BIOL, V251, P334, DOI 10.1006/jmbi.1995.0438; BREUDER T, 1994, P NATL ACAD SCI USA, V91, P5372, DOI 10.1073/pnas.91.12.5372; Bryant NJ, 1998, MICROBIOL MOL BIOL R, V62, P230, DOI 10.1128/MMBR.62.1.230-247.1998; Catty P, 1996, BIOSCIENCE REP, V16, P75, DOI 10.1007/BF01206198; CUNNINGHAM KW, 1994, J EXP BIOL, V196, P157; Cunningham KW, 1996, MOL CELL BIOL, V16, P2226; CUNNINGHAM KW, 1994, J CELL BIOL, V124, P351, DOI 10.1083/jcb.124.3.351; DUNN T, 1994, J BIOL CHEM, V269, P7273; Durr G, 1998, MOL BIOL CELL, V9, P1149, DOI 10.1091/mbc.9.5.1149; EILAM Y, 1985, J GEN MICROBIOL, V131, P623; FOOR F, 1992, NATURE, V360, P682; GARRETTENGELE P, 1995, MOL CELL BIOL, V15, P4103; Halachmi D, 1996, FEBS LETT, V392, P194, DOI 10.1016/0014-5793(96)00799-5; HEMENWAY CS, 1995, GENETICS, V141, P833; IIDA H, 1990, J BIOL CHEM, V265, P13391; JONES JS, 1990, YEAST, V6, P363, DOI 10.1002/yea.320060502; KITAMOTO K, 1988, J BACTERIOL, V170, P2687, DOI 10.1128/jb.170.6.2687-2691.1988; Miller J.H., 1992, SHORT COURSE BACTERI, P150; NAKAJIMASHIMADA J, 1991, P NATL ACAD SCI USA, V88, P6878, DOI 10.1073/pnas.88.15.6878; OHSUMI Y, 1988, J BACTERIOL, V170, P2676, DOI 10.1128/jb.170.6.2676-2682.1988; OHYA Y, 1986, J BACTERIOL, V165, P28, DOI 10.1128/jb.165.1.28-33.1986; OHYA Y, 1991, J BIOL CHEM, V266, P13971; OKOROKOV LA, 1980, J BACTERIOL, V144, P661, DOI 10.1128/JB.144.2.661-665.1980; OKOROKOV LA, 1978, IZV AKAD NAUK BIOL+, V5, P638; Pozos TC, 1996, MOL CELL BIOL, V16, P3730; Rieder SE, 1997, MOL BIOL CELL, V8, P2307, DOI 10.1091/mbc.8.11.2307; ROBINSON JS, 1988, MOL CELL BIOL, V8, P4936, DOI 10.1128/MCB.8.11.4936; Rose MD., 1990, METHODS YEAST GENETI; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; RUDOLPH HK, 1989, CELL, V58, P133, DOI 10.1016/0092-8674(89)90410-8; Sorin A, 1997, J BIOL CHEM, V272, P9895; STANTON MG, 1968, ANAL BIOCHEM, V22, P27, DOI 10.1016/0003-2697(68)90255-8; TANIDA I, 1995, J BIOL CHEM, V270, P10113, DOI 10.1074/jbc.270.17.10113; Tanida I, 1996, FEBS LETT, V379, P38, DOI 10.1016/0014-5793(95)01478-0; Withee JL, 1997, MOL BIOL CELL, V8, P263, DOI 10.1091/mbc.8.2.263	40	55	55	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 26	1999	274	9					5939	5947		10.1074/jbc.274.9.5939	http://dx.doi.org/10.1074/jbc.274.9.5939			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	170KG	10026219	hybrid			2022-12-25	WOS:000078804400090
J	Piossek, C; Schneider-Mergener, J; Schirner, M; Vakalopoulou, E; Germeroth, L; Thierauch, KH				Piossek, C; Schneider-Mergener, J; Schirner, M; Vakalopoulou, E; Germeroth, L; Thierauch, KH			Vascular endothelial growth factor (VEGF) receptor II-derived peptides inhibit VEGF	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE; PERMEABILITY FACTOR; CRYSTAL-STRUCTURE; LIGAND-BINDING; FLT-1 RECEPTOR; FACTOR FAMILY; IN-VIVO; ANGIOGENESIS; MITOGEN; CELLS	Vascular endothelial growth factor (VEGF) directly stimulates endothelial cell proliferation and migration via tyrosine kinase receptors of the split kinase domain family. It mediates vascular growth and angiogenesis in the embryo but also in the adult in a variety of physiological and pathological conditions. The potential binding site of VEGF with its receptor was identified using cellulose-bound overlapping peptides of the extracytosolic part of the human vascular endothelial growth factor receptor II (VEGFR II). Thus, a peptide originating from the third globular domain of the VEGFR II comprising residues (247)RTELNVGIDFNWEYP(261) was revealed as contiguous sequence stretch, which bound I-125-VEGF(165). A systematic replacement with L-amino acids within the peptide representing the putative VEGF-binding site on VEGFR II indicates Asp(255) as the hydrophilic key residue for binding. The dimerized peptide (RTELNVGIDFNWEYPAS)(2)K inhibits VEGF(165) binding with an IC50 of 0.5 mu M on extracellular VEGFR II fragments and 30 mu M on human umbilical vein cells. VEGF(165)-stimulated autophosphorylation of VEGFR II as well as proliferation and migration of microvascular endothelial cells was inhibited by the monomeric peptide RTELNVGIDFNWEYPASK at a half-maximal concentration of 3-10, 0.1, and 0.1 mu M, respectively, We conclude that transduction of the VEGF(165) signal can be interrupted with a peptide derived from the third Ig-like domain of VEGFR LI by blockade of VEGF(165) binding to its receptor.	JERINI BIO TOOLS GMBH, D-12489 Berlin, Germany; Humboldt Univ, Univ Klinikum Charite, Inst Med Immunol, D-10098 Berlin, Germany; Schering AG, Res Labs, D-13342 Berlin, Germany	Shire Pharmaceuticals Limited; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Schering AG	Germeroth, L (corresponding author), JERINI BIO TOOLS GMBH, Rudower Chaussee 5, D-12489 Berlin, Germany.							AdamKlages S, 1996, CELL, V86, P937, DOI 10.1016/S0092-8674(00)80169-5; Barleon B, 1997, J BIOL CHEM, V272, P10382; Birkenhager R, 1996, BIOCHEM J, V316, P703, DOI 10.1042/bj3160703; BRAY AM, 1991, TETRAHEDRON LETT, V32, P6163, DOI 10.1016/0040-4039(91)80779-6; Bussolino F, 1997, TRENDS BIOCHEM SCI, V22, P251, DOI 10.1016/S0968-0004(97)01074-8; Cao YH, 1996, J CLIN INVEST, V98, P2507, DOI 10.1172/JCI119069; DavisSmyth T, 1996, EMBO J, V15, P4919, DOI 10.1002/j.1460-2075.1996.tb00872.x; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; DISALVO J, 1995, J BIOL CHEM, V270, P7717, DOI 10.1074/jbc.270.13.7717; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; FERRARA N, 1992, ENDOCR REV, V13, P18, DOI 10.1210/er.13.1.18; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; FRANK R, 1992, TETRAHEDRON, V48, P9217, DOI 10.1016/S0040-4020(01)85612-X; GAUSEPOHL H, 1992, PEPTIDE RES, V5, P315; GOSPODAROWICZ D, 1989, P NATL ACAD SCI USA, V86, P7311, DOI 10.1073/pnas.86.19.7311; HOUCK KA, 1991, MOL ENDOCRINOL, V5, P1806, DOI 10.1210/mend-5-12-1806; HOUCK KA, 1992, J BIOL CHEM, V267, P26031; JACKSON CJ, 1990, J CELL SCI, V96, P257; JAKEMAN LB, 1992, J CLIN INVEST, V89, P244, DOI 10.1172/JCI115568; Joukov V, 1996, EMBO J, V15, P290; Kaplan JB, 1997, GROWTH FACTORS, V14, P243, DOI 10.3109/08977199709021523; KECK PJ, 1989, SCIENCE, V246, P1309, DOI 10.1126/science.2479987; Keyt BA, 1996, J BIOL CHEM, V271, P5638, DOI 10.1074/jbc.271.10.5638; Keyt BA, 1996, J BIOL CHEM, V271, P7788, DOI 10.1074/jbc.271.13.7788; KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0; Kramer A, 1997, CELL, V91, P799, DOI 10.1016/S0092-8674(00)80468-7; Kramer Achim, 1994, Methods (Orlando), V6, P388, DOI 10.1006/meth.1994.1039; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; Levy AP, 1996, J BIOL CHEM, V271, P2746, DOI 10.1074/jbc.271.5.2746; MAGLIONE D, 1991, P NATL ACAD SCI USA, V88, P9267, DOI 10.1073/pnas.88.20.9267; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; MILLAUER B, 1994, NATURE, V367, P576, DOI 10.1038/367576a0; Muller YA, 1997, P NATL ACAD SCI USA, V94, P7192, DOI 10.1073/pnas.94.14.7192; Neufeld Gera, 1994, Progress in Growth Factor Research, V5, P89, DOI 10.1016/0955-2235(94)90019-1; Olofsson B, 1996, P NATL ACAD SCI USA, V93, P2576, DOI 10.1073/pnas.93.6.2576; PLOUET J, 1989, EMBO J, V8, P3801, DOI 10.1002/j.1460-2075.1989.tb08557.x; Reineke U, 1998, PROTEIN SCI, V7, P951; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; Rudiger S, 1997, EMBO J, V16, P1501, DOI 10.1093/emboj/16.7.1501; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; SHIBUYA M, 1990, ONCOGENE, V5, P519; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; Siemeister G, 1998, P NATL ACAD SCI USA, V95, P4625, DOI 10.1073/pnas.95.8.4625; TERMAN BI, 1991, ONCOGENE, V6, P1677; TISCHER E, 1991, J BIOL CHEM, V266, P11947; VAISMAN N, 1990, J BIOL CHEM, V265, P19461; Wiesmann C, 1997, CELL, V91, P695, DOI 10.1016/S0092-8674(00)80456-0; YEO TK, 1991, BIOCHEM BIOPH RES CO, V179, P1568, DOI 10.1016/0006-291X(91)91752-X	49	40	53	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 26	1999	274	9					5612	5619		10.1074/jbc.274.9.5612	http://dx.doi.org/10.1074/jbc.274.9.5612			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	170KG	10026178	hybrid			2022-12-25	WOS:000078804400049
J	Tsunoda, SP; Muneyuki, E; Amano, T; Yoshida, M; Noji, H				Tsunoda, SP; Muneyuki, E; Amano, T; Yoshida, M; Noji, H			Cross-linking of two beta subunits in the closed conformation in F-1-ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI F1-ATPASE; MITOCHONDRIAL ADENOSINE-TRIPHOSPHATASE; APPARENT NEGATIVE COOPERATIVITY; THERMOPHILIC BACILLUS PS3; DISULFIDE BOND FORMATION; NUCLEOTIDE-BINDING SITE; CATALYTIC SITES; ATP HYDROLYSIS; ALPHA(3)BETA(3)GAMMA COMPLEX; NONCATALYTIC SITES	In the crystal structure of mitochondrial F-1-ATPase, two beta subunits with a bound Mg-nucleotide are in "closed" conformations, whereas the third beta subunit without bound nucleotide is in an "open" conformation. In this "CCO" (beta-closed beta-closed beta-open) conformational state, Ile-390s of the two closed beta subunits, even though they are separated by an intervening alpha subunit, have a direct contact. We replaced the equivalent Ile of the alpha(3)beta(3)gamma subcomplex of thermophilic F-1-ATPase with Cys and observed the formation of the beta-beta cross-link through a disulfide bond. The analysis of conditions required for the cross-link formation indicates that: (i) F-1-ATPase takes the CCO conformation when two catalytic sites are filled with Mg-nucleotide, (ii) intermediate(s) with the CCO conformation are generated during catalytic cycle, (iii) the Mg-ADP inhibited form is in the CCO conformation, and (iv) F-1-ATPase dwells in conformational state(s) other than CCO when only one (or none) of catalytic sites is filled by Mg-nucleotide or when catalytic sites are filled by Mg2+-free nucleotide, The alpha(3)beta(3)gamma subcomplex containing the beta-beta cross-link retained the activity of uni-site catalysis but lost that of multiple catalytic turnover, suggesting that open-closed transition of beta subunits is required for the rotation of gamma subunit but not for hydrolysis of a single ATP.	Tokyo Inst Technol, Resources Utilizat Res Lab, Yokohama, Kanagawa 226, Japan	Tokyo Institute of Technology	Yoshida, M (corresponding author), Tokyo Inst Technol, Resources Utilizat Res Lab, R-1,4259 Nagatsuta, Yokohama, Kanagawa 226, Japan.	myoshida@res.titech.ac.jp	Tsunoda, Satoshi/AAN-7023-2021	Tsunoda, Satoshi/0000-0003-3636-1521				ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; AGGELER R, 1995, J BIOL CHEM, V270, P9185, DOI 10.1074/jbc.270.16.9185; Amano T, 1996, J BIOL CHEM, V271, P18128, DOI 10.1074/jbc.271.30.18128; Boyer PD, 1997, ANNU REV BIOCHEM, V66, P717, DOI 10.1146/annurev.biochem.66.1.717; BULYGIN VV, 1991, BIOCHEM J, V276, P149, DOI 10.1042/bj2760149; CAPALDI RA, 1994, TRENDS BIOCHEM SCI, V19, P284, DOI 10.1016/0968-0004(94)90006-X; CROSS RL, 1982, J BIOL CHEM, V257, P2101; CUNNINGHAM D, 1988, J BIOL CHEM, V263, P18850; DUNCAN TM, 1995, P NATL ACAD SCI USA, V92, P10964, DOI 10.1073/pnas.92.24.10964; EBEL RE, 1975, J BIOL CHEM, V250, P191; Garcia JJ, 1998, J BIOL CHEM, V273, P15940, DOI 10.1074/jbc.273.26.15940; GOGOL EP, 1990, P NATL ACAD SCI USA, V87, P9585, DOI 10.1073/pnas.87.24.9585; Grodsky NB, 1998, BIOCHEMISTRY-US, V37, P1007, DOI 10.1021/bi972349d; Gruber G, 1996, J BIOL CHEM, V271, P32623, DOI 10.1074/jbc.271.51.32623; GRUBMEYER C, 1982, J BIOL CHEM, V257, P2092; HISABORI T, 1992, J BIOL CHEM, V267, P4551; Jault JM, 1995, BIOCHEMISTRY-US, V34, P16412, DOI 10.1021/bi00050a023; JAULT JM, 1993, J BIOL CHEM, V268, P1558; KAGAWA Y, 1984, J BIOCHEM-TOKYO, V95, P295, DOI 10.1093/oxfordjournals.jbchem.a134599; Kaibara C, 1996, J BIOL CHEM, V271, P2433, DOI 10.1074/jbc.271.5.2433; KATO Y, 1995, BBA-BIOENERGETICS, V1231, P275, DOI 10.1016/0005-2728(95)00087-Y; KUNKEL TA, 1991, METHOD ENZYMOL, V204, P125; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MATSUI T, 1995, BBA-BIOENERGETICS, V1231, P139, DOI 10.1016/0005-2728(95)00070-Y; Matsui T, 1997, J BIOL CHEM, V272, P8215, DOI 10.1074/jbc.272.13.8215; MILGROM YM, 1990, BIOCHIM BIOPHYS ACTA, V1020, P43, DOI 10.1016/0005-2728(90)90091-H; Milgrom YM, 1997, J BIOL CHEM, V272, P32211, DOI 10.1074/jbc.272.51.32211; MONTICELLO RA, 1992, J BACTERIOL, V174, P3370, DOI 10.1128/jb.174.10.3370-3376.1992; MUNEYUKI E, 1988, FEBS LETT, V234, P455, DOI 10.1016/0014-5793(88)80137-6; Muneyuki E, 1997, FEBS LETT, V413, P55, DOI 10.1016/S0014-5793(97)00878-8; MUNEYUKI E, 1993, BIOCHIM BIOPHYS ACTA, V1144, P62, DOI 10.1016/0005-2728(93)90031-A; MURATALIEV MB, 1991, BIOCHEMISTRY-US, V30, P8305, DOI 10.1021/bi00098a004; Noji H, 1997, NATURE, V386, P299, DOI 10.1038/386299a0; PAIK SR, 1994, BIOCHEMISTRY-US, V33, P126, DOI 10.1021/bi00167a016; Sabbert D, 1996, NATURE, V381, P623, DOI 10.1038/381623a0; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SENIOR AE, 1988, PHYSIOL REV, V68, P177, DOI 10.1152/physrev.1988.68.1.177; Shirakihara Y, 1997, STRUCTURE, V5, P825, DOI 10.1016/S0969-2126(97)00236-0; Stiggall D L, 1979, Methods Enzymol, V55, P308; VASILYEVA EA, 1982, BIOCHEM J, V202, P15, DOI 10.1042/bj2020015; VASILYEVA EA, 1982, BIOCHEM J, V202, P9, DOI 10.1042/bj2020009; WEBER J, 1994, J BIOL CHEM, V269, P20462; WEBER J, 1994, J BIOL CHEM, V269, P11261; WONG SY, 1984, BIOCHEMISTRY-US, V23, P5004, DOI 10.1021/bi00316a027; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; YOKOYAMA K, 1989, J BIOL CHEM, V264, P21837; YOSHIDA M, 1983, J BIOL CHEM, V258, P4407	47	39	39	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 26	1999	274	9					5701	5706		10.1074/jbc.274.9.5701	http://dx.doi.org/10.1074/jbc.274.9.5701			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	170KG	10026189	hybrid			2022-12-25	WOS:000078804400060
J	Compagno, D; Lampe, JN; Bourget, C; Kutyavin, IV; Yurchenko, L; Lukhtanov, EA; Gorn, VV; Gamper, HB; Toulme, JJ				Compagno, D; Lampe, JN; Bourget, C; Kutyavin, IV; Yurchenko, L; Lukhtanov, EA; Gorn, VV; Gamper, HB; Toulme, JJ			Antisense oligonucleotides containing modified bases inhibit in vitro translation of Leishmania amazonensis mRNAs by invading the mini-exon hairpin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRYPANOSOME MESSENGER-RNAS; SPLICED LEADER SEQUENCE; MODIFIED OLIGODEOXYNUCLEOTIDES; LEPTOMONAS-COLLOSOMA; SECONDARY STRUCTURE; GENE-EXPRESSION; COMMON; COMPLEMENTARY; PARASITES; BINDING	Complementary oligodeoxynucleotides (ODNs) that contain 2-aminoadenine and 2-thiothymine interact weakly with each other but form stable hybrids with unmodified complements, These selectively binding complementary (SBC) agents can invade duplex DNA and hybridize to each strand (Kutyavin, I. V., Rhinehart, R, L,, Lukhtanov, E, A, Gorn, V, V,, Meyer, R, B,, and Camper, H. B, (1996) Biochemistry 35, 11170-11176), Antisense ODNs with similar properties should be less encumbered by RNA secondary structure. Here we show that SEC ODNs strand invade a hairpin in the mini-exon RNA of Leishmania amazonensis and that the resulting heteroduplexes are substrates for Escherichia coli RNase H. SEC ODNs either with phosphodiester or phosphorothioate backbones form more stable hybrids with RNA than normal base (NB) ODNs, Optimal binding was observed when the entire hairpin sequence was targeted. Translation of L, amazonensis mRNA in a cell-free extract was more efficiently inhibited by SEC ODNs complementary to the mini-exon hairpin than by the corresponding NE ODNs, Nonspecific protein binding in the cell-free extract by phosphorothioate SEC ODNs rendered them ineffective as antisense agents in vitro. SEC phosphorothioate ODNs displayed a modest but significant improvement of leishmanicidal properties compared with NE phosphorothioate ODNs.	Univ Victor Segalen, INSERM, U 386, IFR Pathol Infect, F-33076 Bordeaux, France; Epoch Pharmaceut Inc, Bothell, WA 98021 USA; Inst Biorgan Chem, Novosibirsk, Russia	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite de Bordeaux	Toulme, JJ (corresponding author), Univ Victor Segalen, INSERM, U 386, IFR Pathol Infect, 146 Rue Leo Saignat, F-33076 Bordeaux, France.	jean-jacques.toulme@bordeaux.inserm.fr	Lampe, Jed N./J-8930-2019	Lampe, Jed N./0000-0003-0794-2263; Compagno, Daniel/0000-0002-7589-7217; Toulme, Jean-jacques/0000-0002-8432-5034				BANGS JD, 1992, J BIOL CHEM, V267, P9805; BOIZIAU C, 1991, NUCLEIC ACIDS RES, V19, P1113, DOI 10.1093/nar/19.5.1113; BORST P, 1986, ANNU REV BIOCHEM, V55, P701, DOI 10.1146/annurev.bi.55.070186.003413; BROWN DA, 1994, J BIOL CHEM, V269, P26801; BRUZIK JP, 1988, NATURE, V335, P559, DOI 10.1038/335559a0; CANTOR CR, 1970, BIOPOLYMERS, V9, P1059, DOI 10.1002/bip.1970.360090909; CAZENAVE C, 1987, NUCLEIC ACIDS RES, V15, P4717, DOI 10.1093/nar/15.12.4717; CAZENAVE C, 1993, BIOCHIMIE, V75, P113, DOI 10.1016/0300-9084(93)90032-N; Chastain M, 1993, ANTISENSE RES APPL, P55; CHEONG C, 1988, NUCLEIC ACIDS RES, V16, P5115, DOI 10.1093/nar/16.11.5115; CONNOLLY BA, 1989, NUCLEIC ACIDS RES, V17, P4957, DOI 10.1093/nar/17.13.4957; CORNELISSEN AWCA, 1986, NUCLEIC ACIDS RES, V14, P5605, DOI 10.1093/nar/14.14.5605; DEDIONISIO L, 1995, J CHROMATOGR B, V669, P125, DOI 10.1016/0378-4347(95)00153-A; Ecker DJ, 1993, ANTISENSE RES APPL, P387; GAMPER HB, 1993, NUCLEIC ACIDS RES, V21, P145, DOI 10.1093/nar/21.1.145; GARRIGA P, 1993, BIOCHEMISTRY-US, V32, P1067, DOI 10.1021/bi00055a011; HARRIS KA, 1995, RNA, V1, P351; HOWARD FB, 1984, BIOCHEMISTRY-US, V23, P6723, DOI 10.1021/bi00321a068; INOUE H, 1987, FEBS LETT, V215, P327, DOI 10.1016/0014-5793(87)80171-0; IYER RP, 1990, J ORG CHEM, V55, P4693, DOI 10.1021/jo00302a039; Kutyavin IV, 1996, BIOCHEMISTRY-US, V35, P11170, DOI 10.1021/bi960626v; LAPTEV AV, 1994, BIOCHEMISTRY-US, V33, P11033, DOI 10.1021/bi00202a024; LECUYER KA, 1993, BIOCHEMISTRY-US, V32, P5301, DOI 10.1021/bi00071a004; MILLER SI, 1986, NUCLEIC ACIDS RES, V14, P7341, DOI 10.1093/nar/14.18.7341; MISHRA RK, 1995, BBA-GENE STRUCT EXPR, V1264, P229, DOI 10.1016/0167-4781(95)00145-7; MONIA BP, 1993, J BIOL CHEM, V268, P14514; NEWMAN PC, 1990, BIOCHEMISTRY-US, V29, P9891, DOI 10.1021/bi00494a020; PASCOLO E, 1993, BIOCHIMIE, V75, P43, DOI 10.1016/0300-9084(93)90023-L; PASCOLO E, 1994, BBA-GENE STRUCT EXPR, V1219, P98, DOI 10.1016/0167-4781(94)90251-8; Pascolo E, 1996, J BIOL CHEM, V271, P24187, DOI 10.1074/jbc.271.39.24187; RAMAZEILLES C, 1994, P NATL ACAD SCI USA, V91, P7859, DOI 10.1073/pnas.91.17.7859; Toulme J. J., 1992, Antisense RNA and DNA., P175; Toulme JJ, 1996, BIOCHIMIE, V78, P663, DOI 10.1016/S0300-9084(96)80012-5; Toulme JJ, 1997, PARASITOLOGY, V114, pS45; UHLENBECK OC, 1995, RNA, V1, P4; VERSPIEREN P, 1987, GENE, V61, P307, DOI 10.1016/0378-1119(87)90194-6; VERSPIEREN P, 1990, NUCLEIC ACIDS RES, V18, P4711, DOI 10.1093/nar/18.16.4711; WALDER JA, 1986, SCIENCE, V233, P569, DOI 10.1126/science.3523758; Woo JS, 1996, NUCLEIC ACIDS RES, V24, P2470, DOI 10.1093/nar/24.13.2470	39	20	22	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	1999	274	12					8191	8198		10.1074/jbc.274.12.8191	http://dx.doi.org/10.1074/jbc.274.12.8191			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	178LU	10075723	hybrid			2022-12-25	WOS:000079268100082
J	Iwasaki, T; Hori, H; Hayashi, Y; Nishino, T				Iwasaki, T; Hori, H; Hayashi, Y; Nishino, T			Modulation of the remote heme site geometry of recombinant mouse neuronal nitric-oxide synthase by the N-terminal hook region	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXYGEN ACTIVATION; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; CYTOCHROME P-450-CAM; L-ARGININE; TETRAHYDROBIOPTERIN; EXPRESSION; COMPLEXES; DOMAIN; LIGAND	The role of two essential residues at the N-terminal hook region of neuronal nitric-oxide synthase (nNOS) in nitric-oxide synthase activity was investigated. Full-length mouse nNOS proteins containing single-point mutations of Thr-315 and Asp-314 to alanine were produced in the Escherichia coli and baculovirus-insect cell expression systems, The molecular properties of the mutant proteins were analyzed in detail by biochemical, optical, and electron paramagnetic resonance spectroscopic techniques and compared with those of the wildtype enzyme. Replacement of Asp-314 by Ala altered the geometry around the heme site and the substrate-binding pocket of the heme domain and abrogated the ability of nNOS to form catalytically active dimers, Replacement of Thr-315 by Ala reduced the protein stability and altered the geometry around the heme site, especially in the absence of bound (6R)-5,6,7,8-tetrahydro-L-biopterin cofactor. These results suggest that Asp-314 and Thr-315 both play critical structural roles in stabilizing the heme domain and subunit interactions in mouse nNOS.	Nippon Med Sch, Dept Biochem & Mol Biol, Bunkyo Ku, Tokyo 1138602, Japan	Nippon Medical School	Iwasaki, T (corresponding author), Nippon Med Sch, Dept Biochem & Mol Biol, Bunkyo Ku, 1-1-5 Sendagi, Tokyo 1138602, Japan.			Iwasaki, Toshio/0000-0001-9562-4649				ANDERSSON LA, 1991, STRUCT BOND, V74, P1; BAEK KJ, 1993, J BIOL CHEM, V268, P21120; BREDT DS, 1994, ANNU REV BIOCHEM, V63, P175, DOI 10.1146/annurev.bi.63.070194.001135; Crane BR, 1997, SCIENCE, V278, P425, DOI 10.1126/science.278.5337.425; Crane BR, 1998, SCIENCE, V279, P2121, DOI 10.1126/science.279.5359.2121; DAWSON JH, 1987, CHEM REV, V87, P1255, DOI 10.1021/cr00081a015; Eissa NT, 1998, P NATL ACAD SCI USA, V95, P7625, DOI 10.1073/pnas.95.13.7625; GERBER NC, 1994, J BIOL CHEM, V269, P4260; GERBER NC, 1995, J BIOL CHEM, V270, P17791, DOI 10.1074/jbc.270.30.17791; Ghosh DK, 1997, BIOCHEMISTRY-US, V36, P10609, DOI 10.1021/bi9702290; GIOVANELLI J, 1991, P NATL ACAD SCI USA, V88, P7091, DOI 10.1073/pnas.88.16.7091; GrahamLorence S, 1996, FASEB J, V10, P206, DOI 10.1096/fasebj.10.2.8641554; GRIFFITH OW, 1995, ANNU REV PHYSIOL, V57, P707, DOI 10.1146/annurev.ph.57.030195.003423; HASEMANN CA, 1995, STRUCTURE, V3, P41, DOI 10.1016/S0969-2126(01)00134-4; HEVEL JM, 1992, BIOCHEMISTRY-US, V31, P7160, DOI 10.1021/bi00146a019; Hori H, 1997, BIOCHEM BIOPH RES CO, V234, P476, DOI 10.1006/bbrc.1997.6664; IMAI M, 1989, P NATL ACAD SCI USA, V86, P7823, DOI 10.1073/pnas.86.20.7823; IWASAKI T, 1994, J BIOL CHEM, V269, P29444; IWASAKI T, 1997, J INORG BIOCHEM, V67, P103; KLATT P, 1995, EMBO J, V14, P3687, DOI 10.1002/j.1460-2075.1995.tb00038.x; KNOWLES RG, 1994, BIOCHEM J, V298, P249, DOI 10.1042/bj2980249; Lowe PN, 1996, BIOCHEM J, V314, P55, DOI 10.1042/bj3140055; MARLETTA MA, 1993, J BIOL CHEM, V268, P12231; MASTERS BSS, 1994, ANNU REV NUTR, V14, P131, DOI 10.1146/annurev.nu.14.070194.001023; Mayer B, 1997, BIOCHEMISTRY-US, V36, P8422, DOI 10.1021/bi970144z; Migita CT, 1997, BIOCHEMISTRY-US, V36, P10987, DOI 10.1021/bi970823+; MUCHMORE DC, 1989, METHOD ENZYMOL, V177, P44; NAKANE M, 1995, BIOCHEM BIOPH RES CO, V206, P511, DOI 10.1006/bbrc.1995.1073; OGURA T, 1993, BIOCHEM BIOPH RES CO, V193, P1014, DOI 10.1006/bbrc.1993.1726; Park SY, 1997, NAT STRUCT BIOL, V4, P827, DOI 10.1038/nsb1097-827; Possee RD., 1992, BACULOVIRUS EXPRESSI; Poulos TL, 1996, J BIOL INORG CHEM, V1, P356, DOI 10.1007/s007750050064; Poulos TL, 1995, CURR OPIN STRUC BIOL, V5, P767, DOI 10.1016/0959-440X(95)80009-3; POULOS TL, 1992, FASEB J, V6, P674, DOI 10.1096/fasebj.6.2.1537455; Presta A, 1998, BIOCHEMISTRY-US, V37, P298, DOI 10.1021/bi971944c; RAAG R, 1991, BIOCHEMISTRY-US, V30, P11420, DOI 10.1021/bi00112a008; RAVICHANDRAN KG, 1993, SCIENCE, V261, P731, DOI 10.1126/science.8342039; RICHARDS MK, 1994, BIOCHEMISTRY-US, V33, P14723, DOI 10.1021/bi00253a010; Rietjens IMCM, 1996, J BIOL INORG CHEM, V1, P372, DOI 10.1007/s007750050068; RIVEROSMORENO V, 1995, EUR J BIOCHEM, V230, P52; RodriguezCrespo I, 1997, BIOCHEMISTRY-US, V36, P8530, DOI 10.1021/bi970192j; RodriguezCrespo I, 1996, J BIOL CHEM, V271, P11462, DOI 10.1074/jbc.271.19.11462; ROMAN LJ, 1995, P NATL ACAD SCI USA, V92, P8428, DOI 10.1073/pnas.92.18.8428; Sagami I, 1998, J BIOL CHEM, V273, P2105, DOI 10.1074/jbc.273.4.2105; Siddhanta U, 1998, J BIOL CHEM, V273, P18950, DOI 10.1074/jbc.273.30.18950; Silvagno F, 1996, J BIOL CHEM, V271, P11204, DOI 10.1074/jbc.271.19.11204; SONO M, 1982, J BIOL CHEM, V257, P5496; SONO M, 1995, J BIOL CHEM, V270, P19943, DOI 10.1074/jbc.270.34.19943; Sono M, 1996, CHEM REV, V96, P2841, DOI 10.1021/cr9500500; STUEHR DJ, 1991, J BIOL CHEM, V266, P6259; Stuehr DJ, 1997, ANNU REV PHARMACOL, V37, P339, DOI 10.1146/annurev.pharmtox.37.1.339; STUEHR DJ, 1992, J BIOL CHEM, V267, P20547; Summers MD, 1987, TEXAS AGR EXPT STATI; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Vidakovic M, 1998, BIOCHEMISTRY-US, V37, P9211, DOI 10.1021/bi980189f; WANG JL, 1993, J BIOL CHEM, V268, P22255; WANG JL, 1995, BIOCHEMISTRY-US, V34, P7080, DOI 10.1021/bi00021a020; WORLEY KC, 1995, GENOME RES, V5, P173, DOI 10.1101/gr.5.2.173; YEOM H, 1995, BIOCHEMISTRY-US, V34, P14733, DOI 10.1021/bi00045a014	59	7	7	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	1999	274	12					7705	7713		10.1074/jbc.274.12.7705	http://dx.doi.org/10.1074/jbc.274.12.7705			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	178LU	10075660	hybrid			2022-12-25	WOS:000079268100019
J	Orii, KE; Orii, KO; Souri, M; Orii, T; Kondo, N; Hashimoto, T; Aoyama, T				Orii, KE; Orii, KO; Souri, M; Orii, T; Kondo, N; Hashimoto, T; Aoyama, T			Genes for the human mitochondrial trifunctional protein alpha- and beta-subunits are divergently transcribed from a common promoter region	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3-HYDROXYACYL-COA DEHYDROGENASE-DEFICIENCY; DIHYDROFOLATE-REDUCTASE GENE; PSEUDOMONAS-FRAGI B-0771; FATTY-ACID OXIDATION; MULTIENZYME COMPLEX; ENZYME COMPLEX; EXPRESSION; DNA; IDENTIFICATION; SEQUENCE	Human HADHA and HADHB genes encode the subunits of an enzyme complex, the trifunctional protein, involved in mitochondrial beta-oxidation of fatty acids. Both genes are located in the same region of chromosome 2p23. We isolated genomic clones, including 5' flanking regions, for HADHA and HADHB. Sequencing revealed that both of these genes are linked in a head-to-head arrangement on opposite strands and have in common a 350-bp 5' flanking region. The 5' flanking region has bidirectional promoter activity within this region; two cis elements proved critical for the activity. Transcription factor Sp1 functions as an activator for the bidirectional promoter by binding to both elements. Therefore, expression of trifunctional protein subunits are probably coordinately regulated by a common promoter and by Sp1.	Gifu Univ, Sch Med, Dept Pediat, Gifu 5008076, Japan; Shinshu Univ, Sch Med, Dept Biochem, Matsumoto, Nagano 3908621, Japan; Shinshu Univ, Sch Med, Dept Aging Biochem, Res Ctr Aging & Adaptat, Matsumoto, Nagano 3908621, Japan; Chubu Gakuin Univ, Dept Human Welfare, Fac Human Welfare, Seki 5013936, Japan	Gifu University; Shinshu University; Shinshu University	Orii, KE (corresponding author), Gifu Univ, Sch Med, Dept Pediat, 40 Tsukasa Machi, Gifu 5008076, Japan.	kenjior-gif@umin.u-tokyo.ac.jp	Orii, Kenji/AAJ-9069-2020					Aoyama T, 1997, CYTOGENET CELL GENET, V79, P221, DOI 10.1159/000134727; Aoyama T, 1998, J BIOL CHEM, V273, P5678, DOI 10.1074/jbc.273.10.5678; CARPENTER K, 1992, BIOCHEM BIOPH RES CO, V183, P443, DOI 10.1016/0006-291X(92)90501-B; Cohen HT, 1997, J BIOL CHEM, V272, P2901, DOI 10.1074/jbc.272.5.2901; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DIRUSSO CC, 1990, J BACTERIOL, V172, P6459, DOI 10.1128/jb.172.11.6459-6468.1990; HUANG A, 1990, SCIENCE, V250, P991, DOI 10.1126/science.2173145; Ijlst L, 1996, J CLIN INVEST, V98, P1028, DOI 10.1172/JCI118863; ISHII N, 1987, J BIOL CHEM, V262, P8144; JACKSON S, 1992, J CLIN INVEST, V90, P1219, DOI 10.1172/JCI115983; KAMIJO T, 1994, J CLIN INVEST, V93, P1740, DOI 10.1172/JCI117158; KAMIJO T, 1993, J BIOL CHEM, V268, P26452; KAMIJO T, 1994, BIOCHEM BIOPH RES CO, V199, P818, DOI 10.1006/bbrc.1994.1302; KANO M, 1991, GENE, V109, P285, DOI 10.1016/0378-1119(91)90623-J; LENNARD AC, 1991, MOL CELL BIOL, V11, P1281, DOI 10.1128/MCB.11.3.1281; LEONE TC, 1995, J BIOL CHEM, V270, P24622; LINTON JP, 1989, MOL CELL BIOL, V9, P3058, DOI 10.1128/MCB.9.7.3058; MIYAMOTO T, 1993, MOL ENDOCRINOL, V7, P224, DOI 10.1210/me.7.2.224; Orii KE, 1997, HUM MOL GENET, V6, P1215, DOI 10.1093/hmg/6.8.1215; Orii KE, 1996, BIOCHEM BIOPH RES CO, V219, P773, DOI 10.1006/bbrc.1996.0309; OSLEY MA, 1986, CELL, V45, P537, DOI 10.1016/0092-8674(86)90285-0; OSUMI T, 1987, J BIOL CHEM, V262, P8138; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SATO S, 1992, J BIOCHEM-TOKYO, V111, P8, DOI 10.1093/oxfordjournals.jbchem.a123722; SATO S, 1994, J BIOCHEM, V115, P286, DOI 10.1093/oxfordjournals.jbchem.a124330; SCHILLING LJ, 1989, MOL CELL BIOL, V9, P4568, DOI 10.1128/MCB.9.10.4568; SEWELL AC, 1994, EUR J PEDIATR, V153, P745, DOI 10.1007/BF01954492; SHIMADA T, 1989, J BIOL CHEM, V264, P20171; SOININEN R, 1988, J BIOL CHEM, V263, P17217; UCHIDA Y, 1992, J BIOL CHEM, V267, P1034; Ushikubo S, 1996, AM J HUM GENET, V58, P979; WANDERS RJA, 1989, LANCET, V2, P52, DOI 10.1016/S0140-6736(89)90300-0; ZHANG QX, 1994, BBA-GENE STRUCT EXPR, V1219, P567, DOI 10.1016/0167-4781(94)90091-4	33	43	44	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	1999	274	12					8077	8084		10.1074/jbc.274.12.8077	http://dx.doi.org/10.1074/jbc.274.12.8077			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	178LU	10075708	hybrid			2022-12-25	WOS:000079268100067
J	Tung, SF; Chuang, JY; Lin, CT; Lai, MY; Wu, CW; Lin, YS				Tung, SF; Chuang, JY; Lin, CT; Lai, MY; Wu, CW; Lin, YS			Inhibition of hTAF(II)32-binding implicated in the transcriptional repression by central regions of mutant p53 proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR SUPPRESSOR PROTEIN; STEROID-BINDING DOMAINS; VP16 ACTIVATION DOMAIN; WILD-TYPE; NUCLEAR-LOCALIZATION; FACTOR-TFIIB; MECHANISM; GROWTH; PURIFICATION; EXPRESSION	We previously identified a movable and regulable inactivation function within the central region (CRts247) Of a temperature-sensitive p53 (p53(ts)) mutant, p53(N247I). Here we showed that central regions from several p53(ts) mutants behaved similarly, i,e, they repressed a neighboring activation domain only when existing in the mutant status. Using chimeric protein GAL4VP16-CRts247 as an example, we demonstrated that de novo protein synthesis was not required for the reactivation of the chimeric protein, indicating that a post-translational mechanism was involved in the control of CRts247 activity. The CRts247-conferred thermo-regulability did not work via a mechanism demanding either an alteration of the subcellular compartmentalization of or the inactivation of DNA-binding activity of the GAL4 chimera. Further, CRts247 did not function in trans, eliminating the possibility that the observed repression was because of the competition for a putative factor(s) by the mutant p53 domain. Rather, CRts247 bestowed temperature-dependent interaction with hTAF(II)32 to the VP16 activation domain. In a parallel experiment, CRts247 also caused a large reduction in the affinity of hTAF(II)32 to the p53 activation domain at the nonpermissive temperature. These results strongly suggested that inhibition of hTAF(II)32 binding could be one of the mechanisms responsible for the transcriptional repression by mutant p53 central regions.	Acad Sinica, Inst Biomed Sci, Taipei 115, Taiwan; Natl Def Med Ctr, Grad Inst Life Sci, Taipei 100, Taiwan; China Med Coll, Sch Med Technol, Taichung 404, Taiwan; Natl Taiwan Univ, Coll Med, Inst Pathol, Taipei 100, Taiwan; Natl Taiwan Univ, Coll Med, Grad Inst Clin Med, Taipei 100, Taiwan	Academia Sinica - Taiwan; National Defense Medical Center; China Medical University Taiwan; National Taiwan University; National Taiwan University	Lin, YS (corresponding author), Acad Sinica, Inst Biomed Sci, Taipei 115, Taiwan.							CANMAN CE, 1995, GENE DEV, V9, P600, DOI 10.1101/gad.9.5.600; CAREY M, 1990, NATURE, V345, P361, DOI 10.1038/345361a0; CHEN JY, 1993, ONCOGENE, V8, P2159; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CHUANG JY, 1995, J BIOL CHEM, V270, P23899, DOI 10.1074/jbc.270.41.23899; COOK A, 1990, BRIT J CANCER, V61, P548, DOI 10.1038/bjc.1990.123; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FENG XH, 1995, J BIOL CHEM, V270, P24237, DOI 10.1074/jbc.270.41.24237; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FRIEND S, 1994, SCIENCE, V265, P334, DOI 10.1126/science.8023155; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GILL G, 1988, NATURE, V334, P721, DOI 10.1038/334721a0; GOODRICH JA, 1993, CELL, V75, P519, DOI 10.1016/0092-8674(93)90386-5; HOFFMANN A, 1991, NUCLEIC ACIDS RES, V19, P6337, DOI 10.1093/nar/19.22.6337; HORIKOSHI N, 1995, MOL CELL BIOL, V15, P227, DOI 10.1128/MCB.15.1.227; HSU YS, 1995, J BIOL CHEM, V270, P6966, DOI 10.1074/jbc.270.12.6966; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; KLEMM RD, 1995, P NATL ACAD SCI USA, V92, P5788, DOI 10.1073/pnas.92.13.5788; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LILLIE JW, 1987, CELL, V50, P1091, DOI 10.1016/0092-8674(87)90175-9; LIN YS, 1991, CELL, V64, P971, DOI 10.1016/0092-8674(91)90321-O; LIN YS, 1991, NATURE, V353, P569, DOI 10.1038/353569a0; LIU X, 1993, MOL CELL BIOL, V13, P3291, DOI 10.1128/MCB.13.6.3291; LU H, 1995, P NATL ACAD SCI USA, V92, P5154, DOI 10.1073/pnas.92.11.5154; MARTIN KJ, 1990, NATURE, V346, P147, DOI 10.1038/346147a0; MATTIONI T, 1994, METHOD CELL BIOL, V43, P335; MILNER J, 1990, J MOL BIOL, V216, P481, DOI 10.1016/0022-2836(90)90371-R; Picard Didier, 1993, Trends in Cell Biology, V3, P278, DOI 10.1016/0962-8924(93)90057-8; PINHASIKIMHI O, 1986, NATURE, V320, P182, DOI 10.1038/320182a0; PRIVES C, 1993, GENE DEV, V7, P529, DOI 10.1101/gad.7.4.529; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; SHAULSKY G, 1991, ONCOGENE, V6, P2055; SHAULSKY G, 1990, MOL CELL BIOL, V10, P6565, DOI 10.1128/MCB.10.12.6565; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Tantin D, 1996, METHOD ENZYMOL, V274, P133; Uesugi M, 1997, SCIENCE, V277, P1310, DOI 10.1126/science.277.5330.1310	39	2	2	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 19	1999	274	12					7748	7755		10.1074/jbc.274.12.7748	http://dx.doi.org/10.1074/jbc.274.12.7748			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	178LU	10075665	hybrid			2022-12-25	WOS:000079268100024
J	Wu-Wong, JSR; Berg, CE; Wang, JH; Chiou, WJ; Fissel, B				Wu-Wong, JSR; Berg, CE; Wang, JH; Chiou, WJ; Fissel, B			Endothelin stimulates glucose uptake and GLUT4 translocation via activation of endothelin ETA receptor in 3T3-L1 adipocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSULIN RELEASE; ADIPOSE-CELLS; PURIFICATION; MEMBRANE; CLONING; MUSCLE; SIGNAL; NIDDM; RAT	Endothelin-1 (ET-1) is a al-amino acid peptide that binds to G-protein-coupled receptors to evoke biological responses. This report studies the effect of ET-1 on regulating glucose transport in 3T3-L1 adipocytes. ET-1, but not angiotensin II, stimulated glucose uptake in a dose-dependent manner with an EC50 value of 0.29 nM and a 2.47-fold stimulation at 100 nM. ET-1 stimulated glucose uptake in differentiated 3T3-L1 cells but had no effect in undifferentiated cells, although ET-1 stimulated phosphatidylinositol hydrolysis to a similar degree in both. The 3T3-L1 cells expressed similar to 560,000 sites/cell of ETA receptor, which was not altered during differentiation. Western blot analysis and immunofluorescence staining show that ET-1 stimulated the translocation of insulin-responsive aminopeptidase and GLUT4 to the plasma membrane, The effect of ET-I on glucose uptake was blocked by A-216546, an antagonist selective for the ETA receptor. ET-1 treatment did not induce phosphorylation of insulin receptor beta-subunit, insulin receptor substrate-1, or Akt but stimulated the tyrosyl phosphorylation of a 75-kDa protein. Genistein (100 mu M), an inhibitor of tyrosine kinases, inhibited ET-1-stimulated glucose uptake. Our results show that ET-1 stimulates GLUT4 translocation and glucose uptake in 3T3-L1 adipocytes via activation of ETA receptor.	Abbott Labs, Div Pharmaceut Prod, Abbott Pk, IL 60064 USA	Abbott Laboratories	Wu-Wong, JSR (corresponding author), Abbott Labs, Div Pharmaceut Prod, 100 Abbott Pk Rd,D47V,AP9A, Abbott Pk, IL 60064 USA.	ruth.r.wuwong@abbott.com						ARAI H, 1990, NATURE, V348, P730, DOI 10.1038/348730a0; BALDINI G, 1991, J BIOL CHEM, V266, P4037; DEFRONZO RA, 1988, DIABETES, V37, P667, DOI 10.2337/diab.37.6.667; Douglas SA, 1997, J VASC RES, V34, P152, DOI 10.1159/000159219; ECHEL J, 1990, BIOCHEM J, V272, P691; Elmendorf JS, 1998, J BIOL CHEM, V273, P13289, DOI 10.1074/jbc.273.21.13289; FISHER Y, 1996, AM J PHYSIOL, V270, pC1204; Folli F, 1997, J CLIN INVEST, V100, P2158, DOI 10.1172/JCI119752; Hansen PA, 1998, J APPL PHYSIOL, V85, P1218, DOI 10.1152/jappl.1998.85.4.1218; Holloszy John O., 1998, Frontiers in Bioscience, V3, pD1011; INOUE A, 1989, P NATL ACAD SCI USA, V86, P2863, DOI 10.1073/pnas.86.8.2863; Jones BH, 1997, ENDOCRINOLOGY, V138, P1512, DOI 10.1210/en.138.4.1512; Juan CC, 1996, BIOCHEM BIOPH RES CO, V227, P694, DOI 10.1006/bbrc.1996.1571; KAWAMURA M, 1992, DIABETES CARE, V15, P1396, DOI 10.2337/diacare.15.10.1396; Kishi K, 1996, J BIOL CHEM, V271, P26561, DOI 10.1074/jbc.271.43.26561; KOZUKA M, 1991, J BIOL CHEM, V266, P16892; Lenz T, 1998, AM J HYPERTENS, V11, P1028, DOI 10.1016/S0895-7061(98)00086-7; Maeda S, 1998, J APPL PHYSIOL, V85, P425, DOI 10.1152/jappl.1998.85.2.425; Maeda S, 1998, J CARDIOVASC PHARM, V31, pS392, DOI 10.1097/00005344-199800001-00112; Maeda S, 1997, LIFE SCI, V61, P419, DOI 10.1016/S0024-3205(97)00399-8; NERI SGG, 1997, EUR J CLIN INVEST, V27, P761; OPGENORTH TJ, 1997, 5 INT C END KYOT JAP; Rosendorff C, 1997, CARDIOVASC DRUG THER, V10, P795, DOI 10.1007/BF00053038; Ross SA, 1996, J BIOL CHEM, V271, P3328, DOI 10.1074/jbc.271.6.3328; SAKURAI T, 1990, NATURE, V348, P732, DOI 10.1038/348732a0; Sarman B, 1998, DIABETES METAB REV, V14, P171, DOI 10.1002/(SICI)1099-0895(199806)14:2<171::AID-DMR207>3.0.CO;2-G; SHIMIZU Y, 1994, BIOCHEM BIOPH RES CO, V202, P660, DOI 10.1006/bbrc.1994.1981; Thorens B, 1996, AM J PHYSIOL-GASTR L, V270, pG541, DOI 10.1152/ajpgi.1996.270.4.G541; Velloso LA, 1996, P NATL ACAD SCI USA, V93, P12490, DOI 10.1073/pnas.93.22.12490; WADA K, 1990, BIOCHEM BIOPH RES CO, V167, P251, DOI 10.1016/0006-291X(90)91758-K; Wu-Wong JR, 1998, J CARDIOVASC PHARM, V31, pS185, DOI 10.1097/00005344-199800001-00053; WuWong JR, 1996, AM J PHYSIOL-CELL PH, V271, pC869, DOI 10.1152/ajpcell.1996.271.3.C869; WUWONG JR, 1994, AM J PHYSIOL-CELL PH, V267, pC1185, DOI 10.1152/ajpcell.1994.267.5.C1185; WUWONG JR, 1998, AM DIAB ASS 58 SCI S; WUWONG JR, 1999, IN PRESS EUR J PHARM; YANAGISAWA M, 1988, NATURE, V332, P411, DOI 10.1038/332411a0; Zimmerman RS, 1995, METABOLISM, V44, P1532, DOI 10.1016/0026-0495(95)90070-5; ZIMMERMAN RS, 1995, METABOLISM, V44, P1321, DOI 10.1016/0026-0495(95)90037-3	38	73	76	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 19	1999	274	12					8103	8110		10.1074/jbc.274.12.8103	http://dx.doi.org/10.1074/jbc.274.12.8103			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	178LU	10075711	hybrid			2022-12-25	WOS:000079268100070
J	Brown, CT; Nugent, MA; Lau, FW; Trinkaus-Randall, V				Brown, CT; Nugent, MA; Lau, FW; Trinkaus-Randall, V			Characterization of proteoglycans synthesized by cultured corneal fibroblasts in response to transforming growth factor beta and fetal calf serum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KERATAN SULFATE PROTEOGLYCAN; DENSITY-LIPOPROTEIN RECEPTOR; CYCLIN-DEPENDENT KINASES; CELL-ADHESION MOLECULES; DECORIN GENE-EXPRESSION; HAMSTER OVARY CELLS; HEPARAN-SULFATE; BASEMENT-MEMBRANE; CORE PROTEIN; DOMAIN-I	A culture system was developed to analyze the relationship between proteoglycans and growth factors during corneal injury. Specifically, the effects of transforming growth factor beta-1 (TGF-beta 1) and fetal calf serum on proteoglycan synthesis in corneal fibroblasts were examined. Glycosaminoglycan synthesis and sulfation were determined using selective polysaccharidases, Proteoglycan core proteins were analyzed using gel electrophoresis and Western blotting, Cells cultured in 10% dialyzed fetal calf serum exhibited decreased synthesis of more highly sulfated chondroitin sulfate and heparan sulfate compared with cells cultured in 1% dialyzed fetal calf serum. The amount and sulfation of the glycosaminoglycans was not significantly influenced by TGF-beta 1, The major proteoglycan species secreted into the media were decorin and perlecan, Decorin was glycanated with chondroitin sulfate, Perlecan was linked to either chondroitin sulfate, heparan sulfate, or both chondroitin sulfate and heparan sulfate. Decorin synthesis was reduced by either TGF-beta 1 or serum. At early time points, both TGF-beta 1 and serum induced substantial increases in perlecan bearing chondroitin sulfate and/or heparan sulfate chains. In contrast, after extended periods in culture, the amount of perlecan bearing heparan sulfate chains was unaffected by TGF-beta 1 and decreased by serum. The levels of perlecan bearing chondroitin sulfate chains were elevated with TGF-PI treatment and were decreased with serum. Because both decorin and perlecan bind growth factors and are proposed to modulate their activity, changes in the expression of either of these proteoglycans could substantially affect the cellular response to injury.	Boston Univ, Sch Med, Dept Biochem, Boston, MA 02118 USA	Boston University	Trinkaus-Randall, V (corresponding author), Boston Univ, Sch Med, Dept Biochem, Rm L903,80 E Concord St, Boston, MA 02118 USA.			Nugent, Matthew/0000-0002-8630-4712; Trinkaus-Randall, Vickery/0000-0002-8573-9108	NEI NIH HHS [EY110004] Funding Source: Medline	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ANDRES JL, 1989, J CELL BIOL, V109, P3137, DOI 10.1083/jcb.109.6.3137; ASUNDI VK, 1992, EUR J CELL BIOL, V59, P314; AXELSSON I, 1978, BIOCHEM J, V169, P517, DOI 10.1042/bj1690517; BASSOLS A, 1988, J BIOL CHEM, V263, P3039; BERNFIELD M, 1992, ANNU REV CELL BIOL, V8, P365, DOI 10.1146/annurev.cb.08.110192.002053; BLOCHBERGER TC, 1992, J BIOL CHEM, V267, P347; BORDER WA, 1992, NATURE, V360, P361, DOI 10.1038/360361a0; BROWN CT, 1995, J CELL BIOCHEM, V59, P57, DOI 10.1002/jcb.240590108; CINTRON C, 1990, INVEST OPHTH VIS SCI, V31, P1975; CINTRON C, 1978, J ULTRA MOL STRUCT R, V65, P13, DOI 10.1016/S0022-5320(78)90017-5; CONRAD GW, 1977, J BIOL CHEM, V252, P6861; Corpuz LM, 1996, J BIOL CHEM, V271, P9759, DOI 10.1074/jbc.271.16.9759; Costell M, 1997, EUR J BIOCHEM, V243, P115, DOI 10.1111/j.1432-1033.1997.t01-1-00115.x; Couchman JR, 1996, J BIOL CHEM, V271, P9595, DOI 10.1074/jbc.271.16.9595; DAHL IMS, 1978, EXP EYE RES, V27, P175, DOI 10.1016/0014-4835(78)90087-8; DANIELSON KG, 1992, MATRIX, V12, P22, DOI 10.1016/S0934-8832(11)80101-0; DeLuca A, 1996, J BIOL CHEM, V271, P18961, DOI 10.1074/jbc.271.31.18961; Doege K, 1997, MATRIX BIOL, V16, P211, DOI 10.1016/S0945-053X(97)90010-X; Dolan M, 1997, J BIOL CHEM, V272, P4316, DOI 10.1074/jbc.272.7.4316; ERNST S, 1995, CRIT REV BIOCHEM MOL, V30, P387, DOI 10.3109/10409239509083490; FARNDALE RW, 1986, BIOCHIM BIOPHYS ACTA, V883, P173, DOI 10.1016/0304-4165(86)90306-5; FUNDERBURGH JL, 1988, INVEST OPHTH VIS SCI, V29, P1116; FUNDERBURGH JL, 1989, INVEST OPHTH VIS SCI, V30, P435; Funderburgh JL, 1996, J BIOL CHEM, V271, P31431, DOI 10.1074/jbc.271.49.31431; FUNDERBURGH JL, 1993, J BIOL CHEM, V268, P11874; Funderburgh JL, 1997, J BIOL CHEM, V272, P28089, DOI 10.1074/jbc.272.44.28089; FUNDERBURGH JL, 1990, J BIOL CHEM, V265, P8297; GREGORY JD, 1982, J BIOL CHEM, V257, P6965; HASSELL JR, 1980, P NATL ACAD SCI-BIOL, V77, P4494, DOI 10.1073/pnas.77.8.4494; HASSELL JR, 1979, J BIOL CHEM, V254, P2346; HASSELL JR, 1992, INVEST OPHTH VIS SCI, V33, P547; HASSELL JR, 1983, ARCH BIOCHEM BIOPHYS, V222, P362, DOI 10.1016/0003-9861(83)90532-5; HAUSSER H, 1994, FEBS LETT, V353, P243, DOI 10.1016/0014-5793(94)01044-7; HAYASHI K, 1989, INVEST OPHTH VIS SCI, V30, P239; HEIMER R, 1995, J MOL CELL CARDIOL, V27, P2191, DOI 10.1016/S0022-2828(95)91479-X; IOZZO RV, 1994, BIOCHEM J, V302, P625, DOI 10.1042/bj3020625; Iozzo RV, 1996, FASEB J, V10, P598, DOI 10.1096/fasebj.10.5.8621059; JALKANEN M, 1987, J CELL BIOL, V105, P3087, DOI 10.1083/jcb.105.6.3087; KAHARI VM, 1991, J BIOL CHEM, V266, P10608; KALLUNKI P, 1992, J CELL BIOL, V116, P559, DOI 10.1083/jcb.116.2.559; Kay EP, 1998, CURR EYE RES, V17, P286, DOI 10.1076/ceyr.17.3.286.5212; KOKENYESI R, 1995, BIOCHEM BIOPH RES CO, V211, P262, DOI 10.1006/bbrc.1995.1805; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI W, 1992, ARCH BIOCHEM BIOPHYS, V296, P190, DOI 10.1016/0003-9861(92)90562-B; LOPEZCASILLAS F, 1991, CELL, V67, P785, DOI 10.1016/0092-8674(91)90073-8; MAUVIEL A, 1995, J BIOL CHEM, V270, P11692, DOI 10.1074/jbc.270.19.11692; Moscatello DK, 1998, J CLIN INVEST, V101, P406, DOI 10.1172/JCI846; MURDOCH AD, 1992, J BIOL CHEM, V267, P8544; Nietfeld J J, 1994, EXS, V70, P215; NOONAN DM, 1993, KIDNEY INT, V43, P53, DOI 10.1038/ki.1993.10; NUGENT MA, 1992, J BIOL CHEM, V267, P21256; OKane S, 1997, INT J BIOCHEM CELL B, V29, P63, DOI 10.1016/S1357-2725(96)00120-3; Patel S, 1998, J BIOL CHEM, V273, P3121, DOI 10.1074/jbc.273.6.3121; Santra M, 1997, J CLIN INVEST, V100, P149, DOI 10.1172/JCI119507; SANTRA M, 1995, P NATL ACAD SCI USA, V92, P7016, DOI 10.1073/pnas.92.15.7016; SCHRECENGOST PK, 1992, ARCH BIOCHEM BIOPHYS, V292, P54, DOI 10.1016/0003-9861(92)90050-7; SCHWARZ W, 1969, VIRCHOWS ARCH A, V347, P115, DOI 10.1007/BF00544113; Subramanian SV, 1997, J BIOL CHEM, V272, P14713, DOI 10.1074/jbc.272.23.14713; TAKEUCHI Y, 1994, J BIOL CHEM, V269, P32634; Tiedemann K, 1997, MATRIX BIOL, V15, P469, DOI 10.1016/S0945-053X(97)90020-2; Trinkaus-Randall V, 1998, J CONTROL RELEASE, V53, P205, DOI 10.1016/S0168-3659(97)00254-X; TRINKAUSRANDALL V, 1990, INVEST OPHTH VIS SCI, V31, P1321; TRNKAUSRANDALL V, 1997, PRINCIPLES TISSUE EN, P386; WILSON SE, 1992, INVEST OPHTH VIS SCI, V33, P1756; YAMAGUCHI Y, 1988, NATURE, V336, P244, DOI 10.1038/336244a0; YAMAGUCHI Y, 1990, NATURE, V346, P281, DOI 10.1038/346281a0; Yang TT, 1996, ANAL BIOCHEM, V241, P103, DOI 10.1006/abio.1996.0383; YUE BYJ, 1976, J BIOCH, V158, P567	68	43	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 12	1999	274	11					7111	7119		10.1074/jbc.274.11.7111	http://dx.doi.org/10.1074/jbc.274.11.7111			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	175DV	10066769	hybrid			2022-12-25	WOS:000079078400041
J	Hinkle, A; Goranson, A; Butters, CA; Tobacman, LS				Hinkle, A; Goranson, A; Butters, CA; Tobacman, LS			Roles for the troponin tail domain in thin filament assembly and regulation - A deletional study of cardiac troponin T	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RABBIT SKELETAL-MUSCLE; HYPERTROPHIC CARDIOMYOPATHY; MYOSIN SUBFRAGMENT-1; ALPHA-TROPOMYOSIN; ACTIN-TROPOMYOSIN; COOPERATIVE INTERACTIONS; LABELED TROPOMYOSIN; CA2+ SENSITIVITY; CALCIUM-BINDING; ATPASE ACTIVITY	Striated muscle contraction is regulated by Ca2+ binding to troponin, which has a globular domain and an elongated tail attributable to the NH2-terminal portion of the bovine cardiac troponin T (TnT) subunit. Truncation of the bovine cardiac troponin tail was investigated using recombinant TnT fragments and subunits TnI and TnC. Progressive truncation of the troponin tail caused progressively weaker binding of troponin-tropomyosin to actin and of troponin to actin-tropomyosin. A sharp drop-off in affinity occurred with NH2-terminal deletion of 119 rather than 94 residues. Deletion of 94 residues had no effect on Ca2+-activation of the myosin subfragment 1-thin filament MgATPase rate and did not eliminate cooperative effects of Ca2+ binding. Troponin tail peptide TnT1-153 strongly promoted tropomyosin binding to actin in the absence of TnI or TnC. The results show that the anchoring function of the troponin tail involves interactions with actin as well as with tropomyosin and has comparable importance in the presence or absence of Ca2+. Residues 95-153 are particularly important for anchoring, and residues 95-119 are crucial for function or local folding. Because striated muscle regulation involves switching among the conformational states of the thin filament, regulatory significance for the troponin tail may arise from its prominent contribution to the protein-protein interactions within these conformations.	Univ Iowa, Dept Internal Med, GH, Iowa City, IA 52242 USA; Univ Iowa, Dept Biochem, Iowa City, IA 52242 USA	University of Iowa; University of Iowa	Tobacman, LS (corresponding author), Univ Iowa, Dept Internal Med, GH, 200 Hawkins Dr SE610, Iowa City, IA 52242 USA.	larry-tobacman@uiowa.edu						ASHLEY CC, 1991, Q REV BIOPHYS, V24, P1, DOI 10.1017/S0033583500003267; Bing W, 1997, BIOCHEM J, V327, P335, DOI 10.1042/bj3270335; BREITBART RE, 1987, CELL, V49, P793, DOI 10.1016/0092-8674(87)90617-9; BREITBART RE, 1987, ANNU REV BIOCHEM, V56, P467, DOI 10.1146/annurev.bi.56.070187.002343; BUTTERS CA, 1993, J BIOL CHEM, V268, P15565; Butters CA, 1997, J BIOL CHEM, V272, P13196, DOI 10.1074/jbc.272.20.13196; BYERS DM, 1979, FEBS LETT, V104, P106, DOI 10.1016/0014-5793(79)81093-5; CabralLilly D, 1997, BIOPHYS J, V73, P1763, DOI 10.1016/S0006-3495(97)78206-7; Cassell M, 1996, J BIOL CHEM, V271, P12867, DOI 10.1074/jbc.271.22.12867; CHALOVICH JM, 1982, J BIOL CHEM, V257, P2432; CHALOVICH JM, 1992, PHARMACOL THERAPEUT, V55, P95, DOI 10.1016/0163-7258(92)90013-P; Chandra M, 1998, BIOPHYS J, V74, pA52; DAHIYA R, 1994, J BIOL CHEM, V269, P29457; FISHER D, 1995, J BIOL CHEM, V270, P25455, DOI 10.1074/jbc.270.43.25455; FLICKER PF, 1982, J MOL BIOL, V162, P495, DOI 10.1016/0022-2836(82)90540-X; Forissier JF, 1996, CIRCULATION, V94, P3069, DOI 10.1161/01.CIR.94.12.3069; FUJITA S, 1992, J BIOCHEM-TOKYO, V112, P306, DOI 10.1093/oxfordjournals.jbchem.a123896; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Hammell RL, 1996, J BIOL CHEM, V271, P4236; Hammell RL, 1997, J BIOL CHEM, V272, P22409, DOI 10.1074/jbc.272.36.22409; HILL LE, 1992, J BIOL CHEM, V267, P16106; HITCHCOCK SE, 1973, J MOL BIOL, V80, P825, DOI 10.1016/0022-2836(73)90212-X; HOLMES KC, 1995, BIOPHYS J S, V68, P2; Huynh Q, 1996, BIOPHYS J, V70, P1447, DOI 10.1016/S0006-3495(96)79704-7; ISHII Y, 1991, J BIOL CHEM, V266, P6894; LEAVIS PC, 1984, CRC CR REV BIOCH MOL, V16, P235, DOI 10.3109/10409238409108717; LEHRER SS, 1994, J MUSCLE RES CELL M, V15, P232; LESZYK J, 1987, BIOCHEMISTRY-US, V26, P7035, DOI 10.1021/bi00396a027; Lin D, 1996, J CLIN INVEST, V97, P2842, DOI 10.1172/JCI118740; MAK AS, 1981, J MOL BIOL, V149, P541, DOI 10.1016/0022-2836(81)90486-1; Malnic B, 1998, J BIOL CHEM, V273, P10594, DOI 10.1074/jbc.273.17.10594; MATSUSHITA M, 1993, CLIN CHIM ACTA, V216, P103, DOI 10.1016/0009-8981(93)90143-R; MCGHEE JD, 1974, J MOL BIOL, V86, P469, DOI 10.1016/0022-2836(74)90031-X; MCKILLOP DFA, 1993, BIOPHYS J, V65, P693, DOI 10.1016/S0006-3495(93)81110-X; MEEDEL TH, 1993, J BIOL CHEM, V268, P6755; MEHEGAN JP, 1991, J BIOL CHEM, V266, P966; Moolman JC, 1997, J AM COLL CARDIOL, V29, P549, DOI 10.1016/S0735-1097(96)00530-X; MORRIS EP, 1984, BIOCHEMISTRY-US, V23, P2214, DOI 10.1021/bi00305a018; NASSAR R, 1991, CIRC RES, V69, P1470, DOI 10.1161/01.RES.69.6.1470; OHTSUKI I, 1984, J BIOCHEM, V95, P1337, DOI 10.1093/oxfordjournals.jbchem.a134740; OLAH GA, 1994, BIOCHEMISTRY-US, V33, P12800, DOI 10.1021/bi00209a011; PAN BS, 1991, J BIOL CHEM, V266, P12432; PEARLSTONE JR, 1977, CAN J BIOCHEM CELL B, V55, P1032, DOI 10.1139/o77-154; PEARLSTONE JR, 1982, J BIOL CHEM, V257, P587; PEARLSTONE JR, 1983, J BIOL CHEM, V258, P2534; PEARLSTONE JR, 1977, J BIOL CHEM, V252, P983; POLLARD TD, 1973, J BIOL CHEM, V248, P4682; POTTER JD, 1995, J BIOL CHEM, V270, P2557, DOI 10.1074/jbc.270.6.2557; REISER PJ, 1992, J PHYSIOL-LONDON, V449, P573, DOI 10.1113/jphysiol.1992.sp019102; Schaertl S, 1995, BIOCHEMISTRY-US, V34, P15890, DOI 10.1021/bi00049a003; Sorensen BR, 1996, BIOPHYS J, V71, P3407, DOI 10.1016/S0006-3495(96)79535-8; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; Stefancsik R, 1998, P NATL ACAD SCI USA, V95, P957, DOI 10.1073/pnas.95.3.957; SZCZESNA D, 1989, BIOL CHEM H-S, V370, P399, DOI 10.1515/bchm3.1989.370.1.399; TANOKURA M, 1983, J BIOCHEM, V93, P331, DOI 10.1093/oxfordjournals.jbchem.a134185; TOBACMAN LS, 1988, J BIOL CHEM, V263, P2668; TOBACMAN LS, 1986, BIOCHEMISTRY-US, V25, P798, DOI 10.1021/bi00352a010; TOBACMAN LS, 1987, J BIOL CHEM, V262, P4059; TOBACMAN LS, 1987, BIOCHEMISTRY-US, V26, P492, DOI 10.1021/bi00376a022; Tobacman LS, 1996, ANNU REV PHYSIOL, V58, P447, DOI 10.1146/annurev.physiol.58.1.447; TOBACMAN LS, 1990, J BIOL CHEM, V265, P931; TOWNSEND PJ, 1995, J MOL CELL CARDIOL, V27, P2223, DOI 10.1016/S0022-2828(95)91587-7; VanEyk JE, 1997, J BIOL CHEM, V272, P10529; Vibert P, 1997, J MOL BIOL, V266, P8, DOI 10.1006/jmbi.1996.0800; WALSH TP, 1984, J MOL BIOL, V182, P265; Watkins H, 1996, J CLIN INVEST, V98, P2456, DOI 10.1172/JCI119063; WATKINS H, 1995, NEW ENGL J MED, V332, P1058, DOI 10.1056/NEJM199504203321603; WEEDS AG, 1975, NATURE, V257, P54, DOI 10.1038/257054a0; WEGNER A, 1979, J MOL BIOL, V131, P839, DOI 10.1016/0022-2836(79)90204-3; WEGNER A, 1981, BIOCHEMISTRY-US, V20, P5633, DOI 10.1021/bi00522a043; WHITE SP, 1987, NATURE, V325, P826, DOI 10.1038/325826a0; WILLADSEN KA, 1992, J BIOL CHEM, V267, P23746; ZOT AS, 1987, ANNU REV BIOPHYS BIO, V16, P535	73	73	76	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 12	1999	274	11					7157	7164		10.1074/jbc.274.11.7157	http://dx.doi.org/10.1074/jbc.274.11.7157			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	175DV	10066775	hybrid			2022-12-25	WOS:000079078400047
J	Marsischky, GT; Lee, S; Griffith, J; Kolodner, RD				Marsischky, GT; Lee, S; Griffith, J; Kolodner, RD			Saccharomyces cerevisiae MSH2/6 complex interacts with Holliday junctions and facilitates their cleavage by phage resolution enzymes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MISMATCH REPAIR SYSTEM; DNA-BASE PAIRS; GENETIC-RECOMBINATION; CROSSING-OVER; MUTS HOMOLOG; HOMEOLOGOUS RECOMBINATION; DUPLEX OLIGONUCLEOTIDES; SPECIFICALLY BINDS; ESCHERICHIA-COLI; PROTEIN	Genetic and biochemical studies have indicated that mismatch repair proteins can interact with recombination intermediates. In this study, gel shift assays and electron microscopic analysis were used to show that the Saccharomyces cerevisiae MSH2/6 complex binds to Holliday junctions and has an affinity and specificity for them that is at least as high as it has as for mispaired bases. Under equilibrium binding conditions, the MSH2/6 complex had a K-d of binding to Holliday junctions of 0.5 nm. The MSH2/6 complex enhanced the cleavage of Holliday junctions by T4 endonuclease VII and T7 endonuclease I. This is consistent with the view that the MSH2/6 complex can function in both mismatch repair and the resolution of recombination intermediates as predicted by genetic studies.	Univ Calif San Diego, Sch Med, Ludwig Inst Canc Res, Dept Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Sch Med, Ctr Canc, La Jolla, CA 92093 USA; Harvard Univ, Sch Med, Dana Farber Canc Inst, Charles A Dana Div Human Canc Genet, Boston, MA 02115 USA; Univ N Carolina, Lineberger Comprehens Canc Res Ctr, Chapel Hill, NC 27599 USA	Ludwig Institute for Cancer Research; University of California System; University of California San Diego; University of California System; University of California San Diego; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; University of North Carolina; University of North Carolina Chapel Hill	Kolodner, RD (corresponding author), Univ Calif San Diego, Sch Med, Ludwig Inst Canc Res, Dept Med, CMME-3080,9500 Gilman Dr, La Jolla, CA 92093 USA.				NIGMS NIH HHS [GM31819, GM50006] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050006, R01GM031819] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Acharya S, 1996, P NATL ACAD SCI USA, V93, P13629, DOI 10.1073/pnas.93.24.13629; ALANI E, 1995, GENE DEV, V9, P234, DOI 10.1101/gad.9.2.234; ALANI E, 1994, GENETICS, V137, P19; Alani E, 1996, MOL CELL BIOL, V16, P5604; Alani E, 1997, J MOL BIOL, V265, P289, DOI 10.1006/jmbi.1996.0743; BORTS RH, 1987, SCIENCE, V237, P1459, DOI 10.1126/science.2820060; Chambers SR, 1996, MOL CELL BIOL, V16, P6110; CHI NW, 1994, J BIOL CHEM, V269, P29984; Datta A, 1996, MOL CELL BIOL, V16, P1085; Datta A, 1997, P NATL ACAD SCI USA, V94, P9757, DOI 10.1073/pnas.94.18.9757; DETLOFF P, 1992, GENETICS, V132, P113; DEWIND N, 1995, CELL, V82, P321, DOI 10.1016/0092-8674(95)90319-4; DOUTRIAUX MP, 1986, P NATL ACAD SCI USA, V83, P2576, DOI 10.1073/pnas.83.8.2576; DRUMMOND JT, 1995, SCIENCE, V268, P1909, DOI 10.1126/science.7604264; FEINSTEIN SI, 1986, GENETICS, V113, P13; Fishel R, 1998, GENE DEV, V12, P2096, DOI 10.1101/gad.12.14.2096; FISHEL R, 1994, SCIENCE, V266, P1403, DOI 10.1126/science.7973733; Fishel R, 1997, CURR OPIN GENET DEV, V7, P105, DOI 10.1016/S0959-437X(97)80117-7; GRIFFITH JD, 1978, ANNU REV BIOPHYS BIO, V7, P19, DOI 10.1146/annurev.bb.07.060178.000315; HOLLINGSWORTH NM, 1995, GENE DEV, V9, P1728, DOI 10.1101/gad.9.14.1728; Hunter N, 1996, EMBO J, V15, P1726, DOI 10.1002/j.1460-2075.1996.tb00518.x; Hunter N, 1997, GENE DEV, V11, P1573, DOI 10.1101/gad.11.12.1573; Kolodner R, 1996, GENE DEV, V10, P1433, DOI 10.1101/gad.10.12.1433; Lee SM, 1997, J BIOL CHEM, V272, P7532, DOI 10.1074/jbc.272.11.7532; LILLEY DMJ, 1993, ANNU REV BIOPH BIOM, V22, P299, DOI 10.1146/annurev.bb.22.060193.001503; Marsischky GT, 1996, GENE DEV, V10, P407, DOI 10.1101/gad.10.4.407; MATIC I, 1995, CELL, V80, P507, DOI 10.1016/0092-8674(95)90501-4; MESELSON M, 1988, RECOMBINATION GENETI, P91; MODRICH P, 1991, ANNU REV GENET, V25, P229, DOI 10.1146/annurev.ge.25.120191.001305; Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533; PALOMBO F, 1995, SCIENCE, V268, P1912, DOI 10.1126/science.7604265; PaquisFlucklinger V, 1997, GENOMICS, V44, P188, DOI 10.1006/geno.1997.4857; PETIT MA, 1991, GENETICS, V129, P327; PICKSLEY SM, 1990, J MOL BIOL, V212, P723, DOI 10.1016/0022-2836(90)90233-C; Pochart P, 1997, J BIOL CHEM, V272, P30345, DOI 10.1074/jbc.272.48.30345; RADMAN M, 1989, GENOME, V31, P68, DOI 10.1139/g89-014; RADMAN M, 1988, GENETIC RECOMBINATIO, P169; RAYSSIGUIER C, 1989, NATURE, V342, P396, DOI 10.1038/342396a0; REENAN RAG, 1992, GENETICS, V132, P975; ROSSMACDONALD P, 1994, CELL, V79, P1069, DOI 10.1016/0092-8674(94)90037-X; Saparbaev M, 1996, GENETICS, V142, P727; Selva EM, 1997, MOL GEN GENET, V257, P71; SELVA EM, 1995, GENETICS, V139, P1175; SHEN P, 1989, MOL GEN GENET, V218, P358, DOI 10.1007/BF00331291; Winand NJ, 1998, GENOMICS, V53, P69, DOI 10.1006/geno.1998.5447; WORTH L, 1994, P NATL ACAD SCI USA, V91, P3238, DOI 10.1073/pnas.91.8.3238	46	53	55	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 12	1999	274	11					7200	7206		10.1074/jbc.274.11.7200	http://dx.doi.org/10.1074/jbc.274.11.7200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	175DV	10066781	hybrid, Green Published			2022-12-25	WOS:000079078400053
J	Wang, Y; Guo, W; Liang, LZ; Esselman, WJ				Wang, Y; Guo, W; Liang, LZ; Esselman, WJ			Phosphorylation of CD45 by casein kinase 2 - Modulation of activity and mutational analysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE-PHOSPHATASE; LEUKOCYTE-COMMON ANTIGEN; T-CELLS; PHOSPHOTYROSINE PHOSPHATASE; LYMPHOCYTE-ACTIVATION; SIGNAL-TRANSDUCTION; NEGATIVE REGULATION; MURINE LYMPHOMA; EXPRESSION; DOMAIN	CD45 is a receptor-type protein-tyrosine phosphatase (PTP) that is required for antigen-specific stimulation and proliferation in lymphocytes, This study was designed to determine the nature of specific kinases in lymphocytes that phosphorylate CD45 and to determine the effect of phosphorylation on CD45 PTP activity. A major cytoplasmic lymphocyte kinase that phosphorylated CD45 was identified as casein kinase 2 (CK2) by use of an in-gel kinase assay in combination with immunoprecipitation, immunodepletion, and specific inhibition. Mutational analysis of CK2 consensus sites showed that the target for CK2 was in an acidic insert of 19 amino acids in the D2 domain, and Ser to Ala mutations at amino acids 965, 968, 969, and 973 abrogated CK2 phosphorylation of CD45, CK2 phosphorylation increased CD45 activity S-fold toward phosphorylated myelin basic protein, and this increase was reversible by PP2A treatment. Mutation of Ser to Glu at the CK2 sites had the same effect as phosphorylation and also tripled the V-max of CD45. CD45 isolated in vivo was highly phosphorylated and could not be phosphorylated by CK2 without prior dephosphorylation with phosphatase PP2A. We conclude that CK2 is a major lymphocyte kinase that is responsible for in vivo phosphorylation of CD45, and phosphorylation at specific CK2 sites regulates CD45 PTP activity.	Michigan State Univ, Dept Microbiol, E Lansing, MI 48824 USA	Michigan State University	Esselman, WJ (corresponding author), Michigan State Univ, Dept Microbiol, Rm 344 Giltner Hall, E Lansing, MI 48824 USA.	esselman@pilot.msu.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI042794] Funding Source: NIH RePORTER; NIAID NIH HHS [AI/GM42794] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALLENDE JE, 1995, FASEB J, V9, P313, DOI 10.1096/fasebj.9.5.7896000; AUTERO M, 1987, EUR J IMMUNOL, V17, P1503, DOI 10.1002/eji.1830171018; AUTERO M, 1994, MOL CELL BIOL, V14, P1308, DOI 10.1128/MCB.14.2.1308; Bretz J D, 1992, Dev Immunol, V2, P249, DOI 10.1155/1992/34586; Byth KF, 1996, J EXP MED, V183, P1707, DOI 10.1084/jem.183.4.1707; CAMPOSGONZALEZ R, 1992, J BIOL CHEM, V267, P14535; CHANG HL, 1991, J IMMUNOL, V147, P1687; DESAI DM, 1993, CELL, V73, P541, DOI 10.1016/0092-8674(93)90141-C; DESAI DM, 1994, EMBO J, V13, P4002, DOI 10.1002/j.1460-2075.1994.tb06716.x; Doro U, 1996, MOL CELL BIOL, V16, P4996; Fauman EB, 1996, TRENDS BIOCHEM SCI, V21, P413, DOI 10.1016/S0968-0004(96)10059-1; Felberg J, 1998, J BIOL CHEM, V273, P17839, DOI 10.1074/jbc.273.28.17839; GIETZ RD, 1995, J BIOL CHEM, V270, P13017, DOI 10.1074/jbc.270.22.13017; GONZATTIHACES MI, 1982, J BIOL CHEM, V257, P6642; HOVIS RR, 1993, SCIENCE, V260, P544, DOI 10.1126/science.8475387; HURLEY TR, 1993, MOL CELL BIOL, V13, P1651, DOI 10.1128/MCB.13.3.1651; KAMESHITA I, 1989, ANAL BIOCHEM, V183, P139, DOI 10.1016/0003-2697(89)90181-4; Kang SM, 1997, J BIOL CHEM, V272, P11588; KISHIHARA K, 1993, CELL, V74, P143, DOI 10.1016/0092-8674(93)90302-7; KORETZKY GA, 1993, FASEB J, V7, P420, DOI 10.1096/fasebj.7.5.8462784; KORETZKY GA, 1990, NATURE, V346, P66, DOI 10.1038/346066a0; LIAO PC, 1994, ANAL BIOCHEM, V219, P9, DOI 10.1006/abio.1994.1224; LITCHFIELD DW, 1993, MOL CELL BIOCHEM, V128, P187, DOI 10.1007/BF01076770; Litchfield DW, 1996, BIOCHEM CELL BIOL, V74, P541, DOI 10.1139/o96-458; Majeti R, 1998, SCIENCE, V279, P88, DOI 10.1126/science.279.5347.88; MELKERSONWATSON LJ, 1994, J IMMUNOL, V153, P2004; MUSTELIN T, 1992, EUR J IMMUNOL, V22, P1173, DOI 10.1002/eji.1830220510; Neel BG, 1997, CURR OPIN IMMUNOL, V9, P405, DOI 10.1016/S0952-7915(97)80088-X; NG DHW, 1995, J IMMUNOL METHODS, V179, P177, DOI 10.1016/0022-1759(94)00281-Z; NG DHW, 1995, BIOCHEM BIOPH RES CO, V206, P302, DOI 10.1006/bbrc.1995.1042; OSTERGAARD HL, 1989, P NATL ACAD SCI USA, V86, P8959, DOI 10.1073/pnas.86.22.8959; OSTERGAARD HL, 1991, SCIENCE, V253, P1423, DOI 10.1126/science.1654595; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; PINGEL JT, 1989, CELL, V58, P1055, DOI 10.1016/0092-8674(89)90504-7; SELDIN DC, 1995, SCIENCE, V267, P894, DOI 10.1126/science.7846532; SELDIN DC, 1994, BLOOD, V84, P376; SIEH M, 1993, EMBO J, V12, P315, DOI 10.1002/j.1460-2075.1993.tb05659.x; Stover David R., 1993, P193; STOVER DR, 1994, MOL CELL BIOL, V14, P5523, DOI 10.1128/MCB.14.8.5523; TAWFIC S, 1995, J BIOL CHEM, V270, P21009, DOI 10.1074/jbc.270.36.21009; TONKS NK, 1990, J BIOL CHEM, V265, P10674; TROWBRIDGE IS, 1994, ANNU REV IMMUNOL, V12, P85, DOI 10.1146/annurev.iy.12.040194.000505; TUAZON PT, 1991, ADV 2 MESS PHOSPHOPR, V23, P123; Ulyanova T, 1997, IMMUNOL RES, V16, P101, DOI 10.1007/BF02786326; VALENTINE MA, 1991, EUR J IMMUNOL, V21, P913, DOI 10.1002/eji.1830210409; VOLAREVIC S, 1993, SCIENCE, V260, P541, DOI 10.1126/science.8475386	46	41	41	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	1999	274	11					7454	7461		10.1074/jbc.274.11.7454	http://dx.doi.org/10.1074/jbc.274.11.7454			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	175DV	10066810	hybrid			2022-12-25	WOS:000079078400082
J	Mackay, K; Mochly-Rosen, D				Mackay, K; Mochly-Rosen, D			An inhibitor of p38 mitogen-activated protein kinase protects neonatal cardiac myocytes from ischemia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAP KINASE; SUBSTRATE-SPECIFICITY; CELLULAR STRESSES; TERMINAL KINASES; REPERFUSION; APOPTOSIS; HEART; PHOSPHORYLATION; CELLS; STIMULATION	Cellular ischemia results in activation of a number of kinases, including p38 mitogen-activated protein kinase (MAPK); however, it is not yet clear whether p38 MAPK activation plays a role in cellular damage or is part of a protective response against ischemia, We have developed a model to study ischemia in cultured neonatal rat cardiac myocytes. In this model, two distinct phases of p38 MAPK activation were observed during ischemia. The first phase began within 10 min and lasted less than 1 h, and the second began after 2 h and lasted throughout the ischemic period. Similar to previous studies using in vivo models, the nonspecific activator of p38 MAPK and c-Jun NH2-terminal kinase, anisomycin, protected cardiac myocytes from ischemic injury, decreasing the release of cytosolic lactate dehydrogenase by approximately 25%. We demonstrated, however, that a selective inhibitor of p38 MAPK, SB 203580, also protected cardiac myocytes against extended ischemia in a dose-dependent manner. The protective effect was seen even when the inhibitor was present during only the second, sustained phase of p38 MAPK activation. We found that ischemia induced apoptosis in neonatal rat cardiac myocytes and that SE 203580 reduced activation of caspase-3, a key event in apoptosis. These results suggest that p38 MAPK induces apoptosis during ischemia in cardiac myocytes and that selective inhibition of p58 MAPK could be developed as a potential therapy for ischemic heart disease.	Stanford Univ, Sch Med, Dept Mol Pharmacol, Stanford, CA 94305 USA	Stanford University	Mochly-Rosen, D (corresponding author), Stanford Univ, Sch Med, Dept Mol Pharmacol, Stanford, CA 94305 USA.	mochly@stanford.edu		Mochly-Rosen, Daria/0000-0002-6691-8733	NHLBI NIH HHS [HL-52141] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bogoyevitch MA, 1996, CIRC RES, V79, P162, DOI 10.1161/01.RES.79.2.162; Bradham CA, 1997, HEPATOLOGY, V25, P1128, DOI 10.1002/hep.510250514; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; CHOU SY, 1992, MOL BIOL CELL, V3, P1117, DOI 10.1091/mbc.3.10.1117; Clerk A, 1997, BIOCHEM J, V325, P801, DOI 10.1042/bj3250801; Clerk A, 1998, FEBS LETT, V426, P93, DOI 10.1016/S0014-5793(98)00324-X; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; Downey JM, 1997, ADV EXP MED BIOL, V430, P39; Goedert M, 1997, EMBO J, V16, P3563, DOI 10.1093/emboj/16.12.3563; Gray MO, 1997, J BIOL CHEM, V272, P30945, DOI 10.1074/jbc.272.49.30945; Guo YL, 1998, J BIOL CHEM, V273, P4027, DOI 10.1074/jbc.273.7.4027; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Jiang Y, 1996, J BIOL CHEM, V271, P17920, DOI 10.1074/jbc.271.30.17920; Johnson JA, 1996, CIRC RES, V79, P1086, DOI 10.1161/01.RES.79.6.1086; Kajstura J, 1996, LAB INVEST, V74, P86; Kawasaki H, 1997, J BIOL CHEM, V272, P18518, DOI 10.1074/jbc.272.30.18518; KHANDOUDI N, 1998, 6 ANTW JOLL KYOT RES; Knight RJ, 1996, BIOCHEM BIOPH RES CO, V218, P83, DOI 10.1006/bbrc.1996.0016; Kumar S, 1997, BIOCHEM BIOPH RES CO, V235, P533, DOI 10.1006/bbrc.1997.6849; Kummer JL, 1997, J BIOL CHEM, V272, P20490, DOI 10.1074/jbc.272.33.20490; Kyriakis JM, 1996, J BIOL CHEM, V271, P24313, DOI 10.1074/jbc.271.40.24313; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; MAULIK N, 1998, VASCULAR MYOCARDIAL; Mizukami Y, 1997, J BIOL CHEM, V272, P16657, DOI 10.1074/jbc.272.26.16657; Morooka T, 1998, J BIOL CHEM, V273, P24285, DOI 10.1074/jbc.273.38.24285; MURRY CE, 1986, CIRCULATION, V74, P1124, DOI 10.1161/01.CIR.74.5.1124; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; POMBO CM, 1994, J BIOL CHEM, V269, P26546; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SIMPSON P, 1982, CIRC RES, V50, P101, DOI 10.1161/01.RES.50.1.101; Stein B, 1997, J BIOL CHEM, V272, P19509, DOI 10.1074/jbc.272.31.19509; Tombes RM, 1998, BIOCHEM J, V330, P1451; Wang YB, 1998, J BIOL CHEM, V273, P2161, DOI 10.1074/jbc.273.4.2161; WEBSTER KA, 1995, J MOL CELL CARDIOL, V27, P453, DOI 10.1016/S0022-2828(08)80041-7; Weinbrenner C, 1997, J MOL CELL CARDIOL, V29, P2383, DOI 10.1006/jmcc.1997.0473; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yin TG, 1997, J BIOL CHEM, V272, P19943, DOI 10.1074/jbc.272.32.19943; Young PR, 1997, J BIOL CHEM, V272, P12116, DOI 10.1074/jbc.272.18.12116; Zechner D, 1998, J BIOL CHEM, V273, P8232, DOI 10.1074/jbc.273.14.8232	41	262	276	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	1999	274	10					6272	6279		10.1074/jbc.274.10.6272	http://dx.doi.org/10.1074/jbc.274.10.6272			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172BQ	10037715	hybrid			2022-12-25	WOS:000078902800037
J	Vollmer, W; von Rechenberg, M; Holtje, JV				Vollmer, W; von Rechenberg, M; Holtje, JV			Demonstration of molecular interactions between the murein polymerase PBP1B, the lytic transglycosylase MltA, and the scaffolding protein MipA of Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PENICILLIN-BINDING-PROTEINS; OUTER-MEMBRANE PROTEIN; CONTROLLED OVEREXPRESSION; AFFINITY-CHROMATOGRAPHY; CELL-ENVELOPE; GENE; CLONING; WALL; LOCALIZATION; PURIFICATION	Enlargement of the stress-bearing murein sacculus of bacteria depends on the coordinated interaction of murein synthases and hydrolases. To understand the mechanism of interaction of these two classes of proteins affinity chromatography and surface plasmon resonance (SPR) studies were performed. The membrane-bound lytic transglycosylase MltA when covalently linked to CNBr-activated Sepharose specifically retained the penicillin-binding proteins (PBPs) 1B, 1C, 2, and 3 from a crude Triton X-100 membrane extract of Escherichia coli. In the presence of periplasmic proteins also PBP1A was specifically bound. At least five different non-PBPs showed specificity for MltA-Sepharose. The amino-terminal amino acid sequence of one of these proteins could be obtained, and the corresponding gene was mapped at 40 min on the E. coli genome. This MltA-interacting protein, named MipA, in addition binds to PBP1B, a bifunctional murein transglycosylase/ transpeptidase. SPR studies with PBP1B immobilized to ampicillin-coated sensor chips showed an oligomerization of PBP1B that may indicate a dimerization, Simultaneous application of MipA and MltA onto a PBP1B sensor chip surface resulted in the formation of a trimeric complex, The dissociation constant was determined to be about 10(-6) M, The formation of a complex between a murein polymerase (PBP1B) and a murein hydrolase (MltA) in the presence of MipA represents a first step in a reconstitution of the hypothetical murein-synthesizing holoenzyme, postulated to be responsible for controlled growth of the stress-bearing sacculus of E. coli.	Max Planck Inst Entwicklungsbiol, Biochem Abt, D-72076 Tubingen, Germany	Max Planck Society	Holtje, JV (corresponding author), Max Planck Inst Entwicklungsbiol, Biochem Abt, Spemannstr 35, D-72076 Tubingen, Germany.	joachim-volker.hoeltje@tuebingen.mpg.de						BARBAS JA, 1986, J BACTERIOL, V165, P269, DOI 10.1128/jb.165.1.269-275.1986; BAYER ME, 1968, J GEN MICROBIOL, V53, P395, DOI 10.1099/00221287-53-3-395; BAYER MH, 1990, J BACTERIOL, V172, P125, DOI 10.1128/JB.172.1.125-135.1990; Beguin P, 1996, CRIT REV BIOCHEM MOL, V31, P201, DOI 10.3109/10409239609106584; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; BISHOP RE, 1993, FEMS MICROBIOL LETT, V114, P349, DOI 10.1111/j.1574-6968.1993.tb06597.x; BURMAN LG, 1984, P NATL ACAD SCI-BIOL, V81, P1844, DOI 10.1073/pnas.81.6.1844; CASADABAN MJ, 1980, J MOL BIOL, V138, P179, DOI 10.1016/0022-2836(80)90283-1; EDMAN P, 1967, EUR J BIOCHEM, V1, P80, DOI 10.1111/j.1432-1033.1967.tb00047.x; EHLERT K, 1995, MOL MICROBIOL, V16, P761, DOI 10.1111/j.1365-2958.1995.tb02437.x; ENGEL H, 1991, J BACTERIOL, V173, P6773, DOI 10.1128/jb.173.21.6773-6782.1991; Ghuysen JM, 1997, INT J ANTIMICROB AG, V8, P45, DOI 10.1016/S0924-8579(96)00358-5; GLAUNER B, 1988, J BIOL CHEM, V263, P10088; Holtje JV, 1996, MICROBIOL-SGM, V142, P1911, DOI 10.1099/13500872-142-8-1911; Holtje JV, 1998, MICROBIOL MOL BIOL R, V62, P181; HOLTJE JV, 1975, J BACTERIOL, V124, P1067; INOUE H, 1990, GENE, V96, P23, DOI 10.1016/0378-1119(90)90336-P; ISHIDATE K, 1986, J BIOL CHEM, V261, P428; ISHINO F, 1980, BIOCHEM BIOPH RES CO, V97, P287, DOI 10.1016/S0006-291X(80)80166-5; KELLENBERGER E, 1990, MOL MICROBIOL, V4, P697, DOI 10.1111/j.1365-2958.1990.tb00640.x; KOCH AL, 1985, J THEOR BIOL, V117, P137, DOI 10.1016/S0022-5193(85)80169-7; KOHARA Y, 1987, CELL, V50, P495, DOI 10.1016/0092-8674(87)90503-4; KORAT B, 1991, MOL MICROBIOL, V5, P675, DOI 10.1111/j.1365-2958.1991.tb00739.x; KUSSER W, 1980, EUR J BIOCHEM, V103, P277, DOI 10.1111/j.1432-1033.1980.tb04312.x; Lommatzsch J, 1997, J BACTERIOL, V179, P5465, DOI 10.1128/jb.179.17.5465-5470.1997; LUGTENBERG B, 1975, FEBS LETT, V58, P254, DOI 10.1016/0014-5793(75)80272-9; MACKMACKEN R, 1987, ESCHERICHIA COLI SAL, P564; Matsuhashi M., 1994, BACTERIAL CELL WALL, P55; Miller J.H., 1972, EXPT MOL GENETICS; NAKAGAWA J, 1979, AGR BIOL CHEM TOKYO, V43, P1379, DOI 10.1080/00021369.1979.10863634; PARK JT, 1973, BIOCHEM BIOPH RES CO, V51, P863, DOI 10.1016/0006-291X(73)90006-5; Park JT, 1996, ESCHERICHIA COLI SAL, P48; ROMEIS T, 1994, J BIOL CHEM, V269, P21603; ROMEIS T, 1994, EUR J BIOCHEM, V224, P597, DOI 10.1111/j.1432-1033.1994.00597.x; SCHMIDT LS, 1981, J BACTERIOL, V145, P632, DOI 10.1128/JB.145.1.632-637.1981; SCHWARZ U, 1981, FEMS MICROBIOL LETT, V10, P107, DOI 10.1111/j.1574-6968.1981.tb06217.x; Shockman GD., 1994, BACTERIAL CELL WALL, P131, DOI 10.1016/S0167-7306(08)60410-X; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SPRATT BG, 1977, EUR J BIOCHEM, V72, P341, DOI 10.1111/j.1432-1033.1977.tb11258.x; STEVENSON G, 1985, EUR J BIOCHEM, V148, P385, DOI 10.1111/j.1432-1033.1985.tb08850.x; TEMPLIN MF, 1992, J BIOL CHEM, V267, P20039; TOMASZ A, 1979, ANNU REV MICROBIOL, V33, P113, DOI 10.1146/annurev.mi.33.100179.000553; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; vonRechenberg M, 1996, MICROB DRUG RESIST, V2, P155, DOI 10.1089/mdr.1996.2.155; WACHI M, 1989, J BACTERIOL, V171, P3123, DOI 10.1128/jb.171.6.3123-3127.1989; WEIDEL W, 1964, ADV ENZYMOL REL S BI, V26, P193; WITHOLT B, 1976, ANAL BIOCHEM, V74, P160, DOI 10.1016/0003-2697(76)90320-1; ZIJDERVELD CAL, 1991, J BACTERIOL, V173, P5740, DOI 10.1128/jb.173.18.5740-5746.1991	48	149	153	1	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1999	274	10					6726	6734		10.1074/jbc.274.10.6726	http://dx.doi.org/10.1074/jbc.274.10.6726			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172BQ	10037771	hybrid			2022-12-25	WOS:000078902800093
J	Grant, GA; Kim, SJ; Xu, XL; Hu, ZQ				Grant, GA; Kim, SJ; Xu, XL; Hu, ZQ			The contribution of adjacent subunits to the active sites of D-3-phosphoglycerate dehydrogenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOGLYCERATE DEHYDROGENASE; BINDING; ENZYME	D-3-Phosphoglycerate dehydrogenase (PGDH) from Escherichia coli is allosterically inhibited by L-serine, the end product of its metabolic pathway. Previous results have shown that inhibition by serine has a large effect on V-max and only a small or negligible effect on K-m. PGDH is thus classified as a V-type allosteric enzyme. In this study, the active site of PGDH has been studied by site directed mutagenesis to assess the role of-certain residues in substrate binding and catalysis. These consist of a group of cationic residues (Arg-240, Arg-60, Arg-62, Lys-39, and Lys-141') that potentially form an electrostatic environment for the binding of the negatively charged substrate, as well as the only tryptophan residue found in PG;DH and which fits into a hydrophobic pocket immediately adjacent to the active site histidine residue. Interestingly Trp-139' and Lys-141' are part of the polypeptide chain of the subunit that is adjacent to the active site. The results of mutating these residues show that Arg-240, Arg-60, Arg-62, and Lys-141' play distinct roles in the binding of the substrate to the active site. Mutants of Trp-139' show that this residue may play a role in stabilizing the catalytic center of the enzyme. Furthermore, these mutants appear to have a significant effect on the cooperativity of serine inhibition and suggest a possible role for Trp-139' in the cooperative interactions between subunits.	Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)	Grant, GA (corresponding author), Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, 660 S Euclid Ave,Box 8103, St Louis, MO 63110 USA.			Kim, Sung Joon/0000-0002-2007-6606	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056676] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM56676] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AlRabiee R, 1996, J BIOL CHEM, V271, P13013, DOI 10.1074/jbc.271.22.13013; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CORMACK B, 1991, CURRENT PROTOCOLS MO; CREIGHTON TE, 1984, PROTEINS, P7; Grant GA, 1996, PROTEIN SCI, V5, P34; Grant GA, 1998, J BIOL CHEM, V273, P22389, DOI 10.1074/jbc.273.35.22389; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; SCHULLER DJ, 1995, NAT STRUCT BIOL, V2, P69, DOI 10.1038/nsb0195-69; SCHULLER DJ, 1989, J BIOL CHEM, V264, P2645; SUGIMOTO E, 1968, J BIOL CHEM, V243, P2090; SUGIMOTO E, 1968, J BIOL CHEM, V243, P2081; TOBEY KL, 1986, J BIOL CHEM, V261, P2179; Zhao GS, 1996, J BACTERIOL, V178, P232, DOI 10.1128/jb.178.1.232-239.1996	13	26	29	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 26	1999	274	9					5357	5361		10.1074/jbc.274.9.5357	http://dx.doi.org/10.1074/jbc.274.9.5357			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	170KG	10026144	hybrid			2022-12-25	WOS:000078804400015
J	Heiskanen, KM; Bhat, MB; Wang, HW; Ma, JJ; Nieminen, AL				Heiskanen, KM; Bhat, MB; Wang, HW; Ma, JJ; Nieminen, AL			Mitochondrial depolarization accompanies cytochrome c release during apoptosis in PC6 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERMEABILITY TRANSITION; BCL-2; ACTIVATION; MEMBRANE	Cytochrome c is released from mitochondria into the cytosol in cells undergoing apoptosis. The temporal relationship between cytochrome c release and loss of mitochondrial membrane potential was monitored by laser-scanning confocal microscopy in single living pheochromocytoma-6 cells undergoing apoptosis induced by staurosporine. Mitochondrial membrane potential monitored by tetramethylrhodamine methyl ester decreased abruptly in individual cells from 2 to 7 h after treatment with staurosporine. Depolarization was accompanied by cytochrome c release documented by release of transfected green fluorescent protein-tagged cytochrome c in these cells. The results show that mitochondrial depolarization accompanies cytochrome c release in pheochromocytoma-6 cells undergoing apoptosis.	Case Western Reserve Univ, Sch Med, Dept Anat, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Physiol & Biophys, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Biomed Engn, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University; Case Western Reserve University	Nieminen, AL (corresponding author), Case Western Reserve Univ, Sch Med, Dept Anat, W520,10900 Euclid Ave, Cleveland, OH 44106 USA.	axn25@po.cwru.edu			NIA NIH HHS [AG 13318] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R29AG013318] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BERNARDI P, 1994, J BIOENERG BIOMEMBR, V26, P509, DOI 10.1007/BF00762735; Boix J, 1997, NEUROPHARMACOLOGY, V36, P811, DOI 10.1016/S0028-3908(97)00030-0; Bossy-Wetzel E, 1998, EMBO J, V17, P37, DOI 10.1093/emboj/17.1.37; Cai JY, 1998, BBA-BIOENERGETICS, V1366, P139, DOI 10.1016/S0005-2728(98)00109-1; EHRENBERG B, 1988, BIOPHYS J, V53, P785, DOI 10.1016/S0006-3495(88)83158-8; EMAUS RK, 1986, BIOCHIM BIOPHYS ACTA, V850, P436, DOI 10.1016/0005-2728(86)90112-X; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Huser J, 1998, BIOPHYS J, V74, P2129, DOI 10.1016/S0006-3495(98)77920-2; Ichas F, 1998, BBA-BIOENERGETICS, V1366, P33, DOI 10.1016/S0005-2728(98)00119-4; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Kroemer G, 1997, IMMUNOL TODAY, V18, P44, DOI 10.1016/S0167-5699(97)80014-X; Kroemer G, 1998, ANNU REV PHYSIOL, V60, P619, DOI 10.1146/annurev.physiol.60.1.619; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Mahajan NP, 1998, NAT BIOTECHNOL, V16, P547, DOI 10.1038/nbt0698-547; Manjunatha B, 1997, J GEN PHYSIOL, V110, P749, DOI 10.1085/jgp.110.6.749; Marchetti P, 1996, J EXP MED, V184, P1155, DOI 10.1084/jem.184.3.1155; Marzo I, 1998, FEBS LETT, V427, P198, DOI 10.1016/S0014-5793(98)00424-4; Messam CA, 1998, EXP CELL RES, V238, P389, DOI 10.1006/excr.1997.3845; Mills JC, 1998, J CELL SCI, V111, P625; NIEMINEN AL, 1990, J BIOL CHEM, V265, P2399; Nieminen AL, 1996, NEUROSCIENCE, V75, P993; Poot M, 1996, J HISTOCHEM CYTOCHEM, V44, P1363, DOI 10.1177/44.12.8985128; Reed JC, 1997, CELL, V91, P559, DOI 10.1016/S0092-8674(00)80442-0; Rottenberg H, 1997, BIOCHEM BIOPH RES CO, V240, P68, DOI 10.1006/bbrc.1997.7605; Scarlett JL, 1997, FEBS LETT, V418, P282, DOI 10.1016/S0014-5793(97)01391-4; Skulachev VP, 1996, FEBS LETT, V397, P7, DOI 10.1016/0014-5793(96)00989-1; Susin SA, 1996, J EXP MED, V184, P1331, DOI 10.1084/jem.184.4.1331; Tang DG, 1998, BIOCHEM BIOPH RES CO, V242, P380, DOI 10.1006/bbrc.1997.7969; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	31	295	300	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 26	1999	274	9					5654	5658		10.1074/jbc.274.9.5654	http://dx.doi.org/10.1074/jbc.274.9.5654			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	170KG	10026183	hybrid			2022-12-25	WOS:000078804400054
J	Hiraiwa, H; Pan, CJ; Lin, BC; Moses, SW; Chou, JY				Hiraiwa, H; Pan, CJ; Lin, BC; Moses, SW; Chou, JY			Inactivation of the glucose 6-phosphate transporter causes glycogen storage disease type 1b	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICROSOMAL GLUCOSE-6-PHOSPHATASE SYSTEM; MUTATIONS; DEFECT; GENE; IB; 1A; ACID	Glycogen storage disease type 1b (GSD-1b) is proposed to be caused by a deficiency in microsomal glucose 6-phosphate (G6P) transport, causing a loss of glucose-6-phosphatase activity and glucose homeostasis, However, for decades, this disorder has defied molecular characterization. In this study, we characterize the structural organization of the G6P transporter gene and identify mutations in the gene that segregate with the GSD-1b disorder. We report the functional characterization of the recombinant G6P transporter and demonstrate that mutations uncovered in GSD-1b patients disrupt G6P transport. Our results, for the first time, define a molecular basis for functional deficiency in GSD-1b and raise the possibility that the defective G6P transporter contributes to neutropenia and neutrophil/monocyte dysfunctions characteristic of GSD-1b patients.	NICHD, Heritable Disorders Branch, NIH, Bethesda, MD 20892 USA; Ben Gurion Univ Negev, Div Pediat, IL-84101 Beer Sheva, Israel	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Ben Gurion University	Chou, JY (corresponding author), NICHD, Heritable Disorders Branch, NIH, Rm 9S241,Bldg 10, Bethesda, MD 20892 USA.		Lin, Baochuan/A-8390-2009	Lin, Baochuan/0000-0002-9484-0785				Annabi B, 1998, AM J HUM GENET, V62, P400, DOI 10.1086/301727; ARION WJ, 1980, J BIOL CHEM, V255, P396; Arion WJ, 1997, ARCH BIOCHEM BIOPHYS, V339, P315, DOI 10.1006/abbi.1996.9874; BEAUDET AL, 1980, J PEDIATR-US, V97, P906, DOI 10.1016/S0022-3476(80)80418-5; Chen PY, 1998, DIABETES, V47, P874, DOI 10.2337/diabetes.47.6.874; Chen Y-T, 1995, METABOLIC MOL BASES, P935; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; FULCERI R, 1990, BIOCHIM BIOPHYS ACTA, V1022, P129, DOI 10.1016/0005-2736(90)90409-H; Gerin I, 1997, FEBS LETT, V419, P235, DOI 10.1016/S0014-5793(97)01463-4; GITZELMANN R, 1993, EUR J PEDIATR, V152, pS33; IGARASHI Y, 1984, BIOCHEM BIOPH RES CO, V119, P593, DOI 10.1016/S0006-291X(84)80290-9; KILPATRICK L, 1990, J CLIN INVEST, V86, P196, DOI 10.1172/JCI114684; Kure S, 1998, BIOCHEM BIOPH RES CO, V248, P426, DOI 10.1006/bbrc.1998.8985; LANGE AJ, 1980, J BIOL CHEM, V255, P8381; LEI KJ, 1994, J CLIN INVEST, V93, P1994, DOI 10.1172/JCI117192; LEI KJ, 1995, J CLIN INVEST, V95, P234, DOI 10.1172/JCI117645; LEI KJ, 1995, AM J HUM GENET, V57, P766; LEI KJ, 1993, SCIENCE, V262, P580, DOI 10.1126/science.8211187; Lei KJ, 1996, NAT GENET, V13, P203, DOI 10.1038/ng0696-203; Lin BC, 1998, J BIOL CHEM, V273, P31656, DOI 10.1074/jbc.273.48.31656; Middleditch C, 1998, FEBS LETT, V433, P33, DOI 10.1016/S0014-5793(98)00878-3; MOSES SW, 1990, J PEDIAT GASTROENTER, V11, P156; NARISAWA K, 1978, BIOCHEM BIOPH RES CO, V83, P1360, DOI 10.1016/0006-291X(78)91371-2; NORDLIE RC, 1985, ENZYMES BIOL MEMBR, V2, P349; ORITA M, 1989, P NATL ACAD SCI USA, V86, P2766, DOI 10.1073/pnas.86.8.2766; Pan CJ, 1998, J BIOL CHEM, V273, P6144, DOI 10.1074/jbc.273.11.6144; Veiga-da-Cunha M, 1998, AM J HUM GENET, V63, P976, DOI 10.1086/302068	27	123	126	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 26	1999	274	9					5532	5536		10.1074/jbc.274.9.5532	http://dx.doi.org/10.1074/jbc.274.9.5532			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	170KG	10026167	hybrid			2022-12-25	WOS:000078804400038
J	Saikumar, P; Dong, Z; Patel, Y; Hall, K; Hopfer, U; Weinberg, JM; Venkatachalam, MA				Saikumar, P; Dong, Z; Patel, Y; Hall, K; Hopfer, U; Weinberg, JM; Venkatachalam, MA			Role of hypoxia-induced Bax translocation and cytochrome c release in reoxygenation injury	ONCOGENE			English	Article						hypoxia; reoxygenation; cell death; Bax; Bcl-2; cytochrome c	INDUCED CELL-DEATH; PROXIMAL TUBULES; PROTEASE CASCADE; BCL-2; APOPTOSIS; ISCHEMIA; ACTIVATION; DAMAGE; OVEREXPRESSION; CYCLOSPORINE	We investigated mechanisms of cell death during hypoxia/reoxygenation of cultured kidney cells. During glucose-fret hypoxia, cell ATP levels declined steeply resulting in the translocation of Bas from cytosol to mitochondria. Concurrently, there was cytochrome c release and caspase activation. Cells that leaked cytochrome c underwent apoptosis after reoxygenation, ATP depletion induced by a mitochondrial uncoupler resulted in similar alterations even in the presence of oxygen. Moreover, inclusion of glucose during hypoxia prevented protein translocations and reoxygenation injury by maintaining intracellular ATP, Thus, ATP depletion, rather than hypoxia per se, was the cause of protein translocations. Overexpression of Bcl-2 prevented cytochrome c release and reoxygenation injury without ameliorating ATP depletion or Bas translocation, On the other hand, caspase inhibitors did not prevent protein translocations, but inhibited apoptosis during reoxygenation, Nevertheless, they could not confer long-term viability, since mitochondria had been damaged. Omission of glucose during reoxygenation resulted in continued failure of ATP production, and cell death,vith necrotic morphology. In contrast, cells expressing Bcl-2 had functional mitochondria and remained viable during reoxygenation even,without glucose. Therefore, Bas translocation during hypoxia is a molecular trigger for cell death during reoxygenation. If ATP is available during reoxygenation, apoptosis develops; otherwise, death occurs by necrosis. By preserving mitochondrial integrity, BCL-2 prevents both forms of cell death and ensures cell viability.	Univ Texas, Hlth Sci Ctr, Dept Pathol, San Antonio, TX 78284 USA; Case Western Reserve Univ, Dept Physiol & Biophys, Cleveland, OH 44106 USA; Univ Michigan, Dept Med, Ann Arbor, MI 48109 USA	University of Texas System; University of Texas Health San Antonio; Case Western Reserve University; University of Michigan System; University of Michigan	Saikumar, P (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Pathol, 7703 Floyd Curl Dr, San Antonio, TX 78284 USA.		Hopfer, Ulrich/B-5463-2009	Hopfer, Ulrich/0000-0003-1357-0101	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK037139, R01DK054472, R01DK048417, R01DK037139] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK54472, DK48417, DK37139] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Antonsson B, 1997, SCIENCE, V277, P370, DOI 10.1126/science.277.5324.370; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Bargou RC, 1996, J CLIN INVEST, V97, P2651, DOI 10.1172/JCI118715; Borutaite V, 1996, J MOL CELL CARDIOL, V28, P2195, DOI 10.1006/jmcc.1996.0211; Bossy-Wetzel E, 1998, EMBO J, V17, P37, DOI 10.1093/emboj/17.1.37; Cheng Y, 1998, J CLIN INVEST, V101, P1992, DOI 10.1172/JCI2169; Cotran R.S., 1998, ROBBINS PATHOLOGIC B; Dong Z, 1998, AM J PATHOL, V152, P231; DUKE RC, 1983, P NATL ACAD SCI-BIOL, V80, P6361, DOI 10.1073/pnas.80.20.6361; DURAN MA, 1990, TOXICOL APPL PHARM, V105, P183, DOI 10.1016/0041-008X(90)90180-3; FISKUM G, 1980, P NATL ACAD SCI-BIOL, V77, P3430, DOI 10.1073/pnas.77.6.3430; Folbergrova J, 1997, EXP BRAIN RES, V114, P44, DOI 10.1007/PL00005622; GARZAQUINTERO R, 1990, AM J PHYSIOL, V258, pF1075, DOI 10.1152/ajprenal.1990.258.4.F1075; GRIFFITHS EJ, 1995, BIOCHEM J, V307, P93, DOI 10.1042/bj3070093; Gross A, 1998, EMBO J, V17, P3878, DOI 10.1093/emboj/17.14.3878; Hsu YT, 1998, J BIOL CHEM, V273, P10777, DOI 10.1074/jbc.273.17.10777; JACOBSON MD, 1995, NATURE, V374, P814, DOI 10.1038/374814a0; Kajstura J, 1998, AM J CARDIOL, V82, p30K, DOI 10.1016/S0002-9149(98)00535-9; Kato H, 1997, EXP NEUROL, V148, P464, DOI 10.1006/exnr.1997.6707; Kaushal GP, 1998, AM J PHYSIOL-RENAL, V274, pF587, DOI 10.1152/ajprenal.1998.274.3.F587; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Kroemer G, 1997, IMMUNOL TODAY, V18, P44, DOI 10.1016/S0167-5699(97)80014-X; LAZEBNIK YA, 1995, P NATL ACAD SCI USA, V92, P9042, DOI 10.1073/pnas.92.20.9042; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Li Y, 1998, J NEUROL SCI, V156, P119, DOI 10.1016/S0022-510X(98)00036-7; Lieberthal W, 1996, AM J PHYSIOL-RENAL, V271, pF477, DOI 10.1152/ajprenal.1996.271.3.F477; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; LOU X, 1998, CELL, V94, P481; Mancini M, 1998, J CELL BIOL, V140, P1485, DOI 10.1083/jcb.140.6.1485; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; MARTINOU JC, 1994, NEURON, V13, P1017, DOI 10.1016/0896-6273(94)90266-6; Marzo I, 1998, SCIENCE, V281, P2027, DOI 10.1126/science.281.5385.2027; McCarthy NJ, 1997, J CELL BIOL, V136, P215, DOI 10.1083/jcb.136.1.215; MCCORD JM, 1985, NEW ENGL J MED, V312, P159; Miller TM, 1997, J CELL BIOL, V139, P205, DOI 10.1083/jcb.139.1.205; MIN AJ, 1997, NATURE, V385, P353; NARO F, 1993, CARDIOSCIENCE, V4, P177; Nissim I, 1996, KIDNEY INT, V49, P684, DOI 10.1038/ki.1996.97; Noda T, 1998, AM J PHYSIOL-GASTR L, V274, pG270, DOI 10.1152/ajpgi.1998.274.2.G270; Pan GH, 1998, J BIOL CHEM, V273, P5841, DOI 10.1074/jbc.273.10.5841; PASTORINO JG, 1993, J BIOL CHEM, V268, P13791; PIPER HM, 1985, J MOL CELL CARDIOL, V17, P885, DOI 10.1016/S0022-2828(85)80102-4; Qian T, 1997, AM J PHYSIOL-CELL PH, V273, pC1783, DOI 10.1152/ajpcell.1997.273.6.C1783; Schendel SL, 1997, P NATL ACAD SCI USA, V94, P5113, DOI 10.1073/pnas.94.10.5113; Shimizu S, 1996, ONCOGENE, V12, P2251; SHIMIZU S, 1995, NATURE, V374, P811, DOI 10.1038/374811a0; Simm A, 1997, J CELL SCI, V110, P819; Susin SA, 1996, J EXP MED, V184, P1331, DOI 10.1084/jem.184.4.1331; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Vaux DL, 1996, P NATL ACAD SCI USA, V93, P2239, DOI 10.1073/pnas.93.6.2239; VENKATACHALAM MA, 1993, SURVIVING HYPOXIA, P473; Weinberg JM, 1997, J CLIN INVEST, V100, P713, DOI 10.1172/JCI119584; Wiegele G, 1998, NEPHROL DIAL TRANSPL, V13, P1158, DOI 10.1093/ndt/13.5.1158; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; Woost PG, 1996, KIDNEY INT, V50, P125, DOI 10.1038/ki.1996.295; WYLLIE AH, 1994, PHILOS T R SOC B, V345, P237, DOI 10.1098/rstb.1994.0099; Xiang JL, 1996, P NATL ACAD SCI USA, V93, P14559, DOI 10.1073/pnas.93.25.14559; Yang E, 1996, BLOOD, V88, P386, DOI 10.1182/blood.V88.2.386.bloodjournal882386; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Yaoita H, 1998, CIRCULATION, V97, P276, DOI 10.1161/01.CIR.97.3.276; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	63	257	269	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 31	1998	17	26					3401	3415		10.1038/sj.onc.1202590	http://dx.doi.org/10.1038/sj.onc.1202590			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	157XD	10030664				2022-12-25	WOS:000078086200001
J	Farinas, J; Verkman, AS				Farinas, J; Verkman, AS			Receptor-mediated targeting of fluorescent probes in living cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							H+-ATPASE; PH; PROTEIN; TRANSPORT	A strategy was developed to label specified sites in living cells with a wide selection of fluorescent or other probes and applied to study pH regulation in Golgis. cDNA transfection was used to target a single-chain antibody to a specified site such as an organelle lumen. The targeted antibody functioned as a high affinity receptor to trap cell-permeable hapten-fluorophore conjugates. Synthesized conjugates of a hapten (4-ethoxymethylene-2-phenyl-2-oxazolin-5-one, phOx) and fluorescent probes (Bodipy Fl, tetramethylrhodamine, fluorescein) were bound with high affinity (similar to 5 nM) and specific localization to the single-chain antibody expressed in the endoplasmic reticulum, Golgi, and plasma membrane of living Chinese hamster ovary cells. Using the pH-sensitive phOx-fluorescein conjugate and ratio imaging microscopy, pH was measured in the lumen of Golgi (pH 6.25 +/- 0.06). Measurements of pH-dependent vacuolar H+/ATPase pump activity and H+ leak in Golgi provided direct evidence that resting Golgi pH is determined by balanced leak-pump kinetics rather than the inability of the H+/ATPase to pump against an electrochemical gradient. Like expression of the green fluorescent protein, the receptor-mediated fluorophore targeting approach permits specific intracellular fluorescence labeling. A significant advantage of the new approach is the ability to target chemical probes with custom-designed spectral and indicator properties.	Univ Calif San Francisco, Cardiovasc Res Inst, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Cardiovasc Res Inst, Dept Physiol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Farinas, J (corresponding author), Univ Calif San Francisco, Cardiovasc Res Inst, Dept Med, 1246 Hlth Sci E Tower, San Francisco, CA 94143 USA.				NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001614] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK035124, R01DK043840, R37DK035124] Funding Source: NIH RePORTER; NCRR NIH HHS [RR01614] Funding Source: Medline; NIDDK NIH HHS [DK43840, DK35124] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARAI K, 1993, J BIOL CHEM, V268, P5649; BLOOM GS, 1989, J BIOL CHEM, V264, P16083; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; Chesnut JD, 1996, J IMMUNOL METHODS, V193, P17, DOI 10.1016/0022-1759(96)00032-4; CUBITT AB, 1995, TRENDS BIOCHEM SCI, V20, P448, DOI 10.1016/S0968-0004(00)89099-4; DAVIES JM, 1994, P NATL ACAD SCI USA, V91, P8547, DOI 10.1073/pnas.91.18.8547; Demaurex N, 1998, J BIOL CHEM, V273, P2044, DOI 10.1074/jbc.273.4.2044; Griffin BA, 1998, SCIENCE, V281, P269, DOI 10.1126/science.281.5374.269; Kim JH, 1996, J CELL BIOL, V134, P1387, DOI 10.1083/jcb.134.6.1387; Kneen M, 1998, BIOPHYS J, V74, P1591, DOI 10.1016/S0006-3495(98)77870-1; Llopis J, 1998, P NATL ACAD SCI USA, V95, P6803, DOI 10.1073/pnas.95.12.6803; LUKACS GL, 1991, J BIOL CHEM, V266, P24540; Miesenbock G, 1998, NATURE, V394, P192, DOI 10.1038/28190; Miyawaki A, 1997, NATURE, V388, P882, DOI 10.1038/42264; Ormo M, 1996, SCIENCE, V273, P1392, DOI 10.1126/science.273.5280.1392; Proba K, 1998, J MOL BIOL, V275, P245, DOI 10.1006/jmbi.1997.1457; ROOS A, 1981, PHYSIOL REV, V61, P296, DOI 10.1152/physrev.1981.61.2.296; ROSOMER VA, 1997, J BIOL CHEM, V272, P13270; Rybak SL, 1997, BIOPHYS J, V73, P674, DOI 10.1016/S0006-3495(97)78102-5; Seksek O, 1997, J CELL BIOL, V138, P131, DOI 10.1083/jcb.138.1.131; SEKSEK O, 1995, J BIOL CHEM, V270, P4967, DOI 10.1074/jbc.270.10.4967; Siegel MS, 1997, NEURON, V19, P735, DOI 10.1016/S0896-6273(00)80955-1; SWEDLOW JR, 1993, CELL, V73, P97, DOI 10.1016/0092-8674(93)90163-K; TSIEN RY, 1992, AM J PHYSIOL, V263, pC723, DOI 10.1152/ajpcell.1992.263.4.C723; VIRTANEN I, 1980, J CELL BIOL, V85, P429, DOI 10.1083/jcb.85.2.429	25	85	100	0	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 19	1999	274	12					7603	7606		10.1074/jbc.274.12.7603	http://dx.doi.org/10.1074/jbc.274.12.7603			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	178LU	10075643	hybrid			2022-12-25	WOS:000079268100002
J	Nagamatsu, S; Watanabe, T; Nakamichi, Y; Yamamura, C; Tsuzuki, K; Matsushima, S				Nagamatsu, S; Watanabe, T; Nakamichi, Y; Yamamura, C; Tsuzuki, K; Matsushima, S			alpha-soluble N-ethylmaleimide-sensitive factor attachment protein is expressed in pancreatic beta cells and functions in insulin but not gamma-aminobutyric acid secretion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNAPTIC VESICLE DOCKING; FUSION PROTEIN; RECOMBINANT ADENOVIRUS; REGULATED EXOCYTOSIS; VESICULAR TRANSPORT; ENDOCRINE-CELLS; ATPASE ACTIVITY; SNAP RECEPTORS; IN-VITRO; T-SNARE	The function of soluble N-ethylmaleimide-sensitive attachment protein-alpha (alpha-SNAP) in exocytosis still remains obscure. This study was conducted to determine the physiological role of alpha-SNAP in the secretion of insulin and gamma-aminobutryric acid (GABA) from pancreatic beta cells. Reverse transcriptase-polymerase chain reaction analysis of total RNA isolated from rat islets disclosed alpha-SNAP, but not beta-SNAP, mRNA expression, and an immunofluorescence study of rat pancreas showed that alpha-SNAP was present predominantly in the cytoplasm of the islets of Langerhans, alpha-SNAP overexpression in rat islets enhanced insulin release relative to the control levels. An in, vitro binding study showed that both wildtype alpha-SNAP and C-terminal-deleted alpha-SNAP mutant (1-285) can bind to syntaxin 1A. alpha-SNAP mutant (1-285) was overexpressed to evaluate its activity as dominant-negative effector on insulin release. Overexpression of alpha-SNAP mutant (1-285) in rat islets and MING cells decreased glucose-stimulated insulin release to about 50% of the control levels. Suppression of endogeneous alpha-SNAP in MIN6 cells by treatment with an antisense phosphorothioate oligonucleotide resulted in inhibition of insulin release. In order to examine if alpha-SNAP functions in exocytosis from synaptic-like microvesicles in pancreatic beta cells, the functional role of alpha-SNAP in GABA release from MIN6 cells was studied. The data showed no effect of alpha-SNAP mutant (1-285) overexpression on GABA release. We conclude that 1) alpha-SNAP plays a crucial role in insulin exocytosis via large dense core vesicles, but not GABA released via synaptic-like microvesicles, in pancreatic beta cells; and 2) the interaction of alpha-SNAP and syntaxin 1A may play an important role in the insulin exocytotic process.	Kyorin Univ, Sch Med, Dept Biochem, Mitaka, Tokyo 1818611, Japan; Kyorin Univ, Sch Med, Dept Clin Pathol, Mitaka, Tokyo 1818611, Japan	Kyorin University; Kyorin University	Nagamatsu, S (corresponding author), Kyorin Univ, Sch Med, Dept Biochem, 6-20-2 Shinkawa, Mitaka, Tokyo 1818611, Japan.	shinya@kyorin-u.ac.jp						Barnard RJO, 1996, MOL BIOL CELL, V7, P693, DOI 10.1091/mbc.7.5.693; Barnard RJO, 1997, J CELL BIOL, V139, P875, DOI 10.1083/jcb.139.4.875; BECKER TC, 1994, J BIOL CHEM, V269, P21234; BENNETT MK, 1993, CELL, V74, P863, DOI 10.1016/0092-8674(93)90466-4; BETY WM, 1992, SCIENCE, V255, P200; BLOCK MR, 1988, P NATL ACAD SCI USA, V85, P7852, DOI 10.1073/pnas.85.21.7852; CALAKOS N, 1994, SCIENCE, V263, P1146, DOI 10.1126/science.8108733; CHAMBERLAIN LH, 1995, J CELL BIOL, V130, P1063, DOI 10.1083/jcb.130.5.1063; CHAPMAN ER, 1994, J BIOL CHEM, V269, P27427; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; FERRONOVICK S, 1994, NATURE, V370, P191, DOI 10.1038/370191a0; Gaskins HR, 1995, J BIOL CHEM, V270, P30286, DOI 10.1074/jbc.270.51.30286; HANSON PI, 1995, J BIOL CHEM, V270, P16955, DOI 10.1074/jbc.270.28.16955; HAYASHI T, 1995, EMBO J, V14, P2317, DOI 10.1002/j.1460-2075.1995.tb07226.x; JACOBSSON G, 1994, P NATL ACAD SCI USA, V91, P12487, DOI 10.1073/pnas.91.26.12487; KANEGAE Y, 1995, NUCLEIC ACIDS RES, V23, P3816, DOI 10.1093/nar/23.19.3816; Kayo T, 1996, J BIOL CHEM, V271, P10731, DOI 10.1074/jbc.271.18.10731; KEHR J, 1988, J NEUROCHEM, V51, P1308, DOI 10.1111/j.1471-4159.1988.tb03101.x; KiralyBorri CE, 1996, BIOCHEM J, V314, P199, DOI 10.1042/bj3140199; KNIGHT DE, 1989, TRENDS NEUROSCI, V12, P451, DOI 10.1016/0166-2236(89)90095-7; Lin RC, 1997, NEURON, V19, P1087, DOI 10.1016/S0896-6273(00)80399-2; LING ZD, 1994, ENDOCRINOLOGY, V134, P2614, DOI 10.1210/en.134.6.2614; MALAISSE WJ, 1979, METABOLISM, V28, P373, DOI 10.1016/0026-0495(79)90111-2; MARTIN F, 1995, DIABETOLOGIA, V38, P860, DOI 10.1007/s001250050364; Mayer A, 1996, CELL, V85, P83, DOI 10.1016/S0092-8674(00)81084-3; MEGLASSON M D, 1986, Diabetes Metabolism Reviews, V2, P163; Miyake S, 1996, P NATL ACAD SCI USA, V93, P1320, DOI 10.1073/pnas.93.3.1320; MIZUTA M, 1994, J BIOL CHEM, V269, P11675; MORGAN A, 1994, J BIOL CHEM, V269, P29347; MORGAN A, 1995, EMBO J, V14, P232, DOI 10.1002/j.1460-2075.1995.tb06996.x; NAGAMATSU S, 1992, ENDOCRINOLOGY, V130, P748, DOI 10.1210/en.130.2.748; Nagamatsu S, 1996, J BIOL CHEM, V271, P1160, DOI 10.1074/jbc.271.2.1160; Nagamatsu S, 1997, DIABETOLOGIA, V40, P1396, DOI 10.1007/s001250050841; NEWGARD CB, 1995, ANNU REV BIOCHEM, V64, P689, DOI 10.1146/annurev.biochem.64.1.689; Nichols BJ, 1997, NATURE, V387, P199, DOI 10.1038/387199a0; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; OHO C, 1995, NEUROSCI LETT, V186, P208, DOI 10.1016/0304-3940(95)11317-P; ORCI L, 1985, DIABETOLOGIA, V28, P528, DOI 10.1007/BF00281987; PEVSNER J, 1994, NEURON, V13, P353, DOI 10.1016/0896-6273(94)90352-2; PIPELEERS DG, 1985, ENDOCRINOLOGY, V117, P806, DOI 10.1210/endo-117-3-806; PRENTKI M, 1987, PHYSIOL REV, V67, P1185, DOI 10.1152/physrev.1987.67.4.1185; PROTOPOPOV V, 1993, CELL, V74, P855, DOI 10.1016/0092-8674(93)90465-3; REETZ A, 1991, EMBO J, V10, P1275, DOI 10.1002/j.1460-2075.1991.tb08069.x; REGAZZI R, 1995, EMBO J, V14, P2723, DOI 10.1002/j.1460-2075.1995.tb07273.x; ROTHMAN JE, 1994, CURR BIOL, V4, P220, DOI 10.1016/S0960-9822(00)00051-8; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; SCHIAVO G, 1995, NATURE, V378, P733, DOI 10.1038/378733a0; SEINO S, 1996, DIABETES REV, V4, P177; Smismans A, 1997, DIABETOLOGIA, V40, P1411, DOI 10.1007/s001250050843; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; Sudlow AW, 1996, FEBS LETT, V393, P185, DOI 10.1016/0014-5793(96)00880-0; Wheeler MB, 1996, ENDOCRINOLOGY, V137, P1340, DOI 10.1210/en.137.4.1340; WHITEHEART SW, 1993, NATURE, V362, P353, DOI 10.1038/362353a0; WOLLHEIM CB, 1981, PHYSIOL REV, V61, P914, DOI 10.1152/physrev.1981.61.4.914	55	38	39	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	1999	274	12					8053	8060		10.1074/jbc.274.12.8053	http://dx.doi.org/10.1074/jbc.274.12.8053			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	178LU	10075705	hybrid			2022-12-25	WOS:000079268100064
J	Halford, MM; Oates, AC; Hibbs, ML; Wilks, AF; Stacker, SA				Halford, MM; Oates, AC; Hibbs, ML; Wilks, AF; Stacker, SA			Genomic structure and expression of the mouse growth factor receptor related to tyrosine kinases (Ryk)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN INSULIN-RECEPTOR; CPG ISLANDS; SEQUENCE-ANALYSIS; GENE STRUCTURE; FACTOR-I; NUCLEOTIDE-SEQUENCE; CONSERVED FEATURES; MOLECULAR-CLONING; CATALYTIC DOMAIN; C-MET	We report the genomic organization of the mouse orphan receptor related to tyrosine kinases (Ryk), a structurally unclassified member of the growth factor receptor family. The mouse RYK protein is encoded by 15 exons distributed over a minimum of 81 kilobases, Genomic DNA sequences encoding a variant protein tyrosine kinase ATP-binding motif characteristic of RYK are unexpectedly found in two separate exons, A feature of the gene is an unmethylated CpG island spanning exon 1 and flanking sequences, including a TATA box-containing putative promoter and single transcription start site. Immunohistochemical examination of RYK protein distribution revealed widespread but developmentally regulated expression, which was spatially restricted within particular adult organs. Quantitative reduction of Southern blotting stringency for the detection of Ryk-related sequences provided evidence for a retroprocessed mouse pseudogene and a more distantly related gene paralogue. Extensive cross-species reactivity of a mouse Ryk kinase subdomain probe and the cloning of a Ryk orthologue from Caenorhabditis elegans demonstrate that Ryk and its relatives encode widely conserved members of a novel receptor tyrosine kinase subfamily.	Royal Melbourne Hosp, Ludwig Inst Canc Res, Melbourne, Vic 3050, Australia	Ludwig Institute for Cancer Research; Royal Melbourne Hospital	Stacker, SA (corresponding author), Royal Melbourne Hosp, Ludwig Inst Canc Res, POB 2008, Melbourne, Vic 3050, Australia.	Steven.Stacker@ludwig.edu.au	Wilks, Andrew F/R-5542-2019; Hibbs, Margaret L/D-7013-2011	Hibbs, Margaret L/0000-0002-3751-6751; Stacker, Steven/0000-0003-4096-9273; Wilks, Andrew F/0000-0002-8554-2399				ABBOTT AM, 1992, J BIOL CHEM, V267, P10759; Alroy I, 1997, FEBS LETT, V410, P83, DOI 10.1016/S0014-5793(97)00412-2; Andre C, 1997, GENOMICS, V39, P216, DOI 10.1006/geno.1996.4482; ANDRE C, 1992, ONCOGENE, V7, P685; ANTEQUERA F, 1993, P NATL ACAD SCI USA, V90, P11995, DOI 10.1073/pnas.90.24.11995; BICKMORE WA, 1992, METHOD ENZYMOL, V216, P224; BIRD AP, 1987, TRENDS GENET, V3, P342, DOI 10.1016/0168-9525(87)90294-0; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; Blumenthal T, 1996, CURR OPIN GENET DEV, V6, P692, DOI 10.1016/S0959-437X(96)80022-0; BRANDEIS M, 1994, NATURE, V371, P435, DOI 10.1038/371435a0; Burmeister M, 1996, TRENDS GENET, V12, P389, DOI 10.1016/S0168-9525(96)90092-X; CALLAHAN CA, 1995, NATURE, V376, P171, DOI 10.1038/376171a0; Callahan CA, 1996, DEVELOPMENT, V122, P2761; CARRAWAY KL, 1994, CELL, V78, P5, DOI 10.1016/0092-8674(94)90564-9; CHOU YH, 1991, P NATL ACAD SCI USA, V88, P4897, DOI 10.1073/pnas.88.11.4897; Duh FM, 1997, ONCOGENE, V15, P1583, DOI 10.1038/sj.onc.1201338; Erickson SL, 1997, DEVELOPMENT, V124, P4999; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; GAUDINO G, 1994, EMBO J, V13, P3524, DOI 10.1002/j.1460-2075.1994.tb06659.x; George SE, 1998, CELL, V92, P633, DOI 10.1016/S0092-8674(00)81131-9; GIORDANO S, 1989, ONCOGENE, V4, P1383; GOUGH NM, 1995, MAMM GENOME, V6, P255, DOI 10.1007/BF00352411; Greco A, 1996, ONCOGENE, V13, P2463; Gurniak CB, 1996, ONCOGENE, V13, P777; GUY PM, 1994, P NATL ACAD SCI USA, V91, P8132, DOI 10.1073/pnas.91.17.8132; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; Hecker KH, 1996, BIOTECHNIQUES, V20, P478; HENIKOFF S, 1987, METHOD ENZYMOL, V155, P156; Hiratsuka S, 1998, P NATL ACAD SCI USA, V95, P9349, DOI 10.1073/pnas.95.16.9349; HOVENS CM, 1992, P NATL ACAD SCI USA, V89, P11818, DOI 10.1073/pnas.89.24.11818; Hubbard SR, 1998, J BIOL CHEM, V273, P11987, DOI 10.1074/jbc.273.20.11987; IMBERT A, 1994, CYTOGENET CELL GENET, V67, P175, DOI 10.1159/000133817; KAWASAKI K, 1988, JPN J CANCER RES, V79, P1174, DOI 10.1111/j.1349-7006.1988.tb01542.x; KELMAN Z, 1993, ONCOGENE, V8, P37; KOETSIER PA, 1993, BIOTECHNIQUES, V15, P260; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; KRAUS MH, 1989, P NATL ACAD SCI USA, V86, P9193, DOI 10.1073/pnas.86.23.9193; KRAUS MH, 1991, METHOD ENZYMOL, V200, P546; LARSEN F, 1992, GENOMICS, V13, P1095, DOI 10.1016/0888-7543(92)90024-M; LARSSONBLOMBERG L, 1994, FEBS LETT, V348, P119, DOI 10.1016/0014-5793(94)00577-X; LEMMON MA, 1994, TRENDS BIOCHEM SCI, V19, P459, DOI 10.1016/0968-0004(94)90130-9; Lin JC, 1998, ONCOGENE, V16, P833, DOI 10.1038/sj.onc.1201599; MACLEOD D, 1994, GENE DEV, V8, P2282, DOI 10.1101/gad.8.19.2282; MAMINTA MLD, 1992, BIOCHEM BIOPH RES CO, V189, P1077; Matsuoka H, 1997, BIOCHEM BIOPH RES CO, V235, P487, DOI 10.1006/bbrc.1997.6812; MOSSIE K, 1995, ONCOGENE, V11, P2179; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; MOXHAM CP, 1989, J BIOL CHEM, V264, P13238; PAUL SR, 1992, INT J CELL CLONING, V10, P309, DOI 10.1002/stem.5530100509; PerezCastro AV, 1997, GENOMICS, V41, P10, DOI 10.1006/geno.1997.4616; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; Riethmacher D, 1997, NATURE, V389, P725, DOI 10.1038/39593; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; Schlessinger J, 1997, CELL, V91, P869, DOI 10.1016/S0092-8674(00)80477-8; SEINO S, 1989, P NATL ACAD SCI USA, V86, P114, DOI 10.1073/pnas.86.1.114; SIMONEAUX DK, 1995, J IMMUNOL, V154, P1157; Simpson EM, 1997, NAT GENET, V16, P19, DOI 10.1038/ng0597-19; SIYANOVA EY, 1994, ONCOGENE, V9, P2053; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; STACKER SA, 1991, J IMMUNOL, V146, P648; STACKER SA, 1993, ONCOGENE, V8, P1347; STACKER SA, 1985, J NATL CANCER I, V75, P801, DOI 10.1093/jnci/75.5.801; SZABO P, 1994, DEVELOPMENT, V120, P1651; TAMAGNONE L, 1993, ONCOGENE, V8, P2009; TAZI J, 1990, CELL, V60, P909, DOI 10.1016/0092-8674(90)90339-G; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; Wang XC, 1996, MOL MED, V2, P189, DOI 10.1007/BF03401616; Weiss FU, 1997, CURR OPIN GENET DEV, V7, P80, DOI 10.1016/S0959-437X(97)80113-X; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0; WRIGHT JD, 1995, J BIOL CHEM, V270, P12085, DOI 10.1074/jbc.270.20.12085; YEE K, 1993, BLOOD, V82, P1335	74	19	22	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	1999	274	11					7379	7390		10.1074/jbc.274.11.7379	http://dx.doi.org/10.1074/jbc.274.11.7379			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	175DV	10066802	hybrid			2022-12-25	WOS:000079078400074
J	Harada, H; Tagashira, S; Fujiwara, M; Ogawa, S; Katsumata, T; Yamaguchi, A; Komori, T; Nakatsuka, M				Harada, H; Tagashira, S; Fujiwara, M; Ogawa, S; Katsumata, T; Yamaguchi, A; Komori, T; Nakatsuka, M			Cbfa1 isoforms exert functional differences in osteoblast differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BONE MORPHOGENETIC PROTEIN-2; OSTEOCALCIN GENE-TRANSCRIPTION; ALKALINE-PHOSPHATASE GENE; CLEIDOCRANIAL DYSPLASIA; BINDING PROTEIN; RUNT DOMAIN; ELEMENTS CONTROL; MESSENGER-RNA; DNA-BINDING; EXPRESSION	Cbfa1 is an essential transcription factor for osteoblast differentiation and bone formation. We investigated functional differences among three isoforms of Cbfa1: Type I (originally reported as Pebp2 alpha A by Ogawa et al. (Ogawa, E., Maruyama, M., Kagoshima, H., Inuzuka, M., Lu, J., Satake, M., Shigesada, K., and Ito, Y. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 6859-6863), Type II (originally reported as til-l by Stewart ef al. (Stewart, M., Terry, A, Hu, M., O'Hara, M., Blyth, K., Baxter, E., Cameron, E., Onions, D. E., and Neil, J. C. (1997) Proc. Natl. Acad. Sci. U.S.A. 94, 8646-8651), and Type III (originally reported as Osf2/Cbfa1 by Ducy ef al. (Ducy, P., Zhang, R., Geoffroy, V., Ridall, A. L., and Karsenty, C. (1997) Cell 89, 747-754). A reverse transcriptase-polymerase chain reaction analysis demonstrated that these isoforms were expressed in adult mouse bones. The transient transfection of Type I or Type II Cbfa1 in a mouse fibroblastic cell line, C3H10T1/2, induced the expression of alkaline phosphatase (ALP) activity. This induction was synergistically enhanced by the co-introduction of Xenopus BMP-4 cDNA. In contrast, the transient transfection of Type III cDNA induced no ALP activity. In C3H10T1/2 cells stably transfected with each isoform of Cbfa1, the gene expression of ALP was also strongly induced in cells transfected with Type I and Type II Cbfa1 but not in cells with Type III Cbfa1. Osteocalcin, osteopontin,and type I collagen gene expressions were induced or up-regulated in all of the cells stably transfected with each isoform of Cbfa1, and Type II transfected cells exhibited the highest expression level of osteocalcin gene. A luciferase reporter gene assay using a 6XOSE2-SV40 promoter (6 tandem binding elements for Cbfa1 ligated in front of the SV40 promoter sequence), a mouse osteocalcin promoter, and a mouse osteopontin promoter revealed the differences in the transcriptional induction of target genes by each Cbfa1 isoform with or without its beta-subunit. These results suggest that all three of the Cbfa1 isoforms used in the present study are involved in the stimulatory action of osteoblast differentiation, but they exert different functions in the process of osteoblast differentiation.	Sumitomo Pharmaceut Res Ctr, Konohana Ku, Osaka 5540022, Japan; Nagasaki Univ, Sch Dent, Dept Oral Pathol, Nagasaki 8528588, Japan; Osaka Univ, Sch Med, Dept Med 3, Suita, Osaka 5650871, Japan	Nagasaki University; Osaka University	Nakatsuka, M (corresponding author), Sumitomo Pharmaceut Res Ctr, Konohana Ku, 3-1-98 Kasugade-naka, Osaka 5540022, Japan.							Aronson BD, 1997, MOL CELL BIOL, V17, P5581, DOI 10.1128/MCB.17.9.5581; ASLAM F, 1995, MOL ENDOCRINOL, V9, P679, DOI 10.1210/me.9.6.679; BAE SC, 1995, GENE, V159, P245, DOI 10.1016/0378-1119(95)00060-J; Banerjee C, 1996, P NATL ACAD SCI USA, V93, P4968, DOI 10.1073/pnas.93.10.4968; Bruhn L, 1997, GENE DEV, V11, P640, DOI 10.1101/gad.11.5.640; CRAIG AM, 1991, GENE, V100, P163, DOI 10.1016/0378-1119(91)90362-F; DUCY P, 1995, MOL CELL BIOL, V15, P1858; Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092-8674(00)80257-3; EscalanteAlcalde D, 1996, MECH DEVELOP, V57, P21, DOI 10.1016/0925-4773(96)00524-2; Fisher AL, 1998, GENE DEV, V12, P1931, DOI 10.1101/gad.12.13.1931; GENOVESE C, 1984, BIOCHEMISTRY-US, V23, P6210, DOI 10.1021/bi00320a049; Geoffroy V, 1998, MAMM GENOME, V9, P54, DOI 10.1007/s003359900679; Geoffroy V, 1995, J BIOL CHEM, V270, P30973, DOI 10.1074/jbc.270.52.30973; GIESE K, 1995, GENE DEV, V9, P995, DOI 10.1101/gad.9.8.995; GUO XJ, 1995, MOL CELL BIOL, V15, P476, DOI 10.1128/MCB.15.1.476; Harada H, 1998, ENDOCRINOLOGY, V139, P204, DOI 10.1210/en.139.1.204; HERNANDEZMUNAIN C, 1994, MOL CELL BIOL, V14, P473, DOI 10.1128/MCB.14.1.473; Horwitz KB, 1996, MOL ENDOCRINOL, V10, P1167, DOI 10.1210/me.10.10.1167; Kanno T, 1998, MOL CELL BIOL, V18, P2444, DOI 10.1128/MCB.18.5.2444; KASTNER P, 1990, EMBO J, V9, P1603, DOI 10.1002/j.1460-2075.1990.tb08280.x; KATAGIRI T, 1994, J CELL BIOL, V127, P1755, DOI 10.1083/jcb.127.6.1755; KATAGIRI T, 1990, BIOCHEM BIOPH RES CO, V172, P295, DOI 10.1016/S0006-291X(05)80208-6; Kobayashi T, 1998, BIOCHEM MOL BIOL INT, V44, P683; Komori T, 1998, CURR OPIN GENET DEV, V8, P494, DOI 10.1016/S0959-437X(98)80123-8; Lee B, 1997, NAT GENET, V16, P307, DOI 10.1038/ng0797-307; Mundlos S, 1997, CELL, V89, P773, DOI 10.1016/S0092-8674(00)80260-3; NAKASE T, 1994, BONE MINER, V26, P109, DOI 10.1016/S0169-6009(08)80056-6; NOMURA S, 1988, J CELL BIOL, V106, P441, DOI 10.1083/jcb.106.2.441; OGAWA E, 1993, P NATL ACAD SCI USA, V90, P6859, DOI 10.1073/pnas.90.14.6859; OGAWA E, 1993, VIROLOGY, V194, P314, DOI 10.1006/viro.1993.1262; Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092-8674(00)80259-7; SASAKI H, 1995, BIOCHEMISTRY-US, V34, P370, DOI 10.1021/bi00001a045; SATAKE M, 1995, MOL CELL BIOL, V15, P1662; Sato M, 1998, ONCOGENE, V17, P1517, DOI 10.1038/sj.onc.1202064; Shimano H, 1997, J CLIN INVEST, V99, P846, DOI 10.1172/JCI119248; Sodek J, 1996, CONNECT TISSUE RES, V35, P23, DOI 10.3109/03008209609029171; Stewart M, 1997, P NATL ACAD SCI USA, V94, P8646, DOI 10.1073/pnas.94.16.8646; TERAO M, 1987, P NATL ACAD SCI USA, V84, P7051, DOI 10.1073/pnas.84.20.7051; TERAO M, 1990, BIOCHEM J, V268, P641, DOI 10.1042/bj2680641; THIEDE MA, 1988, P NATL ACAD SCI USA, V85, P319, DOI 10.1073/pnas.85.2.319; Thirunavukkarasu K, 1998, MOL CELL BIOL, V18, P4197, DOI 10.1128/MCB.18.7.4197; TOKUNAGA K, 1986, NUCLEIC ACIDS RES, V14, P2829; TOWLER DA, 1994, MOL ENDOCRINOL, V8, P1484, DOI 10.1210/me.8.11.1484; Tsuji K, 1998, BONE, V22, P87, DOI 10.1016/S8756-3282(97)00267-6; Xiao ZS, 1998, GENE, V214, P187, DOI 10.1016/S0378-1119(98)00227-3; YAMAGUCHI A, 1991, J CELL BIOL, V113, P681, DOI 10.1083/jcb.113.3.681; Yamaguchi A, 1996, BIOCHEM BIOPH RES CO, V220, P366, DOI 10.1006/bbrc.1996.0411; Yu XP, 1997, ENDOCRINOLOGY, V138, P3085, DOI 10.1210/en.138.8.3085; Zhang DE, 1996, MOL CELL BIOL, V16, P1231; [No title captured]	50	393	416	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 12	1999	274	11					6972	6978		10.1074/jbc.274.11.6972	http://dx.doi.org/10.1074/jbc.274.11.6972			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	175DV	10066751	hybrid			2022-12-25	WOS:000079078400023
J	Hu, MCT; Wang, YP; Mikhail, A; Qiu, WR; Tan, TH				Hu, MCT; Wang, YP; Mikhail, A; Qiu, WR; Tan, TH			Murine p38-delta mitogen-activated protein kinase, a developmentally regulated protein kinase that is activated by stress and proinflammatory cytokines	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PATHWAY; NECROSIS-FACTOR-ALPHA; MAP KINASE; C-JUN; INSITU HYBRIDIZATION; MAMMALIAN-CELLS; GENE-EXPRESSION; PHOSPHORYLATION; CASCADE; DOMAIN	The p38 mitogen-activated protein kinases (MAPK) play a crucial role in stress and inflammatory responses and are also involved in activation of the human immunodeficiency virus gene expression. We have isolated the murine cDNA clones encoding p38-delta MAPK, and we have localized the p38-delta gene to mouse chromosome 17A3-B and human chromosome 6p21.3. By using Northern and in situ hybridization, we have examined the expression of p38-delta in the mouse adult tissues and embryos, p38-delta was expressed primarily in the lung, testis, kidney, and gut epithelium in the adult tissues. Although p38-delta was expressed predominantly in the developing gut and the septum transversum in the mouse embryo at 9.5 days, its expression began to be expanded to many specific tissues in the 12.5-day embryo. At 15.5 days, p38-delta was expressed virtually in most developing epithelia in embryos, suggesting that p38-delta is a developmentally regulated MAPK. Interestingly, p38-delta and p38-alpha were similar serine/threonine kinases but differed in substrate specificity. Overall, p38-delta resembles p38-gamma, whereas p38-beta resembles p38-alpha. Moreover, p38-delta is activated by environmental stress, extracellular stimulants, and MAPK kinase-3, -4, -6, and -7, suggesting that p38-delta is a unique stress-responsive protein kinase.	Amgen Inc, Dept Cell Biol, Thousand Oaks, CA 91320 USA; Phylogeny Inc, Columbus, OH 43212 USA; Baylor Coll Med, Dept Microbiol & Immunol, Houston, TX 77030 USA	Amgen; Baylor College of Medicine	Hu, MCT (corresponding author), Amgen Inc, Dept Cell Biol, Thousand Oaks, CA 91320 USA.	Mickey_Hu_99@yahoo.com	Tan, Tse-Hua/ABD-7080-2021; Tan, Tse-Hua/E-3983-2010	Tan, Tse-Hua/0000-0003-4969-3170; Tan, Tse-Hua/0000-0003-4969-3170				BOULTON TG, 1990, SCIENCE, V249, P64, DOI 10.1126/science.2164259; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BREWSTER JL, 1993, SCIENCE, V259, P1760, DOI 10.1126/science.7681220; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; Cuenda A, 1997, EMBO J, V16, P295, DOI 10.1093/emboj/16.2.295; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; ENGLISH JM, 1995, J BIOL CHEM, V270, P28897, DOI 10.1074/jbc.270.48.28897; Flury N, 1997, EUR J BIOCHEM, V249, P421, DOI 10.1111/j.1432-1033.1997.00421.x; FRESHNEY NW, 1994, CELL, V78, P1039, DOI 10.1016/0092-8674(94)90278-X; GALCHEVAGARGOVA Z, 1994, SCIENCE, V265, P806, DOI 10.1126/science.8047888; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; Gupta S, 1996, EMBO J, V15, P2760, DOI 10.1002/j.1460-2075.1996.tb00636.x; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Han JH, 1996, J BIOL CHEM, V271, P2886, DOI 10.1074/jbc.271.6.2886; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; Hanks SK, 1991, CURR OPIN STRUC BIOL, V1, P369, DOI 10.1016/0959-440X(91)90035-R; HENG HHQ, 1993, CHROMOSOMA, V102, P325, DOI 10.1007/BF00661275; HENG HHQ, 1992, P NATL ACAD SCI USA, V89, P9509, DOI 10.1073/pnas.89.20.9509; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Hu MCT, 1997, ONCOGENE, V15, P2277, DOI 10.1038/sj.onc.1201401; Hu MCT, 1996, GENE DEV, V10, P2251, DOI 10.1101/gad.10.18.2251; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; Jiang Y, 1996, J BIOL CHEM, V271, P17920, DOI 10.1074/jbc.271.30.17920; KALLUNKI T, 1994, GENE DEV, V8, P2996, DOI 10.1101/gad.8.24.2996; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Kumar S, 1996, J BIOL CHEM, V271, P30864, DOI 10.1074/jbc.271.48.30451; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Lechner C, 1996, P NATL ACAD SCI USA, V93, P4355, DOI 10.1073/pnas.93.9.4355; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; LYONS GE, 1990, J CELL BIOL, V111, P2427, DOI 10.1083/jcb.111.6.2427; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MCDONNELL PC, 1995, GENOMICS, V29, P301, DOI 10.1006/geno.1995.1252; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; Moriguchi T, 1996, J BIOL CHEM, V271, P13675, DOI 10.1074/jbc.271.23.13675; Moriguchi T, 1996, J BIOL CHEM, V271, P26981, DOI 10.1074/jbc.271.43.26981; Morooka T, 1998, J BIOL CHEM, V273, P24285, DOI 10.1074/jbc.273.38.24285; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; ROBBINS DJ, 1994, ADV CANCER RES, V63, P93, DOI 10.1016/S0065-230X(08)60399-1; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; Stein B, 1996, J BIOL CHEM, V271, P11427, DOI 10.1074/jbc.271.19.11427; Wang XS, 1997, J BIOL CHEM, V272, P23668, DOI 10.1074/jbc.272.38.23668; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; Yao ZB, 1997, J BIOL CHEM, V272, P32378, DOI 10.1074/jbc.272.51.32378; ZHENG CF, 1993, J BIOL CHEM, V268, P11435; ZHOU GC, 1995, J BIOL CHEM, V270, P12665, DOI 10.1074/jbc.270.21.12665	56	86	92	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	1999	274	11					7095	7102		10.1074/jbc.274.11.7095	http://dx.doi.org/10.1074/jbc.274.11.7095			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	175DV	10066767	hybrid			2022-12-25	WOS:000079078400039
J	Yamazaki, M; Gong, Z; Fukuchi-Mizutani, M; Fukui, Y; Tanaka, Y; Kusumi, T; Saito, K				Yamazaki, M; Gong, Z; Fukuchi-Mizutani, M; Fukui, Y; Tanaka, Y; Kusumi, T; Saito, K			Molecular cloning and biochemical characterization of a novel anthocyanin 5-O-glucosyltransferase by mRNA differential display for plant forms regarding anthocyanin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PETUNIA-HYBRIDA; GENETIC-CONTROL; UDP-GLUCOSE; SILENE-DIOICA; FLOWERS; LOCUS; IDENTIFICATION; BIOSYNTHESIS; PROTEIN; PETALS	UDP-glucose: anthocyanin 5-O-glucosyltransferase (5-GT) is responsible for the modification of anthocyanins to more stable molecules in complexes for co-pigmentation, supposedly resulting in a purple hue. The cDNA encoding 5-GT was isolated by a differential display applied to two different forms of anthocyanin production in Perilla frutescens var. crispa, Differential display was carried out for mRNA from the leaves of reddish-purple and green forms of P. frutescens, resulting in the isolation of five cDNA clones predominantly expressed in the red form. The cDNA encoded a polypeptide of 460 amino acids, exhibiting a low homology with the sequences of several glucosyltransferases including UDP-glucose: anthocyanidin 3-O-glucosyltransferase. By using this cDNA as the probe, we also isolated a homologous cDNA clone from a petal cDNA library of Verbena hybrida, To identify the biochemical function of the encoded proteins, these cDNAs were expressed in Saccharomyces cerevisiae cells. The recombinant proteins in the yeast extracts catalyzed the conversion of anthocyanidin 3-O-glucosides into the corresponding anthocyanidin 3,5-di-O-glucosides using UDP-glucose as a cofactor, indicating the identity of the cDNAs encoding 5-GT, Several biochemical properties (optimum pH, K-m values, and sensitivity to inhibitors) were similar to those reported previously for 5-GTs, Southern blot analysis indicated the presence of two copies of 5-GT genes in the genome of both red and green forms of P, frutescens. The mRNA accumulation of the 5-GT gene was detected in the leaves of the red form but not in those of the green form and was induced by illumination of light, as observed for other structural genes for anthocyanin biosynthesis in P, frutescens.	Chiba Univ, Fac Pharmaceut Sci, Res Ctr Med Resources, Lab Mol Biol & Biotechnol,Inage Ku, Chiba 2638522, Japan; Suntory Ltd, Inst Fundamental Res, Osaka 6188503, Japan	Chiba University; Suntory Holdings Ltd	Saito, K (corresponding author), Chiba Univ, Fac Pharmaceut Sci, Res Ctr Med Resources, Lab Mol Biol & Biotechnol,Inage Ku, Yayoi Cho 1-33, Chiba 2638522, Japan.		Saito, Kazuki/D-2670-2009; Yamazaki, Mami/A-9050-2010; Gong, Zhizhong/AAS-4796-2021	Saito, Kazuki/0000-0001-6310-5342; Yamazaki, Mami/0000-0001-6157-5287; 				ASHIKARI T, 1989, APPL MICROBIOL BIOT, V32, P129, DOI 10.1007/BF00165875; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUGLIERA F, 1994, PLANT J, V5, P81, DOI 10.1046/j.1365-313X.1994.5010081.x; DOONER HK, 1991, ANNU REV GENET, V25, P173, DOI 10.1146/annurev.ge.25.120191.001133; FEDOROFF NV, 1984, P NATL ACAD SCI-BIOL, V81, P3825, DOI 10.1073/pnas.81.12.3825; FORKMANN G, 1993, GENETICS FLAVONOIDS, P537; Gong ZZ, 1997, PLANT MOL BIOL, V35, P915, DOI 10.1023/A:1005959203396; Heller W, 1993, BIOSYNTHESIS FLAVONO, V1986, P499; HOLTON TA, 1995, PLANT CELL, V7, P1071, DOI 10.1105/tpc.7.7.1071; Horvath DM, 1996, PLANT MOL BIOL, V31, P1061, DOI 10.1007/BF00040724; Imanishi S, 1998, PLANT CELL PHYSIOL, V39, P202, DOI 10.1093/oxfordjournals.pcp.a029358; Ito M., 1996, J PHYTOGEOGR TAXON, V44, P43; JONSSON LMV, 1984, PLANTA, V160, P341, DOI 10.1007/BF00393415; KAMSTEEG J, 1980, Z PFLANZENPHYSIOL, V96, P87, DOI 10.1016/S0044-328X(80)80104-8; KAMSTEEG J, 1978, BIOCHEM GENET, V16, P1059, DOI 10.1007/BF00484526; KONDO T, 1989, AGR BIOL CHEM TOKYO, V53, P797; KROON J, 1994, PLANT J, V5, P69, DOI 10.1046/j.1365-313X.1994.5010069.x; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; MARTIN C, 1992, CONTROL FLOWER COLOR, P219; Matsune T., 1997, ENGEIGAKU ZASSHI S2, V66, P92; OKAMOTO K, 1994, EMBO J, V13, P4816, DOI 10.1002/j.1460-2075.1994.tb06807.x; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; Sambrook J., 2002, MOL CLONING LAB MANU; SEYFFERT W, 1982, BIOL ZBL, V101, P465; SZERSZEN JB, 1994, SCIENCE, V265, P1699, DOI 10.1126/science.8085154; Tanaka Y, 1996, PLANT CELL PHYSIOL, V37, P711, DOI 10.1093/oxfordjournals.pcp.a029004; TEUSCH M, 1986, PLANTA, V168, P586, DOI 10.1007/BF00392280; TOKI K, 1995, PHYTOCHEMISTRY, V38, P515, DOI 10.1016/0031-9422(94)00698-S; YOSHIDA K, 1997, PERILLA GENUS PERILL, P149	29	110	142	0	27	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 12	1999	274	11					7405	7411		10.1074/jbc.274.11.7405	http://dx.doi.org/10.1074/jbc.274.11.7405			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	175DV	10066805	hybrid			2022-12-25	WOS:000079078400077
J	Farooq, A; Plotnikova, O; Zeng, L; Zhou, MM				Farooq, A; Plotnikova, O; Zeng, L; Zhou, MM			Phosphotyrosine binding domains of Shc and insulin receptor substrate 1 recognize the NPXpY motif in a thermodynamically distinct manner	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRS-1 PTB DOMAIN; SIGNAL-TRANSDUCTION; PROTEIN; REGION; PHOSPHORYLATION; PHOSPHOPEPTIDE; ASSOCIATION; ACTIVATION; PEPTIDES; KINASES	Phosphotyrosine binding (PTB) domains of the adaptor protein Shc and insulin receptor substrate (IRS-1) interact with a distinct set of activated and tyrosine-phosphorylated cytokine and growth factor receptors and play important roles in mediating mitogenic signal transduction. By using the technique of isothermal titration calorimetry, we have studied the thermodynamics of binding of the Shc and IRS-1 PTB domains to tyrosine-phosphorylated NPXY-containing peptides derived from known receptor binding sites. The results showed that relative contributions of enthalpy and entropy to the free energy of binding are dependent on specific phosphopeptides. Binding of the Shc PTB domain to tyrosine-phosphorylated peptides from TrkA, epidermal growth factor, ErbB3, and insulin receptors is achieved via an overall entropy-driven reaction. On the other hand, recognition of the phosphopeptides of insulin and interleukin-4 receptors by the IRS-1 PTB domain is predominantly an enthalpy-driven process. Mutagenesis and amino acid substitution experiments showed that in addition to the tyrosine-phosphorylated NPXY motif, the PTB domains of Shc and IRS-1 prefer a large hydrophobic residue at pY-5 and a small hydrophobic residue at pY-1, respectively (where pY is phosphotyrosine). These results agree with the calculated solvent accessibility of these two key peptide residues in the PTB domain/peptide structures and support the notion that the PTB domains of Shc and IRS-1 employ functionally distinct mechanisms to recognize tyrosine-phosphorylated receptors.	CUNY Mt Sinai Sch Med, Dept Physiol & Biophys, Struct Biol Program, New York, NY 10029 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Zhou, MM (corresponding author), CUNY Mt Sinai Sch Med, Dept Physiol & Biophys, Struct Biol Program, 1 Gustave L Levy Pl,Box 1677, New York, NY 10029 USA.		Farooq, Amjad/B-5084-2012					BLAIKIE P, 1994, J BIOL CHEM, V269, P32031; Borg JP, 1996, MOL CELL BIOL, V16, P6229; BRUNGER AT, 1992, X PLOR MANUAL VERSIO; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Eck MJ, 1996, CELL, V85, P695, DOI 10.1016/S0092-8674(00)81236-2; GEER P, 1995, CURR BIOL, V5, P404; GUSTAFSON TA, 1995, MOL CELL BIOL, V15, P2500; HARIAN JE, 1995, NATURE, V371, P167; HE WM, 1995, J BIOL CHEM, V270, P23258, DOI 10.1074/jbc.270.40.23258; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; JOHNSON BA, 1994, J BIOMOL NMR, V4, P603, DOI 10.1007/BF00404272; KAVANAUGH WM, 1995, SCIENCE, V268, P1177, DOI 10.1126/science.7539155; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; KEEGAN AD, 1994, CELL, V76, P811, DOI 10.1016/0092-8674(94)90356-5; LADBURY JE, 1994, J MOL BIOL, V238, P669, DOI 10.1006/jmbi.1994.1328; LADBURY JE, 1995, P NATL ACAD SCI USA, V92, P3199, DOI 10.1073/pnas.92.8.3199; Lemmon MA, 1996, CELL, V85, P621, DOI 10.1016/S0092-8674(00)81022-3; Li SC, 1997, P NATL ACAD SCI USA, V94, P7204, DOI 10.1073/pnas.94.14.7204; Livingstone JR, 1996, NATURE, V384, P491, DOI 10.1038/384491a0; LIVINGSTONE JR, 1991, BIOCHEMISTRY-US, V30, P4237, DOI 10.1021/bi00231a019; Mandiyan V, 1996, J BIOL CHEM, V271, P4770; OBERMEIER A, 1993, J BIOL CHEM, V268, P22963; Olejniczak ET, 1997, BIOCHEMISTRY-US, V36, P4118, DOI 10.1021/bi963050i; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; Ravichandran KS, 1997, MOL CELL BIOL, V17, P5540, DOI 10.1128/MCB.17.9.5540; RICCI A, 1995, ONCOGENE, V11, P1519; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SALCINI AE, 1994, ONCOGENE, V9, P2827; SPOLAR RS, 1994, SCIENCE, V263, P777, DOI 10.1126/science.8303294; SUN XJ, 1993, MOL CELL BIOL, V13, P7418, DOI 10.1128/MCB.13.12.7418; Tamura A, 1997, J MOL BIOL, V273, P1048, DOI 10.1006/jmbi.1997.1368; TRUB T, 1995, J BIOL CHEM, V270, P18205; WANG LM, 1993, SCIENCE, V261, P1591, DOI 10.1126/science.8372354; WISEMAN T, 1989, ANAL BIOCHEM, V179, P131, DOI 10.1016/0003-2697(89)90213-3; WOLF G, 1995, J BIOL CHEM, V270, P27407, DOI 10.1074/jbc.270.46.27407; Xu H, 1998, J BIOL CHEM, V273, P17987, DOI 10.1074/jbc.273.29.17987; Zhou MM, 1995, J BIOL CHEM, V270, P31119, DOI 10.1074/jbc.270.52.31119; Zhou MM, 1996, NAT STRUCT BIOL, V3, P388, DOI 10.1038/nsb0496-388; ZHOU MM, 1995, NATURE, V378, P584, DOI 10.1038/378584a0; Zhou MM, 1995, PROG BIOPHYS MOL BIO, V64, P221, DOI 10.1016/S0079-6107(96)00005-3; ZHOU S, 1995, J BIOL CHEM, V270, P14863	43	26	27	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1999	274	10					6114	6121		10.1074/jbc.274.10.6114	http://dx.doi.org/10.1074/jbc.274.10.6114			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172BQ	10037694	hybrid			2022-12-25	WOS:000078902800016
J	Gallagher, PG; Sabatino, DE; Romana, M; Cline, AP; Garrett, LJ; Bodine, DM; Forget, BG				Gallagher, PG; Sabatino, DE; Romana, M; Cline, AP; Garrett, LJ; Bodine, DM; Forget, BG			A human beta-spectrin gene promoter directs high level expression in erythroid but not muscle or neural cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR GATA-1; PORPHOBILINOGEN DEAMINASE GENE; HUMAN SKELETAL-MUSCLE; KRUPPEL-LIKE FACTOR; PRE-MESSENGER-RNA; DEVELOPMENTAL EXPRESSION; MAMMALIAN-CELLS; CACCC ELEMENT; GLYCOPHORIN-B; PROTEINS	beta-Spectrin is an erythrocyte membrane protein that is defective in many patients with abnormalities of red blood cell shape including hereditary spherocytosis and elliptocytosis. It is expressed not only in erythroid tissues but also in muscle and brain. We wished to determine the regulatory elements that determine the tissue-specific expression of the beta-spectrin gene. We mapped the 5'-end of the beta-spectrin erythroid cDNA and cloned the 5'-flanking genomic DNA containing the putative beta-spectrin gene promoter. Using transfection of promoter/reporter plasmids in human tissue culture cell lines, in vitro DNase I footprinting analyses, and gel mobility shift assays, a beta-spectrin gene erythroid promoter with two binding sites for GATA-1 and one site for CACCC-related proteins was identified. All three binding sites were required for full promoter activity; one of the GATA-1 motifs and the CACCC-binding motif were essential for activity. The beta-spectrin gene promoter was able to be transactivated in heterologous cells by forced expression of GATA-1. In transgenic mice, a reporter gene directed by the beta-spectrin promoter was expressed in erythroid tissues at all stages of development. Only weak expression of the reporter gene was detected in muscle and brain tissue, suggesting that additional regulatory elements are required for high level expression of the beta-spectrin gene in these tissues.	Yale Univ, Sch Med, Dept Pediat, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Genet, New Haven, CT 06520 USA; Natl Human Genome Res Inst, Hematopoiesis Sect, Genet & Mol Biol Branch, NIH, Bethesda, MD 20892 USA	Yale University; Yale University; Yale University; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI)	Gallagher, PG (corresponding author), Yale Univ, Sch Med, Dept Pediat, 333 Cedar St,POB 208064, New Haven, CT 06520 USA.		Romana, Marc/K-6442-2017	Romana, Marc/0000-0002-8715-9836				AHN AH, 1993, NAT GENET, V3, P283, DOI 10.1038/ng0493-283; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; AMIN KM, 1993, GENOMICS, V18, P118, DOI 10.1006/geno.1993.1434; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Beck KA, 1996, AM J PHYSIOL-CELL PH, V270, pC1263, DOI 10.1152/ajpcell.1996.270.5.C1263; BENZ EJ, 1994, MOL BASIS BLOOD DIS, P257; Bewick GS, 1996, J NEUROCYTOL, V25, P367; BLOCH RJ, 1989, J CELL BIOL, V108, P481, DOI 10.1083/jcb.108.2.481; CHANG JG, 1993, GENOMICS, V17, P287, DOI 10.1006/geno.1993.1323; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHU ZL, 1994, BLOOD, V84, P1992; COLIN Y, 1990, J BIOL CHEM, V265, P16729; COX KH, 1995, J BIOL CHEM, V270, P19752, DOI 10.1074/jbc.270.34.19752; CROSSLEY M, 1994, J BIOL CHEM, V269, P15440; Crossley M, 1996, MOL CELL BIOL, V16, P1695; DANIELS MP, 1990, J CELL SCI, V97, P615; EDWARDS JBDM, 1991, NUCLEIC ACIDS RES, V19, P5227, DOI 10.1093/nar/19.19.5227; Ehmer S, 1997, ACTA NEUROPATHOL, V94, P240, DOI 10.1007/s004010050699; ELEOUET JF, 1993, EUR J BIOCHEM, V212, P763, DOI 10.1111/j.1432-1033.1993.tb17716.x; FISCHER KD, 1993, J BIOL CHEM, V268, P23915; FRAMPTON J, 1990, MOL CELL BIOL, V10, P3838, DOI 10.1128/MCB.10.7.3838; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; FUKUSHIMA Y, 1990, CYTOGENET CELL GENET, V53, P232, DOI 10.1159/000132939; GALLAGHER P, 1994, BLOOD, V84, P361; Gallagher PG, 1998, J BIOL CHEM, V273, P1339, DOI 10.1074/jbc.273.3.1339; *GEN COMP GROUP, 1994, GCG SEQ AN SOFTW PAC; GOODMAN SR, 1995, BRAIN RES BULL, V36, P593, DOI 10.1016/0361-9230(94)00264-2; Gregory RC, 1996, BLOOD, V87, P1793, DOI 10.1182/blood.V87.5.1793.bloodjournal8751793; HARTZOG GA, 1993, MOL CELL BIOL, V13, P44, DOI 10.1128/MCB.13.1.44; HOGAN B, 1986, MANIPULATING MOUSE E; HU RJ, 1992, J BIOL CHEM, V267, P18715; JAVAHERY R, 1994, MOL CELL BIOL, V14, P116, DOI 10.1128/MCB.14.1.116; KADONAGA JT, 1986, TRENDS BIOCHEM SCI, V11, P20, DOI 10.1016/0968-0004(86)90226-4; KOPITO RR, 1987, P NATL ACAD SCI USA, V84, P7149, DOI 10.1073/pnas.84.20.7149; KUDRYCKI KE, 1993, AM J PHYSIOL, V264, pF540, DOI 10.1152/ajprenal.1993.264.3.F540; LAMBERT S, 1993, J NEUROSCI, V13, P3725; Lux SE, 1995, BLOOD PRINCIPLES PRA, P1701; MALCHIODIALBEDI F, 1993, J CELL SCI, V106, P67; MASON P, 1993, GENE TRANSCRIPTION P, P47; MAXAUDIT I, 1993, J BIOL CHEM, V268, P5431; MERIKA M, 1995, MOL CELL BIOL, V15, P2437; MIGNOTTE V, 1989, NUCLEIC ACIDS RES, V17, P37, DOI 10.1093/nar/17.1.37; MILLER IJ, 1993, MOL CELL BIOL, V13, P2776, DOI 10.1128/MCB.13.5.2776; Mora M, 1996, DEV BRAIN RES, V91, P70, DOI 10.1016/0165-3806(95)00169-7; MORROW JS, 1997, HDB PHYSIOL 14, P485; ORKIN SH, 1995, CURR OPIN CELL BIOL, V7, P870, DOI 10.1016/0955-0674(95)80072-7; ORKIN SH, 1995, EUR J BIOCHEM, V231, P271, DOI 10.1111/j.1432-1033.1995.tb20697.x; ORKIN SH, 1995, J BIOL CHEM, V270, P4955, DOI 10.1074/jbc.270.10.4955; Porter GA, 1997, CELL MOTIL CYTOSKEL, V37, P7, DOI 10.1002/(SICI)1097-0169(1997)37:1<7::AID-CM2>3.0.CO;2-7; PORTER GA, 1992, J CELL BIOL, V117, P997, DOI 10.1083/jcb.117.5.997; PRCHAL JT, 1990, J CELL PHYSIOL, V144, P287, DOI 10.1002/jcp.1041440215; PRCHAL JT, 1987, P NATL ACAD SCI USA, V84, P7468, DOI 10.1073/pnas.84.21.7468; PUMPLIN DW, 1995, J CELL SCI, V108, P3145; RAHUEL C, 1992, EMBO J, V11, P4095, DOI 10.1002/j.1460-2075.1992.tb05502.x; Sabatino DE, 1998, MOL CELL BIOL, V18, P6634, DOI 10.1128/MCB.18.11.6634; Sahr KE, 1996, BLOOD, V88, P4500, DOI 10.1182/blood.V88.12.4500.bloodjournal88124500; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SPEICHER DW, 1984, NATURE, V311, P177, DOI 10.1038/311177a0; Surinya KH, 1997, J BIOL CHEM, V272, P26585, DOI 10.1074/jbc.272.42.26585; TREISMAN R, 1983, NATURE, V302, P591, DOI 10.1038/302591a0; TSAI SF, 1991, GENE DEV, V5, P919, DOI 10.1101/gad.5.6.919; Viel A, 1996, CURR OPIN CELL BIOL, V8, P49, DOI 10.1016/S0955-0674(96)80048-2; VIGNAL A, 1990, GENE, V95, P289, DOI 10.1016/0378-1119(90)90374-Z; VYBIRAL T, 1992, CELL MOTIL CYTOSKEL, V21, P293, DOI 10.1002/cm.970210405; WALTERS M, 1992, P NATL ACAD SCI USA, V89, P10444, DOI 10.1073/pnas.89.21.10444; WEISS MJ, 1995, EXP HEMATOL, V23, P99; WINKELMANN JC, 1993, BLOOD, V81, P3173; WINKELMANN JC, 1990, J BIOL CHEM, V265, P20449; WINKELMANN JC, 1990, J BIOL CHEM, V265, P11827; WINKELMANN JC, 1988, BLOOD, V72, P328; Wood SJ, 1998, J CELL BIOL, V140, P675, DOI 10.1083/jcb.140.3.675; YAN Y, 1993, SCIENCE, V262, P2027, DOI 10.1126/science.8266097; ZIMMER WE, 1992, BRAIN RES, V594, P75, DOI 10.1016/0006-8993(92)91030-I	73	28	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1999	274	10					6062	6073		10.1074/jbc.274.10.6062	http://dx.doi.org/10.1074/jbc.274.10.6062			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172BQ	10037687	hybrid			2022-12-25	WOS:000078902800009
J	Svensson, M; Sabharwal, H; Hakansson, A; Mossberg, AK; Lipniunas, P; Leffler, H; Svanborg, C; Linse, S				Svensson, M; Sabharwal, H; Hakansson, A; Mossberg, AK; Lipniunas, P; Leffler, H; Svanborg, C; Linse, S			Molecular characterization of alpha-lactalbumin folding variants that induce apoptosis in tumor cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRION PROTEIN; MOLTEN-GLOBULE STATE; HUMAN-MILK; CONFORMATIONAL TRANSITIONS; SCRAPIE; BINDING; INTERMEDIATE; MEMBRANES; ZINC	This study characterized a protein complex in human milk that induces apoptosis in tumor cells but spares healthy cells. The active fraction was purified from casein by anion exchange chromatography. Unlike other casein components the active fraction was retained by the ion exchanger and eluted after a high salt gradient. The active fraction showed N-terminal amino acid sequence identity with human milk alpha-lactalbumin and mass spectrometry ruled out post-translational modifications. Size exclusion chromatography resolved monomers and oligomers of alpha-lactalbumin that were characterized using UV absorbance, fluorescence, and circular dichroism spectroscopy. The high molecular weight oligomers were kinetically stable against dissociation into monomers and were found to have an essentially retained secondary structure but a less well organized tertiary structure. Comparison with native monomeric and molten globule alpha-lactalbumin showed that the active fraction contains oligomers of alpha-lactalbumin that have undergone a conformational switch toward a molten globule-like state. Oligomerization appears to conserve alpha-lactalbumin in a state with molten globule-like properties at physiological conditions. The results suggest differences in biological properties between folding variants of alpha-lactalbumin.	Univ Lund, Inst Lab Med, Sect Microbiol Immunol & Glycobiol, S-22362 Lund, Sweden; Rockefeller Univ, Dept Clin Microbiol & Immunol, New York, NY 10021 USA; Univ Lund, Dept Physiol Chem 2, S-22362 Lund, Sweden; Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94143 USA	Lund University; Rockefeller University; Lund University; University of California System; University of California San Francisco	Svensson, M (corresponding author), Univ Lund, Inst Lab Med, Sect Microbiol Immunol & Glycobiol, Solvegatan 23, S-22362 Lund, Sweden.		Hakansson, Anders/H-8190-2014; Leffler, Hakon/A-2416-2019; Hakansson, Anders P/AAX-1225-2020	Hakansson, Anders/0000-0002-2834-6009; Hakansson, Anders P/0000-0002-2834-6009; Leffler, Hakon/0000-0003-4482-8945; Linse, Sara/0000-0001-9629-7109				ACHARYA KR, 1991, J MOL BIOL, V221, P571; ANDERSSON B, 1983, J EXP MED, V158, P559, DOI 10.1084/jem.158.2.559; Aramini JM, 1996, BBA-PROTEIN STRUCT M, V1293, P72, DOI 10.1016/0167-4838(95)00223-5; BANUELOS S, 1995, J BIOL CHEM, V270, P29910, DOI 10.1074/jbc.270.50.29910; BASLER K, 1986, CELL, V46, P417, DOI 10.1016/0092-8674(86)90662-8; Brew K., 1992, Advanced dairy chemistry-1: Proteins., P191; BYCHKOVA VE, 1988, FEBS LETT, V238, P231, DOI 10.1016/0014-5793(88)80485-X; DAVIS MK, 1988, LANCET, V2, P365; DOLGIKH DA, 1984, FEBS LETT, V165, P88, DOI 10.1016/0014-5793(84)80020-4; DOLGIKH DA, 1981, FEBS LETT, V136, P311, DOI 10.1016/0014-5793(81)80642-4; FERRIN TE, 1988, J MOL GRAPHICS, V6, P13, DOI 10.1016/0263-7855(88)80054-7; HAKANSSON A, 1995, P NATL ACAD SCI USA, V92, P8064, DOI 10.1073/pnas.92.17.8064; HAKANSSON A, 1999, IN PRESS EXP CELL RE, V246; HEINE WE, 1991, J NUTR, V121, P277, DOI 10.1093/jn/121.3.277; HILL RL, 1975, ADV ENZYMOL RAMB, V43, P411; Kuwajima K, 1996, FASEB J, V10, P102, DOI 10.1096/fasebj.10.1.8566530; KUWAJIMA K, 1985, PROTEIN-STRUCT FUNCT, V6, P87; LONNERDAL B, 1985, AM J CLIN NUTR, V41, P113; MUSCI G, 1985, BIOCHEMISTRY-US, V24, P6945, DOI 10.1021/bi00345a029; PFEIL W, 1987, BIOCHIM BIOPHYS ACTA, V911, P114, DOI 10.1016/0167-4838(87)90277-9; PRUSINER SB, 1983, CELL, V35, P349, DOI 10.1016/0092-8674(83)90168-X; RAO KR, 1989, BIOCHEM BIOPH RES CO, V163, P1390, DOI 10.1016/0006-291X(89)91133-9; REDHEAD K, 1990, FEMS MICROBIOL LETT, V70, P269, DOI 10.1016/S0378-1097(05)80006-0; REN JS, 1993, J BIOL CHEM, V268, P19292; SAERKAR NH, 1973, CANCER RES, V33, P626; SAFAR J, 1993, PROTEIN SCI, V2, P2206, DOI 10.1002/pro.5560021220; SAFAR J, 1994, BIOCHEMISTRY-US, V33, P8375, DOI 10.1021/bi00193a027; SAFAR J, 1993, J BIOL CHEM, V268, P20276; SANDER B, 1991, IMMUNOL REV, V119, P65, DOI 10.1111/j.1600-065X.1991.tb00578.x; SCHMIDT DV, 1972, BIOCHIM BIOPHYS ACTA, V263, P714, DOI 10.1016/0005-2795(72)90055-4; SCHULMAN BA, 1995, J MOL BIOL, V253, P651, DOI 10.1006/jmbi.1995.0579; SEMISOTNOV GV, 1991, BIOPOLYMERS, V31, P119, DOI 10.1002/bip.360310111; SEMISOTNOV GV, 1987, FEBS LETT, V244, P9; SREERAMA N, 1993, ANAL BIOCHEM, V209, P32, DOI 10.1006/abio.1993.1079; STAHL N, 1993, BIOCHEMISTRY-US, V32, P1991, DOI 10.1021/bi00059a016; Svanborg C, 1991, Adv Exp Med Biol, V310, P167; Wu LC, 1996, BIOCHEMISTRY-US, V35, P859, DOI 10.1021/bi951408p; WU LC, 1995, NAT STRUCT BIOL, V2, P281, DOI 10.1038/nsb0495-281	38	180	191	0	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1999	274	10					6388	6396		10.1074/jbc.274.10.6388	http://dx.doi.org/10.1074/jbc.274.10.6388			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172BQ	10037730	hybrid			2022-12-25	WOS:000078902800052
J	Huang, STJ; Cidlowski, JA				Huang, STJ; Cidlowski, JA			Glucocorticoids inhibit serum depletion-induced apoptosis in T lymphocytes expressing Bcl-2	FASEB JOURNAL			English	Article						programmed cell death; protection; growth factors	CELL-DEATH; CYTOCHROME-C; DNA FRAGMENTATION; S49 CELLS; ACTIVATION; THYMOCYTES; PREVENTS; CED-9; BAX; MITOCHONDRIA	Depletion of growth factors and glucocorticoids are known to induce apoptosis and inhibit growth in T lymphocytes. We have examined the effect of Bcl-2 expression on the cellular response to growth factor depletion in the presence or absence of glucocorticoids, Cell growth was determined by cell counting and viability was quantitated by dye exclusion. Apoptosis was evaluated by flow cytometry, analysis of DNA integrity, and enzymatic determination of caspase3-like activity. Serum depletion and glucocorticoid administration inhibited cell growth and stimulated apoptosis in Bcl-2 negative cells. Cotreatment with both stimuli had additive effects on apoptosis but not on inhibition of cell growth. Bcl-2 expression abrogated the repressive effect of glucocorticoids on apoptosis but not on cell growth. In contrast, neither apoptosis nor growth inhibition induced by serum depletion of cells was blocked by Bcl-2 expression. However, glucocorticoid treatment of Bcl-2-overexpressing cells protected them from apoptosis induced by serum depletion. Glucocorticoid protection of Bcl-2-overexpressing cells from serum depletion-induced apoptosis was mimicked by other inducers of apoptosis, which act to inhibit protein synthesis. These data suggest that Bcl-2 expression can switch the effect of glucocorticoids from proapoptotic to antiapoptotic when lymphocytes expressing Bcl-2 are exposed to other apoptotic stimuli.	NIEHS, Lab Signal Transduct, NIH, Res Triangle Pk, NC 27709 USA; Univ N Carolina, Dept Cell & Mol Physiol, Chapel Hill, NC 27599 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); University of North Carolina; University of North Carolina Chapel Hill	Cidlowski, JA (corresponding author), NIEHS, Lab Signal Transduct, NIH, POB 12233,MD E2-02, Res Triangle Pk, NC 27709 USA.		Cidlowski, John A/G-2548-2019; Huang, Se-Te/F-6881-2013	Cidlowski, John A/0000-0003-1420-0516; 				Bortner CD, 1996, AM J PHYSIOL-CELL PH, V271, pC950, DOI 10.1152/ajpcell.1996.271.3.C950; CARONLESLIE LAM, 1994, ENDOCRINE, V2, P47; CARONLESLIE LAM, 1994, FASEB J, V8, P639, DOI 10.1096/fasebj.8.9.8005391; Cheng EHY, 1997, SCIENCE, V278, P1966, DOI 10.1126/science.278.5345.1966; Chinnaiyan AM, 1997, SCIENCE, V275, P1122, DOI 10.1126/science.275.5303.1122; CHOI MSK, 1995, EUR J IMMUNOL, V25, P1352, DOI 10.1002/eji.1830250533; CIDLOWSKI JA, 1982, ENDOCRINOLOGY, V111, P184, DOI 10.1210/endo-111-1-184; DENTON RR, 1993, ENDOCRINOLOGY, V133, P248, DOI 10.1210/en.133.1.248; FUKUHARA S, 1979, CANCER RES, V39, P3119; Gilbert MS, 1996, J CELL PHYSIOL, V168, P114; HANADA M, 1995, J BIOL CHEM, V270, P11962, DOI 10.1074/jbc.270.20.11962; HENGARTNER MO, 1994, CELL, V76, P665, DOI 10.1016/0092-8674(94)90506-1; HENNET T, 1993, CANCER RES, V53, P1456; Hughes FM, 1997, J BIOL CHEM, V272, P30567, DOI 10.1074/jbc.272.48.30567; ITOH N, 1993, J IMMUNOL, V151, P621; James C, 1997, CURR BIOL, V7, P246, DOI 10.1016/S0960-9822(06)00120-5; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; MARTIN SJ, 1995, CELL DEATH DIFFER, V2, P253; MEMON SA, 1995, J IMMUNOL, V155, P4644; MIYASHITA T, 1993, BLOOD, V81, P151; MIYASHITA T, 1992, CANCER RES, V52, P5407; Perry DK, 1997, CELL DEATH DIFFER, V4, P29, DOI 10.1038/sj.cdd.4400200; Polverino AJ, 1997, J BIOL CHEM, V272, P7013, DOI 10.1074/jbc.272.11.7013; Robertson NM, 1997, CANCER RES, V57, P43; SCHWARTZMAN RA, 1991, ENDOCRINOLOGY, V128, P1190, DOI 10.1210/endo-128-2-1190; SENTMAN CL, 1991, CELL, V67, P879, DOI 10.1016/0092-8674(91)90361-2; Shimizu S, 1996, ONCOGENE, V12, P2251; TELFORD WG, 1991, CELL PROLIFERAT, V24, P447, DOI 10.1111/j.1365-2184.1991.tb01173.x; TSUJIMOTO Y, 1984, SCIENCE, V226, P1097, DOI 10.1126/science.6093263; VAUX DL, 1992, INT IMMUNOL, V4, P821, DOI 10.1093/intimm/4.7.821; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; YANG YL, 1995, J EXP MED, V181, P1673, DOI 10.1084/jem.181.5.1673; Zha HB, 1996, J BIOL CHEM, V271, P7440, DOI 10.1074/jbc.271.13.7440	35	28	32	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	1999	13	3					467	476		10.1096/fasebj.13.3.467	http://dx.doi.org/10.1096/fasebj.13.3.467			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	174CF	10064613				2022-12-25	WOS:000079016000006
J	Chariot, A; Princen, F; Gielen, J; Merville, MP; Franzoso, G; Brown, K; Siebenlist, U; Bours, V				Chariot, A; Princen, F; Gielen, J; Merville, MP; Franzoso, G; Brown, K; Siebenlist, U; Bours, V			I kappa B-alpha enhances transactivation by the HOXB7 homeodomain-containing protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; DNA-BINDING; HOMEOBOX GENE; EXPRESSION; ACTIVATION; DROSOPHILA; FAMILY; TRANSCRIPTION; VERTEBRATES; HOMODIMERS	Combinatorial interactions between distinct transcription factors generate specificity in the controlled expression of target genes. In this report, we demonstrated that the HOXB7 homeodomain-containing protein, which plays a key role in development and differentiation, physically interacted in vitro with I kappa B-alpha, an inhibitor of NF-kappa B activity. This interaction was mediated by the I kappa B-alpha ankyrin repeats and C-terminal domain as well as by the HOXB7 N-terminal domain. In transient transfection experiments, I kappa B-alpha markedly increased HOXB7-dependent transcription from a reporter plasmid containing a homeodomain consensus-binding sequence. This report therefore showed a novel function for I kappa B-alpha, namely a positive regulation of transcriptional activation by homeodomain-containing proteins.	Univ Liege, Lab Med Chem & Med Oncol, B-4000 Sart, Belgium; NIAID, Natl Inst Hlth, Immunoregulat Lab, Bethesda, MD 20892 USA	University of Liege; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Bours, V (corresponding author), Univ Liege, Lab Med Chem & Med Oncol, CHU B35, B-4000 Sart, Belgium.		Franzoso, Guido/GRR-8628-2022	Chariot, Alain/0000-0002-1691-4347; Franzoso, Guido/0000-0002-0778-988X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000723] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ACAMPORA D, 1989, NUCLEIC ACIDS RES, V17, P10385, DOI 10.1093/nar/17.24.10385; AKAM M, 1989, CELL, V57, P347, DOI 10.1016/0092-8674(89)90909-4; ARENZANASEISDEDOS F, 1995, MOL CELL BIOL, V15, P2689; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BAIER LJ, 1991, BLOOD, V78, P1047; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Batchelor AH, 1998, SCIENCE, V279, P1037, DOI 10.1126/science.279.5353.1037; BEG AA, 1993, MOL CELL BIOL, V13, P3301, DOI 10.1128/MCB.13.6.3301; BOURS V, 1993, CELL, V72, P729, DOI 10.1016/0092-8674(93)90401-B; BROWN K, 1993, P NATL ACAD SCI USA, V90, P2532, DOI 10.1073/pnas.90.6.2532; Brown K, 1997, MOL CELL BIOL, V17, P3021, DOI 10.1128/MCB.17.6.3021; Bushdid PB, 1998, NATURE, V392, P615, DOI 10.1038/33435; Chang CP, 1997, MOL CELL BIOL, V17, P81, DOI 10.1128/MCB.17.1.81; CHANG CP, 1995, GENE DEV, V9, P663, DOI 10.1101/gad.9.6.663; Chariot A, 1998, J CELL BIOCHEM, V71, P46; Chariot A, 1996, BIOCHEM J, V319, P91, DOI 10.1042/bj3190091; CORSETTI MT, 1992, NUCLEIC ACIDS RES, V20, P4465, DOI 10.1093/nar/20.17.4465; CRESSMAN DE, 1993, ONCOGENE, V8, P2567; DEGUCHI Y, 1991, BLOOD, V78, P445; Favier B, 1997, MOL HUM REPROD, V3, P115, DOI 10.1093/molehr/3.2.115; FUJITA T, 1993, GENE DEV, V7, P1354, DOI 10.1101/gad.7.7b.1354; GEHRING WJ, 1994, ANNU REV BIOCHEM, V63, P487, DOI 10.1146/annurev.biochem.63.1.487; GEISLER R, 1992, CELL, V71, P613, DOI 10.1016/0092-8674(92)90595-4; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; GRAHAM A, 1989, CELL, V57, P367, DOI 10.1016/0092-8674(89)90912-4; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; KALIONIS B, 1993, MECH DEVELOP, V43, P57, DOI 10.1016/0925-4773(93)90023-Q; Kanegae Y, 1998, NATURE, V392, P611, DOI 10.1038/33429; LEVINE M, 1984, CELL, V38, P667, DOI 10.1016/0092-8674(84)90261-7; LILL MC, 1995, BLOOD, V85, P692, DOI 10.1182/blood.V85.3.692.bloodjournal853692; Luque I, 1998, MOL CELL BIOL, V18, P1213, DOI 10.1128/MCB.18.3.1213; MORIN PJ, 1993, NUCLEIC ACIDS RES, V21, P2157, DOI 10.1093/nar/21.9.2157; MORIN PJ, 1992, NUCLEIC ACIDS RES, V20, P2452; Na SY, 1998, J BIOL CHEM, V273, P30933, DOI 10.1074/jbc.273.47.30933; Na SY, 1998, J BIOL CHEM, V273, P3212, DOI 10.1074/jbc.273.6.3212; PELLERIN I, 1994, MOL CELL BIOL, V14, P4532, DOI 10.1128/MCB.14.7.4532; Sachdev S, 1998, MOL CELL BIOL, V18, P2524, DOI 10.1128/MCB.18.5.2524; SHANG ZG, 1994, P NATL ACAD SCI USA, V91, P118, DOI 10.1073/pnas.91.1.118; SHEN WF, 1989, P NATL ACAD SCI USA, V86, P8536, DOI 10.1073/pnas.86.21.8536; Shen WF, 1997, MOL CELL BIOL, V17, P6448, DOI 10.1128/MCB.17.11.6448; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; SIMEONE A, 1987, P NATL ACAD SCI USA, V84, P4914, DOI 10.1073/pnas.84.14.4914; THOMPSON JE, 1995, CELL, V80, P573, DOI 10.1016/0092-8674(95)90511-1; VANDESTOLPE A, 1994, J BIOL CHEM, V269, P6185; Whiteside ST, 1997, EMBO J, V16, P1413, DOI 10.1093/emboj/16.6.1413; ZABEL U, 1993, EMBO J, V12, P201, DOI 10.1002/j.1460-2075.1993.tb05646.x; ZAPPAVIGNA V, 1994, GENE DEV, V8, P732, DOI 10.1101/gad.8.6.732	48	27	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 26	1999	274	9					5318	5325		10.1074/jbc.274.9.5318	http://dx.doi.org/10.1074/jbc.274.9.5318			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	170KG	10026139	Green Submitted, hybrid			2022-12-25	WOS:000078804400010
J	Chu, WA; Moehlenkamp, JD; Bittel, D; Andrews, GK; Johnson, JA				Chu, WA; Moehlenkamp, JD; Bittel, D; Andrews, GK; Johnson, JA			Cadmium-mediated activation of the metal response element in human neuroblastoma cells lacking functional metal response element-binding transcription factor-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METALLOTHIONEIN GENE-EXPRESSION; III MESSENGER-RNA; FACTOR MTF-1; ASTROCYTE CULTURES; OXIDATIVE STRESS; TRANSGENIC MICE; MOUSE-BRAIN; I GENE; INDUCTION; PROTEIN	Metal response element-binding transcription factor-1 (MTF-1) binds specifically to metal response elements (MREs) and transactivates metallothionein (MT) gene expression in response to zinc and cadmium. This investigation contrasts the mechanism of mouse MT gene (mMT I) promoter activation by cadmium and zinc in IMR-32 human neuroblastoma cells to determine whether MTF-1 binding to the MRE is necessary for activation by these metals. Cadmium activated a mMT-1 promoter (-150 base pairs) luciferase reporter 20-25-fold through a MRE-dependent mechanism. In contrast, zinc had little effect on the mMT-1 luciferase reporter, IMR-32 cells lacked MRE binding activity, and treatment with zinc in vitro or in vivo did not generate a MTF-1 MRE complex, suggesting that IMR-32 cells lack functional MTF-1 Overexpression of mMTF-1 regenerated a zinc-mediated induction of the MRE without affecting cadmium activation. Because no other transition metals tested activated the MRE, this effect appeared to be cadmium-specific. These data demonstrate that in IMR-32 human neuroblastoma cells, zinc and cadmium can use independent mechanisms for activation of the mMT-I promoter and cadmium-mediated MRE activation is independent of TTF-l and zinc.	Univ Kansas, Med Ctr, Dept Pharmacol, Kansas City, KS 66160 USA; Univ Kansas, Med Ctr, Dept Toxicol, Kansas City, KS 66160 USA; Univ Kansas, Med Ctr, Dept Therapeut, Kansas City, KS 66160 USA; Univ Kansas, Med Ctr, Dept Biochem, Kansas City, KS 66160 USA; Univ Kansas, Med Ctr, Dept Mol Biol, Kansas City, KS 66160 USA	University of Kansas; University of Kansas Medical Center; University of Kansas; University of Kansas Medical Center; University of Kansas; University of Kansas Medical Center; University of Kansas; University of Kansas Medical Center; University of Kansas; University of Kansas Medical Center	Johnson, JA (corresponding author), Univ Kansas, Med Ctr, Dept Pharmacol, G017B Breidenthal,3901 Rainbow Blvd, Kansas City, KS 66160 USA.	jjohnso2@kumc.edu			NATIONAL CANCER INSTITUTE [R01CA061262] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [T32ES007079, R01ES005704] Funding Source: NIH RePORTER; NCI NIH HHS [CA61262] Funding Source: Medline; NIEHS NIH HHS [T32 ES07079, ES05704] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		AMORUSO MA, 1982, TOXICOL LETT, V10, P133, DOI 10.1016/0378-4274(82)90064-9; ANDREWS GK, 1990, PROG FOOD NUTR SCI, V14, P193; Aschner M, 1996, NEUROTOXICOLOGY, V17, P663; Belloso E, 1996, NEUROENDOCRINOLOGY, V64, P430, DOI 10.1159/000127149; Bittel D, 1998, J BIOL CHEM, V273, P7127, DOI 10.1074/jbc.273.12.7127; BRUGNERA E, 1994, NUCLEIC ACIDS RES, V22, P3167, DOI 10.1093/nar/22.15.3167; CHAO SH, 1995, ARCH TOXICOL, V69, P197, DOI 10.1007/s002040050158; CHOUDHURI S, 1993, TOXICOL APPL PHARM, V119, P1, DOI 10.1006/taap.1993.1037; CHOUDHURI S, 1995, TOXICOL APPL PHARM, V131, P144, DOI 10.1006/taap.1995.1056; Cigliano S, 1996, EXP CELL RES, V228, P173, DOI 10.1006/excr.1996.0314; Dalton T, 1996, J NUTR, V126, P825, DOI 10.1093/jn/126.4.825; DALTON T, 1994, NUCLEIC ACIDS RES, V22, P5016, DOI 10.1093/nar/22.23.5016; Dalton TP, 1997, MOL CELL BIOL, V17, P2781, DOI 10.1128/MCB.17.5.2781; Dalton TP, 1996, J BIOL CHEM, V271, P26233, DOI 10.1074/jbc.271.42.26233; Gunes C, 1998, EMBO J, V17, P2846, DOI 10.1093/emboj/17.10.2846; HEUCHEL R, 1994, EMBO J, V13, P2870, DOI 10.1002/j.1460-2075.1994.tb06581.x; JOHNSON JA, 1994, J BIOL CHEM, V269, P18856; KAGI JHR, 1991, METHOD ENZYMOL, V205, P613; Kramer KK, 1996, TOXICOL APPL PHARM, V141, P1; Kramer KK, 1996, TOXICOL APPL PHARM, V136, P94, DOI 10.1006/taap.1996.0011; LAZO JS, 1995, J BIOL CHEM, V270, P5506, DOI 10.1074/jbc.270.10.5506; Lee DK, 1999, BIOCHEM J, V337, P59, DOI 10.1042/0264-6021:3370059; Li QW, 1998, NUCLEIC ACIDS RES, V26, P5182, DOI 10.1093/nar/26.22.5182; MASTERS BA, 1994, P NATL ACAD SCI USA, V91, P584, DOI 10.1073/pnas.91.2.584; MICHALSKA AE, 1993, P NATL ACAD SCI USA, V90, P8088, DOI 10.1073/pnas.90.17.8088; PALMITER RD, 1994, P NATL ACAD SCI USA, V91, P1219, DOI 10.1073/pnas.91.4.1219; RADTKE F, 1993, EMBO J, V12, P1355, DOI 10.1002/j.1460-2075.1993.tb05780.x; Remondelli P, 1997, FEBS LETT, V416, P254, DOI 10.1016/S0014-5793(97)01212-X; RISING L, 1995, BRAIN RES, V678, P91, DOI 10.1016/0006-8993(95)00170-U; Rojas P, 1997, NEUROCHEM RES, V22, P17, DOI 10.1023/A:1027312901477; SINGH PK, 1989, TOXICOL APPL PHARM, V97, P572, DOI 10.1016/0041-008X(89)90262-7; STUART GW, 1984, P NATL ACAD SCI-BIOL, V81, P7318, DOI 10.1073/pnas.81.23.7318; TAKEDA K, 1994, J BIOL CHEM, V269, P22858; TAKEDA K, 1995, BIOCHEM BIOPH RES CO, V207, P160, DOI 10.1006/bbrc.1995.1167; VIG PJ, 1991, BIOCH INT, V239, P27; Wasserman WW, 1997, P NATL ACAD SCI USA, V94, P5361, DOI 10.1073/pnas.94.10.5361; Yu CW, 1997, FEBS LETT, V420, P69, DOI 10.1016/S0014-5793(97)01489-0; ZHENG H, 1995, NEUROCHEM INT, V27, P43, DOI 10.1016/0197-0186(94)00167-S; ZIMARINO V, 1987, NATURE, V327, P727, DOI 10.1038/327727a0	39	27	27	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 26	1999	274	9					5279	5284		10.1074/jbc.274.9.5279	http://dx.doi.org/10.1074/jbc.274.9.5279			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	170KG	10026134	hybrid			2022-12-25	WOS:000078804400005
J	Constantinou, A; Gunz, D; Evans, E; Lalle, P; Bates, PA; Wood, RD; Clarkson, SG				Constantinou, A; Gunz, D; Evans, E; Lalle, P; Bates, PA; Wood, RD; Clarkson, SG			Conserved residues of human XPG protein important for nuclease activity and function in nucleotide excision repair	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PIGMENTOSUM GROUP-G; DNA-POLYMERASE-I; TRANSCRIPTION-COUPLED REPAIR; COCKAYNE-SYNDROME PATIENTS; BACTERIOPHAGE-T4 RNASE-H; COMPLEMENTATION GROUP-G; WILD-TYPE P53; ESCHERICHIA-COLI; RESTRICTION-ENDONUCLEASE; 5'-NUCLEASE DOMAIN	The human XPG endonuclease cuts on the 3' side of a DNA lesion during nucleotide excision repair. Mutations in XPG can lead to the disorders xeroderma pigmentosum (XP) and Cockayne syndrome. XPG shares sequence similarities in two regions with a family of structure-specific nucleases and exonucleases. To begin defining its catalytic mechanism, we changed highly conserved residues and determined the effects on the endonuclease activity of isolated XPG, its function in open complex formation and dual incision reconstituted with purified proteins, and its ability to restore cellular resistance to UV light. The substitution A792V present in two XP complementation group G (XP-G) individuals reduced but did not abolish endonuclease activity, explaining their mild clinical phenotype. Isolated XPG proteins with Asp-77 or Glu-791 substitutions did not cleave DNA. In the reconstituted repair system, alanine substitutions at these positions permitted open complex formation but were inactive for 3' cleavage, whereas D77E and E791D proteins retained considerable activity. The function of each mutant protein in the reconstituted system was mirrored by its ability to restore UV resistance to XP-G cell lines. Hydrodynamic measurements indicated that XPG exists as a monomer in high salt conditions, but immunoprecipitation of intact and truncated XPG proteins showed that XPG polypeptides can interact with each other, suggesting dimerization as an element of XPG function. The mutation results define critical residues in the catalytic center of XPG and strongly suggest that key features of the strand cleavage mechanism and active site structure are shared by members of the nuclease family.	Univ Geneva, Med Ctr, Dept Genet & Microbiol, CH-1211 Geneva 4, Switzerland; Imperial Canc Res Fund, Clare Hall Labs, S Mimms EN6 3LD, Herts, England; Imperial Canc Res Fund, Biomol Modelling Lab, London WC2A 3PX, England	University of Geneva; Cancer Research UK	Clarkson, SG (corresponding author), Univ Geneva, Med Ctr, Dept Genet & Microbiol, 9 Ave Champel, CH-1211 Geneva 4, Switzerland.	Stuart.Clarkson@medecine.unige.ch	Bates, Paul A/AAF-8561-2020; LALLE, Philippe/G-7734-2018; Constantinou, Angelos/E-5337-2013; Wood, Richard D/M-6319-2018; Bates, Paul/A-1651-2011	Bates, Paul A/0000-0003-0621-0925; Wood, Richard D/0000-0002-9495-6892; Constantinou, Angelos/0000-0002-2994-8140				ARLETT CF, 1980, CARCINOGENESIS, V1, P745, DOI 10.1093/carcin/1.9.745; BARDWELL AJ, 1994, SCIENCE, V265, P2082, DOI 10.1126/science.8091230; Bates PA, 1997, PROTEINS, P59; BEESE LS, 1991, EMBO J, V10, P25, DOI 10.1002/j.1460-2075.1991.tb07917.x; Bessho T, 1997, J BIOL CHEM, V272, P3833, DOI 10.1074/jbc.272.6.3833; Bhagwat M, 1997, J BIOL CHEM, V272, P28523, DOI 10.1074/jbc.272.45.28523; Bhagwat M, 1997, J BIOL CHEM, V272, P28531, DOI 10.1074/jbc.272.45.28531; BIGGERSTAFF M, 1999, DNA REPAIR PROTOCOLS; Bontron S, 1997, MOL CELL BIOL, V17, P4249, DOI 10.1128/MCB.17.8.4249; Ceska TA, 1996, NATURE, V382, P90, DOI 10.1038/382090a0; CLOUD KG, 1995, MUTAT RES LETT, V347, P55, DOI 10.1016/0165-7992(95)90070-5; Cooper PK, 1997, SCIENCE, V275, P990, DOI 10.1126/science.275.5302.990; DERBYSHIRE V, 1991, EMBO J, V10, P17, DOI 10.1002/j.1460-2075.1991.tb07916.x; DUNDERDALE HJ, 1994, J BIOL CHEM, V269, P5187; DUTHU A, 1992, ONCOGENE, V7, P2161; Ellison AR, 1998, EXP CELL RES, V243, P22, DOI 10.1006/excr.1998.4147; Evans E, 1997, EMBO J, V16, P625, DOI 10.1093/emboj/16.3.625; Evans E, 1997, EMBO J, V16, P6559, DOI 10.1093/emboj/16.21.6559; Ford JM, 1997, J BIOL CHEM, V272, P28073, DOI 10.1074/jbc.272.44.28073; FORD JM, 1995, P NATL ACAD SCI USA, V92, P8876, DOI 10.1073/pnas.92.19.8876; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; Gerlt J. A., 1993, NUCLEASES, P1; GERSTEIN M, 1996, 4 INT C INT SYST MOL, V4, P59; HARRINGTON JJ, 1994, GENE DEV, V8, P1344, DOI 10.1101/gad.8.11.1344; Hsu YT, 1998, J BIOL CHEM, V273, P10777, DOI 10.1074/jbc.273.17.10777; Iyer N, 1996, BIOCHEMISTRY-US, V35, P2157, DOI 10.1021/bi9524124; KIM Y, 1995, NATURE, V376, P612, DOI 10.1038/376612a0; Lagunavicius A, 1997, BIOCHEMISTRY-US, V36, P11086, DOI 10.1021/bi963125i; LAI JS, 1992, P NATL ACAD SCI USA, V89, P6958, DOI 10.1073/pnas.89.15.6958; LALLE P, 1995, ONCOGENE, V10, P2447; LYAMICHEV V, 1993, SCIENCE, V260, P778, DOI 10.1126/science.7683443; MATSUNAGA T, 1995, J BIOL CHEM, V270, P20862, DOI 10.1074/jbc.270.35.20862; Mizrahi V, 1996, NUCLEIC ACIDS RES, V24, P4845, DOI 10.1093/nar/24.24.4845; Moggs JG, 1996, J BIOL CHEM, V271, P7177, DOI 10.1074/jbc.271.12.7177; Moriwaki SI, 1996, J INVEST DERMATOL, V107, P647, DOI 10.1111/1523-1747.ep12584287; Mu D, 1997, J BIOL CHEM, V272, P28971, DOI 10.1074/jbc.272.46.28971; MU D, 1995, J BIOL CHEM, V270, P2415, DOI 10.1074/jbc.270.6.2415; Mueser TC, 1996, CELL, V85, P1101, DOI 10.1016/S0092-8674(00)81310-0; Murante RS, 1995, J BIOL CHEM, V270, P30377, DOI 10.1074/jbc.270.51.30377; NORRIS PG, 1987, BRIT J DERMATOL, V116, P861, DOI 10.1111/j.1365-2133.1987.tb04906.x; NOUSPIKEL T, 1994, HUM MOL GENET, V3, P963, DOI 10.1093/hmg/3.6.963; Nouspikel T, 1997, P NATL ACAD SCI USA, V94, P3116, DOI 10.1073/pnas.94.7.3116; NOUSPIKEL T, 1996, THESIS U GENEVA; ODONOVAN A, 1993, NATURE, V363, P185, DOI 10.1038/363185a0; ODONOVAN A, 1994, J BIOL CHEM, V269, P15965; ODONOVAN A, 1994, NATURE, V371, P432, DOI 10.1038/371432a0; Okinaka RT, 1997, MUTAT RES-DNA REPAIR, V385, P107, DOI 10.1016/S0921-8777(97)00031-1; PAGE B, 1993, INT J ONCOL, V3, P473; Park MS, 1997, J BIOL CHEM, V272, P27823, DOI 10.1074/jbc.272.44.27823; Richardson J S, 1981, Adv Protein Chem, V34, P167, DOI 10.1016/S0065-3233(08)60520-3; ROBINS P, 1994, J BIOL CHEM, V269, P28535; ROSE JK, 1991, BIOTECHNIQUES, V10, P520; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; Sancar A, 1996, ANNU REV BIOCHEM, V65, P43, DOI 10.1146/annurev.bi.65.070196.000355; SCHERLY D, 1993, NATURE, V363, P182, DOI 10.1038/363182a0; Shen BH, 1997, NUCLEIC ACIDS RES, V25, P3332, DOI 10.1093/nar/25.16.3332; Shivji MKK, 1998, ONCOGENE, V17, P2827, DOI 10.1038/sj.onc.1202352; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; Sijbers AM, 1996, CELL, V86, P811, DOI 10.1016/S0092-8674(00)80155-5; SILLEKENS PTG, 1987, EMBO J, V6, P3841, DOI 10.1002/j.1460-2075.1987.tb02721.x; SPICKOFSKY N, 1990, DNA PROT ENG TECH, V2, P14; STEITZ TA, 1993, P NATL ACAD SCI USA, V90, P6498, DOI 10.1073/pnas.90.14.6498; Vance BA, 1996, J BIOL CHEM, V271, P30811, DOI 10.1074/jbc.271.48.30811; VERMOTE CLM, 1992, BIOCHEMISTRY-US, V31, P6089, DOI 10.1021/bi00141a019; VOLBEDA A, 1991, EMBO J, V10, P1607, DOI 10.1002/j.1460-2075.1991.tb07683.x; Wakasugi M, 1997, J BIOL CHEM, V272, P16030, DOI 10.1074/jbc.272.25.16030; Wood RD, 1997, J BIOL CHEM, V272, P23465, DOI 10.1074/jbc.272.38.23465; Wood RD, 1996, ANNU REV BIOCHEM, V65, P135, DOI 10.1146/annurev.bi.65.070196.001031; Wu XT, 1996, NUCLEIC ACIDS RES, V24, P2036, DOI 10.1093/nar/24.11.2036; XU SY, 1991, J BACTERIOL, V173, P5030, DOI 10.1128/jb.173.16.5030-5035.1991; Xu Y, 1997, J MOL BIOL, V268, P284, DOI 10.1006/jmbi.1997.0967	71	90	93	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 26	1999	274	9					5637	5648		10.1074/jbc.274.9.5637	http://dx.doi.org/10.1074/jbc.274.9.5637			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	170KG	10026181	hybrid			2022-12-25	WOS:000078804400052
J	Gandhi, CS; Shuck, K; Lear, JD; Dieckmann, GR; DeGrado, WF; Lamb, RA; Pinto, LH				Gandhi, CS; Shuck, K; Lear, JD; Dieckmann, GR; DeGrado, WF; Lamb, RA; Pinto, LH			Cu(II) inhibition of the proton translocation machinery of the influenza A virus M-2 protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							M(2) ION-CHANNEL; INTEGRAL MEMBRANE-PROTEIN; CARBONIC ANHYDRASE-II; A VIRUS; M2 PROTEIN; CATALYTIC MECHANISM; AMANTADINE; SAXITOXIN; RESIDUE; MODEL	The homotetrameric M-2 integral membrane protein of influenza virus forms a proton-selective ion channel. An essential histidine residue (His-37) in the M-2 transmembrane domain is believed to play an important role in the conduction mechanism of this channel. Also, this residue is believed to form hydrogen-bonded interactions with the ammonium group of the anti-viral compound, amantadine, A molecular model of this channel suggests that the imidazole side chains of His-37 from symmetry-related monomers of the homotetrameric pore converge to form a coordination site for transition metals, Thus, membrane currents of oocytes of Xenopus laevis expressing the M-2 protein were recorded when the solution bathing the oocytes contained various transition metals. Membrane currents were strongly and reversibly inhibited by Cu2+ with biphasic reaction kinetics. The biphasic inhibition curves may be explained by a two-site model involving a fast-binding peripheral site with low specificity for divalent metal ions, as well as a high affinity site (K-diss similar to 2 mu M) that lies deep within the pore and shows rather slow-binding kinetics (k(on) = 18.6 +/- 0.9 M-1 s(-1)). The pH dependence of the interaction with the high affinity Cu2+-binding site parallels the pH dependence of inhibition by amantadine, which has previously been ascribed to protonation of His-37. The voltage dependence of the inhibition at the high affinity site indicates that the binding site Lies within the transmembrane region of the pore. Furthermore, the inhibition by Cu2+ could be prevented by prior application of the reversible blocker of M-2 channel activity, BL-1743, providing further support for the location of the site within the pore region of M-2. Finally, substitutions of His-37 by alanine or glycine eliminated the high affinity site and resulted in membrane currents that were only partially inhibited at millimolar concentrations of Cu2+. Binding of Cu2+ the high affinity site resulted in an approximately equal inhibition of both inward and outward currents. The wild-type protein showed very high specificity for Cu2+ as only partially inhibited by 1 mM Ni2+, Pt2+, and Zn2+. These data are discussed in terms of the functional role of His-37 in the mechanism of proton translocation through the channel.	Northwestern Univ, Dept Neurobiol & Physiol, Evanston, IL 60208 USA; Northwestern Univ, Howard Hughes Med Inst, Evanston, IL 60208 USA; Northwestern Univ, Dept Biochem Mol Biol & Cell Biol, Evanston, IL 60208 USA; Univ Penn, Sch Med, Dept Biochem & Biophys, Johnson Fdn, Philadelphia, PA 19104 USA	Northwestern University; Howard Hughes Medical Institute; Northwestern University; Northwestern University; University of Pennsylvania	Pinto, LH (corresponding author), Northwestern Univ, Dept Neurobiol & Physiol, Hogan Hall,2153 N Campus Dr, Evanston, IL 60208 USA.	larry-pinto@nwu.edu			NIAID NIH HHS [AI-20201, AI-31882] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R56AI020201, R01AI031882, R01AI020201, R37AI020201] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARMSTRONG CM, 1965, J GEN PHYSIOL, V48, P859, DOI 10.1085/jgp.48.5.859; Chizhmakov IV, 1996, J PHYSIOL-LONDON, V494, P329, DOI 10.1113/jphysiol.1996.sp021495; CONNOLLY ML, 1983, SCIENCE, V221, P709, DOI 10.1126/science.6879170; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; DOYLE DD, 1993, J GEN PHYSIOL, V101, P153, DOI 10.1085/jgp.101.2.153; DUFF KC, 1992, FEBS LETT, V311, P256, DOI 10.1016/0014-5793(92)81114-2; DUFF KC, 1993, BIOCHIM BIOPHYS ACTA, V1145, P149, DOI 10.1016/0005-2736(93)90392-D; FAVRE I, 1995, J GEN PHYSIOL, V106, P203, DOI 10.1085/jgp.106.2.203; Hay A.J., 1992, SEMIN VIROL, V3, P21, DOI DOI 10.1016/J.BMC.2015.06.030; HAY AJ, 1985, EMBO J, V4, P3021, DOI 10.1002/j.1460-2075.1985.tb04038.x; HOLSINGER LJ, 1995, J VIROL, V69, P1219, DOI 10.1128/JVI.69.2.1219-1225.1995; HOLSINGER LJ, 1994, J VIROL, V68, P1551, DOI 10.1128/JVI.68.3.1551-1563.1994; HOLSINGER LJ, 1991, VIROLOGY, V183, P32, DOI 10.1016/0042-6822(91)90115-R; KNOTT GD, 1979, COMPUT PROG BIOMED, V10, P271, DOI 10.1016/0010-468X(79)90075-8; Kovacs FA, 1997, BIOPHYS J, V73, P2511, DOI 10.1016/S0006-3495(97)78279-1; KURTZ S, 1995, ANTIMICROB AGENTS CH, V39, P2204, DOI 10.1128/AAC.39.10.2204; Lamb R. A., 1994, RECEPTOR MEDIATED VI, P303; LAMB RA, 1985, CELL, V40, P627, DOI 10.1016/0092-8674(85)90211-9; NAIR SK, 1991, J AM CHEM SOC, V113, P9455, DOI 10.1021/ja00025a005; PANAYOTOV PP, 1992, VIROLOGY, V186, P352, DOI 10.1016/0042-6822(92)90096-8; Pinto LH, 1997, P NATL ACAD SCI USA, V94, P11301, DOI 10.1073/pnas.94.21.11301; PINTO LH, 1992, CELL, V69, P517, DOI 10.1016/0092-8674(92)90452-I; Sakaguchi T, 1997, P NATL ACAD SCI USA, V94, P5000, DOI 10.1073/pnas.94.10.5000; Sansom MSP, 1997, VIROLOGY, V233, P163, DOI 10.1006/viro.1997.8578; Shimbo K, 1996, BIOPHYS J, V70, P1335, DOI 10.1016/S0006-3495(96)79690-X; SILVERMAN DN, 1988, ACCOUNTS CHEM RES, V21, P30, DOI 10.1021/ar00145a005; Stockel J, 1998, BIOCHEMISTRY-US, V37, P7185, DOI 10.1021/bi972827k; SUGRUE RJ, 1991, VIROLOGY, V180, P617, DOI 10.1016/0042-6822(91)90075-M; TOSTESON MT, 1994, J MEMBRANE BIOL, V142, P117; TU CK, 1989, BIOCHEMISTRY-US, V28, P7913, DOI 10.1021/bi00445a054; Tu Q, 1996, J VIROL, V70, P4246, DOI 10.1128/JVI.70.7.4246-4252.1996; WANG C, 1995, BIOPHYS J, V69, P1363, DOI 10.1016/S0006-3495(95)80003-2; WANG C, 1993, J VIROL, V67, P5585, DOI 10.1128/JVI.67.9.5585-5594.1993	33	108	110	1	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 26	1999	274	9					5474	5482		10.1074/jbc.274.9.5474	http://dx.doi.org/10.1074/jbc.274.9.5474			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	170KG	10026160	hybrid			2022-12-25	WOS:000078804400031
J	Jarrousse, AS; Petit, F; Kreutzer-Schmid, C; Gaedigk, R; Schmid, HP				Jarrousse, AS; Petit, F; Kreutzer-Schmid, C; Gaedigk, R; Schmid, HP			Possible involvement of proteasomes (prosomes) in AUUUA-mediated mRNA decay	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; ESCHERICHIA-COLI; HELA-CELLS; DEGRADATION; PROTEINS; IDENTIFICATION; STABILITY; SEQUENCES; PURIFICATION; EXPRESSION	We have identified a cellular target for proteasomal endonuclease activity. Thus, 20 S proteasomes interact with the 3'-untranslated region of certain cytoplasmic mRNAs in vivo, and 20 S proteasomes isolated from Friend leukemia virus-infected mouse spleen cells were found to be associated with a mRNA fragment showing great homology to the 3'-untranslated region of tumor necrosis factor-beta mRNA that contains AUUUA sequences. We furthermore demonstrate that 20 S proteasomes destabilize oligoribonucleotides corresponding to the 3'-untranslated region of tumor necrosis factor-alpha, creating a specific cleavage pattern. The cleavage reaction is accelerated with increasing number of AUUUA motifs, and major cleavage sites are localized at the 5' side of the A residues. These results strongly suggest that 20 S proteasomes could be involved in the destabilization of cytokine mRNAs such as tumor necrosis factor mRNAs and other short-lived mRNAs containing AUUUA sequences.	Univ Clermont Ferrand 2, UA 987, Equipe Proteasome & Atuosurveill Cellulaire, OVGV,INRA, F-63177 Clermont Ferrand, France; Univ Stuttgart, Inst Biol, D-70569 Stuttgart 80, Germany	INRAE; Universite Clermont Auvergne (UCA); University of Stuttgart	Schmid, HP (corresponding author), Univ Clermont Ferrand 2, UA 987, Equipe Proteasome & Atuosurveill Cellulaire, OVGV,INRA, 24 Ave Landais, F-63177 Clermont Ferrand, France.	hpschmid@cicsun.univ-bpclermont.fr		Gaedigk, Roger/0000-0001-5942-1609				ARRIGO AP, 1985, EMBO J, V4, P399, DOI 10.1002/j.1460-2075.1985.tb03642.x; AVIV H, 1976, CELL, V8, P495, DOI 10.1016/0092-8674(76)90217-8; Baumeister W, 1998, CELL, V92, P367, DOI 10.1016/S0092-8674(00)80929-0; BLOBEL G, 1973, P NATL ACAD SCI USA, V70, P924, DOI 10.1073/pnas.70.3.924; BREWER G, 1991, MOL CELL BIOL, V11, P2460, DOI 10.1128/MCB.11.5.2460; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; CIVELLI OC, 1980, EUR J BIOCHEM, V108, P577; FRANSEN L, 1985, NUCLEIC ACIDS RES, V13, P4417, DOI 10.1093/nar/13.12.4417; GAEDIGK R, 1988, THESIS U STUTTGART S; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; HATTORI M, 1986, ANAL BIOCHEM, V152, P232, DOI 10.1016/0003-2697(86)90403-3; HORSCH A, 1989, FEBS LETT, V246, P131, DOI 10.1016/0014-5793(89)80268-6; ISHHOROWICZ D, 1981, NUCLEIC ACIDS RES, V9, P2989, DOI 10.1093/nar/9.13.2989; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE GTY, 1979, J MOL BIOL, V129, P221, DOI 10.1016/0022-2836(79)90278-X; MALTER JS, 1989, SCIENCE, V246, P664, DOI 10.1126/science.2814487; MARTINS DC, 1986, J MOL BIOL, V187, P479; Myer VE, 1997, EMBO J, V16, P2130, DOI 10.1093/emboj/16.8.2130; NOTHWANG HG, 1992, NUCLEIC ACIDS RES, V20, P1959, DOI 10.1093/nar/20.8.1959; PAMNANI V, 1994, EUR J BIOCHEM, V225, P511, DOI 10.1111/j.1432-1033.1994.00511.x; PEATTIE DA, 1979, P NATL ACAD SCI USA, V76, P1760, DOI 10.1073/pnas.76.4.1760; Peng SSY, 1998, EMBO J, V17, P3461, DOI 10.1093/emboj/17.12.3461; PERRY RP, 1972, BIOCHIM BIOPHYS ACTA, V262, P220, DOI 10.1016/0005-2787(72)90236-5; Petit F, 1997, MOL BIOL REP, V24, P113, DOI 10.1023/A:1006886911852; Petit F, 1997, BIOCHEM J, V326, P93, DOI 10.1042/bj3260093; POUCH MN, 1995, J BIOL CHEM, V270, P22023, DOI 10.1074/jbc.270.37.22023; RAJ NBK, 1983, P NATL ACAD SCI-BIOL, V80, P3923, DOI 10.1073/pnas.80.13.3923; SAVANTBHONSALE S, 1992, GENE DEV, V6, P1927, DOI 10.1101/gad.6.10.1927; SCHMID HP, 1984, EMBO J, V3, P29, DOI 10.1002/j.1460-2075.1984.tb01757.x; SCHMID HP, 1982, J CELL BIOL, V93, P893, DOI 10.1083/jcb.93.3.893; SCHONFELDER M, 1985, P NATL ACAD SCI USA, V82, P6884, DOI 10.1073/pnas.82.20.6884; SHAM G, 1986, CELL, V46, P659; SIPPEL AE, 1973, EUR J BIOCHEM, V37, P31, DOI 10.1111/j.1432-1033.1973.tb02953.x; TOMEK W, 1990, J CHROMATOGR, V521, P221, DOI 10.1016/0021-9673(90)85046-X; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WENNBORG A, 1995, P NATL ACAD SCI USA, V92, P7322, DOI 10.1073/pnas.92.16.7322; WILSON T, 1988, NATURE, V336, P396, DOI 10.1038/336396a0	38	45	50	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 26	1999	274	9					5925	5930		10.1074/jbc.274.9.5925	http://dx.doi.org/10.1074/jbc.274.9.5925			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	170KG	10026217	hybrid			2022-12-25	WOS:000078804400088
J	Meza, JE; Brzovic, PS; King, MC; Klevit, RE				Meza, JE; Brzovic, PS; King, MC; Klevit, RE			Mapping the functional domains of BRCA1 - Interaction of the ring finger domains of BRCA1 and BARD1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING PROTEIN; ZINC-FINGER; OVARIAN-CANCER; SEQUENCE; IDENTIFICATION; MUTATIONS; BREAST; MOTIF; GENE; FAMILIES	Breast cancer I (BRCA1) and BRCA1-associated RING domain 1 (BARD1) are multidomain proteins that interact in vivo via their N-terminal RING finger motif regions. To characterize functional aspects of the BRCA1/BARD1 interaction, we have defined the structural domains required for the interaction, as well as their oligomerization state, relative stability, and possible nucleic acid binding activity. We have found that the RING finger motifs do not themselves constitute stable structural domains but are instead part of larger domains comprising residues 1-109 of BRCA1 and residues 26-119 of BARD1, These domains exist as homodimers and preferentially form a stable heterodimer. Shorter BRCA1 RING finger constructs do not interact with BARD1 or with longer BRCA1 constructs, indicating that the heterodimeric and homodimer interactions are mediated by regions outside the canonical RING finger motif, Nucleic acid binding is a generally proposed function of RING finger domains. We show that neither the homodimers nor the heterodimer displays affinity for nucleic acids, indicating that the proposed roles of BRCA1 and BARD1 in DNA repair and/or transcriptional activation must be mediated either by other regions of the proteins or by additional cofactors.	Univ Washington, Dept Biochem, Seattle, WA 98195 USA; Univ Washington, Biomol Struct Ctr, Seattle, WA 98195 USA; Univ Washington, Dept Genet, Seattle, WA 98195 USA; Univ Washington, Dept Med Genet, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Klevit, RE (corresponding author), Univ Washington, Dept Biochem, Box 357742, Seattle, WA 98195 USA.	klevit@u.washington.edu	Klevit, Rachel/AAI-7038-2021	Klevit, Rachel/0000-0002-3476-969X; King, Mary-Claire/0000-0001-9426-1743	NCI NIH HHS [R01 CA79953, R01 CA27632] Funding Source: Medline; NIGMS NIH HHS [R01 GM46701] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA079953, R01CA027632] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046701] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABEL KJ, 1995, HUM MOL GENET, V4, P2265, DOI 10.1093/hmg/4.12.2265; BARLOW PN, 1994, J MOL BIOL, V237, P201, DOI 10.1006/jmbi.1994.1222; Bellon SF, 1997, NAT STRUCT BIOL, V4, P586, DOI 10.1038/nsb0797-586; BORDEN KLB, 1995, EMBO J, V14, P1532, DOI 10.1002/j.1460-2075.1995.tb07139.x; Brzovic PS, 1998, J BIOL CHEM, V273, P7795, DOI 10.1074/jbc.273.14.7795; CASTILLA LH, 1994, NAT GENET, V8, P387, DOI 10.1038/ng1294-387; Chapman MS, 1996, NATURE, V382, P678, DOI 10.1038/382678a0; COHEN SL, 1995, PROTEIN SCI, V4, P1088, DOI 10.1002/pro.5560040607; EVERETT RD, 1993, J MOL BIOL, V234, P1038, DOI 10.1006/jmbi.1993.1657; FREEMONT PS, 1993, ANN NY ACAD SCI, V684, P174, DOI 10.1111/j.1749-6632.1993.tb32280.x; FRIEDMAN LS, 1994, NAT GENET, V8, P399, DOI 10.1038/ng1294-399; Jensen DE, 1998, ONCOGENE, V16, P1097, DOI 10.1038/sj.onc.1201861; LOVERING R, 1993, P NATL ACAD SCI USA, V90, P2112, DOI 10.1073/pnas.90.6.2112; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Roehm PC, 1997, BIOCHEMISTRY-US, V36, P10240, DOI 10.1021/bi970863d; Saurin AJ, 1996, TRENDS BIOCHEM SCI, V21, P208, DOI 10.1016/S0968-0004(96)80017-X; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; Scully R, 1997, P NATL ACAD SCI USA, V94, P5605, DOI 10.1073/pnas.94.11.5605; SHARAN SK, 1995, HUM MOL GENET, V4, P2275, DOI 10.1093/hmg/4.12.2275; SHUSTER J, 1986, MOL CELL BIOL, V6, P1894, DOI 10.1128/MCB.6.6.1894; TAGAWA M, 1990, J BIOL CHEM, V265, P20021; Wu LJC, 1996, NAT GENET, V14, P430, DOI 10.1038/ng1296-430	23	118	120	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 26	1999	274	9					5659	5665		10.1074/jbc.274.9.5659	http://dx.doi.org/10.1074/jbc.274.9.5659			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	170KG	10026184	hybrid			2022-12-25	WOS:000078804400055
J	Sanders, WJ; Gordon, EJ; Dwir, O; Beck, PJ; Alon, R; Kiessling, LL				Sanders, WJ; Gordon, EJ; Dwir, O; Beck, PJ; Alon, R; Kiessling, LL			Inhibition of L-selectin-mediated leukocyte rolling by synthetic glycoprotein mimics	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIALYL-LEWIS-X; OPENING METATHESIS POLYMERIZATION; CARBOHYDRATE-PROTEIN INTERACTIONS; ENDOTHELIAL-DERIVED LIGAND; EPIDERMAL GROWTH-FACTOR; MAJOR CAPPING GROUP; P-SELECTIN; BINDING-SPECIFICITY; LYMPHOCYTE ADHESION; SULFATED OLIGOSACCHARIDES	Synthetic carbohydrate and glycoprotein mimics displaying sulfated saccharide residues have been assayed for their L-selectin inhibitory properties under static and flow conditions. Polymers displaying the L-selectin recognition epitopes 3',6-disulfo Lewis x(Glc) (3-O-SO3-Gal beta 1 alpha 4(Fuc alpha 1 alpha 3)-6-O-SO3-Glc beta-OR) and 3',6'-disulfo Lewis x(Glc) (3,6-di-O-SO3-Gal beta 1 alpha 4(Fuc alpha 1 alpha 3)Glc beta-OR) both inhibit L-selectin binding to heparin under static, cell-free binding conditions with similar efficacies. Under conditions of shear flow, however, only the polymer displaying 3',6-disulfo Lewis x(Glc) inhibits the rolling of L-selectin-transfected cells on the glycoprotein ligand GlyCAM-1, Although it has been shown to more effective than sialyl Lewis x at blocking the L-selectin-GlyCAM-1 interaction in static binding studies, the corresponding monomer had no effect in the dynamic assay. These data indicate that multivalent ligands are far more effective inhibitors of L-selectin-mediated rolling than their monovalent counterparts and that the inhibitory activities are dependent on the specific sulfation pattern of the recognition epitope, Importantly, our results indicate the L-selectin specificity for one ligand over another found in static, cell-free binding assays is not necessarily retained under the conditions of shear flow. The results suggest that monovalent or polyvalent carbohydrate or glycoprotein mimetics that inhibit selectin binding in static assays may not block the more physiologically relevant process of selectin-mediated rolling.	Univ Wisconsin, Dept Chem, Madison, WI 53706 USA; Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA; Univ Texas, Sch Med, Dept Internal Med, Houston, TX 77030 USA; Weizmann Inst Sci, Dept Immunol, IL-76100 Rehovot, Israel	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Texas System; Weizmann Institute of Science	Kiessling, LL (corresponding author), Univ Wisconsin, Dept Chem, 1101 Univ Ave, Madison, WI 53706 USA.		Kiessling, Laura L/A-4074-2008; ALON, RONEN/GRX-6987-2022	Alon, Ronen/0000-0001-9161-6369; Kiessling, Laura/0000-0001-6829-1500				Alon R, 1996, J CELL BIOL, V135, P849, DOI 10.1083/jcb.135.3.849; Alon R, 1998, P NATL ACAD SCI USA, V95, P11631, DOI 10.1073/pnas.95.20.11631; ALON R, 1995, J IMMUNOL, V154, P5356; ASA D, 1995, J BIOL CHEM, V270, P11662, DOI 10.1074/jbc.270.19.11662; BAUMHUETER S, 1993, SCIENCE, V262, P436, DOI 10.1126/science.7692600; Bertozzi CR, 1997, J IMMUNOL METHODS, V203, P157, DOI 10.1016/S0022-1759(97)00026-4; BERTOZZI CR, 1995, BIOCHEMISTRY-US, V34, P14271, DOI 10.1021/bi00044a001; Borges E, 1997, J BIOL CHEM, V272, P28786, DOI 10.1074/jbc.272.45.28786; BUTCHER EC, 1991, CELL, V67, P1033, DOI 10.1016/0092-8674(91)90279-8; Choi SK, 1996, CHEM BIOL, V3, P97, DOI 10.1016/S1074-5521(96)90285-9; Crocker PR, 1996, CURR OPIN STRUC BIOL, V6, P679, DOI 10.1016/S0959-440X(96)80036-4; CROMMIE D, 1995, J BIOL CHEM, V270, P22614, DOI 10.1074/jbc.270.38.22614; Crottet P, 1996, GLYCOBIOLOGY, V6, P191, DOI 10.1093/glycob/6.2.191; Dias EL, 1997, J AM CHEM SOC, V119, P3887, DOI 10.1021/ja963136z; Dwir O, 1998, CELL ADHES COMMUN, V6, P349, DOI 10.3109/15419069809010793; Finger EB, 1996, NATURE, V379, P266, DOI 10.1038/379266a0; FRASER C, 1995, MACROMOLECULES, V28, P7248, DOI 10.1021/ma00125a030; Fuhlbrigge RC, 1997, NATURE, V389, P978, DOI 10.1038/40166; Galustian C, 1997, BIOCHEMISTRY-US, V36, P5260, DOI 10.1021/bi962887a; Galustian C, 1997, BIOCHEM BIOPH RES CO, V240, P748, DOI 10.1006/bbrc.1997.7737; Goetz DJ, 1997, J CELL BIOL, V137, P509, DOI 10.1083/jcb.137.2.509; Gordon EJ, 1998, BIOORGAN MED CHEM, V6, P1293, DOI 10.1016/S0968-0896(98)00122-9; Gordon EJ, 1998, NATURE, V392, P30, DOI 10.1038/32073; GREEN PJ, 1992, BIOCHEM BIOPH RES CO, V188, P244, DOI 10.1016/0006-291X(92)92376-9; GREEN PJ, 1995, GLYCOBIOLOGY, V5, P29, DOI 10.1093/glycob/5.1.29; Guyer DA, 1996, BLOOD, V88, P2415, DOI 10.1182/blood.V88.7.2415.bloodjournal8872415; HEMMERICH S, 1994, BIOCHEMISTRY-US, V33, P4830, DOI 10.1021/bi00182a011; HEMMERICH S, 1994, BIOCHEMISTRY-US, V33, P4820, DOI 10.1021/bi00182a010; HEMMERICH S, 1995, J BIOL CHEM, V270, P12035, DOI 10.1074/jbc.270.20.12035; HWANG ST, 1996, J EXP MED, V184, P1; IMAI Y, 1993, NATURE, V361, P555; Ivin K. J., 1997, OLEFIN METATHESIS ME; Kanai M, 1997, J AM CHEM SOC, V119, P9931, DOI 10.1021/ja972089n; Kansas GS, 1996, BLOOD, V88, P3259, DOI 10.1182/blood.V88.9.3259.bloodjournal8893259; Kiessling LL, 1996, CHEM BIOL, V3, P71, DOI 10.1016/S1074-5521(96)90280-X; Koenig A, 1998, J CLIN INVEST, V101, P877, DOI 10.1172/JCI1509; Koenig A, 1997, GLYCOBIOLOGY, V7, P79, DOI 10.1093/glycob/7.1.79; Kogan TP, 1998, J MED CHEM, V41, P1099, DOI 10.1021/jm9704917; Kogan TP, 1995, J MED CHEM, V38, P4976, DOI 10.1021/jm00026a004; Kolb HC, 1997, PURE APPL CHEM, V69, P1879, DOI 10.1351/pac199769091879; Konstantopoulos K, 1996, J CLIN INVEST, V98, P2661, DOI 10.1172/JCI119088; LASKY LA, 1992, CELL, V69, P927, DOI 10.1016/0092-8674(92)90612-G; LASKY LA, 1995, ANNU REV BIOCHEM, V64, P113, DOI 10.1146/annurev.bi.64.070195.000553; LAWRENCE MB, 1995, EUR J IMMUNOL, V25, P1025, DOI 10.1002/eji.1830250425; Lawrence MB, 1997, J CELL BIOL, V136, P717, DOI 10.1083/jcb.136.3.717; LAWRENCE MB, 1991, CELL, V65, P859, DOI 10.1016/0092-8674(91)90393-D; LEE YC, 1995, ACCOUNTS CHEM RES, V28, P321, DOI 10.1021/ar00056a001; LEES WJ, 1994, J MED CHEM, V37, P3419, DOI 10.1021/jm00046a027; Liang R, 1997, P NATL ACAD SCI USA, V94, P10554, DOI 10.1073/pnas.94.20.10554; Lowe JB, 1997, J CLIN INVEST, V99, P822, DOI 10.1172/JCI119244; Lynn DM, 1998, J AM CHEM SOC, V120, P1627, DOI 10.1021/ja9736323; Lynn DM, 1996, J AM CHEM SOC, V118, P784, DOI 10.1021/ja950327d; MAAHEIMO H, 1995, EUR J BIOCHEM, V234, P616, DOI 10.1111/j.1432-1033.1995.616_b.x; Mann DA, 1998, J AM CHEM SOC, V120, P10575, DOI 10.1021/ja9818506; MANNING DD, 1995, J ORG CHEM, V60, P6254, DOI 10.1021/jo00125a005; Manning DD, 1997, J AM CHEM SOC, V119, P3161, DOI 10.1021/ja964046x; Manning DD, 1997, TETRAHEDRON, V53, P11937, DOI 10.1016/S0040-4020(97)00707-2; Mitsuoka C, 1997, BIOCHEM BIOPH RES CO, V230, P546, DOI 10.1006/bbrc.1996.6012; Mitsuoka C, 1998, J BIOL CHEM, V273, P11225, DOI 10.1074/jbc.273.18.11225; MOORE KL, 1994, J BIOL CHEM, V269, P23318; MOORE KL, 1995, J CELL BIOL, V128, P661, DOI 10.1083/jcb.128.4.661; MORTELL KH, 1994, J AM CHEM SOC, V116, P12053, DOI 10.1021/ja00105a056; Mortell KH, 1996, J AM CHEM SOC, V118, P2297, DOI 10.1021/ja953574q; NELSON RM, 1993, BLOOD, V82, P3253; Nicholson MW, 1998, J BIOL CHEM, V273, P763, DOI 10.1074/jbc.273.2.763; Norman KE, 1998, BLOOD, V91, P475, DOI 10.1182/blood.V91.2.475.475_475_483; PAVALKO FM, 1995, J CELL BIOL, V129, P1155, DOI 10.1083/jcb.129.4.1155; POUYANI T, 1995, CELL, V83, P333, DOI 10.1016/0092-8674(95)90174-4; Record M T Jr, 1985, Adv Biophys, V20, P109; Renkonen O, 1997, GLYCOBIOLOGY, V7, P453, DOI 10.1093/glycob/7.4.453-c; Revelle BM, 1996, J BIOL CHEM, V271, P16160, DOI 10.1074/jbc.271.27.16160; ROGERS GN, 1983, NATURE, V304, P76, DOI 10.1038/304076a0; Rosen SD, 1996, CURR BIOL, V6, P261, DOI 10.1016/S0960-9822(02)00473-6; Roy R, 1996, BIOORG MED CHEM LETT, V6, P1399, DOI 10.1016/0960-894X(96)00240-5; SAKO D, 1995, CELL, V83, P323, DOI 10.1016/0092-8674(95)90173-6; Sanders WJ, 1996, BIOCHEMISTRY-US, V35, P14862, DOI 10.1021/bi9613640; Sanders WJ, 1997, TETRAHEDRON, V53, P16391, DOI 10.1016/S0040-4020(97)01024-7; SCUDDER PR, 1994, GLYCOBIOLOGY, V4, P929, DOI 10.1093/glycob/4.6.929; Seppo A, 1996, GLYCOBIOLOGY, V6, P65, DOI 10.1093/glycob/6.1.65; Shailubhai K, 1997, GLYCOBIOLOGY, V7, P305; Simanek EE, 1998, CHEM REV, V98, P833, DOI 10.1021/cr940226i; Spevak W, 1996, J MED CHEM, V39, P1018, DOI 10.1021/jm950914+; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; Steeber DA, 1997, J IMMUNOL, V159, P952; TEDDER TF, 1995, FASEB J, V9, P866, DOI 10.1096/fasebj.9.10.7542213; Toppila S, 1997, EUR J IMMUNOL, V27, P1360, DOI 10.1002/eji.1830270610; Tsuboi S, 1996, J BIOL CHEM, V271, P27213, DOI 10.1074/jbc.271.44.27213; Tu LL, 1996, J IMMUNOL, V157, P3995; TURUNEN JP, 1995, J EXP MED, V182, P1133, DOI 10.1084/jem.182.4.1133; Varki A, 1997, J CLIN INVEST, V99, P158, DOI 10.1172/JCI119142; Walcheck B, 1996, J CLIN INVEST, V98, P1081, DOI 10.1172/JCI118888; Wilkins PP, 1996, J BIOL CHEM, V271, P18732, DOI 10.1074/jbc.271.31.18732; Yarema KJ, 1998, CURR OPIN CHEM BIOL, V2, P49, DOI 10.1016/S1367-5931(98)80035-5	93	82	85	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 26	1999	274	9					5271	5278		10.1074/jbc.274.9.5271	http://dx.doi.org/10.1074/jbc.274.9.5271			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	170KG	10026133	hybrid			2022-12-25	WOS:000078804400004
J	Schonherr, R; Hehl, S; Terlau, H; Baumann, A; Heinemann, SH				Schonherr, R; Hehl, S; Terlau, H; Baumann, A; Heinemann, SH			Individual subunits contribute independently to slow gating of bovine EAG potassium channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							K+ CHANNEL; XENOPUS-OOCYTES; RAT EAG; DROSOPHILA; STOICHIOMETRY; ETHER; ACTIVATION; MUTATION; FAMILY; CDNAS	The bovine ether a go-go gene encodes a delayed rectifier potassium channel. In contrast to other delayed rectifiers, its activation kinetics is largely determined by the holding potential and the concentration of extracellular Mg2+, giving rise to slowly activating currents with a characteristic sigmoidal rising phase. Replacement of a single amino acid in the extracellular linker between transmembrane segments S3 and S4 (L322H) strongly reduced the prepulse dependence and accelerated activation by 1 order of magnitude. In addition, compared with the wild type, the half-activation voltage of this mutant was shifted by more than 30 mV to more negative potentials. We used dimeric and tetrameric constructs of the bovine eag1 gene to analyze channels with defined stoichiometry of mutated and wild-type subunits within the tetrameric channel complexes. With increasing numbers of mutated subunits, the channel activation was progressively accelerated, and the sig moidicity of the current traces was reduced, Based on a quantitative analysis, we show that the slow gating, typical for EAG channels, is mediated by independent conformational transitions of individual subunits, which gain their voltage dependence from the S4 segment. At a given voltage, external Mg2+ increases the probability of a channel subunit to be in the slowly activating conformation, whereas mutation L322H strongly reduces this probability.	Max Planck Gesell, Arbeitsgrp Mol & Zellulare Biophys, D-07747 Jena, Germany; Max Planck Inst Expt Med, Abt Mol Biol Neuronaler Signale, D-37075 Gottingen, Germany; Forschungzentrum Julich, Inst Biol Informat Verarbeitung, D-52425 Julich, Germany	Max Planck Society; Max Planck Society	Heinemann, SH (corresponding author), Max Planck Gesell, Arbeitsgrp Mol & Zellulare Biophys, Drackendorfer Str 1, D-07747 Jena, Germany.		Schönherr, Roland/K-8713-2013; Baumann, Arnd/I-7941-2013	Schönherr, Roland/0000-0003-0633-0775; Baumann, Arnd/0000-0001-9456-7275; Heinemann, Stefan H./0000-0002-4144-0251				CACECI MS, 1984, BYTE, V9, P340; COLE KS, 1960, BIOPHYS J, V1, P1, DOI 10.1016/S0006-3495(60)86871-3; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; Frings S, 1998, J GEN PHYSIOL, V111, P583, DOI 10.1085/jgp.111.4.583; HEGINBOTHAM L, 1992, NEURON, V8, P483, DOI 10.1016/0896-6273(92)90276-J; Hille B., 1992, IONIC CHANNELS EXCIT; Hurst RS, 1995, RECEPTOR CHANNEL, V3, P263; ISACOFF EY, 1990, NATURE, V345, P530, DOI 10.1038/345530a0; LIMAN ER, 1992, NEURON, V9, P861, DOI 10.1016/0896-6273(92)90239-A; London B, 1997, CIRC RES, V81, P870; LUDWIG J, 1994, EMBO J, V13, P4451, DOI 10.1002/j.1460-2075.1994.tb06767.x; MACKINNON R, 1991, NATURE, V350, P232, DOI 10.1038/350232a0; MCCORMACK K, 1992, BIOPHYS J, V63, P1406, DOI 10.1016/S0006-3495(92)81703-4; Meyer R, 1998, J PHYSIOL-LONDON, V508, P49, DOI 10.1111/j.1469-7793.1998.049br.x; Occhiodoro T, 1998, FEBS LETT, V434, P177, DOI 10.1016/S0014-5793(98)00973-9; Ogielska EM, 1995, BIOPHYS J, V69, P2449, DOI 10.1016/S0006-3495(95)80114-1; Robertson GA, 1996, NEUROPHARMACOLOGY, V35, P841, DOI 10.1016/0028-3908(96)00113-X; SANGUINETTI MC, 1995, CELL, V81, P299, DOI 10.1016/0092-8674(95)90340-2; Shi WM, 1998, J PHYSIOL-LONDON, V511, P675, DOI 10.1111/j.1469-7793.1998.675bg.x; Shi WM, 1997, J NEUROSCI, V17, P9423; Smith-Maxwell CJ, 1998, J GEN PHYSIOL, V111, P399, DOI 10.1085/jgp.111.3.399; Stuhmer W, 1992, PRACTICAL ELECTROPHY, P121; Tang CY, 1997, J GEN PHYSIOL, V109, P301, DOI 10.1085/jgp.109.3.301; Terlau H, 1997, J PHYSIOL-LONDON, V502, P537, DOI 10.1111/j.1469-7793.1997.537bj.x; Terlau H, 1996, PFLUG ARCH EUR J PHY, V432, P301, DOI 10.1007/s004240050137; WARMKE JW, 1994, P NATL ACAD SCI USA, V91, P3438, DOI 10.1073/pnas.91.8.3438; Wei A, 1996, NEUROPHARMACOLOGY, V35, P805, DOI 10.1016/0028-3908(96)00126-8; Yang YS, 1997, J GEN PHYSIOL, V109, P779, DOI 10.1085/jgp.109.6.779	28	24	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 26	1999	274	9					5362	5369		10.1074/jbc.274.9.5362	http://dx.doi.org/10.1074/jbc.274.9.5362			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	170KG	10026145	hybrid			2022-12-25	WOS:000078804400016
J	Weidemann, A; Paliga, K; Durrwang, U; Reinhard, FBM; Schuckert, O; Evin, G; Masters, CL				Weidemann, A; Paliga, K; Durrwang, U; Reinhard, FBM; Schuckert, O; Evin, G; Masters, CL			Proteolytic processing of the Alzheimer's disease amyloid precursor protein within its cytoplasmic domain by caspase-like proteases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRESENILIN-2 MUTATION N141I; BETA-PROTEIN; PC12 CELLS; IN-VIVO; MISSENSE MUTATIONS; TRANSFECTED CELLS; APOPTOSIS; GENE; EXPRESSION; CLEAVAGE	Alzheimer's disease is characterized by neurodegeneration and deposition of beta A4, a peptide that is proteolytically released from the amyloid precursor protein (APP), Missense mutations in the genes coding for APP and for the polytopic membrane proteins presenilin (PS) 1 and PS2 have been linked to familial forms of early-onset Alzheimer's disease. Overexpression of presenilins, especially that of PS2, induces increased susceptibility for apoptosis that is even more pronounced in cells expressing presenilin mutants. Additionally, presenilins themselves are, targets for activated caspases in apoptotic cells, When we analyzed APP in COS-7 cells overexpressing PS2, we observed proteolytic processing close to the APP carboxyl terminus. Proteolytic conversion was increased in the presence of PS2-I, which encodes one of the known PS2 pathogenic mutations. The same proteolytic processing occurred in cells treated with chemical inducers of apoptosis, suggesting a participation of activated caspases in the carboxyl-terminal truncation of APP, This was confirmed by showing that specific caspase inhibitors blocked the apoptotic conversion of APP, Sequence analysis of the APP cytosolic domain revealed a consensus motif for group LII caspases ((IVL)ExD), Mutation of the corresponding Asp(664) residue abolished cleavage, thereby identifying APP as a target molecule for caspase-like proteases in the pathways of programmed cellular death.	Zentrum Mol Biol Heidelberg, D-69120 Heidelberg, Germany; Univ Melbourne, Dept Pathol, Parkville, Vic 3052, Australia	Ruprecht Karls University Heidelberg; University of Melbourne	Weidemann, A (corresponding author), Zentrum Mol Biol Heidelberg, Im Neuenheimer Feld 282, D-69120 Heidelberg, Germany.	weidemanna@sun0.urz.uni-heidelberg.de	Evin, Genevieve M/E-5891-2013					Borchelt DR, 1996, NEURON, V17, P1005, DOI 10.1016/S0896-6273(00)80230-5; CAI XD, 1993, SCIENCE, V259, P514, DOI 10.1126/science.8424174; Citron M, 1997, NAT MED, V3, P67, DOI 10.1038/nm0197-67; CITRON M, 1992, NATURE, V360, P672, DOI 10.1038/360672a0; Clem RJ, 1998, P NATL ACAD SCI USA, V95, P554, DOI 10.1073/pnas.95.2.554; COTMAN CW, 1995, MOL NEUROBIOL, V10, P19, DOI 10.1007/BF02740836; Deng GM, 1996, FEBS LETT, V397, P50, DOI 10.1016/S0014-5793(96)01142-8; Duff K, 1996, NATURE, V383, P710, DOI 10.1038/383710a0; DYRKS T, 1993, FEBS LETT, V335, P89, DOI 10.1016/0014-5793(93)80446-2; Friedlander RM, 1997, NATURE, V388, P31, DOI 10.1038/40299; Goldberg YP, 1996, NAT GENET, V13, P442, DOI 10.1038/ng0896-442; Guo Q, 1998, NAT MED, V4, P957, DOI 10.1038/nm0898-957; Guo Q, 1996, NEUROREPORT, V8, P379, DOI 10.1097/00001756-199612200-00074; HAASS C, 1993, J BIOL CHEM, V268, P3021; HAASS C, 1994, J BIOL CHEM, V269, P17741; Hartmann H, 1997, J BIOL CHEM, V272, P14505, DOI 10.1074/jbc.272.23.14505; Ida N, 1996, J BIOL CHEM, V271, P22908, DOI 10.1074/jbc.271.37.22908; Janicki S, 1997, J CELL BIOL, V139, P485, DOI 10.1083/jcb.139.2.485; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; Kim TW, 1997, J BIOL CHEM, V272, P11006; Kim TW, 1997, SCIENCE, V277, P373, DOI 10.1126/science.277.5324.373; LANG J, 1995, EMBO J, V14, P3635, DOI 10.1002/j.1460-2075.1995.tb00033.x; LASSMANN H, 1995, ACTA NEUROPATHOL, V89, P35, DOI 10.1007/BF00294257; LEVYLAHAD E, 1995, SCIENCE, V269, P973, DOI 10.1126/science.7638622; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Loetscher H, 1997, J BIOL CHEM, V272, P20655, DOI 10.1074/jbc.272.33.20655; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; NISHIMOTO I, 1993, NATURE, V362, P75, DOI 10.1038/362075a0; ROGAEV EI, 1995, NATURE, V376, P775, DOI 10.1038/376775a0; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Scheuner D, 1996, NAT MED, V2, P864, DOI 10.1038/nm0896-864; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; SMALE G, 1995, EXP NEUROL, V133, P225, DOI 10.1006/exnr.1995.1025; Stennicke HR, 1997, J BIOL CHEM, V272, P25719, DOI 10.1074/jbc.272.41.25719; SU JH, 1994, NEUROREPORT, V5, P2529, DOI 10.1097/00001756-199412000-00031; SUZUKI N, 1994, SCIENCE, V264, P1336, DOI 10.1126/science.8191290; Thinakaran G, 1996, NEURON, V17, P181, DOI 10.1016/S0896-6273(00)80291-3; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; Tomita T, 1997, P NATL ACAD SCI USA, V94, P2025, DOI 10.1073/pnas.94.5.2025; Vito P, 1997, J BIOL CHEM, V272, P28315, DOI 10.1074/jbc.272.45.28315; Vito P, 1996, J BIOL CHEM, V271, P31025, DOI 10.1074/jbc.271.49.31025; WASCO W, 1998, PRESENILINS ALZHEIME, P59; Weidemann A, 1997, NAT MED, V3, P328, DOI 10.1038/nm0397-328; WEIDEMANN A, 1989, CELL, V57, P115, DOI 10.1016/0092-8674(89)90177-3; Wolozin B, 1996, SCIENCE, V274, P1710, DOI 10.1126/science.274.5293.1710; Xia WM, 1997, P NATL ACAD SCI USA, V94, P8208, DOI 10.1073/pnas.94.15.8208; Yamatsuji T, 1996, SCIENCE, V272, P1349, DOI 10.1126/science.272.5266.1349; Yamatsuji T, 1996, EMBO J, V15, P498, DOI 10.1002/j.1460-2075.1996.tb00382.x; Zhao B, 1997, J NEUROSCI RES, V47, P253	50	149	155	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 26	1999	274	9					5823	5829		10.1074/jbc.274.9.5823	http://dx.doi.org/10.1074/jbc.274.9.5823			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	170KG	10026204	hybrid			2022-12-25	WOS:000078804400075
J	Desbaillets, I; Diserens, AC; de Tribolet, N; Hamou, MF; Van Meir, EG				Desbaillets, I; Diserens, AC; de Tribolet, N; Hamou, MF; Van Meir, EG			Regulation of interleukin-8 expression by reduced oxygen pressure in human glioblastoma	ONCOGENE			English	Article						interleukin-8; brain tumors; cytokines; hypoxia; anoxia; AP-1	ENDOTHELIAL GROWTH-FACTOR; NF-KAPPA-B; NECROSIS-FACTOR-ALPHA; HUMAN GLIOMA-CELLS; GENE-EXPRESSION; TRANSCRIPTIONAL ACTIVATION; UP-REGULATION; IL-8 GENE; HYPOXIA; ANGIOGENESIS	Oxygen deprivation is an important biological feature of tumor growth. We previously showed that in glioma, anoxia increases expression of IL-8, a chemokine and angiogenic factor. Here, we analysed for the first time the biochemical mechanisms inducing the IL-8 gene upon anoxia in glioma cells, and showed that they differ from those inducing the VEGF gene. Both genes are induced in biologically and genetically heterogenous glioblastoma cell lines (LN-229, LN-Z308, U87MG, T98G), whereas, in gliosarcoma cells (D247MG), only the VEGF gene is induced. The kinetics of IL-8 and VEGF mRNA inductions differ in these cells and reoxygenation experiments showed that the induction is due to the anoxic stress per se. Furthermore, in LN-229 and Z308 cell lines actinomycin D, DRB and nuclear run-on experiments showed that anoxia stimulates increased transcription of both genes. Electromobility shift assays show increased protein binding to the AP-I site on the IL-8 promoter following anoxia treatment. Finally, in situ hybridization on glioblastoma sections shows that the in vivo expression patterns of IL-8 and VEGF genes overlap, but are not identical. Since intratumoral augmentation of IL-8 and VEGF secretion, following microenvironmental decreases in oxygen pressure, may promote angiogenesis, further definition of these pathways is essential to appropriately target them for antitumoral therapy.	CHU Vaudois, Dept Neurosurg, Tumor Biol & Genet Lab, CH-1011 Lausanne, Switzerland; Emory Univ, Dept Neurosurg, Mol Neurooncol Lab, Atlanta, GA 30322 USA; Emory Univ, Winship Canc Ctr, Atlanta, GA 30322 USA	University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); Emory University; Emory University	Van Meir, EG (corresponding author), CHU Vaudois, Dept Neurosurg, Tumor Biol & Genet Lab, CH-1011 Lausanne, Switzerland.			Van Meir, Erwin G./0000-0003-2444-7707				Albertoni M, 1998, ONCOGENE, V16, P321, DOI 10.1038/sj.onc.1201544; Arenberg DA, 1996, J CLIN INVEST, V97, P2792, DOI 10.1172/JCI118734; BAGGIOLINI M, 1994, ADV IMMUNOL, V55, P97; Colgan SP, 1996, J EXP MED, V184, P1003, DOI 10.1084/jem.184.3.1003; Damert A, 1997, CANCER RES, V57, P3860; DESBAILLETS I, 1994, INT J CANCER, V58, P240, DOI 10.1002/ijc.2910580216; Desbaillets I, 1997, J EXP MED, V186, P1201, DOI 10.1084/jem.186.8.1201; DESBAILLETS I, 1997, THESIS U LAUSANNE SW, P189; FOLKMAN J, 1993, CANCER MED, V1, P153; Gassmann M, 1996, P NATL ACAD SCI USA, V93, P2867, DOI 10.1073/pnas.93.7.2867; GOLDBERG MA, 1988, SCIENCE, V242, P1412, DOI 10.1126/science.2849206; GOLDWASSER E, 1957, SCIENCE, V125, P1085, DOI 10.1126/science.125.3257.1085; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; Hochachka PW, 1996, P NATL ACAD SCI USA, V93, P9493, DOI 10.1073/pnas.93.18.9493; HU DE, 1993, INFLAMMATION, V17, P135, DOI 10.1007/BF00916100; IKEDA E, 1995, J BIOL CHEM, V270, P19761, DOI 10.1074/jbc.270.34.19761; KARAKURUM M, 1994, J CLIN INVEST, V93, P1564, DOI 10.1172/JCI117135; KLEIHUES P, 1997, PATHOLOGY GENETICS T, P255; KOCH AE, 1992, SCIENCE, V258, P1798, DOI 10.1126/science.1281554; KUNSCH C, 1994, J IMMUNOL, V153, P153; KVIETIKOVA I, 1995, NUCLEIC ACIDS RES, V23, P4542, DOI 10.1093/nar/23.22.4542; MARIE S, 1993, J BIOL CHEM, V268, P23881; METINKO AP, 1992, J CLIN INVEST, V90, P791, DOI 10.1172/JCI115953; MUKAIDA N, 1994, J BIOL CHEM, V269, P13289; MUKAIDA N, 1990, J BIOL CHEM, V265, P21128; Muller JN, 1997, J BIOL CHEM, V272, P23435, DOI 10.1074/jbc.272.37.23435; PLATE KH, 1992, NATURE, V359, P845, DOI 10.1038/359845a0; RUPEC RA, 1995, EUR J BIOCHEM, V234, P632, DOI 10.1111/j.1432-1033.1995.632_b.x; Russell DSRLJBDDMREBJM., 1998, RUSSELL RUBINSTEINS; Ryuto M, 1996, J BIOL CHEM, V271, P28220, DOI 10.1074/jbc.271.45.28220; Sambrook J., 2002, MOL CLONING LAB MANU; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; SINGH RK, 1994, CANCER RES, V54, P3242; SMITH DR, 1994, J EXP MED, V179, P1409, DOI 10.1084/jem.179.5.1409; Stevens T, 1995, ENDOTHELIUM-J ENDOTH, V3, P1, DOI [10.3109/10623329509024653, DOI 10.3109/10623329509024653]; STRIETER RM, 1992, IMMUNOL INVEST, V21, P589, DOI 10.3109/08820139209069393; SZEKANECZ Z, 1994, PATHOBIOLOGY, V62, P134, DOI 10.1159/000163891; Tanaka C, 1997, BIOCHEM BIOPH RES CO, V232, P568, DOI 10.1006/bbrc.1997.6264; VAN MEIR E, 1992, CANCER RES, V52, P4297; VAN MEIR EG, 1994, CANCER RES, V54, P649; Wakabayashi Y, 1995, JPN J CANCER RES, V86, P1189, DOI 10.1111/j.1349-7006.1995.tb03314.x; Wang GL, 1996, REDOX REP, V2, P89, DOI 10.1080/13510002.1996.11747034; YAMANAKA R, 1995, J NEURO-ONCOL, V25, P59, DOI 10.1007/BF01054723; YAO KS, 1994, MOL CELL BIOL, V14, P5997, DOI 10.1128/MCB.14.9.5997; Ziesche R, 1996, P NATL ACAD SCI USA, V93, P12478, DOI 10.1073/pnas.93.22.12478	46	92	95	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 18	1999	18	7					1447	1456		10.1038/sj.onc.1202424	http://dx.doi.org/10.1038/sj.onc.1202424			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	167UK	10050881				2022-12-25	WOS:000078651600006
J	Budde, A; Grummt, I				Budde, A; Grummt, I			p53 represses ribosomal gene transcription	ONCOGENE			English	Article						p53; RNA polymerase I; transcriptional repression; pre-rRNA synthesis	RNA-POLYMERASE-I; WILD-TYPE P53; DNA-BINDING; RETINOBLASTOMA PROTEIN; HUMAN FIBROBLASTS; GROWTH ARREST; PROMOTER; SPACER; IDENTIFICATION; MUTATIONS	Induction of the tumor suppressor protein p53 restricts cellular proliferation. Since actively growing cells require the ongoing synthesis of ribosomal RNA to sustain cellular biosynthesis, we studied the effect of p53 on ribosomal gene transcription by RNA polymerase I (Pol I). We have measured rDNA transcriptional activity in different cell lines which either lack or overexpress p53 and demonstrate that wild-type but not mutant p53 inhibits cellular pre-rRNA synthesis. Conversely, pre-rRNA levels are elevated both in cells which express mutant p53 and in fibroblasts from p53 knock-out mice. Transient transfection assays with a set of rDNA deletion mutants demonstrate that intergenic spacer sequences are dispensable and the minimal rDNA promoter is sufficient for p53-mediated repression of Pol I transcription, However, in a cell-free transcription system, recombinant p53 does not inhibit rDNA transcription, indicating that p53 does not directly interfere with the basal Pol I transcriptional machinery. Thus, repression of Pol I transcription by p53 may be a consequence of p53-induced growth arrest.	Deutsch Krebsforschungszentrum, Div Mol Biol Cell 2, D-69120 Heidelberg, Germany	Helmholtz Association; German Cancer Research Center (DKFZ)	Grummt, I (corresponding author), Deutsch Krebsforschungszentrum, Div Mol Biol Cell 2, Neuenheimer Feld 280, D-69120 Heidelberg, Germany.							AGARWAL ML, 1995, P NATL ACAD SCI USA, V92, P8493, DOI 10.1073/pnas.92.18.8493; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; Cairns CA, 1998, EMBO J, V17, P3112, DOI 10.1093/emboj/17.11.3112; CAVANAUGH AH, 1995, NATURE, V374, P177, DOI 10.1038/374177a0; Chesnokov I, 1996, MOL CELL BIOL, V16, P7084; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GRUMMT I, 1985, CELL, V43, P801, DOI 10.1016/0092-8674(85)90253-3; GRUMMT I, 1985, P NATL ACAD SCI USA, V82, P722, DOI 10.1073/pnas.82.3.722; GRUMMT I, 1998, IN PRESS PROG NUCL A; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; HAFFNER R, 1995, CURR OPIN GENET DEV, V5, P84, DOI 10.1016/S0959-437X(95)90058-6; HALAZONETIS TD, 1993, EMBO J, V12, P5057, DOI 10.1002/j.1460-2075.1993.tb06199.x; HALEVY O, 1990, SCIENCE, V250, P113, DOI 10.1126/science.2218501; HALEVY O, 1991, ONCOGENE, V6, P1593; HARPER JW, 1993, CELL, V75, P805; HARVEY DM, 1991, GENE DEV, V5, P2375, DOI 10.1101/gad.5.12b.2375; KASS S, 1987, MOL CELL BIOL, V7, P2891, DOI 10.1128/MCB.7.8.2891; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; KUHN A, 1990, P NATL ACAD SCI USA, V87, P7527, DOI 10.1073/pnas.87.19.7527; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LEVINE HB, 1993, PSYCHOANAL QUART, V62, P651; LIN D, 1992, P NATL ACAD SCI USA, V89, P9210, DOI 10.1073/pnas.89.19.9210; MICHELS S, 1990, LAB INVEST, V62, P67; MOSS T, 1995, PROG NUCLEIC ACID RE, V50, P25, DOI 10.1016/S0079-6603(08)60810-7; OREN M, 1994, SEMIN CANCER BIOL, V5, P221; PAALMAN MH, 1995, MOL CELL BIOL, V15, P4648; PAULE MR, 1994, TRANSCRIPTION MECHAN, P83; PFLEIDERER C, 1990, NUCLEIC ACIDS RES, V18, P4727, DOI 10.1093/nar/18.16.4727; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; Staib C, 1996, VIROLOGY, V219, P237, DOI 10.1006/viro.1996.0241; Voit R, 1997, MOL CELL BIOL, V17, P4230, DOI 10.1128/MCB.17.8.4230; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; ZAUBERMAN A, 1993, EMBO J, V12, P2799, DOI 10.1002/j.1460-2075.1993.tb05941.x	41	133	134	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 28	1999	18	4					1119	1124		10.1038/sj.onc.1202402	http://dx.doi.org/10.1038/sj.onc.1202402			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	165FT	10023689				2022-12-25	WOS:000078510600030
J	Gartel, AL; Goufman, E; Tevosian, SG; Shih, H; Yee, AS; Tyner, AL				Gartel, AL; Goufman, E; Tevosian, SG; Shih, H; Yee, AS; Tyner, AL			Activation and repression of p21(WAF1/CIP1) transcription by RB binding proteins	ONCOGENE			English	Article						p21; E2F; HBP1; Sp1	CELL-CYCLE ARREST; RETINOBLASTOMA PROTEIN; CHLORAMPHENICOL ACETYLTRANSFERASE; INHIBITOR P21(WAF1/CIP1); GENE-EXPRESSION; WAF1/CIP1 GENE; S-PHASE; INDUCTION; P21; E2F	The Cdk inhibitor p21(WAF1/CIP1) is a negative regulator of the cell cycle, although its expression is induced by a number of mitogens that promote cell proliferation. We have found that E2F1 and E2F3, transcription factors that activate genes required for cell cycle progression, are strong activators of the p21 promoter. In contrast, HBP1 (HMG-box protein-1), a novel retinoblastoma protein-binding protein, can repress the p21 promoter and inhibit induction of p21 expression by E2F, Both E2Fs and HBP1 regulate p21 transcription through cis-acting elements located between nucleotides -119 to + 16 of the p21 promoter and the DNA binding domains of each of these proteins are required for activity. Sequences between -119 and -60 basepairs containing four Spl consensus elements and two noncanonical E2F binding sites are of major importance for E2F activation, although E2F1 and E2F3 differ in the extent of their ability to activate expression when this segment is deleted. The opposing effects of E2Fs and HBP1 on p21 promoter activity suggest that interplay between these factors may determine the level of p21 transcription in vivo.	Univ Illinois, Dept Mol Genet, Chicago, IL 60607 USA; Tufts Univ, Sch Med, Dept Biochem, Boston, MA 02111 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Tufts University	Tyner, AL (corresponding author), Univ Illinois, Dept Mol Genet, 900 S Ashland Ave, Chicago, IL 60607 USA.		Goufman, Eugene/AAG-6882-2019	Tyner, Angela/0000-0001-7448-8625	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK056283, R01DK048836, P30DK034928] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044634] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK48836, R01 DK056283-05, R01 DK056283, P30 DK-34928] Funding Source: Medline; NIGMS NIH HHS [GM44634] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Biggs JR, 1996, J BIOL CHEM, V271, P901, DOI 10.1074/jbc.271.2.901; Chin YE, 1996, SCIENCE, V272, P719, DOI 10.1126/science.272.5262.719; Chinery R, 1997, NAT MED, V3, P1233, DOI 10.1038/nm1197-1233; DATTO MB, 1995, J BIOL CHEM, V270, P28623, DOI 10.1074/jbc.270.48.28623; Dimri GP, 1996, MOL CELL BIOL, V16, P2987; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELDEIRY WS, 1995, CANCER RES, V55, P2910; Field SJ, 1996, CELL, V85, P549, DOI 10.1016/S0092-8674(00)81255-6; FOLEY KP, 1993, TRENDS GENET, V9, P380, DOI 10.1016/0168-9525(93)90137-7; Gartel AL, 1996, EXP CELL RES, V227, P171, DOI 10.1006/excr.1996.0264; GARTEL AL, 1996, P SOC EXP BIOL MED, V213, P137; GARTEL AL, 1998, IN PRESS PROGR MOL S, V22; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HARPER JW, 1993, CELL, V75, P805; Helin K, 1998, CURR OPIN GENET DEV, V8, P28, DOI 10.1016/S0959-437X(98)80058-0; Hiyama H, 1998, ONCOGENE, V16, P1513, DOI 10.1038/sj.onc.1201667; JIANG HP, 1994, ONCOGENE, V9, P3397; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; Karlseder J, 1996, MOL CELL BIOL, V16, P1659; Khleif SN, 1996, P NATL ACAD SCI USA, V93, P4350, DOI 10.1073/pnas.93.9.4350; Lavender P, 1997, ONCOGENE, V14, P2721, DOI 10.1038/sj.onc.1201243; Lee SJ, 1998, J BIOL CHEM, V273, P10618, DOI 10.1074/jbc.273.17.10618; Li JM, 1998, NUCLEIC ACIDS RES, V26, P2449, DOI 10.1093/nar/26.10.2449; Lin JY, 1996, MOL CELL BIOL, V16, P1786; Lin SY, 1996, MOL CELL BIOL, V16, P1668; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; Mantel C, 1996, BLOOD, V88, P3710, DOI 10.1182/blood.V88.10.3710.bloodjournal88103710; Matsumura I, 1997, MOL CELL BIOL, V17, P2933, DOI 10.1128/MCB.17.5.2933; MICHIELI P, 1994, CANCER RES, V54, P3391; Moberg K, 1996, MOL CELL BIOL, V16, P1436; MUDRYJ M, 1990, EMBO J, V9, P2179, DOI 10.1002/j.1460-2075.1990.tb07387.x; MURRAY IA, 1991, NUCLEIC ACIDS RES, V19, P6648; Nakano K, 1997, J BIOL CHEM, V272, P22199, DOI 10.1074/jbc.272.35.22199; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; Prowse DM, 1997, J BIOL CHEM, V272, P1308, DOI 10.1074/jbc.272.2.1308; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; SELLERS WR, 1995, P NATL ACAD SCI USA, V92, P11544, DOI 10.1073/pnas.92.25.11544; Shin EK, 1996, J BIOL CHEM, V271, P12261, DOI 10.1074/jbc.271.21.12261; Slansky JE, 1996, CURR TOP MICROBIOL, V208, P1; Somasundaram K, 1997, NATURE, V389, P187, DOI 10.1038/38291; Spitkovsky D, 1997, CELL GROWTH DIFFER, V8, P699; STEINMAN RA, 1994, ONCOGENE, V9, P3389; Tevosian SG, 1997, GENE DEV, V11, P383, DOI 10.1101/gad.11.3.383; Timchenko NA, 1996, GENE DEV, V10, P804, DOI 10.1101/gad.10.7.804; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; WEINTRAUB SJ, 1995, NATURE, V375, P812, DOI 10.1038/375812a0; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Yamasaki L, 1996, CELL, V85, P537, DOI 10.1016/S0092-8674(00)81254-4; Zeng YX, 1997, NAT GENET, V15, P78, DOI 10.1038/ng0197-78	52	63	64	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 31	1998	17	26					3463	3469		10.1038/sj.onc.1202240	http://dx.doi.org/10.1038/sj.onc.1202240			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	157XD	10030670				2022-12-25	WOS:000078086200007
J	Dong, LQ; Zhang, RB; Langlais, P; He, HL; Clark, M; Zhu, L; Liu, F				Dong, LQ; Zhang, RB; Langlais, P; He, HL; Clark, M; Zhu, L; Liu, F			Primary structure, tissue distribution, and expression of mouse phosphoinositide-dependent protein kinase-1, a protein kinase that phosphorylates and activates protein kinase C zeta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLECKSTRIN HOMOLOGY DOMAIN; PHOSPHATIDYLINOSITOL 3-KINASE; SIGNAL-TRANSDUCTION; GLUCOSE-TRANSPORT; AKT; INSULIN; IDENTIFICATION; ADIPOCYTES; SURVIVAL; BINDING	Phosphoinositide-dependent protein kinase-l (PDK1) is a recently identified serine/threonine kinase that phosphorylates and activates Akt and p70(S6K), two downstream kinases of phosphatidylinositol S-kinase, To further study the potential role of PDK1, we have screened a mouse liver cDNA library and identified a cDNA encoding the enzyme. The predicted mouse PDK1 (mPDK1) protein contained 559 amino acids and a COOH-terminal pleckstrin homology domain. A 7-kilo-base mPDK1 mRNA was broadly expressed in mouse tissues and in embryonic cells. In the testis, a high level expression of a tissue-specific S-kilobase transcript was also detected. Anti-mPDK1 antibody recognized multiple proteins in mouse tissues with molecular masses ranging from 60 to 180 kDa. mPDK1 phosphorylated the conserved threonine residue (Thr(402)) in, the activation loop of protein kinase C-zeta and activated the enzyme in vitro and in cells. Our findings suggest that there may be different isoforms of mPDK1 and that the protein is an upstream kinase that activates divergent pathways downstream of phosphatidylinositol 3-kinase.	Univ Texas, Hlth Sci Ctr, Dept Pharmacol, San Antonio, TX 78284 USA; Univ Texas, Hlth Sci Ctr, Dept Biochem, San Antonio, TX 78284 USA; CLONTECH Labs Inc, Palo Alto, CA 94303 USA	University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio	Liu, F (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Pharmacol, 7703 Floyd Curl Dr, San Antonio, TX 78284 USA.	liuf@uthscsa.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052933] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK52933] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alessi DR, 1997, CURR BIOL, V7, P776, DOI 10.1016/S0960-9822(06)00336-8; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Alessi DR, 1998, CURR BIOL, V8, P69, DOI 10.1016/S0960-9822(98)70037-5; Bandyopadhyay G, 1997, J BIOL CHEM, V272, P2551; BOS JL, 1995, TRENDS BIOCHEM SCI, V20, P441, DOI 10.1016/S0968-0004(00)89097-0; BRAM RJ, 1993, MOL CELL BIOL, V13, P4760, DOI 10.1128/MCB.13.8.4760; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; CAZAUBON SM, 1993, J BIOL CHEM, V268, P17559; Cheng XD, 1998, P NATL ACAD SCI USA, V95, P9849, DOI 10.1073/pnas.95.17.9849; Chou MM, 1998, CURR BIOL, V8, P1069, DOI 10.1016/S0960-9822(98)70444-0; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Dong LQ, 1997, J BIOL CHEM, V272, P29104, DOI 10.1074/jbc.272.46.29104; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; Kitamura T, 1998, MOL CELL BIOL, V18, P3708, DOI 10.1128/MCB.18.7.3708; Klippel A, 1997, MOL CELL BIOL, V17, P338, DOI 10.1128/MCB.17.1.338; Kohn AD, 1996, J BIOL CHEM, V271, P21920, DOI 10.1074/jbc.271.36.21920; Kohn AD, 1996, J BIOL CHEM, V271, P31372, DOI 10.1074/jbc.271.49.31372; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; Le Good JA, 1998, SCIENCE, V281, P2042, DOI 10.1126/science.281.5385.2042; LI H, 1994, J BIOL CHEM, V269, P28098; Magun R, 1996, ENDOCRINOLOGY, V137, P3590, DOI 10.1210/en.137.8.3590; Marte BM, 1997, TRENDS BIOCHEM SCI, V22, P355, DOI 10.1016/S0968-0004(97)01097-9; Mellor H, 1998, BIOCHEM J, V332, P281, DOI 10.1042/bj3320281; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.48.28495; Pullen N, 1998, SCIENCE, V279, P707, DOI 10.1126/science.279.5351.707; Standaert ML, 1997, J BIOL CHEM, V272, P30075, DOI 10.1074/jbc.272.48.30075; Stephens L, 1998, SCIENCE, V279, P710, DOI 10.1126/science.279.5351.710; Summers SA, 1997, BIOCHEM SOC T, V25, P981, DOI 10.1042/bst0250981; Ueki K, 1998, J BIOL CHEM, V273, P5315, DOI 10.1074/jbc.273.9.5315	31	89	92	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	1999	274	12					8117	8122		10.1074/jbc.274.12.8117	http://dx.doi.org/10.1074/jbc.274.12.8117			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	178LU	10075713	hybrid			2022-12-25	WOS:000079268100072
J	Faniello, MC; Bevilacqua, MA; Condorelli, G; de Crombrugghe, B; Maity, SN; Avvedimento, VE; Cimino, F; Costanzo, F				Faniello, MC; Bevilacqua, MA; Condorelli, G; de Crombrugghe, B; Maity, SN; Avvedimento, VE; Cimino, F; Costanzo, F			The B subunit of the CAAT-binding factor NFY binds the central segment of the co-activator p300	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							H-FERRITIN TRANSCRIPTION; ENCODING GENE FERH; DNA COMPLEX; FACTOR BBF; CBF-B; CELLS; MOTIF; CAMP; MOLECULE; PROMOTER	We report that the heterotrimeric transcription factor NFY or "CAAT-binding factor" binds the -60 region of the human H ferritin promoter, the B site. DNA binding analysis with specific antibodies demonstrates that NFY/B/C subunits tightly bind this site and that NFY/C subunit is masked in vivo by binding with other protein(s). NFY binds the co-activator p300. Specifically, the NFY/B subunit interacts with the central segment of p300 in vivo and in vitro. cAMP substantially increases the formation of the NFY.p300 complex. Taken together these data provide a general model of cAMP induction of non-CRE-containing promoters and suggest that the NFY-B.p300 complex is located at the 5' end of the promoter and the NFY-B.C.TFIIB on the 3' end toward the transcription start site.	Univ Naples, Dipartimento Biochim & Biotecnol Med, I-80131 Naples, Italy; Univ Catanzaro, Dipartimento Med Sperimentale & Clin, I-88100 Catanzaro, Italy	University of Naples Federico II; Magna Graecia University of Catanzaro	Costanzo, F (corresponding author), Univ Naples, Dipartimento Biochim & Biotecnol Med, Via S Pansini 5, I-80131 Naples, Italy.		Costanzo, Francesco Saverio/K-3168-2018; Condorelli, Gianluigi/Q-6736-2017	Costanzo, Francesco Saverio/0000-0002-3096-9416; Condorelli, Gianluigi/0000-0003-0481-6843; Maity, Sankar/0000-0002-2387-6545; FANIELLO, Concetta Maria/0000-0001-6938-2754				ARENTS G, 1991, P NATL ACAD SCI USA, V88, P10148, DOI 10.1073/pnas.88.22.10148; BAXEVANIS AD, 1995, NUCLEIC ACIDS RES, V23, P2685, DOI 10.1093/nar/23.14.2685; Bellorini M, 1997, NUCLEIC ACIDS RES, V25, P2174, DOI 10.1093/nar/25.11.2174; Bevilacqua MA, 1997, J BIOL CHEM, V272, P20736, DOI 10.1074/jbc.272.33.20736; Bevilacqua MA, 1997, BIOCHEM BIOPH RES CO, V240, P179, DOI 10.1006/bbrc.1997.7632; BEVILACQUA MA, 1994, GENE, V141, P287, DOI 10.1016/0378-1119(94)90587-8; BEVILACQUA MA, 1992, GENE, V111, P255, DOI 10.1016/0378-1119(92)90696-M; BEVILACQUA MA, 1995, BIOCHEM J, V311, P769, DOI 10.1042/bj3110769; BOULARAND S, 1995, J BIOL CHEM, V270, P3757, DOI 10.1074/jbc.270.8.3757; Currie RA, 1998, J BIOL CHEM, V273, P1430, DOI 10.1074/jbc.273.3.1430; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; Janknecht R, 1996, NATURE, V383, P22, DOI 10.1038/383022a0; Kawasaki H, 1998, NATURE, V393, P284, DOI 10.1038/30538; Kim IS, 1996, MOL CELL BIOL, V16, P4003; Mantovani R, 1998, NUCLEIC ACIDS RES, V26, P1135, DOI 10.1093/nar/26.5.1135; Marziali G, 1997, MOL CELL BIOL, V17, P1387, DOI 10.1128/MCB.17.3.1387; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; QIAO L, 1998, EMBO J, V17, P6300; Rangan VS, 1996, J BIOL CHEM, V271, P2307, DOI 10.1074/jbc.271.4.2307; SINHA S, 1995, P NATL ACAD SCI USA, V92, P1624, DOI 10.1073/pnas.92.5.1624; SUSHMA EA, 1993, ONCOGENE, V8, P1639	21	79	82	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 19	1999	274	12					7623	7626		10.1074/jbc.274.12.7623	http://dx.doi.org/10.1074/jbc.274.12.7623			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	178LU	10075648	hybrid			2022-12-25	WOS:000079268100007
J	Giasson, BI; Uryu, K; Trojanowski, JQ; Lee, VMY				Giasson, BI; Uryu, K; Trojanowski, JQ; Lee, VMY			Mutant and wild type human alpha-synucleins assemble into elongated filaments with distinct morphologies in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIPLE SYSTEM ATROPHY; OLIGODENDROGLIAL CYTOPLASMIC INCLUSIONS; PARKINSONS-DISEASE; LEWY BODIES; OLIVOPONTOCEREBELLAR ATROPHY; ALZHEIMERS-DISEASE; NERVOUS-SYSTEM; PROTEIN; COMPONENT; EPITOPES	alpha-Synuclein is a soluble presynaptic protein which is pathologically redistributed within intracellular lesions characteristic of several neurodegenerative diseases. Here we demonstrate that wild type and two mutant forms of alpha-synuclein linked to familial Parkinson's disease (Ala(30) --> Pro and Ala(53) --> Thr) self-aggregate and assemble into 10-19-nm-wide filaments with distinct morphologies under defined in vitro conditions. Immunogold labeling demonstrates that the central region of all these filaments are more robustly labeled than the N-terminal or C-terminal regions, suggesting that the latter regions are buried within the filaments. Since in vitro generated alpha-synuclein filaments resemble the major ultrastructural elements of authentic Lewy bodies that are hallmark lesions of Parkinson's disease, we propose that self-aggregating alpha-synuclein is the major subunit protein of these filamentous lesions.	Univ Penn, Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA	University of Pennsylvania	Lee, VMY (corresponding author), Hosp Univ Penn, Dept Pathol & Lab Med, Ctr Neurodegenerat Dis Res, Maloney 3, Philadelphia, PA 19104 USA.		Shahmoradian, Sarah H/C-7465-2015	Shahmoradian, Sarah H/0000-0001-9752-7287				ABE H, 1992, ACTA NEUROPATHOL, V84, P273; ARIMA K, 1992, ACTA NEUROPATHOL, V83, P453, DOI 10.1007/BF00310020; Arima K, 1998, ACTA NEUROPATHOL, V96, P439, DOI 10.1007/s004010050917; Baba M, 1998, AM J PATHOL, V152, P879; BALIN BJ, 1991, BRAIN RES, V556, P181, DOI 10.1016/0006-8993(91)90306-G; Clayton DF, 1998, TRENDS NEUROSCI, V21, P249, DOI 10.1016/S0166-2236(97)01213-7; Conway KA, 1998, NAT MED, V4, P1318, DOI 10.1038/3311; Crowther RA, 1998, FEBS LETT, V436, P309, DOI 10.1016/S0014-5793(98)01146-6; DALE GE, 1992, ACTA NEUROPATHOL, V83, P525, DOI 10.1007/BF00310030; Davidson WS, 1998, J BIOL CHEM, V273, P9443, DOI 10.1074/jbc.273.16.9443; DUFFY PE, 1965, J NEUROPATH EXP NEUR, V24, P398, DOI 10.1097/00005072-196507000-00003; Forno LS, 1996, J NEUROPATH EXP NEUR, V55, P259, DOI 10.1097/00005072-199603000-00001; GEORGE JM, 1995, NEURON, V15, P361, DOI 10.1016/0896-6273(95)90040-3; Goedert M, 1997, NATURE, V388, P232, DOI 10.1038/40767; GOLDMAN JE, 1983, SCIENCE, V221, P1082, DOI 10.1126/science.6308771; Hashimoto M, 1998, BRAIN RES, V799, P301, DOI 10.1016/S0006-8993(98)00514-9; HILL WD, 1991, J COMP NEUROL, V309, P150, DOI 10.1002/cne.903090111; HIROKAWA N, 1984, J CELL BIOL, V98, P1523, DOI 10.1083/jcb.98.4.1523; Hong L, 1998, NEUROREPORT, V9, P1239, DOI 10.1097/00001756-199804200-00051; IWAI A, 1995, NEURON, V14, P467, DOI 10.1016/0896-6273(95)90302-X; IZIZARRY MC, 1998, J NEUROPATHOL EXP NE, V57, P334; JAKES R, 1994, FEBS LETT, V345, P27, DOI 10.1016/0014-5793(94)00395-5; Jensen PH, 1998, J BIOL CHEM, V273, P26292, DOI 10.1074/jbc.273.41.26292; KATO S, 1990, ACTA NEUROPATHOL, V79, P584, DOI 10.1007/BF00294235; KATO S, 1991, ACTA NEUROPATHOL, V82, P488, DOI 10.1007/BF00293383; Kruger R, 1998, NAT GENET, V18, P106, DOI 10.1038/ng0298-106; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAROTEAUX L, 1988, J NEUROSCI, V8, P2804; McKeith IG, 1996, NEUROLOGY, V47, P1113, DOI 10.1212/WNL.47.5.1113; MURAYAMA S, 1992, ACTA NEUROPATHOL, V84, P32, DOI 10.1007/BF00427212; PAPP MI, 1989, J NEUROL SCI, V94, P79, DOI 10.1016/0022-510X(89)90219-0; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; SCHMIDT ML, 1991, AM J PATHOL, V139, P53; Spillantini MG, 1998, P NATL ACAD SCI USA, V95, P6469, DOI 10.1073/pnas.95.11.6469; Spillantini MG, 1997, NATURE, V388, P839, DOI 10.1038/42166; Spillantini MG, 1998, NEUROSCI LETT, V251, P205, DOI 10.1016/s0304-3940(98)00504-7; Takeda A, 1998, AM J PATHOL, V152, P367; Tu PH, 1998, ANN NEUROL, V44, P415, DOI 10.1002/ana.410440324; UEDA K, 1993, P NATL ACAD SCI USA, V90, P11282, DOI 10.1073/pnas.90.23.11282; Wakabayashi K, 1998, ACTA NEUROPATHOL, V96, P445, DOI 10.1007/s004010050918; Wakabayashi K, 1997, NEUROSCI LETT, V239, P45, DOI 10.1016/S0304-3940(97)00891-4; Wakabayashi K, 1998, NEUROSCI LETT, V249, P180, DOI 10.1016/S0304-3940(98)00407-8; Weinreb PH, 1996, BIOCHEMISTRY-US, V35, P13709, DOI 10.1021/bi961799n	43	440	453	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 19	1999	274	12					7619	7622		10.1074/jbc.274.12.7619	http://dx.doi.org/10.1074/jbc.274.12.7619			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	178LU	10075647	hybrid			2022-12-25	WOS:000079268100006
J	Reddy, LG; Autry, JM; Jones, LR; Thomas, DD				Reddy, LG; Autry, JM; Jones, LR; Thomas, DD			Co-reconstitution of phospholamban mutants with the Ca-ATPase reveals dependence of inhibitory function on phospholamban structure	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARDIAC SARCOPLASMIC-RETICULUM; SODIUM DODECYL-SULFATE; PROTEIN-KINASE; CALCIUM-PUMP; CA2+-ATPASE; PHOSPHORYLATION; IDENTIFICATION; CA-2+-ATPASE; SEQUENCE; MUSCLES	Phospholamban (PLB), a 52-amino acid integral membrane protein, regulates the Ca-ATPase (calcium pump) in cardiac sarcoplasmic reticulum through PLB phosphorylation mediated by beta-adrenergic stimulation. Based on site-directed mutagenesis and coexpression with Ca-ATPase (SERCA2a) in Sf21 insect cells or in HEK 293 cells, and on spin label detection of PLB oligomeric state in lipid bilayers, it has been proposed that the monomeric form of PLB is the inhibitory species, and depolymerization of PLB is essential for its regulatory function. Here we have studied the relationship between PLB oligomeric state and function by in vitro co-reconstitution of PLB and its mutants with purified Ca-ATPase, We compared wild type-PLB (wt-PLB), which is primarily a pentamer on SDS-polyacrylamide gel electrophoresis (PAGE) at 25 degrees C, with two of its mutants, C41L-PLB and L37A-PLB, that are primarily tetramer and monomer, respectively. We found that the monomeric mutant L37A-PLB is a more potent inhibitor than wt-PLB, supporting the previous proposal that PLB monomer is the inhibitory species. On the other hand, C41L-PLB, which has a monomeric fraction comparable to that of wt-PLB on SDS-PAGE at 25 degrees C, has no inhibitory activity when assayed at 25 degrees C, However, at 37 degrees C, a 3-fold increase in the monomeric fraction of C41L-PLB on SDS-PAGE resulted in inhibitory activity comparable to that of wt-PLB, Upon increasing the temperature from 25 to 37 degrees C, no change in fraction monomer or inhibitory activity for wt-PLB and L37A-PLB was observed. Based on these results, the extent of inhibition of Ca-ATPase by PLB or its mutants appears to depend not only on the propensity of PLB to dissociate into monomers but also on the relative potency of the particular PLB monomer when interacting with the Ca-ATPase.	Univ Minnesota, Sch Med, Dept Biochem Mol Biol & Biophys, Minneapolis, MN 55455 USA; Indiana Univ, Krannert Inst Cardiol, Indianapolis, IN 46202 USA	University of Minnesota System; University of Minnesota Twin Cities; Indiana University System; Indiana University-Purdue University Indianapolis	Thomas, DD (corresponding author), Univ Minnesota, Sch Med, Dept Biochem Mol Biol & Biophys, Minneapolis, MN 55455 USA.		Autry, Joseph M./X-6839-2019; Thomas, David D/B-4257-2012	Autry, Joseph M./0000-0002-1144-725X; Thomas, David D./0000-0002-8822-2040	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R37AR032961, R01AR032961] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM027906] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL06308] Funding Source: Medline; NIAMS NIH HHS [AR32961] Funding Source: Medline; NIGMS NIH HHS [GM27906] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARKIN IT, 1994, EMBO J, V13, P4757, DOI 10.1002/j.1460-2075.1994.tb06801.x; Autry JM, 1997, J BIOL CHEM, V272, P15872, DOI 10.1074/jbc.272.25.15872; Autry JM, 1998, ANN NY ACAD SCI, V853, P92, DOI 10.1111/j.1749-6632.1998.tb08259.x; BRIGGS FN, 1992, J BIOL CHEM, V267, P26056; Chu GX, 1997, CIRC RES, V81, P485, DOI 10.1161/01.RES.81.4.485; COLYER J, 1993, CARDIOVASC RES, V27, P1766, DOI 10.1093/cvr/27.10.1766; Cornea RL, 1997, BIOCHEMISTRY-US, V36, P2960, DOI 10.1021/bi961955q; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; Ferrington DA, 1998, BIOPHYS J, V74, pA356; FUJII J, 1987, J CLIN INVEST, V79, P301, DOI 10.1172/JCI112799; HUGHES G, 1994, BIOCHEM J, V303, P511, DOI 10.1042/bj3030511; JONES LR, 1985, J BIOL CHEM, V260, P7721; JORGENSEN AO, 1987, J CELL BIOL, V104, P1343, DOI 10.1083/jcb.104.5.1343; Kargacin ME, 1998, BIOCHEM J, V331, P245, DOI 10.1042/bj3310245; Karim CB, 1998, BIOCHEMISTRY-US, V37, P12074, DOI 10.1021/bi980642n; KIM HW, 1990, J BIOL CHEM, V265, P1702; Kimura Y, 1997, J BIOL CHEM, V272, P15061, DOI 10.1074/jbc.272.24.15061; Kimura Y, 1998, J BIOL CHEM, V273, P14238, DOI 10.1074/jbc.273.23.14238; KIRCHBERGER MA, 1986, BIOCHEMISTRY-US, V25, P5484, DOI 10.1021/bi00367a021; KIRCHBERGER MA, 1976, J BIOL CHEM, V251, P725; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; LEVY D, 1992, BIOCHIM BIOPHYS ACTA, V1107, P283, DOI 10.1016/0005-2736(92)90415-I; LINDEMANN JP, 1983, J BIOL CHEM, V258, P464; MARTONOSI A, 1964, J BIOL CHEM, V239, P648; RAEYMAEKERS L, 1990, CELL CALCIUM, V11, P261, DOI 10.1016/0143-4160(90)90002-C; REDDY L, 1999, IN PRESS BIOCHEMISTR; REDDY LG, 1995, J BIOL CHEM, V270, P9390, DOI 10.1074/jbc.270.16.9390; Reddy LG, 1996, J BIOL CHEM, V271, P14964, DOI 10.1074/jbc.271.25.14964; SASAKI T, 1992, J BIOL CHEM, V267, P1674; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; SHAM JSK, 1991, AM J PHYSIOL, V261, pH1344, DOI 10.1152/ajpheart.1991.261.4.H1344; Simmerman HKB, 1996, J BIOL CHEM, V271, P5941, DOI 10.1074/jbc.271.10.5941; Simmerman HKB, 1998, PHYSIOL REV, V78, P921, DOI 10.1152/physrev.1998.78.4.921; SIMMERMAN HKB, 1986, J BIOL CHEM, V261, P3333; STEWART JCM, 1980, ANAL BIOCHEM, V104, P10, DOI 10.1016/0003-2697(80)90269-9; Stokes DL, 1997, CURR OPIN STRUC BIOL, V7, P550, DOI 10.1016/S0959-440X(97)80121-2; STOKES DL, 1990, BIOPHYS J, V57, P1, DOI 10.1016/S0006-3495(90)82501-7; SZYMANSKA K, 1991, MEMBRANE BIOCHEM, V9, P191; TADA M, 1989, BIOESSAYS, V10, P163; Thomas DD, 1998, ANN NY ACAD SCI, V853, P186, DOI 10.1111/j.1749-6632.1998.tb08266.x; TOYOFUKU T, 1993, J BIOL CHEM, V268, P2809; WATANABE Y, 1991, J BIOCHEM, V110, P40, DOI 10.1093/oxfordjournals.jbchem.a123540; WEGENER AD, 1984, J BIOL CHEM, V259, P1834	43	49	49	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 19	1999	274	12					7649	7655		10.1074/jbc.274.12.7649	http://dx.doi.org/10.1074/jbc.274.12.7649			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	178LU	10075652	hybrid			2022-12-25	WOS:000079268100011
J	Watts, BA; George, T; Good, DW				Watts, BA; George, T; Good, DW			Nerve growth factor inhibits HCO3- absorption in renal thick ascending limb through inhibition of basolateral membrane Na+/H+ exchange	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; NA-H EXCHANGE; APICAL MEMBRANE; INTRACELLULAR-PH; BICARBONATE ABSORPTION; RECEPTOR EXPRESSION; METABOLIC-ACIDOSIS; PROXIMAL TUBULE; MESANGIAL CELLS; MESSENGER-RNA	Nerve growth factor (NGF) inhibits transepithelial HCO, absorption in the rat medullary thick ascending limb (MTAL), To investigate the mechanism of this inhibition, MTALs were perfused in vitro in Na+-free solutions, and apical and basolateral membrane Na+/H+ exchange activities were determined from rates of pH(i) recovery after lumen or bath Na+ addition. NGF (0.7 nM in the bath) had no effect on apical Na+/H+ exchange activity, but inhibited basolateral Na+/H+ exchange activity by 50%. Inhibition of basolateral Na+/H+ exchange activity with ethylisopropyl amiloride (EIPA) secondarily reduces apical Na+/H+ exchange activity and HCO3- absorption in the MTAL (Good, D, W,, George, T,, and Watts, B, A, III (1995) Proc. Natl. Acad. Sci, U,S.A. 92, 12525-12529). To determine whether a similar mechanism could explain inhibition of HCO3- absorption by NGF, apical Na+/H+ exchange activity was assessed in physiological solutions (146 mM Na+) by measurement of the initial rate of cell acidification after lumen EIPA addition. Under these conditions, in which basolateral Na+/H+ exchange activity is present, NGF inhibited apical Na+/H+ exchange activity. Inhibition of HCO3- absorption by NGF was eliminated in the presence of bath EIPA or in the absence of bath Na+. Also, NGF blocked inhibition of HCO3- absorption by bath EIPA. We conclude that NGF inhibits basolateral Na+/H+ exchange activity in the MTAL, an effect opposite from the stimulation of Na+/H+ exchange by growth factors in other systems. NGF inhibits transepithelial HCO3- absorption through inhibition of basolateral Na+/H+ exchange, most likely as the result of functional coupling in which primary inhibition of basolateral Na+/H+ exchange activity results secondarily in inhibition of apical Na+/H+ exchange activity. These findings establish a role for basolateral Na+/H+ exchange in the regulation of renal tubule HCO3- absorption.	Univ Texas, Med Branch, Dept Med, Galveston, TX 77555 USA; Univ Texas, Med Branch, Dept Physiol & Biophys, Galveston, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston	Good, DW (corresponding author), Univ Texas, Med Branch, Dept Med, 4-200 John Sealy Annex 0562,301 Univ Blvd, Galveston, TX 77555 USA.				NIDDK NIH HHS [DK-38217] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038217] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALPERN RJ, 1995, KIDNEY INT, V48, P1386, DOI 10.1038/ki.1995.427; ALPERN RJ, 1996, KIDNEY, V1, P408; ALPERS CE, 1993, LAB INVEST, V69, P703; AMEMIYA M, 1995, KIDNEY INT, V48, P1206, DOI 10.1038/ki.1995.404; AttmaneElakeb A, 1996, KIDNEY INT, V50, P1051, DOI 10.1038/ki.1996.408; Bianchini L, 1997, J BIOL CHEM, V272, P271; BIEMESDERFER D, 1992, AM J PHYSIOL, V263, pF833, DOI 10.1152/ajprenal.1992.263.5.F833; Biemesderfer D, 1997, AM J PHYSIOL-RENAL, V273, pF289, DOI 10.1152/ajprenal.1997.273.2.F289; BIEMESDERFER D, 1993, AM J PHYSIOL, V265, pC736; BOOKSTEIN C, 1994, J BIOL CHEM, V269, P29704; BOONSTRA J, 1983, J CELL BIOL, V97, P92, DOI 10.1083/jcb.97.1.92; BORENSZTEIN P, 1995, AM J PHYSIOL-RENAL, V268, pF1224, DOI 10.1152/ajprenal.1995.268.6.F1224; BORON WF, 1983, J GEN PHYSIOL, V81, P29, DOI 10.1085/jgp.81.1.29; BOYARSKY G, 1990, P NATL ACAD SCI USA, V87, P5921, DOI 10.1073/pnas.87.15.5921; Chambrey R, 1998, AM J PHYSIOL-RENAL, V275, pF379, DOI 10.1152/ajprenal.1998.275.3.F379; Chambrey R, 1997, AM J PHYSIOL-CELL PH, V273, pC1064, DOI 10.1152/ajpcell.1997.273.3.C1064; GANZ MB, 1994, AM J PHYSIOL, V266, pF576, DOI 10.1152/ajprenal.1994.266.4.F576; Good David W., 1998, Journal of the American Society of Nephrology, V9, p6A; Good DW, 1996, AM J PHYSIOL-RENAL, V270, pF691, DOI 10.1152/ajprenal.1996.270.4.F691; Good DW, 1998, AM J PHYSIOL-CELL PH, V274, pC931, DOI 10.1152/ajpcell.1998.274.4.C931; GOOD DW, 1995, J BIOL CHEM, V270, P9883, DOI 10.1074/jbc.270.17.9883; GOOD DW, 1993, SEMIN NEPHROL, V13, P225; GOOD DW, 1990, J CLIN INVEST, V85, P1006, DOI 10.1172/JCI114530; Good DW, 1995, P NATL ACAD SCI USA, V92, P12525, DOI 10.1073/pnas.92.26.12525; GOOD DW, 1997, J AM SOC NEPHROL S, V8, pA6; GRINSTEIN S, 1989, BIOCHIM BIOPHYS ACTA, V988, P73, DOI 10.1016/0304-4157(89)90004-X; GUERRA L, 1993, J MEMBRANE BIOL, V135, P209; HAMMERMAN MR, 1993, ANNU REV PHYSIOL, V55, P305, DOI 10.1146/annurev.physiol.55.1.305; HEBERT SC, 1986, AM J PHYSIOL, V250, pC920, DOI 10.1152/ajpcell.1986.250.6.C920; Hooley R, 1996, J BIOL CHEM, V271, P6152, DOI 10.1074/jbc.271.11.6152; KAPLAN DL, 1994, J BIOL CHEM, V269, P4116; KAPUS A, 1994, J BIOL CHEM, V269, P23544; Khurana S, 1996, J BIOL CHEM, V271, P9919, DOI 10.1074/jbc.271.17.9919; KRAPF R, 1991, J CLIN INVEST, V88, P783, DOI 10.1172/JCI115377; Laghmani K, 1997, J CLIN INVEST, V99, P24, DOI 10.1172/JCI119128; LEVINE SA, 1993, J BIOL CHEM, V268, P25527; LOMENHOERTH C, 1995, J NEUROCHEM, V64, P1780; MA YH, 1994, J BIOL CHEM, V269, P30734; MACKOVICBASIC M, 1990, SEMIN NEPHROL, V10, P122; MALY K, 1989, J BIOL CHEM, V264, P11839; NOEL J, 1995, AM J PHYSIOL-CELL PH, V268, pC283, DOI 10.1152/ajpcell.1995.268.2.C283; Orlowski J, 1997, J BIOL CHEM, V272, P22373, DOI 10.1074/jbc.272.36.22373; PITCHFORD S, 1995, AM J PHYSIOL-CELL PH, V268, pC936, DOI 10.1152/ajpcell.1995.268.4.C936; POUYSSEGUR J, 1984, P NATL ACAD SCI-BIOL, V81, P4833, DOI 10.1073/pnas.81.15.4833; PREISIG PA, 1991, KIDNEY INT, V39, P1077, DOI 10.1038/ki.1991.137; SALIDO EC, 1986, J NEUROSCI RES, V16, P457, DOI 10.1002/jnr.490160302; SCHLATTER E, 1995, J AM SOC NEPHROL, V6, P1223; SUN AM, 1992, AM J PHYSIOL, V262, pF241, DOI 10.1152/ajprenal.1992.262.2.F241; Sun AM, 1997, J MEMBRANE BIOL, V160, P85, DOI 10.1007/s002329900297; VILELLA S, 1992, PFLUG ARCH EUR J PHY, V422, P9, DOI 10.1007/BF00381507; WAKABAYASHI S, 1992, REV PHYSIOL BIOCH P, V119, P157; Wakabayashi S, 1997, PHYSIOL REV, V77, P51, DOI 10.1152/physrev.1997.77.1.51; WALKER P, 1980, BRAIN RES, V186, P331, DOI 10.1016/0006-8993(80)90979-8; Wang H, 1997, BIOCHEMISTRY-US, V36, P9151, DOI 10.1021/bi970802f; WATTS BA, 1994, J GEN PHYSIOL, V103, P917, DOI 10.1085/jgp.103.5.917; WATTS BA, 1994, J BIOL CHEM, V269, P20250; Wu MS, 1996, J BIOL CHEM, V271, P32749, DOI 10.1074/jbc.271.51.32749; YUN CHC, 1995, AM J PHYSIOL-GASTR L, V269, pG1, DOI 10.1152/ajpgi.1995.269.1.G1	58	27	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 19	1999	274	12					7841	7847		10.1074/jbc.274.12.7841	http://dx.doi.org/10.1074/jbc.274.12.7841			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	178LU	10075676	hybrid			2022-12-25	WOS:000079268100035
J	Gupta, N; Scharenberg, AM; Fruman, DA; Cantley, LC; Kinet, JP; Long, EO				Gupta, N; Scharenberg, AM; Fruman, DA; Cantley, LC; Kinet, JP; Long, EO			The SH2 domain-containing inositol 5 '-phosphatase (SHIP) recruits the p85 subunit of phosphoinositide 3-kinase during Fc gamma RIIb1-mediated inhibition of B cell receptor signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FC-GAMMA-RIIB; PHOSPHATIDYLINOSITOL 3-KINASE; POLYPHOSPHATE 5-PHOSPHATASE; TYROSINE PHOSPHORYLATION; PHOSPHATASE SHIP; ACTIVATION; ANTIGEN; KINASE; IMMUNOGLOBULIN; LYMPHOCYTES	Coligation of Fc gamma RIIb1 with the B cell receptor (BCR) or Fc epsilon RI on mast cells inhibits B cell or mast cell activation, Activity of the inositol phosphatase SHIP is required for this negative signal. In vitro, SHIP catalyzes the conversion of the phosphoinositide 3-kinase (PI3K) product phosphatidylinositol 3,4,5-trisphosphate (PIP3) into phosphatidylinositol 3,4-bisphosphate. Recent data demonstrate that coligation of Fc gamma RIIb1 with BCR inhibits PIP3-dependent Btk (Bruton's tyrosine kinase) activation and the Btk-dependent generation of inositol trisphosphate that regulates sustained calcium influx, In this study, we provide evidence that coligation of Fc gamma RIIb1 with BCR induces binding of PI3K to SHIP, This interaction is mediated by the binding of the SH2 domains of the p85 subunit of PI3K to a tyrosine-based motif in the C-terminal region of SHIP. Furthermore, the generation of phosphatidylinositol 3,4-bisphosphate was only partially reduced during coligation of BCR with Fc gamma RIIb1 despite a drastic reduction in PIP3. In contrast to the complete inhibition of Tec kinase-dependent calcium signaling, activation of the serine/threonine kinase Akt was partially preserved during BCR and Fc gamma RIIb1 coligation, The association of PI3K with SHIP may serve to activate PI3K and to regulate downstream events such as B cell activation-induced apoptosis.	NIAID, Immunogenet Lab, NIH, Rockville, MD 20852 USA; Beth Israel Deaconess Med Ctr, Lab Allergy & Immunol, Boston, MA 02215 USA; Beth Israel Deaconess Med Ctr, Lab Signal Transduct, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA 02215 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School	Long, EO (corresponding author), NIAID, Immunogenet Lab, NIH, Twinbrook II,12441 Parklawn Dr, Rockville, MD 20852 USA.	elong@nih.gov	Long, Eric O/G-5475-2011; Cantley, Lewis C/D-1800-2014	Long, Eric O/0000-0002-7793-3728; Cantley, Lewis C/0000-0002-1298-7653	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041890] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM041890] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ashman RF, 1996, J IMMUNOL, V157, P5; AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; BIJSTERBOSCH MK, 1985, J EXP MED, V162, P1825, DOI 10.1084/jem.162.6.1825; Bolland S, 1998, IMMUNITY, V8, P509, DOI 10.1016/S1074-7613(00)80555-5; Chacko GW, 1996, J IMMUNOL, V157, P2234; CHAN PL, 1971, IMMUNOLOGY, V21, P967; Chen RH, 1997, EMBO J, V16, P1351, DOI 10.1093/emboj/16.6.1351; CHOQUET D, 1993, J CELL BIOL, V121, P355, DOI 10.1083/jcb.121.2.355; Damen JE, 1996, P NATL ACAD SCI USA, V93, P1689, DOI 10.1073/pnas.93.4.1689; Downward J, 1998, SCIENCE, V279, P673, DOI 10.1126/science.279.5351.673; EARL PL, 1988, CURRENT PROTOCOLS MO; Fluckiger AC, 1998, EMBO J, V17, P1973, DOI 10.1093/emboj/17.7.1973; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; Gupta N, 1997, J EXP MED, V186, P473, DOI 10.1084/jem.186.3.473; Hemmings BA, 1997, SCIENCE, V275, P628, DOI 10.1126/science.275.5300.628; Hippen KL, 1997, IMMUNITY, V7, P49, DOI 10.1016/S1074-7613(00)80509-9; JACKSON SP, 1995, EMBO J, V14, P4490, DOI 10.1002/j.1460-2075.1995.tb00128.x; Kavanaugh WM, 1996, CURR BIOL, V6, P438, DOI 10.1016/S0960-9822(02)00511-0; Kiener PA, 1997, J BIOL CHEM, V272, P3838, DOI 10.1074/jbc.272.6.3838; Klippel A, 1997, MOL CELL BIOL, V17, P338, DOI 10.1128/MCB.17.1.338; Lioubin MN, 1996, GENE DEV, V10, P1084, DOI 10.1101/gad.10.9.1084; Liu L, 1997, J BIOL CHEM, V272, P8983; Nadler MJS, 1997, J BIOL CHEM, V272, P20038, DOI 10.1074/jbc.272.32.20038; OKADA T, 1994, J BIOL CHEM, V269, P3563; Ono M, 1996, NATURE, V383, P263, DOI 10.1038/383263a0; Ono M, 1997, CELL, V90, P293, DOI 10.1016/S0092-8674(00)80337-2; PHILLIPS NE, 1983, J IMMUNOL, V130, P602; Rameh LE, 1997, J BIOL CHEM, V272, P22059, DOI 10.1074/jbc.272.35.22059; Scharenberg AM, 1998, EMBO J, V17, P1961, DOI 10.1093/emboj/17.7.1961; SCHARENBERG AM, 1995, EMBO J, V14, P3385, DOI 10.1002/j.1460-2075.1995.tb07344.x; SERUNIAN LA, 1991, METHOD ENZYMOL, V198, P78; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; Takata M, 1996, J EXP MED, V184, P31, DOI 10.1084/jem.184.1.31; Tridandapani S, 1997, IMMUNOL TODAY, V18, P424, DOI 10.1016/S0167-5699(97)01112-2; TUVESON DA, 1993, SCIENCE, V260, P986, DOI 10.1126/science.7684160; WENG WK, 1994, J BIOL CHEM, V269, P32514; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; WILSON HA, 1987, J IMMUNOL, V138, P1712; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	40	47	47	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	1999	274	11					7489	7494		10.1074/jbc.274.11.7489	http://dx.doi.org/10.1074/jbc.274.11.7489			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	175DV	10066815	hybrid			2022-12-25	WOS:000079078400087
J	Manes, S; Llorente, M; Lacalle, RA; Gomez-Mouton, C; Kremer, L; Mira, E; Martinez-A, C				Manes, S; Llorente, M; Lacalle, RA; Gomez-Mouton, C; Kremer, L; Mira, E; Martinez-A, C			The matrix metalloproteinase-9 regulates the insulin-like growth factor-triggered autocrine response in DU-145 carcinoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-BINDING PROTEIN-3; FACTOR-I RECEPTOR; BREAST-CANCER-CELLS; PROSTATE EPITHELIAL-CELLS; FACTOR IGF; MONOCLONAL-ANTIBODIES; SOMATOMEDIN RECEPTOR; MITOGENIC RESPONSE; NUDE-MICE; EXPRESSION	The androgen-independent human prostate adenocarcinoma cell line DU-145 proliferates in serum-free medium and produces insulin-like growth factors (IGF)-I, IGF-IZ, and the IGF type-1 receptor (IGF-1R), They also secrete three IGF-binding proteins (IGFBP), IGFBP-2, -3, and -4, Of these, immunoblot analysis revealed selective proteolysis of IGFBP-3, yielding fragments of 31 and 19 kDa, By using an anti-IGF-I-specific monoclonal antibody (mAb), we detect surface receptor-bound IGF-I on serum-starved DU-145 cells, which activates IGF-IR and triggers a mitogenic signal. Incubation of DU-145 cells with blocking anti-IGF-I, anti-IGF-II, or anti-IGF-I plus anti-IGF-II mAb does not, however, inhibit serum-free growth of DU-145, Conversely, anti-IGF-1R mAb and IGFBP-3 inhibit DNA synthesis. IGFBP-3 also modifies the DU-145 cell cycle, decreases p34(cdc2) levels, and IGF-IR autophosphorylation. The antiproliferative IGFBP-3 activity is not IGF-independent, since des-(1-3)IGF-I, which does not bind to IGFBP-3, reverses its inhibitory effect. DU-145 also secretes the matrix metalloproteinase (MMP)-9, which can be detected in both a soluble and a membrane-bound form. Matrix metalloproteinase inhibitors, but not serpins, abrogate DNA synthesis in DU-145 associated with the blocking of IGFBP-3 proteolysis. Overexpression of an antisense cDNA for MMP-9 inhibits 80% of DU-145 cell proliferation that can be reversed by IGF-I in a dose-dependent manner. Inhibition of MMP-9 expression is also associated with a decrease in IGFBP-3 proteolysis and with reduced signaling through the IGF-1R, Our data indicate an IGF autocrine loop operating in DU-145 cells, specifically modulated by IGFBP-3, whose activity may in turn be regulated by IGFBP-3 proteases such as MMP-9.	Univ Autonoma Madrid, CSIC, Ctr Nacl Biotecnol, Dept Immunol & Oncol, E-28049 Madrid, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB)	Manes, S (corresponding author), Univ Autonoma Madrid, CSIC, Ctr Nacl Biotecnol, Dept Immunol & Oncol, Campus Cantoblanco, E-28049 Madrid, Spain.		Kremer, Leonor/L-5445-2015; Llorente, Mercedes/AAA-7646-2021; Manes, Santos/E-4725-2011; MIRA, EMILIA/K-2456-2014	Kremer, Leonor/0000-0002-2235-2010; MIRA, EMILIA/0000-0002-4226-1829; Manes, Santos/0000-0001-8023-957X; GOMEZ-MOUTON, CONCEPCION/0000-0002-1595-6027; Lacalle, Rosa Ana/0000-0003-0082-167X; Llorente Gomez, Mercedes/0000-0001-8759-9148				ADASHI EY, 1992, J CLIN INVEST, V90, P1593, DOI 10.1172/JCI116028; ANGELLOZNICOUD P, 1995, ENDOCRINOLOGY, V136, P5485, DOI 10.1210/en.136.12.5485; ARTEAGA CL, 1989, J CLIN INVEST, V84, P1418, DOI 10.1172/JCI114315; ARTEAGA CL, 1992, BREAST CANCER RES TR, V22, P101, DOI 10.1007/BF01833338; ARTEAGA CL, 1989, CANCER RES, V49, P6237; BAKER J, 1993, CELL, V75, P73, DOI 10.1016/0092-8674(93)90680-O; BASERGA R, 1994, CELL, V79, P927, DOI 10.1016/0092-8674(94)90023-X; BICKETT DM, 1993, ANAL BIOCHEM, V212, P58, DOI 10.1006/abio.1993.1291; BIRNBAUM RS, 1994, J ENDOCRINOL, V141, P535, DOI 10.1677/joe.0.1410535; BLASI F, 1993, BIOESSAYS, V15, P105, DOI 10.1002/bies.950150206; BLAT C, 1994, J CLIN INVEST, V93, P2286, DOI 10.1172/JCI117229; Brooks PC, 1996, CELL, V85, P683, DOI 10.1016/S0092-8674(00)81235-0; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CLEMMONS DR, 1993, ANN NY ACAD SCI, V692, P10; COHEN P, 1994, HORM METAB RES, V26, P81, DOI 10.1055/s-2007-1000777; COHEN P, 1993, MOL ENDOCRINOL, V7, P380, DOI 10.1210/me.7.3.380; COHEN P, 1991, J CLIN ENDOCR METAB, V73, P401, DOI 10.1210/jcem-73-2-401; COHICK WS, 1993, ANNU REV PHYSIOL, V55, P131, DOI 10.1146/annurev.ph.55.030193.001023; CONNOLLY JM, 1994, PROSTATE, V24, P167, DOI 10.1002/pros.2990240402; Conover CA, 1996, ENDOCRINOLOGY, V137, P2286, DOI 10.1210/en.137.6.2286; CONOVER CA, 1992, ENDOCRINOLOGY, V130, P3191, DOI 10.1210/en.130.6.3191; Doerr ME, 1996, J BIOL CHEM, V271, P2443, DOI 10.1074/jbc.271.5.2443; DRUMMOND IA, 1992, SCIENCE, V257, P674, DOI 10.1126/science.1323141; ELGIN RG, 1987, P NATL ACAD SCI USA, V84, P3254, DOI 10.1073/pnas.84.10.3254; EMONARD HP, 1992, CANCER RES, V52, P5845; FIGUEROA JA, 1995, J CLIN ENDOCR METAB, V80, P3476, DOI 10.1210/jc.80.12.3476; FLIER JS, 1986, P NATL ACAD SCI USA, V83, P664, DOI 10.1073/pnas.83.3.664; FOWLKES JL, 1994, J BIOL CHEM, V269, P25742; HOSSENLOPP P, 1986, ANAL BIOCHEM, V154, P138, DOI 10.1016/0003-2697(86)90507-5; HOSSENLOPP P, 1990, J CLIN ENDOCR METAB, V71, P797, DOI 10.1210/jcem-71-4-797; IWAMURA M, 1993, PROSTATE, V22, P243, DOI 10.1002/pros.2990220307; JONES JI, 1993, J CELL BIOL, V121, P679, DOI 10.1083/jcb.121.3.679; JONES JI, 1995, ENDOCR REV, V16, P3, DOI 10.1210/er.16.1.3; KALEBIC T, 1994, CANCER RES, V54, P5531; KATO H, 1993, J BIOL CHEM, V268, P2655; LEAMON CP, 1993, BIOCHEM J, V291, P855, DOI 10.1042/bj2910855; LEE CH, 1993, P NATL ACAD SCI USA, V90, P11713, DOI 10.1073/pnas.90.24.11713; Leventhal PS, 1997, J BIOL CHEM, V272, P5214, DOI 10.1074/jbc.272.8.5214; LI CY, 1995, ONCOGENE, V11, P1885; LIM DJ, 1993, PROSTATE, V22, P109, DOI 10.1002/pros.2990220203; LIU JP, 1993, CELL, V75, P59, DOI 10.1016/S0092-8674(05)80084-4; MACAULAY VM, 1992, BRIT J CANCER, V65, P311, DOI 10.1038/bjc.1992.65; Manes S, 1997, J BIOL CHEM, V272, P25706, DOI 10.1074/jbc.272.41.25706; Manes S, 1997, J ENDOCRINOL, V154, P293, DOI 10.1677/joe.0.1540293; Manes S, 1997, ENDOCRINOLOGY, V138, P905, DOI 10.1210/en.138.3.905; MARCELLI M, 1995, ENDOCRINOLOGY, V136, P1040, DOI 10.1210/en.136.3.1040; MICKEY DD, 1977, CANCER RES, V37, P4049; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; OH Y, 1993, J BIOL CHEM, V268, P26045; Oh Y, 1997, ENDOCRINE, V7, P111, DOI 10.1007/BF02778076; OH YM, 1993, J BIOL CHEM, V268, P14964; PALACIOS R, 1985, CELL, V41, P727, DOI 10.1016/S0092-8674(85)80053-2; PIETRZKOWSKI Z, 1992, CANCER RES, V52, P6447; PIETRZKOWSKI Z, 1992, CELL GROWTH DIFFER, V3, P199; PRAGER D, 1994, P NATL ACAD SCI USA, V91, P2181, DOI 10.1073/pnas.91.6.2181; Quesada AR, 1997, CLIN EXP METASTAS, V15, P26; Quinn KA, 1996, J BIOL CHEM, V271, P11477, DOI 10.1074/jbc.271.19.11477; RAIBOWOL K, 1989, CELL, V57, P393; RESNICOFF M, 1994, CANCER RES, V54, P2218; ROHLIK QT, 1987, BIOCHEM BIOPH RES CO, V149, P276, DOI 10.1016/0006-291X(87)91635-4; ROZENGURT E, 1986, SCIENCE, V234, P161, DOI 10.1126/science.3018928; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; Scotlandi K, 1996, CANCER RES, V56, P4570; Scotlandi K, 1998, CANCER RES, V58, P4127; SELL C, 1994, MOL CELL BIOL, V14, P3604, DOI 10.1128/MCB.14.6.3604; SELL C, 1993, P NATL ACAD SCI USA, V90, P11217, DOI 10.1073/pnas.90.23.11217; SINGH P, 1994, CANCER RES, V54, P6563; SPORN MB, 1985, NATURE, V313, P745, DOI 10.1038/313745a0; STEELEPERKINS G, 1988, J BIOL CHEM, V263, P11486; STEELEPERKINS G, 1990, BIOCHEM BIOPH RES CO, V171, P1244, DOI 10.1016/0006-291X(90)90819-9; STRONGIN AY, 1993, J BIOL CHEM, V268, P14033; TELFORD NA, 1990, MOL REPROD DEV, V27, P81, DOI 10.1002/mrd.1080270202; XIONG LM, 1992, P NATL ACAD SCI USA, V89, P5356, DOI 10.1073/pnas.89.12.5356; ZUCKER S, 1994, CLIN EXP METASTAS, V12, P13, DOI 10.1007/BF01784329	74	149	155	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 12	1999	274	11					6935	6945		10.1074/jbc.274.11.6935	http://dx.doi.org/10.1074/jbc.274.11.6935			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	175DV	10066747	hybrid			2022-12-25	WOS:000079078400019
J	Gutsche-Perelroizen, I; Lepault, J; Ott, A; Carlier, MF				Gutsche-Perelroizen, I; Lepault, J; Ott, A; Carlier, MF			Filament assembly from profilin-actin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							F-ACTIN; ATP HYDROLYSIS; ACANTHAMOEBA PROFILIN; SKELETAL-MUSCLE; BARBED ENDS; BETA-ACTIN; POLYMERIZATION; PROTEIN; MYOSIN; PURIFICATION	Profilin plays a major role in the assembly of actin filament at the barbed ends. The thermodynamic and kinetic parameters for barbed end assembly from profilin-actin have been measured turbidimetrically. Filament growth from profilin-actin requires MgATP to be bound to actin. No assembly is observed from profilin-CaATP-actin. The rate constant for association of profilin-actin to barbed ends is 30% lower than that of actin, and the critical concentration for F-actin assembly from profilin-actin units is 0.3 mu M under physiological ionic conditions. Barbed ends grow from profilin-actin with an ADP-P-i cap. Profilin does not cap the barbed ends and is not detectably incorporated into filaments. The EDC-cross-linked profilin-actin complex (PA(cov)) both copolymerizes with F-actin and undergoes spontaneous self-assembly, following a nucleation-growth process characterized by a critical concentration of 0.2 mu M under physiological conditions. The PA(cov) polymer is a helical filament that displays the same diffraction pattern as F-actin, with layer lines at 6 and 36 nm. The PA(cov) filaments bound phalloidin with the same kinetics as F-actin, bound myosin subfragment-1, and supported actin-activated ATPase of myosin subfragment-1, but they did not translocate in vitro along myosin-coated glass surfaces. These results are discussed in light of the current models of actin structure.	Inst Curie, Phys Sect, F-75005 Paris, France; Ctr Mol Genet, Lab Enzymol & Biochim Struct, F-91198 Gif Sur Yvette, France	UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie	Carlier, MF (corresponding author), Inst Curie, Phys Sect, 11 Rue Pierre & Marie Curie, F-75005 Paris, France.	carlier@lebs.cnrs-gif.fr	Lepault, Jean/AAN-8859-2020					Allen PG, 1996, BIOCHEMISTRY-US, V35, P14062, DOI 10.1021/bi961326g; CARLIER MF, 1987, J BIOL CHEM, V262, P3052; CARLIER MF, 1984, J BIOL CHEM, V259, P9983; CARLIER MF, 1988, J BIOL CHEM, V263, P817; CARLIER MF, 1991, J BIOL CHEM, V266, P1; Carlier MF, 1997, J CELL BIOL, V136, P1307, DOI 10.1083/jcb.136.6.1307; CARLSSON L, 1977, J MOL BIOL, V115, P465, DOI 10.1016/0022-2836(77)90166-8; CASELLA JF, 1986, J BIOL CHEM, V261, P915; Chik JK, 1996, J MOL BIOL, V263, P607, DOI 10.1006/jmbi.1996.0602; COMBEAU C, 1988, J BIOL CHEM, V263, P17429; COMBEAU C, 1992, J BIOL CHEM, V267, P14038; DETMERS P, 1981, J BIOL CHEM, V256, P99; Didry D, 1998, J BIOL CHEM, V273, P25602, DOI 10.1074/jbc.273.40.25602; Fievez S, 1997, BIOCHEMISTRY-US, V36, P11843, DOI 10.1021/bi971206o; Fievez S, 1997, BIOCHEMISTRY-US, V36, P11837, DOI 10.1021/bi971205w; FINKEL T, 1994, P NATL ACAD SCI USA, V91, P1510, DOI 10.1073/pnas.91.4.1510; HOLMES KC, 1990, NATURE, V347, P44, DOI 10.1038/347044a0; HUANG ZJ, 1992, ANAL BIOCHEM, V200, P199, DOI 10.1016/0003-2697(92)90299-M; KAISER DA, 1986, J CELL BIOL, V102, P221, DOI 10.1083/jcb.102.1.221; LORENZ M, 1993, J MOL BIOL, V234, P826, DOI 10.1006/jmbi.1993.1628; MALM B, 1984, FEBS LETT, V173, P399, DOI 10.1016/0014-5793(84)80813-3; MCLEANFLETCHER S, 1980, BIOCHEM BIOPH RES CO, V96, P18; MOCKRIN SC, 1980, BIOCHEMISTRY-US, V19, P5359, DOI 10.1021/bi00564a033; OOSAWA F, 1975, THERMODYNAMICS POLYM, P109; PANTALONI D, 1993, CELL, V75, P1007, DOI 10.1016/0092-8674(93)90544-Z; PERELROIZEN I, 1994, BIOCHEMISTRY-US, V33, P8472, DOI 10.1021/bi00194a011; Perelroizen I, 1996, J BIOL CHEM, V271, P12302, DOI 10.1074/jbc.271.21.12302; POLLARD TD, 1981, J CELL BIOL, V88, P654, DOI 10.1083/jcb.88.3.654; POLLARD TD, 1984, FEBS LETT, V170, P94, DOI 10.1016/0014-5793(84)81376-9; POLLARD TD, 1984, BIOCHEMISTRY-US, V23, P6631, DOI 10.1021/bi00321a054; PRING M, 1992, BIOCHEMISTRY-US, V31, P1827, DOI 10.1021/bi00121a035; ROZYCKI M, 1991, METHOD ENZYMOL, V196, P100; Schafer DA, 1996, J CELL BIOL, V135, P169, DOI 10.1083/jcb.135.1.169; SCHUTT CE, 1993, NATURE, V365, P810, DOI 10.1038/365810a0; SCHUTT CE, 1995, J STRUCT BIOL, V115, P186, DOI 10.1006/jsbi.1995.1043; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; Tang JX, 1996, J BIOL CHEM, V271, P8556, DOI 10.1074/jbc.271.15.8556; TOBACMAN LS, 1983, J BIOL CHEM, V258, P3207; VANDEKERCKHOVE JS, 1989, J CELL BIOL, V109, P619, DOI 10.1083/jcb.109.2.619; WINKELMANN DA, 1995, BIOPHYS J, V68, P2444, DOI 10.1016/S0006-3495(95)80426-1	40	68	70	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	1999	274	10					6234	6243		10.1074/jbc.274.10.6234	http://dx.doi.org/10.1074/jbc.274.10.6234			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172BQ	10037710	hybrid			2022-12-25	WOS:000078902800032
J	Kim, CH; Kim, HS; Cubells, JF; Kim, KS				Kim, CH; Kim, HS; Cubells, JF; Kim, KS			A previously undescribed intron and extensive 5 ' upstream sequence, but not Phox2a-mediated transactivation, are necessary for high level cell type-specific expression of the human norepinephrine transporter gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOPAMINE-BETA-HYDROXYLASE; RAT ADRENAL-MEDULLA; NERVE GROWTH-FACTOR; TRANSGENIC MICE; TYROSINE-HYDROXYLASE; MESSENGER-RNA; REGULATORY ELEMENTS; NEUROTRANSMITTER TRANSPORTERS; NORADRENALINE TRANSPORTER; SEROTONIN TRANSPORTER	The synaptic action of norepinephrine is terminated by NaCl-dependent uptake into presynaptic noradrenergic nerve endings, mediated by the norepinephrine transporter (NET), NET is expressed only in neuronal tissues that synthesize and secrete norepinephrine and in most cases is co-expressed with the norepinephrine-synthetic enzyme dopamine beta-hydroxylase (DBH), To understand the molecular mechanisms regulating human NET (hNET) gene expression, we isolated and characterized an hNET genomic clone encompassing approximately 9.5 kilobase pairs of the 5' upstream promoter region. Here we demonstrate that the hNET gene contains an as-yet-unidentified intron of 476 base pairs within the 5'-untranslated region. Furthermore, both primer extension and 5'-rapid amplification of cDNA ends analyses identified multiple transcription start sites from mRNAs expressed only in NET-expressing cell lines. The start sites clustered in two subdomains, each preceded by a TATA-like sequence motif, As expected for mature mRNAs, transcripts from most of these sites each contained an additional G residue at the 5' position. Together, the data strongly support the authenticity of these sites as the transcriptional start sites of hNET. We assembled hNET-chloramphenicol acetyltransferase reporter constructs containing different lengths of hNET 5' sequence in the presence or the absence of the first intron, Transient transfection assays indicated that the combination of the 5' upstream sequence and the first intron supported the highest level of noradrenergic cell-specific transcription. Forced expression of the paired-like homeodomain transcription factor Phox2a did not affect hNET promoter activity in NET-negative cell lines, in marked contrast to its effect on a DBH-chloramphenicol acetyltransferase reporter construct. Together with our previous studies suggesting a critical role of Phox2a for noradrenergic-specific expression of the DBH gene, these data support a model in which distinct, or partially distinct, molecular mechanisms regulate cell-specific expression of the NET and DBH genes.	Univ Tennessee, Coll Med, Dept Neurol, Memphis, TN 38163 USA; Univ Tennessee, Coll Med, Dept Anat & Neurobiol, Memphis, TN 38163 USA; Vet Affairs Connecticut Hlth Care Syst, Dept Psychiat, West Haven, CT 06516 USA; Yale Univ, Sch Med, West Haven, CT 06516 USA	University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Connecticut Healthcare System; Yale University	Kim, KS (corresponding author), Harvard Univ, McLean Hosp, Sch Med, Mol Neurobiol Lab, 115 Mill St, Belmont, MA 02178 USA.	kskim@mclean.harvard.edu	Cubells, Joe F./V-2543-2018		NIDA NIH HHS [DA 00167] Funding Source: Medline; NIMH NIH HHS [MH48866] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH048866, R29MH048866] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Amara S G, 1998, Adv Pharmacol, V42, P164; AMARA SG, 1993, ANNU REV NEUROSCI, V16, P73, DOI 10.1146/annurev.ne.16.030193.000445; Axelrod J, 1969, Prog Brain Res, V31, P21; Barker Eric L., 1995, P321; Bengel D, 1997, MOL BRAIN RES, V44, P286, DOI 10.1016/S0169-328X(96)00234-3; Bonisch H, 1998, Adv Pharmacol, V42, P183; Bradley CC, 1997, J NEUROCHEM, V69, P1356; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; Bruss M, 1997, MOL BRAIN RES, V52, P257, DOI 10.1016/S0169-328X(97)00267-2; CICCARONE V, 1989, CANCER RES, V49, P219; CUBELLS JF, 1995, J NEUROCHEM, V65, P502; CUBELLS JF, 1995, NEUROSCI LETT, V193, P189, DOI 10.1016/0304-3940(95)11699-W; DONOVAN DM, 1995, MOL BRAIN RES, V30, P327, DOI 10.1016/0169-328X(95)00018-N; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P3, DOI 10.1093/nar/20.1.3; FRIEDMAN S, 1965, J BIOL CHEM, V240, P4763; Fritz JD, 1998, J NEUROCHEM, V70, P2241; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GIROS B, 1993, TRENDS PHARMACOL SCI, V14, P43, DOI 10.1016/0165-6147(93)90029-J; GOODMAN RH, 1990, ANNU REV NEUROSCI, V13, P111, DOI 10.1146/annurev.neuro.13.1.111; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; HIRZMANN J, 1993, NUCLEIC ACIDS RES, V21, P3597, DOI 10.1093/nar/21.15.3597; Hormuzdi SG, 1998, MOL CELL BIOL, V18, P3368, DOI 10.1128/MCB.18.6.3368; HOYLE GW, 1994, J NEUROSCI, V14, P2455; ISHIGURO H, 1993, J BIOL CHEM, V268, P17987; ISRAEL Y, 1973, ANN NY ACAD SCI, V215, P38, DOI 10.1111/j.1749-6632.1973.tb28246.x; JONES KA, 1985, NATURE, V317, P179, DOI 10.1038/317179a0; Kawarai T, 1997, GENE, V195, P11, DOI 10.1016/S0378-1119(97)00131-5; Kim HS, 1998, J NEUROSCI, V18, P8247; KIM KS, 1994, J NEUROCHEM, V63, P834; KIM KS, 1994, J NEUROSCI, V14, P7200; KIM KS, 1995, PRACTICAL APPROACH G, V2, P151; KIM KT, 1993, J NEUROCHEM, V60, P946, DOI 10.1111/j.1471-4159.1993.tb03241.x; KIRSHNER N, 1957, J BIOL CHEM, V226, P207; Klimek V, 1997, J NEUROSCI, V17, P8451; KOBAYASHI K, 1992, P NATL ACAD SCI USA, V89, P1631, DOI 10.1073/pnas.89.5.1631; KOBAYASHI K, 1994, J BIOL CHEM, V269, P29725; KRANER SD, 1992, NEURON, V9, P37, DOI 10.1016/0896-6273(92)90218-3; LIN AMY, 1993, NEUROSCI LETT, V164, P71, DOI 10.1016/0304-3940(93)90860-N; LINGEN B, 1994, FEBS LETT, V342, P235, DOI 10.1016/0014-5793(94)80508-3; LORANG D, 1994, J NEUROSCI, V14, P4903; Lu D, 1996, ENDOCRINOLOGY, V137, P763, DOI 10.1210/en.137.2.763; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; Markel PD, 1997, GENOME RES, V7, P92, DOI 10.1101/gr.7.2.92; Marks D F, 1996, J Health Psychol, V1, P7, DOI 10.1177/135910539600100102; Matsuoka I, 1997, BRAIN RES, V776, P181, DOI 10.1016/S0006-8993(97)01016-0; MCMAHON A, 1990, J NEUROSCI RES, V25, P395, DOI 10.1002/jnr.490250317; MERCER EH, 1991, NEURON, V7, P703, DOI 10.1016/0896-6273(91)90274-4; MORI N, 1992, NEURON, V9, P45, DOI 10.1016/0896-6273(92)90219-4; Morin X, 1997, NEURON, V18, P411, DOI 10.1016/S0896-6273(00)81242-8; MORITA S, 1993, MOL BRAIN RES, V17, P239, DOI 10.1016/0169-328X(93)90007-C; PACHOLCZYK T, 1991, NATURE, V350, P350, DOI 10.1038/350350a0; Porzgen P, 1998, BBA-GENE STRUCT EXPR, V1398, P365, DOI 10.1016/S0167-4781(98)00072-4; PORZGEN P, 1995, BIOCHEM BIOPH RES CO, V215, P1145, DOI 10.1006/bbrc.1995.2582; RAJAVASHISTH TB, 1989, SCIENCE, V245, P640, DOI 10.1126/science.2562787; RAMAMOORTHY S, 1993, BIOCHEMISTRY-US, V32, P1346, DOI 10.1021/bi00056a021; REIS DJ, 1975, J PHARMACOL EXP THER, V193, P775; REIS DJ, 1974, BRAIN RES, V81, P380, DOI 10.1016/0006-8993(74)90956-1; ROESLER WJ, 1988, J BIOL CHEM, V263, P9063; ROSS RA, 1981, CELL MOL NEUROBIOL, V1, P301, DOI 10.1007/BF00710685; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHILDKRAUT JJ, 1965, AM J PSYCHIAT, V122, P509, DOI 10.1176/ajp.122.5.509; Schoenherr CJ, 1996, P NATL ACAD SCI USA, V93, P9881, DOI 10.1073/pnas.93.18.9881; Seo HM, 1996, J NEUROSCI, V16, P4102; SHASKUS J, 1992, J BIOL CHEM, V267, P18821; Smith AF, 1998, AM J PHYSIOL-CELL PH, V274, pC1188, DOI 10.1152/ajpcell.1998.274.5.C1188; SURI C, 1993, J NEUROSCI, V13, P1280; Tiveron MC, 1996, J NEUROSCI, V16, P7649; UHL GR, 1992, TRENDS NEUROSCI, V15, P265, DOI 10.1016/0166-2236(92)90068-J; VALARCHE I, 1993, DEVELOPMENT, V119, P881; Wakade AR, 1996, J PHYSIOL-LONDON, V494, P67, DOI 10.1113/jphysiol.1996.sp021476; Yang CY, 1998, J NEUROCHEM, V71, P1813	71	77	86	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	1999	274	10					6507	6518		10.1074/jbc.274.10.6507	http://dx.doi.org/10.1074/jbc.274.10.6507			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172BQ	10037744	hybrid			2022-12-25	WOS:000078902800066
J	Arbet-Engels, C; Tartare-Deckert, S; Eckhart, W				Arbet-Engels, C; Tartare-Deckert, S; Eckhart, W			C-terminal Src kinase associates with ligand-stimulated insulin-like growth factor-I receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST 2-HYBRID SYSTEM; TYROSINE KINASES; PROTEIN-KINASE; PHOSPHORYLATION; CELLS; SUBSTRATE-1; PP60C-SRC; CSK; BINDING; SITES	Increased expression of the insulin-like growth factor-I receptor (IGF-IR) protein-tyrosine kinase occurs in several kinds of cancer and induces neoplastic transformation in fibroblast cell lines. The transformed phenotype can be reversed by interfering with the function of the IGF-IR. The IGF-IR is required for transformation by a number of viral and cellular oncoproteins, including SV40 large T antigen, Ras, Raf, and Src. The IGF-IR is a substrate for Src in vitro and is phosphorylated in v-Src-transformed cells. Ne observed that the IGF-IR and IR associated with the C-terminal Src kinase (CSK) following ligand stimulation. We found that the SH2 domain of CSK binds to the tyrosine-phosphorylated form of IGF-IR and IR We determined the tyrosine residues in the IGF-IR and in the IR responsible for this interaction. We also observed that fibroblasts stimulated with IGF-I or insulin showed a rapid and transient decrease in c-Src tyrosine kinase activity. The results suggest that c-Src and CSK are involved in IGF-IR and IR signaling and that the interaction of CSK with the IGF-IR may play a role in the decrease in c-Src activity following IGF-I stimulation.	Salk Inst Biol Studies, Mol Biol & Virol Lab, La Jolla, CA 92037 USA	Salk Institute	Arbet-Engels, C (corresponding author), Salk Inst Biol Studies, Mol Biol & Virol Lab, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.	arbet@axp1.salk.edu	TARTARE-DECKERT, Sophie/P-6057-2015	TARTARE-DECKERT, Sophie/0000-0001-8680-5720	NATIONAL CANCER INSTITUTE [P30CA014195, R37CA013884, R01CA013884] Funding Source: NIH RePORTER; NCI NIH HHS [CA 14195, CA 13884] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ausubel FM, 1992, CURRENT PROTOCOLS MO; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; BALTENSPERGER K, 1993, SCIENCE, V260, P1950, DOI 10.1126/science.8391166; Bartel P. L., 1993, CELLULAR INTERACTION, P153; Baserga R, 1997, BBA-REV CANCER, V1332, pF105, DOI 10.1016/S0304-419X(97)00007-3; BERGMAN M, 1992, EMBO J, V11, P2919, DOI 10.1002/j.1460-2075.1992.tb05361.x; BOYCE BF, 1992, J CLIN INVEST, V90, P1622, DOI 10.1172/JCI116032; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; Broome MA, 1997, ONCOGENE, V14, P17, DOI 10.1038/sj.onc.1200798; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; CARTWRIGHT CA, 1987, MOL CELL BIOL, V7, P1830, DOI 10.1128/MCB.7.5.1830; COOPER JA, 1984, J BIOL CHEM, V259, P7835; DENTON RM, 1995, EUR J BIOCHEM, V227, P597, DOI 10.1111/j.1432-1033.1995.tb20179.x; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FRANCIS GL, 1992, J MOL ENDOCRINOL, V8, P213, DOI 10.1677/jme.0.0080213; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GUTHRIE C, 1991, METHOD ENZYMOL, V194, P12; HOWELL BW, 1994, MOL CELL BIOL, V14, P5402, DOI 10.1128/MCB.14.8.5402; KAPLAN KB, 1994, EMBO J, V13, P4745, DOI 10.1002/j.1460-2075.1994.tb06800.x; KAPLAN KB, 1995, GENE DEV, V9, P1505, DOI 10.1101/gad.9.12.1505; KOZMA LM, 1990, MOL CELL BIOL, V10, P3626, DOI 10.1128/MCB.10.7.3626; KUHNE MR, 1993, J BIOL CHEM, V268, P11479; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; Leventhal PS, 1997, J BIOL CHEM, V272, P5214, DOI 10.1074/jbc.272.8.5214; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; LOWE C, 1993, P NATL ACAD SCI USA, V90, P4485, DOI 10.1073/pnas.90.10.4485; Lowell CA, 1996, GENE DEV, V10, P1845, DOI 10.1101/gad.10.15.1845; MORGAN DO, 1989, CELL, V57, P775, DOI 10.1016/0092-8674(89)90792-7; MSUTELIN T, 1994, SRC FAMILY TRYOSINE; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; NEET K, 1995, MOL CELL BIOL, V15, P4908; OKADA M, 1989, J BIOL CHEM, V264, P20886; SABE H, 1992, P NATL ACAD SCI USA, V89, P2190, DOI 10.1073/pnas.89.6.2190; SABE H, 1994, P NATL ACAD SCI USA, V91, P3984, DOI 10.1073/pnas.91.9.3984; Sasaoka T, 1996, ENDOCRINOLOGY, V137, P4427, DOI 10.1210/en.137.10.4427; SASAOKA T, 1994, J BIOL CHEM, V269, P13689; SHENOY S, 1989, CELL, V57, P763, DOI 10.1016/0092-8674(89)90791-5; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; Sun XJ, 1996, J BIOL CHEM, V271, P10583, DOI 10.1074/jbc.271.18.10583; TARTAREDECKERT S, 1995, J BIOL CHEM, V270, P23456, DOI 10.1074/jbc.270.40.23456; TartareDeckert S, 1996, ENDOCRINOLOGY, V137, P1019, DOI 10.1210/en.137.3.1019; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; Tobe K, 1996, MOL CELL BIOL, V16, P4765; TOBE K, 1993, J BIOL CHEM, V268, P11167; TWAMLEYSTEIN GM, 1993, P NATL ACAD SCI USA, V90, P7696, DOI 10.1073/pnas.90.16.7696; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0	50	54	55	1	2	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 26	1999	274	9					5422	5428		10.1074/jbc.274.9.5422	http://dx.doi.org/10.1074/jbc.274.9.5422			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	170KG	10026153	hybrid			2022-12-25	WOS:000078804400024
J	Wakabayashi, H; Natsuka, S; Mega, T; Otsuki, N; Isaji, M; Naotsuka, M; Koyama, S; Kanamori, T; Sakai, K; Hase, S				Wakabayashi, H; Natsuka, S; Mega, T; Otsuki, N; Isaji, M; Naotsuka, M; Koyama, S; Kanamori, T; Sakai, K; Hase, S			Novel proteoglycan linkage tetrasaccharides of human urinary soluble thrombomodulin, SO4-3GlcA beta 1-3Gal beta 1-3(+/- Sia alpha 2-6)Gal beta 1-4Xyl	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERFORMANCE LIQUID-CHROMATOGRAPHY; RECOMBINANT HUMAN THROMBOMODULIN; FALCIPARUM-INFECTED ERYTHROCYTES; HNK-1 CARBOHYDRATE EPITOPE; SUGAR CHAINS; CHONDROITIN SULFATE; PROTEIN-C; OLIGOSACCHARIDES; GLYCOSAMINOGLYCAN; GLYCOPROTEINS	O-linked sugar chains with xylose as a reducing end linked to human urinary soluble thrombomodulin were studied. Sugar chains were Liberated by hydrazinolysis followed by N-acetylation and tagged with 2-aminopyridine. Two fractions containing pyridylaminated Xyl as a reducing end were collected. Their structures were determined by partial acid hydrolysis, two-dimensional sugar mapping combined with exoglycosidase digestions, methylation analysis, mass spectrometry, and NMR as SO4-3GlcA beta 1-3Gal beta 1-3(+/-Sia alpha 2-6)Gal beta 1-4Xyl. These sugar chains could bind to an HNK-1 monoclonal antibody. This is believed to be the first example of a proteoglycan linkage tetrasaccharide with glucuronic acid 3-sulfate and sialic acid.	Osaka Univ, Grad Sch Sci, Dept Chem, Toyonaka, Osaka 5600043, Japan; Mochida Pharmaceut Co Ltd, Pharmaceut Lab, Fujieda, Shizuoka 4268640, Japan; Mochida Pharmaceut Co Ltd, Biosci Res Lab, Kita Ku, Tokyo 1158515, Japan	Osaka University; Mochida Pharmaceutical Co Ltd; Mochida Pharmaceutical Co Ltd	Hase, S (corresponding author), Osaka Univ, Grad Sch Sci, Dept Chem, Toyonaka, Osaka 5600043, Japan.		Natsuka, Shunji/L-9330-2018	Natsuka, Shunji/0000-0003-1726-8946				Bakker H, 1997, J BIOL CHEM, V272, P29942, DOI 10.1074/jbc.272.47.29942; Dudek AZ, 1997, J BIOL CHEM, V272, P31785, DOI 10.1074/jbc.272.50.31785; Edano T, 1998, INT J BIOCHEM CELL B, V30, P77, DOI 10.1016/S1357-2725(97)00078-2; ESMON CT, 1995, FASEB J, V9, P946, DOI 10.1096/fasebj.9.10.7615164; Florea D, 1997, CARBOHYD RES, V302, P179, DOI 10.1016/S0008-6215(97)00129-8; GERLITZ B, 1993, BIOCHEM J, V295, P131, DOI 10.1042/bj2950131; Gysin J, 1997, MOL BIOCHEM PARASIT, V88, P267, DOI 10.1016/S0166-6851(97)00082-0; HAKOMORI SI, 1964, J BIOCHEM-TOKYO, V55, P205; HARA S, 1987, ANAL BIOCHEM, V164, P138, DOI 10.1016/0003-2697(87)90377-0; HASE S, 1994, METHOD ENZYMOL, V230, P225; HASE S, 1992, BIOSCI BIOTECH BIOCH, V56, P1676, DOI 10.1271/bbb.56.1676; HASE S, 1978, BIOCHEM BIOPH RES CO, V85, P257, DOI 10.1016/S0006-291X(78)80037-0; JACKSON DE, 1994, EUR J BIOCHEM, V221, P1079, DOI 10.1111/j.1432-1033.1994.tb18827.x; Kitagawa H, 1997, GLYCOBIOLOGY, V7, P531, DOI 10.1093/glycob/7.4.531; KURAYA N, 1992, J BIOCHEM, V112, P122, DOI 10.1093/oxfordjournals.jbchem.a123850; LIN JH, 1994, J BIOL CHEM, V269, P25021; Makino Y, 1996, ANAL BIOCHEM, V238, P54, DOI 10.1006/abio.1996.0250; MEGA T, 1991, J BIOCHEM-TOKYO, V109, P600, DOI 10.1093/oxfordjournals.jbchem.a123426; MEGA T, 1992, J BIOCHEM-TOKYO, V111, P396, DOI 10.1093/oxfordjournals.jbchem.a123768; Nakano M, 1998, THROMB HAEMOSTASIS, V79, P331; NAWA K, 1990, BIOCHEM BIOPH RES CO, V171, P729, DOI 10.1016/0006-291X(90)91207-9; Ong E, 1998, J BIOL CHEM, V273, P5190, DOI 10.1074/jbc.273.9.5190; PARKINSON JF, 1992, BIOCHEM J, V283, P151, DOI 10.1042/bj2830151; Rogerson SJ, 1997, EXP PARASITOL, V86, P8, DOI 10.1006/expr.1996.4142; SLOMIANY A, 1981, BIOCHEM BIOPH RES CO, V100, P778, DOI 10.1016/S0006-291X(81)80242-2; SUGAHARA K, 1992, J BIOL CHEM, V267, P6027; SUGAHARA K, 1989, P 10 INT S GLYC SEPT, P322; SUZUKI K, 1987, EMBO J, V6, P1891, DOI 10.1002/j.1460-2075.1987.tb02448.x; Takagaki K, 1997, J BIOCHEM-TOKYO, V122, P1129; Takahashi Y, 1997, THROMB HAEMOSTASIS, V77, P789; TAKAHASHI Y, 1995, THROMB HAEMOSTASIS, V73, P805; Voshol H, 1996, J BIOL CHEM, V271, P22957, DOI 10.1074/jbc.271.38.22957; YAMAMOTO S, 1993, J BIOCHEM-TOKYO, V113, P433, DOI 10.1093/oxfordjournals.jbchem.a124063	33	39	40	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 26	1999	274	9					5436	5442		10.1074/jbc.274.9.5436	http://dx.doi.org/10.1074/jbc.274.9.5436			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	170KG	10026155	hybrid			2022-12-25	WOS:000078804400026
J	Jacob, R; Preuss, U; Panzer, P; Alfalah, M; Quack, S; Roth, MG; Naim, H; Naim, HY				Jacob, R; Preuss, U; Panzer, P; Alfalah, M; Quack, S; Roth, MG; Naim, H; Naim, HY			Hierarchy of sorting signals in chimeras of intestinal lactase-phlorizin hydrolase and the influenza virus hemagglutinin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CANINE KIDNEY-CELLS; POLYMERIC IMMUNOGLOBULIN RECEPTOR; POLARIZED EPITHELIAL-CELLS; AMYLOID PRECURSOR PROTEIN; AMINO-ACID CHANGE; MDCK CELLS; CYTOPLASMIC DOMAIN; PHLORHIZIN HYDROLASE; INTERNALIZATION SIGNALS; HIPPOCAMPAL-NEURONS	Lactase-phlorizin hydrolase (LPH) is an apical protein in intestinal cells, The location of sorting signals in LPR was investigated by preparing a series of mutants that lacked the LPH cytoplasmic domain or had the cytoplasmic domain of LPH replaced by sequences that comprised basolateral targeting signals and overlapping internalization signals of various potency. These signals are mutants of the cytoplasmic domain of the influenza hemagglutinin (HA), which have been shown to be dominant in targeting HA to the basolateral membrane. The LPH-HA chimeras were expressed in Madin-Darby canine kidney (MDCK) and colon carcinoma (Caco-2) cells, and their transport to the cell surface was analyzed. All of the LPH mutants were targeted correctly to the apical membrane, Furthermore, the LPH-HA chimeras were internalized, indicating that the HA tails were available to interact with the cytoplasmic components of clathrin-coated pits. The introduction of a strong basolateral sorting signal into LPH was not sufficient to override the strong apical signals of the LPH external domain or transmembrane domains. These results show that basolateral sorting signals are not always dominant over apical sorting signals in proteins that contain each and suggest that sorting of basolateral from apical proteins occurs within a common compartment where competition for sorting signals can occur.	Hannover Sch Vet Med, Dept Physiol Chem, D-30559 Hannover, Germany; Univ Dusseldorf, Prot Secret Grp, D-40225 Dusseldorf, Germany; Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75235 USA; Univ Zurich, Inst Mol Biol Div 1, CH-8057 Zurich, Switzerland	University of Veterinary Medicine Hannover, Foundation; Heinrich Heine University Dusseldorf; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Zurich	Naim, HY (corresponding author), Hannover Sch Vet Med, Dept Physiol Chem, Bunteweg 17, D-30559 Hannover, Germany.		Jacob, Ralf/B-8163-2011; Al Falah, Dr. Marwan/C-6281-2011	Roth, Michael/0000-0002-9056-332X				Alonso MA, 1997, J BIOL CHEM, V272, P30748, DOI 10.1074/jbc.272.49.30748; AROETI B, 1993, J CELL BIOL, V123, P1149, DOI 10.1083/jcb.123.5.1149; Ball JM, 1997, AIDS RES HUM RETROV, V13, P665, DOI 10.1089/aid.1997.13.665; BREWER CB, 1991, J CELL BIOL, V114, P413, DOI 10.1083/jcb.114.3.413; BROWN DA, 1989, SCIENCE, V245, P1499, DOI 10.1126/science.2571189; DANIELSEN EM, 1995, BIOCHEMISTRY-US, V34, P1596, DOI 10.1021/bi00005a016; DANIELSEN EM, 1984, BIOCHEM BIOPH RES CO, V122, P82; DEHOOP M, 1995, J CELL BIOL, V130, P1447, DOI 10.1083/jcb.130.6.1447; DOTTI CG, 1991, NATURE, V349, P158, DOI 10.1038/349158a0; DOTTI CG, 1990, CELL, V62, P63, DOI 10.1016/0092-8674(90)90240-F; FRANSEN JAM, 1991, J CELL BIOL, V115, P45, DOI 10.1083/jcb.115.1.45; GEFFEN I, 1993, J BIOL CHEM, V268, P20772; GONZALEZ A, 1993, J BIOL CHEM, V268, P6662; HAASS C, 1995, J CELL BIOL, V128, P537, DOI 10.1083/jcb.128.4.537; HAURI HP, 1985, J CELL BIOL, V101, P838, DOI 10.1083/jcb.101.3.838; HOBERT M, 1995, J CELL PHYSIOL, V162, P434, DOI 10.1002/jcp.1041620316; HONING S, 1995, J CELL BIOL, V128, P321, DOI 10.1083/jcb.128.3.321; HORTON RM, 1990, BIOTECHNIQUES, V8, P528; Huang XF, 1997, J BIOL CHEM, V272, P27598, DOI 10.1074/jbc.272.44.27598; HUNZIKER W, 1991, CELL, V66, P907, DOI 10.1016/0092-8674(91)90437-4; Jacob R, 1996, EUR J BIOCHEM, V236, P789, DOI 10.1111/j.1432-1033.1996.t01-1-00789.x; JACOB R, 1994, J BIOL CHEM, V269, P2712; Kundu A, 1996, J VIROL, V70, P6508, DOI 10.1128/JVI.70.9.6508-6515.1996; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAZAROVITS J, 1988, CELL, V53, P743, DOI 10.1016/0092-8674(88)90092-X; LEBIVIC A, 1990, J CELL BIOL, V110, P1533, DOI 10.1083/jcb.110.5.1533; LeGall AH, 1997, J BIOL CHEM, V272, P4559, DOI 10.1074/jbc.272.7.4559; Lin S, 1997, J BIOL CHEM, V272, P26300, DOI 10.1074/jbc.272.42.26300; Lin SS, 1998, J CELL BIOL, V142, P51, DOI 10.1083/jcb.142.1.51; LISANTI MP, 1989, J CELL BIOL, V109, P2145, DOI 10.1083/jcb.109.5.2145; LISANTI MP, 1988, P NATL ACAD SCI USA, V85, P9557, DOI 10.1073/pnas.85.24.9557; LOTTAZ D, 1992, FEBS LETT, V313, P270, DOI 10.1016/0014-5793(92)81207-3; LOW SH, 1991, J BIOL CHEM, V266, P13391; MANTEI N, 1988, EMBO J, V7, P2705, DOI 10.1002/j.1460-2075.1988.tb03124.x; MATLIN KS, 1984, J CELL BIOL, V99, P2131, DOI 10.1083/jcb.99.6.2131; Moolenaar CEC, 1997, J CELL SCI, V110, P557; MOSTOV KE, 1986, CELL, V47, P359, DOI 10.1016/0092-8674(86)90592-1; NAIM HY, 1994, METHOD CELL BIOL, V43, P113; NAIM HY, 1995, J CELL BIOL, V129, P1241, DOI 10.1083/jcb.129.5.1241; NAIM HY, 1988, J BIOL CHEM, V263, P7242; NAIM HY, 1987, BIOCHEM J, V241, P427, DOI 10.1042/bj2410427; NAIM HY, 1991, J BIOL CHEM, V266, P12313; Naim HY, 1996, EUR J CELL BIOL, V70, P198; NAIM HY, 1994, J BIOL CHEM, V269, P3928; NELSON WJ, 1992, SCIENCE, V258, P948, DOI 10.1126/science.1439806; Odorizzi G, 1997, J CELL BIOL, V137, P1255, DOI 10.1083/jcb.137.6.1255; Ouwendijk J, 1998, J BIOL CHEM, V273, P6650, DOI 10.1074/jbc.273.12.6650; Panzer P, 1998, J BIOL CHEM, V273, P13861, DOI 10.1074/jbc.273.22.13861; PRILL V, 1993, EMBO J, V12, P2181, DOI 10.1002/j.1460-2075.1993.tb05866.x; RAGNO P, 1992, EXP CELL RES, V203, P236, DOI 10.1016/0014-4827(92)90060-L; RODRIGUEZBOULAN E, 1992, ANNU REV CELL BIOL, V8, P395, DOI 10.1146/annurev.cb.08.110192.002143; ROTH MG, 1983, CELL, V33, P435, DOI 10.1016/0092-8674(83)90425-7; Sambrook J., 2002, MOL CLONING LAB MANU; SCHEIFFELE P, 1995, NATURE, V378, P96, DOI 10.1038/378096a0; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; SOOLE KL, 1992, J CELL SCI, V102, P495; THOMAS DC, 1994, J BIOL CHEM, V269, P15732; THOMAS DC, 1993, J BIOL CHEM, V268, P3313; Tienari PJ, 1996, EMBO J, V15, P5218, DOI 10.1002/j.1460-2075.1996.tb00907.x; ULLRICH O, 1991, J BIOL CHEM, V266, P3518; WANDINGERNESS A, 1990, J CELL BIOL, V111, P987, DOI 10.1083/jcb.111.3.987; Yeaman C, 1997, J CELL BIOL, V139, P929, DOI 10.1083/jcb.139.4.929	62	34	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 19	1999	274	12					8061	8067		10.1074/jbc.274.12.8061	http://dx.doi.org/10.1074/jbc.274.12.8061			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	178LU	10075706	hybrid			2022-12-25	WOS:000079268100065
J	Lai, CF; Ripperger, J; Wang, YP; Kim, H; Hawley, RB; Baumann, H				Lai, CF; Ripperger, J; Wang, YP; Kim, H; Hawley, RB; Baumann, H			The STAT3-independent signaling pathway by glycoprotein 130 in hepatic cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE-PHASE RESPONSE; CYTOKINE RECEPTOR SUPERFAMILY; INHIBITORY FACTOR-RECEPTOR; ACTIVATED PROTEIN-KINASE; GENE-EXPRESSION; GROWTH-FACTOR; HEMATOPOIETIN RECEPTORS; INTERLEUKIN-6 RECEPTOR; SERINE PHOSPHORYLATION; CYTOPLASMIC DOMAIN	Interleukin (IL)-6 is a major regulator of hepatic acute-phase plasma protein (APP) genes. The membrane-proximal 133-amino acid cytoplasmic domain of glycoprotein (gp) 130, containing one copy of the Box3 motif, is sufficient to transmit a productive signal to endogenous APP genes in rat hepatoma H-35 cells. In contrast, a mutant gp130 domain lacking the Box3 motif activates Janus kinases to a normal level but fails to activate signal transducer and activator of transcription 3 and to up-regulate a number of APP genes, including thiostatin, fibrinogen, hemopexin, and haptoglobin. However, in the absence of Box3, gp130 still stimulates the expression of alpha(2)-macroglobulin and synergizes with IL-1 to up-regulate alpha(1)-acid glycoprotein, The Box3 motif is not required for activation of the SH2-containing protein tyrosine phosphatase 2 or the mitogen-activated protein kinase (MAPK), nor is the immediate induction of egr-1 and junB significantly altered. Surprisingly, gp130 without any functional Box3 stimulates prolonged activation of MAPK, leading to an extended period of up-regulation of egr-1 and to an extracellularly regulated kinase-mediated reduction in the IL-B-stimulated production of thiostatin, IL-6 reduces proliferation of H-35 cells through signaling by the Box3, In addition, cells expressing Box3-deficient gp130 showed distinct morphologic changes upon receptor activation. Taken together, these results indicate that Box3-derived and Box3-independent signals cooperate in the control of hepatic APP genes and that Box3 may be involved in the modulation of MAPK activity in gp130 signaling.	Roswell Pk Canc Inst, Dept Mol & Cellular Biol, Buffalo, NY 14263 USA; Toronto Hosp, Oncol Gene Therapy Program, Toronto, ON M5G 2M1, Canada	Roswell Park Cancer Institute; University of Toronto; University Toronto Affiliates; University Health Network Toronto	Baumann, H (corresponding author), Roswell Pk Canc Inst, Dept Mol & Cellular Biol, Buffalo, NY 14263 USA.	baumann@sc3101.med.buffalo.edu		Hawley, Robert/0000-0003-3512-5818; Kim, Hongkyun/0000-0002-4879-7122	NCI NIH HHS [CA26122, CA16056] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016056, R01CA026122] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKIRA S, 1993, ADV IMMUNOL, V54, P1, DOI 10.1016/S0065-2776(08)60532-5; AKIRA S, 1994, CELL, V77, P63, DOI 10.1016/0092-8674(94)90235-6; ASTALDI GCB, 1980, J IMMUNOL, V125, P1411; BAUMANN H, 1994, IMMUNOL TODAY, V15, P74, DOI 10.1016/0167-5699(94)90137-6; BAUMANN H, 1989, ANN NY ACAD SCI, V557, P280; BAUMANN H, 1988, METHOD ENZYMOL, V163, P566; BAUMANN H, 1994, MOL CELL BIOL, V14, P138, DOI 10.1128/MCB.14.1.138; BAUMANN H, 1994, J BIOL CHEM, V269, P16297; BAUMANN H, 1991, J BIOL CHEM, V266, P20390; Boyer B, 1997, EMBO J, V16, P5904, DOI 10.1093/emboj/16.19.5904; CAMPOS SP, 1992, MOL CELL BIOL, V12, P1789, DOI 10.1128/MCB.12.4.1789; DALMON J, 1993, MOL CELL BIOL, V13, P1183, DOI 10.1128/MCB.13.2.1183; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; FOWLKES DM, 1984, P NATL ACAD SCI-BIOL, V81, P2313, DOI 10.1073/pnas.81.8.2313; Fukada T, 1996, IMMUNITY, V5, P449, DOI 10.1016/S1074-7613(00)80501-4; FUKUNAGA R, 1990, P NATL ACAD SCI USA, V87, P8702, DOI 10.1073/pnas.87.22.8702; GANTER U, 1989, EMBO J, V8, P3773, DOI 10.1002/j.1460-2075.1989.tb08554.x; GEARING DP, 1991, EMBO J, V10, P2839, DOI 10.1002/j.1460-2075.1991.tb07833.x; Gerhartz C, 1996, J BIOL CHEM, V271, P12991, DOI 10.1074/jbc.271.22.12991; HATTORI M, 1990, P NATL ACAD SCI USA, V87, P2364, DOI 10.1073/pnas.87.6.2364; HATTORI M, 1993, AM J PHYSIOL, V264, pG95, DOI 10.1152/ajpgi.1993.264.1.G95; Hawley RG, 1996, ANN NY ACAD SCI, V795, P341, DOI 10.1111/j.1749-6632.1996.tb52687.x; HIBI M, 1990, CELL, V63, P1149, DOI 10.1016/0092-8674(90)90411-7; Hirano T, 1998, Int Rev Immunol, V16, P249; HUANG JH, 1990, MOL CELL BIOL, V10, P3619, DOI 10.1128/MCB.10.7.3619; Ihara S, 1997, EMBO J, V16, P5345, DOI 10.1093/emboj/16.17.5345; IHLE JN, 1995, TRENDS GENET, V11, P69, DOI 10.1016/S0168-9525(00)89000-9; IHLE JN, 1994, TRENDS BIOCHEM SCI, V19, P222, DOI 10.1016/0968-0004(94)90026-4; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; Kim HK, 1998, MOL CELL BIOL, V18, P1525, DOI 10.1128/MCB.18.3.1525; Kordula T, 1996, J BIOL CHEM, V271, P6752, DOI 10.1074/jbc.271.12.6752; Lai CF, 1996, J BIOL CHEM, V271, P13968, DOI 10.1074/jbc.271.24.13968; LAI CF, 1995, J BIOL CHEM, V270, P23254, DOI 10.1074/jbc.270.40.23254; LAI CF, 1995, J BIOL CHEM, V270, P14847, DOI 10.1074/jbc.270.25.14847; MARINKOVIC S, 1990, MOL CELL BIOL, V10, P1573, DOI 10.1128/MCB.10.4.1573; Matsumura I, 1998, MOL CELL BIOL, V18, P4282, DOI 10.1128/MCB.18.7.4282; MILLAND J, 1990, AM J PHYSIOL, V259, pG340, DOI 10.1152/ajpgi.1990.259.3.G340; Mosley B, 1996, J BIOL CHEM, V271, P32635, DOI 10.1074/jbc.271.51.32635; MULLBERG J, 1993, EUR J IMMUNOL, V23, P473, DOI 10.1002/eji.1830230226; MURAKAMI M, 1993, SCIENCE, V260, P1808, DOI 10.1126/science.8511589; NAKAJIMA T, 1993, P NATL ACAD SCI USA, V90, P2207, DOI 10.1073/pnas.90.6.2207; NORDAN RP, 1986, SCIENCE, V233, P566, DOI 10.1126/science.3726549; OLIVIERO S, 1989, EMBO J, V8, P1145, DOI 10.1002/j.1460-2075.1989.tb03485.x; PAONESSA G, 1995, EMBO J, V14, P1942, DOI 10.1002/j.1460-2075.1995.tb07186.x; RESZKA AA, 1995, P NATL ACAD SCI USA, V92, P8881, DOI 10.1073/pnas.92.19.8881; RIPPERGER JA, 1995, J BIOL CHEM, V270, P29998, DOI 10.1074/jbc.270.50.29998; ROKITA H, 1990, COMP BIOCHEM PHYS A, V95, P41, DOI 10.1016/0300-9629(90)90007-F; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; Takeda K, 1997, P NATL ACAD SCI USA, V94, P3801, DOI 10.1073/pnas.94.8.3801; Tilg H, 1997, IMMUNOL TODAY, V18, P428, DOI 10.1016/S0167-5699(97)01103-1; VANSNICK J, 1990, ANNU REV IMMUNOL, V8, P253, DOI 10.1146/annurev.immunol.8.1.253; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x; WANG YP, 1995, BLOOD, V86, P1671, DOI 10.1182/blood.V86.5.1671.bloodjournal8651671; WARD LD, 1994, J BIOL CHEM, V269, P23286; WeberNordt RM, 1996, J BIOL CHEM, V271, P27954, DOI 10.1074/jbc.271.44.27954; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; Wen ZL, 1997, NUCLEIC ACIDS RES, V25, P2062, DOI 10.1093/nar/25.11.2062; WILSON DR, 1990, MOL CELL BIOL, V10, P6181, DOI 10.1128/MCB.10.12.6181; Yamanaka Y, 1996, EMBO J, V15, P1557, DOI 10.1002/j.1460-2075.1996.tb00500.x; YAMASAKI K, 1988, SCIENCE, V241, P825, DOI 10.1126/science.3136546; Yang SH, 1998, EMBO J, V17, P1740, DOI 10.1093/emboj/17.6.1740; Zhang DX, 1996, J BIOL CHEM, V271, P9503, DOI 10.1074/jbc.271.16.9503	63	31	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	1999	274	12					7793	7802		10.1074/jbc.274.12.7793	http://dx.doi.org/10.1074/jbc.274.12.7793			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	178LU	10075671	hybrid			2022-12-25	WOS:000079268100030
J	Cupillard, L; Mulherkar, R; Gomez, N; Kadam, S; Valentin, E; Lazdunski, M; Lambeau, G				Cupillard, L; Mulherkar, R; Gomez, N; Kadam, S; Valentin, E; Lazdunski, M; Lambeau, G			Both group IB and group IIA secreted phospholipases A(2) are natural ligands of the mouse 180-kDa M-type receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-MOLECULAR-WEIGHT; FAMILIAL ADENOMATOUS POLYPOSIS; TUMOR-NECROSIS-FACTOR; AMINO-ACID-SEQUENCE; ENHANCING FACTOR; MEMBRANE-RECEPTOR; PANCREATIC PHOSPHOLIPASE-A2; TOXIC PHOSPHOLIPASES-A2; STRUCTURAL ELEMENTS; CHROMOSOME 1P35-36	Snake venom and mammalian secreted phospholipases A(2) (sPLA(2)s) have been associated with toxic (neurotoxicity, myotoxicity, etc.), pathological (inflammation, cancer, etc.), and physiological (proliferation, contraction, secretion, etc.) processes. Specific membrane receptors (M and N types) for sPLA(2)s have been initially identified with snake venom sPLA(2)s as ligands, and the M-type 180-kDa receptor was cloned from different animal species. This paper addresses the problem of the endogenous ligands of the M-type receptor. Recombinant group IB and group ILA. sPLA(2)s from human and mouse species have been prepared and analyzed for their binding properties to M-type receptors from differ ent animal species. Both mouse group IB and group ILA sPLA(2)s are high affinity ligands (in the 1-10 nM range) for the mouse M-type receptor. These two sPLA(2)s are expressed in the mouse tissues where the M-type receptor is also expressed, making it likely that both types of sPLA(2)s are physiological ligands of the mouse M-type receptor. This conclusion does not hold for human group IB and IIA sPLA(2)s and the cloned human M-type receptor. The two mouse sPLA(2)s have relatively high affinities for the mouse M-type receptor, but they can have much lower affinities for receptors from other animal species, indicating that species specificity exists for sPLA(2) binding to M-type receptors, Caution should thus be exerted in avoiding mixing sPLA(2)s, cells, or tissues from different animal species in studies of the biological roles of mammalian sPLA(2)s associated with an action through their membrane receptors.	CNRS, Inst Pharmacol Mol & Cellulaire, UPR 411, F-06560 Valbonne, France; Tata Mem Ctr, Canc Res Inst, Lab Genet Engn, Parel 400012, Mumbai, India	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur; Tata Memorial Centre (TMC)	Lazdunski, M (corresponding author), CNRS, Inst Pharmacol Mol & Cellulaire, UPR 411, 660 Route Lucioles, F-06560 Valbonne, France.		Lambeau, Gerard/GRJ-5624-2022	Lambeau, Gerard/0000-0002-9239-518X				Abe T, 1997, INT J CANCER, V74, P245, DOI 10.1002/(SICI)1097-0215(19970620)74:3<245::AID-IJC2>3.0.CO;2-Z; ANCIAN P, 1995, BIOCHEMISTRY-US, V34, P13146, DOI 10.1021/bi00040a028; ANCIAN P, 1995, J BIOL CHEM, V270, P8963, DOI 10.1074/jbc.270.15.8963; ARITA H, 1991, J BIOL CHEM, V266, P19139; Balboa MA, 1996, J BIOL CHEM, V271, P32381, DOI 10.1074/jbc.271.50.32381; BROUCKAERT P, 1993, IMMUNOBIOLOGY, V187, P317, DOI 10.1016/S0171-2985(11)80347-5; CHEN J, 1994, J BIOL CHEM, V269, P2365; CHEN J, 1994, J BIOL CHEM, V269, P23018; Cormier RT, 1997, NAT GENET, V17, P88, DOI 10.1038/ng0997-88; Cupillard L, 1997, J BIOL CHEM, V272, P15745, DOI 10.1074/jbc.272.25.15745; DAVIDSON FF, 1990, J MOL EVOL, V31, P228, DOI 10.1007/BF02109500; DEHAAS GH, 1968, BIOCHIM BIOPHYS ACTA, V159, P103, DOI 10.1016/0005-2744(68)90248-9; DENNIS EA, 1994, J BIOL CHEM, V269, P13057; Dennis EA, 1997, TRENDS BIOCHEM SCI, V22, P1, DOI 10.1016/S0968-0004(96)20031-3; DESAI SJ, 1991, HISTOCHEMISTRY, V96, P371, DOI 10.1007/BF00271359; Dobbie Z, 1997, HUM GENET, V99, P653, DOI 10.1007/s004390050423; DRICKAMER K, 1993, ANNU REV CELL BIOL, V9, P237, DOI 10.1146/annurev.cb.09.110193.001321; Fan QS, 1997, MOL CELL BIOL, V17, P4238, DOI 10.1128/MCB.17.8.4238; FOURCADE O, 1995, CELL, V80, P919, DOI 10.1016/0092-8674(95)90295-3; Gandolfo G, 1996, PHARMACOL TOXICOL, V78, P341, DOI 10.1111/j.1600-0773.1996.tb01386.x; GELB MH, 1995, ANNU REV BIOCHEM, V64, P653; GUTIERREZ JM, 1995, TOXICON, V33, P1405, DOI 10.1016/0041-0101(95)00085-Z; Haluska FG, 1997, INT J CANCER, V72, P337, DOI 10.1002/(SICI)1097-0215(19970717)72:2<337::AID-IJC22>3.0.CO;2-B; Hanasaki K, 1997, J BIOL CHEM, V272, P32792, DOI 10.1074/jbc.272.52.32792; Hara N, 1997, ADV EXP MED BIOL, V407, P109; HARWIG SSL, 1995, J CLIN INVEST, V95, P603, DOI 10.1172/JCI117704; HIGASHINO K, 1994, EUR J BIOCHEM, V225, P375, DOI 10.1111/j.1432-1033.1994.00375.x; ISHIZAKI J, 1994, J BIOL CHEM, V269, P5897; Kadam Shilpa, 1998, Indian Journal of Experimental Biology, V36, P553; Kennedy BP, 1998, CANCER RES, V58, P500; KENNEDY BP, 1995, J BIOL CHEM, V270, P22378, DOI 10.1074/jbc.270.38.22378; KINI RM, 1989, TOXICON, V27, P613, DOI 10.1016/0041-0101(89)90013-5; KISHINO J, 1994, J BIOL CHEM, V269, P5092; KRAMER RM, 1989, J BIOL CHEM, V264, P5768; Kundu GC, 1997, J BIOL CHEM, V272, P2346; Kuwata H, 1998, J BIOL CHEM, V273, P1733, DOI 10.1074/jbc.273.3.1733; LAMBEAU G, 1990, J BIOL CHEM, V265, P9526; LAMBEAU G, 1989, J BIOL CHEM, V264, P11503; LAMBEAU G, 1991, FEBS LETT, V293, P29, DOI 10.1016/0014-5793(91)81145-X; LAMBEAU G, 1995, J BIOL CHEM, V270, P5534, DOI 10.1074/jbc.270.10.5534; LAMBEAU G, 1994, J BIOL CHEM, V269, P1575; LAMBEAU G, 1991, NEUROCHEM RES, V16, P651, DOI 10.1007/BF00965551; Lambeau G, 1997, VENOM PHOSPHOLIPASE, P389; LEWIS M, 1991, P NATL ACAD SCI USA, V88, P2830, DOI 10.1073/pnas.88.7.2830; MACPHEE M, 1995, CELL, V81, P957, DOI 10.1016/0092-8674(95)90015-2; Minami T, 1997, J GASTROENTEROL, V32, P431, DOI 10.1007/BF02934505; MUKHERJEE AB, 1994, BIOCHEM PHARMACOL, V48, P1, DOI 10.1016/0006-2952(94)90216-X; MULHERKAR R, 1986, FEBS LETT, V207, P142, DOI 10.1016/0014-5793(86)80028-X; MULHERKAR R, 1993, BIOCHEM BIOPH RES CO, V195, P1254, DOI 10.1006/bbrc.1993.2179; MULHERKAR R, 1991, HISTOCHEMISTRY, V96, P367, DOI 10.1007/BF00271358; MULHERKAR R, 1986, J CELL PHYSIOL, V127, P183, DOI 10.1002/jcp.1041270122; Murakami M, 1997, CRIT REV IMMUNOL, V17, P225, DOI 10.1615/CritRevImmunol.v17.i3-4.10; Murakami M, 1998, J BIOL CHEM, V273, P14411, DOI 10.1074/jbc.273.23.14411; MURATA K, 1993, BRIT J CANCER, V68, P103, DOI 10.1038/bjc.1993.294; NAKAJIMA M, 1992, FEBS LETT, V309, P261, DOI 10.1016/0014-5793(92)80785-F; NAKANO T, 1990, FEBS LETT, V273, P23, DOI 10.1016/0014-5793(90)81042-M; Nevalainen TJ, 1997, J HISTOCHEM CYTOCHEM, V45, P1109, DOI 10.1177/002215549704500808; NEVALAINEN TJ, 1993, CLIN CHEM, V39, P2453; NICOLAS JP, 1995, J BIOL CHEM, V270, P28869, DOI 10.1074/jbc.270.48.28869; Nicolas JP, 1997, J BIOL CHEM, V272, P7173, DOI 10.1074/jbc.272.11.7173; OHARA O, 1986, J BIOCHEM-TOKYO, V99, P733, DOI 10.1093/oxfordjournals.jbchem.a135532; OHARA O, 1995, PROG LIPID RES, V34, P117, DOI 10.1016/0163-7827(94)00009-B; OLIVIER JL, 1994, BIOCHEMISTRY-US, V33, P7134, DOI 10.1021/bi00189a017; PUIJK WC, 1979, BIOCHIM BIOPHYS ACTA, V580, P411, DOI 10.1016/0005-2795(79)90153-3; Rae D., 1996, SCAND J GASTROENTE S, V219, P24; Reddy ST, 1997, J BIOL CHEM, V272, P13591, DOI 10.1074/jbc.272.21.13591; RIGGINS GJ, 1995, CANCER RES, V55, P5184; SEILHAMER JJ, 1986, DNA-J MOLEC CELL BIO, V5, P519, DOI 10.1089/dna.1.1986.5.519; SOMMERS CD, 1992, EUR J PHARMACOL, V216, P87, DOI 10.1016/0014-2999(92)90213-N; Spirio LN, 1996, CANCER RES, V56, P955; Taylor ME, 1997, GLYCOBIOLOGY, V7, pR5; THIEME TR, 1987, J IMMUNOL, V139, P1173; Tischfield JA, 1997, J BIOL CHEM, V272, P17247, DOI 10.1074/jbc.272.28.17247; Tischfield JA, 1996, GENOMICS, V32, P328, DOI 10.1006/geno.1996.0126; Tomlinson IPM, 1996, ANN HUM GENET, V60, P369, DOI 10.1111/j.1469-1809.1996.tb00434.x; VADAS P, 1993, J LIPID MEDIATOR, V8, P1; VERHEIJ HM, 1983, BIOCHIM BIOPHYS ACTA, V747, P93, DOI 10.1016/0167-4838(83)90126-7; Wang TC, 1998, GASTROENTEROLOGY, V114, P675, DOI 10.1016/S0016-5085(98)70581-5; Weinrauch Y, 1998, J CLIN INVEST, V102, P633, DOI 10.1172/JCI3121; WERY JP, 1991, NATURE, V352, P79, DOI 10.1038/352079a0	80	121	126	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 12	1999	274	11					7043	7051		10.1074/jbc.274.11.7043	http://dx.doi.org/10.1074/jbc.274.11.7043			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	175DV	10066760	hybrid			2022-12-25	WOS:000079078400032
J	Lai, K; Willis, AC; Elsas, LJ				Lai, K; Willis, AC; Elsas, LJ			The biochemical role of glutamine 188 in human galactose-1-phosphate uridyltransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; URIDYL TRANSFERASE; URIDYLYLTRANSFERASE; GALACTOSE; SEQUENCE; MUTATION; ENZYME; GENE; IDENTIFICATION; HISTIDINE-166	The substitution of arginine for glutamine at amino acid 188 (Q188R) ablates the function of human galactose-1-phosphate uridyltransferase (GALT) and is the most common mutation causing galactosemia in the white population. GALT catalyzes two consecutive reactions. The first reaction binds UDP-glucose (UDP-Glu), displaces glucose-1-phosphate (glu-1-P), and forms the UMP-GALT intermediate, In the second reaction, galactose-1-phosphate (gal-1-P) is bound, UDP-galactose (UDP-Gal) is released, and the free enzyme is recycled, In this study, we modeled glutamine, asparasne, and a common mutation arginine at amino acid 188 on the three-dimensional model of the Escherichia coli GALT-UMP protein crystal, We found that the amide group of the glutamine side chain could provide two hydrogen bonds to the phosphoryl oxygens of UMP with lengths of 2.52 and 2.82 Angstrom. Arginine and asparasne could provide only one hydrogen bond of 2.52 and 3.02 Angstrom respectively. To test this model, we purified recombinant human Gln(188)-, Arg(188)., and Asn(188)-GALT and analyzed the first reaction in the absence of gal-1-P by quantitating glu-1-P released using enzyme-linked methods. Gln(188)-GALT displaced 80 +/- 7.0 nmol glu-1-P/mg GALT/min in the first reaction. By contrast, both Arg(188). and Asn(188)-GALT released more glu-1-P (170 +/- 8.0 and 129 +/- 28.4 nmol/mg GALT/min, respectively). The overall, double displacement reaction was quantitated in the presence of gall-P, Gln(188)-GALT produced 80,030 +/- 5,910 nmol glu-1-P/mg GALT/min, whereas the mutant Arg(188). and Asn(188) GALT released only 600 +/- 71.2 and 2960 +/- 283.6 nmole glu-1-P/mg GALT/min, respectively, We conclude from these data that glutamine at position 188 stabilizes the UMP-GALT intermediate through hydrogen bonding and enables the double displacement of both glu-1-P and UDP-Gal, The substitution of arginine or asparagine at position 188 reduces hydrogen bonding and destabilizes UMP-GALT, The unstable UMP-GALT allows single displacement of glu-1-P with release of free GALT but impairs the subsequent binding of gal-1-P and displacement of UDP-Gal.	Emory Univ, Sch Med, Dept Biochem, Div Med Genet, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Dept Pediat, Div Med Genet, Atlanta, GA 30322 USA	Emory University; Emory University	Elsas, LJ (corresponding author), Emory Univ, Sch Med, Dept Biochem, Div Med Genet, 2040 Ridgewood Dr Bldg, Atlanta, GA 30322 USA.	lje@rw.ped.emory.edu		Amara, Amy/0000-0003-0762-9656	NCRR NIH HHS [M01-RR00039] Funding Source: Medline; NICHD NIH HHS [P0-1 HD29847-04] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD029847] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000039] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		CORNWELL TL, 1987, NUCLEIC ACIDS RES, V15, P8116, DOI 10.1093/nar/15.19.8116; Elsas LJ, 1998, GENET MED, V1, P40; ELSAS LJ, 1995, EUROPEAN J PEDS, V154, P21; Elsevier JP, 1996, J BIOL CHEM, V271, P32002, DOI 10.1074/jbc.271.50.32002; FIELD TL, 1989, BIOCHEMISTRY-US, V28, P2094, DOI 10.1021/bi00431a019; FLACH JE, 1990, MOL BIOL MED, V7, P365; Frey PA, 1996, FASEB J, V10, P461, DOI 10.1096/fasebj.10.4.8647345; FREY PA, 1992, ENZYMES, V20, P141; FRIDOVICHKEIL JL, 1995, AM J HUM GENET, V56, P640; FRIDOVICHKEIL JL, 1993, P NATL ACAD SCI USA, V90, P398, DOI 10.1073/pnas.90.2.398; FridovichKeil JL, 1995, BIOCHEM MOL MED, V56, P121, DOI 10.1006/bmme.1995.1067; Hochuli E, 1990, Genet Eng (N Y), V12, P87; INDGE KJ, 1976, BIOCHEM J, V155, P567, DOI 10.1042/bj1550567; KIM JM, 1990, BIOCHEMISTRY-US, V29, P10590, DOI 10.1021/bi00499a003; KING EL, 1956, J PHYS CHEM-US, V60, P1375, DOI 10.1021/j150544a010; Lai K, 1998, HUM MUTAT, V11, P28; Lai K, 1996, J PEDIATR-US, V128, P89, DOI 10.1016/S0022-3476(96)70432-8; LEGRICE SFJ, 1990, EUR J BIOCHEM, V187, P307, DOI 10.1111/j.1432-1033.1990.tb15306.x; LELOIR LF, 1951, ARCH BIOCHEM BIOPHYS, V33, P186, DOI 10.1016/0003-9861(51)90096-3; LESLIE ND, 1992, GENOMICS, V14, P474, DOI 10.1016/S0888-7543(05)80244-7; MARKUS HB, 1977, J BIOL CHEM, V252, P5363; Moore DD, 1995, GLOB MOB SURV; NEEDLEMAN SB, 1970, J MOL BIOL, V48, P443, DOI 10.1016/0022-2836(70)90057-4; REICHARDT JKV, 1991, AM J HUM GENET, V49, P860; RUNYAN KR, 1989, METHOD ENZYMOL, V171, P164; RUZICKA FJ, 1993, BIOORG CHEM, V21, P238, DOI 10.1006/bioo.1993.1020; SAITO S, 1967, J BIOL CHEM, V242, P2362; Segal S, 1995, METABOLIC MOL BASIS, P967; Thoden JB, 1997, BIOCHEMISTRY-US, V36, P1212, DOI 10.1021/bi9626517; WEDEKIND JE, 1994, ACTA CRYSTALLOGR D, V50, P329, DOI 10.1107/S0907444993012958; WEDEKIND JE, 1995, BIOCHEMISTRY-US, V34, P11049, DOI 10.1021/bi00035a010; Wedekind JE, 1996, BIOCHEMISTRY-US, V35, P11560, DOI 10.1021/bi9612677; WELLS L, 1996, J INHERIT METAB DIS, V20, P633; WILLIAMS VP, 1978, ARCH BIOCHEM BIOPHYS, V191, P182, DOI 10.1016/0003-9861(78)90080-2; WONG LJ, 1974, J BIOL CHEM, V249, P2322; WONG LJ, 1974, BIOCHEMISTRY-US, V13, P3889, DOI 10.1021/bi00716a011; [No title captured]	37	38	38	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	1999	274	10					6559	6566		10.1074/jbc.274.10.6559	http://dx.doi.org/10.1074/jbc.274.10.6559			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172BQ	10037750	hybrid			2022-12-25	WOS:000078902800072
J	Purcarea, C; Evans, DR; Herve, G				Purcarea, C; Evans, DR; Herve, G			Channeling of carbamoyl phosphate to the pyrimidine and arginine biosynthetic pathways in the deep sea hyperthermophilic archaeon Pyrococcus abyssi	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI ASPARTATE-TRANSCARBAMYLASE; ENZYME-ENZYME INTERACTIONS; ESCHERICHIA-COLI; MULTIFUNCTIONAL PROTEIN; HAMSTER-CELLS; ORNITHINE CARBAMOYLTRANSFERASE; SACCHAROMYCES-CEREVISIAE; REGULATORY PROPERTIES; MULTIENZYME COMPLEX; TIME ANALYSIS	The kinetics of the coupled reactions between carbamoyl-phosphate synthetase (CPSase) and both aspartate transcarbamoylase (ATCase) and ornithine transcarbamoylase (OTCase) hom the deep sea hyperthermophilic archaeon Pyrococcus abyssi demonstrate the existence of carbamoyl phosphate channeling in both the pyrimidine and arginine biosynthetic pathways. Isotopic dilution experiments and coupled reaction kinetics analyzed within the context of the formalism proposed by Ovadi et al. (Ovadi, J., Tompa, P., Vertessy, B., Orosz, F., Keleti, T., and Welch, G. R (1989) Biochem J. 257, 187-190) are consistent with a partial channehng of the intermediate at 37 degrees C, but channeling efficiency increases dramatically at elevated temperatures. There is no preferential partitioning of carbamoyl phosphate between the arginine and pyrimidine biosynthetic pathways. Gel filtration chromatography at high and low temperature and in the presence and absence of substrates did not reveal stable complexes between P. abyssi CPSase and either ATCase or OTCase. Thus, channeling must occur during the dynamic association of coupled enzymes pairs. The interaction of CPSase-ATCase was further demonstrated by the unexpectedly weak inhibition of the coupled reaction by the bisubstrate analog, N-(phosphonacetyl)-L- aspartate (PALA). The anomalous effect of PALA suggests that, in the coupled reaction, the effective concentration of carbamoyl phosphate in the vicinity of the ATCase active site is 96-fold higher than the concentration in the bulk phase. Channeling probably plays an essential role in protecting this very unstable intermediate of metabolic pathways performing at extreme temperatures.	Wayne State Univ, Sch Med, Dept Biochem & Mol Biol, Detroit, MI 48201 USA; Univ Paris 06, Lab Biochim Signaux Regulateurs Cellulaires & Mol, CNRS, UMR 7631, F-75006 Paris, France	Wayne State University; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite	Purcarea, C (corresponding author), Wayne State Univ, Sch Med, Dept Biochem & Mol Biol, Detroit, MI 48201 USA.				NIGMS NIH HHS [GM-74399] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM074399] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABDELAL AT, 1975, ANAL BIOCHEM, V69, P652, DOI 10.1016/0003-2697(75)90174-8; ABDELAL ATH, 1977, J BACTERIOL, V129, P1387, DOI 10.1128/JB.129.3.1387-1396.1977; ADAMS MWW, 1994, FEMS MICROBIOL REV, V15, P261, DOI 10.1111/j.1574-6976.1994.tb00139.x; ADAMS MWW, 1993, ANNU REV MICROBIOL, V47, P627, DOI 10.1146/annurev.micro.47.1.627; ALLEN CM, 1964, BIOCHEMISTRY-US, V3, P1238, DOI 10.1021/bi00897a010; BAUR H, 1990, J BIOL CHEM, V265, P14728; BELKAID M, 1988, ARCH BIOCHEM BIOPHYS, V262, P171, DOI 10.1016/0003-9861(88)90179-8; CHRISTOPHERSON RI, 1980, J BIOL CHEM, V255, P1381; COHEN NS, 1992, BIOCHEM J, V282, P173, DOI 10.1042/bj2820173; COLEMAN PF, 1977, J BIOL CHEM, V252, P6379; EASTERBY JS, 1973, BIOCHIM BIOPHYS ACTA, V293, P552, DOI 10.1016/0005-2744(73)90362-8; ERAUSO G, 1993, ARCH MICROBIOL, V160, P338; FUKUSHIMA T, 1989, J BIOL CHEM, V264, P16483; GUY HI, 1994, J BIOL CHEM, V269, P23808; HYDE CC, 1988, J BIOL CHEM, V263, P17857; Irvine HS, 1997, EUR J BIOCHEM, V247, P1063, DOI 10.1111/j.1432-1033.1997.01063.x; Kim JH, 1996, J BIOL CHEM, V271, P15549, DOI 10.1074/jbc.271.26.15549; KUO LC, 1985, BIOCHEMISTRY-US, V24, P4754, DOI 10.1021/bi00339a007; LEGRAIN C, 1995, MICROBIOL-SGM, V141, P1093, DOI 10.1099/13500872-141-5-1093; LOWE SE, 1993, MICROBIOL REV, V57, P451, DOI 10.1128/MMBR.57.2.451-509.1993; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUE P F, 1970, Biochimica et Biophysica Acta, V220, P365, DOI 10.1016/0005-2744(70)90268-8; MAKOFF AJ, 1978, MICROBIOL REV, V42, P307, DOI 10.1128/MMBR.42.2.307-328.1978; MALLY MI, 1980, J BIOL CHEM, V255, P1372; MORI M, 1978, EUR J BIOCHEM, V86, P381, DOI 10.1111/j.1432-1033.1978.tb12320.x; NOWLAN SF, 1985, J BIOL CHEM, V260, P4712; OVADI J, 1989, BIOCHEM J, V257, P187, DOI 10.1042/bj2570187; PENVERNE B, 1994, ARCH BIOCHEM BIOPHYS, V309, P85, DOI 10.1006/abbi.1994.1089; PERBAL B, 1972, J MOL BIOL, V70, P511, DOI 10.1016/0022-2836(72)90556-6; Purcarea C, 1996, EUR J BIOCHEM, V236, P189, DOI 10.1111/j.1432-1033.1996.00189.x; PURCAREA C, 1994, MICROBIOL-SGM, V140, P1967, DOI 10.1099/13500872-140-8-1967; Purcarea C, 1997, J BACTERIOL, V179, P4143, DOI 10.1128/jb.179.13.4143-4157.1997; PURCAREA C, 1995, THESIS PARIS SUD; ROBIN JP, 1989, EUR J BIOCHEM, V183, P519, DOI 10.1111/j.1432-1033.1989.tb21080.x; SMOLEN P, 1990, BIOPHYS CHEM, V38, P241, DOI 10.1016/0301-4622(90)87006-7; SRERE PA, 1990, FEBS LETT, V268, P360, DOI 10.1016/0014-5793(90)81286-W; SRIVASTAVA DK, 1986, CURR TOP CELL REGUL, V28, P1; Thoden JB, 1997, BIOCHEMISTRY-US, V36, P6305, DOI 10.1021/bi970503q; VANDECASTEELE M, 1990, J GEN MICROBIOL, V136, P1177, DOI 10.1099/00221287-136-7-1177; VANDECASTEELE M, 1994, BIOCATALYSIS, V11, P165, DOI 10.3109/10242429409034386; WANDERS RJA, 1984, EUR J BIOCHEM, V142, P247, DOI 10.1111/j.1432-1033.1984.tb08278.x; WELCH GR, 1994, TRENDS BIOCHEM SCI, V19, P193; WILLIAMS LG, 1970, BIOCHEMISTRY-US, V9, P4329, DOI 10.1021/bi00824a013; WILLIAMS LG, 1971, J BIOL CHEM, V246, P973; YANOFSKY C, 1989, BIOCHIM BIOPHYS ACTA, V1000, P133, DOI 10.1016/S0006-3002(89)80013-7	45	27	27	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	1999	274	10					6122	6129		10.1074/jbc.274.10.6122	http://dx.doi.org/10.1074/jbc.274.10.6122			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172BQ	10037695	hybrid			2022-12-25	WOS:000078902800017
J	Viale, A; Ortola, C; Hervieu, G; Furuta, M; Barbero, P; Steiner, DF; Seidah, NG; Nahon, JL				Viale, A; Ortola, C; Hervieu, G; Furuta, M; Barbero, P; Steiner, DF; Seidah, NG; Nahon, JL			Cellular localization and role of prohormone convertases in the processing of pro-melanin concentrating hormone in mammals	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RIBONUCLEIC-ACID; MICROINJECTED XENOPUS OOCYTES; PROPROTEIN CONVERTASE; SECRETORY PATHWAY; PUTATIVE NEUROPEPTIDES; CDNA STRUCTURE; YEAST KEX2; RAT; EXPRESSION; PC2	Melanin concentrating hormone (MCH) and neuropeptide EI (NEI) are two peptides produced from the same precursor in mammals, by cleavage at the Arg(145) Arg(146) Site and the Lys(129)-Arg(130) site, respectively. We performed co-localization studies to reveal simultaneously the expression of MCH mRNA and proconvertases (PCs) such as PC1/3 or PC2. In the rat hypothalamus, PC2 was present in all MCH neurons, and PC1/3 was present in about 15-20% of these cells. PC1/3 or PC2 was not found in MCH-positive cells in the spleen. In GH(4)C(1) cells co-infected with vaccinia virus (VV):pro-MCH along with VV:furin, PACE4, PC1/3, PC2, PC5/6A, PC5/6B, or PC7, we observed only efficient cleavage at the Arg(145)-Arg(146) Site to generate mature MCH. Co-expression of pro-MCH together with PC2 and 7B2 resulted in very weak processing to NEI. Comparison of pro-MCH processing patterns in PC1/3- or PC2-transfected PC12 cells showed that PC2 but not PC1/3 generated NEI. Finally, we analyzed the pattern of pro-MCH processing in PC2 null mice. In the brain of homozygotic mutants, the production of mature NEI was dramatically reduced. In contrast, MCH content was increased in the hypothalamus of PC2 null mice. In the spleen, a single large MCH-containing peptide was identified in both wild type and PC2 nub mice, Together, our data suggest that pra-MCH is processed differently in the brain and in peripheral organs of mammals. PC2 is the key enzyme that produces NEI, whereas several PCs may cleave at the Arg(145)-Arg(146) Site to generate MCH in neuronal cell types.	CNRS, Inst Pharmacol Mol & Cellulaire, UPR 411, F-06560 Valbonne, France; Univ Chicago, Dept Biochem & Mol Biol, Chicago, IL 60637 USA; Univ Chicago, Howard Hughes Med Inst, Chicago, IL 60637 USA; Clin Res Inst Montreal, Biochem Neuroendocrinol Lab, Montreal, PQ H2W 1R7, Canada	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur; University of Chicago; Howard Hughes Medical Institute; University of Chicago; Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal	Nahon, JL (corresponding author), CNRS, Inst Pharmacol Mol & Cellulaire, UPR 411, 660 Route Lucioles, F-06560 Valbonne, France.	Nahonjl@ipmc.cnrs.fr	NAHON, Jean-Louis/O-7977-2016; Seidah, Nabil/I-3596-2013	NAHON, Jean-Louis/0000-0001-9572-7779; Seidah, Nabil/0000-0001-6503-9342	NIDDK NIH HHS [DK 13914, DK 20595] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK013914, P60DK020595, R37DK013914, P30DK020595] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAKER BI, 1994, TRENDS ENDOCRIN MET, V5, P120, DOI 10.1016/1043-2760(94)90093-0; Barbero P, 1998, J BIOL CHEM, V273, P25339, DOI 10.1074/jbc.273.39.25339; BENJANNET S, 1995, J NEUROCHEM, V64, P2303; Benjannet S, 1997, J BIOL CHEM, V272, P26210, DOI 10.1074/jbc.272.42.26210; BENJANNET S, 1991, P NATL ACAD SCI USA, V88, P3564, DOI 10.1073/pnas.88.9.3564; BITTENCOURT JC, 1992, J COMP NEUROL, V319, P218, DOI 10.1002/cne.903190204; BRAKS JAM, 1994, CELL, V78, P263, DOI 10.1016/0092-8674(94)90296-8; BRESLIN MB, 1993, J BIOL CHEM, V268, P27084; DeBie I, 1996, J CELL BIOL, V135, P1261, DOI 10.1083/jcb.135.5.1261; Dhanvantari S, 1996, MOL ENDOCRINOL, V10, P342, DOI 10.1210/me.10.4.342; Furuta M, 1997, P NATL ACAD SCI USA, V94, P6646, DOI 10.1073/pnas.94.13.6646; Grillon S, 1997, NEUROPEPTIDES, V31, P131, DOI 10.1016/S0143-4179(97)90081-0; HALBAN PA, 1994, BIOCHEM J, V299, P1; Hervieu G, 1996, ENDOCRINOLOGY, V137, P561, DOI 10.1210/en.137.2.561; HERVIEU G, 1995, NEUROENDOCRINOLOGY, V61, P348, DOI 10.1159/000126857; Hervieu G, 1996, BIOL REPROD, V54, P1161, DOI 10.1095/biolreprod54.6.1161; Johanning K, 1996, J NEUROCHEM, V66, P898; KIEFER MC, 1991, DNA CELL BIOL, V10, P757, DOI 10.1089/dna.1991.10.757; Laslop A, 1998, J NEUROCHEM, V70, P374; LUSSON J, 1993, P NATL ACAD SCI USA, V90, P6691, DOI 10.1073/pnas.90.14.6691; MARCINKIEWICZ M, 1993, P NATL ACAD SCI USA, V90, P4922, DOI 10.1073/pnas.90.11.4922; Mbikay M, 1997, P NATL ACAD SCI USA, V94, P6842, DOI 10.1073/pnas.94.13.6842; Munzer JS, 1997, J BIOL CHEM, V272, P19672, DOI 10.1074/jbc.272.32.19672; NAHON JL, 1989, ENDOCRINOLOGY, V125, P2056, DOI 10.1210/endo-125-4-2056; NAHON JL, 1994, CRIT REV NEUROBIOL, V8, P221; NAKAGAWA T, 1993, FEBS LETT, V327, P165, DOI 10.1016/0014-5793(93)80163-O; NAKAYAMA K, 1992, J BIOL CHEM, V267, P5897; PARKES D, 1992, ENDOCRINOLOGY, V131, P1826, DOI 10.1210/en.131.4.1826; Presse F, 1997, MOL BRAIN RES, V52, P270, DOI 10.1016/S0169-328X(97)00273-8; PRESSE F, 1992, ENDOCRINOLOGY, V131, P1241, DOI 10.1210/en.131.3.1241; Presse F, 1996, NEUROSCIENCE, V71, P735, DOI 10.1016/0306-4522(95)00481-5; Qu DQ, 1996, NATURE, V380, P243, DOI 10.1038/380243a0; RISOLD PY, 1992, NEUROSCI LETT, V136, P145, DOI 10.1016/0304-3940(92)90035-6; Rossi M, 1997, ENDOCRINOLOGY, V138, P351, DOI 10.1210/en.138.1.351; Rothenberg ME, 1996, MOL ENDOCRINOL, V10, P331, DOI 10.1210/me.10.4.331; ROTHMAN JE, 1992, NATURE, V355, P409, DOI 10.1038/355409a0; ROUILLE Y, 1995, FRONT NEUROENDOCRIN, V16, P322, DOI 10.1006/frne.1995.1012; ROUILLE Y, 1995, J BIOL CHEM, V270, P26488, DOI 10.1074/jbc.270.44.26488; Rovere C, 1996, ENDOCRINOLOGY, V137, P2954, DOI 10.1210/en.137.7.2954; Rovere C, 1996, J BIOL CHEM, V271, P11368, DOI 10.1074/jbc.271.19.11368; Schaner P, 1997, J BIOL CHEM, V272, P19958, DOI 10.1074/jbc.272.32.19958; SEIDAH NG, 1993, ANN NY ACAD SCI, V680, P135, DOI 10.1111/j.1749-6632.1993.tb19680.x; SEIDAH NG, 1992, MOL ENDOCRINOL, V6, P1559, DOI 10.1210/me.6.10.1559; Seidah NG, 1996, P NATL ACAD SCI USA, V93, P3388, DOI 10.1073/pnas.93.8.3388; Seidah NG, 1997, CURR OPIN BIOTECH, V8, P602, DOI 10.1016/S0958-1669(97)80036-5; SEIDAH NG, 1998, MOL B INT U, V2, P49; SHENNAN KIJ, 1991, J BIOL CHEM, V266, P24011; SHENNAN KIJ, 1991, FEBS LETT, V284, P277, DOI 10.1016/0014-5793(91)80703-6; SOSSIN WS, 1989, NEURON, V2, P1407, DOI 10.1016/0896-6273(89)90186-4; STEINER DF, 1992, J BIOL CHEM, V267, P23435; TAKAHASHI K, 1995, NEUROENDOCRINOLOGY, V61, P493, DOI 10.1159/000126872; VANDENOUWELAND AMW, 1990, NUCLEIC ACIDS RES, V18, P664, DOI 10.1093/nar/18.3.664; Viale A, 1997, MOL BRAIN RES, V46, P243, DOI 10.1016/S0169-328X(97)00018-1; Wang W, 1998, BIOCHEM BIOPH RES CO, V248, P538, DOI 10.1006/bbrc.1998.9006; Yoon J, 1997, ENDOCRINOLOGY, V138, P3620, DOI 10.1210/en.138.9.3620; ZHENG M, 1994, J NEUROSCI, V14, P4656; ZHOU A, 1993, J BIOL CHEM, V268, P1763; ZHU XR, 1995, J CELL BIOL, V129, P1641, DOI 10.1083/jcb.129.6.1641	58	45	49	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	1999	274	10					6536	6545		10.1074/jbc.274.10.6536	http://dx.doi.org/10.1074/jbc.274.10.6536			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172BQ	10037747	hybrid			2022-12-25	WOS:000078902800069
J	Howie, SEM; Fernandes, ML; Heslop, I; Hewson, TJ; Cotton, GJ; Moore, MJ; Innes, D; Ramage, R; Harrison, DJ				Howie, SEM; Fernandes, ML; Heslop, I; Hewson, TJ; Cotton, GJ; Moore, MJ; Innes, D; Ramage, R; Harrison, DJ			A functional, discontinuous HIV-1 gp120 C3/C4 domain-derived, branched, synthetic peptide that binds to CD4 and inhibits MIP-1 alpha chemokine binding	FASEB JOURNAL			English	Article						antibody; macrophage; PBMC; monoclonal antibody; CDR2 region	IMMUNODEFICIENCY-VIRUS TYPE-1; ENVELOPE GLYCOPROTEIN; CELL-FUSION; AMINO-ACIDS; RECEPTOR; CORECEPTOR; ANTIBODIES; ENTRY; CCR-5; EXPRESSION	This paper describes a branched synthetic peptide [3.7] that incorporates sequence discontinuous residues of HIV-1 gp120 constant regions. The approach was to bring together residues of gp120 known to interact with human cell membranes such that the peptide could fold to mimic the native molecule. The peptide incorporates elements of both the conserved CD4 and CCR5 binding sites. The 3.7 peptide, which cannot be produced by conventional genetic engineering methods, is recognized by antiserum raised to native gp120. The peptide also binds to CD4 and competitively inhibits binding of QS4120 an antibody directed against the CDR2 region of CD4. When preincubated with the CD4+ve MM6 macrophage cell line, which expresses mRNA for the CCR3 and CCR5 chemokine receptors, both 3.7 and gp120 inhibit binding of the chemokine MIP-1 alpha. The peptide also inhibits infection of primary macrophages by M-tropic HIV-1. Thus, 3.7 is a prototype candidate peptide for a vaccine against HIV-1 and represents a novel approach to the rational design of peptides that can mimic complex sequence discontinuous ligand binding sites of clinically relevant proteins.	Univ Edinburgh, Sch Med, Dept Pathol, Edinburgh EH8 9AG, Midlothian, Scotland; Univ Edinburgh, Ctr Prot Technol, Edinburgh EH8 9AG, Midlothian, Scotland; Univ Edinburgh, Ctr HIV Res, Edinburgh EH8 9AG, Midlothian, Scotland	University of Edinburgh; University of Edinburgh; University of Edinburgh	Howie, SEM (corresponding author), Univ Edinburgh, Sch Med, Dept Pathol, Teviot Pl, Edinburgh EH8 9AG, Midlothian, Scotland.	s.e.m.howie@ed.ac.uk						Berson JF, 1996, J VIROL, V70, P6288, DOI 10.1128/JVI.70.9.6288-6295.1996; Bieniasz PD, 1997, EMBO J, V16, P2599, DOI 10.1093/emboj/16.10.2599; Carrillo A, 1996, J VIROL, V70, P1301, DOI 10.1128/JVI.70.2.1301-1309.1996; ChengMayer C, 1997, J VIROL, V71, P1657, DOI 10.1128/JVI.71.2.1657-1661.1997; CLARKLEWIS I, 1995, J LEUKOCYTE BIOL, V57, P703, DOI 10.1002/jlb.57.5.703; Cocchi F, 1996, NAT MED, V2, P1244, DOI 10.1038/nm1196-1244; COMBADIERE C, 1995, J BIOL CHEM, V270, P16491, DOI 10.1074/jbc.270.28.16491; CORDONNIER A, 1989, NATURE, V340, P574; Cotton GJ, 1996, MOL IMMUNOL, V33, P171, DOI 10.1016/0161-5890(95)00110-7; CROWL R, 1985, CELL, V41, P979, DOI 10.1016/S0092-8674(85)80078-7; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; Dittmar MT, 1997, J VIROL, V71, P5140, DOI 10.1128/JVI.71.7.5140-5147.1997; Doranz BJ, 1996, CELL, V85, P1149, DOI 10.1016/S0092-8674(00)81314-8; Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0; Farzan M, 1997, J BIOL CHEM, V272, P6854, DOI 10.1074/jbc.272.11.6854; HEALEY D, 1990, J EXP MED, V172, P1233, DOI 10.1084/jem.172.4.1233; HOPP TP, 1981, P NATL ACAD SCI-BIOL, V78, P3824, DOI 10.1073/pnas.78.6.3824; Howie SEM, 1998, FASEB J, V12, P991, DOI 10.1096/fasebj.12.11.991; James W, 1996, CURR TOP MICROBIOL, V205, P137; Kwong PD, 1998, NATURE, V393, P648, DOI 10.1038/31405; MOORE JP, 1993, J VIROL, V67, P4785, DOI 10.1128/JVI.67.8.4785-4796.1993; MUESING MA, 1985, NATURE, V313, P450, DOI 10.1038/313450a0; Nibbs RJB, 1997, J BIOL CHEM, V272, P12495, DOI 10.1074/jbc.272.19.12495; OLSHEVSKY U, 1990, J VIROL, V64, P5701, DOI 10.1128/JVI.64.12.5701-5707.1990; Speck RF, 1997, J VIROL, V71, P7136, DOI 10.1128/JVI.71.9.7136-7139.1997; Trkola A, 1996, NATURE, V384, P184, DOI 10.1038/384184a0; Verrier FC, 1997, P NATL ACAD SCI USA, V94, P9326, DOI 10.1073/pnas.94.17.9326; Wu LJ, 1997, J EXP MED, V185, P1681, DOI 10.1084/jem.185.9.1681; Wyatt R, 1998, NATURE, V393, P705, DOI 10.1038/31514	29	10	10	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	1999	13	3					503	511		10.1096/fasebj.13.3.503	http://dx.doi.org/10.1096/fasebj.13.3.503			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	174CF	10064617				2022-12-25	WOS:000079016000010
J	Lu-Kuo, JM; Joyal, DM; Austen, KF; Katz, HR				Lu-Kuo, JM; Joyal, DM; Austen, KF; Katz, HR			gp49B1 inhibits IgE-initiated mast cell activation through both immunoreceptor tyrosine-based inhibitory motifs, recruitment of src homology 2 domain-containing phosphatase-1, and suppression of early and late calcium mobilization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLASS-I MOLECULES; FC-GAMMA-RIIB; IMMUNOGLOBULIN SUPERFAMILY; NEGATIVE REGULATION; LEUKOTRIENE C-4; RECEPTOR; CLONING; ANTIGEN; GENE; PHOSPHORYLATION	We define by molecular, pharmacologic, and physiologic approaches the proximal mechanism by which the immunoglobulin superfamily member gp49B1 inhibits mast cell activation mediated by the high affinity Fc receptor for IgE (Fc epsilon RI). In rat basophilic leukemia-2H3 cells expressing transfected mouse gp49B1, mutation of tyrosine to phenylalanine in either of the two immunoreceptor tyrosine-based inhibitory motifs of the gp49B1 cytoplasmic domain partially suppressed gp49B1-mediated inhibition of exocytosis, whereas mutation of both abolished inhibitory capacity. Sodium pervanadate elicited tyrosine phosphorylation of native gp49B1 and association of the tyrosine phosphatases src homology 2 domain-containing phosphatase-1 (SHP-1) and SHP-2 in mouse bone marrow-derived mast cells (mBMMCs). SHP-1 associated transiently with gp49B1 within 1 min after coligation of gp49B1 with cross-linked Fc epsilon RI in mBMMCs. SHP-1-deficient mBMMCs exhibited a partial loss of gp49B1-mediated inhibition of Fc epsilon RI-induced exocytosis at concentrations of IgE providing optimal exocytosis, revealing a central, but not exclusive, SHP-1 requirement in the counter-regulatory pathway. Coligation of gp49B1 with cross-linked Fc epsilon RI on mBMMCs inhibited early release of calcium from intracellular stores and subsequent influx of extracellular calcium, consistent with SHP-1 participation. Because exocytosis is complete within 2 min in mBMMCs, our studies establish a role for SHP-1 in the initial counter-regulatory cellular responses whereby gp49B1 immunoreceptor tyrosine-based inhibition motifs rapidly transmit inhibition of Fc epsilon RI-mediated exocytosis.	Brigham & Womens Hosp, Div Rheumatol Allergy & Immunol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Katz, HR (corresponding author), Brigham & Womens Hosp, Div Rheumatol Allergy & Immunol, Smith Bldg,Rm 638A,1 Jimmy Fund Way, Boston, MA 02115 USA.	hrkatz@mbcrr.harvard.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL036110] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI041144, U19AI031599, U01AI031599] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-36110] Funding Source: Medline; NIAID NIH HHS [AI-41144, AI-31599] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARM JP, 1991, J BIOL CHEM, V266, P15966; Arm JP, 1997, J IMMUNOL, V159, P2342; BENHAMOU M, 1990, J IMMUNOL, V144, P3071; Binstadt BA, 1996, IMMUNITY, V5, P629, DOI 10.1016/S1074-7613(00)80276-9; Blery M, 1997, J BIOL CHEM, V272, P8989; Blery M, 1998, P NATL ACAD SCI USA, V95, P2446, DOI 10.1073/pnas.95.5.2446; Borges L, 1997, J IMMUNOL, V159, P5192; BUKOWSKI JF, 1995, J IMMUNOL, V154, P998; Burshtyn DN, 1997, J BIOL CHEM, V272, P13066, DOI 10.1074/jbc.272.20.13066; Burshtyn DN, 1996, IMMUNITY, V4, P77, DOI 10.1016/S1074-7613(00)80300-3; Campbell KS, 1996, J EXP MED, V184, P93, DOI 10.1084/jem.184.1.93; CASTELLS MC, 1994, J BIOL CHEM, V269, P8393; Cella M, 1997, J EXP MED, V185, P1743, DOI 10.1084/jem.185.10.1743; Colonna M, 1998, J IMMUNOL, V160, P3096; Colonna M, 1997, J EXP MED, V186, P1809, DOI 10.1084/jem.186.11.1809; Cosman D, 1997, IMMUNITY, V7, P273, DOI 10.1016/S1074-7613(00)80529-4; DAERON M, 1995, J CLIN INVEST, V95, P577, DOI 10.1172/JCI117701; DAERON M, 1995, IMMUNITY, V3, P635, DOI 10.1016/1074-7613(95)90134-5; Echtenacher B, 1996, NATURE, V381, P75, DOI 10.1038/381075a0; Hayami K, 1997, J BIOL CHEM, V272, P7320, DOI 10.1074/jbc.272.11.7320; Helgason CD, 1998, GENE DEV, V12, P1610, DOI 10.1101/gad.12.11.1610; HULETT MD, 1994, ADV IMMUNOLOGY; Katz HR, 1997, J IMMUNOL, V158, P5065; KATZ HR, 1989, J IMMUNOL, V142, P919; KATZ HR, 1990, J IMMUNOL, V145, P3412; Katz HR, 1996, P NATL ACAD SCI USA, V93, P10809, DOI 10.1073/pnas.93.20.10809; KATZ HR, 1983, P NATL ACAD SCI-BIOL, V80, P5916, DOI 10.1073/pnas.80.19.5916; Katz HR, 1998, ASTHMA AND ALLERGIC DISEASES, P97, DOI 10.1016/B978-012473340-4/50011-4; Kubagawa H, 1997, P NATL ACAD SCI USA, V94, P5261, DOI 10.1073/pnas.94.10.5261; Kuroiwa A, 1998, J BIOL CHEM, V273, P1070, DOI 10.1074/jbc.273.2.1070; LAM BK, 1989, J BIOL CHEM, V264, P12885; Lam BK, 1997, J BIOL CHEM, V272, P13923, DOI 10.1074/jbc.272.21.13923; LuKuo JM, 1996, J BIOL CHEM, V271, P22169, DOI 10.1074/jbc.271.36.22169; Maeda A, 1998, J EXP MED, V187, P1355, DOI 10.1084/jem.187.8.1355; Malaviya R, 1996, NATURE, V381, P77, DOI 10.1038/381077a0; Olcese L, 1996, J IMMUNOL, V156, P4531; Ono M, 1996, NATURE, V383, P263, DOI 10.1038/383263a0; Ono M, 1997, CELL, V90, P293, DOI 10.1016/S0092-8674(00)80337-2; Prodeus AP, 1997, NATURE, V390, P172, DOI 10.1038/36586; RAZIN E, 1983, J EXP MED, V157, P189, DOI 10.1084/jem.157.1.189; ROBINSON D, 1968, BIOCHEM J, V107, P321, DOI 10.1042/bj1070321; Samaridis J, 1997, EUR J IMMUNOL, V27, P660, DOI 10.1002/eji.1830270313; SELDIN DC, 1985, P NATL ACAD SCI USA, V82, P3871, DOI 10.1073/pnas.82.11.3871; Wagtmann N, 1997, CURR BIOL, V7, P615, DOI 10.1016/S0960-9822(06)00263-6; Yamashita Y, 1998, J IMMUNOL, V161, P4042	45	69	71	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 26	1999	274	9					5791	5796		10.1074/jbc.274.9.5791	http://dx.doi.org/10.1074/jbc.274.9.5791			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	170KG	10026201	hybrid			2022-12-25	WOS:000078804400072
J	Schliebs, W; Saidowsky, J; Agianian, B; Dodt, G; Herberg, FW; Kunau, WH				Schliebs, W; Saidowsky, J; Agianian, B; Dodt, G; Herberg, FW; Kunau, WH			Recombinant human peroxisomal targeting signal receptor PEX5 - Structural basis for interaction of PEX5 with PEX14	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; PROTEIN TRANSLOCATION; PTS1 RECEPTOR; SNAP HELIX; MEMBRANE; BINDING; IMPORT; BIOGENESIS; DISORDERS; DOMAINS	Import of matrix proteins into peroxisomes requires two targeting signal-specific import receptors, Pex5p and Pex7p, and their binding partners at the peroxisomal membrane, Pex13p and Pex14p. Several constructs of human PEX5 have been overexpressed and purified by affinity chromatography in order to determine functionally important interactions and provide initial structural information. Sizing chromatography and electron microscopy suggest that the two isoforms of the human PTS1 receptor, PEX5L and PEX5S, form homotetramers. Surface plasmon resonance analysis indicates that PEX5 binds to the N-terminal fragment of PEX14-(1-78) with a very high affinity in the low nanomolar range. Stable complexes between recombinant PEX14-(1-78) and both the full-length and truncated versions of PEX5 were formed in vitro. Analysis of these complexes revealed that PEX5 possesses multiple binding sites for PEX14, which appear to be distributed throughout its N-terminal half. Coincidentally, this part of the molecule is also responsible for oligomerization, whereas the C-terminal half with its seven tetratricopeptide repeats has been reported to bind PTS1-proteins. A pentapeptide motif that is reiterated seven times in PEX5 is proposed as a determinant for the interaction with PEX14.	Ruhr Univ Bochum, Inst Physiol Chem, D-44780 Bochum, Germany; European Mol Biol Lab, D-69012 Heidelberg, Germany	Ruhr University Bochum; European Molecular Biology Laboratory (EMBL)	Kunau, WH (corresponding author), Ruhr Univ Bochum, Inst Physiol Chem, D-44780 Bochum, Germany.	wolf-h.kunau@ruhr-uni-bochum.de	Agianian, Bogos/O-8019-2016; Herberg, Friedrich W/B-5572-2015	Herberg, Friedrich W/0000-0001-7117-7653; Agianian, Bogos/0000-0003-1295-6846; Schliebs, Wolfgang/0000-0003-2762-3403				Albertini M, 1997, CELL, V89, P83, DOI 10.1016/S0092-8674(00)80185-3; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Braverman N, 1998, HUM MOL GENET, V7, P1195, DOI 10.1093/hmg/7.8.1195; BROCARD C, 1994, BIOCHEM BIOPH RES CO, V204, P1016, DOI 10.1006/bbrc.1994.2564; Brocard C, 1997, EMBO J, V16, P5491, DOI 10.1093/emboj/16.18.5491; DODT G, 1995, NAT GENET, V9, P115, DOI 10.1038/ng0295-115; Elgersma Y, 1996, BBA-REV BIOMEMBRANES, V1286, P269, DOI 10.1016/S0304-4157(96)00012-3; Elgersma Y, 1996, J CELL BIOL, V135, P97, DOI 10.1083/jcb.135.1.97; Erdmann R, 1996, J CELL BIOL, V135, P111, DOI 10.1083/jcb.135.1.111; Erdmann R, 1997, TRENDS CELL BIOL, V7, P400, DOI 10.1016/S0962-8924(97)01126-4; Fransen M, 1998, P NATL ACAD SCI USA, V95, P8087, DOI 10.1073/pnas.95.14.8087; Gale M, 1996, MOL CELL BIOL, V16, P4172; GOEBL M, 1991, TRENDS BIOCHEM SCI, V16, P173, DOI 10.1016/0968-0004(91)90070-C; Gould SJ, 1996, J CELL BIOL, V135, P85, DOI 10.1083/jcb.135.1.85; HEUKESHOVEN J, 1988, ELECTROPHORESIS, V9, P28, DOI 10.1002/elps.1150090106; HIRANO T, 1990, CELL, V60, P319, DOI 10.1016/0092-8674(90)90746-2; Huhse B, 1998, J CELL BIOL, V140, P49, DOI 10.1083/jcb.140.1.49; Kunau WH, 1998, CURR OPIN MICROBIOL, V1, P232, DOI 10.1016/S1369-5274(98)80016-7; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMB JR, 1995, TRENDS BIOCHEM SCI, V20, P257, DOI 10.1016/S0968-0004(00)89037-4; NEER EJ, 1994, NATURE, V371, P297, DOI 10.1038/371297a0; Otera H, 1998, MOL CELL BIOL, V18, P388, DOI 10.1128/MCB.18.1.388; Pohlschroder M, 1997, CELL, V91, P563, DOI 10.1016/S0092-8674(00)80443-2; Rost B, 1996, METHOD ENZYMOL, V266, P525; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Schatz G, 1996, SCIENCE, V271, P1519, DOI 10.1126/science.271.5255.1519; STENBERG E, 1991, J COLLOID INTERF SCI, V143, P513, DOI 10.1016/0021-9797(91)90284-F; Subramani S, 1998, PHYSIOL REV, V78, P171, DOI 10.1152/physrev.1998.78.1.171; Subramani S, 1997, NAT GENET, V15, P331, DOI 10.1038/ng0497-331; TERLECKY SR, 1995, EMBO J, V14, P3627, DOI 10.1002/j.1460-2075.1995.tb00032.x; Waterham HR, 1997, BIOESSAYS, V19, P57, DOI 10.1002/bies.950190110; WIEMER EAC, 1995, J CELL BIOL, V130, P51, DOI 10.1083/jcb.130.1.51	32	144	144	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 26	1999	274	9					5666	5673		10.1074/jbc.274.9.5666	http://dx.doi.org/10.1074/jbc.274.9.5666			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	170KG	10026185	hybrid			2022-12-25	WOS:000078804400056
J	Zhang, LJ; Yoshida, K; Liu, J; Rosenberg, RD				Zhang, LJ; Yoshida, K; Liu, J; Rosenberg, RD			Anticoagulant heparan sulfate precursor structures in F9 embryonal carcinoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							D-GLUCOSAMINYL 3-O-SULFOTRANSFERASE; DEACETYLASE N-SULFOTRANSFERASE; ANTITHROMBIN-BINDING SEQUENCE; HEPATOCYTE GROWTH-FACTOR; MOLECULAR-CLONING; HIGH-AFFINITY; PROTEOGLYCANS; BIOSYNTHESIS; EXPRESSION; OLIGOSACCHARIDES	To understand the mechanisms that control anticoagulant heparan sulfate (HSact) biosynthesis, we previously showed that HSact production in the F9 system is determined by the abundance of 3-O-sulfotransferase-1 as well as the size of the HSact precursor pool. In this study, HSact precursor structures have been studied by characterizing [6-H-3]GlcN metabolically labeled F9 HS tagged with 3-O-sulfates in vitro by 3'-phosphoadenosine 5'-phospho-S-35 and purified 3-O-sulfotransferase-1. This later in vitro labeling allows the regions of HS destined to become the antithrombin (AT)-binding sites to be tagged for subsequent structural studies. It was shown that sig 3-O-sulfation sites exist per HSact precursor chain. At least five out of six 3-O-sulfate-tagged oligosaccharides in HSact precursors bind AT, whereas none of 3-O-sulfate-tagged oligosaccharides from HSinact precursors bind AT. When treated with low pH nitrous or heparitinase, 3-O-sulfate-tagged HSact and HSinact precursors exhibit clearly different structural features. 3-O-Sulfate-tagged HSact hexasaccharides were AT affinity purified and sequenced by chemical and enzymatic degradations. The 3-O-sulfate-tagged HSact hexasaccharides exhibited the following structures, Delta UA-[6-H-3]GlcNAc6S-GlcUA-[6-H-3]GlcNS3(35)S +/- 6S-IdceA2S-[6-H-3]GlcNS6S. The underlined 6- and 3-O-sulfates constitute the most critical groups for AT binding in view of the fact that the precursor hexasaccharides possess all the elements for AT binding except for the 3-O-sulfate moiety. The presence of five potential AT-binding precursor hexasaccharides in all HSact precursor chains demonstrates for the first time the processive assembly of specific sequence in HS. The difference in structures around potential 3-O-sulfate acceptor sites in HSact and HSinact precursors suggests that these precursors might be generated by different concerted assembly mechanisms in the same cell. This study permits us to understand better the nature of the HS biosynthetic pathway that leads to the generation of specific saccharide sequences.	MIT, Dept Biol, Cambridge, MA 02139 USA; Harvard Univ, Beth Israel Hosp, Sch Med, Dept Med, Boston, MA 02215 USA; Seikagaku Corp, Tokyo Res Inst, Tokyo 207, Japan	Massachusetts Institute of Technology (MIT); Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Seikagaku Corporation	Rosenberg, RD (corresponding author), MIT, Dept Biol, Bldg 68-480,77 Massachusetts Ave, Cambridge, MA 02139 USA.	rdrrosen@MIT.EDU			NHLBI NIH HHS [R-PO1-HL41484, HL66385] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL066385, P01HL041484] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ASHIKARI S, 1995, J BIOL CHEM, V270, P29586, DOI 10.1074/jbc.270.49.29586; ATHA DH, 1985, BIOCHEMISTRY-US, V24, P6723, DOI 10.1021/bi00344a063; ATHA DH, 1984, BIOCHEMISTRY-US, V23, P5801, DOI 10.1021/bi00319a020; ATHA DH, 1984, P NATL ACAD SCI-BIOL, V81, P1030, DOI 10.1073/pnas.81.4.1030; Bai XM, 1997, J BIOL CHEM, V272, P23172, DOI 10.1074/jbc.272.37.23172; Bai XM, 1996, J BIOL CHEM, V271, P17711, DOI 10.1074/jbc.271.30.17711; BAME KJ, 1994, BIOCHEM J, V303, P81, DOI 10.1042/bj3030081; BAME KJ, 1991, J BIOL CHEM, V266, P10287; BAME KJ, 1993, J BIOL CHEM, V268, P19956; Brickman YG, 1998, J BIOL CHEM, V273, P4350, DOI 10.1074/jbc.273.8.4350; CASU B, 1985, ADV CARBOHYD CHEM BI, V43, P51, DOI 10.1016/S0065-2318(08)60067-0; Cheung WF, 1996, BIOCHEMISTRY-US, V35, P5250, DOI 10.1021/bi952325b; CHOAY J, 1983, BIOCHEM BIOPH RES CO, V116, P492, DOI 10.1016/0006-291X(83)90550-8; DEAGOSTINI AL, 1990, P NATL ACAD SCI USA, V87, P9784, DOI 10.1073/pnas.87.24.9784; Dietrich CP, 1998, CELL MOL BIOL, V44, P417; ERIKSSON I, 1994, J BIOL CHEM, V269, P10438; Ernst S, 1998, P NATL ACAD SCI USA, V95, P4182, DOI 10.1073/pnas.95.8.4182; Feyzi E, 1997, J BIOL CHEM, V272, P24850, DOI 10.1074/jbc.272.40.24850; Feyzi E, 1998, J BIOL CHEM, V273, P13395, DOI 10.1074/jbc.273.22.13395; Feyzi E, 1997, J BIOL CHEM, V272, P5518, DOI 10.1074/jbc.272.9.5518; GALLAGHER JT, 1992, INT J BIOCHEM, V24, P553, DOI 10.1016/0020-711X(92)90326-V; GUIMOND S, 1993, J BIOL CHEM, V268, P23906; GUO Y, 1989, ANAL BIOCHEM, V176, P96, DOI 10.1016/0003-2697(89)90278-9; HAHNENBERGER R, 1993, GLYCOBIOLOGY, V3, P567, DOI 10.1093/glycob/3.6.567; HASHIMOTO Y, 1992, J BIOL CHEM, V267, P15744; IOZZO RV, 1989, J BIOL CHEM, V264, P2690; JACKSON RL, 1991, PHYSIOL REV, V71, P481, DOI 10.1152/physrev.1991.71.2.481; Jayson GC, 1998, J BIOL CHEM, V273, P51, DOI 10.1074/jbc.273.1.51; KJELLEN L, 1985, J BIOL CHEM, V260, P8416; KLEIN U, 1976, BIOCHEM BIOPH RES CO, V73, P569, DOI 10.1016/0006-291X(76)90848-2; KLEIN U, 1976, BIOCHEM BIOPH RES CO, V69, P158, DOI 10.1016/S0006-291X(76)80286-0; Koenig A, 1998, J CLIN INVEST, V101, P877, DOI 10.1172/JCI1509; KOJIMA T, 1992, J BIOL CHEM, V267, P4859; Kusche-Gullberg M, 1998, J BIOL CHEM, V273, P11902, DOI 10.1074/jbc.273.19.11902; LINDAHL U, 1983, J BIOL CHEM, V258, P9826; LINDAHL U, 1980, P NATL ACAD SCI-BIOL, V77, P6551, DOI 10.1073/pnas.77.11.6551; LINDAHL U, 1989, ANN NY ACAD SCI, V556, P36; Liu J, 1996, J BIOL CHEM, V271, P27072, DOI 10.1074/jbc.271.43.27072; LOGANATHAN D, 1990, BIOCHEMISTRY-US, V29, P4362, DOI 10.1021/bi00470a015; LYON M, 1994, J BIOL CHEM, V269, P11216; LYON M, 1994, J BIOL CHEM, V269, P11208; MACCARANA M, 1993, J BIOL CHEM, V268, P23898; Maccarana M, 1996, J BIOL CHEM, V271, P17804, DOI 10.1074/jbc.271.30.17804; MARCUM JA, 1989, ANN NY ACAD SCI, V556, P81; NURCOMBE V, 1993, SCIENCE, V260, P103, DOI 10.1126/science.7682010; OLDBERG A, 1980, BIOCHEMISTRY-US, V19, P5755, DOI 10.1021/bi00566a014; ORELLANA A, 1994, J BIOL CHEM, V269, P2270; PARTHASARATHY N, 1994, J BIOL CHEM, V269, P22391; Pikas DS, 1998, J BIOL CHEM, V273, P18770, DOI 10.1074/jbc.273.30.18770; Rosenberg RD, 1997, J CLIN INVEST, V99, P2062, DOI 10.1172/JCI119377; Rostand KS, 1997, INFECT IMMUN, V65, P1; SHWORAK NW, 1994, J BIOL CHEM, V269, P21204; Shworak NW, 1997, J BIOL CHEM, V272, P28008, DOI 10.1074/jbc.272.44.28008; SIVARAM P, 1995, J BIOL CHEM, V270, P29760; Toma L, 1998, J BIOL CHEM, V273, P22458, DOI 10.1074/jbc.273.35.22458; TURNBULL JE, 1992, J BIOL CHEM, V267, P10337; TURNBULL JE, 1990, BIOCHEM J, V265, P715, DOI 10.1042/bj2650715; VARKI A, 1997, J CLIN INVEST, V100, P31; VLODAVSKY I, 1983, CANCER RES, V43, P2704; YAMADA SH, 1993, J BIOL CHEM, V268, P4780; Zhang LJ, 1998, J BIOL CHEM, V273, P27998, DOI 10.1074/jbc.273.43.27998	61	24	24	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 26	1999	274	9					5681	5691		10.1074/jbc.274.9.5681	http://dx.doi.org/10.1074/jbc.274.9.5681			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	170KG	10026187	hybrid			2022-12-25	WOS:000078804400058
J	Krappmann, D; Emmerich, F; Kordes, U; Scharschmidt, E; Dorken, B; Scheidereit, C				Krappmann, D; Emmerich, F; Kordes, U; Scharschmidt, E; Dorken, B; Scheidereit, C			Molecular mechanisms of constitutive NF-kappa B/Rel activation in Hodgkin/Reed-Sternberg cells	ONCOGENE			English	Article						Hodgkin's disease; lymphoma; NF-kappa B; I kappa-B	UBIQUITIN-PROTEASOME PATHWAY; SIGNAL-INDUCED DEGRADATION; TUMOR-NECROSIS-FACTOR; B-ALPHA PROTEOLYSIS; RIBOSOMAL S6 KINASE; IN-VIVO; CYTOPLASMIC RETENTION; NUCLEAR TRANSLOCATION; INDUCED APOPTOSIS; DNA-BINDING	A common characteristic of malignant cells derived from patients wifh Hodgkin's disease (HD) is a high level of constitutive nuclear NF-kappa B/Rel activity, which stimulates proliferation and confers resistance to apoptosis, We have analysed the mechanisms that account for NF-kappa B activation in a panel of Hodgkin/Reed-Sternberg (H-RS) cell lines. Whereas two cell lines (L428 and KMH-2) expressed inactive I kappa B alpha, no significant changes in NF-kappa B or I kappa B expression were seen in other H-RS cells (L591, L1236 and HDLM-2), Constitutive NF-kappa-B was susceptible to inhibition by recombinant I kappa B alpha, suggesting that neither mutations in the NF-KB genes nor posttranslational modifications of NF-kappa B were involved. Endogenous I kappa B alpha was bound to p65 and displayed a very short half-life. I kappa B alpha. degradation could be blocked by inhibitors of the NF-kappa B activating pathway. Proteasomal inhibition caused an accumulation of phosphorylated I kappa B alpha and a reduction of NF-kappa B activity in HDLM-2 and L1236 cells. By in vitro kinase assays we demonstrate constitutive I kappa B kinase (IKK) activity in H-RS cells, indicating ongoing signal transduction, Furthermore, HRS cells secrete one or more factor(s) that were able to trigger NF-kappa B activation. We conclude that aberrant activation of IKK's, and in some cases defective I kappa Bs, lead to constitutive nuclear NF-kappa B activity, which in turn results in a growth advantage of Hodgkin's disease tumor cells.	Max Delbruck Ctr Mol Med, D-13122 Berlin, Germany; Humboldt Univ, Univ Klinikum Charite, D-13122 Berlin, Germany	Helmholtz Association; Max Delbruck Center for Molecular Medicine; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Scheidereit, C (corresponding author), Max Delbruck Ctr Mol Med, Robert Rossle Str 10, D-13122 Berlin, Germany.		Krappmann, Daniel/AAT-4354-2021; Krappmann, Daniel/ABF-4038-2021	Krappmann, Daniel/0000-0001-7640-3234; Krappmann, Daniel/0000-0001-7640-3234; Kordes, Uwe R./0000-0001-6375-2320				Baldi L, 1996, J BIOL CHEM, V271, P376, DOI 10.1074/jbc.271.1.376; Bargou RC, 1997, J CLIN INVEST, V100, P2961, DOI 10.1172/JCI119849; Bargou RC, 1996, BLOOD, V87, P4340, DOI 10.1182/blood.V87.10.4340.bloodjournal87104340; BARROGA CF, 1995, P NATL ACAD SCI USA, V92, P7637, DOI 10.1073/pnas.92.17.7637; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BEG AA, 1992, GENE DEV, V6, P1899, DOI 10.1101/gad.6.10.1899; BEG AA, 1995, GENE DEV, V9, P2736, DOI 10.1101/gad.9.22.2736; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; DiDonato J, 1996, MOL CELL BIOL, V16, P1295; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; ERNST MK, 1995, MOL CELL BIOL, V15, P872; FOSS HD, 1993, BRIT J HAEMATOL, V84, P627, DOI 10.1111/j.1365-2141.1993.tb03138.x; GANCHI PA, 1992, MOL BIOL CELL, V3, P1339, DOI 10.1091/mbc.3.12.1339; Ghoda L, 1997, J BIOL CHEM, V272, P21281, DOI 10.1074/jbc.272.34.21281; Gilmore TD, 1997, J CLIN INVEST, V100, P2935, DOI 10.1172/JCI119843; HATADA EN, 1993, EMBO J, V12, P2781, DOI 10.1002/j.1460-2075.1993.tb05939.x; HENKEL T, 1993, NATURE, V365, P182, DOI 10.1038/365182a0; Hirano F, 1998, MOL CELL BIOL, V18, P2596, DOI 10.1128/MCB.18.5.2596; HSU PL, 1989, AM J PATHOL, V135, P735; HSU SM, 1994, CRIT REV ONCOGENESIS, V5, P213, DOI 10.1615/CritRevOncog.v5.i2-3.60; KALTSCHMIDT C, 1994, MOL CELL BIOL, V14, P3981, DOI 10.1128/MCB.14.6.3981; Kanzler H, 1996, BLOOD, V87, P3429, DOI 10.1182/blood.V87.8.3429.bloodjournal8783429; KAUFMAN D, 1992, CRIT REV ONCOL HEMAT, V13, P135, DOI 10.1016/1040-8428(92)90021-H; Krappmann D, 1997, IMMUNOBIOLOGY, V198, P3, DOI 10.1016/S0171-2985(97)80022-8; Krappmann D, 1996, EMBO J, V15, P6716, DOI 10.1002/j.1460-2075.1996.tb01061.x; Kuppers R, 1996, ANN ONCOL, V7, P27; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Luque I, 1997, SEMIN CANCER BIOL, V8, P103, DOI 10.1006/scbi.1997.0061; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; Maniatis T, 1997, SCIENCE, V278, P818, DOI 10.1126/science.278.5339.818; MAY MJ, 1997, SEMIN CANCER BIOL, V8, P61; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Miyamoto S, 1998, MOL CELL BIOL, V18, P19, DOI 10.1128/MCB.18.1.19; MIYAMOTO S, 1994, MOL CELL BIOL, V14, P3276, DOI 10.1128/MCB.14.5.3276; NAUMANN M, 1993, EMBO J, V12, P213, DOI 10.1002/j.1460-2075.1993.tb05647.x; NAUMANN M, 1994, EMBO J, V13, P4597, DOI 10.1002/j.1460-2075.1994.tb06781.x; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; RICE NR, 1993, EMBO J, V12, P4685, DOI 10.1002/j.1460-2075.1993.tb06157.x; RODRIGUEZ C, 1995, YEAST, V11, P15, DOI 10.1002/yea.320110103; Rodriguez MS, 1996, ONCOGENE, V12, P2425; Roff M, 1996, J BIOL CHEM, V271, P7844, DOI 10.1074/jbc.271.13.7844; SCHERER DC, 1995, P NATL ACAD SCI USA, V92, P11259, DOI 10.1073/pnas.92.24.11259; SchmidtUllrich R, 1996, DEVELOPMENT, V122, P2117; Schouten GJ, 1997, EMBO J, V16, P3133, DOI 10.1093/emboj/16.11.3133; SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X; Serrano D, 1997, HAEMATOLOGICA, V82, P542; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; Sonenshein GE, 1997, SEMIN CANCER BIOL, V8, P113, DOI 10.1006/scbi.1997.0062; Sovak MA, 1997, J CLIN INVEST, V100, P2952, DOI 10.1172/JCI119848; Stancovski I, 1997, CELL, V91, P299, DOI 10.1016/S0092-8674(00)80413-4; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; TRAENCKNER EBM, 1994, EMBO J, V13, P5433, DOI 10.1002/j.1460-2075.1994.tb06878.x; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Visconti R, 1997, ONCOGENE, V15, P1987, DOI 10.1038/sj.onc.1201373; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Watanabe N, 1997, EMBO J, V16, P3609, DOI 10.1093/emboj/16.12.3609; WHITESIDE ST, 1995, MOL CELL BIOL, V15, P5339; Wolf J, 1996, BLOOD, V87, P3418, DOI 10.1182/blood.V87.8.3418.bloodjournal8783418; Wood KM, 1998, ONCOGENE, V16, P2131, DOI 10.1038/sj.onc.1201735; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Wu M, 1996, EMBO J, V15, P4682, DOI 10.1002/j.1460-2075.1996.tb00845.x; Wulczyn FG, 1998, NUCLEIC ACIDS RES, V26, P1724, DOI 10.1093/nar/26.7.1724; Wulczyn FG, 1996, J MOL MED, V74, P749, DOI 10.1007/s001090050078; XERRI L, 1992, INT J CANCER, V50, P689, DOI 10.1002/ijc.2910500504; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7	70	233	239	0	6	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 28	1999	18	4					943	953		10.1038/sj.onc.1202351	http://dx.doi.org/10.1038/sj.onc.1202351			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	165FT	10023670				2022-12-25	WOS:000078510600011
J	Sweetser, DA; Froelick, GJ; Matsumoto, AM; Kafer, KE; Marck, B; Palmiter, RD; Kapur, RP				Sweetser, DA; Froelick, GJ; Matsumoto, AM; Kafer, KE; Marck, B; Palmiter, RD; Kapur, RP			Ganglioneuromas and renal anomalies are induced by activated RETMEN2B in transgenic mice	ONCOGENE			English	Article						ganglioneuroma; ret proto-oncogene; multiple endocrine neoplasia; renal agenesis; neuroblastoma; transgenic; autonomic nervous system	MEDULLARY-THYROID CARCINOMA; TYROSINE KINASE DOMAIN; ENTERIC NERVOUS-SYSTEM; NEOPLASIA TYPE 2B; RET PROTOONCOGENE; CELL-LINE; C-RET; SYMPATHOADRENAL LINEAGE; SYMPATHETIC NEUROBLASTS; KIDNEY DEVELOPMENT	Multiple endocrine neoplasia type 2B (MEN2B) is an autosomal dominant syndrome characterized by the development of medullary thyroid carcinoma, pheochromocytomas, musculoskeletal anomalies and mucosal ganglioneuromas, MEN2B is caused by a specific mutation (Met918 --> Thr) in the RET receptor tyrosine kinase, Different mutations of RET lead to other conditions including MEN2A, familial medullary thyroid carcinoma and intestinal aganglionosis (Hirschsprung disease). Transgenic mice were created using the dopamine beta-hydroxylase promoter to direct expression of RETMEN2B the developing sympathetic and enteric nervous systems and the adrenal medulla, D beta H-RETMEN2B transgenic mice developed benign neuroglial tumors, histologically identical to human ganglioneuromas, in their sympathetic nervous systems and adrenal glands. The enteric nervous system was not affected. The neoplasms in D beta H-RETMEN2B mice were similar to benign neuroglial tumors induced in transgenic mice by activated Ras expression under control of the same promoter, Levels of phoshorylated MAP kinase were not increased in the RETMEN2B-induced neurolgial proliferations, suggesting that alternative pathways may play a role in the pathogenesis of these lesions, Transgenic mice with the highest levels of D beta H-RETMEN2B expression, unexpectedly developed renal malformations analogous to those reported with loss of function mutations in the Ret gene.	Fred Hutchinson Canc Res Ctr, Seattle, WA 98105 USA; Univ Washington, Med Ctr, Howard Hughes Med Inst, Dept Biochem, Seattle, WA 98195 USA; Univ Washington, Med Ctr, Dept Pathol, Seattle, WA 98195 USA; Univ Washington, Sch Med, Dept Med, Seattle, WA 98108 USA; Univ Washington, Sch Med, Populat Ctr Res Reprod, Seattle, WA 98108 USA; VA Puget Sound Hlth Care Syst, Ctr Geriatr Res Educ & Clin, Seattle, WA 98108 USA	Fred Hutchinson Cancer Center; Howard Hughes Medical Institute; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Geriatric Research Education & Clinical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Vet Affairs Puget Sound Health Care System	Sweetser, DA (corresponding author), Fred Hutchinson Canc Res Ctr, 1100 Fairview Ave N,C1-169, Seattle, WA 98105 USA.		Matsumoto, Alvin/AAH-6096-2020; Sweetser, David/ABB-9347-2021	Sweetser, David/0000-0002-1621-3284	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P50HD012629] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [T32CA009351] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052530] Funding Source: NIH RePORTER; NCI NIH HHS [T32CA09351] Funding Source: Medline; NICHD NIH HHS [HD12629] Funding Source: Medline; NIDDK NIH HHS [R01DK52530] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSON DJ, 1993, ANNU REV NEUROSCI, V16, P129, DOI 10.1146/annurev.ne.16.030193.001021; BALJET B, 1975, STAIN TECHNOL, V50, P31, DOI 10.3109/10520297509117028; BIRREN SJ, 1993, DEVELOPMENT, V119, P597; Borrello MG, 1995, ONCOGENE, V11, P2419; BRANNAN CI, 1994, GENE DEV, V8, P1019, DOI 10.1101/gad.8.9.1019; BRODEUR GM, 1997, PRINCIPLES PRACTICE; BUCHMAN VL, 1993, DEVELOPMENT, V118, P989; Califano D, 1996, P NATL ACAD SCI USA, V93, P7933, DOI 10.1073/pnas.93.15.7933; CARLSON KM, 1993, DEVELOPMENT, V119, P1005; CARNAHAN JF, 1991, DEV BIOL, V148, P552, DOI 10.1016/0012-1606(91)90273-6; DALESSIO A, 1995, CELL GROWTH DIFFER, V6, P1387; DARCANGELO G, 1993, MOL CELL BIOL, V13, P3146, DOI 10.1128/MCB.13.6.3146; Durbec PL, 1996, DEVELOPMENT, V122, P349; Edery P, 1997, BIOESSAYS, V19, P389, DOI 10.1002/bies.950190506; EDERY P, 1994, NATURE, V367, P378, DOI 10.1038/367378a0; ENG C, 1994, HUM MOL GENET, V3, P237, DOI 10.1093/hmg/3.2.237; ForssPetter S, 1997, J NEUROSCI RES, V50, P829, DOI 10.1002/(SICI)1097-4547(19971201)50:5<829::AID-JNR19>3.0.CO;2-W; HEINICKE EA, 1987, J NEUROSCI METH, V21, P45, DOI 10.1016/0165-0270(87)90101-4; HOFSTRA RMW, 1994, NATURE, V367, P375, DOI 10.1038/367375a0; IKEDA I, 1990, ONCOGENE, V5, P1291; IKUNO N, 1995, PATHOL RES PRACT, V191, P92, DOI 10.1016/S0344-0338(11)80558-3; Iwashita T, 1996, ONCOGENE, V12, P481; JHIANG SM, 1992, ONCOGENE, V7, P1331; KAPUR RP, 1992, DEVELOPMENT, V116, P167; KAPUR RP, 1991, NEURON, V7, P717, DOI 10.1016/0896-6273(91)90275-5; Kusafuka T, 1996, PEDIATR SURG INT, V12, P11, DOI 10.1007/BF01194794; Lechner MS, 1997, MECH DEVELOP, V62, P105, DOI 10.1016/S0925-4773(97)00667-9; Liu ZZ, 1996, DEV BIOL, V178, P133, DOI 10.1006/dbio.1996.0204; MERCER EH, 1991, NEURON, V7, P703, DOI 10.1016/0896-6273(91)90274-4; Michiels FM, 1997, P NATL ACAD SCI USA, V94, P3330, DOI 10.1073/pnas.94.7.3330; Moore MW, 1996, NATURE, V382, P76, DOI 10.1038/382076a0; PACHNIS V, 1993, DEVELOPMENT, V119, P1005; Pichel JG, 1996, NATURE, V382, P73, DOI 10.1038/382073a0; Rizzo C, 1996, J BIOL CHEM, V271, P29497, DOI 10.1074/jbc.271.46.29497; ROMEO G, 1994, NATURE, V367, P377, DOI 10.1038/367377a0; Rossel M, 1997, ONCOGENE, V14, P265, DOI 10.1038/sj.onc.1200831; SANTORO M, 1994, MOL CELL BIOL, V14, P663, DOI 10.1128/MCB.14.1.663; SANTORO M, 1992, J CLIN INVEST, V89, P1517, DOI 10.1172/JCI115743; SANTORO M, 1995, SCIENCE, V267, P381, DOI 10.1126/science.7824936; SCHUCHARDT A, 1994, NATURE, V367, P380, DOI 10.1038/367380a0; Schuchardt A, 1996, DEVELOPMENT, V122, P1919; SEARLE PF, 1984, MOL CELL BIOL, V4, P1221, DOI 10.1128/MCB.4.7.1221; SNOUWAERT JN, 1992, SCIENCE, V257, P1083, DOI 10.1126/science.257.5073.1083; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; Sweetser DA, 1997, ONCOGENE, V15, P2783, DOI 10.1038/sj.onc.1201452; TAHIRA T, 1990, ONCOGENE, V5, P97; TAKAHASHI M, 1989, ONCOGENE, V4, P805; TAKAHASHI M, 1988, ONCOGENE, V3, P571; TSUZUKI T, 1995, ONCOGENE, V10, P191; vanWeering DHJ, 1997, J BIOL CHEM, V272, P249; Vega QC, 1996, P NATL ACAD SCI USA, V93, P10657, DOI 10.1073/pnas.93.20.10657; WAJJWALKU W, 1992, JPN J CANCER RES, V83, P671, DOI 10.1111/j.1349-7006.1992.tb01963.x; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; Worby CA, 1996, J BIOL CHEM, V271, P23619, DOI 10.1074/jbc.271.39.23619	54	38	39	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 28	1999	18	4					877	886		10.1038/sj.onc.1202376	http://dx.doi.org/10.1038/sj.onc.1202376			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	165FT	10023663				2022-12-25	WOS:000078510600004
J	Wenger, C; Ellenrieder, V; Alber, B; Lacher, U; Menke, A; Hameister, H; Wilda, M; Iwamura, T; Beger, HG; Adler, G; Gress, TM				Wenger, C; Ellenrieder, V; Alber, B; Lacher, U; Menke, A; Hameister, H; Wilda, M; Iwamura, T; Beger, HG; Adler, G; Gress, TM			Expression and differential regulation of connective tissue growth factor in pancreatic cancer cells	ONCOGENE			English	Article						CTGF; pancreatic cancer; fibrosis; TGF alpha; TGF beta	FACTOR GENE-EXPRESSION; IMMEDIATE-EARLY GENE; INHIBITION; PROTEIN; LOCALIZATION; SECTIONS; PRODUCT; MATRIX; ALPHA; CYR61	CTGF is an immediate early growth responsive gene that has been shown to be a downstream mediator of TGF beta actions in fibroblasts and vascular endothelial cells, In the present study hCTGF was isolated as immediate early target gene of EGF/TGF alpha in human pancreatic cancer cells by suppression hybridization, CTGF transcripts were found in 13/15 pancreatic cancer cell lines incubated with 10% serum, In 3/7 pancreatic cancer cell lines EGF/TGF alpha induced a significant rise of CTGF transcript levels peaking 1-2 h after the start of treatment. TGF beta increased CTGF transcript levels in 2/7 pancreatic cancer cell lines after 4 h of treatment and this elevation was sustained after 24 h, Only treatment with TGF beta was accompanied by a parallel induction of collagen type I transcription. 15/19 human pancreatic cancer tissues were shown to overexpress high levels of CTGF transcripts. CTGF transcript levels in pancreatic cancer tissues and nude mouse xenograft tumors showed a good correlation to the degree of fibrosis, III situ hybridization and the nude mouse experiments revealed that in pancreatic cancer tissues, fibroblasts are the predominant site of CTGF transcription, whereas the tumor cells appear to contribute to a lesser extent. We conclude that CTGF may be of paramount importance for the development of the characteristic desmoplastic reaction in pancreatic cancer tissues.	Univ Ulm, Dept Internal Med 1, D-89081 Ulm, Germany; Univ Ulm, Dept Med Genet, D-89070 Ulm, Germany; Univ Ulm, Dept Gen Surg, D-89070 Ulm, Germany; Miyazaki Prefectural Gen Hosp, Miyazaki 880, Japan	Ulm University; Ulm University; Ulm University	Wenger, C (corresponding author), Univ Ulm, Dept Internal Med 1, Robert Koch Str 8, D-89081 Ulm, Germany.			Gress, Thomas/0000-0002-9333-5461				Baldwin RL, 1996, INT J CANCER, V67, P283, DOI 10.1002/(SICI)1097-0215(19960717)67:2<283::AID-IJC21>3.0.CO;2-B; BOCKMAN DE, 1992, GASTROENTEROLOGY, V103, P1883, DOI 10.1016/0016-5085(92)91448-D; BRADHAM DM, 1991, J CELL BIOL, V114, P1285, DOI 10.1083/jcb.114.6.1285; Frazier K, 1996, J INVEST DERMATOL, V107, P404, DOI 10.1111/1523-1747.ep12363389; Frazier KS, 1997, INT J BIOCHEM CELL B, V29, P153, DOI 10.1016/S1357-2725(96)00127-6; FRIESS H, 1993, GASTROENTEROLOGY, V105, P1846, DOI 10.1016/0016-5085(93)91084-U; Grau AM, 1997, CANCER RES, V57, P3929; Grotendorst Gary R., 1997, Cytokine and Growth Factor Reviews, V8, P171, DOI 10.1016/S1359-6101(97)00010-5; Grotendorst GR, 1996, CELL GROWTH DIFFER, V7, P469; IGARASHI A, 1995, J INVEST DERMATOL, V105, P280, DOI 10.1111/1523-1747.ep12318465; IGARASHI A, 1993, MOL BIOL CELL, V4, P637, DOI 10.1091/mbc.4.6.637; Kireeva ML, 1996, MOL CELL BIOL, V16, P1326; Kireeva ML, 1997, EXP CELL RES, V233, P63, DOI 10.1006/excr.1997.3548; LOPEZDELEON A, 1985, J HISTOCHEM CYTOCHEM, V33, P737, DOI 10.1177/33.8.2410480; Menke A, 1997, GASTROENTEROLOGY, V113, P295, DOI 10.1016/S0016-5085(97)70107-0; Oemar BS, 1997, ARTERIOSCL THROM VAS, V17, P1483, DOI 10.1161/01.ATV.17.8.1483; RYSECK RP, 1991, CELL GROWTH DIFFER, V2, P225; Sanvito F, 1995, BIOCHEM BIOPH RES CO, V217, P1279, DOI 10.1006/bbrc.1995.2906; Schutte M, 1996, CANCER RES, V56, P2527; TANIGUCHI S, 1992, CLIN EXP METASTAS, V10, P259; VANLAETHEM JL, 1995, GASTROENTEROLOGY, V108, P1873, DOI 10.1016/0016-5085(95)90152-3; Xin LW, 1996, J CLIN PATHOL-CL MOL, V49, pM91	22	158	168	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 28	1999	18	4					1073	1080		10.1038/sj.onc.1202395	http://dx.doi.org/10.1038/sj.onc.1202395			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	165FT	10023684				2022-12-25	WOS:000078510600025
J	El-Jack, AK; Hamm, JK; Pilch, PF; Farmer, SR				El-Jack, AK; Hamm, JK; Pilch, PF; Farmer, SR			Reconstitution of insulin-sensitive glucose transport in fibroblasts requires expression of both PPAR gamma and C/EBP alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REGULATED MEMBRANE AMINOPEPTIDASE; BINDING-PROTEIN-ALPHA; NECROSIS-FACTOR-ALPHA; 3T3-L1 ADIPOCYTES; ECTOPIC EXPRESSION; GENE-EXPRESSION; ADIPOGENESIS; GLUT4; CELLS; VESICLES	Adipocyte differentiation is regulated by at least two major transcription factors, CCAAT/enhancer-binding protein alpha (C/EBP alpha) and peroxisome proliferator-activated receptor gamma (PPAR gamma), Expression of PPAR gamma in fibroblasts converts them to fat-laden cells with an adipocyte-like morphology. Here, we investigate the ability of PPAR gamma to confer insulin-sensitive glucose transport to a variety of murine fibroblast cell lines. When cultured in the presence of a PPAR gamma ligand, Swiss-3T3 and BALB/c-3T3 cells ectopically expressing PPAR gamma accumulate lipid droplets, express C/EBP alpha, aP2, insulin-responsive aminopeptidase, and glucose transporter isoform 4 (GLUT4), and exhibit highly insulin-responsive 2-deoxyglucose uptake. In contrast, PPAR gamma-expressing NIH-3T3 cells, despite similar lipid accumulation, adipocyte morphology, and aP2 expression, do not express C/EBP alpha or GLUT4 and fail to acquire insulin sensitivity. In cells ectopically expressing PPAR gamma, the development of insulin-responsive glucose uptake correlates with C/EBP alpha expression. Furthermore, ectopic expression of C/EBP alpha in NIH-3T3 cells converts them to the adipocyte phenotype and restores insulin-sensitive glucose uptake. We propose that the pathway(s) leading to fat accumulation and morphological changes are distinct from that leading to insulin-dependent glucose transport. Our results suggest that although PPAR gamma is sufficient to trigger the adipogenic program, C/EBP alpha is required for establishment of insulin-sensitive glucose transport.	Boston Univ, Sch Med, Dept Biochem, Boston, MA 02118 USA	Boston University	Farmer, SR (corresponding author), Boston Univ, Sch Med, Dept Biochem, 715 Albany St, Boston, MA 02118 USA.	farmer@med-biochem.bu.edu		Farmer, Stephen/0000-0003-2483-2795; Pilch, Paul/0000-0003-1997-0499; El Jack, Amr/0000-0002-5892-5538	NIDDK NIH HHS [DK30425, DK35424, DK51586] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK051586, R01DK030425, R01DK051586] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Braissant O, 1996, ENDOCRINOLOGY, V137, P354, DOI 10.1210/en.137.1.354; Brun RP, 1996, GENE DEV, V10, P974, DOI 10.1101/gad.10.8.974; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CORNELIUS P, 1994, ANNU REV NUTR, V14, P99, DOI 10.1146/annurev.nu.14.070194.000531; CORNELIUS P, 1990, J BIOL CHEM, V265, P20506; Darlington GJ, 1998, J BIOL CHEM, V273, P30057, DOI 10.1074/jbc.273.46.30057; DEHERREROS AG, 1989, J BIOL CHEM, V264, P19994; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; FREYTAG SO, 1994, GENE DEV, V8, P1654, DOI 10.1101/gad.8.14.1654; HANEY PM, 1991, J CELL BIOL, V114, P689, DOI 10.1083/jcb.114.4.689; HU ED, 1995, P NATL ACAD SCI USA, V92, P9856, DOI 10.1073/pnas.92.21.9856; HUDSON AW, 1992, J CELL BIOL, V116, P785, DOI 10.1083/jcb.116.3.785; JAMES DE, 1988, NATURE, V333, P183, DOI 10.1038/333183a0; KAESTNER KH, 1990, P NATL ACAD SCI USA, V87, P251, DOI 10.1073/pnas.87.1.251; KANDROR KV, 1995, J CELL BIOL, V129, P999, DOI 10.1083/jcb.129.4.999; KANDROR KV, 1994, P NATL ACAD SCI USA, V91, P8017, DOI 10.1073/pnas.91.17.8017; KANDROR KV, 1995, BIOCHEM J, V307, P383, DOI 10.1042/bj3070383; KELLER SR, 1995, J BIOL CHEM, V270, P23612, DOI 10.1074/jbc.270.40.23612; KOTLIAR N, 1992, MOL ENDOCRINOL, V6, P337, DOI 10.1210/me.6.3.337; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; LIN FT, 1994, P NATL ACAD SCI USA, V91, P8757, DOI 10.1073/pnas.91.19.8757; LIN FT, 1992, GENE DEV, V6, P533, DOI 10.1101/gad.6.4.533; Mandrup S, 1997, J BIOL CHEM, V272, P5367, DOI 10.1074/jbc.272.9.5367; Ogawa W, 1998, MOL CELL BIOCHEM, V182, P13, DOI 10.1023/A:1006862807598; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Rea S, 1997, DIABETES, V46, P1667, DOI 10.2337/diabetes.46.11.1667; Ross SA, 1996, J BIOL CHEM, V271, P3328, DOI 10.1074/jbc.271.6.3328; SCHERER PE, 1994, J CELL BIOL, V127, P1233, DOI 10.1083/jcb.127.5.1233; Schoonjans K, 1996, BBA-LIPID LIPID MET, V1302, P93, DOI 10.1016/0005-2760(96)00066-5; Schwarz EJ, 1997, MOL CELL BIOL, V17, P1552, DOI 10.1128/MCB.17.3.1552; Shulman RG, 1996, MOL MED, V2, P533, DOI 10.1007/BF03401638; Stephens JM, 1997, J BIOL CHEM, V272, P971, DOI 10.1074/jbc.272.2.971; TEBOUL L, 1995, J BIOL CHEM, V270, P28183, DOI 10.1074/jbc.270.47.28183; TONTONOZ P, 1995, MOL CELL BIOL, V15, P351, DOI 10.1128/MCB.15.1.351; TONTONOZ P, 1994, GENE DEV, V8, P1224, DOI 10.1101/gad.8.10.1224; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; WANG ND, 1995, SCIENCE, V269, P1108, DOI 10.1126/science.7652557; Wu ZD, 1998, J CLIN INVEST, V101, P22, DOI 10.1172/JCI1244; WU ZD, 1995, GENE DEV, V9, P2350, DOI 10.1101/gad.9.19.2350; YEH WC, 1995, GENE DEV, V9, P168, DOI 10.1101/gad.9.2.168	41	164	176	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 19	1999	274	12					7946	7951		10.1074/jbc.274.12.7946	http://dx.doi.org/10.1074/jbc.274.12.7946			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	178LU	10075691	hybrid			2022-12-25	WOS:000079268100050
J	Morishige, K; Inanobe, A; Yoshimoto, Y; Kurachi, H; Murata, Y; Tokunaga, Y; Maeda, T; Maruyama, Y; Kurachi, Y				Morishige, K; Inanobe, A; Yoshimoto, Y; Kurachi, H; Murata, Y; Tokunaga, Y; Maeda, T; Maruyama, Y; Kurachi, Y			Secretagogue-induced exocytosis recruits G protein-gated K+ channels to plasma membrane in endocrine cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT ANTERIOR-PITUITARY; POTASSIUM CHANNEL; MOLECULAR-PROPERTIES; INWARD RECTIFIER; EXPRESSION; BRAIN; GIRK1; LOCALIZATION; ACTIVATION; LACTOTROPHS	Stimulation-regulated fusion of vesicles to the plasma membrane is an essential step for hormone secretion but may also serve for the recruitment of functional proteins to the plasma membrane. While studying the distribution of G protein-gated K+ (K-G) channels in the anterior pituitary lobe, we found K-G channel subunits Kir3.1 and Kir3.4 localized on the membranes of intracellular dense core vesicles that contained thyrotropin. Stimulation of these thyrotroph cells with thyrotropin-releasing hormone provoked fusion of vesicles to the plasma membrane, increased expression of Kir3.1 and Kir3.4 subunits in the plasma membrane, and markedly enhanced K-G currents stimulated by dopamine and somatostatin, These data indicate a novel mechanism for the rapid insertion of functional ion channels into the plasma membrane, which could form a new type of negative feedback control loop for hormone secretion in the endocrine system.	Osaka Univ, Dept Pharmacol 2, Fac Med, Suita, Osaka 5650871, Japan; Osaka Univ, Dept Obstet & Gynecol, Fac Med, Suita, Osaka 5650871, Japan; Osaka Univ, Grad Sch Med, Suita, Osaka 5650871, Japan; Shiga Univ Med Sci, Dept Anat 1, Otsu, Shiga 5202120, Japan; Tohoku Univ, Grad Sch Med, Dept Physiol, Sendai, Miyagi 9800872, Japan	Osaka University; Osaka University; Osaka University; Shiga University of Medical Science; Tohoku University	Kurachi, Y (corresponding author), Osaka Univ, Dept Pharmacol 2, Fac Med, Suita, Osaka 5650871, Japan.							CROYLE ML, 1986, DNA-J MOLEC CELL BIO, V5, P299, DOI 10.1089/dna.1986.5.299; DASCAL N, 1993, P NATL ACAD SCI USA, V90, P10235, DOI 10.1073/pnas.90.21.10235; EINHORN LC, 1993, J PHYSIOL-LONDON, V462, P563, DOI 10.1113/jphysiol.1993.sp019569; FERRER J, 1995, J BIOL CHEM, V270, P26086, DOI 10.1074/jbc.270.44.26086; FOMINA AF, 1995, J NEUROSCI, V15, P4982; HILLE B, 1992, NEURON, V9, P187, DOI 10.1016/0896-6273(92)90158-A; Iizuka M, 1997, NEUROSCIENCE, V77, P1, DOI 10.1016/S0306-4522(96)00460-5; INANOBE A, 1995, BIOCHEM BIOPH RES CO, V212, P1022, DOI 10.1006/bbrc.1995.2072; Ishii M, 1997, J NEUROSCI, V17, P7725; Karschin C, 1996, J NEUROSCI, V16, P3559; KARSCHIN C, 1994, FEBS LETT, V348, P139, DOI 10.1016/0014-5793(94)00590-7; KRAPIVINSKY G, 1995, NATURE, V374, P135, DOI 10.1038/374135a0; KUBO Y, 1993, NATURE, V364, P802, DOI 10.1038/364802a0; KURACHI Y, 1995, AM J PHYSIOL-CELL PH, V269, pC821, DOI 10.1152/ajpcell.1995.269.4.C821; LESAGE F, 1995, J BIOL CHEM, V270, P28660, DOI 10.1074/jbc.270.48.28660; LESAGE F, 1994, FEBS LETT, V353, P37, DOI 10.1016/0014-5793(94)01007-2; Liao YJ, 1996, J NEUROSCI, V16, P7137; MARTIN JB, 1970, SCIENCE, V168, P1366, DOI 10.1126/science.168.3937.1366; Maruyama Y, 1996, J PHYSIOL-LONDON, V492, P807, DOI 10.1113/jphysiol.1996.sp021347; Morishige K, 1996, BIOCHEM BIOPH RES CO, V220, P300, DOI 10.1006/bbrc.1996.0400; NEHER E, 1982, P NATL ACAD SCI-BIOL, V79, P6712, DOI 10.1073/pnas.79.21.6712; NORTH RA, 1989, BRIT J PHARMACOL, V98, P13, DOI 10.1111/j.1476-5381.1989.tb16855.x; Nusser Z, 1998, NATURE, V395, P172, DOI 10.1038/25999; OZAWA H, 1989, ANAT EMBRYOL, V180, P207, DOI 10.1007/BF00309773; Passafaro M, 1996, J BIOL CHEM, V271, P30096, DOI 10.1074/jbc.271.47.30096; PENNEFATHER PS, 1988, BRAIN RES, V444, P346, DOI 10.1016/0006-8993(88)90944-4; Ponce A, 1996, J NEUROSCI, V16, P1990; RORSMAN P, 1991, NATURE, V349, P77, DOI 10.1038/349077a0; SUCHER NJ, 1995, NEURON, V14, P1095, DOI 10.1016/0896-6273(95)90257-0; TADOKORO C, 1995, BIOCHEM BIOPH RES CO, V214, P1211, DOI 10.1006/bbrc.1995.2415; Wan Q, 1997, NATURE, V388, P686, DOI 10.1038/41792; WOJTOWICZ JM, 1994, J NEUROSCI, V14, P3688; YATANI A, 1987, MOL ENDOCRINOL, V1, P283, DOI 10.1210/mend-1-4-283	33	31	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 19	1999	274	12					7969	7974		10.1074/jbc.274.12.7969	http://dx.doi.org/10.1074/jbc.274.12.7969			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	178LU	10075694	hybrid			2022-12-25	WOS:000079268100053
J	Qazi, U; Gettins, PGW; Strickland, DK; Stoops, JK				Qazi, U; Gettins, PGW; Strickland, DK; Stoops, JK			Structural details of proteinase entrapment by human alpha(2)-macroglobulin emerge from three-dimensional reconstructions of Fab labeled native, half-transformed, and transformed molecules	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR RECOGNITION SITE; HUMAN ALPHA-2-MACROGLOBULIN; 3-DIMENSIONAL STRUCTURE; ELECTRON-MICROSCOPY; ALPHA-MACROGLOBULINS; BAIT REGION; METHYLAMINE; LOCALIZATION; COMPLEXES; IMAGES	Three-dimensional electron microscopy reconstructions of native, half-transformed, and transformed alpha(2)-macroglobulins (alpha(2)Ms) labeled with a monoclonal Fab Fab offer new insight into the mechanism of its proteinase entrapment. Each alpha(2)M binds four Fabs, two at either end of its dimeric protomers approximately 145 Angstrom apart. in the native structure, the epitopes are near the base of its two chisel-like features, laterally separated by 129 Angstrom whereas in the methylamine-transformed alpha(2)M, the epitopes are at the base of its four arms, laterally separated by 160 A. Upon thiol ester cleavage, the chisels on the native alpha(2)M appear to split with a separation and rotation to give the four arm-like extensions on transformed alpha(2)M. Thus, the receptor binding domains previously enclosed within the chisels are exposed. The labeled structures further indicate that the two protomeric strands that constitute the native and transformed molecules are related and reside one on each side of the major axes of these structures. The half-transformed structure shows that the two Fabs at one end of the molecule have an arrangement similar to those on the native alpha(2)M, whereas on its transformed end, they have rotated. The rotation is associated with a partial untwisting of the strands and an enlargement of the openings to the cavity, We propose that the enlarged openings permit the entrance of the proteinase. Then cleavage of the remaining bait domains by a second proteinase occurs with its entrance into the cavity, This is followed by a retwisting of the strands to encapsulate the proteinases and expose the receptor binding domains associated with the transformed alpha(2)M.	Univ Texas, Sch Med, Dept Pathol & Lab Med, Houston, TX 77030 USA; Univ Illinois, Dept Biochem, Chicago, IL 60612 USA; Amer Red Cross, Jerome H Holland Lab, Dept Vasc Biol, Rockville, MD 20855 USA	University of Texas System; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; American Red Cross	Stoops, JK (corresponding author), Univ Texas, Sch Med, Dept Pathol & Lab Med, 6431 Fannin St, Houston, TX 77030 USA.	stoops@casper.med.uth.tmc.edu			NHLBI NIH HHS [HL 42886, HL 50744] Funding Source: Medline; NIGMS NIH HHS [GM 54414] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL042886] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054414] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASHCOM JD, 1990, J CELL BIOL, V110, P1041, DOI 10.1083/jcb.110.4.1041; BARRETT AJ, 1974, BAYER S, V5, P72; Blacker D, 1998, NAT GENET, V19, P357, DOI 10.1038/1243; BOISSET N, 1993, J MOL BIOL, V232, P522, DOI 10.1006/jmbi.1993.1408; Boisset N, 1996, J BIOL CHEM, V271, P25762, DOI 10.1074/jbc.271.42.25762; Bowen ME, 1998, J BIOL CHEM, V273, P1825, DOI 10.1074/jbc.273.3.1825; BRETAUDIERE JP, 1988, P NATL ACAD SCI USA, V85, P1437, DOI 10.1073/pnas.85.5.1437; DELAIN E, 1988, J BIOL CHEM, V263, P2981; DELAIN E, 1992, ELECTRON MICROSC REV, V5, P231, DOI 10.1016/0892-0354(92)90012-F; ERICKSON HP, 1971, PHILOS T ROY SOC B, V261, P105, DOI 10.1098/rstb.1971.0040; FIGLER NL, 1991, J STRUCT BIOL, V106, P237, DOI 10.1016/1047-8477(91)90073-6; Frank J, 1996, J STRUCT BIOL, V116, P190, DOI 10.1006/jsbi.1996.0030; FRANK J, 1985, NEW METHODOLOGIES ST, P36; GETTINS P, 1989, BIOCHEMISTRY-US, V28, P5613, DOI 10.1021/bi00439a041; GETTINS PGW, 1995, J BIOL CHEM, V270, P14160, DOI 10.1074/jbc.270.23.14160; HALL PK, 1978, BIOCHEM J, V173, P27, DOI 10.1042/bj1730027; HUSSAINI IM, 1990, BIOCHEM J, V270, P291, DOI 10.1042/bj2700291; JENSEN PEH, 1986, J BIOL CHEM, V261, P5863; Kolodziej SJ, 1996, J STRUCT BIOL, V116, P366, DOI 10.1006/jsbi.1996.0054; Kolodziej SJ, 1996, J BIOL CHEM, V271, P28422, DOI 10.1074/jbc.271.45.28422; Kolodziej SJ, 1998, J STRUCT BIOL, V123, P124, DOI 10.1006/jsbi.1998.4027; Kolodziej SJ, 1997, J STRUCT BIOL, V120, P158, DOI 10.1006/jsbi.1997.3911; MIDDAUGH CR, 1993, BIOCHIM BIOPHYS ACTA, V1161, P328, DOI 10.1016/0167-4838(93)90233-H; PENCZEK P, 1992, ULTRAMICROSCOPY, V40, P33, DOI 10.1016/0304-3991(92)90233-A; Penczek PA, 1996, ULTRAMICROSCOPY, V63, P205, DOI 10.1016/0304-3991(96)00037-X; Qazi U, 1998, J BIOL CHEM, V273, P8987, DOI 10.1074/jbc.273.15.8987; ROCHE PA, 1988, J BIOL CHEM, V263, P6715; SCHROETER JP, 1992, J STRUCT BIOL, V109, P235, DOI 10.1016/1047-8477(92)90036-A; Schroeter JP, 1996, J STRUCT BIOL, V116, P131, DOI 10.1006/jsbi.1996.0021; SOTTRUPJENSEN L, 1989, J BIOL CHEM, V264, P15781; SOTTRUPJENSEN L, 1990, J BIOL CHEM, V265, P17727; SOTTRUPJENSEN L, 1989, J BIOL CHEM, V264, P11539; Starkey P. M., 1977, PROTEINASES MAMMALIA, P663; Stoops James K., 1998, Microscopy and Microanalysis, V4, P986, DOI 10.1017/S1431927600025058; STOOPS JK, 1992, J BIOL CHEM, V267, P24769; STOOPS JK, 1991, J ELECTRON MICR TECH, V18, P157, DOI 10.1002/jemt.1060180210; STRICKLAND DK, 1988, BIOCHEMISTRY-US, V27, P1458, DOI 10.1021/bi00405a010; TOYOSHIMA C, 1988, ULTRAMICROSCOPY, V25, P279, DOI 10.1016/0304-3991(88)90003-4; UNSER M, 1987, ULTRAMICROSCOPY, V23, P39, DOI 10.1016/0304-3991(87)90225-7; VLAICU R, 1985, ATHEROSCLEROSIS, V55, P35, DOI 10.1016/0021-9150(85)90164-9	40	14	15	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 19	1999	274	12					8137	8142		10.1074/jbc.274.12.8137	http://dx.doi.org/10.1074/jbc.274.12.8137			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	178LU	10075716	hybrid			2022-12-25	WOS:000079268100075
J	Sadar, MD				Sadar, MD			Androgen-independent induction of prostate-specific antigen gene expression via cross-talk between the androgen receptor and protein kinase A signal transduction pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-I; ESTROGEN-RECEPTOR; TRANSCRIPTIONAL ACTIVATION; LNCAP CELLS; PROGESTERONE-RECEPTOR; RESPONSIVE ELEMENT; STEROID-RECEPTORS; TERMINAL DOMAIN; PHOSPHORYLATION; BINDING	Transcription of the prostate-specific antigen (PSA) gene escapes regulation by androgens in advanced prostate cancer. To determine the molecular mechanism(s) of androgen-independent regulation of the PSA gene, the possibility that the androgen receptor (AR) is activated in the absence of androgen by stimulation of protein kinase A (PKA) was investigated. Activation of PKA by forskolin resulted in elevated expression of the PSA gene in androgen-depleted LNCaP cells, an effect that was blocked by the antiandrogen, bicalutamide, Further evidence that induction of PSA gene expression was dependent on AR was obtained from experiments using PC3 cells devoid of AR. Neither PSA, PB, nor ARR(3) androgen-responsive reporters could be induced by activation of PKA in the absence of transfected AR. In addition, when nuclear AR from forskolin-treated LNCaP cells was incubated with oligonucleotides encoding an androgen response element of the PSA promoter and examined by electromobility shift assay, an increase in AR-androgen response element complex formation was observed. Lastly, cotransfection of an expression vector for a chimeric protein encoding the amino-terminal domain of the human AR linked to Gal4 and a 5xGal4UAS reporter gene construct resulted in activation of the amino-terminal domain of the AR by stimulation of PKA activity. These results demonstrate androgen-independent induction of PSA gene expression in prostate cancer cells by an AR-dependent pathway.	British Columbia Canc Agcy, Dept Canc Endocrinol, Vancouver, BC V5Z 4E6, Canada	British Columbia Cancer Agency	Sadar, MD (corresponding author), British Columbia Canc Agcy, Dept Canc Endocrinol, 600 W 10th Ave, Vancouver, BC V5Z 4E6, Canada.		Sadar, Marianne/E-9136-2012	Sadar, Marianne/0000-0003-0599-9215	NIDDK NIH HHS [P50 DK47656] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P50DK047656] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDREWS PE, 1992, CANCER RES, V52, P1525; ANTRAS J, 1991, J BIOL CHEM, V266, P1157; ARONICA SM, 1991, ENDOCRINOLOGY, V128, P2045, DOI 10.1210/endo-128-4-2045; ARONICA SM, 1993, MOL ENDOCRINOL, V7, P743, DOI 10.1210/me.7.6.743; BERREVOETS CA, 1993, J STEROID BIOCHEM, V46, P731, DOI 10.1016/0960-0760(93)90313-L; Blok LJ, 1998, BIOCHEMISTRY-US, V37, P3850, DOI 10.1021/bi9724422; Blok LJ, 1996, ENDOCR RES, V22, P197, DOI 10.3109/07435809609030508; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chamberlain NL, 1996, J BIOL CHEM, V271, P26772, DOI 10.1074/jbc.271.43.26772; Cleutjens KBJM, 1996, J BIOL CHEM, V271, P6379, DOI 10.1074/jbc.271.11.6379; CULIG Z, 1994, CANCER RES, V54, P5474; ElTanani MKK, 1997, MOL ENDOCRINOL, V11, P928, DOI 10.1210/me.11.7.928; GOUELI SA, 1984, BIOCHEM BIOPH RES CO, V123, P778, DOI 10.1016/0006-291X(84)90297-3; IgnarTrowbridge DM, 1996, ENDOCRINOLOGY, V137, P1735, DOI 10.1210/en.137.5.1735; IGNARTROWBRIDGE DM, 1993, MOL ENDOCRINOL, V7, P992, DOI 10.1210/me.7.8.992; IKONEN T, 1994, ENDOCRINOLOGY, V135, P1359, DOI 10.1210/en.135.4.1359; JENSEN N, 1995, J CLIN ANESTH, V7, P270, DOI 10.1016/0952-8180(95)90006-3; JENSTER G, 1991, MOL ENDOCRINOL, V5, P1396, DOI 10.1210/mend-5-10-1396; KEMPPAINEN JA, 1992, J BIOL CHEM, V267, P968; KUIL CW, 1995, J BIOL CHEM, V270, P27569, DOI 10.1074/jbc.270.46.27569; KUIPER GGJM, 1995, BIOCHEMISTRY-US, V34, P1851, DOI 10.1021/bi00006a005; KUIPER GGJM, 1992, J STEROID BIOCHEM, V41, P697, DOI 10.1016/0960-0760(92)90407-A; KUIPER GGJM, 1993, BIOCHEM J, V291, P95, DOI 10.1042/bj2910095; LUNDWALL A, 1989, BIOCHEM BIOPH RES CO, V161, P1151, DOI 10.1016/0006-291X(89)91362-4; Nazareth LV, 1996, J BIOL CHEM, V271, P19900, DOI 10.1074/jbc.271.33.19900; NEWTON CJ, 1994, J STEROID BIOCHEM, V48, P481, DOI 10.1016/0960-0760(94)90197-X; PALVIMO JJ, 1993, MOL ENDOCRINOL, V7, P1399, DOI 10.1210/me.7.11.1399; Picard D, 1997, BIOCHEM SOC T, V25, P597, DOI 10.1042/bst0250597; RIEGMAN PHJ, 1991, MOL ENDOCRINOL, V5, P1921, DOI 10.1210/mend-5-12-1921; Sato N, 1997, J BIOL CHEM, V272, P17485, DOI 10.1074/jbc.272.28.17485; Sato N, 1996, J STEROID BIOCHEM, V58, P139, DOI 10.1016/0960-0760(96)00018-0; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Schuur ER, 1996, J BIOL CHEM, V271, P7043, DOI 10.1074/jbc.271.12.7043; Snoek R, 1998, PROSTATE, V36, P256; Snoek R, 1996, J STEROID BIOCHEM, V59, P243, DOI 10.1016/S0960-0760(96)00116-1; TURGEON JL, 1994, MOL ENDOCRINOL, V8, P860, DOI 10.1210/me.8.7.860; VANLAAR JH, 1991, J BIOL CHEM, V266, P3734; VELDSCHOLTE J, 1992, BIOCHEMISTRY-US, V31, P2393, DOI 10.1021/bi00123a026; VELDSCHOLTE J, 1992, J STEROID BIOCHEM, V41, P665, DOI 10.1016/0960-0760(92)90401-4; VELSCHOLTE J, 1990, BIOCHEM BIOPH RES CO, V173, P253; Weigel NL, 1996, BIOCHEM J, V319, P657, DOI 10.1042/bj3190657; WILSON EM, 1976, J BIOL CHEM, V251, P5620; ZHOU ZX, 1995, MOL ENDOCRINOL, V9, P605, DOI 10.1210/me.9.5.605; ZILLIACUS J, 1995, MOL ENDOCRINOL, V9, P389, DOI 10.1210/me.9.4.389; ZOPPI S, 1993, J CLIN INVEST, V91, P1105, DOI 10.1172/JCI116269	45	224	246	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 19	1999	274	12					7777	7783		10.1074/jbc.274.12.7777	http://dx.doi.org/10.1074/jbc.274.12.7777			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	178LU	10075669	hybrid			2022-12-25	WOS:000079268100028
J	Walter, T; Aronson, A				Walter, T; Aronson, A			Specific binding of the E2 subunit of pyruvate dehydrogenase to the upstream region of Bacillus thuringiensis protoxin genes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL PROTEIN GENE; DELTA-ENDOTOXIN GENE; GLUTATHIONE-S-TRANSFERASE; ESCHERICHIA-COLI; GEL-ELECTROPHORESIS; NUCLEOTIDE-SEQUENCE; MULTIENZYME COMPLEX; EXPRESSION; TRANSFORMATION; TRANSCRIPTION	During sporulation, Bacillus thuringiensis produces inclusions comprised of different amounts of several related protoxins, each with a unique specificity profile for insect larvae. A major class of these genes designated cry1 have virtually identical dual overlapping promoters, but the upstream sequences differ. A gel retardation assay was used to purify a potential regulatory protein which bound with different affinities to these sequences in three cry1 genes. It was identified as the E2 subunit of pyruvate dehydrogenase. There was specific competition for binding by homologous gene sequences but not by pUC nor Bacillus subtilis DNA; calf thymus DNA competed at higher concentrations. The B. thuringiensis gene encoding E2 was cloned, and the purified glutathione S-transferase-Ea fusion protein footprinted to a consensus binding sequence within an inverted repeat and to a potential bend region, both sites 200-300 base pairs upstream of the promoters. Mutations of these sites in the cry1A gene resulted in decreased binding of the E2 protein and altered kinetics of expression of a fusion of this regulatory region with the lacZ gene. Recruitment of the E2 subunit as a transcription factor could couple the change in post exponential catabolism to the initiation of protoxin synthesis.	Purdue Univ, Dept Sci Biol, W Lafayette, IN 47907 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus	Walter, T (corresponding author), Purdue Univ, Dept Sci Biol, W Lafayette, IN 47907 USA.	twalter@bilbo.bio.purdue.edu			NIGMS NIH HHS [GM 34035] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034035] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS LF, 1991, J BACTERIOL, V173, P3846, DOI 10.1128/JB.173.12.3846-3854.1991; AGAISSE H, 1995, J BACTERIOL, V177, P6027, DOI 10.1128/jb.177.21.6027-6032.1995; ARONSON A, 1995, APPL ENVIRON MICROB, V61, P4057, DOI 10.1128/AEM.61.11.4057-4060.1995; ARONSON AI, 1971, J BACTERIOL, V106, P1016, DOI 10.1128/JB.106.3.1016-1025.1971; ARONSON AI, 1994, FEMS MICROBIOL LETT, V117, P21, DOI 10.1111/j.1574-6968.1994.tb06737.x; ARONSON AI, 1993, MOL MICROBIOL, V7, P489, DOI 10.1111/j.1365-2958.1993.tb01139.x; BAUM JA, 1995, MOL MICROBIOL, V18, P1, DOI 10.1111/j.1365-2958.1995.mmi_18010001.x; BIETLOT HPL, 1990, BIOCHEM J, V267, P309, DOI 10.1042/bj2670309; BRIZZARD BL, 1991, MOL GEN GENET, V231, P59, DOI 10.1007/BF00293822; BULLA LA, 1980, CRC CR REV MICROBIOL, V8, P147, DOI 10.3109/10408418009081124; CALVO JM, 1994, MICROBIOL REV, V58, P466, DOI 10.1128/MMBR.58.3.466-490.1994; DULMAGE HT, 1970, J INVERTEBR PATHOL, V16, P80, DOI 10.1016/0022-2011(70)90209-0; ECKDAHL TT, 1987, NUCLEIC ACIDS RES, V15, P8531; EIDENTWILKINSON B, 1992, J BACTERIOL, V174, P477, DOI 10.1128/jb.174.2.477-485.1992; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; GARNER MM, 1981, NUCLEIC ACIDS RES, V9, P3047, DOI 10.1093/nar/9.13.3047; GIACOMINI A, 1992, FEMS MICROBIOL LETT, V100, P87, DOI 10.1111/j.1574-6968.1992.tb05687.x; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; Hederstedt Lars, 1993, P181; HEMILA H, 1990, J BACTERIOL, V172, P5052, DOI 10.1128/jb.172.9.5052-5063.1990; HOFTE H, 1990, NUCLEIC ACIDS RES, V18, P5545; HOFTE H, 1989, MICROBIOL REV, V53, P242; KALIA YN, 1993, J MOL BIOL, V230, P323, DOI 10.1006/jmbi.1993.1145; LAFFAN JJ, 1988, P NATL ACAD SCI USA, V85, P7452, DOI 10.1073/pnas.85.20.7452; LANE D, 1992, MICROBIOL REV, V56, P509, DOI 10.1128/MMBR.56.4.509-528.1992; Lee MK, 1996, APPL ENVIRON MICROB, V62, P583, DOI 10.1128/AEM.62.2.583-586.1996; LERECLUS D, 1989, FEMS MICROBIOL LETT, V60, P211, DOI 10.1016/0378-1097(89)90511-9; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; Miller JH., 1972, EXPT MOL GENETICS; NAKATA HM, 1960, J BACTERIOL, V80, P801, DOI 10.1128/JB.80.6.801-810.1960; RUSSELL GC, 1991, BIOCHIM BIOPHYS ACTA, V1076, P225, DOI 10.1016/0167-4838(91)90271-Z; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SANCHIS V, 1989, MOL MICROBIOL, V3, P229, DOI 10.1111/j.1365-2958.1989.tb01812.x; SCHURTER W, 1989, MOL GEN GENET, V218, P177, DOI 10.1007/BF00330581; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SMITH GP, 1993, NUCLEIC ACIDS RES, V16, P6240; TABASHNIK BE, 1992, APPL ENVIRON MICROB, V58, P3343, DOI 10.1128/AEM.58.10.3343-3346.1992; TABOR S, 1989, P NATL ACAD SCI USA, V86, P4076, DOI 10.1073/pnas.86.11.4076; WALLIS NG, 1994, J MOL BIOL, V236, P209, DOI 10.1006/jmbi.1994.1130; WALTER T, 1995, THESIS PURDUE U; WAMPLER SL, 1990, J BIOL CHEM, V265, P21223	41	26	28	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	1999	274	12					7901	7906		10.1074/jbc.274.12.7901	http://dx.doi.org/10.1074/jbc.274.12.7901			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	178LU	10075684	hybrid			2022-12-25	WOS:000079268100043
J	Park, CY; Hayman, MJ				Park, CY; Hayman, MJ			The tyrosines in the bidentate motif of the env-sea oncoprotein are essential for cell transformation and are binding sites for Grb2 and the tyrosine phosphatase SHP-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SH2-CONTAINING PHOSPHOTYROSINE PHOSPHATASE; AVIAN ERYTHROBLASTOSIS VIRUS; SCATTER FACTOR-RECEPTOR; GROWTH-FACTOR RECEPTOR; TPR-MET ONCOPROTEIN; POINT MUTATION; PROTEIN-KINASE; SH3 DOMAINS; ONCOGENE; ACTIVATION	The transforming gene product of the S13 avian erythroblastosis virus, the env-sea protein, is a member of the hepatocyte growth factor receptor family of tyrosine kinases comprising Met, Ron, and Sea. Like all three members of this family, the env-sea protein has a so-called bidentate motif (Y(557)INMAVTY(564)VNL) composed of two tandemly arranged tyrosines in the carboxyl terminus. To investigate whether the tyrosine residues in this motif are essential for the env-sea-mediated transformation, we generated tyrosine to phenylalanine mutations. Substitutions of both tyrosine residues resulted in complete loss of the transforming activity. In contrast, single mutations at either tyrosine did not inhibit transformation of Rat1 cells, and mutation of tyrosine 564 actually increased transformation of Rat 1 cells. To define signaling pathways activated by the env-sea protein, we looked for protein-protein interactions mediated by these tyrosine residues. We show that the bidentate motif is responsible for interaction with the adapter protein Grb2, phosphatidylinositol 3-kinase, and the tyrosine phosphatase SHP-2, Furthermore, we show that microinjected Src homology 2 domains from either Grb2 or SHP-2 blocked the transforming activity of the env-sea protein. Together, these results suggest that the tyrosines within the bidentate motif are essential for the env-sea transformation.	SUNY Stony Brook, Inst Cell & Dev Biol, Stony Brook, NY 11794 USA; SUNY Stony Brook, Dept Mol Genet & Microbiol, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Hayman, MJ (corresponding author), SUNY Stony Brook, Inst Cell & Dev Biol, Stony Brook, NY 11794 USA.	hayman@asterix.bio.sunysb.edu			NATIONAL CANCER INSTITUTE [R01CA042573, P01CA028146] Funding Source: NIH RePORTER; NCI NIH HHS [CA42573, CA28146] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARVIDSSON AK, 1994, MOL CELL BIOL, V14, P6715, DOI 10.1128/MCB.14.10.6715; Bardelli A, 1997, ONCOGENE, V15, P3103, DOI 10.1038/sj.onc.1201561; Bennett AM, 1996, MOL CELL BIOL, V16, P1189; BENNETT AM, 1994, P NATL ACAD SCI USA, V91, P7335, DOI 10.1073/pnas.91.15.7335; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; COUSSENS L, 1986, NATURE, V320, P277, DOI 10.1038/320277a0; CROWE AJ, 1993, ONCOGENE, V8, P181; CROWE AJ, 1993, CELL GROWTH DIFFER, V4, P403; CROWE AJ, 1994, ONCOGENE, V9, P537; Denu JM, 1996, CELL, V87, P361, DOI 10.1016/S0092-8674(00)81356-2; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; FIXMAN ED, 1995, ONCOGENE, V10, P237; Fixman ED, 1996, J BIOL CHEM, V271, P13116, DOI 10.1074/jbc.271.22.13116; Fixman ED, 1997, J BIOL CHEM, V272, P20167, DOI 10.1074/jbc.272.32.20167; Giordano S, 1997, P NATL ACAD SCI USA, V94, P13868, DOI 10.1073/pnas.94.25.13868; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; Hadari YR, 1998, MOL CELL BIOL, V18, P3966, DOI 10.1128/MCB.18.7.3966; HAYMAN MJ, 1991, CANCER CELL-MON REV, V3, P302; HAYMAN MJ, 1985, P NATL ACAD SCI USA, V82, P8237, DOI 10.1073/pnas.82.23.8237; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HUFF JL, 1993, P NATL ACAD SCI USA, V90, P6140, DOI 10.1073/pnas.90.13.6140; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; Keegan K, 1996, ONCOGENE, V12, P1537; KNIGHT J, 1988, GENE DEV, V2, P247, DOI 10.1101/gad.2.2.247; KNIGHT J, 1990, VIROLOGY, V178, P232, DOI 10.1016/0042-6822(90)90398-B; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KUHNE MR, 1993, J BIOL CHEM, V268, P11479; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; Matozaki T, 1996, CELL SIGNAL, V8, P13, DOI 10.1016/0898-6568(95)02015-2; MILARSKI KL, 1994, J BIOL CHEM, V269, P21239; MORIMOTO AM, 1994, J VIROL, V68, P1837, DOI 10.1128/JVI.68.3.1837-1842.1994; Neel B G, 1993, Semin Cell Biol, V4, P419, DOI 10.1006/scel.1993.1050; O'Reilly AM, 1998, MOL CELL BIOL, V18, P161, DOI 10.1128/MCB.18.1.161; Ottinger EA, 1998, J BIOL CHEM, V273, P729, DOI 10.1074/jbc.273.2.729; PARK M, 1987, P NATL ACAD SCI USA, V84, P6379, DOI 10.1073/pnas.84.18.6379; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; Ponzetto C, 1996, J BIOL CHEM, V271, P14119, DOI 10.1074/jbc.271.24.14119; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; RODRIGUES GA, 1993, MOL CELL BIOL, V13, P6711, DOI 10.1128/MCB.13.11.6711; RONSIN C, 1993, ONCOGENE, V8, P1195; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; Santoro MM, 1996, MOL CELL BIOL, V16, P7072; SMITH DR, 1989, P NATL ACAD SCI USA, V86, P5291, DOI 10.1073/pnas.86.14.5291; TANG TL, 1995, CELL, V80, P473, DOI 10.1016/0092-8674(95)90498-0; TAUCHI T, 1994, J BIOL CHEM, V269, P15381; Tonks NK, 1996, CELL, V87, P365, DOI 10.1016/S0092-8674(00)81357-4; WEINER DB, 1989, NATURE, V339, P230, DOI 10.1038/339230a0; YAMAUCHI K, 1995, P NATL ACAD SCI USA, V92, P664, DOI 10.1073/pnas.92.3.664; ZHAO ZZ, 1995, J BIOL CHEM, V270, P11765, DOI 10.1074/jbc.270.20.11765; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	54	22	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	1999	274	11					7583	7590		10.1074/jbc.274.11.7583	http://dx.doi.org/10.1074/jbc.274.11.7583			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	175DV	10066827	hybrid			2022-12-25	WOS:000079078400099
J	Hagen, FK; Hazes, B; Raffo, R; deSa, D; Tabak, LA				Hagen, FK; Hazes, B; Raffo, R; deSa, D; Tabak, LA			Structure-function analysis of the UDP-N-acetyl-D-galactosamine: Polypeptide N-acetylgalactosaminyltransferase - Essential residues lie in a predicted active site cleft resembling a lactose repressor fold	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEQUENCE ALIGNMENT; CRYSTAL-STRUCTURE; BINDING-SITES; PURIFICATION; GALNAC; GALACTOSYLTRANSFERASE; IDENTIFICATION; RECOGNITION; EXPRESSION; DOMAINS	Mucin-type O-glycosylation is initiated by a family of UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferases (ppGaNTases), Based on sequence relationships with divergent proteins, the ppGaNTases can be subdivided into three putative domains: each putative domain contains a characteristic sequence motif. The 112-amino acid glycosyltransferase (1) under bar (GT1) motif represents the first half of the catalytic unit and contains a short aspartate-any residue-histidine (DXH) or aspartate-any residue-aspartate (DXD)-like sequence. Secondary structure predictions and structural threading suggest that the GT1 motif forms a 5-stranded parallel beta-sheet flanked by 4 alpha-helices, which resembles the first domain of the lactose repressor. Four invariant carboxylates and a histidine residue are predicted to lie at the C-terminal end of three beta-strands and line the active site cleft. Site-directed mutagenesis of murine ppGaNTase-T1 reveals that conservative mutations at these 5 positions result in products with no detectable enzyme activity (D156Q, D209N, and H211D) or <1% activity (E127Q and E213Q). The second half of the catalytic unit contains a DXXYXXWGGENXE motif (positions 310-322) which is also found in beta 1,4-galactosyltransferases (termed the Gal/GaLNAc-T motif), Mutants of carboxylates within this motif express either no detectable activity, 1% or 2% activity (F319Q, E322Q, and D310N, respectively). Mutagenesis of highly conserved (but not invariant) carboxylates produces only modest alterations in enzyme activity. Mutations in the C-terminal 128-amino acid ricin-like lectin motif do not alter the enzyme's catalytic properties.	Univ Rochester, Rochester Inst Biomed Sci, Ctr Oral Biol, Rochester, NY 14642 USA; Univ Alberta, Dept Med Microbiol & Immunol, Edmonton, AB T6G 2H7, Canada	University of Rochester; University of Alberta	Tabak, LA (corresponding author), Univ Rochester, Rochester Inst Biomed Sci, Ctr Oral Biol, 601 Elmwood Ave, Rochester, NY 14642 USA.	Lawrence_Tabak@urmc.rochester.edu			NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R37DE008108, R01DE008108, T35DE007189] Funding Source: NIH RePORTER; NIDCR NIH HHS [DE08108, T35 DE07189] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Almeida R, 1997, J BIOL CHEM, V272, P31979, DOI 10.1074/jbc.272.51.31979; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; AOKI D, 1990, EMBO J, V9, P3171, DOI 10.1002/j.1460-2075.1990.tb07515.x; BOEGGEMAN EE, 1995, GLYCOCONJUGATE J, V12, P865, DOI 10.1007/BF00731249; Breton C, 1996, GLYCOBIOLOGY, V6, pR7; Breton C, 1998, J BIOCHEM, V123, P1000; Busch C, 1998, J BIOL CHEM, V273, P19566, DOI 10.1074/jbc.273.31.19566; DO KY, 1995, J BIOL CHEM, V270, P18447, DOI 10.1074/jbc.270.31.18447; ELHAMMER A, 1986, J BIOL CHEM, V261, P5249; Frankel AE, 1996, BIOCHEMISTRY-US, V35, P14749, DOI 10.1021/bi960798s; Hagen FK, 1998, J BIOL CHEM, V273, P8268, DOI 10.1074/jbc.273.14.8268; Hagen FK, 1997, J BIOL CHEM, V272, P13843, DOI 10.1074/jbc.272.21.13843; HAGEN FK, 1993, J BIOL CHEM, V268, P18960; Hazes B, 1996, PROTEIN SCI, V5, P1490, DOI 10.1002/pro.5560050805; Imberty A, 1997, PROTEIN ENG, V10, P1353, DOI 10.1093/protein/10.12.1353; JONES DT, 1992, NATURE, V358, P86, DOI 10.1038/358086a0; Karlin S, 1997, P NATL ACAD SCI USA, V94, P14225, DOI 10.1073/pnas.94.26.14225; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; Lewis M, 1996, SCIENCE, V271, P1247, DOI 10.1126/science.271.5253.1247; NAGAHASHI S, 1995, J BIOL CHEM, V270, P13961, DOI 10.1074/jbc.270.23.13961; SINNOTT ML, 1990, CHEM REV, V90, P1171, DOI 10.1021/cr00105a006; SUGIURA M, 1982, J BIOL CHEM, V257, P9501; Ten Hagen BG, 1998, J BIOL CHEM, V273, P27749; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; VanDie I, 1997, GLYCOBIOLOGY, V7, pR5; VRIELINK A, 1994, EMBO J, V13, P3413, DOI 10.1002/j.1460-2075.1994.tb06646.x; Wandall HH, 1997, J BIOL CHEM, V272, P23503, DOI 10.1074/jbc.272.38.23503; WANG YC, 1992, J BIOL CHEM, V267, P2728; Wiggins CAR, 1998, P NATL ACAD SCI USA, V95, P7945, DOI 10.1073/pnas.95.14.7945; Wragg S, 1997, BIOCHEM J, V328, P193, DOI 10.1042/bj3280193; WRAGG S, 1995, J BIOL CHEM, V270, P16947, DOI 10.1074/jbc.270.28.16947; Zara J, 1996, BIOCHEM BIOPH RES CO, V228, P38, DOI 10.1006/bbrc.1996.1613	32	101	123	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	1999	274	10					6797	6803		10.1074/jbc.274.10.6797	http://dx.doi.org/10.1074/jbc.274.10.6797			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172BQ	10037781	hybrid, Green Submitted			2022-12-25	WOS:000078902800103
J	Barton, VA; Hudson, KR; Heath, JK				Barton, VA; Hudson, KR; Heath, JK			Identification of three distinct receptor binding sites of murine interleukin-11	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN GROWTH-HORMONE; LEUKEMIA INHIBITORY FACTOR; MOLECULAR-CLONING; HUMAN IL-6; EXTRACELLULAR DOMAIN; SIGNAL-TRANSDUCTION; CRYSTAL-STRUCTURE; RATIONAL DESIGN; GP130; MUTAGENESIS	Interleukin-11 (IL-11) is a member of the gp130 family of cytokines. These cytokines drive the assembly of multisubunit receptor complexes, all of which contain at least one molecule of the transmembrane signaling receptor gp130. A complex of IL-11 and the IL-11 receptor (IL-11R) has been shown to interact with gp130, with high affinity, and to induce gp130- dependent signaling. In this study, we have identified residues crucial for the binding of murine IL-11 (mIL-11) to both the IL-11R and gp130 by examining the activities of mIL-11 mutants in receptor binding and cell proliferation assays. The location of these residues, as predicted from structural studies and a model of IL-11, reveals that mIL-11 has three distinct receptor binding sites. These are structurally and functionally analogous to the previously defined receptor binding sites I, II, and III of interleukin-6 (IL-6). This supports the hypothesis that IL-11 signals via the formation of a hexameric receptor complex and indicates that site III is a generic feature of cytokines that signal via association with gp130.	Univ Birmingham, Dept Biochem, Canc Res Campaign, Growth Factor Grp, Birmingham B15 2TT, W Midlands, England	University of Birmingham	Heath, JK (corresponding author), Univ Birmingham, Dept Biochem, Canc Res Campaign, Growth Factor Grp, Birmingham B15 2TT, W Midlands, England.	j.k.heath@bham.ac.uk						BAZAN JF, 1991, NEURON, V7, P197, DOI 10.1016/0896-6273(91)90258-2; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BRAKENHOFF JPJ, 1990, J IMMUNOL, V145, P561; Ciapponi L, 1995, J BIOL CHEM, V270, P31249, DOI 10.1074/jbc.270.52.31249; CLACKSON T, 1995, SCIENCE, V267, P383, DOI 10.1126/science.7529940; CUNNINGHAM BC, 1991, P NATL ACAD SCI USA, V88, P3407, DOI 10.1073/pnas.88.8.3407; CUNNINGHAM BC, 1993, J MOL BIOL, V234, P554, DOI 10.1006/jmbi.1993.1611; CUNNINGHAM BC, 1991, SCIENCE, V254, P821, DOI 10.1126/science.1948064; CUNNINGHAM BC, 1989, SCIENCE, V244, P1081, DOI 10.1126/science.2471267; Czupryn M, 1995, ANN NY ACAD SCI, V762, P152; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; DiMarco A, 1997, J BIOL CHEM, V272, P23069, DOI 10.1074/jbc.272.37.23069; Du XX, 1997, BLOOD, V89, P3897, DOI 10.1182/blood.V89.11.3897; DUBRIDGE RB, 1987, MOL CELL BIOL, V7, P379, DOI 10.1128/MCB.7.1.379; EHLERS M, 1994, J IMMUNOL, V153, P1744; FENG DF, 1987, J MOL EVOL, V25, P351, DOI 10.1007/BF02603120; FONTAINE V, 1993, EUR J BIOCHEM, V211, P749, DOI 10.1111/j.1432-1033.1993.tb17605.x; Fuhrer DK, 1996, EXP HEMATOL, V24, P195; Gordon MS, 1996, BLOOD, V87, P3615, DOI 10.1182/blood.V87.9.3615.bloodjournal8793615; Harlow E., 1988, ANTIBODIES LABORATOR, P341; Heinrich PC, 1998, BIOCHEM J, V334, P297, DOI 10.1042/bj3340297; HILTON DJ, 1994, EMBO J, V13, P4765, DOI 10.1002/j.1460-2075.1994.tb06802.x; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Hudson KR, 1996, J BIOL CHEM, V271, P11971, DOI 10.1074/jbc.271.20.11971; Karow J, 1996, BIOCHEM J, V318, P489, DOI 10.1042/bj3180489; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; MURAKAMI M, 1993, SCIENCE, V260, P1808, DOI 10.1126/science.8511589; Nandurkar HH, 1996, ONCOGENE, V12, P585; NEBEN TY, 1993, BLOOD, V81, P901; PAONESSA G, 1995, EMBO J, V14, P1942, DOI 10.1002/j.1460-2075.1995.tb07186.x; PAUL SR, 1990, P NATL ACAD SCI USA, V87, P7512, DOI 10.1073/pnas.87.19.7512; SAITO M, 1992, J IMMUNOL, V148, P4066; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; SAVINO R, 1994, EMBO J, V13, P5863, DOI 10.1002/j.1460-2075.1994.tb06931.x; SAVINO R, 1994, EMBO J, V13, P1357, DOI 10.1002/j.1460-2075.1994.tb06389.x; SAVINO R, 1993, P NATL ACAD SCI USA, V90, P4067, DOI 10.1073/pnas.90.9.4067; Simpson RJ, 1997, PROTEIN SCI, V6, P929, DOI 10.1002/pro.5560060501; Somers W, 1997, EMBO J, V16, P989, DOI 10.1093/emboj/16.5.989; SONIS S, 1995, ORAL ONCOL, V31B, P261, DOI 10.1016/0964-1955(95)00015-A; WALKER PA, 1994, BIO-TECHNOL, V12, P601, DOI 10.1038/nbt0694-601; WANG XY, 1995, J BIOL CHEM, V270, P27999; WARD LD, 1994, J BIOL CHEM, V269, P23286; YAMASAKI K, 1988, SCIENCE, V241, P825, DOI 10.1126/science.3136546; YIN TG, 1994, J BIOL CHEM, V269, P3731; YIN TG, 1993, J IMMUNOL, V151, P2555; YIN TG, 1994, EXP HEMATOL, V22, P467	46	53	62	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 26	1999	274	9					5755	5761		10.1074/jbc.274.9.5755	http://dx.doi.org/10.1074/jbc.274.9.5755			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	170KG	10026196	hybrid			2022-12-25	WOS:000078804400067
J	Carraway, KL; Rossi, EA; Komatsu, M; Price-Schiavi, SA; Huang, DM; Guy, PM; Carvajal, ME; Fregien, N; Carraway, CAC; Carraway, KL				Carraway, KL; Rossi, EA; Komatsu, M; Price-Schiavi, SA; Huang, DM; Guy, PM; Carvajal, ME; Fregien, N; Carraway, CAC; Carraway, KL			An intramembrane modulator of the ErbB2 receptor tyrosine kinase that potentiates neuregulin signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMARY ADENOCARCINOMA; SIALOMUCIN COMPLEX; ASCITES ADENOCARCINOMA; NEURAL DEVELOPMENT; BREAST-CANCER; ONCOGENE; HETERODIMERIZATION; PHOSPHORYLATION; HEREGULIN; LIGAND	The ErbB2 receptor tyrosine kinase plays a critical role in a variety of developmental processes, and its aberrant activation may contribute to the progression of some breast and ovarian tumors. ASGP2, a transmembrane glycoprotein found on the surface of the highly metastatic ascites 13762 rat mammary adenocarcinoma cell line, is constitutively associated with ErbB2 in these cells and in mammary tissue from pregnant rats. Expression studies indicate that ASGP2 interacts directly and specifically with ErbB2 through one of its epidermal growth factor-like domains and that the co-expression of the two proteins in the same cell dramatically facilitates their direct stable interaction. Ectopic expression of ASGP2 in human melanoma tumor cells potentiates the response of endogenous ErbB2 to the neuregulin-1 growth factor. These observations point to a novel intramembrane mechanism for the modulation of receptor tyrosine kinase activity.	Beth Israel Hosp, Harvard Inst Med, Div Signal Transduct, Boston, MA 02215 USA; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02215 USA; Univ Miami, Sch Med, Dept Biochem & Mol Biol, Miami, FL 33101 USA; Univ Miami, Sch Med, Dept Anat & Cell Biol, Miami, FL 33101 USA; Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Harvard Medical School; University of Miami; University of Miami; University of California System; University of California San Diego	Carraway, KL (corresponding author), Beth Israel Hosp, Harvard Inst Med, Div Signal Transduct, Rm 1018,330 Brookline Ave, Boston, MA 02215 USA.			Komatsu, Masanobu/0000-0001-7548-137X	NCI NIH HHS [CA14395, CA52498, CA74072] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA014395, R01CA074072, R01CA052498] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alroy I, 1997, FEBS LETT, V410, P83, DOI 10.1016/S0014-5793(97)00412-2; CARRAWAY CAC, 1983, P NATL ACAD SCI-BIOL, V80, P430, DOI 10.1073/pnas.80.2.430; CARRAWAY KL, 1980, NATURE, V285, P508, DOI 10.1038/285508a0; CARRAWAY KL, 1995, J BIOL CHEM, V270, P7111, DOI 10.1074/jbc.270.13.7111; CARRAWAY KL, 1982, J CELL BIOL, V94, P624, DOI 10.1083/jcb.94.3.624; CARRAWAY KL, 1994, J BIOL CHEM, V269, P14303; CARRAWAY KL, 1994, CELL, V78, P5, DOI 10.1016/0092-8674(94)90564-9; Carraway KL, 1997, NATURE, V387, P512, DOI 10.1038/387512a0; Carraway KL, 1996, BIOESSAYS, V18, P263, DOI 10.1002/bies.950180403; Gassmann M, 1997, CURR OPIN NEUROBIOL, V7, P87, DOI 10.1016/S0959-4388(97)80125-0; GrausPorta D, 1997, EMBO J, V16, P1647, DOI 10.1093/emboj/16.7.1647; GRAUSPORTA D, 1995, MOL CELL BIOL, V15, P1182; GUY PM, 1992, J BIOL CHEM, V267, P13851; HYNES NE, 1994, BBA-REV CANCER, V1198, P165, DOI 10.1016/0304-419X(94)90012-4; Juang SH, 1996, ONCOGENE, V12, P1033; Karunagaran D, 1996, EMBO J, V15, P254, DOI 10.1002/j.1460-2075.1996.tb00356.x; Komatsu M, 1997, J BIOL CHEM, V272, P33245, DOI 10.1074/jbc.272.52.33245; LEE KF, 1995, NATURE, V378, P394, DOI 10.1038/378394a0; LONARDO F, 1990, New Biologist, V2, P992; MORIARTY J, 1990, CANCER RES, V50, P6800; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; Riese DJ, 1996, J BIOL CHEM, V271, P20047, DOI 10.1074/jbc.271.33.20047; Rossi EA, 1996, J BIOL CHEM, V271, P33476, DOI 10.1074/jbc.271.52.33476; SHENG Z, 1990, J BIOL CHEM, V265, P8505; SHENG ZQ, 1992, J BIOL CHEM, V267, P16341; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; STERN DF, 1988, MOL CELL BIOL, V8, P3969, DOI 10.1128/MCB.8.9.3969	28	166	167	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 26	1999	274	9					5263	5266		10.1074/jbc.274.9.5263	http://dx.doi.org/10.1074/jbc.274.9.5263			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	170KG	10026131	hybrid			2022-12-25	WOS:000078804400002
J	Fanger, CM; Ghanshani, S; Logsdon, NJ; Rauer, H; Kalman, K; Zhou, JM; Beckingham, K; Chandy, KG; Cahalan, MD; Aiyar, J				Fanger, CM; Ghanshani, S; Logsdon, NJ; Rauer, H; Kalman, K; Zhou, JM; Beckingham, K; Chandy, KG; Cahalan, MD; Aiyar, J			Calmodulin mediates calcium-dependent activation of the intermediate conductance K-Ca channel, IKCa1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT SKELETAL-MUSCLE; POTASSIUM CHANNELS; ION CHANNELS; BETA-SUBUNIT; RYANODINE RECEPTOR; T-LYMPHOCYTES; BINDING SITES; EXPRESSION; BRAIN; MODULATION	Small and intermediate conductance Ca2+-activated K+ channels play a crucial role in hyperpolarizing the membrane potential of excitable and nonexcitable cells. These channels are exquisitely sensitive to cytoplasmic Ca2+, yet their protein-coding regions do not contain consensus Ca2+-binding motifs. me investigated the involvement of an accessory protein in the Ca2+-dependent gating of hIKCa1, a human intermediate conductance channel expressed in peripheral tissues. Calmodulin was found to interact strongly with the cytoplasmic carboxyl (C)-tail of hIKCa1 in a yeast two-hybrid system. Deletion analyses defined a requirement for the first 62 amino acids of the C-tail, and the binding of calmodulin to this region did not require Ca2+. The C-tail of hSKCa3, a human neuronal small conductance channel, also bound calmodulin, whereas that of a voltage-gated K+ channel, mKv1.3, did not. Calmodulin coprecipitated with the channel in cell lines transfected with hIKCa1, but not with mKv1.3-transfected Lines. A mutant calmodulin, defective in Ca2+ sensing but retaining binding to the channel, dramatically reduced current amplitudes when co-expressed with hIKCa1 in mammalian cells. Co-expression with varying amounts of wild-type and mutant calmodulin resulted in a dominant-negative suppression of current, consistent with four calmodulin molecules being associated with the channel. Taken together, our results suggest that Ca2+ calmodulin-induced conformational changes in all four subunits are necessary for the channel to open.	Univ Calif Irvine, Sch Med, Dept Physiol & Biophys, Irvine, CA 92697 USA; Zeneca Pharmaceut, Target Discovery Dept, Wilmington, DE 19850 USA; Rice Univ, Dept Biochem & Cell Biol, Houston, TX 77251 USA	University of California System; University of California Irvine; Rice University	Chandy, KG (corresponding author), Univ Calif Irvine, Sch Med, Dept Physiol & Biophys, Joan Irvine Smith Hall,Rm 291, Irvine, CA 92697 USA.	gchandy@uci.edu		Fanger, Christopher/0000-0002-8268-9053	NIGMS NIH HHS [GM41514, GMOD54872] Funding Source: Medline; NINDS NIH HHS [NS14609] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R55GM054872, R01GM041514] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS014609, R56NS014609, R37NS014609] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ATKINSON NS, 1991, SCIENCE, V253, P551, DOI 10.1126/science.1857984; BENDER PK, 1988, J BIOL CHEM, V263, P9733; Bowen T, 1998, MOL PSYCHIATR, V3, P266, DOI 10.1038/sj.mp.4000400; BRUGNARA C, 1995, J MEMBRANE BIOL, V147, P71, DOI 10.1007/BF00235398; BUTLER A, 1993, SCIENCE, V261, P221, DOI 10.1126/science.7687074; Chandy KG, 1998, MOL PSYCHIATR, V3, P32, DOI 10.1038/sj.mp.4000353; Cox DH, 1997, J GEN PHYSIOL, V110, P257, DOI 10.1085/jgp.110.3.257; DECOURSEY TE, 1985, J NEUROIMMUNOL, V10, P71, DOI 10.1016/0165-5728(85)90035-9; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; GALLIN EK, 1991, PHYSIOL REV, V71, P775, DOI 10.1152/physrev.1991.71.3.775; GARDOS G, 1958, BIOCHIM BIOPHYS ACTA, V30, P653, DOI 10.1016/0006-3002(58)90124-0; Ghanshani S, 1998, GENOMICS, V51, P160, DOI 10.1006/geno.1998.5333; GRISSMER S, 1992, J GEN PHYSIOL, V99, P63, DOI 10.1085/jgp.99.1.63; GRISSMER S, 1993, J GEN PHYSIOL, V102, P601, DOI 10.1085/jgp.102.4.601; GRISSMER S, 1990, P NATL ACAD SCI USA, V87, P9411, DOI 10.1073/pnas.87.23.9411; GUERRINI R, 1995, BIOCHEMISTRY-US, V34, P5120, DOI 10.1021/bi00015a024; Hanner M, 1997, P NATL ACAD SCI USA, V94, P2853, DOI 10.1073/pnas.94.7.2853; Hanselmann C, 1996, J PHYSIOL-LONDON, V496, P627, DOI 10.1113/jphysiol.1996.sp021714; HILLE B, 1993, IONIC CHANNELS EXCIT, P121; Hirschberg B, 1998, J GEN PHYSIOL, V111, P565, DOI 10.1085/jgp.111.4.565; HOGER JH, 1991, NEURON, V6, P227, DOI 10.1016/0896-6273(91)90358-7; Holmgren M, 1998, NEURON, V21, P617, DOI 10.1016/S0896-6273(00)80571-1; IKEDA SR, 1992, PFLUG ARCH EUR J PHY, V422, P201, DOI 10.1007/BF00370422; Ishii TM, 1997, P NATL ACAD SCI USA, V94, P11651, DOI 10.1073/pnas.94.21.11651; Jensen BS, 1998, AM J PHYSIOL-CELL PH, V275, pC848, DOI 10.1152/ajpcell.1998.275.3.C848; Joiner WJ, 1997, P NATL ACAD SCI USA, V94, P11013, DOI 10.1073/pnas.94.20.11013; Kaczorowski GJ, 1996, J BIOENERG BIOMEMBR, V28, P255, DOI 10.1007/BF02110699; Kohler M, 1996, SCIENCE, V273, P1709, DOI 10.1126/science.273.5282.1709; LATORRE R, 1989, ANNU REV PHYSIOL, V51, P385, DOI 10.1146/annurev.ph.51.030189.002125; Logsdon NJ, 1997, J BIOL CHEM, V272, P32723, DOI 10.1074/jbc.272.52.32723; MAHAUTSMITH MP, 1995, J PHYSIOL-LONDON, V484, P15, DOI 10.1113/jphysiol.1995.sp020644; MAUNE JF, 1992, J BIOL CHEM, V267, P5286; MCMANUS OB, 1991, J PHYSIOL-LONDON, V443, P739, DOI 10.1113/jphysiol.1991.sp018861; Meera P, 1997, P NATL ACAD SCI USA, V94, P14066, DOI 10.1073/pnas.94.25.14066; Mukherjea P, 1996, PROTEIN SCI, V5, P468; ONEIL KT, 1990, TRENDS BIOCHEM SCI, V15, P59, DOI 10.1016/0968-0004(90)90177-D; PRAGNELL M, 1994, NATURE, V368, P67, DOI 10.1038/368067a0; Rhoads AR, 1997, FASEB J, V11, P331, DOI 10.1096/fasebj.11.5.9141499; Romoser VA, 1997, J BIOL CHEM, V272, P13270, DOI 10.1074/jbc.272.20.13270; Sah P, 1996, TRENDS NEUROSCI, V19, P150, DOI 10.1016/S0166-2236(96)80026-9; SAIMI Y, 1994, FEBS LETT, V350, P155, DOI 10.1016/0014-5793(94)00782-9; SAIMI Y, 1990, SCIENCE, V249, P1441, DOI 10.1126/science.2169650; Schreiber M, 1997, BIOPHYS J, V73, P1355, DOI 10.1016/S0006-3495(97)78168-2; Scott K, 1997, CELL, V91, P375, DOI 10.1016/S0092-8674(00)80421-3; TRIPATHY A, 1995, BIOPHYS J, V69, P106, DOI 10.1016/S0006-3495(95)79880-0; TSENGCRANK J, 1994, NEURON, V13, P1315, DOI 10.1016/0896-6273(94)90418-9; Vandorpe DH, 1998, J BIOL CHEM, V273, P21542, DOI 10.1074/jbc.273.34.21542; Varnum MD, 1997, SCIENCE, V278, P110, DOI 10.1126/science.278.5335.110; Vergara C, 1997, EXP NEUROL, V146, P282, DOI 10.1006/exnr.1997.6486; Verheugen JAH, 1998, J PHYSIOL-LONDON, V508, P167, DOI 10.1111/j.1469-7793.1998.167br.x; Wallner M, 1995, RECEPTOR CHANNEL, V3, P185; Warr CG, 1996, BIOCHEM J, V314, P497, DOI 10.1042/bj3140497; WEI A, 1994, NEURON, V13, P671, DOI 10.1016/0896-6273(94)90034-5; WEINSTEIN H, 1994, ANNU REV PHYSIOL, V56, P213, DOI 10.1146/annurev.ph.56.030194.001241; Xia XM, 1998, NATURE, V395, P503, DOI 10.1038/26758; Zhang S, 1998, NEURON, V21, P443, DOI 10.1016/S0896-6273(00)80553-X	56	251	262	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 26	1999	274	9					5746	5754		10.1074/jbc.274.9.5746	http://dx.doi.org/10.1074/jbc.274.9.5746			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	170KG	10026195	hybrid			2022-12-25	WOS:000078804400066
J	Hilpert, J; Nykjaer, A; Jacobsen, C; Wallukat, G; Nielsen, R; Moestrup, SK; Haller, H; Luft, FC; Christensen, EI; Willnow, TE				Hilpert, J; Nykjaer, A; Jacobsen, C; Wallukat, G; Nielsen, R; Moestrup, SK; Haller, H; Luft, FC; Christensen, EI; Willnow, TE			Megalin antagonizes activation of the parathyroid hormone receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; OPOSSUM KIDNEY-CELLS; MEDIATED ENDOCYTOSIS; EPITHELIAL-CELLS; DEGRADATION; BINDING; GENE; PEPTIDE; PROTEIN; GROWTH	Parathyroid hormone(PTH) is predominantly cleared from the circulation by glomerular filtration and degradation in the renal proximal tubules. Here, we demonstrate that megalin, a multifunctional endocytic receptor in the proximal tubular epithelium, mediates the uptake and degradation of PTH. Megalin was purified from kidney membranes as the major PTH-binding protein and shown in BIAcore analysis to specifically bind full-length PTH and amino-terminal PTH fragments (K-d 0.5 mu M) Absence of the receptor in megalin knockout mice resulted in 4-fold increased levels of amino-terminal PTH fragments in the urine, In F9 cells expressing both megalin and the PTH/PTH-related peptide receptor (PTH/PTHrP receptor), uptake and lysosomal degradation of the hormone was mediated through megalin. Blocking megalin-mediated clearance of PTH resulted in 3-fold increased stimulation of the PTH/PTRrP receptor. These data provide evidence that megalin is involved in the renal catabolism of PTH and potentially antagonizes PTH/PTHrP receptor activity in the proximal tubular epithelium.	Max Delbruck Ctr Mol Med, D-13125 Berlin, Germany; Humboldt Univ, Franz Volhard Clin, D-13125 Berlin, Germany; Univ Aarhus, Dept Med Biochem, DK-8000 Aarhus, Denmark; Univ Aarhus, Dept Cell Biol, DK-8000 Aarhus C, Denmark	Helmholtz Association; Max Delbruck Center for Molecular Medicine; Franz-Volhard Clinical Research Center; Humboldt University of Berlin; Aarhus University; Aarhus University	Willnow, TE (corresponding author), Max Delbruck Ctr Mol Med, R Roessle Str 10, D-13125 Berlin, Germany.	willnow@mdc-berlin.de	Moestrup, Søren Kragh/AAD-1735-2019; Moestrup, Søren Kragh/A-1403-2014	Moestrup, Søren Kragh/0000-0003-3862-2107; Nielsen, Rikke/0000-0003-3105-3474; Nykjaer, Anders/0000-0001-6422-6736; Willnow, Thomas/0000-0001-9515-7921; Luft, Friedrich/0000-0002-8635-1199				ABOUSAMRA AB, 1992, P NATL ACAD SCI USA, V89, P2732, DOI 10.1073/pnas.89.7.2732; BROWN RC, 1991, AM J PHYSIOL, V260, pE544, DOI 10.1152/ajpendo.1991.260.4.E544; Cui SY, 1996, AM J PHYSIOL-RENAL, V271, pF900, DOI 10.1152/ajprenal.1996.271.4.F900; DAUGAARD H, 1994, ENDOCRINOLOGY, V134, P1373, DOI 10.1210/en.134.3.1373; DAUGAARD H, 1988, AM J PHYSIOL, V254, pE740, DOI 10.1152/ajpendo.1988.254.6.E740; DECHIARA TM, 1990, NATURE, V345, P78, DOI 10.1038/345078a0; DEMAY M, 1985, AM J PHYSIOL, V249, pE437, DOI 10.1152/ajpendo.1985.249.5.E437; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; GILMAN AG, 1970, P NATL ACAD SCI USA, V67, P305, DOI 10.1073/pnas.67.1.305; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; GSTRAUNTHALER GJA, 1988, RENAL PHYSIOL BIOCH, V11, P1; HUANG ZM, 1995, J BIOL CHEM, V270, P151, DOI 10.1074/jbc.270.1.151; JUPPNER H, 1991, SCIENCE, V254, P1024, DOI 10.1126/science.1658941; KAU ST, 1977, AM J PHYSIOL, V223, pF445; KERJASCHKI D, 1983, J EXP MED, V157, P667, DOI 10.1084/jem.157.2.667; LAU MMH, 1994, GENE DEV, V8, P2953, DOI 10.1101/gad.8.24.2953; Lepage R, 1998, CLIN CHEM, V44, P805; Lewin E, 1995, Curr Opin Nephrol Hypertens, V4, P324, DOI 10.1097/00041552-199507000-00007; LIU JP, 1993, CELL, V75, P59, DOI 10.1016/S0092-8674(05)80084-4; MAHONEY CA, 1983, J CLIN INVEST, V72, P411, DOI 10.1172/JCI110989; MARTIN KJ, 1979, NEW ENGL J MED, V301, P1092, DOI 10.1056/NEJM197911153012005; MOESTRUP SK, 1995, J CLIN INVEST, V96, P1404, DOI 10.1172/JCI118176; Moestrup SK, 1996, P NATL ACAD SCI USA, V93, P8612, DOI 10.1073/pnas.93.16.8612; Morales CR, 1996, BIOL REPROD, V55, P676, DOI 10.1095/biolreprod55.3.676; RIZZOLI RE, 1983, ENDOCRINOLOGY, V112, P1303, DOI 10.1210/endo-112-4-1303; SAITO A, 1994, P NATL ACAD SCI USA, V91, P9725, DOI 10.1073/pnas.91.21.9725; Silver J, 1994, Curr Opin Nephrol Hypertens, V3, P379, DOI 10.1097/00041552-199407000-00003; STEFANSSON S, 1995, J BIOL CHEM, V270, P19417, DOI 10.1074/jbc.270.33.19417; STJOHN A, 1992, NEPHRON, V61, P422; TEITELBAUM AP, 1982, ENDOCRINOLOGY, V111, P1524, DOI 10.1210/endo-111-5-1524; TEITELBAUM AP, 1986, ENDOCRINOLOGY, V118, P595, DOI 10.1210/endo-118-2-595; VANDESTOLPE A, 1993, J CELL BIOL, V120, P235, DOI 10.1083/jcb.120.1.235; WANG ZQ, 1994, NATURE, V372, P464, DOI 10.1038/372464a0; WEAVER CA, 1984, GENE, V28, P319, DOI 10.1016/0378-1119(84)90149-5; Willnow TE, 1996, EMBO J, V15, P2632, DOI 10.1002/j.1460-2075.1996.tb00623.x; Willnow TE, 1996, P NATL ACAD SCI USA, V93, P8460, DOI 10.1073/pnas.93.16.8460; YAMAGUCHI T, 1992, ACTA ENDOCRINOL-COP, V127, P267, DOI 10.1530/acta.0.1270267; YAMAGUCHI T, 1988, ENDOCRINOLOGY, V123, P2812, DOI 10.1210/endo-123-6-2812	38	87	87	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 26	1999	274	9					5620	5625		10.1074/jbc.274.9.5620	http://dx.doi.org/10.1074/jbc.274.9.5620			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	170KG	10026179	hybrid			2022-12-25	WOS:000078804400050
J	Yang, B; Gonzalez, L; Prekeris, R; Steegmaier, M; Advani, RJ; Scheller, RH				Yang, B; Gonzalez, L; Prekeris, R; Steegmaier, M; Advani, RJ; Scheller, RH			SNARE interactions are not selective - Implications for membrane fusion specificity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN INTERACTIONS; SYNTAXIN-BINDING; GOLGI-APPARATUS; T-SNARE; V-SNARE; TRANSPORT; COMPLEX; EXOCYTOSIS; RECEPTORS; CLEAVAGE	The SNARE hypothesis proposes that membrane trafficking specificity is mediated by preferential high affinity interactions between particular v (vesicle membrane)- and t (target membrane)-SNARE combinations. The specificity of interactions among a diverse set of SNAREs, however, is unknown. We have tested the SNARE hypothesis by analyzing potential SNARE complexes between five proteins of the vesicle-associated membrane protein (VAMP) family, three members of the synaptosome-associated protein-25 (SNAP-25) family and three members of the syntaxin family, All of the 21 combinations of SNAREs tested formed stable complexes, Sixteen were resistant to SDS denaturation, and most complexes thermally denatured between 70 and 90 degrees C, These results suggest that the specificity of membrane fusion is not encoded by the interactions between SNAREs.	Stanford Univ, Sch Med, Dept Cellular & Mol Physiol, Howard Hughes Med Inst, Stanford, CA 94305 USA	Howard Hughes Medical Institute; Stanford University	Scheller, RH (corresponding author), Stanford Univ, Sch Med, Dept Cellular & Mol Physiol, Howard Hughes Med Inst, Stanford, CA 94305 USA.		Gonzalez, Lino/E-4102-2012	Gonzalez, Lino/0000-0003-3817-6450				Advani RJ, 1998, J BIOL CHEM, V273, P10317, DOI 10.1074/jbc.273.17.10317; BENNETT MK, 1993, CELL, V74, P863, DOI 10.1016/0092-8674(93)90466-4; BENNETT MK, 1994, ANNU REV BIOCHEM, V63, P63, DOI 10.1146/annurev.bi.63.070194.000431; CHAPMAN ER, 1994, J BIOL CHEM, V269, P27427; Darsow T, 1998, J CELL BIOL, V142, P913, DOI 10.1083/jcb.142.4.913; Fasshauer D, 1998, BIOCHEMISTRY-US, V37, P10354, DOI 10.1021/bi980542h; FERRONOVICK S, 1994, NATURE, V370, P191, DOI 10.1038/370191a0; Grindstaff KK, 1998, CELL, V93, P731, DOI 10.1016/S0092-8674(00)81435-X; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; Hanson PI, 1997, CELL, V90, P523, DOI 10.1016/S0092-8674(00)80512-7; Hay JC, 1997, CELL, V89, P149, DOI 10.1016/S0092-8674(00)80191-9; HAYASHI T, 1994, EMBO J, V13, P5051, DOI 10.1002/j.1460-2075.1994.tb06834.x; JAHN R, 1994, ANNU REV NEUROSCI, V17, P219, DOI 10.1146/annurev.ne.17.030194.001251; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee J, 1998, P NATL ACAD SCI USA, V95, P9274, DOI 10.1073/pnas.95.16.9274; Lin RC, 1997, NEURON, V19, P1087, DOI 10.1016/S0896-6273(00)80399-2; Lowe SL, 1997, NATURE, V389, P881, DOI 10.1038/39923; MOLLARD GF, 1997, J CELL BIOL, V137, P1511; Nagahama M, 1996, J CELL BIOL, V133, P507, DOI 10.1083/jcb.133.3.507; Nichols BJ, 1997, NATURE, V387, P199, DOI 10.1038/387199a0; Nicholson KL, 1998, NAT STRUCT BIOL, V5, P793, DOI 10.1038/1834; PALADE G, 1975, SCIENCE, V189, P347, DOI 10.1126/science.1096303; PEVSNER J, 1994, P NATL ACAD SCI USA, V91, P1445, DOI 10.1073/pnas.91.4.1445; Poirier MA, 1998, J BIOL CHEM, V273, P11370, DOI 10.1074/jbc.273.18.11370; Poirier MA, 1998, NAT STRUCT BIOL, V5, P765, DOI 10.1038/1799; Prekeris R, 1998, J CELL BIOL, V143, P957, DOI 10.1083/jcb.143.4.957; Ravichandran V, 1996, J BIOL CHEM, V271, P13300, DOI 10.1074/jbc.271.23.13300; Rice LM, 1997, FEBS LETT, V415, P49, DOI 10.1016/S0014-5793(97)01091-0; ROTHMAN JE, 1994, CURR BIOL, V4, P220, DOI 10.1016/S0960-9822(00)00051-8; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; SOGAARD M, 1994, CELL, V78, P937, DOI 10.1016/0092-8674(94)90270-4; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; Steegmaier M, 1998, J BIOL CHEM, V273, P34171, DOI 10.1074/jbc.273.51.34171; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; Sutton RB, 1998, NATURE, V395, P347, DOI 10.1038/26412; Volchuk A, 1996, MOL BIOL CELL, V7, P1075, DOI 10.1091/mbc.7.7.1075; Weber T, 1998, CELL, V92, P759, DOI 10.1016/S0092-8674(00)81404-X; Weimbs T, 1998, TRENDS CELL BIOL, V8, P260, DOI 10.1016/S0962-8924(98)01285-9	39	258	264	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 26	1999	274	9					5649	5653		10.1074/jbc.274.9.5649	http://dx.doi.org/10.1074/jbc.274.9.5649			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	170KG	10026182	hybrid			2022-12-25	WOS:000078804400053
J	Florenes, VA; Lu, C; Bhattacharya, N; Rak, J; Sheehan, C; Slingerland, JM; Kerbel, RS				Florenes, VA; Lu, C; Bhattacharya, N; Rak, J; Sheehan, C; Slingerland, JM; Kerbel, RS			Interleukin-6 dependent induction of the cyclin dependent kinase inhibitor p21(WAF1/CIP1) is lost during progression of human malignant melanoma	ONCOGENE			English	Article						melanoma; IL-6; sensitivity; p21(WAF1/CIP1); p27(Kip1); STAT	GROWTH-FACTOR-BETA; TUMOR-SUPPRESSOR GENE; CARCINOMA CELL-LINES; TGF-BETA; MAMMALIAN-CELLS; BREAST-CANCER; POTENTIAL MEDIATOR; EPITHELIAL-CELLS; CDK INHIBITORS; IL-6 FUNCTIONS	Human melanoma cell lines derived from early stage primary tumors are particularly sensitive to growth arrest induced by interleukin-6 (IL-6), This response is lost in cell lines derived from advanced lesions, a phenomenon which may contribute to tumor aggressiveness. We sought to determine whether resistance to growth inhibition by IL-6 can be explained by oncogenic alterations in cell cycle regulators or relevant components of intracellular signaling, Our results show that IL-6 treatment of early stage melanoma cell lines caused G(1) arrest, which could not be explained by changes in levels of G1 cyclins (D1, E), cdks (cdk4, cdk2) or by loss of cyclin/cdk complex formation. Instead, IL-6 caused a marked induction of the cdk inhibitor p21(WAF1/CIP1) in three different IL-6 sensitive cell lines, two of which also showed a marked accumulation of the cdk inhibitor p27(Kip1). In contrast, IL-6 failed to induce p21(WAF1/CIP1) transcript and did not increase p21(WAF1/CIP1) Or p27(Kip1) proteins in any of the resistant lines, In fact, of five IL-6 resistant cell lines, only two expressed detectable levels of p21(WAF1/CIP1) mRNA and protein, while in three other lines, p21(WAF1/CIP1) was undetectable. IL-6 dependent upregulation of p21(WAF1/CIP1) was associated with binding of both STAT3 and STAT1 to the p21(WAF1/CIP1) promoter. Surprisingly, however, IL-6 stimulated STAT binding to this promoter in both sensitive and resistant cell lines (with one exception), suggesting that gross deregulation of this event is not the unifying cause of the defect in p21(WAF1/CIP1) induction in IL-6 resistant cells, In somatic cell hybrids of IL-6 sensitive and resistant cell lines, the resistant phenotype was dominant and IL-6 failed to induce p21(WAF1/CIP1), Thus, our results suggest that in early stage human melanoma cells, IL-6 induced growth inhibition involves induction of p21(WAF1/CIP1) which is lost in the course of tumor progression presumably as a result of a dominant oncogenic event.	Univ Toronto, Dept Med Biophys, Toronto, ON M4N 3M5, Canada; Sunnybrook Hlth Sci Ctr, Div Canc Biol Res, Toronto, ON M4N 3M5, Canada; Toronto Sunnybrook Reg Canc Ctr, Div Med Oncol, Toronto, ON M4N 3M5, Canada	University of Toronto; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center	Kerbel, RS (corresponding author), Univ Toronto, Dept Med Biophys, 2075 Bayview Ave,S-218, Toronto, ON M4N 3M5, Canada.				NCI NIH HHS [CA 41223] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; BARNHILL RL, 1993, AM J PATHOL, V143, P99; BORSELLINO N, 1995, CANCER RES, V55, P4633; CALDAS C, 1994, NAT GENET, V8, P27, DOI 10.1038/ng0994-27; Catzavelos C, 1997, NAT MED, V3, P227, DOI 10.1038/nm0297-227; Chin YE, 1996, SCIENCE, V272, P719, DOI 10.1126/science.272.5262.719; Chiu JJ, 1996, CLIN CANCER RES, V2, P215; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CORNIL I, 1991, P NATL ACAD SCI USA, V88, P6028, DOI 10.1073/pnas.88.14.6028; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; EUSTACE D, 1993, GYNECOL ONCOL, V50, P15, DOI 10.1006/gyno.1993.1156; Florenes VA, 1996, ONCOGENE, V13, P2447; Florenes VA, 1998, AM J PATHOL, V153, P305, DOI 10.1016/S0002-9440(10)65572-1; Flores JF, 1996, CANCER RES, V56, P5023; FYNAN TM, 1993, CRIT REV ONCOGENESIS, V4, P493; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; HIRAMA T, 1995, BLOOD, V86, P841; ISHIKAWA M, 1988, CANCER RES, V48, P665; ISHIKAWA M, 1988, CANCER RES, V48, P4897; JENNINGS MT, 1991, INT J CANCER, V49, P129, DOI 10.1002/ijc.2910490124; JIANG HP, 1994, ONCOGENE, V9, P3397; JIANG HP, 1995, ONCOGENE, V10, P1855; Kamb A, 1994, Nat Genet, V8, P23; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KAWANO M, 1988, NATURE, V332, P83, DOI 10.1038/332083a0; KISHIMOTO T, 1995, BLOOD, V86, P1243, DOI 10.1182/blood.V86.4.1243.bloodjournal8641243; KISHIMOTO T, 1989, BLOOD, V74, P1, DOI 10.1182/blood.V74.1.1.1; KOFF A, 1993, SCIENCE, V260, P536, DOI 10.1126/science.8475385; LAIHO M, 1990, J BIOL CHEM, V265, P18518; Loda M, 1997, NAT MED, V3, P231, DOI 10.1038/nm0297-231; LU C, 1992, P NATL ACAD SCI USA, V89, P9215, DOI 10.1073/pnas.89.19.9215; LU C, 1993, J CELL BIOL, V120, P1281, DOI 10.1083/jcb.120.5.1281; MacDougall John R., 1993, Molecular and Cellular Differentiation, V1, P21; MACDOUGALL JR, 1995, CANCER RES, V55, P4174; Maelandsmo GM, 1996, AM J PATHOL, V149, P1813; Maelandsmo GM, 1996, BRIT J CANCER, V73, P909, DOI 10.1038/bjc.1996.181; Martin-Castellanos C, 1997, TRENDS CELL BIOL, V7, P95, DOI 10.1016/S0962-8924(96)10055-6; Matsumura I, 1997, MOL CELL BIOL, V17, P2933, DOI 10.1128/MCB.17.5.2933; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MIKI S, 1989, FEBS LETT, V250, P607, DOI 10.1016/0014-5793(89)80805-1; MITZUTANI Y, 1995, CANCER RES, V55, P590; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; Oh JW, 1997, ONCOGENE, V15, P569, DOI 10.1038/sj.onc.1201213; Okamoto M, 1997, CANCER RES, V57, P141; OTSUKI T, 1995, CANCER RES, V55, P1436; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; PARRY D, 1995, EMBO J, V14, P503, DOI 10.1002/j.1460-2075.1995.tb07026.x; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; Porter PL, 1997, NAT MED, V3, P222, DOI 10.1038/nm0297-222; Rak J, 1996, EUR J CANCER, V32A, P2438, DOI 10.1016/S0959-8049(96)00396-6; REED JA, 1995, CANCER RES, V55, P2713; RESNITZKY D, 1992, P NATL ACAD SCI USA, V89, P402, DOI 10.1073/pnas.89.1.402; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; Sandhu C, 1997, MOL CELL BIOL, V17, P2458, DOI 10.1128/MCB.17.5.2458; SHAO ZM, 1995, ONCOGENE, V11, P493; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SHIOHARA M, 1994, BLOOD, V84, P3781, DOI 10.1182/blood.V84.11.3781.bloodjournal84113781; SLINGERLAND JM, 1994, MOL CELL BIOL, V14, P3683, DOI 10.1128/MCB.14.6.3683; SPRUCK CH, 1994, NATURE, V370, P183, DOI 10.1038/370183a0; STEINMAN RA, 1994, ONCOGENE, V9, P3389; SWOPE VB, 1991, J INVEST DERMATOL, V96, P180, DOI 10.1111/1523-1747.ep12460991; TAM SW, 1994, ONCOGENE, V9, P2663; VIDAL MJ, 1995, MELANOMA RES, V5, P243, DOI 10.1097/00008390-199508000-00006; Welch DR, 1996, MOL CELL DIFFER, V4, P91; Zeng YX, 1996, ONCOGENE, V12, P1557; ZHANG XG, 1989, BLOOD, V74, P11	73	72	72	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 28	1999	18	4					1023	1032		10.1038/sj.onc.1202382	http://dx.doi.org/10.1038/sj.onc.1202382			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	165FT	10023678				2022-12-25	WOS:000078510600019
J	Levenberg, S; Yarden, A; Kam, Z; Geiger, B				Levenberg, S; Yarden, A; Kam, Z; Geiger, B			p27 is involved in N-cadherin-mediated contact inhibition of cell growth and S-phase entry	ONCOGENE			English	Article						cell adhesion; cadherin; cell growth; cell cycle; p27	DEPENDENT KINASE INHIBITOR; BETA-CATENIN; P27(KIP1); CYCLE; DROSOPHILA; ADHESION; PATHWAY; ARREST	In this study the direct involvement of cadherins in adhesion-mediated growth inhibition was investigated. It is shown here that overexpression of N-cadherin in CHO cells significantly suppresses their growth rate. Interaction of these cells and two additional fibroblastic lines with synthetic beads coated with N-cadherin ligands (recombinant N-cadherin ectodomain or specific antibodies) leads to growth arrest at the G1 phase of the cell cycle. The cadherin-reactive beads inhibit the entry into S phase and the reduction in the levels of cyclin-dependent kinase (cdk) inhibitors p21 and p27, following serum-stimulation of starved cells. In exponentially growing cells these beads induce G1 arrest accompanied by elevation in p27 only. We propose that cadherin-mediated signaling is involved in contact inhibition of growth by inducing cell cycle arrest at the G1 phase and elevation of p27 levels.	Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Geiger, B (corresponding author), Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel.			Levenberg, Shulamit/0000-0001-5471-7339				BECKER KF, 1994, CANCER RES, V54, P3845; Caveda L, 1996, J CLIN INVEST, V98, P886, DOI 10.1172/JCI118870; Chen H, 1996, J STRUCT BIOL, V116, P56, DOI 10.1006/jsbi.1996.0010; Coats S, 1996, SCIENCE, V272, P877, DOI 10.1126/science.272.5263.877; Deleu L, 1998, MOL CELL BIOL, V18, P409, DOI 10.1128/MCB.18.1.409; Dietrich C, 1997, ONCOGENE, V15, P2743, DOI 10.1038/sj.onc.1201439; Fagotto F, 1996, J CELL BIOL, V132, P1105, DOI 10.1083/jcb.132.6.1105; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; HOLLEY RW, 1975, NATURE, V258, P487, DOI 10.1038/258487a0; Huber O, 1996, CURR OPIN CELL BIOL, V8, P685, DOI 10.1016/S0955-0674(96)80110-4; Huttenlocher A, 1998, J CELL BIOL, V141, P515, DOI 10.1083/jcb.141.2.515; JOHNSON M, 1994, MOL CARCINOGEN, V11, P59, DOI 10.1002/mc.2940110202; KAM Z, 1993, BIOIMAGING, V1, P71; Kandikonda S, 1996, CELL ADHES COMMUN, V4, P13, DOI 10.3109/15419069609010760; Kato A, 1997, J BIOL CHEM, V272, P8065, DOI 10.1074/jbc.272.12.8065; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; Levenberg S, 1998, J CELL SCI, V111, P347; LEVENBERG S, 1998, IN PRESS CELL ADHE C; MILLARD S, 1997, J BIOL CHEM, V272, P7039; Miller JR, 1996, GENE DEV, V10, P2527, DOI 10.1101/gad.10.20.2527; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; Peifer M, 1997, SCIENCE, V275, P1752, DOI 10.1126/science.275.5307.1752; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; Sanson B, 1996, NATURE, V383, P627, DOI 10.1038/383627a0; TSUKITA S, 1993, J CELL BIOL, V123, P1049, DOI 10.1083/jcb.123.5.1049; vandeWetering M, 1997, CELL, V88, P789, DOI 10.1016/S0092-8674(00)81925-X; VOLK T, 1986, J CELL BIOL, V103, P1451, DOI 10.1083/jcb.103.4.1451; WEISER RJ, 1986, J CELL BIOL, V103, P361; WEISER RJ, 1985, EXP CELL RES, V158, P493	30	141	147	1	8	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 28	1999	18	4					869	876		10.1038/sj.onc.1202396	http://dx.doi.org/10.1038/sj.onc.1202396			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	165FT	10023662				2022-12-25	WOS:000078510600003
